<SEC-DOCUMENT>0001193125-15-111761.txt : 20150330
<SEC-HEADER>0001193125-15-111761.hdr.sgml : 20150330
<ACCEPTANCE-DATETIME>20150330161257
ACCESSION NUMBER:		0001193125-15-111761
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20150330
DATE AS OF CHANGE:		20150330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cerulean Pharma Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-202917
		FILM NUMBER:		15734648

	BUSINESS ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		STREET 2:		5TH FLOOR
		CITY:			Cambridge
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-551-9600

	MAIL ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		STREET 2:		5TH FLOOR
		CITY:			Cambridge
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d887761ds1a.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 1 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on March 30, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-202917 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>To </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION
STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>CERULEAN
PHARMA INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><B>20-4139823</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>840 Memorial Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, MA 02139 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617)&nbsp;551-9600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Christopher D. T. Guiffre </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Cerulean Pharma Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>840
Memorial Drive </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, MA 02139 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) 551-9600 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Steven D. Singer, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Lia Der Marderosian, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>60 State Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA
02109</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (617)&nbsp;526-6000</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Patrick O&#146;Brien, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Marko S. Zatylny, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Ropes&nbsp;&amp; Gray LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Prudential Tower</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>800
Boylston Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02199</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (617)&nbsp;951-7000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared
effective. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933 (&#147;Securities Act&#148;), check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange
Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any
state where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#de1a1e"><B>Subject to completion, dated March 30, 2015 </B></FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$50,000,000 </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g24k11.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cerulean Pharma
Inc. is offering $50,000,000 of shares of its common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common
stock is listed on the NASDAQ Global Market under the symbol &#147;CERU.&#148; The last reported sale price of our common stock on the NASDAQ Global Market on March 27, 2015 was $9.73 per share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012, and as such, have
elected to comply with certain reduced public reporting requirements. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our common stock involves a high degree of risk. Before buying any shares, you should carefully read the discussion of material risks of investing in our common stock in &#147;<A HREF="#toc887761_2">Risk Factors</A>&#148; beginning on page 9 of this
prospectus. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Cerulean Pharma, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:13%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We have agreed to reimburse the underwriters for certain expenses in connection with this offering. See &#147;Underwriting.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to $7,500,000 of additional shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon
the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to
deliver the shares of common stock to investors on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" ALIGN="center"><B>Leerink Partners</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Barclays</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:14pt">
<TD VALIGN="bottom" NOWRAP><B>Canaccord&nbsp;Genuity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>JMP&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Wedbush&nbsp;PacGrow</B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.45pt; font-size:8pt; font-family:Times New Roman"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_3">Special Note Regarding Forward-Looking Statements and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_4">Price Range of Common Stock.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_10">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_14">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_15">Certain Relationships and Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_19">Material U.S. Tax Considerations for Non-U.S. Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc887761_24">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus or in any free writing prospectus we may authorize to be delivered or
made available to you. We have not authorized anyone to provide you with different information. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The
information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock. Our business, financial condition, results of operations and
prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: We have not and the underwriters have not done
anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of
this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. You should read this entire prospectus carefully, especially the &#147;Risk Factors&#148; section beginning on page&nbsp;9 and our consolidated financial statements and the related notes appearing at
the end of this prospectus, before making an investment decision. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As used in this prospectus, unless the context otherwise
requires, references to &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, the &#147;company&#148; and &#147;Cerulean&#148; refer to the consolidated operations of Cerulean Pharma Inc., and its consolidated subsidiary, Cerulean Pharma Australia Pty
Ltd. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage, oncology-focused company applying our proprietary Dynamic Tumor Targeting&#153; Platform to develop differentiated therapies. This platform utilizes nanoparticle-drug conjugates, or NDCs, which consist of proprietary polymers that
are covalently linked to anti-cancer therapeutics, or payloads. We believe these NDCs dynamically target tumors by exploiting the leakiness of new blood vessels in tumors as an entry portal into tumor tissue, followed by active uptake into tumor
cells and the sustained release of the anti-cancer payload inside the tumor cells. We believe that our NDCs are differentiated from other nanoparticle technologies by our linker technology, which allows for preferential delivery of our anti-cancer
payloads. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
current development stage pipeline consists of CRLX101 and CRLX301. As described in more detail below, we are pursuing clinical development of CRLX101 in three lead indications, and we began clinical development of CRLX301 in 2014. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="73%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Product<BR>Candidate</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Indication</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Stage</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Design of Ongoing Clinical Trials</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Relapsed<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Renal Cell</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Carcinoma</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Phase&nbsp;2</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Ongoing randomized Phase 2 company-sponsored trial
of CRLX101 in combination with Avastin</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">Ongoing single-arm Phase 1b/2 IST of CRLX101 in
combination with Avastin that has completed enrollment</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>CRLX101</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Relapsed<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Ovarian</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Cancer</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Phase 2</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Ongoing 2-part, single-arm Phase 2 IST of CRLX101
as monotherapy and in combination with Avastin</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">&#149;&nbsp;Part 1: monotherapy arm that met primary efficacy and safety endpoints</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">&#149;&nbsp;Part 2: ongoing single-arm of CRLX101
in combination with Avastin, for which the Avastin is provided by Genentech</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Neoadjuvant<BR> Rectal<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Cancer</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Phase 2</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">Ongoing single-arm Phase 1b/2 IST of CRLX101 in combination with CRT</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>CRLX301</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Solid<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Tumors</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Phase 1</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">Ongoing Phase 1 dose-escalation trial of CRLX301 as monotherapy</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;1&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CRLX101 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, CRLX101, is a dynamically tumor targeted NDC in Phase 2 clinical development and has the potential to improve
outcomes for patients in combination with other cancer treatments. We believe CRLX101, which contains camptothecin as its anti-cancer payload, is a potent, durable and combinable inhibitor of topoisomerase 1, or topo 1, a commercially validated
cancer target, and hypoxia inducible factor, or HIF, a novel target of increasing interest in cancer research. Two products that have been marketed by other companies, irinotecan and topotecan, inhibit topo 1, but their utility is limited by
toxicities. Recent research suggests that HIF, and in particular the HIF subunit HIF-l<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is a master regulator of multiple cancer cell survival pathways. Over 250 patients have been administered CRLX101 in
multiple indications at several clinical trial sites. In clinical trials evaluating CRLX101 as a single agent, CRLX101 was generally well tolerated with a toxicity profile generally characterized by low-grade (Common Terminology Criteria for Adverse
Events grade 1-2) adverse events. No treatment-related trial deaths have been observed to date. In ongoing clinical trials, CRLX101 also appears active and combinable with Avastin (bevacizumab) and chemoradiotherapy, or CRT, which is a combination
of capecitabine and radiation. In addition, preclinical data indicate that CRLX101 may be combinable with other anti-cancer therapies. We are pursuing development of CRLX101 in combination with anti-cancer therapies in multiple ongoing clinical
development programs that include a company-sponsored trial and investigator-sponsored trials, or ISTs. These trials consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Relapsed renal cell carcinoma:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 2 randomized, controlled, company-sponsored trial is being conducted comparing CRLX101 administered in combination with Avastin to investigator&#146;s choice of standard of care in patients with renal cell
carcinoma, or RCC, who have received two or three prior lines of therapy. We refer to this study as the RCC Trial. The RCC Trial is currently being conducted at approximately 30 sites in the United States, with eight additional sites planned in the
United States and five additional sites planned in South Korea. Based on results from the Phase 1b/2 IST in relapsed RCC, discussed below, we believe that the combination of CRLX101 and Avastin may provide therapeutic benefits to patients with
relapsed RCC who have received two or three prior lines of therapy including a tyrosine kinase inhibitor, or TKI, and/or an inhibitor of a mammalian target of rapamycin, or an mTORI. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1b/2 single-arm IST of CRLX101 in combination with Avastin in patients with relapsed RCC is being conducted at the University of Pennsylvania and Thomas Jefferson University Hospital. A total of 22 patients were
enrolled in this trial. The last patient was enrolled in December 2014, and the trial has met its primary endpoint of at least 50% of patients achieving four months progression free survival, or PFS. Preliminary data from this clinical trial has
been submitted for presentation at the 2015 annual meeting of the American Society of Clinical Oncology, or ASCO. As of February 3, 2015, the date of the abstract submission to ASCO, the median PFS, or mPFS, of patients on the trial was 9.9 months,
with seven of the 22 patients still receiving treatment. Based on third-party published data, the mPFS of the standard of care in this setting is approximately 3.5 months. In addition, the Response Evaluation Criteria in Solid Tumor, or RECIST,
partial response rate of patients on the trial as of February 3, 2015 was 23%. Several recent studies in advanced RCC suggest that after treatment with a TKI, subsequent therapies, including Avastin alone, achieve RECIST partial response rates of
between 2% and 4%. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Relapsed ovarian cancer:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">A Phase 2 single-arm IST of CRLX101 as monotherapy and in combination with Avastin in patients with relapsed ovarian cancer is being conducted at
Massachusetts General Hospital and affiliated Harvard University teaching hospitals. As previously reported, the first stage of the trial, administering CRLX101 as monotherapy, met its primary endpoint of PFS at six months for at least four
patients. RECIST responses, as well as encouraging PFS, were observed for several </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;2&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
patients. Platinum-resistant ovarian cancer patients are being enrolled in the second stage of this trial, administering CRLX101 in combination with Avastin. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have commenced start-up activities for a Phase 1b single-arm company-sponsored trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer conducted in collaboration with the GOG
Foundation, Inc. (formerly known as the Gynecologic Oncology Group), or GOG. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Neoadjuvant rectal cancer:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1b/2 single-arm IST of CRLX101 in combination with CRT in patients with non-metastatic rectal cancer is being conducted at the University of North Carolina at Chapel Hill and several other sites, including the
University of Indiana, Wake Forest University, Rex Hospital Inc. and Southeastern Medical Oncology Center. No dose limiting toxicities, or DLTs, have been reported in the Phase 1b stage of the trial, in which a maximum tolerated dose, or MTD, and
recommended Phase 2 dose, or RP2D, of 15 mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> of CRLX101 was established when administered in combination with capecitabine and radiotherapy. Patients are currently being enrolled in the RP2D
expansion Phase 2 stage of the trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold issued patents in the United States, Japan and Europe covering the
composition of matter of CRLX101 that expire in 2023 and 2024, excluding any potential patent term extension. Due to the ability of NDCs to target the &#147;leaky&#148; vasculature that is present in all solid tumors and CRLX101&#146;s apparently
favorable adverse event profile observed to date, we believe CRLX101 may have significant clinical utility in several cancer indications, particularly in combination with other cancer therapies. Our development focus is on tumor types where HIF is
up-regulated, topo 1 inhibition is desirable, and drug combinations with CRLX101 can be pursued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CRLX301 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX301, our second platform-generated clinical candidate, is a dynamically tumor-targeted NDC in Phase 1 clinical development. CRLX301 is
designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. Docetaxel is a microtubule stabilizer that is extensively used in clinical practice and is approved by the FDA for the treatment of locally
advanced or metastatic non-small cell lung cancer, locally advanced squamous cell carcinoma of the head and neck, androgen-independent prostate cancer, locally advanced or metastatic breast cancer and advanced gastric cancer. In preclinical studies,
CRLX301 delivered up to ten times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was superior to docetaxel in seven of seven animal models, with a statistically significant survival
benefit seen in five of the seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies. We hold issued patents in the United States, Japan and Europe covering
the composition of matter of CRLX301 that expire in 2023 and 2024, excluding any potential patent term extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our NDCs are
polymer-based nanoparticles that are covalently linked to anti-cancer payloads. These NDCs form particulate structures that, we believe, dynamically target tumors in a three-step process. First, we believe our NDCs exploit the leakiness of new blood
vessels in tumors as a preferential entry portal into tumor tissue over normal tissue. Second, we believe our NDCs are actively taken up by tumor cells and, due to their size, our NDCs are not easily removed from cancer cells. Third, we believe our
NDCs are differentiated from other nanoparticle approaches by the sustained release of the anti-cancer payload inside the tumor cells. Taken together, these properties may result in improved safety by largely sparing healthy tissue from the
anti-cancer payload and improved efficacy by prolonging drug exposure in tumor cells, thus providing for an improved therapeutic index as compared to conventional cytotoxics. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;3&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, we expect to commercialize our product candidates in the United States directly
with a focused commercialization organization. We expect to seek one or more strategic partners for commercialization of our product candidates outside the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to be a leader
in the discovery, development and commercialization of NDCs for the treatment of patients with inadequately treated forms of cancer. Key elements of our strategy to achieve this goal are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Advance the clinical development of our lead product candidate, CRLX101, in multiple tumor types.</I></B> Based on confirmatory signals of activity observed in the ongoing relapsed RCC IST, we initiated a
randomized Phase 2 clinical trial of CRLX101 in combination with Avastin in this patient population in 2014. We are exploring development opportunities in two additional tumor types, and we intend to explore additional development opportunities,
alone and in collaboration with strategic partners, to capitalize on the various opportunities to use CRLX101 in combination with other cancer treatments. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Advance the clinical development of our second product candidate, CRLX301, into selected indications.</I></B> Assuming we are successful in establishing a safe maximum tolerated dose, or MTD, and/or a recommended
Phase 2 dose in the Phase 1 trial, we plan to rapidly advance CRLX301 into Phase 2 development. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Leverage our platform to discover and develop a proprietary pipeline of highly differentiated product candidates with anti-cancer payloads</I></B><B>.</B> Using our Dynamic Tumor Targeting Platform, we have
created two product candidates, CRLX101 and CRLX301. We have used our platform to create additional NDCs, and we intend over the longer term to develop additional product candidates from the platform. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Leverage our platform beyond our proprietary pipeline to enter into strategic partnerships for the development of product candidates.</I></B> We believe that our platform can be used with a wide range of payloads.
While our focus is on oncology, our preclinical data demonstrates that our platform may also be applicable in certain inflammatory diseases. We plan to explore the possibility of entering into partnerships with companies that have proprietary active
pharmaceutical ingredients, or APIs, that can be used as NDC payloads for use in the treatment of oncology or inflammation indications. We envision selective partnerships with pharmaceutical companies, in which we would leverage the partner&#146;s
expertise, in combination with our platform, to generate novel NDCs incorporating the partner&#146;s approved therapeutic or development candidate. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Build core capabilities that allow us to commercialize our products in the United States.</I></B> In order to maximize the value of our product candidates, if approved, we expect to commercialize our products in
the United States with a focused commercialization organization and to seek one or more strategic partners for commercialization outside the United States. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this Prospectus
Summary. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have incurred significant losses since our incorporation. We expect to incur losses over the next several years and may never achieve or maintain profitability. As of December&nbsp;31, 2014, we had an accumulated
deficit of $121.8 million. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;4&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our approach to the discovery and development of product candidates based on our Dynamic Tumor Targeting Platform is unproven, and we do not know whether we will be able to develop any products of commercial value.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are particularly dependent on the success of our product candidate, CRLX101. If we are unable to develop, obtain marketing approval for or successfully commercialize CRLX101, either alone or through a collaboration,
or experience significant delays in doing so, our business could be materially harmed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are currently focusing the clinical development of CRLX101 on combinations with Avastin in relapsed renal cell carcinoma and relapsed ovarian cancer and with capecitabine and radiotherapy in neoadjuvant rectal cancer
and may focus on additional combinations in the future. If the FDA revokes its approval of, or if safety, efficacy, manufacturing or supply issues arise with, either Avastin or capecitabine, or any other therapeutic that we use in combination with
CRLX101 in the future, we may be unable to market CRLX101 or may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We believe we may, in some instances, be able to secure approval from the FDA or comparable non-U.S. regulatory authorities to use accelerated development pathways. If unable to obtain such approval, we may be required
to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We rely on third parties to conduct ISTs of some of our product candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our drug candidates may delay or impair our
ability to obtain regulatory approval for our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize
technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CRLX101 and certain aspects of our platform technology are protected by patents assigned by or exclusively licensed from other companies or institutions. If these third parties terminate their agreements with us or fail
to maintain or enforce the underlying patents, or we otherwise lose our rights to these patents, our competitive position and our market share for any of our approved products will be harmed. In addition, if we fail to comply with our obligations
under our intellectual property agreements with third parties, we could lose rights that are important to our business, including our rights to important intellectual property or technology. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware on November&nbsp;28, 2005 under the name Tempo Pharmaceuticals,
Inc. In October 2008, we changed our name to Cerulean Pharma Inc. Our executive offices are located at 840 Memorial Drive, Cambridge, Massachusetts 02139, and our telephone number is (617)&nbsp;551-9600. Our website address is www.ceruleanrx.com.
The information contained on, or that can be accessed through, our website does not constitute part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;5&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an
emerging growth company, we are permitted and intend to rely on exemptions from specified disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would
cease to be an emerging growth company if we have more than $1&nbsp;billion in annual revenue, we have more than $700 million in market value of our stock held by non-affiliates or we issue more than $1 billion of non-convertible debt over a
three-year period. We may choose to take advantage of some or all of the available exemptions. We have taken advantage of certain reduced reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the
information you receive from other public companies in which you hold stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth
company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and therefore, we will be subject to the same new or revised accounting standards as other public
companies that are not emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;6&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered </P></TD>
<TD>$50,000,000 of shares of our common stock </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>25,508,429 shares </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>The underwriters have an option for a period of 30 days to purchase up to $7,500,000 additional shares of our common stock. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $46.4 million, or approximately $53.4 million if the
underwriters exercise their option to purchase additional shares from us in full, assuming a public offering price of $9.73 per share, which was the last reported sale price of our common stock on The NASDAQ Global Market on March 27, 2015. We plan
to use the net proceeds from this offering to fund clinical development of CRLX101, to fund research and development of CRLX301 and other future product candidates and for working capital and other general corporate purposes. See &#147;Use of
Proceeds&#148; in this prospectus for more information. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section beginning on page&nbsp;9 of this prospectus and other information in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">NASDAQ Global Market symbol </P></TD>
<TD>&#147;CERU&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 20,369,683 shares of our common stock outstanding
as of February&nbsp;28, 2015 and assumes the issuance and sale of $50,000,000 of shares of common stock at an assumed public offering price of $9.73 per share, which was the last reported sale price of our common stock on the NASDAQ Global Market on
March 27, 2015. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">300,564 shares of common stock issuable upon exercise of warrants outstanding as of February&nbsp;28, 2015, at a weighted-average exercise price of $8.39 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,417,346 shares of common stock issuable upon exercise of stock options outstanding as of February&nbsp;28, 2015, at a weighted-average exercise price of $5.64 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,839,628 and 701,250 shares of common stock reserved and available as of February&nbsp;28, 2015 for future issuance under our 2014 stock incentive plan and our 2014 employee stock purchase plan, respectively.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a one-for-14.5074 reverse stock split of our common stock that was effected on March&nbsp;31, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the outstanding options or warrants described above; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their option to purchase up to $7,500,000 of additional shares of our common stock. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;7&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our consolidated financial data. We have derived the following summary of our consolidated statement of
operations data for the years ended December&nbsp;31, 2014, 2013 and 2012 and our consolidated balance sheet data as of December&nbsp;31, 2014 from our audited consolidated financial statements included in this prospectus. You should read this data
together with our audited consolidated financial statements and related notes and the information under the captions &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations,&#148; contained in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands, except share data</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Consolidated Statement of Operations Data:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Decrease in value of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total other (expense)&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Basic and diluted (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Weighted-average common shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,548,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Long-term debt (including current portion)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(121,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See notes 2 and 3 within the notes to our consolidated financial statements appearing elsewhere in this prospectus for a description of the method used to calculate basic and diluted net loss per share applicable to
common stockholders. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma balance sheet data give effect to (i) our draw of $15.0 million under the loan and security agreement that we entered into with Hercules Technology Growth Capital, Inc., or Hercules, and certain costs and
expenses related to our entry into the loan and security agreement, (ii) our use of $3.3 million of the proceeds from such draw to repay in full our outstanding indebtedness to Lighthouse Capital Partners VI, L.P., or Lighthouse, and certain fees
related to the repayment and (iii) our issuance and sale of 135,501 shares of our common stock to Hercules in a private placement for proceeds of $1.0 million, all of which occurred on January 8, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The as adjusted balance sheet data give effect to our issuance and sale of $50.0 million of shares of common stock being offered by us at an assumed public offering price of $9.73 per share, which was the last reported
sale price of our common stock on the NASDAQ Global Market on March 27, 2015, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;8&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks
described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. If any of the following risks occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product
development programs or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our ongoing activities,
particularly as we advance the clinical development of CRLX101 and CRLX301 and continue research and development and initiate additional clinical trials of, and seek regulatory approval for, these and other future product candidates. In addition, if
we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In particular, the costs that may be required for the
manufacture of any product candidate that receives marketing approval may be substantial, and manufacturing our nanoparticle-drug conjugates, or NDCs, for commercial sale will require expensive and specialized facilities, processes and materials.
Furthermore, relative to previous years when we operated as a private company, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in
connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to use our current cash and cash equivalents to fund our ongoing research and development efforts. We will be required to expend
significant funds in order to advance development of CRLX101, CRLX301 and our other potential product candidates. Our existing cash and cash equivalents will not be sufficient to fund all of the efforts that we plan to undertake, such as additional
randomized trials of CRLX101 or CRLX301. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations or licensing arrangements or other sources. Adequate and additional
funding may not be available to us on acceptable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2015, we entered into a loan and security agreement,
which we refer to as the Hercules Loan Agreement, with Hercules Technology Growth Capital, Inc., or Hercules, and drew the first tranche of $15.0&nbsp;million under the Hercules Loan Agreement. Although the Hercules Loan Agreement provides for two
additional tranches in an aggregate amount of up to $11.0 million that we may borrow if we meet certain clinical and financing milestones, we may fail to meet these conditions and be unable to obtain this funding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to obtain any additional debt financing, our ability to do so may be limited by covenants we have made under the Hercules Loan
Agreement and our pledge to Hercules of substantially all of our assets, other than our intellectual property, as collateral. We have also granted Hercules a negative pledge with respect to our intellectual property, which, among other things,
prohibits us from selling, transferring, assigning, mortgaging, pledging, leasing, granting a security interest in or otherwise encumbering our intellectual property. This negative pledge could further limit our ability to obtain additional debt
financing. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our cash and cash equivalents as of December&nbsp;31, 2014, plus the $15.0&nbsp;million in proceeds we borrowed from Hercules
under the first tranche of the Hercules Loan Agreement and the $1.0 million in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;9&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeds we received from the sale of our common stock to Hercules in a private placement transaction that was completed in connection with the Hercules Loan Agreement, will enable us to fund our
operating expenses, debt service and capital expenditure requirements into the third quarter of 2016. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our
future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and development requirements of the product candidates we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, timing, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs, timing and outcome of regulatory review of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or in-license other medicines and technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our headcount growth and associated costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and
conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product
sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all.
Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to technologies or product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through
a combination of public or private equity offerings, debt financings and/or license and development agreements with collaboration partners. In addition, we may seek additional capital due to favorable market conditions or strategic considerations,
even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be
materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our existing stockholders. Debt financing and preferred equity financing, if available, may involve agreements
that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, additional debt financing would result in increased fixed
payment obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise funds through collaborations, strategic partnerships or marketing, distribution or licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise
additional funds through equity or debt financings when needed, we may be required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;10&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop
and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing and any future indebtedness could adversely affect our ability to operate our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, we had $3.3 million of outstanding indebtedness under our loan and security agreement with Lighthouse Capital
Partners VI, L.P., or Lighthouse Capital. On January&nbsp;8, 2015, we entered into the Hercules Loan Agreement and drew the first tranche of $15.0 million. We used $3.6 million of the proceeds from our draw under the Hercules Loan Agreement to repay
in full our outstanding indebtedness under our loan and security agreement with Lighthouse Capital. As of February&nbsp;28, 2015, we had approximately $15.1 million in outstanding indebtedness under the Hercules Loan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our outstanding indebtedness combined with current and future financial obligations and contractual commitments, including any additional
indebtedness beyond our borrowings from Hercules, could have significant adverse consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requiring us to dedicate a portion of our cash resources to the payment of interest and principal, and prepayment and repayment fees and penalties, thereby reducing money available to fund working capital, capital
expenditures, product development and other general corporate purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing our vulnerability to adverse changes in general economic, industry and market conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents. Nevertheless, we may not
have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under our existing debt. Failure to make payments or comply with other covenants under our existing debt instruments could result in an event of
default and acceleration of amounts due. If an event of default occurs and Hercules accelerates the amounts due, we may not be able to make accelerated payments, and Hercules could seek to enforce security interests in the collateral securing such
indebtedness, which includes substantially all of our assets other than our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since
incorporation. We expect to incur losses over the next several years and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
incorporation, we have incurred significant operating losses. As of December&nbsp;31, 2014, we had an accumulated deficit of $121.8 million. We do not know whether or when we will become profitable. We have not generated any revenues to date from
product sales and have financed our operations primarily through the public offering of our common stock, private placements of our preferred stock, convertible debt financings and secured debt financings. We have not completed development of any
product candidate and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials. We expect to continue to incur significant expenses and operating losses over
the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders deficit and working capital.
We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate and continue company-sponsored clinical trials of CRLX101, our most advanced product candidate, including single-arm trials and randomized trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">support ongoing and any new investigator-sponsored clinical trials, or ISTs, of CRLX101; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;11&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our Phase 1 clinical trial of CRLX301, our second most advanced product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and preclinical development of additional product candidates utilizing our Dynamic Tumor Targeting Platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek regulatory approvals for any product candidates that successfully complete clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the future, establish a sales, marketing and distribution infrastructure in the United States and scale up external manufacturing capabilities to commercialize any products for which we may obtain regulatory
approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add equipment and physical infrastructure to support our research and development; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and
eventually commercializing products that generate significant revenue. We do not expect to generate significant revenue unless and until we are able to obtain marketing approval for, and successfully commercialize, one or more of our product
candidates. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval
for these product candidates, manufacturing, marketing and selling any products for which we may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government
payors. We are only in the preliminary stages of most of these activities and have not yet commenced other of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to
achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable
to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the United States Food and Drug Administration, or FDA, or the European Medicines Agency, or EMA, to
perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to
become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A
decline in the value of our company could cause our stockholders to lose all or part of their investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our planned expenditures
for the next several years, including, without limitation, expenditures in connection with our clinical trials of CRLX101 and CRLX301, our independent registered public accounting firm may conclude that there is substantial doubt regarding our
ability to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and no history of commercializing pharmaceutical products, which may
make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations to date have been limited to organizing and
staffing our company, developing and securing our technology, raising capital and undertaking preclinical studies and clinical trials of our product candidates. We have not yet demonstrated the ability to successfully complete development of any
product candidates, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently,
any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;12&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming we obtain marketing approval for any of our product candidates, we will need to
transition from a company with a research and development focus to a company capable of supporting commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the discovery and development of product candidates based on our Dynamic Tumor Targeting Platform is unproven, and we do not know whether
we will be able to develop any products of commercial value. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on applying our proprietary Dynamic Tumor Targeting
Platform to develop drugs that address serious unmet medical needs. We believe that our Dynamic Tumor Targeting Platform has the potential to create drugs that may have significant utility in several cancer indications, particularly in combination
with other cancer drugs and with radiotherapy. While the results of preclinical studies and early-stage clinical trials have suggested that certain of our product candidates may have such utility, we have not yet succeeded and may not succeed in
demonstrating efficacy and safety for any of our product candidates in later stage clinical trials or in obtaining marketing approval thereafter. For example, we have not yet advanced a compound beyond Phase 2 clinical development. Moreover, the
only compound for which we have completed a Phase 2 clinical trial, CRLX101 for the potential treatment of patients with advanced non-small cell lung cancer, or NSCLC, who had progressed through one or two prior regimens of chemotherapy, failed to
meet its primary endpoint of improvement in overall survival. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have never had a product candidate receive approval or
clearance from the FDA or a non-U.S. regulatory authority. While the FDA has approved nanoparticles such as Doxil<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (doxorubicin hydrochloride liposome injection) and Abraxane<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (nab-paclitaxel), to our knowledge, the FDA has not yet approved a polymeric nanoparticle such as our NDCs, which are a new way of targeting tumors. The regulatory review process for novel
product candidates, such as ours, can be more expensive and take longer than for product candidates based on more well-known or extensively studied technologies due to regulatory authorities&#146; lack of experience with them. As a result, we may be
required to conduct additional studies and/or trials beyond those we anticipate and it may take us longer to develop and/or obtain regulatory approval for our existing and any future product candidates than we expect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are particularly dependent on the success of our product candidate, CRLX101, and our ability to develop, obtain marketing approval for and
successfully commercialize CRLX101. If we are unable to develop, obtain marketing approval for or successfully commercialize CRLX101, either alone or through a collaboration, or experience significant delays in doing so, our business could be
materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and have invested a significant portion of our efforts and
financial resources in the development of CRLX101 for the treatment of patients with inadequately treated forms of cancer. Our prospects are substantially dependent on our ability to develop, obtain marketing approval for and successfully
commercialize CRLX101. The success of CRLX101 will depend, among other things, on our ability to successfully complete clinical trials of CRLX101. The clinical trial process is uncertain, and failure of one or more clinical trials can occur at any
stage of testing. For example, in 2011, we initiated an open-label, randomized Phase 2 clinical trial of CRLX101 as monotherapy in patients with advanced NSCLC who had progressed through one or two prior regimens of chemotherapy. In this Phase 2
clinical trial, CRLX101 failed to meet its primary endpoint of improvement in overall survival of the CRLX101-treated group as compared to the control arm of the study, which was best supportive care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the successful completion of clinical trials, the success of CRLX101 will also depend on several other factors, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA or other applicable regulatory authorities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;13&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of our future collaborators for CRLX101, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of supply arrangements with third party raw materials suppliers and manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of arrangements with third party manufacturers to obtain finished drug products that are appropriately packaged for sale; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protection of our rights in our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launch of commercial sales if and when approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of CRLX101 following any marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commercial acceptance, if and when approved, by patients, the medical community and third party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing and maintaining pricing sufficient to realize a meaningful return on our investment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition with other therapies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to develop, receive marketing approval
for, or successfully commercialize CRLX101, or experience delays as a result of any of these factors or otherwise, our business could be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, we may not achieve our clinical development on our anticipated
timeline, or at all, and our receipt of necessary regulatory approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to
initiate or continue clinical trials for CRLX101 or any of our other product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials. Patient enrollment is a significant factor in
the timing of clinical trials, and is affected by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and nature of the patient population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the severity of the disease under investigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected or serious adverse events that occur in the trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity of patients to sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the eligibility criteria for the trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">efforts to facilitate timely enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">investigators&#146; engagement with, or enthusiasm about, the trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complexity of initiating or expanding trials with sites outside of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing trials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the
indications we are investigating. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, with respect to our company-sponsored trial of CRLX101 in combination with
Avastin (bevacizumab) in patients with 3rd and 4th line relapsed renal cell carcinoma, or the RCC Trial, which we initiated in August 2014, site accrual was slower than expected, so we are adding additional sites with the goal of completing
enrollment according to plan; however, we may not be able to achieve this goal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;14&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for our clinical trials could result in
significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, delay or halt the development of and approval
processes for our product candidates and jeopardize our ability to achieve our clinical development timeline and goals, including the dates by which we will commence, complete and receive results from clinical trials. Enrollment delays may also
delay or jeopardize our ability to commence sales and generate revenues from our product candidates. Any of the foregoing could cause the value of our company to decline and limit our ability to obtain additional financing, if needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently pursuing the clinical development of CRLX101 in combinations with Avastin in relapsed renal cell carcinoma and relapsed ovarian cancer
and with capecitabine and radiotherapy in neoadjuvant rectal cancer and may focus on additional combinations in the future. If the FDA revokes its approval of, or if safety, efficacy, manufacturing or supply issues arise with, Avastin, capecitabine,
or any other therapeutic that we use in combination with CRLX101 in the future, we may be unable to market CRLX101 or may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are ongoing ISTs evaluating CRLX101 (1)&nbsp;in combination with Avastin in patients with renal cell carcinoma, or RCC, that has
relapsed, (2)&nbsp;in combination with Avastin in patients with relapsed ovarian cancer and (3)&nbsp;in combination with capecitabine and radiotherapy in patients with neoadjuvant rectal cancer. We have also commenced the RCC Trial, which is a
company-sponsored trial, and we expect to commence additional company-sponsored trials of CRLX101 in the future. Avastin is currently approved to treat various cancers, and the combination of capecitabine and radiotherapy is currently the standard
of care in neoadjuvant rectal cancer in the United States. However, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, Avastin or capecitabine. We may also seek to develop our product candidates in combination
with other therapeutics in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA revokes its approval of either Avastin or capecitabine, we will not be able to market
CRLX101 in combination with such revoked therapeutic. If safety or efficacy issues arise with Avastin or capecitabine or any other therapeutics that we seek to combine with our product candidates in the future, we may experience significant
regulatory delays, and the FDA may require us to redesign or terminate the applicable clinical trials. Moreover, if Avastin or capecitabine were to receive regulatory approval in combination with a different therapeutic in any indication for which
we are pursuing approval, such approval could impact the feasibility and design of any subsequent clinical trials that we may seek to conduct evaluating CRLX101 in combination with Avastin or capecitabine, as applicable. If capecitabine and
radiotherapy is replaced as the standard of care for treatment of neoadjuvant rectal cancer, the results, if any, of the ongoing IST or our planned company-sponsored clinical trial in neoadjuvant rectal cancer may be less meaningful, and the FDA may
require us to conduct additional clinical trials of CRLX101 prior to any regulatory approval in this indication. In addition, if manufacturing, cost or other issues result in a supply shortage of Avastin, capecitabine or any other combination
therapeutics, we may not be able to complete clinical development of CRLX101 on our current timeline or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if CRLX101 were to
receive regulatory approval and be commercialized for use in combination with Avastin or capecitabine or another therapeutic, we would continue to be subject to the risk that the FDA could revoke its approval of Avastin or capecitabine, that safety,
efficacy, manufacturing, cost or supply issues could arise with one of these therapeutic agents, or that capecitabine and radiotherapy may be replaced as the standard of care in patients with neoadjuvant rectal cancer. This could result in CRLX101
being removed from the market or being less successful commercially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2014, the FDA approved Genentech, Inc.&#146;s
supplemental Biologics License Application for Avastin plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. This approval may alter the regulatory and commercial landscape of ovarian cancer drug development.
We are commencing start-up activities for a Company-sponsored Phase 1b trial with the GOG Foundation, Inc. in which we will evaluate the combination of CRLX101 with weekly paclitaxel in patients with relapsed ovarian cancer.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;15&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Based on the data generated by that trial, we will further evaluate the regulatory requirements and the commercial opportunity for CRLX101 in relapsed ovarian cancer. It is possible that we will
determine that the threshold for regulatory approval is too high or that the commercial opportunity is too narrow and, for either reason, we might abandon our efforts to develop CRLX101 in relapsed ovarian cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our hypothesis regarding the role of HIF in cancer cells proves incorrect, it may adversely affect our ability to commercialize and market CRLX101.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the anti-cancer activity shown by CRLX101 in preclinical tumor models is due in part to its inhibition of HIF, and
we have prioritized the clinical development of CRLX101, among other criteria, on HIF-driven tumor types. While HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> has become a target of increasing interest in cancer research and recent research
suggests that HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is a master regulator for many cancer cell survival pathways, the science underlying HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is based on recent discoveries and not fully
understood. Moreover, the exact role of HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is less well described and understood. If our hypothesis with respect to the role of HIF in cancer cells proves incorrect, CRLX101 may not have the same
level of therapeutic benefit as it might otherwise have, and in that case we may be unable to receive marketing approval for, or successfully commercialize, CRLX101, and our business could be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two of our
product candidates are in clinical development, all of our other potential product candidates are in preclinical development, and the risk of failure of all of our product candidates is high. It is impossible to predict when or if any of our product
candidates will prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct
extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one
or more clinical trials can occur at any stage of testing. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy in a clinical
trial or across a broad population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable
non-U.S. regulatory authority that a drug product is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of
a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate
that is greater than the actual positive effect, if any. Similarly, in our clinical trials, we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well
tolerated when that is not in fact the case. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outcome of preclinical studies and early clinical trials may not be predictive of the
success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, although a Phase 1/2a clinical trial of CRLX101 supported advancement of CRLX101 as monotherapy into Phase 2 clinical
trials for patients with advanced NSCLC who had progressed through one or two prior regimens of chemotherapy, CRLX101 failed to meet its primary endpoint of improvement in overall survival of patients in this indication. Many companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we cannot be certain that we will not face additional setbacks. Moreover, there
are currently multiple open-label ISTs of CRLX101 ongoing, including: a Phase 1b/2 open-label IST of CRLX101 in combination with Avastin in patients with relapsed RCC; a two-part Phase 2 open-label IST in patients with relapsed ovarian cancer,
consisting of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;16&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
single-arm trial of CRLX101 as monotherapy and a single-arm combination trial of CRLX101 and Avastin; and a Phase 1b/2 open-label IST of CRLX101 in combination with chemoradiotherapy in patients
with neoadjuvant rectal cancer. Interim investigator-reported data from subsets of the total patient populations in certain of these ISTs have been reported. These ISTs are still in progress and final results are not yet available. The preliminary
results reported from the ISTs have in some cases been observed in only a small number of patients and may not be achieved by other patients on these or other clinical trials. There can be no assurance that company-sponsored trials will confirm the
data seen in the ISTs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The design of a clinical trial can determine whether its results will support approval of a product, and flaws in
the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing
approval. For example, we believe that sphincter preservation is a clinically meaningful endpoint for the treatment of neoadjuvant rectal cancer, but there can be no assurance that the FDA will agree. In addition, preclinical and clinical data are
often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product
candidates. Even if we believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable non-U.S. regulatory authorities may disagree and may not grant marketing approval of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of
the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols, variability in
the quality of clinical supply batches and the rate of dropout among clinical trial participants. Any Phase 2, Phase 3 or other clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval
to market our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience any of a number of possible unforeseen events in connection with clinical trials of our product
candidates, potential marketing approval or commercialization of our product candidates could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval of our product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates may produce unfavorable or inconclusive results, such as with our Phase 2 clinical trial of CRLX101 as monotherapy for patients with advanced non-small cell lung cancer who had
progressed through one or two prior regimens of chemotherapy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, patient enrollment in these clinical trials may be slower than we anticipate or participants may drop out
of these clinical trials at a higher rate than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third party contractors, including those manufacturing our product candidates or components or ingredients thereof or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet
their contractual obligations to us in a timely manner or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">investigators may deviate from the trial protocol, fail to conduct the trial in accordance with regulatory requirements or misreport study data; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may experience delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;17&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prospective clinical trial sites may be unwilling to participate in one or more of our combination clinical trials due to a perceived difficulty in obtaining reimbursement from managed care plans, government, or other
third party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patients who enroll in a clinical trial, or the investigators enrolling such patients, may misrepresent the patients&#146; eligibility to participate in the trial or may otherwise not comply with the clinical trial
protocol, resulting in the need to drop the patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial&#146;s duration; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for any given trial we may find it necessary to open more clinical trial sites than originally planned; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks, unexpected or serious adverse
events or other unexpected characteristics of a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their respective
standards of conduct, a finding that the participants are being exposed to unacceptable health risks, unexpected or serious adverse events or other unexpected characteristics of the product candidate or other therapeutic agents used in our clinical
trials or findings of undesirable effects caused by a chemically or mechanistically similar drug or drug candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or comparable non-U.S. regulatory authorities may disagree with our clinical trial design or our interpretation of data from preclinical studies and clinical trials, or may change the requirements for approval
even after it has reviewed and commented on the design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or comparable non-U.S. regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third party manufacturers with which we enter into agreements for
clinical and commercial supplies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an
acceptable cost, or we may experience interruptions in supply; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval policies or regulations of the FDA or comparable non-U.S. regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product development costs for us will increase if we experience delays in testing or pursuing marketing approvals and we
may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be
restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors
to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays
may ultimately lead to the denial of marketing approval of any of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have conducted and intend to conduct additional
clinical trials for certain of our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted, currently are conducting and intend in the future to conduct, clinical trials outside the United States. Opening trial sites
outside of the United States may involve additional regulatory, administrative and financial burdens, including compliance with foreign and local requirements relating to regulatory submission and clinical trial practices. For example, in late 2014,
we commenced in Australia the Phase 1 portion of a Phase 1/2a clinical trial of CRLX301 in patients with advanced solid tumor malignancies. In addition, we are expanding the RCC Trial to South Korea where we expect to have additional clinical sites
open in the second quarter of 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;18&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA may accept data from clinical trials conducted outside the United States,
acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with good clinical practices, including review
and approval by an independent ethics committee and informed consent from trial patients. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in
ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for which we intend to seek approval in the United States. In
addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. Since we currently do
not have an active IND in the United States for CRLX301, unless we are able to obtain an active IND, we would be unable to conduct clinical trials in the United States. There can be no assurance that the FDA will accept data from trials conducted
outside of the United States and no assurance that we will be successful in obtaining an IND for CRLX301. If the FDA does not accept the data from our Phase 1/2a clinical trial of CRLX301 in Australia, for example, or any other trial that we conduct
outside the United States, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our development of CRLX101, CRLX301 or any future other product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting
international clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign regulatory requirements that could burden or limit our ability to conduct our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administrative burdens of conducting clinical trials under multiple foreign regulatory schema; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign exchange fluctuations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing, customs, shipment and storage requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cultural differences in medical practice and clinical research; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diminished protection of intellectual property in some countries. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials of our product
candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable non-U.S. regulators, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of these product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not permitted to commercialize, market, promote or sell any product
candidate in the United States without obtaining marketing approval from the FDA. Comparable non-U.S. regulatory authorities, such as the EMA, impose similar restrictions. We may never receive such approvals. We must complete extensive preclinical
development and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome.
We have not previously submitted a new drug application, or an NDA, to the FDA or similar drug approval filings to comparable non-U.S. regulatory authorities for any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical and clinical development could result in additional costs to us and impair our ability to
generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if (1)&nbsp;we are required to conduct additional clinical trials or other testing of our product candidates beyond the trials and testing
that we contemplate, (2)&nbsp;we are unable to successfully complete clinical trials of our product candidates or other testing, (3)&nbsp;the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or
(4)&nbsp;there are unacceptable safety concerns associated with our product candidates, we, in addition to incurring additional costs, may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;19&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as we intended or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing or other requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be required to remove the product from the market after obtaining marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A fast track
designation by the FDA may not actually lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek fast
track designation for some of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may
apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to
grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation
is no longer supported by data from our clinical development program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A breakthrough therapy designation by the FDA for our product candidates may
not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug that is
intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on
one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA
and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also
eligible for accelerated approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we
believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a
product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of
our product candidates qualifies as a breakthrough therapy, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may request Priority Review or Accelerated Approval for one or more of our product candidates at the time of the submission of the NDA to FDA. The
FDA may not grant Priority Review or Accelerated Approval for any of our product candidates. Moreover, even if the FDA designated Priority Review for one of our product candidates, that designation may not lead to a faster regulatory review or
approval process and, in any event, would not assure FDA approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A ten month standard NDA review clock will begin at the
conclusion of the 60 calendar day filing review period that starts on the date of FDA receipt of the original submission. This results in a total of twelve months until the FDA is to take regulatory action. We may be eligible for Priority Review
designation for our NDA submission if the FDA determines that our product candidate treats a serious condition and, if approved, would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;20&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide a significant improvement in safety or effectiveness. The six month Priority Review clock will begin at the conclusion of the 60 calendar day filing review period that starts on the date
of FDA receipt of the original submission. Therefore, if granted Priority Review, the FDA has a total of eight months to take action on an application rather than the total of twelve months for a standard review from their receipt of the original
submission. We may request Priority Review for CRLX101 if and when we submit an NDA for CRLX101. Our current clinical development timeline assumes CRLX101 will receive Priority Review. The FDA has broad discretion with respect to whether or not to
grant Priority Review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Thus, while the FDA has granted Priority Review to other
oncology product candidates, CRLX101 may not receive similar designation. Moreover, even if CRLX101 or one of our other product candidates is designated for Priority Review, such a designation does not necessarily mean a faster regulatory review
process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving Priority Review from the FDA also does not guarantee approval within the eight-month review/approval cycle or thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We believe we may in some instances be able to secure approval from the FDA or comparable non-U.S. regulatory authorities to use accelerated
registration pathways. If unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of,
necessary marketing approvals. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we may seek an Accelerated Approval development pathway for certain of our
product candidates and indications. Under the Accelerated Approval provisions in the Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA&#146;s implementing regulations, the FDA may grant Accelerated Approval to a product designed to treat a
serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to
predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of Accelerated
Approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical
endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The Accelerated
Approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted,
Accelerated Approval is contingent on the sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#146;s clinical profile or risks and benefits for Traditional
Approval. If such post-approval studies fail to confirm the drug&#146;s clinical profile or risks and benefits, the FDA may withdraw its approval of the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we choose to pursue Accelerated Approval, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and
receive such Accelerated Approval. There can be no assurance that the FDA will agree that our endpoint is an appropriate surrogate endpoint. There can also be no assurance that after our evaluation of the feedback and other factors we will decide to
pursue or submit an NDA for Accelerated Approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback that we will continue to pursue or apply for Accelerated
Approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for Accelerated Approval, there can be no assurance that such submission or application
will be accepted or that any expedited review or approval will be granted on a timely basis, or at all. The FDA or other non-U.S. authorities could also require us to conduct further studies prior to considering our application or granting approval
of any type. Even if the FDA agreed that we could pursue an Accelerated Approval registration pathway, we might not be able to fulfill the FDA&#146;s requirements with respect to chemistry, manufacturing and controls, or CMC, in a timely manner,
which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;21&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to obtain Accelerated Approval or any other form of expedited development, review or
approval for our product candidates would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Serious adverse events of CRLX101 or any of our product candidates may be identified during clinical development. Further, other unexpected
properties of our product candidates may be identified during manufacture or development. Such adverse events or unexpected properties could delay or prevent the continued development and/or marketing approval of any such product candidate.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Serious adverse events caused by, or other unexpected properties of, our product candidates could cause us, an institutional
review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable non-U.S.
regulatory authorities. If any of our product candidates is associated with serious adverse events or other unexpected properties, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in
which those undesirable characteristics would be expected to be less prevalent, less severe or more tolerable from a risk-benefit perspective. If we learn that the manufacture of our product candidates generates unexpected impurities or product
degradants, these properties could contribute to serious adverse events and our overall development cost and timelines as we address those properties. Many compounds that initially showed promise in clinical or earlier stage testing have later been
found to cause serious or unexpected adverse events and negatively affect overall development costs and timelines, which may even prevent further development of the compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both camptothecin, the anti-cancer payload of CRLX101, and docetaxel, the anti-cancer payload of CRLX301, have been associated with
toxicities. These toxicities led to discontinuation of the clinical development in the case of camptothecin and have led to dose adjustments, treatment discontinuation and extensive supportive care in the case of docetaxel. While we believe that our
Dynamic Tumor Targeting Platform has the potential to improve the unfavorable adverse event profiles of both camptothecin and docetaxel, if this hypothesis is wrong and we experience unexpected or more severe toxicities in our ongoing clinical
trials or in clinical trials we conduct in the future, whether due to the inclusion of camptothecin or docetaxel or another therapeutic as the anti-cancer payload in our NDCs or otherwise, we may not receive approval to market, or achieve commercial
success with respect to, any of our product candidates, which could prevent us from ever generating revenues or achieving profitability. In addition, our Dynamic Tumor Targeting Platform may have other limitations with respect to targeting tumors
and limiting exposure of normal tissue to our NDCs&#146; anti-cancer payload. For example, liver tissue has pore sizes that are generally larger than other normal tissue, and therefore, our NDCs and their anti-cancer payloads may preferentially
concentrate in the liver. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to identify or discover additional potential product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of new NDCs based on our Dynamic Tumor Targeting Platform is a key area of research for us. The drug discovery that we are
conducting using our Dynamic Tumor Targeting Platform may not be successful in creating compounds that have commercial value or therapeutic utility. Our research programs may initially show promise in creating potential product candidates, yet fail
to yield viable product candidates for clinical development for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">newly designed NDCs may not demonstrate satisfactory efficacy or other benefits, either alone or in combination with other therapeutics; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product candidates may, on further study, be shown to have harmful toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve
market acceptance. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research programs to identify new product candidates will require substantial technical, financial
and human resources. We may be unsuccessful in our efforts to identify new potential product candidates. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;22&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, we may focus our efforts and resources on one or more potential product candidates that ultimately prove to be unsuccessful. If we are unable to identify suitable additional compounds
for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock
price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if one of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians,
patients, third party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never commercialized a product. Even if CRLX101 or any of our other product candidates is approved by the appropriate regulatory
authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third party payors and others in the medical community. For example, physicians are often reluctant to switch their patients
from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians
recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to
educate the medical community and third party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market
acceptance, we may not generate significant revenues and may not become profitable. The degree of market acceptance of CRLX101 or any of our other product candidates, if approved for commercial sale, will depend on a number of factors, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential advantages of the product compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product is approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings, including distribution or use restrictions, contained in the product&#146;s approved labeling; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to offer the product for sale at competitive prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain pricing sufficient to realize a meaningful return on our investment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the product&#146;s convenience and ease of administration compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of the target patient population to try, and of physicians to prescribe, the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of sales, marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of alternative treatments already approved or approval of other new products for the same indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the standard of care for the targeted indications for the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of our approved products as well as competitive products and other therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability and amount of reimbursement from government payors, managed care plans and other third party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength and efficacy of our marketing and distribution efforts; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;23&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse publicity about the product or favorable publicity about competitive products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product liability claims. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential market opportunities for our product
candidates are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many assumptions, including industry knowledge and publications, third party research reports and other surveys. While we believe
that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent
source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed
or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials.
Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or, alternatively, fail to identify undesirable side effects. If,
following approval of a product candidate, we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw their approval of the drug or seize the drug; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to recall the drug or change the way the drug is administered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as a &#147;black box&#148; warning or a contraindication; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the drug may become less competitive; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could have a material and adverse effect on
our operations and business and could adversely impact our stock price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales, marketing and distribution
capabilities or enter into acceptable sales, marketing and distribution arrangements with third parties, we may not be successful in commercializing any product candidates that we develop, if and when those product candidates are approved.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a sales, marketing or distribution infrastructure and have limited experience in the sale, marketing or
distribution of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. If approved, we expect to commercialize our
lead product candidates in the United States directly with a small and highly focused commercialization organization. The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and
could delay any product launch. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;24&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expect that we will commence the development of these capabilities prior to receiving approval of any of our product candidates. If the commercial launch of a product candidate for which we
recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur for any reason, we could have prematurely or unnecessarily incurred these commercialization costs. Such a delay may be costly, and our
investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire or retain a sales force in the United States that is sufficient in size or has adequate expertise in the medical
markets that we plan to target. If we are unable to establish or retain a sales force and marketing and distribution capabilities, our operating results may be adversely affected. If a potential partner has development or commercialization expertise
that we believe is particularly relevant to one of our products, then we may seek to collaborate with that potential partner even if we believe we could otherwise develop and commercialize the product independently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to seek one or more strategic partners for commercialization of our product candidates outside the United States. As a result of
entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues may be lower, perhaps substantially lower, than if we were to directly market
and sell products in those markets. Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on terms that are favorable to us. In addition, we may have little or no control over
such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not establish sales and marketing capabilities, either on our own or in collaboration with third parties, we will not be successful
in commercializing any of our product candidates that receive marketing approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition from other pharmaceutical and
biotechnology companies and our operating results may suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and
commercialization of new drug products is highly competitive. We expect that we will face significant competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to CRLX101,
CRLX301 and any other future product candidates that we may seek to develop or commercialize. Specifically, due to the large unmet medical need, global demographics and relatively attractive reimbursement dynamics, the oncology market is fiercely
competitive and there are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of cancer. Our competitors may succeed in
developing, acquiring or licensing technologies and drug products that are more effective, have fewer or more tolerable adverse events or are less costly than any product candidates that we are currently developing or that we may develop, which
could render our product candidates obsolete and noncompetitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several companies are marketing and developing oncology products.
Companies with marketed nanoparticle oncology products include Celgene Corporation (Abraxane indicated for breast cancer, NSCLC and pancreatic cancer), Janssen (Doxil<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for ovarian cancer and,
in combination with botezomib, for multiple myeloma) and Spectrum Pharmaceuticals (Marqibo <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (vincristine sulfate liposome injection) indicated for relapsed Philadelphia chromosome-negative
acute lymphoblastic leukemia). Companies with nanoparticle oncology product candidates in clinical development include BIND Therapeutics, Inc. (BIND 014 for NSCLC and metastatic castration-resistant prostate cancer), Nippon Kayku Seizo Co., Ltd.
(NK105 in breast cancer), Celator Pharmaceuticals, Inc. (CPX-351 for acute myeloid leukemia), Celsion Corporation (ThermoDox <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (lyso-thermosensitive liposomal doxorubicin) for solid tumors),
Cytimmune Sciences, Inc. (CYT-6091 for oncology and autoimmune diseases) and Supratek Pharma Inc. (SP1049C for solid tumors). In addition, at least two companies have clinical-stage oncology product candidates that are irinotecan reformulations:
Merrimack Pharmaceuticals&#146; liposomal irinotecan (MM-398 for pancreatic and colorectal cancer) and Nektar Therapeutics&#146; etirinotecan pegol (NKTR102 for breast cancer). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;25&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their
product candidates before we are able to obtain approval for our product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market. The competition for CRLX101 in our targeted
indications includes the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Renal Cell Carcinoma. </I>In advanced RCC, several drugs in development have the potential to
obtain FDA marketing approval and change the standard of care. If this occurs, currently available treatments could be replaced or altered and our commercial opportunity could be reduced. For example, Exelixis, Inc. is developing cabozantinib in
advanced RCC and the data from its ongoing phase 3 trial are anticipated in 2015. Acceleron Pharma Inc. is developing dalantercept in combination with axitinib, and TRACON Pharmaceuticals, Inc. is developing TRC105, also in combination with
axitinib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these tyrosine kinase inhibitor and tyrosine kinase inhibitor combination programs in advanced RCC, immune
checkpoint inhibitors, including nivolumab and pembrolizumab, are also being developed in RCC. Although these product candidates are being tested for earlier lines of therapy, they also have the potential to change the standard of care in advanced
RCC, which, among other things, could result in existing first line therapies being prescribed instead for later lines of therapy. If this occurs, it would potentially reduce the commercial opportunity for CRLX101 in relapsed RCC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Relapsed Ovarian Cancer.</I> In relapsed ovarian cancer, the recent FDA approvals of Avastin with chemotherapy and Lynparza<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in BRCA mutated patients has changed the standard of care, which could reduce the commercial opportunity for CRLX101. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Neoadjuvant Rectal Cancer. </I>In neoadjuvant rectal cancer, Isofol Medical AB is developing a molecule that is currently labeled [6R]
5,10-methylenetetrahydrofolate; Karyopharm Therapeutics Inc. is developing Selinexor in combination with chemoradiotherapy; Merck KGaA is developing tecemotide with chemoradiotherapy; Genentech, Inc. is testing Avastin in combination with
capecitabine; and Kadmon Corporation, LLC is developing KD018 in combination with capecitabine and radiation. If any of these product candidates receives marketing approval, our commercial opportunity in neoadjuvant rectal cancer could be reduced.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our existing and potential future competitors have significantly greater financial resources and expertise in research and
development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even
more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA or comparable non-U.S. regulatory authorities approve generic versions of any of our products that receive
marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an NDA is approved, the product covered thereby becomes a &#147;reference listed drug&#148; in the FDA&#146;s publication, &#147;Approved
Drug Products with Therapeutic Equivalence Evaluations.&#148; Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an
ANDA, a generic manufacturer need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;26&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed
in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices.
Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be typically lost to the generic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has
expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. Specifically, in cases in which such exclusivity has been granted, an ANDA may not be filed with the FDA until the
expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit
its application four years following approval of the reference listed drug. While we believe that CRLX101 and certain of our other NDCs would be treated as new chemical entities by the FDA and, therefore, if approved, should be afforded five years
of data exclusivity, the FDA may disagree with that conclusion and may approve generic products after a period that is less than five years. Manufacturers may seek to launch these generic products following the expiration of the applicable marketing
exclusivity period, even if we still have patent protection for our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition that our products may face from generic versions
of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CRLX301 is, and any additional product candidate that we may develop in the future may be, an NDC that includes a generically available therapeutic as
its anti-cancer payload. If physicians and/or third party payors do not believe our product offers substantial advantages over other therapies incorporating the same generic anti-cancer payload, we may not be able to successfully commercialize our
product. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have intellectual property rights, including composition of matter patents, covering our product candidates,
if approved, we expect that our product candidates will compete in the same indications against other nanoparticles and delivery platforms incorporating the same generic therapeutics. In particular, if any of our product candidates is approved and
becomes commercially successful, other companies may intensify their efforts to develop a competing product that includes the corresponding generic therapeutic. If physicians, rightly or wrongly, do not believe that a product that we develop offers
substantial advantages over another nanoparticle or delivery platform incorporating the same generic therapeutic, physicians might not prescribe our product. In addition, third party payors might refuse to provide reimbursement for a product that we
develop when another nanoparticle or delivery platform incorporating the same generic therapeutic offers a cheaper alternative therapy in the same indication, or might otherwise encourage use of another nanoparticle or delivery platform
incorporating the same generic therapeutic over our product, even if our product possesses favorable pharmaceutical properties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able
to commercialize any product candidate that we develop, the product may become subject to unfavorable pricing regulations, third party payor reimbursement practices or healthcare reform initiatives that could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of
our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other
third party payors. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high
enough to allow us to establish and maintain pricing sufficient to realize a meaningful return on our investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;27&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to third party payor coverage and reimbursement of newly
approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review
period begins after marketing or product licensing approval is granted. In some non-U.S. markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might
obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to
generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize CRLX101 or any other product candidate will depend in part on the extent to which coverage and reimbursement for
these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third party payors, such as private health insurers and health
maintenance organizations, decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and third party
payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. These payors may not view our products, if any, as
cost-effective, and coverage and reimbursement may not be available to our customers, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us to decrease the price we
might establish for products, which could result in lower than anticipated product revenues. If the prices for our products, if any, decrease or if governmental and other third party payors do not provide adequate coverage or reimbursement, our
prospects for revenue and profitability will suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may also be delays in obtaining coverage and reimbursement for newly approved
drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable non-U.S. regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases
or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement
rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, increasingly, third party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new
technologies and are challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net
reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly
obtain coverage and adequate payment rates from both government-funded and private payors for any our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise
capital needed to commercialize products and our financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could divert our resources, cause us to
incur substantial liabilities and limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product
liability claims as a result of the clinical testing of our product candidates despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we commercially sell any product that we may
develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of
defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;28&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur
substantial liabilities or be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates or products that we may develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant costs to defend resulting litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced resources of our management to pursue our business strategy; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any products that we may develop. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain general
liability insurance of $2.0 million in the aggregate, umbrella insurance in the amount of $3.0 million in the aggregate and clinical trial liability insurance of $7.5 million in the aggregate, this insurance may not fully cover potential liabilities
that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if and when we begin selling any product candidate that
receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability
claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct ISTs of some of our product candidates. Any failure by a third party to meet its obligations with respect to the
clinical development of our drug candidates may delay or impair our ability to obtain regulatory approval for our&nbsp;product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on academic institutions to conduct and sponsor clinical trials relating to some of our product candidates. We do not control the
design or administration of ISTs, and our reliance on third parties to conduct the ISTs could, depending on the actions of such third parties, jeopardize the validity of the clinical data generated and adversely affect our ability to obtain
marketing approval from the FDA or other applicable regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such arrangements provide us with certain information rights
with respect to the ISTs, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we do not control patient enrollment in, or the timing
and reporting of the data from, ISTs, nor do we own the data from the ISTs. Moreover, if we are unable to confirm or replicate the results from the ISTs or if negative results are obtained in the ISTs, we would likely be further delayed or prevented
from advancing further clinical development of our drug candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our drug candidates, or if the data proves to be inadequate, then our
ability to design and conduct any future clinical trials ourselves may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or non-U.S. regulatory authorities
may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by ISTs, or our interpretation of preclinical, manufacturing or clinical data from ISTs. If so, the FDA or other non-U.S.
regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;29&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials and/or may not accept such additional data as adequate to initiate our planned trials. Moreover, there will be no independent review of the results of the ISTs. Therefore, the
investigators may interpret the results of the ISTs more favorably than an independent review would. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, ISTs of our product
candidates may continue even after we commence company-sponsored trials in the same or different indications. To the extent the results of these ISTs are inconsistent with, or different from, the results of our company-sponsored trials, the FDA or a
non-U.S. regulatory authority may question the results of the company-sponsored trial, or subject such results to greater scrutiny than it otherwise would. In these circumstances, the FDA or such other non-U.S. regulatory authorities may require us
to obtain and submit additional clinical data, which could delay clinical development or marketing approval of the applicable product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on third party clinical research organizations, or CROs, to conduct our clinical trials. We expect to continue to rely on
third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. Our agreements with these third parties generally allow the third party to terminate the agreement
at any time. If we are required to enter into alternative arrangements because of any such termination the introduction of our product candidates to market could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve
us of our responsibilities. For example, we design our clinical trials and will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover,
the FDA requires us to comply with standards, commonly referred to as good clinical practices for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the
rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. We also are required to register ongoing clinical trials
and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties
do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining,
marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the
part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to enter into collaborations with third parties for the development and commercialization of our product candidates. If we fail to enter
into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek third-party collaborators for development and commercialization of our product candidates. Our likely collaborators for any
marketing, distribution, development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We are not currently party to any
such arrangement. However, if we do </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;30&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enter into any such arrangements with any third parties in the future, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the
development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations involving our product candidates would pose the following risks to us: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the
collaborators&#146; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are
more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or
arbitration that diverts management attention and resources; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a
collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to establish collaborations, we may have to alter our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund
expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend,
among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;31&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United
States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our
ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or
technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from
entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large
pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate
collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs,
delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to
fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our
product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of our product
candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an
acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or
operate manufacturing facilities for the production of clinical quantities of CRLX101 or CRLX301 and have limited personnel with manufacturing experience. We currently rely on and expect to continue to rely on third party contract manufacturers to
manufacture supplies of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX101 and CRLX301 must be manufactured through complex, multi-step synthesis processes that are time-consuming and involve special
conditions at certain stages. Drug substance manufacture requires high potency containment, and drug product manufacture requires high potency containment under aseptic conditions, also referred to as sterile manufacture. In 2013, we experienced a
batch contamination issue with the manufacture of a batch of CRLX301 drug substance, and the process of obtaining a new batch required several months to complete. Any additional performance failures on the part of our existing or future
manufacturers could delay clinical development or marketing approval of our product candidates or result in our inability to generate sufficient supplies to meet commercial demands. Although we currently have backup suppliers for several stages of
the manufacturing process, we rely on one supplier for each stage of this process. If our current contract manufacturers cannot perform as agreed, or become unavailable to us for any reason, we may be required to replace such manufacturers. Our
agreements with our third party manufacturers can be terminated by us or such manufacturers on short notice. If any of our existing manufacturers should become unavailable to us for any reason or should be unable to secure additional manufacturing
capacity in the event of higher than anticipated product demand, we may incur additional cost or delay in identifying or qualifying replacements. In addition, while we believe that our existing supplier of drug substance or an alternative supplier
would be capable of continuing to produce drug substance in commercial quantities, we will need to identify a third-party manufacturer capable of providing commercial quantities of drug product. If we are unable to arrange for such a third-party
manufacturing source, or fail to do so on commercially reasonable terms, we may not be able to successfully produce and market CRLX101 or any other product candidate or may be delayed in doing so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;32&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to establish such arrangements with third party manufacturers, reliance on
third party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reliance on the third party for regulatory compliance and quality assurance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of manufacturers to consistently produce intermediates, drug substance or drug product that meet required quality specifications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of the manufacturing agreement by the third party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory
requirements outside the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, our
ability to secure and/or maintain regulatory approval for our product candidates could be adversely affected. Our failure, or the failure of our third party manufacturers, to comply with applicable regulations could result in sanctions being imposed
on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of
which could significantly and adversely affect supplies of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX101, CRLX301 and any future product candidates that we may
develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we generally rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product
candidates for our clinical studies. There are a small number of suppliers for certain capital equipment and raw materials that are used in the manufacture of our drugs. Such suppliers may not sell these raw materials to our manufacturers at the
times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial
production of these raw materials. Any significant delay in the supply of a product candidate or the raw material components thereof for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay
completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product
candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit
margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;33&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not
sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect
to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances,
we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted
and enforced in a manner consistent with the best interests of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of non-U.S. countries may not protect our rights to the same extent as the laws
of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, and in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the
inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and
commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not issue as patents that protect our technology or products, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our owned or licensed issued patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United
States patent law. The Leahy-Smith Act includes provisions that affect the way patent applications are prosecuted and affect patent litigation. The United&nbsp;States Patent and Trademark Office, or USPTO, recently developed new regulations and
procedures to govern administration of the Leahy-Smith Act. However, many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&nbsp;16, 2013.
Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned
or licensed patent applications and the enforcement or defense of our owned or licensed issued patents, all of which could have a material adverse effect on our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to third party preissuance submissions of prior art to the USPTO, or become involved in opposition, derivation,
reexamination, inter partes review, post-grant review or interference proceedings challenging our owned or licensed patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce
the scope of, or invalidate, our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;34&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize
products without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or
commercialize current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our owned and licensed patent applications issue as patents, they may not
issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by
developing similar or alternative technologies or products in a non-infringing manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to
its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate, or in
patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent
protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our owned or licensed patents or other intellectual property. To counter infringement or
unauthorized use, we may be required to file or participate in infringement claims, which can be expensive and time consuming. Any claims we or our licensors assert against perceived infringers could provoke these parties to assert counterclaims
against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our licensor is invalid or unenforceable, in whole or in part, construe the patent&#146;s claims
narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or licensed
patents at risk of being invalidated or interpreted narrowly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CRLX101 and certain aspects of our platform technology are protected by patents
assigned by or exclusively licensed from other companies or institutions. If these third parties terminate their agreements with us or fail to maintain or enforce the underlying patents, or we otherwise lose our rights to these patents, our
competitive position and our market share in the markets for any of our approved products will be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to
several license agreements and certain aspects of our business depend on patents and/or patent applications owned by other companies or institutions. In particular, we hold exclusive licenses from Calando Pharmaceuticals, Inc., or Calando, and
California Institute of Technology, or Caltech and have been assigned certain patents from Calando for CRLX101, CRLX301 and cyclodextrine polymer-based, or CDP-based, product candidates. We also hold an exclusive license from the State University of
New York, or SUNY, related to taxane-containing NDCs, such as CRLX301. In addition, we hold an exclusive license from the Massachusetts Institute of Technology, or MIT, for polymeric NDC-based, or PNP-based, product candidates. We are likely to
enter into additional license agreements as part of the development of our business in the future. If we are unable to maintain these patent rights for any reason, our ability to develop and commercialize our product candidates could be materially
harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our licensors may not successfully prosecute certain patent applications under which we are licensed and on which our business
depends. Even if patents issue from these applications, our licensors may fail to maintain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;35&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these patents, may decide not to pursue litigation against third party infringers, may fail to prove infringement, or may fail to defend against counterclaims of patent invalidity or
unenforceability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risks with respect to parties from whom we have obtained intellectual property rights may also arise out of
circumstances beyond our control. For example, in March 2014, Calando entered Chapter 7 bankruptcy and, as a result, the intellectual property rights we have obtained from Calando are subject to potential risks that may arise in connection with
bankruptcy. For instance, while our ability to develop and/or commercialize our current product candidates and our ability to utilize our platform are not dependent on the rights that we license from Calando, our license agreements with Calando
could be rejected in connection with Calando&#146;s bankruptcy, in which case, we could, subject to elections and other rights and defenses that may be available to us, lose certain rights granted to us under such licenses. On March&nbsp;3, 2015,
Calando&#146;s bankruptcy trustee submitted an application with the bankruptcy court seeking authority to retain a broker to sell Calando&#146;s rights in certain assets including its rights in the license agreements with Cerulean. We have reserved
our rights with respect to any such sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in spite of our best efforts, our licensors might conclude that we have materially
breached our intellectual property agreements and might therefore terminate the intellectual property agreements, thereby removing our ability to obtain regulatory approval and to market products covered by these intellectual property agreements. If
our intellectual property agreements are terminated, or if the underlying patents fail to provide the intended market exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products similar or identical to
ours. Moreover, if our intellectual property agreements are terminated, our former licensors and/or assignors may be able to prevent us from utilizing the technology covered by the licensed or assigned patents and patent applications. For example,
under our agreements with Calando, which relate to CRLX101 and our CDP platform, if we fail to meet our payment obligations and do not adequately cure such failure, or if we terminate one or both of these agreements, other than for specified safety
concerns, we are required to grant Calando an exclusive (even as to Cerulean), royalty-free license under the patent rights assigned pursuant to such terminated agreement and to assign the related IND to Calando. Moreover, if we fail to meet our
diligence obligations under one or both of our agreements with Calando, Calando may convert the license to a non-exclusive license, and we will be required to grant Calando a non-exclusive license under the patent rights assigned to us pursuant to
such terminated agreement. This could have a material adverse effect on our competitive business position and our business prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to
comply with our obligations in our intellectual property agreements with third parties, we could lose rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to multiple intellectual property agreements that impose, and we may enter into additional intellectual property agreements that
may impose, various diligence, milestone payment, royalty and other obligations on us. Under our existing intellectual property agreements, we are obligated to pay royalties on the net sales of product candidates or related technologies to the
extent they are covered by the agreement. We also have diligence and development obligations under those agreements. If we fail to comply with our obligations under current or future intellectual property agreements, our counterparties may have the
right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product that is covered by the agreement or face other penalties under the agreement. Such an occurrence could materially adversely affect
the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with
less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;36&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some intellectual property which we have licensed may have been discovered through government funded
programs and thus may be subject to federal regulations such as &#147;march-in&#148; rights, certain reporting requirements, and a preference for United States industry. Compliance with such regulations may limit our exclusive rights, subject us to
expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the intellectual property rights we have licensed may have been generated through the use of United States government funding and may
therefore be subject to certain federal regulations. For example, some of the intellectual property rights licensed to us under the MIT agreement, and which are relevant to our PNP-based NDCs, may have been generated using United States government
funds. In addition, some of the intellectual property rights licensed to us under the SUNY agreement and which are relevant to taxane containing NDCs such as CRLX301 may have been generated using United States government funds. As a result, the
United States government may have certain rights to intellectual property embodied in our current or future PNP-based products or in CRLX301 pursuant to the Bayh-Dole Act of 1980. These United States government rights in certain inventions developed
under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States government has the right to require us to grant exclusive,
partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet public
health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#147;march-in rights&#148;). The United States government also has the right to take title to
these inventions if we fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the United States government may acquire title to these
inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require
us to expend substantial resources. In addition, the United States government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The
manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to
manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may limit our ability to contract with non-U.S. product manufacturers
for products covered by such intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not plan to apply for additional United States government funding,
but if we do, and we discover compounds or drug candidates as a result of such funding, intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh-Dole Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
and could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends upon our ability to
develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and
pharmaceutical industries. We may become party to, or be threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation
proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to infringe a third party&#146;s intellectual property rights, we could be required to obtain a license from such third party
to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;37&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease
commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could
prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that we or our employees have
misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our
employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or
know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s former employer.
Litigation may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors
who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in timely obtaining such an agreement with each party who in fact develops intellectual property
that we regard as our own. Even if timely obtained, such agreements may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our
intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail in prosecuting or defending any such claims, we may lose valuable intellectual property rights or
personnel, in addition to paying monetary damages. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to
incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating
losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could compromise our ability to compete in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our
business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and product
candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and
confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;38&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our
proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. Even if we are successful in prosecuting such claims, any remedy awarded may be insufficient to fully compensate us for the improper disclosure or misappropriation. In addition, some courts inside
and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they
communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary clinical trials, the marketing approval process is expensive, time consuming and uncertain and may prevent us from
obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates,
and our ability to generate revenue will be materially impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates and the activities associated with their
development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and
other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. Our
product candidates are in the early stages of development and are subject to the risks of failure inherent in drug development. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We
have only limited experience in conducting and managing the clinical trials, and in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third party CROs to assist us in this process. Securing marketing
approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing marketing
approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective
or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are indicated only for patient
populations that have not responded to an existing therapy or have relapsed. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if
additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval
policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application.
Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition,
varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or
post-approval commitments that render the approved product not commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining approval or if
we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;39&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materially impaired. For example, if the regulatory landscape in the United States, Europe or Asia shifts unexpectedly, it may adversely affect the feasibility of study arms, standards of care or
statistical assumptions currently reflected in our clinical development plans for CRLX101, potentially delaying the development of CRLX101 in a particular indication and increasing the time required to obtain marketing approval for CRLX101. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market and sell our products in the European Union and many other jurisdictions, we must obtain separate marketing approvals and
comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The
regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement
before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in
other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing
approvals and may not receive necessary approvals to commercialize our products in any market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain marketing approval for our product
candidates, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could materially impair our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive
regulation governing the labeling, packaging, storage and promotion of the product and record keeping and submission of safety and other post-market information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing
approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#146;s approved labeling. Thus, we will not be able to
promote any products we develop for indications or uses for which they are not approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of approved products
and those manufacturers&#146; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and
quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance
with cGMPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, assuming we receive marketing approval for one or more of our product candidates, we and our contract
manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by
regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative
effect on our operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;40&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidate for which we obtain marketing approval could be subject to post-marketing
restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data,
labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing
information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of
samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including
the requirement to implement a risk evaluation and mitigation strategy. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of our product candidates receives
marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of the product. The FDA and other agencies, including the Department of Justice, closely regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions
of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding off-label use and if we market our products for unapproved indications, we may be subject to enforcement action for off-label marketing.
Violations of the FDA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well
as state consumer protection laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with our products,
manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation involving patients taking our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on such products, manufacturers or manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the labeling or marketing of a product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on product distribution or use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to conduct post-marketing studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of the products from the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending applications or supplements to approved applications that we submit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall of products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, restitution or disgorgement of profits or revenues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of marketing approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">damage to relationships with any potential collaborators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable press coverage and damage to our reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to permit the import or export of our products; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;41&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-compliance by us or any
future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties.
Similarly, failure to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and
regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third party payors will play a primary role in the recommendation and prescription of any product
candidates for which we obtain marketing approval. Our future arrangements with third party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or
financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or
reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be
presented false or fraudulent claims for payment by a federal government program, or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing
a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding
the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal law requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the PPACA, requires manufacturers
of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">analogous state laws and regulations such as state anti-kickback and false claims laws and analogous non-U.S. fraud and abuse laws and regulations,
may apply to sales or marketing arrangements and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;42&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with
the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and
other health care providers or marketing expenditures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some state laws require pharmaceutical companies to comply with
the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value
to physicians and other healthcare providers or marketing expenditures. State and non-U.S. laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are
not preempted by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will
comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or
other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded
healthcare programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and
commercialize our product candidates and affect the prices we may obtain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some non-U.S. jurisdictions,
there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect
our ability to profitably sell any product candidates for which we obtain marketing approval. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider our products, if approved, to be cost-effective compared to other available therapies, they may not cover our
product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to realize a meaningful return on our investment. The United States government, state legislatures and non-U.S. governments
have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for
branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our products, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the marketability of our products, if approved, could suffer if the government and third-party payors fail to provide adequate
coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing
regulation may change at any time. Even if favorable coverage and reimbursement status is attained for one or more of our products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way
Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;43&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost
reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow
Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More recently, in March 2010, President Obama signed into law the PPACA, a sweeping law intended to broaden access to health insurance, reduce
or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional
health policy reforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the provisions of the PPACA of importance to our potential product candidates are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new requirements to report financial arrangements with physicians and teaching hospitals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. These changes included aggregate reductions
to Medicare payments to providers of up to 2%&nbsp;per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The
implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
product candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and
post-marketing testing and other requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;44&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governments outside the United States tend to impose strict price controls, which may adversely affect our
revenues from the sales of our products, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, particularly the countries of the European Union, the pricing
of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or
pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or
amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or
other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar
regulations of comparable non-U.S. regulatory authorities, provide accurate information to the FDA or comparable non-U.S. regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud
and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct
could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results
of operations, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws
and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to
numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and
flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of
contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur
significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we
maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential
liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;45&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are in a period of transition following the resignation of our former president and chief executive officer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Oliver Fetzer, our former president, chief executive officer and director, resigned from his positions effective October&nbsp;29,
2014. On March 20, 2015, our board of directors appointed Christopher D. T. Guiffre as our President and Chief Executive Officer and a director, effective immediately. We anticipate that we will continue to experience a transitional period until Mr.
Guiffre is fully integrated into his new roles. In connection with Dr.&nbsp;Fetzer&#146;s resignation, Paul A. Friedman, M.D., a member of our board of directors, was appointed Executive Chairman of our board and will continue in that role following
Mr. Guiffre&#146;s appointment. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If either Dr.&nbsp;Friedman or Mr.&nbsp;Guiffre ceases to fulfill his respective new
responsibilities, our business, financial condition, and results of operations could be materially and adversely affected. Moreover, we cannot provide any assurance that this transitional period will not result in a disruption that adversely impacts
our business and employee morale. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate
qualified personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the scientific, business development and clinical expertise of our management,
scientific and clinical teams. The loss of this expertise could impede the achievement of our goals. Any of our employees may terminate their employment with us at any time. We do not maintain &#147;key person&#148; insurance for any of our
executives or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing finance and sales and marketing
personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to
successfully implement our business strategy. Furthermore, replacing executive officers and key employees, including finance personnel, may be difficult and may take an extended period of time because of the limited number of individuals in our
industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or
motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from
universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and
advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a
result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience
significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and
distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our
limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;46&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing lease will expire in February 2016. If we elect not to exercise our extension right under this
lease and are unable to lease suitable space, our need to relocate our facilities could delay our research and development efforts, adversely affect our business and damage employee morale. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease laboratory and office space in Cambridge, Massachusetts under a lease expiring on February 29, 2016. We have the right to extend the
lease for an additional three year term, subject to reaching agreement with the landlord on market rent for the term of the extension. Our landlord is attempting to sell the building in which we are located, and the efforts to sell the building may
make it more difficult for us to reach an agreement on the market rent for the term of the extension. If we elect not to exercise our extension right, or are not able to reach agreement on market rent for the term of the extension, we will need to
relocate our laboratory and office space. In these circumstances, we may be unable to obtain alternative facilities due to our financial condition or for other reasons, and we may be unable to fully relocate our existing operations before
termination of our existing lease, thereby disrupting our business and research and development activities. In the event that we relocate to a new location, the new location we choose may adversely affect employee retention or recruitment, and the
process of moving our offices to a new location may disrupt our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Ownership of our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock has been and may in the future be volatile and fluctuate substantially. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price has been and may in the future be volatile. From April&nbsp;10, 2014 to March&nbsp;27, 2015 the sale price of our common stock
as reported by the NASDAQ Global market ranged from a high of $10.87 per share to a low of $3.35 per share. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often
been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated results from, and any delays in, our clinical trials, including the ongoing and any new ISTs of CRLX101, our ongoing and planned Phase 2 and Phase 3 clinical trials of CRLX101 or our Phase 1
clinical trial of CRLX301, as well as results of regulatory reviews relating to the approval of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commencement or termination of any collaboration or licensing arrangement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures and capital commitments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or those of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new products, product candidates or new uses for existing products introduced or announced by our competitors, and the timing of these introductions or announcements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of clinical trials of product candidates of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic and market conditions and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;47&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions or trends in the biotechnology and biopharmaceutical industries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in earnings estimates, development timelines or recommendations by securities analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of common stock by us or our stockholders in the future, as well as the overall trading volume of our common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the other factors described in this &#147;Risk Factors&#148; section. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock
market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those
companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in companies&#146; stock prices, securities
class-action litigation has often been instituted against such companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#146;s attention and resources, which could materially and adversely
affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Following this offering, our executive officers and directors and their affiliates will continue to
own a significant percentage of our stock and will be able to exercise significant influence over matters submitted to stockholders for approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers and directors and their affiliates beneficially own, in the aggregate, shares representing approximately 36.7% of our
common stock before this offering. If we issue and sell the shares of common stock that we are offering hereby, then assuming a public offering price of $9.73 per share, which was the last reported sale price of our common stock on the NASDAQ Global
Market on March 27, 2015, our executive officers and directors and their affiliates will own, in the aggregate, shares representing approximately 29.4% of our common stock after this offering, assuming no exercise by the underwriters of their option
to purchase additional shares of our common stock and no exercise of options outstanding as of December&nbsp;31, 2014. As a result, following this offering, if these stockholders were to choose to act together, they would be able to exert a
significant degree of influence over matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would substantially influence the election of directors and
approval of any merger, consolidation or sale of all or substantially all of our assets. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This concentration of ownership could: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, defer or prevent a change in control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entrench our management or board of directors; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not be sustained following this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have listed our common stock on The NASDAQ Global Market, an active trading market for our shares may not be sustained following
this offering. In the absence of an active trading market for our common stock, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which
they acquired their shares or sell their shares at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;48&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
times they would like to sell. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our
ability to acquire other companies or technologies by using our shares as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares may
be sold into the public market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the
market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have outstanding 25,508,429 shares of common stock, which is based on 20,369,683 shares of our
common stock outstanding as of February 28, 2015 and assumes the issuance and sale of $50.0 million of shares of our common stock at an assumed public offering price of $9.73 per share, which was the last sale price of our common stock on the NASDAQ
Global Market on March 27, 2015. This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of approximately 6.9 million shares of our common stock have rights, subject to conditions, to require us to file registration
statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. In connection with this offering, the holders of these securities waived these registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the shares described in this risk factor, 9,556,080 shares are subject to a 90-day contractual lock-up period as described in the
&#147;Underwriting&#148; section of this prospectus. These shares can be sold, subject to any applicable volume limitations and federal securities laws, after the expiration of or release from the 90-day lock-up period. The balance of our
outstanding shares of common stock may be freely sold in the public market at any time to the extent permitted by applicable federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, there were 2,417,346 shares subject to outstanding options. In August 2014, we registered all of these shares
under the Securities Act of 1933, as amended, on a registration statement on Form S-8. These shares can be freely sold in the public market upon exercise, as permitted by any applicable vesting requirements, except to the extent they are held by our
affiliates, in which case such shares will become eligible for sale in the public market as permitted by Rule 144 under the Securities Act. Furthermore, as of February&nbsp;28, 2015, there were 300,564 shares subject to outstanding warrants to
purchase common stock. These shares will become eligible for sale in the public market, to the extent such warrants are exercised, as permitted by Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The public offering price of our common stock is substantially higher than the net tangible book value per share of our common stock.
Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after giving effect to this offering. To the extent shares are issued under
outstanding options or warrants, you will incur further dilution. Based on the assumed public offering price of $9.73 per share, which was the last reported sale price of our common stock on the NASDAQ Global Market on March 27, 2015, you will
experience immediate dilution of $6.10 per share, representing the difference between our as adjusted net tangible book value per share after giving effect to this offering and the assumed public offering price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;49&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to
emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148;
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company through 2019. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from
certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some, but not all, of the available exemptions. We cannot predict whether investors will find our common
stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of
this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently incurring and expect to continue to incur increased costs as a result of operating as a public company, and our management will be
required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a newly public company,
we are incurring and expect to continue to incur additional significant legal, accounting and other expenses that we did not incur as a private company. We expect that these expenses will further increase after we are no longer an &#147;emerging
growth company.&#148; We expect that we will need to hire additional accounting, finance and other personnel in connection with our continuing efforts to comply with the requirements of being a public company, and our management and other personnel
will need to continue to devote a substantial amount of time towards maintaining compliance with these requirements. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the Securities and Exchange Commission and NASDAQ
have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial
amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will be required to furnish a report by our management
on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;50&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public
accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard,
we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control
processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. If we identify one or more material
weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently plan to retain all of our future
earnings, if any, to finance the growth and development of our business. Furthermore, the terms of the Hercules Loan Agreement prohibit us from paying any dividends without the prior written consent of Hercules, and any future debt agreements may
also preclude us from paying dividends. Accordingly, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion over the use of our cash and cash equivalents, including the net proceeds we receive from this offering, and may not use them
effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion to use our cash and cash equivalents, including the net proceeds we receive
from this offering, to fund our operations and could spend such proceeds or cash in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could
result in financial losses, and these financial losses could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest such
proceeds or cash in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our certificate of incorporation, our by-laws or
Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our certificate of incorporation, our bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other
change in control that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in
the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions might frustrate or
prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors such that all members of the board are not elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allow the authorized number of our directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit the manner in which stockholders can remove directors from the board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to the board or for proposing matters that can be acted on at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;51&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit who may call a special meeting of stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board to issue preferred stock without stockholder approval, which could be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer,
effectively preventing acquisitions that have not been approved by our board; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are governed by Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation
from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring or merging with us, whether or not it is desired by,
or beneficial to, our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative
evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock relies in part on the research and reports
that industry or financial analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could
decline. In addition, if one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to
decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;52&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements other than
statements of historical facts contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are
forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or
achievements expressed or implied by forward- looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;, &#147;expect&#148;,
&#147;hypothesize&#148;, &#147;intend&#148;, &#147;may&#148;, &#147;plan&#148;, &#147;predict&#148;, &#147;project&#148;, &#147;target&#148;, &#147;potential&#148;, &#147;will&#148;, &#147;would&#148;, &#147;could&#148;, &#147;should&#148;,
&#147;continue&#148;, &#147;contemplate&#148;, or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current
expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus include, among other things, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to advance the development of, and commercialize, CRLX101, CRLX301 and our other future product candidates, including in combination with other drugs and therapies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and planned preclinical studies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to leverage our platform to discover and develop additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans with respect to possible future collaborations and partnering arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify and develop additional product candidates with significant commercial potential; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intellectual property position and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations relating to the use of proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments relating to our competitors and our industry; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of government laws and regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed
in the forward-looking statements we make. We have included important factors in the cautionary statements included in this prospectus, particularly in the &#147;Risk Factors&#148; section, that we believe could cause actual results or events to
differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration
statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and
studies conducted by third parties. Industry publications and third party research, surveys and studies generally indicate that the information contained therein has been obtained from sources believed to be reliable, although they do not guarantee
the accuracy and completeness of such information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;53&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from the sale of the $50.0 million of common stock that we are offering will be approximately $46.4
million, assuming a public offering price of $9.73 per share, which was the last reported sale price of our common stock on The NASDAQ Global Market on March 27, 2015, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional shares, we estimate that our net proceeds will be approximately $53.4 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, we had cash and cash equivalents of approximately $51.2 million. We currently estimate that we will use the net
proceeds from this offering and our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $50.0 million to fund clinical development of CRLX101 described below; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $25.0 million to fund research and development of CRLX301 described below and other future product candidates; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder for working capital and other general corporate purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of
net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary
significantly depending on numerous factors, including the progress of our clinical development, the status of and results from clinical trials, any collaboration(s) that we may enter into with third parties for our product candidates and any
unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our planned use of the net proceeds from this offering and our existing cash and cash equivalents described above, as well as the
drawdown of funds under the Hercules Loan Agreement described below, we estimate that such funds will be sufficient to enable us to complete our ongoing randomized Phase 2 clinical trial of CRLX101 in combination with Avastin in relapsed renal cell
carcinoma, initiate and complete a second randomized Phase 2 clinical trial of CRLX101, complete our Phase 1b clinical trial of CRLX101 in combination with weekly paclitaxel in relapsed ovarian cancer, complete our ongoing Phase 1 clinical trial of
CRLX301, initiate and complete our planned Phase 2a clinical trial of CRLX301, support the ongoing CRLX101 investigator-sponsored trials and fund our operating expenses, debt service and capital expenditure requirements for at least the next
twenty-four months. We do not expect that the net proceeds from this offering, the additional funds that we may borrow under the Hercules Loan Agreement and our existing cash and cash equivalents will be sufficient to enable us to fund the
completion of clinical development of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Hercules Loan Agreement, we drew the
first tranche of $15.0 million on January 8, 2015 and may draw up to $5.0 million on or prior to December&nbsp;15, 2015, subject to the satisfaction of customary financing conditions, if we meet certain clinical milestones specified in the Hercules
Loan Agreement. In addition, we may draw up to an additional $6.0 million, subject to the satisfaction of customary funding conditions, on or after September&nbsp;30, 2015 but prior to December&nbsp;15, 2015, provided that prior to December&nbsp;15,
2015, we have received net cash proceeds of at least $40.0 million from the issuance and sale of our equity securities and/or upfront cash payments from one or more strategic corporate partnerships, which will be satisfied by this offering. The
foregoing discussion assumes that we will satisfy these clinical and funding milestones and draw the remaining available $11.0 million amount under the Hercules Loan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending use of the proceeds as described above, we intend to invest the proceeds in a variety of capital preservation instruments, including
short-term, interest-bearing, investment-grade securities and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;54&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_4"></A>PRICE RANGE OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock began trading on The NASDAQ Global Market under the symbol &#147;CERU&#148; on April&nbsp;10, 2014. Prior to that time, there
was no public market for our common stock. The following table sets forth the high and low sale prices per share of our common stock, as reported on The NASDAQ Global Market, for the periods indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter (beginning April&nbsp;10, 2014)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter (through March&nbsp;27, 2015)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2015, the last reported sale price of our common stock as reported on The NASDAQ
Global Market was $9.73 per share. As of March 27, 2015, we had approximately [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] holders of record of our common stock. The actual number of stockholders is greater than this
number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in
trust by other entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;55&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not declared or paid any cash dividends on our capital stock since our incorporation. We currently intend to retain all of our future
earnings, if any, to finance the growth and development of our business. We do not intend to pay any cash dividends to the holders of common stock in the foreseeable future. Our ability to pay dividends on our common stock is prohibited by the
covenants of our loan and security agreement with Hercules Technology Growth Capital, Inc., and may be further restricted by the terms of any future indebtedness we may incur in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;56&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of December&nbsp;31, 2014, on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to give effect to (i) our draw of $15.0 million under the loan and security agreement that we entered into with Hercules Technology Growth Capital, Inc., or Hercules, and certain costs and expenses
related to our entry into the loan and security agreement, (ii) our use of $3.3&nbsp;million of the proceeds from such draw to repay in full our outstanding indebtedness to Lighthouse Capital Partners VI, L.P., or Lighthouse, and certain fees
related to the repayment and (iii) our issuance and sale of 135,501 shares of our common stock to Hercules in a private placement for proceeds of $1.0 million, all of which occurred on January&nbsp;8, 2015; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as adjusted basis to give effect to our issuance and sale of $50.0 million of shares of our common stock in this offering at an assumed public offering price of $9.73 per share, which was the last reported sale
price of our common stock on The NASDAQ Global Market on March 27, 2015, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following table together with &#147;Description of Capital Stock&#148; appearing elsewhere in this prospectus, and our
consolidated financial statements and the related notes appearing at the end of this prospectus and the &#147;Selected Consolidated Financing Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; sections of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands, except share and per share data) </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt (including current portion)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, par value $0.01 per share; 5,000,000 shares authorized, no shares issued or outstanding, actual and as
adjusted</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.0001 per share; 120,000,000 shares authorized, actual and as adjusted, 20,125,049 shares issued and
outstanding, actual; 20,260,550 shares issued and outstanding, pro forma, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above does not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">128,663 shares of common stock issuable upon exercise of warrants outstanding as of December&nbsp;31, 2014, at a weighted-average exercise price of $11.52 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,126,176 shares of common stock issuable upon exercise of stock options outstanding as of December&nbsp;31, 2014, at a weighted-average exercise price of $4.97 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,434,928 and 500,000 shares of our common stock reserved and available as of December&nbsp;31, 2014 for future issuance under our 2014 stock incentive plan and our 2014 employee stock purchase plan, respectively.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;57&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the public offering price per share and the as adjusted tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value as of December&nbsp;31, 2014 was $45.2 million, or $2.25 per share of our common stock. Historical net
tangible book value per share represents the amount of our total tangible assets less total liabilities, divided by 20,125,049 shares of our common stock outstanding as of December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our issuance and sale of $50.0 million of shares of common stock in this offering at an assumed public offering price
of $9.73 per share, which was the last reported sale price of our common stock on The NASDAQ Global Market on March 27, 2015, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our
as adjusted net tangible book value as of December&nbsp;31, 2014 would have been $91.6 million, or $3.63 per share. This represents an immediate increase in as adjusted net tangible book value per share of $1.38 to existing stockholders and
immediate dilution of $6.10 in as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share
after this offering from the public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares or if any additional shares are
issued in connection with outstanding options, you will experience further dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing table and calculations are based on
20,125,049 shares of our common stock outstanding as of December&nbsp;31, 2014 and excludes as of such date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">128,663 shares of common stock issuable upon exercise of warrants outstanding as of December&nbsp;31, 2014, at a weighted-average exercise price of $11.52 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,126,176 shares of common stock issuable upon exercise of stock options outstanding as of December&nbsp;31, 2014, at a weighted-average exercise price of $4.97 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,434,928 and 500,000 shares of our common stock reserved and available as of December&nbsp;31, 2014 for future issuance under our 2014 stock incentive plan and our 2014 employee stock purchase plan, respectively.
</TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing table and calculations also do not give effect to our issuance and sale, on January 8, 2015, of 135,501
shares of our common stock to Hercules Technology Growth Capital, Inc. in a private placement for proceeds of $1.0 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;58&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_10"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following selected consolidated financial data in conjunction with &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and our consolidated financial statements and the related notes appearing elsewhere in this prospectus. We have derived the consolidated statement of operations data for the years ended
December&nbsp;31, 2014, 2013 and 2012 and our consolidated balance sheet data as of December&nbsp;31, 2014 and 2013 from our audited consolidated financial statements included in this prospectus. We have derived our consolidated balance sheet data
as of December 31, 2012 from our audited consolidated financial statements that are not included in this prospectus. Our historical results for any prior period are not necessarily indicative of the results to be expected in any future period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands, except share data and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in value of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense)&#151;net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted(1)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,548,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,699</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt (including current portion)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(121,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(98,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(81,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(80,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See notes 2 and 3 within the notes to our consolidated financial statements appearing elsewhere in this prospectus for a description of the method used to calculate basic and diluted net loss per share applicable to
common stockholders. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;59&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and the related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and
strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that could cause
actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage,
oncology-focused company applying our proprietary Dynamic Tumor Targeting&#153; Platform to develop differentiated therapies. This platform utilizes nanoparticle-drug conjugates, or NDCs, which consist of proprietary polymers that are covalently
linked to anti-cancer therapeutics, or payloads. We believe these NDCs dynamically target tumors by exploiting the leakiness of new blood vessels in tumors as an entry portal into tumor tissue, followed by active uptake into tumor cells and the
sustained release of the anti-cancer payload inside the tumor cells. We believe that our NDCs are differentiated from other nanoparticle technologies by our linker technology, which allows for preferential delivery of our anti-cancer payloads. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, CRLX101, is a dynamically tumor targeted NDC in Phase 2 clinical development and has the potential to improve
outcomes for patients in combination with other cancer treatments. We believe CRLX101, which contains camptothecin as its anti-cancer payload, is a potent, durable and combinable inhibitor of topoisomerase 1, or topo 1, a commercially validated
cancer target, and hypoxia inducible factor, or HIF, a novel target of increasing interest in cancer research. Two products that have been marketed by other companies, irinotecan and topotecan, inhibit topo 1, but their utility is limited by
toxicities. Recent research suggests that HIF, and in particular the HIF subunit HIF-l<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, is a master regulator of multiple cancer cell survival pathways. Over 250 patients have been administered CRLX101
in multiple indications at several clinical trial sites. In clinical trials evaluating CRLX101 as a single agent, CRLX101 was generally well tolerated with a toxicity profile generally characterized by low-grade (Common Terminology Criteria for
Adverse Events grade 1-2) adverse events. No treatment-related trial deaths have been observed to date. In ongoing clinical trials, CRLX101 also appears active and combinable with Avastin (bevacizumab) and chemoradiotherapy, or CRT, which is a
combination of capecitabine and radiation. In addition, preclinical data indicate that CRLX101 may be combinable with other anti-cancer therapies. We are pursuing development of CRLX101 in combination with anti-cancer therapies in multiple ongoing
clinical development programs that include a company-sponsored trial and investigator-sponsored trials, or ISTs. These trials consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Relapsed renal cell carcinoma:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 2 randomized, controlled, company-sponsored trial is being conducted comparing CRLX101 administered in combination with Avastin to investigator&#146;s choice of standard of care in patients with renal cell
carcinoma, or RCC, who have received two or three prior lines of therapy. We refer to this study as the RCC Trial. The RCC Trial is currently being conducted at approximately 30 sites in the United States, with eight additional sites planned in the
United States and five additional sites planned in South Korea. Based on results from the Phase 1b/2 IST in relapsed RCC, discussed below, we believe that the combination of CRLX101 and Avastin may provide therapeutic benefits to patients with
relapsed RCC who have received two or three prior lines of therapy including a tyrosine kinase inhibitor, or TKI, and/or an inhibitor of a mammalian target of rapamycin, or an mTORI. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">A Phase 1b/2 single-arm IST of CRLX101 in combination with Avastin in patients with relapsed RCC is being conducted at the University of Pennsylvania
and Thomas Jefferson University Hospital. A total of 22 patients were enrolled in this trial. The last patient was enrolled in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;60&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
December 2014, and the trial has met its primary endpoint of at least 50% of patients achieving four months progression free survival, or PFS. Preliminary data from this clinical trial has been
submitted for presentation at the 2015 annual meeting of the American Society of Clinical Oncology, or ASCO. As of February 3, 2015, the date of the abstract submission to ASCO, the median PFS, or mPFS, of patients on the trial was 9.9 months, with
seven of the 22 patients still receiving treatment. Based on third-party published data, the mPFS of the standard of care in this setting is approximately 3.5 months. In addition, the Response Evaluation Criteria in Solid Tumor, or RECIST, partial
response rate of patients on the trial as of February 3, 2015 was 23%. Several recent studies in advanced RCC suggest that after treatment with a TKI, subsequent therapies, including Avastin alone, achieve RECIST partial response rates of between 2%
and 4%. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Relapsed ovarian cancer:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 2 single-arm IST of CRLX101 as monotherapy and in combination with Avastin in patients with relapsed ovarian cancer is being conducted at Massachusetts General Hospital and affiliated Harvard University teaching
hospitals. As previously reported, the first stage of the trial, administering CRLX101 as monotherapy, met its primary endpoint of PFS at six months for at least four patients. RECIST responses, as well as encouraging PFS, were observed for several
patients. Platinum-resistant ovarian cancer patients are being enrolled in the second stage of this trial, administering CRLX101 in combination with Avastin. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have commenced start-up activities for a Phase 1b single-arm company-sponsored trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer conducted in collaboration with the GOG
Foundation, Inc. (formerly known as the Gynecologic Oncology Group), or GOG. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Neoadjuvant rectal cancer:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1b/2 single-arm IST of CRLX101 in combination with CRT in patients with non-metastatic rectal cancer is being conducted at the University of North Carolina at Chapel Hill and several other sites, including the
University of Indiana, Wake Forest University, Rex Hospital Inc. and Southeastern Medical Oncology Center. No dose limiting toxicities, or DLTs, have been reported in the Phase 1b stage of the trial, in which a maximum tolerated dose, or MTD, and
recommended Phase 2 dose, or RP2D, of 15 mg/m2 of CRLX101 was established when administered in combination with capecitabine and radiotherapy. Patients are currently being enrolled in the RP2D expansion Phase 2 stage of the trial. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold issued patents in the United States, Japan and Europe covering the composition of matter of CRLX101 that expire in 2023 and 2024,
excluding any potential patent term extension. Due to the ability of NDCs to target the &#147;leaky&#148; vasculature that is present in all solid tumors and CRLX101&#146;s apparently favorable adverse event profile observed to date, we believe
CRLX101 may have significant clinical utility in several cancer indications, particularly in combination with other cancer therapies. Our development focus is on tumor types where HIF is up-regulated, topo 1 inhibition is desirable, and drug
combinations with CRLX101 can be pursued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX301, our second platform-generated clinical candidate, is a dynamically tumor-targeted NDC
in Phase&nbsp;1 clinical development. CRLX301 is designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. Docetaxel is a microtubule stabilizer that is extensively used in clinical practice and is
approved by the FDA for the treatment of locally advanced or metastatic non-small cell lung cancer, locally advanced squamous cell carcinoma of the head and neck, androgen-independent prostate cancer, locally advanced or metastatic breast cancer and
advanced gastric cancer. In preclinical studies, CRLX301 delivered up to ten times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was superior to docetaxel in seven of seven animal
models, with a statistically significant survival benefit seen in five of the seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies. We hold issued
patents in the United&nbsp;States, Japan and Europe covering the composition of matter of CRLX301 that expire in 2023 and 2024, excluding any potential patent term extension. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;61&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have devoted substantially all of our resources to our drug discovery and development efforts,
including conducting clinical trials of our product candidates, protecting our intellectual property and the general and administrative support of these operations. To date, we have generated no revenue from product sales. We expect that it will be
several years before we commercialize a product candidate, if ever. Through December&nbsp;31, 2014, we have funded our operations primarily through $84.2 million in proceeds from the sale of shares of our convertible preferred stock in private
placements, net proceeds of $59.9 million from sales of shares of our common stock to the public, $17.3 million in proceeds from our sale of convertible promissory notes, and $10.0&nbsp;million in proceeds from borrowings under our loan and security
agreement with Lighthouse Capital Partners VI, L.P., or Lighthouse Capital. We refer to our loan and security agreement with Lighthouse Capital as the Lighthouse Loan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2015, we entered into a loan and security agreement with Hercules Technology Growth Capital, Inc., or Hercules. We refer to
this loan and security agreement as the Hercules Loan Agreement. Pursuant to the Hercules Loan Agreement, we are eligible to borrow up to an aggregate principal amount of $26.0 million, subject to certain conditions. On January&nbsp;8, 2015, we
borrowed $15.0 million under the Hercules Loan Agreement, and we used a portion of those proceeds to repay our outstanding indebtedness under the Lighthouse Loan Agreement. In connection with entering into the Hercules Loan Agreement, we sold
135,501 shares of our common stock to Hercules in a private placement and received $1.0 million in proceeds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never been
profitable and have incurred significant operating losses since our incorporation. As of December&nbsp;31, 2014, we had an accumulated deficit of $121.8 million. We incurred net losses of approximately $23.3 million, $17.1 million and $22.2 million
for the years ended December&nbsp;31, 2014, 2013, and 2012, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant and increasing
expenses and operating losses for the foreseeable future as we advance our product candidates from discovery through preclinical studies and clinical trials, and as we seek regulatory approval for, and eventually commercialize, our product
candidates. Our net losses may fluctuate significantly from quarter to quarter and from year to year. We will need to raise additional capital in the future to support our expenses and operating activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;15, 2014, we completed the sale of 8,500,000 shares of common stock in our initial public offering, or IPO, at a price to the public of $7.00 per share. On May&nbsp;7, 2014, we completed the sale of an additional 1,069,715 shares of
common stock at a price to the public of $7.00 per share, pursuant to a partial exercise by the underwriters of their option to purchase additional shares of common stock. The sale of the shares to the public resulted in aggregate net proceeds to us
of $59.9 million after deducting underwriting discounts and commissions and offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each of the
following occurred in the second quarter of 2014 in connection with the completion of our IPO on April&nbsp;15, 2014: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all outstanding shares of convertible preferred stock into 6,826,004 shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of $17.8 million of outstanding principal and accrued interest on convertible notes into 2,902,233 shares of our common stock; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of warrants to purchase 1,857,226 shares of convertible preferred stock into warrants to purchase 128,663 shares of our common stock and the reclassification of the $0.4 million warrant liability to
additional paid-in capital. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;62&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales for the next several years, if ever. In the future, we may generate revenue from a combination of product sales, license fees, milestone and
research and development payments in connection with strategic partnerships, and royalties resulting from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter
to quarter as a result of the timing and amount of any such payments. Our ability to generate product revenues will depend on the successful development and eventual commercialization of our product candidates and our dynamic tumor targeting
technology. If we fail to complete the development of our product candidates in a timely manner, to fully realize the value and potential of our technology platform, or to obtain regulatory approval for our product candidates, our ability to
generate future revenue and our results of operations and financial position would be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, our only
revenue has consisted of a government tax credit that we received in 2010 and payments we received in 2011, 2012, 2013, and 2014 from four material transfer agreements and a research agreement. Pursuant to each of the agreements, we received
payments in exchange for a pharmaceutical company&#146;s use of our proprietary technology for research purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense consists of costs incurred in connection with the discovery and development of our Dynamic Tumor
Targeting Platform and our product candidates. These expenses consist primarily of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses, including salaries, benefits and stock-based compensation expense; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with contract research organizations, or CROs, investigative sites that conduct our clinical trials and consultants that conduct a portion of our preclinical studies;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses relating to scientific and medical consultants and advisors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of acquiring and manufacturing clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilities, depreciation of fixed assets and other allocated expenses, including direct and allocated expenses for rent and maintenance of facilities and equipment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lab supplies, reagents, active pharmaceutical ingredients and other direct and indirect costs in support of our preclinical activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">license fees related to in-licensed products and technology; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs associated with non-clinical activities and regulatory approvals. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research
and development costs as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting a significant amount of research and development is central to our business model. Product
candidates in late stages of clinical development generally have higher development costs than those in earlier stages of clinical development primarily due to the increased size and duration of late-stage clinical trials. We plan to increase our
research and development expenses for the foreseeable future as we continue to support multiple clinical trials of CRLX101 and CRLX301, and advance our earlier-stage research and development projects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our employee and infrastructure resources across multiple research and development programs. We track external research and development
expenses and personnel expense on a program-by-program basis and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;63&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have allocated expenses such as stock-based compensation and indirect laboratory supplies and services to each program based on the personnel resources allocated to each program. Facilities,
depreciation and scientific advisory board fees and expenses are not allocated to a program and are considered overhead. Below is a summary of our research and development expenses for the years ended December&nbsp;31, 2014, 2013 and 2012 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRLX101</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRLX301</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NDC platform</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overhead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes our research and development programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CRLX101 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX101 is currently being
studied in multiple clinical trials, including the RCC Trial and the three ISTs described above. We expect to conduct additional trials of CRLX101, including a Phase 1b trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed
ovarian cancer, which we will conduct in collaboration with GOG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our license agreement with Calando Pharmaceuticals, Inc., or
Calando, pursuant to which we obtained rights to CRLX101, or the CRLX101 Agreement, we are obligated to pay milestone payments which could total, in the aggregate, $32.8&nbsp;million, if we achieve certain development and sales events with CRLX101.
In addition, under the CRLX101 Agreement, if we, or one of our affiliates, sell CRLX101 we are required to pay tiered royalty payments ranging from low- to mid-single digits, as a percentage of worldwide net sales, depending on whether there is
patent protection for CRLX101 at the time of the sale. In the event we license or sublicense the intellectual property that we purchased or licensed from Calando, we are required to pay Calando a percentage of the income we receive from the licensee
or sublicensee to the extent attributable to such license or sublicense, subject to certain exceptions. The percentage of such license income that we are obligated to pay Calando ranges from the low- to mid-double digits depending on the development
stage of CRLX101 at the time we first provide or receive draft terms of a license arrangement with the third party that results in a license agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CRLX301 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX301 is currently in early
stage clinical development, with a Phase 1 trial ongoing. Assuming we are successful in establishing a safe maximum tolerated dose, or MTD, and/or a recommended Phase 2 dose in the Phase 1 trial, we plan to rapidly advance CRLX301 into Phase 2
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our license agreement with Calando pursuant to which we obtained rights to Calando&#146;s cyclodextrin system for
purposes of conjugating or complexing certain other therapeutic agents to the system, or the Platform Agreement, we paid a $250,000 clinical development milestone to Calando in January 2015 in connection with the initiation of our Phase&nbsp;1
clinical trial of CRLX301 in December 2014. We may also be required to make milestone payments in an aggregate amount of up to $18.0&nbsp;million to Calando if we achieve certain development and sales events with respect to any CDP-based product.
Further, under the Platform Agreement, if we, or one of our affiliates, sell CRLX301, or any CDP-based product, we are required to pay tiered royalty payments ranging from low- to mid-single digits, as a percentage of worldwide net sales, depending
on whether there is patent protection at the time of the sale. In the event we license or sublicense the intellectual property that we purchased </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;64&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or licensed from Calando, we are required to pay Calando a percentage of the income we receive from the licensee or sublicensee to the extent attributable to such license or sublicense, subject
to certain exceptions. The percentage of such license income that we are obligated to pay Calando is in the low-double digits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nanoparticle-Drug
Conjugates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the expenses related to our NDC&#146;s will continue to increase as we seek to identify additional targets
for preclinical research and add personnel to these projects. We cannot accurately predict future research and development expenses for our NDC&#146;s because such costs are dependent on a number of variables, including the success of preclinical
studies on any such NDC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful development of any of our product candidates is highly uncertain. As such, at this time, we
cannot reasonably predict with certainty the duration and costs of the current or future clinical trials of any of our product candidates or if, when or to what extent we will generate revenues from any commercialization and sale of any of our
product candidates that obtain marketing approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of development of our product candidates will depend on a variety of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope and rate of progress of our ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of any product candidate once approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, timing, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results from ongoing as well as any future clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant and changing government regulation in the United States and abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs, timing and outcome of regulatory review or approval of our product candidates in the United States and abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of arrangements with third party suppliers or raw materials and third party manufacturers of finished drug product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture, market, commercialize and achieve market acceptance for any of our product candidates that we are developing or may develop in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of competing technologies and products and other adverse market developments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in
the cost and timing associated with the development of that product candidate. For example, if the FDA, or a comparable non-U.S. regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be
required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the
completion of clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the uncertainties discussed above, we are unable to determine when, or to what extent,
we will generate revenues from the commercialization and sale of any of our product candidates. We anticipate that we will make determinations as to which additional programs to pursue and how much funding to direct to each program on an ongoing
basis in response to the scientific and clinical data with respect to each product candidate, as well as our ongoing assessment of the product candidate&#146;s commercial potential. We will need to raise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;65&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional capital in the future in order to complete the development and commercialization of CRLX101 and CRLX301 and to fund the development of our other product candidates, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist principally of salaries and related costs for personnel in our executive, finance, business
development, marketing, legal and human resources functions. Other general and administrative expenses include patent filing, patent prosecution, professional fees for legal, insurance, consulting, information technology, auditing and tax services
and facility costs not otherwise included in research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative
expenses will increase in the future for, among others, the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we expect to incur increased general and administrative expenses to support our research and development activities, which we expect to expand as we continue to pursue the development of our product candidates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we expect our general and administrative expenses will continue to increase as a result of increased payroll, expanded infrastructure, higher consulting, legal, accounting and investor relations costs, director
compensation and director and officer insurance premiums associated with being a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may begin to incur expenses related to sales and marketing of our product candidates in anticipation of commercial launch before we receive regulatory approval of a product candidate. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income
consists of interest earned on our cash and cash equivalents. The primary objective of our investment policy is capital preservation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest
Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists primarily of interest, amortization of debt discount and amortization of deferred financing
costs associated with interest expense on our convertible notes and our debt facility with Lighthouse Capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Extinguishment of Debt
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt is associated with the loss recorded on the conversion of the convertible notes we issued in 2014,
or the 2014 Convertible Notes. The loss is an amount equal to the difference between the fair value of shares of our common stock into which the 2014 Convertible Notes converted and the carrying amount of the 2014 Convertible Notes at the closing of
the IPO on April&nbsp;15, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Preferred Stock Warrant Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock warrant liability is associated with warrants to purchase shares of our preferred stock issued to lenders and investors.
The change in fair value consists of the calculated change in value based upon the fair value of the underlying security at the end of each reporting period as calculated using the Black-Scholes option-pricing model. The preferred stock warrants
were automatically adjusted on the date of the closing of the IPO, April&nbsp;15, 2014, to provide for the issuance of shares of common stock upon their exercise. The preferred stock warrant liability has been reclassified to additional paid-in
capital as of April&nbsp;15, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;66&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial
statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued
expenses and stock-based compensation. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments
and estimates in light of changes in circumstance, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are described in more detail in Note 2 of the notes to our consolidated financial statements appearing at
the end of this prospectus. We believe the following accounting policies are critical to the judgments and estimates used in the preparation of the consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the
process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have
been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us
monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the
accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued clinical expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fees paid to CROs in connection with clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fees paid to investigative sites in connection with clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fees paid to contract manufacturers in connection with the production of clinical trial materials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fees paid to vendors in connection with the preclinical development activities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our
expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these
agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial
milestones. In accruing the service fees, we consider the terms of each agreement, the time period over which the services will be performed and the level of effort required to complete the service. If the actual timing of the performance of the
services or the level of effort varies from our estimate, we adjust the accrual accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services
performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. We have not experienced any significant adjustments to our estimates to
date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;67&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We issue stock-based awards to employees and non-employees in the form of stock options. We apply the fair value recognition provisions of the
Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718, <I>Compensation-Stock Compensation</I>, or ASC 718. ASC 718 requires all <FONT STYLE="white-space:nowrap">stock-based</FONT> payments to employees,
including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statements of operations based on their fair values. We account for stock-based awards to non-employees in accordance with
FASB ASC Topic 515-50, <I>Equity-Based Payments to Non-Employees</I>, which requires the fair value of the award to be re-measured at fair value as the award vests. We recognize the compensation expense of stock-based awards on a straight-line basis
over the vesting period of the award for employees and non-employees. We have issued performance-based grants where the vesting of the grant is tied to milestone performance, and, in these cases, the compensation is recognized as expense when the
probability of the milestone is met (and stock vested). Compensation expense related to our stock-based awards is subject to a number of estimates, including the estimated volatility and underlying fair value of our common stock, as well as the
estimated life of the awards. We estimate the fair value of our stock-based awards for recording stock-based compensation expense using the Black-Scholes option pricing model. Determining the appropriate fair value model and calculating the fair
value or stock-based awards requires significant judgment and the use of assumptions which may differ materially from actual results. Actual results, and future changes in estimates, may differ substantially from our current estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our IPO, we were a private company with no active public market for our common stock. Therefore, we periodically determined for
financial reporting purposes the estimated per share fair value of our common stock at various dates using contemporaneous valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants
Practice Aid,&nbsp;<I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>, or the Practice Aid. We performed these contemporaneous valuations as of December&nbsp;31, 2011,&nbsp;December&nbsp;1,
2012,&nbsp;September&nbsp;30, 2013 and December&nbsp;31, 2013. In conducting the contemporaneous valuations, we considered all objective and subjective factors that we believed to be relevant for each valuation conducted, including our best estimate
of our business condition, prospects and operating performance at each valuation date. Within the contemporaneous valuations performed, a range of factors, assumptions and methodologies were used. The significant factors included: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices of our preferred stock sold to or exchanged between outside investors in arms&#146; length transactions, and the rights, preferences and privileges of our preferred stock as compared to the rights of our
common stock, including the liquidation preferences of our preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our results of operations, financial position and the status of our research and development efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the composition of, and changes to, our management team and board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of liquidity of our common stock given that we are a private company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our stage of development and business strategy and the material risks related to our business and industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the achievement of enterprise milestones; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of peer companies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any external market conditions affecting the life sciences and biotechnology industry sectors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event for the holders of our common stock and stock options, such as an initial public offering, or a sale of our company, given prevailing market conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the state of the initial public offering market for similarly situated privately held biotechnology companies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any recent contemporaneous valuations prepared by our board of directors and management in accordance with methodologies outlined in the Practice Aid. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;68&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dates of our contemporaneous valuations did not always coincide with the dates of our
stock-based compensation grants. In determining the exercise prices of the options granted, our board of directors considered, among other things, the most recent contemporaneous valuations of our common stock and our assessment of additional
objective and subjective factors we believed were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent contemporaneous valuation and the grant dates included, when
available, the prices paid in recent transactions involving our equity securities, as well as our stage of development, our operating and financial performance and current business conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2013, based on our review of overall market conditions and the improving market for biopharmaceutical initial public offerings,
our board of directors determined that a significant shift was occurring with respect to the valuation that we could achieve in an initial public offering and directed us to begin preparation of a confidential draft registration statement for an
initial public offering. We selected underwriters and held an organizational meeting in December 2013. We believe these events increased the probability of an early initial public offering scenario and therefore, in connection with the preparation
of our consolidated financial statements, we re-assessed the fair value of our common stock for financial reporting purposes at interim dates between the contemporaneous valuations where there were stock option grants or modifications to existing
grants. For these interim periods, we adjusted the fair value based on market conditions, progress made in our development programs and whether we achieved company milestones. A retrospective valuation was conducted as of May&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2013, our board of directors approved the modification of stock options held by certain employees in connection with the
reduction-in-force we implemented between April and August 2013.&nbsp;In exchange for a release of claims, vested stock options held as of termination by these employees were modified to extend the post-employment exercise period from 90 days to two
years after the termination date.&nbsp;In addition, in June 2013, our board of directors approved accelerated vesting on certain stock options held by an executive officer included in the reduction-in-force.&nbsp;In December 2013, with the benefit
of hindsight, and our belief that the probability of an initial public offering scenario had increased from April 2013, we conducted a retrospective valuation for our common stock as of May&nbsp;31, 2013.&nbsp;The retrospective valuation for our
common stock as of May&nbsp;31, 2013 was used to record stock compensation expense for the modification on stock options for employees with termination dates in the second quarter of 2013.&nbsp;The contemporaneous valuation we conducted as of
September&nbsp;30, 2013, was used to record stock compensation expense for the modification on stock options for terminated employees with termination dates in the third quarter of 2013.&nbsp;In total, we recorded additional stock compensation
expense of $0.1 million in connection with the stock option modifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were significant judgments and estimates inherent in the
determination of fair value of our common stock, including the contemporaneous valuations. These judgments and estimates included assumptions regarding our future operating performance, the time to completing an IPO or other liquidity event and the
determinations of the appropriate valuation methods. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per common share could have been significantly different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our IPO, we have determined the fair value of our common stock based on the closing price of our common stock on The NASDAQ Global
Market on the applicable date of such grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Fair Market Value of Common Stock Prior to IPO </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock Valuation Methodologies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our IPO, our contemporaneous and retrospective valuations discussed below were prepared in accordance with the guidelines in the
Practice Aid, which prescribes several valuation approaches for setting the value of an enterprise, such as the cost, market and income approaches, and various methodologies for allocating the value of an enterprise to its common stock. We generally
used the market approach, in particular the guideline company and precedent transaction methodologies, based on inputs from comparable public companies&#146; equity valuations and comparable acquisition transactions, to estimate the enterprise value
of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;69&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Methods Used to Allocate Our Enterprise Value to Classes of Securities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of
capital stock to determine the fair value of our common stock at each valuation date. The methods we considered consisted of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Current Value Method.</I>&nbsp;Under the current value method, once the fair value of the enterprise is established, the value is allocated to the various series of preferred and common stock based on their
respective seniority, liquidation preferences or conversion values, whichever is greatest. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Option Pricing Method.</I>&nbsp;Under the option pricing method, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity
class. The values of the preferred and common stock are inferred by analyzing these options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Probability-Weighted Expected Return Method, or PWERM.</I>&nbsp;The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment
returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years
Ended December&nbsp;31, 2014 and 2013 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our consolidated results of operations for the years ended
December&nbsp;31, 2014 and 2013, together with the changes in those items in dollars and as a percentage (in thousands, except percentages): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income/(expense), net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:4%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue. </I></B>For the year ended December&nbsp;31, 2014, revenue was
$80,000 compared to $6,000 for the year ended December&nbsp;31, 2013. For both periods, revenue is from two material transfer agreements and reflects timing of activity and payments received under the agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development.</I></B> The following table summarizes our research and development expense by program for the years ended
December&nbsp;31, 2014 and 2013, together with the change in spending by program in dollars and as a percentage (in thousands, except percentages): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRLX101</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRLX301</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dynamic Tumor Targeting platform</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overhead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;70&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense for the year ended December&nbsp;31, 2014 was $11.8 million
compared to $9.7 million for the year ended December&nbsp;31, 2013, an increase of $2.1 million, or 21%. The increase was primarily attributable to an increase in costs associated with the CRLX101 program and partially offset by lower costs
associated with our Dynamic Tumor Targeting Platform new discovery research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2014, costs associated
with the CRLX101 program increased $2.6 million, or 55%, to $7.2 million from $4.6 million for the year ended December&nbsp;31, 2013. The increase was primarily due to ongoing costs associated with the RCC Trial. CRLX101 clinical trial expenses
increased by $2.0 million in 2014 compared to the prior year as a result of increased costs for our CRO and laboratories, as well as clinical site initiation costs and patient fees for the RCC Trial. Salary, benefits and other expenses allocated to
CRLX101 increased $0.6 million in 2014 compared to the prior year to support CRLX101 development and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2014, costs associated with the CRLX301 program were $2.4 million compared to $2.3 million for the year ended December&nbsp;31, 2013, an increase of $0.1 million, or 6%. The increase in CRLX301 program expense was primarily due to
costs associated with the Phase 1 clinical trial that we initiated in December 2014. CRLX301 clinical trial expenses increased by $0.3 million in 2014 compared to the prior year. The increase was due to CRO and laboratory costs associated with
initiating our Phase 1 clinical trial of CRLX301, including costs associated with setting up clinical sites and laboratories. Salary and benefits expenses allocated to CRLX301 increased $0.4 million in 2014 compared to the prior year. The increased
CRLX301 expenses were partially offset by a $0.3 million decrease in research costs and a $0.3 million decrease in chemistry manufacturing and controls development activities as CRLX301 transitioned into clinical stage development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses associated with our Dynamic Tumor Targeting Platform decreased $0.8 million in 2014 as compared to 2013, mainly as a result of
reduced staff in new discovery research as we continue to shift our emphasis to the development of our existing product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative.</I></B> General and administrative expense for the year ended December&nbsp;31, 2014 was $8.6 million
compared to $6.2 million for the year ended December&nbsp;31, 2013, an increase of $2.4 million, or 39%. The increase was primarily attributable to the incremental costs of being a public company, including an increase of $1.1 million for board of
director fees, insurance for directors and officers, audit and tax fees, and corporate communication and printer fees. Salary and benefits expense increased $0.4 million in 2014 compared to the prior year reflecting additional resources in finance
and accounting, legal and corporate communications, along with an increase in stock-based compensation expense. Professional and recruiting fees increased by $0.5&nbsp;million in 2014 compared to 2013, primarily reflecting increased recruiting and
placement fees. Other consulting costs also increased $0.4 million year over year. These increases in general and administrative costs were partially offset by a decrease in legal fees of $0.4 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other expense, net.</I></B> Other expense, net for the year ended December&nbsp;31, 2014 was $3.1 million compared to $1.3 million for
the year ended December&nbsp;31, 2013, an increase of $1.8 million. The increase in net other expense primarily resulted from a loss of $2.5 million incurred on the conversion of convertible debt to common stock. The increase was offset by a
decrease of $0.3 million due to a decrease in the value of the preferred stock warrant liability and a decrease in interest expense of $0.4 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;71&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December&nbsp;31, 2013 and 2012 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our consolidated results of operations for the years ended December&nbsp;31, 2013 and 2012, together with the
changes in those items in dollars and as a percentage (in thousands, except percentages): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income/(expense), net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue. </I></B>Revenue for the year ended December&nbsp;31, 2013 was $6,000 compared to $0.6 million
for the year ended December&nbsp;31, 2012. We recorded revenue in 2013 and 2012 in connection with two material transfer agreements, each with a different pharmaceutical company. Pursuant to each of the agreements, we received payments in exchange
for the pharmaceutical company&#146;s use of our proprietary technology for research purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development.</I></B>
The following table summarizes our research and development expense by program for the years ended December&nbsp;31, 2013 and 2012, together with the change in spending by program in dollars and as a percentage (in thousands, except percentages):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRLX101</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRLX301</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nanoparticle-drug conjugate platform</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overhead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense for the year ended December&nbsp;31, 2013 was $9.7 million compared to $15.8
million for the year ended December&nbsp;31, 2012, a decrease of $6.1 million, or 39%. The decrease was reflected across all programs. The $3.7 million decrease in CRLX101 expense was primarily the result of winding down our Phase 2 clinical trial
of CRLX101 as monotherapy in patients with NSCLC, which was substantially completed in March 2013. Clinical trial expense decreased $2.1 million and contract manufacturing expense for clinical trial material decreased $1.6 million. The decrease in
spending on the CRLX301 program in the year ended December&nbsp;31, 2013 from the year ended December&nbsp;31, 2012 was the result of our completion of development activities, such as investigational new drug enabling studies and process
development, early in 2013. Expenses associated with our Dynamic Tumor Targeting Platform decreased $0.6 million, mainly as a result of reduced staff in new discovery research as our primary emphasis shifted to the development of our product
candidates. The $0.3 million decrease in overhead expense was due mainly to a reduction in retainer-based advisory agreements and reduced depreciation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative. </I></B>General and administrative expense for the year ended December&nbsp;31, 2013 was $6.2 million
compared to $6.4 million for the year ended December&nbsp;31, 2013, a decrease of $0.2 million, or 4%. The decrease was the result of a $0.4 million decrease in outside corporate and intellectual property legal expenses, offset by a $0.1 million
increase in personnel costs and a $0.1 million increase in consulting expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;72&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense), net.</I></B> Other expense, net for the year ended
December&nbsp;31, 2013 was $1.3 million compared to $0.5 million net expense for the year ended December&nbsp;31, 2012, an increase of net other expense of $0.8&nbsp;million. The increase in net other expense primarily resulted from $0.9 million
increase in recorded interest expense on our borrowings under the Lighthouse Loan Agreement. In addition, the adjustment to the fair value of our outstanding preferred stock warrants resulted in $0.2 million of other income for the year ended
December&nbsp;31, 2013 compared with $39,000 of other income for the year ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From our incorporation through December&nbsp;31, 2014, we have raised an aggregate of $171.4 million to fund our operations, of which $84.2
million was from the sale of preferred stock in private placements, $59.9 million was from our IPO, $17.3 million was from the sale of convertible promissory notes, and $10.0 million was from borrowings under the Lighthouse Loan Agreement. As of
December&nbsp;31, 2014, we had cash and cash equivalents of approximately $51.2 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indebtedness </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Recent Financing Activity</I>. On January&nbsp;8, 2015, we entered into the Hercules Loan Agreement and borrowed $15.0 million from
Hercules. We used a portion of those proceeds to repay our outstanding indebtedness under the Lighthouse Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Hercules
Loan Agreement provides for up to three separate tranches of borrowings, the first of which was funded in the amount of $15.0 million on January&nbsp;8, 2015. We may draw the second tranche of up to $5.0&nbsp;million, subject to the satisfaction of
customary funding conditions, on or prior to December&nbsp;15, 2015, provided that we meet certain clinical milestones specified in the Hercules Loan Agreement. We may draw the third tranche of up to $6.0 million at no less than $3.0 million per
draw and subject to the satisfaction of customary funding conditions, on or after September&nbsp;30, 2015 but before December&nbsp;15, 2015, provided that between January&nbsp;8, 2015 and December&nbsp;15, 2015, we have received net cash proceeds of
at least $40.0 million from our issuance and sale of equity securities and/or upfront cash payments from one or more strategic corporate partnerships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our indebtedness under the Hercules Loan Agreement will mature on July&nbsp;1, 2018. Each advance under the Hercules Loan Agreement accrues
interest at a floating per annum rate equal to the greater of (i)&nbsp;7.30% or (ii)&nbsp;the sum of 7.30% plus the prime rate minus 5.75%. The Hercules Loan Agreement provides for interest-only payments on a monthly basis until December&nbsp;31,
2015. The interest only period may be extended at our option for a three month period if we attain certain clinical milestones specified in the Hercules Loan Agreement, and for an additional three month period if we attain certain clinical
milestones and receive net cash proceeds of at least $30.0 million from the issuance and sale of our equity securities and/or upfront cash payments from one or more strategic corporate partnerships. Thereafter, amortization payments will be payable
monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. We may prepay the indebtedness under the Hercules Loan
Agreement in whole or in part upon seven business days&#146; prior written notice to Hercules. Any such prepayment is subject to a prepayment charge of (i)&nbsp;3.0% if such prepayment occurs on or before January&nbsp;8, 2016, (ii)&nbsp;2.0% if such
prepayment occurs after January&nbsp;8, 2016, but on or before January&nbsp;8, 2017, and (iii)&nbsp;1.0% if such prepayment occurs after January&nbsp;8, 2017. Amounts outstanding during an event of default are payable upon Hercules&#146; demand and
shall accrue interest at an additional rate of 5.0%&nbsp;per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), we shall make a final payment to Hercules in the amount of
6.70% of the aggregate original principal amount advanced by Hercules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Hercules Loan Agreement is secured by substantially all of our
assets other than our intellectual property. We have also granted Hercules a negative pledge with respect to our intellectual property, which, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;73&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
among other things, prohibits us from selling, transferring, assigning, mortgaging, pledging, leasing, granting a security interest in or otherwise encumbering our intellectual property. The
Hercules Loan Agreement includes restrictive covenants that may restrict our ability to obtain further debt or equity financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Lighthouse Loan Agreement</I>. In 2011, we entered into the Lighthouse Loan Agreement, which permitted us to borrow up to an aggregate
principal amount of $10.0 million. We borrowed $5.0&nbsp;million in March 2012 and an additional $5.0 million in August 2012. Interest accrued under the Lighthouse Loan Agreement at an annual rate of 8.25%. As of December&nbsp;31, 2014, there was
$3.3&nbsp;million in aggregate principal amount outstanding under the Lighthouse Loan Agreement. We repaid in full our outstanding indebtedness under the Lighthouse Loan Agreement on January&nbsp;8, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Convertible Notes</I>. In 2014, we issued and sold the 2014 Convertible Notes, in an aggregate principal amount of $8.5 million, to certain
of our stockholders and one additional purchaser. The 2014 Convertible Notes accrued interest at an annual rate of 7%. In connection with the completion of our IPO on April&nbsp;15, 2014, all principal and accrued interest under our 2014 Convertible
Notes converted into an aggregate of 1,582,931 shares of our common stock, at 77.5% of the IPO price, or $5.43 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, we
issued and sold convertible promissory notes, or our 2013 Convertible Notes, in an aggregate principal amount of $8.8 million to certain of our stockholders. Our 2013 Convertible Notes accrued interest at an annual rate of 7%. In connection with the
completion of our IPO on April&nbsp;15, 2014, all principal and accrued interest under our 2013 Convertible Notes converted into an aggregate of 1,319,302 shares of our common stock, at the IPO price of $7.00 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Plan of Operations and Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and
development services, contract manufacturing services, laboratory and related supplies, clinical trial costs, legal and other regulatory expenses and general overhead costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our cash and cash equivalents as of December&nbsp;31, 2014, together with the net proceeds we received from Hercules on
January&nbsp;8, 2015, will enable us to fund our operating expenses, debt service and capital expenditure requirements into the third quarter of 2016. We have based this estimate on assumptions that may prove to be wrong, and we could use our
capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and development requirements of the product candidates we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, timing, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs, timing and outcome of regulatory review of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or in-license other medicines and technology; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;74&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our headcount growth and associated costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and
conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product
sales. In addition, our product candidates, if approved, may not achieve commercial success. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings,
debt financings and revenue from collaboration arrangements. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may
include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through collaboration arrangements in the future, we may have to relinquish valuable rights to our
technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce
or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
sets forth the primary sources and uses of cash for each period set forth below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working
capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $19.1 million for the year ended December&nbsp;31, 2014 compared with $16.6 million
for the year ended December&nbsp;31, 2013, an increase of $2.5 million. The increase in cash used in operating activities resulted from an increase in operating expenses of $4.5 million, partially offset by changes in the components of working
capital of $1.7 million and a decrease in interest payments on our debt facility with Lighthouse Capital of $0.3 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used
in operating activities was $16.6 million for the year ended December&nbsp;31, 2013 compared with $21.0 million for the year ended December&nbsp;31, 2012, a decrease of $4.4 million. The decrease primarily resulted from a $6.3 million decrease in
operating expenses, which was partially offset by a $0.7 million increase in interest payments on our debt facility with Lighthouse Capital, $0.6 million in revenue from material transfer agreements recorded in the year ended December&nbsp;31, 2012
and $0.6 million resulting from net changes in the components of working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities reflects purchases of property and equipment of $225,000 for the year ended December&nbsp;31, 2014
compared to $7,000 for the year ended December&nbsp;31, 2013, an increase of $218,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;75&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The increase is attributable to purchases of laboratory, office and computer equipment of $173,000 and furniture, fixtures and leasehold improvements of $52,000 in the year ended
December&nbsp;31, 2014, compared to laboratory equipment purchases of $7,000 in the year ended December&nbsp;31, 2013. The increase for the year ended December&nbsp;31, 2014 was partially offset by proceeds of $40,000 from the sale of property and
equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $7,000 for the year ended December&nbsp;31, 2013 compared to $180,000 for the year
ended December&nbsp;31, 2012. The decrease was primarily due to purchases laboratory equipment, employee computers and office equipment and furniture in the year ended December&nbsp;31, 2012 compared to the year ended December&nbsp;31, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Provided by Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $65.0 million for the year ended December&nbsp;31, 2014 compared with $5.4 million for the year
ended December&nbsp;31, 2013. For the year ended December&nbsp;31, 2014, we raised net proceeds of $59.9 million from our IPO and $8.3 million through the sale of convertible promissory notes compared to raising $8.8 million through the sale of
convertible promissory notes for the year ended December&nbsp;31, 2013. We repaid indebtedness under the Loan Agreement with Lighthouse Capital in the amount of $3.3 million for the year ended December&nbsp;31, 2014 compared to repayments of $3.1
million for the year ended December&nbsp;31, 2013. We received $0.1 million of proceeds from the exercise of common stock options for the year ended December&nbsp;31, 2014 compared to $35,000 for the year ended December&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $5.4 million for the year ended December&nbsp;31, 2013 compared to $22.5 million during the year
ended December&nbsp;31, 2012. During the year ended December&nbsp;31, 2013, we sold $8.8 million in convertible promissory notes, repaid indebtedness under the Lighthouse Loan Agreement in the amount of $3.1 million and paid $0.4 million of debt
issuance cost related to the convertible note issuance and this offering. In the year ended December&nbsp;31, 2012, we sold preferred stock for net proceeds of $12.9 million, borrowed $10.0 million under the Lighthouse Loan Agreement and repaid
indebtedness under the Lighthouse Loan Agreement in the amount of $0.4 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Contingent Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes our significant contractual obligations as of December&nbsp;31, 2014 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Payments Due by Period ($)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:76.50pt; font-size:8pt; font-family:Times New Roman">Contractual Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Less&nbsp;than<br>1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">1 to 3<br>years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">3&nbsp;to&nbsp;5<br>years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">More&nbsp;than<br>5&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Lease Obligations(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt Obligations(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents minimum future lease payments under our non-cancellable operating lease. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes. On July&nbsp;11,
2014, we signed a lease amendment to expand our leased premises at 840 Memorial Drive, Cambridge, Massachusetts, by approximately 8,628 rentable square feet. The amendment became effective on July&nbsp;15, 2014, and the lease expires on
February&nbsp;29, 2016. For the year ended December&nbsp;31, 2014 total base rent for all of our rented space at 840 Memorial Drive amounted to approximately $737,000. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of payment obligations for principal and interest to Lighthouse Capital under the Lighthouse Loan Agreement. As of December&nbsp;31, 2014, we had $3.2 million in outstanding borrowings under the debt facility,
bearing interest at 8.25% with a one-time final payment of 6% of the original principal amount of $10.0 million due on December&nbsp;1, 2015. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;76&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone and royalty payments associated with our license agreements have not been included in
the above table of contractual obligations as we cannot reasonably estimate if or when they will occur. Possible future payments under our intellectual property agreements include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Under the CRLX101 Agreement, we will be required to pay to Calando: (1)&nbsp;milestone payments in an aggregate amount of up to $32.8&nbsp;million upon the achievement of certain development, regulatory and commercial
milestones, (2)&nbsp;tiered royalty payments ranging from low- to&nbsp;mid-single&nbsp;digits, as a percentage of worldwide net sales, if we or one of our affiliates sells CRLX101 and (3)&nbsp;a percentage, ranging from the low- to mid-double
digits, of any licensing or sublicensing income we receive from our license or sublicense of CRLX101. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Under the Platform Agreement, we paid to Calando in January 2015 a $250,000 clinical development milestone to Calando following the initiation of our Phase 1 clinical trial of CRLX301 in December 2014. In addition,
under the Platform Agreement, we will be required to pay to Calando: (1)&nbsp;additional milestone payments in an aggregate amount of up to $17.8 million to Calando upon the achievement of certain regulatory and commercial milestones,
(2)&nbsp;tiered royalty payments ranging from low- to mid-single digits, as a percentage of worldwide net sales, in the event we or one of our affiliates sells CRLX301 and (3)&nbsp;a percentage, in the low-double digits, of any licensing or
sublicensing income we receive from our license or sublicense of CRLX301. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contractual obligations table does not
include potential payments we may be required to make under manufacturing and CRO agreements as the timing of when these payments will actually be made is uncertain and the payments are contingent upon the initiation and completion of future
activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC
rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014 the FASB issued Accounting Standards Update, or ASU, 2014-15, <I>Disclosure of Uncertainties About an Entity&#146;s Ability to
Continue as a Going Concern</I>, or ASU 2014-15. ASU 2014-15 requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity&#146;s ability to
continue as a going concern and provide related disclosures. ASU 2014-15 is effective for annual and interim reporting periods beginning January&nbsp;1, 2017, and we do not expect that it will have a material impact on our consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2014, the FASB issued ASU No.&nbsp;2014-10, <I>Development Stage Entities: Elimination of Certain Financial Reporting
Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</I>. This accounting standard eliminates all incremental financial reporting requirements from generally accepted accounting principles in the
United States for development stage entities. This ASU is effective on a prospective basis for annual and interim reporting periods beginning on or after December&nbsp;15, 2014, with early adoption permitted. We elected to early adopt the ASU
starting with our June&nbsp;30, 2014 financial statements and, accordingly, have not included inception to date information in our financial statements appearing at the end of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risk related to changes in interest rates. As of December&nbsp;31, 2014, we had cash and cash equivalents of
approximately $51.2 million, consisting primarily of investments in United States Treasuries and certificates of deposit. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United
States interest rates, particularly because our investments are in cash and cash equivalents. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not
have a material effect on the fair market value of our investment portfolio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;77&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage,
oncology-focused company applying our proprietary Dynamic Tumor Targeting&#153; Platform to develop differentiated therapies. This platform utilizes nanoparticle-drug conjugates, or NDCs, which consist of proprietary polymers that are covalently
linked to anti-cancer therapeutics, or payloads. We believe these NDCs dynamically target tumors by exploiting the leakiness of new blood vessels in tumors as an entry portal into tumor tissue, followed by active uptake into tumor cells and the
sustained release of the anti-cancer payload inside the tumor cells. We believe that our NDCs are differentiated from other nanoparticle technologies by our linker technology, which allows for preferential delivery of our anti-cancer payloads. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, CRLX101, is a dynamically tumor targeted NDC in Phase 2 clinical development and has the potential to improve
outcomes for patients in combination with other cancer treatments. We believe CRLX101, which contains camptothecin as its anti-cancer payload, is a potent, durable and combinable inhibitor of topoisomerase 1, or topo 1, a commercially validated
cancer target, and hypoxia inducible factor, or HIF, a novel target of increasing interest in cancer research. Two products that have been marketed by other companies, irinotecan and topotecan, inhibit topo 1, but their utility is limited by
toxicities. Recent research suggests that HIF, and in particular the HIF subunit HIF-l<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, is a master regulator of multiple cancer cell survival pathways. Over 250 patients have been administered CRLX101
in multiple indications at several clinical trial sites. In clinical trials evaluating CRLX101 as a single agent, CRLX101 was generally well tolerated with a toxicity profile generally characterized by low-grade (Common Terminology Criteria for
Adverse Events grade 1-2) adverse events. No treatment-related trial deaths have been observed to date. In ongoing clinical trials, CRLX101 also appears active and combinable with Avastin (bevacizumab) and chemoradiotherapy, or CRT, which is a
combination of capecitabine and radiation. In addition, preclinical data indicate that CRLX101 may be combinable with other anti-cancer therapies. We are pursuing development of CRLX101 in combination with anti-cancer therapies in multiple ongoing
clinical development programs that include a company-sponsored trial and investigator-sponsored trials, or ISTs. These trials consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Relapsed renal cell carcinoma:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 2 randomized, controlled, company-sponsored trial is being conducted comparing CRLX101 administered in combination with Avastin to investigator&#146;s choice of standard of care in patients with renal cell
carcinoma, or RCC, who have received two or three prior lines of therapy. We refer to this study as the RCC Trial. The RCC Trial is currently being conducted at approximately 30&nbsp;sites in the United States, with eight additional sites planned in
the United States and five additional sites planned in South Korea. Based on results from the Phase 1b/2 IST in relapsed RCC, discussed below, we believe that the combination of CRLX101 and Avastin may provide therapeutic benefits to patients with
relapsed RCC who have received two or three prior lines of therapy including a tyrosine kinase inhibitor, or TKI, and/or an inhibitor of a mammalian target of rapamycin, or an mTORI. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">A Phase 1b/2 single-arm IST of CRLX101 in combination with Avastin in patients with relapsed RCC is being conducted at the University of Pennsylvania
and Thomas Jefferson University Hospital. A total of 22 patients were enrolled in this trial. The last patient was enrolled in December 2014, and the trial has met its primary endpoint of at least 50% of patients achieving four months progression
free survival, or PFS. Preliminary data from this clinical trial has been submitted for presentation at the 2015 annual meeting of the American Society of Clinical Oncology, or ASCO. As of February 3, 2015, the date of the abstract submission to
ASCO, the median PFS, or mPFS, of patients on the trial was 9.9 months, with seven of the 22 patients still receiving treatment. Based on third-party published data, the mPFS of the standard of care in this setting is approximately 3.5 months. In
addition, the Response Evaluation Criteria in Solid Tumor, or RECIST, partial response rate of patients on the trial as of February 3, 2015 was 23%. Several </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;78&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
recent studies in advanced RCC suggest that after treatment with a TKI, subsequent therapies, including Avastin alone, achieve RECIST partial response rates of between 2% and 4%.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Relapsed ovarian cancer:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 2 single-arm IST of CRLX101 as monotherapy and in combination with Avastin in patients with relapsed ovarian cancer is being conducted at Massachusetts General Hospital and affiliated Harvard University teaching
hospitals. As previously reported, the first stage of the trial, administering CRLX101 as monotherapy, met its primary endpoint of PFS at six months for at least four patients. RECIST responses, as well as encouraging PFS, were observed for several
patients. Platinum-resistant ovarian cancer patients are being enrolled in the second stage of this trial, administering CRLX101 in combination with Avastin. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have commenced start-up activities for a Phase 1b single-arm company-sponsored trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer conducted in collaboration with the GOG
Foundation, Inc. (formerly known as the Gynecologic Oncology Group), or GOG. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Neoadjuvant rectal cancer:</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1b/2 single-arm IST of CRLX101 in combination with CRT in patients with non-metastatic rectal cancer is being conducted at the University of North Carolina at Chapel Hill and several other sites, including the
University of Indiana, Wake Forest University, Rex Hospital Inc. and Southeastern Medical Oncology Center. No dose limiting toxicities, or DLTs, have been reported in the Phase 1b stage of the trial, in which a maximum tolerated dose, or MTD, and
recommended Phase 2 dose, or RP2D, of 15 mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> of CRLX101 was established when administered in combination with capecitabine and radiotherapy. Patients are currently being enrolled in the RP2D
expansion Phase 2 stage of the trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold issued patents in the United States, Japan and Europe covering the
composition of matter of CRLX101 that expire in 2023 and 2024, excluding any potential patent term extension. Due to the ability of NDCs to target the &#147;leaky&#148; vasculature that is present in all solid tumors and CRLX101&#146;s apparently
favorable adverse event profile observed to date, we believe CRLX101 may have significant clinical utility in several cancer indications, particularly in combination with other cancer therapies. Our development focus is on tumor types where HIF is
up-regulated, topo 1 inhibition is desirable, and drug combinations with CRLX101 can be pursued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX301, our second platform-generated
clinical candidate, is a dynamically tumor-targeted NDC in Phase&nbsp;1 clinical development. CRLX301 is designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. Docetaxel is a microtubule
stabilizer that is extensively used in clinical practice and is approved by the FDA for the treatment of locally advanced or metastatic non-small cell lung cancer, locally advanced squamous cell carcinoma of the head and neck, androgen-independent
prostate cancer, locally advanced or metastatic breast cancer and advanced gastric cancer. In preclinical studies, CRLX301 delivered up to ten times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available
docetaxel and was superior to docetaxel in seven of seven animal models, with a statistically significant survival benefit seen in five of the seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported
with docetaxel in similar preclinical studies. We hold issued patents in the United&nbsp;States, Japan and Europe covering the composition of matter of CRLX301 that expire in 2023 and 2024, excluding any potential patent term extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, we expect to commercialize our product candidates in the United States directly with a focused commercialization organization. We
expect to seek one or more strategic partners for commercialization of our product candidates outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;79&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to be a leader in the discovery, development and commercialization of NDCs for the treatment of patients with inadequately treated
forms of cancer. Key elements of our strategy to achieve this goal are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance the clinical development of our lead product candidate, CRLX101, in multiple tumor types.</I> Based on confirmatory signals of activity observed in the ongoing relapsed RCC IST, we initiated a randomized
Phase 2 clinical trial of CRLX101 in combination with Avastin in this patient population in 2014. We are exploring development opportunities in two additional tumor types, and we intend to explore additional development opportunities, alone and in
collaboration with strategic partners, to capitalize on the various opportunities to use CRLX101 in combination with other cancer treatments. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance the clinical development of our second product candidate, CRLX301, into selected indications.</I> Assuming we are successful in establishing a safe maximum tolerated dose, or MTD, and/or a recommended Phase 2
dose in the Phase 1 trial, we plan to rapidly advance CRLX301 into Phase 2 development. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Leverage our platform to discover and develop a proprietary pipeline of highly differentiated product candidates with anti-cancer payloads</I>. Using our Dynamic Tumor Targeting Platform, we have created two product
candidates, CRLX101 and CRLX301. We have used our platform to create additional NDCs, and we intend over the longer term to develop additional product candidates from the platform. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Leverage our platform beyond our proprietary pipeline to enter into strategic partnerships for the development of product candidates.</I> We believe that our platform can be used with a wide range of payloads. While
our focus is on oncology, our preclinical data demonstrates that our platform may also be applicable in certain inflammatory diseases. We plan to explore the possibility of entering into partnerships with companies that have proprietary active
pharmaceutical ingredients, or APIs, that can be used as NDC payloads for use in the treatment of oncology or inflammation indications. We envision selective partnerships with pharmaceutical companies, in which we would leverage the partner&#146;s
expertise, in combination with our platform, to generate novel NDCs incorporating the partner&#146;s approved therapeutic or development candidate. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Build core capabilities that allow us to commercialize our products in the United States.</I> In order to maximize the value of our product candidates, if approved, we expect to commercialize our products in the
United States with a focused commercialization organization and to seek one or more strategic partners for commercialization outside the United States. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach to Developing Dynamically Tumor Targeted NDCs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Dynamic Tumor Targeting Platform is designed to create NDCs with the aim of providing safer and/or more effective therapies for patients
living with cancer. This platform has thus far generated a lead candidate, CRLX101, and a second candidate, CRLX301, and has the potential to expand our pipeline, alone and in combination with partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary Dynamic Tumor Targeting Platform utilizes cyclodextrin polymer, or CDP, technology, which we use to create NDCs that contain
small molecules such as camptothecin in the case of CRLX101 and docetaxel in the case of CRLX301. NDCs use a covalent linker to attach an anti-cancer payload to a nanoparticle backbone. The linker determines the release speed of the anti-cancer
payload from the nanoparticle backbone. After the anti-cancer payload is released from the nanoparticle backbone, we believe the nanoparticle backbone disassembles into its component polymer strands. The linker and polymer strands in CRLX101 and
CRLX301&#151;cyclodextrin, polyethylene glycol, cysteine and glycine&#151;have been extensively used in human pharmaceuticals or are part of humans&#146; natural metabolism. Our NDCs are generally too large to be readily eliminated from the
bloodstream, but the polymer strands are small enough to be eliminated by the kidneys into the urine. The released anti-cancer payload follows a separate metabolic pathway. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;80&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dynamic Tumor Targeting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our dynamic tumor targeting exploits the leaky vasculature present in new blood vessels essential for tumor growth and results in
selective uptake of the NDC and sustained release of the NDC&#146;s anti-cancer payload into tumor cells. Based on our preclinical studies and the CRLX101 clinical trials, we believe dynamic tumor targeting involves a three-step process, as
described and illustrated below, each of which contributes to the achievement of desirable anti-cancer payload exposure in tumors and the reduction of undesirable anti-cancer payload exposure in normal tissue. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g89f77.jpg" ALT="LOGO">
 </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><I>Tumor targeting via leaky vasculature</I>. After intravenous infusion, the NDCs circulate in the bloodstream. In contrast to typical small molecule drugs, once in the bloodstream, our NDCs are generally too large to
be rapidly eliminated by filtration in the kidneys and to escape from the bloodstream into normal tissue. However, they are small enough to exploit the leaky vasculature found in the immature blood vessels of growing tumors as a selective entry
portal into tumor tissue. As tumors grow, they stimulate the formation of new, immature blood vessels, the inner surfaces of which are less densely lined by endothelial cells as compar7ed to mature blood vessels. As a result, immature blood vessels
of growing tumors have larger pores that confer leakiness. Generally, pore sizes of normal tissue are less than ten nanometers, and pore sizes of tumor tissue are greater than 100&nbsp;nanometers. Our CDP-based NDCs are typically between 10 and 40
nanometers in diameter. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">CRLX101 has a relatively low tissue distribution. A compound&#146;s volume of distribution refers to
the theoretical fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma, with higher volume of distribution values indicating more extensive distribution into tissue. In human
patients, the volume of distribution of CRLX101 is approximately 2.4 liters. In contrast, in human patients, the volume of distribution of irinotecan, an analog of camptothecin approved for the treatment of metastatic colon cancer, is approximately
263&nbsp;liters, and the volume of distribution of topotecan, which is approved for the treatment of ovarian, cervical and small cell lung cancer, is approximately 130 liters. This low tissue distribution of CRLX101 spares key organ systems from
extensive drug exposure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Our NDCs are designed to be stealthy, meaning that they are designed to be not readily detected by the
body&#146;s immune cells and therefore avoid producing an immune response. This results in slow metabolism and long systemic circulation, allowing our NDCs to penetrate from the bloodstream into tumors via the leaky vasculature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;81&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><I>Transport into tumor cells</I>. Once inside the tumor, tumor cells actively transport our NDCs into the interior of tumor cells. We believe that macropinocytosis acts as the primary mechanism of uptake.
Macropinocytosis is a cellular uptake mechanism that allows small particles to be transported into cells. It is induced by the tumor&#146;s rapid growth and ensuing demand for cellular building blocks. Macropinocytosis is up-regulated in tumor
cells, and CRLX101 exploits this feature to drive active uptake of the NDC and its anti-cancer payload. Following their entry into the cancer cells, we believe our NDCs, due to their size, are not easily removed from cancer cells by their existing
efflux pumps. Efflux is the process by which toxic substances are moved out of the cell and which confers tumor resistance against anti-cancer agents. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><I>Sustained release of anti-cancer payload from within tumor cells</I>. Since the anti-cancer payload is covalently linked to the polymer of the NDC, the anti-cancer payload has to be cleaved from the polymer to be
active. We believe the cleavage of the linker connection between the anti-cancer payload and the NDC occurs primarily by hydrolysis and therefore is affected by pH. Typically, the pH level in tumors is lower than in the bloodstream, which further
slows the cleavage of the linker and thereby prolongs the release of the anti-cancer payload within tumor cells. We believe sustained release contributes to enhanced anti-tumor activity. In rapidly proliferating cells, such as growing tumor cells,
the cell replication cycle takes approximately 24 hours to complete, and the S-phase of the cell replication cycle, during which new DNA is synthesized, lasts for approximately five to eight hours. Many chemotherapeutics, including the camptothecin
class, interfere with DNA synthesis during the <FONT STYLE="white-space:nowrap">S-phase,</FONT> rendering cells more susceptible to inhibition if they are in S-phase and less susceptible to inhibition if they are not in S-phase. Since cells enter
the cell replication cycle independently of each other, at any given time not all cells are susceptible to inhibition by an anti-cancer therapy that acts during the S-phase. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Unless sustained drug concentrations in tumors can be achieved for the entire duration of the replication cycle, the anti-cancer agent will
only kill the cells that are in a susceptible phase while drug levels are above the minimum therapeutic threshold, thus allowing the replication and escape of tumor cells during intervals of low drug levels in tumors. For example, topotecan has a
terminal half-life, which is the time required for the plasma drug concentration to reach half of its original value, of two to three hours in humans, whereas CRLX101 has a plasma terminal half-life of approximately 28&nbsp;hours, covering the
entire duration of a typical cell replication cycle. Therefore, the third step of dynamic tumor targeting leverages the enrichment of the NDCs within the tumor cells by releasing the payload in a sustained fashion to achieve durable drug
concentrations for the entire duration of a typical cell replication cycle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As initial clinical evidence of selective entry of CRLX101 in
tumor tissue, we obtained differential post-therapy biopsies of tumor tissue and adjacent normal tissue from two gastric patients. These patient biopsies, taken between 24 and 48 hours after a single dose of CRLX101 was administered, indicated that
camptothecin was present in the tumor tissue, and very little camptothecin was present in the adjacent normal tissue. These human data support our belief that our platform achieves higher drug concentrations in tumors compared to normal tissue. In
addition, we believe that the observed safety profile of our lead drug candidate, CRLX101, across more than 250 cancer patients, can be explained by the targeted delivery of the anti-cancer payload and the sparing of key organ systems from extensive
drug exposure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Application of the Platform </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platform is applicable to a range of API payloads. It can be applied in oncology, and we believe it may also be applied in certain types of
inflammatory diseases where leaky vascular occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have created NDCs with a variety of small molecule payloads, including
camptothecin, docetaxel, Jevtana<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (cabazitaxel), Gemzar<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (gemcitabine),
Trexall<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (methotrexate) and Xeljanz<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (tofacitinib). We select the small molecule payload based upon several factors, including our
ability to conjugate the payload to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;82&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
polymer, the biological rationale for prolonging circulation and providing sustained release of the payload, a relatively high potency of the payload, as well as intellectual property, regulatory
and commercial considerations. As discussed below, in preclinical testing, our NDCs generally show improved pharmacokinetics, activity and tolerability as compared to the payload alone. We intend to develop NDCs alone and potentially in
collaboration with partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may expand beyond anti-cancer therapies to capitalize on the additional opportunities that
our platform affords. As an example, in inflammatory diseases our NDCs may offer clinical advantages. Like tumor tissues, in certain inflammatory diseases the pores of blood vessels can become enlarged as part of the inflammatory process. We believe
our platform may prove useful in inflammatory diseases characterized by leaky vasculature. While we do not intend to focus our business on inflammatory diseases, this aspect of our platform may afford us with future expansion opportunities by
pursuing anti-inflammatory opportunities through collaborations with companies that have expertise in inflammation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current development stage pipeline consists of CRLX101 and CRLX301. As described in more detail below, we are pursuing clinical development
of CRLX101 in three lead indications, and we began clinical development of CRLX301 in 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Product<BR>Candidate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Indication</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Stage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Design of Ongoing Clinical Trials</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Relapsed<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Renal Cell</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carcinoma</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">Phase&nbsp;2</TD>
<TD NOWRAP VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ongoing randomized Phase 2 company-sponsored
trial of CRLX101 in combination with Avastin</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ongoing single-arm Phase 1b/2 IST of
CRLX101 in combination with Avastin that has completed enrollment</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CRLX101</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Relapsed<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ovarian</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cancer</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">Phase 2</TD>
<TD NOWRAP VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ongoing 2-part, single-arm Phase 2 IST of
CRLX101 as monotherapy and in combination with Avastin</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;Part 1: monotherapy arm that met primary efficacy and safety endpoints</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;Part 2: ongoing single-arm of
CRLX101 in combination with Avastin, for which the Avastin is provided by Genentech</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Neoadjuvant<BR> Rectal<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cancer</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">Phase 2</TD>
<TD NOWRAP VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">Ongoing single-arm Phase 1b/2 IST of CRLX101 in combination with CRT</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CRLX301</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Solid<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tumors</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">Phase 1</TD>
<TD NOWRAP VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">Ongoing Phase 1 dose-escalation trial of CRLX301 as monotherapy</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CRLX101 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX101 is a dynamically tumor targeted NDC that is administered intravenously. It includes a CDP to which camptothecin is covalently linked.
We have demonstrated in preclinical studies that CRLX101 is a potent, durable and combinable inhibitor of topo 1 and HIF. We believe that the properties of CRLX101 could translate into important benefits for patients. We are focusing the clinical
development of CRLX101 on cancer indications in which we expect the durable inhibition of topo 1 and HIF, in combination with other cancer treatments, will lead to differentiated efficacy. Initially, we are focusing on combinations with vascular
endothelial growth factor inhibitors, or VEGF inhibitors, or CRT. Accordingly, we are currently developing CRLX101 in combination with Avastin in relapsed RCC and relapsed ovarian cancer, and in combination with CRT in rectal cancer in the
neoadjuvant setting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;83&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Preclinical Efficacy, Potency and Selectivity of CRLX101 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Camptothecin is a natural product and a potent inhibitor of topo 1. Camptothecin can exist in two forms: an active lactone form that inhibits
topo 1, and an inactive carboxylate form. In human plasma, camptothecin is rapidly converted from its active form to its inactive form. This rapid conversion was not appreciated when camptothecin was originally developed, and in clinical trials
patients were dosed until unacceptable toxicities of hemorrhagic cystitis and bone marrow suppression were observed. As a result, camptothecin has never been approved for use by the FDA or any other regulatory agency. To address the issue of rapid
conversion of camptothecin to its inactive form, CRLX101 covalently binds camptothecin in its active lactone form to a polymer system that protects camptothecin from metabolism in the plasma, drives delivery of the active form of camptothecin into
tumors and tumor cells and minimizes tissue distribution and toxicity related to camptothecin. Our hypothesis is that this delivery mechanism results in the release of the active form of camptothecin into the tumor cells, allowing it to exert its
anti-cancer effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Topo 1 is an essential enzyme required for DNA replication and transcription. In the nucleus, DNA exists as a
supercoiled double helix. Topo 1 cuts one DNA strand of the double helix to allow the DNA to uncoil such that the enzyme complexes that drive DNA replication and transcription can access the DNA template. Once these processes are complete, topo 1
re-ligates the DNA back into its super-coiled form. Camptothecin and its analogs, irinotecan and topotecan, bind to the topo 1 DNA complex and prevent the re-ligation of the DNA. The accumulation of unrepaired DNA breaks causes the cell to undergo
apoptosis, or cell death. Since tumor cells replicate and transcribe their DNA more frequently than normal cells, they require frequent re-ligation of broken DNA strands and are more sensitive to topo 1 inhibitors than normal cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has approved topotecan for the treatment of ovarian cancer, cervical cancer and small cell lung cancer, and irinotecan for the
treatment of metastatic colorectal cancer. Compared to CRLX101, both of these drugs have shorter half-lives, more extensive toxicities and lack of tumor targeting. However, topotecan and irinotecan clinically and commercially validate the inhibition
of topo 1 as an important anti-cancer target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX101 demonstrates a linear and predictable pharmacokinetic, or PK, profile across a
number of animal species and in humans. There is little PK variability between doses, between patients and between single and multi-dose administration in patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical study in which rats were dosed with 2.59 mg/kg of CRLX101, and the concentrations of camptothecin, total and
unconjugated, meaning after its release from CRLX101, were measured using liquid chromatography/tandem mass spectrometry. As illustrated in the graph below, plasma concentration of camptothecin in the rats following dosing of CRLX101 declined
gradually and lacked a rapid distribution phase. Specifically, the half-life of total camptothecin in the rats in this study was 24 hours following a single dose of CRLX101, whereas the published half-life of camptothecin in rats is only 1.3 hours.
Consistent with this prolonged half-life, the clearance of total camptothecin in the study was 1.2 milliliters per hour following a single dose of CRLX101, whereas the published clearance of camptothecin in rats is 1,534 milliliters per hour. The
volume of distribution for CRLX101 in rats in the study was 37 milliliters following a single dose of CRLX101, whereas the published volume of distribution of camptothecin in rats is 1,306 milliliters, suggesting less camptothecin is distributed in
tissue following a single dose of CRLX101 as compared to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;84&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
camptothecin. The graph below shows the plasma concentration of camptothecin in rats, total and unconjugated, over time following administration of a single dose of CRLX101. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CRLX101 Rat Pharmacokinetic Study </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g24i88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results from this pharmacokinetic rat study, demonstrating long half-life, slow clearance and low
volume of distribution, were consistent with the results of our Phase 1/2a clinical trial of CRLX101 in advanced multiply pre-treated solid tumor malignancies, in which human patients were dosed with 15 mg/m2 of CRLX101 which is the single agent
maximum tolerated dose. In the Phase 2a trial, blood was drawn from 36 patients after their first dose of CRLX101 and analyzed for total and unconjugated camptothecin using liquid chromatography/tandem mass spectrometry. The half-life of conjugated
camptothecin following the first dose of CLRX101 in human patients in the trial was 28 hours, the clearance was 91 milliliters per hour and the volume of distribution was 2418 milliliters. The graph below shows the plasma concentration of
camptothecin in human patients in the trial, total and unconjugated, over time following administration of a single dose of CRLX101. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g51t74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted preclinical testing of CRLX101 as monotherapy in over 15 xenograft tumor models, which is
a model in which human tumor tissue is transplanted into animals, encompassing colorectal cancer, gastric cancer, head and neck cancer, lymphoma, ovarian cancer, pancreatic cancer, NSCLC, RCC, small cell lung cancer and triple negative breast
cancer. In our xenograft tumor model studies, CRLX101 demonstrated superiority over commercial comparator drugs as measured by median survival, tumor shrinkage and tumor growth delay. In these tumor model studies, the commercial drugs were
administered at their respective optimal doses and dosing schedules, as determined by the literature. In several of these tumor model studies, CRLX101 achieved complete tumor eradication, which was not achieved by the commercial drugs tested in
these models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graphs illustrate the tumor volume results and post-treatment survival rates in a preclinical study comparing
CRLX101 to Paraplatin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (carboplatin) and cisplatin, which are platinum-based chemotherapeutic agents, in an ovarian xenograft model. In this study, we treated nude mouse xenograft models
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;85&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in which human A2780 ovarian cancer tumor cells were implanted subcutaneously in mice and allowed to establish tumors. We administered 10 mg/kg of CRLX101, 7 mg/kg of cisplatin, 100 mg/kg of
carboplatin or saline, which we also refer to as the vehicle, by intravenous infusion. Each dose group consisted of ten animals and all mice were treated weekly for three weeks. All dose levels were close to the MTD in this model. CRLX101,
carboplatin and cisplatin all delayed tumor growth and improved survival rates as compared to the saline-treated mice, however, as compared to both carboplatin and cisplatin, the CRLX101-treated mice displayed much higher tumor regression, and 100%
tumor-free survivors at the conclusion of the study. These results are illustrated in the graphs below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g45g36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical testing of CRLX101 in combination therapy in multiple subcutaneous and orthotopic xenograft
models, which is a model in which a tumor is grafted into the animal in its natural location, encompassing RCC, ovarian cancer, head and neck cancer, and triple negative breast cancer, demonstrated additive or synergistic effect, meaning greater
than additive effect, when CRLX101 was combined with chemotherapy, platinum, VEGF inhibitors or radiotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical
study in which a single 6 mg dose of CRLX101 reduced available topo 1 protein for at least one week. We treated 18 nude mouse xenograft models (three per time point) in which human <FONT STYLE="white-space:nowrap">NCI-H1299</FONT> non-small cell
lung cancer tumor cells were implanted subcutaneously in mice and allowed to establish tumors. We administered a single dose of 6&nbsp;mg/kg CRLX101 or saline (vehicle) to the control group and collected tumors at various time points, including one,
three, five, seven and nine days after treatment using western blot analysis. Tumors were flash-frozen and topo 1 protein levels were measured and calculated as a percentage of topo 1 protein levels in saline-treated mice. As shown in the graph
below, a single 6 mg/kg dose of CRLX101 reduced available topo 1 protein, and topo 1 protein recovered to baseline levels by nine days after treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Topo 1 Protein in Tumors After CRXL101 Treatment </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g16c79.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;86&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to inhibiting topo 1, CRLX101 is a potent, durable and combinable inhibitor of HIF-1<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and <FONT STYLE="white-space:nowrap">HIF-2</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein expression. The compounds in the camptothecin compound family, including camptothecin and topotecan,
have been described as inhibitors of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> in the past. However, the literature suggests that to achieve durable inhibition of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, sustained
concentrations of camptothecin or topotecan must be achieved within tumor cells. Due to its short half-life, low tumor targeting and high toxicities, topotecan cannot effectively achieve durable HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>
inhibition unless it is dosed metronomically (continuous or frequent treatment with low doses of anti-cancer drugs), which is not considered to be clinically feasible given its toxicity profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> has recently become a target of increasing interest in cancer research. The literature on
the subject has grown substantially and, as summarized in a review paper published in Nature Reviews Clinical Oncology in 2012, many believe that HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is a master regulator for several key cancer cell
survival pathways. When cancer cells proliferate, they can become starved of oxygen, or hypoxic, as tumor growth outpaces the growth of new blood vessels. The lack of oxygen can be exacerbated when new blood vessel formation is inhibited by
anti-angiogenesis drugs, such as Avastin, Zaltrap and Votrient, or as a consequence of radiotherapy. Under hypoxic conditions, the normal degradation of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> slows down, thus leading to a buildup of
HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>. According to the Nature Reviews Clinical Oncology paper, independent researchers demonstrated that the buildup of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> in turn up-regulates cancer
cell survival pathways such as angiogenesis, drug resistance, radiotherapy resistance, cancer stem cell formation and metastasis. Cancer stem cells are associated with chemo and radiotherapy resistance and cancer metastasis. While anti-angiogenesis
drugs can achieve impressive tumor shrinkage and PFS benefits in patients, they often fail to improve overall survival. This lack of consistent correlation of tumor response to survival following treatment with anti-angiogenesis drugs may be
ascribed to hypoxia-induced up-regulation of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and the consequent triggering of cancer cell survival pathways that permit a sub-population of cells to survive treatment and regrow the tumor in a more
aggressive form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The schematic below illustrates the role of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> in up-regulating cancer
cell survival pathways in hypoxic conditions in tumor cells, which are exacerbated by radiotherapy and angiogenesis inhibitors, such as Avastin, Zaltrap and Votrient. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g89u83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> may be a major factor in explaining why oxygen-deprived
tumors can survive and trigger the formation of heterogeneous, resistant and distant tumors. Therefore, HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> has emerged as an important target for cancer research. To effectively inhibit HIF-1<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, however, we believe durable target inhibition is required. Topotecan and irinotecan have been shown to inhibit HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> only transiently and metronomic dosing of
topotecan and irinotecan is believed to provide a more durable inhibition of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, but these dosing regimens have not been shown to be clinically feasible due to excessive toxicity encountered at the
approved doses of these drugs. To our knowledge, there is no other durable and tumor targeted inhibitor of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> currently on the market or in advanced clinical development, thus making CRLX101 unique in
this respect. We hypothesize that the simultaneous inhibition of topo 1 and HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> by CRLX101 will lead to significant clinical benefit, particularly if combined with anti-cancer therapies that are known
to create hypoxia and up-regulate HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;87&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to showing that CRLX101 inhibits HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>
in preclinical tumor models, we have further demonstrated that the NDC is synergistic with Avastin in an ovarian xenograft model. We believe that this synergy is at least partly caused by the ability of CRLX101 to inhibit the up-regulation of HIF-1<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> caused by anti-angiogenic therapy. We have further confirmed this synergy in a highly metastatic ovarian cancer orthotopic tumor model, as well as in a triple-negative breast cancer orthotopic tumor model.
Finally, we have also observed the synergy of CRLX101 with other VEGF inhibitors such as Votrient and Zaltrap. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted animal
tumor model studies comparing CRLX101 to certain leading anti-angiogenesis drugs and the combination of CRLX101 and these anti-angiogenesis drugs. In these studies, we treated nude mouse xenograft models in which human A2780 ovarian cancer tumor
cells were implanted subcutaneously in mice and allowed to establish tumors. We administered 5 mg/kg CRLX101 weekly by intravenous infusion alone or in combination with one of three different antiangiogenic drugs: Avastin, Zaltrap or Votrient.
Avastin was dosed intravenously at 5 mg/kg twice per week. Zaltrap was dosed intraperitoneally at 25 mg/kg twice per week. Votrient was dosed orally at 150 mg/kg daily. Vehicle-treated mice were dosed with saline. Each dose group consisted of ten
animals. We administered a CRLX101 dose level that was half the maximum-tolerated dose so that we could compare the effect of the applicable CRLX101 combination to CRLX101 as monotherapy. All other dose levels were the maximum effective dose in this
model, as indicated by the literature. For the analysis of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> in tumors, mice were dosed for ten days, and three days following the final dose tumors were flash-frozen and HIF-1<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein levels were measured via western blot analysis, quantified using infrared fluorescence detection, normalized to actin levels and compared to HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein
levels from saline-treated mice. For the survival analysis, mice were dosed for three weeks, tumors were measured using calipers twice per week, and each animal was euthanized at the earlier of the time when its tumor reached a volume of 2,000 cubic
millimeters or the end of the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In these animal tumor model studies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein expression was significantly up-regulated in the presence of each tested anti-angiogenesis drug; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein expression was significantly down-regulated when exposed to a low dose of CRLX101; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">when CRLX101 was combined with any of the tested anti-angiogenesis drugs, HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein expression was down-regulated compared to control, thus confirming that the CRLX101
down-regulation can counteract the HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein expression up-regulation normally produced by these anti-angiogenesis drugs alone; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the combination of a low dose of CRLX101 with the anti-angiogenesis drugs was synergistic and resulted in markedly longer animal survival than either drug by itself. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;88&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein expression and survival rate
results are illustrated in the graphs below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g30t48.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have achieved similar results in a preclinical study of the effect on cancer stem cells of exposure
to CRLX101 alone and CRLX101 in combination with Avastin. In this study, we treated nude mouse xenograft models in which human SUM159 triple-negative breast cancer tumor cells were implanted orthotopically in mice and allowed to establish tumors. We
administered 6 mg/kg of CRLX101 weekly by intravenous infusion alone or in combination with Avastin. Avastin was dosed intravenously at 5 mg/kg twice per week. Each dose group consisted of 20 or more mice. We administered a CRLX101 dose level that
was half the maximum-tolerated dose so that we could compare the effect of the CRLX101-Avastin combination to CRLX101 as monotherapy. The Avastin dose level was close to the maximum effective dose in this model, as indicated by the literature.
Vehicle-treated mice were dosed with saline. Mice in the primary tumor group were dosed for two weeks and tumor volume was measured. As can be observed in the primary tumor growth plot below, CRLX101 as monotherapy and Avastin as monotherapy each
resulted in some tumor growth inhibition, and the combination of CRLX101 and Avastin resulted in increased tumor growth inhibition. At the end of these two weeks, tumors were extracted and 100 tumor cells were implanted orthotopically into new,
untreated mice. This secondary group of mice was observed for 90 days without treatment, and the percentage of these mice that grew new tumors is plotted in the graph below as the percentage of tumor formation. Tumors that are enriched for cancer
stem cells in the primary tumor model are more likely to grow new tumors in the secondary tumor model, that is, tumors enriched for cancer stem cells have a greater tumor-initiating capacity, and tumors that have lower numbers of cancer stem cells
in the primary tumor model will have a lower tumor-initiating capacity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;89&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In these cancer stem cell functional experiments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pre-treatment with CRLX101 led to a reduction in tumor-initiating capacity, consistent with a reduction in the number of cancer stem cells in the primary tumors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pre-treatment with Avastin led to greater tumor-initiating capacity compared to control, consistent with an increase in the number of cancer stem cells in the primary tumors; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pre-treatment with a combination of CRLX101 and Avastin led to a reduction in the tumor-initiating capacity compared to Avastin treatment alone, thus demonstrating that CRLX101 may reduce the number of cancer stem cells
in primary tumors induced by Avastin pre-treatment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary and secondary tumor model results from these cancer stem
cell functional experiments are illustrated in the graphs below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g85r27.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to inhibiting HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> CRLX101 also appears to
durably inhibit HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>. In a preclinical study, we treated nude mouse xenograft models in which human HCT-116 colorectal cancer tumor cells were implanted subcutaneously in mice and allowed to establish
tumors. We administered a single dose of 6 mg/kg CRLX101 or saline (vehicle) to the control group and collected tumors at four different time points: one, three, five and seven days after treatment using western blot analysis. Tumors were
flash-frozen and HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein levels were measured via western blot analysis, quantified using infrared fluorescence detection, normalized to
actin levels and calculated as a percentage of HIF protein levels in saline-treated mice. As shown in the graph below, in each case, a single 6 mg/kg dose of CRLX101 reduced HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> by over 90%, and
reduced HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> by approximately 80% in tumor tissue, in each case compared to control beginning three days after treatment and continuing for as long as one week. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g99m46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Radiotherapy is frequently used for the treatment of solid tumor malignancies that have not extensively
metastasized and are accessible, and thus a radiation beam can be deployed with the goal of destroying the tumor. For example, rectal cancer and head and neck cancers are often treated with radiotherapy. Radiotherapy causes single strand DNA breaks
in the irradiated tumor cells and, if not repaired, these DNA single strand breaks lead </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;90&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the death of the irradiated tumor cells. It is well documented that topo 1 inhibitors can enhance the effects of radiotherapy, i.e. act as a radiosensitizer. However, the combined toxicities
of radiotherapy and either irinotecan or topotecan, the two approved topo 1 inhibitors, are often too severe for this therapy to be clinically useful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Radiotherapy also causes extensive cell damage, which leads to hypoxic regions in the irradiated tumors. This hypoxia results in the
up-regulation of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, which in turn has been shown to up-regulate cancer cell survival pathways and thereby reduce the effectiveness of radiotherapy. Thus, a beneficial chemotherapeutic agent to
combine with radiotherapy would be (1)&nbsp;a topo 1 inhibitor to enhance the effects of radiation, (2)&nbsp;a <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor to prevent the radiotherapy-induced
up-regulation of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and its associated induced resistance to radiotherapy, (3)&nbsp;a tumor targeted agent that focuses the radiosensitization in the tumors, (4)&nbsp;an agent with a favorable safety
profile to allow the combination with radiotherapy and (5)&nbsp;an agent with durable topo 1 and HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibition since radiotherapy is frequently administered daily and thus requires durable
counteracting of DNA repair and HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> up-regulation. We believe that CRLX101 may be a beneficial agent for combination with radiotherapy since it satisfies all of the above criteria. This is evidenced by
animal tumor models of head and neck cancer and colorectal cancer in which CRLX101 was shown to be a potent radiosensitizer, thus suggesting that CRLX101 may have clinical utility in combination with radiotherapy in certain cancer types. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there are other possible combinations for CRLX101, including with Poly ADP ribose polymerase inhibitors, or PARP inhibitors. PARP
inhibitors hinder a cell&#146;s ability to repair single-strand DNA breaks. Topo 1 inhibitors, such as camptothecin and its analogs, create persistent single-strand DNA breaks, and preclinical experiments have shown that PARP inhibition potentiates
the DNA damage resulting from topo 1&nbsp;inhibition. Results from preclinical studies have established the combined activity of topo 1 inhibition and PARP inhibition, however, clinical trials of this combination approach, including clinical trials
of veliparib plus topotecan and Lynparza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (olaparib) plus topotecan in solid tumors, resulted in significant toxicities that necessitated dose reductions, which in turn resulted in
sub-therapeutic dose levels for both drugs and limited clinical development progress. CRLX101 has been shown to be generally well-tolerated as monotherapy and appears to be a combinable topo-1 inhibitor at its MTD. The observed safety profile of
CLRX101, along with clinical experience combining CRLX101 (at its MTD) with other agents, supports our hypothesis that CRLX101 may facilitate PARP inhibitor and topo 1 inhibitor combinations that are not possible with the currently approved topo 1
inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The graphs below show data from mouse experiments we conducted in which CRLX101 was combined with each of two different PARP
inhibitors. In the study with the first PARP inhibitor, nude mouse xenograft models were implanted subcutaneously with human NCI-H1048 small cell lung cancer tumor cells and allowed to establish tumors. The mice were divided into three dose groups,
with each dose group consisting of three animals. We administered one intravenous dose of 5 mg/kg of CRLX101 to the first dose group, ten daily oral doses of the PARP inhibitor at its MTD to the second dose group, and one dose of 5 mg/kg of CRLX101
in combination with ten daily doses of the PARP inhibitor 1 at 75% of its MTD to the third dose group. The graphs in the top row reflect the results of the combination of CRLX101 and the first PARP inhibitor in the mice. As illustrated in these
graphs, treatment with CLRX101 and the PARP inhibitor resulted in a mean bodyweight loss in the mice of approximately 10% that was recoverable. In addition, the mice in this experiment experienced tumor growth delay and survival rates that were
superior to the tumor growth delay and survival rates experienced by the mice that received placebo, CRLX101 or the PARP inhibitor alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the study with the second PARP inhibitor, nude mouse xenograft models in two separate experiments were implanted subcutaneously with
NCI-H1048 small cell lung cancer tumor cells and allowed to establish tumors. In one experiment, the mice were divided into three dose groups, with each dose group consisting of six animals. Mice in the first dose group were administered one
intravenous dose of 5 mg/kg CRLX101, mice in the second dose group were administered ten daily oral doses of the second PARP inhibitor at 66% of the MTD and mice in the third dose group were administered one dose of 5 mg/kg CRLX101 in combination
with ten daily doses of the PARP inhibitor 2 at 33% of its MTD. In the second experiment, the mice were divided into three </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;91&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dose groups, with each dose group consisting of six animals. Mice in the first dose group were administered one intravenous dose of 50 mg/kg irinotecan, mice in the second dose group were
administered ten daily oral doses of the second PARP inhibitor at 66% of its MTD, and mice in the third dose group were administered one dose of 50 mg/kg irinotecan in combination with ten daily doses of the PARP inhibitor at 66% of its MTD. The
three graphs in the bottom row reflect the results of CRLX101 and the second PARP inhibitor in the mice and also show the results of the same PARP inhibitor and irinotecan in a separate experiment. As illustrated in these graphs, the mice dosed with
the&nbsp;MTD of CRLX101 and 33% of the MTD of the second PARP inhibitor experienced tumor regression after a single dose, and the mean tumor volume did not return to its size at the onset of dosing until day 33 of the study. In contrast, mice dosed
with 66% of the MTD of this second PARP inhibitor together with a sub-MTD dose of irinotecan did not achieve the same extent of tumor growth inhibition, and two of the six mice died during treatment. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g08s44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Irinotecan and PARP Inhibitor 2 experiments were not performed at the same time as CRLX101 and
PARP Inhibitor 2 experiments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CRLX101 Clinical Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the properties of CRLX101, we have prioritized its clinical development in accordance with the following criteria: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Topo 1-sensitive tumor types; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIF-driven tumor types; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Solid tumors with increased hypoxia as a result of radiotherapy or anti-angiogenic drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Potential for synergy in combination with chemoradiotherapy or VEGF inhibitors that increase levels of HIF; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;92&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earlier lines of therapy with less advanced tumors in which the durable inhibition of HIF may confer greater benefit in preventing therapy resistance and metastases. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, we currently are focusing on combinations with other cancer therapies in three indications: relapsed RCC in combination with
Avastin, relapsed ovarian cancer in combination with Avastin and neoadjuvant rectal cancer in combination with CRT. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>CRLX101 Phase
1/2a Clinical Trial </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, we completed a Phase 1/2a clinical trial of CRLX101 in 62 patients with advanced multiply pre-treated
solid tumor malignancies. This clinical trial began in June 2006. From June 2006 to June 2009, Calando Pharmaceuticals, Inc., or Calando, conducted a Phase 1 trial of CRLX101, in which it dosed 18 patients. We continued the Phase 1 trial from June
2009 to April 2010 and then began the Phase 2a portion of the trial. Ultimately, the Phase 1 portion of the trial enrolled a total of 24 patients, and from April 2010 to January 2011, we enrolled 38 patients in the Phase 2a portion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from the Phase 1 portion of the clinical trial showed that patients were able to tolerate CRLX101 administered intravenously at an MTD
of 15mg/m2 camptothecin equivalent every two weeks and that toxicities at this dose were generally low grade and reversible upon termination of treatment. The primary dose limiting toxicity identified in the Phase 1 portion of the clinical trial was
myelosuppression, which is a well-documented side effect of many chemotherapeutic agents and is considered an on-target effect resulting from the activity of topo 1 inhibitors, such as camptothecin, in the bone marrow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After determination of the MTD in the Phase 1 portion of the clinical trial, an additional 38 patients were enrolled in a Phase 2a MTD
expansion cohort, with a focused selection of patients with cancer types that historically have demonstrated sensitivity to topo 1 inhibitors, including 21 NSCLC patients. Pursuant to the design of the trial, CRLX101 treatment continued until
disease progression, which was determined based on RECIST criteria, (as described below) patient withdrawal, excessive toxicity or adverse events delaying treatment for 28 days or resulting in death. Patients continuing CRLX101 treatment also
received additional supportive care. A total of 44 patients, six of whom were in the Phase 1 portion and 38 of whom were in the Phase 2a portion of the trial, with an average of 3.5 prior regimens of therapy, received CRLX101 at the MTD of 15mg/m2.
Mean elimination unconjugated Tmax values, which is the time after administration of a drug when the maximum plasma concentration is reached, generally ranged from 17.7 to 24.5&nbsp;hours, confirming the sustained release of camptothecin. Maximum
plasma concentrations and areas under the curve were generally proportional to dose for both conjugated and unconjugated camptothecin confirming consistent camptothecin release at different dose levels. The primary objectives of the Phase 1/2a
clinical trial were to determine the safety, toxicity, MTD and plasma PK of CRLX101 when administered intravenously to patients with advanced solid tumor malignancies. All of the objectives of the Phase 1/2a trial were met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RECIST defines disease progression and tumor response based on the sum of the longest diameters of a set of target tumor lesions identified
when the patient enters the trial, which we refer to as baseline. A 20% or greater increase in the sum of diameters in target lesions as compared to baseline, or unequivocal progression in non-target lesions, or the appearance of a new lesion, is
defined as progressive disease. A reduction in the sum of the diameters of at least 30% as compared to baseline and no new lesions is defined as a partial response. A complete disappearance of target and non-target lesions, and the normalization of
any tumor markers, constitutes a complete response. Both partial and complete responses must be confirmed by repeat assessments at least four weeks after the partial or complete response is first documented. Stable disease refers to patients who
exhibit neither response nor disease progression. Objective response rate is typically defined as the sum of the patients with partial and complete response divided by the number of patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Median progression free survival, or mPFS, for patients treated in the Phase 1/2a trial at the MTD was 3.7&nbsp;months. The best response per
RECIST criteria was stable disease in 28 patients, or 64%, treated at the MTD, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;93&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of which 15 patients, or 34%, had confirmed stable disease at subsequent evaluations. Six patients went on to receive treatment with CRLX101 for longer than six months, and one such patient with
pancreatic cancer with liver and lung metastases experienced stable disease and received a total of 24 cycles of CRLX101 at 6 mg/m2 weekly dosing prior to discontinuing for progressive disease, or PD. In a subset of 22 patients with NSCLC, mPFS was
4.4 months for all patients and 4.8 months for patients with non-squamous histology, and stable disease was reported in 16 patients, or 73%, eight of whom had confirmed stable disease at subsequent evaluations. None of the patients treated in the
Phase 1/2a trial reported excessive treatment-related toxicities or treatment-related adverse events resulting in death. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>CRLX101
Phase 2 Clinical Trial in NSCLC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, we began an open-label, randomized Phase 2 clinical trial of CRLX101 as monotherapy in
patients with advanced NSCLC who had progressed through one or two prior regimens, which we also refer to as second and third line therapy, respectively, of chemotherapy. This clinical trial was conducted under an investigational new drug
application, or IND, and we enrolled 157 patients between July 2011 and April 2012 at sites in Russia and the Ukraine. The trial had a treatment arm, which consisted of patients treated with CRLX101 and best supportive care, and a comparator arm,
which consisted of patients receiving best supportive care. For every two patients enrolled in the CRLX101 treatment arm, one patient was enrolled in the best supportive care comparator arm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Phase 2 clinical trial failed to meet its primary endpoint, which was improvement in overall survival of the CRLX101 intention to treat
group as compared to the best supportive care arm of the trial. The difference in the overall survival of the CRLX101 intention to treat group as compared to the best supportive care arm of the trial was analyzed with a log rank test in a
Kaplan-Meier survival model. The p-value associated with this test was not statistically significant (p=0.14). In clinical trials comparing CRLX101 to a control using a specified endpoint, the p-value is a measure of compatibility between the
observed outcomes and the hypothesis that there is no treatment effect attributable to CRLX101; the p-value represents the likelihood that the observed outcome occurred by chance alone. Adverse events experienced in the CRLX101 arm of the trial were
generally low grade and manageable and were similar to the adverse events experienced on the best supportive care arm of the trial. This adverse event profile was consistent with the adverse events seen in other clinical trials of CRLX101. Secondary
endpoints of the trial included safety, tolerability, mPFS, objective response rate and overall survival in particular patient subgroups. Although the trial failed to meet its primary endpoint, we observed evidence of activity for CRLX101 as
measured by RECIST responses and observed PFS and overall survival comparable to the PFS and overall survival observed in approved cancer therapies in this setting. Disease progression and tumor response rates were determined in accordance with
RECIST criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Median overall survival for patients administered CRLX101 was 6.3 months compared to 11.9 months for patients
administered best supportive care. However, the best supportive care population was significantly enriched for more slowly progressing patients primarily because of (1)&nbsp;selective patient withdrawal, which was possible due to the open-label
protocol of the trial, and (2)&nbsp;access to post-treatment therapy; we did not anticipate either of these factors when the trial protocol was developed. An analysis of the patient populations indicated that 16% of the best supportive care
patients, versus 5% of the CRLX101 treated patients, withdrew from the trial before or during the first treatment cycle, which was four weeks in duration. The patients who withdrew from the best supportive care arm were more rapidly progressing than
the remaining patients in the best supportive care arm, as measured by prognostic factors including a high percentage of males, a shorter time since initial diagnosis and a shorter time since relapse. The result was that rapid progressors tended to
withdraw from the best supportive care arm while slower progressors tended to remain in the best supportive care arm. A time to treatment failure analysis confirmed the impact of the selective withdrawal of the best supportive care patients since
the median time to treatment failure for best supportive care patients was 1.7 months, compared to 2.1&nbsp;months for the CRLX101 patients. In addition, 40% of the best supportive care patients received post-trial cancer therapy, versus 28% of the
CRLX101 treated patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;94&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these imbalances in withdrawal rates and post-trial cancer treatment between the
CRLX101 and best supportive care arms caused an upward skewing of the median overall survival of the best supportive care population. This belief is supported by benchmark data on median overall survival in previous second and third line
registration trials of Iressa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (gefitinib), Tarceva<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (erlotinib) and docetaxel in NSCLC. For example, the 11.9&nbsp;month median
overall survival of the best supportive care population observed in our trial (1)&nbsp;is more than double the median overall survival for the relevant second and third line best supportive care benchmarks in NSCLC, which range from 4.6 to 5.1
months; and (2)&nbsp;greatly exceeds the median overall survival for second and third line approved treatments for NSCLC, which range from 5.6 to 7.5 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the best supportive care arm of the trial had performed in line with Phase 3 benchmarks, we believe the NSCLC trial would have failed
to meet its endpoint because the results of the CRLX101 treatment arm did not meet our expectations. As a result, we are not planning further clinical development in this indication, however, based on several analyses, we believe that this trial of
CRLX101 as monotherapy provides important information for the CRLX101 development program (1)&nbsp;suggesting CRLX101 is active in a refractory solid tumor patient population and (2)&nbsp;reinforcing CRX101&#146;s apparently favorable safety
profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graph shows the change in tumor size for the 81 NSCLC patients who received computed tomography, or CT, scans on
the CRLX101 arm of the NSCLC trial. Each vertical bar in the graph represents the percentage change in tumor size from the time when the patient entered the clinical trial until the largest tumor size reduction or smallest tumor size growth, as
applicable, was measured for that patient in accordance with RECIST. These results reflect that the majority of patients treated with CRLX101 in the trial achieved disease control, which includes stable disease, partial responses and complete
responses. Six of the eight RECIST responses were confirmed by a subsequent CT scan, one of which was a complete response. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g57v19.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;95&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adverse events experienced in the CRLX101 arm of the clinical trial were generally low grade
and manageable. They were similar to the adverse events experienced on the best supportive care arm of the trial, and they were relatively less severe than the adverse events experienced in clinical trials of docexatel, Tarceva and Iressa, as
illustrated by the graphs below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g64s23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential for Combinability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug eligible for combination therapy should demonstrate a safety profile that does not overlap with or exacerbate the safety profile of the
combination agent. The visual depiction below represents the adverse events experienced by patients in the CRLX101 arm of the NSCLC trial and the adverse events experienced by patients in clinical trials of approved camptothecin-class therapeutics,
irinotecan and topotecan. As CRLX101 was generally well tolerated in the NSCLC trial, we believe this early safety profile supports our view that CRLX101 may be combinable with anti-cancer therapies. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g06z67.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing CRLX101 Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Relapsed Renal Cell Carcinoma </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Current Treatments for Renal Cell Carcinoma:</B> The American Cancer Society estimates that 62,000 new cases of kidney cancer will occur in
the United States in 2015 and that approximately 14,000 people will die from kidney cancer in 2015. According to the most recently available data from the Surveillance, Epidemiology, and End Results Program of the United States National Cancer
Institute, the incidence of kidney cancer has been generally rising each year. RCC is by far the most common type of kidney cancer, accounting for nine out of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;96&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
every ten kidney cases. Up to 30% of patients with RCC present with metastatic disease and five-year survival among these patients is less than 10%. There is currently no cure for RCC that has
metastasized beyond the lymph nodes to one or more distant organs, which we refer to as metastatic RCC. There is currently no treatment specifically approved for the treatment of RCC in patients who have progressed on two or more prior lines of
therapy. This unmet need creates an opportunity for a new class of therapies in this indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Systemic therapeutic options for
advanced stage RCC include molecularly targeted therapies and, less often, chemotherapy and immunomodulatory therapies such as interferon alpha and interleukin-2. Molecularly targeted therapies used for the treatment of RCC have only modestly
extended the median overall survival of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently six FDA-approved therapies commonly used for the treatment of
RCC, they represent only two mechanistic classes &#150; those that target VEGF signaling, including tyrosine kinase inhibitors, or TKIs, and those that inhibit the mammalian target of rapamycin, or mTORIs. Recent drug development has focused on
improvements within these classes but has produced only incremental gains such as the two-month PFS advantage of Inlyta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (axitinib) over
Nexavar<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (sorafenib) in the second-line treatment of advanced RCC. No new class of targeted therapy has been introduced in the field since the mTORI, Torisel<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (temsirolimus), in 2007. A second mTORI, Afinitor<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (everolimus), was shown to extend PFS only modestly over placebo in the second-line
setting, from 1.9 months to 4.9 months. We believe that there is a significant need for therapeutics with novel properties, such as CRLX101, to treat relapsed RCC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Rationale for Use of CRLX101 for Relapsed RCC:</B> A variety of renal epithelial cell types can transform into RCC. Clear cell RCC
comprises approximately 85% of renal cell carcinomas. The most commonly identified genetic aberrations in clear cell tumors are those resulting in loss of the von Hippel Lindau tumor suppressor gene. This loss in turn leads to higher intracellular
levels of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, resulting in paracrine signaling, which is a form of cell-to-cell communication in which a cell produces a signal that alters the
behavior or differentiation of nearby cells, by tissue growth factors such as VEGF, a key mediator of angiogenesis. Therefore, angiogenesis is an early pathophysiologic step in the tumorigenesis and disease progression in many renal cell carcinomas.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As highlighted above, CRLX101 appears to durably suppress HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and HIF-2<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> in preclinical animal studies and has demonstrated notable synergy in combination with VEGF inhibitors including Avastin. We hypothesize that a CRLX101-mediated override of acquired resistance to Avastin,
achieved through the inhibition of HIF, could facilitate the translation of PFS and response rate benefits achieved with Avastin in this setting into meaningful overall survival benefits for RCC patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical data suggest that CRLX101 is an inhibitor of both HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and HIF-2<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> protein expression. While the role of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> as a master regulator of cancer cell survival pathways is well documented, the exact role of HIF-2<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is generally less well described. Both HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> expression have been shown to correlate with poor prognosis
in multiple tumor types. But in the case of RCC, the specific roles of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> are not yet well understood. Some leading oncologists and researchers
have suggested that inhibiting HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and HIF-2<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> simultaneously may be better than inhibiting HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> or HIF-2<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> individually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have chosen Avastin as a CRLX101 combination therapeutic for several reasons.
Avastin is a monoclonal antibody with affinity for VEGF that demonstrates clinically worthwhile activity in the treatment of advanced RCC and is approved by the FDA for use in the treatment of patients with metastatic RCC. Additionally, Avastin is
generally well tolerated and its adverse event profile does not appear to overlap to a large extent with the adverse event profile of CRLX101. Avastin has a track record of success in enhancing the activity of chemotherapy in the treatment of solid
tumors, and it is an active compound. By contrast, the less selective orally available small molecule inhibitors have been difficult to combine with chemotherapy and have shown mixed clinical activity usually accompanied by enhanced toxicity. In
addition, Avastin has been successfully combined with multiple chemotherapeutic agents, including the topo 1 inhibitor irinotecan. Finally, Avastin is administered by intravenous infusion once every two weeks, as is CRLX101, facilitating the
administration of CRLX101 and Avastin as combination therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;97&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Clinical Development of CRLX101 in Relapsed Renal Cell Carcinoma:</B> We are currently
enrolling a Phase&nbsp;2 randomized company-sponsored trial of CRLX101 in combination with Avastin in relapsed RCC. This trial is being conducted in approximately 30 cancer centers in the United States, with eight additional sites planned in the
United States. and five additional sites planned in South Korea, and is designed to enroll 110 patients with unresectable metastatic RCC who have received two or three prior lines of therapy. The primary endpoint of this trial will compare PFS among
90 clear cell RCC patients treated with concurrently administered CRLX101 and Avastin versus an investigator&#146;s choice of standard of care agent not previously used in the same patient. Statistical power is set at 80% to detect a 2.3 month
improvement in median PFS over an expected 3.5 months in the comparator arm. Secondary and exploratory endpoints include overall survival, response rate, safety, pharmacokinetics, and plasma biomarkers of efficacy. Additionally, 20 patients with
non-clear cell RCC histologies will be evaluated independently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Laying the foundation for this randomized trial, a single arm Phase 1b/2
IST of CRLX101 in combination with Avastin was conducted and has now completed enrollment at the University of Pennsylvania and Thomas Jefferson University Hospital. Relapsed RCC patients with metastatic or locally advanced disease who were
previously treated with at least one prior molecularly targeted therapy, such as a TKI or mTORI, were eligible to participate. Two dose-levels of CRLX101, 12 mg/m2 and 15 mg/m2, delivered intravenously once every two weeks, were evaluated in
combination with standard Avastin dosing of 10 mg/kg delivered intravenously once every two weeks. This clinical trial employed a two-stage design, with 12 patients to be treated in an initial dose-finding stage and an additional ten patients to be
treated at the MTD of CRLX101 administered in combination with Avastin. CT-based tumor evaluations occurred every two cycles. The primary endpoint of the Phase 1b stage was to identify the MTD of CRLX101 in combination with Avastin in this
indication, and the primary endpoint of the Phase 2 stage was PFS at four months. Secondary objectives include objective response rate and assessment of toxicity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The last patient was enrolled in this Phase 1b/2 IST in December 2014, and the trial has met its primary endpoint of at least 50% of patients
achieving four months PFS. Preliminary data from this clinical trial has been submitted for presentation at the 2015 annual meeting of the American Society of Clinical Oncology, or ASCO. As of February 3, 2015, the date of the abstract submission to
ASCO, the mPFS of patients on the trial was 9.9 months, with seven of the 22 patients still receiving treatment. Based on third-party published data, the mPFS of the standard of care in this setting is approximately 3.5 months. In addition, the
RECIST partial response rate of patients on the trial as of February 3, 2015 was 23%. Several recent studies in advanced RCC suggest that after treatment with a TKI, subsequent therapies, including Avastin alone, achieve RECIST partial response
rates of between 2% and 4%. CRLX101 in combination with Avastin was generally well tolerated in this trial. Full data for all 22 patients has been submitted for presentation at the 2015 annual meeting of ASCO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our planned initial indication for CRLX101 in the treatment of RCC is in combination with Avastin in patients who have progressed to a third
or fourth line treatment regimen.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Relapsed Ovarian Cancer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Current Treatments for Ovarian Cancer:</B> The American Cancer Society estimates that approximately 21,000 women in the United States will
receive a new diagnosis of ovarian cancer in 2015 and that approximately 14,000 women in the United States will die from ovarian cancer in 2015, which would make ovarian cancer the leading cause of death among gynecologic malignancies in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">First-line therapy for ovarian cancer, including epithelial, tubal and peritoneal cancers, is typically inclusive of a platinum
and taxane containing therapy with or without Avastin; however, Avastin was not approved for use in ovarian cancer until November 2014. Some patients will be primary refractory, meaning they will never achieve a RECIST-based response to initial
therapy; the prognosis for these patients is extremely poor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of patients with advanced ovarian cancer who achieve a
RECIST-based response will eventually experience cancer recurrence. Therapy selected for later-line treatment of patients who achieve a RECIST-based response to frontline therapy depends on whether the patient is defined as platinum sensitive or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;98&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
platinum resistant. Platinum sensitive includes those patients who achieved initial response and whose cancer does not recur for six months or longer after completing platinum-based therapy.
Resistant disease includes those who experience recurrence in less than six months. Treatment of patients with platinum-sensitive disease will typically include another platinum containing therapy, usually a doublet where the second agent is a
taxane or Gemzar. Alternatively, Doxil (liposomal doxorubicin) may be used. Avastin may also be considered, although it was not FDA approved for this indication until November 2014 when it was approved in combination with any one of three chemo
therapies based on data from the AURELIA trial, which is described below. Treatment of patients with platinum-resistant disease is more challenging and may include one of several agents, including Avastin, Doxil, topotecan, docetaxel, gemcitabine,
weekly paclitaxel and etoposide, none of which have been established to prolong survival. There remains considerable unmet medical need for patients with recurrent ovarian cancer and in particular for those who are platinum resistant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Rationale for use of CRLX101 for Relapsed Ovarian Cancer:</B> Publicly released data from an international Phase 3 randomized clinical
trial, which is referred to as the AURELIA trial, for the treatment of patients with second and third line platinum-resistant ovarian cancer conducted by Genentech, Inc. indicated that the addition of Avastin to chemotherapy provided notable
response rates and PFS and a trend toward improvements in overall survival in particular patient sub-groups. Although the AURELIA trial did not achieve a statistically significant improvement in overall survival among all patients, it was the basis
for FDA approval of Avastin in combination with any one of three chemotherapies in November 2014. Based on the AURELIA data and other trials evaluating the use of Avastin in ovarian cancer, it appears that benefits of VEGF inhibitors such as Avastin
are suggested in this setting. We hypothesize that HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> contributes to resistance to VEGF inhibitors, including Avastin. Furthermore, a comprehensive analysis of over-represented genes in ovarian cancer
identifies HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> as a highly active pathway common to both basal breast and serous ovarian cancers and suggests that HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> may be an important therapeutic
target in ovarian cancer. As highlighted above, CRLX101 appears to durably suppress HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and demonstrates notable synergy in combination with VEGF inhibitors, including Avastin, in preclinical tumor
models of ovarian cancer. We hypothesize that a CRLX101-mediated override of acquired resistance to Avastin, facilitated through the inhibition of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, will potentiate the translation of PFS and
response rate benefits achieved with Avastin in relapsed platinum-resistant ovarian cancer into meaningful and statistically significant overall survival benefits for these patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combination of CRLX101 with Avastin in platinum-resistant ovarian cancer capitalizes on several important aspects of this indication,
specifically: ovarian cancer is a HIF overexpressing tumor type, the combination of CRLX101 with Avastin in preclinical ovarian cancer models is synergistic, and preliminary clinical evaluation of this combination appears to be generally well
tolerated thus far. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also believe that CRLX101 could provide benefit to patients with relapsed ovarian cancer in combination with other
cancer treatments, including paclitaxel. Weekly dosing of paclitaxel demonstrates both cytotoxic and anti-angiogenic activity in ovarian cancer and clinical trials have demonstrated both PFS and overall survival benefits of weekly paclitaxel dosing
in this setting, even among patients with prior progression through dose-dense paclitaxel. Therefore, we hypothesize that CRLX101&#146;s potential to overcome HIF-related chemotherapy resistance is relevant to weekly paclitaxel and this combination
has demonstrated greater than additive activity in pre-clinical models. We have commenced start-up activities for a company sponsored Phase 1b clinical trial, conducted in collaboration with GOG, evaluating CRLX101 in combination with weekly
paclitaxel in relapsed ovarian cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Clinical Development of CRLX101 in Relapsed Ovarian Cancer.</B> A single-arm Phase 2 IST of
CRLX101 as monotherapy in 29 advanced relapsed ovarian cancer patients was conducted at Massachusetts General Hospital and affiliated Harvard teaching hospitals in Boston, Massachusetts. The primary endpoint of this trial was to achieve PFS at six
months for at least four patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary PFS endpoint was met with seven patients having achieved PFS of six months or longer. In
addition, 15 patients achieved net tumor shrinkages, with four patients having achieved RECIST-based partial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;99&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responses. In addition, two patients remained active on trial for more than one year. In the platinum-resistant patient subpopulation (22 of 29 patients), 19 of 22 patients were receiving CRLX101
as third or later line of therapy, and three of 22 patients received CLRX101 as second line therapy. Of the 19 evaluable platinum-resistant patients, 18 demonstrated scan results showing stable disease or better for their target lesions, with three
of these 19 patients having achieved a RECIST partial response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The graph below shows the change in tumor size for the 19 evaluable
platinum-resistant patients in this trial. Each vertical bar in the graph represents the percentage change in tumor size from the time when the patient entered the clinical trial until the largest tumor size reduction or smallest tumor size growth,
as applicable, was measured for that patient in accordance with RECIST. The changes in tumor size are unaudited and based on CT-scan assessment performed at the treating center. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g98g61.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data suggest activity of CRLX101 as monotherapy in relapsed ovarian cancer. Since ovarian cancer
has been identified as a HIF overexpressing tumor type and CRLX101 was generally well tolerated in this trial, we are also supporting a combination IST of CRLX101 with Avastin in relapsed platinum-resistant ovarian cancer. This ongoing single arm
Phase 2 clinical trial of CRLX101 dosed at 15mg/m2 every two weeks in combination with Avastin dosed at 10mg/kg every two weeks in second and third line platinum-resistant ovarian cancer patients has been initiated at Massachusetts General Hospital
and affiliated Harvard teaching hospitals in Boston, Massachusetts. The primary endpoint of the trial is PFS at six months in eight patients, and secondary objectives include assessment of response rates and toxicities as assessed by the National
Cancer Institute&#146;s Common Terminology Criteria for Adverse Events, Version 4.0. A maximum of 43 patients will be enrolled in the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on preliminary data provided to us by the IST sponsor, as of March 19, 2015, there were nine evaluable patients treated with the
CRLX101-Avastin combination. All nine of these patients demonstrated stable disease or better based on RECIST tumor response criteria, with one of these patients having achieved a RECIST partial response. The CLRX101-Avastin combination has been
generally well-tolerated to date in this IST. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our planned initial indication for CRLX101 in the treatment of ovarian cancer is not
yet determined. We intend to use data from the ongoing IST in combination with Avastin and data from the planned trial in combination with weekly paclitaxel to help us determine the optimal approach to developing CRLX101 in ovarian cancer.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;100&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Neoadjuvant Rectal Cancer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Current Treatments for Neoadjuvant Rectal Cancer:</B> The American Cancer Society estimates that approximately 39,600 people in the United
States will be newly diagnosed with rectal cancer in 2015. Patients without distant metastases are candidates for neoadjuvant therapy, which consists of approximately six weeks of CRT. The goal of CRT is to shrink the tumors as much as possible
prior to surgical resection. In clinically manageable treatment therapies that have been evaluated, a pathologic complete response, or pCR, is observed in approximately 10% to 20% of patients. A pCR following neoadjuvant chemoradiotherapy is
associated with excellent long-term survival versus patients who do not achieve pCR (five-year odds ratio of 3.28, p=0.001), long-term disease free survival (five year odds ratio of 4.33, p &lt; 0.001) and lower rates of local recurrence and distant
failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Rationale for use of CRLX101 in Neoadjuvant Rectal Cancer:</B> Radiotherapy causes DNA single strand breaks which, if not
repaired, lead to desired apoptosis of radiated tumor cells. Since it is well documented that topo 1 inhibitors can enhance the effects of radiotherapy, we expect CRLX101 to be an effective and well-tolerated radiosensitizer. In fact, combinations
of irinotecan plus capecitabine or 5-FU plus radiotherapy have demonstrated pCR rates between 21% and 37% across various trials, which is greater than the pCR rates that have been demonstrated across various trials using capecitabine or 5-FU plus
radiotherapy. However, the toxicity of irinotecan prevents its addition to this therapy beyond clinical trial settings. CRLX101 in combination with radiotherapy in a head and neck cancer animal model and in combination with CRT in a colorectal
animal model demonstrated notable synergy, which we believe was due to direct anti-cancer effects and enhanced radiosensitization. In addition, local tumor hypoxia is a byproduct of radiotherapy, and there is a well-documented role of
hypoxia-induced HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> up-regulation in causing resistance to radiotherapy. Accordingly, we believe that CRLX101, with its durable topo 1 and HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>
inhibition, as well as its favorable safety profile, offers strong potential as an add-on drug to standard of care CRT in neoadjuvant rectal cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Clinical Development of CRLX101 in Neoadjuvant Rectal Cancer:</B> A single-arm open-label Phase 1b/2 IST of CRLX101 in combination with
capecitabine and radiotherapy in patients with non-metastatic rectal cancer is being conducted at the University of North Carolina at Chapel Hill and other sites, including the University of Indiana, Wake Forest University, Rex Hospital Inc. and
Southeastern Medical Oncology Center. This clinical trial is designed to identify the MTD of CRLX101 administered in combination with capecitabine and radiotherapy and to detect signals of increased clinical benefit over capecitabine and
radiotherapy alone. The trial is designed to enroll up to 53 patients and has a primary endpoint of pCR rate as well as secondary endpoints of disease free survival and overall survival. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on preliminary data provided to us by the IST sponsor, as of March 19, 2015, there were no dose limiting toxicities in the nine patients
enrolled in the Phase 1b stage of the trial, leading to the establishment of the MTD and RP2D as 15 mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>. The trial has therefore progressed to the Phase 2 stage. The first eight patients
enrolled on the trial had post-treatment surgical specimens available for efficacy analysis. Two of these patients achieved a pCR. Additionally, seven of the eight patients achieved a tumor regression score of 0 or 1 on the staging system of the
Union Internationale Contre le Cancer/American Joint Committee on Cancer, or the AJCC/UICC. The AJCC/UICC staging system rates tumor regression on a scale of 0 to 3, with 0 being the best response (a pCR) and 3 being the worst (poor treatment
response). Two additional patients have received treatment on this trial but were not yet evaluable for efficacy analysis as of March 19, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we see pCR rates in excess of 30% for a limited number of patients in the IST, we expect to transition into a randomized Phase 2 trial of
approximately 80 to 120 patients. This randomized trial would compare the safety and efficacy of CRLX101 plus CRT to CRT alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming supportive data, we expect to transition into the Phase 2 randomized clinical trial. We also expect to engage with the FDA prior to
the initiation of a Phase 2 randomized clinical trial to understand whether the agency agrees that pCR is an appropriate surrogate endpoint for use in connection with treatment of patients in the neoadjuvant setting as the basis for accelerated
approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;101&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our planned initial indication for CRLX101 in the treatment of rectal cancer is in combination
with CRT in patients being treated in the neoadjuvant setting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other ISTs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Gastric Cancer.</B> A single-arm Phase 2 pharmacodynamic clinical trial of CRLX101 in advanced HER 2 negative gastric cancer patients was
conducted in an IST at the City of Hope National Comprehensive Cancer Center in Duarte, California. The trial objectives were to utilize tumor biopsies to establish differential NDC penetration between tumor and adjacent normal tissue and to
establish signals of activity in HER-2 negative gastric cancer patients. Biopsies have been analyzed for differential drug accumulation between tumor and normal tissue using immunoflourescence techniques. Data from patient-samples measuring
camptothecin levels in tumor and adjacent normal tissue between 24 and 48 hours after a single dose of CLRX101 was administered indicated that camptothecin was present in the tumor tissue and very little camptothecin was present in the adjacent
normal tissue. We believe these data illustrate Dynamic Tumor Targeting of CRLX101 in patients and confirm in human patients results we have observed in animal tumor models. We believe that these CRLX101 data in human cancer patients validate the
Dynamic Tumor Targeting properties of our platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Small Cell Lung Cancer.</B> A randomized Phase 2 clinical trial of 112 patients
comparing CRLX101 as monotherapy to topotecan in advanced small cell lung cancer, or SCLC, was conducted in an IST at the University of Chicago and at other major medical centers in the United States. The trial objectives were to establish
feasibility of enrolling this advanced patient population and to differentiate the safety and efficacy of CRLX101 at 15mg/m2 dosed every two weeks versus topotecan, the only approved second line SCLC agent. We expect this trial to close due to slow
enrollment sometime in the second quarter of 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Additional CRLX101 Development Opportunities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several factors that may allow combinations of CRLX101 with anti-cancer therapies beyond Avastin and CRT. This may include
combinations with other chemotherapeutics, targeted chemotherapeutics, molecularly targeted agents and nanoparticles, and may extend CRLX101 into indications beyond our current target indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several approved anti-cancer therapeutics work by reducing blood vessel formation, and thus we believe CRLX101 may be combinable with approved
anti-angiogenesis inhibitors other than Avastin, such as Zaltrap, Sutent, Nexavar and Votrient, among others. In preclinical tumor models, in addition to Avastin, we have tested the combination of CRLX101 with Votrient and Zaltrap and have observed
synergy between CRLX101 and each of these agents. HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> assays across multiple tumor models have shown CRLX101 to be a durable inhibitor of HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and to
provide synergistic HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibition when combined with Avastin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond exploiting the
apparent synergies from combining topo 1 and HIF inhibition with VEGF inhibition or radiotherapy, as is the focus of our current combination clinical trials, extensive preclinical modeling of CRLX101 combinations with other agents that demonstrate
synergistic or additive properties with traditional chemotherapeutic agents, such as taxanes and platinum-based agents. These combinations could further enhance the utility of CRLX101 as a backbone agent in combination therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may investigate combinations of CRLX101 with poly ADP Ribose Polymerase, or PARP, inhibitors. PARP&#146;s main role is to
detect and signal single-strand DNA breaks to the enzymatic complex that repairs single strand DNA breaks. A combined inhibition of PARP and topo 1 has been shown to be a well-established cooperative interaction in preclinical research because PARP
inhibitors prevent repair to single strand DNA breaks caused by topo 1 inhibitors. To date, the clinical potential of this combination has remained unrealized, as Phase 1 trials of PARP inhibitors with topotecan conducted by others have shown
toxicities necessitating dose reductions to sub-therapeutic levels, limiting the ability to readily progress in further clinical development. We believe that, due to its potential for improved tolerability as compared to approved topo 1
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;102&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inhibitors, CRLX101 may be combinable with PARP inhibitors at therapeutically active doses. The FDA recently approved the first PARP inhibitor, AstraZeneca&#146;s Lynparza, as monotherapy in
patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CRLX301 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRLX301 is an NDC with docetaxel as its anti-cancer payload. Docetaxel, a member of the taxane family, is a highly active chemotherapeutic that
binds to microtubules to trigger cell death in dividing cells. Docetaxel is extensively used in clinical practice and is FDA approved for the treatment of locally advanced or metastatic NSCLC, locally advanced squamous cell carcinoma of the head and
neck, androgen-independent prostate cancer, locally advanced or metastatic breast cancer and advanced gastric cancer. Docetaxel causes toxicities, including death attributable to toxicities, hepatotoxicity, neutropenia, hypersensitivity, severe
fluid retention and peripheral neuropathy. These toxicities lead to dose adjustments, treatment discontinuation and extensive supportive care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because CRLX301 is synthesized in a similar manner as CRLX101, we can utilize some common intermediates and manufacturing facilities, thereby
creating manufacturing synergies across the two programs. We believe the clinical development risk of CRLX301 is somewhat mitigated because the efficacy of docetaxel in humans is extensively validated. In addition, the safety risk of the
nanopharmaceutical is reduced since CRLX101, sharing the identical nanopharmaceutical backbone, has been tested in over 250 patients without serious toxicities attributed to the nanopharmaceutical backbone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our target product profile for CRLX301 aims to demonstrate improved efficacy, safety and combinability over docetaxel. The potential
advantages of CRLX301 would be to increase docetaxel&#146;s proven anti-tumor activity by targeting sustained release of docetaxel from within tumor cells, thereby achieving sustained drug concentrations in tumor cells. We expect lower tissue
distribution with CRLX301 compared to docetaxel, based on preclinical studies, potentially enhancing tolerability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that
enhanced therapeutic benefit and a favorable safety profile for CRLX301 would enable combination therapies incorporating CRLX301 with other anti-cancer therapies that may not be combinable today due to docetaxel&#146;s toxicities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CRLX301 Preclinical and IND-Enabling Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted the following PK studies in mice, rats and dogs in which CRLX301 demonstrated prolonged circulation as compared to docetaxel:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a study in which 40 mice were administered a single dose of 15&nbsp;mg/kg CRLX301 and the PK levels of such mice were compared to the PK levels of 40 mice that received the same dose of docetaxel; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a study in which 18 rats were administered a single dose of 10 mg/kg CRLX301 and the PK levels of such rats were compared to the PK of docetaxel obtained from published data in rats that received the same dose of
docetaxel; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a study in which six&nbsp;dogs were administered a single dose of 0.75 mg/kg CRLX301 and the PK levels of such dogs were compared to the PK of docetaxel obtained from published data in dogs that received the same dose
of docetaxel. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;103&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each of these studies, the concentrations of docetaxel, total and unconjugated, were measured
using liquid chromatography/tandem mass spectrometry. As illustrated in the graphs below, plasma concentration of docetaxel in the mice following dosing of CRLX301 was prolonged, lacked a rapid distribution phase and resulted in an approximately
500-fold increase in plasma exposure of total drug compared to docetaxel in mice treated with docetaxel. We also observed similar increases in exposure when we compared CRLX301 PK data to published data for docetaxel in dog and rat, also as
illustrated in the graphs below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g09a90.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also measured tumor levels of CRLX301 that were approximately ten-times the tumor levels of
docetaxel in a mouse tumor PK study. We measured concentrations of docetaxel in mice following administration of a single dose of either CRLX301 or docetaxel in mice, in which certain mouse melanoma tumor cells were implanted subcutaneously and
allowed to establish tumors. After administration of a single dose of 15 mg/kg docetaxel or 15 mg/kg CRLX301, tumors were extracted from the mice at various time points up to one week post-administration, frozen and homogenized, and unconjugated
docetaxel concentrations were measured using liquid chromatography/tandem mass spectrometry. These data were then multiplied by the tumor weight to estimate the amount of docetaxel delivered to the tumor. As shown in the figure below, approximately
ten times the amount of docetaxel released from CRLX301 was detected in tumors of the mice that were dosed with CRLX301 as compared to the mice that were dosed with the same amount of docetaxel. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g47p16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We tested the anti-tumor activity of CRLX301 in animal xenograft models of prostate cancer, squamous
non-small cell lung cancer, adenocarcinoma non-small cell lung cancer, ovarian cancer, multi-drug resistant ovarian cancer, triple-negative breast cancer and in a syngeneic melanoma model. In all of these models, CRLX301 was either superior or
comparable to docetaxel in either delay of tumor progression and/or complete response rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;104&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In one such study, we treated nude mouse xenograft models in which human DU-145 prostate cancer
tumor cells were implanted subcutaneously into mice and allowed to establish tumors. We administered 30 mg/kg of CRLX301, 30 mg/kg of docetaxel or saline (vehicle) by intravenous infusion. Each dose group consisted of eight animals, and all mice
were treated weekly for three weeks. Both CRLX101 and docetaxel delayed tumor growth and improved survival rates as compared to the saline-treated mice, but only CRLX301-treated mice displayed complete tumor regression and 100% tumor-free survival
at the conclusion of the study. These results are illustrated in the graphs below and are representative of the other animal xenograft models tested. In all such models, we observed longer lasting or equivalent tumor growth inhibition and higher or
equivalent survival rates with CRLX301 as compared to docetaxel. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g66h73.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These preclinical studies were not designed to demonstrate a statistically significant effect of
treatment with CLRX301 as compared to treatment with docetaxel. Nonetheless, in four of the seven animal xenograft models we conducted, CRLX301 demonstrated superior tumor growth inhibition, which was statistically significant (in each case,
p&lt;.05). CRLX301 also demonstrated a statistically significant survival advantage in five of these seven animal xenograft models (in each case, p&lt;.05). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted Good Laboratory Practice, or GLP, toxicology studies in 148 rats and 32 dogs that revealed similar target organ effects for
CRLX301 as compared to docetaxel; however, the MTD for CRLX301 was approximately 20% higher compared to published data of the MTD for docetaxel in dogs. We observed no evidence of platform-based toxicities. The higher MTD for CRLX301 and a greater
than 50-fold reduced volume of distribution in plasma PK studies in rats and dogs are consistent with a decreased tissue distribution of CRLX301 compared to published data for docetaxel, as measured by a volume of distribution that is 50 and
138&nbsp;times lower for rats and dogs, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Clinical Development of CRLX301 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our clinical development of CRLX301, we plan to focus on the utility of this NDC to provide effective delivery of docetaxel into tumors for
prolonged periods of time with reduced tissue distribution, enhancing anti-tumor activity while potentially reducing the toxicity observed with traditional taxanes. We commenced the Phase 1 portion of a Phase 1/2a clinical trial at two cancer
centers in Australia in December 2014. This clinical trial allows first-in-human dosing of CRLX301 in patients with advanced solid tumor malignancies in order to evaluate the safety of the drug and establish an MTD. Patients in this Phase 1 portion
of the clinical trial receive an intravenous infusion of CRLX301 on day one of a 21-day cycle and continue treatment every three weeks until progression of disease or excessive toxicity is observed. Tumor response evaluations are performed using
RECIST guidelines, and patients are considered evaluable for efficacy if at least one dose of study drug is received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 1 patients
are being enrolled, initially in single patient cohorts, and starting with the third cohort, in the standard three-plus-three dose escalation format. Enrollment in a particular dosing cohort will be halted when
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;105&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
two or more out of six patients in a cohort experience a dose-limiting toxicity during cycle one following initiation of study drug. The MTD will be defined as the highest dosing level in which
fewer than two out of six patients experience a dose-limiting toxicity during cycle one of therapy. Up to 36 evaluable patients may be enrolled in these Phase 1 dose escalation cohorts, with the exact number being dependent on the actual number of
patients per cohort and the number of cohorts investigated. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began Phase 1 clinical testing in Australia, and we submitted an IND
to the FDA in February 2015, which went into effect in March 2015. The IND allows us to include additional cancer centers in the United States to the clinical trial. The Phase 2a portion of the trial is expected to enroll an additional 24 to 30
patients so that CRLX301 can be evaluated at the recommended Phase 2 dose established in the Phase 1 portion of the trial in tumor types of interest. Tumor types of interest will be determined based on biological rationale, clinical need, regulatory
path, commercial opportunity and results observed during the Phase 1 portion of the trial. For clinical development of CRLX301, we expect to choose from among those tumor types in which docetaxel is approved and active, in which docetaxel is not
approved but where taxanes have demonstrated efficacy or in which resistance to prior taxanes has been established. Such possible tumor types include, among others, ovarian cancer, cervical cancer, breast cancer, gastric cancer, prostate cancer,
melanoma and head and neck cancer. In addition, once we have established a MTD, we may choose to conduct a randomized Phase 2 clinical trial in a pre-identified lead indication of interest in order to conduct a head-to-head comparison of CRLX301
against the standard of care in this tumor type of interest. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. While we believe that our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty
pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and
new therapies that may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial, manufacturing,
marketing, drug development, technical and human resources than we do. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the large
unmet medical need, global demographics and relatively attractive reimbursement dynamics, the oncology market is fiercely competitive.&nbsp;In each indication we are pursuing, there are approved cancer therapeutics and agents under clinical
development for use as monotherapy and combination therapy.&nbsp;Each of the top ten global pharmaceutical companies and most of the mid-size pharmaceutical companies has a strong research and development and commercial presence in oncology. Smaller
companies also focus on oncology, including companies such as Agios Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc., BIND Therapeutics, Inc., Clovis Oncology, Inc., Endocyte, Inc., Epizyme, Inc., ImmunoGen, Inc., Incyte Corporation, Infinity
Pharmaceuticals, Inc., MacroGenics, Inc., Merrimack Pharmaceuticals, Inc., OncoMed Pharmaceuticals, Inc., Onconova Therapeutics, Inc., Pharmacyclics, Inc., Puma Biotechnology, Inc., Seattle Genetics, Inc.,TESARO, Inc. and Verastem, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several companies are developing and marketing oncology products. Companies with marketed nanopharmaceutical oncology products include Celgene
Corporation (Abraxane (nab-paclitaxel) indicated for breast cancer, NSCLC and pancreatic cancer) and Spectrum Pharmaceuticals (Marqibo (vincristine sulfate liposome injection) indicated for relapsed Philadelphia chromosome-negative acute
lymphoblastic leukemia). Companies with nanopharmaceutical oncology product candidates in clinical development include BIND Therapeutics, Inc. (BIND 014 for squamous and KRAS mutated NSCLC), Celator Pharmaceuticals, Inc.
(CPX-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;106&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
351 for acute myeloid leukemia), Celsion Corporation (ThermoDox (lyso-thermosensitive liposomal doxorubicin) for liver cancer and breast cancer), Cytimmune Sciences, Inc. (CYT-6091 for NSCLC) and
Supratek Pharma Inc. (SP1049C for solid tumors). In addition, at least two companies have oncology product candidates in clinical development that are irinotecan reformulations: Merrimack Pharmaceuticals&#146; liposomal irinotecan (MM-398 for
pancreatic and colorectal cancer) and Nektar Therapeutics&#146; etirinotecan pegol (NKTR-102 for breast cancer). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe CRLX101 is
the only non-nucleotide oncology product candidate in clinical development that targets the HIF pathway. F. Hoffmann-La Roche AG acquired a Locked Nucleic Acid oncology product candidate that targets
HIF-1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> (SPC-2968, which was referred to as EZN-2968 when it was being developed by Enzon Pharmaceuticals, Inc. and Santaris Pharma A/S). In addition, there are drugs and biologics in development that
could compete with CRLX101 in each of its lead indications: relapsed RCC, relapsed ovarian cancer and neoadjuvant rectal cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
relapsed RCC, the six FDA-approved therapies commonly used for treatment represent only two mechanistic classes&#151;VEGF inhibitors and mTORIs&#151;and there are no approved cytotoxic drugs. Antibodies against PD-1/PD-L1 are in late stage
development in relapsed RCC. Exelixis&#146; TKI, cabozantinib, TRACON Pharmaceuticals, Inc.&#146;s TRC105, and Acceleron Pharma, Inc.&#146;s dalantercept (the latter two are in combination with axitinib) are in development in second line or later
stage relapsed RCC. Regardless of the results of these trials, we believe that there will remain a place for VEGF targeted therapies, and therefore a role for CRLX101, if approved, in treating patients who progress on a VEGF targeted agent. In
relapsed ovarian cancer, there are multiple approved therapies, including most recently Avastin, in combination with chemotherapy, and Lynparza, and multiple companies developing therapeutic candidates in various stages of development. For example,
OncoMed Pharmaceuticals is developing demcizumab, and Genentech, Inc. is developing DMOT4039A. Although each of these agents has the potential to be used in combination with CRLX101, thereby expanding the market for CRLX101, they also have the
potential to compete with CRLX101. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In neoadjuvant rectal cancer, capecitabine, which is marketed by Genentech, Inc., was approved for use
in rectal cancer in 2005. Capecitabine is used in the neoadjuvant setting in combination with radiotherapy, and this chemo-radiotherapeutic regimen represents the current standard of care in the United States. CRLX101 is being developed as a
combination agent to be used with radiotherapy and capecitabine. There are also several development programs for the treatment of rectal cancer in the neoadjuvant setting. Isofol Medical is developing a molecule that is currently labeled [6R]
5,10-methylenetetrahydrofolate, Karyopharm Therapeutics, Inc. is developing Selinexor in combination with chemoradiation, Merck KgAA is developing Tecemotide with chemoradiotherapy, Genentech, Inc. is testing Avastin in combination with
capecitabine, and Kadmon is developing KD018 in combination with capecitabine and radiation. Immunomedics, Inc. has IMMU-130, an anti-CEACAM5 antibody conjugated to SN-38, a topo 1 inhibiting drug. This program is currently in Phase 2 trials in
metastatic colorectal cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several companies are developing taxane-containing nanoparticles for oncology that are competitors to
CRLX301. For example, BIND Therapeutics Inc.&#146;s BIND-014 is a docetaxel containing nanoparticle in active clinical development in squamous and KRAS NSCLC. Nippon Kayaku&#146;s NK105 is a paclitaxel micelle nanoparticle in late stage clinical
development for breast and stomach cancer. Drug-polymer conjugated nanoparticles are also being developed, such as CTI BioPharma&#146;s paclitaxel poliglumex, in late stage clinical development as maintenance therapy for advanced ovarian cancer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of all our therapeutic product candidates, if approved, are likely to be their
efficacy, safety, dosing convenience, price, the level of generic competition and the availability of reimbursement from government and other third party payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;107&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent
protection intended to protect, for example, the technology platforms used to generate our product candidate, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets and careful
monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment
and additional compositions created or identified from our platform and ongoing development of our product candidates. Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for
commercially important technology, inventions and know-how related to our business; defend and enforce our patents; maintain our licenses to use intellectual property owned by third parties; preserve the confidentiality of our trade secrets; and
operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our
proprietary positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold intellectual property, including patent rights that are important or necessary to the
development of our product candidates or use of our platform. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license
from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of
biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and patent
scope can be reinterpreted by the courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings which may result in further narrowing or even cancellation of patent claims.
Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Any patents that we own or license may be challenged, narrowed, circumvented or invalidated by third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially even
longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate
in interference proceedings declared by the United States Patent and Trademark Office, or USPTO, to determine priority of invention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Patents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent
portfolio includes issued patents and pending applications worldwide. These patents and applications fall into three broad categories: (1)&nbsp;covalent linkage of therapeutic agents to a cyclodextrin-containing polymer, or CDP, as in CRLX101 and
CRLX301; (2)&nbsp;association of a therapeutic agent to a polymer and (3)&nbsp;polymeric nanoparticles which can be used to deliver various types of therapeutic agents including large molecules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;108&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cyclodextrin Polymer (CDP) Platform Technology: Covalent Linkage of Therapeutic Agent to
Cyclodextrin-Containing Polymer: CRLX101 and CRLX301 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own, in some cases through an assignment from Calando, or exclusively
license from Caltech, 16 patent families generally related to CDPs and/or to linear CDP-therapeutic agent conjugates (CDP-agent conjugates), including CRLX101 and CRLX301, methods of delivering the CDP-agent conjugates, methods of making the
CDP-agent conjugates and methods of treating various disorders by administering the CDP-agent conjugates. These patent families include 19 issued United States patents and 31 issued foreign counterparts, as well as over 22 pending United States
patent applications and over 54 pending foreign applications. These patents and applications, if issued, generally will expire between 2018 and 2035. These patent families include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of patents and patent applications licensed from Caltech claiming linear cyclodextrin-containing polymers, methods of making the polymers, compositions containing the polymers, and methods of delivering the
compositions (one issued United States patent expires in 2018 and foreign counterparts, where issued, expire in 2019). Foreign counterparts are issued and/or pending in other major markets, including Europe, China and Japan, as well as several other
countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of Cerulean-owned patents and patent applications claiming linear cyclodextrin-containing polymers and CDP-agent conjugates and formulations, methods of delivering and methods of making CDP-agent
compositions, CRLX101 composition of matter and formulations, methods of delivering and methods of making the CRLX101 compositions, composition of matter and formulations relating to CRLX301, and methods of delivering and methods of making the
compositions relating to CRLX301 (issued United States patents expire in 2023 or 2024 and foreign counterparts, where issued, expire in 2023). This family was assigned to us pursuant to our agreements with Calando. Foreign counterparts are issued
and/or pending in other major markets, including Europe, China and Japan, as well as several other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Three families of Cerulean-owned patent applications claiming methods of treating disorders, including cancers such as ovarian cancer and colorectal cancer (e.g., rectal cancer) by administering CRLX101, alone or in
combination with other therapeutic agents (e.g., angiogenesis inhibitors) at selected doses and dosing schedules (United States patents and foreign counterparts would, if issued, expire between 2030 and 2034). One of these three families of
Cerulean-owned patent applications was assigned to us under our agreements with Calando. Foreign counterparts for at least some of these families are pending in other major markets, including Europe, China and Japan, as well as several other
countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Three families of Cerulean-owned patent applications claiming methods of treating various disorders, including, for example, cancer and inflammatory disorders, by administering CDP-agent conjugates, including for
example, CRLX101 and CRLX301 and other CDP-agent conjugates (United States patents and foreign counterparts would, if issued, expire in 2031 or 2033). Foreign counterparts for at least some of these families are pending in other major markets,
including Europe, China and Japan, as well as several other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of Cerulean-owned patent applications claiming CDP-taxane conjugate compositions of matter, including compositions relating to CRLX301, and methods of treating disorders, including cancer, by administering
such a CDP-taxane conjugate alone or in combination with other therapeutic agents, at selected doses and dosing schedules (United States patents and foreign counterparts would, if issued, expire between 2030 and 2032). Foreign counterparts are
pending in other major markets, including Europe, China and Japan, as well as several other countries; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Seven families of Cerulean-owned patent applications claiming technology relating to potential future product candidates, including CDP conjugates in which other therapeutic agents such as epothilones, proteosome
inhibitors, peptides, and janus kinase inhibitors are covalently linked to the linear cyclodextrin-containing polymer or CDP conjugates administered in combination with another agent (United States patents and foreign counterparts would, if issued,
expire between 2030 and 2035). One of these seven families of Cerulean-owned patent applications was assigned to us under our agreements with Calando. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;109&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional CDP Platform Technology: Association of Therapeutic Agent to Polymer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own through an assignment from Calando, or exclusively license from Caltech and Calando, six patent families generally directed to
supramolecular complexes that include linear cyclodextrin-containing polymers and therapeutic agents where the polymers are cross-linked, e.g., with cross-linking agents. These patent families include over eight issued United States patents and over
11 issued foreign counterparts, as well as, over five United States patent applications and several foreign applications. These patents and patent applications, if issued, generally will expire between 2019 and 2030. These patent families include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of patents and patent applications licensed from Caltech claiming supramolecular complexes of linear cyclodextrin-containing polymers and therapeutic agents wherein the polymers are cross-linked, e.g., with
cross-linking agents, and methods of making and delivering the supramolecular complexes (one issued United States patent expires in 2018 and foreign counterparts expire in 2019). A foreign counterpart patent issued in Europe; no other foreign
protection is being pursued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of patents and patent applications licensed from Calando and Caltech claiming compositions that include the following components: (1)&nbsp;a cyclodextrin-containing polymer, (2)&nbsp;a complexing agent which
includes a moiety that forms an inclusion complex with the cyclodextrin in the linear cyclodextrin-containing polymer and is covalently linked to a stabilizer or agent that increases solubility of the composition, a ligand which is covalently linked
to the stabilizer or agent which increases solubility of the composition; and (3)&nbsp;a therapeutic agent, and methods of making these compositions and methods of treating patients by administering the compositions (issued United States patents
expire between 2021 and 2022 and foreign counterparts, where issued, expire in 2021). Foreign counterparts are issued and/or pending in other major markets, including China and Japan, as well as several other countries; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Three families of patents and patent applications licensed from Calando claiming compositions comprising polynucleotides and cyclodextrin-containing polymers, and methods for the delivery of polynucleotides with a
cyclodextrin-containing polymer (issued United States patents expire between 2026 and 2030 and foreign counterparts, where issued, expire between 2022 and 2029); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of Cerulean-owned patents and patent applications claiming polymer compositions that include a (1)&nbsp;linear biocompatible polymer with a plurality of inclusion hosts, (2)&nbsp;linking molecules, each
linking molecule comprising moieties that form inclusion complexes with the inclusion hosts, and (3)&nbsp;at least one therapeutic agent covalently attached to a moiety that forms an inclusion complex with the inclusion hosts, wherein the linking
molecules cross-link the polymer solely through inclusion complexes (one issued United States patent expires in 2028 and any additional United States patents, if issued, would expire in 2023; we are not pursuing foreign protection for this family).
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Polymeric Nanoparticles (PNP) Platform Technology: Small and Large Molecule Delivery </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own, or exclusively license from MIT, 13 patent families which generally relate to nanoparticles containing selected polymers linked to a
therapeutic agent or another molecule. These patent families include 18&nbsp;United States patent applications and 36 foreign applications and one issued foreign patent. These patent applications, if issued, generally will expire between 2025 and
2035. These patent families include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Two families of patent applications licensed from MIT claiming nanoparticles containing selected polymers covalently linked to a therapeutic agent and nanometer-sized vehicles that include radionuclides for use in
diagnostics (United States patents, if issued, would expire in 2025 or 2026 and foreign counterparts, if issued, would expire in 2025) A foreign counterpart for one of these families is pending in Europe; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of Cerulean-owned patent applications claiming nanoparticles that include polymer-therapeutic agent conjugates, amphiphilic polymers and surfactants (United States patents and foreign counterparts, if issued,
would expire in 2030). Foreign counterparts are pending in other major markets, including Europe, China and Japan, as well as several other countries; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;110&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Four families of Cerulean-owned patent applications claiming nanoparticles that include various combinations of polymer-therapeutic agent conjugates, amphiphilic polymers, cationic moieties and surfactants wherein the
therapeutic agent is a nucleic acid agent (e.g., siRNA, mRNA, antisense molecule) and their use in nucleic acid delivery (United States patents and foreign counterparts, if issued, would expire between 2031 and 2035). Foreign counterparts for at
least some of these families are pending in other major markets, including Europe, China and Japan, as well as several other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One family of Cerulean-owned patent applications claiming nanoparticles that include various combinations of polymer-therapeutic agent conjugates, amphiphilic polymers, cationic moieties and surfactants wherein the
therapeutic agent is a polypeptide (United States patents and foreign counterparts, if issued, would expire in 2031) Foreign counterparts are pending in other major markets, including Europe, China and Japan, as well as several other countries ;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Two families of Cerulean-owned patent applications claiming PNPs that include therapeutic agents such as epothilones and proteosome inhibitors that are covalently linked to the polymers contained in the PNP (United
States patents, if issued, would expire in 2030; we are not pursuing foreign protection for this family); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Three families of Cerulean-owned patent applications claiming optimized PNP formulations that include the use of cyclic oligosaccharides as lyoprotectants, PNP platform technology to treat various disorders such as
neurological and metabolic disorders, and optimized methods of making PNPs (United States patents, if issued, would expire between 2031 and 2033 and foreign counterparts would expire in 2033). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base term of a
United States patent is 20 years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a United States patent can be lengthened by patent term adjustment, which compensates
the owner of the patent for administrative delays at the USPTO. In some cases, the term of a United States patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of a United States patent may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act
of 1984, referred to as the Hatch-Waxman Act, to account for at least some of the time the drug is under development and regulatory review after the patent is granted. With regard to a drug for which FDA approval is the first permitted marketing of
the active ingredient, the Hatch-Waxman Act allows for extension of the term of one United States patent that includes at least one claim covering the composition of matter of an FDA-approved drug, an FDA-approved method of treatment using the drug,
and/or a method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14 years from the date of the FDA approval of the drug. Some foreign
jurisdictions, including Europe and Japan, have analogous patent term extension provisions which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. In the future, if and when our
pharmaceutical products receive FDA approval, we expect to apply for patent term extensions on patents covering those products, their methods of use, and/or methods of manufacture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to
patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We typically rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent
protection. For example, significant elements of the making and formulating of our products are based on trade secrets and know-how that are not publicly disclosed. We protect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;111&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial
partners. These agreements provide that all confidential information developed or made known during the course of an individual or entity&#146;s relationship with us must be kept confidential during and after the relationship. These agreements also
provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other
appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek trademark
protection in the United States and in foreign jurisdictions where available and when appropriate. The name &#147;CERULEAN&#148; is a registered trademark in the United States, Australia, China, the European Union, India, Israel, Japan, South Korea,
Liechtenstein, Mexico, Norway, Russia, Singapore, Switzerland, Turkey, and the Ukraine and is covered by pending applications for trademark registration in Canada and China. The trademark is solely owned by Cerulean Pharma Inc., in the field of
pharmaceutical preparations as well as in the field of diagnostic and prognostic preparations. The Cerulean logo is a registered trademark in the United States and Mexico and is solely owned by Cerulean Pharma Inc. The term &#147;Leadership in
Nanopharmaceuticals&#148; is a registered trademark in the United States and is solely owned by Cerulean Pharma Inc. The symbol &#153; indicates a common law trademark. Other service marks, trademarks and trade names appearing in this prospectus are
the property of their respective owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assignments and In-License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Calando Pharmaceuticals, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June
2009, we entered into two agreements with Calando, the CRLX101 Agreement and the Platform Agreement, each of which we subsequently amended. Under these agreements, Calando assigned and licensed to us certain assets. These assets include the clinical
asset then known as IT-101, later renamed CRLX101, and rights to Calando&#146;s cyclodextrin system for purposes of conjugating or complexing certain other therapeutic agents to the system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CRLX101 Agreement: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the CRLX101 Agreement, we obtained certain rights to CRLX101. As noted below in the description of the Platform Agreement, Calando also assigned to us certain patents and patent applications, including, with respect to composition of matter and
methods of use, for CRLX101. In addition, under the CRLX101 Agreement, Calando transferred ownership of the CRLX101 IND to Cerulean. Also, under the CRLX101 Agreement, Calando initially granted to us a worldwide, royalty bearing, exclusive (even as
to Calando) license, with the right to grant sublicenses, to Calando&#146;s interest under certain patents, patent applications, and know-how owned or controlled by Calando, to research, develop, make, have made, use, market, offer to sell,
distribute, sell and import CRLX101 formulated for intravenous, intrarterial, intrathecal and/or intraperitoneal therapy, to treat and/or prevent disease in humans. As noted below in the description of the Caltech Agreement, all of the patents,
patent applications and know-how that were initially licensed to us by Calando under the CRLX101 Agreement and upon which CRLX101 is dependent are now directly licensed to us by Caltech, and we retained the license described above from Calando for
patents, patent applications and know-how that are directed to other aspects of the cyclodextrin system but on which CRLX101 is not dependent. For purposes of our obligations to Calando under the CRLX101 Agreement, we treat the intellectual property
licensed to us by Caltech as if it were still licensed to us by Calando. These licensed and assigned patent rights are described in more detail above under &#147;Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CRLX101 Agreement, we are obligated to use commercially reasonable efforts to develop CRLX101 throughout the world and, following
the first commercial sale of CRLX101 in a particular country, to make CRLX101 commercially available in such country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;112&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering the CRLX101 Agreement, we paid Calando approximately $1.3 million, which included
the purchase of CRLX101 drug substance and drug product inventory. If we achieve certain development and sales events with CRLX101, we are obligated to pay milestone payments which could total, in the aggregate, $32.8&nbsp;million. If we or one of
our affiliates sells CRLX101, we are also required to pay tiered royalty payments ranging from low-to mid-single digits, depending on whether or not there is patent protection for CRLX101 at the time of sale as a percentage of worldwide net sales.
Our royalty payment obligations in a particular country begin on the date of first commercial sale of CRLX101 in that country and end on the later of ten years from the date of first commercial sale of CRLX101 in that country or the expiration of
all patents licensed to us by Caltech or Calando, referred to as Licensed Patent Rights, or assigned to us by Calando, referred to as the Assigned Patent Rights, which cover CRLX101 in that country. With respect to CRLX101 that is developed and sold
by an unaffiliated third party to whom we grant a license or sublicense under any of the intellectual property that we purchased or licensed from Calando, we are required to pay Calando a percentage of the income we receive from the licensee or
sublicensee to the extent attributable to such license or sublicense, subject to certain exceptions. The percentage of such sublicense income that we are obligated to pay Calando is in the low- to mid-double digits, and varies depending on the stage
of development of CRLX101 at the time that we first provide or receive draft terms of a license arrangement with the third party that results in a license arrangement, unless the negotiations terminate, in which case the percentage depends on the
development stage of CRLX101 when the negotiations restart. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the first right to enforce the Licensed Patent Rights and Assigned
Patent Rights, other than one subset of licensed patents on which CRLX101 is not dependent, which Calando has the sole right to enforce. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Calando are required to indemnify each other for losses and expenses in connection with any third party claims arising out of the
indemnifying party&#146;s breach of the CRLX101 Agreement, the negligence or willful misconduct of the indemnifying party or its affiliates or sublicensees under the CRLX101 Agreement or any product liability arising out of CRLX101 developed, made,
used or sold by or on behalf of the indemnifying party or its affiliates or sublicensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CRLX101 Agreement will remain in effect
until the expiration of all of our royalty obligations to Calando. We also have the right to terminate the CRLX101 Agreement for any reason on thirty days prior notice to Calando, in which case, unless we certify that the termination was due to
specified safety concerns with CRLX101, we will grant Calando an exclusive (even as to Cerulean), royalty-free license, under the Assigned Patent Rights, to research, develop, make, have made, use, market, offer to sell, distribute, sell and import
CRLX101, we will assign the IND for CRLX101 to Calando and, if consistent with our business plans, we will discuss granting Calando a license under know-how that we developed that relates to CRLX101. If we fail to meet our diligence obligations
under the CRLX101 Agreement after a specified cure period, the license may convert to a non-exclusive license and we will have to grant Calando a non-exclusive license under the Assigned Patent Rights to research, develop, make, have made, use,
market, offer to sell, distribute, sell and import CRLX101. If the license is converted to a non-exclusive license, the royalties payable to Calando will be reduced by a specified percentage. If we fail to meet our payment obligations under the
agreement and are unable to cure such failure within specified time periods, Calando can terminate the agreement, we are obligated to grant Calando an exclusive (even as to Cerulean), royalty-free license, under the Assigned Patent Rights to
research, develop, make, have made, use, market, offer to sell, distribute, sell and import CRLX101 and to assign the IND for CRLX101 to Calando, resulting in our loss of rights to CRLX101. If we or one of our affiliates challenges the validity or
enforceability of any of the licensed patents, Calando has the right to terminate the agreement. For any breach of the CRLX101 Agreement not described above, the non-breaching party&#146;s sole remedy if such breach is not cured within a specified
time period is to seek money damages from the breaching party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Platform Agreement: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Platform Agreement, Calando assigned to us the Assigned Patent Rights and granted to us a worldwide, royalty bearing, exclusive (even
as to Calando) license, with the right to grant sublicenses, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;113&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Calando&#146;s interest under certain patents, patent applications, and know-how owned or controlled by Calando (a)&nbsp;to conduct research and development on the cyclodextrin system, including
making improvements thereto, in order to research, develop, make, have made, use, market, offer to sell, distribute, sell and import CDP-based Products and (b)&nbsp;to research, develop, make, have made, use, market, offer to sell, distribute, sell
and import CDP-based Products. The field of the license is the treatment and/or prevention of disease in humans. CDP-based Products are defined as products conjugated or complexed to the cyclodextrin system, other than any products containing
cytolysin, tubulysin, certain second generation epothilones or a nucleic acid, which we refer to as Retained Products, and CRLX101, which is covered by the CRLX101 Agreement described above. Under the Platform Agreement, we are obligated to use
commercially reasonable efforts to develop CDP-based Products throughout the world and, following the first commercial sale of CDP-based Product in a particular country, to make CDP-based Product commercially available in such country. These
exclusively licensed patent rights, as well as patent rights assigned to us pursuant to the agreement, are described in more detail above under &#147;Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon entering the Platform Agreement, we paid to Calando approximately $1.2 million, which included the payment for assignment of the Assigned
Patent Rights and cyclodextrin-containing polymers and precursor inventory. We granted Calando a worldwide, royalty-free, exclusive (even as to Cerulean), perpetual and irrevocable license, with the right to grant sublicenses, under the Assigned
Patent Rights to research, develop, make, have made, use, market, offer to sell, sell and import the Retained Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we achieve
certain development and sales events with respect to any CDP-based Product, we are obligated to pay milestone payments which could total, in the aggregate, $18.0 million per CDP-based Product. Upon the initiation of our CRLX301 Phase 1 trial in
2014, we made a milestone payment of $250,000 to Calando. If we or one of our affiliates sells a CDP-based Product, we are also required to pay tiered royalty payments ranging from low-to mid-single digits, depending on whether or not there is
patent protection at the time of sale, as a percentage of worldwide net sales. Our royalty payment obligations in a particular country begin on the first date of first commercial sale of the CDP-based Product in that country and end on the later of
ten years from the date of first commercial sale of that CDP-based Product in that country or the expiration of all patents licensed or assigned from Calando which cover that CDP-based Product in that country. With respect to a CDP-based Product
that is developed and sold by a third party to whom we grant a license or sublicense under any of the intellectual property that we licensed from Calando or that Calando assigned to us, we are required to pay Calando a percentage of the income we
receive from the licensee or sublicensee to the extent attributable to such license or sublicense, subject to certain exceptions. The percentage of such sublicense income that we are obligated to pay Calando does not exceed the low double digits.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the first right to enforce the licensed patent rights and the Assigned Patent Rights, other than one subset of licensed patents
which Calando has the sole right to enforce. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Calando are required to indemnify each other for losses and expenses in connection
with any third party claims arising out of the indemnifying party&#146;s breach of the Platform Agreement, the negligence or willful misconduct of the indemnifying party or its affiliates or sublicensees under the Platform Agreement or any product
liability arising out of a CDP-based Product developed, made, used or sold by or on behalf of the indemnifying party or its affiliates or sublicensees. Calando also indemnifies us for losses and expenses in connection with any third party claim
arising out of a Retained Product developed, made, used or sold by or on behalf of Calando or its affiliates or licensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Platform
Agreement will remain in effect until the expiration of all of our royalty obligations to Calando. We also have the right to terminate the Platform Agreement for any reason on thirty days prior written notice to Calando, in which case we will grant
Calando an exclusive (even as to Cerulean), royalty-free license, under Assigned Patent Rights, to research, develop, make, have made, use, market, offer to sell, distribute, sell and import the CDP-based Products and, if consistent with our
business plans, we would discuss granting Calando a license under know-how that we developed that relates to the cyclodextrin system or CDP-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;114&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Products. If we fail to meet our diligence obligations under the agreement after a specified cure period, Calando may convert the license to a non-exclusive license and we will have to grant
Calando a non-exclusive license under the Assigned Patent Rights to research, develop, make, have made, use, market, offer to sell, distribute, sell and import CDP-based Products. If the license is converted to a non-exclusive license, the royalties
payable to Calando will be reduced by a certain percentage. If we fail to meet our payment obligations under the agreement and are unable to cure such failure within specified time periods, Calando can terminate the agreement, resulting in our loss
of rights to the CDP-based Products and an obligation to grant Calando an exclusive (even as to Cerulean), royalty-free license, under the Assigned Patent Rights to research, develop, make, have made, use, market, offer to sell, distribute, sell and
import CDP-based Products. If we or one of our affiliates challenges the validity or enforceability of any of the licensed patents, Calando has the right to terminate the agreement. For any breach of the Platform Agreement not described above, the
non-breaching party&#146;s sole remedy if such breach is not cured within a specified time period is to seek money damages from the breaching party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>California Institute of Technology </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the patents, patent applications, and know-how licensed to us under the CRLX101 Agreement and the Platform Agreement were licensed
to Calando by the California Institute of Technology, or Caltech, pursuant to an agreement entered into between Calando and Caltech in May 2000 and subsequently amended, which we refer to as the Calando/Caltech Agreement. In August 2013, we entered
into an agreement with Calando and Caltech under which Calando terminated its rights and obligations under the Calando/Caltech Agreement and Caltech agreed to directly honor the exclusive license, including the right to grant further sublicenses,
granted to us by Calando under the Caltech intellectual property formerly licensed to Calando. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to pay Caltech minimum
annual royalties and the costs it incurs to prosecute and maintain the licensed patent rights. We may offset those prosecution and maintenance costs against any milestones or royalties that we owe to Calando under the CRLX101 Agreement or the
Platform Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the earlier of our receipt of notice from Calando that it has made certain payments to third parties or the
first anniversary of the first commercial sale of a product covered by the Caltech patent rights, we will directly pay to Caltech the amounts that it would have been entitled to receive from Calando with respect to our sales of the licensed
products, and we will pay to Calando the remainder of the royalties we owe them under the CRLX101 Agreement and the Platform Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the first right to enforce the Caltech licensed patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate our rights and obligations to Caltech and Calando with respect to any of the Caltech licensed intellectual property either in
its entirety or as to any jurisdiction or as to any part of the intellectual property upon a specified period of prior notice to Caltech and Calando. Caltech has the right to terminate the agreement if we fail to make a payment, or otherwise
materially breach the agreement, and fail to cure such breach within specified grace periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Massachusetts Institute of Technology </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2006, we entered into an exclusive license agreement with MIT, which we refer to as the MIT Agreement. The MIT Agreement has been
amended five times, including to extend or suspend the time period for achieving certain diligence milestones, and the most recent amendment was entered into in February 2015. Under the MIT Agreement, we have a worldwide exclusive license, with the
right to grant sublicenses, in all human and veterinary therapeutic and diagnostic areas, under certain patent rights owned by MIT, to develop, make, have made, use, sell, offer to sell, lease and import products covered by the licensed patent
rights, and to develop and perform licensed processes. These exclusively licensed patent rights are described in more detail above under &#147;Intellectual Property.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;115&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to use commercially diligent efforts to develop licensed products or licensed
processes, to introduce licensed products or licensed processes into the commercial market and thereafter to make licensed products or licensed processes reasonably available to the public. By June&nbsp;1, 2015, we are required to present MIT with a
plan, satisfactory to MIT, to develop the licensed products and a proposal for specific diligence terms for licensed products. We and MIT will then negotiate in good faith the diligence terms, but if we and MIT are unable to agree to such diligence
terms by the end of September 2015, MIT will have the right, in its sole discretion, to terminate the agreement. If, prior to the end of September 2015, MIT becomes aware that another party with whom we are not in active negotiations wishes to
obtain a license under the patent rights and we have not yet submitted a satisfactory development plan to MIT, MIT will request a development plan from us and from the other party, and MIT will select either our development plan or the other
party&#146;s development plan based on MIT&#146;s determination of which plan is in the best interests of commercializing the licensed patents. If MIT selects the other party&#146;s development plan, MIT may, in its sole discretion, terminate the
exclusive license agreement with us, limit our field of use under the exclusive license agreement, or convert our exclusive license to a non-exclusive license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MIT Agreement, as of December&nbsp;31, 2014, we had paid MIT approximately $0.5 million in the aggregate, consisting of annual
maintenance fees and reimbursement of patent-related fees incurred by MIT, and we issued a certain number of shares of our common stock to MIT and individuals affiliated with MIT. We are obligated to pay MIT annual license maintenance fees that
escalate beginning in January 2015. We are also obligated to pay royalties at a low single digit percentage of net sales of licensed products or licensed processes by us, our affiliates or our sublicenses. We are also required to pay a percentage,
in the low double digits, of the payments we receive from our sublicensees which are attributable to the granting of a sublicense under the licensed patents, subject to certain exclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MIT retains the right to practice the licensed patent rights for research, teaching and educational purposes. We may not assert the licensed
patents against any non-profit entity using the licensed patents for research purposes not benefitting a for-profit entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the
licensed patent rights claiming inventions that were funded by the government are subject to certain rights retained by the United States government under a law commonly called the Bayh-Dole Act. These rights include, among other things, a
royalty-free, non-exclusive license for the United States government to practice these inventions. Any products used or sold in the United States and covered by these patents must be substantially manufactured in the United States, unless a waiver
is obtained from the U.S. government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MIT controls prosecution and maintenance of the licensed patents. We are responsible for all costs
associated with filing, prosecuting and maintaining the licensed patent rights. As long as our license remains exclusive, we have the first right to enforce the licensed patents against infringers in the licensed field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to indemnify MIT for any liabilities and expenses in connection with any claims concerning any licensed product, process or
service under the MIT Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to terminate the agreement for any reason by providing MIT with a specified amount of
prior written notice. MIT has the right to terminate the agreement if we cease to carry on our business related to the agreement, if we fail to pay any amounts due and payable under the agreement, subject to a grace period, or if we materially
breach the agreement and fail to cure such breach within specified grace periods. The MIT Agreement otherwise terminates, on a country-by-country basis, upon the expiration or abandonment of all licensed patents and patent applications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Research Foundation of State University of New York on behalf of University at Buffalo </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2007, we entered into an exclusive license agreement with The Research Foundation of State University of New York on behalf of
University at Buffalo, which we refer to as the SUNY Agreement. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;116&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SUNY Agreement has been amended four times, including to extend the time period for achieving certain diligence milestones, and the most recent amendment was entered into in September&nbsp;2013.
Under the SUNY Agreement, we have a worldwide, royalty bearing, exclusive license, with the right to grant sublicenses, for the treatment and/or prevention of disease in humans, under certain patent rights owned by SUNY, to research, develop, make,
have made, use, offer for sale, sell, have sold, import and export certain products covered by the licensed patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
required to diligently proceed with the research, development, manufacture, use and sale of licensed products under the agreement, to use commercially reasonable efforts to commercialize and market licensed products as soon as practicable, and to
make licensed products available on commercially reasonable terms once introduced into the marketplace. In particular, we are required to fulfill specific development and regulatory milestones by particular dates and, during each calendar year prior
to the first commercial sale of a licensed product, spend a specified amount on the research, development or commercialization of licensed products or precursor technologies or products, and if we fail to do so SUNY may elect to increase our license
maintenance fee and, in the case of a second failure, our exclusive license will be converted to a non-exclusive license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the SUNY
Agreement, as of December&nbsp;31, 2014, we had paid SUNY approximately $0.2 million in the aggregate, consisting of an upfront license fee, a field-of-use expansion fee, annual maintenance fees and reimbursement of patent-related fees incurred by
SUNY. We are also obligated to pay SUNY an escalating annual license maintenance fee and development milestone payments which could total, in the aggregate, less than $0.1 million and royalties in the low single digits as a percentage of net sales
by us, our affiliates or our sublicensees of licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUNY retains the right to practice the licensed patent rights for
educational purposes and internal research and development, including collaborations with researchers at other academic and non-profit research institutions. Any of the licensed patent rights claiming inventions that were funded by the government
are subject to certain rights retained by the United States government under a law commonly called the Bayh-Dole Act. These rights include, among other things, a royalty-free, non-exclusive license for the United States government to practice these
inventions. Any products used or sold in the United States and covered by these patents must be substantially manufactured in the United States, unless a waiver is obtained from the U.S. government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUNY controls prosecution and maintenance of the licensed patents, although we have an approval right over certain actions. We reimburse SUNY
for all reasonable costs associated with filing, prosecuting and maintaining the licensed patent rights. SUNY has the first right to enforce the licensed patents against infringers in the licensed field. We have the right to enforce the licensed
patents if SUNY does not institute an infringement action within a specified period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to indemnify SUNY for any
claims and expenses resulting from the exercise or practice of the license granted to us, including liabilities arising from the production, manufacture, sale, use, lease or advertisement of the licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SUNY Agreement will remain in effect until the expiration of all licensed patents and patent applications, unless we elect to earlier
terminate the entire license, or the license with respect to certain patent families, subject to providing SUNY with a specified amount of prior written notice. SUNY has the right to terminate the SUNY Agreement if we have a bankruptcy action filed
against us, have a receiver appointed for us, or if we materially breach the agreement, and fail to cure such situation or breach within a specified grace period. The SUNY Agreement will automatically terminate if we cease to carry on our business,
file for bankruptcy, become insolvent, make an assignment for the benefit of creditors, or we challenge the validity or enforceability of any of the licensed patents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with
third parties for the manufacture of our product candidates for preclinical studies and clinical trials and intend to do so in the future. We do not own or operate manufacturing facilities for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;117&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
production of clinical or commercial quantities of our product candidates. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. To meet our
projected needs for commercial manufacturing, third parties with whom we currently work will need to increase their scale of production or we will need to secure alternate suppliers. Although we rely on contract manufacturers, we have personnel with
manufacturing experience to oversee our relationships with contract manufacturers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contract manufacturers have manufactured what we
believe to be sufficient quantities of CRLX101 drug product to support clinical trials through 2015, and have begun manufacturing additional supplies to continue clinical development of CRLX101 beyond 2015. The current drug substance and drug
product manufacturing processes for CRLX101 are scaled to support Phase 2/3 clinical development under current Good Manufacturing Practice, or cGMP, standards, and we believe are adequate to support further development and scale up for commercial
demand at a reasonable cost of goods. While we believe that our existing supplier of drug substance is capable of producing drug substance in commercial quantities, we have also identified a new third party manufacturer capable of providing
commercial quantities of drug product. If we are unable to arrange for third-party manufacturing with this or other alternative vendors, or fail to do so on commercially reasonable terms, we may not be able to successfully produce and market
CRLX101. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Processes for producing CRLX301 have been developed and used successfully to produce drug substance and drug product for GLP
safety studies and cGMP Phase 1 clinical supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both CRLX101 and CRLX301 include complicated polymer backbone structures as well as
cytotoxic agents. Although these characteristics may limit alternative third party manufacturers, we believe that there are alternate sources of supply that can satisfy our clinical and commercial requirements, and we have or are pursuing back-up
suppliers for certain stages of the manufacturing process. We cannot be certain, however, that identifying and establishing relationships with additional alternate sources, if necessary, would not result in significant delay or material additional
costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
intend to build the commercial infrastructure in the United States necessary to effectively support the commercialization of CRLX101, if approved, and future oncology products, if approved. The commercial infrastructure for specialty oncology
products typically consists of a targeted, specialty sales force that calls on a limited and focused group of physicians supported by sales management, internal sales support, an internal marketing group and distribution support. Additional
capabilities important to the oncology marketplace include the management of key accounts such as managed care organizations, group-purchasing organizations, specialty pharmacies, oncology group networks and government accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of physicians who treat RCC, ovarian, and rectal cancer and the size of competitive sales forces, we believe that we can
effectively target the relevant U.S. market with a focused sales force. If CRLX101 is approved in additional indications, we might need to increase the number of representatives. To develop the appropriate U.S. commercial infrastructure, we will
have to invest significant amounts of financial and management resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may utilize one or more strategic partners to
optimally commercialize CRLX101 and our other products globally. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the
European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval
monitoring and reporting, and import and export, of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;118&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial
resources and the successful outcome of those processes cannot be guaranteed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval of Drugs in the United States
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to
comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by
the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or DOJ or other governmental entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#146;s good laboratory practice, or GLP, regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND, which must take effect before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of the clinical trial(s) by an independent institutional review board(s), or IRB(s), representing each clinical site before each clinical trial may be initiated; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trial(s) in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparation and submission to the FDA of a new drug application, or NDA summarizing available data to support the proposed approval of the new drug product for the proposed use; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review of the product by an FDA advisory committee, as may be requested by the FDA to assist with its review; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of FDA inspection(s) of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP,
requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of user fees (per published PDUFA guidelines for that year) and securing FDA approval of the NDA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by the FDA. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Nonclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nonclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical
ingredient and the formulated drug or drug product. They also include in vitro and animal studies to assess the safety and activity of the drug to start dose assessment for initial testing in humans and to further establish a rationale for
therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical
data or literature and plans for clinical studies, among other things, are submitted to the FDA as part of an IND for clinical investigation in the United States. Some long-term preclinical testing, such as animal tests of reproductive adverse
events and carcinogenicity, may continue after the IND is submitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;119&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Human Clinical Studies in Support of an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with IND and GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under
written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol
amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the
trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial
before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol, major amendments and informed consent information
to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their
ClinicalTrials.gov website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 1: Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely
monitored and may be conducted in patients or normal volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the toxicities associated with increasing doses, and, if possible, to
gain early evidence on effectiveness. During Phase 1, sufficient information about the drug&#146;s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The
total number of subjects and patients included in Phase 1 studies varies with the drug, but are generally smaller than later stage studies. Phase&nbsp;1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism
of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 2: Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or
indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively
small number of patients, usually involving no more than several hundred subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 3: Phase 3 studies are expanded trials,
generally at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety
that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 studies usually include from several hundred to several thousand subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA through the IND and more
frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any
time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if
the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;120&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to protect the rights and welfare of human research subjects and to verify the quality
and integrity of data submitted to the FDA in support of marketing applications, the FDA monitors all aspects of FDA-regulated research through a comprehensive program of on-site inspections and data audits. Under the Agency&#146;s Bioresearch
Monitoring Program, FDA field investigators and headquarters&#146; scientists conduct site visits of research sponsors, clinical investigators, contract research organizations, IRBs, radioactive drug research committees, and non-clinical (animal)
laboratories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the FDA accepts foreign safety and efficacy studies that were not conducted under an IND provided that they are
well designed, well conducted, performed by qualified investigators, and conducted in accordance with ethical principles acceptable to the world community. The conduct of these studies must meet at least minimum standards for assuring human subject
protection. Therefore, for studies submitted in support of an NDA that were conducted outside the United States and not under an IND, the agency requires demonstration that such studies were conducted in accordance with Good Clinical Practices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expanded Access to an Investigational Drug for Treatment Use </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expanded access, sometimes called &#147;compassionate use,&#148; is the use of investigational new drug products outside of clinical trials to
treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to
investigational drugs for patients who may benefit from investigational therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering an IND application for expanded
access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context of the disease or condition to be treated; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The expanded use of the investigational drug for the requested treatment will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or
otherwise compromise the potential development of the product. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations allow access to investigational drugs under
an IND by the company or the treating physician (see investigator-sponsored trials below) for treatment purposes on a case-by-case basis for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intermediate-size patient populations (groups of patients, n &gt;1); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">larger populations for use of the drug under a treatment protocol or Treatment IND Application. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Investigator Sponsored Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investigator sponsored trials are clinical trials where the investigator of the trial is also the &#147;sponsor&#148; of the trial for
regulatory purposes. An &#147;investigator&#148; conducts clinical investigations and is the person under whose immediate direction the study drug is administered or dispensed to patients. A &#147;sponsor&#148; initiates and takes responsibility for
a clinical investigation. A person who both initiates and conducts a clinical trial, and is responsible for all regulatory requirements, is designated as a &#147;sponsor-investigator&#148; by the FDA. Clinical investigators at academic medical
centers who initiate clinical trials with a lawfully marketed drug to be used in a patient population or investigational (unapproved) indication often fit within this designation. In addition, as is </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;121&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the case with our investigator-sponsored trials, a company may provide a sponsor-investigator with supply of its unapproved product candidate and funding for the trial. Investigators who initiate
and conduct such trials are responsible for obtaining an IND from the FDA and for ensuring compliance with the IND and associated regulatory requirements. As provided by the FDA&#146;s regulations, the sponsor of a clinical trial is responsible for,
among other things, selecting qualified investigators, providing them with the information they need to conduct the trial properly, ensuring proper monitoring of the trial, ensuring that the trial is conducted in accordance with the protocols
contained in the IND, maintaining an effective IND with respect to the trial, and ensuring that the FDA, the company, and all participating investigators are promptly informed of significant new adverse effects or risks with respect to the
drug.&nbsp;In contrast, in a company-sponsored trial, the pharmaceutical company whose drug will be studied is the sponsor of the trial and, as such, is responsible for ensuring compliance with all regulatory requirements, including obtaining the
IND.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our ongoing investigator sponsored trials of CRLX101, we have entered into agreements with the institutions at
which the trials are being conducted. The terms of these agreements are customary and generally provide that (a)&nbsp;the institution is responsible for obtaining and maintaining any necessary IND for the trial, for conducting the trial in
accordance with an agreed upon protocol and applicable regulatory requirements and for safety reporting to us, the IRB, and the FDA, (b)&nbsp;the institution grants to us a license to use the trial data for any legally permissible purpose and
assigns to us all intellectual property rights relating to the trial drug developed during the course of the agreement, (c)&nbsp;we are responsible for supplying the trial drug and making agreed upon payments to the institution to fund the trial and
(d)&nbsp;the term of the agreement is the duration of the applicable trial, however, the agreement can be terminated for convenience with notice, upon the request of an applicable regulatory agency, for safety reasons or following an uncured
material breach by the other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Submission of an NDA to the FDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Detailed information and results from preclinical and clinical studies and other requirements relating to the product&#146;s chemistry,
manufacture, controls and proposed labeling are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an
application user fee, currently exceeding $2.3 million, and the sponsor of an approved NDA is also subject to annual product and establishment user fees, currently exceeding $110,000 per product and $569,000 per establishment for fiscal year 2015.
These fees are typically increased annually. Important exceptions or waivers for user fees include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A small company (fewer than 500 employees, including employees and affiliates) may submit a written request for a waiver by the FDA to waive the application fee for its first human drug application. After a waiver for a
first human drug application is granted, the small business is assessed appropriate user fees for all subsequent human drug applications and supplements submitted for review. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Products with Orphan Drug Designation for a particular indication are not subject to an application user fee provided there are no other intended uses in the NDA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#146;s
receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted
with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified
performance goals in the review process of NDAs. &#147;Standard review&#148;, representing most such applications is generally reviewed within ten months from the date of filing. &#147;Priority review&#148;, as may be designated by the FDA for a
drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness, are targeted to be reviewed within six months from the date of filing. The review process may be extended by the FDA for three
additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;122&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where the
product is or will be manufactured. These pre-approval inspections usually cover all facilities associated with an NDA submission, including drug component manufacturing (such as Active Pharmaceutical Ingredients), finished drug product
manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of
the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites meeting specific criteria to assure compliance with GCP. The FDA may also inspect the company to evaluate,
for example, processes, safety reporting procedures, training and compliance with US regulations as the sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a
condition of approval, the FDA may require an applicant to develop a risk evaluation and mitigation strategy or REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the
potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or
potential adverse events and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not
limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes
aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an
advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fast
Track, Breakthrough Therapy and Priority Review </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is authorized to designate certain products for expedited review if they are
intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are fast track designation, breakthrough therapy designation, intended to expedite drug development, and priority review
designation, intended to expedite review and approval of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the FDA may designate a product for fast track review if
it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition.
For fast track products, sponsors may have greater interactions with the FDA regarding drug development and the company may submit sections of a fast track product&#146;s NDA before the application is complete. A rolling review must be communicated
to and agreed upon by the FDA. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information. The sponsor must pay the applicable user fee upon submission of the first module in the rolling
submission. However, the FDA&#146;s time period goal for reviewing a rolling NDA does not begin until the last module of the NDA is submitted. Notably, fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no
longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, Congress enacted the Food and Drug Administration Safety and
Improvement Act, or FDASIA. This law established a new regulatory scheme allowing for expedited review of products designated as &#147;breakthrough therapies.&#148; A product may be designated as a breakthrough therapy if it is intended, either
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;123&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapies on one or more clinically significant endpoints. The FDA may take certain actions with respect to breakthrough therapies, including holding increased meetings with the sponsor
throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking
other steps to design the clinical trials in an efficient manner. In oncology, new products with breakthrough therapy designation have occasionally been approved well before the PDUFA review timeline, even for priority review, has elapsed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An NDA for a drug will receive priority review designation by the FDA if it is a drug that treats a serious condition and, if approved, would
provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed drug represents a significant improvement when compared with other available therapies. Significant improvement may be
illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious
outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a
marketing application from ten months to six months after the application is accepted for filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accelerated Approval Pathway
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic
advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition
when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality
or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and
effectiveness as those granted traditional approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as
a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than
clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated
approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional
approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is
required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drugs for
treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival
benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accelerated approval will be subject to the requirement that the applicant study the drug further, to verify and describe its
clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome. Post-marketing studies would usually be studies already underway. When required
to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;124&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to conduct required post-approval studies, or confirm a clinical benefit during
post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The FDA&#146;s Decision on an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#146;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing
facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally
outlines the deficiencies in the submission and may require additional, sometimes substantial, testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s
satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA
approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be
conducted to further assess the drug&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management
mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After
approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such
as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as
well as new application fees for supplemental applications with or without clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other
entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for
compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and
impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
control to maintain cGMP compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;125&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or
imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on post-approval clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which
regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription
pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Abbreviated New Drug Applications for
Generic Drugs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs
that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. In support of such
applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug, or RLD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the
active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#147;bioequivalent&#148; to the innovator drug. Under the statute, a generic drug
is bioequivalent to a RLD if &#147;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug[.]&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon approval of an ANDA, the FDA indicates whether the generic product is &#147;therapeutically equivalent&#148; to the RLD in its
publication &#147;Approved Drug Products with Therapeutic Equivalence Evaluations,&#148; also referred to as the &#147;Orange Book.&#148; Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the
RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#146;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the
prescribing physician or patient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;126&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of
non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with
the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, as discussed below, in which case the applicant may submit its application four years following the original product approval. The FDCA
also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to
the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Section 505(b)(2) NDAs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA approval of most new drug products is based on applications containing two full clinical trials that contain substantial evidence of the
safety and efficacy of the proposed new product. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of
application allows the applicant to rely, in part, on the FDA&#146;s previous findings of safety and efficacy for a similar product, or published literature, if the investigations made to show whether the drug is safe and effective and relied upon
by the applicant were not conducted by or for the applicant and the applicant has not obtained a right of reference from the person by or for whom the investigations were conducted. If the 505(b)(2) applicant can establish that reliance on the
FDA&#146;s previous finding of safety and efficacy is appropriate, the applicant may eliminate the need to conduct certain preclinical or clinical studies of the proposed new product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman Patent Certification and the 30 Month Stay </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
applicant&#146;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to
the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that the Section&nbsp;505(b)(2) applicant is relying
on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the applicant must certify with respect to each patent that: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the required patent information has not been filed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the listed patent has expired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the listed patent is invalid, unenforceable or will not be infringed by the new product. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
certification that the new product will not infringe the already approved product&#146;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents
or indicates that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired (other than method of use patents involving indications for
which the ANDA applicant is not seeking approval). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the
applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;127&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement
lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in
the infringement case that is favorable to the ANDA applicant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pediatric Studies and Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act of 2003, a NDA or supplement thereto must contain data that are adequate to assess the safety and
effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food
and Drug Administration Safety and Innovation Act, or FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans
to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#146;s internal review committee must then review the information submitted,
consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA
may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.
Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan
designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Best Pharmaceuticals for Children Act (BPCA) is intended to improve the FDA and applicant accountability for the
agreed-upon pediatric studies by creating a new mechanism for funding pediatric studies that sponsors or holders of approved applications declined to conduct voluntarily. Pediatric exclusivity, if granted, provides for the attachment of an
additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity, which is discussed below. This six-month exclusivity may be granted if an NDA sponsor submits
pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the
FDA&#146;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent
protection that cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some oncology indications, where pediatric studies are impossible or highly impractical (because, for example, the number of pediatric
patients is so small or geographically dispersed), it may be possible to request a waiver. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan Drug Designation and Exclusivity
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a drug product as an &#147;orphan drug&#148; if it is intended to treat a rare
disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States. A company must request orphan product designation before submitting a NDA. If the request is granted,&nbsp;the FDA will disclose the
identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product
generally will receive orphan product exclusivity. Orphan product exclusivity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;128&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval
of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives
marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies developing an orphan drug to treat an uncommon disease may be eligible for the research tax credit for qualified
research expenses or the orphan drug tax credit for development costs attributable to qualified clinical testing incurred in developing the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by regulation, the pediatric data requirements under the Pediatric Research Equity Act do not apply to products with
orphan designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Patent Term Restoration and Extension </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent
restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a NDA, plus
the time between the submission date of a NDA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#146;s approval date. Only one patent applicable
to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be
extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval of Drug Products in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of
other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a
product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process
ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively
impact the regulatory process in others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials
in the European Union has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is
to be conducted. Furthermore, the applicant may only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational medicinal product dossier with
supporting information prescribed by the European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain marketing approval of a drug under European Union regulatory systems, an applicant must submit a marketing authorization
application, or MAA, using the appropriate registration procedure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;129&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;centralized procedure&#148; provides for the grant of a single marketing authorization
by the European Commission that is valid for all European Union member states. The centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan
medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases. The working definition includes all malignant and borderline malignant neoplasms, following the current
International Classification of Diseases for Oncology, including primary or secondary malignant neoplasms, carcinoma in situ, and neoplasms classified as uncertain whether benign or malignant. Medicinal products for cancer treatment include
antineoplastic agents (including modulators and enhancers of antineoplastic activity) and adjuvant treatments. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for
which a centralized process is in the interest of patients, the centralized procedure may be optional. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee for Medicinal
Products for Human Use, or CHMP, is responsible for preparing EMA&#146;s opinions on all questions concerning medicines for human use, in accordance with European regulation. In the centralized procedure, the CHMP is responsible for conducting the
initial assessment of medicines for which an EU-wide marketing authorization is sought. The maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be
provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from
the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Data and Market Exclusivity in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two
years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic (abbreviated) application for eight years, after which generic
marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years,
the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with
existing therapies. Even if a compound is considered to be a new chemical entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company
can complete a full MAA with a complete database of pharmaceutical test, preclinical tests and clinical trials and obtain marketing approval of its product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical Coverage, Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities.
Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and
managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is
approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;130&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor&#146;s decision to provide coverage for a drug product does
not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be
marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies. For example, the European
Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states
may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices
for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new
products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not
allow favorable reimbursement and pricing arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Healthcare Law and Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of drug products that are
granted marketing approval. Arrangements with third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations. Such restrictions under applicable federal and state healthcare laws and
regulations, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal healthcare Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal
government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements
relating to healthcare matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding
the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal transparency requirements under the Health Care Reform Law will require manufacturers of drugs, devices, drugs and medical supplies to report to the Department of Health and Human Services information
related to payments and other transfers of value to physicians and teaching hospitals and physician ownership and investment interests; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;131&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some state laws require pharmaceutical companies to comply
with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians
and other health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, we had 39 full-time employees, including a total of 12 employees with M.D. or Ph.D. degrees. Of our workforce, 15
employees are engaged in research and development. None of our employees is represented by labor unions or covered by collective bargaining agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal facilities
consist of approximately 23,000 square feet of office and laboratory space located at 840 Memorial Drive, Cambridge, Massachusetts.&nbsp;The lease expires in February 2016, subject to our option to extend the lease for an additional three years.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014,
Calando Pharmaceuticals, Inc., or Calando, entered Chapter 7 bankruptcy in the District of Delaware and, as a result, the intellectual property rights we have obtained from Calando are subject to potential risks that may arise in connection with
bankruptcy. For instance, while our ability to develop and/or commercialize our current product candidates and our ability to utilize our platform are not dependent on the rights that we license from Calando, our license agreements with Calando
could be rejected in connection with Calando&#146;s bankruptcy, in which case, we could, subject to elections and other rights and defenses that may be available to us, lose certain rights granted to us under such licenses. On March&nbsp;3, 2015
Calando&#146;s bankruptcy trustee submitted an application with the bankruptcy court seeking authority to retain a broker to sell Calando&#146;s rights in certain assets including its rights in the license agreements with Cerulean. We have reserved
our rights with respect to any such sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;132&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers and directors as of March&nbsp;1, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D. T. Guiffre, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward G. Garmey, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen L. Roberts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Finance and Administration</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul A. Friedman, M.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Chairman of the Board</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D.(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lead Independent Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan L. Crane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven E. Hall, Ph.D.(1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan L. Kelley, M.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William T. McKee(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Parkinson, M.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Sasisekharan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert I. Tepper, M.D.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of audit committee. </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of compensation committee. </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(3)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of nominating and corporate governance committee. </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(4)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of clinical advisory committee </I></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Christopher D. T. Guiffre, J.D.</I> has
served as our President, Chief Executive Officer and a member of our board of directors since March 2015. He previously served as our Chief Operating Officer from October 2014 to March 2015 and prior to that as our Senior Vice President and Chief
Business Officer. Prior to that, Mr.&nbsp;Guiffre held a number of senior executive positions at various biopharmaceutical companies, including President and Chief Executive Officer of Alvos Therapeutics, Inc., Chief Business Officer at Hydra
Biosciences, Inc. and a senior executive at Cubist Pharmaceuticals, Inc., most recently as Senior Vice President, General Counsel and Secretary. Mr.&nbsp;Guiffre has also held several positions at Renaissance Worldwide, Inc., including Vice
President, General Counsel and Clerk. Prior to that, he was an Associate at Bingham, Dana&nbsp;&amp; Gould LLP (now part of Morgan Lewis &amp; Bockius LLP). Mr.&nbsp;Guiffre received a B.S. from Babson College, a J.D. from Boston College Law School,
and an M.B.A. from Boston College Carroll School of Management. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Edward G. Garmey, M.D. </I>has served as our Chief Medical
Officer and Senior Vice President since 2011. Prior to joining Cerulean, Dr.&nbsp;Garmey held a variety of positions at ArQule, Inc., a clinical-stage biotechnology company, including as Vice President for Clinical Development and as Clinical
Development Liaison. Dr.&nbsp;Garmey previously served as Medical Director at GPC Biotech, a German biopharmaceutical company and now a subsidiary of Agennix AG, where he helped oversee global clinical development studies. Dr.&nbsp;Garmey received
his A.B. from Harvard University and his M.D. from New York University. He is a member of the Scientific Advisory Board for the Harvard-MIT Broad Institute&#146;s Cancer Vaccine Initiative, and he serves on the Board of Visitors of Hearth, a
Boston-based non-profit organization dedicated to the elimination of homelessness among the elderly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Karen L. Roberts</I> has served
as our Senior Vice President, Finance and Administration since 2010. Prior to joining Cerulean, Ms.&nbsp;Roberts served as Vice President, Finance and Administration of Elixir Pharmaceuticals, Inc., a biopharmaceutical company where she was the
senior financial executive responsible for all aspects of finance, accounting and administration. Ms.&nbsp;Roberts previously served in a number of roles, including Corporate Controller and Chief Accounting Officer and Vice President, Finance, at
Frontline Group, Inc., a provider of business performance improvement services and products. Prior to that, Ms.&nbsp;Roberts served as Director of Finance at Dyax Corp., a biotechnology company, and as Corporate Controller and Director, Financial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;133&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administration at T Cell Sciences, Inc., a biopharmaceutical company. Ms.&nbsp;Roberts received her B.S. from Salem State College. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Paul A. Friedman, M.D.</I> has served as our Executive Chairman since October 2014 and as a director since January 2014. Previously, he was
Chief Executive Officer of Incyte Corporation, a public biotechnology company, where he also served as President. Prior to that, Dr.&nbsp;Friedman was President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont
Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), President of Research and Development of The DuPont Merck Pharmaceutical Company, and Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and
DuPont, Dr.&nbsp;Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr.&nbsp;Friedman is a Diplomate of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation.
Dr.&nbsp;Friedman is a director of Incyte, public biopharmaceutical company Synta Pharmaceuticals Corp. and private biopharmaceutical company Gliknik, Inc. Dr.&nbsp;Friedman was a director of Bausch&nbsp;&amp; Lomb Incorporated, Sirtris
Pharmaecutials, Inc. and Auxilium Pharmaceuticals, Inc., until the acquisition of each of these companies. Dr.&nbsp;Friedman received his A.B. from Princeton University and his M.D. from Harvard Medical School. We believe that Dr.&nbsp;Friedman is
qualified to serve on our board of directors due to his management and research and development experience and his experience serving on the boards of life sciences companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>William H. Rastetter, Ph.D.</I> has served as a director since January 2014 and as our lead independent director since April 2014. He is a
Co-Founder of Receptos, Inc., a biopharmaceutical company, where he serves as Director and Chairman of the Board, and previously held the role of Acting Chief Executive Officer. Dr.&nbsp;Rastetter served as a Partner at the venture capital firm of
Venrock Associates. Prior to his tenure with Venrock, Dr.&nbsp;Rastetter was Executive Chairman of Biogen Idec, from the merger of the two companies (Biogen and Idec Pharmaceuticals). He joined Idec Pharmaceuticals as Chairman and Chief Executive
Officer. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and served as well in a scientific capacity at Genentech. Dr.&nbsp;Rastetter also serves as the Chairman of public life sciences companies Illumina, Inc., Neurocrine
Biosciences, Inc., Fate Therapeutics Inc. and Receptos, Inc. and as a director of Regulus Therapeutics, Inc. Dr.&nbsp;Rastetter has held various faculty positions at the Massachusetts Institute of Technology and Harvard University and is an Alfred
P. Sloan Fellow. Dr.&nbsp;Rastetter holds a B.S. from the Massachusetts Institute of Technology and received his M.A. and Ph.D. from Harvard University. We believe Dr.&nbsp;Rastetter is qualified to serve on our board of directors due to his
extensive experience in the biotechnology industry, his broad leadership experience with Idec Pharmaceuticals, Inc. and on several public and private biotechnology company boards, and his experience with financial matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Alan L. Crane</I> is one of our co-founders and has served as a member of our board of directors since 2006. Mr.&nbsp;Crane served as our
Chairman from 2009 to 2014. From our founding until 2009, Mr.&nbsp;Crane served as Cerulean&#146;s Chief Executive Officer. Currently, he is a partner and entrepreneur at Polaris Partners and previously served as a Venture Partner at Polaris.
Mr.&nbsp;Crane has also served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc. Prior to this, he was Senior Vice President of Global Corporate Development at Millennium Pharmaceuticals, Inc. Mr.&nbsp;Crane serves on the
boards of public life sciences company, T2 Biosystems, Inc., and private life sciences companies Visterra, Inc. Seventh Sense Biosystems, Inc., Navitor Pharmaceuticals, Inc., XTuit Pharmaceuticals, Inc., Arsia Therapeutics, LLC and Vaccinex, Inc.
Previously, he served on the boards of Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline), Adnexus Therapeutics, Inc. (acquired by Bristol Myers Squibb), Ocular Therapeutix, Inc. and Hydra Biosciences. Mr.&nbsp;Crane received his B.A., M.A.
and M.B.A. from Harvard University. We believe that Mr.&nbsp;Crane is qualified to serve on our board of directors due to his role in our founding, his institutional knowledge as a result of his continuous service on our board since 2006, and his
significant experience as an investor in, and executive and director of, life sciences companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Steven E. Hall, Ph.D.</I> has served
as a director since 2010. Dr.&nbsp;Hall serves as a general partner at Lilly Ventures, the venture capital arm of Eli Lilly and Company and serves as President and Chief Executive Officer at privately held Esanex, Inc. Prior to joining Lilly
Ventures, Dr.&nbsp;Hall was Senior Vice President, Research and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;134&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Development, at Serenex, Inc., a biotechnology company (acquired by Pfizer), where he was also a co-founder. Dr.&nbsp;Hall has held multiple research management positions, at companies including
Eli Lilly, Sphinx Inc, and Bristol-Myers Squib. Dr.&nbsp;Hall is the author of more than 40 papers and 60 patents. Dr.&nbsp;Hall currently sits on the boards of privately held life sciences companies FORMA Therapeutics, Inc., Esanex, Inc., Nimbus
Discovery, LLC, Lysosomal Therapeutics, Inc., Numerate, Inc. and Hydra Biosciences, Inc. Dr.&nbsp;Hall received his B.S. from Central Michigan University and his Ph.D. from Massachusetts Institute of Technology. We believe that Dr.&nbsp;Hall is
qualified to serve on our board of directors due to his broad experience in the life sciences industry as a venture capitalist, director and senior executive and his research knowledge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Susan L. Kelley, M.D.</I> has served as our director since October 2014. Dr.&nbsp;Kelley has been developing drugs in oncology and
immunology for over 25 years. She was previously Chief Medical Officer of the Multiple Myeloma Research Consortium and its sister organization, the Multiple Myeloma Research Foundation. Dr.&nbsp;Kelley has held positions of increasing responsibility
at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head &#150; Oncology, where she led the Bayer team responsible for the development and worldwide regulatory
approval of Nexavar<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (sorafenib), including a renal cell carcinoma indication. She also held positions of increasing responsibility at Bristol-Myers Squibb in Oncology and Immunology drug
development. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served
as a Clinical Assistant Professor of Medicine. Dr.&nbsp;Kelley currently serves as a member of the boards of directors of public oncology-focused biotechnology companies ArQule, Inc. and Alchemia, Pty Ltd. Dr.&nbsp;Kelley received her M.D. from Duke
University School of Medicine. We believe that Dr.&nbsp;Kelley is qualified to serve on our board of directors due to We believe that Dr. Kelley is qualified to serve on our board of directors due to her experience in life sciences and clinical
development and her experience as a director of other life sciences companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>William T. McKee</I> has served as a director since
January 2014. Mr.&nbsp;McKee served as Chief Operating Officer and Chief Financial Officer at EKR Therapeutics, Inc., a private specialty pharmaceutical company until EKR was sold to Cornerstone Therapeutics Inc. Prior to that, Mr.&nbsp;McKee served
as the Executive Vice President and Chief Financial Officer of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited, a generic pharmaceutical company, and the successor entity to Barr Pharmaceuticals, Inc., a public
specialty pharmaceutical company, which was acquired by Teva. Mr.&nbsp;McKee was also Executive Vice President and Chief Financial Officer of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at
Barr until its acquisition. Prior to joining Barr, Mr.&nbsp;McKee served as Director of International Operations and Vice President-Finance at Absolute Entertainment, Inc., a private developer and marketer of entertainment software. Mr.&nbsp;McKee
previously worked at Gramkow&nbsp;&amp; Carnevale, CPA&#146;s, an accounting firm, and also worked at Deloitte&nbsp;&amp; Touche. Mr.&nbsp;McKee serves on the board of directors of Agile Therapeutics, Inc., a public specialty biopharmaceutical
company, and previously served on the board of Auxilium Pharmaceuticals, Inc. until its acquisition. Mr.&nbsp;McKee received his B.B.A. from the University of Notre Dame. We believe that Mr.&nbsp;McKee is qualified to serve on our board of directors
due to his financial and leadership experience as a chief financial officer and a certified public accountant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David Parkinson,
M.D.</I> has served as a director since October 2014. Dr.&nbsp;Parkinson is a venture partner at New Enterprise Associates. Dr.&nbsp;Parkinson previously served as President and Chief Executive Officer of Nodality, a San Francisco-based
biotechnology company. Prior to that, Dr.&nbsp;Parkinson was Senior Vice President of Oncology Research and Development at Biogen Idec, Vice President of Oncology Development at Amgen and Vice President of Global Clinical Oncology Development at
Novartis. Dr.&nbsp;Parkinson also worked at the National Cancer Institute, serving as Chief of the Investigational Drug Branch and as acting Associate Director of the Cancer Therapy Evaluation Program. He has also held academic positions at the M.D.
Anderson Cancer Center, University of Texas and New England Medical Center at Tufts University School of Medicine. Dr.&nbsp;Parkinson is a past Chairman of the Food&nbsp;&amp; Drug Administration Biologics Advisory Committee and is a recipient of
the FDA&#146;s Cody Medal. He is a past President of the International Society of Biological Therapy, and past editor of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the<I> Journal of
Immunotherapy</I>. He has served a term on the FDA&#146;s Science Board, on the Board of Directors of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;135&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the American Association of Cancer Research and on the National Cancer Policy Forum of the Institute of Medicine. Dr.&nbsp;Parkinson received his M.D. as gold medalist from the University of
Toronto Faculty of Medicine, with internal medicine and hematology/oncology training in Montreal at McGill University and in Boston at New&nbsp;England Medical Center. We believe that Dr.&nbsp;Parkinson is qualified to serve on our board of
directors due to We believe that Dr. Parkinson is qualified to serve on our board of directors due to his experience in life science sciences and his knowledge of regulatory issues related to drug development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ram Sasisekharan, Ph.D.</I> is one of our co-founders and has served as a consultant and as a member of our board of directors since 2006.
Dr.&nbsp;Sasisekharan serves as a Professor of Biological Engineering at the Massachusetts Institute of Technology and is Director of the Harvard-MIT Division of Health Sciences&nbsp;&amp; Technology and Edward Hood Taplin Professor of Biological
Engineering&nbsp;&amp; Health Sciences&nbsp;&amp; Technology and also a member of the Koch Institute for Integrative Cancer Research. Dr.&nbsp;Sasisekharan founded Momenta Pharmaceuticals, Inc. and Visterra, Inc., and he serves on the board of
directors of Visterra, Inc. Dr.&nbsp;Sasisekharan&#146;s research on complex polysaccharides has led to over 125 publications and over 50 patents, including the core technologies of Momenta Pharmaceuticals, Inc. He has won both the Burroughs
Wellcome and Beckman Foundation Young Investigator Awards and was the recipient of the 1998, 1999, 2000, and 2001 CaPCure Awards from the CaPCure Foundation. Dr.&nbsp;Sasisekharan serves on the steering committee of the Consortium for Functional
Glycomics. Dr.&nbsp;Sasisekharan received his B.S. from Bangalore University, his M.S. from Harvard University and his Ph.D. from Harvard Medical School. We believe Dr.&nbsp;Sasisekharan is qualified to serve on our board of directors due to his
experience in science and research and his institutional knowledge as a result of his continuous service on our board since 2006. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert I. Tepper, M.D.</I> has served as a director since 2006. Dr.&nbsp;Tepper has over 25 years of experience building and operating
leading research and development operations. Dr.&nbsp;Tepper co-founded Third Rock Ventures, L.P. and focuses on the formation, development, and scientific strategy of its portfolio companies, as well as actively identifying and evaluating new
investments. Prior to joining Third Rock Ventures, L.P., Dr.&nbsp;Tepper served as President of Research and Development at Millennium Pharmaceuticals, Inc. Before joining Millennium Pharmaceuticals, Inc., he served as principal investigator in the
laboratory of tumor biology at Massachusetts General Hospital Cancer Center. Dr.&nbsp;Tepper is also a founder and former member of the scientific advisory board of Cell Genesys/Abgenix. Dr.&nbsp;Tepper serves as an adjunct faculty member at Harvard
Medical School and Massachusetts General Hospital and is an advisory board member of several leading healthcare institutions, including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical
School. Dr.&nbsp;Tepper is a board member of private life sciences companies Alcresta, Inc., Allena Pharmaceuticals, Inc., Constellation Pharmaceuticals Inc., Jounce Therapeutics, Inc., and Kala Pharmaceuticals, Inc., as well as public
biopharmaceutical company bluebird bio Inc., and is also on the board of overseers at Tufts University. Dr.&nbsp;Tepper holds an A.B. from Princeton University and an M.D. from Harvard Medical School. We believe that Dr.&nbsp;Tepper is qualified to
serve on our board of directors due to his experience in the venture capital industry, particularly with biotech and pharmaceutical companies, combined with his experience building and operating research and development operations, on the boards of
public and private life sciences companies and as faculty and advisory board members of several healthcare institutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and
Election of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of ten members who are, in accordance with the terms of our
certificate of incorporation and bylaws, divided into three classes: class I, class II and class III, with members of each class serving staggered three-year terms. The members of the classes are divided as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the class I directors are Mr. Guiffre, Dr.&nbsp;Sasisekharan, Dr.&nbsp;Tepper and Dr.&nbsp;Kelley, and their term will expire at the annual meeting of stockholders to be held in 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the class II directors are Mr.&nbsp;Crane, Dr.&nbsp;Hall and Dr.&nbsp;Parkinson, and their terms will expire at the annual meeting of stockholders to be held in 2016; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the class III directors are Dr.&nbsp;Friedman, Mr.&nbsp;McKee and Dr.&nbsp;Rastetter, and their terms will expire at the annual meeting of stockholders to be held in 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;136&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the term of a class of directors, directors in that class are eligible to
be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. In accordance with the terms of our certificate of incorporation and bylaws, the authorized number of directors may be changed only
by resolution of the board of directors, our directors may be removed only for cause by the affirmative vote of the holders of 75% or more of our voting stock and any vacancy on our board of directors, including a vacancy resulting from an
enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no formal policy
regarding board diversity. Our priority in selecting board members is identification of members who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively
to the collaborative culture among board members, knowledge of our business and understanding of the competitive landscape. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable NASDAQ rules require a majority of a listed company&#146;s board of directors to be comprised of independent directors
within one year of listing. In addition, the NASDAQ rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be independent and that audit
committee members also satisfy independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Under applicable NASDAQ rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion
of the listed company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for
purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any
consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that all of our directors, other than Messrs. Guiffre and Crane, are independent directors, as defined
by the applicable NASDAQ rules. In making such determination, the board of directors considered the relationships that each non-employee director has with our company and all other facts and circumstances that the board of directors deemed relevant
in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no
family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lead Independent Director </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has appointed Dr.&nbsp;Rastetter to serve as our lead independent director. As lead independent director,
Dr.&nbsp;Rastetter presides over periodic meetings of our independent directors, serves as a liaison between our Executive Chairman and the independent directors and performs such additional duties as our board of directors may otherwise delegate.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board has
established four standing committees&#151;audit, compensation, nominating and corporate governance and clinical advisory&#151;each of which operates under a charter that has been approved by our board of directors. Current copies of each
committee&#146;s charter are posted on the Corporate Governance section of our website, www.ceruleanrx.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board has determined that
all of the members of our audit committee, the compensation committee and the nominating and corporate governance committee satisfy the independence standards for such committees established by the SEC and the NASDAQ listing rules, as applicable. In
making such determinations, our board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;137&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances that our board of directors deemed relevant in
determining independence, including the beneficial ownership of our capital stock by each non-employee director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are Drs. Hall and Rastetter and Mr.&nbsp;McKee. Mr.&nbsp;McKee chairs the audit committee. The audit
committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing our internal audit function; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing our risk management policies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing policies regarding hiring employees from the registered public accounting firm and procedures for the receipt, retention and treatment of accounting related complaints and concerns; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">meeting independently with our internal auditing staff, registered public accounting firm and management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving or ratifying our policies and procedures for related person transactions and review and approve or ratify all related person transactions; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing the audit committee report required by SEC rules to be included in our proxy statement for our annual meeting of stockholders. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All audit and non-audit services, other than <I>de minimis</I> non-audit services, to be provided to us by our independent registered public
accounting firm must be approved in advance by our audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that Mr.&nbsp;McKee is an
&#147;audit committee financial expert&#148; as defined by applicable SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are Drs. Hall, Parkinson and Tepper. Dr.&nbsp;Tepper chairs the compensation committee. The
compensation committee&#146;s responsibilities include: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or making recommendations to our board with respect to, the compensation of our executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing an evaluation of our senior executives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing and administering our cash and equity incentive plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and making recommendations to our board with respect to director compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis&#148; if and to the extent then required by SEC rules; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing the annual compensation committee report if and to the extent then required by SEC rules. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;138&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and corporate governance committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our nominating and corporate governance committee are Dr.&nbsp;Rastetter and Mr.&nbsp;McKee. Dr.&nbsp;Rastetter chairs the
nominating and corporate governance committee. The nominating and corporate governance committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending to our board the persons to be nominated for election as directors and to each of the board&#146;s committees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and making recommendations to the board with respect to management succession planning; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing and recommending to the board corporate governance guidelines; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing an annual evaluation of the board. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical advisory committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our clinical advisory committee are Drs. Kelley, Parkinson and Friedman. Dr.&nbsp;Kelley chairs the clinical advisory committee.
The clinical advisory committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review, evaluate, and advise the board and management regarding the long-term strategic goals and objectives and the quality and direction of our clinical programs and regulatory strategy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">monitor and evaluate regulatory trends and make strategic recommendations to the board regarding the same; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assist the board with its oversight responsibility for enterprise risk management in areas affecting our clinical programs and regulatory strategy; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review such other topics as delegated to the committee from time to time by the board. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation
Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our executive officers serves as a member of the board of directors or
compensation committee or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None of the members of our
compensation committee is, or has ever been, an officer or employee of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics and Code of Conduct </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the code on our website, www.ceruleanrx.com. If we make any substantive amendments
to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;139&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the material elements of our executive compensation for our &#147;named executive officers&#148; and the most important
factors relevant to an analysis of these policies and practices. It provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our executive officers named in the &#147;Summary Compensation
Table&#148; below, or our &#147;named executive officers,&#148; and is intended to place in perspective the data presented in the following tables and the corresponding narrative. Our &#147;named executive officers&#148; for 2014 are Oliver S.
Fetzer, our former President and Chief Executive Officer, Christopher D.T. Guiffre, our President and Chief Executive Officer, Edward Garmey, our Senior Vice President and Chief Medical Officer and Karen L. Roberts, our Senior Vice President,
Finance and Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a newly public company, we have begun a thorough review of all elements of our executive compensation
program, including the function and design of our equity incentive programs. We have begun, and expect to continue in the coming months, to evaluate the need for revisions to our executive compensation program to ensure that our program is
competitive with the companies with which we compete for executive talent and are appropriate for a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers during
our fiscal years ended December&nbsp;31, 2014 and 2013. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D.T. Guiffre, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,168</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">831,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer(3)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Garmey, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,168</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President and<BR></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">303,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">75,750</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="top">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">389,718</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen L. Roberts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,168</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President Finance</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>and Administration</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="top">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">298,468</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oliver S. Fetzer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,614,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,785</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">352,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">176,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">146,088</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="top">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">685,056</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The 2014 amount reflects the discretionary bonus earned in 2014 and paid in March 2015, and the 2013 amount reflects the discretionary bonus earned in 2013 and paid in March 2014. Due to his resignation effective
October&nbsp;29, 2014, Dr.&nbsp;Fetzer will not be paid bonus for 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in the &#147;Option Awards&#148; column reflect the aggregate fair value computed as of the grant date of the options awarded during the year computed in accordance with the provisions of Financial
Accounting Standards Board, or FASB, Accounting Standard Codification, or ASC, Topic 718. See note 10 to our consolidated financial statements appearing at the end of this prospectus for assumptions underlying the valuation of equity awards.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr. Guiffre served as our Senior Vice President and Chief Business Officer through October&nbsp;28, 2014, was named Chief Operating Officer on October&nbsp;29, 2014 and President and Chief Executive Officer on
March&nbsp;20, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of $10,400 that we matched pursuant to our 401(k) plan and $768 in life insurance premiums. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of $10,200 that we matched pursuant to our 401(k) plan and $768 in life insurance premiums. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 10,400 that we matched pursuant to our 401(k) plan, $640 in life insurance premiums and $3,745 accrued vacation paid at termination. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;140&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Narrative to summary compensation table </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Base salary. </I>In 2014, we paid base salaries of $317,128 to Mr.&nbsp;Guiffre, $309,000 to Dr.&nbsp;Garmey, $242,000 to Ms.&nbsp;Roberts
and $324,438 to Dr.&nbsp;Fetzer. We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all of our employees, including our named executive officers. None of our named executive officers are party to an
employment agreement, or other agreement or arrangement that provides for automatic or scheduled increases in base salary. In June 2014, our board of directors, upon the recommendation of our compensation committee, approved a 2014 base salary of
$425,000 for Dr.&nbsp;Fetzer. In October 2014, our board of directors promoted Mr.&nbsp;Guiffre to Chief Operating Officer and approved a 2014 base salary of $350,000 for Mr.&nbsp;Guiffre. In February 2015, our compensation committee approved 2015
base salaries of $364,000 for Mr.&nbsp;Guiffre, $321,360 for Dr.&nbsp;Garmey and $281,680 for Ms.&nbsp;Roberts. In March 2015, our board of directors promoted Mr. Guiffre to President and Chief Executive Officer and increased Mr. Guiffre&#146;s 2015
base salary to $435,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Annual bonus.</I> Our board of directors may, in its discretion, award bonuses to our named executive
officers from time to time. We typically establish annual bonus targets based on a set of specified corporate goals for our named executive officers and conduct an annual performance review to determine the attainment of such goals. Our management
may propose bonus awards to the compensation committee of the board or the board primarily based on such review process. Our compensation committee makes the final determination of the eligibility requirements for and the amount of the bonus awards
paid to our executive officers other than our Chief Executive Officer, and our board of directors makes the final determination of the eligibility requirements for and the amount of the bonus awards paid to our Chief Executive Officer. With respect
to 2014, we awarded bonuses, payable in March 2015, of $115,500 to Mr.&nbsp;Guiffre, $98,880 to Dr.&nbsp;Garmey and $59,895 for Ms.&nbsp;Roberts, such amounts representing 83%, 80% and 83% of bonus targets for Mr.&nbsp;Guiffre, Dr.&nbsp;Garmey and
Ms.&nbsp;Roberts, respectively. In each case, such bonuses are based on the combination of each of Mr.&nbsp;Guiffre&#146;s, Dr.&nbsp;Garmey&#146;s and Ms.&nbsp;Roberts&#146; achievement of individual goals (25% of such bonus) and our attainment of
corporate goals (75% of such bonus). Due to his resignation effective October&nbsp;29, 2014, Dr.&nbsp;Fetzer was not awarded a bonus for fiscal year 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity incentives. </I>Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive
officers, or any formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our
executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the vesting period.
Accordingly, our compensation committee and board of directors periodically review the equity incentive compensation of our named executive officers and from time to time may grant equity incentive awards to them in the form of stock options. Prior
to our initial public offering, or IPO, which was completed in April 2014, our executive officers were eligible to participate in our 2007 stock incentive plan, as amended, or the 2007 Plan. Following the closing of our IPO, our employees and
executives became eligible to receive stock options and other stock-based awards pursuant to the 2014 stock incentive plan, or our 2014 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use stock options to compensate our executive officers in the form of initial grants in connection with the commencement of employment and
also at various times, often but not necessarily annually, if we have performed as expected or better than expected. Prior to our IPO, the award of stock options to our executive officers, other than our Chief Executive Officer, was made by our
board or compensation committee, and the award of stock options to our Chief Executive Officer was made by our board. We have granted stock options to our executive officers with both time-based and performance-based vesting. Upon initiation of
employment, the options that we have granted to our executive officers and other employees with time-based vesting typically become exercisable as to 25% of the shares underlying the option on the first anniversary of the grant date, and as to an
additional 1/48th of the shares underlying the option monthly thereafter. Beginning in 2014, following our IPO, options that we grant to existing executive officers and other employees with time-based vesting typically vest ratably over 48 months
from the vesting commencement date. None of our executive officers is currently party to an employment agreement that provides for automatic award of stock options. The options that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;141&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we have granted to date to our executive officers with performance-based vesting become exercisable upon the occurrence of specified business transactions or other specified milestones. Vesting
and exercise rights cease shortly after termination of employment except in the case of death or disability. Prior to the exercise of an option, the holder has no rights as a stockholder with respect to the shares subject to such option, including
no voting rights and no right to receive dividends or dividend equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically granted stock options with exercise
prices that are equal to the fair market value of our common stock on the date of grant as determined by our board of directors, based on a number of objective and subjective factors. Following our IPO, the exercise prices of all stock options
granted are equal to the fair market value of shares of our common stock on the date of grant, which is determined by reference to the closing market price of our common stock on the NASDAQ Global Market on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, our compensation committee granted an option to purchase 75,000 shares of our common stock to Mr.&nbsp;Guiffre, an option to
purchase 43,000 shares of our common stock to Dr.&nbsp;Garmey and an option to purchase 43,000 shares of our common stock to Ms.&nbsp;Roberts. These options have an exercise price of $8.16 per share and vest monthly as to 1/48th of the shares
underlying the option over four years following the grant date. In March 2015, in connection with the promotion of Mr. Guiffre to President and Chief Executive Officer, our compensation committee approved the grant to Mr. Guiffre of an option to
purchase 407,520 shares of our common stock. This option will vest monthly as to 1/48th of the shares underlying the option over four years following the date of his promotion and will have an exercise price equal to the closing market price of our
common stock on the NASDAQ Global Market on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Outstanding Option Awards at Fiscal-Year End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding option awards for each of our named executive officers at December&nbsp;31,
2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities&nbsp;Underlying<BR>Unexercised Options<BR>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised Options<BR>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise&nbsp;Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D.T. Guiffre, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,562</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/24/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,698</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/24/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,620</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,236</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,444</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/9/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,965</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/23/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,157</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/28/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Garmey, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,590</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/8/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,826</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/24/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,314</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,340</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/9/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,965</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/23/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen L. Roberts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/27/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,447</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/24/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,347</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,340</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/9/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/23/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,169</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/16/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;142&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities&nbsp;Underlying<BR>Unexercised Options<BR>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised Options<BR>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise&nbsp;Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oliver S. Fetzer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,265</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,433</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,098</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,309</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265,834</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,280</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,123</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The unvested shares underlying this option are scheduled to vest in approximately equal monthly installments through January&nbsp;17, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">This option vests as follows: (i)&nbsp;27,572 of the underlying shares shall vest in 24 approximately equal monthly installments, commencing upon the closing of a transformative business development transaction, as
determined by our board of directors and (ii)&nbsp;the remaining 24,126 shares shall vest upon the occurrence of a change in control event meeting certain objective criteria. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The unvested shares underlying this option are scheduled to vest in approximately equal monthly installments through December&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">This option vests as follows: (i)&nbsp;4,988 of the underlying shares shall vest in 24 approximately equal monthly installments, commencing upon the closing of a transformative business development transaction, as
determined by our board of directors and (ii)&nbsp;the remaining 4,248 shares shall vest upon the occurrence of a change in control event meeting certain objective criteria. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">The unvested shares underlying this option are scheduled to vest in approximately equal monthly installments through May&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">The unvested shares underlying this option are scheduled to vest in approximately equal monthly installments through September&nbsp;30, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">The unvested shares underlying this option are scheduled to vest in approximately equal monthly installments through May&nbsp;2, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">The unvested shares underlying this option are scheduled to vest in approximately equal monthly installments through December&nbsp;31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">The unvested shares underlying this option are scheduled to vest in approximately equal monthly installments through December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the terms of the separation agreement we entered into with Dr.&nbsp;Fetzer on October&nbsp;29, 2014 and amended on March&nbsp;3, 2015, the unvested shares underlying this option will not vest. Any
unexercised vested shares and the unvested shares will expire on September&nbsp;30, 2015. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, we entered into an employment agreement with Mr. Guiffre in connection with his continuation of employment with us. In March
2015, in connection with the promotion of Mr. Guiffre to President and Chief Executive Officer, we entered into an amended employment agreement with Mr. Guiffre containing the following terms. Mr. Guiffre is employed at will, and either we or Mr.
Guiffre may terminate the employment relationship for any reason, at any time, with or without notice. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr. Guiffre is eligible to
receive a performance-based annual cash bonus, which is based upon quantitative and qualitative performance objectives that will be mutually agreed between our board of directors and Mr. Guiffre and which will be determined by our board of directors
in its sole discretion. The target annual bonus for the applicable fiscal year is 50% of base salary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;143&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Mr. Guiffre&#146;s employment without cause or if Mr. Guiffre terminates his
employment with us for good reason, other than in connection with a change of control, upon execution and effectiveness of a release of claims, we are obligated to pay Mr. Guiffre (a) an amount equal to his base salary for twelve (12) months, and
(b) the amount of any bonus for the prior year that was approved but not yet paid to Mr. Guiffre at the time of termination. We must also continue to provide Mr. Guiffre and certain of his dependents with group health insurance for a period of
twelve (12) months following such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Mr. Guiffre&#146;s employment without cause or if Mr. Guiffre terminates
employment with us for good reason, following a change of control, upon execution and effectiveness of a release of claims, we are obligated to pay Mr. Guiffre (a) an amount equal to his base salary for eighteen (18) months, payable in a lump sum
payment, and (b) an amount equal to 1.5 times the higher of Mr. Guiffre&#146;s target performance-based annual bonus or the last annual bonus paid to Mr. Guiffre. We must also continue to provide Mr. Guiffre and certain of his dependents with group
health insurance for the duration of the severance period and to accelerate in full the vesting of any outstanding equity awards that are subject to time-based vesting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with Dr.&nbsp;Garmey and Ms.&nbsp;Roberts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, we entered into employment agreements with each of Dr.&nbsp;Garmey and Ms.&nbsp;Roberts in connection with their continuation of
their employment with us. These agreements provide that each of Dr.&nbsp;Garmey and Ms.&nbsp;Roberts are employed at will, and either we or each of Dr.&nbsp;Garmey and Ms.&nbsp;Roberts may terminate the employment relationship for any reason, at any
time, with or without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to such agreements, Dr.&nbsp;Garmey and Ms.&nbsp;Roberts are eligible to receive a
performance-based annual cash bonus, which is based upon quantitative and qualitative performance objectives that will be mutually agreed between our board of directors and Dr.&nbsp;Garmey and Ms.&nbsp;Roberts and which will be determined by our
board of directors in its sole discretion. The target annual bonus for the applicable fiscal year is 40% of base salary for Dr.&nbsp;Garmey and 30% of base salary for Ms.&nbsp;Roberts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate employment with Dr.&nbsp;Garmey or Ms.&nbsp;Roberts without cause or if Dr.&nbsp;Garmey or Ms.&nbsp;Roberts terminates
employment with us for good reason, in each case, excluding following a change of control, upon execution and effectiveness of a release of claims, we are obligated to pay such individual (a)&nbsp;an amount equal to his or her base salary for six
(6)&nbsp;months, payable in six (6)&nbsp;substantially equal monthly installments, and (b)&nbsp;the amount of any bonus for the prior year that was approved but not yet paid to such individual at the time of termination. We must also continue to
provide such individual and certain of his or her dependents with group health insurance for a period of six (6)&nbsp;months following such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate employment with Mr.&nbsp;Guiffre, Dr.&nbsp;Garmey or Ms.&nbsp;Roberts without cause or if Mr.&nbsp;Guiffre, Dr.&nbsp;Garmey or
Ms.&nbsp;Roberts terminates employment with us for good reason, following a change of control, upon execution and effectiveness of a release of claims, we are obligated to pay such individual (a)&nbsp;an amount equal to his or her base salary for
six (6)&nbsp;months, plus one (1)&nbsp;additional month for each year of service by such individual with us, up to a maximum of nine (9)&nbsp;months, payable in a lump sum payment, and (b)&nbsp;an amount equal to such individual&#146;s target
performance-based annual bonus pro-rated to the severance period in months divided by twelve (12)&nbsp;months. We must also continue to provide such individual and certain of his or her dependents with group health insurance for the duration of the
severance period and to accelerate in full the vesting of any outstanding equity awards that are subject to time-based vesting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Separation, Transition
and Release of Claims Agreement with Dr.&nbsp;Fetzer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fetzer voluntarily resigned from his position as our President, Chief
Executive Officer and director, effective October&nbsp;29, 2014, or the separation date. In connection with Dr.&nbsp;Fetzer&#146;s termination of employment with us, we entered into a separation, transition, and release of claims agreement with him.
To assist us in our leadership transition, Dr.&nbsp;Fetzer agreed that for one hundred and eighty (180)&nbsp;days following the separation date, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;144&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or the consulting period, he would make himself reasonably available to us by telephone or e-mail from time to time, upon reasonable notice and on an as-needed basis to provide us with any
reasonable information and guidance that we may request from him. On March&nbsp;3, 2015, we amended the separation, transition and release of claims agreement with Dr.&nbsp;Fetzer, to extend the consulting period until September&nbsp;30, 2015. As a
result of the extension of the consulting period until September&nbsp;30, 2015, all stock options held by Dr.&nbsp;Fetzer, which ceased vesting as of the separation date, will remain exercisable until September&nbsp;30, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into
non-disclosure, non-competition and assignment of intellectual property agreements with each of our executive officers. Under the non-disclosure, non-competition and assignment of intellectual property agreements, each executive officer has agreed
(1)&nbsp;to protect our confidential and proprietary information, (2)&nbsp;to assign to us related intellectual property that is developed during such executive officer&#146;s employment and that relates to our business or research and development
or from the use of our property, premises or confidential information, (3)&nbsp;not to compete with us during his or her employment and for a period of one year after the termination of his or her employment and (4)&nbsp;not to solicit our employees
or customers during his or her employment and for a period of one year after the termination of his or her employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option and Other
Compensation Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2007 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2007 Plan was first adopted by our board of directors in February 2007 and first approved by our stockholders in March 2007 and was amended
in May 2007,&nbsp;April 2009,&nbsp;September 2009,&nbsp;March 2010,&nbsp;November 2010,&nbsp;October 2011,&nbsp;December 2011,&nbsp;November 2012,&nbsp;January 2013,&nbsp;February 2013 and January 2014 to increase the number of shares available for
issuance under the plan.&nbsp;The 2007 Plan provided for the grant of incentive stock options, nonstatutory stock options, restricted stock, restricted stock units and other stock-based awards.&nbsp;Our employees, officers, directors, consultants
and advisors were eligible to receive awards under the 2007 Plan.&nbsp;However, incentive stock options could only be granted to our employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, there were outstanding under the 2007 Plan options to purchase an aggregate of 1,038,486 shares of common stock
at a weighted-average exercise price of $5.05 per share. We no longer grant stock options or other awards under the 2007 Plan. However, any shares of common stock subject to awards under the 2007 Plan that expire, terminate, or are otherwise
surrendered, canceled, forfeited or repurchased at their original issuance price pursuant to a contractual repurchase right become available for issuance under the 2014 Plan (subject, in the case of incentive stock options, to any limitations of the
Internal Revenue Code). In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or
distribution to holders of our common stock other than an ordinary cash dividend the number and class of securities and exercise price per share of each outstanding option under the 2007 Plan shall be equitably adjusted by us (or substitute awards
may be made, if applicable) in a manner determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a reorganization event, as defined in the 2007 Plan,
our board of directors may, in the case of awards under the 2007 Plan, take one or more of the following actions as to all or any, or any portion of, outstanding awards, other than restricted stock awards: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that each outstanding award will be assumed or a substantially similar award will be substituted by the acquiring or succeeding corporation (or an affiliate thereof); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide, upon notice to the participant, that unexercised awards will terminate immediately prior to the consummation of such reorganization event unless exercised within a specified period of time following the date of
such notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to such awards will lapse, in full or in part, at or immediately prior to such reorganization event;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;145&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the event of a reorganization event pursuant to which holders of our common stock will receive a cash payment for each share surrendered in the reorganization event, make or provide for a cash payment to a
participant equal to the excess, if any, of (i)&nbsp;the acquisition price times the number of shares of our common stock subject to such participant&#146;s outstanding awards (to the extent then exercisable at prices not in excess of the
acquisition price), over (ii)&nbsp;the aggregate exercise price of all such outstanding awards and any applicable tax withholdings, in exchange for the termination of such awards; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that in the event of a liquidation or dissolution, awards will convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable tax withholdings); or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of the foregoing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is not obligated under the 2007 Plan
to treat all awards, or all awards of the same type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may at any time provide that any award under the
2007 Plan shall become immediately exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part. Our board of directors may amend, modify or terminate any outstanding award under the 2007
Plan, including but not limited to, changing the date of exercise or realization, and converting an incentive stock option to a nonstatutory stock option, subject in certain cases to the participant&#146;s consent. Our board of directors may amend,
suspend or terminate the 2007 Plan or any portion thereof at any time, subject to any stockholder approval requirements under the Internal Revenue Code with respect to incentive stock options. Unless otherwise specified in the amendment, any
amendment to the 2007 Plan will apply to, and be binding on the holders of, all awards outstanding under the 2007 Plan at the time the amendment is adopted, provided that our board of directors determines that such amendment does not materially and
adversely affect the rights of participants under the 2007 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, our board of directors adopted and our stockholders approved the 2014 Stock Incentive Plan, or 2014 Plan, which became effective
upon our IPO. The 2014 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our employees, officers, directors, consultants and advisors are eligible to receive awards under the 2014 Plan; however, incentive stock
options may only be granted to our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors administers the 2014 Plan. Pursuant to the terms of the 2014 Plan,
our board of directors selects the recipients of awards and determines: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock covered by options and the conditions and limitations applicable to the exercise of options; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the type of options to be granted; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise price of options, which must be at least equal to the fair market value of our common stock on the date of grant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the duration of options, which may not be in excess of ten years; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock subject to any stock appreciation rights, restricted stock awards, restricted stock units or other stock-based awards and the terms and conditions of such awards, including the issue
price or purchase price (if any) and conditions for vesting and repurchase (or forfeiture), provided that the measurement price for stock appreciation rights must be at least equal to the fair market value of our common stock on the date of grant
and the duration of stock appreciation rights may not be in excess of ten years. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;146&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, (i)&nbsp;there were 1,839,628 shares of our common stock
reserved for issuance under the 2014 Plan and (ii)&nbsp;there were outstanding options to purchase an aggregate of 1,378,860 shares of common stock at a weighted-average exercise price of $6.09 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent permitted by applicable law, our board of directors may delegate its powers under the 2014 Plan to one or more committees or
subcommittees of our board or to one or more of our officers. If our board of directors delegates authority to an officer to grant awards under the 2014 Plan, the officer will have the power to make awards to all of our employees, except executive
officers. Our board of directors will fix the terms of the awards to be granted by such officer, including the exercise price of such awards (which may include a formula by which the exercise price will be determined), and the maximum number of
shares subject to awards that such officer may make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any stock split, reverse stock split, stock dividend,
recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, our board of
directors is required by the 2014 Plan to make equitable adjustments, in a manner determined by our board, to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and class of securities available and the share counting rules under the 2014 Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and class of securities and exercise price per share of each outstanding option; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the share and per-share provisions and measurement price of each outstanding stock appreciation right; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares and the repurchase price per share subject to each outstanding restricted stock award or restricted stock unit award; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the share and per-share-related provisions and purchase price, if any, of any outstanding other stock-based award. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a reorganization event, as defined in the 2014 Plan, our board of directors, may, in its sole discretion, take any one or more of the
following actions pursuant to the 2014 Plan, as to some or all outstanding awards, other than restricted stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that all outstanding awards will be assumed, or substituted equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon written notice to a participant, provide that the participant&#146;s unvested and/or unexercised awards will terminate immediately prior to the consummation of such reorganization event unless exercised by the
participant (to the extent then exercisable) within a specified period following the date of such notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon the reorganization event; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the event of a reorganization event pursuant to which holders of our common stock will receive a cash payment for each share surrendered in the reorganization event, make or provide for a cash payment to the
participants with respect to each award held by a participant equal to (i)&nbsp;the number of shares of common stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior
to such reorganization event) multiplied by (ii)&nbsp;the excess, if any, of the cash payment for each share surrendered in the reorganization event over the exercise, measurement or purchase price of such award and any applicable tax withholdings,
in exchange for the termination of such awards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that, in connection with a liquidation or dissolution, awards convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable
tax withholdings); and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of the foregoing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;147&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is not obligated under the 2014 Plan to treat all awards, all awards held
by a participant, or all awards of the same type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of certain restricted stock unit awards, no assumption or
substitution will be permitted and the restricted stock unit awards will instead be settled in accordance with the terms of the applicable restricted stock unit agreement, and in certain circumstances, any unvested restricted stock unit awards will
be terminated immediately prior to the consummation of the reorganization event without any payment in exchange therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
occurrence of a reorganization event other than a liquidation or dissolution, the repurchase and other rights under each outstanding restricted stock award will continue for the benefit of the successor company and will, unless our board of
directors may otherwise determine, apply to the cash, securities or other property into which our common stock is converted pursuant to the reorganization event in the same manner and to the same extent as they applied to such restricted stock. Upon
the occurrence of a reorganization event involving a liquidation or dissolution, all restrictions and conditions on each outstanding restricted stock award will automatically be deemed terminated or satisfied, unless otherwise provided in the
agreement evidencing the restricted stock award or any other agreement between a participant and us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time, our board of directors
may provide that any award under the 2014 Plan shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect to certain actions requiring stockholder approval under the Internal Revenue Code or the rules of the NASDAQ Stock Market,
our board of directors may amend, modify or terminate any outstanding award under the 2014 Plan, including but not limited to, substituting therefor another award of the same or a different type, changing the date of exercise or realization, and
converting an incentive stock option into a nonstatutory stock option, subject to certain participant consent requirements. Unless our stockholders approve such action, the 2014 Plan provides that we may not (except as otherwise permitted in
connection with a change in capitalization or reorganization event): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amend any outstanding stock option or stock appreciation right granted under the 2014 Plan to provide an exercise or measurement price per share that is lower than the then-current exercise or measurement price per
share of such outstanding award; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cancel any outstanding option or stock appreciation right (whether or not granted under the 2014 Plan) and grant in substitution therefor new awards under the 2014 Plan (other than substitute awards permitted in
connection with a merger or consolidation of an entity with us or our acquisition of property or stock of another entity) covering the same or a different number of shares of our common stock and having an exercise or measurement price per share
lower than the then-current exercise or measurement price per share of the cancelled award; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cancel in exchange for a cash payment any outstanding option or stock appreciation right with an exercise or measurement price per share above the then-current fair market value of our common stock; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">take any other action that constitutes a &#147;repricing&#148; within the meaning of the rules of the NASDAQ Stock Market. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No award may be granted under the 2014 Plan after March&nbsp;26, 2024, but awards previously granted may extend beyond that date. Our board of
directors may amend, suspend or terminate the 2014 Plan or any portion thereof at any time, except that stockholder approval will be required to comply with the Internal Revenue Code or stock market requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;148&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, our board of directors adopted and our stockholders approved the 2014 employee stock purchase plan, or the 2014 ESPP, which
became effective upon the IPO. Our board of directors administers the 2014 ESPP. All of our employees or employees of any designated subsidiary, as defined in the 2014 ESPP, are eligible to participate in the 2014 ESPP, provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such person is customarily employed by us or a designated subsidiary for more than 20 hours a week and for more than five months in a calendar year; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such person has been employed by us or by a designated subsidiary for at least 30 days prior to enrolling in the 2014 ESPP; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such person was our employee or an employee of a designated subsidiary on the first day of the applicable offering period under the 2014 ESPP. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No employee may purchase shares of our common stock under the 2014 ESPP and any of our other employee stock purchase plans in excess of
$25,000 of the fair market value of our common stock (as of the date of the option grant) in any calendar year. In addition, no employee may purchase shares of our common stock under the 2014 ESPP that would result in the employee owning 5% or more
of the total combined voting power or value of our stock or the stock of any of our subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to make one or more offerings
to our eligible employees to purchase stock under the 2014 ESPP beginning at such time as our board of directors may determine. Each offering will consist of a six-month offering period during which payroll deductions will be made and held for the
purchase of our common stock at the end of the offering period. Our board of directors may, at its discretion, choose a different period of not more than 12 months for offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the commencement date of each offering period, each eligible employee may authorize up to a maximum of 15% of his or her compensation to be
deducted by us during the offering period. Each employee who continues to be a participant in the 2014 ESPP on the last business day of the offering period will be deemed to have exercised an option to purchase from us the number of whole shares of
our common stock that his or her accumulated payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. Under the terms of the 2014 ESPP, the purchase price shall be determined by our board of directors for
each offering period and will be at least 85% of the applicable closing price of our common stock. If our board of directors does not make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of
our common stock on the first business day of the offering period or on the last business day of the offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An employee who is
not a participant on the last day of the offering period is not entitled to purchase shares under the 2014 ESPP, and the employee&#146;s accumulated payroll deductions will be refunded. An employee&#146;s rights under the 2014 ESPP terminate upon
voluntary withdrawal from an offering under the 2014 ESPP at any time, or when the employee ceases employment for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be
required to make equitable adjustments to the number and class of securities available under the 2014 ESPP, the share limitations under the 2014 ESPP, and the purchase price for an offering period under the 2014 ESPP to reflect stock splits, reverse
stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications of shares, spin-offs and other similar changes in capitalization or events or any dividends or distributions to holders of our common stock other than
ordinary cash dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;149&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with a merger or other reorganization event, as defined in the 2014 ESPP, our board
of directors or a committee of our board of directors may take any one or more of the following actions as to outstanding options to purchase shares of our common stock under the 2014 ESPP on such terms as our board or committee determines: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that options shall be assumed, or substantially equivalent options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon written notice to employees, provide that all outstanding options will be terminated immediately prior to the consummation of such reorganization event and that all such outstanding options will become exercisable
to the extent of accumulated payroll deductions as of a date specified by our board or committee in such notice, which date shall not be less than ten days preceding the effective date of the reorganization event; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon written notice to employees, provide that all outstanding options will be cancelled as of a date prior to the effective date of the reorganization event and that all accumulated payroll deductions will be returned
to participating employees on such date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the event of a reorganization event under the terms of which holders of our common stock will receive upon consummation thereof a cash payment for each share surrendered in the reorganization event, change the last
day of the offering period to be the date of the consummation of the reorganization event and make or provide for a cash payment to each employee equal to (1)&nbsp;the cash payment for each share surrendered in the reorganization event times the
number of shares of our common stock that the employee&#146;s accumulated payroll deductions as of immediately prior to the reorganization event could purchase at the applicable purchase price, where the acquisition price is treated as the fair
market value of our common stock on the last day of the applicable offering period for purposes of determining the purchase price and where the number of shares that could be purchased is subject to the applicable limitations under the 2014 ESPP
minus (2)&nbsp;the result of multiplying such number of shares by the purchase price; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that, in connection with our liquidation or dissolution, options shall convert into the right to receive liquidation proceeds (net of the purchase price thereof). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may at any time, and from time to time, amend or suspend the 2014 ESPP or any portion thereof. We will obtain
stockholder approval for any amendment if such approval is required by Section&nbsp;423 of the Internal Revenue Code. Further, our board of directors may not make any amendment that would cause the 2014 ESPP to fail to comply with Section&nbsp;423
of the Internal Revenue Code. The 2014 ESPP may be terminated at any time by our board of directors. Upon termination, we will refund all amounts in the accounts of participating employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, there were 701,250 shares of our common stock reserved for issuance under the 2014 ESPP and no shares have been
issued under this plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) retirement plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution employee retirement plan for our employees. Our 401(k) plan is intended to qualify as a tax-qualified plan
under Section&nbsp;401 of the Internal Revenue Code so that contributions to our 401(k) plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k) plan. Our 401(k) plan provides that
each participant may contribute up to 100% of his or her pre-tax compensation, up to a statutory limit, which was $17,500 for 2013 and 2014. Participants who are at least 50 years old can also make &#147;catch-up&#148; contributions, which in 2013
and 2014 could be up to an additional $5,500 above the statutory limit. Under our 401(k) plan, each employee is fully vested in his or her deferred salary contributions. Employee contributions are held and invested by the plan&#146;s trustee,
subject to participants&#146; ability to give investment directions by following certain procedures. We match participant contributions up to 4% of a participant&#146;s annual compensation, subject to statutory limits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;150&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation earned by our non-employee directors during 2014. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan L. Crane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul A. Friedman, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,450</TD>
<TD NOWRAP VALIGN="bottom">(4)(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven E. Hall, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan L. Kelley, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,850</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William T. McKee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,012</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Parkinson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,801</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,012</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Sasisekharan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert I. Tepper, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amount reported in the &#147;Option Awards&#148; column reflects the aggregate fair value computed as of the grant date of the options awarded during the year computed in accordance with the provisions of FASB ASC
Topic 718. See note 10 to our consolidated financial statements appearing at the end of this prospectus for assumptions underlying the valuation of equity awards. Including these options, as of December&nbsp;31, 2014: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Crane held stock options to purchase 33,232 shares of common stock, which were vested with respect to 22,565 shares in the aggregate; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Friedman held stock options to purchase 113,786 shares of common stock, all of which were unvested; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Kelley held stock options to purchase 15,000 shares of common stock, all of which were unvested; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;McKee held stock options to purchase 13,786 shares of common stock, all of which were unvested; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Parkinson held stock options to purchase 15,000 shares of common stock, all of which were unvested; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Rastetter held stock options to purchase 13,786 shares of common stock, all of which were unvested; and </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Tepper held stock options to purchase 3,447 shares of common stock, all of which were fully vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Crane served as Chairman of our Board until Dr.&nbsp;Friedman&#146;s appointment as Executive Chair in October 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">In 2013, we granted an option to Mr.&nbsp;Crane in recognition of his services to us other than in his role as a director. In July 2014, this option was modified to reduce the number of shares to a total of 16,000
shares and to modify the vesting to time-based vesting beginning in March 2013 through March 2016. The amount of the incremental fair value of the amended option, computed in accordance with FASB ASC Topic 718, was $213. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">In October 2014, in connection with his appointment as Executive Chair of the board of the directors, we granted Dr.&nbsp;Friedman option to purchase 100,000 shares with an exercise price of $4.36 per share. The option
will fully vest on the first anniversary of the grant date. Dr.&nbsp;Friedman also receives an annual cash retainer of $155,000 for his service as our Executive Chairman. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">In January 2014, in connection with their election to our board, we granted each of Dr.&nbsp;Friedman, Mr.&nbsp;McKee and Dr.&nbsp;Rastetter an option to purchase 13,786 shares of our common stock. The options each have
an exercise price of $10.59 and vest in three equal annual installments beginning on the first anniversary of such director&#146;s election. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">In October 2014, in connection with her election to our board, we granted Dr.&nbsp;Kelley an option to purchase 15,000 shares of our common stock with an exercise price of $4.74 per share. The option vests in three
equal annual installments beginning on the first anniversary of Dr.&nbsp;Kelley&#146;s election. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">In October 2014, in connection with his election to our board, we granted Dr.&nbsp;Parkinson an option to purchase 15,000 shares of our common stock with an exercise price of $4.36 per share. The option vests in three
equal annual installments beginning on the first anniversary of Dr.&nbsp;Parkinson&#146;s election. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr. Guiffre, one of our
directors, who also serves as our President and Chief Executive Officer, does not receive any additional compensation for his service as a director. The compensation that we pay to our President and Chief Executive Officer is discussed in the
&#147;Executive Compensation&#148; section of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to his resignation in October 2014, Dr.&nbsp;Fetzer, one of our
directors who also served as our President and Chief Executive Officer, did not receive any additional compensation for his service as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;151&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director compensation policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board has established the following compensation policy for non-employee directors, which became effective upon the closing of our IPO:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director will receive, on an annual basis, a cash retainer of $30,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director who has then served on our board of directors for at least six months will receive, on the date of the first board meeting held after each year&#146;s annual meeting of stockholders, an option
to purchase 8,000 shares of our common stock, which shall vest in full on the earlier of the first anniversary of the date of grant or immediately prior to the first annual meeting of stockholders occurring after the date of grant;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the chairman of our board of directors will receive an additional cash retainer of $30,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director who serves on the audit committee will receive a cash retainer of $7,500 per year ($15,000 for the chair); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director who serves on the compensation committee will receive a cash retainer of $5,000 per year ($10,000 for the chair); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director who serves on the clinical advisory committee will receive a cash retainer of $1,875 per year ($3,750 for the chair) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director who serves on the nominating and corporate governance committee will receive a cash retainer of $3,500 ($7,000 for the chair); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director elected to the board following the closing of our IPO will receive a one-time award of an option to purchase 15,000 shares of our common stock, which option shall vest in three equal annual
installments. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we will continue to reimburse our non-employee directors for reasonable travel and other
expenses incurred in connection with attending board of director and committee meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, we have adopted provisions in our certificate of incorporation that limit or eliminate the personal liability of
our directors. Our certificate of incorporation limits the liability of directors to the maximum extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breaches
of their fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any unlawful payments related to dividends or unlawful stock repurchases, redemptions or other distributions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
limitations do not apply to liabilities arising under federal securities laws and do not affect the availability of equitable remedies, including injunctive relief or rescission. If Delaware law is amended to authorize the further elimination or
limiting of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law as so amended. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will indemnify our directors and officers to the fullest extent permitted by law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may indemnify our other employees and other agents to the same extent that we indemnify our officers and directors, unless otherwise determined by our board of directors; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will advance expenses to our directors and officers in connection with legal proceedings in connection with a legal proceeding to the fullest extent permitted by law. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;152&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification provisions contained in our certificate of incorporation are not exclusive.
In addition, we have entered into indemnification agreements with our directors and executive officers. These indemnification agreements require us, among other things, to indemnify each such director and executive officer for some expenses,
including attorneys&#146; fees, judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these provisions and agreements are necessary to attract and retain qualified persons as directors and officers. Insofar as
indemnification for liabilities arising under the Securities Act of 1933, which we refer to as the Securities Act, may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we understand that in
the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we maintain standard policies of insurance under which coverage is provided to our directors and officers against losses arising
from claims made by reason of breach of duty or other wrongful act, and to us with respect to payments which may be made by us to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;153&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_15"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2012, we have engaged in the following transactions with our directors and executive officers and holders of more than
5% of our voting securities and affiliates of our directors, executive officers and 5% stockholders. We believe that all of the transactions described below were made on terms no less favorable to us than could have been obtained from unaffiliated
third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bridge Financings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
August 2013, we issued and sold 7% convertible promissory notes in an aggregate principal amount of $8,823,903. We refer to these notes as our 2013 convertible notes. The following table sets forth the principal amount of our 2013 convertible notes
that we issued to our directors, officers and 5% stockholders and their respective affiliates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Principal&nbsp;Amount&nbsp;of<BR>2013 Convertible Notes ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;Issued<BR>upon Conversion of<BR>2013&nbsp;Convertible&nbsp;Notes(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVF, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">448,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Partners(2) . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock(3) . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,655,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lilly Ventures Fund I LLC(4) . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,285,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Lux Capital(5) . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter(6) . . . . . . . . . . . . . . . . . . . . . ..</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Our 2013 convertible notes converted into shares of our common stock at our initial public offering price of $7.00 per share. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;Polaris Venture Partners V, L.P. in a principal amount of $2,487,507; (b)&nbsp;Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P. in a principal amount of $48,481; (c)&nbsp;Polaris Venture
Partners Founders&#146; Fund V, L.P. in a principal amount of $17,039 and (d) Polaris Venture Partners Special Founders&#146; Fund V, L.P. in a principal amount of $24,875. Alan Crane, a member of our board of directors, is a general partner of
Polaris Venture Partners, an affiliate of Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P., Polaris Venture Partners Founders&#146; Fund V, L.P. and Polaris Venture Partners Special Founders&#146; Fund V,
L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2013 convertible notes issued and sold to (a)&nbsp;Venrock Associates V, L.P. in a principal amount of $1,493,634; (b)&nbsp;Venrock Partners V, L.P. in a principal amount of $126,635 and (c)&nbsp;Venrock
Entrepreneurs Fund V, L.P. in a principal amount of $35,094. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Steven E. Hall, a member of our board of directors, is a general partner of Lilly Ventures Fund I LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2013 convertible notes issued and sold to (a)&nbsp;Lux Ventures II, L.P. in a principal amount of $228,139; (b)&nbsp;Lux Ventures II Sidecar, L.P. in a principal amount of $9,567 and (c)&nbsp;Lux Ventures II
Partners Fund I LLC in a principal amount of $12,294. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2013 convertible notes issued and sold to William H. Rastetter and Marisa G. Rastetter as community property. Dr.&nbsp;Rastetter is a member of our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;154&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, we issued and sold 7% convertible promissory notes in an aggregate principal
amount of $6,000,000. The following table sets forth the principal amount of the convertible promissory notes that we issued to our directors, officers and 5% stockholders and their respective affiliates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Principal&nbsp;Amount&nbsp;of<BR>2014 Convertible Notes ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;Issued<BR>upon Conversion of<BR>2014&nbsp;Convertible&nbsp;Notes(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVF, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Partners(2) . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,151,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock(3) . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,381,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lilly Ventures Fund I LLC(4) . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Lux Capital(5) . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">530,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter(6) . . . . . . . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The 2014 convertible notes converted into shares of our common stock at $5.43, which was equal to 77.5% of our initial public offering price of $7.00 per share. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2014 convertible notes issued and sold to (a)&nbsp;Polaris Venture Partners V, L.P. in a principal amount of $2,075,573, (b)&nbsp;Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P. in a principal
amount of $40,453, (c)&nbsp;Polaris Venture Partners Founders&#146; Fund V, L.P. in a principal amount of $14,218 and (d) Polaris Venture Partners Special Founders&#146; Fund V, L.P. in a principal amount of $20,756. Alan Crane, a member of our
board of directors, is a general partner of Polaris Venture Partners, an affiliate of Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P., Polaris Venture Partners Founders&#146; Fund V, L.P. and Polaris
Venture Partners Special Founders&#146; Fund V, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2014 convertible notes issued and sold to (a)&nbsp;Venrock Associates V, L.P. in a principal amount of $1,246,257, (b)&nbsp;Venrock Partners V, L.P. in a principal amount of $105,662 and (c)&nbsp;Venrock
Entrepreneurs Fund V, L.P. in a principal amount of $29,281. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Steven E. Hall, a member of our board of directors, is a general partner of Lilly Ventures Fund I LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2014 convertible notes issued and sold to (a)&nbsp;Lux Ventures II, L.P. in a principal amount of $479,876, (b)&nbsp;Lux Ventures II Sidecar, L.P. in a principal amount of $20,124 and (c)&nbsp;Lux Ventures
II Partners Fund I LLC in a principal amount of $30,081. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2014 convertible notes issued and sold to William H. Rastetter and Marisa G. Rastetter as community property. Dr.&nbsp;Rastetter is a member of our board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a
second Series D convertible preferred stock purchase agreement with certain holders of our common stock (who were formerly holders of our preferred stock prior to our initial public offering and the conversion of such preferred stock into our common
stock), including some of our directors and 5% stockholders and their affiliates and entities affiliated with certain of our directors. The second Series D convertible preferred stock purchase agreement provides these holders the right to demand
that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. See &#147;Description of Capital Stock&#151;Registration Rights&#148; in this prospectus for additional
information regarding these rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;155&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in Our Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our director and principal stockholders and their affiliated entities purchased 4,113,172 shares of our common stock in our initial
public offering at the initial public offering price of $7.00 per share. The following table sets forth the aggregate number of shares that our directors and 5% stockholders and their affiliated entities purchased. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:59.25pt; font-size:8pt; font-family:Times New Roman"><B>Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>Purchased&nbsp;in&nbsp;Initial<BR>Public Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Partners(1). . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated Venrock(2) . . . . . . . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Lux Capital(3). . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Lilly Ventures(4). . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">733,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Crown Ventures . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">827,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter(5) . . . . . . . . . . . . . . . . . . . . . . . . . . . .</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;1,419,015 shares of common stock held by Polaris Venture Partners V, L.P., (b)&nbsp;27,657 shares of common stock held by Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P., (c)&nbsp;9,720
shares of common stock held by Polaris Venture Partners Founders&#146; Fund V, L.P. and (d)&nbsp;14,190 shares of common stock held by Polaris Venture Partners Special Founders&#146; Fund V, L.P. Alan Crane, a member of our board of directors, is a
general partner of Polaris Venture Partners, an affiliate of Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P., Polaris Venture Partners Founders&#146; Fund V, L.P. and Polaris Venture Partners Special
Founders&#146; Fund V, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;852,033 shares of common stock held by Venrock Associates V, L.P., (b)&nbsp;72,238 shares of common stock held by Venrock Partners V, L.P. and (c)&nbsp;20,019 shares of common stock held by Venrock
Entrepreneurs Fund V, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Steven E. Hall, a member of our board of directors, is a general partner of Lilly Ventures Fund I LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;89,577 shares of common stock held by Lux Ventures II, L.P., (b)&nbsp;3,756 shares of common stock held by Lux Ventures II Sidecar, L.P. and (c)&nbsp;12,891 shares of common stock held by Lux
Ventures II Partners Fund I LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 18,869 shares of common stock held by William H. Rastetter and Marisa G. Rastetter as community property. Dr.&nbsp;Rastetter is a member of our board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we have entered into indemnification agreements with our directors. See &#147;Executive
Compensation&#151;Limitation of Liability and Indemnification&#148; for additional information regarding these agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for
Related Person Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written related person transaction policy that sets forth policies
and procedures for the review and approval or ratification of related person transactions. This policy covers any transaction, arrangement or relationship in which we were or are to be a participant, the amount involved exceeds $120,000, and one of
our executive officers, directors, director nominees or 5% stockholders, or their immediate family members, each of whom we refer to as a &#147;related person,&#148; had or will have a direct or indirect material interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a &#147;related person
transaction,&#148; the related person must report the proposed related person transaction to our general counsel, or if we do not have a general counsel, our chief financial officer. The policy calls for the proposed related person transaction to be
reviewed and, if deemed appropriate, approved by our audit committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;156&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the audit committee will review, and,
in its discretion, may ratify the related person transaction. The policy also permits the chairman of the committee to review and, if deemed appropriate, approve proposed related person transactions that arise between audit committee meetings,
subject to ratification by the audit committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the audit committee
after full disclosure of the related person&#146;s interest in the transaction. As appropriate for the circumstances, the audit committee will review and consider: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the related person&#146;s interest in the related person transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approximate dollar value of the amount involved in the related person transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approximate dollar value of the amount of the related person&#146;s interest in the transaction without regard to the amount of any profit or loss; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the transaction was undertaken in the ordinary course of our business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third party; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purpose of, and the potential benefits to us of, the transaction; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular
transaction. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee may approve or ratify the transaction only if it determines that, under all of the
circumstances, the transaction is in our best interests. The audit committee may impose any conditions on the related person transaction that it deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the transactions that are excluded by the instructions to the SEC&#146;s related person transaction disclosure rule, our board
of directors has determined that the following transactions do not create a material direct or indirect interest on behalf of related persons and, therefore, are not related person transactions for purposes of this policy: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interests arising solely from the related person&#146;s position as an executive officer of another entity (whether or not the person is also a director of such entity), that is a participant in the transaction, where
(a)&nbsp;the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity, (b)&nbsp;the related person and his or her immediate family members are not involved in the negotiation of the terms of
the transaction and do not receive any special benefits as a result of the transaction, and (c)&nbsp;the amount involved in the transaction equals less than the greater of $200,000 dollars or 5% of the annual gross revenues of the company receiving
payment under the transaction; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that is specifically contemplated by provisions of our certificate of incorporation or bylaws. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy provides that transactions involving compensation of executive officers shall be reviewed and approved by our compensation
committee in the manner specified in its charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our initial public offering, we did not have a written policy regarding the
review and approval of related person transactions. Nevertheless, with respect to such transactions, it was the practice of our board of directors to consider the nature or and business reason for such transactions, how the terms of such
transactions compared to those which might be obtained from unaffiliated third parties and whether such transactions were otherwise fair to and in our best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;157&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock, as of February&nbsp;28, 2015 and on
an as adjusted basis to reflect the sale of the common stock offered in this offering by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current executive officers and directors as a group. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentages in the
column entitled &#147;Shares Beneficially Owned Prior to Offering&#151;Percentage&#148; are based on a total of 20,369,683 shares of our common stock outstanding as of February&nbsp;28, 2015. The percentages in the column entitled &#147;Percentage
of Shares Beneficially Owned After Offering&#148; are based on 25,508,429 shares of our common stock to be outstanding after this offering, including the 5,138,746 shares of our common stock that we are selling in this offering, assuming a public
offering price of $9.73 per share, which was the last reported sale price of our common stock on the NASDAQ Global Market on March 27, 2015, but not including any additional shares issuable upon exercise of the underwriters&#146; option to purchase
additional shares or outstanding options or warrants. The percentages in the column entitled &#147;Percentage of Shares Beneficially Owned After Offering Assuming Underwriters Exercise Option in Full&#148; are based on 26,279,240 shares of our
common stock to be outstanding after this offering, including the 5,909,557 shares of our common stock that we will sell in this offering if the underwriters exercise in full their option to purchase additional shares, assuming a public offering
price of $9.73 per share, which was the last reported sale price of our common stock on the NASDAQ Global Market on March 27, 2015, but not including any additional shares issuable upon exercise of outstanding options or warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with
respect to our common stock. Shares of our common stock subject to options or warrants that are currently exercisable or exercisable within 60 days of February&nbsp;28, 2015 are considered outstanding and beneficially owned by the person holding the
options or warrants for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have
sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise set forth below, the address of the beneficial owner is c/o
Cerulean Pharma Inc., 840 Memorial Drive, Cambridge, Massachusetts 02139. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially<BR>Owned Prior to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Shares&nbsp;Beneficially<BR>Owned&nbsp;After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Shares Beneficially<BR>Owned After Offering<BR>Assuming&nbsp;Underwriters<BR>Exercise Option in Full</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:133.00pt; font-size:8pt; font-family:Times New Roman"><B>Name and address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Partners(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,724,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,034,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,431,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Lilly Ventures(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,356,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Crown Ventures(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,259,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D. T. Guiffre, J.D.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Garmey, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen L. Roberts(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul A. Friedman, M.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan L. Crane(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,830,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven E. Hall, Ph.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,356,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan L. Kelley, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;158&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially<BR>Owned Prior to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Shares&nbsp;Beneficially<BR>Owned&nbsp;After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Shares Beneficially<BR>Owned After Offering<BR>Assuming&nbsp;Underwriters<BR>Exercise Option in Full</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:138.05pt; font-size:8pt; font-family:Times New Roman"><B>Named Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William T. McKee(12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David R. Parkinson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D.(13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Sasisekharan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert I. Tepper, M.D.(14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group(15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,574,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent of our outstanding common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;1,405,750 shares of common stock held by Polaris Venture Partners IV, LP (&#147;Polaris IV&#148;), (b)&nbsp;26,351 shares of common stock held by Polaris Ventures Partners Entrepreneurs&#146; Fund
IV, LP (&#147;Polaris EFund IV&#148;), (c)&nbsp;3,148,044 shares of common stock held by Polaris Venture Partners V, LP (&#147;Polaris V&#148;), (d)&nbsp;61,353 shares of common stock held by Polaris Venture Partners Entrepreneurs&#146; Fund V, LP
(&#147;Polaris EFund V&#148;), (e)&nbsp;21,562 shares of common stock held by Polaris Ventures Partners Founders&#146; Fund V, LP (&#147;Polaris FFund V&#148;), (f)&nbsp;31,478 shares of common stock held by Polaris Venture Partners Special
Founders&#146; Fund V, LP (&#147;Polaris SFFund V&#148; and together with Polaris IV, Polaris EFund IV, Polaris V, Polaris EFund V and Polaris FFund V, the &#147;Polaris Funds&#148;) and (g)&nbsp;5,242, 98, 24,213, 471, 165 and 241 shares of common
stock issuable upon the exercise of warrants held by Polaris IV, Polaris EFund IV, Polaris V, Polaris EFund V, Polaris FFund V and Polaris SFFund V. Each of the Polaris Funds has the sole voting and investment power with respect to the shares
directly held by it. The general partner of each of Polaris IV and Polaris EFund IV is Polaris Venture Management Co. IV, LLC (&#147;Polaris Management IV&#148;). The general partner of each of Polaris V, Polaris EFund V, Polaris FFund V and Polaris
SFFund V is Polaris Venture Management Co. V, LLC (&#147;Polaris Management V&#148;). Each of Polaris Management IV and Polaris Management V may be deemed to have sole voting and investment power with respect to the shares held by the Polaris Funds
of which they are general partner, and each of Polaris Management IV and Polaris Management V disclaim beneficial ownership of all the shares held by such Polaris Funds except to the extent of their proportionate pecuniary interests therein. North
Star Venture Management 2000, LLC (&#147;North Star&#148;) directly or indirectly provides investment advisory services to various venture capital funds, including the Polaris Funds. The members of North Star (the &#147;Management Members&#148;) are
also members of Polaris Management IV and Polaris Management V, and as such, they may be deemed to share voting and investment power over the shares held by the Polaris Funds. The Management Members disclaim beneficial ownership of such shares,
except to the extent of their proportionate pecuniary interest therein. Alan Crane, one of our directors, has an assignee interest in Polaris Management IV and Polaris Management V. To the extent that he is deemed to share voting and investment
powers with respect to the shares held by the Polaris Funds, Mr.&nbsp;Crane disclaims beneficial ownership of all the shares held by the Polaris Funds except to the extent of his proportionate pecuniary interest therein. The mailing address of the
beneficial owner is c/o Polaris Venture Partners, 1000 Winter Street, Suite 3350, Waltham, MA 02451. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;2,720,455 shares of common stock held by Venrock Associates V, LP (&#147;VA5&#148;), (b)&nbsp;230,647 shares of common stock held by Venrock Partners V, LP (&#147;VP5&#148;), (c)&nbsp;63,915 shares
of common stock held by Venrock Entrepreneurs V, LP (&#147;VE5&#148; and collectively with VA5 and VP5, the &#147;Venrock Funds&#148;) and (d)&nbsp;17,164, 1,454 and 403 shares of common stock issuable upon the exercise of warrants held by VA5, VP5
and VE5, respectively. Venrock Management V, LLC (&#147;VM5&#148;), Venrock Partners Management V, LLC (&#147;VPM5&#148;) and VEF Management V, LLC (&#147;VEFM5&#148;) are the sole general partners of VA5, VP5 and VEF5, respectively, and may be
deemed to own the shares held by the Venrock Funds. VM5, VPM5 and VEFM5 disclaim beneficial ownership of all the shares held by the Venrock Funds except to the extent of their proportionate pecuniary interest therein. The mailing address of the
beneficial owner is 3340 Hillview Ave., Palo Alto, CA 94304. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Based on information supplied by FMR LLC on Schedule 13G filed with the SEC on May 12, 2014, Fidelity SelectCo, LLC (&#147;SelectCo&#148;), 1225 17th
Street, Suite 1100, Denver, Colorado 80202, a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;159&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<FONT STYLE="white-space:nowrap">wholly-owned</FONT> subsidiary of FMR LLC and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is the beneficial owner
of 2,431,400 shares of our common stock as a result of acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940 (the &#147;SelectCo Funds&#148;). Edward C. Johnson 3d and FMR LLC,
through its control of SelectCo, and the SelectCo Funds each has sole power to dispose of the 2,431,400 shares owned by the SelectCo Funds. The ownership of one investment company, Select Biotechnology Portfolio, amounted to 1,901,400 shares or
10.000% of the Common Stock outstanding. Select Biotechnology Portfolio has its principal business office at 245 Summer Street, Boston, Massachusetts 02210. Members of the family of Edward C. Johnson 3d, Chairman of FMR LLC, are the predominant
owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement
under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting
agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Edward C. Johnson 3d, Chairman of FMR LLC, has the sole power to vote or
direct the voting of the shares owned directly by the Fidelity Funds, which power resides with the Funds&#146; Boards of Trustees. Fidelity carries out the voting of the shares under written guidelines established by the Funds&#146; Boards of
Trustees. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Steven E. Hall is a general partner at Lilly Ventures Fund I LLC and has shared voting and shared investment power over such shares, and may be deemed the indirect beneficial owner of such shares. Dr.&nbsp;Hall
disclaims beneficial ownership over such shares, except to the extent of any pecuniary interest therein. The mailing address of the beneficial owner is 115 W. Washington Street, Suite 1680-South, Indianapolis, IN 46204. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Richard H. Robb, manager of CVF, LLC, exercises voting and investment power with respect to shares held by CVF, LLC. Mr.&nbsp;Robb disclaims beneficial ownership of all shares held by CVF, LLC except to the extent of
his pecuniary interest therein. The mailing address of the beneficial owner is 222 N. LaSalle Street, Suite 2000, Chicago, IL 60601. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares of common stock issuable upon the exercise of options exercisable within 60 days after February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;6,892 shares of common stock and (b)&nbsp;67,113 shares of common stock issuable upon the exercise of options exercisable within 60 days after February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares of common stock issuable upon the exercise of options exercisable within 60 days after February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares of common stock issuable upon the exercise of options exercisable within 60 days after February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;the shares described in note (1)&nbsp;above, (b)&nbsp;77,201 shares of common stock and (c)&nbsp;27,898 shares of common stock issuable upon the exercise of options exercisable within 60 days after
February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;the shares described in note (4)&nbsp;above. Dr.&nbsp;Hall is a venture partner at Lilly Ventures Fund I and has shared voting and shared investment power over such shares, and may be deemed the
indirect beneficial owner of such shares. Dr.&nbsp;Hall disclaims beneficial ownership over such shares, except to the extent of any pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares of common stock issuable upon the exercise of options exercisable within 60 days after February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;60,307 shares of common stock (b)&nbsp;379 shares of common stock issuable upon the exercise of warrants and (c)&nbsp;4,595 shares of common stock issuable upon the exercise of options exercisable
within 60 days after February&nbsp;28, 2015. William H. Rastetter holds the aforementioned shares jointly as community property with his wife. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;18,954 shares of common stock and (b)&nbsp;3,447 shares of common stock issuable upon the exercise of options exercisable within 60 days after February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;7,296,836 shares of common stock, (b)&nbsp;30,809 shares of common stock issuable upon the exercise of warrants and (c)&nbsp;246,987 shares of common stock issuable upon the exercise of options
exercisable within 60 days after February&nbsp;28, 2015. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;160&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and provisions of our certificate of incorporation and bylaws are summaries and are qualified
by reference to the certificate of incorporation and bylaws. Copies of these documents have been filed with the Securities and Exchange Commission as exhibits to our registration statement, of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 120,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred
stock, par value $0.01 per share, all of which preferred stock is undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, we had issued and
outstanding 20,369,683 shares of our common stock, held by 54&nbsp;stockholders of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, except that unless
otherwise required by law, holders of our common stock are not entitled to vote on any amendment to the certificate of incorporation that relates solely to the terms of one or more outstanding series of preferred stock, if the holders of such
affected series are entitled, either separately or together as a class with the holders of one or more such other series, to vote thereon pursuant to the certificate of incorporation. Holders of our common stock do not have cumulative voting rights.
An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared
by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available
for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our
outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to
and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our
certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences,
privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays
associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more
difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. As of February&nbsp;28, 2015, there are no shares of preferred stock outstanding, and we have no present
plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, options to purchase 2,417,346 shares of our common stock at a weighted-average exercise price of $5.64 per share
were outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;161&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;28, 2015, we had outstanding warrants to purchase an aggregate of 300,564 shares of our common stock, at a weighted average
exercise price of $8.39 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Anti-Takeover Law and Certain Charter and Bylaw Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to
Section&nbsp;203 of the Delaware General Corporation Law. Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148;
for three years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed
manner. A &#147;business combination&#148; includes, among other things, a merger or consolidation involving us and the &#147;interested stockholder&#148; and the sale of more than 10% of our assets. In general, an &#147;interested stockholder&#148;
is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. The restrictions contained in Section&nbsp;203 are not applicable
to any of our existing stockholders that will own 15% or more of our outstanding voting stock upon the closing of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered board;
removal of directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and our bylaws divide our board of directors into three classes with
staggered three-year terms. In addition, a director may be removed only for cause and only by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors.
Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it more
difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Super-majority voting
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on
any matter is required to amend a corporation&#146;s certificate of incorporation or by-laws, unless a corporation&#146;s certificate of incorporation or by-laws, as the case may be, requires a greater percentage. Our by-laws may be amended or
repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors. In addition, the affirmative vote of
the holders of at least 75% of the votes which all our stockholders would be entitled to cast in an election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of
incorporation relating to the classification of our board of directors and the limitations on the removal of directors and filling of vacancies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder action; special meeting of stockholders; advance notice requirements for stockholder proposals and director nominations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly
called annual or special meeting of such stockholders and may not be effected by any consent in writing by such stockholders. Our certificate of incorporation and our bylaws also provide that, except as otherwise required by law, special meetings of
our stockholders can only be called by our Chairman of the Board, our Chief Executive Officer or our board of directors. In addition, our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting
of stockholders, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;162&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including proposed nominations of candidates for election to our board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of
meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper
form to our secretary of the stockholder&#146;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a
majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our common stock, because even if it acquired a majority of our outstanding voting stock, it would be able to take
action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but unissued shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject
to any limitations imposed by the listing standards of the NASDAQ Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued
and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right to Invest Letter </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2015,
we entered into a right to invest letter with Hercules Growth Technology, Inc., which we refer to as the RTI letter. Pursuant to the terms of the RTI letter, Hercules has the right to participate, in its discretion, in one or more of our equity
financings that are broadly marketed to multiple accredited investors in a private placement for financing purposes in an amount of up to a total of $2.0 million on the same terms and conditions as purchased by the other investors in each such
equity financing. The RTI letter, and all rights and obligations thereunder, will terminate upon the earlier of (1)&nbsp;such time when Hercules has purchased an aggregate of $2.0 million of our equity securities pursuant to the RTI letter and
(2)&nbsp;the later of (a)&nbsp;the repayment of all indebtedness under our term loan agreement with Hercules and (b)&nbsp;the exercise in full by Hercules of the warrant issued in connection with our term loan agreement with Hercules or the
expiration or termination of the exercise period for such warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a second Series D convertible preferred stock purchase agreement, dated November&nbsp;30, 2012, which we refer to as the
second Series D purchase agreement, with certain holders of our capital stock and warrants. As of February&nbsp;28, 2015, we believe that holders of approximately 6.9 million shares of our common stock, including shares issuable upon exercise of
warrants, will have the right to require us to register these shares under the Securities Act of 1933, as amended, or Securities Act, and/or to participate in future registrations of securities by us, under the circumstances described below. After
registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. If not otherwise exercised, the rights described below will expire in April 2018, which is five years after the closing of
our IPO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand registration rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to specified limitations set forth in the second Series D purchase agreement, at any time, the holders of 58% of the then-outstanding
shares having demand registration rights under the second Series D purchase agreement, which we refer to as registrable shares, may at any time demand in writing that we register all or a portion of the registrable shares under the Securities Act.
We are not obligated to file a registration statement pursuant to this provision on more than two occasions, and we may defer the filing of a registration for a period of not more than 90 days if we determine in good faith that it would be seriously
detrimental to us for a registration statement to be filed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;163&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form S-3 registration rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at any time after we become eligible to file a registration statement on Form S-3, subject to specified limitations set forth in
the second Series D purchase agreement, the holders of registrable shares and certain other parties to the second Series D purchase agreement may demand in writing that we register on Form S-3 all or a portion of the registrable shares so long as
the total amount of registrable shares being registered has an aggregate price to the public of at least $1 million. We are not obligated to file a Form S-3 pursuant to this provision on more than two occasions in any 12-month period, and we may
defer the filing of the Form S-3 registration statement for a period of up to sixty days if in the good faith judgment of the underwriters it would be seriously detrimental to us for the Form S-3 registration to be filed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incidental registration rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we propose to file a registration statement under the Securities Act, subject to specified exceptions, the holders of registrable shares and certain other parties to the second Series D purchase agreement will be entitled to notice of the
registration and have the right to require us to register all or a portion of the shares then held by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any
registration in which the holders of registrable shares or such other parties elect to participate pursuant to the second Series D purchase agreement is intended to be an underwritten public offering, we have agreed to enter into an underwriting
agreement in usual and customary form. Holders of registrable securities or such other parties must agree to any such underwriting agreement as a condition to participation in the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any registration in which the holders of registrable shares or such other parties participate pursuant to the second Series
D purchase agreement is an underwritten public offering, we will use our best efforts to include the requested registrable shares to be included, but may be limited by market conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the second
Series D purchase agreement, we are required to pay all registration expenses, including registration and filing fees, exchange listing fees, printing expenses and accounting fees and the fees and expenses of one counsel to represent the selling
stockholders, other than any underwriting discounts and commissions, that are related to any demand, Form S-3 or incidental registration described above. The second Series D purchase agreement contains customary cross-indemnification provisions,
pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or
omissions in the registration statement attributable to them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on the NASDAQ Global Market under the symbol &#147;CERU.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;164&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_19"></A>MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-U.S. HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general discussion of material U.S. federal income and estate tax considerations relating to ownership and disposition of
our common stock by a non-U.S. holder. For purposes of this discussion, the term &#147;non-U.S. holder&#148; means a beneficial owner (other than a partnership or other pass-through entity) of our common stock that is not, for U.S. federal income
tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof or the District of Columbia;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust, if a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or if the trust has a
valid election in effect to be treated as a U.S. person under applicable U.S. Treasury Regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is
based on current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings, and judicial decisions, all publicly available and as
in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to non-U.S. holders
described in this prospectus. In addition, the Internal Revenue Service, or the IRS, could challenge one or more of the tax consequences described in this prospectus and we have not obtained nor do we intend to obtain an opinion of counsel with
respect to the U.S. federal income or estate tax consequences to a non-U.S. holder of acquiring, holding, and disposing of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion addresses only non-U.S. holders that hold shares of our common stock as a capital asset (generally, property held for
investment). This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#146;s individual circumstances nor does it address the
alternative minimum tax, the Medicare tax on net investment income or any aspects of U.S. state, local, or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not
address the special tax rules applicable to particular non-U.S. holders, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insurance companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers or dealers in securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulated investment companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pension plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">passive foreign investment companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security, or other integrated investment; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain U.S. expatriates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this discussion does not address the tax treatment of
partnerships or persons who hold their common stock through partnerships or other entities that are pass-through entities for U.S. federal income tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;165&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her, or its own tax advisor regarding the tax consequences of the purchase,
ownership, and disposition of our common stock through a partnership or other pass-through entity, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Prospective
investors should consult their own tax advisors regarding the U.S. federal, state, local, and non-U.S. income and other tax considerations of acquiring, holding, and disposing of our common stock. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in the
&#147;Dividend Policy&#148; section of this prospectus, we do not expect to pay dividends in the foreseeable future. If we pay distributions on our common stock, those distributions generally will constitute dividends for U.S. federal income tax
purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a
tax-free return of the non-U.S. holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below under the heading &#147;&#151;Gain
on Disposition of Common Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income
tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if
an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States are generally exempt from the 30% withholding tax if the non-U.S. holder
satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States
persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower
rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS Form W-8BEN or W-8BEN-E
(or successor form) and satisfy applicable certification and other requirements. A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by
timely filing an appropriate claim with the IRS. Non-U.S. holders are urged to consult their own tax advisors regarding their entitlement to benefits under a relevant income tax treaty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
non-U.S. holder generally will not be subject to U.S. federal income tax on gain recognized on a disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with the non-U.S. holder&#146;s conduct of a trade or business in the United States and, if an applicable income tax treaty so provides, the gain is attributable to a permanent
establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S. holder will be taxed on a net income basis at the regular graduated rates and in the manner applicable to U.S. persons, and if the
non-U.S. holder is a foreign corporation, an additional branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty, may also apply; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;166&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the non-U.S. holder is an individual present in the United States for 183 days or more in the taxable year of the disposition and certain other requirements are met, in which case the non-U.S. holder will be subject to
a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by U.S.-source capital losses of the non-U.S. holder, if any; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we are, or have been at any time during the five-year period preceding such disposition (or the non-U.S. holder&#146;s holding period, if shorter), a &#147;U.S. real property holding corporation,&#148; unless our common
stock is regularly traded on an established securities market and the non-U.S. holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five year period ending on the date of the disposition or
the period that the non-U.S. holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then a purchaser may withhold 10% of the proceeds payable to a non-U.S. holder
from a sale of our common stock and the non-U.S. holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a
corporation is a &#147;U.S. real property holding corporation&#148; if the fair market value of its &#147;U.S. real property interests&#148; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its
other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax
purposes. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rule described above. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such holder
and the tax withheld, if any, with respect to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup
withholding at the applicable rate, currently 28%, with respect to dividends on our common stock. Generally, a non-U.S. holder will comply with such procedures if it provides a properly executed IRS Form W-8BEN or W-8BEN-E (or other applicable Form
W-8) or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or otherwise establishes an exemption. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above
under the heading &#147;&#151;Dividends,&#148; will generally be exempt from U.S. backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and backup
withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and
satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside
the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner
similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is
incorporated under the provisions of a specific treaty or agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Rather, any amounts
withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the
IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;167&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code (commonly referred to as the &#147;Foreign Account Tax Compliance Act&#148; or &#147;FATCA&#148;)
generally impose a 30% withholding tax on dividends on, and gross proceeds from the sale or other disposition of, our common stock if paid to a foreign entity after certain dates (see below) unless (i)&nbsp;if the foreign entity is a &#147;foreign
financial institution,&#148; the foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; the foreign entity
identifies certain of its U.S. investors, or (iii)&nbsp;the foreign entity is otherwise excepted under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable U.S.
Treasury regulations, withholding under FATCA generally applies currently&nbsp;to payments of dividends on our common stock made after June 30, 2014 and will apply to payments of gross proceeds from a sale or other disposition of our common stock
made after December&nbsp;31, 2016. If withholding under FATCA is required on any payment related to our common stock, investors not otherwise subject to withholding (or that otherwise would be entitled to a reduced rate of withholding) on such
payment may be required to seek a refund or credit from the IRS. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this section. Non-U.S. holders should consult their
own tax advisors regarding the possible implications of FATCA on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable
requirements to prevent the imposition of the 30% withholding tax under FATCA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Estate Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common stock owned or treated as owned by an individual who is a non-U.S. holder (as specially defined for U.S. federal estate tax purposes) at
the time of death will be included in the individual&#146;s gross estate for U.S. federal estate tax purposes and, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of material U.S. federal tax considerations is for general information only. It is not tax advice. Prospective
investors should consult their own tax advisors regarding the particular U.S. federal, state, local, and non-U.S. tax consequences of purchasing, holding, and disposing of our common stock, including the consequences of any proposed changes in
applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;168&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC and Barclays Capital Inc. are acting as joint book-running managers of the offering and as representatives of the
underwriters. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from
us, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock set forth opposite its name below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners&nbsp;LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaccord Genuity Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JMP Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers&#146; certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering, the public offering price, concession or any other term of
the offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before expenses to
us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of our common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;169&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at $0.6
million and are payable by us. We have agreed to reimburse the underwriters in an amount not to exceed $50,000 for expenses related to the clearing of this offering with the Financial Industry Regulatory Authority and all expenses relating to the
qualification of our common stock under state securities laws. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30&nbsp;days after the date of this prospectus, to purchase up to $7,500,000 of
additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional
shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and certain of our significant stockholders have agreed not to sell or transfer any common stock or
securities convertible into or exchangeable or exercisable for common stock, for 90&nbsp;days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC and Barclays Capital Inc. Specifically, we and these
other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of or transfer any common stock;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file&nbsp;a registration statement related to the common stock; or</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of any common stock, whether any such swap, agreement or transaction is to be settled
by delivery of shares or other securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lock-up provision applies to common stock and to
securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power
of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares are listed on the NASDAQ Global Market under the symbol &#147;CERU.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing
our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;170&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater than the underwriters&#146; option described above. The underwriters may close out any covered short position by either exercising their option or purchasing shares in the open market. In
determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares
through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be
created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of
various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the closing of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or slowing a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the NASDAQ Global Market, in the over-the-counter market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any
of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any
representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as e-mail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other
Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates may in the future engage in investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They may in the future receive customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a
&#147;Relevant Member State&#148;), no offer of shares may be made to the public in that Relevant Member State other than: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">A. to any legal
entity which is a qualified investor as defined in the Prospectus Directive;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">B. to fewer than 100 or, if the Relevant Member State has
implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;171&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, provided that no such offer of shares shall require
the Company or the representatives to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive or supplement a prospectus pursuant to Article&nbsp;16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article&nbsp;2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article&nbsp;3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a
non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member
State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the representatives and each of our and the representatives&#146; affiliates will rely upon the truth and accuracy of the foregoing
representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Relevant
Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Relevant Member State of shares
which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or any of the underwriters to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus
Directive in relation to such offer. Neither the company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the company or the underwriters to publish a
prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any
shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as
the same may be varied in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending
Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;172&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Wilmer Cutler Pickering Hale and Dorr LLP, Boston,
Massachusetts. Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts, has acted as counsel for the underwriters in connection with certain legal matters related to this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December 31, 2014 and 2013, and for each of the three years in the period ended December 31, 2014,
included in this prospectus, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein and elsewhere in the Registration Statement. Such consolidated financial
statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_23">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with
respect to the shares of our common stock we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement and the exhibits, schedules and
amendments to the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and schedules to the registration statement. Statements contained in this
prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement.
Each of these statements is qualified in all respects by this reference to such contract, agreement or document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may read and copy
the registration statement of which this prospectus is a part at the SEC&#146;s public reference room, which is located at 100 F Street, N.E., Room 1580, Washington, DC 20549. You can request copies of the registration statement by writing to the
SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the SEC&#146;s public reference room. In addition, the SEC maintains an Internet website, which is located at www.sec.gov,
that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is a part at the SEC&#146;s Internet website.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting and information requirements of the Exchange Act and, as a result, file or will file, periodic reports,
proxy statements and other information with the SEC. These periodic reports and other information are available for inspection and copying at the SEC&#146;s public reference room and the website of the SEC, in each case, referred to above. We also
maintain a website at www.ceruleanrx.com. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the
Exchange Act free of charge through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. The information contained on, or that can be accessed through, our website is not
a part of this prospectus. The reference to our web address does not constitute incorporation by reference of the information contained in, or that can be accessed through, our website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;173&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERULEAN PHARMA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc887761_24"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin887761_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin887761_2">Consolidated Balance Sheets as of December&nbsp;31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin887761_3">Consolidated Statements of Operations for the years ended December&nbsp;31, 2014, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin887761_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Equity (Deficit) for the years
 ended December&nbsp;31, 2014, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin887761_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2014, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin887761_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin887761_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerulean Pharma
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Cerulean Pharma Inc. and subsidiary (the &#147;Company&#148;) as of December&nbsp;31, 2014 and 2013, and the related consolidated statements of operations, redeemable convertible preferred stock and
stockholders&#146; equity (deficit), and cash flows for each of the three years in the period ended December&nbsp;31, 2014. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an
opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but
not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the
amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position
of Cerulean Pharma Inc. and subsidiary as of December&nbsp;31, 2014 and 2013, and the results of their consolidated operations and their cash flows for each of the three years in the period ended December&nbsp;31, 2014, in conformity with accounting
principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 19, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin887761_2"></A>CERULEAN PHARMA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(In thousands, except
share data and par value) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, prepaid expenses, and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment &#151; Net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of loan payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes payable to shareholders</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term liabilities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan payable &#151; net of current portion</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent accrued interest</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Note 8)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments (Note 13)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.01 par value; 5,000,000 shares authorized, no shares issued or outstanding</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 120,000,000 shares authorized, 20,125,049 and 785,531 shares issued and outstanding at
December&nbsp;31, 2014 and 2013, respectively</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERULEAN PHARMA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin887761_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(In thousands, except per share and share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in value of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense) &#151; net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,548,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERULEAN PHARMA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin887761_4"></A>CONSOLIDATED STATEMENT OF REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(In thousands, except share data and par value) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable</B><br><B>Convertible&nbsp;Preferred&nbsp;Stock</B><br><B>$0.01 Par Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="BORDER-RIGHT:1px solid #000000;border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B><br><B>$0.0001 Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="BORDER-RIGHT:1px solid #000000;border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">BALANCE &#151; December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,374,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Sale of Series D Convertible Preferred Stock at $0.83 per share, net of issuance costs of $73</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,662,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accretion of issuance costs to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="BORDER-RIGHT:1px solid #000000;border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">BALANCE &#151; December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,037,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of preferred stock into common stock at $14.51 to $39.21 per share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,830,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="BORDER-RIGHT:1px solid #000000;border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">BALANCE &#151; December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,207,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">785,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock from initial public offering, net of underwriting fees and issuance costs of $7,126</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,569,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of convertible preferred stock into common stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,207,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,826,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Reclassification of warrants in connection with initial public offering</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of convertible notes, net of issuance costs of $187</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,902,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="BORDER-RIGHT:1px solid #000000;border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">BALANCE &#151; December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,125,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(121,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="BORDER-RIGHT:1px solid #000000;border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERULEAN PHARMA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin887761_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Noncash rent expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Change in carrying value of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Loss (gain) on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable, prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from sale of common stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from initial public offering, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from loans payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payments on capital lease</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payments on loans payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash paid for debt issuance costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from sale of redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents &#151; Beginning of year</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents &#151; End of year</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Supplemental disclosures of noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of redeemable convertible preferred stock into common stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of convertible notes and accrued interest into common stock, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Reclassification of warrants to additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Fair value of preferred stock warrants issued in connection with debt</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Supplemental cash flow information &#151; Interest paid</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERULEAN PHARMA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin887761_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NATURE OF BUSINESS AND OPERATIONS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Nature of Business</B> &#151; Cerulean Pharma
Inc. (the &#147;Company&#148;) was incorporated on November&nbsp;28, 2005 as a Delaware corporation and is located in Cambridge, Massachusetts. The Company was formed to develop novel, nanotechnology-based therapeutics in the areas of oncology and
other diseases. In 2013, the Company formed a wholly-owned subsidiary, Cerulean Pharma Australia Pty&nbsp;Ltd as an Australian-based proprietary limited company, to perform clinical activities in Australia. To date, operations of the Australia
subsidiary have been immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s operations to date have consisted primarily of raising capital, product research and
development, and initial market development. Accordingly, the Company is considered to be in the development stage at December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any revenue related to its primary business purpose to date and is subject to a number of risks similar to those
of other development stage life science companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products, and the need to obtain adequate additional financing to fund the
development of its product candidates. The Company is also subject to a number of risks similar to other companies in the industry, including rapid technological change, regulatory approval of products, uncertainty of market acceptance of products,
competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and dependence on key
individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has an accumulated deficit of $121.8 million at December&nbsp;31, 2014. The Company has financed its operations
primarily through private placements of its preferred stock, proceeds from borrowings, and an initial public offering completed in 2014. The Company has not completed development of any product candidate and has devoted substantially all of its
financial resources and efforts to research and development, including preclinical and clinical development. The Company expects to continue to incur significant expenses and increasing operating losses for at least several years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering</B> &#151; On April&nbsp;15, 2014, the Company completed the sale of 8,500,000 shares of its common stock in its
initial public offering (the &#147;IPO&#148;), at a price to the public of $7.00 per share. On May&nbsp;7, 2014 the Company completed the sale of an additional 1,069,715 shares of common stock at a price to the public of $7.00 per share under a
partial exercise by the underwriters of their option to purchase additional shares of common stock. The sale of shares to the public resulted in net proceeds of $59.9 million after deducting underwriting discounts and commissions and offering
expenses payable by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In preparation for the IPO, the Company&#146;s board of directors and stockholders approved a
1-for-14.5074 reverse stock split of the Company&#146;s common stock effective March&nbsp;31, 2014. All share and per share amounts in the consolidated financial statements contained herein and notes thereto have been retroactively adjusted, where
necessary, to give effect to this reverse stock split. In connection with the closing of the IPO, all of the Company&#146;s outstanding redeemable convertible preferred stock and convertible notes automatically converted into shares of common stock
as of April&nbsp;15, 2014, resulting in the issuance by the Company of an additional 9,728,237 shares of common stock. The significant increase in shares outstanding in April 2014 is expected to impact the year-over-year comparability of the
Company&#146;s net loss per share calculations in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the completion of the IPO on April&nbsp;15, 2014, the Company&#146;s
outstanding warrants to purchase 1,857,226 shares of the Company&#146;s preferred stock automatically converted into warrants to purchase an aggregate of 128,663 shares of the Company&#146;s common stock and, as a result, the Company reclassified
the warrant liability to additional paid-in capital. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SIGNIFICANT ACCOUNTING POLICIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates</B> &#151; The preparation of
financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On an ongoing basis, the Company&#146;s management evaluates its estimates, including estimates related to clinical trial accruals,
stock-based compensation expense, and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be
reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Principles of Consolidation</B> &#151; The consolidated financial statements include the accounts of the Company and its wholly-owned
subsidiary. All intercompany accounts and transactions have been eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Segment Information</B> &#151; Operating segments are
identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company
views its operations and manages its business in one operating segment; however, the Company operates in two geographic regions: United States (Cambridge, MA) and Australia (Sydney, NSW).&nbsp;There is no revenue generated or long-lived assets
located within the Australian location. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents</B> &#151; Cash equivalents include all highly liquid investments
maturing within 90&nbsp;days from the date of purchase and consist primarily of money market funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Concentrations of Credit Risk</B>
&#151; Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. Substantially all of the Company&#146;s cash and cash equivalents are held at one financial
institution that management believes to be of high-credit quality. Deposits with this financial institution may exceed the amount of insurance provided on such deposits; however these deposits may be redeemed upon demand and, therefore, bear minimal
risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash </B>&#151; At December&nbsp;31, 2014 and 2013, the Company has restricted cash of $117,000 representing a letter
of credit for the Company&#146;s facility lease that is scheduled to expire in February 2016. The letter of credit is secured by certificates of deposit that renew monthly. The restricted cash is included within other assets in the balance sheet.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment</B> &#151; Property and equipment are recorded at cost and depreciated over their estimated useful lives using
the straight-line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Depreciation is provided using the straight-line method over the following estimated useful lives: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Laboratory equipment</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Computer equipment</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office furniture and equipment</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Lesser of useful life or remaining lease term</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Impairment of Long-Lived Assets</B> &#151; Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If
this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value. For the years ended December&nbsp;31, 2014 and 2013, the Company has not recorded an impairment
charge for its long-lived assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition</B> &#151; The Company&#146;s revenue to date has been insignificant and has
been generated from short-term research agreements with pharmaceutical companies and federal grants. There have been no multiple element arrangements. Revenue is recognized when four basic criteria are met: (1)&nbsp;persuasive evidence of an
arrangement exists, (2)&nbsp;delivery has occurred or services have been rendered, (3)&nbsp;the fee is fixed or determinable, and (4)&nbsp;collectability is reasonably assured. Accordingly the Company has recognized revenue under its agreements as
the services were performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Loss</B> &#151; Comprehensive loss consists of net loss and changes in equity during a
period from transactions and other equity and circumstances generated from non-owner sources. The Company had no items of comprehensive loss, other than its net loss, for each of the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Research and Development Costs</B> &#151; Research and development expenses consist of expenses incurred in performing research and
development activities, including compensation and benefits for full-time research and development employees, an allocation of facilities expenses, overhead expenses, manufacturing process-development and scale-up activities, clinical trial and
related clinical manufacturing expenses, fees paid to clinical research organizations, or CROs, and investigative sites, payments to universities under the Company&#146;s license agreements and other outside expenses. In the early phases of
development, the Company&#146;s research and development costs are often devoted to expanding its product platform and are not necessarily allocable to a specific target. Research and development costs are expensed as incurred. Nonrefundable
advanced payments, if any, for goods and services used in research and development are recognized as an expense as the related goods are delivered or services are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Warrant Liability</B> &#151; Freestanding warrants related to shares that are redeemable or contingently redeemable are
classified as a liability on the Company&#146;s balance sheets. The Company uses the Black-Scholes option-pricing model to estimate the fair value of the warrants. Changes in the fair value of these warrants are recorded in the statements of
operations. All of the Company&#146;s warrants to purchase preferred stock were converted to warrants to purchase common stock upon the Company&#146;s IPO in April 2014. Accordingly, the preferred stock warrant liability was reclassified to
additional paid-in capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Redeemable Convertible Preferred Stock</B> &#151; The Company classifies redeemable convertible preferred
stock that is redeemable outside of the Company&#146;s control outside of permanent equity. The Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being
increased by periodic accretion to its redemption value. In the absence of retained earnings these accretion charges are recorded against additional paid-in capital, if any, and then to accumulated deficit. The Company amortizes the accretion using
the interest method. All of the Company&#146;s redeemable convertible preferred stock was automatically converted to common stock in connection with the Company&#146;s IPO in April 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B>&#151; The Company accounts for stock-based awards at fair value, which is measured using the Black-Scholes
option-pricing model. The fair value measurement date for employee awards is generally the date of grant. The fair value measurement date for nonemployee awards is generally the date the performance of services is completed. Stock-based compensation
costs are recognized as an expense over the requisite service period, which is generally the vesting period, on a straight-line basis for all time-vested awards. The Company issued performance based grants where the vesting of the grant is tied to
certain milestone performance and in these cases, the compensation is recognized as expense when the probability of the milestone is met. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stock-based awards to nonemployees are remeasured at each reporting date and recognized as
services are rendered, generally on a straight-line basis. The Company believes that the fair value of these awards is more reliably measurable than the fair value of the services rendered. Stock-based compensation is classified in the accompanying
consolidated statements of operations in the department where the related services are provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Net Loss per Share Attributable to
Common Stockholders</B> &#151; Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. During
periods where the Company might earn net income, the Company would allocate participating securities a proportional share of net income determined by dividing total weighted average participating securities by the sum of the total weighted average
common shares and participating securities (the &#147;two-class method&#148;). Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods where the Company incurred net
loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The Company computes diluted loss per common share after giving consideration to the dilutive effect
of stock options and warrants that are outstanding during the period, except where such nonparticipating securities would be antidilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Income Taxes</B> &#151; Deferred income taxes are provided for the temporary differences arising between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes and for operating loss carryforwards and credits. Deferred tax assets and liabilities are recorded using tax rates expected to be in effect in the year in
which the differences are expected to reverse. A valuation allowance is provided for any net deferred tax assets for which management believes it is more likely than not that the net deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company provides reserves for potential payment of tax to various tax authorities related to uncertain tax positions. The tax benefits
recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its filings or positions is &#147;more likely than not&#148; to be realized following resolution of any uncertainty related to the tax benefit,
assuming the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. At December&nbsp;31, 2014 and 2013, the Company
has not identified any significant uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Guarantees and Indemnification</B> &#151;&nbsp;As permitted under Delaware
law, the Company indemnifies its officers, directors, and employees for certain events or occurrences while the officer or director is, or was serving at the Company&#146;s request in such a capacity.&nbsp;The term of the indemnification is for the
officer&#146;s or director&#146;s lifetime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B>&#151;&nbsp;In August 2014 Financial Accounting
Standards Board (the &#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2014-15,<I>&nbsp;&#147;Disclosure of Uncertainties About an Entity&#146;s Ability to Continue as a Going Concern&#148;</I>&nbsp;(&#147;ASU 2014-15&#148;).
ASU 2014-15 requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity&#146;s ability to continue as a going concern and provide related
disclosures. ASU 2014-15 is effective for annual and interim reporting periods beginning January&nbsp;1, 2017 and is not expected to have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June 2014, the FASB issued ASU No.&nbsp;2014-10, &#147;<I>Development Stage Entities: Elimination of Certain Financial Reporting
Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic&nbsp;810, Consolidation</I>.&#148; This accounting standard eliminates all incremental financial reporting requirements from U.S. GAAP for development stage
entities, thereby improving financial reporting by reducing the cost and complexity associated with providing such information. The Company will no longer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
be required to present inception-to-date information. This ASU is effective on a prospective basis for annual and interim reporting periods beginning on or after December&nbsp;15, 2014, with
early adoption permitted. The Company elected to early adopt the ASU starting with its June&nbsp;30, 2014 financial statements and, accordingly, has not included inception to date information it the accompanying financial statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes
the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share data and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of preferred stock issuance costs to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,548,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has reported a net loss for all periods presented, therefore diluted net loss per common share is
the same as basic net loss per common share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities outstanding have been excluded from the
computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact due to the losses reported (in common stock equivalent shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,126,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,046,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,826,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,992,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">754,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PROPERTY AND EQUIPMENT </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&nbsp;31, 2014, 2013 and 2012
was $126,000, $197,000 and $346,000, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ACCRUED EXPENSES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued contract manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2010 and September 2010, the Company
issued one-year convertible notes payable in the amounts of $5,000,000 and $1,500,000, respectively, to existing investors, with a stated interest rate of 7%. In November 2010, the principal and accrued interest of $176,000 were converted into
9,021,175&nbsp;shares of Series&nbsp;C Preferred Stock at $0.74 per share. The Company also provided for the issuance of seven-year warrants to purchase Series&nbsp;C Preferred Stock with the notes. The issuance of the warrants was contingent upon
the conversion of the notes to Series&nbsp;C Preferred Stock. The number of shares included in the warrants was determined by dividing 10% of the note principal converted to Series&nbsp;C Preferred Stock by the Series&nbsp;C Preferred Stock per
share issue price. Concurrent with the conversion of the notes, warrants to purchase 878,370&nbsp;shares of Series&nbsp;C Preferred Stock at $0.74 per share became exercisable. The Company estimated the fair value of the warrants on the issue date
to be $474,000 using the Black-Scholes option-pricing model with the following assumptions: volatility of 80%, contractual term of seven years, risk-free interest rate of 1.85%, and no dividend yield. The Company determined the fair value of the
warrants at the end of each subsequent reporting period using the Black-Scholes option-pricing model (see Note 11) until their conversion to warrants to purchase 60,532 shares of common stock upon the IPO in April 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2013, the Company issued convertible promissory notes in the amount of $8,824,000 to existing investors, with a stated interest rate
of 7%. Outstanding principal and unpaid accrued interest due under the notes were automatically converted into shares of the Company&#146;s common stock upon the closing of the Company&#146;s IPO in April&nbsp;2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In February and March 2014, the Company issued convertible promissory notes in the aggregate amount of $6,000,000 to existing investors and a
convertible promissory note in the amount of $2,500,000 to a new investor. All the notes had a stated interest rate of 7%. Outstanding principal and unpaid accrued interest due under the notes were automatically converted into shares of the
Company&#146;s common stock upon the closing of the Company&#146;s IPO in April&nbsp;2014, at a conversion price equal to 77.5% of the IPO price. The Company recorded a loss on the extinguishment of the notes of $2,493,000 in April 2014, equal to
the difference between the fair value of the shares into which the notes converted and the carrying amount of the notes upon the closing of the Company&#146;s IPO. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LOAN AGREEMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2008, the Company entered into a Loan and Security
Agreement (the &#147;Loan Agreement&#148;) with a bank to borrow up to $1,500,000 in one or more advances to finance certain equipment purchases made by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company through May&nbsp;31, 2009. In September&nbsp;2008, the Company received its only advance totaling $695,000 and issued a note payable to the bank. No additional advances were made. The
note was payable over a 48-month period in equal principal payments, plus interest on the outstanding balance, fixed at the 8.75%. The note was secured by a security interest in the specific equipment financed. In September 2012, the Company paid
the remaining balance in accordance with the original repayment schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the Loan Agreement, the Company issued the
bank a warrant to purchase 15,000&nbsp;shares of the Company&#146;s Series&nbsp;B Preferred Stock at an exercise price of $2.00 per share. The warrant was immediately exercisable and expires 10&nbsp;years from the date of grant. The value of the
warrant was recorded as a discount to the note payable and was amortized to interest expense using the effective interest method over the 48-month repayment term. The Company estimated the fair value of the warrant on the grant date to be $25,000
using the Black-Scholes option-pricing model with the following assumptions: volatility of 79%, contractual term of 10&nbsp;years, risk-free interest rate of 3.89%, and no dividend yield. The Company determined the fair value of the warrants at the
end of each subsequent reporting period using the Black-Scholes option pricing model (see Note 11) until their conversion to common stock warrants to purchase 1,695 shares of common stock upon the completion of the IPO in April 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In December&nbsp;2011, the Company entered into a loan and security agreement with Lighthouse Capital Partners VI, L.P. (&#147;Lighthouse
Capital&#148;) to borrow up to $10,000,000 in one or more advances by December&nbsp;31, 2012. Debt proceeds are available to the Company to fund research and development activities and other general corporate purposes. The Company granted Lighthouse
Capital a first priority security interest in all unsecured present and future assets, other than intellectual property, and the Company entered into a negative pledge agreement with the lender, whereby the Company agrees not to grant a security
interest in or encumber any of the Company&#146;s intellectual property. The Company also has restrictions on its ability to obtain additional debt that is not permitted under the agreement. In both March&nbsp;2012 and August 2012, the Company
borrowed $5,000,000 under the loan and security agreement, for a total of $10,000,000. This amount was being repaid over 36&nbsp;months beginning on December&nbsp;1, 2012, at an interest rate of 8.25%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company is required to make an additional interest payment in the amount of $600,000 at the end of the loan term. The amount
is being accrued over the loan term as interest expense. The amount accrued as of December&nbsp;31, 2014 was $574,000 and is included in accrued expense in the accompanying balance sheet. As of December&nbsp;31, 2013 the amount accrued was $391,000,
and was included as non-current accrued interest expense in the accompanying balance sheet. The minimum future principal payments are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:92.45pt; font-size:8pt; font-family:Times New Roman"><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized discount relating to warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less current portion</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2015, the Company repaid in full the amount outstanding under the Lighthouse Capital loan with the
proceeds from a new loan (see Note 18). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the loan and security agreement with Lighthouse Capital, the Company issued
the lender a warrant to purchase a maximum of 66,436&nbsp;shares of the Company&#146;s Series&nbsp;D Preferred Stock, at an exercise price of $12.04 per share. The warrant was immediately exercisable for 29,067&nbsp;shares at the date of issue and
expires 10&nbsp;years from the date of issue (December 2021). The exercisable shares increased in March 2012 and August 2012 as the Company borrowed under the loan and security agreement. At </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2014 and 2013, 66,436&nbsp;shares were exercisable. The fair value of the warrant was estimated on the date of issue for the exercisable shares at that date and the fair value
of each increment was estimated on the date the shares became exercisable, using the Black-Scholes option-pricing model. The Company estimated the fair value of the warrant for shares exercisable on the issue date in December 2011 and incremental
shares exercisable in March 2012 and August 2012 to be $284,000, $182,000 and $178,000, respectively. The following table shows the Black-Scholes assumptions used to value the preferred stock warrants in connection with the loan and security
agreement on the respective dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D Preferred Stock Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;August&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.69&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.29&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The value of the warrant is recorded as a discount to the loan and is being amortized to interest expense
using the effective interest method over the 36-month repayment term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company determined the fair value of the warrant at the end of
each subsequent reporting period using the Black-Scholes option pricing model (see Note 11) until their conversion to warrants to purchase 66,436 shares of common stock upon the completion of the IPO in April 2014. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REDEEMABLE CONVERTIBLE PREFERRED STOCK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the IPO in
April 2014, all of the Company&#146;s outstanding convertible preferred stock automatically converted to common stock resulting in an additional 6,826,004 shares of common stock of the Company becoming outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, preferred stock consisted of the following (in thousands, except share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred</B><br><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares</B><br><B>Issued and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption</B><br><B>Value&nbsp;/Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December 2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,307,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May 2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,307,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,077,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December 2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,562,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July 2009</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,842,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,310,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November 2010 and June 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,836,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,698,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;2011&nbsp;and&nbsp;November&nbsp;2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,158,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,894,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,207,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Common Stock</B> &#151; As discussed in Note 1,
during 2014 the Company issued 19,297,952 shares of common stock in connection with its IPO, the conversion of preferred stock and convertible notes into common stock, and the partial exercise of the underwriters&#146; overallotment option in the
IPO. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Reserved Shares of Common Stock</B> &#151; The Company has reserved the following number of
shares of common stock at December&nbsp;31, 2014 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,954,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,561,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,201,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,689,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,156,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>STOCK OPTION PLANS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2007 Stock Incentive Plan </B>&#150; The Company&#146;s 2007
Incentive Stock Plan, or the 2007 Plan, provides for the grant of qualified incentive stock options and nonqualified stock options or other awards to the Company&#146;s employees, officers, directors, advisors, and outside consultants to purchase up
to an aggregate of 1,275,211 shares of the Company&#146;s common stock, as amended in January 2014. The stock options generally vest over a four-year period and expire 10&nbsp;years from the date of grant. Certain options provide for accelerated
vesting if there is a change in control, as defined in the 2007 Plan. Effective with the IPO, no additional grants will be issued from the 2007 Plan and all shares available for grant under the 2007 Plan were transferred to the 2014 Plan.
Accordingly, at December&nbsp;31, 2014, there were no shares available for future grant under the 2007 Plan. At December&nbsp;31, 2013, there were 139,076 shares available for future grant under the 2007 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Prior to the IPO, in determining the exercise prices for options granted, the Company&#146;s board of directors considered the fair value of
the common stock as of the measurement date. The fair value of the common stock was determined by the board of directors at each award grant date based upon a variety of factors, including the results obtained from a common stock valuation, the
Company&#146;s financial position and historical financial performance, the status of technological developments within the Company&#146;s products, the composition and ability of the current research and management team, an evaluation or benchmark
of the Company&#146;s competition, the current business climate in the marketplace, the illiquid nature of the common stock, arm&#146;s-length sales of the Company&#146;s capital stock (including redeemable convertible preferred stock), the effect
of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2014 Stock
Incentive Plan</B> &#150; In March 2014, the Company&#146;s board of directors adopted and its stockholders approved the 2014 Stock Incentive Plan, or the 2014 Plan, which became effective upon the closing of the IPO. The 2014 Plan provides for the
grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. As of December&nbsp;31, 2014, there were 1,434,928 shares available for future grant
under the 2014 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A summary of stock option activity for employee and nonemployee awards under the 2007 Plan and the 2014 Plan during
the year ended December&nbsp;31, 2014 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Life (Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding &#151; January&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,138,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding &#151; December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,126,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options expected to vest &#151; December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">859,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable &#151; December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The total intrinsic value of stock options exercised in the years ended December&nbsp;31, 2014,
2013 and 2012 was $161,000, $15,000, and $0, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The weighted-average per share grant date fair value of options granted during
2014, 2013 and 2012 was $3.33, $2.90, and $2.61, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has recorded stock-based compensation expense of $885,000,
$622,000 and $529,000 during the years ended December&nbsp;31, 2014, 2013 and 2012, respectively, which is based on the number of awards ultimately expected to vest. As of December&nbsp;31, 2014, there was $2.2 million of unrecognized compensation
cost related to unvested stock-based compensation arrangements granted under the 2007 Plan and the 2014 Plan. The compensation is expected to be recognized over a weighted-average period of 3.02&nbsp;years at December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing
model based on the assumptions noted in the table below. Expected volatility for the Company&#146;s common stock was determined based on an average of the historical volatility of a peer-group of similar public companies. The Company has limited
option exercise information, as such, the expected term of the options granted was calculated using the simplified method that represents the average of the contractual term of the option and the weighted-average vesting period of the option. The
assumed dividend yield is based upon the Company&#146;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the contractual life of the option is based upon the U.S. Treasury yield curve in effect at
the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees during the years
ended December&nbsp;31, 2014, 2013 and 2012 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.71%-2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.09%-1.92</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.83%-1.12</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54%-60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59%-79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77%-79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded stock-based compensation expense related to nonemployee awards of $56,000, $85,000 and
$39,000 for the years ended December&nbsp;31, 2014, 2013 and 2012, respectively. The compensation expense related to the nonemployee awards is included in the total stock-based compensation each year and is subject to re-measurement until the
options vest. The Black-Scholes assumptions used to estimate the fair value of these awards for the years ended December&nbsp;31, 2014, 2013 and 2012 were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.86%-2.53</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.11%-2.86</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.99%-2.05</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56%-62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56%-79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76%-79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company did not grant any nonemployee stock option grants in 2014 or in 2013, except for a
performance award grant in 2013 to the Company&#146;s board chairman for non-board related services. During the year ended December&nbsp;31, 2014, the board of directors changed the vesting conditions of this award from performance-based vesting to
time-based vesting and reduced the total number of shares subject to the stock option. As a result, the 16,000 shares subject to this stock option now vest over three years, with the first third vesting on March&nbsp;26, 2014. The change in vesting
condition was accounted for as a modification of this stock option, which had an immaterial impact on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2013 and 2012 the Company granted to the Company&#146;s Chief Executive Officer (&#147;CEO&#148;) options to purchase up to 53,489 and
56,053 shares of common stock, respectively. The vesting of these awards was contingent upon either (i)&nbsp;a change of control at a minimum price per share or (ii)&nbsp;the registration of the Company&#146;s common stock under the Securities
Exchange Act of 1934 and the stock being quoted, listed or traded on an over-the-counter market or national securities exchange at a certain price per share. The CEO resigned in October 2014 and although the Company completed its IPO in April 2014,
the minimum price per share required was never achieved therefore these awards will not vest. Also in 2012, the Company granted options to purchase 60,934 common shares to a second Company officer that will vest upon the achievement of business
milestones as defined within the stock option agreement. These awards have not vested as of December&nbsp;31, 2014. Compensation expense for the awards will be recorded if and when the awards are determined to be probable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2014 Employee Stock Purchase Plan </B>&#150; In March 2014, the Company&#146;s board of directors adopted and its stockholders approved the
2014 Employee Stock Purchase Plan (the &#147;2014 ESPP&#148;), which became effective upon the closing of the IPO. The 2014 ESPP will be administered by the Company&#146;s board of directors or by a committee appointed by the Company&#146;s board of
directors. The 2014 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate 500,000 of shares of the Company&#146;s common stock. The number of shares of the Company&#146;s common stock reserved for
issuance under the 2014 ESPP will automatically increase on the first day of each fiscal year, commencing on January&nbsp;1, 2015 and ending January&nbsp;1, 2024, in an amount equal to the least of (i)&nbsp;600,000 shares of the Company&#146;s
common stock, (ii)&nbsp;1% of the total number of shares of the Company&#146;s common stock outstanding on the first day of the applicable year, or (iii)&nbsp;an amount determined by the Company&#146;s board of directors. The Company did not offer
shares to its employees under the 2014 ESPP during the year ended December&nbsp;31, 2014. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FAIR VALUE MEASUREMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial instruments consist of cash
equivalents, accounts payable, accrued expenses, debt obligations, and preferred stock warrants. The carrying amount of accounts payable and accrued expenses are considered a reasonable estimate of their fair value, due to the short-term maturity of
these instruments. The carrying amount of debt is also considered to be a reasonable estimate of the fair value based on the short-term nature of the debt and that the debt bears interest at the prevailing market rate for instruments with similar
characteristics. If recorded at fair value, Level 2 measurements, as defined below, would have been used to estimate the fair value. Included in cash and cash equivalents as of December&nbsp;31, 2014 and 2013, are money market fund investments of
$50,541,000 and $5,233,000, respectively, which are reported at fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to
measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accounting standard describes a fair value hierarchy based on three levels of inputs, of
which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;1 &#151;</I> Quoted prices in active markets that are accessible at the market date for identical unrestricted assets or
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;2 </I>&#151; Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted
prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;3 </I>&#151; Unobservable inputs that are supported by little or no market activity and that are significant
to the fair value of the assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A summary of the financial assets and liabilities that are measured on a recurring basis
at fair value as of December&nbsp;31, 2014 and 2013, is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements Using</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in</B><br><B>Active Markets</B><br><B>for Identical</B><br><B>Assets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Observable</B><br><B>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s money market funds have been valued on the basis of valuations provided by third-party
pricing services, as derived from such services&#146; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and asked prices, broker/dealer quotations, prices or yields of securities with similar
characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to
determine the valuation for a security. The Company is ultimately responsible for the consolidated financial statements and underlying estimates. Accordingly, the Company assesses the reasonableness of the valuations provided by the third-party
pricing services by reviewing actual trade data, broker/dealer quotes and other similar data, which are obtained from quoted market prices or other sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2014 and 2013, there have been no transfers between levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The reconciliation of the Company&#146;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level&nbsp;3) is
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in fair value recorded in other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value reclassified to additional paid-in capital in connection</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">with the IPO on April&nbsp;15, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s warrants were valued using the Black-Scholes option-pricing model. The fair
values were derived by applying the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4-8&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">64%-84</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preferred stock warrants were automatically adjusted on the date of the closing of the IPO to provide for
the issuance of shares of common stock upon their exercise, and is no longer measured at fair value. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INCOME TAXES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#146;s deferred taxes at
December&nbsp;31, 2014 and 2013 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has provided a valuation allowance for the full amount of deferred tax assets as the realization
of the deferred tax assets is not determined to be more-likely-than-not. The valuation allowance increased in 2014 and 2013 by approximately $7.6 million and $7.1 million, respectively, due to the increase in the deferred tax assets by the same
amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the
financial statements is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal income tax expense at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration of state net operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.2</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32.2</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35.5</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, the Company has approximately $77.3 million of federal and $58.1 million of state
net operating loss carryforwards that expire at various dates through 2034. At December&nbsp;31, 2014, the Company has approximately $1.2 million of federal and $0.8 million of state research and development credit carryforwards that expire at
various dates through 2034 for federal credits and 2029 for state credits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Realization of the future tax benefits is dependent on many factors, including the Company&#146;s
ability to generate taxable income within the net operating loss carryforward period. The future realization of the net operating loss carryforwards may also be limited by the change of ownership rules of the Internal Revenue Service under
Section&nbsp;382 of the Internal Revenue Code. If substantial changes in ownership should occur, there could be annual limitations on the amount of carryforwards that can be realized in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the United States, the Commonwealth of Massachusetts, and Australia. The tax years 2006 through 2014
remain open to examination by these taxing jurisdictions, as carryforwards attributes generated in past years may be adjusted in a future period. The Company is currently not under examination by the Internal Revenue Service or any other
jurisdictions for any tax years. At December 31, 2014 and 2013, the Company has not identified any significant uncertain tax positions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>COMMITMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Facility Lease</B> &#151; On November&nbsp;1, 2009, the Company entered
into a noncancelable operating lease with a third party for office and laboratory space that was scheduled to expire in February 2013, subject to a three-year renewal option. In June 2012, the Company exercised its renewal option extending the lease
through February 2016. On July&nbsp;11, 2014, the Company signed a lease amendment for additional office space in the same building which expires concurrent with the lease agreement in February 2016. The lease agreement and amendment include base
rent escalation over the lease term, therefore, the Company is amortizing the cost of the lease on a straight-line basis over the lease term and the resulting deferred liability recorded in other current and long-term liabilities as of
December&nbsp;31, 2014 and 2013 was $41,000 and $12,000, respectively. Rent expense under this lease was $766,000, $598,000 and $517,000 for the years ended December&nbsp;31, 2014, 2013 and 2012, respectively. The lease requires the Company to share
in prorated expenses and property taxes based upon actual amounts incurred; those amounts are not fixed for future periods and, therefore, not included in the future minimum obligations listed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments, including the three-year extension, under the non-cancelable operating lease are as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:95.55pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LICENSING AGREEMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Massachusetts Institute of Technology License</B>
&#151;&nbsp;The Company&#146;s license agreement with the Massachusetts Institute of Technology (&#147;MIT&#148;), as amended, requires the Company to pay MIT nonrefundable annual license maintenance fees that increase each year beginning in 2015
through 2020 and remain constant thereafter. The annual license fee is not material in any individual year. In addition, the Company may be required to pay milestone payments and/or product royalties in the event future partner collaborations or
product sales incorporate technology covered by this license agreement. In connection with this agreement, the Company recorded research and development expense for annual maintenance fees of $10,000 each in the years ended December&nbsp;31, 2014,
2013 and 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Calando License</B> &#151;&nbsp;The Company has a product license agreement and a platform license agreement with
Calando Pharmaceuticals, Inc. (&#147;Calando&#148;). Under the product license agreement, the Company may be required to pay Calando up to $32.8&nbsp;million upon the achievement of specified regulatory and commercial milestones and pay tiered
royalty payment ranging from low-to mid-single digits on commercial sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the platform license agreement, the Company was required to pay Calando a $250,000 clinical
development milestone upon initiation of a Phase&nbsp;1 clinical trial for CRLX301. In addition, the Company may be required to pay Calando up to $17.8 million upon the achievement of specified regulatory and commercial milestones and pay royalty
payments ranging from low-to mid-single digits on commercial sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with this agreement, the Company recorded research and
development expense of $250,000 for the year ended December&nbsp;31, 2014 upon initiation of the Phase 1 clinical trial for CRLX301 in December 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In March 2014, Calando entered Chapter 7 bankruptcy in the District of Delaware and, as a result, the intellectual property rights the Company
has obtained from Calando are subject to potential risks that may arise in connection with bankruptcy. For instance, while the Company&#146;s ability to develop and/or commercialize its current product candidates and its ability to utilize its
platform are not dependent on the rights that it licenses from Calando, its license agreements with Calando could be rejected in connection with Calando&#146;s bankruptcy, in which case, the Company could, subject to elections and other rights and
defenses that may be available to it, lose certain rights granted to it under such licenses. On March&nbsp;3, 2015 Calando&#146;s bankruptcy trustee submitted an application with the bankruptcy court seeking authority to retain a broker to sell
Calando&#146;s rights in certain assets including its rights in the license agreements with the Company; the Company has reserved its rights with respect to any such sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SUNY License</B> &#151;&nbsp;The Company is party to a license agreement with The Research Foundation of State University of New York
(&#147;SUNY&#148;) for certain intellectual property. The agreement as amended requires the Company to pay nonrefundable annual license maintenance fees each year until the date of first commercial sale of a licensed product pursuant to the license
agreement, as amended. The annual license fee is not material in any individual year. In the event of future partner collaborations or product sales incorporating technology covered by this license agreement, the Company may be required to pay
milestone payments and/or product royalties. In connection with this agreement, the Company recorded research and development expense of $30,000, $25,000, and $10,000 for the years ended December&nbsp;31, 2014, 2013 and 2012, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RETIREMENT PLANS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has a 401(k)&nbsp;retirement and profit-sharing plan (the
&#147;401(k)&nbsp;Plan&#148;) covering all qualified employees. The 401(k)&nbsp;Plan allows each participant to contribute a portion of their base wages up to an amount not to exceed an annual statutory maximum. Effective January&nbsp;1, 2010, the
Company adopted a Safe Harbor Plan that provides a Company match up to 4% of salary. The Company contributed a match of $163,000, $145,000 and $165,000 to the&nbsp;401(k)&nbsp;Plan for the years ended December&nbsp;31, 2014, 2013 and 2012,
respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RELATED PARTY TRANSACTIONS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In April 2013, the Company entered into a laboratory,
equipment sharing, services and license agreement with an entity affiliated with one of the Company&#146;s directors. Fees recorded offsetting research and development expenses under this agreement and paid in the year ended December&nbsp;31, 2014
and 2013, were $39,000 and $84,000, respectively. On April&nbsp;1, 2014, the Company sold used equipment to this entity and recorded proceeds from the sale of $30,000. The agreement was terminated on April&nbsp;1, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2013 and February 2014, the Company issued convertible promissory notes to existing investors, as described in Notes 6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In April 2014, these notes were converted into the Company&#146;s common stock in connection with the IPO. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the Company converted all outstanding shares of the Company&#146;s preferred stock
held by existing investors into 6,826,004 shares of the Company&#146;s common stock in connection with the IPO. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REVENUE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company entered into a material transfer agreement in February 2012 with a
biopharmaceutical company and amended the agreement in March 2012. The terms of the agreement provided revenue in exchange for conducting research using the Company&#146;s proprietary technology and the pharmaceutical company&#146;s proprietary
compounds. The Company received $625,000 under this agreement and recognized this amount as revenue during 2012, the period when the research work was performed and all deliverables were completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In October 2013, the Company entered into a material transfer agreement with another biopharmaceutical company to conduct feasibility studies
using the Company&#146;s proprietary technology. The Company recognized revenue of $61,000 and $6,000 for the years ended December&nbsp;31, 2014 and 2013, respectively, in connection with this material transfer agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2013, the Company entered into a material transfer agreement with another biopharmaceutical company to conduct feasibility studies
using the Company&#146;s proprietary technology. The Company recognized revenue of $19,000 for the year ended December&nbsp;31, 2014, in connection with this material transfer agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SUBSEQUENT EVENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2015 (the &#147;Closing Date&#148;), the Company
entered into a term loan facility of up to $26.0 million (the &#147;Term Loan&#148;) with Hercules Technology Growth Capital, Inc., or Hercules, the proceeds of which were used to repay the Company&#146;s existing term loan facility with Lighthouse
Capital and for general corporate and working capital purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Term Loan is governed by a loan and security agreement, dated
January&nbsp;8, 2015, between the Company and Hercules (the &#147;Hercules Loan Agreement&#148;). The Hercules Loan Agreement provides for up to three separate borrowings, the first of which was funded in the amount of $15.0 million on the Closing
Date. The second borrowing of up to $5.0 million may be drawn by the Company, subject to the satisfaction of customary funding conditions, on or prior to December&nbsp;15, 2015, provided that the Company meets certain clinical milestones. The third
borrowing of up to $6.0 million (the &#147;Term C Loan Advance&#148;) may be drawn, at no less than $3.0 million per draw and subject to the satisfaction of customary funding conditions, on or after September&nbsp;30, 2015 but before
December&nbsp;15, 2015, provided that between the Closing Date and December&nbsp;15, 2015, the Company has received net cash proceeds of at least $40.0 million from the issuance and sale by the Company of its equity securities and/or upfront cash
payments from one or more strategic corporate partnerships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Term Loan will mature on July&nbsp;1, 2018. Each advance under the Term
Loan accrues interest at a floating per annum rate equal to the greater of (i)&nbsp;7.30% or (ii)&nbsp;the sum of 7.30% plus the prime rate minus 5.75%. The Term Loan provides for interest-only payments on a monthly basis until December&nbsp;31,
2015. The interest only period may be extended at the Company&#146;s option for a three month period if the Company attains certain clinical milestones, and for an additional three month period if the Company attains certain clinical milestones and
receives net cash proceeds of at least $30.0 million from the issuance and sale by the Company of its equity securities and/or upfront cash payments from one or more strategic corporate partnerships. Thereafter, amortization payments will be payable
monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. The Company may prepay the Term Loan in whole or in
part upon seven business days&#146; prior written notice to Hercules. Any such prepayment of the Term Loan is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subject to a prepayment charge of (i)&nbsp;3.0% if such prepayment occurs within twelve months of the Closing Date, (ii)&nbsp;2.0% if such prepayment occurs after twelve months following the
Closing Date but on or prior to twenty-four months following the Closing Date, and (iii)&nbsp;1.0% thereafter. Amounts outstanding during an event of default are payable upon Hercules&#146; demand and shall accrue interest at an additional rate of
5.0%&nbsp;per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), the Company shall make a final payment to the lender in the amount of 6.70% of the aggregate original
principal amount advanced by the lender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the Hercules Loan Agreement, the Company issued to Hercules a warrant to
purchase shares of the common stock of the Company at an exercise price of $6.05 per share. The warrant is initially exercisable for 137,521 shares of common stock. On such date (if any) as a Term C Loan Advance is made to the Company, the warrant
shall automatically become exercisable for an additional 34,380 shares of common stock. The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of Common Stock, subdivision or
combination of the shares of common stock or certain dividend payments. The warrant is exercisable until January&nbsp;8, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In
connection with the Hercules Loan Agreement, the Company entered into a stock purchase agreement with Hercules, whereby Hercules purchased 135,501 shares of common stock from the Company at a price per share of $7.38, which was equal to the closing
price of the common stock on The NASDAQ Global Market on January&nbsp;7, 2015, for an aggregate purchase price of approximately $1.0 million. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY FINANCIAL DATA (unaudited) </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the unaudited
quarterly financial data for the last two fiscal years: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands, except share data and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>First<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Second<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Third</B><br><B>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fourth<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in value of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense) &#151; net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,883,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,124,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,125,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>First<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Second<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Third</B><br><B>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fourth<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in value of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense) &#151; net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">612,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">726,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$50,000,000 </B></P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g24k11.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" ALIGN="center"><B>Leerink Partners</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><B>Barclays</B></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>Canaccord Genuity</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><B>JMP Securities</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>Wedbush&nbsp;PacGrow</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Expenses of Issuance and Distribution. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses
to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission
registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">605,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Indemnification of Directors and Officers. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation
Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director
breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an
improper personal benefit. Our certificate of incorporation provides that no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any
provision of law imposing such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director,
officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or
completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that we will indemnify each person who was or is a
party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer,
or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being
referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect
to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in
the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner,
employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a
manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless
a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the
merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us,
among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as
one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of
claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in connection
with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), against certain liabilities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Recent Sales of Unregistered Securities. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding
securities issued by us within the past three years that were not registered under the Securities Act of 1933, as amended, or the Securities Act. Also included is the consideration, if any, received by us for such shares and options and information
relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Issuance of securities </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2015, we issued and sold 135,501 shares of our
common stock to Hercules Technology Growth Capital, Inc., or Hercules, at a purchase price of $7.38 per share, for an aggregate purchase price of $1.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2015, we issued a warrant to purchase shares of our common stock at an
exercise price of $6.05 per share to Hercules. This warrant is initially exercisable for 137,521 shares of our common stock, and is exercisable for up to an additional 34,380 shares of our common stock in the event that we draw down certain amounts
under our term loan with Hercules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February and March 2014, we issued convertible promissory notes in an aggregate amount of
$8.5&nbsp;million to 16 investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2013, we issued convertible promissory notes in an aggregate principal amount of $8.8
million to 14 investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2012, we issued and sold 15,662,650 shares of our Series D preferred stock to 16 investors, at a
price per share of $0.83, for an aggregate purchase price of $13.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing issuances of
securities. The securities described in this section (a)&nbsp;of Item&nbsp;15 were issued to accredited investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the
Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were
accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">for
sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such
securities issued in such transactions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Stock option grants </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2012, (i)&nbsp;we have issued to certain
employees, directors and consultants options to purchase an aggregate of 1,357,230 shares of unregistered common stock at prices ranging from $3.77 to $10.59, (ii)&nbsp;through the filing of our registration statement on Form S-8 on August&nbsp;13,
2014, options to purchase 51,100&nbsp;shares of common stock were exercised and (iii)&nbsp;options to purchase 132,942 shares of common stock were forfeited or cancelled. As of March&nbsp;27, 2015, options to purchase 2,641,864 shares of common
stock remained outstanding at a weighted-average exercise price of $6.32 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuances of stock options and the shares of
our common stock issuable upon the exercise of the options described in this paragraph (b)&nbsp;of Item&nbsp;15 were issued pursuant to written compensatory plans or arrangements with our employees, directors and consultants, in reliance on the
exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such
registration was required. All recipients either received adequate information about us or had access, through employment or other relationships, to such information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Issuance of warrant </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the foregoing securities are deemed restricted securities for
purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15 included appropriate legends setting forth that the securities have not been registered and the applicable restrictions
on transfer. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits and Financial Statement Schedules. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits to the registration statement are listed in the Exhibit Index attached hereto and
incorporated by reference herein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Undertakings. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or
paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The undersigned hereby undertakes that: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this Amendment No.&nbsp;1 to Registration Statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of March, 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CERULEAN PHARMA INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher D.T. Guiffre</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Christopher D.T. Guiffre</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Amendment No. 1 to
Registration Statement has been signed by the following persons in the capacities held on the dates indicated. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher D.T. Guiffre</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christopher D. T. Guiffre</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">President and Chief Executive Officer and Director (principal executive officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen L. Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Karen L. Roberts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Senior Vice President, Finance and Administration (principal financial and principal accounting officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Paul A.
Friedman, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Executive Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Alan L.
Crane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Steven E.
Hall, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Susan L.
Kelley, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">William T.
McKee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David R.
Parkinson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">William H.
Rastetter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ram
Sasisekharan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert I.
Tepper, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;30,&nbsp;2015</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher D.T. Guiffre</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Christopher D.T Guiffre</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Attorney-in-Fact</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated By Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:43.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:46.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date of Filing</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:31.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed<BR>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Restated Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>April&nbsp;16,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated By-Laws</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>April&nbsp;16,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Stock Certificate evidencing the shares of common stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;31,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2007 Stock Incentive Plan, as amended</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2007 Stock Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Nonstatutory Stock Option Agreement under 2007 Stock Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014 Stock Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 31, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Incentive Stock Option Agreement under 2014 Stock Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 31, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Nonstatutory Stock Option Agreement under 2014 Stock Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 31, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014 Employee Stock Purchase Plan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 31, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.26</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated as of May 22, 2000, as amended, between California Institute of Technology and Insert Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive Patent License Agreement, dated as of December 21, 2006, as amended, between the Registrant and Massachusetts Institute of Technology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Patent License Agreement, dated as of August 31, 2007, as amended, between the Registrant and The Research Foundation of State University of New York, on behalf of University of Buffalo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IT-101 Agreement, dated as of June 23, 2009, as amended, between the Registrant and Calando Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated By Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:43.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:46.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date of Filing</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:31.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed<BR>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Platform Agreement, dated as of June 23, 2009, as amended, between the Registrant and Calando Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated as of August 6, 2013, between the Registrant and California Institute of Technology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Series D Convertible Preferred Stock Purchase Agreement, dated November 30, 2012, as amended</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;10,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Commercial Lease Agreement, dated September 8, 2009, between the Registrant and Rivertech Associates II, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Lease Amendment to the Commercial Lease Agreement between the Registrant and Rivertech Associate&nbsp;II, LLC, dated July 11, 2014.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>July&nbsp;17,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Loan and Security Agreement, dated January&nbsp;8, 2015, between the Registrant and Hercules Technology Growth Capital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>January&nbsp;8, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock Purchase Agreement, dated January 8, 2015, between the Registrant and Hercules Technology Growth Capital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>January 8, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Right to Invest Letter, dated January 8, 2015, between the Registrant and Hercules Technology Growth Capital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>January 8, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Separation, Transition and Release of Claims Agreement, dated October 29, 2014, by and between the Company and Oliver S. Fetzer, Ph.D</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>October&nbsp;30,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to purchase shares of Series B Convertible Preferred Stock issued by the Registrant to Silicon Valley Bank</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Stock Purchase Warrant of the Registrant to purchase shares of Series C Convertible Preferred Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.19</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preferred Stock Purchase Warrant to purchase shares of Series D Convertible Preferred Stock issued by the Registrant to Lighthouse Capital Partners VI, L.P., as amended</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>333-194442</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated By Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:43.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:46.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date of Filing</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:29.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed<BR>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant, dated January 8, 2015, issued to Hercules Technology Growth Capital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>January 8, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement dated March 27, 2015 by and between the Registrant and Christopher D.&nbsp;T. Guiffre</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement dated July 21, 2014 by and between the Registrant and Edward Garmey</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10-Q</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>November&nbsp;13,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement dated July 21, 2014 by and between the Registrant and Karen Roberts</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;19,&nbsp;2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10.28</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock Option Agreement and Contingent Consideration Award Agreement, dated March 31, 2013, between the Registrant and Alan Crane</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-194442</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 10, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10.24</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to the Stock Option Agreement and Termination of Contingent Consideration Award dated September&nbsp;16, 2014, by and between the Registrant and Alan Crane</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10-Q</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>November&nbsp;13,&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amendment, dated as of February&nbsp;17, 2015, to Exclusive Patent Agreement, dated as of December&nbsp;21, 2006, as amended, between the Registrant and Massachusetts Institute of Technology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;19, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10.31</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10-K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>001-36395</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;19, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">21.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Deloitte &amp; Touche LLP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature&nbsp;page)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-202917</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-202917</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-202917</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Calculation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-202917</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-202917</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Label Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-202917</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Presentation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">333-202917</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March 20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d887761dex11.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERULEAN PHARMA INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware
corporation) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>UNDERWRITING AGREEMENT </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: [<FONT
STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>], 2015 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERULEAN PHARMA INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of the several
Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Federal Street,
Floor 37 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays Capital Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">745 Seventh Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cerulean Pharma Inc., a
Delaware corporation (the &#147;<U>Company</U>&#148;), confirms its agreement with Leerink Partners LLC (&#147;<U>Leerink</U>&#148;), Barclays Capital Inc. (&#147;<U>Barclays</U>&#148;) and each of the other Underwriters named in
<U>Schedule&nbsp;A</U> hereto (collectively, the &#147;<U>Underwriters</U>,&#148; which term shall also include any underwriter substituted as hereinafter provided in Section&nbsp;10 hereof), for whom Leerink and Barclays are acting as
representatives (in such capacity, collectively, the &#147;<U>Representatives</U>&#148;), with respect to (i)&nbsp;the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of
common stock, par value $0.0001 per share, of the Company (&#147;<U>Common Stock</U>&#148;) set forth in <U>Schedule&nbsp;A</U> hereto and (ii)&nbsp;the grant by the Company to the Underwriters, acting severally and not jointly, of the option
described in Section&nbsp;2(b) hereof to purchase all or any part of [&#149;] additional shares of Common Stock. The aforesaid [&#149;] shares of Common Stock (the &#147;<U>Initial Securities</U>&#148;) to be purchased by the Underwriters and all or
any part of the [&#149;] shares of Common Stock subject to the option described in Section&nbsp;2(b) hereof (the &#147;<U>Option Securities</U>&#148;) are herein called, collectively, the &#147;<U>Securities</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the Representative deems
advisable after this Agreement has been executed and delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the
&#147;<U>Commission</U>&#148;) a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (No. 333-202917), including the related preliminary prospectus or prospectuses, covering the registration of the sale of the Securities
under the Securities Act of 1933, as amended (the &#147;<U>1933 Act</U>&#148;). Promptly after execution and delivery of this Agreement, the Company will prepare and file a prospectus in accordance with the provisions of Rule 430A (&#147;<U>Rule
430A</U>&#148;) of the rules and regulations of the Commission under the 1933 Act (the &#147;<U>1933 Act Regulations</U>&#148;) and Rule 424(b) (&#147;<U>Rule 424(b)</U>&#148;) of the 1933 Act Regulations. The information included in such prospectus
that was omitted from such registration statement at the time it became effective but that is deemed to be part of such registration statement at the time it became effective pursuant to Rule 430A(b) is herein called the
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<U>Rule 430A Information</U>.&#148; Such registration statement, including the amendments thereto, the exhibits thereto and any schedules thereto at the time it became effective, and
including the Rule 430A Information, is herein called the &#147;<U>Registration Statement</U>.&#148; Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein called the &#147;<U>Rule 462(b) Registration
Statement</U>&#148; and, after such filing, the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. Each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that
omitted the Rule 430A Information that was used after such effectiveness and prior to the execution and delivery of this Agreement is herein called a &#147;<U>preliminary prospectus</U>.&#148; The final prospectus, in the form first furnished to the
Underwriters for use in connection with the offering of the Securities is herein called the &#147;<U>Prospectus</U>.&#148; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or
any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system or any successor system (&#147;<U>EDGAR</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means [&#149;]:[&#149;] [A.][P.]M., New York City time, on [&#149;], 2015 or such other time as
agreed by the Company and the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;General Disclosure Package&#148; means any Issuer General Use Free
Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus that is distributed to investors prior to the Applicable Time and the information included on <U>Schedule&nbsp;B-1</U> hereto, all considered
together. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Free Writing Prospectus&#148; means any &#147;issuer free writing prospectus,&#148; as defined in
Rule 433 of the 1933 Act Regulations (&#147;<U>Rule 433</U>&#148;), including without limitation any &#147;free writing prospectus&#148; (as defined in Rule 405 of the 1933 Act Regulations (&#147;<U>Rule 405</U>&#148;)) relating to the Securities
that is (i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or
(iii)&nbsp;exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with
the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer General Use Free Writing Prospectus&#148; means any Issuer Free Writing Prospectus that is intended for general
distribution to prospective investors (other than a &#147;<I>bona fide</I> electronic road show,&#148; as defined in Rule 433 (the &#147;<U>Bona Fide Electronic Road Show</U>&#148;)), as evidenced by its being specified in <U><FONT
STYLE="white-space:nowrap">Schedule&nbsp;B-2</FONT></U> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Limited Use Free Writing Prospectus&#148;
means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Testing-the-Waters Communication&#148; means any oral or written communication with potential investors undertaken in
reliance on Section&nbsp;5(d) of the 1933 Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Written Testing-the-Waters Communication&#148; means any
Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the 1933 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Representations and Warranties</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof, the
Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Registration Statement and Prospectuses</U>. Each of the Registration Statement and any amendment thereto has become
effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary
prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#146;s knowledge, contemplated. The Company has complied with each request (if any) from the Commission
for additional information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Registration Statement and any post-effective amendment thereto, at the time it
became effective, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the
Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with this offering and the Prospectus was or will be
identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Accurate Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time, at the
Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading. As of the Applicable Time, none of (A)&nbsp;the General Disclosure Package, (B)&nbsp;any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package, nor (C)&nbsp;any individual
Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time
of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto,
including any prospectus wrapper) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only
information so furnished shall be the information in the first paragraph under the heading &#147;Underwriting&#151;Commissions and Discounts,&#148; the information in the second, third and fourth paragraphs under the heading
&#147;Underwriting&#151;Price Stabilization, Short Positions and Penalty Bids&#148; and the information under the heading &#147;Underwriting&#151;Electronic Distribution&#148; in each case contained in the Prospectus (collectively, the
&#147;<U>Underwriter Information</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Issuer Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus
conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. The Company has made available a
Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) such that no filing of any &#147;road show&#148; (as defined in Rule 433(h)) is required in connection with the offering of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Testing-the-Waters Materials</U>. The Company (A)&nbsp;has not engaged in any Testing-the-Waters Communication other
than Testing-the-Waters Communications with the consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the 1933 Act or institutions that are accredited investors within the meaning
of Rule 501 under the 1933 Act and (B)&nbsp;has not authorized anyone other than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms that the Representative has been authorized to act on its behalf in
undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications other than those listed on <U>Schedule B-3</U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Company Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment
thereto, at the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not
and is not an &#147;ineligible issuer,&#148; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Emerging Growth Company Status.</U> From the time of the initial filing of the Registration Statement to the Commission
through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the 1933 Act (an &#147;<U>Emerging Growth Company</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>Independent Accountants</U>. The accountants who certified the financial statements and supporting schedules included
in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933 Act Regulations and the Public Company Accounting Oversight Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Financial Statements; Non-GAAP Financial Measures</U>. The financial statements included in the Registration
Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of the Company and its consolidated subsidiary at the dates indicated and
the statement of operations, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiary for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting
principles (&#147;<U>GAAP</U>&#148;) applied on a consistent basis throughout the periods involved, except in the case of unaudited, interim financial statements, subject to normal year-end audit adjustments and the exclusion of certain footnotes as
permitted by the applicable rules of the Commission. The supporting schedules, if any, present fairly, in all material respects, in accordance with GAAP the information required to be stated therein. The selected financial data and the summary
financial information included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the
audited financial statements included therein. The pro forma financial statements and the related notes thereto included in the Registration Statement, the General Disclosure Package and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Prospectus present fairly the information shown therein, have been prepared in accordance with the Commission&#146;s rules and guidelines with respect to pro forma financial statements and
have been properly complied on the bases described therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein.
Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the
1933 Act or the 1933 Act Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <U>No Material Adverse Change in Business</U>. Except as otherwise stated
therein, since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition, financial or otherwise, or in
the earnings, business affairs or business prospects of the Company and its subsidiary considered as one enterprise, whether or not arising in the ordinary course of business (a &#147;<U>Material Adverse Effect</U>&#148;), (B)&nbsp;there have been
no transactions entered into by the Company or its subsidiary, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiary considered as one enterprise, and (C)&nbsp;there has been no
dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Good
Standing of the Company</U>. The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to
conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to
transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good
standing would not result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <U>Good Standing of Subsidiary</U>. The subsidiary of the
Company (the &#147;<U>Subsidiary</U>&#148;) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and
operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not result in a Material Adverse Effect. Except as otherwise
disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of the Subsidiary has been duly authorized and validly issued, is fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and is owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital
stock of the Subsidiary were issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only subsidiary of the Company is the subsidiary listed on Exhibit 21 to the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) <U>Capitalization</U>. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in
the Registration Statement, the General Disclosure Package and the Prospectus in the column entitled &#147;Actual&#148; under the caption &#147;Capitalization&#148; (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to
reservations, agreements or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
employee benefit plans referred to in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to the exercise of convertible securities or options referred to in
the Registration Statement, the General Disclosure Package and the Prospectus). The outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any securityholder of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) <U>Authorization of Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) <U>Authorization and Description of Securities</U>. The Securities to be purchased by the Underwriters from the Company
have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and
fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company, except as have been duly and validly waived in
writing as of the date of this Agreement, copies of such waivers having been made available to you. The Common Stock conforms, in all material respects, to all statements relating thereto contained in the Registration Statement, the General
Disclosure Package and the Prospectus and such description conforms, in all material respects, to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability by reason of being such a
holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) <U>Registration Rights</U>. There are no persons with registration rights or other similar rights to have any
securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration
Statement, the General Disclosure Package and the Prospectus and have been waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) <U>Absence of Violations,
Defaults and Conflicts</U>. Neither the Company nor its subsidiary is (A)&nbsp;in violation of its charter, by-laws or similar organizational document, (B)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or
condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or its subsidiary is a party or by which either of them may be bound or to which any
of the properties or assets of the Company or its subsidiary is subject (collectively, &#147;<U>Agreements and Instruments</U>&#148;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or
(C)&nbsp;in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company
or its subsidiary or any of their respective properties, assets or operations (each, a &#147;<U>Governmental Entity</U>&#148;), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The
execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the
Securities and the use of the proceeds from the sale of the Securities as described therein under the caption &#147;<U>Use of Proceeds</U>&#148;) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary
corporate action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or
imposition of any lien, charge or encumbrance upon any properties or assets of the Company or its subsidiary pursuant to, the Agreements and Instruments (except for such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result
in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or its subsidiary or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a
&#147;<U>Repayment Event</U>&#148; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or
repayment of all or a portion of such indebtedness by the Company or its subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) <U>Absence of Labor
Dispute</U>. No labor dispute with the employees of the Company or its subsidiary exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or
its subsidiary&#146;s principal suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) <U>Absence of Proceedings</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and
the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or its subsidiary, which would
reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in this Agreement or
the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or its subsidiary is a party or of which either of their respective properties or assets is the
subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) <U>Accuracy of Exhibits</U>. There are no contracts or documents which are required to be described in the
Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <U>Absence of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration,
qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder or the consummation of the
transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the NASDAQ Stock Market LLC, state securities laws or the rules of the Financial
Industry Regulatory Authority, Inc. (&#147;<U>FINRA</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi) <U>Possession of Licenses and Permits</U>. The
Company and its subsidiary possess such permits, licenses, approvals, consents and other authorizations (collectively, &#147;<U>Governmental Licenses</U>&#148;) issued by the appropriate Governmental Entities necessary to conduct the business now
operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its subsidiary are in compliance with the terms and conditions of all Governmental Licenses, except
where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company
nor its subsidiary has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii) <U>Title to Property</U>. The Company and its subsidiary have good and marketable title to
all real property owned by them and good title to all other properties owned by them (excluding for the purpose of this Section (1)(a)(xxii), Intellectual Property (as defined below)), in each case, free and clear of all mortgages, pledges, liens,
security interests, claims, restrictions or encumbrances of any kind except such as (A)&nbsp;are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B)&nbsp;do not, singly or in the aggregate, materially
affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or its subsidiary; and all of the leases and subleases material to the business of the Company and its
subsidiary, considered as one enterprise, and under which the Company or its subsidiary holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company
nor its subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or its subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights
of the Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiii) <U>Intellectual Property</U>. To the knowledge of the Company, the Company owns or has valid, binding and enforceable
licenses or other rights under the patents, patent applications, licenses, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures),
trademarks, service marks, trade names or other intellectual property reasonably necessary to carry on the business of the Company as described in the Registration Statement, the General Disclosure Package and the Prospectus (collectively, the
&#147;<U>Intellectual Property</U>&#148;); the patents, trademarks, and copyrights, if any, included within the Intellectual Property are valid, enforceable, and subsisting; other than as disclosed in the Registration Statement, the General
Disclosure Package and the Prospectus, (A)&nbsp;the Company is not obligated to pay a material royalty, grant a license to, or provide other material consideration to any third party in connection with the Intellectual Property, (B)&nbsp;the Company
has not received any notice of any claim of infringement, misappropriation or conflict with any asserted rights of others with respect to any of the Company&#146;s drug candidates, processes or Intellectual Property, (C)&nbsp;to the knowledge of the
Company, neither the sale nor use of any of the discoveries, inventions, drug candidates or processes of the Company referred to in the Registration Statement, the General Disclosure Package or the Prospectus do or will, to the knowledge of the
Company, infringe, misappropriate or violate any right or valid patent claim of any third party, and (D)&nbsp;to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property that is owned by the Company,
other than any co-owner of any patent constituting Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office (the &#147;<U>USPTO</U>&#148;) and any co-owner of any patent application constituting Intellectual
Property who is named in such patent application, and, to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property in any field of use that is exclusively licensed to the Company, other than any
licensor to the Company of such Intellectual Property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiv) <U>Patents and Patent Applications</U>. All patents and patent
applications owned by or licensed to the Company or under which the Company has rights have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications
have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude
the grant of a patent in connection with any such application or would reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxv) <U>Environmental Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and the
Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither the Company nor its subsidiary is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy
or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &#147;<U>Hazardous Materials</U>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling of Hazardous Materials (collectively, &#147;<U>Environmental Laws</U>&#148;), (B)&nbsp;the Company and its subsidiary have all permits, authorizations and approvals required under any applicable Environmental Laws and are each
in compliance with their requirements, (C)&nbsp;there are no pending or, to the knowledge of the Company threatened, administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigation or proceedings relating to any Environmental Law against the Company or its subsidiary and (D)&nbsp;there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or
remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or its subsidiary relating to Hazardous Materials or any Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvi) <U>Accounting Controls and Disclosure Controls</U>. The Company and its subsidiary have established effective internal
control over financial reporting (as defined under Rule <FONT STYLE="white-space:nowrap">13-a15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the rules and regulations of the Commission under the 1934 Act (the &#147;<U>1934 Act
Regulations</U>&#148;)) and a system of internal accounting controls sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (B)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific
authorization; and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the Registration Statement, the
General Disclosure Package and the Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (1)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not
remediated) and (2)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially adversely affected, or is reasonably likely to materially adversely affect, the Company&#146;s internal control over financial
reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvii) <U>Tests and Preclinical and Clinical Trials</U>. The studies, tests and
preclinical and clinical trials conducted by the Company (&#147;<U>Company Trials</U>&#148;), and, to the Company&#146;s knowledge, the investigator-sponsored trials (&#147;<U>ISTs</U>&#148;), that are described in the Registration Statement, the
General Disclosure Package and the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols submitted to the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;) or any foreign
governmental body exercising comparable authority, procedures and controls pursuant to, where applicable, accepted professional and scientific standards, and all applicable laws and regulations. The descriptions of the Company Trials and, to the
Company&#146;s knowledge, the ISTs, and the results thereof, contained in the Registration Statement, the General Disclosure Package and the Prospectus are accurate and complete in all material respects. The Company is not aware of any other
studies, tests or preclinical and clinical trials other than the Company Trials and the ISTs, the results of which call into question the results described in the Registration Statement, the General Disclosure Package and the Prospectus. The Company
has not received any notices or correspondence from the FDA, any foreign, state or local governmental body exercising comparable authority or any Institutional Review Board requiring the termination, suspension, material modification or clinical
hold of the Company Trials or the ISTs, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxviii) <U>Payment of Taxes</U>. All United States federal income tax returns of the Company and its subsidiary required by
law to be filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have
been provided. The United States federal income tax returns of the Company through the fiscal year ended December&nbsp;31, 2013 have been settled and no assessment in connection therewith has been made against the Company. The Company and its
subsidiary have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect, and
have paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its subsidiary, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by
the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments for additional income tax
for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxix) <U>Insurance</U>. The Company and its subsidiary carry or are entitled to the benefits of insurance, with financially
sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no
reason to believe that it or its subsidiary will not be able (A)&nbsp;to renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to
conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Company nor its subsidiary has been denied any insurance coverage which it has sought or for which it has applied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxx) <U>Investment Company Act</U>. The Company is not required, and upon the issuance and sale of the Securities as herein
contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required, to register as an &#147;investment company&#148; under the Investment
Company Act of 1940, as amended (the &#147;<U>1940 Act</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxi) <U>Absence of Manipulation</U>. Neither the Company nor, to the
Company&#146;s knowledge, any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the
stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxii) <U>Foreign Corrupt Practices Act</U>. None of the Company, its subsidiary or, to the knowledge of the Company, any
director, officer, agent, employee, affiliate or other person acting on behalf of the Company or its subsidiary is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt
Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;<U>FCPA</U>&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an
offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined in the FCPA) or
any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the
FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiii) <U>Money Laundering Laws</U>. The operations of the Company and its subsidiary are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#147;<U>Money Laundering Laws</U>&#148;); and no action, suit or proceeding by or before any
Governmental Entity involving the Company or its subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiv) <U>OFAC</U>. None of the Company, its subsidiary or, to the knowledge of the Company, any director, officer, agent,
employee, affiliate or representative of the Company or its subsidiary is an individual or entity (&#147;<U>Person</U>&#148;) currently the subject or target of any sanctions administered or enforced by the United States Government, including,
without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively,
&#147;<U>Sanctions</U>&#148;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend,
contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the
subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxv) <U>Lending Relationship</U><I>. </I>Except as disclosed in the Registration Statement, the General Disclosure Package
and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any banking or lending affiliate of any Underwriter and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Securities
to repay any outstanding debt owed to any affiliate of any Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvi) <U>Statistical and Market-Related Data</U>. Any statistical and
market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent
required, the Company has obtained the written consent to the use of such data from such sources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvii) <U>Rating of
Debt Securities</U>. The Company has no debt securities or preferred stock that is rated by any &#147;nationally recognized statistical rating organization&#148; (as that term is defined by the Commission for purposes of Rule 436(g)(2) under the
1933 Act). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Officer&#146;s Certificates</I>. Any certificate signed by any officer of the Company or its subsidiary delivered to the
Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Sale and Delivery to Underwriters; Closing</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Initial Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set forth in <U>Schedule&nbsp;A</U>, that
number of Initial Securities set forth in <U>Schedule&nbsp;A</U> opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become obligated to purchase pursuant to the provisions of
Section&nbsp;10 hereof, subject, in each case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Option Securities</I>. In addition, on the basis of the representations and warranties herein contained and subject to the terms and
conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional [&#149;] shares of Common Stock, at the price per share set forth in <U>Schedule&nbsp;A</U>, less an
amount per share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be exercised for 30&nbsp;days after the date hereof and
may be exercised in whole or in part at any time from time to time upon notice by the Representatives to the Company setting forth the number of Option Securities as to which the several Underwriters are then exercising the option and the time and
date of payment and delivery for such Option Securities. Any such time and date of delivery (a &#147;<U>Date of Delivery</U>&#148;) shall be determined by the Representatives, but any Date of Delivery occurring after the Closing Time shall not be
later than seven full business days nor earlier than two full business days after the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the
Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Securities then being purchased which the number of Initial Securities set forth in <U>Schedule A</U> opposite the name of such Underwriter
bears to the total number of Initial Securities, subject, in each case, to such adjustments as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Payment</I>. Payment of the purchase price for, and delivery of certificates for, the Initial Securities shall be made at the offices of
Ropes&nbsp;&amp; Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199, or at such other place as shall be agreed upon by the Representatives and the Company, at 9:00&nbsp;A.M. (New York City time) on the third (fourth, if the pricing
occurs after 4:30 P.M. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such other time not later than ten business
days after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called &#147;<U>Closing Time</U>&#148;). Delivery of the Initial Securities at the Closing Time shall be
made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the
event that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery of certificates for, such Option Securities shall be made at the
<FONT STYLE="white-space:nowrap">above-mentioned</FONT> offices, or at such other place as shall be agreed upon by the Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company.
Delivery of the Option Securities on each such Date of Delivery shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company against
delivery to the Representatives for the respective accounts of the Underwriters of certificates for the Securities to be purchased by them. It is understood that each Underwriter has authorized the Representatives, for its account, to accept
delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Leerink and Barclays, individually and not as representatives of the Underwriters, may
(but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter whose funds have not been received by the Closing Time or the relevant Date of
Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Covenants
of the Company</U>. The Company covenants with each Underwriter as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Compliance with Securities Regulations and Commission
Requests</I>. The Company, subject to Section&nbsp;3(b), will comply with the requirements of Rule 430A, and will notify the Representatives promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration
Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration
Statement or any amendment or supplement to the Prospectus or for additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of
any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings
for any of such purposes or of any examination pursuant to Section&nbsp;8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of the 1933 Act in
connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it
deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make
every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Continued Compliance with Securities Laws</I>. The Company will comply with the 1933 Act
and the 1933 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a
prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&#147;<U>Rule 172</U>&#148;), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any
event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not
include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;amend or supplement the General Disclosure Package or the Prospectus
in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the
light of the circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the
requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)&nbsp;give the Representatives notice of such event, (B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to
make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or
supplement and (C)&nbsp;file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall reasonably object.
The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or the 1934
Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of
any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Underwriters shall reasonably object. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Delivery of Registration Statements</I>. The Company has furnished or will deliver to the Representatives and counsel for the
Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also deliver to the
Representatives, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto
furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Delivery of Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary
prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus
relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request.
The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Blue Sky Qualifications</I>. The Company will use its best efforts, in cooperation with
the Underwriters, to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may reasonably designate and to maintain such qualifications
in effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in
securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section&nbsp;11(a) of the 1933 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Use of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Securities in all material respects in
the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Listing</I>. The Company will use its best efforts to effect and its reasonable best efforts to maintain the listing of the Common Stock
(including the Securities) on the Nasdaq Global Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Restriction on Sale of Securities</I>. During a period of 90 days from the
date of the Prospectus, the Company will not, without the prior written consent of the Representatives, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration statement under the
1933 Act with respect to any of the foregoing or (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether
any such swap or transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (A)&nbsp;the Securities to be sold
hereunder, (B)&nbsp;any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure
Package and the Prospectus, (C)&nbsp;any shares of Common Stock issued or options to purchase Common Stock granted pursuant to employee benefit or stock incentive plans of the Company referred to in the Registration Statement, the General Disclosure
Package and the Prospectus; (D)&nbsp;any shares of Common Stock issued pursuant to any non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus;
(E)&nbsp;the filing by the Company of any registration statement on Form S-8 or a successor form thereto or (F)&nbsp;shares of Common Stock or other securities issued in connection with a transaction that includes a commercial relationship
(including joint ventures or other strategic acquisitions), provided that (x)&nbsp;the aggregate number of shares issued pursuant to this clause (F)&nbsp;shall not exceed 5.0% of the total number of outstanding shares of Common Stock immediately
following the issuance and sale of the Securities at the Closing Time pursuant hereto and (y)&nbsp;the recipient of any such shares of Common Stock and securities issued pursuant to this clause (F)&nbsp;during the 90-day restricted period described
above shall be subject to the restrictions set forth in a lock-up agreement described in Section&nbsp;5(i) hereof for the remainder of such restricted period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Reporting Requirements</I>. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Issuer Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior
written consent of the Representatives, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#147;free writing prospectus,&#148; or a portion thereof,
required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on <U>Schedule&nbsp;B-2</U> hereto
and any &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or agrees that it will treat each such free writing
prospectus consented to, or deemed consented to, by the Representatives as an &#147;issuer free writing prospectus,&#148; as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect
thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such
Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or
would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend
or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Testing-the-Waters Materials</U>. If at any time following the distribution of any Written Testing-the-Waters Communication there
occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Written
Testing-the-Waters Communication to eliminate or correct such untrue statement or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Emerging Growth Company Status</U>. The
Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of the Securities within the meaning of the 1933 Act and
(ii)&nbsp;completion of the 90-day restricted period referred to in Section&nbsp;3(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Payment of Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement,
including (i)&nbsp;the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters
of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors,
(iii)&nbsp;the preparation, issuance and delivery of the certificates for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to
the Underwriters, (iv)&nbsp;the fees and disbursements of the Company&#146;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws in accordance with the provisions of Section&nbsp;3(e) hereof,
including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with the preparation of a &#147;Blue Sky Survey&#148; and any supplement thereto, (vi)&nbsp;the fees and expenses of any transfer agent or registrar for the Securities, (vii)&nbsp;the
costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show
slides and graphics, fees and expenses of any consultants engaged by the Company in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants (provided that
the travel, lodging and any car travel expenses of the representatives of the Underwriters shall be paid by the Underwriters), (viii)&nbsp;the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in
connection with, the review by FINRA of the terms of the sale of the Securities, (ix)&nbsp;the fees and expenses incurred in connection with the listing of the Securities on the Nasdaq Global Market, and (x)&nbsp;the costs and expenses (including,
without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a breach of the representation
contained in the third sentence of Section&nbsp;1(a)(ii). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Termination of Agreement</I>. If this Agreement is terminated by the
Representatives in accordance with the provisions of Section&nbsp;5, Section&nbsp;9(a)(i) or (iii)&nbsp;or Section&nbsp;10 hereof, the Company shall reimburse the Underwriters for all of their reasonably documented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including the reasonable fees and disbursements of counsel for the Underwriters; provided, however, that if this Agreement is terminated by the Representatives pursuant to
Section&nbsp;10, the Company shall have no obligation to reimburse any out-of-pocket expenses of the Underwriters that have failed to purchase the Securities that they have agreed to purchase hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Conditions of Underwriters&#146; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the
accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or its subsidiary delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and
other obligations hereunder, and to the following further conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Effectiveness of Registration Statement; Rule 430A
Information</I>. The Registration Statement, including any Rule 462(b) Registration Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the
Company&#146;s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information. A prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner
and within the time frame required by Rule 424(b) without reliance on Rule 424(b)(8) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements
of Rule 430A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Opinion of Counsel for Company</I>. At the Closing Time, the Representatives shall have received the opinion and
negative assurance letter, dated the Closing Time, of Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, together with the opinion and negative assurance letter of Lando&nbsp;&amp; Anastasi, LLP, special counsel for the Company with
respect to intellectual property, each in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced copies of such letter for each of the other Underwriters to the effect set forth in
<U>Exhibits&nbsp;A-1</U> and <U>A-2</U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Opinion of Counsel for Underwriters</I>. At the Closing Time, the Representatives shall
have received the opinion and negative assurance letter, dated the Closing Time, of Ropes&nbsp;&amp; Gray LLP, counsel for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters with respect to
such matters as the Representatives may reasonably request. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State
of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives, and the negative assurance letter of K&amp;L Gates LLP, special counsel for the Underwriters with respect to
bankruptcy. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its subsidiary and
certificates of public officials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officers&#146; Certificate</I>. At the Closing Time, there shall not have been, since the date
hereof or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business
affairs or business prospects of the Company and its subsidiary considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a certificate of the President and Chief Executive
Officer of the Company and of the Senior Vice President, Finance and Administration, dated the Closing Time, to the effect that (i)&nbsp;there has been no such Material Adverse Effect, (ii)&nbsp;the representations and warranties of the Company in
this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied
at or prior to the Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has
been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<I>Accountant&#146;s Comfort Letter</I>. At the time of the execution of this Agreement, the Representatives shall have received from Deloitte&nbsp;&amp; Touche LLP a letter, dated such date, in form and substance satisfactory to the
Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with
respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Bring-down Comfort Letter</I>. At the Closing Time, the Representatives shall have received from Deloitte&nbsp;&amp; Touche LLP a
letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e)&nbsp;of this Section, except that the specified date referred to shall be a date not more than three
business days prior to the Closing Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Approval of Listing</I>. At the Closing Time, the Securities shall have been approved for
listing on the Nasdaq Global Market, subject only to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No Objection</I>. FINRA has confirmed that it has
not raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Lock-up Agreements</I>. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of
<U>Exhibit&nbsp;B</U> hereto signed by the persons and entities listed on <U>Schedule&nbsp;C</U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Conditions to Purchase of Option Securities</I>. In the event that the Underwriters
exercise their option provided in Section&nbsp;2(b) hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company
and its subsidiary hereunder shall be true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Officers&#146; Certificate</U>. A certificate, dated such Date of Delivery, of the President and Chief Executive Officer
of the Company and of the Senior Vice President, Finance and Administration of the Company confirming that the certificate delivered at the Closing Time pursuant to Section&nbsp;5(d) hereof remains true and correct as of such Date of Delivery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Opinion of Counsel for Company</U>. If requested by the Representatives, the opinion and negative assurance letter of
Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, together with the opinion and negative assurance letter of Lando&nbsp;&amp; Anastasi, LLP, special counsel for the Company with respect to intellectual property, each in form and
substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section&nbsp;5(b) hereof.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Opinion of Counsel for Underwriters</U>. If requested by the Representatives, the opinion and negative assurance
letter of Ropes&nbsp;&amp; Gray LLP, counsel for the Underwriters, together with the negative assurance letter of K&amp;L Gates LLP, special counsel of the Underwriters with respect to bankruptcy, dated such Date of Delivery, relating to the Option
Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section&nbsp;5(c) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Bring-down Comfort Letter</U>. If requested by the Representatives, a letter from Deloitte&nbsp;&amp; Touche LLP, in
form and substance satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to Section&nbsp;5(e) hereof, except that the &#147;specified
date&#148; in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Additional Documents</I>. At the Closing Time and at each Date of Delivery (if any) counsel for the Underwriters shall have been
furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory
in form and substance to the Representatives and counsel for the Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Termination of Agreement</I>. If any condition
specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the
obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such
termination shall be without liability of any party to any other party except as provided in Section&nbsp;4 and except that Sections 1, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is
defined in Rule 501(b) under the 1933 Act (each, an &#147;<U>Affiliate</U>&#148;)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including the Rule 430A Information, or the omission or alleged omission therefrom of a material fact required to be
stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A)&nbsp;in any preliminary prospectus, any Issuer Free Writing Prospectus, any
Written Testing-the-Waters Communication, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B)&nbsp;in any materials or information provided to investors by, or with the approval of, the Company in
connection with the marketing of the offering of the Securities (&#147;<U>Marketing Materials</U>&#148;), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically), or the omission or
alleged omission in any preliminary prospectus, Issuer Free Writing Prospectus, Prospectus or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the
extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any
such alleged untrue statement or omission; provided that (subject to Section&nbsp;6(d) below) any such settlement is effected with the written consent of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the
Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue
statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including the Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with the Underwriter Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of Company, Directors and
Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of
Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a)&nbsp;of this Section, as incurred, but only with respect to
untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including the Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or
supplement thereto) in reliance upon and in conformity with the Underwriter Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Actions against Parties; Notification</I>. Each indemnified party shall give notice as
promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any
liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties
indemnified pursuant to Section&nbsp;6(a) above, counsel to the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified pursuant to Section&nbsp;6(b) above, counsel to the indemnified parties shall be
selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be
counsel to the indemnified party. In no event shall the indemnifying parties be liable for the reasonable fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in
connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified
parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which
indemnification or contribution could be sought under this Section&nbsp;6 or Section&nbsp;7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i)&nbsp;includes an
unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on
behalf of any indemnified party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Settlement without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall
have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;6(a)(ii) effected without
its written consent if (i)&nbsp;such settlement is entered into more than 60 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at
least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the
Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above
but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other
relevant equitable considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative benefits received by the Company, on the one hand, and the Underwriters, on the
other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before
deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate initial public
offering price of the Securities as set forth on the cover of the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative fault of the Company, on the one hand, and the
Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied
by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section&nbsp;7. The aggregate
amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section&nbsp;7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in
investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission
or alleged omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;7, no Underwriter shall be required to contribute any amount in
excess of the underwriting commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the 1933 Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;7, each person, if any, who
controls an Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and each Underwriter&#146;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each
director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act shall have the
same rights to contribution as the Company. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to the number of Initial Securities set forth opposite their respective names in
<U>Schedule&nbsp;A</U> hereto and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Representations, Warranties and Agreements to Survive</U>. All
representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or its subsidiary submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i)&nbsp;any
investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii)&nbsp;delivery of and payment for the
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Termination of Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Termination</I>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time
(i)&nbsp;if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the
Prospectus, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiary considered as one enterprise,
whether or not arising in the ordinary course of business, or (ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation
thereof or other calamity or crisis or any change or development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the
Representatives, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading in any securities of the Company has been suspended or materially limited
by the Commission or the Nasdaq Global Market, or (iv)&nbsp;if trading generally on the NYSE Amex or the New York Stock Exchange or in the Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading have
been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;a material disruption has occurred in commercial banking or securities
settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi)&nbsp;if a banking moratorium has been declared by either Federal or New York authorities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to
any other party except as provided in Section&nbsp;4 hereof, and provided further that Sections 1, 6, 7, 8, 14, 15 and 16 shall survive such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time or a Date of
Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &#147;<U>Defaulted Securities</U>&#148;), the Representatives shall have the right, within 24&nbsp;hours thereafter, to make arrangements for
one or more of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein
set forth; if, however, the Representatives shall not have completed such arrangements within such <FONT STYLE="white-space:nowrap">24-hour</FONT> period, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the
underwriting obligations of all <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if the number
of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the
Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after
the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i)&nbsp;Representatives or (ii)&nbsp;the Company shall
have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the
Prospectus or in any other documents or arrangements. As used herein, the term &#147;Underwriter&#148; includes any person substituted for an Underwriter under this Section&nbsp;10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Notices</U>. All notices and other communications hereunder shall be in writing
and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, or by email at Syndicate@Leerink.com, or by phone at 800-808-7525; Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019, Attention: Syndicate Registration; notices to the Company shall be directed to it at Cerulean
Pharma Inc., 840 Memorial Drive, Cambridge, MA 02139, attention of Christopher D.T. Guiffre (facsimile: (617)&nbsp;494-1544). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12.
<U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Securities pursuant to this Agreement, including the determination of the initial public offering price of the Securities
and any related discounts and commissions, is an arm&#146;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering of the Securities and the
process leading thereto, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, its subsidiary or their respective stockholders, creditors, employees or any other party, (c)&nbsp;no
Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is
currently advising the Company or its subsidiary on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d)&nbsp;the
Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice
with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Parties</U>. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their
respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling
persons and officers and directors referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement
and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal
representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and
affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO
THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>Consent to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or
proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall&nbsp;be instituted in (i)&nbsp;the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan
or&nbsp;(ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#147;<U>Specified Courts</U>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for
proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN,
SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>Effect of Headings</U>. The Section headings herein are for convenience only and shall not affect the construction hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature page follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CERULEAN PHARMA INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIRMED AND ACCEPTED,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of the date first above written:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LEERINK PARTNERS LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BARCLAYS CAPITAL INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and as Representatives of the other Underwriters named in <U>Schedule&nbsp;A</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Underwriting Agreement </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price per share for the Securities shall be $[&#149;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for the Initial Securities to be paid by the several Underwriters shall be $[&#149;] for the Initial Securities set forth
opposite such Underwriter&#146;s name in the column entitled &#147;Number of Initial Securities to be Sold to the Public&#148;, being an amount equal to the public offering price set forth above less $[&#149;] per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for the Option Securities to be paid by the several Underwriters shall be $[&#149;], subject to adjustment in accordance with
Section&nbsp;2(b) for dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>Name of Underwriter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<br>Initial&nbsp;Securities&nbsp;to&nbsp;be<BR>Sold to the Public</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaccord Genuity Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JMP Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch A-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE B-1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Terms </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Company is selling
[&#149;] shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional
[&#149;] shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The public offering price per share for the Securities shall be $[&#149;]. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE B-2 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Free Writing
Prospectuses </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. [Issuer Free Writing Prospectus dated and filed with the Commission on [&#149;], 2015.] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE B-3 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Written
Testing-the-Waters Communications </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch B - 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>List of Persons and Entities Subject to Lock-up </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch C - 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF OPINION OF COMPANY&#146;S COUNSEL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO BE DELIVERED PURSUANT TO SECTION 5(b) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Form of Lock-Up Agreement </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">March &nbsp;&nbsp;&nbsp;&nbsp;, 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink
Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc., </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of
the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One
Federal Street, Floor 37 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays
Capital Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">745 Seventh Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Proposed Public Offering by Cerulean Pharma Inc.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, a
stockholder, officer and/or director of Cerulean Pharma Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), understands that Leerink Partners LLC (&#147;<U>Leerink</U>&#148;) and Barclays Capital Inc. (&#147;<U>Barclays</U>&#148;) propose
to enter into an Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;), as representatives of the several underwriters named in Schedule A thereto (&#147;<U>Representatives</U>&#148;), with the Company providing for the public
offering (the &#147;<U>Public Offering</U>&#148;) of shares (the &#147;<U>Securities</U>&#148;) of the Company&#146;s common stock, par value $0.0001 per share (the &#147;<U>Common Stock</U>&#148;). In recognition of the benefit that such an
offering will confer upon the undersigned as a stockholder, an officer and/or a director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each
underwriter to be named in the Underwriting Agreement (collectively, the &#147;<U>Underwriters</U>&#148;) that, during the period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the
&#147;<U>Lock-Up Period</U>&#148;), the undersigned will not, without the prior written consent of the Representatives, directly or indirectly, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the Company&#146;s Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock,
whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &#147;<U>Lock-Up Securities</U>&#148;), or exercise any right with respect to
the registration of any of the Lock-up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii)&nbsp;enter into any swap or any other agreement or any
transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash
or otherwise. If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed Securities (if any such program is offered) the undersigned
may purchase in the Public Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer
the Lock-Up Securities without the prior written consent of the Representatives, provided that (1)&nbsp;the Representatives receive a signed lock-up agreement for the balance of the Lock-Up Period from each donee, trustee, distributee, or
transferee, as the case may be, (2)&nbsp;any such transfer shall not involve a disposition for value, (3)&nbsp;in the case of clauses (i)&nbsp;through (v)&nbsp;below, such transfers are not required to be reported with the Securities and Exchange
Commission on Form 4 in accordance with Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), and (4)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report
regarding such transfers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">as a <I>bona fide</I> gift or gifts; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, &#147;immediate family&#148; shall mean any relationship by blood,
marriage or adoption, not more remote than first cousin); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">as a distribution to limited partners, members or stockholders or other equity holders of the undersigned; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">to any corporation, partnership, limited liability company or other entity all of the beneficial ownership interests of which are held by the undersigned or the immediate family members of the undersigned; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">to the undersigned&#146;s affiliates or to any investment fund or other entity controlled or managed by the undersigned; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">pursuant to a qualified domestic relations order or in connection with a divorce settlement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">by will or intestate succession upon the death of the undersigned. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, during the
Lock-Up Period, the undersigned may (a)&nbsp;sell shares of Common Stock of the Company purchased by the undersigned in the Public Offering (provided that such shares of Common Stock shall not include any shares purchased by the undersigned through
any directed share program established in connection with the Public Offering and except as provided in the last sentence of the first paragraph of this agreement) or on the open market following the Public Offering if and only if (i)&nbsp;such
sales are not required during the Lock-Up Period to be reported in any press release or public report or filing with the Securities and Exchange Commission, or otherwise and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any press
release, public filing or report regarding such sales during the Lock-Up Period and (b)&nbsp;exercise an option to purchase shares of Common Stock granted under any of the Company&#146;s equity incentive plans existing as of the date of the
Underwriting Agreement, or a warrant or other security existing as of the date of the Underwriting Agreement for shares of Common Stock, if and only if the shares of Common Stock received upon such exercise shall remain subject to the terms of this
lock-up agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the restrictions on transfer and disposition of the Lock-Up Securities during the Lock-Up Period shall
not apply to the repurchase of Lock-Up Securities by the Company in connection with the termination of the undersigned&#146;s employment or other service with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Representatives release, in full or in part, any officer, director or equity holder of the Company (a
&#147;Stockholder&#148;) from the restrictions of any lock-up agreement signed by such Stockholder with the Underwriters (a &#147;Triggering Release&#148;), then the undersigned shall be released in the same manner from the restrictions of this
agreement (i.e., in an amount equal to the same percentage of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the shares of Common Stock being released in the Triggering Release relative to the undersigned&#146;s ownership of Common Stock at the time of the request of the Triggering Release); provided
that (i)&nbsp;in order to request a Triggering Release, the Stockholder requesting the Triggering Release must make a request in writing to the Company setting forth the number of shares of Common Stock to be released; (ii)&nbsp;the Company must
notify the other Stockholders of the requested Triggering Release within three business days; (iii)&nbsp;any other Stockholder that intends to request a release of a pro rata portion of the shares of Common Stock held by them (the &#147;Pro Rata
Stockholders&#148;) must (x)&nbsp;make such a request in writing to the Company and (y)&nbsp;certify in writing to the Underwriters and the Company the total number of shares of Common Stock held by such Pro Rata Stockholder; (iv)&nbsp;the Company
must (x)&nbsp;make a request in writing to the Representatives setting forth for the Stockholder requesting the Triggering Release and for each Pro Rata Stockholder the number of shares of Common Stock for which each such Stockholder is requesting a
release and (y)&nbsp;provide to the Representatives the total number of shares of Common Stock of the Company outstanding as of the date of the request of such Triggering Release and certify in writing to the Underwriters that such number is true
and accurate. If the Company fails to notify the undersigned within three business days of the request of the Triggering Release, the failure to give such notice shall not give rise to any claim or liability against the Representatives or the
Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, (i)&nbsp;no release by the Representatives of any shares of Common Stock will constitute a
Triggering Release if the aggregate of such releases granted to any individual Stockholder requesting a release does not exceed one percent (1%)&nbsp;of the outstanding shares of Common Stock outstanding immediately prior to the Public Offering
during the Lock-Up Period (for the avoidance of doubt, each individual affiliate of the undersigned that is a party to a separate lock-up agreement with the Underwriters shall be treated as a separate Stockholder); (ii)&nbsp;if the release, in full
or in part, of any shares of Common Stock from the restrictions of its lock-up agreement is in connection with another follow-on offering of common stock (the &#147;Follow-On Offering&#148;), then the shares of Common Stock held by the undersigned
shall be released only if the undersigned enters into a new lock-up agreement with the Underwriters with respect to the shares of Common Stock that are not being released, upon terms and conditions reasonably satisfactory to the Underwriters but
with restrictions that will be no more restrictive than those set forth herein and only to the extent that the undersigned agrees to participate as a selling stockholder in the Follow-On Offering and to sell any of the shares of Common Stock
released from the restrictions of this agreement in such Follow-On Offering; and (iii)&nbsp;the Representatives shall not release, in full or in part, any Stockholder from the restrictions of any lock-up agreement signed by such Stockholder with the
Underwriters unless such Stockholder shall have first made a request pursuant to the clause (i)&nbsp;of the preceding paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a trading plan that complies
with Rule 10b5-l under the Exchange Act (&#147;10b5-l Trading Plan&#148;) or from amending an existing 10b5-l Trading Plan so long as in either case there are no sales of Lock-Up Securities under such plans during the Lock-Up Period; and provided
that, the establishment of a 10b5-1 Trading Plan or the amendment of a 10b5-l Trading Plan shall only be permitted if (i)&nbsp;the establishment or amendment of such plan is not required to be reported in any public report or filing with the
Securities and Exchange Commission, or otherwise and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar
against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions. This lock-up agreement shall automatically terminate, and the undersigned shall be released from its obligations hereunder, upon the earliest to
occur, if any, of (i)&nbsp;prior to the execution of the Underwriting Agreement, the Company advises the Representatives in writing that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it has determined not to proceed with the Public Offering, (ii)&nbsp;the Company files an application to withdraw the registration statement related to the Public Offering, (iii)&nbsp;the
Underwriting Agreement is executed but is terminated prior to the closing of the Public Offering (other than the provisions thereof which survive termination), or (iv)&nbsp;May&nbsp;31, 2015, in the event that the Underwriting Agreement has not been
executed by such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature page follows) </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d887761dex51.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g887761g47i54.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">March 30, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g887761g12j29.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cerulean Pharma Inc.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">840 Memorial Drive</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cambridge, MA 02139</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Registration Statement on Form S-1</U> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in connection with a Registration Statement on Form S-1 (File No.&nbsp;333-202917) (the &#147;Registration
Statement&#148;) filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for the registration of shares of Common Stock, par value $0.0001 per
share, of Cerulean Pharma Inc., a Delaware corporation (the &#147;Company&#148;), with a proposed maximum aggregate offering price of $57,500,000 (the &#147;Shares&#148;), including Shares issuable upon exercise of an over-allotment option granted
by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares are to be sold by the Company pursuant to an underwriting agreement (the &#147;Underwriting Agreement&#148;)
to be entered into by and among the Company and Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named in the Underwriting Agreement, the form of which has been filed as Exhibit 1.1 to the Registration
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined
signed copies of the Registration Statement as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, minutes of meetings of the stockholders and the Board of Directors of the Company as provided to us by the
Company, stock record books of the Company as provided to us by the Company, the Certificate of Incorporation and By-Laws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of
rendering the opinions hereinafter set forth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination of the foregoing documents, we have assumed the genuineness of all
signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all
signatories to such documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the
Commonwealth of Massachusetts, the General Corporation Law of the State of Delaware and the federal laws of the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are
issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887761g85i97.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g887761g47i54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 30, 2015 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.
This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might
affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion with the Commission as an exhibit to the
Registration Statement in accordance with the requirements of Item&nbsp;601(b)(5) of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus under the caption &#147;Legal matters.&#148; In giving such
consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WILMER CUTLER PICKERING</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HALE AND DORR LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lia Der Marderosian</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Lia Der Marderosian, Partner</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>4
<FILENAME>d887761dex1026.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 10.26</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.26 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the &#147;Agreement&#148;), made this 27th day of March, 2015 (the &#147;Effective
Date&#148;), is entered into by Cerulean Pharma Inc., a Delaware corporation with its principal place of business at 840 Memorial Drive, 5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Cambridge, MA 02139 (the &#147;Company&#148;),
and Christopher D.T. Guiffre (the &#147;Employee&#148;). In connection with the Company&#146;s appointment of the Employee as the Company&#146;s President and Chief Executive Officer on March&nbsp;20, 2015 (the &#147;Appointment Date&#148;), this
Agreement amends and restates in its entirety the Employment Agreement between the Company and the Employee dated July&nbsp;21, 2014. In consideration of the mutual covenants and promises contained herein, and other good and valuable consideration,
the receipt and sufficiency of which are acknowledged by the parties hereto, the parties agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Term of Employment</U>.
The Company hereby agrees to continue to employ the Employee and the Employee hereby accepts continued employment with the Company, upon the terms set forth in this Agreement. There shall be no definite term of employment, and the Employee&#146;s
employment shall be at-will such that both the Company and the Employee remain free to end the employment relationship for any reason, at any time, with or without notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Title and Capacity</U>. The Employee shall serve (i)&nbsp;as President and Chief Executive Officer of the Company and shall report to the
Board of Directors of the Company (the &#147;Board&#148;) and (ii)&nbsp;while President and Chief Executive Officer of the Company, as a member of the Board. The Employee shall be based at the Company&#146;s headquarters in Cambridge, Massachusetts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee agrees to undertake the duties and responsibilities inherent in such position and such other duties and responsibilities as
the Board shall from time to time reasonably assign to him. The Employee agrees to devote his entire business time, attention and energies to the business and interests of the Company. The Employee agrees to abide by the rules, regulations,
instructions, personnel practices and policies of the Company and any changes therein that may be adopted from time to time by the Company. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation and Benefits</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Base Salary</U>. The Company shall pay the Employee, in accordance with the Company&#146;s regular payroll practices, a base salary at
the annualized rate of $435,000 effective as of the Appointment Date, subject to adjustment thereafter by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2 <U>Bonus</U>. In
addition to a base salary, the Employee will be eligible to receive a performance-based annual bonus for each fiscal year in which he is employed by the Company in the capacity of President and Chief Executive Officer. This bonus shall be based upon
reasonably attainable annual quantitative and qualitative performance objectives established by the Board. The Employee&#146;s annual bonus level target shall be set at fifty percent (50%)&nbsp;of the Employee&#146;s base salary for the currently
applicable fiscal year and shall be subject to adjustment thereafter by the Board. The Board will determine, in its sole discretion, based upon its review of the achievement of the performance objectives for a given fiscal year and its consideration
of the recommendation of the Compensation Committee, whether (and in what amount) a bonus award is payable to the Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be
eligible to receive a bonus award, the Employee must be an active employee on the date any such bonuses are distributed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.3 <U>Employee
Benefits</U>. The Employee shall be entitled to participate in all benefit plans and programs that the Company establishes and makes available to its employees to the extent that the Employee is eligible under (and subject to the provisions of) the
plan documents governing those programs. The Employee shall be entitled to twenty-five (25)&nbsp;days paid vacation per year plus personal days and paid holidays generally offered by the Company to its employees, each to be administered in
accordance with Company policy. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.4 <U>Reimbursement of Expenses</U>. The Company shall reimburse the Employee for all reasonable
travel, entertainment and other expenses incurred or paid by the Employee in connection with, or related to, the performance of his duties, responsibilities or services under this Agreement in accordance with the Company&#146;s expense reimbursement
policies as set forth in the Company&#146;s employee handbook, a copy of which has been provided to the Employee. The reimbursement of expenses hereunder shall be subject to the terms and conditions set forth in Section&nbsp;18(e) of this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.5 <U>Equity</U>. On March&nbsp;23, 2015, in connection with the Company&#146;s appointment of the Employee as the Company&#146;s
President and Chief Executive Officer, the Company granted the Employee an option to purchase 407,520 shares of common stock of the Company $.0001 par value per share (&#147;Common Stock&#148;) at an exercise price equal to $9.84 per share, the fair
market value of the Common Stock on the date of the grant. The shares subject to such option shall vest over a four (4)&nbsp;year period in accordance with the terms and provisions of the Company&#146;s 2014 Stock Incentive Plan and the applicable
stock option agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6 <U>Withholding</U>. All salary, bonus and other compensation or benefits payable to the Employee shall be
subject to applicable withholdings and taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Payments Upon Resignation By The Employee Without Good Reason or Termination By The
Company For Cause.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1 <U>Payment upon Voluntary Resignation or Termination for Cause</U>. If the Employee voluntarily resigns his
employment other than for Good Reason (as defined in Section&nbsp;4.2), or if the Company terminates the Employee for Cause (as defined in Section&nbsp;4.3), the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall pay the Employee all accrued and unpaid base salary through the Employee&#146;s date of termination and any vacation that is accrued but unused as of such date. The Employee shall
not be eligible for any severance or separation payments (including, but not limited to, those described in Sections 5 and 7 of this Agreement) or any continuation of benefits (other than those provided for under the Federal Consolidated Omnibus
Budget Reconciliation Act (&#147;COBRA&#148;)), or any other compensation pursuant to this Agreement or otherwise. The Employee also shall have such rights, if any, with respect to outstanding equity awards as may be provided under the agreement
applicable to each. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2 <U>Definition of &#147;Good Reason&#148;</U>. For purposes of this Agreement, &#147;Good Reason&#148; means the
occurrence, without the Employee&#146;s written consent, of any of the events or circumstances set forth in clauses (a)&nbsp;through (c)&nbsp;below, <U>provided</U>, <U>however</U>, that an event described in clauses (a)&nbsp;through (c)&nbsp;below
shall not constitute Good Reason unless it is communicated in writing, within 90 days of the first occurrence of an event giving rise to the claim, by the Employee to the Board or its successor and unless it is not corrected by the Company or its
successor within thirty (30)&nbsp;days of the Company&#146;s receipt of such written notice: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the material diminution of the
Employee&#146;s duties, authority or responsibilities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) a material reduction in the Employee&#146;s base salary; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) a change by the Company in the location at which the Employee performs his principal duties for the Company to a new location that is both
(i)&nbsp;outside a radius of 50 miles from the Employee&#146;s principal residence and (ii)&nbsp;more than 30 miles from the location at which the Employee performed his principal duties for the Company. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company fails to timely correct an event of Good Reason, the termination of
Executive&#146;s employment shall become effective 60 days after such notice is received by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3 <U>Definition of
&#147;Cause</U>&#148;. For purposes of this Agreement, &#147;Cause&#148; is defined as: (i)&nbsp;a good faith finding by the Board (excluding the Employee, if applicable) of (a)&nbsp;the Employee&#146;s failure to (1)&nbsp;perform reasonably
assigned lawful duties or (2)&nbsp;comply with a lawful instruction of the Board so long as, in the case of (2), the instruction is consistent with the scope and responsibilities of the Employee&#146;s position, or (b)&nbsp;the Employee&#146;s
dishonesty, willful misconduct or gross negligence, or (c)&nbsp;the Employee&#146;s substantial and material failure or refusal to perform according to, or to comply with, the policies, procedures or practices established by the Company or the Board
and, in the case of (a)&nbsp;or (c), the Employee has had ten (10)&nbsp;days written notice to cure his failure to so perform or comply; or (ii)&nbsp;the Employee&#146;s indictment, or the entering of a guilty plea or plea of &#147;no contest&#148;
with respect to a felony or any crime involving moral turpitude. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Termination Without Cause; Resignation for Good Reason</U>. If the
Employee&#146;s employment with the Company is terminated by the Company without Cause (as defined in Section&nbsp;4.3), or by the Employee&#146;s voluntary resignation for Good Reason (as defined in Section&nbsp;4.2), other than in connection with
a Change in Control (as defined in Section&nbsp;7.2(a)), then the Employee shall be paid all accrued and unpaid base salary and any accrued but unused vacation through the date of termination. In addition, subject to the Employee&#146;s execution
and non-revocation of a binding severance and mutual release agreement in a form satisfactory to the Company (hereinafter, a &#147;Severance Agreement&#148;) and subject to the terms and conditions of Section&nbsp;18 of this Agreement, the Employee
shall be eligible to receive the following separation benefits: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1(a) an amount equal to the product of (i)&nbsp;one twelfth (1/12)&nbsp;of the Employee&#146;s
then-current annualized base salary (<U>provided</U>, <U>however</U>, that if Employee&#146;s employment is terminated by the Employee&#146;s voluntary resignation for Good Reason as a result of the Company&#146;s material reduction of the
Employee&#146;s base salary, then the Employee&#146;s then-current annualized base salary shall refer to his base salary as in effect immediately before such material reduction took effect) and (ii)&nbsp;twelve (12), less any amounts required to be
withheld under applicable law, which amount shall be payable in twelve (12)&nbsp;substantially equal monthly installments, in accordance with the Company&#146;s payroll practices in effect from time to time beginning on the Payment Commencement Date
(as defined below); and (b)&nbsp;the amount of any bonus for the prior year that was approved but not yet paid to the Employee at the time of the Employee&#146;s termination of employment, less any amounts required to be withheld under applicable
law, which amount shall be paid in a manner and timing consistent with the payments to other similarly situated employees and consistent with the requirements of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;) but in no event later than March&nbsp;15 of the year following the year of performance; provided, in both cases, that the Severance Agreement has been executed and any applicable revocation period with respect thereto has expired
within sixty (60)&nbsp;days following the Employee&#146;s date of termination (such 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day, the &#147;Payment Commencement Date&#148;); <U>provided</U>, <U>however</U>, that if the 60<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day following the Employee&#146;s date of termination occurs in the calendar year following the year of termination, then the Payment Commencement Date shall be no earlier than January&nbsp;1 of the
year following the year of termination; and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2 upon the Employee&#146;s termination from employment pursuant to this Section&nbsp;5, the
Company shall make contributions to the cost of COBRA (Consolidated Omnibus Budget Reconciliation Act) coverage on behalf of the Employee and any applicable dependents for a period of twelve (12)&nbsp;months after the Employee&#146;s termination if
the Employee elects COBRA coverage, and only for so long as such coverage continues in force; <U>provided</U>, <U>however</U>, that if the Employee commences new employment and is eligible for a new group health plan, the Company&#146;s
contributions toward COBRA coverage shall end when the new employment begins. The cost of COBRA shall be determined on the same basis as the Company&#146;s contribution to Company-provided health and dental insurance coverage in effect immediately
before termination of the Employee&#146;s employment for an active employee with the same coverage elections. At the end of the twelve (12)&nbsp;month period, the Employee may continue such COBRA, if applicable, and shall be responsible for all
premiums thereafter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Termination by Reason of Death or Disability.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1 If the Employee&#146;s employment with the Company is terminated by reason of the Employee&#146;s death or Disability (as defined below),
then the Employee (or his estate, if applicable) shall be paid, within thirty (30)&nbsp;days of the date of the Employee&#146;s death or determination of Disability, all accrued and unpaid base salary and any accrued but unused vacation through the
date of termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2 For purposes of this Agreement, &#147;Disability&#148; shall mean the Employee&#146;s absence from the full-time
performance of the Employee&#146;s duties with the Company for 180 consecutive calendar days as a result of incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its
insurers and acceptable to the Employee or the Employee&#146;s legal representative. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Termination Following Change of Control</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1 <U>Benefits to Employee Upon a Change of Control Termination</U>. In the event of a Change of Control Termination (as defined in
Section&nbsp;7.2(c) below), the Employee shall be entitled to all accrued and unpaid base salary and any accrued but unused vacation through the date of termination. In addition, subject to the Employee&#146;s execution and non-revocation of a
binding Severance Agreement and subject to the terms and conditions of Section&nbsp;18 of this Agreement, the Employee shall be eligible to receive the following separation benefits: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) an amount equal to the product of (i)&nbsp;one twelfth (1/12)&nbsp;of the Employee&#146;s then-current annualized base salary
(<U>provided</U>, <U>however</U>, that if Employee&#146;s employment is terminated by the Employee&#146;s voluntary resignation for Good Reason as a result of the Company&#146;s material reduction of the Employee&#146;s base salary, then the
Employee&#146;s then-current annualized base salary shall refer to his base salary as in effect immediately before such material reduction took effect) and (ii)&nbsp;eighteen (18)&nbsp;months, less any amounts required to be withheld under
applicable law, which amount shall be payable, in full and in a lump-sum cash payment on the Payment Commencement Date; <U>provided</U>, <U>however</U>, that if the Employee&#146;s date of termination occurs prior to the closing of the Change of
Control, then the severance payable hereunder shall be paid in the manner set forth in Section&nbsp;5.1(a); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) an amount equal to
the product of (i)&nbsp;the higher of (x)&nbsp;Employee&#146;s target performance-based annual bonus pursuant to Section&nbsp;3.2 for the year in which the Employee&#146;s date of termination occurs and (y)&nbsp;the performance-based annual bonus
paid to Employee for the year immediately preceding the year in which the Employee&#146;s date of termination occurs and (ii)&nbsp;1.5, less any amounts required to be withheld under applicable law, which amount shall be payable, in full and in a
lump-sum cash payment on the Payment Commencement Date; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) contributions to the cost of COBRA coverage as provided in section 5.2 hereof, provided that
in the event of a Change of Control Termination, such contributions shall last for eighteen (18)&nbsp;months; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) full and immediate
vesting of any equity awards subject to time-based vesting that are outstanding at the time of the termination of the Employee&#146;s employment. Any of the Employee&#146;s outstanding awards at the time of the termination will remain exercisable
following termination to the extent set forth in the applicable award agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2 <U>Key Definitions</U>. As used herein, the
following terms shall have the following respective meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Change in Control</U>&#148; means an event or occurrence set
forth in any one or more of subsections (i)&nbsp;through (iii)&nbsp;below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection), provided that
such event constitutes a &#147;change in control event&#148; within the meaning of Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i) the acquisition by an individual, entity or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Securities Exchange Act
of 1934, as amended (the &#147;Exchange Act&#148;)) (a &#147;Person&#148;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the
Exchange Act) more than 50% of either (x)&nbsp;the then-outstanding shares of common stock of the Company (the &#147;Outstanding Company Common Stock&#148;) or (y)&nbsp;the combined voting power of the then-outstanding securities of the Company
entitled to vote generally in the election of directors (the &#147;Outstanding Company Voting Securities&#148;); or </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii) the consummation of a merger, consolidation, reorganization, recapitalization or share
exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a &#147;Business Combination&#148;), unless, immediately following such Business Combination,
all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or
indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring
corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company&#146;s assets either directly or through one or more
subsidiaries) (such resulting or acquiring corporation is referred to herein as the &#147;Acquiring Corporation&#148;) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding
Company Common Stock and Outstanding Company Voting Securities, respectively; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii) approval by the stockholders of the Company of a
complete or substantially complete liquidation or dissolution of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Change in Control Date</U>&#148; means the
first date during the period of time the Employee is employed pursuant to this Agreement on which a Change in Control occurs. Anything in this Agreement to the contrary notwithstanding, if (a)&nbsp;a Change in Control
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occurs, (b)&nbsp;the Employee&#146;s employment with the Company is terminated prior to the date on which the Change in Control occurs, and (c)&nbsp;it is reasonably demonstrated by the Employee
that such termination of employment (i)&nbsp;was at the request of a third party who has taken steps reasonably calculated to effect a Change in Control or (ii)&nbsp;otherwise arose in connection with or in anticipation of a Change in Control, then
for all purposes of this Agreement the &#147;Change in Control Date&#148; shall mean the date immediately prior to the date of such termination of employment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Change of Control Termination</U> occurs where the Employee is terminated without Cause (as defined in Section&nbsp;4.3) or resigns for
Good Reason (as defined in Section&nbsp;4.2), in either case within twelve (12)&nbsp;months following the Change in Control Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Mitigation</U>. The Employee shall not be required to mitigate the amount of any payment or benefits provided for in Sections&nbsp;5 or 7 by seeking other employment or otherwise except with regard to medical and dental coverage if new employment
is obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Survival</U>. The provisions of Sections&nbsp;5 and 7 shall survive the termination of this Agreement for any reason.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Invention and Non-Disclosure Agreement</U>. The Employee and the Company acknowledge (a)&nbsp;that they have entered into an
Invention and Non-Disclosure Agreement and (b)&nbsp;the continuing effectiveness of such Invention and Non-Disclosure Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<U>Notices</U>. Any notices delivered under this Agreement shall be deemed duly delivered three (3)&nbsp;business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one (1)&nbsp;business day after it
is sent for next-business day delivery signature required via a reputable nationwide overnight courier service, to the Company&#146;s address set forth in the introductory paragraph hereto or to the home address of the Employee then on file with the
Company, as applicable. Either party may change the address to which notices are to be delivered by giving notice of such change to the other party in the manner set forth in this Section&nbsp;11. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Pronouns</U>. Whenever the context may require, any pronouns used in this Agreement shall
include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Entire Agreement</U>. This Agreement and all exhibits hereto constitute the entire agreement between the parties and supersedes all
prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Amendment</U>. This
Agreement may be amended or modified only by a written instrument executed by both the Company and the Employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Governing Law</U>.
This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflict of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating
to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and the Employee each consents to the
jurisdiction of such a court. The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of both parties and their respective
successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business; <U>provided</U>, <U>however</U>, that the obligations of the Employee are personal and shall not be
assigned by him. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Acknowledgment</U>. The Employee states and represents that he has had an opportunity to
fully discuss and review the terms of this Agreement with an attorney. The Employee further states and represents that he has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and
conditions hereof, and signs his name of his own free act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Payments Subject to Section&nbsp;409A. </U>Subject to the provisions in
this Section&nbsp;18, any severance payments or benefits under this Agreement shall begin only upon the date of the Employee&#146;s &#147;separation from service&#148; (determined as set forth below) which occurs on or after the date of termination
of the Employee&#146;s employment. The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Employee under this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate
&#147;payment&#148; for purposes of Section&nbsp;409A of the Code and the guidance issued thereunder (&#147;Section 409A&#148;). Neither the Company nor the Employee shall have the right to accelerate or defer the delivery of any such payments or
benefits except to the extent specifically permitted or required by Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If, as of the date of the Employee&#146;s
&#147;separation from service&#148; from the Company, the Employee is not a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then each installment of the severance payments and benefits shall be made on the dates and terms
set forth in this Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If, as of the date of the Employee&#146;s &#147;separation from service&#148; from the
Company, the Employee is a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(i) Each installment of the
severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period
(as defined under Section&nbsp;409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation &#167; 1.409A-1(b)(4) to the maximum extent permissible under Section&nbsp;409A and shall be paid in the manner (and at the
times) set forth in this agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(ii) Each installment of the severance payments and benefits due under this Agreement that is not
described in paragraph c(i) above and that would, absent this subsection, be paid within the six-month period following the Employee&#146;s &#147;separation from service&#148; from the Company shall not be paid until the date that is six months and
one day after such separation from service (or, if earlier, the Employee&#146;s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months
and one day following the Employee&#146;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; <U>provided</U>, <U>however</U>, that the preceding provisions of this
sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of
the application of Treasury Regulation &#167;&nbsp;1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation
&#167;&nbsp;1.409A-1(b)(9)(iii) must be paid no later than the last day of the Employee&#146;s second taxable year following the taxable year in which the separation from service occurs. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The determination of whether and when the Employee&#146;s separation from service from the
Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation &#167; 1.409A-1(h). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of
Section&nbsp;409A to the extent that such reimbursements or in-kind benefits are subject to Section&nbsp;409A, including, where applicable, the requirements that (i)&nbsp;any reimbursement is for expenses incurred during the Employee&#146;s lifetime
(or during a shorter period of time specified in this Agreement), (ii)&nbsp;the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii)&nbsp;the
reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv)&nbsp;the right to reimbursement is not subject to set off or liquidation or exchange for
any other benefit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything herein to the contrary, the Company shall have no liability to the Employee or to any
other person if the payments and benefits provided hereunder that are intended to be exempt from or compliant with Section&nbsp;409A are not so exempt or compliant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">19.1
No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall
not be construed as a bar to or waiver of any right on any other occasion. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">19.2 The captions of the sections of this Agreement are for convenience of reference only and in
no way define, limit or affect the scope or substance of any section of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">19.3 In case any provision of this Agreement shall
be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Remainder of page intentionally left blank.</I>]<I> </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set
forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CERULEAN PHARMA INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert I. Tepper</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Robert I. Tepper, M.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chairman, Compensation Committee of the Board of Directors</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EMPLOYEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ </I>Christopher D. T. Guiffre</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Christopher D. T. Guiffre</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Amended and Restated Employment Agreement</I>]<I> </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d887761dex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
consent to the use in this Amendment No. 1 to Registration Statement No. 333-202917 on Form S-1 of our report dated March 19, 2015, relating to the consolidated financial statements of Cerulean Pharma Inc. appearing in the Prospectus, which is part
of this Registration Statement, and the reference to us under the heading &#147;Experts&#148; in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte &amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 30, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g887761g06z67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g06z67.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X80X:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*
M("`@('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*
M("`@('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B"B`@("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+VUM+R(*("`@('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(@H@("`@>&UL;G,Z
M<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*("`@('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N
M861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B"B`@("!X;6QN<SIX;7!44&<]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM
M96YS:6]N<R,B"B`@("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+W-4>7!E+T9O;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+V<O(@H@("`@>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@("`@>&UL;G,Z17AT96YS:7-&
M;VYT4V5N<V4](FAT='`Z+R]W=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E
M;G-E+R(*("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@
M("!X;7`Z365T861A=&%$871E/2(R,#$U+3`S+3,P5#$Q.C$Y.C0X*S`U.C,P
M(@H@("!X;7`Z36]D:69Y1&%T93TB,C`Q-2TP,RTS,%0Q,3HQ.3HT."LP-3HS
M,"(*("`@>&UP.D-R96%T941A=&4](C(P,34M,#,M,S!4,3$Z,3DZ-#@K,#4Z
M,S`B"B`@('AM<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*2(*("`@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#I%-S!&
M1D(R,CE$1#9%-#$Q.3@S0SDX040Q0C,W.#%$1"(*("`@>&UP34TZ1&]C=6UE
M;G1)1#TB>&UP+F1I9#I%-S!&1D(R,CE$1#9%-#$Q.3@S0SDX040Q0C,W.#%$
M1"(*("`@>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED.C5$,C`X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X(@H@("!X;7!-33I296YD:71I;VY#
M;&%S<STB9&5F875L="(*("`@:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4]
M(E!R:6YT(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#TB5')U92(*
M("`@>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD](D9A;'-E(@H@("!X
M;7!44&<Z3E!A9V5S/2(Q(@H@("!P9&8Z4')O9'5C97(](D%D;V)E(%!$1B!L
M:6)R87)Y(#$P+C`Q(CX*("`@/&1C.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@
M("`@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG,#9Z-C=?,3(\+W)D
M9CIL:3X*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIT:71L93X*("`@/'AM<#I4
M:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:0H@("`@("!X
M;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM<$=);6<Z:&5I9VAT/2(Q.#`B
M"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'(@H@("`@("!X;7!'26UG.FEM
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M:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7`V:7!Q<75S
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M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E=.+VU3:5`U0S$U2%5-:E=C
M;UI32V=G:6A"0GA6<B]!2E9L)B-X03LK5S,O049+96IF.$%C4'1F*W%E2W4O
M-59L*U<S+U5P-DXO,T0W6"]Q;FER=BM66F9L="\Q2V5J9CEW*S$O=T-Q94MU
M+S56;"M7,R]5)B-X03MP-DXO,T0W6"]Q;FER=CA!;%=8-6)F.$%5<#9.+W="
M=RLQ+S9P-'$W+VQ76#5B9CE3;F\S+V-0=&8K<65+<V8O041%+TQV.$%,*S`O
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M1DMK+T-T5TE"5E,S42]0>C9R<3EV6D14:D)")B-X03MC0F5%-U--5S5'0G`O
M=T,W.4U$:4]02&QY;U0Y;79&*TIP5UA91F1I<G-69&ER<U99-2M9,R]+0S8U
M+WI#4V9Q>%9K94MU>%8R2W5X)B-X03M6,DMU>%9J6#5M+RM3,C@R9CES8E50
M.$%Q1FMX5FMU2V]'8EA.1V=V,#`K82MG:G9P0V]J=&UK55-%=CEM:6LQ,W`K
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M5F1I<DA0>D<O-5%86%`K65-4.5=+<VIX5C)+=7A6,DMU>%8R2W-A+TTS+WE7
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M8B]L0F1C+S5H2E`Q67%Y4$9867$W1EA9<3=&)B-X03M867%X<CAZ9B]*8F5B
M4#A!=&IA:"]W0E%S;4MS13AH>7I3*V9,,3E8,4=!<$A*3&)A6C5C-5)M-&=+
M4V-K=4AT648T<4MC9TI(4TYG)B-X03M.,G)80W(P2%9F4&YL6%-D5&94=%)V
M;'1:-&Q34UHU1EI963!C,$134VME;7%G;&%K;F)K2S1&64QO24TO=T-5=FQK
M44]P.5-A6#`S)B-X03LV<6%R9%5/,V)#:$])<E<T=&TX,5$S1$DP>3)C>%EX
M9VAD-U=):6QD*VU+;WEF.$%V<D@O04IJ3'8O=757,DMP9%`X03AD:R\X>&QR
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M1VAP>%5Y*VY25FUU:E=S1VYA)B-X03LK,G`S3V]/24IV,'9Y:G5$06M%6"LU
M1TE$:7=22#-0.#=N1DQ-3%<W=&)U1517<S!D>$-344I9;41Q4T11+T5P23)/
M0E981EA9<7AZ)B-X03LX>'8K548Q>B]M16LO5FER23A69&ER<U9D:7)S5F1I
M<D=V>DXO=T1*8F5B4"LR3G%(+U5,2FER02])5V]8;#$K8VUV=DAC5C!Y6DQG
M)B-X03MR87)+<CA:-#-H4U1N2$=Z0E18.71I95A91'-66G9R,VY,53E-,39,
M5#1T0W4W=7DT;S`Q+T5K:F<X:E(Q:5=.2#5.1W9X;7!&845$)B-X03MF07)&
M4$Q$0G9Y=#AQ<T%11&-31VA&1#!U=6]/1D1)3E$O-#9(;3,O04IG-68K;U-(
M1EA4+W=".5DO.$%-6F0O.3%Y,GA6,$@Y.69F)B-X03LX>&QP+W=",7DU>%8R
M:V8W,V%"+WI"-F8O=T)19"]I<5=82"]!0VE/<F8X04U9,R]!1D)*:7).<D0O
M:G,V<"]Z=R\U3FY!;'9Z3"]Y)B-X03MJ;7$O.'=D>"]W06UM>%9H;FTR,G9:
M-S=6+W%Q4G1W9W8R;#E6,E-I:7IS2SAE2U-64'1T.#A+1D8W94\T,5)O2F$K
M;DQD6%-V>%IK)B-X03MA:#%U,C9-<$1$-D1I<DUV3$YP1&%7.35B=SAV4VIV
M2F=V3C-K8G-D,F-S>"MK-$5P>&ER<U9D:7)S5EE2*UEK06YV.4IJ4%)O-V]&
M)B-X03M11DI917=G;T%3<DAK0U%1<$9254UY>#@R0D-S97-86"]$3G%Q,'`V
M5GA1,4A1859,,&]/,64R,WIR<V]22&XR,G9:.5%V>F%R1V94)B-X03M3+V%2
M<$A:0W$O53=!5E1I<B]&=E1S845Q0T]824MP,U`O9E=0+TU:9"\X061C='-6
M44=P82]Q=&IR3CE"87I836-35$I)1F=T5%!')B-X03M7;&Y:1SEA45)3*VU/
M2T-L5UAV:7))4$QN;5<O,4LW:&IU64EO-#=M,6$V:4UB35=52UEX>&)K3B]W
M0SDW94=+5U-91EDU*UDS+TM#)B-X03LV-2]Z0U-F<7A6:V5+=7A6,DMU>%8R
M2W5X5FI8-6TO*U,R.#)F.7-B55`X07%&:WA6:5@U9F%'<B]M1')F;515=$UU
M-TQ7<F]32DA-)B-X03LQ=DI&8DY!5U%C1$DV='ID9E1&1S4P24]Y9TM+1EAQ
M5T)8;&YL=CA!.&QF-5<O-6E:9C%85T9#9F%H+W@P4$YV+TU(3"]W0E%K3TMU
M)B-X03MN+W9R2"]M374O.$%U=5<R2W5G+W9R-R]!2FI,5"]U=5A/2W4P:B]E
M-U%0*UE05"]!4'%$=CA64WDT+S522%9V*UEX=BMO2DU66G19)B-X03MF.&1N
M5E`X06YH+WEB3T),9FU8+T%*4GI69CA!;41U4"M45%EQ>'96+W=$93=8+RM9
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M1&-02'EA9&])+S-N<#A6-6QF,FIT6&9':W)V>D<O-5%86%`K)B-X03M94U0Y
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M1S`Q-4Q:<E-&-"M:,V@U145J<E1&2V%A0C5L=&1A-2MJ8GHR+T-+1V-E=4DO
M:6IN-3A#4%1E5"]!2#)A,7=+;2M+<TPO34)B)B-X03LQ<C-44'%51%A--&EU
M4W-3>4Q'86@T0T=Q-TMV=W-!95(U8U!T9U95145+>'EY441Y,6)K;7`T5"]W
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M3&Y&6&%2+W9D)B-X03MO2"]-2'`O+T%&0C,K2W!:8V8X04M)-G0O=T%X:F8X
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M03-B:&-!9$LO.&-Q5W98+U`K)B-X03MB.6Y&0V%E859,6"MS94%G=GEF;W1.
M4"MJ<C0O4CA63592<R\Y.5DO.'AL,R]W0C%Y,GA6;R\W,"M:9BMJ8B]Q26UX
M5G10.$%P:F8K)B-X03M94F8K>%A&6%=(,DY5+S=B14@O9%5/2W!L*UDS+TM#
M-C4O>D-39G%W2E,S>E@O>'DY92\U:D(O,U0T<TM%>&<O-51Y8B]M1&LO6&(T
M)B-X03MP659A-F9C;E(Y3W5*5$4Y;DIC2V=J-&MU4V)*=71F:'!I:%!T5W,W
M9&)Z5VQJ5#!K9V=V<#1L:4IJ0WEP85=(1C9)5C-&9'-64F)A)B-X03LU-7`K
M=4UK:W1M;'!C5'IW,G!I:&LY6D)&<55.;T,U95)K8CDS2U-A2TXO=7A3:G)8
M>DQ,1$1*2&115%AC='9*24QI-6A71D564')C)B-X03LQ=D=3<GE)83!H,S1G
M-'%L6&YN6$ET42],<GI3<3(P,$%K,$,K=5E8;#E/:GA087E566-(8VHU34)G
M54TS>%9*9DUM:F%T<4IS-4Y-)B-X03LQ3#E(5#)K;G%G<VIY>'5246=01VMK
M0F1D=4Q,>3-6:C!.1&ER>D=Y:#%7>&ML.&EP-6IT1$XU5G0S,4]D,C!3-E`W
M<W!Z3DA';T%3)B-X03M(:F1B0D8Y=6]W<6]N>EAE,U9J839U4$U6<#9(;D]:
M.4UT9CEW5C!#2E!G=%=Q1'%8-W9D0E1M9F]X5D93835Q:&XQ,5<X>%=F3'EI
M)B-X03MZ,T=P,#!+-S9Z6&$S6D59+U-.6D(V;'918U(Y;G8S>%9:86599%-L
M=G1"=&]V359K6G9/1DQV4S8V2&1&4TQ7-6MV4GE),4PT45AL)B-X03M0:CA.
M2S`V-'%O>"MA-WEY<SE2,6(O159P.5@X;WDR*VTS:DA18G5V<5)E=&%P.%`V
M4D1(+V5H:7IB1'!I<4QT>'$Y-65X*U5K.'DV)B-X03ME=#5Q.75M<DQ',FM4
M2S1I;6A-67!853DO:&HS;W!O92M+;R]Y3#5O.'HK83=V5EHY2C%U=U-A,RMR
M+U<Q=61%=4958S!B:'=:3E9D)B-X03M34G=93W9,:W)#:D%(8D%R2DY6,'8X
M=UID3'9)<FY8.4I7,FMG:U=:;SE(=6DT46]1>%5F<$IT-F1.<U9E97DK8W)M
M-S!I2%AZ-6IT)B-X03M0<6YM2S1N,&TS<&].,$=-<S91=T]+2%5V9W`Y5U5$
M:V5T9F]+;RLW,6I6;W17,6I4-5!-3FXY6CAR4E,V;'%02%%R<W%%;'5)<C@X
M)B-X03M0.7E.6"M*1D$T:G!89G9I<6E034=P3DAP9#$O:4=Z-"ME2E9I<U`Y
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M;G`K;4]03VUP,#55-C1&4U!Z-68X06UB>35B5VUT-C-R*VY#2EI$6G=#,C!3
M-VM*965K;GA!)B-X03MA;G1T8C=.554K9$U64U=32%9,5%9R<GEI,VU3,"MU
M85I9>3,Y>%123&]R.5A.<UE'-'8K:TM/4DA.54MO*S%H5D-A:#5L=6(W4G),
M)B-X03MZ1$PU:W16=%!-;'A.<#%P=S!+-D1'5UE2,GIG9S9K9E0O,VQ!0EDY
M>CE#<5E487IQ=C92,74P8GI&6D=F>6UK="]Q45A1<G-G3$QC)B-X03M*9DAH
M+W52<2]W06-.0GA(4W4O9D950G%N;D,O,#=2-V98<#ED=&YS9DY+;#17:C!/
M9&Y#,C`S85`Y2T)Q:WHX=4MH;31G;6Q&2GA6)B-X03M&+W`O56A$<44S*TER
M4#`O24E&<F5(.4$S9%-E66HR6#E).'!0:71U<6=#;2]41E9F5&15,6%A*S!Z
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M5U=/4U`V<V%4;C%42GE*<3(O43164T-X='136'EX*U=S-3!Z4C1R;V%R26PO
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M)B-X03M#92M&5U(V='`Q>"]I<C@P259S=$I7,6)3,FQS-5AJ="M4>F5L17A7
M649E3&-(,U!*86=S3CDX5E5M:'9(,'HX;VYU3#)$4C598C1M)B-X03MB5')2
M;E=/5GID=W(Y6%=+3C9(:4-Y=E=V2&5V=SAS5E-M-W4O33A(;#,X,&)R5$PU
M8FY7,C%20F8R8V,Y,6-,6DET>F-55T@Q;V)5)B-X03M666-%55)M44YS0W%J
M-%%Q;C)L47I(>F0K5W5P6&QI:C,W84M*=%%U1V5#,FY%+S%6,5%.1WE"=6)$
M:V]!9%$Q2TA:0FER1T]/;S9T)B-X03LU2C@W6#$O3EIA<'!-;#EA:E0T8FTY
M,#A+:S,Q:BLX1GI$>F=T,65.,55Q-SAV.$%+,W%66#!8-6-J:FDX=F%82$=%
M5TY,4T)55TIL)B-X03MK:D%%4V="2%%+:DPT1E)1.7-#=E!F.$%N265#9'9+
M96Y4,FQV650S8U=O;V]';W)'67A#65I7;%!*>'E52C99;&9I=V]Q5D]W24MQ
M)B-X03M5-GAP-TXK879M,D8W4%12<#!U9U-U;'E9:TYW2GEK8VI+=U%&,S1V
M*SE98U,R-FUV5$-R1F)/,W1P9GDR+TPR-3!/=S`U-&8P=$EK)B-X03MO=5%:
M4DA(.5EK3'E*3&-P1$M!:C%*23)"4&9&5U%89&Y$8RM99GI8:G9,>4A5;W!B
M14UU;'9/,T-%>%)K25AA5#%)-&Y,9$)X-V)5)B-X03M',DMP3CEA.#(R=#4K
M54YN6C(O,6)3,V5L*VM00V-#43-K9C%H2D9J-%)O239+2W)';VI,1E%E,DMR
M<FHV.5EA1"MA,%-X-F995T,S)B-X03LX34U6,6%-.$5Q,F)8:SA44W8X055O
M6FY0<%4Y269U.6EJ:'5813%65$A3<GI612]-5#AT65`P<F)Z-E90;S9'>D%A
M.&MU3&=#,6-V)B-X03M),'-S55-M<#,S0T5J-U-B3%)6-G0K63,O2T,V-2]Z
M0U-F<7=+=V)Z2&(V1"]W0D1$-D9"9%%7.&PQ<4=K>6A56EI1-V9U-W!*95E%
M)B-X03MB47EI4TI1=GAT5E%N=4U664AP;6EA+W%F-5A7*VU3-E!B>5!D87DW
M='%';#)53CAK9')W=&<P-6A73F\S85E%>2]"=W%&1DM':316)B-X03M:3C5H
M;3!I2#@Q.6-G,5A6=E-T-61%:FEH=%!R>3)H3%)#2V%O:75614MS06AF;7HX
M858R3$)Q2W!F-7573%4O26YL:E19.55!='!T)B-X03M53FA9,UEV<F4V;49O
M1D560DYB>#--57-Q:G-P16QE:#8T<78X=S9/;#$U;2]-=E,S,49T44PV26IX
M84]L>DEB9TI:<$$O26PQ=496)B-X03LR3S%04S-Q2U4U2$95=C!#6%%R97<O
M2W5+>3E$5#=O,V,X8U56-4A$9GE01"MK,&(P,756<W!)+U9O-TU'5C175&Y8
M<3%#<6YM:&%0)B-X03MQ3G(K6&XU;C9L9C)$-E9.<6QH97I2-EDQ:W1O:T58
M,5<T94].6E93350X0DPV6DY.=4YE:D1!<C-01EA9<3AY=DY),6EX.'AE9$YF
M)B-X03LQ1%19-U=Z=71-;%,Q=DQ.-3=V-G=655(X<#=C=$E&;$55559!;'-D
M=59764%62W9.-V)364@X<652<E)D1W-B;7IK,6E5-G)C2F)W)B-X03M25VQF
M<E,R-4AP,W%7.7E80T%,*SAI87$W9D5E3D95=W9T1S%D-R\X>#5,=E%:234W
M=RML63-U;5(R-GE.14@K4&QD6$UC3D%+>&UI)B-X03LX95A$87)+5WA6:T]I
M*V-B>E-P=GDR,$-/,&4V8E4W5UI497IZ=DY+<%)32$PK;%-'43!897)(:50Y
M3TMS5S@P955P-U0X=DYF;CAX)B-X03LK5C%T.5%V.5AJ=F)E3&<W>&-V:DUL
M>$DY;F5Z<DA73C5.;6%.07I!8B]A>%9.8E-0>79P;C4P-E9)=6YR1'$Y;#5C
M5V(Q-"M%3FQ))B-X03M98F%21UE34T1A:UE#0U%/>3AE<F)9<7I(.&AB4V4Q
M.&MY4GEP-E,O6$I04E)7;&MJ0TQ&16XW<5-1=7)X,54X4%-::U9F:$1-5DQ%
M)B-X03M+>FY827(R6%(W,DMX9VAU8G531C!H=#=H,FEH8W-T3TQU:75Y9S$W
M1$98:#-M;GDO<71H-50X<&%29C9!:%-,5FI,<4-83'=83G)$)B-X03M'>CA/
M36(S9'IC>70X3%98;'E7;7I,,$=&5EA63$%396-F>D=E,7-B2V4W1VQ3>#9F
M13EJ3D1-230T;V]*43!K;&\P8VDX4U)(-DQ()B-X03MM4'1B8U=65E8X<V55
M=&-U5CAH0G9+<5<Y=&\W+U=D46Y%34U!=')M4U9:2$U91C%B4$E#<5)69C`U
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M)B-X03MY<'`W3'E.=4ML2D=1:%9"2$US>%941%0Y275B;GIT*UA44W@V:F57
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M85)H2D].2"]D<7HK;C9F2D]4:7`U3%%!<454*U8S:T@V.35,,'5B5C=Z55)D
M4GE33DU*;VUT)B-X03LS;FE--E1P2$ET,FMK=U98:E5Q.&)+>&]0:7!I;%<P
M-WEJ-7)M.#!E8V138E-)3$-B52]4:'1B=68P=E1V8F%/6E)*2$PV9'IE96XV
M)B-X03MS0V5N6#9T5V@U2&8T8U939GI:<'-':2M9+WDQ<W135S!&-TIQ8S='
M0S%%<40Q1VYT>&)S1V=H4EIF4F=J5T=S<7!Z<'DR0VUI<44P)B-X03MU6C(P
M3#@V65!R1W`S1G9A,BMO43(W86<W4W=+<7)F0FQT6%HU4U96-FAT+T%M:$I'
M0EAV1TMU>%9*9D]M;U<R;BM5=%=V3&QG;'9()B-X03MA>4-2>5EX>%9L-#$O
M9D52;6Y,;S-8<&ER>5!Y>C5,:#$W>4PU1V4Q=$HY54=J6&XQ-C%V-$ID4'1)
M1E`Q=7-I>E)7.&MV,E98;%)$)B-X03MY-4-J1W12:%9*3EHX,%%C4'I183)S
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M86%Q-T98<'8U4UA+6%`U8S9*4$A1<$I#-59G)B-X03MZ=GE(<78X04=8:V\W
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M,W!2:4Y9:4%O6FEE0S`R<51T9U9I=C5',CET0BM8.7-K1G4Y<5!8;4UK36YO
M0C%C='968F8Y)B-X03LR=G111&)C:F9%<7HO1E=/-C$U23`O5G9-=6UE64IR
M;5=/-3!Q;F]1<$9:=D<Y1TQF1S@Q=DQ.,R]9:U=N5F%.=FER0W)R>61E*UA0
M)B-X03MY,S@Y1S5T=$]T=G)7:5A#<TY.:5-0,7!98E-C4UA%;D=',S0K<GI&
M279J0U5.1U!,1EAQ*TMU>%8R2W5X5C1M-7521BMA83)C+W)V)B-X03MY2G0W
M84\T:FUL:6U-:VQ714YO579%<3-X1&Y1,49%1$%62E98.'`K4F9-970V;#58
M.#$V<$I+3&I3231594LO:S%'2V%/4TI(:G5/)B-X03M.=F1Q>E`V<&%O:UIX
M554K5TMV6F-#=D]&.&YE6FXO3VME84QT;F)223=6;V))>'1!-%4K:T8Y3U-S
M8U4P849N:V5I;'=7-#%044)6)B-X03LV4&ER<U9D:7)(=GI%4TXO269M0DI'
M-%)T65A!6BMA>%5(<&YF;7=:5G`O;$-N:G1I<6PK5VIU+VM84T=E9$QL>D4S
M2V5/5T-D5TEK)B-X03M912MP86MW12M)46M!-U9.2S1Q>6)&6%EQ-T9867$W
M1EA9<3@T+T]#9W5V2VI,8W)A>D15,31-.7AB5S9S<$$U;U1D1&EE42]K<2\X
M)B-X03MQ=#))5C909U8R2W9*=GE3+U-2.'EE96XQ5%5)8G4O;#%"6&UT;U!R
M=VIG2U18341#4#8R;VHY3G!96$,K:S=F6F]A54-H5C9Z:7)()B-X03M0>D<O
M-5%86%`K65-4.5=+<')R,3%A,FUH-FID6&,O,5<Q=#=A85<T=78S;C=Q3DEY
M>GEF=5=35#112R]!=V)W24]+=FXW45!,9FUV)B-X03M7+WEW.41Y=G!0,4]A
M.3%/4V$K;617='`R5TM+36]13'4U=4MH<$I:1TY864LY94MQ9#%+=F4Y6C!3
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M361U3U`K<D5G+WEC5E1N1EA9<3=&6%EQ-T974&5F4$QL-S5J)B-X03LX='IA
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M.4@R,S$O9V(W,&LK=&U+=G`K)B-X03MR>$AQ8TLW.&5685E&4D=+=7A6,DMP
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M8E189$1+,F%Y,C@P2TU#;C%K4W(O96QK<CA%)B-X03MC36EK2U(K.#4O<S`T
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M)B-X03M2:4XK45E&0U`X='AF;5I093(Q,6,V<&(S5FQ&8W=W,SA-5'AK9G5)
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M8V-O:4Y*0R]P.&U*2$=0;'I0:'-A2W`O8V57)B-X03LW94,S;&U/;S9K4D5J
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M.6A5:%9#,TAN,WE61%!.8D<O,7<S1G-K8S`X8E142T)&2D@V;DY73&-8-&I9
M:%-46&)X>%900F4V13AC<G<S,G-30DQ/,W8T)B-X03MY3&UA:E)84U-V2'DS
M4'!B44Y5>3A13G9(1E4Q,&I2-TQ63DMT3E-H=CE54T<X:%-E3DAV2E%W5C%$
M04U!>#,S>%-X6%9D971R1G(W)B-X03LP-3=Y84]Y85I8-6%T3D4U3G5Z0U0T
M5$=13TMP>DHU54%O2SAI1GA1:618.'=E5SE+,75F4V)U.#%N,5E%9'I*2&13
M3T0V54,S36Q&)B-X03M$.'%#2GAV5&,Q03-P5E9#85`U,CAK-G1Q5G)9,C)P
M-C!$97=M83%K95<U2$PP>$E:5EI0=&]5.4EJ-&AV,G%..%5P>D%L:G%F;$<W
M)B-X03LQ,U1D4C%73E5I=7I$-G0Q24=$,GI34B]%=DIH.75/=$U66FQP-W9*
M65=Z=654=D5J37@W:W%#5&=66'A6,DMU>%8R2W5X5C)+=7A6)B-X03LR2W5X
M5C)+=7A6,DMP6G)/:E,V:$Q:>G=8:C)6>%I/-WAY26E06&UH:EE&6D%W-DYI
M<4)L.'1A<DTO3V)75VME;$]4,FQO>'`X>DAH)B-X03M68W9L-U=&0T)D8F-#
M3W9P,'1B56-A.650=V)9<3<O1'5R,7(K;6YR54=V,5,Q<E5(:U`Y,2M/*TMU
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M4&%T3F$K6&](:U=A4TXT:&1X>6-%57IE;7I%1DXU06M90S`O87)5-%9C+VY$
M)B-X03MZ-'-K2"]/=E<Y2DHU16QH*W52.#%H37%X,CAG2DDU97%#5'-T3W=X
M5D<O-'4Q,31,<5-'=W1:56IT-35)8FE/.&EE3#$T63EO;6]2)B-X03LY<5=Q
M.'$W54YA1VQ657)U+U`S;E=);FHU9&=I:FEL6#9X4&,S:7A2<&(X<$$P<6MR
M4C9"54%O86-M;U--8597:#@W964O<DYL2&1E)B-X03M6;V])2E%P,4,T3B]#
M1G1Q<$5X,F)I5S-K6E(W.&9E:7%8-G`K6EAN=7IU<&UJ.')7.'5M,G%/,3%C
M='%50VQ':FY61U5G8VHX36)!)B-X03LY3W!(5&%Q<7!9+VU*-3EU<F4S=50U
M5%-&3&@K2U)36&MA4T93:D]'2W9W6D123C%:86IL=E1I8U940E!.+VXP-F1(
M3R]L94IB<%I$)B-X03M(95<T=F]Z-EAW44]V>$96,U!R4V)%02]"+VQ$1E50
M8RME4%`X8E)R0C58=#=I8FA$.6%T>'%-0W1#,&I-5TI/.58Y34-N=VEP4#A!
M)B-X03M,=497,S@U9FU';G!T3#5A=#=E2#!G6C-A.6IF:DU::7!!-#A2=U-)
M0C)*238P.3A6471P*UEF-6E3,WI7:S-K,S!7:70R;'5'3C)N)B-X03M%4S=&
M23!C9TI*6&5V1FIX,DIO0TU64F,O;DPX>%DP=%!4.'%24W9)<5-8448W0W9P
M:'`U05DQ<6%&=E%61U9I44]453)X5F%03W8U)B-X03MI;&XY4'ER851+;'@V
M3'1&<6%.>%0Q46EY3E=.86-K4$E$<B]!05968FYZ;C4Y4FE)=DQ&<C92=DAT
M-'`U3E-J5EAH<31I:T%%6E!*)B-X03MU0S%4+TQ7:#8X5E9+,C@V9FU1*VMF
M5TIV2T5A,S5K8TQA:2]H-&Q"8DY+=GA$;"]U-$-/;W%#4&DY<U9212]N6'I4
M*VXW;E,W8E)O)B-X03MN:FIJ;65+6G`P1&-K9VQE3E=4;%AI-W!(*S@K>4]8
M2')I<4$O=T%D+VU0.5A2-&9+.79D,55L6FMV6556*TYD=4A+5&=8<#`U3GAQ
M)B-X03M+,6]C5E1:4$Y0;3-N8DQ,<$U#4$E*2DIO;&YJ96E,0GE6435D94HY
M67%H67!4-&@P-C1O4S=4=E!F;G4V=#-M=69,54YM<3)Z4R]$)B-X03ME4EA8
M-S)O0W!32F<S,F55;$M62S`V1W5+55<S;50X>#-T;TI)9DQC9C%G>71(8U<W
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M5F503T@U;W1&1$HO9V]+.&\K3T)R>5`T0T=51W)G2',U+UHO6E`X=WA61C-V
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M62]1+S946#E)5BMT8U`P;CA8)B-X03MQ96XO04QT-55P>C0O0E-L3RM+<%)R
M6"]!0V]4-C@S-E4O,W)P6CAU9C%J-U`Q1696+SA!2G`Y6#8K+UAF1EA4+W=$
M2VEF,%)A."]6)B-X03LK;V98-W8P3U`Q=78Q>CEZ.5DU9G16+W4O=&92,WA6
M1%A(+U%U9&(O04IE;C9L9CE.-&979E8O,VXS<E0Y-50P<3$K;C-X5D5A=CA!
M)B-X03LY0RLK=%`X07!0,'95.5!49E<Y5#$K4'`K:D(Y4W(K>E0P94@P5B]Y
M<U9525`K:&4O=T)$95EV43E4.4=C62\P,39F,3)N1#8T,4]0)B-X03M(-"M0
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M4W(Y4U!+;DPY=C9T5&Q8=C<X<U9E-S9:.58O4CEV.54U9E9E03E$;GHU8U`R
M)B-X03MF-WHT=6Y3=4)55&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<B\O
M,E$]/2(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<#I4:'5M8FYA:6QS/@H@
M("`\>&UP34TZ1&5R:79E9$9R;VT*("`@('-T4F5F.FEN<W1A;F-E240](GAM
M<"YI:60Z138P1D9",C(Y1$0V130Q,3DX,T,Y.$%$,4(S-S@Q1$0B"B`@("!S
M=%)E9CID;V-U;65N=$E$/2)X;7`N9&ED.D4V,$9&0C(R.41$-D4T,3$Y.#-#
M.3A!1#%",S<X,41$(@H@("`@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)U
M=6ED.C5$,C`X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X(@H@("`@<W12
M968Z<F5N9&ET:6]N0VQA<W,](F1E9F%U;'0B+SX*("`@/'AM<$U-.DAI<W1O
M<GD^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C
M=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z
M-4%$.3E"-#<W03@X13,Q,4$R.#=#.#4Q,30Q,C%%-#DB"B`@("`@('-T179T
M.G=H96X](C(P,30M,#$M,CA4,3DZ,C8Z,#(M,#<Z,#`B"B`@("`@('-T179T
M.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R($-3-B`H5VEN9&]W
M<RDB"B`@("`@('-T179T.F-H86YG960](B\B+SX*("`@("`\<F1F.FQI"B`@
M("`@('-T179T.F%C=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN<W1A;F-E
M240](GAM<"YI:60Z13<P1D9",C(Y1$0V130Q,3DX,T,Y.$%$,4(S-S@Q1$0B
M"B`@("`@('-T179T.G=H96X](C(P,34M,#,M,S!4,3$Z,3DZ-#@K,#4Z,S`B
M"B`@("`@('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R
M($-3-B`H5VEN9&]W<RDB"B`@("`@('-T179T.F-H86YG960](B\B+SX*("`@
M(#PO<F1F.E-E<3X*("`@/"]X;7!-33I(:7-T;W)Y/@H@("`\>&UP5%!G.DUA
M>%!A9V53:7IE"B`@("!S=$1I;3IW/2(V,3(N,#`P,#`P(@H@("`@<W1$:6TZ
M:#TB,3`P."XP,#`P,#`B"B`@("!S=$1I;3IU;FET/2)0;VEN=',B+SX*("`@
M/'AM<%109SI&;VYT<SX*("`@(#QR9&8Z0F%G/@H@("`@(#QR9&8Z;&D*("`@
M("`@<W1&;G0Z9F]N=$YA;64](D%R:6%L350B"B`@("`@('-T1FYT.F9O;G1&
M86UI;'D](D%R:6%L(@H@("`@("!S=$9N=#IF;VYT1F%C93TB4F5G=6QA<B(*
M("`@("`@<W1&;G0Z9F]N=%1Y<&4](D]P96X@5'EP92(*("`@("`@<W1&;G0Z
M=F5R<VEO;E-T<FEN9STB5F5R<VEO;B`U+C$P(@H@("`@("!S=$9N=#IC;VUP
M;W-I=&4](D9A;'-E(@H@("`@("!S=$9N=#IF;VYT1FEL94YA;64](F%R:6%L
M+G1T9B(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1&;G0Z9F]N=$YA;64](E9E
M<F1A;F$B"B`@("`@('-T1FYT.F9O;G1&86UI;'D](E9E<F1A;F$B"B`@("`@
M('-T1FYT.F9O;G1&86-E/2)296=U;&%R(@H@("`@("!S=$9N=#IF;VYT5'EP
M93TB3W!E;B!4>7!E(@H@("`@("!S=$9N=#IV97)S:6]N4W1R:6YG/2)697)S
M:6]N(#4N,#4B"B`@("`@('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B`@("`@
M('-T1FYT.F9O;G1&:6QE3F%M93TB=F5R9&%N82YT=&8B+SX*("`@(#PO<F1F
M.D)A9SX*("`@/"]X;7!44&<Z1F]N=',^"B`@(#QX;7!44&<Z4&QA=&5.86UE
M<SX*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*
M("`@(#PO<F1F.E-E<3X*("`@/"]X;7!44&<Z4&QA=&5.86UE<SX*("`@/'AM
M<%109SI3=V%T8VA'<F]U<',^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI
M/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N"B`@("`@("!X;7!'.F=R;W5P3F%M
M93TB1&5F875L="!3=V%T8V@@1W)O=7`B"B`@("`@("!X;7!'.F=R;W5P5'EP
M93TB,"(^"B`@("`@(#QX;7!'.D-O;&]R86YT<SX*("`@("`@(#QR9&8Z4V5Q
M/@H@("`@("`@(#QR9&8Z;&D*("`@("`@("`@>&UP1SIS=V%T8VA.86UE/2)7
M:&ET92(*("`@("`@("`@>&UP1SIM;V1E/2)#35E+(@H@("`@("`@("!X;7!'
M.G1Y<&4](E!23T-%4U,B"B`@("`@("`@('AM<$<Z8WEA;CTB,"XP,#`P,#`B
M"B`@("`@("`@('AM<$<Z;6%G96YT83TB,"XP,#`P,#`B"B`@("`@("`@('AM
M<$<Z>65L;&]W/2(P+C`P,#`P,"(*("`@("`@("`@>&UP1SIB;&%C:STB,"XP
M,#`P,#`B+SX*("`@("`@("`\<F1F.FQI"B`@("`@("`@('AM<$<Z<W=A=&-H
M3F%M93TB0FQA8VLB"B`@("`@("`@('AM<$<Z;6]D93TB0TU92R(*("`@("`@
M("`@>&UP1SIT>7!E/2)04D]#15-3(@H@("`@("`@("!X;7!'.F-Y86X](C`N
M,#`P,#`P(@H@("`@("`@("!X;7!'.FUA9V5N=&$](C`N,#`P,#`P(@H@("`@
M("`@("!X;7!'.GEE;&QO=STB,"XP,#`P,#`B"B`@("`@("`@('AM<$<Z8FQA
M8VL](C$P,"XP,#`P,#`B+SX*("`@("`@(#PO<F1F.E-E<3X*("`@("`@/"]X
M;7!'.D-O;&]R86YT<SX*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@
M/"]R9&8Z;&D^"B`@("`@/')D9CIL:3X*("`@("`@/')D9CI$97-C<FEP=&EO
M;@H@("`@("`@>&UP1SIG<F]U<$YA;64](D=R87ES(@H@("`@("`@>&UP1SIG
M<F]U<%1Y<&4](C$B/@H@("`@("`\>&UP1SI#;VQO<F%N=',^"B`@("`@("`\
M<F1F.E-E<3X*("`@("`@("`\<F1F.FQI"B`@("`@("`@('AM<$<Z<W=A=&-H
M3F%M93TB0STP($T],"!9/3`@2STQ,#`B"B`@("`@("`@('AM<$<Z;6]D93TB
M0TU92R(*("`@("`@("`@>&UP1SIT>7!E/2)04D]#15-3(@H@("`@("`@("!X
M;7!'.F-Y86X](C`N,#`P,#`P(@H@("`@("`@("!X;7!'.FUA9V5N=&$](C`N
M,#`P,#`P(@H@("`@("`@("!X;7!'.GEE;&QO=STB,"XP,#`P,#`B"B`@("`@
M("`@('AM<$<Z8FQA8VL](C$P,"XP,#`P,#`B+SX*("`@("`@(#PO<F1F.E-E
M<3X*("`@("`@/"]X;7!'.D-O;&]R86YT<SX*("`@("`@/"]R9&8Z1&5S8W)I
M<'1I;VX^"B`@("`@/"]R9&8Z;&D^"B`@("`\+W)D9CI397$^"B`@(#PO>&UP
M5%!G.E-W871C:$=R;W5P<SX*("`@/$5X=&5N<VES1F]N=%-E;G-E.G-L=6<^
M"B`@("`\<F1F.D)A9SX*("`@("`\<F1F.FQI"B`@("`@($5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1+:6YD/2)/<&5N5'EP92`M(%14(@H@("`@("!%>'1E;G-I
M<T9O;G1396YS93I&86UI;'D](D%R:6%L(@H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I/=71L:6YE1FEL95-I>F4](C`B"B`@("`@($5X=&5N<VES1F]N=%-E
M;G-E.D9O=6YD<GD](DUO;F]T>7!E(%1Y<&]G<F%P:'DB"B`@("`@($5X=&5N
M<VES1F]N=%-E;G-E.E9E<G-I;VX](C4N,3`B"B`@("`@($5X=&5N<VES1F]N
M=%-E;G-E.DME<FYI;F=#:&5C:W-U;3TB,"(*("`@("`@17AT96YS:7-&;VYT
M4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3TB,C4Y,#DT-3@U,"(*("`@
M("`@17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T](C(U.3`Y-#4X-3`B"B`@
M("`@($5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)!<FEA;$U4
M(B\^"B`@("`@/')D9CIL:0H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT
M2VEN9#TB3W!E;E1Y<&4@+2!45"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z
M1F%M:6QY/2)697)D86YA(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I/=71L
M:6YE1FEL95-I>F4](C`B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D9O=6YD
M<GD](DUI8W)O<V]F="(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO
M;CTB-2XP,R(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K
M<W5M/2(P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR
M7T-H96-K<W5M/2(R,S<P-S4U.3DR(@H@("`@("!%>'1E;G-I<T9O;G1396YS
M93I#:&5C:W-U;3TB,C,W,#<U-3DY,B(*("`@("`@17AT96YS:7-&;VYT4V5N
M<V4Z4&]S=%-C<FEP=$YA;64](E9E<F1A;F$B+SX*("`@(#PO<F1F.D)A9SX*
M("`@/"]%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^_]L`0P`!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``$0@`^@%E`P$1
M``(1`0,1`?_$`!\``0`!!`,!`0$````````````'!08("0,$"@$""__$`%,0
M``("`@(!`00"#0@%"P,#!00%`P8"!P$(``D1$A05$Q87&#<X6'=X>9BVN+G6
M"B$B(S4V.9<9<7:WTR0F,3(S676(M+78-$%44Y/2)41A<G3_Q``8`0$!`0$!
M`````````````````0(#!/_$`#<1``(`!`('!@8"`P$!`0$````!`A$A,4%1
M87&!D;'!\!(R0H*AT0,B4G*RPN'Q$S/2HD-BXO_:``P#`0`"$0,1`#\`]_'@
M#P!X`\`>`/`'@#P!X`\`>`/`'@#P!X`\`>`/`'@#P!X`\`>`/`'@#P!X`\`>
M`/`'@#P!X`\`U0>K%KRC[;KW176.S*LFN^OKSZBVA4%PI]B#P8(;(D(HNY)9
MU;=?+[830I98(9,X)>,L.9(H\_9[V&//`U`VFVJ-0LOC_0Z^EK^`;UH_RT2?
M\+P7_)']3'^AU]+7\`WK1_EHD_X7@?Y(_J8_T.OI:_@&]:/\M$G_``O`_P`D
M?U,?Z'7TM?P#>M'^6B3_`(7@?Y(_J8_T.OI:_@&]:/\`+1)_PO`_R1_4Q_H=
M?2U_`-ZT?Y:)/^%X'^2/ZF/]#KZ6OX!O6C_+1)_PO`_R1_4Q_H=?2U_`-ZT?
MY:)/^%X'^2/ZF/\`0Z^EK^`;UH_RT2?\+P/\D?U,\<7\J+ZJ]<NH^T.HBKK)
MIFA:+6W6A;586T+6J,>L#V(Y-8:>,J*;1K_H^#)E\!YL0F<OMYAP*GQP]G$F
M7M';X3<7:[592E/"<S^B)X/,/`'@#P!X`\`>`/`'@#P!X`\`>`/`'@#P!X`\
M`>`/`'@#P!X`\`>`/`'@#P!X`\`>`/`'@#P#6EZCW]L^G7^<MZ__`*A;I\&H
M?%]K-EO@R/`'@#P!X`\`>`/`'@'@Z_EBGW7^COXMMT?K10_!Z/@>/R\SWB^#
MSEKV6[TREX#2W"VUFJ1FPN"`Y+(]5H\"QZ\G,L+Z<;)F4-Q/"D0+F#MO+%SE
M@M4`EL3,H0QIIL`.E5]DZZNYAB^F7VF6T]<O3MSP:S9TCTL%58086:!D6,K-
M*F&`=K2!V"DR;#`=B%/`4))-!+')D$B]?`'@#P!X`\`>`/`'@#P!X`\`>`/`
M'@#P!X`\`>`/`'@#P!X`\`>`/`'@#P!X`\`>`/`-:7J/?VSZ=?YRWK_^H6Z?
M!J'Q?:S9;X,CP!X`\`>`/`'@#P!X!X.OY8I]U_H[^+;='ZT4/P>CX'C\O,]X
MO@\Y$&X-+5;=*Q"!8RVRLBLLW#A&W1<JHV@+!O3;/3<I,96JML/)`)#9N7<0
M4@V01;I*DR:CL%@Y2PP)];9\C4%ZG/4JNZ=Z.=D-XTC;O8.N['U-4;5M"@/:
M9MVR:LE37^RD4Z.[O&/.HY*');@+DRKBE\?4KG)8:>E:PY_51"@`RP`B&X7.
M*%-*3:3FITGIM*=&JF4M5]0.X,VNOV-GT57$>M-CM=EKTEC1;E96:\"0Z]U3
MMS;41+2B'Z=JB*&5TGU&S69C";'-Q6,FP/.)+(6$B;BN%I)N5>LC%)N&;G#>
M:I=+-O'([H/J.+\5;1M9NO6TZL-#H:[[\K^,]CU6WDLR.C--9JC:Z/PGNQ7"
MM\?/M6N2`YMN157$,#+DD^"2"+"=)TTV"DYR=G)WQGHT';;^H]5*.CV8[VII
M39U$^QLOTTQE7Y6/3;.:Q0[MV0VU;6<5K8C9B:J*N5UD4YRNYK58D`@ZN;`D
M8DN?'D3DX6KXZ4%\U4\\\%.TIZB>.K?;C7G;-3>FM!26=#]CRS`U5\'966M7
M669S*OK;().N;:JV)LNLE"Y+VD&$L>;V!D,5'+&2OACY@EGG5Y\"M2_IKT:3
M,I_!!X`\`>`/`'@&./;#:-UT]I1E===_5;&XR[`T?1D\]T2MK'60?LK[QUSJ
MM@T9(D=FIK1K\I57,YF$$+:$WTS`03&<O@;Z:.0JM+,9Z$WN398/5G<>W]A6
MW<=)VZ?K9T?KR+73!*[UO1;/K\,H*[A6>4D)HEL^S=I33%`$5SC.`\1T%%-"
M9S#(NQS@^GFK4G()S2:I.=)SMIDN!F9Y`/`'@#P!X`\`>`/`'@&$O:OM;=-"
M7C3^M-<:C0;=O&WT&S[$J4V#9S;6(@0&KF^J%STJ=ROU7LQ<$I7KMH9VFR6.
MU2U*N5VO55EC\T:6)M7:\S%2G.;E+^=.@QCE]3RS.,*=S0-+ZLLD3?4*W=5R
ML3WL>]JNO:7KR38NYZ#8-@<7T?KS9$YVM:[CIR1OC9GN%/?666\5!'5J8W93
ML_EPO9TO=6J5)3O7T-F>HK_%MC4^L-IP*Y$D.RM>4J_PI92\3Y5$5RK:RQ1J
MY#L!Q,#9`,&/`F9>(HV)&47,V(\/&?$>(RZ-K(D/P!X`\`>`/`'@#P#6EZCW
M]L^G7^<MZ_\`ZA;I\&H?%]K-EO@R/`'@#P!X`\`>`/`'@'@Z_EBGW7^COXMM
MT?K10_!Z/@>/R\SWB^#SCP#6CZQW^%_W5_$JX_\`<E7@U!WX?NAXHQ$^P5K.
MJZ+ZA;51J7@]WLEA[!_-V!5ZOK57/\XZ3=VC&'P]5;6<ZIK?I2!XLH?EB,/X
M/#'*$+X>&22/-/#`.\=%KDI]Y8RF1Q??[D5O\W3O_P#7'I7YT?\`\]G(YP>/
M[E^Q.K#[O3S_`,5].3]LR[^/B8;>1?A]W;'^*-C^I/O@^VG^T6G?]TB3SF:=
MEJYLR<\$'@#P!X`\`>`8:=]_O=./Q_\`3C]L/1'E5UK7$8/[8OQ9"O7C8-"U
MKMCL[8]C7>H4"O9+>O2[%[=K*FJJ;)@4NVG(,!BT>F@`\F$1CD20"\3_`$\N
M$$V4>&6,6?.-C[SV<$2#N0ZXN1L)I=]HNR$N-DUW=*G?:[D40#B_I=C3VE+D
M:+[GQ0>+5&8<#R4-])'\0/Q/]+#])A])AC[V/MR64KEV>`/`'@#P!X`\`>`/
M`-2'J)X\2;RZYXG8825J+1/;`ZV<6@S`/2XJ8#8?3>?!MOH03."TWK72AGPO
M,"TO2BQ76\+YC3=8-YH*-8K>:&-0V>M:[.WOA>\C7]3BV><Z9LU9WK*,+0.K
M',UBNE248A+K_)V[[XCT^R,='+E(YVS.U<[XR430&EX4_.NJOL9F[V1::V6R
MU;1E4@T_>5?_`,PXTIF[M6Q,R];]XKSI_K)4HJYH^L7:H=>.JFC'=S>.=R,Z
M786F,76:A[39#UJKAZ>NBXO(=`W&#"D9VY1P<WPGAGP7!XX'2:4+:;R,N7:D
MW)Q-RI/&6>9NE\R9'@#P!X`\`>`/`-:7J/?VSZ=?YRWK_P#J%NGP:A\7VLV6
M^#(\`>`/`'@#P!X`\`>`>#K^6*?=?Z._BVW1^M%#\'H^!X_+S/>+X/.1SM^W
M.:#JO8EUKBK!Y8*M3;"\1*)8IIAV#A>L)(6#&8P3B28KY#<(?F$_)@,(P7!!
M!#``>*4R`%IL:"/4Q[A[/MGIY]I*Q:]&W%N+<M/2)&#'6M5S(#U.7(JU^XAO
M6T6CVX\K?L9;!,<V3BD.J5G:,`X*<3%$PN4#+YPN'2%+M0UJHE?&MEIM1YUD
M996+[TCI+_M#O#]AWO#X,N\>W\D8M7W^Y%;_`#=._P#]<>E?G1__`#V<CG!X
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M2W1OS)J9%*J$F-><1`J1H!LN<XH6VTL"Q.&&4YUR4\$\6LS9CIZ^Y;5U)JW:
M&:O%'GLC7-(ON:7$SECBGRN%966')7BPY&"Y.Q7\L>1.#.0Q.2N(?I^1H.<_
MHL,AT;61(W@#P!X!AIWW^]TX_'_TX_;#T1Y5=:UQ&#^V+\6:UK/#"1OU/%/%
M'/%EV`TK[T4V&,D>7N]0>^>6/O89\98\^S+CC+CV\?S<\<<\?S\<>;_^G7TF
M5_JW_E"7+3;WL^M7ZZ:[UA?RM8`7'?6X+"_:(ZQ2WS(G.C]?>EHRA</%=*_8
MU004F=T:$FY#+<#9YH0^,"XHL)XYS4XVNK(K<H(7*;DE6>/:<Z2>&9.FK^Z^
MWX:Q5ZB70A-V;!Q,WS/8+@VMZ/58TU?UUV=VUI2I9YK$=&=KB7AB>@BD.>5R
MU(NX)XR(''X^+R@'SV9MI8/$K:23=$TK*=>RF\=.DV'Z6V2-N;3FIMP!*24(
M>UM:439(B,PF(PM,->:NJL\"DHP?".`HA=$TQ#G)ACCBGDARECPPPRXQXR'1
MM9$F>`/`'@#P!X`\`U)>H-[D797J(9'(.(V%U?VD^K#02#*RW]?:2;SU$&4?
M8/UB7A+5MA;U/^E)7ZY)O<?-'U202SW=9OB5>MR%C$:AL]:W5N\K:79&O"AK
MR![)4PAE;`2U9]7Z_74J]/LYO:=X3R&]F.^XUCINN;JS)D55[-JBA8"[D[H/
MCOK5K#5@EK&IAHUOW"*^3C3],Y4M#TH<7>Q6\/O.>SOY&FI?W=>H?.D/<BV\
M#G'W_A_=^YZ8?.8'@#P!X`\`>`/`-:7J/?VSZ=?YRWK_`/J%NGP:A\7VLV6^
M#(\`>`/`'@#P!X`\`>`>#K^6*?=?Z._BVW1^M%#\'H^!X_+S/:;:>T77*D68
MNGV[=VL:Y8UL\8KE:VN*4/*NESX1R#"6@F4O@*KEEX30YA"V`E;.;C-#R+'-
M]+'[PX2=Y,G6*6.:..:&3"6&7#"6*6+/&2.2.3'C+"2//'GG'/#/'GC+#/'G
MG'+'GCGCGGCGP0UJ>L=_A?\`=7\2KC_W)5X-0=^'[H>*(BL7WI'27_:'>'[#
MO>'P'>/;^2,7;R%.SIE76BE_+R6'IV;]"'/^'P+^"G+N?2J"(OX63..,GX:2
M3&;X?.3#";W/H\L\>,N<N-Q44#T>QCX=XOOA_8R&L>J[7JO?S==:]C\;'):L
MO3F-%.XIZZG_`"Z"+N;=X,A/A5S)G@9]))QS-\1))%EA[?H^,.>./>\RVW<V
MDDJ*2^?&?A1?&WM=U/:?;933KL$P85\WMQ0BB!E=BLE6,RF`].WL04+E@YJ;
M=(Z@QPFCQRDB@81Q$8\<Q$82Q998<P8>7]R%$=-K^ONQ"&G548P.OHF_?\98
M,>Y=6`R*&6Y]"2\\9W-B8-71V7,Y$N7$A[`J7##G&+#/&&../#<%WJYHYQ]W
MS0\(BUM$_P!MV7\FZE_M9>H1YJ&\6OFQ\6T.W\8#;WU"^]-ZO_D[Z4_W:UGS
MD;=WK?$R(\$'@#P###OY`[*ZWYC5M5&\?S[\Z=1)DTS&!1$S8Y]PM$8B`R-"
M8YAP,"9N<8LBYHI(X.,OI,\,N,>>/$Y-/2N(O-9PQ?BS6HV77Y9OQ,-L:GBT
MA_SV#TO+&F$LX%LBS79=/N^7`YO+1<*(/AG/+B3'R)S%S)%Q!QGEGSQ+CQQM
M.<<^K$:E\)K7^4!W*K]\`9^-CLE_N']/WS2[[U>Q(O\`7#Y?W/QHC^^P_P#X
M1VE_>&]H?$-XM?-B/N0;/PA-IG1K[RCI]^2YH#_=14_.1MW>M\3*7P0>`/`'
M@#P!X!J5]0+XB7L=U=`"^.(+::'[B@3*4>/-==/D?-LZADV)2PW5S[T?736>
M:H:8W<NX889[`#K4%_4:##)LBW4Z/,:5GK7/#'0M])FMJ@YH9EP(D4VMBZE+
MTYI;!T"JIQ=.T,10%7:SO"9(\V+;>6&;*L]5J_-\H9R=<$I_-J["V#G66MB6
MF-!4['Y)=;C3G>M]L^RO_6G"KO(N[#[SGL[^1IJ7]W7J'SI#W(MO`YQ]_P"'
M]W[GIA\Y@>`/`'@#P!X`\`UI>H]_;/IU_G+>O_ZA;I\&H?%]K-EO@R/`'@#P
M!X`\`>`/`'@'@Z_EBGW7^COXMMT?K10_!Z/@>/R\STY$;=V]MK?1^O\`4]FX
MKM!T9N,R#:96MZ2A9G-0K)L@H7-=?:&;>IGBR*":E;$K#*U#2M&ESYNLFW^=
M,)*LNJEJ.'&4E7%35='K>?I.<T;1X80%`$0X\0:Q6L#CA@@ACA"`7@!0\811
M118<1CB!B#QXX1QX8QPP0Q\8X\888<<<#)K-]8%NJ9^F#W7Q6LU[#+#1A9N>
M(1HQ>6(;,U;.M+RX@DDYQ&80QR3!3\^R(N+#.2#.3#'GG@:@[\/W0\41E8OO
M2.DO^T.\/V'>\/@.\>W\D8O,P-GB)Z1G?-6LJ`NF]/[=WR-D=:Z788WOLOW2
M?F3Z$:KNVI8'T<',$_/S*$;WN",8\/;)'+CAJ)IR2G1>VDD,,FW.<XX<&OJ]
MS/7LI]\I'_K].W]M>\>9*K+S_BCX\^_=K_Y6%._=R]BO`P\O[D"M_OKX/_'N
M_?ZU=`_-P7V<T<X^YYH>$1$VD*ENVSO+%GJ"JZLLD`'6ZF?63/9&TK;KB4'X
MCMEZ@_*WY)%6-,[8P=_3X0,>3OCIJ]\#E`%B/\QX-GR7E%V8HE*=>;-1PJ)0
MS<I:)^&'2B%I*^"WZT[SNYQ+WFU:WZU:<RH3@6T65?-4<D_IZ]?K>LY0Q+VP
MHJ_D.T,V+^+F`?'GEJ:29G[TTV>7*%+LMRJI\!$VOB0K!NMJ_.UP,W&>Y.QF
M%Y.MT'8F^CH!.\U6TS'JZ.EZ#SHN6N3^X%7TD:@D83Z:FV9SF3261G&3?'8F
M#J)O+P>.PAQCC'QG979G6?\`,A/YE#)2<,YUG/LMYROH-D-7[3=8[Q<Q-<4O
ML9HBW[#/.;K`:'5]O:^?W,UE7PV3%\O$JZFPEO"3DB].W.;B0@YSK0U3(HR.
M&`$G.+)9/)[B=_!#&+MS]RJJ?E.])?VS=">1VVKBBJ^Q\&8*]F?OMZ_^./0_
M[)'J!^;@[RV\&2+_`%Q=>*`ABJ_?`&?C8[)?[A_3]\VN^]7L9B_UP^7]S\:(
M_OL/_P"$=I?WAO:'Q#>+7S8C[D&S\(3:9T:^\HZ??DN:`_W45/SD;=WK?$RE
M\$'@#P!X`\`>`:DO40]W'>O6Z8Z.#)`%I'M.>_)M)'OZB4CB[+Z9?+'FW:FM
MSBN&WDJU_(IYI.AZ5)RVW-MB:@T=GP'66+QTH&H;/6M=G9V6MV1K[IJK;-A;
MU3.BU38=^LL&B];-61EL<:GKC37Q@W:GU`##MVVG6%ARK])L^[:3#&PCI&+;
M.+4.J;O8F%\-JMGL5;UY46HK:5&Y3HI3K\L..6>,K%0P^\Y[._D::E_=UZA\
MZ0]R+;P,1]_X?W?N7+=3VWVS%AOO-^M$[=5ZC&D=1"DG[%V/3*'5$]A[6ZCP
M(UNG1Q6WA;N[>%YID###BG+E@]"U'UV!<O[*M@=6\;"]\SI*DI>&=INSW+GH
M5-OM5[R:&N-ZK]`32;*X96J\6'75=>,M/[,4TIO;:QS9L6:X2YL:P/7N8N<Z
M@_C"/D/C`/S#QQ%(E^('^DLG*>!SW;U/=.>)E_Y`/`'@#P!X!K2]1[^V?3K_
M`#EO7_\`4+=/@U#XOM9LM\&1X`\`>`/`'@#P!X`\`\'7\L4^Z_T=_%MNC]:*
M'X/1\#Q^7F>K[;=@T55-R`Z^>;_[*U-[?+/6('&M:(_V*QJ1++9#O-6K-*MP
M]8?O]8(I7IB56[^QYL2AI:5/;Z22Y&KL%S1'LQP4\EZ8:,=J>BQEMLW5X&Q=
M16S4F#1@C766H$U&%GB2S8%ABR!8AP9&S\M0G+4?/"/"%MAR]!9M@I"X.7(A
M17Q\8DZSVFBGU1^CIE`]/GM3=1M^;`5X5/5S9U.DH*A%5H-B0E!Z^2L:9MUO
M9N-AO[QKY=S35,M(70,T%SK8V1P[N_W$P\MG,.D,7S0T56E-UE\UUIKJT&3E
MB^](Z2_[0[P_8=[P^#+O'M_)'/V4_N%HS\W[O;];^B_@0_M#S)-[*??*1_Z_
M3M_;7O'@*R\_XH^//OW:_P#E84[]W+V*\##R_N0*W^^O@_\`'N_?ZU=`_-P7
MV<T<X^YYH>$1(W0;^TML?DVZR_:N]2#S#[\76,1T=EUX836X;LBCUOK%V2J3
MRR`+;(]ZTZA^4*2/I_B3OF7IO]=%H/T/N0YQ?\I.AE&C]^3#^LPY][V8^S+G
M<+2A=<^!F*&)_$A:4TG5ZHVS(!QMG5<-W:ZPEV7K^+94OJ;TCZ/7DERKF%YD
M]_U"J4ZP]RI9,N'^?OIN.6V/NK^?>6<<G\>T7CZ7RS78E.N6T-/MIR<NQ>5.
MX\20.NO]X?3P_'?LG]E?MYY'W%K]R?\`T^)J_:$WG^8*8Q=N?N553\IWI+^V
M;H3R.VU<457V/@S!7LS]]O7_`,<>A_V2/4#\W!WEMX,D7^N+KQ0$,57[X`S\
M;'9+_</Z?OFUWWJ]C,7^N'R_N?C1']]A_P#PCM+^\-[0^(;Q:^;$?<@V?A";
M3.C7WE'3[\ES0'^ZBI^<C;N];XF4O@@\`>`/`'@#P#4AZ@N7$79KI_.-G%!8
M,=6]K!JB4H%QL.V,+,PM_4L$4/KY2&.'-2=[N;KYV:FN6Z]2"TW3-=,MNY;,
M5\AHS,4L:5GLGZW=Y:KV(=Z80?#06(.8>$$03JYJ;DQ>186NPJTOX#[6>H-"
M-D]V$PXC?[+$6EYQ0)19?<=[4>2+6)^,<.+,D32ZSV9:\%/09^)+Y<=E+05>
MC1BY(QOP^\Y[._D::E_=UZA\U#W(MO`1]_X?W?N75>YBQ]\,)227@A!_J1ZJ
M3UXEVO`M;AI6Q.[>A&UNK.GZT"-*-J[4(3F>O6'?>_K;%"\N-^+UKHY"Y*C#
MK*Y)S.G_`#N^6[TWDLJYE]:9M<)5UZN5[BK[/%E&[F;4XY?M-/[63T(CZ%AV
M/RYY7[*:TT/7K/&;WO=#R76<K$_/C.,+DB3#/''<UV)8_P`G-0M.)X.%8K.'
M"<_0W^^8`\`>`/`'@&M+U'O[9].O\Y;U_P#U"W3X-0^+[6;+?!D>`/`'@#P!
MX`\`>`/`/!U_+%/NO]'?Q;;H_6BA^#T?`\?EYGHGW*I0S^H.L5V';.N!WI+3
MK<U`4;-L?537E^FK>.U<K37]>ZDQL'7R\;?V:AXN=)%99)Q;W3GF=KE7A5YZ
MNL'"JV+W76OD<5W;9VGE=UECD;GO!DUH^L=_A?\`=7\2KC_W)5X-0=^'[H>*
M(BL7WI'27_:'>'[#O>'P'>/;^2.?LI_<+1GYOW>WZW]%_`A_:'F2;V4^^4C_
M`-?IV_MKWCP%9>?\4?'GW[M?_*PIW[N7L5X&'E_<B&'4TVWNW'"*'95_UCDM
M;]^VW+C7@^N2&A_&-NZ`!_+3<=E:]V,IQ7Y<E<%99`J@F/Q`T'&+#$;D@8BI
MM6)).%S4ZK/*+)HO'H>IY0N]P(LF3!SDEZZ:W4Y.&V*[!HUY7=LO4B#Y9,L4
MZ]2IQ8'<P_%&8JU2Q=P1+)P"O"&XB&CSXGJ7%EBLNO#"1)J7_#@[S?DTU3]U
M;UD\I7WEK_9F1)GWNK_\YO3_`-Z;1_!,?+^ACCUYU9M9`Z].V^/]@Z]<4%UO
M#8_R2H)]8V-%;U?S'JKV])6_-+P;M>P)7'P(T,T!WPE!2?,)Y8B(/EL<.8TU
MG1+!!I=J-J<VLU+O0X2YF\7R&3&+MS]RJJ?E.])?VS=">1VVKBBJ^Q\&8*]F
M?OMZ_P#CCT/^R1Z@?FX.\MO!DB_UQ=>*`ABJ_?`&?C8[)?[A_3]\VN^]7L9B
M_P!</E_<_&B/[[#_`/A':7]X;VA\0WBU\V(^Y!L_"$VF=&OO*.GWY+F@/]U%
M3\Y&W=ZWQ,I?!!X`\`>`/`'@&I?U!,Y>>PO6H./@PF%CU^[D#N5`DGU47N:S
M!;NH+&QB;"W9EQG'H/2@:T&1SN780\4K]C1UA]`IL#"Y7)"F:C4-GK6^LFEB
M\B$.DF4&<19*V17*-EU@U'BF/I=>DJR/.<KLYZAV(&.N-8MRBB$;)@#R3C40
MGTY(>MZU\V(='<\+I."ZL>O7+/%T2)\3PWG/77LP[&[ULJO(A55HLG8'2CM3
M?XMQ;4I,53Z:ZKXSI-1%U%+4;-\H]./3[K+FP37/5%PN<?+3&?Y2Q^KEPKW&
M*R&+)9PM:\S,Y4VE+!FFEVH9J;3HYNGS/3+T.Q:ALN=ZWZ-:/EE-)ZE779U:
MPZ78S<#YE`?=S5*FJ6C?MJ8Y88(**M<&/:_HGK34\I8;SL)CL'>#M>;$O<-Z
MI"Y?;^MES>S0\^*J3&%I/I\9-QES$)V_O9,O&''&6?,<#3LO+GQAQSSCQSE[
MN'/N\<Y<<<\^SCGGC_I\&<_MA_4R)U-VTAVDUU*$7H7=VLU.[Z67>M<VJ_%:
M**2.%(M>4VK$8D76^[]AV=2Q*1.1C1XFE=%%QYC(&*,&+QC@E$:EBGA2?-(R
MX\$'@#P!X!K2]1[^V?3K_.6]?_U"W3X-0^+[6;+?!D>`/`'@#P!X`\`>`/`/
M!U_+%/NO]'?Q;;H_6BA^#T?`\?EYGHGW[>;B?WJUL77=F/4%*#;:OUG<$^>U
MH*_!1G4_8JGS!08Z\3[>6H+))M\:J?5:.6R5<6URU39'P\X]Z$B7ZV#'%2D_
M2FBM98:\,+FW2\6T&AU"QW)B`Y:!UM08VF65Y82Y>LOA8N<XUZE8+CE*6>;+
M]&,-AES$/A)+C*60,)A,1$,GGU]3/U`ZAL/TXNQ%<?46QUTG;N@T_%3RJ:V_
M;2R36:Q4[5E^-5;/^K6M10]35O.*]\!TB_7H]37;P-6WK#+*N38@K#!TAA^:
M&MHIY6>&;I95JC*FQ?>D=)?]H=X?L.]X?!EWCV_DCG[*?W"T9^;]WM^M_1?P
M(?VAYDF]E/OE(_\`7Z=O[:]X\!67G_%'QY]^[7_RL*=^[E[%>!AY?W&E?OUV
M7_G]_7KT]?!,'K7!E)Z7_P!^=]_B+I/[7_J4>3%ZEQ979=>&$@W4O^'!WF_)
MIJG[JWK)Y2OO+7^S,B3/O=7_`.<WI_[TVC^"8^7]#YJW[F7I@?CPM7[(W<CP
M'>/;^2-G'@R8Q=N?N553\IWI+^V;H3R.VU<457V/@S!+LZGN[[MJ@5:Y555U
M<"MQZ&Y4K;K:6]+K1&,'4GU`B&'+&R(J9L%HOYA6Q&3A\#5)IP8=&,#-D`.3
M*Q$TG)S$IP-3E?">,&E$,U)1<T6_2U6PEE837`3;'9+APMIEF:W&M#93:(]/
MX@'A99'=/H+1EQ*ME#G*Y*J2CD4Z0D*'$V`:)B7N%SB;T>QF-2^'"LNSH^O6
M2%U)TMIS<=]+&V[J;6>U!D*/LW.C'V/1*M>($TY_J(=IXSIE45G5-(UTIL8H
MV!<@>,.9.`\&,W.?$,?&.'=ZWQ-3E##*E%^,)L.Z0P0"]+^H@PT,0XP_6'0<
M`X\$>$,$$$.JJI'%##%'QC'%%%'CCA''ACCAAACQCCQQCQQQY`[O6^)E!X(/
M`'@#P!X`\`U'^HECACOKK(:;@-@H5:<[.LV#*R2RL=<H"A]H]+XZV^NNME4F
M-KWNU!M,Z6+4FAZS"83LG=16O5YHXH8N;Q,-*SUK7C;!:6\)D1=.?BLS;-@S
M^?2N9NK&O,6D=XD1J]C%0X]J/4&G?87MS5X^*K5`\98HRMIMJSQBNS.@A25B
M&7%FO&FTL?[6[%Y+69^)AA5V^V%TRAI5WD<VIO\`#F[L?D;43]V1I?S)M]Y:
M_P!F0C=J/N`_<%FMF5<TNVU.E]571ABADVN=I3/JFU/[;Z836.PC:V`UE\AV
M'V#L&`XM61W=WM4D37FA5Y*U/7*ZPL+_`"O"5.L_>G`34Y5GV,J=UR4YVQE+
M.>!G*J^X!U0_*PV/_P"L[-^"9_;#^I#FX[`ZJ?23K-::TV<H;%6O3DW[8$#V
MNE,`;`E=)NF"UBJ;(C5.6#41RN.&@,6%+,\&`YL,$H>6).$?/`>+S<R/4.];
MQJ"\V(O5;+L7@4PU]0DT"CN&L[GMZA%8-A=K.O6G!+8IJ_8^P4]J\FK*'9-A
M)*AH-A3_`$LTBX*P,AHBP/>T^RVE#C>_,RNU*)QRI52[."B;[NI7V&R/K#N;
M<-[V)MW7.W6&M7A-#I^HKDC>ZXHEHU]!-!LAOM],<J:I[-L_:<A,RV36(Q8C
M(1NOPEP;SC3+O>$C)F1+LN5PFG"FE*<Z3G:6A&:7F0/`-:7J/?VSZ=?YRWK_
M`/J%NGP:A\7VLV6^#(\`>`/`'@#P!X`\`>`>#K^6*?=?Z._BVW1^M%#\'H^!
MX_+S/19=J4;N7O9A;=#66I\9Z\MVKL[XJXJF6MIW,.O=KXKMUV42Z/M`EX[Q
M*H^-<*U8]XH>W6PZFP7:&H6'+7+BH?%6L<<*SQQSM2=*UK?3AN9\&361ZQ`8
M8_IA]V9AQ1H)9=(L89988(HI)816"W$6*3/#''+.,;&23$?#+GG&''//B/C'
MC++VC4'?A^Z'BB*[%]Z1TE_VAWA^P[WA\!WCV_DCG[*?W"T9^;]WM^M_1?P(
M?VAYDF]E/OE(_P#7Z=O[:]X\!67G_%'QY]^[7_RL*=^[E[%>!AY?W&E?OUV7
M_G]_7KT]?!,'K7!E)Z7_`-^=]_B+I/[7_J4>3%ZEQ979=>&$@W4O^'!WF_)I
MJG[JWK)Y2OO+7^S,B3/O=7_YS>G_`+TVC^"8^7]#YJW[F7I@?CPM7[(W<CP'
M>/;^2-G'@R8Q=N?N553\IWI+^V;H3R.VU<457V/@S&.[??\`FO\`\<.GOV+O
M44\I5W7MXP$*7;[\6W_C:W]^S9Z=GFX+[.:,?$[BUK]R0>@/W0[#_L]V0_>)
M=KO,N[UOB:\,.I?C"<6EN[-(T=U>T#5VFL=PW?G6_2_KKL"\O:(NUY.DKR!I
MJ,8^#Z;FW;)I[A@=&OK+0Z<9,H98XPXP11RRES?#8DFYRPN'+M2FDW$TE7/0
MF;7@3(&(0;`;G+(8X4<P?G/'G#+F`F+">+G+#G^?'+F//'GG'G^?'GV\<_\`
M1Y"':\`>`/`'@#P#4EZ@.6&'9_I]R+EQA9I]4=M5U-^K@<;?=)=@:6?J>OS3
M]>5C'C"MJ=K/41#I3)M"U&+J]IC7A=]V:W/"65XTP8:5GLU8WQEH5W(ACI5Q
M".&ZBAC6!JANKFGY.!UCYEL&A+\1NU7J"Q*I\+B8.,_VA`"1+`-1A)886>PV
MDZYV<%'(/).!5UG_`!I>"W.?$P>G+1!*>-\,7J.[J;_#F[L?D;43]V1I?R&G
MWEK_`&9?5CYRPK]NSDS)CSD]3+4HP4A<$9LTPN'?;1L[`&MA11Y8J4N$V8AE
MKMS#C&4IA(FJXA,F7(T05PZW\DM;UX\:^S]/1:<7)%^JON`=4/RL-C_^L[-^
M0UG]L/ZD);R^\7ZY?FVNPO[%8'@>/S<R6_4'^Z)K_P#V=T_^\1Z->576M<2>
M&+4_QB.QJ;<&O=*[V[!6;8[LI*J:ZQZGUI5POKUFM;1J^-M'<!B.L65^H)WS
M]B5RN4M&$N(:R;$<%>861E$./+)CJ.ZU<V9@K!#KBY&PC4^Z-<;O2NG^M7AC
MH"N6*6IOXV=9M=0;)K%"E1V/)4S07-)7GP<^:"RH'`^<ZW"$I<V"*&EEBFQR
M\P5J74R4O`-:7J/?VSZ=?YRWK_\`J%NGP:A\7VLV6^#(\`>`/`'@#P!X`\`>
M`>#K^6*?=?Z._BVW1^M%#\'H^!X_+S/8(BZ:5.K[3#VM7MM;S4G@6C95E$J8
M]MK,E)B@W%M(/<>SJOPK*I1#/*KW"]`#,&`F3G)B*+AR"J:KX,N>/!PG24EA
MG@I+$S!\$-:/K'?X7_=7\2KC_P!R5>#4'?A^Z'BB(K%]Z1TE_P!H=X?L.]X?
M`=X]OY(Y^RG]PM&?F_=[?K?T7\"']H>9)O93[Y2/_7Z=O[:]X\!67G_%'QY]
M^[7_`,K"G?NY>Q7@8>7]QI7[]=E_Y_?UZ]/7P3!ZUP92>E_]^=]_B+I/[7_J
M4>3%ZEQ979=>&$@W4O\`AP=YOR::I^ZMZR>4K[RU_LS(DS[W5_\`G-Z?^]-H
M_@F/E_0^:M^YEZ8'X\+5^R-W(\!WCV_DC9QX,F,7;G[E54_*=Z2_MFZ$\CMM
M7%%5]CX,QCNWW_FO_P`<.GOV+O44\I5W7MXP$,W"D[`OO<>X)=;/:=7G\.V-
M_,)SKPB=V%/FK@ZV^G7`0-$"A?UPW`^0@H.2$G,_,>.&(F/,63.:*2&IRJ2)
M)PR<\)2UQ\B_N@BIRBV-8TMC+6,'ZJO]D5[HY*(4O3F-!/43[70'$JP3C&!H
M8$Q.$D@@Q9YA$,&6$<Q,\F.4F4=:E=%"M7XPF+%%T7IO9W53;%JV)K&DW6R5
M3TO^KWU:>66O+FS1%]!UDOS&'Y689!+,']$?'@7A]#EC[I&.,O']+CV^"SKY
MWR-\]1_NI6/]GDO_`+:-X,%P^`/`'@#P!X!J6]0G'*??G7,&7XHE.;UZ[C<6
MI1*1A5*0XJ(-RZ?M+#'NS;LF&?.I]`JPP?GVVV@'N.[M7E6.L$\;<FZ<U>PC
M4-GKAX166+RR]2%NE4G$^3`L66(S*?K'JG%8Q05DRDR%E'=G?40^BCI&K7A,
MI=.<-0>3/E\-BDSSU;6N7<3,Z+.`J3.K'I:V]&6+D3XEX=;TNT&JN;HI3S1V
M]3?X<W=C\C:B?NR-+^0T^\M?[,OEYA_S?OV,.&7TF?J9:4)/P7%R9$2"1=^-
M,P`FV<V;GC%<C@*S*%K=1!YYR=/)6MAG@SA%-G&N'6BVG-Y:S/C7V6\F.C+3
MJ+^5?<`ZH?E8;'_]9V;\A<_MA_4A+>7WB_7+\VUV%_8K`\#Q^;F2WZ@_W1-?
M_P"SNG_WB/1KRJZUKB3PQ:G^,1CQ9Z6PV%V5`IRNW-:(>YM_4W`>UI%R)LT4
M\AZ\]2IC)F*OLRUND(Y+B$S`EX.7D8QP%22P<1DQPRQ[C<HD]'N2#_7GWN,.
M1^9M?[ZJ^U+YI#6FQ;[?&S+M)?G=H:0[''T`XLH:?I5TL8J\V;W6]9A%^@02
M6'(050(I&@8X\X&GRREC<29YFFVXE.>7]FI)0J4E)*5.U=Q3HWS-E711CL)A
MUW"BVFR;-;L@VYV3IS(AY;2[VT'"I'8[:M00*B+B>*$=8\4M>2JTXS0P:(DD
M4&#*;CF3C++G+T6([[%A+!88$)^H]_;/IU_G+>O_`.H6Z?!8?%]K*AM_U$(M
M2[2V=K_#JMV8OU7U!9JE5[WN&D5:NGZS4&VFBT#8<T\C<NRASQ#5VN[&12/.
M31@Y8)L"_HHI1OA2204,Y55<)UO+(V,?3P^_]']-%])[?9]'])A[_M_Z?9[G
MM][V^S_[>SP9.G`X4E$<B#-%Q!?'.?'(L!HTI'',7M^DXYACERDXYC]G/O\`
M'./]#V<^][/9X!4?`'@#P!X`\`>`>#K^6*?=?Z._BVW1^M%#\'H^!X_+S/>+
MX/.6/LM*ZLFO;K7ZX+7#GSNL.52@.X3N!ZF2P.!F&%ALN=?YQ=2(9)9,<6PJ
MS.(LT#F<..:'Z?F7`#0)ZGO5?=]`]/SM194^Y@*16U&G^<KU7`UT&RV&VZU`
MFUXGXH3MR\K]%6TE;2F]99G4)Y1:TOP"5W5\E!JU9"BYB8CI`UVH:3^92PE6
M].<[*;9E18OO2.DO^T.\/V'>\/@R[Q[?R1S]E/[A:,_-^[V_6_HOX$/[0\R3
M>RGWRD?^OT[?VU[QX"LO/^*/CS[]VO\`Y6%._=R]BO`P\O[C2OWZ[+_S^_KU
MZ>O@F#UK@RD]+_[\[[_$72?VO_4H\F+U+BRNRZ\,)!NI?\.#O-^335/W5O63
MRE?>6O\`9F1)GWNK_P#.;T_]Z;1_!,?+^A\U;]S+TP/QX6K]D;N1X#O'M_)&
MSCP9,8NW/W*JI^4[TE_;-T)Y';:N**K['P9C'=OO_-?_`(X=/?L7>HIY2KNO
M;Q@/UKG[_F]?[<]C/V>_38\!]U;.,9\Z>?=WV9_YI_WD';7P'9=>&$@71?WF
MV^/S7_6/]E?8/@N*^]\40=M"NW4V_P"_;\%J';+Z&I]B.NJQ5N9/L.BK:K2E
ML6NNJ<Q2^-`RW0AO48($K=C*>(CUNR',D<%9C1L<B#.<=)KLM2KG)$2;BAJI
M2<TU5UBT2T5:)<K5\[1Y[83W4XCLCQ0V'??9FJLK2??-)SZ1*U\K[6;&U8IK
M`U$$O4^S80AZXE7542:>@#FX-0N&Q!6(F?+J24EC/9(5G+Y9=F<I/M3[,[RS
MK?1H)87]A^R^OM(]<^R-XV54]D)]RZDL.QGVL!M8@4D=68+U"VAV0"7)[@"_
M<,\8!GM#"KG,YJTO.=2:23+%R9A%SQ!)3:K3&>E+)9YDW]>NTNUMC;G1ZMV%
M7]2PA6;3]^V@M;ZWL=C:&+B*):]05V5.V"=@0Q<PM(MK<%#ECD8202HY8LH)
ML2^,Q]10]F59S,JL[J32JKSG;<;`/,@>`:H^_5!V#L+L/UE7ZTGI$=J3:/[9
M613SL_&PF:T5MU%^Z=SH[I=*^ED'5V<+73CX.\IE-TFGJL%I1HG?"IK9D]:@
MP2GUNZTEG*%MSNK92BG7#G;7!?3D4P(JSK7;>*Q.A^JNNQ'S9A-(*PL407:G
MU!>;`VL5EG7JI$5,+*'C;74CY4M/=2_*TT2^',W-41I8_P!UPDL7D\*LGQ'.
M5*.>BG9@N\%GL1V=3?X<W=C\C:B?NR-+^9-OO+7^S+UL?T>5;N?O_"9Q1>J+
MISZ/DJ#(``5K/WGTI_,)CCEQ+:[R8M@R]A7/M#JU/&S]N,)!LG#.X/K''1Q;
MQPP^^OM_1[^"ULD)5]P#JA^5AL?_`-9V;\AK/[8?U(2WE]XOUR_-M=A?V*P/
M`\?FYDP>H"C-LVRM<UU:XSKS!ZBTVH!?1@C-)$Q;'U%.C(@[3!:9SB(?D#++
MB3B&3EC`1S'Q%+SQAGESXG*3TKB%9SM__,18"C6=CU7W6I]>L^PB-E'F6[JT
MXB>DUA/5)!1"-5^IT'&JX7)9)19L()@)R^#),N").3<H<^/HQXO;6VW-A)*&
M24E7&>,),E-^_P!;Y^/+;/[#W0'R!]U;.,9D[U,^YI=/RF^Y7[6VZO!'?8N"
M,;?4>_MGTZ_SEO7_`/4+=/@L/B^UG2VI]RSU3?QP)_V-NG_D5WKY(*\&S\F8
M*`:L&POXVSN.J&<!>7J;O\>>T'RWK]Q]+CEZC[RO^SYE%L/+>W.,L/\`S"]D
ME#Q]N/\`R?/C&I__`-5\W-=F4JYR6>9)1=J?:^7L]V;^C*4KUOZER:,ZV:DZ
M[H/3Y[90'6`EXY.M-GN0>%6U$-A@M8=&^T%[L.*UG6];U>]M"<9D>.`45EO3
MC`WGGB5Q(P8XP,A\]67M,TW/M+F_J6F1GGQZCNNEZ:T/[GIC>NNU=;T;>NP,
M!5MYT5+#8J1KMCK]9815)%3WI:!EKS&?9E5E&CN,]62\BSFSE/!,0"/=K35S
M"D[.=4J)W<]%;83+\ZM=Z=1]MK-?ZEKI6]7-]<HJC8WG+&V:0N:Z=;=&%J6*
M>!&ND]O[97C&Q%4]I\8O>D)3<8)`B1(3()I,X9U>?`LNI-<4C-+P0>`/`'@'
M@Z_EBGW7^COXMMT?K10_!Z/@>/R\SWB^#SCP#6CZQW^%_P!U?Q*N/_<E7@U!
MWX?NAXHB*Q?>D=)?]H=X?L.]X?`=X]OY(Y^RG]PM&?F_=[?K?T7\"']H>9)O
M93[Y2/\`U^G;^VO>/`5EY_Q1\>??NU_\K"G?NY>Q7@8>7]QI7[]=E_Y_?UZ]
M/7P3!ZUP92>E_P#?G??XBZ3^U_ZE'DQ>I<65V77AA(-U+_AP=YOR::I^ZMZR
M>4K[RU_LS(DS[W5_^<WI_P"]-H_@F/E_0^:M^YEZ8'X\+5^R-W(\!WCV_DC9
MQX,F,7;G[E54_*=Z2_MFZ$\CMM7%%5]CX,QCNWW_`)K_`/'#I[]B[U%/*5=U
M[>,!^M<_?\WK_;GL9^SWZ;'@/NK9QC/G3S[N^S/_`#3_`+R#MKX#LNO#"0+H
MO[S;?'YK_K'^ROL'P7%?>^*);9_<)[D?E*Z6_P!VW3GP(;PZGQB*^L^X52OS
MG&T/WC6WO!,?+^ACWM+_``Y^B?Y+MF_=9]BO!5WGK_9%:[9ZAHVOV-)"TO5J
MEI)[>NJ&X:XQM&L:POH[7/%MV0]/M'&2<72<JLV88AC/FF.,.+@.?F`\\<<T
M3XV:7D1-M.===<(LS('I[IBU:"[&=CM>O-JO-EJB=*=6KFJC927*%<C8.[UV
MU2.,P%ENV)L3D<UJ-5$F+(X`Y=P=`L5CE"R\K1YO#<W9*BMM#<TJ8O+1DD;(
M?!DP=WOQC]MEUXEDXCXA'Z\=K9\YR\LIU@<V.U.E6()1:2#GXRU&QG9C8UVL
MC1S<LK+(IYSCP^@P(@JY=5PTO*8?=?W+92+#'0LY&&W6+*;"U;(R*S:1Q0:(
MUZ03F['&,%%8Q]P/41C`,=`K,,N++;H3Y<8:S55G,B]E9".&/P\O"@"8>K'E
M=[[+-Y:Q':'6M7=@O*K>27!%#U-_AS=V/R-J)^[(TOYDV^\M?[,OFP_28(+A
MEED5')-ZF&I(!<YL(6!9(,??C1DYPB47#'*.O5>`K(0JRV(SC!@Z>YIZ]`1R
M.(`/Y<'U+WT+"K,^-?9M?R6T)7;U(OY5]P#JA^5AL?\`]9V;\A<_MA_4A+>7
MWB_7+\VUV%_8K`\#Q^;F9"=S_N[Z3_UZ&_>1=$O([;5Q05GUX8AM;_$`H'__
M`']4/]W?JG>4+NO;Q@/M-^_UOGX\ML_L/=`?`?=6SC&9.]3/N:73\ION5^UM
MNKP1WV+@C&WU'O[9].O\Y;U__4+=/@L/B^UG2VI]RSU3?QP)_P!C;I_Y%=Z^
M2"O!L_)G[@^]F`_.;N?WN3SRC'R_H0W<?O&>@W^QER_=K=P?`QBZ\2(%L]?W
M"EA03;-HE7J"\OH!O[ZO%5_86=UG:^YL_H]D1\<)G4*S\H^B@S$DP]A##Z;.
M>2+^K^@]^7447:E24C*4NTTYSB6CZC,CMBC36;?3.LV)6`[KMC6^GTD?HV@L
M)REVG8=T+S`>J:@$82#'KC8,LH2PBHY1R(LLHY8\\.>>/,FE9>;\46G9'&Q.
MMNR]BZRZ7:ETK"^V;V&U52$U+M69]$UHB%DZG[)VW:+!")2Q(\HW)N.JQPO=
MC'CC,D.YF*DSS@B]H*MVZ+;?^21M6]B>WVQ+0CT_84/7W6^WP2.PDEZ.A7W[
M8U%Q#TZ=ULA1BUL:"VT5OB6]"["PE,S3V)4`<U<R%&"DX/YG%!I7JU31>>AY
M$Q:^[B4J.I+(=R/0%>R\7FTTS9-0:5L.Q`S@:VW/L33\%J@5)%MS95Y39S=?
M'&@".FA$D9'!X`Y['Y=,1X)+E=I74\99EXN>Z/5RO@P,VVY:N*KGIR#8/+3&
M-P4L%I5I0Q6E!96;$-80$I5LJW-"]AG:3A\X*9,#I\8ALN)/`D^I899[#QM?
MRQ3[K_1W\6VZ/UHH?@[_``/'Y>9[Q?!YQX!HL]:;N#I:I](>XVEKY8!Z#8[3
MK^QT769MK9(P0=IW50%0+'8JO318VD[J5JD7W-'EE"U5K/FG'#,A1R:"ND+D
M&X$W%#+ZD_7^&8Q//4R]/\CK-U)JT/;O1<MBI[S;L]H387E9R>AA<]0^WE-5
M2LH/?]X;`^U7*JH!LL_9Q*S?K!N/Z9.'M%[$<XOE=;;TSEWYZFGI^V&F:?"2
M=O-%M"TO2C<=&:CA7E9-*ON#JS]/BU-<*PQS]L39@-2[7,*)E_62QH&?./'_
M`";/P%!&O"^\L,ID@[[]47T[[#OS"PI.X^A&B3CGHU[6@=\5S!<?4+MG;[A<
M_P"NQS]W_FU5S!7K?_\`#6D1$R>S#/CGP%!'+NOQ>JDCXW]47T[YNW"2XQ=Q
M]"25:#LG5[/,^QOBOE9'7A.BF\Z`2XS)]_W.`(+H_2UF2?V^[BX9AA\_UDV/
M'@=B.4NR^[E_^I\!J?U1?3O4=LS[@T[CZ$!J\GVZ?N/2;XKC6Y?7BX](3:A[
MI.6?N<_6(2B7$A5_^7%6VV<?MX$D]@?XXY/Y7=<RF=4O5`]/.HW#<YEG[B:&
M1B.]/5)*H(8WM6/$Q;!]G^^]J*7BYYY^R4J"N;"I#J6+'^EBOM"8CG^@9'[9
MB]2YAP1R7ROI0KDR(-9^I/T(5]$.X&OV/;32`=UN>@JW7JI6"+LMC</W@WIR
M]?=:$*U@?.?TA1L-_KKVHR0X<<Y8O51H//\`6P9<>4K@B[2?9>?_`*9.97JB
M^G?GHQT@Q[CZ$R=3^H)5]BPK.+XK^,DHHGJ+5'91-JPA]_WN4L-!#*MLAO\`
MV6*,>4[GGZ+'GGP3L1S[K[LO_,N)\UWZHOIWK=?^GJN/[CZ$$.UQMVQN;V+/
M?%>$U45$]9>T]6'/=X<Y^T(::Q6RM)L)9?9CDP=KA_\`KD8<>!V(YQ?*ZVWI
MFP3_`$Q7I:_AX]:O\R4W_$\$_P`<?TLQ\[->K/Z:=IUQ6UE=[N==W+`7L'U)
ML9`:_8:DB>%%3^U>F+;:&LD>&?MQ"0UE(W>,I^?Z(RY<43G[,(LN?(^:XHJ^
M'']+L^#,?;;ZHOIWF=TJ5>!>XVA)Z@#M'5S8RQ17Q7DJ&6J>J'>:HLC92^,_
MH\!PK/?:8C(DYY]D;*RJ!N?Z9D?MH[$<FNR\</M]F?:+ZHOIW@=T+C=S>X^A
M!:B;<-Z&"6*:^*\%1`K_`$AT)1)2(BN<_<SB9N=?7=:'GQS[)BZNYAQ_I!R>
MP.Q')+LO=DXO<=7/5%].^J;DO[JR=Q]")5+'[8OX%@POBL<4KZR]\.R^P$'T
M,N>?NY_-Z5:*]9P?9_VZ=R`9C_5D8<\@X(Y+Y7TH5R9#.GO4JZ#)>J^Y*FU[
M;:/7V5WZ>G7W7"E(5=UL3%A>ZYUSNU:>U04;+/WY7:I^<&H-"QX^DA.)B@RX
M][/CP7L13[K[S=L*$F,/4^]/633O:=+AW"T/FVMF_-3V&M+\;VKY*=HU%"ZM
M+V;1=%[_`+Q`0)U3LHI,V'MQBF2,<,N?:-G[`4$2</RNB<_7W*TO]47T[X].
MU-+GW'T)@V#]038>Q2E^5\5\%045EWLV=?@+5)%[_O8I2Z6U6V:`WG^KS3FC
MF<<_1R<<^"=B.?=?=E_YEQ(1V)ZD_0AET5Z=T$#MKH\NZ4OKP_K=LK,%W6YN
M*^^(].K>>MH%+0/C/Z04Z6_/TM2P@SXXRR>,PP>/ZV;'CP501=IOLN_[)\"6
M>UGJ?^GI;K+J(JL]P]#/!TVC;V@:S+KVK)C`<L.Q_1"S!+"<L,^>(BRJ_0+J
MWABR_I9@5AQ/Q_0#DYX$4$<G\KZ42YHR6K?JS^FF+VKW/;2.[G7>&LN^OG66
MN*'DFPU.*YB]JVQ^VS.Q*A2><_<E-3+[A5S&$&//O#P/ELF?\Q.'MF+U+F/\
M<<E\KN^1D'_IBO2U_#QZU?YDIO\`B>4G^./Z68A;C]5CTWVW9?1MR4=T^OIB
M&K:+[,(VM@5WQ02>H>W"_=4LZZG2ERYXKTUBLRZMVF()TPFAB4I5EC9821\A
MY315=9;=&)'\./L]UW5E-V=LGA/28I=>/4FZ#5*R7=@\[7Z-00\Z2J%>7$C[
M+$F+^=Q]F>\CDNO5&5AD,/PYFK.Q*>7-=6>`Y=;J-GQ.AR$EL61`Y.7\VVX[
M/8L?PXVE*%TNTJJD*II<I3P*=K7U)>A2OHIVTH+#MGI`.Z7#JO3JE5ZS/=EL
M;A[90O3\U1KHM(M#YS^D)8CWI0SJLH^''.>+H$D+G^MCRX\AIP1=I/LN_P"S
M?`NUWZF'0#)';!A^W&B\YW/J"ZMV3",NV&#',PH=:[D:ENA]XL!LO/',E925
M0)NW25I;](#E%$\N3#WN8\IEMPZZVZ$C/8C[2^5R[,K8]G'@L)MY%[+O4_\`
M3TBTKUM1R=P]#8.*QV3O=GL*[*]J^"T]>8%=@<@G!\7O^]``5C8D64,^7]#/
MAJ%SQ_VV/D*X(Z_*^ZE;[?8B3;_J3]"'/3[1-,5=M='GVM!T+W?KYT@%NZR5
MFLNSWJ<%4$U7,&QS]^%RRL^&:(0/+^LF98\C8\>_QX'8C[4^RY=J?J3=VM]4
M7T[[=N/4KJL]QM"/%*?G37S1@NOBLD4#Y)WRZ<[`;?$RX9\XQ_+Z32K99RO>
M_P"R3U]H9E_5BY\\1\UQ04$=?E>[1$ALCU1?3O9]UJ5>5_<;0AE/!-ZVYF6.
M"^*Y%(V%8HWJ+@6'*4OC/Z/#A.;LJ@C'\\\_U$UM1X9?SG1>VCL1R:[+W9N'
MV/M5]47T[Q.YERNQ/<?0D%2-V_LIR)89+XKQ5$*FG43I735Y\17.?T>8IEJH
M]O0CR\<^[(SKK4;C^F))[`[$<I=EX<8O=&0?6KU:/32J]`M:ZP]W.NZ<XOL#
MVHL0HI^PU(\TZ*V]E]L6BM-8\,\_;D$[KKA6Y73\?T2`#AI\/Z,G'@."/Z79
M<$0+WO\`5(].V_M>C$U*[D:#L\5"[]Z4V%<\T]]5&8UJD(Z9M<%Q:6_,>?/P
MB9<6W6#EF2>R.*4X;'+GVR<>`H(U/Y76%HZFQO5$]/!GKGU%EJ_N-H4L_9.T
M%;6@B07Q7)/;5L75?J_4Y34<?&?M.'PLM4LB3*2+V\<,4K`;_KCY\>18Z^2'
M8CG#\KI?>V?N+U1?3OQZ_A5WGN/H3AYAZ@C78N:KZ^*_C<:++ZFCC:45JYA]
M_P![A+GKJ:*Y8F_]ER@DQ/\`;]%SQSY1V(Y]U]V7_F7$BNT>I?T"+Z?],*8-
MVYT;/:Z15;4);D$=X69,ZZ27T'[0Z]&@:C<9^^+)/=[76ZO'C)[.<G+I>'Q_
M6$8<>!V(YQ?*ZVWIEQ]CO4X]/JRH];#H.W^B6\RSI5O6C,(@;TLGS#M[^\=-
M3TM<GXPSY^C:LPZ3;20Q>?ZR:&O-,\>/8+G[`[$<NZ[K@R[]^>J+Z=]AW[%8
M4?<;0C1'QST;]K0*^*Y@N/J%VRMUON?MFQS]W_FU5S!7K?\`_$6D1$R>S#+C
MP%!']+\6&:20>>J+Z=\_;>NW"'N-H26K#=F:=:9WV%\5\K8:Z%T.[&:_+<YD
M\9^YB`/=K*@K$I'//N8N&X(?/]9/AQY'AKY,+X<=?E=N:/UJ[U1?3O5=QK%=
M&7<?0@53)X[;_06`B^*XU<OUPD]/_FK>X5SG[F7S[C7=YY6^SG_E/U5=>Y[?
M@I/91V(Y2[+PXQ>Z/G4[U1?3OJ&VMGN+/W'T(B5M4U]@6GLKXK&&-F8=V>XU
MZ!C'DSS]V3(JGW6IV.'CC_KJ;`K+X_JRL.>0<$=/E>[1"C'O67J1=#5?1;LU
M06/;'205TM/1S6%#KM9(NRV-PYN2KI`AHC*M+P^<_I"&X5R'GK9`F'',D;>+
M,3GCZ3'GCP7L1]I?*[_LWP-6?\K-V10MOV;T]MFZOMJ*^:_NFHMQ.ZI<*RPA
M:(7ZDBTT;"(]8>/EE"2/GG')'[V//MQDCSCRXQSPRQX&_@*7;3H_EYGO[\'G
M'@%JXT6D8MK&^QIM5Q>7"`$6VN<:\HX;6D56+P$L&L;'@/XQW`N"QQ$!A9S%
M1B"X\#CXQQ<<8>`8*ZEW#L9YVVVI5K%>2WFM:_K&UVT?7F&JK8A8ULJ.XUF6
MIY+AF>C*]:6S2/7C0&-THYV+;F+*WMG6":LP@BK1U8U*BIC*<_YINM*N?SKG
MM';]AV%V95WJ\\6\&GDIPJ<HPU5;%HM1=L&3]1*&*NBTG0K+8$F#8+&4C+FQ
M7R=76XU<Q%B*SX;V`D1RI+KU?!<E:VA=O[IL'7C?]FL^PB+?=D!=E!HMEFU1
M:!I*\?!42'HL$M:5==*2W)7*<?A8N&QNN[3S/9(6,$@#(.5.B/%<IK+&NG6^
M)UEFXMRR=('][DVK[VS?K!P`IVT?J*SEQKTX%OK":PMF%.1]>QL@<>8)[!+6
M(3]4EXSI9E&38OAA`Z:*0DNUHR3W5GSO0Y]@[PW8LZU=<++3&%LL6P;_`']0
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MH&`BFFO,G!-E+L77D\ED=Q;$;LY&[KF_:N@:)8J]P*@8\1D\W$*2Z]*Y:/XM
M*IVSL/:^T+Q'7[>R8ZOJEKM\=B%:T'X751J$.P5M0(@IUYPT*H(97.G+_K>M
MM:WC=3B;+8<:OD.,RM(KJF4!A;+&NZ>ZEMYL/^''_P#T(?\`]K#_`/CX(1CN
M=PTJ^J-BNJM)&OM85)M<]58Y5IY9Q%ME@K[(A&P9**U7;2W(6AL81YS>!Z^V
MYRAPYBQ7'2RQ!$`KHP9I&X-M-^G%PO$FU)FEYCM_*9#M:345B9E+J\H+JV-O
M=ET>O:"3\A29!#W@ZEXM-9L%@\)U1`L[5@QQ:9QC323MLFMTYOK`_-CW%N(7
MI=1-@0W\U3L-P19F;:\PZP?OF$R`-Y:5U663CKNNC%#7K`6R+UZI>&.]-*0C
M4\-R/K*[,D<5K"%)Z-=.//:4_L9N/>%4ZUZ0LE2V-)5-@NM=4=M;;0)J>R/!
MK/<;`A1EXXXS<=>;^@4K"8%]]9-44E,IMC#:R4O'..LJB2E3`%*;I379;]6)
M(G;3:.RJ%L_0".D;,24A58[$JBMJ#ZK2N9'X$[>&$[!ZZDU%L0"L(\@82C!F
MA#W7),:5'?3X36^:S$FK@K.FWIKGA3/DVYM#8Z+N/JW7B'9B9)0F5;J;%]0/
MJK)-&?DWO!=>9-;/<2-1V5>FC,Q)1UBIJ0=GU%PXNEBJ@^:J%7*6>Y$\,Y8R
MGT^137-O[#.>V#^G4&WM<Z+4-@4F>PI3=?9$:N'UW+2-9M;G39;K!H2<Z/;N
M43JTW12-'NG-9F*VIJO@?$B9JD6"TE;#;=Z;;,RI=?=F[2N?9G;=:LMXSL5`
M6+;JT0U<C6[ZEC5B*/88"6E+5Y=CTI2FC9HKK`C..\%&[%M4$MD98@I5,0R0
MUAX#2DJ5IEE//5AQ*3H#;>\F</90';+D7"P4-56"*5$WU+L=)`L-M!^R`8+?
MPF)TSKQTXU*6X3@`I9PY+BZ2H*?8"KA8^9(\K(Y!I4ECUG?=A29)72VV;/N=
M0V1-MNRL[:U4[09+ZV58Z.51'P%-*K=9=5\%BE/TWI*::3(1IP;RTXJD\)\Y
M9/(C*0&(6"`2*6&76+XF97PX_P#^A#_^UA__`!\$,-.[&P+MKC7"!GKNU,*(
M?C=%DUF>*M=NKH<53X4UCE*KR,@74NW*TEL3Y]!7UP;*T5_%<`+,67)/])B.
M*:+#*=<NL5Q(7[.[;W=3-8:+/I^PHZG;7--5$W%FOU9:7JRX7AXLK,:>"%S+
MH#8B5%6898[N]L2N5#4KAS##7`A8T,9\V4`JELUJ<MZK;1<N_L5M79=7[':+
MIE,OGU6J]BNNN4+NI3:X?SCVX4ZU?2;`E(N1NE+LEF$QK+&IIZW]7+U2.`79
M]GSL3X;-4/@*"2D]3QW8K&]\,SELFS=I8]V=9T!5=I@-8N,+1PXU\1K2PK8&
M:]34'L8K*2UN=)F12&\75%8#(V"K;J-$V0P4[!8J)Q+8F6$2DM/6$]6#Q."J
M;9V&1W7V)0VNREKC6**M'%!Z]64PWB-86*L@+AQ7O<=/0&6>U$<BL^.*\BVO
M:N<R*[?^<E(9*H:N(Q9477/D=WK!L?:MUWAOA%=[SA:ZF@.=DUA'GK]O3P:N
MNCO]CJ*4-0:[TSK\Y]R.33K<ML)9-SO(HYZ\)4L:,S55E9^`TI+UW+2\]!%F
MA-B=H[+2[W?W%U9V.L\:3+@K+"Y:@L`W,^[C%Z.:J7[7ZNI=;=<O+7HM](:Z
M8?28@79X`E$3%L,1\BR\.`:4Y6K@\-,W<K6O-P;2/ZB[:V$]V['-84NQ\$56
MV8[UN;`]%J7)^O51/`=!!T/4IFES<2LK)C0$8VKK;%,\=U9(P*LLT#"+`*3M
MNM/7-TS<U3([P^VMQ?:=ZSNV=TR>;.?;"<5I\XJ5;R:7:Q+UMXORZ9'24:SK
MK98B;BD4U\3Y]SQUX,7<IJW;S.14X_&-V5A2=J27!:>?L9R:H<06S6&N[/R;
M*ZRL%)J[F1N?&'\P92L4H1<IC#@.K4D7`\B27*0V*"F5*.(K*6/&M(O<^5BC
M)@GZCL$/#GT[/9#%Q[?4LZ_X\^R/#CV\<T+='MXY]G'\_'/_`-^.?YO!J'Q?
M:RZ.PNU=EUCLGH^ETV^?5>JV&W:[1.JA-KA_,/;8#;5G-?R";F;I2Z)9@L*L
M;5TM;QK=\I7P;]A8I;"]$^4Q80@E-.EO3+%:<\*'*_V=M+CNYK?7ZV[3!:P<
M8VSAOKTC6EA5P,%B>CN\`64EK=:2*BG897Q)83L&"K;Z-`SK@E/C5JSLCF$[
MX*2>>O3E/+1F5W5VVK39.U.QM?/W]BR1AJYW50J<U185JNBUN5132UQ)X]DZ
M\U]_':<)V;'X[#G>[\*7F663"K`9\9IZV)@NN?)$`5G>6]F#+MA@'MZGV$NG
MLR!-:B,JI&BJ]8,BOB53$$N+;Z@I)%M5"IW`<ED:17#80@:^T47%,_9FLI'A
MHKE2E)5K5YXOD95W"_[@1]<MP;+%,TJYLE?IMP<4Y[5Y;9'3U/%<5ML&SY]Q
M,CNCEO\`58]<2=,C1H61C?A9.F'%S-(CX\$I-)3PO*9!RCL0S9=<]RYP;*M-
M7V_JQS41[<VVEK9U]<:8LNK]'$KP75"#K!JG*R/;`AY<P:\6@Z<LO#*R&)(S
M\VX9L46(LJJE'.4G>6U[:ZB@/>PNQJWU'U?86VV:@HVW=;1?*[/=G*M5ED7"
MAMESK\X:9;-K*L*VE[I0,:ET:@XUBH7V>&D6M9S/703<[LK"5;.5^>FFVFDJ
M.Y=N[HFZY=>VNJ-B99;/O-&HMM;V&BZO=[%DV!@RJ(KEF94L4>B-EUTI:;'`
MW,-YAIU6^7%,J@R*)JJ4Z-&[!2FZ4K1_VN/N2%N+;EVJ&Y-$U>2P/T-:LTU<
M2/1:_3VHT3^YE.JMRS@9N[!UOV2I95"=0_#%PD16C41Z@_EV&PL&)N,F=*$5
MG[_RN>%,_)E_+$^..-O='.......-:[GXXXXX]G'''%GH?''''''\W''''_1
MQX._P/'Y>9[QO!YQX`\`U<=8[?7AN[78K6838A@WAYVK<YQ><U8?"T9CLJJY
M$1F5H&XL3T_.39H:.K:.:35B;:$'E;XLV"^R*K#;!IJB>I=.5;9N5BG=)F;8
M^U]OJ)G!7"JW4G!ZI6D!LNKIOEY#AM>36":=M3F+]^8MX8SLD'UEN(">.$BO
MF_#HX&?-BJ]/"*T.;5;X22(^ZPLF5TZ$]F4K;.M-TZ:L7^H+,X++IU<OB4)J
M%D&.,P9U2TMZH&)"BB4OH+)<[D'@W&:_3RGA5L8&WN17+M+8W?KT]:+KN[Z2
MQ]+AKLF]N`N(4=LUW<IG-?SUH1@?S5-R:^>,`(XJA;%-*K,V%A7-JC"3->X6
M0D88UA9$AMCLZJ&)+YFEI6.1-5YK>E]\]8](5?:%9VE=40I\MVKA>NM5$[J6
M86JFX6BIKFYV<E,W#17JJ(MT0[K!32*P5:Y0"+FH<]FIQ1([0%--VWI>W\:&
M0]V^K_RS2738BWBH:=A1M<YSM$5M1]?;?<Z?:5-)UYDL+K<FZ+;3W;AW36Z^
M4"S5O6Z6Q,-B(R6U8/4`,6=7*B%5W*M<)KAGA.Q+79ETVK/=KKK*FFK@,US#
MUW6CL&5@U8.SLJ]9M9@2<-"#='0=I3855*\>GJY:FE;,;ZZ?PUU0:I<(8QW(
MBL]$\'2FC/3:5JG>NVL+@%WLINYU^EK0WKJ>Q9B&6>LK*B1@?#:M)RTPR_M[
M2[V8K=#B5LU<EHTFN5NOI,!P^3+VOLIDKJP(N0G\LI])VVWGL+1ZG`/(^X6V
MS;$NI(]DDJURCM35%6M`_6%J=C9=?CJHK/:]>6UGL7ZVK$X0P5^`L*X]`;:8
M)N0CE(:BO"L0?=7\Z=F[W-KW@R01VD"%8]9>Q*\TW):&=HS;(A3'!?`US`')
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MX1P%WR6S86BN"I*;6&5=],K5S+][Y`!9[AZHOG9U3#CK=[KYZK%G7.OUBLH%
M@-O%21P35K[*5QKVQR(Y"FR]B7%JM`[8Y$5E<'*)E,ZBE7"*S]WR7$KEK3N;
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MG3"5<NI2,FO3%`7K]&6V%`CH%<J<NT&Q%55Z\NB2Y+,DV58J<(KAAG7=W=@5
M*1M988(K$8HPO_!\<C3F=NHR:3%6:SB17V8J7)<#8]X,FO7U'V,J+5.J++"2
ML6<U_L)1BBG[$BB9RUM(TK5ZK-I=*4.PWE?16MO#5'KP85+&=(8)@5-9LA"%
MM>9>X-0XXT?)X$*]S;):456Z>7."&K*;>15[`F*D*MFGRP^6]DJM`8XT]<9<
MV*6L3HG5I2J,F>SJ\O9J:RM219?)X1+4O,`!*<U=4P>FM)X63ST%V]E+?7Z7
MWET%PP;$1,KPGU35Q%,6:M9D1-%M]^(ND&SFN*%S;OI);.?,T6KJW;0J:K52
MM&>:;FT!BV(%-K15^GI;1/AV["W<H_4KJ"!1E7Q@[Q6\G5D6R/=79N&"^O:W
M?KU]@C$:.<-F"%$FQRJHT%>K4L.2VG3/IG+!0Z=8T8*=ETK@Z_UO]CI4)>`M
M]2_8S2=A5,K!9:0V7Q<)ZSU^YLI"%"HI1685F;U.YLMYC?UK)1B(=?ZFI78#
MU8$0,R:"U`B!`^ZOYT[.92^LIEY/V[VX!7JE(A]9=;"6:L(7W+)]#`K;7HAG
MSA15CW<MU7QU<J]0V/#94O-;U9PLL*977UJW#$:&I4`'9>NZF"PU\W9_3ZOQ
MG=5.SJK"NZYR7.]9L%F2"E!Z`H=1>%EZYLP["0.Z:BL[BI15-W&4*(E:VH<+
MFNK8YFLK5NM-SQ5BOO+7IM.E'7=L.A4[AL&V^GQ:RH5E1V/&\VA2J:ZDP'H+
M>-O3';76*2Y2*Z%K/7W8A.<YQL;!W6UU5*K%RM^*+B.ZJ![(\BJ]7>B4465\
M[UE=IY9;"M[^634/HYJT4!`#7J2C:.1[-0#J2C@)Q6KR[1<0F*-=M75'7A%7
M+"E(K&;41A:M>T+E@&<R"0#66Y.JDS<!XN%7HR;>YO=,V(]9CX&G7/0S$7(/
M(8S3VMR!_EZ5'7`<89:@HRBC#K]9:/*VE&CPYQC@5U]RT2`QXXC*CRP(X)LQ
M'=ZV8A>H]_;/IU_G+>O_`.H6Z?!8?%]K*+V.M]?IG>S1$;!L1$SN]=U37!%,
M6:M;R1(-N"R`K\QLI;BB=6[*:>W&3LUJZM6L*G*5!#9I(GXL8P[X)-K?P3V6
MVSUG9=.FR+U+*S7U<M<%"NZ/)S9%DM@U9FY8!H]5NUZ^PQALW6.SA32C1\$T
M=:KU;SBX5U&>S3N&25TXBI@4[+_G1LMMW5ZW49$OM/8'8.X[WK?8M!W(^4XE
M_P!=H[<6NJ+\CL"Q$Q;U!I<M@U0A?:K7K^T3/4\K=)?P*KL+XS&QI:%"NK-4
M^JX.TL,*KA[VS+*ZZ*ZC8+MV^J;;7U->V39CJ]O(X4%JUY3&6Z5]?VC=4N!?
M,=`U1KRXT)G5V`$:0IA?;J_N$SL(VTAY%_3FV<\'9:-?-N>Q2MF3_6*6RU)J
M'LP3:M?\ZYU$/J5JS74JP;8>[CR^*`0;':[*;%L;6NV4*K2NP3J_ARHAJMG%
M(,#=,#ZF]S-S!8!.;6<_ZM+J53'VCTC);TQ[&C&577U+NV-O7H+15[BDZ\V<
M=*C3$4FU`ZVV-<I%&E--;#6M1;=8+"`]+)68547:$RL1J;>$14YHN*O:E7IJ
MKM?QD6R>D:2]'.OI.LLF5IXK.P=EU%&B2U!I(:_SQM>T$:%+A/U3W50JTAFA
M=(EJ`C:]2;V5&UQ();M"45+N-Y:Q">)SU[]:>N4M52X.V#<#+JAUG47VF-CK
M2304;0.Q[(IX;..F72'5V*S+*P';3T#V&B7WXLAF7'$BM`-5L;>*![$]M4.`
M[J"85=YRZKH:ZP+FOB(79O:_7`.V-<[`CKFO9*!G0KQ1=#[:;CD6VM+-;7&I
MV!OLY%7KYJM)2FU@V-M2FLE":2O,*032,K4[V'SQE5":L)X;[)KA?!;Y2N>9
MG^6*?=?Z._BVW1^M%#\';X'C\O,]XO@\X\`>`:R^J&RN=D=J-]R(;'97U75U
M\AX=!L$J^5B[(9[O>"L*A6.-5/M[VL*LKJZ)3+D!F/;.O.@[\D5<T_+A:X%M
M;MV[&G1+E)ZZRYM7R+.Z>IZY:[SONS+F(U@YKZ6Q5(.M\;MNUE25_,J[;.@9
M4H;5@N]]GEU_7\/$`T:X.\ZKU==%#C%L+7Z:*N@75VG@Z2]N<N;YN---851;
MU([37QRY/.%-H@^OH+';]U[/M%<8DQ4!2`&A6/E'97:5=##KUH8<(J>\J.TJ
MAL5)-/*EM["GV>`VS-0=TN"K^*=L):2YE839?TQV59*8XV)$\N^WZW*397>P
M-Z7^X6J0#95#4KE)B^A[JOKPUI>@.)=>MX-";3Q4LJ_BM&+E7YAM*?7Q?$IX
M3I)*5-,M=?6[R7)W?5M>]6M,O;\RV'P;;;74*.%%K+&XXW*6])WS-X753\]K
MV9M<4@\>5&>5R_`[#M&38`*![7'109>64(XDJO:ZY;/25-ACYW/OK7;%BZ[)
M-36':`CNU54.[UA-J[8_R!F97MF%5N'"];#JR'<FJN!:Q0D"UN2GL%[?RT0J
MT-\%:H:XOX(J/9PAQG*^*RP[KOOXEU[U5W.H]V*3:D.>S2E=]+Z\KWTE7!W_
M`/5Q96E6QW-<.@9N5?9!/I@T,=N\686.J,=)%9I:W=VEP@"?%'VYK$"[N_%<
M.S/UT4H5?E9L8+U!46-9L^R&NM(6EJDO*(-WOVQZYKDS;3LC]6%:36V;K4B*
MTF6AYFU75`5BC7(JO+KJ52EB9O(,L@\.Z5L]]N95.O\`!957<7=PF:YAE4'_
M`!L:Q`E%R[-D9*S);/0\X)G0K+"#4H%?N&!S!GK`VJ&V!]8JXL83G9(R5=B4
M"".4EGLECMZRD;(/!"!>SUK!I^A-HL#G5PK'+2HN*JOM-$1NWECJCFWAS5M+
M:!_D;2NYHAJ\T9BMC;6VMM(KM6%$E=O[Q45@1#\`57777.R39A/6GI=O].TF
M\GFK_D=C8U"]5US#LFV#LTU-CV-2W`5CSNCCLQ=HZ=>ZS""6^4Q\=E?L=H+&
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MV9\QKL*#`81BV4A22S7";]:[JD*:W>)*-O7L%NY^'N&.'6NN>QV[UM1MF&[M
M<5\NM'VV*S09ZHHU\J=#71!ODF$LVZ@;UG902-Q95JR401>H4_&#BNR5,%AZ
MR])87J2EU+BIL-([,VRC]I;9NY)(M.K,:@"\&7JY:QDU=/L^H$6NNPOMO[,K
M2[+;!JXN\4&).EU]5V"0:O<CHN5$`@:<1X34MDE65**=-K)1Z!33FZFLS.:W
MJ+5&SN^)0\"&UEVI77H^*338)%N6;7<&\G"9T:1%,]LBIA>\LLGC8UIBF"F9
ME'-!'JE_>I&=/@A@7Z@;A2FUYJ>=K8#*G\1NF`-?94]_DUE95+"74>WI,<ZU
M;R=QZ'K(+`\2$M2P'N&QU:@^ML'HB@4Z[2U.+@:AQU93Q6%?[T3,;.T%+6U+
M1G62G"Q\#P2ZKM]&7+:ONK9Y$=C;V]-K^2+4ZNSF;^H5XV3IZU$PE#3UA"ZV
M=M@BOU^HPZLHK(18V^7`G5[[+#&S2?I>;)!VG=1UO<S0NH:=:+OFQ4YTJK3U
MC8%BVHFKN:]"&XV(]M=>L[#L+0W&X7S:B?3(W+^?5'8FHEVM*HI5TM57<\VE
M24$OE;?I+A*E=*<L)2*+=,:I>N_2*O#-'9/"N[HYGZJG;4V76DXMAKNE;07B
M_L];J6[ZS-AL0,>9$CC,XTT_U\TUY*(KM5S+L<BM?30\/5:JU-=)WJ?O1=@L
MET[P;9V"O>[3;:]25NTK+!"+?S;WJ-38D9*Q5%3ZNF3[:9U%K;QYAW4CX?7.
MF6+RLEH%M7M5IJEL*L@&T0:HK5W\%36]^';ZBU\&3LAMZQ,Y-HJV`,%PL"A'
M?\MUTE&(EV#LZT-5I&M:%>:O0P1:6R`+C(MRVXCVMD-LWC(RK2K%@,;%N#PM
MA:4Z+&4RU>LT3VN].^QU<NB/VJ*OH\W`;ZSS[P^`S40ZMLHIM-OT[_--;%%^
MKD"O$?:5>U2-"'7>6RZ.L65DZGRB2@^\FL7HO/#1E.Y;B@:AK^FN_+@[V3#B
MGV3LBKBL-C7O9XO8H;X"M@Z[YQ:6X-GM+MEIJNWOX=(QKE7)33N`YQ`]3%65
M+._BC!C"LTE=;.2<L[8V*R4[N=>Z+]?41K1@\?VVQN6(Y](I5\9U:W*.+1;+
M,HK3E7J!#UU<C5YK2"_G0[D837J-LQK`F1D5I!<Y!6,'WGS:T9S7&6RFP[K$
M-;A.O^HH;L](L3SC7]3RY9,:?:*,_P"0<D*_D`:U5ZZ6BWVB"UBC^[#8B7;;
M!B6TQ(F,`")RFAX$=V8E>H]_;/IU_G+>O_ZA;I\%A\7VLZ^YME\F=Y].ZZK=
MCLL;S`JJJ&52M!5\HE'P&4Q.=D6.T4J<#>^LXMD,&M*-Y1'FK]*;WU_Q9$*F
MB66R5)F-9DF8+NVSK1Z,G+>KS4RDKU5SH_J`9"#9[-*JFQ+VUL3PX0#L!!18
M,Y]&F\UY<V.?=D+%IQ\,9,D:P!LEFE5,R@^D158<:OP):A.:'AP])WP4I^N)
M<^AMI'6'MSM+7Q?8&P7A8@XLSRKZ\9M:DW%^2.A:8X"LR]M2*'4AYZ^'`^D5
MUY$]:V$E8%G@7R8R+FP;<@U1.6W?IVV+.Z[4!'EOG?86RJI=[L+>;1>:ZN;V
MG23`[2C40EG8W$J9);'!30!GS$A7-HK(QXI5*K+:S-G55R?699'JRJ54&Z+1
MIK313G3;.)NC-7O+K1>Q"=7-J4[D-N6F[1R,D>Z4I&6Q4X3+*UW1,VQT*H8Q
MZJXL5;,@IR^I7*O_`%A(%0SXV`NL#75HHH8L4I[\WJNUKRURK/&T5S;2'5.]
MIK+!]BE+>]NQSTJBZMV3FKL6OJ]8F*FSSZZH]C3\42T6FRWBU)K9\#2-9<2V
M).'L+.D:\F:)*@L*S$N\Z8X\4MM*39:2Y4_SZIZ)U1OY=L.>GWFN;0<;,>V:
MHWK<]L%LD%NB=:QUQ9XM<WK<=F5#-X;*87PX&VJ4Z&!UV+0%EIKUJLJ_Y2&+
M:DLLJK3+@1[V@K2%5UCZKUJV)N*&3<YA3C%VQ[2-8B=7NI]=P7`RFIR.PW83
M2"SD1/8T@6(%=M6Q7;I=@GX5C41S7\;-\A%5WR5'N3X8WSF[L5=-D:^WCUZ2
M5'9%@65"^%:C3M*>;M72]9KK)2LO02AN.F76A>1M9C87$CZMB,"D%Z<Q6A.4
M>")/*V2!([J(I2>W!Y4T;_Z\N/\`+%/NO]'?Q;;H_6BA^#M\#Q^7F>\7P><>
M`/`*24A3&G\-B%HG+C!2P0PO(HL1WHB9K,&2Q6@NQOHFH`AA2Y<7/$$9!CF8
MO`+_`/J0AI8@-7W5D.EN[3V>I#"5Y==95NM*4/"K=CVV;%)E"6/KP?+\EYON
MS-YJ[)KV97S7FXC89>I(/S)5-C4;L)NBR%&GAOI+DE6<]1976!@HRZC=NC*H
MHH:A3POO#4*GP5W2"-0NY^HQ<3AK8VD/7G0VJ'(CUPN<LIX=AZ^<P"?0&Y6V
MQ%H68JY,#[RO.F?NWN>X[0M0US9NG-DMJJOVO?-3RV6@'U>);BD_8$]9"+MP
M1!)L:M5EIJ/M!SK,E4$ZF`N%'HVL&M;I]=H.#&E:WU7*0RC6BU[59)UG*FF5
MUOGM93>P):RC]0^L&KV.Q*W2;$UV(G,%JGP-4TXHM=&1"7M\\I=LKC^V=)\4
M=)GKWPE3MK)>@H`EJ?F+%<NLU(5Y^4K1%5NG&^=)[+ZZ3-D=9U%K2RU+7+:Z
M4ZD;(LJJB4Y=%>;74*0]?L<%RD62`_%F'$Z71<$%R$-(XT#4M+"29-*I*G&D
MC(D$F]2R(WO?5$:X;^I&_N-A.V!U0LREY#KK8BT?8>M$T8""6N%&ZS13&H#M
M:7,P67EKA:0&K@&.R0".S*RQF@^BS%G24MJH]N?L8[+H5Y?J0G<\M:_PXK<'
M(141M)T!/<'P[C4[>Q+\N+H1+5-Y@+J^(_Y0+!JY7+PDF3(\1V=RD(,N@%;#
MPX^LK[M\N$\J=,=<HM46Q[=LKA)R980#@"M=Z[KH6K="KYS68C&6RI]4`'/Y
M,;R9\%'`VN#RV/VA^$YV,/P`Q>0F`C<_=U>J>1DSX(/`,.^YU?U6HZV[+<6W
M7U(?K`3E]AC5MJM23X6%TL3I75(38H[;JK;]<CLMBX=?5OEVYUZ]CD@:R#LR
MU*^4ETN&H9S2GU?-&*KR-"IZ3ZA=GV"[`-*9LJZ)*O%H=D?0#`FG%TV75SZS
M#6=6O.JE;MT5+0CN%;]R'64B:02OV'9(E:`49L6HH8O5C7+-12G_`!,X>Q#U
M6NZK=3&EQ:KUL<FM$1"U[3M@(*.0SV1CJE,34JI4=EVULLVK1:_<#\&'#'9]
M`V+6K?6J^OYDLE@D6M3F(8*[EPPGE:F4I95D;%UFC]91<HV5@IU>N]L11`8A
M7J^(:[:[]C\JEXE2\EW(U/BY8F(H\!A`'!9$CB7`.`T\\UKF4P($F\R+_M7/
M^>O-E^RQ<_J_SN;C>?-*^KNM?A?KCQEQQQ']:_J7]>?EWP>/"/G'ZQ?'<UCV
MUGXWY+S\'X$Z6X^\O0J.NNMT-)V58=GS7&8$NP2V+@G7^KT(VJ=1G\O#<B,+
M1::<N8/65QVAA!SS$QV`ZM&<AI$DY2U&BPSC%A"?3KNR6@Z6@NJ%3ZY6Z_OZ
M+97[95L>%3*^!NHJ2P6WYNAQR%5GD;1C7+KY<O:NG+A;,-J-=A7-R?F,R+NG
MO03CF`W/^+::66R2T$Z[$I\]_I5AIHUPN%!FL`/P.-OH#(1-<4F/,\,LDZ%J
M:O:0KBYXHLP\S,`\BX!R)Y%Y`1^(QHXA%76C1QV@:2_J#-\DN![>^VRY$7,-
M"Z46>S?6=ARP@EV"SL=PO3RX6A$-E!51;4SL,Y1=30UI?F,-PLXQR%;GU_",
MB?!#!3OIRH7436U@(<;:566/::FIT>'4=JNRARTLUZ2/40B\FN5#<.GL+1A-
MQ[<<<S&3DI"+DP/#!"7RO&H@U#C:TZRPUI^ABGW#&H4.I.L+MI7]/S[%8ZGS
M/7[#PJVO;VGJJ*AT%,\(MJ0S8_77>KFVT.HL+#F8E0I7="LSR*QX8KV!,K1F
MS0@L>%IMX4:EZI&X9DH4N8QH6ZM<UA"8KVX<3((8Z,1LI*C.5-!L"HI<8&*P
MV&$Q>;%Q@2&5%&0-+'-'CGP,FMW9<:5WWIJM3ELUAJEX:@)I40]'V13J(Q+I
M2ZAWIV;=+`(@D4W+9$RNX)@J^HU+M<'9="R4QNKLHJ^,`SEA6Q59\93RIDM=
MS.M=I[520QJSKNNJ;573H%DN8V*H5Y94K1,*WX]K'B*SUL978!)R9/=(Y,#9
M0&1EQPF0SQE0Q38"3>9CYJ[IU7-*5[=M8H+Y8^2;ISX:LUVXJ!6]AQ8V3&JJ
M*7]+;CD>5`L&U*V6@0K?G0&P7CBZ6%Q*[>.MBF'OC\\A6YRT4IKGLX:#GYZ_
M5C577[=%7?;#V,YK3VIV)TYYAN!&OU%%6K*^202FU,'37FOA]54L3@:6:!$M
MMJJ#$;*49W9Y`Y"B_`FZ44]4YO3.<R!>M-!8[RU2LL(^Q]@T]S0NPQ.RZ=8G
M0\5FVAQ\RT`%2X5^T5&X7>Z>5S65#L=J<H!@?YE!5G"BG1_)R)VB;$5N3SI+
M1?"4LBH=I]85C4_44:E6:PS6&JX[:;/;I=+AG6$X<`^W+S>;);97E;484JLM
MT3,Z_,*0+75A-:8*U[L%_7&H]QKJ<V0$YNVS4J7GD9H=?5BE-HC3"I`;&R1K
M]5T`1.Q@&B"'8+(:LKP!-&"'),&"&+&XBG&"$*G"#@DC&#DY%BB\$=WK,,/4
M>_MGTZ_SEO7_`/4+=/@L/B^UFQQDH4N8Q8FZM<UB!8@-PHF00QT8;943&:K:
M"X%12XCL5ID418!L7&!(9,<<X\L<N&.?`R:Q0*ZBJ_J$U]J^LCBR6]Y)LT!`
MMM1(VVDE-56JMPVCA91K8[@UNTT=8QU5;`,GHJ(;<XH=3NQBZ3)&#?U#^0:G
M\LL+Y5GMGHM;0=)8NW%;.PNS9!!KW4A[]5;)6H)29;LAM]0RN".KUN5^*3<7
MJ+6.P:II]N&98JXKUJK2OPH9V+5;97S)PT%M844L=TFE/;73ML9-=>NL1FC+
M._?X':56JG-,2U6:K:/T*;I10S,1L#3!;3;H)]K[)PM=A@%.*6A'<CK#8A3#
M<"2F&,\,8HC<\]KGR1#WIKVD)IJ4BKBQFX<4^O:T@"DFV4_V0`;7CJKG#7V2
M_AMMG<,5"X.'5$2Y:XGL">T5H7X#.QUH$=@B-9"Q7Z7);\<S/FU4JFWM?"HN
M]2K-R5#&1L1UEJ0JK"O@810$#1'0A-Q3!HC(ABRAXRL(\9\("2(L<^(YI,<A
MF<K'?0U]#5E(:"L)%%<1+L9,%Z5"M#4*0<)IY29L`UR^$<,;&4F:8B3&&'#B
M2>667+CF23/+D#7-ZB#2YL<=,:YIEK'I#.X7GG$5[+LR"FCYS*ZS;;<:&U5"
M7;7KWD69%2FP"NRXV`Y2M;-L!\ZX8XF4N$0U#*L\LD]&.OJSH6^H`+=V*U%\
M\JMF95+2MFTJD=[$6/4\P1&S+FU%RIZ?9?`.Y:0K9JQU=ED^!#M-"L!@#6__
M`$Z1#(+L5!!8P5G6\Z=)\K7R\P_\L4^Z_P!'?Q;;H_6BA^#M\#Q^7F>\7P><
M>`/`*+9,SHZ\^D5PN2&4:5IFN@KG->QL,YV(,^0D*'*W20U3%S(1Q'@KYL\T
M5>X.R@Y=28+?B<N`-;_2_3&\:'SOZ\66F/-7[$VL776Z9/M)%UGL"-02#FWQ
MFQ:6GK$UK;B[M2^"OF#T8I-0JNB(+%7509^5%8+8_&HI4DYRRGP=NK%X7JA7
M/2G73L\Q;U[7-L@MZ%NQ74#4M;%U)0ZSS)5)PG5F8QO=N4\CDT]IC\_L+BO7
MFMVPN:`+A"3@[B'81"7:G[X[=4C%JZIPK!TR'GNM3L$]@>;FE5UL;:BO?4EA
MN[&PW*IUL.V[BXUQMF\VT%>N6Q?$EYYVFYIP$%9K;-#7$^2@&G+!;17PK*66
M&'I.Z+KV^^'HG33J2XB3/ZV36=J`*U]=JK?8.N,YB\=?;JJYDH-F?[WTQ;ZQ
M3/@"&5NA>;"O\7,E1%C,M=65SD31UL,7)KT>*T.;U8V-IVM'PEIUQ0+.!F3(
M#8Z357P4ADI1!F8CA$`P&S+G.8-CIB<H2,,IY3&K,J27G+,A@9-SF3(,LO;P
M#5YE:FYWJ&)E;#.Y(<Q[(P5"(37JB:5I71M%W$L9T!7%?8&/'/238V`9IE9C
MNO+1T-N+,:KGWL;A?BIJ8UX7;IZKZ)VP-H?@R/`'@$;[4K]OM55GK]2XUO/P
MVDS!L2[:E39W2JMZV4&7"<LG1K']?^(D*FS%XS^.(+`D#Q+'F"DSFCDA`UZ]
ME-![W.T!K;1U3KMEV*>7;-B'V%YJI-UOK^N=7(FMJ9V"G1BT+L&ZDLK$>B(7
MT-!UQ4=:W2F8%5]6\%MEVK2S-&M.&DU.=M<[XVSQG/46SW'XL=-U9H#7"/6>
MP6QRS3KQ#$2@XJB>S,.0J;7$IFJ['3M(;]TUB+2'Q(*B+;N=$!?:QKTG--%I
M<?!<B4]""O.<J].;3TRG7GMS@Q]R&''Z/"+W8H\?HHO^SC]F'''T<?\`1Q_H
M8>SW</Z./]'CC^CQ_P!'@R<O@#P!X`\`>`/`-=?J`ZRV]N%3KFB:UH^R+(NS
M=D61U:ZIQU:8(=<-*_(%FALV58WT6GM]EO4GQC`"KBT2VT5,(KGLI5LM.?.*
MJL60:A:4Y\^1*FV=);*V)KNO4&I%ZCK29505BVOL-D:K'LM_UQ>AD9J8"[5#
M*C6RNT*K6:J#D`D(LJDKA`3.@R>49V*>0*"`2=>-ZKB9@>"&KTYY8''J!IED
M>N;>$G4V:'EF5BPE8T(CD73-S&#V;9HJGOLRO)MA2QY)*U4UMPTOF^(H3)*P
M:S#'_58NFC7ANN=\)J>=G+UGM"\&1X!8VST3FT:TV'6:Y]7^;#8J-;42'BV!
MPL:K\Y;H&"]7]9EY*QT.=7_CB(/G(9"=M"2N^)AE6'QYY"R@NI$*]0M5YZ@U
M%'6,\:YEP98#WD1=9M];O@)XY:]0&.1+:JQI/0PC.:*%?@`/\73##`U0:X'!
M^2M&7+%`K<WU[O$IW:"<F0C7ZQLKO4%%RQN;LF^:OHFX-@;!I>RE2Y4MUQBE
M7:1FDN2=<X7V"^3V)T4H8UHY2CEHSDA;E=0II076K;LXX$L:!6-$VC=/*7E:
MQIKI;K*CA-ZIC,R(^KS,:MKHCU&<[IU9',DP)6,L$^3>QV)I]-A)\P?NC.)F
M90.[UF%WJ/?VSZ=?YRWK_P#J%NGP6'Q?:S9;X,FJC<;^CU'OCKG93B>16)4F
M.-+M5BQU]9[2J',LFF;LXP42MT'4]V#6[`*F^26EU;F/9Q-S6M>+R\'JT"KL
M_E#0:7=>^^G7KPN5'3M=I^7J/;_?<,S%]Z$K/PY%)G&^,ER0RKZ?*)?<[()J
M],P^7OY&F:T>NV3:%H!'B6)1U:G`2LU:*M!X5KZQY+UKLP?/$U93,[!86H*-
M&G#G/:N&94`*]:$/ASG.6685G@.-!#AQSEG--GC'AQQ[<N>./!DUZ>F[:#7N
MO+,$SM,UT800T:P3V.1]>[`0=C:D)1..5KDNN\MU1(-H22+YC=C4ZNRUQ37&
MI@D<<;B(H<H8:BO:76I;.D;(?!D>`6L_HU)M<\!5HI]6LA(L/(XQ#^OJ7$X\
M'.?,G,,$S$0B2*'F3+*3F./+'#G/GG+G'WN>>?`(SL/7B@V2WS6TPRYAPLGU
M4M5EIJ>XNE5$M]HHO"'"HOK)6A",("C$\-6K0DXP<P*NQ+D"A7;5[]:`.)@+
M/FMYXK_Y8I]U_H[^+;='ZT4/P=_@>/R\SWB^#SCP!X`\`>`0)VG#&8]:M]+S
M(&Q0I^H[^$0,BDXC;D1%UEB/G"!S\HL/,D\G$GN<#X5RR2DX\Y#0UNP2RX)C
M15=:T8(6U;;2_3MNZA<ERK-R%NJ..GY`I[V!RXL`>VJBPJSK7`:33]-V&0X+
M;8B0U$R73RO,NV!\3X8,*AR)<3Q9_-/VRTM\3[;D6T=DZPTHB'+[`_5*.CW<
MYM9=+,VK.XYW97;<TE8U_MK/8]EI-ED^0))':S:BW)!7[&YNB\P`%IKZ!'&J
M)!7<Y+7;91[-&9LSUK-82-<T`BW)?JW:YZ359K/7?CYVOR&PRH@,W27YH4<S
M*9?*V61(/QY+)A.9]!\1,<7))E/(,E[>`:F4#8YWZBZX%A+9DQXKO9KR`_::
M.MZX;6.K5"@%T0*AZ.EC`?6[:&K9C[0-L`Q;.UIE=->U-_LB`=DQ4DCFC7AP
MV3]:R3]<*&V;P9'@#P!X`\`UO^H0N),AU&6KK;6UO$\FQ6:]&,`S>`-(HDR2
M,A7"@2ZCW.P+N32>4$"F&$5VM)(9IFRAG?DL[Y<DLXU#KE;CK5,Z[*36QV/G
MG*./GG#*/GG#'GG#/W/?PYYQXYYPS]S+/#WL?^C+W,\L/;QS[N67'LYY&3]^
M`/`'@#P!X`\`>`/`'@&MQBO*@]0H-PMK#=J.:,D5/FTP#!GDBY'U3:RQFZME
M!J5JA04_#Z1>G9B--W5=WQ;'/TPE`D@LZP^ZC7AOLVK3R>.-MD?@R/`('[/E
M2!]>MQ$<QQRK<-?V7BS?2K)''$5+S6$878B-=#<J`3.0-4LG,XO(=J7G0DQQ
M3APLB8XEA@JNNM6#X$">G4@4H-"'Q*K(#;N3;VPF-L(!FGBHCY%U4IM=6891
MZ)V%L?7`62ZN(T:J,96T4FR#`P'MDF)YLSAR+%?^]>*3QQ,\_!D>`:TO4>_M
MGTZ_SEO7_P#4+=/@U#XOM9LM\&33[914N/J64-#?%ZFRLGSBRCTUF?JZO%Y1
MUI3JUML*.LG6RT]E.;:3F@L+[YFD=UGKVZJV'(/")9(M+K%L>5$:\..FKENE
M+U]BX.K[/:]M[2.;?>]>7*II6:^ZN(*NTTWNRE5^C6NR5C4I[^PB[$O.$-.M
M1[$[!IJ9DG5?$"NVFN3MKTF)#6+I(EC!R2IGFJWRZK+`V>7.O$VVIV*L!VBR
M4HI^G/4P6ZG3JQ;57)#A\Q^&]>)=*GBH9N%[_P!,"0<H800SXX29#2<X\>P9
M(-ZS:$;:"1W!([M2[83"QVQE9.=A%KK1CL1^(P./*`5[$LEQN^P'EP+J@A42
M2O.)7PHT".*!:&@4#B88D"MSZZD9,>"#P!X`\`\'7\L4^Z_T=_%MNC]:*'X/
M1\#Q^7F>\7P><>`/`'@#P#$_NI<0:QH*UHC&>JDTNTX6&J%S3=MH'IVKPSK=
M7'_/$EL?L*/L1,,)F&O+A%&?U1FE9,)!%IPQ>)>(!8JNK[+F*5K%41=$)ZRE
M35W>R9[=4XL;[6EFT'O.D5MP-LRNLD%C/R:4_K_KVXR5VSBJIQ*Q%0LOI+",
M`OL!XR[(VS`"^+*6M86Q:]MQF7U2UBSU-J%95FE<IE6(S,Y:_*:AJNBZ>FQD
M+5*86!-OJ&L;3<-><6XEN*QD*84]QFHG3\I!>(OC`BR"!&YO^9F27@@\`_.6
M&&7.&66..7,>7.<?.6/'/.&?.&4?.6'//'MQRYPSSPYRQ]G/N9Y8^WV9<\<@
M?KP!X`\`>`/`-6O>:S5JQ[2HNL'=^ZZT+"EU#'8QY>W=ST;4MY)^OK&RU1#S
M1Y=E==][5L]#%S0K)%;(U<*MY*477\ISEB\+@*U#4.==D^33ZW;2,?\`JX__
M`'_H\?S\<^WC_H_^W/''''/^OCCC_5QX,GZ\`>`/`'@#P!X`\`>`/`-6E#LM
M9V+WC;W/"_\`709BGM=SUNKI%>W/1<-UL,M7`7JBN\;CJMWUVRV0Q=#N%KMJ
M'\BW>E2`TW,0P4)FN7GDW$:M#C@[4XR]/XVE^#(\`A[L%%:IM'[8QI;AH@LG
M%`M,H#6OUQG:[0-A"G+E-QIR)/;*0Q*NQ`&!(U,E'LR_D&SS*3Y,#HALUY0J
MNC'GT_7K&RZ8?.CY_I(S[_-.".L%L(]%60R4+7^9ZO6\EGM]U:&UH)]DXC=E
MY-AX>=C_`%\'C5@Y#YXY@Z/J=W?JTC.?P0>`:TO4>_MGTZ_SEO7_`/4+=/@U
M#XOM9LM\&3&'6VGMT4+9]JLA^\45MUE9FEA,BUVUUO:\7R`1OL';>Q0HTMSF
MW2?7Q6@A^T0ZTS:XZUXB<4F@4]#"M4S+XF4(K:E:O]:-&>)D]X(/`'@#P!X`
M\`>`>#K^6*?=?Z._BVW1^M%#\'H^!X_+S/>+X/./`'@#P![?9_/S_-QX!26:
M),ZG3$-5PAY%>;8OD<A,>,DBMQ@O8*<60?//\\16*YLR"XEX_GX@-(C_`.C/
MGP"U-B:FU?MU6&DVIKVF;&3+S<&0*J[5M39EX;"/CW8SA@W`I8\)6''\V$^$
M>,N'LX]W+CGCCP)RL7/7:X@J*1;6JLF65VO)AL0E*1,$.N5K1,.<LL!@01(X
MAAH,><LN<8H8\,..<N>>./Y_`*UX`\`>`/`'@#P!X!\XYXY_GXYXYX__`,?S
M^`4J%$G'>L;-`N%BL#=2E1,V^$7'!QR>NF/F"-<1-_UI!59MHL1(<7/\T,S@
M[/C^>?+P"K>`/`'@#P!X`\`>`/`*44]2!'BJC7*H1H;Q'R&M*8"#GE\2R9PQ
M<BARS8$3\22QR11\Q1Y\9R89X8^W+'GC@"J^`4A*C35X2=>B7B*PYF[YX0*%
M'C%%FYM+MA:+"PDPQ_\`[MP^<,G!TG/]*<P^>?+^>3P"K^`<?$T.4V8^,L?,
M\4<4TD'&>/,T<,^4V$$N<?'/OX1S9CD819Y8\8R9038X<\\Q9\8@1MMS79&T
M*;Q6`K4RI3`:T46W*[(J!6,RP&E"NB&ZKL,E[B`A>8&:8AA`803Q^W,$DCB&
M2*?Z.7`$Y=9G'IK7SK5FNJU0'=]<;(SJBI6@66:P+5*UU.F2J5ZA="T^30#B
ML#^(P<B3&DD6))Q14TDO'''&&/`-S<R4?`'@&M+U'O[9].O\Y;U__4+=/@U#
MXOM9LM\&1X!TXF*^;/&.$X.63.8D?".(F&3/.<++W3(<<<,^<LIA,OZ),?''
M.<&7\TN.'/@'-P1!SQQSQ/#SQEC#ECSQ)ASQSB1ESB/EQ[,OY\9\N.<8>>/Y
MI<N.>,/>YXY\`^<%#<RQ0<$P<SSPR$PP\31\RS#Q9182SQ1\9>_)#'G/#A)+
MAQSAAE-%CEEQS)AQR!RXY8YXXYX98YX9X\989X\\98Y8Y<>W'+'+CV\98Y<<
M\<\<\<\\<\<^WC^;P#]>`/`'@'@Z_EBGW7^COXMMT?K10_!Z/@>/R\SWB^#S
MCP!X`\`B7?>N)MPZ1VWJ@;)+$1LG75PHT!-A"S9)0IK2B.2Q,3P(\<LS(UN9
MF)^`^'N92S#QXXRP\\\2X"IR:>3F8F;$ZM6V-;9;6;V3N&OE^$>X[%8WL.Q=
MG(0*\ML$>Y#Z,,O;#7]5Q5*5JC"XZ^)PKBB1/5#(]90S2J!^3N>8!9VHO31H
MT/>4ESU-W';[-;+HI[-/HRC8MRUBI,EMNV.1]2B[NVOO$UE7A87.5&`_ITQU
M/U[G1%H*^K+H-;XVA5E7;87\O5!.U%A.BT<;[<KTAKUBWXYK-XUS7.V-F$NA
M"U;+/8Y]J;./OVO5;P#*).F$A7.%%?G7POTQEK7[!84@.X6\2%]K?DQ(LP^L
M*L)V;2W*K_K#.LL#+S3>I+CK>PW]U9MGV>_#74F5@,L?OK6X"KK&796W;5SD
M@#L5@<@5U;C3+M0:1&DK(J9/%!KH4J('#$J*$81N<J6]E_>TG[P0>`/`'@#P
M#JG@`M`3%C,,5BM8BD`,%YX\)8)X)<.8Y89@A&$D!0I4$DD!`\\><,T.><<F
M&6&66/(&LJY]0KUJ_6-A@TWM5/J=%7]=;7/E"K;BR:=JX=G;*]R%\65AE4;`
MFK,61T=WH>#J\V0(MY0`=.)V--+`.:<L*^-)YJ==;=J>F>)6"^GVZK`$+BT[
M#6-VJQLE:O8"TJ_[JX@C%KVUJIM!#JK%C]?<R9*ZFQK?R\#<,XTFXB_CL1V!
M>5<%YK9(3K:EK5M*?\6VU*>)H7<-:83TH[N"V>[`=J;\(D$N.S+Z,RBL-\JO
MLH^P$]5K%@K'.?(6&I]AL@=8L<K#5%D<%PL=39C2U]Z(R":O*E,%@[3VJNQS
MN31HSKCMG6KU%8[SV`O6QBUQUG'.7/+=>7"<RHN(VTJ-"0H:V#FLG.JX>2FD
MQO&=7"L)XZB4;&0`)D0!P(WHE[YV]+&9_@@\`>`/`'@#P#'/=W7X3;K5;8P7
M@=0MR/7NU*77K@/7HV%EKK38",1:BM*1S"R4M%IM'9CYO5D8!XA69LV68+-.
M3QR9R*G+5BLS$UIU8VXD;\,;)V8*K5:C:U9?7\8W6V,Q[`;9MD74Z/3)*N?;
M&,8>NF<=VJ.O<,PLR+\U`J=;F%LJ0-?@HC%FLNDKVGA/+1B=JN=*-APF(;+7
M^UMJ'!966FW]\>CALGQ5UF!UWI6GCGEGO+[8\B^8H]4'25T@[@^8U#L1\BN9
M%O\`H)SG03T9_M[^AS+NI^S+18ZKF/VO91(-9956E;#J%.BV.`;8ST+6>V6P
M&R6)ON%Y=%C2_IGU;;%<E.B^!()PFZZ,T1F.<2$TL+SE.6.S!KD96ZBZ[4[5
MC2*Z93,;+M$BA5_7%AV"U;V,MA8*U5IY)$4!@;A\ZAY+%A^%@G:32$MC\A,2
M#3YIR"LYAF?N9`^`/`'@#P#6EZCW]L^G7^<MZ_\`ZA;I\&H?%]K-EO@R4:QI
M^;#7GR#%DQ39/$S1/BX3S_"ME7+,&<+ADK)]W+X=B#S/\4%/[N7T),44GN\^
M[[/`-=3KID$I)T5>++:M+Z^QT">O@7AT;4BRI56]-S+SUTGKA%AS.<LK0IL#
M-AIX14DBIEE6LLVSVIUIJ5?ZLH=U*]#4[WKIU^_3M=VN.JMG&RZY6AS?]?V/
M#16L:WKQ*/7*HSBK&TZVNIC.L+WMV^,LS/A@RK^##AUK24;@D*H2639$$.+/
MB]XFH@;O2[W5ZGLR*'KKJ7*O?:VGYN&J;,9H76E1TW9*Z/2B,@^6%-U7NVLH
MJJ:-,\)S24RUU#L;7[78ZL0-/SG]64N87QR^Q"D(@G1K.;]5OL9H:7I#/66H
M-7:W<,P73/7VOZA2"W"P,A>"UDJB$!#BQ'`**-(#P-C`P)Y%E,)Y@SDRCXGE
MQQXSY&75MYDF>`/`'@'@Z_EBGW7^COXMMT?K10_!Z/@>/R\SWB^#SCP!X`\`
M>`1SMBEFWZC,*\K,#"<0MJE:$DC*.65/.]HEO0WE(N>Q#\<DRUYLVKH:NPQC
M<<E9I3#\1N.9^8^.0_GUH1*ZZQ*K`,C7,;O9L%*+:UCVA&"#"L%D:CW;8%\O
MMYUW83>1I)W.O+;G<5R1L@FXCPE7T])+])R3E/ER+/A+5I6DDFK4)XIV-9;V
M\>BM\V^O=>T2#*`'$$TR6GN]A/F#MM@/C$%'R;/>HPE:L:.:-7$M/,Q,DS?R
MA@"=<"5_`'@#P!X`\`>`/`(\VU2B=C:RO5%".'6'6FL-E"\XV#,M<.P)%DX`
MR;`Q212,4N1G$.#E9C+%RR59&`_2Q?$>_B!BZRZ-TU_9[';'5C)R8/+@UO@>
M$=;JK&=3:6:;>`H#IBP=J#Q[@]H;;>;2?6SMTEBRJB"CT&NCKI(UC0YN+-\L
M=&G&5=;&KNER[4<-,`KMMD-7*+37G;S$D0T?X-=5;WO_`&HJ4TC@UF_9JAY[
MCN_)"7@ZL#J7['R<I-D84P;$,.`<3?6I<M]3.7P0>`/`'@#P!X`\`>`1W?J4
M5;"]>-EQXX+37NPUEU#P.'S*7,!I$=BI=B7E0Q9Q2\$2U&XV"9$3A)Q@!9QT
M;`F,H,4D,@"&E_5*MKLM02Q7BZ93:1J<=.IOO1U3@4Q2MIB"LU7*V@8UO@2U
M$T=^BRV-4)6L4O"6ZM6)4&'*WD9<.+.]%7K/&ST$PT6CG55[LY^Q:PLB=A7)
M;8XXX!>!>``DVOZ51!82\L.<(3F9W-1F=&FQ"!X0XM!TD4<PJ48L@3(DCP!X
M`\`>`/`-:7J/?VSZ=?YRWK_^H6Z?!J'Q?:S9;X,CP".MH4LR]5U:L7&B@GI[
MUK>["Y'Q23@%YT&_5RYRJR\(N><H\6HR.9<,?Q$3DG/)$=1AFRKHQ9@5/7U4
MB(QNKE>P#TD`;<K6>'HKZO+ZU!S@C&X=U:M(*+POJEGS@5\2G`8[.UG0]P\G
MAR+W/UHK`*+YAS2B6U=9"SOIZX-K;G)DFT:A.*[;;O;K`_B>LK.LH->@G'!A
M6\D*Z.C*PY<.A!8X0<K.\LMBM)1TRV`9?"ACJZ<8;#Y1)+,(2IX`\`>`/`/!
MU_+%/NO]'?Q;;H_6BA^#T?`\?EYGO%\'G'@#P!X`\`>`/`(PW-MZEZ%UC;MN
M[#G;#TVD@CL'4B)&TLSG*,MB&I$'5H$@QC9L<4P8""C!+Q9R9I9L<<(^?!4F
MW)7,:OM]:+^#[WD_0G[&_P`!>2:T[G["3T;U[C[?6B_@^]Y/T)^QO\!>)K3N
M?L)/1O7N/M]:+^#[WD_0G[&_P%XFM.Y^PD]&]>X^WUHOX/O>3]"?L;_`7B:T
M[G["3T;U[C[?6B_@^]Y/T)^QO\!>)K3N?L)/1O7N/M]:+^#[WD_0G[&_P%XF
MM.Y^PD]&]>X^WUHOX/O>3]"?L;_`7B:T[G["3T;U[C[?6B_@^]Y/T)^QO\!>
M)K3N?L)/1O7N/M]:+^#[WD_0G[&_P%XFM.Y^PD]&]>X^WUHOX/O>3]"?L;_`
M7B:T[G["3T;U[C[?6B_@^]Y/T)^QO\!>)K3N?L)/1O7N/M]:+^#[WD_0G[&_
MP%XFM.Y^PD]&]>X^WUHOX/O>3]"?L;_`7B:T[G["3T;U[C[?6B_@^]Y/T)^Q
MO\!>)K3N?L)/1O7N/M]:+^#[WD_0G[&_P%XFM.Y^PD]&]>X^WUHOX/O>3]"?
ML;_`7B:T[G["3T;U[C[?6B_@^]Y/T)^QO\!>)K3N?L)/1O7N/M]:+^#[WD_0
MG[&_P%XFM.Y^PD]&]>X^WUHOX/O>3]"?L;_`7B:T[G["3T;U[C[?6B_@^]Y/
MT)^QO\!>)K3N?L)/1O7N/M]:+^#[WD_0G[&_P%XFM.Y^PD]&]>X^WUHOX/O>
M3]"?L;_`7B:T[G["3T;U[C[?6B_@^]Y/T)^QO\!>)K3N?L)/1O7N/M]:+^#[
MWD_0G[&_P%XFM.Y^PD]&]>X^WUHOX/O>3]"?L;_`7B:T[G["3T;U[DDZ3[8:
MWWM=;GKFNUO<5+O%$JU1NSVL[BTWL/4+7*J7AM;D5;>JA;\A22.%YS>BVE?D
M0NX(P')531S\X9<X<97JTN(::_M.VK64WMSU9&[6T[7=?CVOL'2EGU/N*I;P
MH.Q-:AT9E8DEUIJJRIUF>:S8U2NU48K\P[4RYG$8(2.,I\!9.,^,(Y(I@3E@
MG24G/DTR`/M)>V/_`'LW<+_*3HQ_\5?!>TOHAWQ_]#[27MC_`-[-W"_RDZ,?
M_%7P.TOHAWQ_]#[27MC_`-[-W"_RDZ,?_%7P.TOHAWQ_]#[27MC_`-[-W"_R
MDZ,?_%7P.TOHAWQ_]#[27MC_`-[-W"_RDZ,?_%7P.TOHAWQ_]#[27MC_`-[-
MW"_RDZ,?_%7P.TOHAWQ_]#[27MC_`-[-W"_RDZ,?_%7P.TOHAWQ_]#[27MC_
M`-[-W"_RDZ,?_%7P.TOHAWQ_]#[27MC_`-[-W"_RDZ,?_%7P.TOHAWQ_]&$G
M;+T`J;WM;TQ[VZ[V]N]QM==KFZFDERI.L-*Y1+WY(9CD?B*AZ`KL##@XE:!+
M](QB)F'Y']T>2/"63'(:A^(X9]F&%3OWG;7$>@?P<QX`\`>`/`'@#P#!OU)/
MO+-T?_ZZ]_WJT;P:@[RV\&3+VHL=NJ/77<-EH;1RCMJ6CMCDCJO*1'KQ.1%A
MA]*T4J#E#\(\]>+S.6/`4D:P<R0\92`DXX\QY"*ZG:9A3:]FZZ"JUE,K_?[L
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M9".PDSNN8QR+&OE@KARTKXKX!1.`:/&)2:O*DY^MB\MAV'</UKU<%6$MA4*6
MVP@N'#:NXHK/7.-=#YU\IOQL]78*:':*W87&$[%#6PZ4[P7I,LV%ML=J/Q3!
M4QR"E75Z_P`7KJTF2'@AI\W_`+CV"B[%[@K3GL5NG4571D42.@5ZDT6EG(#D
MK#7M;:.6\#9[I.]GLR)K:6^$*DY?9Q"R!_`QBC_#<XY:2AE5RZU,/M4[,*BI
M5UO-THUA(J/7G:^][8W[,+*-M?:&[X*]IO5SB@$;`IU%1S*K^XLVV@[4%5#H
MM;ZM0-[!+6DU;,`3VHPM!&WB2?-BE2IF?/*?9P<\^I(JG)=J%0N;SM32WG8F
M%IL[NRAI#YM3M597(U<#Q'4UNR0U)=PMS<JU[1YC-=,J3)J);6$N58JU`6+U
M&>JL&:EQLE:QM#Z1#6[([QR7Y?ZU+.>.G#45=/LGNO+MF$([5U:BUDTO@B4\
MUJI*"YJM8!MGR\SY#.CLK]G96#>H$EV*.^O1D=1S.0@J.*O79WF',HE.L_9;
M]+)H";[TBW%LR!4G)L6NH55&XK@M\8I:6E5N\I[+Q<,:@ZK=!=6*PP3K>*N9
M"-8.6@>!DAH_-D13QRJ.`I+37E+F7)U]*W87KR23L"`E7[&QNFPHYHJ].-.D
MSK7%V>94W)5\,*+G@MAJ^:L);RR^(>$KQ13GY4[HL[+@'*=+?P1[W/O%]U[I
MB&Q:]8['3LN=D:N4O6^IJ2EV!?%M.=7=.LM)26O6*D;&1\<<*R98CV[.G-Q4
M:^4IMGB+R)P9`"WWT84Q7$P*^S'N>"P:X%J7:3MK>F\>Y=$)+37K)U,J2ZGW
M5%=]TT)+?*\&S#Z4T1PAIE.UB\L9EGV<=:JI-Q,JE9+<$>`YN:VTE2_5]>$K
M9L*>*ADDYN;O*DOFP]<C,OBR]KL-EV-6'7F6:XEXT%#:/PZ>?J>LU?/;M545
M=DD1I0ZQL.SNV.F#&]I<E'[@RB3751:U1U'`5$T7(Z%I+J<Y;J.6%L;D4Y;D
M]0-J.*2/H1$D.7EVQD$FP`%R'O0XFKWSBOUFPN6FP)<-;?`;&EK-3:,A1[/Q
M="933ZLS1UI.8V;B4S]-/K2N!DP':]XDU_K^U=H\0'CS8Q@.W%50KYDR<>E3
MU[8`R=@1#:\.+'6@^7<=!:,/9SRU7SS%`SR3+,#9,PI7TWKE,[Z9GNDC>:,=
MT`P7:_DU;9)K@I`G1O*$IOV-AJ/%/FJ]Q,I50NSD@Y%E;XVPA?'P8I$/&1"5
M;%BF8N0I+3/TK_!D3X(:"K=V7[3\;`V]\7LWMY1X*CN7<^L*3KJN]:J$>AO1
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MPFK:=?,?\N5KYEZX82F'5?:1"-6_Q*]Z_D-=4/\`?YW/\%P6M\$9R^"#P!X`
M\`>`/`'@#P!X`\`>`/`'@#P!X`\`>`/`(,[*:4C[%:0OVF9+2;2>;L`L'@M:
M]8&Y,1&J'RJP@'Q*F$D(3#Z,U0/C(*3+'%+%EGCEEQ[?!4Y.9!WV">ZWX>HO
MZ*NL?XE\%G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]
M/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+
M^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]
M/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+
M^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]
M/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+
M^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]
M/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+
M^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]
M/JQ]@GNM^'J+^BKK'^)?`G#]/JQ]@GNM^'J+^BKK'^)?`G#]/JRY=&=;-AZ[
MW+L7>6V-]%;LNM\UEK;4\'NZSK.M5E?J^M;5LZWKOH0ZZQ8<,3CVVU'GQ1)6
M4?,8XH44>//&.7/@C:<DE*^,[R]C+_P0>`/`'@#P!X`\`>`/`'@#P"PK+M'7
M=/\`K1Q9;BA534FMK;C;@YSXI&%<J;<UHO665NM'YF/"1&&)',$+28;$+G)2
MRRYFXP")RC`J-=O=-MH8IU<LR9L.:::L'X&.AX(R:+>".6*K,*7*,R!HOX#+
MR/6SP1G!XC3Y$P1<12<X@<(&Q:$T(3"+KG632K$KY=HQAW:^0AJIQ"4,N3PH
M<2.9)Q_ES]*?QGACS[0F@17'',$^$G('6(VAKD4H`(B[U>(EFSE3@1Y.0?82
MQ@J4%\F'CDXFYB_JJ:4'8\YLL\1\59P!',OL.$XF`N;!XFD(B%C:`23S<FXQ
MQQE0R>]FM-!6GQ>]AGEAQ.*P9`!3099<38%%10<X?29>[P!UB[36%YJY8?8D
M03%P#.S4@%M@!C&BX4]*K)/7C3$83&A#L[)7ETQ0V$D,1SU.)GGQ.S"CF`ZY
M-UIP<8LI=LK0L1Q@R\*0AZKAP,/,=#UL0(7*0K'$@LFQ%BH8!XN<Y97),"S#
M#(V:.#(#L<6FL98P98V-#EB5@#(-EPW7\XD1LQRBULD'/!'LEP8"@FD@Y1^]
MB6.&5-!S)&/+E@!^YK+7!Q8#IWZ2`$D4HX8R9J#&*0$#CAD:9`1G/C#**'C)
MAD41'GE$/CGAS+GAQEQ[0.H)=::?$1.#;*T9"(82N*F%>JYXQF`3P^L&`D9Q
M%98PF"V54TKY`TG.,T+M<<JDPQ.$(@C`_!=XI@&4&)MLK@OQ.)&4&1#I=%')
MB(7(`3EQ)F1Q'QC"?%*!)SEEQQB;%()_]1'G'P!4XWR.;*3"%TIESBA/)EPC
M8AYY1CJB\@&9$F.,W/.$*X['((^7+CB,,O'(<C*.;CG#P#BCLM<ER'QBL"27
M(OY=\+C&U`SR)^<1YS*?A^,9^>9OFD4<DJ[Z/WOC8X\\QOI<<<N>`.J)<Z@=
M@3(':$!&`31TD,YC;@<_"N*YF7&_6$<<S\<PG)N0#<F0TG&,H<0LTTV.$4>6
M?`'$1>J2+$).3<*L/">2$$#+-8%,49AC)T!6UPHN>9?&)!!UB:JT(<,7.<A+
MEB"LAQS-+'@D`^BWBF&\F\"6RN$?+O;R=E$Z79X#8<*TKK*67/@CW.(<5%DK
M['*?C+F'$-TLGRSXP-'YD`XC+_1URX]L?;JZ$M5X%2,#"VX(\(D8637$B2;F
M:;#G'##Y$ZRPS]GNS8*CY(>9(Q9LL`.RYN=1KN$DCZSH$^,)24&;YDV!#YA,
ML9?P"`:7&>?#*.=T9QD,LCSQXR-EPDQ'XDYCD]T#M%V6N`?$?'/T@?PF.&1?
MQ;4$?X7&3(["/(CZ:?#Z'&3-8RPPYD]WC/)>=CC[>1)^(P.?YXD^A()^<*_A
MQ"A0BI_F`GT(QAW`>00A$OTWN0E&8L`,A8),L92.#@^8L,^"8??`X9[)71><
MN"GZ4;G$>,K+B=H##SB+-D/A$3EQ)/C[!Y<C!,8YN?ZO/(H?C'+GF>+C(#I@
M72G-%<[M9:ZVP3"QQRE-@GBPI8-%-ESC%).?`5F+#'+ECEC%G)+CC)SQSQAS
ME[/`.<RU5E?%%.;8$HD$S!BIC(G9AQ#\LU`#-JU`RGRFXBC+6+4K<T^"3/&0
M,9:;*1C'B-+SB!0'.TM<UX8,MU=*\O&/9,5(LL[&#W9#4\G,;GC+W,L^81DO
M\TKEA/Q&O4C98%L2AA9,)L@*H7>:6#'Q*9;:V/'DS3I<<I':[CVM[`SR2HUG
M''Q'//QS=MA(M7"^SZ8LV*8>'#.2&7'`#K<[%H/$CV'ZZ5?.:KU@2ZV.*)ZM
MFD15!ADZQ`LS7"(G/(%$=E6[!B&S(XC#*Y2->()<^0"?HP.R'>J6<K!=BVNO
MYJ62V5P$=FV!A@G603PB$FXY3S1\XCB&$0!&YR<8?!FRX!E<0DY<1>`=)GLO
M7J:!T2UNE9`@K;#E2_E)<@QX)V>"C-_*O8<\S?\`)3($44SHD>7W91E,!#$C
M&,,>:;`#KO\`:FN*NLS<V"ZUU6LC:8I,RR&4'T?#7)%S:>0_=CRSDYDBJF$E
ML(RXPYC%JD)%G(SB1#SL(P*HPO=)4@LF;*W5H(!.+D:U+(=K8X%XF,Y(W)!>
M?)/L@B^*",&QRD]G&1(I`^/MFADPQ`^G7FFK)T(Y]H1C36<^577\9&0ONMF$
M!<*^44.3&3F.27!F2&IYX]_CCEP>O4<<\LF`0LX'')?J1$+8#9+;7<`JG8!:
MI9R\FX/`U?LQN*7,5"YG^F^B7-9L;&ARQ!+SBGXX;@>]AC\3'[0.T7<:F`3B
M$9944!V:-S9H@,VH7Q\U=KDX8K]X.#C-R60J2E,5XK0Z"&08$DX,<B2.8J##
M,`)<J@>N5N`K57"U+Q8O=I68SM9.O;IFT@D*ILL,C*R'/6LICP8@#A9)13)3
M1(QY9,R(>,P/RMNM.<!@,5%LK30!K\!\L-7O59@C'YJ+(<K^!('*DB+^9!12
MF`?09R?&"QR$#_20X99\`?G*[TW`E>)E:Z[P0VBAF61?.5_M/C)Y&X%Y$R^(
M]R?DSXL?D+"/++,S"3WQ<9<,<\L0/I=UIP`,C,RU5X==#PHRF.E<+\1(<'[/
MA*DEEG^(^BBA:M\OEH$V>6,11G&8\6>4F&>.('9EM-8@RQPGL:&'/(CX/'"5
MNOCRR+^$@/\`A<<<R..>2/@2A3?H../I?A"8"?=^AFCSR`I!FR->K^&_QMYJ
M(V2!?RU=QR6)3Q,J6\96+#XX^#@OF84;+.H6N/"67#''.6LOX\.<I%##$<"K
MS6JLCY1836!/AG,7F!#'PQ$SED,B9P)IQL(L)<I,I16I,"\O'C'VB%RXPD_1
M9^WC@#BAN%3(-$6CV5$2>>)RP#$':@SD$@\"8'\&Q1PSYY9"Y`R1F1D>SZ*0
M7/&>//*+GWO`.,:ZT\QE$G$M->*:3J8'T(`S@"<J5*5-$,*VCBB(SRS7DSSP
MQ#EX\<PSYRQXQ9Y^_C[0.;ZVU3W<<OK/7O=R7\ML<OG2WW<E7`N1O+/'GXGV
M<K^`\<B^3./^3<"XY3\R?1<<Y^`5_'+'/''/#+'/#/'C+'+'GC+'+'+CVXY8
MY<>WC+'+CGCGCGCGGCGCGV\>`?KP#%?=>]M")&5PTILUBX%+LFM9OK-RNKK\
M@?BK729A3EJOZPK`)X('EA:F\HJTJCGR8'OG"L%?#(>R&BE%4Z-9\*]8&&YN
MQ^BV=\0;Q6*=GMK)5R5UAC-24^Q<A&"[=VVUO2MF2`Q`%Y=9FV9[/L(.%#E-
M:QJ\B%0<P<E\R4UL+\SIGR7\:BWKS1_3YJBQ>UMSK8AJ;8VK:F-B%"S8/^(=
M=8NRRT"(LI<*6WK@XEBK#^P%.XF@>*>"FOUYUF`J0V:(T$XO5O"]GMK8DZ\J
MNH=!'.TZZPMO#1+=K%?PY`)%IS1E<*5I>G;GL=G$A^`FKL<4]&KHC084].'6
M&UC6-D_`(D1@$1@2;EU)-M2ZG0J=CL/6371L^DFM>O%,IU/2;@U\ML"AC/GE
MG]9?L=;%V5-\6/(39DIM=E?U6^I+S.8#9%4]5.M&,XJF2N-K>%76\VN<KTT9
M8%JW#:G2_:;75%*<\[#B%KV=UTQ2Y5M<+@7J#+8$A17+6D\,"DZ22!+2HH$<
MK\.&<)&GSY8);/);HU#P,*J>I.KNL'OZJ6I;NO\`U0H=4VJ3<ZKLNQO-7(:Y
MJZS"R/:DJ>;'J^J*7K.^P66GKDA4`H,2NEVI?7?A0.:[9&T6#(AL`58,@[EB
M$W-:7/4WUIRS0V;0NA-)LKK6-XL6RH3$5LIKJW!I<#2E,EBL:])8\7=@FJM=
MRPBC(A0U!Z[CPC#&32\K_JP$L&LED%<!-^DEPIB[ZR\MC'=7YZ=K]F^K6UJE
M763K?TL,-?Q7C,:[!KK<S<^\L&:W"-H5"MBMC%TT#45[&2)E5S"EKH)N**M7
MQ"5X+>J+<0[LW4/5*@JX"EP>Q*H`%G;5EYLLORJS95%)8[_9-#;!A4@G1\EN
M6#YT,>CQ9"<,EM=A`KCX9=E>K+5U%R%4YZ;RSQ76RF%9L$_1"H_&JL)-H+GJ
M@A=4K48$F"9,%*'4&4PT2:Q@,T#BJ,T:4XWC7CFLS*&!=I9!G"65:ZG,?NFP
MOS/DM+QE>>*RNJ$Q:OU=T_XV$DUM2![=,=N/JO;G4\+-D.H&-U"_+J--7([$
M"=$KM+.PQ)K%\N0#F!M>4:Y4T96F6.S.E[1X)6^3];N6&E^A0($W1LNW6IX$
MMO#:RT>S-[I.CB#9+\T=PJ:.PW88)9C-"ID`:6RJ:A;O*L&Y9P#A(JW%P'/4
M^+/#!8P^:6R6%NFI_P`4C]U+T`M+L(FT57:2JT#3[LU[G5)45D<%-QL+A8;5
M:<FTP@SP4J%]9'\C%!9RG,!$OP0JMFYC3P,QC07:PE64K:E[2UYE0,I_IWVB
MHV/9$+>Z9T1))5-<'0K)G@:$^/7RW,>-E7`LUT>3+Z%-JYW)8&M<GY9.A:H<
MS%@,*DKIA@3BIG?"=<\KX[2TWQ/2`R*QYA6+9-3NK:S5_:R]VUI9]FSL;@1=
M]>$VUHJDM5!@8+85-FN3/ZDB?5I<8,R88E44Z1=2%JT'VI5U89_PJX9E374/
MH#8B*MJ+EQN.(EY9M</EM?*$?+)K&9?<:G/5[D=C%7\#)JS82\-=<SL<LHE%
M;.X@'`BKGO;)CS"<2F]F%)3MZT6>DOS8[[HI:-GV79-S=[$8V\;9R6O2*)4+
M\Y*ZM&M3JU3/E%<3LJZ6O+K7U@'J*=XR@G@6"N[.MSS;)^+9/,<%986>6*WV
MX6H68O5>GT0_2`BI]FD1VHRX5M;;+$G;%JA+*M3H=16BVN#KR'.WC/LX-I&+
MG>V<$JN,G%9.8<C#/W.`MQ#YMTJ3SJI2Y5V6JUE&Z`ZZ1[!TRY-V2:*&[R:6
MC(<2Q7%ACS4G[JFN.,W<*UIR\A+ME]OR=B$]Y;V/EJSL9"F`$1)62U0J[5TM
M&&7M*V&TY=FU#H'4MD6^M75'>>"ZM3X55X)P%?-DU;JUFL$-FIQWNYBFV(E`
MN)V-G2*B8BC,KU;7)@Z5Q!%S2%D:01=JGISX8WK>;.-Q8^ARQ7OO6Q5AVR&=
M=LZ9#M&EJ4]BC>+HM76J.O\`$*Z!57_EQPU;>%):+?7_`"38.9`SJ<I;/"`#
M*Y/('S4]*Y[:4U:*S*[LIKU!U2);=*16':,C^@V`[>#VHU>`O*P9@V"EQ8R<
M55BP7+J?\G`BEI1K,3`GZ/%R^0#W<B278C25T$FY.2K13W=8RJK37$Q?=6$6
M@:Z_)$VP.MD7I592:`3X2V*]?/:QUUK<:5_.4*P7C(`Z:1UU,(LE>EXO43<=
M3::PS46J%Y*N%^:>WU7:YSYT+3.1^GP[LN0\!6RFIBNT:DUJ,G31."DN;E?6
M5L&K*THGB7Y#PQ;"2U'AZ.[6,A)(3X6YS-[46K@Z(X/FV5?O-:&\=A?E0VIT
MP0U>O:\UW8MG0F6TQ[K.G,TGSRH6J4T9W?K>5;U)6(:"$##%I=;\\3/BU$2D
MLU3]%B%F5`DB-&9/%=4IZK2=78)73MQ;ZS4K:'L^SLM2X':["78*!%E8'<:'
M)96OG)O7TZI5"!)"O/=.PW8=<5UBRI%@LP_+";&IXEBUKU1WY:?4H0-UZ)Y5
MAAK]38]D+U5A.EVT\@,JCG+%>JV+0G-`EG=-S*_@N6`YZ^OI5PCEL)I!X8L@
M13:4Z<2:LYA\RX7R=EC=8&<?/5'6D],GI?!MAB53.QW81@1:[@P.+'5*?39:
MW#@U:Q5EKW-&5<P,(RELV`[4^1Y7L43-;72$HS/K;,LTOH7H`EJ,VQ#M8\@(
M3D``/"Q<E`@P6=;$FM><$3,(^7DJS*HOAF9T\\QD!DQ-@3SJ[.40[E%F^&6%
MNMEB]*]U)U%6*!2]8*8K)#3*.]YL"U9B]S@G+/BE%E72&LPQA68Y2C%>O$"<
MI"T]CF6PGJ6;EBLLUO$L`3;<V5D+K1KA2BNU7236I77K_:!KR^5R6(JQQ?74
M*>FE!V4.>Y864N$B$FCIR)%4D\]</GG:RM$I^9^?.`3?+#46O5.F^FJ;&>,G
MALW(!VJ[3I;!>8\X)'7ZYN3<FPO42^;D+$^/,BQ'M'4;,@PEG"2RF#Q+^4"J
MUH`=I\]N9T[ATLTW=E*-&WDM\"U#KBMZJ'@5/!E^1=-JHSY<H7L)HE?,Q'."
MFT/UI'&.<0T_!\37,;ZP*43A6$WSVT]B-+#Z<6C&Q.6:TFP*0FQE*'MP4LP[
M'-Y3J,6B8JZ<`?S$&:ABF-JU;XG?QRG/AP`30UAB^1RP+D%[3XRUO$D,CI%I
M,C@;/W+)"7E=+'?7QD)B7VVZPV[BJR6"6PKY:_*E^&(8TRO/5(Z56FXJ#]<(
MWI.=;,`6R!"3?I+=UZL[U!Z7Z1UR,2$B7NY5YT:?E@M.8B?+69B:^+-BQM&@
M"Y:N$9L2WZ53$7*?$1#@H"S6+X`8&3GYB#;=RU%GI[]954,@\549DQ<IK!7A
M/CG&14JU-9\L"'`0168_!?LF9\F-QR"YRBP#&$XX)`ZH96M7"]IYG#QZ>_7O
M*-U@1%=3LK&(D7/YS[/B66U6UTL4]0'.9*NY*AR&.6)2<V84HKLK-1'&6SG@
M;66%X)VGGU7W93G/IZZ6>/>)S"W_`#428D<CJJXSQ1DN#Z<A95"C>]98,8&(
M"JL5!L6ES#!@B:V4B!<\M3]RY@,+8"]IKU]9,D5/TWU(GL]^N6!EV,LNR:H;
M3[*S(LF(N>*UDD8)6$R0=.O5AH"R.&S5E!BH'$`5,SYLT@"P.,8*`2;V*RZY
MEI8>GWUQS%:`LT]F<B.64SIE$;9)Q)"FY@9`9YV9J0=0PX^-PEAFY`Q+X4@D
M@ASJ5Z[/&;F<.T]UM'7]G[+Z!=>RQDT7*^R"EIG]CM>+=>V"7LV5FLZJLKF#
M5O(&HA&-'P+J*%_'6N18Z<2]!A):5UB+`*$.$WZ2V=8W,N:I6E%+J];IU?'Y
M$0U-`GK207G+W^1E")<.K6C\Y^S'W^80Q88^<O=X][G'V^SCV^SP0K_@%'(K
MR`MGBZ*1IR7&`HX&#8A:%,SP!$90N1`\3Y(<BL116XP[4<?B7B&%E!"='AB5
M%A+B!3>:)2.0Y%_--JO($Q/QDP/->4<ARE_,IW/Q4@WP?T.9/S<DEK]/EAS+
M\R(G.][XJ627(#@+UWK]A`&*?1:<:,O5P(P!BZRD)@!2"YXR#)PX9@<XQE8T
MF&.<"^''`2'/''*.''GCCG@)EB6:GU)DPN)[&KUT\Z9A7X9334BPHN6&P!H:
MX^BD)G&DFSC=UX`!"WPRSYQ9)@A%9G$P(T,&`3Z]>))1%/J1;0QX75ZZ4Z8`
M1JCW!"19,T.5Q<3<1+3&$@V19($?!!'$8<TV8^'$\W&,?'TN?O`4\?7.O1)!
M91:)31I0IEI`4@]720R"3I999T\PN<8..0\RF:::9;)%SAF#+++(+E%G)ESR
M!7&*!$X$,7MDJEH`Q(&+8!,5P9PAY060F09)@Q,,L)1`F2\#(::?#.2#((3F
M++#D:'W`.KE4ZMFT*=YUJOY.CLQ)36^29=DT,D`BBA!D*/Y&Y+(S"AAAB$SE
MESR'BBBCAYPPCQXX`L\ZAT;YS3TOU,JGR=4BM42M3]75'RU;%*WJ+26,`#X/
MX4..5D"$QDP'BCQS.#%+RXY('BDP`YZW3JBVJE*F:U:N,YER[AJOE8)%AL@#
M2P"92OF0>9(LF0I[N4TV5N9!S@0RD+*S,DFR(EYS`K,^O:"3.0431Z>0260R
M+*)GK*66<DMS!**X*(FD"RDF(:BSSC,II,LI#H)I82LI8Y,\>0*I-7D&0:T+
M)&GR"4<JXE(F2P+D57&K8JF"R-</S!]$%@N/3J#0,!L(L1"U:XD?B.8$;.(#
MKB4VH`&2,0:I6PF$OS?F4X1&K',DYL!,1C[F0J$7"?/YV7!`4W][/GYD3#%.
M9]-+'AEP!U9]?T(J"`4JD5$D449@$*-/6DTT`P;83%>U$@AD"RCA&9`88!,(
M(\<8C!,<1B<)(<>,.`F<F5$I&89"_.FU7(`QG`[+!RKRC(,IR-#`.,W(&Y#Y
MAG9CCBC00'RX9%10CP11RXX11XX@.*)2.`Y%W%-JO"^4G$V4'BO*.`Y#,&,;
M?$N0;X/Z',G%M#$TQGRPYEX8Q1F\9\$X8R\`?OZDTSXV-G]4:Q\QA(5&0L/D
M"KXV(M"&0N1E1E_"?3X$)EYA8"J?&3B5<&40*'E#!/+AD`FI-,(@:BSU&L3C
M/964[L>9`JD@<3.<@<V\S6',3*-A*UR6+<F4A>,V9V2\'DKF7D2#F,#Z52J:
M=.&4;4JR84O*Y-`)*0JB)P3<C1&>18<THF<@Q63$`%AR1#EA+R:$(5SG].-#
M)@!Q3T2CD\->":;5".'LWQ#SB>O*)>')'Q0QWT[7Z0/+YC-\:$&9]*7]-G\4
M(,1[WTL$6>`'=RJM8S/8-<ZXAS:-^`^&K+).OR/9\+^(.%_#`SD?D@W@'@8;
M@/XF27X;@>#B'W.(H_=`X1J;4`QH`PZK6Q`Q@\%PP@R-7`,.OB^#^C`@@B%Q
MBB#C^7@>X+'CC!A\"'[N''PT/N`=@ZKUIIP5PSKJ-CP:/.(;P<I`+X+$*@%&
M*%*^('D^(')&!!'GAE]^.:`,6*3'*,>''`#A-J-390"BL:Q73Q@2X&`0YJ5:
M5`&>*OX4C&BPSC21CECJN.%D!,..$T2_C@.//$;CZ/P#&.Q:[U^1V;HRN>C4
MZ985JG8[@E=+64L@)#<VP(0C&LXF860\S(L-HS$).DCR)G%8G02RYQ%D82"X
M/6N9DS+3*?.>&UGJE:F:+Y#)0&4J)7(>#*PRPR/D#,S%Y(&D.RCPR,SADPR)
MRPPYFYSYQX]@@PIE/C+F/CJE:C/)):&D&X(E>)9!CR$0=T7,3B+Q-*2X@``@
M:3R9Y2L(0A(R\YL!H<<`+"U[K/6X^OZ&(/KZD0"!4JL`ABPU1#$.(%!R%8H`
MQH<`,8X!8;!CB]B'BQPBC<\<,\,.#>.)_`)<''@$@@%%@A&%&AC'&&'CPA@'
M@APQCA@@ACQQCBABCQQCCCCQQPPPQQQQQXQXXX\`YO`'@#P!X`\`>`/`'@#P
..!X`\`>`/`'@#P!X!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g887761g08s44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g08s44.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[24V4&AO=&]S:&]P(#,N,``X0DE-!`0`
M`````#D<`5H``QLE1QP!6@`#&R5''`%:``,;)4<<`5H``QLE1QP"```"=_X<
M`@4`#7!R:6YT;6=R(&9I;&4`.$))300E```````0*[T-<45W$F!G%6)S7_T\
M;#A"24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%````
M`%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/<')I
M;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``````
M#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T`'4`
M<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT:6Y0
M<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$`````$``````!)P
M<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R8F]O
M;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```````
M3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT<F)O
M;VP``````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D;W5B
M0&_@````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!OX```
M`````````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L=```
M`````````````%)S;'15;G1&(U!X;$!A1_Y`````````"G9E8W1O<D1A=&%B
M;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N=$8C
M4FQT````````````````5&]P(%5N=$8C4FQT````````````````4V-L(%5N
M=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````#F-R
M;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P``````
M```-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N9P``
M````.$))30/M```````0`\`````!``(#P`````$``CA"24T$)@``````#@``
M```````````_@```.$))30/R```````*``#_______\``#A"24T$#0``````
M!````'@X0DE-!!D```````0````>.$))30/S```````)```````````!`#A"
M24TG$```````"@`!``````````(X0DE-`_0``````!(`-0````$`+0````8`
M``````$X0DE-`_<``````!P``/____________________________\#Z```
M.$))300(```````0`````0```D````)``````#A"24T$'@``````!``````X
M0DE-!!H``````S4````&``````````````)+```"\P`````````!````````
M``````````````````$``````````````O,```)+````````````````````
M``$`````````````````````````$`````$```````!N=6QL`````@````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<```)+`````%)G:'1L;VYG```"
M\P````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````
M!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN
M96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E
M96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG```"2P````!29VAT;&]N9P```O,````#=7)L5$585```
M``$```````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A
M;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L
M;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R
M>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V56
M97)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L
M:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````````
M``IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``````
M```+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````"/_``````
M```X0DE-!!$```````$!`#A"24T$%```````!`````<X0DE-!`P`````&UD`
M```!````H````'P```'@``#H@```&ST`&``!_]C_[0`,061O8F5?0TT``__N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`'P`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/4FL934&5,#65MVLK8```T0UC&^UC4'%S3D$M?1;CNU
M(;:`)`VRYNQS_P!]/?9:S(QVM,5V.+7``3(:^QON=^9^C^BUF_\`X3]\6-;E
M6Y0.30,=P8\-:'BR1-?NEK6[4E-2[I6[*+&=2S:3<76>DQ[2V7.+_:ZRJQS&
M,^@RK?L11T6WT+*G]2S'NL<QPL<Y@<W82_:P5U5LV63^FW-]_P#Q7Z-39DUV
M];?15ML./3&06O:34]Q8^FNVK=ZK'9%5CK*O9]"K_BUH)*<>WH=H&]_5\YM;
M`2YN^L`@-CWO%'J_2_2?HK*E(=#>:,9C.HYE?V</VOWC>X6.;8&W[V;;/1:S
MT:_49ZGI?X3U?TBM]4O%&#8XLLL#RVK;4W>_],]N/OV#\VOU?4L_X-6TE.;@
M=(OPKV//4,G)I8QS/1O+7"3Z8K?O8RM_Z-M=OT_YSU_^#K5K*R_LVTFJRQAD
MN>P`AH&I<_56%E69)91GLM+W[[+&5>USMH]-GM<YNYK6[G?R$E.JL(_57;3Z
M575>H-B75DW-<`\RYEA'I^_T[7>IZ>[T_P#2>Q;.1>S'Q[<BP.+*6.L<&-+W
M0T;G;*V!S['_`,AB:C(IR*Q94Z0="#HX&)-=C'>ZNQOY];_>Q)3FV_5VNW)=
MDC/SJW.K966,O(9[-GZ3TRUWZ:ST_P!+9^>ET_ZONP\AF39U',RGL)]MMOZ-
MPA]=;;:FM:U^QEG_`&]^E_<5G/ZUTWIN1C8^=<*'YF\4.<"&%S-LUFSZ#;'^
MHWT6._GO\$J'2Z^K9`=FTYKW=/S]]M++PTVULN/JT9&._8W;6VOTZZ>GY-7Z
M'?ZM^19_1DE.Q=E8U`<;;6L%>TODC0/.RO=_QC_:Q%52GIU%;Z[GN=?DU[XR
M+(#SO^EO])M53MK?97^C_1JVDII?M&TY8QAA9$'U/TWZ,,`KVAKO=<U[O7W_
M`*+8S_C?346=4L?G/P_L.2-C=PO/I>DZ!2YS&.]??O\`UC\^O_!VHC++W=0+
M;:A6QC7BI^X.WM_0$OVQ^C]_L5',Z<6=5;FLS,IAN+-U#;?T(VVX;#MI<QVW
MU6,].W^19<DIEU#IMF;>,AMN?AO#/3(QK:FM(#M\[+'6LW_RV_\`I-5']+M^
MVNI9?U9GJU/?ZC;JC6P;O390UUKK+/5KWNLIW;_^$N?8NB6;G]-%W5,'.^U9
M-1H<YGV>JTLHL!:]WZU3'Z;;M]J2D^*'XN+3C,IN>VBMM;7O=67D,`9NL=ZG
MN>Z/<BXV1ZXL_1OJ-;S60^-8`.]FQS_9[D9#II](V'>Y_J/+X='MD`;&;6M]
MGM_.24__T/2\O^?P]!K<1)F1^BN=[-KF>[3_`(3]'O0\;[=]J'VWTMVQVST=
MT1-<[O41LG9Z^)N!+O5.TB-#Z5WTI_-V_NJNSU\:UUF;D,M#:K'[]HJ:QH-9
M=N.ZSV_RTE,L-]3\_-+2WU&EC;&B-PT.SU&_2]S/?7_(5Y9?U;J+.D4W.JHI
MLRMV2]N*[?5^F>_(:670WU=S+=SW_P`WZG\U^C6HDI!DZNHK_?L!_P`P.N_Z
MJM'52W&HOZC1=94U]F&USZK'#5CK?T4UG_BF6L>K:2E+)NS<6C$SQD93`2Z\
M#U'-;&U@<ZMHG_!,_P#2BO4MWY5]TF!MJ:).WV2]SPWZ&[?:ZMW_`!2K5M#:
M\^UX:Y_J/=!VN(`K8UF[;[OH-^@_WI*><ZM]9,[J?6W?5WH[-KB*;<7J#][:
M/58S]HWGUJ+/UFIN/D=-]/']/WO?;]J_5K*T:^W-Z)2[)ZAA4N^S7,L.>R[T
MZ65.%S/7N=D;K+.I7W.=CYOHXWZ6K-Q_TMGI>G7I=`P6X+:^F8P<W'Z<;C9Z
MCA8?5OL=D5M%K=GT:+O5^A_,Y-"W$E.9TOH]F(RQN;DNZ@7O:^MUXW.KAWVC
MTQ8Z?4;5E.?9C[O?55Z%7^`6D``(&@'`3I)*4JG56AW3<D'>6^F2X5@%Y`U<
MU@+J_I-_EL5M5NI,MLP+ZZ6>K8]A:QF@DG03O+6I*8L^T_;XN%8KVO\`0V3N
MV?H)]7=[=^_=]!1S_P"?H^7_`)^Q5)K+V]0W6V!['M>:F!NW8W]7:6.=N=ZG
MOW/W('5*^HG)QK,8T?9VN8V[U=^^79&*?T7I^S^8KO\`I_X;T?\`!^HDITEG
M==JR7X+K<?/'3#C!]S\DUUV`-;5:WW?:?T;&UO>R]S_^!]/_``BT4SFM>TL>
M`YK@0YI$@@\@A)2'!RL?+Q*\C&R*\NIX@7U.:]CBT['EKZBZOZ;7?11UF8'[
M2QW8N+=1BU,<V]]XH>Z&Q8WT/08ZFK?N;=^GW>G^D6FDI__1]0MI-EM+]T-I
M<7;8U)+75M]T_P`MRYSZR>KB55,SR[+Z3;ZC^K9#PW]#BL#":F48X;?;]IO]
M)KW-;?Z>/Z__`!BZA4\O#L?OMQW'[0XC;OLL#`)9O;LJ<WZ36)*6IZUT6ZEU
MU&?C64UM+W6,NK<UK&Z/L<]KMK:V?G.5:WZT=%!]+%R69^4[:*L?%<+7.=8U
M]N.S>P^C3ZS*G;;<BRJG]^Q++^KGU=>VV_)Z?18=GZ1[F`N+6>]K=Q]WLV^Q
M9]%'U=KQ;3>17ZAL^U.Q7Y%=9V$-VVM99N]7TG5_3^G_`&&)*=;I?3WT6Y6=
ME54LZAFO_3OHW$.KJ+Z\%K_4_P`)7C%OJ_\`#>HK&5F5T%M0(=DV_P`S3J2>
MV]VW<YE#'.;ZMWYBQ#9TEF4^NW-N&/N)97Z^7ZGJ5GT[6N)L_FMSV[*V?GH^
M'^R[G5U='L!)L+\@N??N<QGZ&XMLWM=ZN]M7\XDIUL.CT,=M9#0\R^W;P;'G
MU+GB?W[7/<J-_3VNQ<Q^774]PLLR,?:/H^STV/.C?TVWZ:MVX8-;A4YXL@["
MZVTMG\W=ML#E$X=F1CU,S'D6,,V"A[V,=HYFQ\G>^O8[\])3:#6@D@`%VI/C
MV3JI3AO_`$GKN=],^ELMN^A^9OW6?SG]55,G(Q<?/;19<YK/3>XUFR\V.<(>
MWTMMGIN]F_V?3_T:2G626)E]0Z>*B,;)+;0\-)N?D;1'N>QVQS=K]BD.K]`(
M!&79#A(]]_`^:2G925+$Q'G'8<IY-QDN-5MP9J?;M]2S?]%3HIR:LI_N:<5S
M1M!=8ZS<(Y-KWLV?3^@DI9M5C.H;WVNL;8UY8P@`,`]!NQD#>[<X;_>Y1ZO=
M=1@NNIH=E6,?6X4L<QA,6,=].]U=;?\`.3YF'98774./KD-:W?98U@;N!LAE
M#F>Y[5#/Z=BVXEC;;,AC&CU"ZN^UCAL]_P!)MG_024W6DN:'$;20"6F)'E[5
M)8V'F8'V>AM^0]]CQL]2M]^PO!]+9+G;O4]OYZA5U/IHMM&1E';N_0AC\@.#
M0/=ZVYWTOZO^#24ZMV#AY%]61?2RVZ@/;38]H):+`T7!D_1]38W>EC86)B>K
M]EI93]HL-UVP!NZQP:U]KX_/=L:J.+91G7M?AW&S$:R;9LO%FYXWU;=SVLV[
M59R,2\5AV$^+@01ZUEKF1YM;8DI__]+U0F`3X*IA]0.39Z;L:['.TN!N#0#&
MR8VO<[_")\I[V9>(`XQ8Y[2R8&C'V!VGTG>S;^Y_P:%B.ZD<MGV]E+#Z3]OH
MO<[O1NW>I6S\Y)3H)B6M!<8:.7$Z<=RG5?.:RW'.,]H>W*_0N:X`@M<#ZP<U
MWM_F?424G:6N`>T@AP!#AK([)U5PA:U]U8;4S#I+:L1E;2TAK&M;8UVOI^RS
M]'7Z3/9L47^F;K<US03BL=74X_Y]VV/WG!E7_6TE-EMC7/<P:ED;O"3KM_K;
M4'+S#CLW5U/R7!P#V5%NYK2'/]1_J/K;M]O[R?`KR:\2H9FPY;FAV2:I]/U2
M)M]'U/TGHM?[:?4]_I*K$Y?4W`S^BK:0#W#;':MC=N]_[R2G1!!`(X.H2@?=
MPFK_`)MOP'Y%))2Q`(@\)U5NS(O&-C!F1D-=6;ZMX::JGDCUWZ/_`''^C7_A
M]G]=+(<;[78(#@US-UMHT`:Z6>FQ_P#IG_\`4)*;22#ZN+CXIM-C68U+-SK7
M.&UK&#W/?:\_08UON>]RFZVMK`]S@&&(=.FOT=4E-1W4<@9;<88-[FN<X&X.
MJ#`UH_G??<VUS7.V,]M?YZ*,NPW^B<:T>W<7$UQSMV_SNY,+7.ZB*S6YH96^
M'F-KI-/T-=WM_JJ?_:W_`*U_WY)37_:5_P"SSFC`NW^EZOH%](=,;O3]3U_1
MW?RM^Q%^UV?:OL_V6R"S>;9KVSNV;?YW?_+4/^\;_P!!O^^*655>'OR:[BP,
MI<T,#6GW#WBS<[_J$E*Q<V^_&JO=AW5.M:'&ISJBYL_FNV7.8B49%UEUM;\:
MREE>W9:\UEMFX;G>F*K;;&^C]"SUJZO^"]14\#'S\9V%3D9QR6LQ7MOFIE8M
ML#J/3R/T?\QZ;#97Z#/T?Z7_`(-::2G_T_2\ISAE80#G@&UTAL[3^BMTMCV[
M?ZW^$0<:C-IS6_:LK[4'5V;/T;:RT;J?W/I(^2XMR<0!L[WN:721`].Q_;VN
M]S/SU6P\6FC-'I9%N02RP.]6UUNT@T^V''VI*=)99OR;W.ZC0^,=E5E6/C75
M.87W%X97D&Q_Z5E3W,]*O]#^EJL^T*UFWAGIX_N#\DEH>UKB&-:#9=998T;:
M/T;=E=EG^'?4Q"QGOS+J\BDM'3JVN;6QU;F6.M:[TO5;O+/U9C/48S]!^F_G
MZW^CZ7J)25AMQL%@>&NR-H!#9VNN=]*-WNVNM=N0G8]K/LN%18',J<+<IUH+
MG.8-[F@.:6?IK,G8_=_HZ[D/*SL1CSG6V/\`0PW^@UK`YV^^QS:-OIL:[?L<
M]M3'_P"#]2_U%9I8,*BV[*N+BYSK;;'[0&S_`(-FUM?Z&EOZ.K=^D_TGZ1)3
M:67D4T9+^H5Y`%S6!CVUO:T-:?3,1[=]G]9[_P#@EJ+,L$W]2-3JQ?LK#I.^
M&!KG?I:F%CV?2NV>])3H5N#FC62``[R,!VOWJME9MM?J,QJ1:]E;GFVQXKQV
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M3T?YFO\`Z\I7=(P[LEF7;1COR*P\-M-7O`L;Z=NQ^[<WU&>Q_P#(24YN'T0L
MJL`Q.EML9B.Q7=/JI!K#G.LR/1LS-@N^QW^JQ]M#L'Z?J7_I/46KGLG%I#FM
M!;=1[=Q#0?5K'MAON]/Z56^OZ:+50ZENRKTV,TAK61H!'[Z:_'MOK:QSV@ML
MKL)VG7TW-MVCW^W=L24P;>+.H^F&/;Z5;P7N:0UTFD_HW_GH[\?'LL%KZVOL
M`@.<`2!.Z-4!N17;U'TF274UO#S!B2:3H_Z#E;24X.;3TWI[,]M/37;:<&O8
M,?&#@YH.5MQL?8`Q]M7T_0_,]>O_`$BNN;BWXN6YN$6FGU*P'5-W6%K?IT-U
MWL?.UBM9HG#O`Y]-_P#U)3XP(%DB)L?^5)3BY^9B8[ZWMZ=D6.HH.0[T<:2-
MK\8^D/HN^T/;O].O\_T;_P#1KH%2RY/VP#G[,/\`T>KJ2G__U/4GTUOLKL<"
M7526:F`7#:3M^B[VK!ZWD6]+L<_HF#1?U&RJYSFN/I"7`/KLL>UGZ;U,BNNO
MT/6IW[_YUGIK;.72"1[W;202VM[A(Y]S6%J@;Z#8VPMMW-!:/T=L0[;N]NS;
M^8DIY7'Z].2Z[J/3NJY=@RMV.YF(115-/H-;6:[?UC'=9Z_IVW_S-UWZ6NBS
M](CGZV69H>!A]0PVMK==4VS$N:'%A>QN-F75TY;ZVY,>K^I466^A_AO5_0+<
MR=AQ_3QZW.<+/5#;!>P;M_K._2,8Y[?=_8_D*N]^:]^XX[`,AH9EC?D2&[BW
M]!MQ]F^NAV__``?JW?H_T?\`.I*:&%UG#Q[;LM]>?9=>VHNK.+E''J`8RLLZ
M=6[%]5E+G>[(V4^IZG\]Z:M,ZOCO?3;?7DVW"QU)'H6TTUD!WZ=S+PUSZ7N8
MRNJ_]9?ZEOZ)GTT4?:FOH<VIEGV<.;4X_:&;6GV-;Z?I7^NYM.S])8_Z:BT9
M#JQ39BAM-SQ;D`69!>VPN]6QU3A3[J]X]E;;*DE,J.JN=;5D95QI:*2+L*NI
M]C18XL=ZGVOT6/M]'T[:V[*ZZ[/45C*<S&;DY%UI<W+#:Z6-K<X@["&L_1>H
MY_J/_D?\&B$XAMLNB_?<P5O(;>!M&Z-C8VU.]_TZO>FG!9A?9"VP8S:_2(<R
MW^;#=GNL<W?]#\_>DIR\^QV4-N+=F8=C2V^N^JBT.+MAHNH=7?B75.I?7L_G
M*OT=^S(_G:$;'SACXK<3&QCC8]>VJD5TY/LK$,.UIP]OJ-]_IK8].MUC;HE[
M6EK73^:[:YW^=Z;%F'"ZAZ;Z/L^,:G.=<)LM$VEWJ-=MVOV^_P!WTTE)Z^IX
M%+!777D,8P:-&+D:#_MA2_:V)^YD:_\`=7(_](*O]AZD66W.;C#+R&.9D`&W
M8\-!KQ]K]V_']KW66>G7_P!<_P`,H##ZFST=F-BM?B,>W#(LMV,!VUMKL&UN
M[=5_Y[24V_VOB<[,CP_HN1\/]`C8V75D[O3%C=D3ZE5E7/[OKLKW_P!E5Z.G
M5V8ME672QANN]>QE3WD%X<VP/W^Q_P!.MO\`(5H8M#<EV6&_IWL%;GR?H@[F
MMVSM^DY)36R<VBG.8UPM<YM;MPKJMLC<ZO9N=178WW;')QU?$(!#,@@\?JN1
M_P"D%:-;#:VTCWM:YK3)X<6N=I_UMBJY>([T:FXM=;G4V^JQMCG``^]V[<SW
M?3?_`"TE(<O-Z;EXMV+DUY+J+6.KN:,?*:=KA[AOKJ98SVG\QRH4W='9=NKJ
MRBX]0?;9^@S7`7.8YF^'5N:QFTL_[IJZ["S[K"RZG&^S9+6_;`'VAY<"?YLM
M#6[6UMJ_<W_]6YQ^KUW'(:S&MN]$5^J38R3N<_T_2_2L95_USU$E(LK*Z;G?
M:,7)KR78^32VM[&T9+'$387B:JV75^U_]O\`[<1<:[IE>9=D5,RA?F&MEKK*
MLHLE@]*J&WL]#'^E[WL]+?\`SER?%PLEEF/4_'I9B8H!HVV6.L8=FW;[O:_Z
M7[ZM'IV&ZJRHUS7=9ZUC=SM7R';OI?O-^A]!)3__U>\R-G[3Z<7&H.]7*V!^
M592\QO+_`$,&L>CU':S^<]?^C,_2*E6[!LM<TOJ<7-&P,S;2=FTOM8^K?]'8
M][ZF?X3]'9;]FL_F[667'JW2FB`!=E.,XKKOWV>W-:W9@>USOSF>O_4WUV#J
MNN==Z9+RZZ-A?A%NT&IS=C[-K:W,>[]+_(]/[,DI+1UAE-;*&VXQ+/:`_)WD
MB'M:UV0_?8Y_JNQ6;_?_`#J)^V,H#UK*\9N.TM#[!DM(ASZZO78_8UOHL<;F
M?I/3L]2I579=7I$0\V/:[T[?L+B6S7ZC-C8V>RRUC_?_`.I5-KK6%UK<@%HK
ML]!C<,M+=CJW.VL=^FM_PFVNO^?_`$G^B24W<3J&7E.FNNE[`?>&VDELN8W]
MSW_HO6N9^_\`S*O4NM=2QUS0RTM!L:#(#H]S0?ZRQ!=G4/L/K[0W:XL;A.FP
M$OK9Z;JK'-?O_1U_\'775ZGT_41_M^00^JQ]U3@T_IOLY:-U(=]H<QC_`%7>
MG:YFZK^=_P""?8DIUT+*_HUW]1WY"LMF9E68_J-RW;`XG?\`9'[W-<352&LG
M_2L?_@_5]'TO^.?8JKS1BVVWY)OKLI):UU8K<"07?1'N;[?S'I*;]?\`-M^`
M_(I*-?\`-M^`_(I)*4DDDDI22222E))))*4DDDDI22222G__UN[OJM=U7I[F
M-R#7ZF3ZCJKF5U-ASG-^T8]CA=D;G?\`<?\`Z[[$-E.62X$YS62TL=Z['!PD
M.=[MNYOIN=_U_P#P/KUJ61^S_P!H4^KZ?VS?9]C]3T_4^F?4]*?^$_F_4_L(
M/^09_P"TDSK_`#<S)^E_*W)*;#*,LL=N^W%WIE@8;:QK%KM^]OI[;?977O;O
M_G*?\!ZMB"]N:YY;^N5,V%I_6*3O<UKF^G5M+K&VV6>WU?WTJ?V-N_0?9MWI
M:1L_F9?]#?\`X+=ZOT%(_LC[4V?LGVS<-L>CZF_<[;'\OU=__7$E+..8?T=C
M<Z'M<!8+L=I`>YT6_H[/ITT_^J_9^BO5W7UN+S5>7N:TMJM>W\^UY>W]'NKW
M8U;_`-]_Z#8LNS_FY'Z7['WG=Z?[OOW_`/6_I>HK#/V;L=Z?H^E-F^-FR=H^
MT^K^9_,[/5]7_`I*;@ZEFN9+,$EX=M<#=6`T;=S7.=N_?_0[-N_U?^"_2(PR
M/M/3[+2`UQ8\.8'!T&#^<W^3[EFV?LO_``WV;^;$^IZ4>EN9LW[_`/!^MZ7I
M^I_A/YM%J]/T;_LL;-I];T?3_=\_Y/T?S/\`P1)3K5_S;?@/R*2BR-C8X@0I
M)*4DDDDI22222E))))*4DDDDI22222G_V0`X0DE-!"$``````%4````!`0``
M``\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`#8````!`#A"24T$(@`````!
M+DU-`"H````(``<!$@`#`````0`!```!&@`%`````0```&(!&P`%`````0``
M`&H!*``#`````0`"```!,0`"````'@```'(!,@`"````%````)"':0`$````
M`0```*0```#0`!488@``)Q``%1AB```G$$%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I`#(P,34Z,#,Z,3<@,3`Z,CDZ,#,```.@`0`#`````?__``"@
M`@`$`````0```O.@`P`$`````0```DL`````````!@$#``,````!``8```$:
M``4````!```!'@$;``4````!```!)@$H``,````!``(```(!``0````!```!
M+@("``0````!``````````````!(`````0```$@````!.$))30/]```````(
M``````````#_X0$P34T`*@````@`!P$2``,````!``````$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-````/``````0```\`````!061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHQ-R`Q,#HR.3HP,P```Z`!
M``,````!__\``*`"``0````!```"\Z`#``0````!```"2P`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``````````````\`````!```#P`````'_
MX3]B:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E
M(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU
M-CHR-R`@("`@("`@(CX*("`@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX*("`@("`@
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@
M("`@/'AM<#I#<F5A=&5$871E/C(P,34M,#,M,3=4,3`Z,3`Z-#$K,#4Z,S`\
M+WAM<#I#<F5A=&5$871E/@H@("`@("`@("`\>&UP.D-R96%T;W)4;V]L/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X;7`Z0W)E871O<E1O;VP^
M"B`@("`@("`@(#QX;7`Z36]D:69Y1&%T93XR,#$U+3`S+3$W5#$P.C(Y.C`S
M*S`U.C,P/"]X;7`Z36]D:69Y1&%T93X*("`@("`@("`@/'AM<#I-971A9&%T
M841A=&4^,C`Q-2TP,RTQ-U0Q,#HR.3HP,RLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B`@("`@("`@(#QP9&8Z
M4')O9'5C97(^36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P-SPO<&1F.E!R
M;V1U8V5R/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z9&,]
M(FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*("`@("`@("`@
M/&1C.G1I=&QE/@H@("`@("`@("`@("`\<F1F.D%L=#X*("`@("`@("`@("`@
M("`@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYP<FEN=&UG<B!F:6QE
M/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.D%L=#X*("`@("`@("`@/"]D
M8SIT:71L93X*("`@("`@("`@/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF
M;W)M870^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(*("`@("`@("`@
M("`@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*("`@("`@("`@("`@>&UL;G,Z<W12968]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B/@H@("`@("`@("`\>&UP34TZ26YS=&%N8V5)1#YX;7`N:6ED.C8X-#`Q
M.#1&-C)#0T4T,3$Y-T)!03)%,D(U134X-S,T/"]X;7!-33I);G-T86YC94E$
M/@H@("`@("`@("`\>&UP34TZ1&]C=6UE;G1)1#YX;7`N9&ED.CDR-S,Y141$
M-3E#0T4T,3$Y-T)!03)%,D(U134X-S,T/"]X;7!-33I$;V-U;65N=$E$/@H@
M("`@("`@("`\>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.3(W
M,SE%1$0U.4-#130Q,3DW0D%!,D4R0C5%-3@W,S0\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*("`@("`@("`@/'AM<$U-.DAI<W1O<GD^"B`@("`@("`@
M("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.CDR-S,Y141$-3E#0T4T,3$Y-T)!
M03)%,D(U134X-S,T/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@
M("`@("`\<W1%=G0Z=VAE;CXR,#$U+3`S+3$W5#$P.C$Y.C0X*S`U.C,P/"]S
M=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@
M("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-C<T,#$X-$8V,D-#130Q,3DW0D%!,D4R0C5%-3@W,S0\+W-T
M179T.FEN<W1A;F-E240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N
M/C(P,34M,#,M,3=4,3`Z,CDZ,#,K,#4Z,S`\+W-T179T.G=H96X^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@
M("`@("`@("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@
M("`@(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B`@
M("`@("`@("`@("`@("`@(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B`@("`@("`@("`@
M("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.C8X-#`Q.#1&-C)#0T4T,3$Y-T)!
M03)%,D(U134X-S,T/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@
M("`@("`\<W1%=G0Z=VAE;CXR,#$U+3`S+3$W5#$P.C(Y.C`S*S`U.C,P/"]S
M=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@
M("`@("`@("`@(#PO<F1F.E-E<3X*("`@("`@("`@/"]X;7!-33I(:7-T;W)Y
M/@H@("`@("`@("`\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@("`@("`@("`@("`\<W12968Z:6YS=&%N8V5)1#YX;7`N
M:6ED.C8W-#`Q.#1&-C)#0T4T,3$Y-T)!03)%,D(U134X-S,T/"]S=%)E9CII
M;G-T86YC94E$/@H@("`@("`@("`@("`\<W12968Z9&]C=6UE;G1)1#YX;7`N
M9&ED.CDR-S,Y141$-3E#0T4T,3$Y-T)!03)%,D(U134X-S,T/"]S=%)E9CID
M;V-U;65N=$E$/@H@("`@("`@("`@("`\<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z.3(W,SE%1$0U.4-#130Q,3DW0D%!,D4R0C5%-3@W,S0\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*("`@("`@("`@/"]X;7!-33I$
M97)I=F5D1G)O;3X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP
M+R(^"B`@("`@("`@(#QP:&]T;W-H;W`Z0V]L;W)-;V1E/C$\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`\+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^_]L`0P`!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``$0@!F`(,`P$1``(1
M`0,1`?_$`!\``0$``@,!`0$!`0`````````(!PD%!@H$`P(!"__$`%,0``$$
M`P$``0$$!`@("`X`!P4#!`8'`0((``D4$1(3%188(7@*%S<X6)BWN"(C,566
MUM?8&20F-5EU=[8E)S(S-D%"459TE9>SU$1V87$T4IG_Q``4`0$`````````
M````````````_\0`%!$!`````````````````````/_:``P#`0`"$0,1`#\`
M]_'@>!X'@>!X->?RCW;>O,'$O0W3]"RN#!)/SY4%A6CM'I]7KV=!)JXC07\P
M%A5U1TVACT`V_';K8=O&RA!9=-QKKHDAE#[RH89C7R,HTSMS16G2:Y^R[<Z8
MY>M#K8)(*LK<!"H)&(74%41JQ)E"B+([:ADTXD"^2+U&*OT-%F1/=9%L75":
M-<O7`8O*_/!S@PK#:W6=%]+G(:/XJ@7>DI<C0U1INHC1\]D3F-M$2S8G;X_9
MY,Q+IJJY)`0.Q=NJTUS^5$R+C7+?P=_E'S3\T05&XV\YKJ](K**F%<REQ\(?
M@(*]DEGH=>/4A5&M(+D+81,(@3D1A=(8383,S$U0"^=UB64V26[G`?C)OF?I
M"-GWU<(T1T=)KW#=4MN/C]"1D;4#F?B+8,5N0M6)N-BA.WQ->/HC,8@/V=@3
MX^;.,975^G)-1^S9[EN%5=P]B[\;<+W#V(3K<X1*UO5[.8-:N,.F#4JC*S^P
ML8%B\L)@'4@%CD1,A-LVDM)AGQEBT:,R3@4\)::ME5PA)E\D4HY\>[:]5WK6
ML\FD<XWFW6EC<_5CS)<=;RYU&(R``2K<[0=I3R3NZHM2+AM'[^)F/KI*+67-
M9;;?F0M^/,!4@RTG\O-?*HU^-UY?ZA1L2R*)LKJ,#53QE1R$Q2YRK0.$+.K9
M?ND[N<1!`9*E)`.%0^-IRA::D2FRB1"-BD-,.-@PU,_X0AQ'#883GV8O>TAC
M?\4O.-WPQ>.PZ+NG]EUQT45/"]#D,%.INR?J8IW$6D;^YTCB`7,78A2"@K:0
M;H;IX#^K"^:!-Y9?.<6YWY\EUG0VVN_+&X9D,R/&(/'VATS6==$)D=E--.?T
M]PPD(U0FVR':$Y8I'ANR@B1-G&&Y!LQ0>!UOE3Y6Y0WO*Z*>Z?#V$;9S'Y6;
M\XEYYGX>-5:SA<%;16-,9+`:VE>D?.!YB45T19E1^9CF+RI10B08X-2#9G]K
MMJ%=_*5U;='*<"Y:=4:XA`^3W[W#SCS$:,3N*D9B.!1"Y#Q((<-C`@Z3Q+=<
M\,P@W=#<NBN66=M%$G#=357&R824(^9<5SM8/75$]KZABT_YNZ&HZF*_FM2A
M&T.!74WZ7CI>6UFW?"Y_.-HS74GBXN/G])\].V$A%-1PK0ZQ>M]G61"(=24^
M7@S;W;?$T6IQS*H)1,K9]]!.@H!/0E4-5);).;(974BAYZ-6IN7/Q3:&;I25
MT6#3"'V6PB99H_SK)GJ6!JR+(,XN/G6Y4;`^C3B4'M61M^7`-.SNSU*Z*4C:
M8C^*BXI"WCC6U(Y*ZZN&21,U%X.X65?SMAH;0E@T.T<DA<=,M\)95"^^:^Q:
MWZKF714<JD++'D8YTLUE4A*U7FD;4KFR)A^BPB3R)&L"@B1E2AL?#<FV8&1$
M"P<$A@]JX;"LDVJ.SSP5IX'@>!X'@>!X/)1\@7R4=V4AT/\`*)K5=L3L)7?$
M[SX\CT,&M*GH"1T9"X;>13;2\R709L]!2-[O`+\*U<.X^ZK4ZX-A%D2:NB*3
M5)OE`-B,@^;*#1^0RHZG3CL_SE7G8=1<-S:Z1L^UTEVUQ6V("O!LJB%.:PIV
ME(ZB%D9-'6#Z1+66)E[E!^Y(AX&3;#\_4A)Q3Y3.@ND>JOC=G_.]>%@//-HV
M9\E$/C==KV^H-D'4[GFJ@Y[H`;V3%4JV<"*S'JV/%M7\#RE)[#?:J[X(&QP1
M1%)H["_N#_ENA/R"69#X%3=3%6XM/F<3>5[R<I,FJN]!6*>FQ2"B^=I`#:QO
M*A>P]B4:EI,ANZ(QA0:`!ID5PV=RC1K@(1^4'O7O'FOJ:Z.6J$GP1*=]14-S
MLX^/-F:A<$?MH?=A:[\UI=::RKV'%WDO2:Q#?,V<L9:WE;(2GHSP.9-DG&[?
M<,>\U_.-84CB%X=:6)^D-@T-%8KP7S56]0Q.%A6K@WW%><38%;:<O9%%H<>L
M%L$82R4@HV:&L!<L<QUH,>_HK7!F0KM!),,U7%\O;F'V9SC(;^YR[&YR91NY
M.G0)4:,*2Z"5A<$/J'F4Y<.\['Q6ZJ!JVQKN@1`>T<BHZ)*1RDB48L8=NN2<
MDAC/3ZP,$]G?,]=DVX_O(7!:D*\RV5(OCXK3O6F[0A5WZ363!X'..C:VK$+&
MC8_:L(2UC<Z("9`[>F$Q1^4@AS1Q@<B9)*KKKM`S%T9\R_0M?5#<8*LJ4KP%
MT%S5TEP13<[_`(R+"-32#RZ`=ANH[@))1Q&.PF.DATU<(.B8>3BE&I01"'^/
MT@#&[+;(HAWX>CN/KGW(04XE0P.&DBS!LH<$Q\X]DH0<3V3UR[:"I`1CT3?F
M6""WWDVQ%W&03ATGC5546SVVRCJ',>!X'@>!X'@>!X'@>!X'@>!X-!_R;=@=
MG<P]#CRPV"];9X/%47N0DUK\(4WS_?EJPN['9XN\,'+VBMV!IF^BU)02M069
M,F7B$.0W?$'CIN5D6^5!H]`,?;?/+#8#2ELRUE!S72@_GCAKD_JI>XT2C"H=
MN@DN@3P:$JJ)5[F'ED:M)-B;IP>),$W!Q@W7RN$9,F:**3G`4!//EFM8$R[_
M`)3`>(RUCUW\>LCE0*S9.A?(`(:E^D1B,+GI5:&PG2O#AM=VA#I$?,KLW.^K
M73,919MRCMR:^X+"=+/^8:,W785.LJ7@]N/*J;=N<P4/#[@K2^0<`BUPV7<5
M%RBWRD%F(I>J)VH>JZ#"G,6'3L6/*L"10\;';LWP_8"]9/`S/0OS>PZ^R,)C
M3"F!U=RP7474EK=:I6A<S&,Q#C-'F:<D*U<#;5ER5?$=G3&:RT>HNP.8!!,B
MX?M^E6HHOKKD;D(5[.^9N?V;3]A5]4P>7<]VY5]\?'%)F=CP(]9*\/M"B.F;
MVB03=S&"=OT=SS861<D#?FPE[^/6>\9D`%Z@3CLJ+M7>^K</5_X'@>!X'@>!
MX'@>!X'@>!X,.="T17G3]'6ISQ;+(B2K.Y82=KZ<L!!1R$)O(U(V:C`HW8EV
M><.QSE1NIOJD[;YPJCMG&^F?MQX)QN;XYN<KOTI%:0Z6!&CG/E8S"F:WE<%F
MSZ/21I6$_A+*O9E#S#W=N_;&QA^,,&[5WL^9[NTG.OY@S<MGF-%M0Q;K\/G$
MNE722GM8G-_T)EG(46X=,M/XPC^7RM`0XPZ.@PJ)#*GU"$@1(/%]UY/IG\R<
M)[824V^[KCP=JG/Q5\;601M0O,(/(2I.W:]H:N9$^S,CC=T''\S+_6TK(H<N
MW635C$TA9/5(JTDP_?5XX(()*N\+)XW2W#[8]\8/*,?D\6GV04R.63&^EL=;
MOK)D$S)$)K-[P2B3V",9'.RFFC9$\-$1!]L`"QO5FR!"1[=JDQ8H93VV4"T;
M0K&O[IKJ;5):L3#SJM[&C1>'S:'R!MAV'D,<.LU6),8]1^W3?&B[=;?\-=!1
M%TT6PDZ9KH.D45M`UY:?#_QZZ_,]Y5I<5A.%^9Y5Q_'7T_MZ4R8I!.>YDMNJ
M<@40*NE="2*:NNR;9L:.NCQYFT;MFR!+1-'7'@RO9_QQ\V6DUJSZUK/(?(*@
MI$WS=%IQ7DX)Q2;.J)DT<'Q>15E(3S?1=0U'B[`4.=*[.$=2C(PT2,""(XA]
MY?8.DR7XD>#Y1+J#F#RF&C)QS30$WYDJ8((*/6$9#T_/8B7A)>/D0VFVZ1MV
MR!'SNH$P246)!GY@F3:+ZOGBZ^X?E&/B;X\@U$\T\_06/SB&Q;D6T7]S4+)P
M$Z*H6'$+'+J2K<W(W,K=:.U9"N=3F<@;&4)`T)-B"#M/5=+.[5NHF'8FGQA<
MH-)('EN`$R7/!.QS_>#1ZYFY=3\3HN3",!#$B=(ZYT16!.67VYQ&/N:BDE]L
MK)IZYS]F`S7U3R-4G8<4K^)6WF6MV]66_!+V@1>%25Q%ST>LZM73M[#9`W?(
MHN4G&!+UXHZPP?-7+!RKHE]4W5TT^YD,&D?BVY!-5Y,H.>B,I/'Y]<P/HJ47
M65G$@7OY[><4<?B0VS&UL:.$I")-PICC]'X@/$;,8S'8MNO&!@%`$\>L'`<9
M:/Q7<P7N3#F[\(W/=YD+#KTK]F0LBVI&5SI#.BH1'*^LJ.H,1WY2)%C'<=BX
MW(IJ#'BDAAA8H?TU5,%G[Q<.IY^*:BX37_2+*L<R"361?7)+7D90K>\R-SJ)
M(5U$XH:C-;`B(9NT1P@'BR9;7"R@EHF6?MFVNRKK<AML^R&:OC;XGB_QY<6T
M?R;&B#8^XK6/.MYC,$&VS=6<6#)2KZ2S:6N<K:ZO%?S0^4=Z#L/ME73((V%"
M\J?@L$=-`N;P/`\#P/`\#P1#9GQQ\9W%.[.L:QZ>4DL@NW^+W6Z1ZECVR,@E
MQH5/NFI7#&V*M"SL=65D#(<HG^*$%3.(FQK951PKEKNHZ<[*ASY#@?D$I::-
MR/*.C6TU2FL5LS=%`C)V4#>V?!A"H&%VB6J5D=;U09L^)!E?RZ-V,6A3V:A6
MJ+1,<<;_`$+/*`<3"?CNXWKFV(I=<)IEM'I_`9E9U@P!5G-K)WA\`F5T#"@>
MUS\#K%S,5ZQA;RP1Y@@C*=8Q#Q3<JHH@Z<([.V3%=L'2/C^^/6!\&,^CB`,Z
M-F=@=0]$V#T)94Q&PEM`6>7DP(J.04,$1UN?D^6@"&,55FK)14RX7(OGQ0NX
M3;K/]D$@HNR.5N>K>N*D^@+)JR.RVY.<G,F>4G/B.Q+0Q`'$Q8)#)'N+T:/V
MS!WJ29HHZY2+LR*359)-VRT;/--5\!B^,?'9Q+#*7LWGB-<Y5^,IFXIX>M&Q
M8-J@5=,3UCR-RQ>OYPB0>DW)L#*&CX8-?QXS'"8A]$GXY@^BJP9VS;+)!\CK
MX[^2GI*/24M5NT^F,-,2R1Q&3798-O7N^'G9G7*M3G/S=6U+&DI&3QM]`%E(
MNYAQ@HK'L"'#U)@S'.GSA[L$54K\(O/\0F5HR.ZWXFWHC87.\0Y9$4C'A]PP
MRFX+342L-O::8&.C+&Z'OF?#]G4S&`7C8:`L6.0L"Q"HLP,.'J$#+LB%TROX
M^^.)PA<K>545&C&.@7E3$[:76)RI!])C%$ZI8IXZU(M#[<A%I!7>Z"#B,GX>
MY`&6+Q%)[A]N[3T7P%81\&RC(,5'ARYARP#,&PYFXD$A/RTXLW:IZI)*%9-*
MB9F2'G^VNN,N2APL1)O%/O+.W:ZVVV^0YCP/`\#P/`\#P/`\#P/`\#P/!+%M
M\6\Y7A*I',[$ALB='YK"6E;3Y6*VO;];#+(K]AN8V:0RSH]6L]B,=LJ-))R`
MZS_)YV*D+'<:7(BE$=QKQ=KN&,K6^,/A*Z,YTG7/8#1@K5\2I0@`@TGL&IXH
M=J.`EL'8-7,HB%4RZ%Q>5P^'EM4GL8!R4059`U&S34:DV29M=$0H:(<WT?`U
M;J6BM=!1F>BY(_E]V)[*DB+:PY"4CK.)$2!IH4?/6NF'L<'M!+AF/19,%&R/
M[6OXFZBFX8*@7QK\-5=7=5U/7W.L.BE>4E<R?0M6Q@4_E*;.)7*B@0:HSQLN
MI(%7[\FBU*/6B+4P[(BDFJB;9,?J@V:IHASH7X^N+H_(NG96)YUKMN<[-&+A
M>GW"K%Z]:W$)=LR;!\.DHI\^<B4&9%`R4W)H!6(M,F\>K$'^KA_G5SJ&/$_B
MKX)_",)OJ$2D"I].G$#!"7V5<,T,OVO/D@0D]*L5CLML$T9P/K8PU:*Q@?H_
MT9,V31H(V;JAVR#!,-A/@>!X'@>!X'@>!X)_Z$JLK:8:!(`5U6AF(6=%IBR?
MZF'XQ$9H.P_9O2:K1JY2:F56+1^JLS'D6[Q+5UA-TV23>H-UTPU5YX2NA5DU
M1'T_!8[ON+<MQ#9"51K5O`5!,=W'6B,'O&"'UBK'K][JX:RLH-3T(89%52]@
M-M"F7K18+1I-K8E3VYS=2CQSM#X-(>:NKYJ1I9@RA#B-0HS";ZYS4K9@&-!@
MFQ=OO"(-=YZ`K"PLHW@:[$:+5&`4E1[9^H&P/P/!@F];&D%?IU"TBNH]R;L6
M]JXKG`QVV4>O"4?*N")N>;!6:"Z#A4@!KV.RN7.7*6KA,."CID\^0R,%/54@
M4-8LAM0?:4L):CT(NRO:VJZKMDBV4;FF<>I63*TK*]I1MA=RS<D"UPU[9\@C
M[E@M^'M7YB&)D$&1U(LQ;!G;P/`\#P/`\&.;AG32KJCM.S'[QL.8UU7,WG3P
M@]0<.F;%I$8R3D#AX[:M-=G3ELU1'[KKH-M=G"R6FZ:.N5-M<>#EJ]=RLA`8
M._GC%`7.7L/C+N9C&V$]6PZ5N0K):1,6^J+EZEJ@T,;O&Z6$GCM/":>N-'*^
MOV*[AW#P/`\#P/`\#P:L+<Y<FY@\\"1^HV9YK)[QLRT`]R_I/&"DWITA)8O"
MV88O'5YV<1D`%J7D;`DI(G$*4(&6,4")1`2$U$G-<C0YVDP-DT5*>6*RU'-*
M>AD]D?1*QRA(WI"342"#F$,#FXXB@=8A'+UFY:R,*=FB&(>;!C7:UAG4)8//
M%$&CH<&S+P/`\#P/`\#P/`\#P/`\#P/!PXR0@33V0C0YH64(1$PA'I4Q'OVK
MQW&SSD`#E;<*<;MU5%111>,2>.2)%@^T0=*!#P<IHEED2:++!AGH7HV"<UQN
M-R>=-CK]G))</C>C:.,D'SL0(U:O3DTL$]]2[9-`]>U;"1!^?V+)WSI!D!BH
M)\MKET27&#7X9^\#P/!P4H"HR.,R*/./J?ISP,L&7^C(/A+O\$FP<,E/I2HQ
MRS)#7'W%\_@OQ[MJ]9J?=<-7"*Z>BFH:16/!5RCFVC->J868_+FPT::=JR>-
M+*V47=Q\F-K*?$\OM/QLD.3%'#0;%_SS?<ONQRN8@F^Q9FW1>A'E`?$;8CSY
M6>GNR!EK[P27P;L&T$)'>T1E,')W$6KZV>+*0-12K1%73[E275>V'10E8S++
MN6%)40(/!>Q5I^2.)&U;S0J&^?\`5RN'^GQUG_H=PK_N6^#5O\T/"?25U?&G
MU1&H/\@?0B9./UP:L<J(G@GGF.Q&80^N6+J6S:#FRM#\YU=8*3671,87":M4
M),J`)+.TALH#E`3M\CJ$AU5\<WR?4G\@_P`?420^0TJ>I.C_`(_RU4S=5-[#
M&M@$P,6_BRC%FKPH%+^8;&K]91>S#54GHL^LIO,[$/PV`.P1^TP#XB@[0#T"
M?JY7#_3XZS_T.X5_W+?`_5RN'^GQUG_H=PK_`+EO@?JY7#_3XZS_`-#N%?\`
M<M\#]7*X?Z?'6?\`H=PK_N6^!^KE</\`3XZS_P!#N%?]RWP1U\@OQ[=`=2<5
M](\^1;NB[BT@M:LC$5%#;:CG*@RMGCIPHV<ZH3`A5G((6PVH?;5KM^,K$BS`
MOA3"6$7&FF5/M"'?@*^,'HGD3X[8'%Y3V?8$-4MR09Z(!1_G\/0AV'L8Q;4"
MKXH%2-/+]Y9FLS3FB*#+9M(&H\\XBR/X#+(?&5-WJZX;I_U<KA_I\=9_Z'<*
M_P"Y;X'ZN5P_T^.L_P#0[A7_`'+?`_5RN'^GQUG_`*'<*_[EO@?JY7#_`$^.
ML_\`0[A7_<M\$$=XT'U2-%4*O`^E)Y=^<WM#M1$8OJ4TO4<7#W'E?_Q#S0B0
MYUXP8R^60Z(3O[#T\@SDX%0DXIBU'-7J+E7ZMH&Y\?N_48,E"K9HS)J-&VY%
MF/>K$V#1_LCIL\;,B+D>)<$&B#C*B39ZN*&+.T==%U1[/=39LF'U^!X'@>!X
M'@DV8_SZ><_W3>T?[8."/!67@>"3;P_Y0=%\4PYA_@EHS85R=`$=W'^+9[06
M"\_6%1)I!LMK^(HJ?WFO4E:K,1^Z*35<$VE#Y0@@Y%LF!4'$?_&N>A4EU_P$
M+&M+HZX6+;/[51PRZ>D+9MD4'=[X_P`!5^%&S-J)(+(_\77?,G"S;_$;I^"L
MO`\#P/`\#P2;VO\`^%J%?UM_YY*]I_47/YP8G^Q\9KVY+1B4%N=@*6Q_A,B:
M=(EK')-"B6=7(;(_8NTSETQ1UV"LO`\#P/`\#P/!C1O=%.N[&=TZUMBM'-N#
MV6I)_5C>=Q=:QF0[=L@]T(.X0F5VDS9ENS=-G>KI89HALV<(+X4RDJGOL&2_
M!)EQ_P`Y_C?_`*QOK^RO?P5GX'@>!X'@>!X'@>!X,-ANB^?)'9I2E(]>U-GK
MD";$-#52AK/A)2S1&XE/18KH4@;$XO*A^PQ%314AJ[%)99)[Z;N<)Z[8SD,R
M>#^=MM=<?;MMKKC.VNN,[9QC'WM]L:::_;G_`-K;?;777'^7;;.-<?;G.,>#
M$-IW)':U:HCD<(RFPS9&-`(?6HLFQ3DTA/S1R;:1?59MNHHY$1Q?,9E18Q*7
M+-4>&C,.F9_9-VA&"2*8:QG\*ZQX%!V1=0`O3?3TLO.8Q^.-*+;C)50KDE=E
MO7+,C`63;VS()[<+0\+"%[8V!S79A5<):A:4@3:8#0XA*"OX\8#/T8Y_KKNJ
MNXM>G0ZLI/+V-79P&(KVNKDNNL(G6]<V"T'-9]3<@0KR4UD7F9LH["M@]TM[
M'$?4*R8`I$E8S'A\<3$:AL-&#T!(T>*:J/E6HQBT'ME29,D:)*(,D$VR*A`R
M9=ORY9]NFGKL[)E7STD_7RHZ?.W#I55;</N\#P/`\$F\Y_RP=[_O90[^XMQ=
MX*R\$(?)]:-=5!\>?9DNM"9QZ"1IQS;<D3;&9*10&LG4GFU?R"*1(`T47VQE
MT7D,C+#@XI@WU4<NWKM)--/./O;:ABIIV+RK.?D6YY@<.Z$J633"?<1W!-X6
M`"38&0?R>+S">T/,8N5#:-G>Z;W4[$(?*)4-:I*9?.(V!)G-&OY6U4=8"_(G
M<%8SN;657$/FP&13FGG<686=&1;OZ@E"WDVCC>711N:3QKA-'<[&W;<PQ_#4
M5QNT5UVWSIO]NF`R1X'@>!X,']*WQ6/,-"6M?]SGG$8JVJX<3E,W/M0QB0N!
M01MKHW6=)!8^Q)&B.VJKE'7Z<<P=.-L;9VU2SKKMG`:-N1/G^^*:&\P<`5[)
M.F-ADGLBJJPIT"W5K"UU&3"P8".B=5RH+*BB$+4'1),;*\H9P2D+D>-=`7K&
M3-':X)VB_P!P]'/@>!X'@DOK?;70;S[G;;77'ZV=`8^W;.,8^W:5[:ZX^W/V
M8^W;;.-=<?Y<YSC&/VY\%:>!X'@>"("-[S&X[*=5)2YDK4N03VQ&!*R9W4:L
MH$2TW6DG:1.0A*^3<2X$Q>L1139_H:-/4-]<J)LFX_37=57?(5C!F\X:1@:U
ML8C&S,O;?5($S$3'$`P0LFD[7T'D4`Q-Z4="'+P=AJN1&_FA-NS(;N46;YPT
MU1WR']MYY!W>&^S69Q1SJ[_.?I<MY$(6PY_1W&V9!]/E-YMA;\BQIODS^'][
M\LQIME[^!]W/V!-DA(,"W;?-!,4^9DQK_D7LQVQ(#W*+QB]:KV]P.HBY:.VV
MZB#ENMIMC=)9%3=-33.-M-LXSC/@K[P/!',[?[J=D09^CIKHK5G)5\GL:*9R
MIH9WL>QJ511;Y^[^'LQU#[5)ONJI]KG)#4[KKIJRR.SL]#L_%+#1CR-S=OHI
MMODS34!E:N-L8QA%S-(\RESMJG]G^5!FZ-K-&^VWVJ;H(I[*YRIG;.0I_P`#
MP/`\#P/!)O0W_*"V^.X`C_QO9]>!^R3X]E_C3#"(513UBDTY<HDG^(JSBPRT
MSM2Q(^:<-\C4B4]C4<5=M"LJ"_C!67@>!X'@>!X'@T_05W(X[WDXYJ.M9I*Z
M;"%RUC0G$R5YY91]"?.X^VM<C,(C!(!Q?#9H@VBA^4:@G%A$NDG)EY)C>4Y"
MP/.B[C98-P/@DRX_YS_&_P#UC?7]E>_@K/P/`\#P/`\#P/`\#P>3>L?BA;US
M\O?8_P`N\-[<"U=%-9W9D::1.852`.9*RHW%A4=LM%1X\FC=X1@P.PALK@(9
MN/C\<G,DE$0.M@3O82-%&IL'Q_$I\IO1\WZ*Z%U[MNBW=(I':YGTAM*'6'RF
M5HZN.9+EC5[3".@(-&R;F!M98E%RE,"8?'X\.DDH/FC-H-BX*1-U;/E0-28!
MMVZF`W%WQ7\50Y?_`(NBE'#)&C-0=G2"XIW4J]FRH5&3KJKK0I.<US7%I.<1
M&J+*4BL]C<F<QS+.R3X09)8!(0@2+@I3-PY+GO@2QZ7ZLST>6MJ+3)H2B,KB
M1IC*A]R67;B8*4Q6GVZ4.%7M;UV3F1:06,3VK'\Q"QM0$D)RO/)4HF+&DWGU
M^`V-3NNJ^M*/JQ.S8)#;&BJSIL^6C,[C`27Q]5ZRWRHS=JAI`Q(#E'33?;;=
MLXV;950WSG9+?3.<Y\')16)16"1X7$81&8_#8H#;Y:!8Q%0HV/1X.UV547V;
M"PHALS&CV^RZRJV46C9%/*JJBF=?O[[9R'8/`\#P/!UI2:0Y$LH!5ED:2.(O
MAXM8,H=%Z%DB19LL]%#E!VSK#S1\39MW#L>TV1PX>MD%EVR:B26^VH3ESG_+
M!WO^]E#O[BW%W@K+P1IWYPW3?R,<LV-R?>N\C:0:?Z"'J1J)%=Q,BC,HC)-N
M=BTD&J9PJR>J!S+-LY5$EFKP43;869NV_P!BNBR(:/(+_!]^+Z<^5GDNT8Y]
M6=@E0\:S$.RI*=0BN)3"IIFJ(E"^=A!ZPLK1IJC*96797(ZGQV0N1*;MW-HR
M&(:X3QNMG`55\>WQG0CBGY0_D2MVL+0DB\7O6N:9EYRG=H-5\8A($Q/)Q:K\
M!B.9A44CRXD=7(R"&(_'Q8Q(>P+L)N2>RI`T;$!2;8-\G@>!X'@E_M/EZ.]J
M\JWGRG+9.:AD:O2"$(&9E,<;,79P&R(K-EE'PQL3T48+.D\MM==-'6FR6<;;
M?;C[<8\'E3D/\%)XZJJR?CL@S"];J)M@EUV$\F9K<37XX]/MA$?DMWM$71!H
M!SL)0;MZV"0IFGC4GABS>&#3?['CW5JB'M,\#P/`\$0=O\O6)U-&*XCD&L>$
M5[BOIS_&@S=3.O3<_P!6]EQD8YTJ&;C60J?0E@LZJN5O5)\.C\F;2.,R"4B(
MMN=&KBA#T68"W_`\#P/!`W?.K\/75;O8]N;!H.;D9-9:3B<EO*OULQTC"+!?
MNDC\NYE;YND<%(2QE&'#C,77;MG\A0`ZRE1>/9*-UPKR+H."%81]LQ=_==O8
M(+09OGKR4',:N7(!!-NZ=OYCNG,R^,*[Z*KNY0HG)G^,;*F=]2BKG;`:>1GQ
M[7VD&V%+B*=;_5(JX0<.)D3*/(OI'A+A-P%'/&E7`_K@%].W*T<L-!-N*<1J
M#;-!KG:>N6KC=^%0UA7AVN>HN5`DCPR&%T^1NZE743CQ/8G#(G@QTGQG+&H&
M,KJAP:KAF!925M%T'WY6+0="X^*PV#C$DL-\!LB\#P:3?DR?WTI#?DA)\X'1
ML1N6L/C9A:\#ECL\0C&P`99<UZ4)V;(&Y<<'/$DI:`BE*-E*WW#MQ+EK)2"Z
MBQ9LNH-*`PV$<-P*[ZIX^YOJWI!>&.[OK.HX=7MAOZ\)NB\+*&(2+1C*!>/O
MGL;B+K+(N+%CR>S5>/,%![AVL/SEY]+]>Z"JO`\#P/`\#P><"I_F&K_H'YZW
M_`+&F)C')5SK6755-YL-U)0CZ/R<B1*4I9AXU@.BS1(C639E2`L6(:_CNEW+
MJ1OUWF[5(8WU?!Z/_`\#P/`\#P/!K&I]6W5.T9DE+@4H%19#4AF+O])IWD<B
M9&&9A$;P'3)QVQC#7EL3-<&]B:A1\$$OR6=4,-6R69&L6-;A39+K:JA'U6Y%
MI.F;5C:LVJ)Z_<PLLW8,SU?PYW-Y&;>NG&J2;.(:B&:B(DZZRC@^^4;I!6KY
MNX2=;!A=2UQ5Q7AQI*Q\>E,.<IR/HL06A\W;A6DLCQ$?5NBF&IAO'3LF":[O
M1CP6;:9'G2&OY8788=[-"&73!J&P;P/!/75_3E7\9<YV[U%="YU&L:6B+J82
MO6,"-CTC>-DG#9@Q%`A/X[-%V7,EGS`2/P^?C12+IZDX+E18M%V0;!CO@GNJ
MC/D;YHA_5//"LHTKR8$Y.$U#S@8,"S2.FXF<>!"@B3"@QN2"F+_?#9L7:)LC
MI'14,5%N55$'"ZS1N%D^!X'@>#4#Q7\V/(W>'9'0'#E,1F\A5P\W#;-*3XI8
M$.B`2!O6U46G':ADNL9-!;"DID@JXE$G'.!&I"."=70;1T[<[LG2:;%8,Y?(
MQ\G7*OQ>U0'M/J&4EP:$T7DP*L@06*2V2/)W-X_&W4B0B.CR,`#S6-;EM$$6
M:)R1X8A&BKG55RZPFDI]@1_\?M$3FSI'4/63I_")333F-LG\"D<KC<Q$SRQ`
M1BN@!]Y80^LI8$0#0/4_TX<N.Y:KF+AWO8`2KK(6BB:`!E*S@9L&VF^J<:7U
M6A&M7LTE\`0?GX/(?TE@Z4.=&T5X+-X].68U4=8$2G4,,`3CR.H!9.$D,4,#
MS$=?DQVZ*2CA-R@')4K58RD*KA%4!S\BE0V#AM`[612W8'M(R^N'"[I1Z5UC
M(.-1U%PHLY4^ZV!Q\,*:(X2;,1S5LDFEJ&4?`\#P/`\#P/!IYF?#EX2#KPY=
M30=5*\/,F'R.YDG*R6)2/2*3"N).!L&.1YO7?X8285H$@A:'MV3F9%E)8O,%
MCHZ009HQ=`B05WRN'V"6KW^TV+F365^Q@Q3#HX[3>NT,%^*>."6HQNJDW;:Z
M"Q.KK`X.VRGLHU&-FK=1=PHGLLH%E^!X)-/_`,^FI_W3>A/[8.9/`KW^>?U!
M_P!B/)G_`'BZ@\%9>!X'@>!X),O?^<#Q!_VOVO\`W8[G\%9^!X'@>!X'@>!X
M'@A/OZ7$8A6E;.&\C;1H,7N00'EKLG?$ZYEC[L#O`;&)(,9%=]7@9-8T(';R
M09'W33>)`G[@\=:!XR;PVBID^\;A7\!72=06&.45VSE%Q%8^LDX9RHO.FBZ:
MHEIOHLUFT@:L3LO;JZ[8W1DYIDS*GD]M2A!J@[=*I:!VWP2;,?Y]/.?[IO:/
M]L'!'@K+P/!Y,^;J\^3A;KGY&)OUQ88*8<TW1V_0-%\].5"<<.&HR)J7L-*;
MU^&`LPK84]C\0A$&DI>,%P#Y'30I-RI<MAVJ_'D"4A#UF>!X'@>!X'@>#5OS
MSQMRPW[][.ZXCM#UO'KPCD^A-3;V(RCK;$T>R$O1$+MNQ)UB0:_AJH+6`'OV
M/0XT-R@JIOI7:1%4BX3,)#Q(;2/`\#P/`\#P/!KFJZIIVEVM9MVG*(_18/-=
ME<ZSZ3P_G8U*6OY'!HC`&#`!:,8M0_;K&*'VL00-HQ1S#F@]L]*$/S##%9=?
M94*M/4#7\E:&1YE,L\82"P2%D%F>SY+1!T;*0M6!/F6WW&FJFH9<`NKILUT4
MPYPZVROJ]QK_`(KP2XZIJ,U'?_%(A@0-S`TU+=,+.9].,@R$[+;2*M!JI'0@
M6"`H^QT0W:QZ+B]FPT4.;NF,5C^Y%)Z08?7J!L/\#P0_U\P@?103]1YZK&9A
MB]MLA+XA:CEJ^>@.<&:#0M:#TVFAMN1BCB:C'0.M(>;8J#)H-/6(-F<"?AW\
M4<S"+!*O86(_Q1RC37"/!>XWFR>6\2.5QS\A`(-8MD$*;A<<2*V?<%LA*ZKV
M"6O,Y6J+RMH#4?O8^0%M[#M>,GI>Z=CMB#,@%64YW32<H@,)Q<<XBM"7LI30
M*TK5H*W)$/A-JUFC]'$FDJ7D,1D[:+2+0$+E$Q`AF4CWC0L>96.@OHVC9P6;
M#]`ZKSA\@5>=&]$6G3,74!_D()M(UZH/9(D!TOG2M2%XY#;_`$SU>'Q8H_$Q
M\&G<SBH**FGB>4YYG:99'L&C>#.2)@-A'@ZC/Y[#JL@TOLJPI`PBD$@,;-2^
M824ILIH/!1N/#URA@H[_``4UE]TF;%LLME)NBLY7SIA%L@LONFEN'@AZ3^'3
MJ-AR-;7>5'TE!.*>J^EW2TXL)^IV%?86Z0KJ^^L0U@"*Z=B3@>O:OJ,AN.D4
M:@DM=O9G)FR[@`)37'Q'<[+BHH,X0CXA>@^__CGX#"=.A9S?6]:CKO?2J2L.
MKT+'L)S,3(>SXU#!^H*736MJYAD;K>Q2$=S8HYA.9%;<N+P,O"9B]C6C)DL/
M#V=<[P3^*[G^C*R_(G47_BZIVLH)^C3^1-)>^COZ(PH)'_R)Y+!XP*PE#H3^
M7_0.)$R#"6AM9ON2;#&"+G1JD&8O`\#P/`\#P/!Q)XV-C04I(#"JZ(L,Q<D7
MZC5B_*.M6K1+997Z4:*;/29!SG77.J#$<S=/G:N=$&K=9=31/8,(5)TE#K?D
MLFB`R-6#%)%%E7*;UA-8VBPT6PSV9X=Z8?AB9\:**-M20Y=Q%I(\!3%%H_;/
M5(]JSRHNF%"^"3><_P"6#O?][*'?W%N+O!67@>"33_\`/IJ?]TWH3^V#F3P*
M]_GG]0?]B/)G_>+J#P5EX'@>!X'@DR]_YP/$'_:_:_\`=CN?P5GX'@>!X'@>
M!X'@>"9^E6=2#P(*96A:LOI?+(LVB@.;0B;&8@9>/)2Y;X3BN&PU(@TD.I5P
M.1=:,WH,FN/U8."#)4<DF0<;!E:JX_#XU`(TQ@95^?BCQC^?B9&5E!>:D9*E
M)5%#ZDC>2HZ0*$SBIQ8BH3P]6>JH[)N=$V6B#%-LW2#C6EZ4B0^CPPN.JWN2
M.TRU'X:6%$G/U^U=85S8.K/\$OO]5M!<(+9F6$/OYC&$5?SOZ'\/?[`P42D`
M"6=F\O2:+&Q$EC9[C[L@J#D$?),C(0R,>VYP,NS(BBHY9RP(L':.^BS9XS<+
M-UTMM5$E-]-L9R%D^!X-3539_3;/&&&W_A->U.JNJ^R#;;?_```,LHX4$O<+
M7EC(H./N"B`W$GN;DV71$5IA4MDD3"3\4.T4BQ,L%#;+X'@>!X'@>!X)-XW_
M`/"M;3F?*?X]S:70/04WR3=?XPX2#ZVO)HA"4I$[W^^LY?1JO8G$80,15=/D
M0D6B\>C(MQJ%"#&K8*R\#P/`\#P/`\&JCF^?65>'64SG.TNEY2K*W4EE7MM1
MC]A^1/C@YP^<(,[#B4,OV4P6)&4F3]+Z?<G5"=FORD>3=RE:FV!,3`),&U?P
M29<?\Y_C?_K&^O[*]_!6?@P_`>AJ!M:32&%5=>-/V3,HCJYWED2@-F0N8R:,
M:,B&!+S>0@8Z;(E0NK0KMJ,<[$FC;"!#;#-7.CG.$_!Y`JYDG-W!/RI?,)\G
M#WJ4W;TZ:5)8D=8\E#:\L&33!`O(9_&&D)<GYX!9D(@-BA>=TZE"(;N\V8:Q
MD#+F3R3/`C+5NN0#;M\:70,#NZLB'RT]>V)5E03ZV1Z7/C0!-YM'(7#>;L5X
M;=!;*J`<^F)]5<!(I3:L8)OB(DM)R"TE!1*(V`+"P]].)7'4POI;D"O+0Z+A
M_9PR\)Q)4%24&L&)1H(A1DBJ@T%"51+H'#VXB49JHI81"#.&-ERZQQ:8RSMF
MJLYDF)2,>IM681DP#LMNQ.+UUT-SE?34)'PFA`Y/*!G<C0$,&JVC._48V5B;
MTJ_2;ZJ;N3]SUC6<$8N]\J/W!V=#F.JVC,@2^^&J[^$6,NAYKS]RC3G+/3]C
M\KVQ976?XQ*<U)-;(B\W7K&#\X="2J5H*"*B+#;!ET6UDC2"-"8L6B_'MI`3
MB;TBWU538*8"=^-NT.D.P`_$_#'3W.%GLX?'CU2TAV1>,ZM$'F:V?T777#`?
MN$1%ST2ASA4Z+@<V<BP)Z=DC\E8E99KHVK>11%TPDUGA8J'J3(C!IABX&%A[
M$H-=Z83=#R+1N]8N4]=M=]4W#1RFJW6TUWTTWQJHGMKC;77;&/MUQG`!HL:&
M8MQ@<<Q$C6FNVC4>-:-V+%MIOOLKOJW:-4TFZ.NRF^ZFVJ:>N-M]]M\XSMMG
M.0^[P/`\#P/`\#P/!BB]2CT+35GEAS4@](#X3(73%H).E(R47>)#E]FV@\\$
MU4,BWN5ON9;.A22Y'57&FK)NX<;)HJ!+G"]92RNX_)9'9F^J<[N)SK,-,ER)
MAA+'@ML3./W*!:$&PD<6!.F1.4.#;URD'%OW.TL0;GHY$GC)&/M`K%U<M0,9
M4K!'UK5LSF[<R`CB\-=3F,-Y4C(94P>E8N"5CRQ30NF9D@P82(@!>[/5\88#
MWKP<@X;M%U$PPMSG_+!WO^]E#O[BW%W@K+P/!)I_^?34_P"Z;T)_;!S)X%>_
MSS^H/^Q'DS_O%U!X*R\#P/`\#P>6OYU/F6D'QL=K?'M70J@AEN-9"ZD5E+DW
M$W*QX@VWE;66T*N'9AQD1D:I%1FRF"LD:[(JX<OGK%$-HUTPZ^L2#)%)_P`(
M#=7G\U#KXI0/,!2+Q!GO-V:UQSN02:(V!H0A-*$[8<8>4V?@@Q\&1?NQ^H5N
M@7-M7VC%;4ME#?&Z+=0/29X'@>!X'@>!X'@U]_(Z+!2.H*\B9T<\<8D]U1QD
M*-A8KT)/)9#RXF&SZ5H2.(0?E>60>])07RVCKL"^:PN4#=!<9.2"22+5]&`A
M@<["M(I%V>],1V%B/PP(]2LQ48&?0QD_$$P[3>+H"F>6</E+M:41G0>EE/*$
M<D3Y4\(PEJ-+.MR#==;(:Q-/C_O!P!1`.C]:ZM7#%DU<+&IS.YX2"YKU(FXA
MS(88+U^&?EH[:90BLVL>.NMQ#"MX8JC!X+B6@!`EL@&8ZWJDC6O8/."TE>K[
MS0[R3W`[DX@3-9=(J\!O"727',T_+(0'/:"!+%N,7FCL*M)1\-BIJ6CA(160
ML]<"Q;$:&RCP8GOBP%:II*W+,;K,T'D"K>:2P>J0;N';#!,''B!`7J]:M=M'
M#AJH00;)N$D5$M]TM]]<*I?;^)J$JU'7K"O;\YQJ1CJ^P)YMX)Q"8_J[<H/"
M;9O)955$073DSQJEHU=O'#"CA/Y:LW08(KNF<C71T<I;838AL"\#P/`\#P/!
MUB;3*-5S#)=84T*)@X=!(P?F4L-*MWCM(/&HN*=FSI11J/;NW[E,>+8NG>[=
MBT=/%M4<IMFZRVVB>P8;Y$ADE@/+]"1B<BU`MB(59#RMH#57#1RHWM>3"&\G
MM/;=0:X="==G%A&)*ZRW"+9`M/QOI`2:`=%D@F%%^!X'@>!X'@>#7K!Y)SM.
M+\*5Q"^R+)FAB!SA^[?\RB9T%(1J*S4$W83<BJ8.CH.E<K^/#US+=[F*2RXC
M-4-'CQ&&,XTBV#C(N)#85X),N/\`G/\`&_\`UC?7]E>_@Z-\A/R+<W?&/20'
MH#J-_,AU>22R@=3C%X/%5I@7VETACDNE0Y)86@[9[I#]A,(.[+/<JYU27T:H
MYTSEQC;4/^;/\</RGUK\8W;GR+=('8U<R0KK".S`7SG('-:#1AIBUMNRXS=,
M,LJ21B0G'@=,>-K&5Q:P$0S8A*?S5B>CFR+0J,,H[.`WC<,?##?/:-5VU(Q5
MAT[S?S8^F73;WCV>$:=6LWLJ.N[!NGGR>U@=NQI:VQP5N%B]3TU#84'9Q*<U
M_:\:2C,;`NI,K&5)*#+A:O1_\&VOBS?C3D_)+'MPA=72LYZS(],3>\KF.W7`
M*OE2TE<E"$GW*TI'YY;T/4GCLD^P[VFOY)DJ147=;KNV.?LU7#N?(/RGU1\8
M5I\O?`):53W-;73=-P*O*PWLVD@H*15?,C,HK=.V0.P!B=/1V<M=73`XT!OE
MS,<8A03_`%7+GCHV*,R)]B$LA/E^^1+H_OON#BBVN<2T:Y\@'\=CJA/T6YLM
M<U>J,MJ6Z(2QILLLK`SECLYX2A;I=A,YBWKH4HF_8Q\@1%R6-C4=Y&/#>C\?
MB$RZ#M^5=.W(VD#ZQJWC)&GRQ"2U1.::8(V<5>BFDI8PZIK62_3JNP,8K>#0
M"71MHZ='\M3'2UU,TYJ44-G@00+9:\)<=LNG%>SVG.=6-^K%U'*RU]I1IOK9
M*BKN$;5LYWVD&,_CYV7@>^\44S]G^$&VRT_\C/@K+P/`\#P/`\#P/`\#P=9F
MFS32(R;)")NIVPR#)ZO84Q8AR;N5M-VBNCB/MQTA>C03Y0LCMNRU:&"#,:X_
M&_">.$D-M]\!(?(>G.QHE8$@J&D7=6R<"Z0BLE=24M7LDDR2#A9=VK'6;V&V
MA:3F-!FC\?\`?=Q=P\CK/5\W041$K;M/Q&X8%D7#MR$.C#=EC))"58(</RC#
MW61S>:F9&F&GMD0JSGDDBT7<P=P!KZ3UTK",0H"!CLH6%60QDN9C+#\;(PP!
M&WH4;RE'F49M/Y`&#!V=>HNNRA1M160R0_*7NCJ0<6\=&GC9L0D9$H^:!VCI
M\JV!@FSA(-'1*3,&"8C@[!DR0"S_``/!)I_^?34_[IO0G]L',G@5[_//Z@_[
M$>3/^\74'@K+P/`\#P/!B:?T)1=KF@DDM*EZFLJ11I/5&.'I_7,/F)H`EH[P
M_P!$@A21!R+X4GJ^QAYKHQ70UU=XPXQC"V/O^"7,4Q3PWY'1%DCJHK5A8K[F
M";FGL^906+M9J[,N+'AD;7+.I2@+3.N":\><N0*S]5_NZ4"N%Q>ZNS%51#8+
M\\#P/`\#P/`\#P17W:.9E:>%);2$Q&C`Z<!S((I&X1T=8$@:/D!9UANN/"<K
MW-15LL]-VI)PT=FV\X_1]FW=;M3`A_L_9[-PHRG%9$O4=7+R\>H)EBU>0M63
M"EGI,DJ-D"D<&[F&"I$U(I<8?*,R&7#?=X6E<F).=D\K/CY=UNJ0<!DCP2;,
M?Y]/.?[IO:/]L'!'@K+P0UWM8]>`ZMB%+2V>0R.2+IVX*4I(##9!*`8&36-"
M9E=M91J]1L)8DWS0@1(B*<D,L>N'X9-9X`57'.T,Z$UQ23D(CX'^0*O^K_E&
M^4ZHA;L0Q,\]M:#I6%LFB1+ZJ:1*EREQ:65+E'[G9080=`;BM@Y$GS<5]'L)
M'H1UL_8;.E%"Q0-X/@>!X'@>!X-:_P`K?4G/W-/'ME,;^MF&U0-O6/'*0CSJ
M7$=A^YO:>CMX_+V\=W_#53WD`:#%)!(1^SA)=HW<#$G+QF_:I+,EPV"0V41J
M<1"*36&&6<CA\PC8.4120CE?QQYZ-2`6U+`C+!;[NGXS,H+=M7S57[NOXB"^
MF_W<?;]F`[)X'@>!X'@>!X-4D*Z!,@>[)_"+EF8N(Z2"7#XI7T(%7$?+1AHN
M0K6";1L&8B.U"1N.NIU*G"BTK0<N+6>OV#65@P*;=[LV8H[AV"T.R;HK\S,4
M-XO6>K>!3ZP&RP!-&3'#\]A$?>U>*C0>+/\`4['D!,]=?QCXD<@>*A),)9M6
M"$=9A%%'N\G:AK,^0[NCN:##^*9#RE6%,7;U/FW[\`N"9V!6RUY@*5V+H65S
M>4R,><!SWZH?(`H,,D#:1W-DFSI^4,G+4/'G3TZ'`M@D?YW);8?R9?&;\8_*
M-?4\G9?>O>C&C>L837$/D#6"16N?T7H!_,K@F#MQ-Y'A!K%1S6QBT)`BIA(-
MVZ#8L[,$)$H;C(]N:#0AWI_!I?D%K2@.-)>%D%Y=0VO,X^`8WGS[$*W92$-R
MPK&:DJ.`NE`<GB4\+5U*M@L8@$/K=8LFYCAB?C:^BSQ%Z79`G[P0'_1$^/-@
MOKQS1\N>IKI$+@C+B^W:9!'*1QHC>Y<C;(4')%=]U5'D@B,;EX6&DW6RRJ>R
ML>PDSVU'HM$DPM'P0^=^-SA^3=;#N[3O/43(];"78=\.NQ8G+=)(U=Q^))00
M.MH/1D2<;SLQB2"01+&X3?79MIA1751SG*^0F[YP9_T12WQWVC?_`"!&C\EZ
MLH^94W+Z/0BD$>69(FQ4_;4-K:??1P5D.+J2-@1J"<V&&/LEACUNW!$2!;[K
M1T,:DF(<5\#]@=&VO\:=1V;UK%I!$.AY]870\LLP3*8"^K$\H9-7]9#UN4?P
ML@.$N!&2XM1B0;_='-6[MHNW>-M-D%]-]PW#>!X'@>!X'@>!X'@>!X&?\F?!
MK7^.^M:BA"%R%:K#68#U?&HO#2[>7IP(C!GJ,"0/Z"S-6SFNPP\;8($LM(2S
MIS))(^<SEPGD9N>%`&JPEJN&RCP2;SG_`"P=[_O90[^XMQ=X*R\#P2:?_GTU
M/^Z;T)_;!S)X%>_SS^H/^Q'DS_O%U!X*R\#P/`\#P/!XI>S_`.$?3#E;Y9.G
MZ7;\B,)NAS#15L0D4<;V/)$7LTT!0Z/WRV,$0XNMC.8X/6>"=8^3>_5$!P<4
MHXD3Q[JBT4;>#?5\+'R;&OEDX[?]2GJ@%TD^97%-JLQ#!$S=SIHHA$@T0*IF
M<FWD<BRVJK[:4;H;L?RS;1##/535RKE?.J0;</`\#P/`\#P/!`OR"UW'9G6D
M1?D`-;OB["<L12)27!N=',QT"EA!I9X"K0]T_"IW508Z3-CX\0+HG`BVQ.*!
MC[43E*09$.$0L6M1!T!74"!2A./(R8+#8P*D*428Z#(JD<'A630JG&AJ3=HD
MP`Z/D5]1#)-JV3;,,-T=&Z.NF$]0ZP5OZC@97\C,V]6PHSC:8ZY%D)I'VC_7
M:O6>Q"=Z[M5G^BNFT/8Z*.Y)KMKC8,@FHJ_PAJGOG`8+=2B-S7LCER61`Z)D
M\8D''_99,'(`3]L4#EQSFWN"-D'HX@S45:NVRNO[=%D5-]-OV_9G[<9\%H>#
MSE?-%\<M%=M=3<0VM:D[G$,:<>0:_.D[-;Q=]JY:S"HZG-U&6&P-FW,EOT=A
M$ZE=AFA>(_*OR=+:11018`TH]?.XQ$M0P;O^:*],UG2,$CTK5;NI\0'NIK:#
MYGJYU9/[5L(B\G%E.1FC]!N21!XFD@--XVR)Z;$!<;;B1+I555CG?8,[>!X'
M@>!X'@T9_-C\;%9_*DQXWYAL>QIQ6K+6ZK!L!8W!F8)T1U`1>DYOH0WTS(&;
MUEEUB3D80Q2;?@_>5&DS#K7;&['3P;?:2J\92%,5'2P4D^,AJAK"`U>),%-&
MZ9,L,@$4$Q1@2(IM-$VNCY\U$I.G>C9--OJX54U1TU3QKK@,G^!X'@>#7'\A
M,GOQ''.=>\Z`R,BG<QM.12S`D1(XL#R05IZLY=8$+9S=61N1[D/3V]KLJ\<V
M-+@;U=]HHTC58J@S;:VMT4`V.>!X-3"0*K)Y\@\HBLS)A9!)HJ_KV5O(\/CO
M0@`6A:0F"1V;0X[JYSTF1I5W+&<9A`A^Z)Z40V*O8T)$Q4I*"'TBK=R&T%]"
MH:4?#29.)1DB2#&%Y"'(/@(IV^%'W0_82Y.#7;AHHX8F'`O;8:N3:J)/51^V
MS-1?9OG*?@UN]O<J4Y?3[GSF0]7M<I5Y-HYU3&18!_`0!:)10O)Z6.M&TI&1
M'"+`<F2$%3;DXBJP5%O5'RCA5(BU<.E'/@\C/\#->R23=8=P9GTKD<_+U#15
M9U?`2\K.&#:L3A6EAR)!S&HLB7(D-8]'7&\;#JZ`QVR;%KA@V30TUU3SG8/<
M+VW(&X7EBYQN5V>"U@0TC4L5&.'&B;V1RZV-/XOH[&8ZUSOJN8E1LC(4F<<"
M,='#XJ6W;-&[9?93*>0I8*,3"AQ(9%3=9$2,8#$EE<:X4538-4FNBBF-,8UQ
MOOJEC;?&N,:XVSG[,8Q]G@Y/P/`\#P/`\#P/`\#P/`\#P/`\'QD&#,HR<CR"
M&KED[2V1<M]\[8U52V_\K3.=-M=OLS]G_L[8S_\`U\$!?'N)"(PN>26/R:IY
M$(FLB82,'^@)]G))FUC1%FN]`JV\[#,8Y'14U>-7>^SF-!(>.0"N42'WSAO#
MM)D!"P)#<E2Q*5#(+*++@L>FAIT`8B8F9E(4=(B3R5JF6\9;,P[IXD_<+2!>
M/'4`VB:&V2*P@BDT_%W:+:Z!A;G/^6#O?][*'?W%N+O!67@>"33_`//IJ?\`
M=-Z$_M@YD\"O?YY_4'_8CR9_WBZ@\%9>!X'@>!X'@Q@6I*F#\M>3X[458&IT
M1#O(\0FI:`Q0C+7X`B'<1X@#>2-X)6,.@[X`[=`W@Q=YNR<AW+@8NANR640V
M"=OCOA<.@W(]7BX3$XU#QCS>7%'8Z+`A<?8NB:TS/-%B+EH):M&Z[Y5JR9ME
M':J>SC=NT;([*9302UT"V/`\#P/`\#P/!,O53RK$X"!#W.RM)[7LFFPX.8UJ
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M51#_`!7U,[OH]I8=G-##=U^*HZ_1N$5E03J(%128]HG^GM@C"#HZ[31;1@*R
M\#P/`\#P2:+_`/&#V5*27_GP'.-.`HBP=)?XQMFTKW+N)7.0KG;_`!.[0O#Z
MT@%0&,)8^M;/Q5P-5<Y:.1NN%PK+P/!JXYV*BY+VC:Y1K$ZW1."PQ\`4EMTP
MVN8IVP_#A#+5B.2ACV&CTI-+^7TU5DVX`[8*C>0-3&JX];=TA]`BU#:/X),N
M/^<_QO\`]8WU_97OX)V^.&81)PG?,!%0V'1-(9<EHV'39P&@,R9MOFVS+.F)
MJ,V64(BF2`MQHK:J=KQ\&,#OB*"-9C*JG"^4!]EQYP1#IO;`*4=>W3".;Z`F
MM.F9#SX-DMQ6]N=/$79+GRXB0T$,Y7E1/2'8*%P,_P!VQ:T9I!8X_;1XLJUC
MVD\&R<`N"C^LC#;.UPYPV;X>[(;O,((X=[M=%$FV[G">OX^S=-5195-#97[^
M4=%555-$\ZZ[J;[8SMD/W\#P/`\#P/`\#P/`\#P/`\#P/!UJ92T!`HI(II*7
MWY;'(N(?&S+[\%9QLW'CT-W#C=-LV35<N5LZ:?<0;-TE5W"VVB**>ZF^NN0U
MZ?'^2>/9?TBV47_+V`^0Q=LSBKR2%9:41>-2]BBS<L;&R=(TCHK&C)44XB3-
MDP'RYJ,E5?35AO*EG2#ABT#YYOP/-3G5TVZ+$W>\)@K-`0.'R6`S6/QYRG#X
M]&)5^DK]2N34;CP0UH_0P+#LXRC+RLA0'*FYD\=+KZ.AK)N&:>4@>T?M/Y`&
M6QHZ=RY[*%%\/)"^3?O6^#?%O'1742V62;-=4PX;#O`L&TRGONR$M&;51=QN
MCLNH%G^!X//'>S/YAG'SL4V8I:$19?@"/\VSH&5FTR9@&T#^IFL91*2`#)SH
M7=U8N9-K<%>ULZC8T:PR[0';NUU$\Q9^5=(A^?QG$/EG=?*O\EB/<PBE&-%H
MPVJ=*V7K]5;?;#-*023^(?2L]U=\&7D!=PA:X75ENITAI(D;0U8M!7X+),JT
M;AZ(/`\#P/`\#P1;\BW05I\I<.=.]'TG#1-@VE3%4GY]#X<>"R*1`S3\'^`X
M<)&`T2*!9$]&-1WUK]]@66'K(-FJCG=TD@BKMX-.GP&?)5TSU5\?XN:3WBVQ
M):3B%MV+7@\S0;NBHI#%0X_4#*$47XWH7JN(3I22(/I<0U?/&@5*.*C_`,J2
M'KKO$">V`Q'8WSN=EQ?YS:9^,O7EZ"UU1UC2.JA!Y_:H=0U?81A-X/K)"I%*
M3T]T%/*7T3R_VQ^2;:-2RK4<HF@:::$L*:Z!ZN?`\#P/`\#P1#WJ-=G:GB$=
M%)ERYX_:`=B!@XZ(DYNPL-^WB4U+N(W(@0JTZ5<*!Q@<84G*#A2S(V@@?AX/
M.V#"FR0(F%35B+?A*WK\,5?R(J4$0J+#").78;XE9%\P!L6KM])L-'I%K@^[
M7247,8;D'Z.""CC\)ZZT^Q?<.\>"39C_`#Z><_W3>T?[8."/!1TRE0:"Q"53
M>1D!XF/0Z-G)4>*EG[<6*&!H\,=%RA`F3=YU:CA[)BS7<O7[G;#=FV34<+9P
MFGMGP:=_BY*UI8=P])R0`-%I693PN#UY>JN`#$<98]/7^J2ZPZ@U)O6VJ*J<
MEP;L&K:OL$&JV;9CT@HH?$TQ\?91,?%(\&ZSP/`\#P/`\#P2;R#_`,I878=T
M[_X6+_NBQ[(!+8_PD'=:C"VE9TR8'[K?^$4A\QJ*OX58?Y:4P@]#E)F5'*L!
M>R&1S8*R\#P/`\'Y+KH-4%G+E9)NV;I*+N'"ZFB2"""6F5%5EE5,ZII)))Z[
M;J*;[:Z:::YVVSC&,Y\$K\=(+&*H)V^]153>=%6+/KV8*.4]T'JM=S8^XTHK
M!%DOC+L471H(75Z1\([675#2/4RPUR@DCHT;A5O@>"&HDOR]5/1A"'2&13'/
M1,DQEU'Y/=\IG,E4ES"5J;/M0]1'Y61>U\";(N%'P1&MZ]1BA)JF))*I1'<4
MKN7(A<O@DRX_YS_&_P#UC?7]E>_@PI>,/IWADJ.["K6G8]%(J#&O*]Z#B]*U
M@';RF:P67DVBT,.QZ*P\4R(3"P(K:ND>%B`S/&7QV-SZ9(:HES;&*LT0^'@2
MAI6"4D/6A^U%9&^Z[!K6I(HFVA8@&FX8366E;"IA64']2!-^?DU/53*VM.AS
M+!M&/SB&LA`F2L28^$UR.A8;+/`\#P/`\#P/`\#P/`\#P/`\#P/!U&>PH-8\
M+E$$D.7>H66!7X,BHP520?(-WZ&R.7+)9=!R@F\;;9U<-=G#9RWPNEI^.V72
M^^EN&/:9H&&4@D6S&R,G.$3;`&+(&I629OB&X\"N<*I-4DA0P**0U?RV73B;
ME5DANCEW)9J=VPND%1`A0H9P\$F\Y_RP=[_O90[^XMQ=X*R\#P/!)M>_SS^H
M/^Q'DS_O%U!X*R\#P/`\#P/`\#P28Z_GU`OW3)9_;##/!6?@>!X'@>!X(J[M
M@(^?5+&4R8`-+&D7LD/*=XK*>9Y9UQ#Y!E&,R\)AI*Z1B$R@SX\-9X.[&&!1
MX9W8Q^1#`971DH2;CEVP4G4Q((7JJMB\<V"YCI.`Q$B#WCL97A,>R&>1\>Y&
M[`X<Z>DG,2#_`$2B.1T;<D7ZX)G^",6>.5&NRVX<(-Z!H4PB-<"+NJ(JW,Z2
MY40N-LF&OD2J=?I;K3Q0:JU-*Z/M(2BDHK+MVNRNL;23W4,Y9:Z;9P&$B$BC
M\M[-Y>D\4.AY-&CW'W9)0'(8\39&@9D8\MS@99H1$EAJ[E@18.D=M56SQFX6
M;KI[:[I*;:YQGP:+/X5C$;YOKDWG'E#E/>VY??%O=),SN],5)C.%YY6%?U99
MTBE!.7+MTF:OY=%R[4`7``R4F$!SQ!J1)8%'BD18/8T&UOXO_C7H?X^JR,%J
MF9VZQGW0X"M)ST#O:UESJ9OS]LCXZZ5D<L>1V62N5CHK,S1:0E=9BL(?NW))
M1F*'D2Y9O'Q:R0;0O`\#P/`\#P:9OGFE_9<3^/>3I<!E9Z+ZFEMJ5-"Z\TK'
M0;O-RJ)R3:_I,)"8*)*M=%7,;:E%%UL?A.&[9!5=NNBLGKO@,N?#)'^FXG\9
M')T7[&#2B/=&QR'RL'80.9L10R2BD15FS=C"F))D$21&(?3U\A%-&?T^GWE!
M^&JKC91THLIL&SWP/`\#P0G\A7Z=2.C@],UJDJ^EG0-H0*IW0D;/7]:2(G7C
MXKF26\W!34?%9BK&\+5A&Y2R/GMA&5P\7>F7P'+^7IQH"9"B>>1%DQZBJBCE
MQ#8>)M&.5Y%([.F5?FRTBA.)&!#M1!!S%RYT+'C+D,_49_7LDB8EN]8I.L,'
M"KU1KE^Y#,?@>#7/#*CO`1UW-5I,8D\[J`\;2FKHK,(OQRA%2PX;$H<I!V2F
M\"K.)]#D+-KZS@F<1TK*='$18U_'8FOB7E9>P31U#Z>YHST2;,U$XYZ>RY&2
M)O#+)#\N<S!G#!)%9T#=Y/RU6*2(6*<_<`LS@EDRL825B&_YDJN/4;2A$4@^
M##U3A;/%7)Q?F2.Y6,@>3'36D5AEP,I<<O,=MO7R&V2$NL"3SDN[<"U2*<FW
M%1TE'WY'44^!/64I9!46D:;AL'O6B8CT'$Q$-F9>:AA@291N=L74$E3^)%<G
MHFNL\!_5/V&-MG@UJ041);BW.BC-R^8L%G"2F&V--@[C6=>Q^IJ\A%81/8IM
M%Z_BX2'QW\Z)N3)30)'AZ`P8D])O-MG+Q9%FV12_%4SC_!TUTTUT3UUTU#O'
M@>!X'@>!X'@>!X'@>!X'@>!X'@>!X,7+WC2K66NH`YN"KF\[8G@,5>PI>P(F
MC+6<HE(YR8C$;=1M0MJ9;GI&)9NR@$.LRT(%QS5R]'MW#9!574,/<Y_RP=[_
M`+V4._N+<7>"LO`\#P2;7O\`//Z@_P"Q'DS_`+Q=0>"LO`\#P/`\#P/`\'E)
MZDXI^:*1?/M7_6_-DZ/Q/B1@.K.+&GTEN%E(ZJ81A.OVX^QQYOF1*YJ_D$H#
M.Y:EDD[%!]03P@>2:2=@1U?M$'V`]`?Z'=U?TC>3/ZEMP_[_`!X-$7SH\A?.
MET/7G/;#AN_A;Z31.>2XM.=>92\NX<*)AW8,4B&S+CTT[#FK*Q!.Q!NYPQCZ
M#1KD4XPX>.-UTG>$]0])E0-9NQJ:KV5F+;N+(9UW"6M@.%7#-VHO-V\:&)2M
M91V.SL/=;JGM'^^[ACMLS6VVRHUSE#;3/@R)X'@>"+NDHI:MC3V)P(+4L!MJ
MIG,'D4ADXJR;(EM3Q]A.1<CC32+.F<JA-0VB9?EM@I&2Z8`+JA!ZC/\`'?J:
MOUVJ7TP50`#8"PH-'F4>CH'`J+CPS2*"7"KF)!L,123)O'QKO(<4LO'A^$M!
MS1QD`.55'))J9$-=MOH]`U?'>)KXGK5V_E6*1C<IE>C1]-W`*5RV3!4C,)6,
M/H:SB0]:J(1J.A<K;DA\"F4:63PY!P:/M=TS4\+DGF4@YYX$)4+?%)2&1EXF
M.F0WB[Y`C+O4O.#+2I1DB/\`1_'<U"`D'IK0(P9"6\AFJ<6WE2<:!2`^*;!T
M7S7&!X84/#5%_!Q^L.B_E"EO6??W68J`/)K7)L/Q_2TAK-HD,@P6#LF[*TK+
MBD=%*FS1!91T<*U_)R4R=?@.Y:D8&CW!(L)B4:#0P/53X'@>!X'@>!X/*C\3
M'SJB_F2^1)_5:_,C^CA?+O.UTVE'MGUO-[,9&9V0LFGJFVE&X[6MH1@6<#PF
M7RF/1PBW<+JL`LYGXUU]<D?;[C0]5W@>!X'@>#7Q2]KC>GNM;@*;@3H>*<B;
M.*XJ[4Y@9JRL"6S-X>CUFW8"19D7RZ@40[@QFFH(^>M1;]-)K:I)/#\'.!&S
M0-@_@>!X-,%$R):Q>^BUO$:_#1=C*5'0L,78G@9V:.2"U6*,P3,V6S6X"0(U
MZ\@]<N#KB`ZR\H)C=FO]BK+!W1TJ5:AN?\$F7'_.?XW_`.L;Z_LKW\%9^!X'
M@>!X'@>!X'@>!X'@>!X'@>!X'@>!X-:-B\IW39'13RT20^F1D98:N81$2C&8
MRO,D%5H>EU>SZ2&\PU"J!PA*SEY17Z2V[]Q/#38FW*M=4BL?T`*MI&&7^4HZ
MPC%I_(`P'.3KI!WV4*.*J2&4266O='LAXMXZ-/T&Q*5%C)%F';O'RR`./-'2
M`&,B=&8&.#10,>P'-@L_P/`\$D01=!KV1U,Z=+)-FS:C.4%W#A=31%!!!$_U
M"HJLLJIG5-)))/7;=13?;73337.VV<:XSGP5BW<(.T$'35=%RU<HIN&SENIH
ML@X06TU417063VV35153VU4343VVTWTVUVUVSKG&?!^W@>!X'@>!X'@>!X'@
M>!X'@>!X'@>#S8_//PC;'?EK<EU=4]>5?9Q0'S7\AA9W'K.N"6TK@2Z.[\AP
MZ*SN"RF+U[9#1W8<$EQX-(HJ'EX-&'N'S7"YI^BBVUUW"&?CZ-\T?P9N*3&(
M]NL[\Y_@?444H(M%Y?.8W&K>'3#H2KX*;$](M0VG,\YN[6,`W)Z0@CT$9R9G
M'76T,<LQ3Q8L8`/RA(/89")C'[$A<0L")O-R,5G47`3&,D%6KIBH^C\G$M#8
M9XHR>I-WK/=R.?-EMVKM!%TWVWRDX235TWTU#M'@>!X,>V9;=4TM&OTSN.S:
M]J:'_F#43^EEF3..0.-?FK_5;=B,_/922%"_S!YHV<;-67U7U+C5!;9%/?"6
M^=0AWL/Y;^`>%:XJ"WN@[Y&L*ROEZ>8U-.*YCLJN:-3-6--F3HPL++U0&F#'
M9DW2?M\:/]U]&;A7*J#=915!;30-%,0Y,^5/IOYQA?79XQT@C\-%JK*RIA6D
MBZQ*0R%F:_>\DK1Z'+EN8X]<K:0BP,NN1$))W,+,PIB_<M2^7%AQ<?NYD@I`
M/353W''(G/$E(S2@.5N;Z-F)<*XC1:64]1U8UG)2D<=OQQ5V`(G85%PA1Z%=
M%!`DDX%.72K%9^+'/%$-G#)LHD%(>!X'@_S;;77'V[;8UQG.NOV[9QC'WM]L
M:ZZ_;G_U[;9QKKC_`"YVSC&/MSG'@A&2=`RJS>AI/RS`L_H*$:LE6!6[4W>C
M@XL8B@B,R6VHA6XS#1Z'S)!D>M&JQ@B4%'V?T;.+V8N2C"[R$QUK+`S52/+%
M(<ZO#Y&IHR>"OI,,$!2[N0619UB+[B`9B3R`8,'[V/,9;D(P1/325FEF@3\N
M0>E3Q$@^T<NEOQ<!0O@>!X,$P[EOF6NYR\L^O^=*)@MED%":K^PX=45?QB<O
ME365-C"CR6A(\Q/N5"VRJN2>ZQ#?9_E53+K*N=]OM#.W@DRX_P"<_P`;_P#6
M-]?V5[^"L_`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P2;SG_+!WO^]E#O[B
MW%W@K+P/`\'D;Z'^.?Y`;&O;YM_I^VP<9AW2//\`"Y8+BH9E-&*<1`GV<X@4
M?C))9HNDSD@AG0]93^&&1;@8BHK()7&S04T*R'-JG@]%7`L<MJ(<4<M1>\YK
M'['M./T?7HF43N,AR`$;*_H8\S0"&G`LF_).$3SR.:"%)6NBN@-?RC\X?AQ@
M82Z9"&(5UX'@>!X'@>!X'@>!X'@>!X'@>!X.+-FA$;#E9#(";$*"!CGA<R8)
MND60T6+'-U';\@_>.-TT&K-FV257<+K;ZII))[;[[8UUSGP2&YE,<FW8_+<M
MB!P9)8Q(./\`LLF$/!7B)`458.+?X(RB[8O&^^Z+A!3&,_=W3VSC[<9US]F<
M9Q@,)?)9\;,-^1$;1J,K1JIVI1LELR0LQ-L0*R)\"DK.R*FDU9D8]AK7M\4<
MN$^ZX-BI6B><.SI)B;B8#81^5(9+ZE`\H48^!_Y1*V:U:AI;G9`F10SF,`@&
M?5WTH,L6O4^OX=<(21:K3J(R3H2NL+T"9JPJ\@$<'1AD`>!F<+8D3T=,$E'?
MZ3AW^5WM_""XC?5K!86W^0-42)E!H#TM<3'AR,JP6Q1<8[8@,`BUN\$568CM
MR@$I3CDLJL,WBQ9_K&);`(2[GQMI)[(9+3\@%42?O?YYZSY`Y>4(5[6U=2Z7
MRSJ-U+NI.RF"(*S9+%*Y/=`26K899G(<,IZIFU23N81")5M%X2[B!Z9)S)W(
M(T36",43$A)@P@CA47\IED?)S%.T++N.=1TS:*3DA(.4ZUG6M@:"$YEQA";!
M4DP"HK4D\)K\,T=D9:]SO&CX\4$@$MC\OA.9X[GX*.CY:&N*)<"===5I=;U]
MUQU->*$1M]HTL+G5A'Y:RZM&)W#KUL^J"LX!9-41J:GWL';6`7*-0(::U^<0
M@D)2L>K3LDE3N/3&*QR5AO<(?'/\1$_^.OC"C.CW?2L]D?-S(T(=FX?55F\N
MV-)\-2!)2_YT_@MJ!#"<NBW.,;BTP,V>G59R>N!*4".L@^3Q\D&"NP]!M4_(
M9RZ#F`2CPIE2.T7#:\CD2KKH>=NR$5@TZF$6!Q%UO`HZ[EP".)2I!U6$O@5@
MPNR(J_/0^Q0RLW>B%V8V')%)`%@ANI^<9`$N.3AKJKM_%N?1^YFYI6C)6&(I
M7X!*'8GR\E-2=130%F+-8KJ](O90Q(.X^R7#202[)(F8Q(1XP,D%+(K\'%0T
MY-36+B(9(74/8@I63.#F,>+O+"+B(_!6H\NY<),73B8'#X,1'$D5]MS!(N.9
ML<+N'B">X8A/]=\\1*WY72$PLV.0R<0R&16<'=IB_;16-IC9B\.M@XH?*#RP
M\*9E.B`!8N6C`EV],A`9..%BS5FSDH-1\$HV?\H-2MH):)"BV)2PI9$38.)1
MV52".RP5SULXF)H?!8Y:LKN($'.!6%(#[1=':Y.'A^RTD>S6LK@C8$"Y_BML
M`Q%@P?=\&[+^1JC*DED);TA7M2R9SBR&E;*7;<L'G[*31X2])TS.C-R0ZFB>
M[@Y7=M?HW.'59QJ'Y@"Q.MM6JEK7-"YZU4BP;(ZGY4H.I#+*=0REZR@UCJBW
MZ)H_"06H_&Y.3(AE)HX9+JZZN=]I*0!CG)@H[T_.3ZC!H\..7;["BN0H[P/`
M\#P/!T676?74!)1@/-IO&(H4FCYP,B;`^98BW4A(-4=5W+04D[62V=K();I[
MJZI8S]S\1+7;.-E-,;!+,JGL*LV^.)YI7DJ`S6)%B?0^@R1QHFU+AG^XZN7@
MQ]JU?LU%6ZVS0@S=,W&NF^<I.$%4ML8VTSCP7!X'@>!X'@>!X'@>!X'@>!X'
M@>!X'@>!X'@Z;-K#@M;#&1FP)='H:*(F!\?8$)(59B&CPV54RD.%-EGBJ6BS
MYYOKO^"W3SLIMKHIO]F-$]]M0G_G+.,W!WMG&?MQGK*&YQG'[<9QGA;B[[,X
MSX*R\#P/!J^D=GUN9NKY/1XF?0TB^K/DREQ%B-&<E#N%X*3:QCJ*1NF,M23>
M;;1]RU`G0Q=RD4PUV;CR;)TMC1)?3;(7+S__`"#TG_V1UO\`]S0W@RYX'@>!
MX'@>!X'@>!X'@>!X'@>!X,=6W"GEBUI-(4.?-!I*0@G;(8^(ME7HQN3U^ZX&
M[%62*J*ST3L]003*LTEDE'8_=RWTWUV4QG`3L+XQKV1!H$5MG:6.K0B(JPV.
M))5=T7I4S`8WM>?[65.(\"Q7,_A+AQ'7LC1!Z9V,(+$"36*1C8GLHH&'Z-0E
M6U:XY;K:VV6LEGG<(AC#8C)6#^!BK][Q,A[0)RLA`GHZ1Q8TUNE1>0/:J&!C
MFIAK'M'C1H.F19X463V#::8"NV/&U#$F30B/D/1;Q@_:MWK)VW[7[)5;NFCI
M+1=LY05TOO.JB*Z*FBJ2FN<Z[Z;:[8SG&?!]7ZE-(_YYZ1_KI]E?[>_`_4II
M'_//2/\`73[*_P!O?@PK?'-?+4%@ZPZ:VQU56>+&4?UU'9A&.S^PE)0`D$@!
M%]FY^/Y?7'(!;0G'6K1T<:$C80F"8NV#;<JR>-]_HW`=8C/!'`72M8$5G5<V
MU*H%,7NK25PFS+ZZQ3^M)Q62M#;-I-H-+K>VSL^%200(E(E,V/441>MPDC89
MU5U8/,!DT+\9?'$<C45AD>A%F@8?!=R*D(B@7I[J87&H<H8%G0A92*@F-T("
MX]N4"RB3"".PAJSV>BY$='N<JM"Y!)P'2AWQ`_'F'L!K;`BB3`JTV+?+1E98
MZ].B6-@-&N8FE`\MFLR;6RE(V[?,&00AF44B6B>8FBE'?N_DZ>C/`1IT!\/G
M*4!8B[U?322F9K5LQ@Q:IW%LUZ*N,>`0$WD=N-*OMXI4F]#6?>?Z6RN5/@S]
MW<MJ6))'@++E(F7?8+2QR=#@0GQ\0*_*KTH"-]*V`?G<%#W,QG!:^8CT_8=-
MGXY>HF?QD6UJ^@K/ZF0AD<+<U`9PE`H$]3,S3:LB0,.V-#UC>S95N%AUU\-?
M#U4[ILX)'K<C<5;S66V$P@X._+>`@!<IG`"+QJ4+C"@*7#)TU#EAL'A6[N+Y
MF*D8<D(=$RKL0X)1L,Z9!G:/?'?RW$5E'$4#W1&'"H41'%5X]UGUH%64CT??
MR`J!`J*C;O;;[A0A.62DB(%[;98C7\ED#QD@BX,D5'(=E6XNHU!)5=8WTAHD
MBGNJKOGM/LO.-$T]<[[[9QB^LY^S77&<Y^S&<_L_9CP1S7L9XKGECC?T?LCM
MQRM8K`5$1$5-]0=NC(5%7\6=RPLSDKEXM;+9U'2UL-Y*S&#',A/KC96VB,69
M1D6,*H&]S(65^I32/^>>D?ZZ?97^WOP/U*:1_P`\](_UT^RO]O?@?J4TC_GG
MI'^NGV5_M[\$O#))QI7,V@%BQ>V.I6WZ(&[))[*/+IZKL^M9:G'@5E5@^BDX
MC]H3&<1<J--G<%CM7:LQ[$K+9O"HJ3AQE^P^QD<#9)`9P"LB(AIK&_S#40;2
M<[(MRXUV&,,'3!\Z%E!9@0_32>BRPDHR>C"8]VGHX9OFCANKKC=//@EOK'E^
M3=%%()D-+QT8$!VIP/(57&3:19FP,O`CU4H`T#N6P\\^RD'4&X`S'5U'&CAX
MQES)%*41D(Y3#XXOQ?%I%%8LI>ZK\G8T<DTQE#`Q2]EW+306.NY:+`Q9ZVCB
MM>S>&G56KV+1,'H^3..G_P!.1=GTQ?T@XDL@J$ZVY7W(T$F;`+)Y=WG'",`,
MIR+87&NCNZ7X>V6C^+&H^^CK%;:U":TS!1+>6,)P>UACH<]"'(J$>/BZH=@=
M"D@JUCQM0Q)DT(CY#T6\8/VK=ZR=M^U^R56[IHZ2T7;.4%=+[SJHBNBIHJDI
MKG.N^FVNV,YQGP?5^I32/^>>D?ZZ?97^WOP/U*:1_P`\](_UT^RO]O?@PE?7
M-_+$#A2@N;6SU96FUD:FH#&Y=%^SNPUI2!-D8J?(YD$>R]N*0BVA2-#1;\\R
M(FPA,&T?,&>";%ZDMJR<AVRL.=N:K<B+2:1,QU2B-=.G[!9A(NN.W(W(1;\:
MZ4:NF)D`7O1L3%.\?=3<I(NT$]EV+EF]1^^V=(J;AD']2FD?\\](_P!=/LK_
M`&]^!^I32/\`GGI'^NGV5_M[\'0K+YQYKJB($)K+#?4>1;!1FVT9A>P.UC9L
MH0(.4V;`6&#L+W5>DR3QPKKH@U;I[;YQC=3;.J2:F^H8XI*AN69J_F,*CM@]
MG2<S&31V0OG]@=8=J@76[&8RL\;T`1QRK;<=9EP-:.'W\6Z2#=JY*QMH`$A9
M60)R'5V6(A0GZE-(_P">>D?ZZ?97^WOP/U*:1_SSTC_73[*_V]^#\U>+J-02
M575-](:)(I[JJ;Y[3[+SC1-/7.^^V<8OK.<XUUQG/[,9S^S]F,^"/Z[C?%E@
MV&-0CMA=LKN)\R'1@3'#G3W<`J&QQ_&W$J+,SJ[]Q;C=8&6M!D:3:BU3AQ9C
M)V,2C[>/C1Q)`ML6"Q/U*:1_SSTC_73[*_V]^!^I32/^>>D?ZZ?97^WOP/U*
M:1_SSTC_`%T^RO\`;WX)=$R;C.O9G7%DQ6V>I&^L8)6&>UW>75U79U;RUF&`
MV;6+F+SN.VA,9Q&20XZ=3,G*O2;C6!F53F$18C$2SUEKEB;#91!9H$L2)A9G
M'?K]1)MNJJB@6'NA!=@X:NEV!$68$ODTGHLP))-'8PJ-=IIN6!!HY:KZ:JI;
M8P';?!-O2E,R6Y(['A\3,@`Y022-H.\R5J0=C5H],(D=A,B5::CM]5D3XT6>
M6)`55=%&BSUK^7O,MVSY5VW#&\FX[YVB3>Q+(69]#ZDCKY]/IQI772?7#,O,
M)$@$&!\O&<.@%P,4")G8%'P,9!"@XA-)@$"@(R':L@@<8Q9A@*EZLY%L282&
M.1FP^U39>2;*S9N.FW57:X07$/H@T8#&ZU!/%+;$)-BL:62;2&110L\,2825
ME!1PX??ENS5@+"I/U*:1_P`\](_UT^RO]O?@?J4TC_GGI'^NGV5_M[\&C.1_
MP7_G1B?[]FM2]0]#5I*>Y8Z_ACLL4ELWE*%7P.:'QDIN2/O=Q=EP8Q=:5BD1
M[D?G^.8_*`@F,/UQA@!+2/XQUP%7<+\U\W1"&5_0QWK#L_J6?I`GH76U3U^=
M;UI$7RE7N3U>Y!AQ44N%K&8X6>LZV.']@:AHP^D.@XU-!F60`DP'M@V/?J4T
MC_GGI'^NGV5_M[\#]2FD?\\](_UT^RO]O?@_!UQE1+)LX>.S_1K=JT05<N7"
MW:W9.B2#=!/95997?-]_9HFDGIMOOMG]FNNN<Y_9CP29"()QW+K'$9%SWN3.
M]FC!T8CD;D737<(>"!7$2(3)^VEK<@[M=HY%OK73.8$C")D^[#RM""`1\:'#
M##$]DP%=?J4TC_GGI'^NGV5_M[\#]2FD?\\](_UT^RO]O?@?J4TC_GGI'^NG
MV5_M[\$8BH]Q.<LY!NQLOMS#M,\9J)>)*]/]O(0M(PTD(1MK81-VI;.7C(4X
M,$1T0!2Q<\WC;]8LHRT'K._NO&X6=^I32/\`GGI'^NGV5_M[\#]2FD?\\](_
MUT^RO]O?@?J4TC_GGI'^NGV5_M[\$WPR=<?T]8`:TH?:G3#UDK7]L1-81)+3
MZ8N*JSF-)H,U2*/@=K26<,F]A;&:6DT?I@D"W%NY6(/S1D(TD#:2!U4@V*P2
M;`[&B02:1O9]^3G6RBS=$H/="2S)=LY78$!A<2^32>BRXHBU=C2HUVDFY8$&
MCEJOIJJEMC`=N\#P/`\#P1?9?)AZRYS,9H]O"1C%#.P3,*;(0R'O759-QP9]
M'2HJ/$R#9?+T-(A)Z6Y(LR;)5?)21J$5'KC\J#MF85Z$$,(\&$@!:6R`P&,8
M"!R.ZFZVR+`:U29-$ME5,[**[)MT4],J*;;;[YQG;;.=LYSX.3\#P0C;D#Y,
M[3G+2`O+63-V?1A,IN6B]<W#(PQ<,Q5*!T)9'YM"8O*6`60#'9`8%9$F\O!&
MM0[U%I]-JQ=J_P"-"F:;K':IX;^CCN4$IL;>F"L@D4N+LAPQ\?,%5]?O.U!@
MA%N+8:-V#=@-208H)Z;I,='*_P"*[7<K*@KV\Z;MDM+`-96?!YZ:@A!45,A4
M4D@PV_C)%`@1$+,S35BX658+)%1!4:IJOKK]U\-?-,YPNU6TT#)B[UFU5:(N
M7;9NL0<;-&"2ZZ2*KUUHV</-FS1-3?79RXU9M'3K9%'&ZF&S9POG7"2*FVH8
M/MVNX5TQ69N%)GPKU@C)<H_F6@N/S@..ED(.J-7XPW&S23T":P,*LGHDV!*I
M?8FX3706P@Z0QG0.ATMSW"N<9(E^'89`FE*&WZ%5K&)'^2L,B7"R!&=S@;'U
MFJ3<C(W\H?`R,S>-R&[U8(Q$/4Q>&XY-[G<*Q662;I*KKJIH(()[K+++;ZII
M(I)ZYW4554WSKHFFGIKG????.-=-<9VVSC&,Y\'$$I+'@XY,N5."AXM9LN[0
M?NG[9%JY;-1KDPX7:K;*8T<IHB63PFILWRI]U@U<.\_XA%134/O?-$B3!XP5
M4630(,W#115JML@XT2=([H[J-G"><;HK:Z*9V16TSC9/?&N^N?MQCP0K57!\
M?JR51R2M+,DA5`8<;')$`Q&XD##RU>-Z+;U_N[2"CFJ@E[&"CI_)#!(1NW<S
MJ2E"Q62_C[$G2*@7MX'@>"()_P`0QB?%2#Q>PI:('&2\FDA<4P81Y75U)WLJ
METW@QI%\['K.FBE<RN:%RXMHGG=H;W39-3J;IHFNBY"GJM@6M9P8-#OSEW(W
M+%8T2*R!\U:,7)P_)CQ242(NHP8:Z,1^")TR1>)CV6FK1BDMHT;:X11TQX,@
M^!X(LL?DD_8\YFLV?WE)!ZQQ<*I"4$89$'KNL6@X(\CA(+'23]NOJ]!GA)V7
M;/V9)@HYW+2=<FN^=?E09LQ"P`@=A'@P@`+2V0&`QC`..1W4W6W18#&J3)HE
MLLKMLHKLFW03TV44VVWWSC.V^V=LYSX.3\#P0=>D`Y,ZPM8%5DEMG7-W4]DR
MMO!H3<,AC\B9A3XL$0D826U\!E#`))!Y(<XBA==K+8\;48M<#'K5-LU=*[+A
M3=-UCM4\-_1QW*"4V-O3!602*7%F0X8^/F"BVOWG:@P0DW%#]6X]N/&I(,4$
MT]TV.KE?\5XX<K*A_M=7G3=ND)0*JZSX/8!.$OLC)<PB4D%G'<<?ZO'X_+4N
M@P<+*,E</Q9)E]BVNN/JA[QOC/XK9;30,F.GK-CHFH]=MF::SELS14=+I-]%
M7CU?1LS:I[*[Z:[N7;E5-NV0USE5==31)+7=3?77(8/MVNX5TS6)N$IGPCT>
MG(\H?F:8N/S@..E<).*-GXTU'#*;T$:_+"C)X*,@BB7V).-%D5<(.D-=M`Z)
M4%!PCF1^^,.;%?.@I?`"!PH=+-PHUI'',HD?U3L(.(HIMG9\M/I\52>-]"JS
MIXD^7;"1.-=5E<.`J]==!J@LY<K)-FS=)1=PX74T10002TRHJLLJIG5-))+3
M7;=13?;73337.VV<8QG/@^1R6%LV:)!V28-F#C9KHW>KNT$FKC=]OHFRT07W
M4PDMN\4523::)[;;.=U$]$<;[;ZXR'X_>'24']]H]RX$GQ/WFQ`:YSIE<>59
M_:B\8/$<_>TRHV7U7:N4L_;KG;173/VXQX(CJ;A0#5,JCTD:V9(R[86;0/&X
M]^C<1!AY,^C[9ZW@KARF$&M5!CV/.290Z;?#-T%YS)2A$U(LJJO722P7EX'@
M>"')[PY%9X3=.UK"EPA@2>2`P7&,&,?5^ND2TMFL[@1M-\['K.F:M<2V>&BX
MMHEG9F;VT9-#J3IHDX1<A4U8P;6MX0%B'YNZD#IAL4?EC[QLV8N3I^0F2,CD
M9E1@RQJR'_FIXL1?Z#V6NK-AHXU9M==6Z*>N`[[X'@Z78T9-32!RZ)1R9%:\
M.20`2##)P":,'YF+.B#;=MH:%M"B2S!5^RPIE5K]2GMIHMC537.N^FFV`P!3
M?*[6IY>.EJL](R/\LC>PQL`3C8*.`D9&\#QJ-F)8@D-U5?ZKDXY#H^.R*</W
M3)!PB_*9W6>O_OMPK/P/!BNYYK4T'KTZ\NR9@8+7QY!2'EC4@DZL/:J_I.W<
M#-1C20-7XP@/)OT55TV+@4_:%$%<?4,'"#A'170)FYWXTJZH2T0FU4V1,I'7
M::TLG4<!G)6^L9B6-6`0G!$7+TK%E).134T@PAMCDXLQU?2,FT,CFXDZ^57-
M)+OG84E95]4K3;^-B[7M2"5V1F'YAF+LIA)18%R>T$K#&Y548D0<(;.D!JYH
M0D_<)XRBS4)L=7"B>72.-PRSC?3;3"FN^NR>VN-]=\;8SIG3./O8WQMC/W<Z
MYU_;C;&?LSC]OV_9X.JDBT2._3PYR=%+NIQ%CY,4,;DVN2!R*LM0PT\:#IIJ
M[*O!@[:61Y%V2:ZJMFJIT3A137+YMA0(YJOA2(5'(XW(Q4Y(:CP1A,Z>C@Z*
M1*,1^3JQM![K7ZKUL%8M\"',17)%"Y-^'RT5FAH@\)2/"VSAPFJ%O`S@>3!1
M$CCI1@;`'QC$R$,BW2+X86$$VJ3T<2'/6^ZC=VQ?,UT7+1RAONBN@JFJGOMI
MMC.0_7)47JQ<E,DF&!C+#[9X1R\;X8M-1BBZ)++EWE3Z=#`]9LY2?954TPT4
M;KZ./P]DE,:A_HTF/,,D"(MXW?L'/XF4';5359!;\)7=!3\-33.==ON+)J)[
M?9G]F^FV/\N/!!D4X"C44F6\N:6?*U?JY@F9-"-0,49,Y!%V$D%3,-'32S(<
MB[?R)"4AA[\W9BRNTSEC)NB,.NW*+5DJU#8#X'@>"'9YP]&)R4</=[$EP9F]
M(')$]',&$>6PK,<RR<S>`R9)X['JN6ZM=26P#1$>.USNP.;-Q:)M-=NW<)/`
MJ2KX(G6D%!PW4N[D"XW\S>%#[YNU9NCIT^8(2*0F5F+'1-BPR4.EB+[5@Q3T
M9L=%]6C331NBGK@._>!X'@>!X'@>!X'@U6NJLZ,7*V.C'Z@-@'\`>]@S"`S$
MG/H,'96T9NK+K6O8O"7L(L=6>1AOC#O<I(RTW3JU8,?$1O`=XO\`>6/@0QIR
MO$NIH=9=*5/;4WF#UZ_;VI9-L1<I;)B22&"PFN[@LUYSRF]15MRYS+(7:H2T
MH\&D3(O:4UW*I46VC#V3RUF-..E@[:GQ[<$*J@Q(&<BNB=V.<GLB2,5_%;(K
M^LC`:G7MOV=.QT)JV=0;6G';#1R3ET?EQEY.;.)R-TP'/H]^DF$E50#\,;@.
M9.P=NN*)GMA,['G-?5].P$OF\B=7J92"I&-J,,5V@2@,3;W\PC1>-#)0:?$)
MP`*T!79]-DZ(982"[M#CMB/#XI=QSU\XG%Q2N(2FTXVD4G5OR2N@T1Z,DL,B
M6=#N_1$TAY%W"P$X$QI1X2LDS2[XSN<$K.7C%LJ&.?C1C$E&.0_*1UIU98O5
MM@S^M!EBEHU4=L="-769A>S]E7TB>'>3DXQ4D>K*$[SI1>`DHS.Y.8UD$I$Q
MN#*)ZS!J[92&0(8+KQ,.%@')W<YV!X'V:>MIJ^9YFH`,">=$3%FU6@\[L*UM
MB#&6"T.B+C_.R#6M)-%!C!>4V;99>++,6R,4E6C@.S=(AA"5\=_(&;L^LRX"
M)V]&X#6%2'HY%Q+?IXH@[!V,IRP8J^OI:DHZZPDP1T]CDODCQC*'P&$P5=+.
MI=WOO;+9ZVD*P6K..=NNIG+;$8Z'KB"@#,T7>ECP?HR01H;,1>2\X+0AQ6;2
M,V2T.5D*AT5>0R'38,Q$U]^EDF9N'ZP^8CVFTK)!M.KQK)&,`@[*8J[KRYG$
M(TUE*ZKA)XHM(VX9DD;54=H[;HNMU"6CG?=PEONFOMG*FFVVNV,Y#N'@>!X'
M@>!X'@>!X'@>#5/;E5=''9'>`:!4^>260M^:7_`+.=S^#1V/2[=QRL,J0#`H
M@O&;.&VS'IV4FRBZ+DB>%5E&1H(>^)-[(9OE1>%PQ_RC%NHH59E+U1;LSEY)
MZ18VU8UJQ8K;)B22"!0RO[=LYSSOEZ@M;ESEV@NT@=J1\-(61BTIJH3UHQG&
MWDFEK06;=J!VAGQ[<$#IEV69R*Z)[9AR4X9R6"1BR*_K,V)J5K8]DRX9`ZLG
M,#UIE5@WU+S,7*BKZ:640DI$>Q>@5I2LCO\`D+T.@.>9^O#,\SF>L[%GD:&3
MCE>>E"BEXF6#0F>K:PZB*R7>N!R%_#HS^3#0P:<&Y$(-4Q3Q%9\CHBTD5R/R
MK5PQ#D+$Y#ZDD$@DCN,R2SHJ(4F%IFPHR`=!R>M1#K2<VM=\IR4(B89-8\W?
M$GP.05WOAT527>#OP]6S;9JY8O<:!B0E4_9-HKW(YB0ZR)"?@]G@4'6LYO\`
M=I027R2#RBCY8'&5S']IXOI7KV&8!SY4S)Q8*"J$W$@&ZA#<EV456C@?1".2
M.[)%7Q,;9IRV47VC6:QB/QXAT5,&C-:#SR4W_@HPE0A+HJY-"Y1O"I968Y@\
ME-F629BZHQJE%I8GD&FX1#C=N5^US\T%(E85:8NI(@QYS<@8?OT65<O]SE5S
MRD";4HB[=]52H*L8C\5&V!^DGY;%ZV:$RHQ[HH0MIX_C<B7#OL)Y?[D*1`7%
M;#D]W,2^C6/IV=*&O4,C::S\VQ$6@\`%Z]?QBT?S^#"8N.)UE#)T-9M()B;S
M,.2..QLT%,\SJ1!N7KQK)&,`@[*8JJ+RYG#XTUE*RKA)XJM(VX9DD;54=H;;
MHNE%"6CG?=PEONFOMG*NFVVNV,Y#N'@>!X'@>!X'@>!X'@>"=>D6,SWC]?2"
M#UW(K3)PBV(E+WT+B1:!AI$3#,&IED^W&.[*F,"B.56N22*ZJ!"3L%%&VBWT
MNKIQJFV5#51+JP["J"2L[&>NS%>556=6%S9I$1<AMO!WY_\`+6\PAU9`0JM\
M(1A1=O82"56(,$><@:Y4<\#90L^3CI`8CPP+)EW*EK6,3HAL6MRQ(FS`<RW)
M7]O2N,/J\,$YK+K..4B4?1(UFTH18YA")&]XS,5L/H9B.GP+0<.'#90*TW:(
MJAA*$4+U(+GM/Y2"7@)@H$PN#G8F:]*%Y*!=NLQ#4)8%DZX"W^Z-Z1&7J_8K
M3<55%2QI%R+3?4G2E1N9#K-X6'(2?E&\3T/X3CX!I/(:WIKFZP:RM3`6ZB<4
MF(P\^CE))QL.K-HA/=9`?'O)/7+IZNL+E!%DH@.8ZE]_IU\-M@ZT*J'IB.W-
M"(-N^O,ZFV:K2T(>=='GR<2B@YP1J'>=$K,#'K'V>V*/,NT;+CL4CC@1.48Z
M\+MM!0&,1Q5J=#!AN@>1^ZF6@J'65O94'KYA75>18J)BG1\\$)9D4#B\H%IN
MXH<C_3$J>,(^\4>17&Z<-A5"ME70YT)-0Z0C0PJ4F`X$_P`>=ODHT/K,3';&
M&Q?>)='"IH\=]$R=V.G&EKJ](KMFSM9'J5`5H9)R2>UX;TV,TC('F@;7=[M:
M$0*@-8<Y#/#/G+KV2:U""D2W0`-'2150ZL&1)=2&AC,=2HV5-EY_5!?$1NM8
MZ2M-WC&IMS8,?8EW;V+I/(TSM/97=$`^#:E2`*6Q>GZTC<\=D'\Q`0L`&D;T
ML:6DA5V4&CT6;AP3D+AT^='2"N4<;O"[MZ\=D7&5';MTX<+*K;AE+P/`\#P/
M`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/
M`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P=.GL^B
M=8Q8A,YJ35%1\:HP0<.&PLN<?+.RI!L*&,!H./L"ATP2(DGC5DQ&B!KY^Z<+
MZ)H-U-LY^P)\3[HY56;ZOD;8;+"]G`-IH<1B4]5CN[P^(Q(&K/21IQ;8%L\&
M@?Q3DI::D,N(4'9D2DQ3!,1I!=L&8:[NRJ[8T*[U_,QDA_)3CJ.OT]$WPY?\
MS9HIN5,,FY=HP7*CUFJFCI@:%)O0Q-KG+D:_=(:[*8#*?@>!X'@>!X'@>!X'
M@>!X'@>!X'@>!X'@Q/<5R16CHKB93$;-B(31PX3>[PB#R>=.Q+)B))'"ATRS
MC`TBN)CXD4)>NB)E]J@R0SJ@VU44=NFK=8,?T]U_SU>3\>&@=AB\R`^W>%(?
M&)-A2(2F?1=D.&%]YQ7\;D>!QJ:P5069%$$Y;'6+\+AJ0:*+.D<.$L;A3'@>
M!X'@>!X'@>!X'@>!X'@>!X'@>!X'@XD\<%1@&9DAUZB-!Q\40-F2+C.V$&`H
M4T6?$'BV=<;;?A-6B"RRGW==MON:9^S&<_9CP2T0[AH`>CHO^:31_J[C4;DH
M=(56\X(.9%I*FX%^.`QYHW";.BTO;").".&8HV1V-A0C_!0FS;-6SQ1N$D=+
M_.A\8/)YVNH]:G2X,B^M%\<#QE:K`4AN(8VD$9(A!<BB\I*UH.DP^'RH$\D8
M70O&9,X%G!NC]!5ZP03WQMD-J/Z713_XGCW_`-:&_P#[/@?I=%/_`(GCW_UH
M;_\`L^#$D<Z=I&56`<K8/.1JDA"[%44W3C"C2-2%Y&WB0V9#(A*G&J8"5%(*
M570#S8:$?O'D9+J*C"B2#UB119AEO]+HI_\`$\>_^M#?_P!GP1I1'R5\6]*7
M_P!$<Q4]=8>37)RR:R`N.-KC#@-F&)H%GD?)I!9`;',`,K3!R!@Y!&W$<($D
M1Q371LMO_C--]@LO]+HI_P#$\>_^M#?_`-GP8TN7H>I:'JFP;FG\GUQ"*PB9
MF:RS>+,7TTD"$?`-%'Y5R,BL60*R$VNU9HJN-F0D<[=[))*;ZHYUTVS@.@\H
M]J\W]JT+!^E>?K#;2.I;$WDZ<6,GAY&%%7FT/EYZ"G<.8U+&P@^.PWD<:+M4
M,OAZ&'C=%)\U_%9N6ZR@=ZM[HFJZ4AV)K+C;@B.6D<3B3$7"Q[F:24I()M(Q
ML5CHX9'H_J])O%'ADJS15430_`9H;*NW2J+9%534/ZJ'H:K+L@[:?Q`ZJP$+
M2";15<=,62\-DHR05Y-)!7\L&%8Y(,,BC!<=*(P89:;+M\)/$$$G[-1=DY;K
MJ!@SMGY&.1OCVJ,7>/4-G?HG79F=!ZX8$XU'S]A$%)6>#2(\-9[@X0/.%T6J
MHV*F55"2K/1@@H@B@LXT6=-M%`S/1'35)=(TY6U\U/.1IBM;9B0F;PDH4PK&
MR+^/&V^'(]R\`GM!YD2X42SC*C$DR;.T,_X*J.FW[/!EG]+HI_\`$\>_^M#?
M_P!GP/TNBG_Q/'O_`*T-_P#V?!P\ALZMXD`.2J43Z&1Z,QD.3D$B/F),&'"`
M8(*R7)%S!4@Z>)-F(T:/;.'KYXX430;-455EM]$]-ML!@?CGN'EWOJK'=R\H
M6N%M>!#I2<A9=^.0(BR822`'6R#D<;CYMH/-B=GK7+8R&5?L$$3($@.,C=W#
M%XDKD*Q\#P/`\&)[NB5HSFMSL6IVT!-.3HKN-196`9@;FQVX@;H1:JG6[>,M
M)M7KC)`L'T>"F!=&3M%P+EYH7;(N7+-%+(:V%OBW.Y<*.`EOU+7VA*,RV%RI
MA6G.4H!BYG'K-@+FN;&=R9G*.D9MN2FFH-VLO6\T5<9)18BLZ6G:-M-WSUJX
M#YY%Q?%*GMGB2Q)RZA]I6=!NFQ\(J2>IUPVB!RN*S<<Y7$`<QE@X5DDL=N3,
MC&@@^L[D#%\#&2=80*V;10$BRU;J!N'\#P/`\#P/`\&-9W<M1U:5A8*R[/K^
MOS5CF'$?@`J:2\!&2$T-M&>Y!T*C#0R_9KFWS9FG^,NW'Z+J)840TWQA1RWT
M5#)7@>!X'@>!X'@EIP2(V9U0UCS)^]2@_,\782T_D>Z708'+KML+*X['XR3<
M,5-</7%<U$L9E)V(EU,,,:755LOV&/R+&.DP05+X'@Q;9EW5'32(Q>T[#BL&
MU-;KZ"$Y`409N27TGX.':C-G]NSMPW:9<-M7;I-'9LUW=-4UU4]W*&J@8WO6
MJ/UHZZB8V'W21B4((%!TK(O(8PB<PC5JQG8<YV'1T[L5;/VI6%/';IB<<LQ;
MUNTD&1S08:R4C;HH'(A'IGDR#4?;W%4K<OOXQ[#_`%FTX@$L651B(M9?&:Z!
M<A]4M`<""E0@9BZ;A&NJCA=_OE;+DVZ5U<%-E]VZ'X8;7/`\#P/`\#P/`\#P
M/`\#P/`\#P/`\#P/!\[MMJ\:.FF^VVFCINLVWVU^S[VNJZ>R6VVOVXSC[V,;
M9SC[<9Q]O^7'V>"$"O!D>=.1KT-:\[CKN,#@:L(7:"X:^S%9F-CL:A):;):$
M@#G0N[DD&B[*+D`A?5T#:MWA)^/9MR2[=RT#69*O@W^._M>[;J>7C59M?3F3
MJZ,-(0,@\O*P,-(!93C+AB22$7.1D?\`IT#FDH.B]R<B,L_RF5%'A4NZ6D/U
M+O59$-S'ZFG(']%/FW_[&5A_JOX'ZFG(']%/FW_[&5A_JOX(O@O#'(2/=O0N
MJ_.-*$10V@N;;"CD;(557RT9BLKM25]&0&Q"8((G&D6>F\HC_/=6ZKX):$OR
ME\),O(YD,I,)=@V%H?J:<@?T4^;?_L96'^J_@U]\M_&AP#".L?D$GD=Y%HM&
M22NVJT:DU"D%%R,.T;$:-KB=%&\9BTC3+1:%(%Y?+#T@,)0T,!3+D'NBA+5U
MJQ'Z-`V"?J:<@?T4^;?_`+&5A_JOX.%D?$G&A>/'A1'DSFMT/)A2@]\VWHZL
M]='#-ZQ7;.D-MDXSHIKJL@INGMMIOKOC&V<Z[:[?9G`3APMQAR`GQ1R)MGEC
MG5=9US-19!VY>4O7+YX\?DZRC)`B^>/7L<7=NWCY\Z<.W3ERLJNNX6454WVV
MVSGP<-W[Q?R\VXVZ*F,1HBEJ]FU353-;L@<OB%(TM@J(G--Q\C9$1W<,I)7D
MCCIH&N>C3%K(8^<!D19P*L^&.T/PW/XF@437/Q\\:UO$VL5:<XTG*-DR4C.$
MI),:>JDG(SQZ6R,K+)$6(JL82*$,_KSIHBY:AH^'"1D`S4;A(T##`AX\8U"%
MOEL^+?A3H#@+HT?)^>*\A[ZJ:QL2]H-)JEB\=JZ4B9_5U<3(Q'5'!F(B!ZI@
M`Z_%=CS<:-:$`Q%H[RYPT0,L`Y4:%M4_\</#%'U;`*@A7+5(.8G6\5#Q``ZF
M%:PZ;2IV."M$VB#N0RV3A29^0&'6$\N'Y,F^7<.7"BFWVII_<2T#)'ZFG(']
M%/FW_P"QE8?ZK^!^IIR!_13YM_\`L96'^J_@X>0\+<52N/G(N?Y(YM?@I(')
M@#3'^).N6OUHDPR7'$FGU+*.MWC?ZEFY61_':.$'*/W_`,1!9)773?4.N\+\
M"\Q_'+2JM!\J0AY"X`[F$CG1/4Q("TJD!B121SINLY*R`VX<D':(L8V&Q\,W
MVWU3:!Q+/"OU)-8D2?A9G@>!X,#V%>:L1.ZQB%U%:EY2%!EJ3.CJHS6#=&+C
MMW;M@FL;.6M9M7QK=]N[8ND\1L*:,2O5-/#K<#JS52<;AEN,GVTJCXB1,V)H
M8V,,4'R0^1A24</,M5M?MRU+`R[=H2%OD=OM37:/&Z:J>^N<?9G7[NV0YWP2
M;T[_`.F''7[V07^PR^?!67@>!X'@>!X'@T1_(]\7U)_)[W;QL1G<VM.)O.%`
MA"[9EO!#8AL/*,[%F(Y6FX?AA*@<A%,S$@G%*2B0'Y!'ARS]"$0QY&)0BW=S
M.L9)&@WN>!X'@>#7MWP,F\@><G1J"BG\N=F^BG[8_7@V_K0YS5F$:_B$NM-5
M8A.ZE%EY(J!AQY>/30L*=,E!2V`C9QMA4HW%MUPIWFJ%SRM^=*#KRTC.LCLV
M!TO5\-L20ZR8[-=3LYC,)"!988UF,I:,)-+,$CS)^\Q)9$Q9G3N%OS0LU;OW
M3A+0.TVQ8XBI*ZEEB&T5WK:-C/QF09E][<M*)"_<("8I#(\U327<DI3-I._$
M1**!F+9X2-R,T+$#&3T@];-5@ZGSY7!>N:Y:Z3!9![9TY*E+,MXBT^[^7.+/
MG*VIF5#X_IA5RHVAD3741A-?,'C\P4&P*-1I@:D,F,MR$B*AF_P/!KD^1HY8
M4,@4`E51SP-6LT6L$,Q/&EQTVR7DE?!6!R0R./:%ZYJ*Y9.B-%CT"<C69.HT
MV`J9:K*/C0G&=E5@M>IC<0DE<Q,[!7P8G&B@O5TU?@1OY,/=/MEEM3:N0^[1
M@X$$/SS4EJ8%OV+(H.+ZOF95HW(HND=`PCTI_*5P_P#O9/O[IO5'@K+P/`\#
MP/`\#P/`\#P/`\$4=GVP=@+&F(C$I_8<`.61:C9G(R]/ULSMRSP]4``!AY-)
M8'ACZKKE9MP`F3/J[CLAEI2O2HD*YF8(4H['EY($45#+_+,CL"8\R<[2ZV=#
M2=IRBC:GD5DIR2-XALATGAJ!@24NU/1#`D#B+&=3[DA@G',`@V`CW\<;@4.P
MV^D1#/'@>!X'@>!X'@DWG/\`E@[W_>RAW]Q;B[P5EX'@DV'?SZ>C/W3>+O[8
M.]_!67@DRA_YP'<'_;#5/]V&EO!6?@^(E_S<_P#_`))U_P#@4\$S\-?S)^/?
MW6N??[)HCX.(^0-\R'\(]H.'[QJQ;YY3Z$;X7>.$FR.7#JI9<V:H856WTTRL
MY<*IH()8V^^LLIHDGKMOOKKD*S9O&9%J@^'NVSYDZ3U6:O&:Z3EJY1WQ]NBJ
M#A';=)9/?'[=5$]]M=L?MQG/@C3Y!)?$QO%'9X<C*(ZP+[\G]"Z:"WIH:U([
M[NJ?E_TVFK%=SHYVV<??T_`UPEG*WWM?P\;?>Q]H66S>,R+5!\/=MGS)TGJL
MU>,UTG+5RCOC[=%4'".VZ2R>^/VZJ)[[:[8_;C.?!\#>0@'11R#:G`[DVSTV
M5>!VY-DL4:IZ92QLHY'IK[.T--<KHXVW51UUQE9+[<X_$T^T.8\#P/`\#P/!
MK1NH0$Y9L2-2.D182%3:]CMI%)],DN:+<ZA.%E7!IG.26SZK>=2D,L<S]49-
M_3(ST_("("!#VS(&LQWVD;99$+GM>72*"UW(I?&!4-,E@;-$AEO84[<5="6P
M]-RADR6DTV0B<[>1T4&$Y>E5UF\2.NE<M-6:;3&Z_P".D&KYM\H5F;!1Q<IR
MH)!*EXI:<^'BBM\KM26L,Y]%$R-WOR;1>F$7(LPWV8-]:GC[EO\`53EH4:.)
M^O3+I`F/8!\TA[3$6Q</$5<S:'YKN=SKIIE-ZM$`B$KLH1**W;<X6_(/SN3S
M!C7,<BU=2INP/#M'L-D)-1-ZZ551ADBF>&!?<:&Y'P/`\#P/`\#P2;R9_P`L
M`MG]`J?M3Z'M(],8EC_+_P"*2(-V=74\2T4Q]-LHE.H-"Q]LI-2`<-((YK8W
MZ$R)LZ*158B\#`?RZ=?7UPAPI:G4G.=5Q*XI_6I:!9<PZ:N"*(+:,269AHJ;
M*;I!SL?+OGK#\Y:_0,!;Q9XY=+)ZZ,76F%-<!;U(F;)D5-U5(+D#`8Y;1VNX
M:9LN/19`TUC@&=%(^/>RD,$;2/;<^W&BS*[QBT0-;[E$4D-4WNVSC53.0RAX
M'@DVN/\`QJ])6G;>_P#C8W23`OS-6;I/_P#Q210RI`)_T)(&#MO]K8HPVF4>
MKNJW6KA==Q'YI2DY$)M!BVY-0L%9>#RO59\O%H=??/C+?B]DE2P*+T7RQ.+/
MF0B1,2DA*S>=3&GH']-'R4H47791],6VE4A<3(,'8!$U!!$7'TW)(RY%?F3D
M/5#X'@>#6S\F`_5_6M88(KR41&=++52E$IA,Y@M?3$$.>PJ5,DFPL[8%UT6%
M<BY*[71CDH!8E)/8V`(O6+F/$&&[O9`+MK6&1>OX0`BL-&_E4>9-UWK1IL[6
M?JY<G'CDZ5>.7SA^45>/"18D^(O'.Q%[JLZ=*[IN54\Z;9#`W2G\I7#_`.]D
M^_NF]4>"LO`\#P/`\#P/`\&%;YZ/H3ER$I63T;<%>TC7ZYMC&TYI9LH%1",Y
M/$T'CD<(R9,N&K'1^^1'O-VK?=;7=?Z=35/&VV,:Y#(4(FT0LJ&1*Q:^DH69
MP.>1H',H5+XV1;%X[*HI)AC8S'I$!*LE%69,.:$O6A$8_:JJ-WC-RBX14W34
MUVR':/!T6P[#CU9QW:0R#9XOLX>M0T?`B&V2$CETG)?B:AHI%Q6N^BA0\763
MWT:M\;I-FR"3HH4=#PX\B1:!T*GJZD`W=U9UKY8DKLF##Z4ZNR<[/`D%C67F
M7PRLX-]]-/5E'A6=6SDZ]TPJ^ETIT<G"I!ZU;@&8<,[^!X'@>!X'@>!X)-YS
M_E@[W_>RAW]Q;B[P5EX'@DV'?SZ>C/W3>+O[8.]_!67@DRA_YP'<'_;#5/\`
M=AI;P5GX/B)?\W/_`/Y)U_\`@4\$S\-?S)^/?W6N??[)HCX/UZ[IN0WE4H^(
M1B.5Q,R@>U*;L3,,MHF^#5_+A]:6;&)N3C<@*CX/9+A@D68!'#9JXS")$CH]
MV;_4,OP<[K)!@FB>/+@AL"=#9%T?9U-OREB7!,FU3<^&*:D5-UP#G]LS6<1J
M%P0Q9?+3&8O!<>CTA&#5\D!PMDB1;O6X(4,`)#&+<-&7RP?#Q?/>#VP>.H1-
MZD)RVR;9A7;0[K>_S"7\<#*&UK3,,YD)4$3C-3<Y@!6X->2*:SP*;'2QJRPV
MSLQ)Q=8OKL96#</P[\=]O<O<A<Z\\R3M2^$#].U5%8$61K!.B<5ZF^`L=6J^
MD/Q.><RLPP!QMK_Q#](R+TK^%]GU3A3?[<^#4)RY\.'0-0?PC&Y^Z2710&<5
MZ+@`ZS)$+/*/V]K3*-=%P*ZZ6BH>0ZQ2$1"O79&-S.D5Y*8;M6`X/@;B-.F"
M;LXT<?@!ZU_`\#P/`\#P:R?D5C*TS(<^QI,AT*(U7/SXEDES#8M3U3:B*@X"
M)TT0TF5XS"&UO^BSE-XMB01]5\O*RVR8YU'4,M!1W&P7;:-302ZH2XK^R!+\
MW%7KX$579,9))8J_P3C95D>!/T#T-,@3K-X+,CV))LLP*(9T>-$%L9SE/3[`
MPQIP]R]C17#JLU"ZS@D**KOY%.K'DQ9=V+9O!RN%C,AEY,JJRDC`@_93\8H\
MV&66T?/&]A-).DY6TW#&=J5!7%023E5A7,90C;61=EC#Q=--\6);KOEJ)O=-
M-)!<R_(KL!#!'7#<-'AZC4`":YV:A1C!OONGL%^>!X'@>!X'@F7K>0&6-.O(
M1%2"XB9WC(XS0L5-M,ZX?1E>U2:<;D<W&?BZ[-52U=P5>66"&9/<ILBQ:+L0
M[A5/4A][`4%'H^&B8`)%HX/0$Q^-B1P(&+:XWPV&B!+-%@.8H?B;;J?@M6:"
M*">5-]U,ZZ8SOOMMG.V0F"Y$4;.Z`H2F,I)N`D-R?Z4L?\735=LH/B".T#JV
M(NV^V--TUI;/)D_FS)]HJX:?04I(@1)CMB0L7"(5OX'@P]?EG.J?J673H2*;
MGY,T1&@X/'7;A1JUD=A3$R.A]?@':S;1<AHQ+S$Z$8D,B&10WJP6=;A0Y@IJ
MT%NPY"EJQ:TY5\0KEL5<'UX\/6V,R-VW39N9-)S#YV=EDF78H;J-QV\BDQ,L
M9_+&N^68S5[J/9?=:-D=<!DU99%NBJX<*IH(()[K+KK;ZI(HHI:YW4554WSK
MHFFGIKMOOOOMC737&=MLXQC.?!(W'P0=(H`0Z'?`AC:4=,RPM>Z1#(EHS,(0
M>7B00.H1[O[K=%=B094A%ZU'GFV4V;ER=;%"!AIH<>E,[A7O@>!X-4ORD&J)
M-1>J:BLV>5/%)A+9:_,1#:S^B*]Y]'@$0\=-.=YDY.SBI;VPJDR(M&C,#KI5
MQ4<\E.XX<3(MF*SIF^#:%'FZ+,`#:-E$UF[4.,;MUD7F"*2J*#)!))1(AJ@U
MP^3WTUUVT>8:ML.M<X7P@CC?\/4)EZ4_E*X?_>R??W3>J/!67@>!X'@>!X'@
MX(O*(R`>QT8>D0((2EY=2/Q,>7+CQKV4'DA),\J$CK1XX17-%T@84P:4&C4W
M+S02))D=D<,V#I9((`ZFH*NOE%J:Q.8Y\.5<<F'_`+14SGHM,7B5SF8QXFFZ
M&ITH5,##+`"-@\A8(NBMHX%D,%RS16*Q)-PPP?-(A?\`%HV'AD9CL0CS7#$!
M%00B-@V6NVV^&8@&P;C!K7&^V<[;X;LVJ*7W]LYVV^Y][;.<YSX.;WWT3TW4
M4WU333UVWWWWVQKIIIKC.VV^^VV<:ZZZZXSG;;.<8QC&<YS]G@TT<!:6%;4F
MYSMJ>Z=(RT>WY4:SV1R6^-7^8(VZ'FX^!COTJIMD0P@S;Y*0B0VP*:$P;'1N
MSA\A>"FRC1D;6;.PW,^!X'@>!X'@^`D5%AFNSXN28"F6FVFF[PD\;L6NNZF?
MNIZ;.'2B26NV^W[--<[XSMG]FN,Y\'U(+HN44G#99)PW73T60704T51615UQ
MNDJDJGG;11-33;7?133;.N^N<;:YSC.,^#61?M)6*M-K(L&%N+JPH9L.I4A4
M3"3RZC\+DS>.QN1NR+A]'(]>M=N:YCIJ42H</.G*_5T#M=H6!=RF&'0R1Y$D
M&3>+&]EMI_W^G:Y2#EI/MVQHL/6K\"?CH1I"G''G(2U?B7S222B7$'\K#PO<
M&,F4@0)LQ,CE+4L<"1Z,B7[,`/"[_`\$FP[^?3T9^Z;Q=_;!WOX*R\$F4/\`
MS@.X/^V&J?[L-+>"L_!\1+_FY_\`_).O_P`"G@F?AK^9/Q[^ZUS[_9-$?!4O
M@>"37G\^F/?NFS'^V""^"LO!)L._GT]&?NF\7?VP=[^"LO`\#P/`\#P0_P!B
M0>K#>D/-6G>$(J@:X>8CXD=:T/J.P867+I)$2:;L`"ML(4:A)@@RW?ZKFP+E
MKN\$IHMC31^F.%;L@K^)@=XO&PT?5/GY2J*8HM%I'*7;1](3:VF,Y5)%G+!B
M,';/'2FVRJB8X8.'(8VP@P8,VB:+=,.P^"3>G?\`TPXZ_>R"_P!AE\^"LO`\
M#P/`\#P2F4W1LOK>.`MT/JH]S)7Z]A.5/Q-OI]+DNQ$[`X6NBX:X1WT+0RH1
M-O-BP%ZZ>,G`NZXT=?!F[UE$B_@JSP2GS:W6F,AO2^BVGWGMB6D?@D*T4VU5
MW`5%1;]W5\>#-7*64-'+63SP+9=P*+.Q(XV/7L_]#";@T/A0`HJ%6>!X(&%6
M_5_672%>QRL)Y&9U`.=!:EYR8G'2C8L(D=BRMI.:IK@`U41VV9&F<+'*6!-9
M'A+9YK'I,M3IC&K9X[$N]0OGP2;USG,RAL7YY'9^I-]%RX3!2@[7_"TUI\8]
M9R&^BQ;7'W]$@.*O9&HEG=\V<B"LKFD/AQ+3&LL1^T*RQC&,8QC]F,?LQC_^
MF/`\#P/!&G1,!MP[*"+^#Q+%B!YK4A.JFS1>RMJ]0J20OS2Y-6QM$OI7>YM(
MSA6/Y)/@NFTLCFU?"DP(\KI(B&1X9#OB5656=0"SD(?1MW(Q,EJT1(RDJ8D2
M2;H`4F$=C\H5%C![H?LYD!E%]NQ&K/"+5D&5(J'UT#.PE..F`U@QWHB]+=O7
MB<:49P*S*[SU4>+3.S`1U*)$:?E3[C;HH@#I=&"-P)E.>OF+MQ(F4D./99%3
MT-_*QB9L&87D"7Y:&\;P/`\#P/`\#P>7OY-.*IC\M_R"\!:5K,=8W2O$EC2.
MQ+F+)''?X,S@Y8_&/OGHU^6MG@O'YS,JIDM.P=1QL[WF[AA>"NKJ,BJQ=*2H
M/3P.'#Q`]B)$L68P4+9M1PP:/;(LF`X>R0T;,V+%FVT3;M&;1LDFW;-D$TT4
M$4]$DM-=--=<!]G@EGIPB_E32&<X1UXX9'^A'I@-)B0U7?4M%J+C"0US=LL8
MZHYT7:.'88R#JL)(LK(-HK-[6AQU7!5PT9QH\%,C1S`./8"13-N/&"V34<.8
M,TM$&C%@R0T;,V;5!/&J:+=LW23102TUQHFEIKIKC&N,8\'XFS0>-ARLAD!1
M@$`@ASTN9,%'2+$:*%CFZCM^1(/7.Z;=HS9M4E7#EPLIHDBBGNHIMKKKG/@\
MG7PR]'?P@.RN@NL6O8]62.95$-9,75%*=11W7D.):M7$V/)HO(!+ZRY&FQ&Q
M'+J,:"MG#(U^"BS&Y:$T7;E=VIX,HG>U_GW:_,>VYR'<6P53AK<M'VZL[;@[
M9?TQAD[YU'3`GOMV7_$FV6212L]9T+<._P"(??(^2:J5SA!UHW_2E4-CG>G,
M_P`B74O''1--P?H#GBN9I:=:&F$3!PFK+4CTAC<A5V0+"HDUZ*>WH[T710=-
M4XZ\L=#GV).S[7*IAM#H"H0^B#!T/X&.-NO>&.&GE)=LRQ"9W,M=U@31$PVL
M@Q::>(<>#0UF#9_I.<32>Z[(.PY;;(S&OX+3\7"B><Y<[^#=/X-:'R13P+#X
MQ`!RE'+WA,9.H;&0Q@W@3^U]XDNYDE<ARLD4KLA%CE<OME6YQN#"G)J2&D&L
MO*QB*Q`3*R$U>A\A8?.<<'QBD*S9CPP./[$8>!D)4/%T7K.+LI!(A;4Q(-(V
M*>IM\A`BA=V\68!FS`8S'I*?@MQC'&,H:AFSP2;SG_+!WO\`O90[^XMQ=X*R
M\#P:P6<AZ<2Z_ML]7=5Q&2REY"A$'GT5L^62^H*YCM1P:=6"_P"79I#;E"U)
M;6UERFP\2R\CLUB`""HI09X51B,LD`E>!1@E:X47^F/=7]'+DS^NE</^X/X-
M/O"]R?,\8[Y^2T+<O#M.1"EU;*C1:J9;,;5L&M(/($8\'8UO&5ZQM8=25G/K
MK&R.NH@`DATAM6<%S'BV=D#;6(&".(2W#M87LCYFGORZ33E=SQSSSCE8#SA'
M[+:2?:W9VWA>A`[G#1A),=$:4LZ/O39&:BY9"$:U5YZ'O-&\??%]=M@K32:$
M`VED)CW1^7OOO<Y\FXU^C<_>SKVC<&V<8_!W^W.-<\$:XVSC'^3&=M<9S^S[
MV/\`+X)TXNEO:Z/'7)R07G[EL@&2YIHE,2_*=@VR')O1FE7175@[(B6G#9QJ
M+?.6N$EG8YL:,-V3C=1LB4()I:NU@I?],>ZOZ.7)G]=*X?\`<'\#],>ZOZ.7
M)G]=*X?]P?P2Z[EO:OZZ@%;//_+F#>.79:FF/QV!;&1>PO-L0K99YN8SPYAW
MH0T=X003&Z@U&ZK=15UL6151T9KA47Z8]U?T<N3/ZZ5P_P"X/X)9B\N[9U[0
MZ$6:<_<M*2#?EGD--X.6Z_MA,2V')6MW%N$>-"^O#^SM^^?O5C:!08N&%MQ3
M8<*<M3!=4T\:@`S_`,66E<5H1J1/;-_%+M!Z$?0<R9T#;QA05<R;F2B>@:7$
M#6S=OH>B-(3D*A&`,V4TT(.G3TS`I#N1E5<'SI<+:\#P/`\#P:M_DM@"-JZ4
M+`E!AIWE_)9@:6>12`6=9DF38`!H-=T(VBM86M4!!Q$3BKEHE*5RTD(#-=V@
M9ON!>?4[.V`7Q<;^9!JAL0K79$.&FHF$GB,:)G0S@\*&D1XQ=TD[<@6Q`8J5
MRVT1W4;#<DFB3EUJ@@X<:-]E=O!I-L_L/I:&SN1C'G08%HJ1&%#<0`0!U54S
M;QN0QVG\RBM:<M*!R3G$!-ZTFW2-F)M0$:3WM2R,V&(6*1RI7<.E*P,OJ'9X
MOT#>MFVKQZ),M][C@3[K-![/+8P1@$22H2PD>;;=?NZ(Q$`($,2F/Y><>E`_
MWU\OI=!-A64+!,EG1<:HD&]OP/`\#P/!@_IBU)!1W/ES6_$HBUL"65Q7$KET
M6@;R0M(JC-9*'$N70&)ZGWR:Z`]Q(BVC00SVP@X<.'CQ!HS;KO'"".X:QO@?
MZ"Z8ZJXYGO0?7M"E:!ONRNG;;>R\,2B\EA#>7MHZ-A4+CTC"1"9.7LKCP:,1
M^-#:;18GWKM^H[JIZ^_&^F>-T]`M/L_L.H>:H"=CA:]:>KKH"=1O411,$F]A
MP,#-97-ID9;P&$$XU")440(2H<QFQ@=L]V1&.@^-&3Q(JZ:,T7CAN%.5=7X*
MIZTKVK8PCNWC=;PB*P,`BHX=.U4P\2!,0(W55V]6</7:WT;!'\9T]<.';E3[
MRSE=9?=138.]>#J%@SF/5C!)E8TM=;LHO!(N=ET@<I:8572$1X:Y*O\`+9#;
M=/ZAWLV:J:-&V-]=W+G9)#3/WU-?!#W%G,=OU<'I:7W-8$7+%X%S6SIJ.U_&
M*Y(11>'#CQ"#R8LSEDJ(V%+=9J?#KPP2%R1&1R%,%%M2CO\`+,ZN6J+0-B'@
M\X7Q+_,-7ORQ=R]/BV=,S*K"_+51`8C!AYZ1A):&QDO:TW%W#*D"(]H"<LRL
MSU"4R/&#G`4ED:,B!W*)QE@V]9$@]'O@>!X'@U==\*]/3:;5M1G/OX38;-QV
MYF8DCNEGB!#;4$Y+/F.H&;58$'YCA/?5@NB:TGUFQL2[?N*_VC@*0-D)XR<!
MLQ$I?8('-U]U76Z#)HW74>*-W#G=PU2336V>*-]U6RCS5=+;+C9%3=/ZC7?*
M>V<8QGP2WT<V;MK(XCU;((M]5.MB*RFJ"6B6%%E.3NJ,J*[X3UUQNHIG]NZF
MWV[;9_;MG/@KCP/`\#P/!^:JJ2"2BZZB:***>ZJRRN^J:222>N=U%%%-\XTT
M3TTQG;??;.-==<9VVSC&,Y\$@VQ-Q]QO)33$4E*+*KQ<2D#CIFV(T5^W,.CC
M@0(>:5(!D(Q;7\BL*?PX\^D160"7JDCK*`-6QYLW"2*>UO)FH:/^K^]NN^,[
M@X;>\T<>2RU8MW3>1.T;?BL&C`60FPW,T,@(FOJSJ>)1<5(6+^#3V/4T'CEN
MR\X\%L:W`2]BM#A$SEP%.0+N`](L#M&O+/C&DQ@,Q`2B.?:Y2=$!A%NK^4/F
M"R[0L'/MMM]7<>/`W[5X+D``V@P,@"S%^*,,61%BZ;(AWE55)!)5==5-%!%/
M=5997?5-)))/7.ZBJJF^<:)IIZ8SMOOMG&NNN,[;9QC&<^#41SU\AG&,NZN-
MUS+;_A3+L&_5`3:I:(=H'49J(Y[90YU9--"]-4PV`NSJ>0HH<Z#(KN2*C]MB
MR-8PL_<L8L%;MPV#7)U%S/SJO'FO0/0]&T8[EJ9):)M+@MF!5J[E*0?=BF6W
MC;:9GPJYW48H3&I$/RI-W]&H18IN/P]WC?50.K@01N^S8BP)^()Q^J`!-B>J
MJK#[%R*.R,R+<IN!EHV\">I?BLG(\DT2,U/7CG?"D90V'SJ?,D;*W"1:I0X4
M?WMQ<7>VB+%=.TP2,4Q8W\3]C@V,X#.SX*U]ARI)O6S0$@XW+R2<D$VSY@)B
M\69&C)<^*-1@6S=R,(6%,@TVE_FFZY;_`"TAN0P?QQ7Z=XU(UGM)\7`C6<M9
MVZ_#X*MACOH=C'2;T>,:4N$,J;QUY`B8Q"X'C15M($13>3.A]8O@WQU]T-2-
MI)%OT(LR*E",=T^]*XR]?_H[.(7M],Y?80G<!DJ8B:P9YL/:."6K*7``KS<8
MEDEJAECG5QL'/5'<-5W[7D=MJD["B-J5C+=2FT9GL$.,))%3N`AHC'#'Y69&
M+.&3O(L^(*AG^J2NVS4D.>,UL:+MU=-0R1X(FZ^>TY'2513B?]!\X\^V%#BD
MI?5*?Z2$UB?CCEX\:!F<H>QP5-Y;7<J0D0ACN.21.UW8<8?#$B^S4_J8%%-1
MJ@4C4C9=.`1]^XM#>Y=I"TUE*5C):QQ(+(VLCQJ79N8BWB:.@1M"=6KI%.((
M(/#CK6/ZL-B4FDQ+=V>(!DCP2;SG_+!WO^]E#O[BW%W@K+P/`\#P/!)H/^?3
M9_[IM$_VP=%^"I27_-S_`/\`DG7_`.!3P3/PU_,GX]_=:Y]_LFB/@J7P/!)K
MS^?3'OW39C_;!!?!67@DV'?SZ>C/W3>+O[8.]_`XN_D?F/[V7>_]^GHSP5EX
M'@>!X'@U6?*#(*^_0Z&1Q^2KUW:#)8U(H1&9><YB8J)+O!;P6,+EF_1%Q5.X
M&Q%^7;?E1,[!=9.<UT2>))!7>6V4=@VGH_;^$E]OW?M_#T^W[N<;:_;]W'_D
M[8QC&VO_`+LXQC&<?MQC'^3P?IX)-Z=_],..OWL@O]AE\^"LO`\#P/!@'IWJ
M.A.-*6EW0_3%BC:KIR"_E6)-,B8R0&TV2QPLS!!VC4)%!!Z2F"!,N09L&0X(
M&(OW"Z^N$V^VNN^VH8NIJ2A>R-*LZD$O?S'G%Y&6LZYP".F[M'%DIRI,08B?
M14I#$D&;X$NG'T\XJ.$G!S60Q4?)#$KFS`;.GH6.5P%G^#4EUCQ+17R.=><Z
MD[3CJ)>-_'%.V5KZ%]&0I9277%.&(HT*IMTX)L'R^T'C8:.P>S;,9M$FJ)XN
M2JH2-,+.`LT8"@VV^!X)-N?_`,;=M5AS^P_Q@6*F8=T;<;S'^"F/#UK-1\@I
M.)IK8^ZXP<FMP1AC+4,L-MT&T5J.6LI"LQUDL;9R(*R\&".@K`.PZ)"XS!5D
M4;8MXVM6%2+.4$W3`9-2<;D![,J,-=]%MW`""QV/'IL<11:/5G`X`NVU:J?C
MYVT#&O+_``/R#QPH^*<[<_U=6$SD,:$QF=6%%(>'#SFQ6XK9-SE].I*T;ZEI
M*2(%=539)X5=NG#PNY</UU%'"NZFP6#X'@>!X->?=$RK*OE:]/V+3USRAN6V
M,1Y*T:@Z+AW+^L7SJT5+M(A+K',]-\VF'8J3O&6-V4?V+&@#EXW_`!UFNQ1-
MFV<!;T"CD;B4-C<>B`-G&HV.$M=!0-@HBNU'-U]/JMD='*"[I)XILLNHJN^U
M=.OKE]U7>SEQLME;<)[Z4_E*X?\`WLGW]TWJCP5EX'@>!X-2GS$_(M9?QU<Q
M:V-S]1B'3M_2&6@(]&*=9EEUBPR-$,$MS=I%H1'-U;"EL-CKI@PCC]*',LK-
M3DJ!NB9`:';DG:0?:WB/7GR.<1,6=MDA/"K7ICFM)E+*Y@K22V);L8(VM`/L
M*-I-+9B,JG:#J`MSJ@LO7@6*$C6JHU?3>V-D"2PYF$=<,_&I%_BTY+B7QQK7
MS_'8!M.Y+/Z>Z?L8S#V-61\/SA%HM%49\.+QIU+9:-90.8$(C5=-RD,8G)0M
M+(_8EDR!H(>PR,3!A&PW$<^""4N<R;HZ8B2`F66VBU'0X$:16;E('1<<)F5Z
MUC+IBHBTT'R"48+$[0G.FS#0NS/3)O`2AF3AZTB134//W\Y]>S;LRHKSJ[ED
M=+*>L>.=$UYS=.>@*B+_`)F8O,\=I>(3Q7GJRH763-W9<CKARG8T&'%WRWYG
MF*3""#'AL0E$8\262#&M\75US75,0'ANW;2Z4AMJ07A!]%XH&'PZE^G)-\AW
M0Z9T&"&55<X6""YN?K,U*(!%'A+:N!-Q(F9Q5]LS4\0M68NJ;DTE-A7['X%N
M;.@._P"'?++9W1<ZO2PCK6/'R<+8QZO@]#RK4;4>E3L&`H,.%O90*C0@8BV7
M$C7LQ-R!BZ%M6Q^0FWZ3]XZ#J?RM_P`'`J_Y)YMS8?AW1<KYFB-$JS-,Q`4H
M_.;K!2`;,2T&(.&5;B9C>`6&45E!&)/\.]87"G8N0%C2)P^((.Q.B;P-^MK6
M<ZA2\1A\4$MY+:5F/R8J!1YZY48B$M`K#\SDDPEA!%-=P-A</8;MG!ERU0<$
M"!$@"C(A!4U(1NO@UL?')\)7('QKV_>?052LSLGN>^'#E,O+I0XW40@D8-.!
M)^50&N!^[AXZ$0^0S@;B4.-#Q:323"38$%=R0@V`HN'0;B/!-/4G(M"=C5;,
M*GO6#,)&&E\/D4*_2-CG(:?1<7)FOTQ%:%S<?A&0QITIG1!9?1@]T'E,(:L3
M;$H*6=,'`3E\5WQLP#XK^517+]?698ML,6TKE,Q*2N?E'>$U2DE)K/-FD6AB
M1%[&X(&;-?IM'(V.IHX-&?S&1EUG1(FIE$-D?@A[Y"HI$97S@93L&7G8+`PY
MX:6ELG$1@]-AXH;NQ+!6CV41")22,S"0`6)PR)()MHLY?E&4A9@3"PQ42-).
MF84-00!I%*+IB+L)3K.6,;JJO@+.:ZCG(?67-1$3$L$)-J)>O23P9J=2;ZD]
M1[PB0=L\.L-W+YVNGNX4":YAW()BMA6G7Z-;%S3ZL9(*"+;-Y0#'$C0K2"J6
M'-)<V!E4VCE&.Q("BLT;.4EWRDD/I_E3)-IKMJ[R'\<46A#;=GWR`RN"NR[T
M(R[;S#'"QN)RR&N\2"`<@<B0R3HHBIF$`%78UO(`9%`5(6;)Q'9..3;2"+EC
M,>(CBCL+R\#P/`\#P:(9!\K/*]:?-7:'&,X?2V.3QIR?63$O+B(1+$$''H\^
ME5RM1&K]H^=EG>#<&N(4JV?)"-46IH,2%.=,:JM7B@5AU)\J/(_.O.URWDI.
MD;$TJZ`'Y?M!XHD];2248%M-E/R<*N:8,123]U][[J&[]VW;8S_YQ77'[?!+
MGQ9_*ES!</QI<M6)J;6AA\%2C.OMZUDBFF),Y.T?^8U*MC0BS26CK="9$H)N
M:`JNBB*306;'8,*,G"3S1$*7^+SY+17R=5I;=H1_GVUJ`$5+;QBDGXJVW(#<
MZ9FT5',7LR28-8\X>M=!\:<E&`5R\R]5_'-Z%F&$TE!*V50V=>#5%8_4@FLN
M[FDDG49_1RG`2C_B\M:;Z1LMM6EP2BF0/:0M7,0:LG)A2*J0$+B+[&-%\N,2
M]\@C^7?EFBK_`%#/TT^07FT$'9YALW'61-)#+(%`(3!0FSX6_D\ULV<QRNH>
M*R5,#6XP0/6DDI%[&"[O=1,4(T?$-6KU1MHS7#2[6?SJTJQ^::\.-KAI^<T]
M.WE45?3L@EY&21B5P.,R+GYCTO>)1VJ_C^=C!0=*@USQT""V9!L+HFV1#\P1
M09X0<*!V"+_-/`N1>Q*'^-RR^=;6<3/L._9G9E06F&/0E:%J5]VKU7:5AUF:
MD8EP30D@8D&#3P<C+`'T;EX/>MG"""KC?[-=0],/@>!X'@>"!>S:W87B7@55
M`[9B]=61EJ9.AQ$C+3*-/C@YZW<"&TLA[V'R")D);)*U*)[&&\14)&8WJH4:
M+34&FT)@W2P7QIKG7777.V=LZZXUSMG[/MVSC&,9VS]GV8^W/^7/V8^S_P!W
M@_KP2;T[_P"F''7[V07^PR^?!67@>!X'@UW=ZT35O<XB-<#VK&$Y=6]E[M+7
MO1JJ]("ORNJ*T.,70-D&,!738V-G4VM)2)CXTNR5&HLXD`LT_D^S-1^/`)6%
MGU+5<#HRKJ\IBK0"$5K:JH9&Z^@<:;+NG+<#$HD):@P`I)R^7<O'&C$:R;M\
M+NW"[A;[GXBRJBFVVV0^.Y+,85!6LIG[UB[,N0[-!K'(T.PCL7F4U//FL?@L
M&!Z.%VC90[-I@4"14+J[>,F6"1=MN_?,66KAX@'$4+6;^JZV%`Y&^:&[!-O"
M<VM:4M<JJZ2RT)@\4-S0TDX<H-G6XE,HYV"Q)BHV:-H["1$:B@8<(``10=@&
M9?!UZ72R.P.*R6;R\LV`Q2'@2TGDIM[^)]()`@F"Y,L1<81356V19L6R[C?1
M%)5;?5/.B22BFVNFP8/YHB<C:Q4Y:MAB7(BU+W.8L67"RGX>QF&@5F2`^M*K
M=X1W69CMJU@3<.&-!PRZP+-@.)Y)VSHN6E9R1G`I'P2;3'_CFLN4=*/?_1H-
MI,:6H-GG]NV8(PD05*S+">Z9_&21(6;8\'T0`:L72[=2L(1`#+O\O/R20Q\*
M%9>!X'@>!X-77R5NC<.'4Y:(FSI!"5HM*9$T&,'$[H:M*^R7>026*8=%Y1<'
M)/43AY+I"S36A4+BS)J!9G39AD@WW_-L(**!<]#65O;U20RP5PCF.NS3%XW(
MB7+U$IHW*`2K^/%51Q=N*!(&P;PB*=/0!Q("!U-!'#`I^1A\N\C6H8KZ4_E*
MX?\`WLGW]TWJCP8.^5GY'8G\5_(QKK"85;,;A'#9S"8&UAL.67&*J$)F_<-T
MR1V4?D9X5$0;%JR>9P8/MFPU^<5"15L\U.R,,V<A4_*_0$>ZNYJH7IF)!#$:
MC-^5)`K;!QZ0[,MS@,;/(V.D;4254'+N6*KX>F0PU<+-%]T%MTLJI_=UWQIJ
M'?+.MFJZ3B+RP+FLROZC@8YRQ9$)M9TSCD"B+%X4<Z,AK1Y))42$AFKDB\53
M:,4%WNBKMRIH@WT45WUTR$#TI\J',O:LCM&K>`K#CG15HU:;&`Y@62'2P?3\
M':E6&22,TDD[P&3;'HRXU;%`<;:PG<R3E\T'+@VNPF/L)/-(P%QUC5S2!HDS
M1<A^EMERY1)_/K`>-,-WQQ_KK]J0@,V57>K1N`Q_.RC2&0EN_=LP+#.Z[MX8
MD9$_(C(?1=,Y/5A4-GV3&(8O8I^OX%*YJ*@3,@[%OYDZBX1Z;UC(Q\P!29XB
M5-:LMAXK5N`**+D5VS?#7;\7.VH>6RH?D2+_`",!:UEDBKN\^:1?8TX6DMCN
M8/!770T^JSA&C!DJ_B1CZL<%5)/@(F*]4=(Q&R&4E+V+69P%/(2E+H@Z!26%
M2&'%`02'WCW#\X4ENCX_J.H\-:]E5#-H_1,GZB/5)RW;,!?-I1,)UD)**FZ*
MN&-10\E791E7J(F86`W@41JM:`KSI[H2AJVT:!?@AG7YIOBFL;K:NJ^YTHB=
M<ITC?QN_JEF+"FJPBW0\.K<@BW@1ZJ6\A/2,#(Y16$')!Z]TQ(=P[:B64W+0
M:JBI0)(2;!@4&^#T'_'_`,`P3DO@ZFN4YM&(G))8TJJOF/1!Y@8D<M96+=`V
MO8Q%9K,&,PEC<9,W@]J[`-Q%;O'+4`^AL)!Q$#&Q<7'Q\4*'!J8'6U\QO+?R
M_%^?8%RN<Z$^.&1Q36PWT[1=19&3/`Y/(9*46-M:#]*MJ\UO.-R3)`/_`!/9
M%1TW9L;2UD<K)6#890K>1D,^](_PD;X^^:'-.L)FPOI(G;<Z/1+(20T])JQD
M,1!`M)("7L4F%M9*%*E8:G:`#:LB3X.X7P%--)4L5W:J191@1#9+'9Y":79#
MI19<G"VIU1<3%FW?Q&K2HR42>5$0;?1Z[KJE(\2>1]5K55;;%EL(E3&D<8)-
M7.\YLPLC*)(3)NPZM/\`MTA*ZFGA_D"E+NZ`G(T!+FP)=A5KF'Q('+HXH2#%
M4##J[I)2#&7D(:?9Y;%H!#)"YE$A*(*QD6NQ61.EXX&?>;)1/I3#2CF7N9)(
MP#`ZL/KJQYY$TJXL6RXFFT;*?I--:T;QR*(1(FW**O@6CK2+PG26:BE)0QKR
M'@R0=(@%$^!X'@AKO<;J^JR+?0Y-NY@O8`<9```8PM'ECLI59$S&$4)-O.*]
M$0PFS!@33MK,3,D;M1['0J%21<N)$F@H%;U^W(-()"VI;_G1M%(\@1_Y3NYK
M_P`>2$M$W?\`RQ(,AKZ5_P"/U4_Y1O1S%T;_`.<G#1NJYV1T#"\WY.J.Q)`5
MD\MQ."9<F1;/D5OXPYBBF";:M5F1F/QE!(OJE'XK+VCA9"8QD;JB&D2>^,/F
MFV4TLIAP'-Z::-N=YI)::II)=7PM--/3&-==$].%>+==--<8_9C777&,8QC]
MF,8QCP5KX'@>!X'@Q*I0M)K7*GT2M4]>KWPA$&\`:W`O$@B]C,X4V<E7:498
M2Y5GN:8A]ESA79=HS>()NM'FZ#K"R&B2:8=KL"'Q*?PB50N>1>.S:'24$1$R
M.)RX(,DD9D`IRWWU<C#8$RV>BRH]QKC[J[-^U7;*X_8HGMCP3)\=L,A\!X.X
M[C<$B<:A4=TYLIHSH!B0(7'`NIB40$%)I,5U%AVK-CJ2D4D+EI"=?80PZ+G"
MA$L05</WKEPJ'[<.!0X>H;#4$B1HO<SV)WZ:,;CF#5CN5,.>XNA&S@L2V;))
M9?$EV[1H@L_=95=*HM6Z6ZNVB*>NH6)X,&;\V4LI<*-][PW?-IH&/TC3/8DT
MOU&XDW\7J]3?I1M#M3^(2I*<5HX6@^)*I'=SN(UO^5X(8;:ZZ:AD:<P6*65%
MBD+FP=(Y&S'T6[QBHX>,EDW8LBT,AR@TF,<LBH4X"-#QQR/G@[Y@:`'!P\R'
M?L2;%HZ1#5U\<'`O'T/KOF?MP1145<]<V7S!49N=]$R5Y(II:\G-S^I(<K,C
M9*6S(T>);F9%IE1F1+)*)$%!;AV'T<Z"GCIFL'"W#\<'#+?N[C2\V_,U9M[=
MS9EDS;,_0'/49!F2P>O'$HA1#ZE-_KI^%$#0@4O%QOX7Y4`:CF0H4R:"6R3'
M4-QG@>!X'@>#`%N4A$+GD$9'67)21:$#_IC+6F]E`3&.2B11Y]N^0DIEQH.Q
M,RF@=1V+^T2-/CP6<(Z(&V1,>5?L'8=SN6)$9S4MBPX,^D`TI(8:?%C7$5/N
M(H?R]<#5]6K09)63EB^`+$%L:#]RPXB+(L$'*KD>5%O$T"#8-+,]Y@ZR*'"B
M@RI;#(;Y'S\25.I7%`VC>6S^41(LPYUMANB[L1)]N(YG*+H:2#4PU'2(<]5;
M'X%&K%=BFVVH<]':)O&(VMQU*YN9LBJ0(/J]L-DE3/CM:S&-WG.R?-MO#Y!<
MQHHP_3*2A4/SD4N6B"(B5PHH7W-&%[`B&54`[=H&]3P/`\'$GCH:+`S4FD9-
MD%CT=$D3ITR27T:CA(80S6(%";]TKG5)LR8,6Z[ITNIMC1%!)13?.-=<Y\$\
M<R`C),+*;WFHQZ,G?0)5E,,"S2"B1^$U4.:*,Z:K%YHXQAR)_1N+NG,KD$73
MPDP#6G8-G/$4EGYHH2)!2;Y\R&,G9(D[:CQP]JX?/W[YPDT9,F31+==T[=NE
M]TT&S5L@FHLX<+*:)(I:;J*;ZZ:YS@(SA<[A'4]_+R.!RJ*613'+_P!T:WD,
M3D`T_&R73DTC`\NX31?!WKA(PZJ:D9>(636TV<1+)&]5-4E2LY@BVD""UO`\
M&H7N.,V+;%V&ZDC45NZT=<5+SO,(-&ZCM_%<PBJS[?H"P-[&G'0P%6X:G!S6
M-3Z.@(0SKH!)Q%N*%-JFM/6)PX7NQE*L@#;UX/,+\R7R<=H4)W!S[\??/W/+
M2QZ6Z9K^F_X[;:#1*UC4ZK,%<=[3FIY9H.D4(+MH]$4%H-$"+@:8,#]20]=4
MN48D4%![9=B'IM&C1X8<P$"&+,6*%,FHT8,'MD6;`</8H)M63%BT;Z)MVK-H
MV22;MFR">B*"*>B26FNFNNN`^WP/`\#P/!KW^0J`7[,:_A&_.P2S)%)M+(B>
MDO'5I>$MITTC!D,&4B#YLY$7A1XETW;J%MES2&\@<DB+=L/PD*+N!0K1@%[!
MTWB(<4D1QKH_2&L4WVNKA=WKJ\T:I:NL:NW2JSESKA;&^,.'"RJZV,?B+*J*
M;;;Y#7?TOTO0";CFFV%;?@*-:4[U?+%;2G*\A8H1F!H1CD'JD@?<R8JLIHU&
M-!;#79XZ=K[X;8;:[+Z*[IXSM@-!GSQ_)A7UI<832V>4>E`SFLZAF,*#0*QH
MG&*IN:D;9Z/+O!$D%1>5CIZ+EL9G`2/0!C.48F*"`Y$8`6@,/ST_%V#"J`,N
M9AMGX:ZHK."\N5]=W\9@\QS4E1M6GKM/.E(N*"4'+<`2F3M^L6$002B>.=KT
M=HY(DMH$.C\<I631B2E95&`;YY=[&F0\X?R^_,=P1\A'5CCXR[_NN!PSXQAH
M^$6N][CH(M/+5L->Y@$),R$4*CXZ``9O$W485)R3^+@U'C-=3C#%\U?RK8T(
M*8"_HN&8/X--V=\5\"NCM.I*!J*(\R(C!]8M6U\3_H:Q+/?]'Q2%/#L+83`2
ME/:%J413<8<KZI6',@\@*@B;R460V31CVX.,:I0X/3+VO\LG$O!W.8WJ6VK/
MUFM4&[3$TN#(46F,MQV6L@O'S<MUC:2D<+_D;!RQBL<,R`CN:-C$F[%HBEIL
ML1)"F+X//?\`(%\\5/WSRQT%;7/]Y774E6#.<8#*>?6$BY4.26"]!WX6D%L@
MYC7EHS)K";#!0N*PP^VJ"..8]8,CKB-3J6;E!^JMD5F3<:G`R#_!;I=T1V'\
M;9A>V;)48PZ(=#S^O#,]C!=ZE?\`;80-%J_/BZZF4Q>!=EXM`(J,G!0*)-Q(
M_O/E0SP.!B):JVT)P_F@>L8&!@]6P](0`&1N!06*#W[O5FQ081^-@!J6[HJ5
M?*XUPV8,6^%5'I0H^7V3UW65=OWJVRBBRVP1=1],JV=,"?1<D*2(#!Y1=9^Y
MZXI#8<R9QW4@*AK2HH7;,F</V'Z0DSLRCXHC:+4,FJ*C`A_*(B[0%$)-#E)M
M*0O_`,#P07*OC-XML4_7LAM>F0MN+TM)V<CH,;8ZJ\@!4(R9:[[)P:IPVN6C
M(!6RSI3ZA]!7R9<`1:,(I&W[5S#ZYK..0T,V/>4.>_R!^"BM5PVKE7A(,>0D
M=01T+5\M$R2-_F&([(Q4BAH\2_0+!="Y=LUW6W<M%QADX$(M'P0X8&O@S1$H
MI'()%8U"(>(9Q^)0X`'BT8`CM,IL`L>CX]N*#"62>VV^VC0<.:-FC?3;?;;5
M%'3&=MLXSG(=@\#P/`\$#?(8I4ARF4ZYM**BI_K)""$B$08K,.A8'J7TC!<"
M'6>,Y'S17EEV/L51/36*@P,;9QU?$ND4D#QYFF[)OF;-8*.YK%,`7.U#!19U
MC*!@BFZS&#I*+V,[C9`Q8PP*V:FF&\BW4D&[,F@DF\;;G-]C&R*VFQ+['N5L
M8#-?@DWG/^6#O?\`>RAW]Q;B[P5EX'@>!X'@>#XB7_-S_P#^2=?_`(%/!,_#
M7\R?CW]UKGW^R:(^#XN+OY'YC^]EWO\`WZ>C/!67@>!X)-X(_F+<7?NF\Y_V
M/P[P+G_G+\9__P`Q7E_8V9\%9>!X'@>!X-67RD3`+`H54\G*O8&"<HRJ1#@,
M@F<^D,!64.O0.BXV&#RD:O[GA^Q'31RQ3:R"3N)-*!D1:CVQ5]!CFFVF[,-I
M*6?M23S^S'VIZ9_P=OOZ_MUQ_DW_`/;Q_P"[;_VL?M_]?@_3P2;T[_Z8<=?O
M9!?[#+Y\%9>!X'@E'I5)6RW\`YD8XSA"WGCV16>0TSC*@6CJW(Q\E-FR.-,_
MBI$K#.%(E5K!?&S-<:*ETFE0I]J7B;-H["K<8QC&,8QC&,8QC&,8^S&,8_9C
M&,8_9C&,?Y,>"7.D50UJQ>8<L,(N!L8];\"/1N:@Y&@X?0*#5U+1Q$&_E-K9
M%N4"3,>:;:F!T!C3%=E(K#D@YXS"/08&/3:=0@,'?%C\>$%^+WCZ(\HP609F
M6@663V:2:=+`QP`A-)%,Y*[?IER;-AINMLX'QE&-Q9KL5)'2343'AHS)IZQ'
ML<)!L5\'3I_.H[6D/.3>4N=VX<&W2WRBW3^I)ER;]VW%@(S'AVNV'!N5RP\^
M&1B(QP?JL6DLG+B0`=J[*$F;94,7<Y0611J&$)E83;1&W+@-N;*LQ/"GU&0)
M$RDDG'*Z9N<ZZX4#U5#T`<`8*()MD"KD&2E*[70Q)"Z[D,CV98D>JB"R2?2?
M+U49'1RSM,4(;?F,DDQ7;'X06(0\)JHFZDLVEQ;=G'(;%AOXI:324F+!"F[@
M@_;([AT:D*_D$>8GK`LA$;M<MJ+"C-@9&N-B(V,,Q;19"*U;&2KG&SYS#Z_;
M/B?TGWU=6)28R"=S5@.#;3-T+;!G3P/`\#P/`\&J/Y"]=L6!3BS'65KK(([*
M2!MR\SE#WN'\GQ(&?Y.[AV@(<3C25&MC><ZV*YLINE&T7CAI^CSQM--PN=PV
MG():K#44<_5ZZ*L4TL_69SE]KKNWQI_QK;?.^V7>,9_Q^=\[9RM][.V<Y^W[
M0\YW;_Q+!;[C]+U?;5M2D(;M:>2[FJ/G:JD=A1J&AJX=<<=.#H_)YG5#>:"X
M38=A#7+-,AL].LMVC5!8G'ARZ0`X9:/0TX5K_!BN7BU/6/P[9%K'HK9;+O61
MJ5MU\,@S0E,B04'SI'Y..YFF,*7ER$:`J2R$E$NAXI)F+HBD6'NGD5=N`YP,
M@PD`;-&'P>Q&ROCNDG,M4WWT+%.H>?:EZ"XW"D9IT39F::+NI%&'\+V;V'5A
M%M9T4&TC=T1<UY=+"'1B)DR=:MC$5_0,B!E45RHB'EGF7\%PZ#@7"5*RF4/@
MX;Y$KSZH>Q&.TP>N:"Q&KHQS@-I.P9L_<S3:81,"Z96ZWF-<%%OK`MB'(6I$
MSL8'I-=Y,^=ZL`VW?$7_``<FS(G11.Z\67&PR?4?-,:CDFA5L-3$I$O2A,C'
M):908!J2M8'%CU6%U1SH(-5LTQ.%#X0CL_DU-A7++0:4#:GU;_!V>)+^H/IH
MS>,.YPYFLZ43%K9\"M^A1)&HZHY_C\/J&OH$@.(QI0U%X6]C;TC%9E,I:Z,"
M6K+!*;+EEM73X,@NL%V\\_'YRU+(7`JV8P4K+>,>:X1M37/T(G4VF,QBURN'
M487B%D6]-Q!4VZB-CPQU'=Q\&J-;8,U!8^VUI6+9%HM,:]=`PM2K>&^5*,A;
MNN:1J`33,$?H&$GD2J8],*W!.7$@0:-2YE4?#)$%0WE#QJ/'M-I;G7])TFC!
MBV;ETD&;9-(,,3&A*X.SF.\Q0-.=*15-->R.C'1FW;<F:S*M)8%D,6CE?86G
MDXD3%UFY9!%G`DP)?-#[(?6L:L7#,3&I/,(Q-1X5PE1==H-T6J2,SU1;B%P:
M6O\`&I:>VVHYROAPKKLKM,]E5'>%=<?@DE-]B3=+_$-W:2&<IY#@6O,U3,Y:
MA-T$;&Q(&[9NT2V5O&\'`?\`!:AD@*/XD7<6*K%UE?RU'3"KA8.HX7???++J
MJ%E%'VX=A2H^OD4&K;1.9_A,QK\2A]ZT[244PR)Y^UWA5929;+.76?\`^'(N
M5%2#'_\`@G3?P=/D_*=-S!<>Y.(6=LJ,&MA+3\IO^_8VGADTQG5'#E".6:)0
M?.OLSG\4@^3<$'&?VN'2N<8SX.X)4=7J*+=!-.9_AM6)0<C]^T[25W^E,*;J
MOL**JS/=5=QG??;Z1XONH\&Z_8F-7:)ZZZX#CC7/58R`2X"DTIYE@Z&#A"V&
M%Q7$'>99"G;)ZSPF3#SQB30=8<#VWU)%!XF1?HX7:OW3EJ\=HKA_H7GNL@`H
M<&&I3S#`6Q+CF>'UPW`7>8:G'*SLCAR3+SM\3?N,KKJ99/7[MR]%)?<;BG#)
MNBDEH'W;4;7FZ&6^R<T_"V"H1_/V6K:FJGY8W7RY2QA;6:86P^_%SG\0QA3!
M=9/_`!"SY1'&$\!P0?FBIP1LS(1R-B8)GEWK@EE[=]W%F&52&7F7/T(<K8CT
M.)3SE\X_`1$L&*+/&4<,TT,-6N$0[[&ZSB43)-RH721:O&H1./(Y*3B<2%K^
M6)+_`%.F%!\@D10>N_\`Q<_X1A=JH843_P`3N_V1_P`7X.I6Q0%>7.6AAR9:
M25(O`LF\QQ_&98?BJZ'Y]L&=N-7F0;YGJ1U8FXS%Y0&P]U6_*)3&`!YA^"_&
M(*X#)<3BP&#1:-0J+#TA,9B($1&(\+1VWW2'!`(]N+%,4]U=MU=]&K%J@AKN
MKONIOC3[RF^V^<[9#L'@DWG/^6#O?][*'?W%N+O!67@>!X'@>!X/B)?\W/\`
M_P"2=?\`X%/!,_#7\R?CW]UKGW^R:(^#XN+OY'YC^]EWO_?IZ,\%9>!X'@DW
M@C^8MQ=^Z;SG_8_#O`N?^<OQG_\`S%>7]C9GP5EX'@>!X'@UO?(-)W5>*TE9
M"4X)0!G'2L\&$CD?G5>UW(<-#P43OE)"069"9_&U0N,B/QC8S(-!VMLF.?(%
MF>!VZ+L-C^F?MTTS]OV_;KKG[<YQG.?MQC]N<XQC&?\`^^,8Q_[L8\$KS/M3
MG:OSLEC\LDTV&N8A(,18^40I*\B\2:'$@BDF*M6\Z"UN1A11&+QI!S(YP0$G
MWPV!`&CTU-'8$:R=.D0P[8UY5C=\EY:>UH?>G&\8['!B"VQ"+2^)J?C+4+?#
MIB1&(3`"`<'HV7;9RY`RX"D2BT@;Z*KA#+]))7?0-AG@>#J,^G48K&%2FPIH
M0V%16&@R$@./4VCPBY38#6^[A1)@+&H.RA@H[SKJT%!1+-X6,DEVHL6S=D';
M9LJ&DGXIOBXZ$X]ZC[1Z\OCIRPK+4Z\<AWT8I*5R8C+7%6BUY$:L!8;.I,L0
M=`))*H0:EAV%1)S#6C*/-(XL=*)[[KRU04!#._R"VKU;?G,EIP3XF9BY5Z,&
MX$$05]1S^*4Q5,?(1\XP+&:UTD-F.WD5D4SFH%!R'3;@@<B'Q-F5;F)2:C"K
MR.)F@OSG>HR%-U7%XS*Y0YL6T7`<,_N*VBJ+-.0VQ9WY.P9RB=&LL&`IDC^9
MO&N4@H48+$1^*QQN(BL7!@8V&%!F(9Q\#P:535W'^ANJV$=CEQ/I#!JS[4K!
M"&T<PK)NV"3FI0O.\&EQFYEID1CS>22:+1FXY9+"L<E@`YB$/G\*C[A@N9&-
M%=R(;@YE-8A7<;)3">28%#XL'U0V)R"2%&8<2SR[=(,622SU\JBAAP_?N6H]
M@VQOEP_?NFS%HDLZ<(H[AYNJ_IWY4K0^?!]T;/8K>(?XH=H:T.5E#+!N6'*5
M\%G(N@0,>CDO3YR5L1S,85+7UA:FCB>A.N!DACI<L\7.8'$-GVVH>FSP/!._
M5%YZ<[4G*K.T;(D"8W8</##<BCTF>N7A%XDD]?#(3$4',SL%U%P.IB:.('#$
M?THE`F-DAHER.75R39AR7/%@G['@3@N<<L9"B*D96.1ZR@K+<5'+ACHE%CAE
M9D<#KY^I%C2[E=\(7TQKN$)&014]"'YRO2T2D)8,[>!X'@@/NCK$US4,K]M"
MQDY)SB3G7#INV&<Y71==?N8J#%E"LLUF1ZJ`CIW$<L0P]X3:.1CXE(62C5$J
MO$#L>1(([A9T",R*0PV.G)8%$1^0E!B#TF(CYU])@C55;[=D\B3I..Q(F28.
M$,I.FJY*,`".$E]4GPEBZ350T">^E/Y2N'_WLGW]TWJCP=0L6#1MYU3K%9.P
M_&B73=#/F+W*2[D9LPLSFZ7L3<0/@RS19BZ"V.K&K<,%0!P"\TE^K.J695H[
M9-H`P<-@U>U#?'01OJ&EXDKT9"F+?I&GS\.Z`E<*YI+"9E5MLT@6B8RGA4ZD
MDNN.1UP*N6Y!LTL"*N9NG3+".R+,`$Q`="!!#6O]XZ&Y,'R3S^.T<.I+70*U
MI43W3<2&P;G8L[5GDD?ZXV^^[(R&9MBBK%KC9134;&HXB"AD98Y0!1&-Q^.L
M!HAD'<RMG4G5$8)(N99!8G'*]="X:ZCX1R-PI'C#@.U)QV!C8A'M5R6),3".
M&#F,080(5/F&;MA@$'=ZNFNJH:E?E'X<Z!^8+DR1T*!F)?D*%;2:-6#7Q8H:
MDC296V3#+.40S*[*\:`6;J$U2B%,.)@G7A=T]LM]8XR%J2<?5R\$(#94&TOE
MJCW/-/.=+T`[LF87`YJ&O(Y`U;,G_P!!^E\RS'V*;+4P:U&((-=%E---46Z6
M<O':3)%LF1*&"&KHJ\#G+BM-:LAL4;!H[B6SFQI<A`*[C;HMK&@A25N`)^3Y
MQ)):JP*-HN#91^+G23LCD:4(/%&:`2/!3LD*B`SX,;\?[)26I4;D(;I.9O?)
M3>R;">M4,I"L2-,<.AC<+&'&?Q=2D)BP*)B8[#)`T(&1<K`#FDO#G38R0-2K
ML*H\#P/`\#P/`\#P/`\#P/!J(NFCK#L2TK;.A.>K0`H-[)K8@*=:%:'DT#O]
MQ&!L@29SB=CYE;3XUM%8\^.M1S4$O&(G)88&!-#,192$DNV#!PH3BB)R:&SW
MY`14LL&0645>=MYD29R2,(P.=B!,HY`Y$D`."CD(F"CP]6.5Z((LX5&'KYDY
MD;\`#'/)08.2!8B7>!>?@>!X'@>!X/B)?\W/_P#Y)U_^!3P3/PU_,GX]_=:Y
M]_LFB/@^+B[^1^8_O9=[_P!^GHSP5EX'@>"3>"/YBW%W[IO.?]C\.\"Y_P"<
MOQG_`/S%>7]C9GP5EX'@>!X'@UZ=,PCH&XK/DE81R!"Y;2*54U\0?Y,].7)R
MZU)265R&Y0,[C?YO4=&6?O9(U[%!4/\`T@C9X^*:QY-P*<("]LR95YL&PG37
M[NFFN-<:XUUUUQKKG.==?LQC'W=<YQKG.,?Y,9SC&<X_;]F/\G@UL6I\<X&R
M;4F-HCYQ&J[)35&9`I"I`J8B4<D<QAEI1-U"+*#VA*PY0<XLJ0[1YVKI64W-
MCT3-<D/M=NDYBW<OV+P,7S'C*"53;?$-AR-\E9%C0CJ!"'U=,R(74&0K^MG_
M`#M<`+:),D6A1\@2?D!8`2E)I&ZPEN=<,&B[<6'T2R@H&WGP=*LFQ(;45>SF
MU+$/#XM`JWB4AG,SDA9R@S&@HO%A3HV<*O73E1%!!NQ&LG#A3=5733&J?V9V
MQ]O@TY\B_)QS9\G,(8=<P-O9://M36PG6=8TZ?A"ZUR61U>*@FLJD+EY7\*?
M35M*(Q7U>V1$GL#W1/*QT++=Y[9T[:`655U_/!X?GQ_Q)VD4Z8[2L/NV\+=E
M/.$QG,>7Y,YDST`6ED&C,$D`923S5G83J-(1,A+,A3I=I`&$.DB3J-L48N;V
M^KL0(5"27<-W3%@Q%LVX\:S:#F#-+5!HQ8MT6C-JCI^S1%NV;Z)HH):X_9JF
MEIKIK_ZL8\'U^#"USWG&:11@6#L>GDL+69-%X%#8W745=2Z0%)`TA,QL-[KE
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MF<TD(6)1"*!R,AD\HDA1D$C\>`AVBK\J:-F"*S9@+%C62"SM\_>N$6S5LDHL
MLKHGIMM@.#K*S:]N>OXA:U43*/6%6\^!,9-#9I%";<O'Y$"))85:$!I!KOND
MLGOC[R:J><ZKM7":S1TDBZ061T#O7@@/Y!D33VMX>QC\6!RE_P#I:X=K)$!1
M`^48--8X98HZL!`:SJF*Y$R0N_%PR5$]9.N+'`9$ZW-`S#!7=IL%U!M5M`XK
M1PS;CW&@UCJNP9YURT8K:M4L*LVN=/\``RW;;XV10SI_@_A::_=_9]G@E_I3
M^4KA_P#>R??W3>J/`[*_Y/54%N5'_$N^<[*A%WJ$_P#R<!(<!>N(Q<9==77[
MRR0YM14PM#0WEJBY>+@EB;1FV6<N4M/`[M469<<](GF,:DTN-PNI998L5`PM
M$:M,'$WK5AM/X,[BWYL_%-$9`(F$;"&0[S4H,>L'[!!Z+(L2;=FZ2#27R]_"
M8N/)IP$\ZB[2(A>8+D#,#.Q'FL1+@L@MJRQ&J@MM%YO1\(W-L9J^C4ZW-)M(
M\ZEC6,*-'@61'57F8&Q'S8D'8/A3^(FN^<;5NSY)E[U/=#%.VV+>R:<2EI4=
M8CJN*TLPFWL9LZ.VL[<&7MH6:_:J@!3^R`RD79O18]TDJ&<J$<;#P](W@>"*
MI5$8UUM:I:,R\*QEO/5"E5QCT412_P#!,WZ59_D!9D=$/VN=7+]IS^*=/12!
M`>128B[E/&6RB.L_IILXC86.,&#0HY@'#CV(D0*9MAPL6,:(,!PT>R1T;LV+
M!BU32;,V;1NFF@V:MTDT$$=-$DM---==<!]W@>!X'@>!X'@>!X'@>!X'@DWG
M/^6#O?\`>RAW]Q;B[P5EX'@>!X'@>"9^S8UT),N4.A8KR?)A,-Z2D%2S,32L
MG.+MF@P-8#T.Y1`NUWCP6::,E,.=OPVKYT-<MV3Q1!TME!-+9PD&N'@.B?EQ
MIWX\:9H>[[*YBVO:%5.;@GYV593F1'(VV:NCXZKQA*70DD&C)(I"(5M$@;HP
M(CI%/9R%V65>RESJL8*A&_P1TK\R564/?F_45S5%."A;IVZ`T71M4C-+)>M"
M4(M">`;DD((I!YF!!CQ4SO;:QR2C1Y%!<C?/&JQY^1)!B\<'``J7Y"*>^3.R
M9)Q=K7O9,1YK9J=4PN&6&VHD5-0>+#K64I*R";L9#K*7TM2>F`4:@152"(IZ
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M:N'#1NX).&(Q9)DDNZ;H[N-T]5%D],YWP'FYZ?\`X5O$+H^-OI"Y>%HK-Z3Z
M4KF70*)#4+E95&93!1^92:(BE)B+#/9UMM,"!!@7E30(-B,=GCN+$XLH?GX8
M)%W@EZ5"R>(YK:GS1<L5SGIOH3EN1/[CH`D<D-5Q2)V-/1.L=)8802S"@VIG
MA6HZMCMFUT=+!0Y>1V.^[&C\:L`U^#%8S5HU,M'9L%\_"1\3L6^*KDX75YUG
M"91?Q>6V.>LNV8\.=_5R%J?E.J4;%,R15RY>)!VD*C,&069,&L>8.GXWZ]X!
M1+Y>.G`;DW[]B*8O29-ZT&C1K1P_(D7[A%FQ8,6:.[AV]>NW&Z;=JT:MTU%W
M#A=31%!'3=57?737;;`8B:=(<\/X$4M4??%-$*P"&$X\9L5A9\)>P85(%<#L
MH@2,L:FU0+,VM@N)_!$N'Z9!7)0;A-OME\UPJ&M'K;N6RVLCB6G-!2<1\+O5
M=LR2/O9GSW-V,0O>WH].*'$U_6<?D<O@JT@1C!>,S68EW<[B$;>`3#)=J\B$
MBD3R,284+"R2?'`FSW\<EO1%J7%9$[BI9S(8FXKVV;6YQAU=FB0$U&2NT!C=
M$SN#D]M'$>D1J/Z%K!DL_E>@0B_8)R%)N5+I/@T;]S?/I47Q@=$\E_'WS#SM
M"NFHA.(?7D,`34;U>1%AZS)/[$(5*-A9\IM5MXF92_`:"F120%R4M<R7*CM9
ML5:*DTE'+H-_P3F2%&-G$BOIG'N@["*:IY=F["AT<*1J+-OMW<;1:KX<18D6
M,,A[5^X>+MM7#D[,RJ:K;283.4;BQ.[`,],4(S$F,=C0U$%&1OV(QR)Q]BF/
M#,?L'"GCY`%'12&&S?[&(,0_>(BQJ'_%10MXXT0T:,EMT@P9,>H:W#G3%?P!
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MM/YN^*3_`'9,/CHJXC.;GZ9BX7?9F%K..(F(<?G@O4@^F59IV(_("X3'3\`C
MS+!Z6FY<=!0UFIJ]AS21/K':(PQZ&9NB^0["[^H^S:2ZFDXZK:<M:)E(XXIJ
MIDQDJ/M_JT,J`SE@6S*@V4C!L`52%R5I%Z\BD2$`)`-R/5GECBM&Y50.W?&W
MP'5OQG<C5SR74QR2RP+#=BQN0S*5/'2A.93F3N_S*5R5,,H_?C(B.)$,_:.B
MD?V3%"FB2>RRA,TY+G2P7=X-<W8G#DOZ=L",3:.V94$4:@HRWCSD':_.I:\<
M*Y01L%!5P#?#[VJ1,`U)_ITT?&&"@TQL_+PF&D?K$?RG1#(;!08[<.$#B%7/
MUJ@L6/'*/,IY1R[W8M$6V[G*.RSC9+\?9+*OX>RZ^4_O_=RLIG'W]@F'I3^4
MKA_][)]_=-ZH\%/F@XZ0ARP`PU1?B#@Q^'*,7*2:[=X.)M563YJNBMHHBLBX
M;+JHJI*I[IJ:;[:*:;:YSKD).XCM`%,Z8%U\D9>DIC0ZI2FY9@LW*H/S+6LI
M7*JMC-DC'1AN@M*(3:+*O7DGA\Y'J/Q,D0V():O\FA1U@/#1SV5\/'Q`WKW;
M,+OFNL6LVVIK2I*AW?!],R>&#)$=MM`::,(70F)$R%O(:[EL2KAEM]0X^ACD
M4%MXRQD[U(J??N!4H#;C7/7_`"16-"0F.<X0VQY'`*[K4"$@=84M1-OS`?"8
MY'@39A&(:=.1J&G(?`$6C-G^5I$IG*!PG[H@RZP6>HB"3A,/OI?ND<9@C':V
MHO/)%.Q[EP-,S/E_G'IN].>INHCJBOI(JFLBO:XGXHQ'<8<Y"/VQ(YH<%2<,
M?&O&>&S9D]>A\5R=SIMP#X53</GC*7;`W)IZ3NJI[6I!R"COZ3PV#;G8!`KC
M@<+D]ZREK);`C#1E"X"P(I;D'XP05(HR:3P&(3L+;K*O([54#C,!BVK[<3'1
MB+3\Q+KY>R$^0W^U<O*)44422<&Y;)RBKL]*3KW3Z\V?($"C[;9TZ5VR'?/`
M\#P/`\#P/`\#P/`\#P/`\$F\Y_RP=[_O90[^XMQ=X*R\#P/`\#P/`\#P2;Q=
M_(_,?WLN]_[]/1G@=1_\_P#)?[V4,_LSMSP5EX'@DW@C^8MQ=^Z;SG_8_#O!
M67@>!X'@>!X'@>#\U5-44E%=_M^XDGNIO]F/MS]W37.VWV8_]>?LQG[,>#SX
M]W]EU+9L*I"L>E.9;REM=VA<S]J;A5'U;;_36LQI"<<ZVT$PUE&]15\D3ALU
ME8:<[I_H*GAZ\V;BI._BLEDC.,'"`P-4\SX5^`F2\XG>:X[\<7RJ5D%,SQ.Q
M&]IP[X]>XCE[1TWE&+,R`^.6?:](V638Q8N-B3`<^B;AL\`()OCK\2Q&&3A$
MHL$-VE0]3`N<X'07+<:^8SC.T.>XI=-1\[VWM0'R91^.]+2*TIL3MV,:D(Y"
M8"LI!<.&`(6<N)$'6^A`Q,A4T#Q*N2L%@U>V@["7>"ZP^6.2%:B@_9$\[)#U
MHO=YV;/E.P>4>K.A*MIE5M5%CPE2Q+2C'2_'\VI!"-E6+Q@R&SQ]<N6M4-9`
MI*"L%:K_`)^>C`1+1=/?(CQ?T+TTU5YM^1\KO>923U16MB4-S_;U'559\A2F
MKJP&9*25I-^49Z:E-0O0$3,3%>H(3"X[)64=$.]Q^BXD(X'K!9/S'0_J*SZ2
MN@)9L4ZNZDM)[?U0]"B^HN=.?F\_X",5X-HX=2QJ/D;>%<Q<Y/HK:`9R'!N"
MAJJ6<XJ"4MVL=B<IRK/XNJ>"!3T=[L^2$)\;S'C#;FSYL:%LZ'<IA*$H]<)R
M[$7L5G]K@XD*!)C(D>$490MYQ%BQ@P*<D4&"$MOV>L8QL6LA%5O):H9'7X=.
M^);K7NEO0S6DNMN0_F`Z/BME6^?L03T8A"+5O2`!*]4B$7%.X@/KZVPC.O+$
MUDA6%%H^75M&<SBN6H*2F0P>M4RYJ1/3`;'[@_A#GR%PZ:\ZP:IOB!Z?A\9E
M4G/0TR)M#@VW(S/3PN.P]\0'I\_0T-8[L3)Y6R#!CEJF("HZ'M(M&XNYAVLE
M-"_K[1$!A[LWYA_DL8US(YUR1\=_R=0_I[25*FCW6]Y<+3&N8A%*%8"%GY>M
M\43@KT%6^L=`N&_XC(G(9`HW8IID)\^5UF[TH6>!EQ7OOL.R(!6Z/2?,G64N
ML6TH+!H)+A5Q<^=I1J6U_)VC\59%DM.7W'.GQ+P0%`;0*QF,SO*DM9FK<E<:
MS$X;+8E.$15>&-I.'<J_^<_Y#X%VLI5$/^'*X(3PH#K9C&XO"(ES%UI&R,:,
M-5WBS:W4"X#D?6=(5^9?H$(BQB"7-S19+Z=J]UV:/4#"JX<%W;\V_P`MJW0O
M%J/*W%MV5C3ZEH:XN`6IR+VW8Y>R=]6114S#R32T.2^>#)(&/J]&:SQA&*I8
MGIBL_AA&4.S`=O%QR3H-HCSY,YS-6;H=,7'R.UT*+-U]7?ZO?PK]>!9X$543
MVU2;1^P+H@5T1G9KC;;_`(T\?4]@NJE_S6\!O-4WV@:@_C-@O-7"$KZ8_6I<
M?*[UD)ZDZ$D,FK2L[+^.KNI.&RURL+/RUY)+,@YJK-15NW[+(R*D+ZQ4-VAF
M+D(O#G)E<.008*+Q\-T,*[%^.JN+]D74$!^/CY!89>,KJF+TD>G$9^*_M,(X
M>UC#'3=S&XOD6.IYN$1;C=!X8>DZ0')O\AH[&PFSK(D"+9M@H(A\TW-8EV#8
M%>>/DH&/I.46!QID0^-7LQD[D)MN$,25<.#;.:C36+%$(Y'CY]8>PT<.TP@,
MP5W1U8C'JZ`<I_PQ-#?T8/D\_P#^8G:_^QWP9>H#Y*J-Z(MX/2$>K#L&MYU(
M8O*I<`Q?_&O1]#QLT(A:@-.2982RSJ\CL?W<C<R(/A1%5^EC94@R::;Y?$!S
M5V&PCP2KTYTPTHNOIQ(X>QBUCS:N<0LS-:^_3D2&.Q>#RD\F-WE9@8EH3/(I
MNVB)%O$FWY/JA(Y!HU9*D!8=,R=$!K)Z`[JM8(?X^R>Y#NZ^YO$^K7CHYKR(
M/KV40Y7);BVPYE&XX-)7%;%6+;RUW%KG0>J,=EE!ZK.NYL95?BM'T0$G@SW_
M`,)Y;G_0_P#RM_Z"\9_[[/@@=]>U8"3$!&7Y\+GR2WBFX*&*HYMC%Y4/P%.Q
ME=!BHHM91:OH4R)];/62Q1X-@10B2F9I',H,1B$QD,9-$7H3=^;"EW_7J#NO
M6=6C_@\^3:)0<3JUS&PT`K/BRO\`6&NA[O+\82A+F&]K!',0)C'^=GK!_'E1
M[ANONKG7?.BZ^BH=A;_*,9J8=6U?,_A_^46'BS1%O6U:1QI7O'"#1T1$1&0R
MEO'!22':BFB6[6(PR1%<;.=TM-FPASG=?=UNGHL'8(K\A\R@L>%1&$?"S\G<
M-B@)MAD#C$5JOB*/1X,SPINKAH*"B.T&8T<VPJHHIA!FV12_$4WW^Y][?;.0
MZA8'R2*E9!5.+&^&?Y-BLBQ/-]:ER?K'B\@Z2GXR)R:9_>![*=HK:-R3"-P\
M])VZJ^4T6SN-,RK;;0V*#+(AD_\`X3RW/^A_^5O_`$%XS_WV?!ULY\M<WC12
M&A3OQ*_*F-*6#)'40AC->!\<Y5/R5E$)5/G0EGE+M1335PC#X1*SNVSC=!'Z
M0*ZUU5RXV016#LG_``GEN?\`0_\`RM_Z"\9_[[/@ZV<^6N;QHI#0IWXE?E3&
ME+!DCJ(0QFO`^.<JGY*RB$JGSH2SREVHIIJX1A\(E9W;9QN@C](%=:ZJY<;(
M(K!V3_A/+<_Z'_Y6_P#07C/_`'V?!ULY\M<WC12&A3OQ*_*F-*6#)'40AC->
M!\<Y5/R5E$)5/G0EGE+M1335PC#X1*SNVSC=!'Z0*ZUU5RXV016#LG_">6Y_
MT/\`\K?^@O&?^^SX.MG/EKF\:*0T*=^)7Y4QI2P9(ZB$,9KP/CG*I^2LHA*I
M\Z$L\I=J*::N$8?")6=VV<;H(_2!76NJN7&R"*P=D_X3RW/^A_\`E;_T%XS_
M`-]GP=;.?+7-XT4AH4[\2ORIC2E@R1U$(8S7@?'.53\E91"53YT)9Y2[44TU
M<(P^$2L[MLXW01^D"NM=5<N-D$5@[)_PGEN?]#_\K?\`H+QG_OL^#OU1?(H>
ML:X:QJ&>?'_WGS7_`!M&Y%&(G8]^Q/G$97&9/'*YF]HJ1]^^K7IBS92@1*16
MO90J*^GB3IHH[9:HO'3))3ZC4-D_@>";NE+FDM-QV/$(F$`F2A8D;7>:R1V0
M9CD([#XF=FTC3:;#4E%UY`1%@5AH%%79)HF]=?7O,KMF*K1P&K>MOD'LB#7Q
MW@,$?&1\C-I,W'60_;215K$.6W@#*8/E#EN&LUOQ99U=$"?X,I'1AE8,:SD7
MA1:"3*).BR8>1N#<9!!G3_A/+<_Z'_Y6_P#07C/_`'V?!UN,?+7-YFU*/8Q\
M2ORIF&H622.(%%FT#XYUU9R6(F'8"2"5?Q^U$MLN!)AB[8.-M,;H[+(;Y155
M3^[OD.R?\)Y;G_0__*W_`*"\9_[[/@X",?+)/IF&0D$9^(_Y5RH=RZ*LD7J5
M?\>(:*.@A9\#*)83=]IMU\9:%1SUIMMLEC139#91'91'9-3<.?\`^$\MS_H?
M_E;_`-!>,_\`?9\'6XE\M<XG8)O)HC\2ORI'`3MV78MR32!\<ZH*NP)A^`+H
M:X7[415^\Q,"W[!7.4\:Y6;;Y3SNGG3?8.PJ?)_;*6FZBGQ`?*UKHGIMOOMF
M"\:?9KIIC.VVV?L[8^W[,8QG/[/!UF.?+C-9?"0-BQ?XDOE9/0R4187-8Z:&
M5UR"ZU,Q@V)0.B"@]BGV?DFYU(BG+=VT:)LLOEL+)HZM<N-L)>#61\;7SRFY
MMS+TI9I/XR^[#E?5#T[V++I++ZB#4;(PT-B\IM&:=(F`]B)6C=U-R,//J_#V
M2X$RT,#C9\5K@0@Z9E]B#MX%&!V'Y(_EI[/B!SB9Y47Q$=D,!KOK*&"2Z_0H
MVHXSN8F\D'$(;6D+@RM/7A;C#\SE6\HEFB[Z?O(.`:E1T98(F5LF'F6(;()9
M\LD^@\6DLUE7Q'_*N(B\/`&93)"RM?\`'CA(6!CXYR6,$5$&?:;AVLFR'M'#
MG=)JW7<J:I9T0155VUTV#^C_`,HEN:)@1FOQD]Y4VO+YY6M<L[6Z*C7-@2CZ
M](V?848KL;+;-(UKU//IRE%@C^4-GKU"/19Z[?;)),%7@-FY<GA@3]3?R.S[
MDFD1M&S/ACK[HT#RFO#^8=.D.58I012C+'_09A#:VC!<%FT.HX9-V9DH1>BA
M,@'.0&XT?(U7*(XH^&:://!3W_">6Y_T/_RM_P"@O&?^^SX.MR7Y:YQ#TPJL
ME^)7Y4A"<BD@:(!-G,#XYVP0DLA<9:!1*/X/:BN<."#G&4D=E/N(XV_\XKIC
M]O@[)_PGEN?]#_\`*W_H+QG_`+[/@R%3_P`B!VR;?K>HY[P'W?S/_&J7D,<B
M5B]`13G0973B41VOYE9BD:<O:SZ6M"4(E2<4@,I=B_PXHLQ45&;I/'K+7?13
M(;(_`\#P/!_F<8VQG7;&,Z[8SC.,X^W&<9Q]F<9Q_P"O&<?LSCP:T[U"Q+DQ
MA#]Z8@5>);J2.;W>95M9>=V$Y^Y6$4^G6B]9/S,YT?021D(_*RD>@61ZY"&P
M`.N<2$UX_9/'`_8-E>N?O:Z[?9]GWM<9^S/^7'VX^W[,_P#]O!&G8DRL>%M*
M?+U_`(O+4`UAO)9,I3(XO$9TM4\2CD/D.A>?@8;(;^Y_-DRC=H57"KD829F$
MB#!BY1=&#2'"^K%8+(05T71163VQNFLDFKIOC7;3&^BFF-]=L:;_`.'KC;&<
M9QKM_A:_;]FW[<9\$+=36?845LBIHA'(I3R2IQ?<K6=FVBT-RUO`[,5E<%JU
MY(7,1#DH8LDP0@EP2H`RV'ST08D1:0(@\/@HM9[N5"HJ7G;NT:>JJRW[!N*?
M6#7,*FSP8T456:#W<IC8TVX9M%EL866:MEGNZ3957&%5$---U,8VVSX).ZTL
MZ[XQ,HO':HIBOK(D[...)_4;N0.8V7D["P&D_K*II6:#QR;V70T2T_(:DNNP
M%63'^.>,R&9NMEXR/?"T7VZ1H*[J>6K3JM81+G;QN_?G8X->%730`M%FVYG\
M#5$SHC'%Y+--PB:!1)VA@;K,98BU_"_";R4ZWU2*.@A+J2X+G`7C6\.KS7G2
M2M4YQ$V@XE/:\F\D(\WR*:ARD.&6U,Y2-LR*!'3V5,9-):[B-5!FD2EQYA)G
M9O6?:@4S(S8+DIB=.K1I^JK+?#T!3VPJYA,W>#&JJB[4>ZE4;&G'#)JLMC59
M9LU5?;HMU5==5%$=--]\8VVSCP0WU;;72H&SA(.@X33=W&8L3C14/#EX8V)S
M^GR,F1Q#7ME$YA/.BZ'K-^;+1"73H)%J@;2*#3.3@G!4D/FSL=L1"JA>56RO
M,YKF$R]1\W).)!&Q1)X]:`W$9;+D%FJ?YCLA'G1^5KA4]7VKA/4;O*))JTQI
M^"F?,)::$7(0'U?>%QP._J3A(050JP&>3G2,T[8MA0LK+$Z?NA6'DD"A22+!
M;AC!UT9.U1(;)#BHZPBT!')BC#!):X"CR6J0K4+RIV=+VC4E766Y&Z!W-A5Y
M#)NX$I+;N4AB\JC@XXJ/2<J)HJ.$F:C[9NDONDENLFGJILGIMMG7`07UW<?1
M\)M:#A*MJVJ;9W>F4<4OEX!AQ:5P:U]&+,','V7DYZ?HX:4E>]'3:V7["%);
MUJFYCFFK)I;)TI+MX4F%_P!72O,YKJ$R_9^W)K2&-"2;M^T!N8RU<OEVB>7^
MZ$>=GI2X"I8>X7TT&J2>1X9XU_!T/%T]-"#@->73/<#Z(='1#FNN6U;L)X\W
M3T&S*X(E,BP6.31\U$N-R(9@-*0Q(P)0KV0G`RY,7-!.[Z2R)O&4"6N&4@8.
M0V%U5,U;'K"N;"7'ZB5YU!8E,%A::VSE,:K)0#`RHQ3<;IH[N$VF[W*&BVZ2
M6RNJ>%-D],[9UP&M#JWN2QX1U#">>Z#@$8DLN8QZ5G+"E<IAPV0R&&0X/'Q,
MQE9B$Q:87ES2TGD?:CU8FC(]8;9!0QJ]<*KM8R=7AA`8H&UP02:F1(LNQ<:/
M&14<R),W::"S71TU?-DG3=QHV<_\8;Z+I*Z*ZH./\<EC;":O^'KMX/Q/1\'*
M!;@'(Q`XZ&>;M5'0LJT0?,'.[)V@_9[+M7&BB*N6SUJV=HYWTS^&X025U^S?
M37.`U\6J4!\WV3S=4%/,ZYJV'O96-*Q^JA\,CVNUI&)?:<)K^=H0_P"\RV)A
MBE;5Y.Y;8Q=]$ON%,#M=53JR$)''$EPV/>"#NJ+2F4#N[ET4.E,4"08N>D3N
M4`U"M=XL^6'OS6%1V.,J[BLYCI@M)&3,%(IO^FG\7;\--!XI^U5;.MF"CW38
M+Q\&NKL>XK%K&>P4;^GU<U761Z/NWZEH2&+CC1:IS#.RZ>A!2R'QB7.=H>,:
M;1RSS,,%MGHG5BP='MS9TT]8JX!-@L6D)8?GE,5).)6T382B95G!93(V*35P
MP2:'3\7%E2S=)B\UT=LDTGSM?1-HZTU<-M,816UPIIMCP1EVS;5VUN;8-X/+
MJ=A01:`OI0"DE@/8[&'46.!+:I*&RR4+6%830W`X\Z7KBSYG&XH,(Q==FN;>
MI;F3BS0IJ+'A:U02=69U;7\J<.2CQR=B80@Z>FFPMH4>NEF*7U+QVB$;,POW
MW:^%'&BH9JW$N$E-'`U%-DJAK@-7G6_5CR&=(B:TBO6M109N$-11"UF,R`U;
MEYS.%EH5!J$G@1U+G2QN03^48*OA3]5XCM!H?`9DBZD[,4Z(1Y67AL_IB52"
M=4_54VE@W4-*9A7,)D\D$Z-7;'08=/1H:4+,-&1#31^SU:/W2Z&K1[IJ[;ZZ
M81<ZX6TWQX-7?8?44OB]TGH#3_3]#L97!THJ2F$"LTK3<`UI0><6CS+:01Z:
M6"WD!$C:LAB!J8[):OP[R$`XN<'M9.Q!+G`;V3AM)J&3*S.KH!*G#@J\<'8F
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M#M_OX48I)M=TM<!K$Z][(ED$Z%CM/(D"-&P]JVW4VO>?4;)B</`FMT8]LZGD
M<M251=:EQPK\IE3NIDM2<CT)N)+)BS)VU;)[`$9$&SJIY(<F56UM+Y.-P&DD
MI@40D4@$8;NV>!9LU'QY(J/U:/\`31\UU9OG*[?5L]TU=H83PDXUPMIOCP:Q
M.R.M[3B5RN*J@R+.L&T8CS8Z-LZVX._AL,7)ZR"O&<HED'OFQH(?H@6NU@<[
MDL!"CRY!8D4ECXN.(M6+'8/D^&T&L9`I*ZX@DF56).5C\1CQ99R8;,&A1PL_
M%M7*K@@V$H-A2+I=1395;48W0'_?WSEDBFVREI@.\^#ILWKN"64,9!K`B,>F
M0H<7'GV`^1BVA9HS-BE,JCBC9%VDKHB]:;[;_A+Z8QOC511/.<IJ;Z[!,G.5
MIGIM;G0D<(E(^1;@9.JN]$AA`<<1@I=A))/!!<>DSH9CZXH5.P.$P^7-G,F4
M5,ZC"C3#'?6-;`VC(+-\$;\<V#)9V&MO26'X[(BP6WYBGJO"'4,*0L6/(E';
ML<!8%X<!`J+R0>UUT5FPZ6)D9@+/O%<&2:VSI%%N%$6N5E`*L;"-PE8,VEP>
M&20I&W,B:NWX-L88"';MBY*L&+EF[?LD%TM5EF+=ZR4>:Z?38>M/Q<N4@DGC
M&_9[=!&=HS.3@Y&N,&`B;X.&%#1BE9''9F4ALPHEA@HL\4<E`(()-DL'E=R?
MX<@V=,]OR%X)0;!1G14KFT&I2P9?7CD"SET>#:$QCJ2L'140@BW?L]BBBPYF
M[8+/'.!/UWY<AL\;M]B.6F7:F&N%L9#$O,M@R633SH6)'SL=),X58+A&,!(4
MYASV,P^.$"!K+`*0S'`0DX'G;K5IDS+P$P=%"2+@BV+#W"8DNTTR'(=?6Y_%
M'"H>\97!%*GDLIGX>,Q)M*DHEHSL4ZX;/7:<&4+35\T"@!;IFT=E9`63QDRF
M'%N6H!PV,.F6%PX/BJUI!:$)E'YN:CT@9Q@R&&#E8P'$!!4/</(P*(FJCPQ!
M8_+TW54D5]XPKJK]TLW2U;LS&F7S51PX#C.F)U&JE+U9!XY.ZNKLI;DSE3IY
M4TC#0(4&O!N^7'NK*<'B4A_"V^S1@7=NBFH!B^ETNDYP*US^9)+/6#T.V\<S
M:16[0L/D]FGP=BS@:8(Z&)<'6A4@ASN2LL[86?UU(86&#QXM'1FA%<(,,,V"
M15NHV)!R[QZ49$';D,7_`"$]`3SG>O8G,:YGL8CQ]23-&+J('!04J^E4?(O&
M`L^?&,"3E$N;1K<8_<3`I'HEJW-.6;/8L\()@`Q9@2"A:+.IW+0X5[-G@"S1
M<E1EP!\:7%@WD:LJ+CI0?C0R3*BF2"D:>"9Q'1[([NW'MU`+IN5S]"GL/41U
M\$N=22ES0&L)@=&DJ2@8PI&++>ITR3`0&,QW\V2BTC-1BTG3'=C];I&XA8(V
M.OI.3!B]1D>9[$#<K^O3<#OH0KSG>7OY[2M?2PH;<R4D6#*9?R)RK&7.#KMD
M0>CG!AD^A@T/%"@<DJSV>`C,>%L!)H*LP*LVR2+S77P13V%U',:YO.(5`/T5
M@D+>UFYG!FY995A<S"(J:Q9U>1O23C9\=#;U@/(5Q'2Y8B29FS/XC5])XX0>
ML5&#-5-P%[4])S$UJJNY=($DTC<DAL>-%-44<MT-WI`8W<KN$&^?M_`1=;J9
M<I(XSMJDFKKIKMMKKC;(:W^H.J;.`W-8-<1O=G6XJL1%5R,)-K"B&L4:D%CY
M=V.FQ^K[.LR%&:ID$@)QP\O7<;C0]P^-.C#:5L-]$=R+)-0-JP9[^9!Q1'&C
MQ/Z\:Q>_AD&^K1_I]4U27^X^::8QJU>:_B?8Y;ZXQJBMC=/&/LUQX.2\#P/`
M\'5)1!(/.-@&TUAL4F&T3D`^6Q;:41T1(-HU*A&VVXJ3`,EF;O(:0#-]]]AY
MH=],29;;[;-G*>=LYR':_!TZ8UW7UB(AFU@06'3IO'#C&3QY"8Q@))T0,E%[
M;;C)"&2-L7V@LX.VWVV8EF.J#]IMMMENX3SG.<AW'P2-T[8]7QM45"K3YZ.7
MI$I)"Y<<FSQ&,5!+(=!JXCLB@"4E)SL)9DWCAHR!W+$XP86"P:+SPFX_1K\P
M7"8<BA7XX=O;=1\^,_SL9B;MPFD/1?INF9**RZ.(Y&@F1IPH]C*12.CTI/']
MVT6DK<(9B.#`0XZB\C&`'A!]'RS5D'RR>:<VVW3Q"P9C'!%H581;*Q9X/D=.
MR.;D#K4K(@C?$:0K$E"BDSD*)^0,(T_'A643?ZR+Z:/'AS5^RU%D/!B&-=]<
MVZS<W58,780F,0>*AW@:?#:ID&U1'T',=J(P!A5</(\R?%#TF="[KK4?'HD(
MB^KHN4.,8W'4"!AP.'/`Y)I'^$.BF5CWJQH^H;N?,$B$5GDV7YO:3&:252/C
M&6Y"&Z.3-?+RB=/!2"3(,[CHW\YW&%6GZ-O&S4J-7'M0Z#0_>32\KE"5K#H'
M$HM`%HR&/Z$CUA93L$>-D55!+&B0(C7H2&/8C&I2HR?%,/88I9Q`R.CL=(2!
M5LW304')AQYZ>?&C9TZG,CGM44M)I:Y?@81(K"L#G409*3@>5#,WS1[L>-0=
M_)#M7C@Z8?9U89E-&KT1KD&[:29P)=CW>X48TZPYZ&@XTZ$R!9"(DA,AUCBP
MN(2!MHHG#Y56\!;`X]"TQ"$T-+'CEI09C`T8E$BXV4-#`IP!=.&AF.[EPZ2)
MDO"/3$JDV<12F[2E!NODLRLS-*=:NE)%78`B*(N@9243B%MV<A%PD\\#YD\1
M4*/EH#)MVC.3"`9U/5#0.=&]KT0Y*@8XV5FZ9$K`%Y]H/95Q+2R@T2@E`5&,
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MKKKKC&,:ZZXQC&,8QC&,8QC&/L\'0YU5-76@D,0LRMH#8B`5Z@2#HSJ'1Z6I
M"2+5RW>M7XQ,^.(:,'K9XT:NT'37"2Z+ELW734U513WU#OV,8QC&,8^S&/V8
MQC]F,8Q_DQC'@>#\MT$%%$E5$4E%4,[;(*;IZ;*([;Z_<WREOMC.R>=]/\';
M.F<9VU_P<_;C]G@_7P?BHW;K*(JJH(JJM]MMVZBB6FZB&^V/N[;([[:YV2VV
MU_9MMIG7.<?LSG[/!^W@CVT^CI)!K6*P_%4`)-6$-%TT\L^<KV"L.F(%&])Q
M*('&5HQ6BU?$`DP#@C472)31<A9T2)L03E1Y'@<I*,$0[X/T7[CY\&G)Y'#Q
MN1Q4C6SR1,Y3I)8>>#I,DHW%IA,E'^NSAIC.!YF/5_-'T857T;JR+2./L"T%
M\*,LN@_6+=B4W8E,RJ[P8&RBL%B[QD.?-G-82/0Z2U);"]F[D6#=,\*.QFF"
M31<J]6W;MH]HW=J2/83^7NOP0GEW\I-0CKP4K92%3!6J]^:(GT4!O`>S?N@T
MF0FYJ&"8C#`493":;N'A[].X\S'O]CR:^)*NI'G8-IHGDKX*.J;J2G>@X5/K
M)J6,3*P!$(QA@]W;P/=@0D\@3%Z$7T-BZDDW$M#$B"[[MQ!YFN_9L@AE70<2
M?-MT7.R`8*JGL"Z[8Z!IL"WI&21#G6R>:P-ZN[+?0";&P(X[*8>`D;"NWUML
MMFL#&R05N7?9<L,AUQQ!D(QLWE*)M]B,(!RP/Y!:`D4BE#4E#IX-&,"L09!I
M(1K>0+JR:*2J-#9+FRW0W8'H_!5<,9EPGXTO*;[#MT2K!=3#7;91NB'8D_D)
MHI=\_0&MIN_&C-C8Y+Z&"3%T=DAT99-9U0,&04(QCSIE)VY:86<#$Y4U.CR@
MYPJRW4!K#7;DD,#OT,ZVH:RY3&8W'<GR3J:0QA*F)Q[!#3:.HMG4-;V-B+'S
M[UCHT"R\?$'3`^2B9;=N1'(/6FJZ.CK?9'0,/G?D9KB.[U=HZKNSRN+%9LC3
MQ>*1.0R9C$H_(X-)[&A.Q,B/!_0+20_$`0\R2CV7+-"+#C&Y(N:P,%K/5P[D
MIW%SV<B@>9QA1U+69]K%S"B.\??,7R5>'`$*F3N=KX>C5-5(N`C<\`O'3Q91
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M@V'D7@WB#0R32W(;+S\NP5_1X.\*_EV7^6C_`.BP]^E^GR[^A>?3X4RK]*X^
MY^%N$P,^P14&7TCM\U\M6\^5L",0,@WK=U(;9KKZV<L`#J!%$;'=0"M72J,A
MVD#2/IL#$-"FTY$+/M!XXJ"#YD2X=\@W75+6;8H2K8:]DAX]((KK+VKUO$S&
MT80#*`Q4@2R2D&6_Y<R<JLC#=#+==3'X!1-40[V;DMVK9R$\]#_(]7M"S(K7
MP2J;%GT]"KR0E+0C2/F(SAK%XS7$[GJ\N'OE8^6V.L2&($\!"5U&P\>]46V)
MIEORMLDJ\#+,5[?YVLN=LZQCSB22&7.IT[A`\7B$%'*3@B*UE>"\B;.MT-VN
MD3#+PB5M'TF5419Z+"?O-\KMR(E=^&)^@NN[IA4PD-<T=SC.I&5`R#6/D)/O
M7IZ<"5%Y)`Y`>C4VP!@95N1%P!&5BDP)N0R%VT-D7"2R,9B9IHZ3-M0RA;_8
M];4L9K*-SV,3.02&4+Q8>3(1NO9.3&1@_+HU*#$;!J*8$.EFLSEQ*)N1<<A#
MC9F=6V=M%7NS3[S71Z'U`>V*7D*1AK$4)'HM&"]2!I`C((?*8J."$[;LJ/UJ
MSCSMSI'R>S:8ASDAT1(1QPR;XT));M7Y(8P0,F@P<7%^].?IX=C\>&"[25)&
M"$.;H_FE/S-JW!#[,;B-JXE,A<N17X<>B]@Z'6K>,FG^44GBB1)%UHT_+7WX
M(<G9/9L%JXD>!8A,ZE"T>L".5]^'!HR6DR">2;^N11<\1TCHLGN!!A"UD#HX
MRR\2^I/R<2:$,&Z2+!8AH'Y#.W:.EX-0G%F\A-R?_P`-#1$))1MX)DY,V)W+
MI&XR@DY;N=$2#!N%</CFGW]VP@4NR(F5&C);99(*YCQ80?`!#P!=%T"-B!I<
M*Y;:XT;N1)-FB]'.$-,8UQJBLT7153UQKC[--L8^S'^3P<FJ@BOKG1=%);3;
M39/;55/137;3?[/OZ9UWQG&=-_NZ_>USC[-ONX^W&?LQX/TQC&N,:ZXQC&,8
MQC&,?9C&,?LQC&,?LQC&/V8QC_)X/R6;-W&,ZKH(KZY^[]N%DM%,9^YM]_3[
M<;Z[8_P-\8WU_P#]=L?>Q]F?V^#]O`\#P/`\#P/`\#P3G=7/>+F/QTHK8\NA
M@AE%Y5!9C&XX/BCAI/X7,2L2*F0),D=`E3(+\3>(MFJ9*+OA!'5H0?Z9<94R
MV40"5$OC?C(J;J2IK,2DLWD]R5[9LO*R_0$QD(YA5[^R#<:'CGD;B;5]/"CU
M2PGT))D[`-KKI0/Z=EHX>:"&8MR&:$N,@+;G$QSFTLF8MA!N4[2AY(40T#0T
M5PM)6<A(1A2!-(LVK7>$G-6B@^21#6)I@9!H4-O2C)=Z8?JK!B+'QB5#K7#*
ML_TRE;L(Q&A1VB9B/UP=&N-8U!N>X6`^MC):'.XR[:#]^;("<W%K"MASMVY/
M,5F_Y6[:-&(5%R]S7"N4JK3J6`N5G(#632B6[;;@HC&4-"TP**&36H^/P:/Q
MB+B&"A)=RX09"PS5)+*^_P!_*N^=E-@RC`H")@%;0ZL&#AZ1!PV%@8,S=$MT
M?S!\+`!&H)!=]NT1:H?6.6K77=SLV0;I?C;[Y122U^[KJ$6?\'R$4V<Y>7M;
MCS5VFG&%]-FE<-]=ZEU!BHZK5/VM(0AM@4Y&!!>JTI^W]-/J&ZJZ1U++E;7(
M=EA?"$$B&\27VGDV+NH?*Y/+&&=V4*!#5'4GM.C+6=-$X]&(L&CXAI^>4)&\
M/-0`P5DP\D<UDA7ZF2GMRJ(=3H+C"45+9EAX+2QN0HAS&K!CE=PW!I`L?RK<
M,@$2VRCAQ5K7,+WCJST\/>JLQ>DDL'3?!95=L3!)-=1JX?AO\?\`N8"(C3U[
M3]HGF#XC#F.`A$$7ABADBC6#.9GW(\_$B)60"Y\SJH0UDD&E)4S$%V$@E8G<
M:X'DDTT`_P!K/@D76C=P`$EF&L<&0?G>J(ZXWVQDF\A-,&F9V1GB@H6"`1T%
M+9PV$Q.%*LH\UV%,H]`8P0U>96^\&9!L9\#P/`\#P/`\#P/`\$X3CF*%6!:*
M%GFI-83;*K>O6\D@0B1,Q]?3C^*F1G9?7RDN%ZAE#;[6.260/2NK)A(1@LQN
MFU9R%@7&)J,E@GYW\;]/Z&RQ`.6*?E<TN&`VM8@>3,FQK<JA6TAE\SC<4BQ(
M$O#UP35>4S`AB0&)6C8A(_$5R,0??:W>-"`L.^[<(4QO!K0@RA2>+I6Q,8K-
MY))'I6/DI,F7A!=N:BNB:Y*+.PYM$8[0VU<.9J%E9<^DY7S)BAIQ^`N@'5'?
MQL<VNA4=$Y2FZ:47I>+40+7_`$B9.E/T*@SN,%H:NZ;$`CT8Z.1V0PR+R-F]
M5'Y:.B8=)`J/(AG1`2\"FJ.HJ"\^0G>!P#!K8,N46-NUSY38L2>%G8\:/>O5
MG/X+9)/9WH+;K;MFK=LR06W5U9-6K7\)LD'<()`8Y75>0^KXZW7Q$H/#P,%!
MM2#C9ZY_1Z.!FH$<@]=;XUV=K?ES1%-POOKKLOO]]3;&,[9QX)$9?'=1#'??
M=,W;2V-R87[VCJP73C3,&CX87'AE1;YW8?B*UDD$`@!S@2MNH<?Z!FCI_(G)
M!P2=OPY()P!0@6QB=K;[SHU-B94.2W+FY,DY610CUHP*X`8I15J+9NC#4;-:
MY`.="4D<FY,[&J/Q1$^\9J-$V0<3".'!\`OF.63'[$<M*HB<"5C`FET@)+.Y
M*5N8@VK]S/99-'<T>L3C_P#0EFTC[8>R@@/\%NQ8++D7:Z*^[H.M2;XT*6G@
M.""9O++)=JUZVAJ8/]'#R`,"X)UH*>1:N)2:BA9G*0QZ31N$+-(P]R93?Q>1
MZ,L/BL5V4W20;!R\:^/R`Q1CD")D.=(X.INH>>(RDJ!WWD#.FJTD>TE,`)":
MU/Z#3TAFRRJHAS)!<<BZ`J/I#QV`111CAVL&P'P/`\#P/`\#P/`\#P=5G,/$
M6%"Y;`S^7FH.9QLU%C&P]QAH_P!1AX<X&/MF3K*:N&[K5LY4RW7RDIA)7&F^
M4]\:_=R$B'.`ZEDSV)'I++K0E$SBTM8S1>:R4U&BQR6EPQ&%DXVC)T]HB@*;
M#XVM7L2;B-82.AA-%B/>-]RN^YPZL2#L=4\:0&MSM<S1P5)$YE7Q"TY`W3#)
MJQZ`+RFW3<G*R0P,A3]_*'P%$:PEA**1P>WECO5M$VD?%''$@4BL9=B`ZF2^
M.V@"]A6%99!Q/5Y'8XZ9BB?W3XM!N*93P#-X^?3$.&\>2,+[8:V'*%Q:DC*R
M#<0X=MDAV6XYBU8)!W:L>*Z8J>P-[)C&)0I(-),;E8Y!^3&ZB1!&2#Y8P.)-
M&(D*)R\;/]YM(7OWSBY=^S579L1SYF#%C!+0*0&P\,*E4GF331Q@W+F4=8&=
MU%]MVV[>+IDTQ6&[?.,:H;Z:EGGX^VN<_C9RGG/V?<Q]H3Q=O'57WS+!4PEA
MZR@A$.Y`F&K.$S)6."%)A#T)"W@T\=L-&+K5U+(4G*37Y&Y54R+7RJRP?$F]
M0P74>'"@^&*5"%G!K9[8!M\X0@N,J2"7;D]DG\'M",7)^;H+;,$G2;R66-$`
MDEEC3#C(1P_P67"B02TBD*I0.@'>!A6+<JN>U]9)"`Q"',:M&6##=!)XT;M,
M71Z(-.IP[J6:SX.#!"8VJ!1<OTG%?R0@95(&,?F;!-_C1$.[VAP[6EOOIKF6
M2BP1@&<2C22%P$%D:L-3()[MX(Z>1\Z18Z.'Q8&K,:^#SIJDAN+>M#;TZQW?
M.X^:("%PZI#N`8/7+\:O!Y8\9I`HI<;&/DC4;$/I8+G5TM0`B03C0D!5BD4R
MB*CX#1@$C[:"LE$7A4V0='721-P/V"Y8^"&1<"$C01MJS#1T0-!"6>NVVVK4
M8)9HL&#;7;?.=MM4&K=)+&VV<[9QK]N<YS]N?!R_@>!X'@UG<\<G\LVT$MR=
M6KS50%F3<IU7UVU)S&P:;KJ9RHBU"]*6>%#MG\AD<<)%WB`D,/8"1B+AXHFP
M&,FC!KJDU;(I:!BV]S_P4<Q2Z$P/H"/_`!KU/+[$6RE$@,PK*@ASU^GJ\V'Y
M(/?LBRJ($-A^FLQ_/9`J*#?6(.6OU_X[9?1,+%4X4X/U8*$4>+.3WK?5IL]2
M^@YPIYVH[1PCE?3Z+5&'[?5;KZ?9]-JEG/XVV^F-,Y^]C/@GX+6WQ/&@4,E.
M.9^.@L8FM0N+S:R.4<[4S&`4>KEJY!,7):;%3<39,H:X;D3[88X'GUF3EN28
MF6*^B;D2]32#I^K/X;<60*KIU3'Q^#TY1!(=.X%.R%?\L-:^LI";2^90D7':
M[D2B.-9A)T#<))IO!@9LZTUU<L$F[ER[4<-FP?K90/XC:G@<NF4PYRX40,1B
M.V[)QU9#Z]Y,)67.AU+/94/EZ,%CK579,\31=P\RR5&:OD'@(JW<`Y8G'S0T
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MJ2`P:0+!GO*?3[AX)5,QB/BR*@QVX9,UW+#=SEJNLT:JJI;[MTMM`V2^!X'@
M>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@
M>"3>-_Y.K-_>R[-_O3VWX//W\B'\$ZY"[9O^,7=5=J%.01F6;5E:%;5S60:4
M1V=*(EG1%W((XL]ED<3@4L,(O7*!<JH,EPUZZT:E-P6'>K[\Q#TC\X\[U;RG
M3,)H2F!1@-7,`8+L0#$_+)1-B^/K7KDF0</9',2YPX\5>$GCMUA!1_\`0#]%
MM1XAF.%-F;!N$:N_C9%O(WT>`WN*1)YN"S8U/*K7&CI%%<40`B-M/K_$5T*?
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MJGMMKC&^N<ASW@>#C7)D0R(#!#PJ-:%C?UOY,,<OFJ!`O^6H8=$/RQDJKHY?
M_0-MM7#WZ5)7Z5#;"J_W$\XV\')>!X'@>!X'@>!X'@>"3>E/Y2N'_P![)]_=
M-ZH\%9>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'
M@>!X'@>!X'@>"3>-_P"3JS?WLNS?[T]M^#QT_*K\/W\(=NKL::3[F[L*U;6J
M4E'HF@`DZ70D9Y9306;#<ZO@&E35B;AT7::`5]_R_20X#8*R31+!(L[=NU-U
M?!['>)ZRO&G^2:)K/HJURUQWE%*U`C)_8)T;&F1)Q(?HM5=@KC:*MFH@[I#$
MU4(DA*E-5B\Q;@TI/(7CXZ7(O%PU@ROE;23\]R.IE^,GB_7Q((*`VCTS(*ZK
MR5@[5*[6#$W<]EIFPG\K926QX58;=HXDS:LS"B2(H'AO$G(>.(Q]!)@'9J1J
MBS^5>@:\>%.>9J7C,2#]:QHZ6YY@L='TON0MJ4\MR6ORU3U<RD++>L(46C<"
M-_I5$]4G>1%JBY\2<%9#I(V<F.!GVK*<E(2];GL29U',<U%+Q=S:4W#V[P8L
M6JG<@10S;*@T((<L78(AT^6;*3>,KC33LB._#7'O'$<<R%5G@(Y:<_6,=Y9Y
MFB\VY@LF7,J_I3JJLVM62D!&#,D@=\3200U[15NKIR&1O46J8`,.ES$;9+4J
MZ.Q!X<4=I[H[D'CG0+TA,-F,>[Y%2<C7MCO&#[C\)7LTM[=)1S7!2Q0\E#F\
M-6RCD^IABZ6%-'6BS@;'F:#LA^&W>K+KX35P'`5S2>P3O^?W1#ZGEXE*<ZS3
M>XYO:%74,V8ZOA<9KR$0!S1MMQJ-)7>4%2@=#M7IJ+2J;R*,,F&SA94+%#.&
MP]0)G1J3OEF<<2Y*7]%.B6#S^8)`'MI87BFYAGVLJ-#B,QW\YT'ZQ7;E)\\W
M7B*>$XX_&ZM"Q,>YFXT:^:!BB+W7;L^M^6U)&IY9TRLV00FU*0Z";?QDMIM4
M$0NV;WA!8W%7L(C\;F)X%6+.&4J/NZ7@1.HF%R(C&(<4W-LRLI$%U6H9+:0/
MJ?G&.]9D<:&*_I]I+;@EE3NHI((U%V$6KM.914E9LKF!"1'605M-3E0CBR//
M1LBNSBD0.C'V9,B-($&9'(9&I*:V_9G'_0TMI`[><MC);HT2G2I<Q.\3FV3'
M.C(Q3S6U]*UL&0RR1)%C*H=*XF4*+:3%^J/DNOT(PBQ+#4$6(=<JFD6'6%<1
M&,VQ2CVQ&T>ZQOQBYL#J&.!K"M>LJ(K.UGY(!7[.9SE>4S9G(IH\:Q:--<L#
M*[A.):2DBN:;$!8_1R&1X?7-Z&N\(#/K`BMV/L0.=]4I/Y>2D.^.>A-4RL2B
M,H=C7<4UEBHM*0NHL@)9R\FWB*$AVEB4CP9([,%AWXH41RZQZ#:V;:RMPZV-
M^@"V'6:"2E)AD_V%P+]*BWUHZR=&KM99[:*I'";X$3<[$<(54M%Q2S].2M);
ML_#^N*`!>+ONI!CVM+'KH(7Z4E,RANU@HJ_;)(T?BT08X+`WKH^??N&.QL$9
MSJW>K-MF355CHW;(M%6Z287/X'@>!X'@>!X'@DWI3^4KA_\`>R??W3>J/!67
M@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'
M@>!X'@DWC?\`DZLW][+LW^]/;?@T`_.Y_"`)Q\7'0'-M'0NM199Z6FD<M6UE
M]Y.$+/Y/SNW7?@RD>9B,,]UX6>E)G!/8._(.,N]=8EE?'T[`EINX#>/<G3<@
M2^/:P>LZVP."'-^>B]OP19ANVL@>UPYCFYV-OVJ;!FFA*?Q&:K1ZD.18_?=+
M*8'[-MUL;)9"0;"[8OFG*=R_,$"Q63'K)*%*BD%G4H?@$^L.G*VK8785A(2"
MHF0044BQ.23I-Q1\+/%(Y%L_=E829K"56S%)\9#HA[OB^W]TW<_@DEV_B7#$
MY.A4Q>0PZME*GDH(9Q)!>A6(P)*A,C6MEQ<:LJF"1U@$E4?$P8W!&,C;"WY`
ML"711"P.6;;Z!LFC;"FDJD4P?C%ZABLLK^S+`I3^)R5HV$9@Y8Q-1`RNS@$!
MK(8'$7FD6?Q67D8TU9R5P9-BTGDA8AM".P8(K+Y`;T_0&`%95`X3,@PJ)\/)
M6S8JDM=Q>8%93V2I&PS4G#JY$0)Y%M&,,/29HY?,R$M%X?"--\,]OK$\Z+!C
M6!_()T`-HKG$=;D>#N9Y:],\]V.#LB%S9'8F>;6"<90PX3G<?(U:Q`ARN2CU
MD?5CL6P\&/6KAR-0.AMVZ:RH=>6^1[I&-<^5\QE,6BKJ]'=$57:(B81R:J%(
MY(MK)YGZ4L,._L<(O5X[Z$UK**%<O2\+CB+0>X0-BWPB2[,F#T6Z"O4^X+DB
MNT'%3JKZU?O&,"YLF=ME(U84FSE5KTU9!6LH7M5`E[73;:7/1+X,L9E[(JXC
M:#!-XV&A71=7.JVP4ESM<]L=`<YH7(]C=?U@8FX)^=K=FB4D%GCQP[""Z(Y]
M-A^657KN76Q!JLNX!`CJ">X_9!/60MW>ROX(<MRC<9>V>9><;#GQB._QG6O1
M,-L@N/':MQ&A0F_BP$E)R(&/*/73Q,,Q)FVFBJ:2SU,9H0'MW+O;=PCNJ&L^
MF^Q>SK:)\FP`YH,@F;(EAUM9]QLJUUP&ED6LV@;CM:C4JI2/+D(S^D\+*0%\
M/LS3;!Q!):*"]GHX:VL!HW:!V>K;9ZRF4EIR,G>JTPC6>0_LV<R"4/*?J?1J
M'2YJN&`UI&6:Z.1+)JG'R(J3$3DN<;.FQ+9RAIJ,+!FFF=?!LVYGM$U=E!5-
M;$A&#Q!J>PL3(B#01J]U"J+/$]OND@>I+;<AJ",I:)F`FKU19U@4^9X7774^
M\KN&<O`\#P/`\#P/`\#P/!)O2G\I7#_[V3[^Z;U1X*R\#P/`\#P/`\#P/`\#
MP/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\$F\;_R=6;^]
MEV;_`'I[;\$T=PSSXR:DN?G$)V/25"S*V>L+`:T_7$EGE'UI8)S+MBU108.Y
M;(Y0&>%Q$,:%28")M"2BKIHU/R@$-T023>*+(AL&=16IX-6+N*/8W7D/IJ+Q
M=TS?QIT'C<?K*/0H:S45>M7895LTBHF+CV"2RCI!9LW$M6B:FZNJ:.NV<!.#
MSM+D]%05)7KZ89+O'+2%P[93FR_5IE+6LI&&Y0BWK0+BI=Y;/H>5#P(P?=G8
M$//0_+&/ID7Q/1'5BJH'98<<X]LF%R@=!@52S*"@Q4*L^3@`%=#BP75L\CB3
MZ"R16-MHTJF3-H1Z+MFP9)J.>2$3H!9AM&S-T/;,D@Y&8=`\H!*LF#^=3^K&
M%*1RLHX=F3N28':U>UK:>#'C:+BB*K]IF*O$I4':J-Q4&TRY,E!KL:BB`5;&
MA.KX.&5DW'=92.)T4WC=:Q5Y)$ZZU!Q./U/E&%#=FY);>FV,@,`(AO`8*0<F
MQ2R=0B9>5CY`J<89;0-H[)H82U#N$&5Y=M=S)0=>,*8GJE$2!K4$B9QL'$SC
M2LI%&F(64-Z[PHS8KL@3V,-RP4AO'6"B?Z.OEDD%FS$FV501#GH=0_/-<AUP
M=>TO34&`##B\D<!857$*C8IC)E`:PQP=4%@0S-J@?5C9-P.4)90U)*!2*K/9
M;9B\W24"7JOL'XYI%%6EA5W"Z>C\<H&($;7B1A_SP\K%U!X%)</R!"RJE82V
MMXJ9=1&5+LW^?TQK!D_#28IKNS1(D":VB"@9"EO0O'(`<&I63/(PXA,TK^*&
MOT;:U1)Y-3+6L+0)D8[$'\\-A825J>#0J:$V106-WL$M'@Y-5L\1^S?717[`
MXKGJ3<5&9UF.<[`H[%#U=Q>PX4#CL;JF75-#=(L/L0>SM+2M1Y*'1&!S$:PL
M<0'8S4]76#S=J:T#MS!!/9Z/U<!E.NK5YQGT7"EX8]B;.,0.:RB&19.0Q!Y7
M2<:FL%=E:^E(Z(!YR!B[QF[`O')R'.WT>8X:Z;KEP:3O?7=ZWR&.WB7&-Y@3
MNYFJ*=M#2B)?:3-O$I56,#/G(O*X=)';2?DX?'9.-448*DI*/55WD`W1B@=?
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MJDNIC7.?!U1WT75H^U&-,$EYX,G)54F@)R3INXQT),+AHT\EY1`/:CV!(5:6
M69QX>^?JICIDYW^^U78Z:[$$]FF`Z&R[9YR>P@/9&\JF(B$2$HQ&`3\HI:\(
M>V-)OP:LGTD0I"55R&>D(&SC:"\@,V.U;*P``$06*G)*.8I*+ZA1,;ET<F"1
M=>-%42[<$?*Q<FY:IN/I43P-75L8'HN544T'NXUWG9B\68J.6R!!!V/46P]9
MNT$0QE:71555(!''9#(-"WYS.@M:A@T2V:R(Z4G!U1;Z6/-F#1WKA-\W:-'Y
M0CJ\7:Z#Q8Y\\<[::(?9L'"33KCFZN6USNYW;L5BJ?/`V*F+I3+K/$'-?CIN
MR2?Q-R7:Z-%'#C0\W63P/_*4R.5W.<L\8^KQE#`8_-=^\PQTU,8\;D5GC2T!
M?Q\5*V[CFOI?"0PG+S;6.0P>F]UJ'9B3>S<V]:#X.U$N7ZTS6<)[1C0LEM^)
MX**K.U8%<$=5E%>GOSL:T*/`)9LZ%F8[(8W(1VJ&Y"-RZ(R<<&E<.DK!)TT<
M/([*0H@VU;/&3I=AHW>-E50P?TI_*5P_^]D^_NF]4>"LO`\#P/`\#P/`\#P/
M`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/!)O&_\G5F_
MO9=F_P!Z>V_!HD[<^-CON[>H>\9T'J*ENBJLZ1IF+TMSV7N+M&QZ^D/+@MF@
M%E,CD-7PE#GFT!45+$+=CD3G;9..2$+JF0AHUUNXW>/,N&(;E:6YMM\I\=D-
MY?Z5L(H9N\Q07\7=M66XF!NVWSF>E!#AJ:DVLJE2((U,6VA1?ZQ%,LF,5<L=
M-!FZB*6NJV`ZQ:_+U_\`3Z%0`[TE$'KL#4UE?IG@MSE8]TPZP#VJM-6]6;@R
M%F@;]`35?$-2T_!&6D7'OI$.^@'EA1F2G1[K(]X''4+SGU/S[,I60!I<VR8#
M,876$/>.]2LV@3@1M48>41D&980H!794"OM)QK\*:/BFQ\&U&&53;$8X=,]&
M3U8.+4X=LJ%\H]0\ZUK):W,$NDHQ+WS\]*1[F$C@]KW(#>A+E.X:PN,%,J0W
M9XXUE$"`[-5R8G99>'.2R8)F)>L0[-).3+=ETU;DR)BM!D7L,QRE,[D29OI*
M2D,=D_*TN'S08)K-=S&V+.0`IP_!!!CPK(MHH0B[74L28C##PBDW9!FFB*EM
MJ#6QUC+IVI7Z47O6T0\^A>\+D$C(R4.S"U;`ZG19R)L;B088V?+C:^8R+*PQ
M^50;$"[D3C5RW&I$R`?-0_+YZF9??<F)W;:%DH6[+D3XL3.#(0DS%-TZQK:#
MY>$DQD3`J+2/5["7>B3QLX^AUCJPQGLSV?(.7*@3-"/C>-0[GRIJJ;W?)E;$
MCD=I:"SBTBB0.5+"ZZJ9XWEZD$J>,R2*N8N+CAN?A@+IPUE8$RY=`TE42KY\
MN/$I(!T,%\9%BB"+HZ1NS]*34!@-90*F4RA&6B8;*P53W-<-D1N.]'U9&5Q-
M76.!<1:PX]#4]'$.)9AQ2-_IK`6D=-Z-?M"M.4>.TN?]7$EETT.V!/\`8U=3
MD%]:6V<PN`1ZX[;)6<8`0,/L)&+CL/\`;6,MCI`EL2?NUP.FK1RV8*J-E0E?
M'QO367"Y9I9KVG'Y4A"/D%C,4V1'EY4VCYGL>Z0EMQ*2(.3\<&.![V"ZLWH8
MNJ.;_5.E-&3X8YUPJL@W#B9I\6\CD5,E(2*F-=BK'D,ZZJDDFL7$=?IE)$!Z
M"I^U*Y#`319NVU.%$0)B;1LT5;OW"[)PC&]<M$]G:#'.@<0K\8]HEFDL".S]
M,1)KB9]#2H#+XDTD3B8V,C?-\"[<1%6KJM'0B3!A`QHW48.:L2TRP7-:#26B
MX%L-V;/0[*E\==CA(6'B`,7SF49Q)UTE&0PR2M#V8S(XQT.8P8:VM)@;*#J)
MLKHJI-#6.QMNU5+#C$9-RD>E+XK^;:[(!;_+?,C7G9*S5G;\1*I'/9JP/*S?
M(E)O+BP857<`A#-O*RVZ6SP@0W<0UP35U^K<,TLOD\)9RIJIMX,?\_5QT]3`
MES'C82H"?\8G5%FV9+BD7DDE-L8I6-E/YE8!331*0"($_<2=E(U04/$J#VAU
MJKH3W.$!B#1NY3:AG<E6$J)VG+;2=&`#MX,KE>!4O'"+4D\CT<=F-=RDME,M
M;)+LUB!"4FD(\%=-1BR.6,1BR23%^F^D)71$(]B7`0W%9VC'9#!*<KY:2%VT
M@JRGJ6-6!&:+JPX/K[>!NGB:4<:5RX."K"0775LV&9AP^%RL1JA'I("E">Q`
MB0#(O/7*5DTK.;$3=VR;,U29B;B/0\/O.)^7?(O2&@7?)YU#3SMQ!(7(@[UI
M(W[V20G7\XLHQ,2,BG*NQ9DWW7";ZX^->5A3E2$9H0I[<=44EH'3`N/`B+YO
M90FBQ%P,-[,FR!<(R11M^=.+/9J%L:X--&"8+?;:4F%':.&8=^O_`.-H/>YS
MI:8DI@H-E%NLY>TAK-NHKI%-DY!SW!ZE!HVD+RQ<.)$VA,UB.;&BN@IRUV%E
MMV;O&5W"6Z/@[Q=O(=B3@E?,GA<DA>IVQYEQI-XD+D^YP>);O.6;"`SHB+D9
M04+,/&C66X"_ES%\,%$U1N7'U*[%Q^'^%N%"4#5$R@C^WI_91.+N[%O&?#9S
M)A$&2(8AD40`0*(5S'XX$(F&[$S)ED`D.:OR\K+"PSPN3(+HHAA8L>-9I!UG
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M\)M7],[GIJK*DEM8Q6V[1EML&Y3+2S-_8MTSTI=+:O@?.LXC<!Q+1OT`LSNP
M8R8JT:.9FZ)-(PU\&.GL0[.GI\-)977E_1S%$T=6L.F.RKVU?XQM3,$OVTAA
MZPZ,Q`Y=K55RV@_K$3"9J5&.U)VA+Q1!D)8:D":B8<H%K<*4S?`^?S&Y9]I(
MH3&BUA]>,%@$ML&Y)#,K1$R3I0^3J"2'ZSLB.@([4PF&0`3AO"$(BN>4.QF3
ML-]7(H6DDQ7"=X!OURT#RL'41GI^K@[,U\F]G$71VF31P[*IG$+ZBCGEB(-'
MG2U7S-VC"I=7!TDE$`L';#TY;'F3Q&)DVS\"X=C@ZH49]P0"GKFF\-!6P=)7
M)<773<USR6H6+RZ%,1I?G&QI]#+!;A"M8E+#+/3]P1F)PH>@?EA2KY,RD*,,
MU@KL\1;DW`<9$R774-A-X0R!Q6]I/L_GG:,GE55V)RQE.KXO^>="NY13\@J@
M])Z5%XM\G8+$X5(O``Z:VG'6@)Q]:F#B*@5KL^#O<%E7758UIB*$[([:4596
MUU)M-99CEU&SIM')`UFDJ,<\P>OV6O+Y9I,J/LD,^5)R6Q1[&<#8LL+C<186
M16#`HFU;A>W.)#HV58Z&E72Y:P`PYD5;Q>*U.#A@<0`%1[^*"N)!)CT`.QV'
M)6K.#&TY+SH`',,)J88;[LM18@6H=&ZO<!B'C2S8Q'5Y.;_1/HNL(M=%G0:"
MU52%PUMTN,DT7)I165$WLJ,$^@(Z+<;%I:'`/34U8PDN>AL(%Q<(F\?[R(B7
M6=APFC2_EN_9"M)1$TD<%,S`A#6`U:M[Q9P2)\[NJ*V(9F\:NH--6U':R=S;
M:;J-E8*]B2MGN%B^Q`>X1&L&!1(.`D/*,W-<]3:8P`]:=1O#EB2&VA->NS%\
MRV6B:[CE>2^%5\)#Q9.;-)\UM!59^.N%")NEMFJMB;#(I*(R\;!T&K0,Z\H3
M_H[%EV;65N5O($,HM2T]=SPH%L1L$4E!=O"7PR.`YD>')UK(([EM("T2`@JX
M*/BD3;U8^)SW10S+T7SD(-.#NONH0=5UW;.+\>1=];W,4EO0?)>;X9'@L'FV
M)'/'%K5;%!TYH)6)6ESY$-!T0+-Y\<'V8PP]0$O=[/,Y?Y;L0[GUS2_:$I)?
M(`K3$AM$+`9Y#,11LQ"2"="9.(8UWSA#9C""O+@H*WSMF236RUI95<O4A+@8
MNJL7T?Y4>'(DW'K!^M^\[E`D_P"FIH-B'2+V/84XA+#,0>0]*RK9^--W4Z<=
M,)P2*0HX7(&7FT'2^V9AH,%>%!HC**;=BTU61TW"P*'6M2-5CU2:J2(60XB#
M)T8+\C0.^V\^`RPD385>.6?"G(FULC[0C<$/VN@^2CXV>ZB3C=-P7=-D1\<=
M`M]0B:+]&]0'C,WB&MI=>&*_'2.ED9O8+OC1B*Z%K5K-JBL>02`9#*31Y6T)
M.8D1L\#%8S^DLKJ&Q/R((]?+HRIZU63E;(,JP4IU)3_!W",=K`%;C6R&5(P<
M#;45+4S^<GHM$1\`$ZSF9'Q9".CG`*ZH!NGH]@59;)??G\K</HDO7)IMHLZC
M(4KWP6/B:1JXS%-NABDA'="<R%]$J4A-TR65%8N,N."D['VG\2I2*$"FT2S6
M[66/),+DX!E&]UD]1VS'4JH-&J!CUR2ZA*_(]51HM5UML>?D*VO&+C)$&D0+
M%/:C'#>IS49E<[CJ<E1D#.PRYE.0B&#"719D3&#FVK.)LU4T9J4<!L_\#P2;
MTI_*5P_^]D^_NF]4>"LO`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/
M`\#P/`\#P/`\#P/`\#P/`\#P/!)O&_\`)U9O[V79O]Z>V_!J9>?+=TM<3;M2
MZ.-^2>6>CN8>%IY8<.>W;(NQC\(DLQ=UO240MJP",)B8CF.PQR'T@B9+Q1/&
MDWUV?%Q9)BZ4:H9SGP;@..^GX%V9S!2_3=9E8\8C=M001(U4XP?TDH@#*M4/
MH)O"=#^C-A@@]@LS9G8:6<;,&2GYH$>:JLVRFNZ&@3XP^2&JV\#D!VP`IRN)
MH+2Z2(-HI^C=F6@(:Q;F2P)#6<YGTMEM2UK+FD0A>DFCZF=GQ1EA\FP?,,MV
M+Q^YT8Y#*8[OGEM\_-#UI^:%:1[:SVY.1G:MMV.0)<G2ZI)&T0H&PY%`Q4*D
MQN([!BB[P''SI$RZ8LE7[!@Z:8_&\'7FOR#T:5M*L*N`B;?+O[)S8;1=Y_$7
M=8M[`3-?(5F_<#[&BA>O&4KA#`L&M..'VLHE(H-%F@%9`R^+HC2+%TL';6W=
M/-CT:_)LI/-WVK9S&&XH<SI*[W4AG24T6.HQ8K5480KO>16Y'C?Z,2)RSDM9
M#)8`V8!21+<EH/:JN=0^N9=M<]5UNMF?&K#A;!.#';$;R"443>H.*%8Y&(`]
MM&0(`):1K=O&I#*A,"%F)$\@@0H_FZ;<(=;?H]E^%*-6@?(1[-K-]4ESV?70
MF<S<C20IH1DE>F*^L:KYHOL5&MS`#=`!8T+!2#<,>%N,$A<D8`28A\Q0=K,%
MGNS59+4,-N?D,8(08;-F%8(RYN-KN>W-:.L&LH&?'5Y4U<2?$8DIM`D\"A7,
MIES5PB57V@2(D021R!+L73Y`AHQ;/PSK;7:O.U(S-M`;"E$L:2=R'@9WZ6-U
M%<$^'M!UHR<S":YV)GX%`Y*`$NYO,0)"+1D:3)M"1<_]"*9M%7I48B\#K)'O
M/E)-M7A=Q+).20FCV-ZQUV/I*Z#JD4(32P7M*Q[-A?EE=/EJ:<EK#U+P+&]G
M:PQ1(FR/,7>R*`TMLW#JA/O&*1N_W=42D`F+@^S>S64>GPY\:DQZ6S&L9-2L
M**1&,UW'(N3.2`DO,+5,Q_+<"X*$6KN"&-U1V4-7RHL,WP_J^D9Y;:M(QDY*
MW4]U&STLS^NJRU`<,.,JND,?B=A9B]G'(6.K65N8A)90$"FV,;EA1\T?NED,
MM\[,"'TH=09=D5S/#QBOZ/9G;)M)N`D$HC$?/1.S*M@L]CT-EP&&S0S"KFEU
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M<)H(Z.'.$M7"^B6FJR^$,;:HX65UUQNKA'7??5+&^VV$\;;8T^S&V?M#]O`\
M#P/`\$F]*?RE</\`[V3[^Z;U1X*R\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#
MP/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\$F\;_R=6;^]EV;_>GMOP2C=/Q6
M?'185HST]9>EH12==920J1FD-B/;W5=*1VZI,E!!D9D.4JBKF^H5"I&^4KR+
M#1TA:B8FKLYCPC78JDJU24W\&RZOH!%*K@$+K"!"_P`@A->Q*/P>("-'3Q_L
M)C46$-`8-CE^57?$""C,:Q;([OB;IZ^>*)Y<OG+EPJJKN$%L>..8``>U(#);
MQE$C(2BM.C8+/5)5/:J&28%#>FY^O9EGO5649A<58A5$)6<7=1XF1"[-Q#0D
MDR<Z/T/HL)!W+/%W+U@P*.0K4^4E\-VDW1D]$:#YL&?:'7E_N9@RM'=(@'8Z
M[/!89]/RJ`7<8JBJ`>ZBTW[UZNCMJX#Z8WQI6@F6Q:P&5W6F7MA.63$T9LI\
M5IQ[*;4%EH[!H),J]E0EO52,(S$DXY6$%`O,0.'P^7A=XWH\;RI@;)'2!0,2
M0OXY>4Z*&)OJ[L%S3^RTFB[RJ9A%([RI"SM>'8YB3#1(^+2ME0K)_:2[D+)Y
M#&'#6_GEVO7`QV[W1W2-*NRJP<E.?BZYSL>Q#DUFLULP_+)#$IR!<*$7-1NI
M<F*L*II%2<N=IV.XJA6Z7XQU'Y:5(L8N:L4M74>E:S9_'XB*;HI#?!6#KG4$
MB0M8_$9W8]>2^VV-9,BLQB)"*;FXYFIV^K2-.8PTE</E$;^\[:?BLY"RDP"2
MB#3-RZ:.!NK9?=+(3BYXJYYEF7L":W).G4O7$V"$O+\IFE:.YQ=$0M*5M9;9
M49MP5^A#Q`"#E$AW3V76J\#5A6/LWZX2)E8Z(?J,%`R;;%'\Z2V1O+2GD[2C
MVTL_5]%HO<3>,@HXZ4Y=N(W=5?M!*A!MNBHM^F94@UE*"3Q?=\&03'MM!3E!
M1[L$D6)P+&SME0N,4YTFQKD*@?B\XN&M'.L7ELUMC6$=!G.H80T(9WW9%@(`
M#.I9(-6KF/-Q#UU&CBK$P0,H-Q^4`STQXAH&1/JF4>RM\^NOFN#3",`9W#C8
M%G-X3+[?D<7GD[LQNB\9R(B`F,RDD66>+?FN[H.>`'Y3'9&(D@(T^:;AUZB>
M5'=?=:S2P2W0XV;@H)$[085MSXQ&QQD\IP)TO8D=L>3&I"[8[:25^E)SM;N]
MX_O(M5Q^FJI]K'MF0L<V&L@X*!<=5,5G[TC7?4$HEM6QJD+.I76L`TIKPHXJ
M:'WC*X!8C81"IE#P(V2@H^L%B3]@-6L!U-IBX`%F"\?F@ML$9YV#,ML<GTKT
M[']<QNR95#(L<II_1<BVHDW7&`TXI*4L6)1A!R*Y^$SQ`:&:LW*)2,%H0K%3
M[<>873;FUPA/9HJ&6);SA$)C9,)M<C))VSF-:-!C&NG(HT-:,(<ST76Q,&X\
M9N$79DT[/$;MXY/,29,[E4,.&_HMF+%6:93(<$1JN&6'TK#[R$7I*]I92\.E
M]>*U7%2M1$86F)L$D`(2G28L75?&[(9DRY&$11311K.P>&6T700&MVB;Z0IE
MPH$C+(L(+"P):2@!9PYG.H4*1,CF18QG7;&FV!8YRY2>$,Z[YQIG#1%;.-LX
MUS^W]G@^+6?07?$ASI-(GOB(X^]*\ZR,/MB,:_:KC[9#G#S/Y+C[4%\?:2^F
MQ]J*N/\`*GO]@<\T)C7^=,,2#%YE5BT)IX:.V[C*@TA^+]`0TPBIOG=B]_`7
M^D=Z_:@Y_!5_!4W_``]_L#X59-&T&JKU>0`T62!/(5=VJ68)M43&%\-<B57&
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M2^^<^AH9+5.?Y3:0*.C>J`,FG=3F^>8B'E[ZWI#S"9@4R%UE)K+J<?`FN8Q5
MI:/S2,QX/A!&;1XI)&*)5K+T":X9KK&A)X!O2\[,F],I&*ULX3:3*#5G^D$+
M,.JY1=O&B4N9I!B4K3A?W^L%F>)B;2%D$V@0H@T&31XRU*F'C,)/"\K7ECFO
MGB&&N7"9%>O:"ZMI)2G2\BH%SB!3NU#L*>U+;#1TE:KZ$8C\:"@3X59]&CY"
M>QML;4U"QAQJZ=Z>"U834TZBO<HNQ5:>+J1UYR2!JF<WZU?56@-EM@`9&)-,
M]"HW2>:VJ1T;#&;D:T(/(*JS:NU<-DG.HW.7W@R5'X=UVWZLF$L.VI5KSFQW
M!(6Q"0MK4LQ:R#\R9R&UW!`<Q/+=)%`XJ7L696%.)1/5:HR+F@A,6`'1X(Z`
MK/TPCJ.<>7[%)??=X#1U;XG`Z[^C;.Y]AX2)"(O/YD5LR,/H7$U[9OS^,0XB
M3JK5`XYDB]=(0&+%F!`*!?/G9E\!'#GH3WMP!UH3_0"K=X]5<&AM5RVWIG!9
M.Q)P^[:[;_QI4NV$OH^4C=IP@%)<ZFK;:2`_(WHZOT'@K,[4>QPPOAJ\R@&<
M.7N%[)86D0L.P(S&:6AD6L6C9E`(<L$CT^O-TI5?*]4T[N)<]%`K-,M4*VR=
MC\A&DHPM7K232Y)AN8>GQHR2.`NH=CEG--VRGJ^U3H:'V)6]66/T51<AGMBU
M];06JS-E5'#N9+*A\A9X.5=90FW4&(RT'4,;+#7[:/&55%FQL!JJ@/<DQX8F
MB_(/7PJ432SW!:V6]E!R?+$<KPFCT<<31E5>UOTQ8;B?(V:P:6/H)M-9/G8\
M+;NG%PH2HN4V>./RI16:[D5]@X.C>9.VXG8C*62@+=3"SCAKG`A(K8<]%""%
M4.XG#(7F/W6`LNO1=RN'EE3:0#$G,=B!HY5\IT!F'8*1!)E&\"G;S`<;1W)O
M8-<16=N)?'NC2UE63(.6YI;TDCO6;I-:Q(?&Z1H2"7K7T5=..B0R<2O)S-8%
M)7?\9C$?"\%H:CN&!W,S0*-A>@6=RC2'2(>W%)Q?DCMW]$XW4@$15D5.7U(Y
M$-%EGEP]*.E!5FQT#8)@!9EBQFCY-2,;DL[F*<R9&I$'3,")*=/`\2%(.-B8
MJ<02^;?OHCQ_*ZY9QB+R>L:I!P+%!98W%I,;,ASI:8RXO![-+R]>5SJ1#Q)"
M.MI;!A(6MHGI)RLEDF#,D)L!X=I[8IV9VZ7@[&OZ0?FI6R.U4:WN%JG0R0AF
M(BMEI20G!I?))G(QMVQ<**0:K2)J0IP*3)/G9=5DBNCMN0;N`Q82Y#.VWT%8
M15U5)ZA:M,5L2`KO]!W-^&A"P@UW5E:<7DT3"P0A,'5EB):4@I603MOTE'--
MV*9)H!C8QNVDLY;*!^_,M(=4T1;-;A4`[O>DB$1C@.6NS#JJ"9*.1.%1BSXU
M$(?*3#`RA*DY3'D!5,EA`FJ@#ZJ]I).[R</GV$MH\0W#"3GXYK>>/\2)TH*7
MC+WNQIU$7IM940MN\F`SN[>7#KC4D.YW8#NPUY2VTV>0W+7:0.30\*W^YH98
M;A5P[&:XO.PV8!YD+Y/C=AA!OR'61=92&PYG0K,J8I:0<W6'7L9*IM9]+X/%
MW+1G.I(-VQ&")QL8'ZJ+E4`^<);;Y#8?R)6TMJNF48Q,`[2).'<_M>6Q^O1Y
M1N;85?"IM9,HE<,K=H59;J#7"<1CA8>.W:AE%(\&7U6`QI9>/"A;A4*<\$F]
M*?RE</\`[V3[^Z;U1X*R\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`
M\#P/`\#P/`\#P/`\#P/`\#P/`\$F\;_R=6;^]EV;_>GMOP:/;T[JZV,SV[)-
M-[$;<*7AR>>`"N=^`&V$KL-=P&)HOEF$D1A^RB0,S;<`ME#)&OX$*I-INYJ*
M3L#LVFYA4@!09,0]!?/TUM^Q*@B<POBFF_/-IFD":LFJ9I8P>UTXCA`N0:B/
MMG04*"$EER@1`<<<-T!2>H=P04#+JO%AZKM<-0(GMOH$?4UKM])C&KF1@]?_
M`"(6W))U+7#2-2UU$>;+]F-606NX@YH0360B/D'<89B'*D[V35/L'*&Y%-,B
MY(-W`T,M._D0NB)QIY9<AK2!'H`2E'8,!A<4B2\NWL#4SRRK/]V9R2'"3IV)
M="Y8T@#U(D-&@]7H;*Z9?0N0TRL+;A_$>[*Z+E72-55^E-:"90@>2N>.6">C
MX0F:K^XB4>AG.5BQ0=5Y]Y+-2H>=#A-H2F+)B$Y$=9/C@8N_?""";=`<&#B*
MP^2JY;,$L%5ZZKVM\6$?KAA"IK8#G=E"ZT3FS:?$RH6UA[*P7!\P7`-(:+!,
MBR*E<#CTQES,']`+7%J)D`_&Z_D_FU22<VP`,Z?MH.RK"V"6CB)Z2$<&'6=5
M?.$PO9VR0FSJ6D5YI#R;N#O0R*XVO(Y]@>1!C+21/UF3AB0"S:KZ1L]=Y>\9
MM."L9?+J;3JHRW9T('+.UI&$MJ/8-#Q[$#,#_P!2L6BZJ+U(L1V,,V9,>EH2
M;#1JN%!V`PC8?8-FS;XYV_2T+C%ETA8<C%4,X;IYB4.)R5'-ERFLFIY[6H>9
M)S.+R!!R,EY,7$7DK$KHKD4TE7PO7\+&=@PM:_7'3%$PB'CY`[N`M)F<RG-P
M9R1Y\4LFVI+S!7+B,-E0-Z`N=JN-U[4AJ=E3DF'@YFS$P,:W"Q9@^</F)5"3
M-\A@J?=N]/C6/6MAQZX)N&A@`/VFI2AN117FXG3I[^*>L74DK&/T8Y!PA6QR
M=U!"&&DR=#;O.FX;,H$&G3@)'I+@=]9'@NAM8?2\5XZZ[L>93RS8\ZAU;2^8
M439-O12B@5RCMPE5_GCXG*HM#(,TI[<:QG;=TA%=2<'RX)!/MU.,G6V6KUR&
M&2O;]^"H=*U?J(+(X/%)-6E`J3K_`(TC;4JF%H<G0BY6MLIO8PB!K4/J,D\R
MT36"`XCHP(-$]G`O('""+-<,"V%W'TA$.<V4(G3P"M9K[DZ%6[%+5KT_.(Z6
M%;V+RMUQ*VCN2Z/"JZ4LE\>D]`-R.Y-PV:1LLYD>A9.+""T='+*AVF_^_>A8
MK44T#19_6IJW(9')40B-R5JZE!:N6I)3C2Y;Q'MC$7<GBPN:36'$:]QI(`,F
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MF(65)TZX`/*F'Q6%[U_`;@D%@"D'J@A7(<I+^N;%M7B;,_YR/2"$VZG;G,50
M#Y98X*K)&X)$+5L&BFZILD,AK^3USNC+X1:378J/$K,B$1(%"(K=A')"$_!9
MA/L\Z#[/ET=O^=.K,L_EG>/,N19'7%6L*XI%241(3:5OS6F9\PG.+:J2R7I)
M61.(BZF$=42W'+#6;P'LEOEHH\8N`R`UO"[(%;ET"5NM)3:)VK^O.?N?H=SY
M-XOSFD]LN!6'77.1:;FM4:SIR`V0E-A>ME3ZPOTF&&4X*$&1QU^:Q)&-CG:S
M$-T'@DWI3^4KA_\`>R??W3>J/!67@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>
M!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@U\U1++OHYI9,(><<=`V`B\Z`Z*
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M6_Q>WING,E$5I>GM_P`'GMI*UF[G=Z@K)-,]@YU.*(/%%':.Y3#K9)RINOIG
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MAZ`D>MHT3[(U;ZJL1;5L-9J:IXW:CVZ#-#.C=)-/4/Z<6Y,W>NNCOXW>D'6F
MC%`7IHX+<!+:Z#6S4@R;#M=5.R=L:L6[,L5:(-,8PW2:DR"":>J3QSHH'PBK
M(D`(2B!"?&;T$'!MUWSIN%%._CZ'B4')1FL/)N$1S3L5%FDN18.'#%\MHCJH
M[9KK-G&RB*N^FP?F.L0X(=`WPGXR;^%O8R/="8V\'./CY9.H\+?;.-WHT&X;
M=B)*B1[S=V[W=,V&[=NXV=.-E4]\K*9V#[RML2\]'TXD<^-KHTS%4DVB*49*
ME.`2,?228?<^A23#/.R%AVB;+\-/Z335MC5M]S3\'&GW<?8'$QV>'H@<WD45
M^-;I:.%=HP-AB:@21\(C&;2,"3!L^S#C13/M)(2+;9,R(L0>;#F35<FX7;[$
ME7>HX;JT#EV-LS`7^8X&?&WT<.P8,(R$OAB4X!:?FD@;.$7C<X1^G[(3^N,(
M.V[=TB3<_BO4G""*^B^JJ6FVH<VXO^U':C19U\??5+E8>ONZ8*N)5P@LHR<J
M-7#%1PTW4[0VV;+[LG;MGNLCG139JZ<-]MLI+*:;!Q`VWIJ&&:!0_P`;_20H
M,F1_.$Q(TOP&Q&:%\$-2V"FC!KV2DUU(X*Z:$_KL)8<_F&FKW\7ZG7"F`^YW
M>=DO\N=GWQX]0/-GB;%)YL[D?!;C+I(8Y5>#4W.5NS=\KICW:RSICHK][5HY
M5570PFJIMMD.&1M"4-Y2XG+?XT^AT)L\1^G=S%%_\?J4I=-\-T6F$'$@T[&U
M++HX:-T&OX2KO;3Z=!%'[OX:>FNH=L_6-N'^@/UG_ICPK_OI>#&\HD=TW/;'
M+6JG)%ZU='*UO4I8TRFUCR[E5Q'A4?TY^O:!M]-&%8]*V5,B!%_)YY'&#9L-
MBCM)--PX>/G#-FT67U"^_`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P/`\#P
7/`\#P/`\#P/`\#P/`\#P/`\#P/!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g887761g09a90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g09a90.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X4VC:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!44&<](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM96YS:6]N<R,B"B`@("!X;6QN
M<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+T9O
M;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+V<O(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@("`@>&UL;G,Z
M<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!X;7`Z0W)E
M871E1&%T93TB,C`Q-2TP,RTS,%0Q,3HT-"LP-3HS,"(*("`@>&UP.D-R96%T
M;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@("!X
M;7`Z36]D:69Y1&%T93TB,C`Q-2TP,RTS,%0Q,3HT-"LP-3HS,"(*("`@>&UP
M.DUE=&%D871A1&%T93TB,C`Q-2TP,RTS,%0Q,3HT-"LP-3HS,"(*("`@<&1F
M.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2`Q,"XP,2(*("`@9&,Z9F]R
M;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!44&<Z3E!A9V5S
M/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3TB1F%L<V4B
M"B`@('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E(@H@("!X;7!-
M33I$;V-U;65N=$E$/2)X;7`N9&ED.C,X,T$R.#E%03%$-D4T,3$Y.#-#.3A!
M1#%",S<X,41$(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C,X,T$R
M.#E%03%$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240](GAM<"YD:60Z,S!#,34Y1C8U1D$S13,Q,4$P,T)"0D9$
M1D%!-#E%0S4B"B`@('AM<$U-.E)E;F1I=&EO;D-L87-S/2)D969A=6QT(CX*
M("`@/'AM<#I4:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL
M:0H@("`@("!X;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM<$=);6<Z:&5I
M9VAT/2(X."(*("`@("`@>&UP1TEM9SIF;W)M870](DI014<B"B`@("`@('AM
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M.'%/>G=Y9W`F(WA!.S`K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM
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M(WA!.WAA1T-E2G`S2U1O5VMD<#!A=&8R94\O231Q<4@X;2]03$=:,R]-:E9'
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M9FMJ;$5Q>7`Q2C1I;39Q<79M<CAY0VIL=DDS1FQ#1D8O4W0F(WA!.W%E4F%*
M;5E6-#=C6D%Q93EA.4)I<60K5"]-:2M:4$PY=G)!=&UT4%=E94TR-W-(2W1B
M>G9!,WA!1'%9<3E-5E1N1EA9<7A0.'=035@F(WA!.VUZ4DET3VPX=F%39%EA
M85HP=F)D63586EDO5%!",61$>%-K;DAL>4)Q=&%B-'%X4%)F>F$O34]A,S`Y
M3E(O3#8O1GA.87I46',X87HF(WA!.W=X<$Y$17II35)3475W37)Q06\U;EIH
M=5=$2T9782M2+TTK<BM9=$YU3')63D)U9DPX.$YW,$M7=#)35VM12W)#5F%R
M1V5*3$5F6C<F(WA!.UEQ>5!&6%EQ-T972#-N;6(X>$ER:#0W9GE73&U&5$E&
M;4=P,GE"9W%":TE6;'(X8C%89G`Q3TMT858U-3%M5'I(66%"<F9L.3E*=DXF
M(WA!.U%H;75)5T8Q1F1)1F=33715>&=F='E&9CEJ6'9I<DUC5F1I<G-696,K
M9&90+VYJ45!.-C)7;2M7<FI83D0K<'AZ1U<R=&)K=CE99'`F(WA!.U$P6#%H
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M=#%I:4LX944F(WA!.V%Q44(P66EM2W`Q<C,U:BM3.4-V:G`K<C9H.5=U<4UX
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M>%8U>&0O;4@F(WA!.S5.,4PX>F9,375N6$Q88VEI.3`R5FQ2-'A&3$PV45AK
M2FMJ3$%V4F%Q5#%W<3E7=TMX4U-Y,3=Y-W%56#9"<V8P:#5E=6UK93@P-5HF
M(WA!.TDT-6)34VY)3EII46]J2DMX*TM)<T%P,UAR5$95,'-F3F5I,V1Y=&TP
M<E=E;U`X05IS3'A'='`R<#$T2DE&.5%$*V%0:U!F1E4S>%8F(WA!.S)+=7A6
M,DMU>%8R2W-A,3-Z<V1)=GI:+V]$5V11,EIH8S)&;THT5'=J16XR*V$W;FQX
M1S,R9U)I<D9.0S!'5S8X=7=E85!+<U5$95HF(WA!.W)3.#%32WIK=7<X16,Q
M<DQQ,7<P,71/079*4G576#1A:'=/>&%Q<E!T1C$V,#%26E562'1R-C))5SDP
M*V-"6C174%1K05-#<E4K1C$F(WA!.TI6=7A/2W!L:7)S5F1I<G-69&ER<U9D
M:7)!+WEK<S)T8DQ8*TTS<3)T>'%R,T=N:C`O5$M7571T8G1A4C=G3597,TM"
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M>7-!5TE205=9.%9"2C)(441&6&DS;3=Z:#5).#`O;49O96MX>7I81G101F0V
M6F,S,$-013@F(WA!.T9X3$Q%<U%8,4DV,45O6#1Q1F1X,3-W<3E!9V=U4$HQ
M>DI.8U@Q,7%(;"LX8T<T=7(V67I3,DUU>7%Z3R]7,V):4V5Q2&,Q56MQ1EHF
M(WA!.V-#0TMJ8TA&5D,K,"MW,4,R83%V<F%+-G1N*S-$36EY269M<D%J1E5G
M;CAN,S!%.7,K9S8U9#960D1)6&YS6'!E5SAQ.$-O44QC8S,F(WA!.VE516<P
M:F12-U9O47%I:$8U,F=O4F-A8F9G52M";UHW36UN:31K=7A5+S9N,%EQ-&%V
M-6UH;TQR441-9'%N5#=U1UEB+W=$358Y4D\F(WA!.S-Y>%8S*TQR3TTP=DQ(
M56).:%-O97EN;%56.%I,6EHT:%1X-5EQ=6DX-BM52DIO-$)R5FMT>DMY>'@R
M,&LX8V-X9'I21CE*>7(X;5`F(WA!.U%5,WA63W-64U1Z1C4Q.',K6$=J6%=B
M=S)P;59N:B]D5%-!:$9:;3-J4GAS14]+<U4O27I83&Y5=DQ/;U<Y,$E24%DV
M<&5+4F)Q>7`F(WA!.U-E6G)H=G1-,6%44U-+3VUW2'I+<DUT83!#2%57:G59
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M6$96=6]7,78F(WA!.V5397!Q+VMX-VEC9CAF:U`Q2UIL-V9$23!S3G=$+W%R
M:%9#+U=.1G1Q96AQ974V2V4O,6E+-VQH2'1Z=C1B;4E$,E)H:7%*<W9-3B\F
M(WA!.TTT5%1F34=I-C)2.%!O1B]Q.'A0*UA*1$IC<E@U441!<5`X04LS;5<W
M,6DU,5<Q=3=A,W1P.4UN141P8EAC9#)#84=V3&E%6DXQ4#(F(WA!.VQ(:#%$
M04MS9WA6,DMU>%8U5C4K<V)F>E`U=S!8+T0R<5=4-GI:=U1V8DXV<V)I2U='
M83)N571W.5(Q*T94*W=2=G9T:%9M2&LW5F8F(WA!.TUU<#)T-5HK6G1)5WEU
M3$IV<7)Z:'I*0F4X86\X,&%T2$9X:F9J>4,W-TYG5G)4=G(R9V%T8F%';'90
M96%*9#@O=T)(6%-!=4Q)4G(F(WA!.WE.=D\Q0E-,+V9,5DHO6C=!-'%Y8D98
M67$W1EA9<3=&5DLT<S=3-3E0-GI"2%`V36EZ42MO<79W:U0W3')Y0F]Y.6E.
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M1'A-:68Q>%8F(WA!.S,V5#`S+VQR:"\U1TPO6$989G!45$LP*W515D\T2'%*
M,BMN1EAF<%!49CA!;')H+S5'3"]!1GA60S-P.',V9VAJ=F9Q5C)G,DM496PF
M(WA!.TM0;%)Q-'%H=$<P+WEJ;UIU>G!9=$Q*3'515%1P139);%9124%Q9SA5
M5VDQ-')T56LY4V-65%`Y2V%B+T%-=&-0+TEX4#8T<75J,4,F(WA!.W=K:U=/
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M(WA!.UIF3&<S3W$R9%`X06U):2\U<7A6=SAZ95=Y05)Q=&U19'=28U)F.$%.
M5TMQ;'9R=6@S13915RMO,C`P.&A):FEJ;6I:,DE"63A60DHF(WA!.TY&0D]+
M<DY$.'8V6&]L<SEV<#9Y<DA)=V1J4%!08W952T5!1#-$>75&5E9!0V<P2%E9
M<6IP;UE:-&UI;6I75TIX4C0S05I34$%G-T@F(WA!.T95:#!0>51O*VXR2G0W
M<3%S-S):<'`U:E`Y5&=H,FYM855,>%5%9D1Z<%AV,7A64C@P95)B3%9.2&MS
M.4M7>C!I.&0T,E<Y*V]W6%`F(WA!.T5)-%IH-F(X5E!)0VQA-UEQ;6-0;&I1
M16AJ4UA48D]74E9!950V=$5V2F=.,F]&,G)I<5$K669,5VA71W!7;78S371H
M<#)I,D,K;&4F(WA!.S)Z,D5$3$E*,D-F1D]25TUE;UEZ54QT>#-.0V-+=6DQ
M-SAO2F):8FM8=6A*0SAA>D%Y=&%X15)U;V176E@T<W1664AC9#A#<G9,2&LF
M(WA!.TM'>&UV3&I53&EY,6DS=DA-,7-G,#8R9T596C-95650;'HO9$UI9C='
M=E5N1E58-6PX:#9,<D=J5#9F8E<Y='`X<S-(+U-9-UI#44$F(WA!.W=*2'<K
M;3(Y2V)-4#19<6E.2#AN-E9:-EAA,G0Y8E=D+V51>'%K.34Y5&=H.59H*S$V
M84%Q=&9!67%G3F0X:E0S3C-A6&5G6'1V;TTF(WA!.SEP>EI(:C`K,FYB;3A5
M:UA)33-!:F%88U9O8U9:5V=926]9.&U!04Q5<%4K3DU64T16+TIE:S9R<CEN
M<70U8E=K.&1T1DUK,7906G<F(WA!.WI.2SAO44DO<D]#>3A"2%-N9C9-5E9V
M.$4K5%`K<D)P,R]32D(O>E)I<51A2BM75VM75V]A:F-A:$)P,F\R,35)6DQA
M,2]2;')$-D$F(WA!.S5T46,Q1$8V4F5M;2]W1$QY-G-C5E1(55!)6&QA97=U
M24Q84TY.=&)M5TXP:'5467=30TXR56A8-$96-6-4=E-U2W-D,'5$.'`Y3$,F
M(WA!.V58=%=M,%-F6$Y/:CE/*VQN=$Q7,5IM:FI74FU:0W9"9C-B:'%!.4MN
M<S%&5W)J>7`U2CAZ,SA4*U9R+T%%3E4P='8Y>49T85=6:&8F(WA!.TAM-V=,
M-FA'.&19,&QJ05`X,65Q:D975B]W0T-F2FXO04993D\O-E))4#A!;6I&56<P
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M23<P2%1&56PX,6%7;&I+;FU)>E)W-EAO.$QZ,VUN>%=-33@F(WA!.S`V2W)'
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M;B]63$989G`K>"\S,65F.4E6-2]W0E5S5F0K;C=(+T%(,65F.4E6-2\Q4WA6
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M:U,O17@T;V]&5'1I<DQV3&UN,T=H2F5"3%!6-RM3*W58=7!P-S9E>6UK-5`F
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M/2(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<#I4:'5M8FYA:6QS/@H@("`\
M9&,Z=&ET;&4^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG
M/2)X+61E9F%U;'0B/F<P.6$Y,#PO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\9&,Z8W)E871O<CX*("`@(#QR9&8Z4V5Q/@H@
M("`@(#QR9&8Z;&D^<G(U,#4P-S$\+W)D9CIL:3X*("`@(#PO<F1F.E-E<3X*
M("`@/"]D8SIC<F5A=&]R/@H@("`\>&UP5%!G.DUA>%!A9V53:7IE"B`@("!S
M=$1I;3IW/2(V,3(N,#`P,#`P(@H@("`@<W1$:6TZ:#TB-SDR+C`P,#`P,"(*
M("`@('-T1&EM.G5N:70](E!O:6YT<R(O/@H@("`\>&UP5%!G.D9O;G1S/@H@
M("`@/')D9CI"86<^"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M
M93TB07)I86Q-5"(*("`@("`@<W1&;G0Z9F]N=$9A;6EL>3TB07)I86PB"B`@
M("`@('-T1FYT.F9O;G1&86-E/2)296=U;&%R(@H@("`@("!S=$9N=#IF;VYT
M5'EP93TB3W!E;B!4>7!E(@H@("`@("!S=$9N=#IV97)S:6]N4W1R:6YG/2)6
M97)S:6]N(#4N,3`B"B`@("`@('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B`@
M("`@('-T1FYT.F9O;G1&:6QE3F%M93TB87)I86PN='1F(B\^"B`@("`@/')D
M9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M93TB5&EM97,M0F]L9"(*("`@("`@
M<W1&;G0Z9F]N=$9A;6EL>3TB5&EM97,B"B`@("`@('-T1FYT.F9O;G1&86-E
M/2)";VQD(@H@("`@("!S=$9N=#IF;VYT5'EP93TB5'EP92`Q(@H@("`@("!S
M=$9N=#IV97)S:6]N4W1R:6YG/2(P,#$N,#`P(@H@("`@("!S=$9N=#IC;VUP
M;W-I=&4](D9A;'-E(@H@("`@("!S=$9N=#IF;VYT1FEL94YA;64](E1)0E]?
M7U\N4$9".R!424)?7U]?+E!&32(O/@H@("`@/"]R9&8Z0F%G/@H@("`\+WAM
M<%109SI&;VYT<SX*("`@/'AM<%109SI0;&%T94YA;65S/@H@("`@/')D9CI3
M97$^"B`@("`@/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q
M/@H@("`\+WAM<%109SI0;&%T94YA;65S/@H@("`\>&UP5%!G.E-W871C:$=R
M;W5P<SX*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D*("`@("`@>&UP1SIG
M<F]U<$YA;64](D1E9F%U;'0@4W=A=&-H($=R;W5P(@H@("`@("!X;7!'.F=R
M;W5P5'EP93TB,"(O/@H@("`@/"]R9&8Z4V5Q/@H@("`\+WAM<%109SI3=V%T
M8VA'<F]U<',^"B`@(#QX;7!-33I(:7-T;W)Y/@H@("`@/')D9CI397$^"B`@
M("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@("`@("!S
M=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C,P0S$U.48V-49!,T4S,3%!,#-"
M0D)&1$9!030Y14,U(@H@("`@("!S=$5V=#IW:&5N/2(R,#$T+3`S+3`T5#$S
M.C,U.C,S*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@("`@("!S=$5V=#IC:&%N
M9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A
M=F5D(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C,X,T$R.#E%
M03%$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("`@("!S=$5V=#IW:&5N/2(R
M,#$U+3`S+3,P5#$Q.C0T*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@("`@("!S
M=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`\+W)D9CI397$^"B`@(#PO>&UP34TZ
M2&ES=&]R>3X*("`@/'AM<$U-.D1E<FEV961&<F]M"B`@("!S=%)E9CII;G-T
M86YC94E$/2)X;7`N:6ED.C,W,T$R.#E%03%$-D4T,3$Y.#-#.3A!1#%",S<X
M,41$(@H@("`@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HS-S-!,C@Y14$Q
M1#9%-#$Q.3@S0SDX040Q0C,W.#%$1"(*("`@('-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#TB>&UP+F1I9#HS,$,Q-3E&-C5&03-%,S$Q03`S0D)"1D1&04$T
M.45#-2(*("`@('-T4F5F.G)E;F1I=&EO;D-L87-S/2)D969A=6QT(B\^"B`@
M(#Q%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@("`@/')D9CI"86<^"B`@("`@
M/')D9CIL:0H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#TB3W!E
M;E1Y<&4@+2!45"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/2)!
M<FEA;"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE
M/2(P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/2)-;VYO='EP
M92!4>7!O9W)A<&AY(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I697)S:6]N
M/2(U+C$P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS
M=6T](C`B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?
M0VAE8VMS=6T](C(U.3`Y-#4X-3`B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E
M.D-H96-K<W5M/2(R-3DP.30U.#4P(@H@("`@("!%>'1E;G-I<T9O;G1396YS
M93I0;W-T4V-R:7!T3F%M93TB07)I86Q-5"(O/@H@("`@(#QR9&8Z;&D*("`@
M("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64](E1I;65S+4)O
M;&0B+SX*("`@(#PO<F1F.D)A9SX*("`@/"]%>'1E;G-I<T9O;G1396YS93IS
M;'5G/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`*/#]X<&%C:V5T(&5N
M9#TB=R(_/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`?_``!$(`+H"*@,!$0`"$0$#$0'_Q``?``$``@(#`0$!`0``
M````````"`D'"@0%!@,"`0O_Q`!%$``!!`("`0`&!@@$!`4$`P`%`P0&!P$"
M``@)$1(3%!48%B%869?6"A<B(Y:8U]@9,3.9)#(V024T.5%30F%Q=GBVN/_$
M`!@!`0$!`0$````````````````!`@,$_\0`.A$``@$"`P4%!P,$`@(#````
M``$1`B$Q05$287&!D0-2H;'P(C*2P='2XD*BX1-3<O%B@C/"(T.R_]H`#`,!
M``(1`Q$`/P#?XX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!4/U
M\N"_NY=G>2R/-K?D=!*];[^,=8:&$QB.0@EB)K1>O@AK-T3$9+XR;VGREAGY
M+[\R#F%48XRA@=@TC+45(5B,L>#322IM,K:?-M1RCJ^16YV6\@'<"K.Z'=#K
MS"+],#C4>[`^,RI^KBLZ@M38ZZ18[V(@KN=W+&+RFVT#UF`V-ST($DNL$=)G
M]I4A(6;$1'3+3&RZ:PTJ5LIM95MN;V2B%.3<NV!,;N'?_9+K%WPKF'2#L@8&
M]0NY0Z)U4&D.D9K74ETCO,C*&^D<,N2^]8%M"D8[`"`$IAE8N+;='@XNQD3[
MY]E>+11X,<"))TX7IEN_O+K^G%QD9_J*YKD(>6+M#UVD%K2$W2-6]3J!LF)0
M<F(@3=H/F4Y.RD+)SSN0"X>,E3[+QK'&KG1B\/J"6;MR^5;,44=VZ+41I;%+
MB[=4OA$;LS%G=;L[V`ZS]J>M5C1.56C,NLEJ5EV5T*QX=$Z;D]&2RSHQ0<KM
MF@X%'#(!LG>T:DLA1KV62LQ.'Y8]##C!NS"@F[5D^+YB0M*3IJG%1K-W#W9K
MUC$*FO(AVWE75GN9*"<_]ZG=:>)+KCY`H/8>89#5M(E;EJ]?+0L.70W`;('$
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M<`UA'[:I>ZP].(05Q8"==OVXB16?EV=E5;M+2$U0V+M8J5CKUZ/E.R(O(FQC
M>82<+%IJ<)RSB=<#!"_G/W;5V5LI7JB_R$'==[[[+)MT;K';O7,%ZS=FMNLU
ML,-M%*W1T0D"AU1G(8$TQNLTDK-=9B>>PS+?#Y<7^G>)S2PS:VEX8[R;@KR-
MQ0CV^@G5#>MR;=S8\]L:NXW,6\QCIM9N8KSKQ%>QVY*41L`F3:105(8L<*B!
M`DS+$+#1(A694I`6,5DHD]D9V;3/J6O66*F5!7^6N_R16)WD[V4=UML212,;
M0/:OI`+CHB3`Z"8U97]!6M3K.P[^938N5BXRS#>JNQ%=6%;Q)X?GK)^U%-&R
M^PO4OEP-12E2VL::L)Q3A>7`_G13RWV05ZQ1)7LA#E;`M07TK;=NW=H?3NL8
M&-L2-N.Q<NH@BWEK5^#KN`U6^`$Q+(I[=D_.#BD03V(:HMY9M]%7(CI4VLIB
M+N+3OGUQ)-:^6%[(&M="ZVZTFIU8MA]K^TG3H?"G-EL(.U_6GUKB,PF.'[0_
M,(6-6UB<Y'1)1!-W)P,1/19X_30)1U[NV7QP-B)E_I57)M++.^];SP+GS&R5
MK)#435ZG;H&A=A=UZE10<WJ-PCO8?1VLQ=NV(U(N&=:/DF48D<.>O6<9D`_)
MM_F7#\"7L=2`O$Y6F&QH]'ADW"\8Z\3+(WRSP4G)>K(Y*I3Z,>[29Z?(@26\
MUB[V31I?N96DVL.`NC4,!IF%!@:/*0_,;-OI>:A3Z0/7!8A70>:#8J;62$V<
M;X3SA^N&>)_8IY4VDXBW7RP8UU_D:];=O+9C=.=9IX^L".-1$JEY:;7@#-L;
M'%MA9"4UJXC4*I!_83C5B`G+!ZA*P$42)H21N<:BQ=B[4^ZI=LK?-QD1)BOF
M"VFG;7KH3#%UP=)=G>GHI6"TM8JP6+@V':5UW/<=?2:QVV14$DY8(S&LH[,@
MXMR0>:Q:8J,`C,$"Q,Y2!8.A=BSU3N\XV9PGUK![`9Y6)A5Y>TXH3KJ373(U
M>R_DKC(/$KL>'0\7"PG1R$`[1-0L&1BM.MW+Z'/8R]>"X"1D(DS-,%L)-Y>7
M?,W/Q8:)LX96I>OO<S+3GR^"Y.)F#VF>NECV$M".OM*W=+EELF&XV#?,'UJG
M_9"O$YH_CT0E`@1"QPR+Q>)S28N#C9ZQ.3;12.QB2,8X<<H,2;.$N);71I/&
M-9CZF!:R\K$S`R>AB]Z-"KZ47]T9\<\]CE9PXQ%T*<=6_P!T+GD%:AY1N:)5
MVQL&#N%G:NI&<-GTDF<5BL.`ILXT.E<FU3=%1IT8QE54F\XI2>&'#?HB4W<#
MLKW"KB%]=+5CG6NTG\:T>VR_[6=>Z2F592_LV!B8%-I'X?8=5-EDWXRTHE'#
M;QG*3L?C?PB1D$917S&2M13+>71I0923E3PJ=J>>D_7$BJ2\O<GJH0M+1HT=
MV3H>L_&31O<M[9)$GBL+<N(G:UP/JCV)E8LQ@+B(0PVQ<Q,P[*1`8@Q$-WY-
MWE%^BD@R##!K8Y/;JIC&(4\],259/R>MC-AGJ!B]1$_UO/NZ]I])H?KO/F0P
M`[<U;U\$=AY=;KF3.8,9^!-AL*-HLPT35BLA<DI=HU8*O=0JSPPR$V+3-ME5
M/FXCKX&!>H7DUM?/7#QN:7A$MK1LSNM0LQ-1JWGDA"P87-NP4.?)J-:@)1Z*
MUZJ%C!B;@B#<I'#C9NS![-0DGV6&HY"J*NQ:J5-<84M6N[:\M_4OEU]/HQZV
M,8V]&/6QKG.V,9]'UXQMG77.V,9_RSG77.<?7ZN/\N#F?W@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@&!#W6&BY'/9)9A"!HMYG.!H4-89$">E,68VB)CJ*K0"-MF/
M1@X(C=K,A`Y=P''MK$$29)L"<.`26NH=PLQW%E^LN&G(\)+^B/4>P'=W/9Q1
M\5EJW9!.$IWCI(71\JUL?]6BS5:MU#S!X858X<5[[FW;P9TP;LW,18Z[CH^J
M.'K+ME`VJE$-^S,;IQZG:SWICUJM2(3R`V76V)]#;/>PDA/X[,)?/)$.E+NN
M=&FD)5)IE90ZVWQ'MAXY=FDENDCN\'#GSE-=XP:+H@FTY5GN/@8Z5=:C\CFL
MO*U^0<RFR("&JRP)!I8EGM"\VKB/M-F0F$RE^SF;=P=C;9LJZUW%DMW#9TH_
M*+O-'"Y4BJZ#:>&^<%CK@>I@_5F@*VETAG,)K0,!D$GD;B8E<HNS3H'K,7D9
MS"R$P$1,@3=Q2.2TI$-E8N7DT=""CA<`Y>""3]TP>NT%@EZX6Y8P=0QZ=]9Q
M==6!4HJHHX)KJTX\QAU@182N9&,9-!Q0%2+"8`\68%&[Y&O`\87=1L/`&3IK
M#1(!\1##@C8<1?-G`2Y3FZP]>KW.5*>I?7R:PNGJ]E->IF8=U_D<3F%,AG,F
MF6FM>2N`H;-8+)(^]0D2)%(Y"FN^[6(E'#QP\C3911N%69(J;Z;!+4WQL]\X
MG6W1TQZQ=B)$ZEET5(#GDD=PP77JADF2D;1\E#@D]"6D("LU1!H=\/3'6)&X
M_,&KMAAL02.AAKW5WZ[1'U`536#C/PCR9UX#H]U6BPUT%CM1"Q`)_+B$[)1Y
MF>F"<=*R@I/&=GOB!8!](LABJ"MA#VDPT%$63D.W.H^_-F"*FZGKAM/7U$>1
MY3/CEZ4[1_>*;4'&]XXI7\XJI0-N:F6[%6N;,G_ZT[#AJJ.TDSA4%-K$QK,)
M0R4SMH:.:Z.W^5]M-<8%VJM='S2A>!Z:.]%NIT3M(?=<<IB/B;3%38I8XZ9-
MB<G^)LYT?@*%7R24HIJ'5&.I>50-HRCLM<9:9^E;=@/=2+4F0'LW:`DN(FT1
MRF8ZF2H9UYIZO+`MNU(7#\1^PKW<"7EN2MF?D^Q.<O``_<1'7A;+@TNAH[C@
M??(:..6*+1>/AL)B0ZC(<DDVT!MN%I@8'V\;71[>)JP53KQ$5(@M5S>E?@"I
M*6*CT:M96/BWQ\,9IJ2';9@+%V?KK.1.[+=N]$R)-,@.=-5$D_5%VZIF;S/.
M(GH>UC?2'JQ$"\8/1JHA(<O#+<EU\QE\U.2W"PFX9\*3!S:?H^TD"FBIV5B-
M5QY]1SHNW*-B9U-VW5^D!S)`3:>N27)8+UNT."YZ']2W99X=<4V(4,$)7<DY
M>$<GICJY6E_86,)PRZY#G?21Z^J3LF*I:`I,X3QIEV/QE'3"7K;9R&T]=/"Z
M\3I1OCKZ5AY#%I4*H&*CS\)5I9Q%2+0E*D%`KKKJ'<QND'C5%.0:MMGU:QAX
MZBL:?+HJNVT4<*QA59<#OD?P7:=[XS//'J>L"]).K$;&D0\=IT`"%/K'TMYD
M.#D9(-9Q&S-33F1*36M6[,TBE51UX<>OB9)U6FL4^*.GSW<EHZP[<84$EO/*
M.7S//2'Q\=,)2(;1\YU[@SH"SJ</1K4(AJ8'"$*G`38=90J%)C1A5FSU&-K`
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M;YO'J9M(==:E);05=8$=;$JV`2Z+PZ0";`L4'*QH*?N0#Z;L'<N"RL?)SNLL
M(Q6.EI`O("Q1T5,!V)AXNJ31P[R$X[]R]+D8UE?0SIW-D-6DFZ]5T08:4:UZ
MU)BTA:PT0C18YV[?B*X0$"G3(8@$`/2!%W&U46FA.-N")!4$_';OG650VGJ\
M9YZ_74(=$>IC9CNQ0IL0ELK::=WJE]3TQ^E*MO8C.84\L968YD>96K+3L.VW
MBDJ,*&=G4OCBJH64[EQJRK;<)>N4;HTC"-V!PHMTW@L'E-(CH?K&`'7KKB/;
ME:4H-O!6#M&O+42%VC%75A1ZP215Z=;,2$'M<T`5B"HY=!B^&"#84R+SN9'%
MQ=IN9Q>+U5GYHF+P9'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`'`*P;GD==*S[1B%(=YI1<12\:V@B.`X_O?`:KC0&4
M7+$X=+2PM2O8U#>M!**5G""\@DS"4R=K(XZ?8QQ`A-9!,&3AZZ?3=?H_/`TO
M^L0^[.&^_JQ(RZ1/8!H>B*E;R67EHBTKE^)G+4:VKM`X3,)6_P!?]B$D9.'H
MH:KB>OJ<3N]*-M@>@B+-2RJN^1:9=:*X8TBC/U9_."(RNGD7^%!?6^G7T@^!
MK8E7LE*3^%YE'ZG''ZJ-H_[+?&,#T[<]VSV#PMC#!4CZOT4T4KCWO'!?9G=:
M,=;SRPW8W/T_U\B_T;+_``G$WQ,?@CGZ+9<J4I\%Q._H%7F+!S(<.%,Z9ARD
MM_61^H;5+&=4S^4LS'5*%8C&-1?9^N.MHY8^%R-DM\BW;R@O(_TMZ,SZOZR+
M5;VL4L8H&FDE=2!:]P,0`R>SMXLC*40+]E`4#GT2"0G139%L:>+[*E-S^Z!S
MVV,"JE.BJI.],6RR_DO\X.8X`X`X`X`X!^=],*:;Z;9VQC?7;3.=-]T]\8VQ
MG&<Z*)[:[Z;8QG]G?3;7?7/HVUVQG&,\`UH,]Q>V-30[R)=;Y9:,M/6LWH.>
M=SNG%S%!(E^7C77UM`9QBP`KURD%W&++4O958.(5&2\@:EC#TM:<%?'G#E)?
M3U!T23V'&-2IJ6^?FKY*S2@SO3OE=S7M*4<+GT,EEH%8EUT\9,Q[&VH5E.K.
M3OYEY"7S>)!C$.BND:>MICJ$DNCN3RQHF:B`\<+(I@(DR<K"]1J8FS.Z]<+_
M`!4W<VMKQ>ID0/Y=#AF5M(>/ZL$SILD1\F(`.&B=KIFI"?E'CE+B0RT?`BGU
M;`F[YW>+PV.;1GVQ1FI&'RN6CQ`[CV:ZHNQ:9[CP[_/+Q/G5OF+#7798"JJE
MH2163+%(8"L2<!(J4G3:2PB+OKSBU'RT<7BLRIV(F`,[JIV]G$ML>+6$G`F+
M(-#A#:,2.5K6#''.@CHC%\-_LSDWC9+^"ZK@P.`.`.`.`.`.`,__`&^K/`*P
MY"Q[TCS(1BU*V`>#LYGAM)S8Y.GV:IBG$KOO?28/F+1)%ANUM!_5&*'<0M(:
MS9IM1VS]$;HVDFLJ3X->S'+?C"^<_P"CR.NGD7^$`_>\3CZ2_`$_I9ELI2GP
M;Z;_`*JS'ZM-H]A+?_IC2ROA&;_U6UPFJ6]A]#]%(!\8QD/9^F.$Y\L/&YW$
M:_Q%4UE%-4'CF1IL66\.;6*]KYI5J\VUJ1EFR4+<=PE%].&U:N;APMI53B",
MGLB:,=BBJK7>*Z!$-@]GZXS$Y93&MO$\MX5O(I9?DVZIS6_;5@D&KR1Q>_)A
M4C8'7^Y]0(N)C<(K64-R2^TC)E7V22[R;/VRWLW";;W9HT]1OHK[;=06NG8J
MA.;(M[X,#@#@#@#@#@#@&OKY:>W5J=6^T=$Z1N4WGK5ICJ#W5LFP(+2>1+T\
M[DE0QR(NH!/$!YI5!)-I7Y"3/9%)L(K+C'4>8.'4D`R(8*V8Y'2BE5)Z[5*4
M[YGK_H]VMY/9YUCZR]8S]YM*^[.3J4]<J*MJSK5J"P@(@3+4K2NJLJ44DL.@
M@>)O3"8M':RF$HVF$CCE8U6?,L%(,"."),89`AH;,NJ+0W">Y-P^F4OS)K=+
M>R-J]@;+[Z@9^%B`J+]=NXA^@:RVCA!^X)KQB-5-4LG64D3=V$9)J/WY&8.3
M^Y)(FY]1P;=1I(<@PC#$W(AFI)*G?3+ZLGSP9'`'`'`'`'`'`'`..\05<M'3
M9%XX'K.&ZZ"3]GJTW=L554MDTWC71^U?,-W#;;;"R&KUD\:;*Z:X<M7".=TM
MP*P$:J[D,VT4:G35E2MN+AU?,9PH"M\>"+2\0,"T8S/1@&]2E451#6IM.(_<
MLP.V&EK'T#<0DK6*H3!WE^S#14:E>.G'<[1%MQY<74OD'1W;:E)L?=&]6#)L
ML>1L9EB+?K8UN1^<;6AO'=3339>FV%%J-(*9K+00UR8E^N'NE:N76GZQ,!-/
MK&,^<W3\<CJ9P`[WUO"9[8T1D!6-[P:L#\MAJ%O3G-H@HWB)UA=+N8A+,#"9
MTJ^GY>8V:ZK&60XHT(%=X[#0[B/ZR*':,G,5/"J'"=[K"TW6%E%I7%SP]#X5
M>Z-Q]^NA\.[&WLE$$;".SVR8X]T@X1U'H_@=%9&J+%Y0&O"IE=-Q[MICWE79
M^IA93'KXT3_Y>!72J:FE,6Q+9.#`X`X`X`X`X`X!4=VHL"T=/)_T,Z_1RUI_
M!JNN^CNWAFP0,/,-QV"4BJX#"WU?R%NJ\8$=6A&./Y*1=X1U3V$G,X:,Y.,-
MC6R;+@TDMFIQ=.F.<SY?0A'UT\UMA#.LC,]=59*6Y8U:41VJ[$6+8XL@PK(%
M95&=8^R`B@F<V@8AC&C0,O8$^3,+E=@+/,2A."<8(J-BH(;(A+(6-OLU-G9N
ME:PZE/3Q+%:Y\A4LM#M&/H".=:Y&VB[BT+,@9:P3<H+#S<6BL`I"J;D!VY(X
M*WKI^R%0.U%;3:0FNW)"<,E"IT5MJJHF]=/0X08=-IG)>+:B9Q47M]2SC@R.
M`.`.`.`.`.`.`.`4ZV:SALA\AX<\8B2!-\@O1P&*$#D'ZIHG6)N!S>8O)$1%
MJ]G)'';^T!COB`HJ.DW6H"7$/6FJQN%ID9KA8@6&E[O77-*,+<F7%<&1P!P#
M4C\T?8BC.L?FC\4%T7!+2@`)6<6E!><;LHTH7:1Z#2LI-XHPE;MRP,J&%M$)
M"HM[V*8Q-VM\('$R#4@Z=MDPS@=J$WV=:6[._KSP-LP45&'18TX%?LRH<R/9
ME1)0>X2=L"0PBW3=L'[%TAMNBY9O&JR3ALX1WW2614T43VVTVQG(XG8<`<`<
M`<`<`_.^FJFFZ>WK>KOKMIMZNVVFWJ[8SKGU=],Z[Z;>C/U;:;:[:Y^O7.,X
MQG@&$W'6ZB7D5>PE[5L3>Q@E#9/71`8]89>8>U_-B;8S,(.Z>.5%7Z\1E!-F
MW>'XXHZV#EE-,ZOF:Z:BNFX2]=/##ID=2.ZG];!*D"4'4K7[7-8"(;'X(GH!
M;Y0CH*MRCLY6@9LVW]9NX%UB;?/#%9L'Z3MK795TN0AB0-VKNMD67KC?KCUS
MUS//[=(^HF\H/S53KE4:DLE#RS7YR0*0P0H4>O;I:-V-N.<.MT-MVBUDMVVF
M)KNR]VS(E57CDG[PY?OE7`2]7EF\L.F1V^W43K*I*8O.7-)0!_.(<2D)<#-B
M@5,K,4B,K?L2LC=$I22V='3^Q<H+$DG>D@?E$]GX@.\UTU<"1RC8)<1+C221
MO!!P!P!P!P!P!P!P!P!P!P#6V_1@8@ZKCI;V>K8JQ.!3L$[^W7'3$?E85.,2
MX([&UG1K!1E)8OJ=DN\?*I.&;ENZ&[G2WNKINX;X(N]D-U.#IVOO3DZ4UI&X
MV2>#F.`.`.`.`.`.`8@E5`TQ.;'BUO3"MHM)+,A`0W&HA-3`_5Z=CD=DR"C6
M3`A#I;;;#,1)6JNS61#DM-6AUKC1L61>()))Z!+B)MID8,6\<W1)P("@%>J%
M(;!(W$U()'A.(,)T'@X;O.-;,UC`AIHEJB."MK"PI-&+!IHDW'25T0+L-&SP
MD_5<B[3U>N+SL_"Q(6%TO4U=2NP9S`Z[B41E]KEV9^R)#'PK,83F9M@+9!FI
M4\X:IIY>OM!@YBT4<;8PHXT:(;N-E54]=\"2WGAAN,F\`<`<`<`<`<`<`<`<
M`<`<`Q?=P-Q)J7MZ-M$%'3J0U?/P;9LDJQ;JN'!:*%F"*":Y-Z.&HJ+*.-4]
M%2!!@Q3VVQN[>M4-5%]!5BN)3)^C=1AY"?&6#AQ!JLQ?Q3L'V0C3UDX<"W:[
M1V!L\L)<MEG00D9#.5FZS/=%1P*+E!JV^FRC`B^:;(NEAOM??XI>1?7P<QP!
MP!P!P!P!P#"-@];J)M>:1ZQ;(JZ)S.<Q("<B\9E!UAEX7`QN4)9;RD"*=;*X
MV9")0VSAG)AZ&-&LA9:),C"3UJBDCH++PEQB?.3=9>O4Q%Q('(Z7K<D"@D>6
MAT1!YB8AH%!PATZ`/GD":"6+9L.S7[][$XJ])01=LM$2+N,1QR^#.%P8O=J$
MO7'U]>KU(LP[QO5A#.T)GM2*ELP8SL[;<JMLNH!DM@1G61N)3%7L45A,PC8:
MPD*>DD+'LG3-9OZU/L)@1=1V-OY!+S!EL7+'!74VH^F6EIXW?D6,<&1P!P!P
M!P!P!P!P!P"GGMA5]A7-VIW@\/C=J3&/98]<2DTD\<NB:U7'J5:`K%DDDT1T
MBP/L'56)H/LMB)?L)9+XA$3,VA(MLX=B%IW(!$8AH$:6&6<2DYLLXRZ<+EG3
M',DK.GA^#3HM:TM@5=,$S!!O\+$&[#D$9CB*9(GI@R4:B!I"3D&:[[;5^7T:
M-%GFVJKS?1/U]AGP^1#.0>01F#T%+_JJ=.FT@C\ND@3;Z9)(.-V-84B&O6ST
M2[7Z,+9$O&4<.-!-?IZJ/D9T7T76)N(2$PB67&E3*Q]-POYW:G#)^1(8(`GY
M2]JE]L#C$/!V*6]UF#=8MM"Y]'8D;K+<:.5CC=N^E9)>7LV=AQK8DV;5PT;+
M&4SLM8NAOOH;-XF]^JQ_AY[C73\ZT1ISR6=CNE'4^"X'UMWU-SFWZU>F)4UL
MMY7@V`0C:WF*;!":-X\/BTCC)BUJ]7SH8$QIS.00XNB[(1]#&'(%0=>S;H55
M3O2HS6<93C'\%I7@X*6KU6B]A>+CN-,BCOM/0Y5Q9E>)F)&_DT1L#K--&P1M
M'#=&RHVV'%9'#(9,&\@`'A#H<R>PXN10$[,VR&/AXL8[2'[=/NNW!K)\KFP-
MP<QP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P".UO7VO5DPBT-2@A`^XF<=7?
M@SRIT6'CN),XMJF*@!1DEOIH7D+-NZ-70(-&SZ,<>M0T?%/%&#20E5M12(J4
M^MS?R(P*^11AH)!&]*F>;L9,!F,B$:[31'1WAA5%2?K=MA,FAI&%4V#I@*S@
M56F$W#QG93KTDW3V%`L?$N"[._TW"CGCA'$YZ'D0C+5B3D<EKHL'AD9CT8G<
MO+C"Q"5GAL`L.%1R;5^2`PT#$5R\QE:C"0Z(3V#A-]B$/V:>W"/IRB1$Y>AL
MWB;Y97Y^#P>Z\:A'@"[F=6>K'DX[IUH.O?2,]2KYS,]J6G-I$6D%B9;Z`3LQ
M(JO)3LY8[P(4`R/>N#,K%,-RN&SLV5?+HE6B+]1@D@._:4U.BEQ=8Q?*_D;^
M<8E,9F\>#2Z&2,%+HG(Q[8M'I/&"X\_'CHIXGA5H3#&A3AV-*#W26<*-GK)R
MNV73SC=)3;7.,\'F.]X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!%6\.PL
M@J68#(NA$XRL./QP,0$S"3S18`%8F"=MUO63Y.3)(QTA\'CXAO8PXNB7U?.7
M!DDGB/\`N`E/=,RJ*E/^MS?R(F1_R6D3Z(Y]K4`]B@0CHN:ZAUYTNI*,C'-L
M2.HUZZ8#,11+0G=!9['MIA"H=A5HA)8^X79;/!RP[)-Z+L[_`%$SPOCX'72/
MR.!?HQ+D[&IC$W@C""HOIX*J`XZM0U,HS,:5M:V""5:QSX!'OIV/C$?K<A"9
M[A5Z'PVDQAQKHHV;A%$28*EZP]]LTKZ8R8A_1Y#4%DGCR7D%7B-X_6YOM#VH
M+P`"HR3';A824N`^_B0C<>BX=HL=AL><#66S-%TY2:[(903<+:IX4V&NTE57
MQV:?)3XR7F<',<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`K.N:J*(*]DX
MYO*;WBPVXGA.*%HF-.4AUZLJXH'N2E+]Q!$J\L>55%)Y-!1&98D2=1':9_2?
M88^0?[1@@+9L$4AXTIC"W%WLYST\MY9&S'I-1C44HJX((-F*`_=8HME^[?)(
MM]6VRI%PMC.SQPYTUSN[65QG+A7=3=3&<[YX,GC'-2U6]6=N'E9U\[7?YCVS
MY=S#(XNL]VB3?W2*;.U%1N^[C,9:_P##1[*VV^0K?]R-]V3_`&>!(TJ6JDW"
M;O2LZ^T=I$)(72=:0R.:N$BTR9ICI>336P-PIH0E8]%)C)'NNV')QFDFV**N
MD--=,!+U-<#R#P5"-^>#PLKQN,M`$)%@+,C8]N#"ZBHZ.>?#K#*:BV23!F@(
M:*9;Y6=X8H;)K>IG=QAO[/.RG!UI?_Q]IK;S2^9)?S@>(.QO*2.ZW&*@N&(5
M#/:".3S?+F7B"^[,X%GN(6XRZ:R*,MG<A&&(H1A#9R'8ZMU!SW8T_74=#731
MNJX$[.O8F5*<>'^R2?0?NR3D+\7T<[;`"5*]\:9@X4:?B4N.9-A^QD5C0M(3
MCL#14^<H,D+-C,LT&.#DE8I))RR'&-S`V1C<?"W)#82JG]2:=+>66YK(M6X,
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'1FXQ&I*@NUD<>!R!LY&$0CEN;$L
M"J#@,8V9[EA*Z3]NNFJ,*;CA^Y%@IKLU>[,&>SE)7+5#.@'E]ZAJ939;=2KZ
M[4W<;1K9QOO"HUMLOM#&GN$/V6VV&9RKM%&/_!1K.^=L@FG_``POW5']C@2<
MMA6%:"B3`R+KR##3`HJ>.BRK")`&9(:;E2"364&6#YN/3=,RLD:H(-CQ!NJF
M[,((I(D%G":>FN`DU)/`YT;J[N+X<^V?4KL<`D`P))>[EBC#3L2@C'+$A<CB
M$`Z]F0Q@`[D8)^J"D`,NSSKE$H$7169.BH8J-<C2A%DX';M*G3VFTM%P)T]3
M+[A'A=D,>\8O<B;M8K1SDG(C_C][.G1[W`:T(1,+`W*RBH+:=@QS@9%+8K&9
M3U/9_)W3<'!S42-BBCG:*ZZ#FI89J6W[=-W^I:.,5N<6T-BO@YC@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@'%=L&+])5!\S:O45D5&RR+MNBX25;JYTV505
M36TWT414V3TRHEOC.F^=-,[:YSKCT`?'(D5LMLXV&#\K[O4B6ZV6;;*VQ%!K
MJR0(;*93]?9ZBRTT:).L[973:ZZM]%,):XTP!AKL-'QJO7V\&K-@)9+;4M;@
M]FXVT&#$66AF'F%'V/?G:C%D.:O'>J3HBNY>,V6RB6KM^OIJEE?058KBBFK]
M&/8[C/%)`1RJK995C<U\,U%F3X>29JJ-)Z\;;J-"(EV0%OVRFR6=D'HU^]8.
MDLZ.&;MRV426W&^U]]\%Y&P5P<QP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P"J*]U)4+[LPTU$7<R%[&7W7L2O'(N-[)/XQ;8UG9IT5-"4HG5;VE'.O]:N
M*M`O23QZ#N"!R(O8C`:G%DER[8B##B1I8/#/3RB;[G;$M=X,F-Y)<53PYZ8&
MRNR8-'",>0C[H\/,R@,/?!6LJTD:T<=%FCEXFX'M3+:'RUZP<NTTD%QT6D9'
M53W$(3<-0.FV["40FMLW5N.LT5M"4A$*:+36/(^R)1)H/?29JOLJ0TT0W!,R
MXAR4V5VT3:(EA6ZN^N"++VXL/1_[P*:>_`9C-/)%X8KUB9"JY%"'=[6E7K61
MB@6']C*FF53VN1(#$IV@^V;)PH<N,?,RD-48ZO6<U9J.':R"[)=IJ-T^YVBO
MA3GJUEZL7[\',A_W'Z3T[W6@0J,V)H<BL[@I7$LI6\Z^(;QJX:-G[;*2H^9U
MQ+VF-7HURFY;,]BH=;=8'($&J"!9BNHU8N&8JJ=.&=FG@UO(<=>.[-Q]?K9B
M_2+R9;@P=LR5SD+UL[?!!^L?HSN*S;>JDR%NL9S@;5/8K"&4-9%6!!PB,/E=
M\N(.NLU+1UD6&G2FMJG#.G.GZK1];EP_!@<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`X1(D.#CWY<N_9"A(MFY(DR9)T@Q'CA[)'=R\?/WKI1)LT9M&Z2CARZ<*
MIH((I[JJ[Z::;;8`QBYOVC&>SO5W<E6M=F"8%5]JYGL70V9)2@3\?CBKO54I
MKLW3.`?_`!T7NMC35X%QDJAG=AC+C`L/1G-'793A@LP`";6K@F<*G#49&!F$
MUCCPH0D<<;#WI\$R8-R2CIR7"LRPET4'HI;NF+8H-7<I)I/VFRPD/0IR\"%?
ME:IJ#OK6IT?70HS!O)]V4C!,;4<=>1&KV+T/`Z/9N&L!BY!X0?`(HBHEMH%%
M.WSM=DRPD@HNIMIG;+^?"QNMRT[^ZL;OF3H[V^-GJAY%HI&8]V4A!(P:KY*5
M*5;/XO)S\2FM;%I<P8M")B/OPS]LQ(;Z.1`(MH'E(X_'%R8(6N]#NM4-DU!*
M:ZJ?=<3CO(X=4.VEQT1<87Q[>0XRS<W0];.\=5^U6K/0)`.ZT&#XTTU:N/3O
MLQB79*,,MVJ,^KU5SG<\MMI((WN0:$F3HL*Z4UM4X9TXNGZIY/ED7!<&!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P#RDYG,0K.'R.?SZ0C(I#(B)=G)'(C#C#
M8<*%L4\J.'*ZGHVWWV^K":#=#15T[<J(M&B"[I9%'<#&S_LM1XPZ^C3Z>-4#
M`TXWCSYM\'D:B+9XN7,QU5^H_1#J#OHR*DD=/1F13+5WM$8Q)A!".R(V+--5
M6.HL/3UZRS/'&NRE$3B,'8X&MF/AGTEB!])L8D45*.!$;2(0H_)!9F6"92+&
M!FX\E%`YB<1L/+W(EI8T-"E#$=V+QU-T03"&LO7JVY[RIS]'"MJL)WTEL>$P
M6S([8T@K?M-?ZLL=`HK]`-%1L^L,Y*H++6\#PV:MHK'YY'E?C@`.,U5%A=-7
MT815T>1Y^S:#?:)IJ5$TT[\$EX1'CF;!'!S'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`*+>Q,.>1+OA!7B<0D<DB9FT>NQG4T2=UL!:QZ226Z4C2("N4(
M[TQELW<,U7*4ZL:1>U[&PXK)5XS/6\O>BQA$<2D@VL'?7R_RY8:%Z7!@B_<?
M5>(7$7D9U_(I%&B<HCP*,$EP*0/.NPP9$+VKX@KC0D*>^U)E87V$F@O1\YV7
MP.>#(H_0051%/!Y,5./7!_(PZ8\>5<'Q1B/E+!L-0`?BHVO"H]M]%&ZRE<Q)
M:)OZVB[5]F-JKMG$$,0X<31D.VJQ:2Y?%F<I4*LU!B0D7:>[&>>$FG5Y?(:A
M`O+VG#H]>]\B+J;4Y!I5UGS4>5(:;-=TKPNPQO&A9R32E4#!()"';JS3ALK+
M8NH_#XB`A"OGYI2:8DF^!VH_\<PFKIM]U*\9O##5Z8;@GCF[<61V6K^Q(%V"
MKS2LNU75B:"*1[(Q\6;"R:'F9^G"(W*$I[!3L>45&9C,Y'FM#2$>WW^)Q)WN
M[C[_`&=ZLFI,@.-2B&G-+NGG$Q#WKIH6)\&3"?8?KI3':RI932%^00/8=<2Y
MMA(D$+)[Z+LGJ&-MAQ^/E6VZ)2.2<*OM[V#D85VR+B7>N%V;M+;.V-A4VFFG
M#14S$K_O/Q22<!2G>.8R*Z^C)XJRC%"]_#B>SZ6TVJ^7T91RI>Z:K1+&B;77
M;=N'B_8/5!$064PTQ-,,5WSU2,#<*M33"J6-.N^G[>FA;[3=YTSV(A2%D41:
M<!N"!."#X0E+JYE(>7`,%AFR>I$4J2"NWC=N29>V0W=,%]TW:*3ALLHCJDX1
MW4&&FK--/?8RKP0<`<`<`<`<`<`<`<`<`<`<`<`<`ZLT(9'Q!,(201<L"K%R
MP=HKHHN$MT726R6_K(+Z*(J>KC;UM=5--M/6UQG.,^C@$$2WC\AI1D+&_K&F
M#=A'@4FC<;1U'Q]3<8*LFJDJ?M;"Z^S+"A-Y*8TCH4`.'>?9PV3:ZN6[8L!]
MI'%!K:>Z]WR<KUUN?EWX\:W,CBD:DLUFAJ&22,`:[E4>071CKHS6$&911K7$
M4:RB-["Y+'2D85B+-V1FL>(CI)(E217"KD?KH"^!!M.9SEOKCCZMQ*C_`-%"
M=%'OCNNIV:=D'Y=QW>ME4B]+.'3LFZ>;5+0>5UW[E[NH[7=*;^G995SONMOO
MG.RFV=LYSP;[;W^2-G3@Y$;.U_4^F^YM.&Z6NH&Y?@WSEH<C,F!N\AIU6LY#
M[;KQBQZWE"&F[Z*SB+/=O>Q)=IZVBFFSD64:D0A$D,>"JITN5_M:,@7U3[87
M)U[N,!X]O(<<;/[:)H.DNIW;/+3`>"]SH6(]1-,.8WVWW8Q/LQ&66S1&:P==
MWMF4J;I'(^J0^),'<@&G2FMNE6SI[O\`#R9</P8'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`/*SJ'B+#A,Q@!_+O4%.(K(8>:V8+:MGV!$F$.PI++)QNDOH@[PS
M>K9;+;HK:I+>IOLDIC7.F05KD;#?2JIC\E/R9\6G'M9*L8:%Q210#\)<0V5S
MF3V7.ZYRFM&5G_T0GD[EQB12-38AO+$E/<14>E((`/:B4Q9?J>">.46(\=B.
MA%'I]>[[6,[S*<)N*1E6#XB6$0;\9-5Z]HZ=5S62DC:CHT+4V5@,.D)`,$P#
M6"Z%5<M3,PTE$A9M2R8JJ<K*ZPRO?KZL:?GB%7?>*KKG7'F0++F;*HJW)/9'
M4KL[4`9!LQG,%$[S,4^KFS*S1)2$/'9F6;2B$:B3X.3+B'`\6>>:!WV-")!\
M)'?M/;J="Q4-=+I\L/'4WZJ#NZ!]E*5J^_:O=$7E?6["@,\B2Q<<J)+8#R!B
MD];MR@U;939D2:94W:/D-%G"&CI!7W9TZ;>R<JCSM0VGBG'0R[P0<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`J1L*-V\_[W.R$7T*J-4C/75:4&*T6[!BQ(
MNOQTP-/V@ZVP8V^X!4LI+OA&)6QW,:0V9)L(ZZ;*2@$=8,1\1=#5MGKIHO\`
MBWIFBV[@R.`.`::/Z0'(^EI7R8=#8=V.L:61B-:A0`7M?&V,5D8",%^L2M@N
M;#"*2.QXSA.8GAJ]B1)LU0!11D0T`[)G"@@\!EB2^N@[]FJMBIJ+7IUVHC##
M!YG;=D.OT5Z;6+75I]`YCW^Z\]'>T/5LM9`LYTQ#VM>3NRNW(APV*45M8<4M
M,38$SC(RRX/)=%B!0YH(VL78:P"OGX=-H3.,7K?X^D1.4U5LMJK"IJF$\8B,
M^FES88\8O;'YQ.F5,6=))='I'=0V)!X;V.#B&>X$Q"+VC;!`=8,7F$,=-!I"
M%25$P@L^>`7`MBRTU>)N0.CB/KC'2PYU**FLLMZR:>?$L`X,F#^RU`0CM305
MM]=+(5,MH/<<'-P61/8Z\2'GQS,RVRDF4"NW#9ZT2*"G6K<BQ]^8OF"CELFD
M_8O6>Z[545-IIK%7*:NMG@!A74.O=XWUO[^=\J;F3HV_D9F102QX>PKZ3F'"
M;9FQ<RBCB\).P`UL.%L63##U9/0Z[T1SHN;]QPV'M1M]HZG>FE\G,<9GY;B0
M7ZI?-=37_0/;7IWW)#H_M;#.S-#R?KU-U&J?UX9LYEUZ-'8HL4WTUPGJ2)U\
M@S74V]*[1KZ<KZO7KUOW$FAXJI<'/@_J/\07O+4O[/9_Q+]@<BV_[I6;=-;+
MK'MD,(9T^I0@W@23^MK.&M/3^\RR7CQ`AJE]3;5^KCU,ALTO"M<*I3ZPUXGK
M(9YJ_''(C:$0F][+]=)[OZ-7<$[55_8/7`Z,4SMC3*3Y_:T;CD3SMIOGU%=V
M4E>(H[8]"JNGIQZ0V*LE*_XM5>4EDD%L>O+0")2:LYY#+$CB_J^PD$%E`.6A
M%O7U]?3V14`^(,%/6U_:U]1?/K:_7CTX^O@P>SX`X`X`X`X`X`X`X`X`X`X`
MX`X!K<?HUQBNXY0O<FDP4LTWF$+[ZW:8<0"61&/TY;HF&+PNG8X'D<QZ_C7R
MSZKFSXP",!OA&K;`@8;$%0#1VHY%N4DAU[693:QI5U=<GF;(_!R'`(X=J^J=
M-=RZ;/4E=T?6*QLHNT,`CHAWL(FE>301G=:,V)7<F0TW?1:;Q=[O[V',,_6U
MVUV<C";8B$(DQCP5-TN45*5YY,ROCVM2)]#/*A-U74X,$``SK-W&&A57$.[%
M5D:+*1H";N)F-4=N:OL^*%4V<?L8D31WC+Y=?24K%4QN5Y$7&W3M+:H5OU+3
MAJM,R_1LY;O&Z#MFNBZ:.D4G#5TV5T7;N6Z^FJB*Z"R6VR:R*R>VJB2J>VVB
MFFVN^FV=<XSP<S[<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`\):0W!FLK&#Y8
M%RN"L$EXW(N/H"7)XEA]'R#7+`(V/)K`W!=Y[7W<:@925$JO%$4R*>[/9;7(
M+%%&O@FIJN)YXO3E-VO5@R8U^MV:[/`3U77=#H+)$U$0-TF/<Q$ZB#88Y@*I
MT*]'-LD&H<;@$P/,-E`*2#1LR]F.G:/VY3RINI62S^>A@9[W#CO@C[:PKHO8
MB1^9=&^SLC&37JR>V)IHD^H",SG+B.V+6$@)R91L/DU+123DF4PCR[<YK)(+
M%S#]L1;G<Y8J+B[+[1.I>\K/_EOX^<+4V>DE4ETDET%4UD%D]%45DM]5$E4E
M-<;IJI*:9SHHFIIG&VF^N<Z[:YQMKG.,XSP<CZ<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`II[/Q(R_[^UM.FT)K@Z%B[;KA'7]@D:TIDZO69Z1]@`A",8F
MDSEE:'[5&F#P,-8\=KC,'F.!L?E$UAKAPPK0K(&=@FQI>Z^>N2OG&CNNN!<M
MP9,572"G,BKLN.K<\7CLP]]`/!CP,Z#L7+I$>?&/"8I=X:8OF[8>5%HO&1!1
MK[D3RU543'$F+K?1?4"O635OWY<Y-_1`[+!1I9B<2`&"MD1YS'&5G*22$.)!
M/G8A0^5]I4<L@C271VL8"K'B"\$D[S<L_@<:5=CY*&&ELY^EDLKZO/7)ZLGZ
M0.;O6'=F.LL6LG>%#XX\JZXST3BTM(V,5N*S*KVNUU)6/52Y+#KR1SE.?LYR
MWB<*%0YFW=Z:BBY)ZS+S_P![>O33H=NS2AXNZPP3CWLFHESY9&\OUY<VD]HN
MI'MVQF&PFVGM?QA[/X37K9ZTA<*DCL4W</H='DB!`JZV817*NH##C9\HB\6'
M*NVB;9HN@U1'G>[`@%VPZ+V0&MA[WF\>YP#5?<-LQ:H6?7IS;=C1O=&("<9W
M3@=UBFFR*`N>-F_M6\`N1EAN?`N5=19QZJ%60(Q\:IJ7NU76N=/#YK,D'TK[
MT5MW*C<G8LP9^H[^J8@C&.PO6:QM-!]J4M,O4_;9EF.VB&#\/,9TW>0JP0R&
MT>EHC9)RALQ))D0XX*J73O3P:P?K-8HF[P9'`'`'`/)S.`P6QPB\:L.%Q.>1
MQUZ<.8_,XX'E`1QZVN=-O;BCC-\P6].F<ZY]HAMZ=<YUS]6<XX!6W.O"QXW9
M<;5ET8Z\,Z$GF?6V93OJ],ISUOD`M;;;U_;LF]02**1S=3&_[S70@`?-\*>A
M3V'KXQM@;VZL)E:.&O$\9_AW]T:G_;ZM^6CLL/'H_O$X;W`@E9=OP;O&G[28
MS:6FAM?V8,8Y]&$M7;>6/22*?[2JS[./4V#:ISH7%-KZKP'ZS?-K3/\`UKUB
MZ7=T0B'[M-YUYNR8=:["<MD_V<NW\7O@-*X-L3WUQ[7+(;.VC!=3/L]'##7.
M,:A'9O.JGBI7"U_`?XPL,KG]SVYZ:=\.HNK3]@Q,IIUZ-VO3S-7'^IEG:5`.
M[.'OFZ6/3MNLN)';^SQE75#*/[S@;&E5+W)P^C@S4&\NWC'/P`Y9@SO%UVWB
MT;9)$#:3RP1@N7#VJ[E!FAE2NBN65AJ++O'*#1!HA%U7:SI75NFALMZ=,";%
M4QLN>!-:J+9K6]*ZBEMT_-H]8M:SD9\7B<SBQ!(F#-L,.%V:RC5RE]>J[-\U
M=CB+)?1%Z-),W@T@W;/FCANF,M-.'9HR'P!P!P!P!P!P"#'8:"]FBLCGI"J9
M+,GD=-1F!I1L")ET9BNX&4C8;V4&NU@+C*L;>H"VMCG.O4XF>3ADDO)`80T!
M02D01GF`NQI1:>O3Y2O4D?9+57D"+C)`,B4PD,4EQ0&7&1F9R"P!Y.%1NUW2
ML%3EUG&XV-E3LL0IV4@VTQ8U57C`4Y+P$VY5(JQ"%N'@H^##V9O=:;LEQU?C
MC.GUX-?CE567TT[D3T!&*]IIUW3O[K1:W:83)YB]L2<6#:M$`WE?U9?8XN:U
MA@JH"DT/`B@&:Y9OUM9RGE4WJ!=(M9`3'?M+[5*EO932R23O&K^1_HS-';5^
MU;OF+EN]9/$$G+1XT63<M739?351%PW<([;I+H+)[:J)*I;[)J:;:[:;9USC
M/!YCD<`<`C'V"Z7]4.UQ&&%NR77VK;L(5YDOB&NK$B@Z1;@TCR2"1AHAJ]3W
M37'O_=6BZPY[HY8>^LV9#1OJ^:MW"8JJ:P;4XPX(&N?$FK1KA<]XX.VUZ]('
MF%E7B=0*D]^PO5!^X6WV7=ZN:(MP@3S'%"2F<H*$(+,(UN,;*[?#&2>S=IJ@
M-;<^\E5OPJZKYIGP^<7R1=6?^&[G]&T^PL`8?LNNQ/CL)/I^X3:X_92>R?JY
M8#@5:PU1)OKE^??P\[,!3+.KK0>U6T3:IN`V:7[M4;J[=&K=8)C=9/(9TT[@
M;K#:$ON%RF9,LKIF:N,+O(/<$><L_6U(-CM43=I'Y^/V'K)K-W3K>/[#L+(J
MX1>K)ZX4R(Z:J<5&_%=58F?P9'`'`'`'`'`'`'`'`'`'`'`'`(*7'1U]R&>R
M0_7\^--@4@)QIX'9.+,EH-"%R)G&BX5"9,PXW7(Y_'HF_P!AI5U5^<:1R>NW
M3HG($ERK7"SL:34*VN2NO6>1$F8TIWFK"MY_8`:Z5(D>@]7.)1&Y`7G4KN`?
M$35?=>YZ'L-<G`Y6J."V(C<=NN(W8HIL>=82CK,5N1=:ACC!C'WHJ=+:48O<
MOU6OE:48U_1NIO(K,\9H:Q9<Y1>2F>=A>R$SD;QLU08H.STJLXK(#3E%DVT3
M;-$ER9%VJDV;IZ(-T]M44M-4]-<8%[1)5M+)4KI2BZ.T*>JB[8P0A=OUQ";,
MBI0<4$O04WC0F2#]V!MGL/*H))%&KGW3+YGOE!99IL@OG3&F=5==D]-M1S3:
MP<<"F141V(\-JRCV*-K$[6^+)NILL1AFBA&;]D^AP7U\[K/X@LX4<&KIZU1Y
M'.VSR/N5G,ZK8`CH[8K$1(,HN=>N!NU>BKZ*KCI5YLN>J:W*RO>NXK;5.3B.
MV/6TW%I&(M,8J12)ABS%7.VFWLUDLX4;O&CA-9D3&/$VQ(21;NAI-HT?M7#9
M(8::<.S1D7@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%1788I'\>0.JHM+2C..
M[&TJ(*0^/##P1+6V7H6PI._V<3R$E.S==XEBU=E1K4E"BBM"60YASC*T@BY4
MR?9;`(\-+W7S\O\`%^:Y8ENO!D<`<`T>/TM:&%A5Q],KM13D(]F(B4RAP22"
M58RBV83QJ0*2^*:;+OI0W,ME&IAH-($7>T7^#-0J3Q?20_%$T1*P]'8NU2X/
M/#/!:;\<C9K\;/?U?R"5C/)WFC9_3>U63I2H)*XFA"(D!DHLV,CD-[';0IQ%
M#IU%_'XJ6<M!V2ZB^&KUT[49M%%7`LEH@.-5.RU=.5-IP>$RE'`L<X,E<7=3
MH/K?<DC'9'KS.\]<.]52#EFU5WZ&8X<#)2#QO[RYIV^HZCIE&R:<DBNN$78P
MD@\)Q-TK@[&<^TT?B#(U35%G>EXKYK1[S\=+._&UZR>2]:.QT$QUP[V5,-2=
M6=1!5[[P%F@#7?+9O<O7^2+[Y2LBGI&JGLN@]'N'AB'N]]P$HURJBR,&`JIB
MZO2\'\GH_2+(.#(X`X`X`X`X`X`X!7GWC\7G3KO_`%M(8'=57@P\B-.&#]A=
M->QV&1^[(P1'NTW>CD'/2$7-NMF[[751B8$EVI0058.5='++WI-F[:#5-=5+
ME/ED9TZ>=3ZIZ/\`7*M>K]*:2#-=5@Q+MA#R6$T3,G+OY#(2TLD)L\2:L1C)
M<F9D)PH17T'C!HQI[QJS&#F+!NV:I"-NIMO%DF."#@#@#@#@#@#@#@&EIXV?
M'K9W83Q)=H^I4?6C$>GE4^5TS*B=<WNS)#JXLO-,1_KZ7)TY=B%8R6<%!<1D
M^[/"9I2&265N&1`>PW'$WFNF'Z8[55)=IM9.FS64K%3%^AR+?\('D?@50QUA
M!)A#+\3#P^_C-:]=H%?UM4%6G1J[[!L%M84(G/5PDJX'&+2%PX6U>Q./@+:)
MB/=RI35THG@>X=.FH+M*6W-E:7";K25T])QMU-G'H-VMA';KKA#)U'3)Q>;Q
M%HUK2\XA-AND>LVM[NA;!H)L.'65%?3A:.RAJ<1</=F^4]6C]@\:$QNRC%VC
MMP<ZJ=EQS6::R:9-+@R.`.`.`0Z[->/[IQW"T2<=@Z"@LWDS+".0]BMF;F)6
MO'E6GJ[,EH]:L-=`+!#Y9*IHKMT&4B29^V00V5;*ZIZZ\&E553@X\NF!`Z7]
M1?)!TZBDFE/1#N=(.R<6BL?,F0G4OOB%UMY^>5&CW#UM%:\[&Q\I!;.$$'6K
M=,'#@DV(%XXD[6'Z&CS-HDZ>[#6U15[U.SOIMS=-UT_UBOJOY)?*@VIL%*>Z
M/B+OHF<=$#7MY+UO=5NU+N1#8@J@RP\Z\61:K6S8^50T352RH\*Y9'D=6Q06
M@V;/-$L`Z:)]FM<Y\TH)%_XV?4F*_L]@JW[G]2M\?4KGL=TXO2,L4-O_`'6.
MPR+3Z.ZM_P#O[_@OL.]7]Y[Y[+T;Y$V'DZ:N%2\K._4D56'E*\<=Q^[IU[W<
MZT%7SOU?=0I2VHC$I(XSOZ/1JE&)@2`2'?;&<XQMIJ,SMIMG&N^-=LXQP1T5
M+&E]&3A#'`DC'-R\>,"SPEWKZ[4H&(-"@YSI]6?6;O6*R[9;7T9Q^TFKMCZ\
M?7P9.TX`X`X`X`X`X`X`X`X!&[N/-XW6O4?L_8,Q3(+12%]?;BDLC1%81R36
M"!Z^D#TDD.]X;O&^'JK1%71KE=H[1PMMIE1LXTQE'<6G%1C*\S73_1=.ZE&2
M7KVKT*`MYD/NZN-K?OLJ-)L!C^,MZUD%C19L(T2F(E1FT(R)KM/X\S)C\1P%
MND[2*>D>PPUPTU'7M:7.UDX7.-.7K$VO>#B?S.,9QG&<8SC./1G&?KQG&?\`
M/&<?]\9X!2[;72J[NF-BROM;XO!XE9C*RBLH['>/@R43CE,7POG&NQ6;T@[W
MUV&4;?BK1/U,.&#9&#395%@G(!J*S-1(X-[2J45Y656:W/5>*RT)K]2>^/7C
MN/$TRU<2C>-3\85?Q:P:&LA-"&7I5<\"([J2.#SNN"CC0XP,!<H.LJ.V2+X*
M0;M5W@PD[;(K[I".ETXKFKIK)I[R9G!D<`<`<`<`<`<`<`<`<`<`<`<`<`<`
MJ<L0T.FDDUNE0\^CHG;NM4_7Z<4H(L:#:9L1.GNQ*,`K:<GV9RG#T[#S@79F
MPJRV5<PB?Q,1**38"RA8ZX?E7HY0:2CX6YOFN/C&);'P9'`*[[C[Q2"GS<^&
MDJI&E,0.7R@1J.8SE;<_,`(=CUB6$+QMCB*>SVDQ73LJT./@65':0@-"B2/O
MSYP3][$#2IF(>/\`/T*0^^5F]:>ZWD4\;W6RU:;=N[0+6)?]>SB<L!CLK45C
MT`9K:[Z\+C:IM-WJ/Q*$-94W2?%DF<?26B$H359?%'+L4DY<#I3--%;3M[,;
MG*Q7!F1^NG8*D_`-<$G\='9NX)8MU1.5D*[']5+E.5].):7CS\L1<Q^\JFES
M2LX6<V5PYG8HO:L=>B!*HN."9$18R8HB[)A$E`:?:+;2]J=FI2EP=WP7'`V.
M*9N*N^P560:ZJE-NI+6ED@6LHA$B>1R3Q-0['GVRGP\PD!F0:/R1HQ(I)^]C
M5B(=G@B.6:DF6%Q[QHY6')IIM/%8F3>"%1?F6ZBR;LAU4(SJBH6>(=OJ$/1&
M?T#/:QD3B!7M%632:QO:V@]53H>_%.6YR4U7I+1XZ-DG3H"</?!_:#%S#80X
M;#=%4._NNS3NGI*W."!/2RQO*'1+F[RU/=)>VO8SIN<F485I6`=\NS,2K#NQ
M7Z@^&#$[0>,VEI:R7$@@,@F*CEQ$H]))J#69X8+N@RBNIAYK@::H<352G>=E
M/9>F&#Y:$Z/\9&KJ]_==L^I_>SIYJV_=DY7:76J5SFJ4%]?]7(^SJ*4M,(09
MI9SC.[M9N/SII^^6;HH9U5V&=AY54U<''G!+2DO(KT0[&Y:(TKVXH&=E7OJ>
M[QEC94:'33.5/1C3"L&./A<P;YWSGU-<.0:6<J8V3]'KZ[:X$=-2QI:Y6ZDS
ML9]/UX^O&?KQG'_?@R.`.`.`.`.`.`.`.`.`.`.`.`8PN.P7]6UZ;G(Z,[2U
M8*L)RN)^,-P2>&+TPQ'D'ZI%=J^VUU&LW2SU-LW8.W#]PBBQUU;IN%'S4"M;
ML%WXEOZJKG`1.J"^9(O3\_+QEW`)T9+V&BF>-QNJ(*UBT<"P5L6=7</F$]%%
M9+6XHIH[A[-N+6%RR0%S(]BF-TTIQ?-8\)O?",S3H_1V+VMBJNZO4Z#`)P:U
MJ*\I7=<%F]1Z7;*%P+Z:[5P^D*-IEJ51RA&QYADQA(H"Q/O6[YX33T1S[\A\
M/;(8N2]?Z.O:WVYNZ=EI[,0FXV=K/&3_`$C^0\Y3QW+ZV6]U]N1YY)^B<84D
M-M,Q(\9V\ZPBU,LA'<JGH_IMZK\0T2TW;M.R%:C?>75;2=-LH2D;%-:&O,%4
M7*`$T-TM-;-6'Z7W7]'FN98AUH[)U#VWI:%7W1\G2E%?S@?ERS5W3PT,`RK7
M?+8Y$Y4(VWW<`);&":;@1(0CO/MV!!LIKKNNVW;N5AEITMIXHSOP0<`<`<`<
M`<`<`CK9_4'J?=GO&;BZRT!:2CKULKN;`I^OI<\VWW]/I5U>G8^^>)+XSG.V
MKA)?1?3?]O137;&,\%536#:X-H@^9\'7C1<$%SL'H4Q1DH6V]=.3=>;CNBDR
M#17Z\ZJ-F$`GP:-YV3SZ,I8<@G&B7HQA/37'IQD:_J5ZSQ2?FF=5_A;6_!?^
M(Z_>5GR)UXY2_P#)"[8L"O.T<08:Z?Z**`.Y:])%U&J6/1I[LZE#C3*>N$]?
M9X]/I#;6=%+X)T^30_4UYLZT_P"B>Z_2OLRCI_RH=C.J\QIA^MI_\:ICK]8I
M!BFX]'U>^I1?*'K9RI\*]7T(\":,U4N#3\&OF/F7\PU<?N+$\:-)7L@A];R1
M]8>YT?CN<II_ZBP^%]@(+#"#WU\8SNDVVDR#G/U)ZZ*J;?4$495-<:?HV/\`
M%RQ#?W5_>.WR54A[M]161YZUYN*O&&<?\^^)I1\KGWM&^GUY]LN&9^TQC.4=
M%/K]`;'_`"H?./-(_;GSR^*,<!/'#G:X9%W4:8Y>EHA,*QN>'6%KG"FB/N(^
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M:INUQ]A5_5E>1<37,$LFMIK38>G9!`-AQ6U[+5:;`)#<;N9#'$B9:$391)X5
M&>J41'7M4]EROU)V;=VG+<X+)&_KP><<`<`I1[T>%BO.WW;6L>\<"OJP>L/9
M*J(^$9Q^7UY$X/(A9.6P@L2-UY-I0#D#!/Z1$`;DED-(6)-\X;2Z&#0T3<;C
M&(_VJPW36Z:73":>L\\#ZZ][NW_1_;4+Y-*&UF-0#]L()=]^H,=D,SK!J.3S
MZNAB_P"BDDB%F4TJBVU26/22.MY?!E2[S#$&BW:)94U%V::O<=^[5CR>#YP6
MO5'<U37[!`]G4G8\,M2OCZ?M!,O@DA&R0&YWUUTV6:[/1CAQHU(L\[ZI$!;O
MV!$:X]9J_:MG.FZ6HPTTX:A[S)?!!P!P!P!P!P!P!P!P!P!P!P!P"K>=W:.@
M?=(0$.=6^N3B:O5HNS5[#,9/,"%G`:^EUBPRIP"94FVZG+^[RIYF?QU7>!-+
M4=`0PY^BK)IF!C+EO(%1J+8OAOB==,RTC@R.`<7=BR461<*,VJCANXV=(+[M
MTMUD'6[79CNY15VTSNFXV9;[,]EM-M5-FNVS?.V4LYTR!K*^1F.:,_/=X82;
M+00S%MP=F!41S8@#;.T=]1E@/M-D8ZD03-Z#M=,;:?$TPV`VKG.&>Q##W?5K
ML.M/_C[3EKJL_6^Q9+Y2_&;'/)!"*="[S(A6<QJ^S&:[F;@G+L><*4386K>'
M]CZK1?LM5%$V]AUPLM[LBX17'.I"!`LRNN@9V4SD9HJV9M,KQQ3Y,QJ(\<_<
MWK<)&".D/DPM1C"(R.9#H[1O<ZOH?V:K]L*%-DV0:*!Y^/1KVVH5%Q+%%`>,
M:C#AK9B/01::I+:I(;(!M)^]2N-/LOYKP.Q^;/RHT)^[[+>.N+]B(RR_;*6I
MX_+B8R%]LAC_`+L>O%[8A5A.W2FF,J9;"9D:U25]+;"JNOLW2H10\*HW5+YJ
M?)'C;!_2!_'K4D/*FK7=W]5D_!+#DS-`6A04ZK:\6:)%\D/R[:1F=-H]'I$W
M'.5M,EM8I+3SI@UPJ_5;>XH+N4P79U/"'O3MZXDNNCWD=I7OZ[MIG3<%O:)[
MTH1C86=;7-6FU;[-#\I9/B8X`S:/33XDY,("F6I4FTW9(?#AY(,Y<[Z:EQ^%
MQ*J73$M.9B'.!8!P9(EW;T+Z5=C_`'M6\^JM"V81>^O[:0R6L(FXEVNRGI]I
MNUF2`QO*V*BGI].ZK(RW4VSZ,[;9SC&<"JJI8-K@V0QSX7Z%@?I5ZH]A>[?2
MW9+/M6@&A>S\](5W[SK^TG@A6MQ+6E$WP[7?Z\C$6;%NFGZ46>S-/T8P-;;S
M5-7&E>:A]1^H+S+4]^W57?#K3VJ&)?LM8SV_ZU.ZQ,)--/JT;*67UKD#/8@]
MRGC&,%W]>J;>U_>.F;W/K>N$T/&EK_%SX/Z]!\[GDCJ+]GL7XIY;.@;']E_8
M'2>_ZWNS4AZO^HL*J"P<5/8Z.,ZXVV1;[+$=E,>C39PFKG">0V:'A7&ZI1XJ
M3LPWFXZ$M";2-WA)K>Z@S-XKA#2']NZ"MFCGR:O_`->B\C.Q=U`$\IYQGU\X
MF.VN=<963SNAC*N`V*LHJ_Q:?@G/@6*55?U%7J-^,TE=%4V^)]EJOL1K"PXE
M/&2:6WHQC=5Q%RY1)''IVQKG"NVF==\^IMC&WU<&6FL4UQ4&6^"#@#@#@#@#
M@#@#@'Q7;MW2.[=T@BY05QC"B"Z6BR*F,9QMC&Z:FNVF^,;8QMC&VN<8SC&?
M\\8X!T:40B:#Q(@A%XZB_0,$)$B^2"#4WB,@+--F!4ZDYT;863,$V.VS(@3T
MWP]>M-MFSE=1'.=.`?YW?0(+`^GW26B_(NG7S"27SUE\Q,DI=\G%8S&YC++3
MI^V:-KN,3>MAY4,Y))&#0=DZ-2.HWC<P88`9:^+:`?9J3`B]W?/`]%;=555,
M^SL3=PK7EX+C/R-ZGI1W6J3OG4!*Z::$6&`C0:P)5618-:,71ATO&RV&8'8/
ML7X%$L8V9^Z*DT6VVCARFZT<I.4%VJ&Z/HV'!K9T<I.SE0\+DO>"%('92J["
M\;EUS3R#=5HD8F772R".I_R%]48DWRNX<)I:XT?]P*-`)[)MFEI15CKL[MR,
ML\-F5EQELN9?>['F"TB9GZ]>OF;3VDJ6[KW6_P#\MZ::<"X"J[3KR[ZYAEN5
M/+0\[KBP0#"3P^6@'/O0LT&(I^T0<([9UT6072VPHU?CWB3<@,((.AI)JU?M
M7+9(8::<.S1[_@#@#@#@#@#@#@#@#@#@#@#@&$[^ZXT9VFK<[478.LHO:=>2
M1%!$I'I*T5VQGW5ZV(M7(XJQ69&P9!H^9M7;4F$)#B+9='11!TGMCZQ4VG*<
M,]95=5UW2%=0ZI*FB(>!UO7X-G&X?$0*.Z`L&&8ZYPBU;X546<+*;[[*.';U
MXNX?$'BSA\_<N7CA==01MMR[MF0.`.`.`89['-=GW7F^&6JB*6SRF;0:ZJN7
M+9FW3V<0@XCA1P[>K-F;5'3._K*N7;A!L@GC95=9)+7??458KBC_`#EO&]I+
MJ_Z<-+A@1EU6LVZX>4FMR!'M5'(*:N]CUUK:<T+,HE8DB/P&NTC1*PZSGJH.
M-1.2#A3KX,7]X!X^+8]LPW7'IKO5#O-#]EN)<IXY/CH;O_BS\AX'NEU5K>9V
MI.*K!]C<26:5E9M=B2>D2-I3>&RL\($KZ5Q*"&)?'7\XA8\#/THR[077'HGU
M&J&VR3/;5(<*Z=EQ>(33Z9JUG8M0X,#@#@'YVUUWUVTWUUWTWUSKMKMC&VNV
MNV/1MKMKGTXVUVQG.,XSC.,XSZ,\`JAMSQ15TE.S-]]';,EOC][)%5/?3,JI
M!B.=4O9SU/?=9)"[^MY3*593]FHNJY77?L&48DN[]SN4<''CI)/'!K;>%7M+
M?CRJQ7EN,=M/(SV'Z=.FT4\J77[Z$0Y-PB.']Z.L@^369U8,844U;M7MHQ;1
MJ^M/KZ_=;[MT5=I(,/Q9R25=;L33(4VPM@7957N/_J[/ED_/<6XU[8U?VU#P
M=A5;-XI8L$DK35_'YC")`+E$9---LYU]N--AG3P>[TUWQLFI[%QOE)73=)7&
MBFFVF!@]GP!P!P!P!P!P!P!P!P!P!P"EOMB^C.OD*H5P\3@+I\*(T&R?9=4E
M-IS939N2N-FP&:`;;C]!S6M:QC8Z82:`O)&+MV8DC#W!Q@3K,UUPD:PZ?S\:
M7NOZ[M)4X/AORNDX,C@'A)M9]>UON!3GDP`Q3>4.C+,!J:?),\DEH[&#4S/[
M(>OGT:M@L6CQDV4>K>S9L63+;=RNGNJWT5""C[O0L(L3R)^&NXXE-XZ_B^O8
MFUZ]7ASRLVX:Q&4B%U+;:Q$F5EA_`RP00M@X%O0#JN"L>9COC&FLBV6P\313
MW'2GW*UNI?6I9?,O\X.8X`X!C"X:7JR_J_DE77'!8U84&E0@F%+@I.(8EFV6
MI9@X'.7#'+U!;<:32;N5-F)5CL@0'N,)NF;A%PDFIJ";3E6:*<Z&_1Y/'O5%
M10V(2Z'S*=7"`1+*'^Q8&V+@J>S904*'"1=%\\<UM8,>89T#-'S8(+;.6CM#
M5@,:JN$E7FZZVXZ/M*FYG@H32X2C+O\`A.2*&?OJ&\F/DLJ91O\`4,!2&_0U
M\P$=KK_II)Q.[(/,'>6Z><8QANG(D$=M?6QOIMMOG?`FVLZ*7RV7^UKR'RY>
M9"N?W\!\D/7N_4TO_+`^S/2\;#<[::?Z:+^5]?+#BSAWG?&,:J.D(PR6^O.V
M=%-_VLA-#_0UPJ^33\Q^N;S95M_UKTEZ6=E4=/\`F7ZZ]K9A3CY;3_Y$1-_U
MH]9IN/1]?N2LD]AZ_P"[^*^I^_X$4/\`54N-,^3GP'^*'=L&_<7]XG?(A!7*
M?_FW].PRL>TT898T_P!954K4%C.S"[9/&-ML+L8R[]*>N=]M$\<#965=+ZKS
M7S.:.\Y/C<1>MPUD7%-.O\D74PEM'.Q%#7K3CULK_P!TG!27UXSBVJFN<;8W
MT3D"N4_5VVWQKIZ-LA_3JR2?!I^3)<0SN/T6[%C%`4'[-]7+C'F4L(.HP)MJ
MKYBH[T5]'H:$XO@X]=Z[[>G'K,R`[17Z\>LCCTXX,NFI8IKBFC!]I>'_`,:%
MQD,2(]U#J>,R?.^7K::4TT*41+4GV^,[:%DI+2A6!DUW^,[84P[=.7.5_JPX
M]NEG;3855UK]3X.ZZ.45P=U?$9:\>@$#UZ^6WW/[BTJ$MN'F[P\?MW=R'R4,
MMFH!293=[&Z^L28Z")$!(AS2@,MF*2:QL1:1#63Q'UFYIL+PZ&U6G.TJ4VK5
M*G![U\XDL6\35!WEUQZH+0&\@KJ!.']Q6U,ZHH]]8^]O/^N5'2J2[/ZUHAY9
MGOA)"8K04=ASZ";,F29II$TF#=YOJS]308K:;E:*7A+2NTLBS+@R.`.`.`.`
M.`.`8CVOJG,'<QE.Q(TZ-Z3$A7SEFP>Y(8'3,5F(HDH^7=,4W#,,]8D9_!@+
MKXJX9H(RF8Q>)[K8DIX8*="P]#7/\?'CKK;M)U4[T=5NPDG*:LZJ\Q5XRU"6
M]<APCKVAK/*YKZIQHDU"(P#;R(97P))4J\=C(X#54T"[:,DV)#7#37?=\G]?
M2-U50TTL:$H?M6=KSB05[S^"[MS2=JJ@_&K%.TUMTS+Z9.&39DQW?B->/8YV
M?D<S/[O9@182*>UH\E"?T9:QUZ5TV#.VIIZ^W4=FEGK==!!.,J?KJ:5<I2Z:
M=EJVQ,T=U0G&Z#<AHD%*(O1]-QF<:.$II':JKP%+TW9!`L[3E`B(AQ\@T=%6
MSI\V)N-"S=WJL0;O7B#U3&SE)TX34U5W')XN,),J;:XVQG7;&-M=L9UVUVQC
M.-L9QZ,XSC/U9QG'U9QGZLXX(:C/;J>]F?$CW$G=?]&<E05`WK&X-V`J3JP;
MHB=7)6]R]F9-:C^&7%0-!R:!LT<=>43<5W%V@;'$B>0HPLJCM'Q8P27:M=1V
MIBNE;6*E-S#5,2FY]Z+HVX6^ZJB"*BZ.6RRB*>ZS?*FBN4%=M-=E$<JIYRFI
ME+?.=,J)YSIOG7UM<YUSC@XGVX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!%65
M]I*$(A3L?VMQ"$;ED9M$LSLM'"S"-PDN*<S"+;&9!(94#0A`)FH=A\HUAKZ8
MOV4;G[B/.4HTY/M5D?>18>G\Y_[C`UN_T8>9Q(#9?E`JXC:T9ETM?]ITR$:?
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M5B+.OSQ*SR1]-NT;X8_.:U7`B4=;=6[QD.NFN-A\\I&;B#U5`)*\9:K,HY,`
M(>-MQ!1;1T6T42<.R#<=%7E6MI:_J7!X\B</CP:=TF/4:JVWD%?QHEVI31D/
MZP749Q%?99:;28MM%$S&\$0;09:1HQ?(I(RM#T-`>[G7]SNX<X=.EAFK9VGL
M^[ET^I-?@R.`.`.`.`.`.`.`.`.`47=F3V6WD%AL)G$J@RS-])>L]@`$!M?H
MQRQ46HB^(K#8K#6)!WV(%XLA@4+SY\2EAHG4Q4-D3']TXP"D4ZKH2G$QI8/F
MO![M-_2;WH\&1P#&MHU-#KA!M(W-V[UX%:N#2^[)F]488>:2"$RVORK1TNCK
M[S[NO'9H;3U]U6;.$G>S5RDXURAZFXJ<>MZ?R-6?N71,+I[](3\2I>.($B4H
ML4?:$BL6>G=F&\DG,AQFSG+=^>W"C`@#18<U(JCAS4.$$LVHM%LVT:Y]E[38
M=:7/95\K9+#_`'O9MQ<'$<`<`<`<`<`<`<`<`X1$:.+LG`TLP9%!SM/*3I@1
M:H/63E+/^:;AJY35063SZ/KT43VUS_[<`AG9OC9\?=Q^\*63TLZQR9\Z];VY
MM6EX$.DN_K^GU_1*`X0=(D_6SGUL^S*:?M^C?_FQC.!I55+"I]2+FW@]Z*QW
M;9S1FG9'JL2SME30EUJ[9=@ZX]V5SGTZJL@RT_.QAAG3/_*FR!((?5^TCM]?
MI%_J59Q5QI3^4E>WDG\']LVCUX)G(CW,[3]LS?7]9S<U6]>^U3N$VVC8,@C+
M;WHQ7:%@QB)5]9R&L\CJ#^-MQJ)];0P56!ZD%L.VK,NP&J.T2?NJF;-TV:G/
M-6QP+5?$AT=9]`ND-7TV_&#V-H2)-Q:EY+CM=<H*VS.D6CXZ';K846PN,@HU
M`/7@1;53;5R(B;-]MC+AVXWW&*ZMJIO+!<%]<>99AP9'`'`'`'`'`'`(D6WT
MLIN[GDOVL/:4%@-AOR2U@PY,B*0C<R#%Q5&#"43+8^![G&L?=[]>:[(K;`C8
M<[L\T.(?&_A)A46D-*IK#+!Z8_5E&WZ)BWW:>."X&JB6Z&[?NO:J.R*FNVFZ
M64ZCH+3U-M-\8VUVU]'HSC;&,X]'U\&^V]_DC:`X.0X`X`X`X`X`X`X`X`X`
MX`X`X`X`X`X`X`X`X`X`X!`/MOU.I"5T7V",2*)ZGM'=6W'(C4?-O%"L2E!E
M>/6)(Q+J4QTGEP*,:120S.4&XHW=I8:!"AE5^FGLX9#%6`TFY5\U\OH:8GZ.
M944H9=U^C%D'AE4Q.(FZ9[JF8#)Q0HBSGMMG(P71@4RA,E-:)KL3TE@K63"9
M:`3QLU'L:\6>ZX>JD]-&2AWC=//'$[=K^N]3ET6;]FE0\%E,.=\'^AOP><<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`J7[)F94W[?1OX5J1=0X3)NH",R
MG?O;1N=I@E([E-`XS':]$+7-$'YD->:Q-6%V@\&5T52P"(JHEG-MM@B%?P(:
M40];QOM?++%7QT+:.#(X`X!K[>1Z*Z[>7CPUS7Z.3/.^MC63%_I;J%A6:]UU
MVK2RB_T=WD.S?]8F)EME/!30-HZ^AF0::K[=O\=U14P.E/N=IRUU7+UH;!/!
MS'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`-?+]'-B[>$]9NY$1:
M1Z;1-M&_(_V!#(1FR(A#:_GP))A7-%M]!<PA%>8Q!8K(6>NF$2@*)8P`&NM5
M&PW'NVB?"^OF=.T<U3N6$M=7<V#>#F.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`>)LL8Y-5S/PS,>6+/"T)E0QJ*`%V4>.DW+\$_:H#PI\EC8<#+/
M55=6PXN_QED->*(O76,H(J8X"-'VO+(SU$Z`>.Z\&%<6<0N^CO,'V0!1J'-C
M,9FL]=0<J=M:/]A:FDDP1*"@QH_*(`.=CEI.'PX$FYC'V#[*;<*^4<HHZY'=
MPZJMITQ_33G)80\-7AHS<&Z0]O8/WLZW0GLS7<4FL)BLW*3D0TC%AM@C27"W
ML`G4B@!E,JWCIN1"$_:EXT^7:>ZEW.<LU4-E\(+Y403'&I;+A[L-ZG=J2RX(
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`4WGZYM:17Q'+=/T5V'/7[#^TVH
M"'V214H\E142ZN.NQ^D;?:QT"0G2I00/>=8%',J)'F4/3M12?N73E`EKOAN%
M3&K1$J(PO,QPUY%R'!D<`_.^N=M-M<;;:9VUVUQOIZOKZ9SC.,;:^MKMKZVO
M^>OK:[:^G&/3KG'U<`UNN[G3KR!GNP_01[6_<&%Q>-PGL5:)2&Z3Z!PBQ)14
M3DN(MIN)L@C(+)M>)2_L`N:B\KB\"WK<6*W>1@B41*I/GK$=INH.BJIBJ5=I
M9Q,-:*T1.\F7\J?F"^]OJ7_;?@/]>N"31W'\?XCY4_,%][?4O^V_`?Z]<":.
MX_C_`!'RI^8'[V^I?]M^`_UZX$T=Q_'^)%FJQ'E[LJZ+7KK;RL=;!T$CVD&4
MHRSPO4SK]-U.PR92+O3%G*`(#'NP&TCB.E2'6J4:+;EG!/4]LOL78Y9,FZJ>
M17L))[%6];3MI?9S^A*;Y4_,%][?4O\`MOP'^O7!)H[C^/\`$?*GY@OO;ZE_
MVWX#_7K@31W'\?XGFIEUV\O</B4FE3CRWTM[*/`BACU"GCXK&.CEE![)9RBV
M>'BM^Z#`R#I9--ON2?[8:,L*^\+_`+O3;'`FCN/XOX,:=>*L\S-R59&Y7,?*
M'1M:6=ADBRM:GQG2:E[3>U!/D=,9-UY(9=#[Y2#OS@)3.J3S9)FPVSG;&WNB
M6,XQP5NA/W&UD]IJ5K>DSA\J?F"^]OJ7_;?@/]>N"31W'\?XCY4_,%][?4O^
MV_`?Z]<":.X_C_$C+V&BWF,I=Y5XR.>4GKS/"\NLZ$A;`$F>H="U60J^D3+H
MFWG=_KM9E?NZ\N`5RF/T6>Q<,DV)G<K*HL"391FOG@J=#_0_B;EY+W<R1P_K
M'Y<BS!B5%>7VF28LFS;$!I(?XZ*Z>L"#!ZCHY9OF+QM?JC=VS=MU$UVSE!11
M%=%315+??3?7;(DT=Q_'^)S/E3\P7WM]2_[;\!_KUP)H[C^/\1\J?F"^]OJ7
M_;?@/]>N!-'<?Q_B1;C(7R_2+L1):BQY5NMJ5<-(R/Q!KA9=2^OYEQ85ML7Q
M+%E4T.JUAV`S+QDCK`#B-2*0D'+ETENTE+)'8>QW;[JKB^Q$[%4Z;3PR<[.=
M^A*3Y4_,%][?4O\`MOP'^O7!)H[C^/\`$?*GY@OO;ZE_VWX#_7K@31W'\?XG
M6D>MGEJ#[#]2WF$I,7L6()B16I'QVUNRV)E5F[EVD,'X<W^EEZ05:LGCE-DV
M]HYW;M'*VJ>4T%=M`FCN/X_Q)(>.JYK<L#JY3*?;2>UH8[6GVMFD9>+ATEJ]
MS@Z$`V]/X_%I"#$5G(Y!&U1F\+$Q[W]4"^?H,"6KUB771.-B;=$2I)-PG%L9
MQA2KP3^X,C@&`;^A%MS,9$,TU8*U>2D&;DSS!5SIL0C&BQ.L)]'8X4EL517'
M+SP-&IJ8C$AWA:IH8-+;,/>'6^'K`6\8"K>I7\ZY%!W17J=Y<HRZ[J;QCNQU
MYK/,E[XWM*I$H5ZO1^S=;'DY,/7S<I:(K0#=Z>:Z#R;#!NS:5B:]J>C"H9PN
M_5VU*(8U?R;;HM[#]U?JC7=?B3S^7;S-_>3]8_Y#\?USX)-'<?Q_B/EV\S?W
MD_6/^0_']<^!-'<?Q_B86[`0[S4TW5LIF$<[_=6;&L%N+?)UI4OR@QR"FK<G
M.K558)7D7.2:]-AJ4@D*R?NS'&S9[MKMG*GNJNNFV."IT-^XXS>TW"S?NY'M
MZ^JGS$V##(]+QGDNZGJ)F1C9P\;B.E@J2M!)?5/5,T!V-AKX6&OG@$IH[$/U
M6NV-,/&:^N4T]L93U$FCN/XOQ/9?+MYF_O)^L?\`(?C^N?`FCN/X_P`1\NWF
M;^\GZQ_R'X_KGP)H[C^/\2.MJBO-;6=L4K",]\>JQ2`V`K-OUIVR0ZI1*)B*
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MQ_B/EV\S?WD_6/\`D/Q_7/@31W'\?XF.+:K?S+5A7LJF.GD;ZIFC@P(74A\1
M?=-`L16G\T2%/7<8K\0</7OH-:')@4;(!!6Z^B^-'+O5;9LLFDIID)H[C^+\
M3B4M7OF?MBKH3.2/D.ZKQ.4&HR`=3R`-^G`*9NZQGSH*/?2^LSDACUZY%$)!
M!#3MS'3"S5)MHL[8[N-&K=)9-/`K=";6PWH]K%9/#/$RE\NWF;^\GZQ_R'X_
MKGP2:.X_C_$?+MYF_O)^L?\`(?C^N?`FCN/X_P`3'VBWE=ICL%UA%V#VYZZ=
MC*IG5Y:UY=T6A]`1&FY-#(KK`#,P6,Z%3-O2$D]?:*XBZ>P$$&<'=6$B8F,H
MX&;95W#V&G[+32E7F\\"Z4!(8_*Q#.018X'DH$CJKN/-@";(P(?:H+JM5]F9
M(<NY9NM472"[97*"V^$UT54=\X43WUP,'<<`<`C1V1I:PK>9PI6K+@/4=-(N
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ME>C23Q87*G!"8%X4W9`V`,1(=%L$':J+1P>>1V.X6^(R$8V="IT-W[.V<.I_
M,D'%^G7?>:A&DDB?F]N(^"?*/46Q,;U,Z@.&V[D8_="2C3?;6!^LB]%E6+T6
M39+ZINQQ)F[8/$4';99'03:I_MKXJOJ=_P#(AY&OOI+Q_E%ZA?D/@;5/]M?%
M5]1\B'D:^^DO'^47J%^0^!M4_P!M?%5]2*$^I3R60KL9!:W7\TI]O4[V)DMK
M+FIND>E0F;PJQ3R^%*AB;:`K0S#XBPGX@'/RNYE1--(:UB+ESOMAIE5;06:8
M;_IWRO5$9YY6)7_(AY&OOI+Q_E%ZA?D/@FU3_;7Q5?4?(AY&OOI+Q_E%ZA?D
M/@;5/]M?%5]3KC'2CR"QX04/GO-M<88&#'/C!DP4ZG].V(P4*&-E7I$D1>N8
M,FV9L6+-!9T[=.%$T&[=)197?5/3;;`;5/\`;7Q5?4C+URI#R96R:MJ/37S.
MRF/FH[:<[:58(AE#=,IF5F5%`<Q=M'+%DP]O!_>HA*79([NREL$>I)%88HXC
MV#35EM(AF'0K=%HHR4WJLWECH2K^1#R-??27C_*+U"_(?!-JG^VOBJ^H^1#R
M-??27C_*+U"_(?`VJ?[:^*KZF!.Q_6?R9U16,@(P3S-SN0W&7&O!M,5[.>O'
M32""+&L5;V#6-Q-:1O80FF)0,&7HP1L2V]"2#XH-:>O[V09(.!4Z7_\`7;-I
MU674]O575/R`VA!(]+P_F[LXMN_&C_C.8MU@Z<2`../[#VCHH,:E6D'W2>MV
MRKK7=B]QGV9(8LQ*M=E6+]JNJ)M4_P!M?%5]3(GR(>1K[Z2\?Y1>H7Y#X&U3
M_;7Q5?4?(AY&OOI+Q_E%ZA?D/@;5/]M?%5]3#\&8=QZ.[8=:3,R\IP[M/U>(
M.>R[#L<%GD.ZIU0C&5JQK<XV`[C'L#CXR3F'$?LI-5*8MQI)M]&%8TLB=QAM
M\1;8%]EI^Q#M$.IXO?JL"WK3L+0N^FFVUT58VVVUUVV;OI[&![U#;.,9RB\8
M/B;=ZQ=)9SZCAF\;H.FRNNZ+A%)73?348AZ/H9AX(.`.`.`8+M6D6]GR^MI6
MK(W`;Z!/$-W8](:F^P;'M;.I^W6S5!UN\:Y$/<2^D8>W6?J-RR"L;?24;H-1
M)OQ1T&*G$^LFO)LSIP0<`^:VFRB*NFF4]=]T]]--E4_;):[;:YQKE1'&Z>54
M\9SC.Z?M$_7U].OKZ^GUL`0JJSJ"^@<]C=CR.RF<ME`\@,-RL@/@JD86F\@C
MD0MZ#QDP_P#;3.2(",LH]=DJ&.Q`9LVCS<3':XC<*$P:+1%<&;&F\LLMV'T\
MYEW)L\&1P#!G8JBQ?8NK3M6F)9)X<Q-).\;E8OJ!<+^W5$%!K/XB+DP4\&+,
MASPB@?9M7+'1PTD`8&9&OAQ04R>HBIPY]>O6!QZ?I5E4!25$%)6M(',JV9A`
M^CI@V%;L(T'DMB3D0)<^R=./I!(T"5CR[<G(]$QN2HIL(T4#-W`MZ0)!.'K1
M?+K)G=)9)?7.Z*J:VF%%4L[I;ZJ:X505W073SMIG.,*(KIJ(JZ>GUDU4]T]\
M8WUVQ@0^G`(?W#U+:VG;8>WVE@%XJ;!HU8Z:C4V;\H(>&Z8ELSFL(3+L=9(*
M9/8>\D$T4?S:.),VAB0.8Q#W`B7Q980YW)"IPL-?&)YVQ\"15:PIK6U=P6O&
M+YP39P:(1R(MB3M--%R01CHAH)3>KH(_N&ZKK5IA?=NWQANWRI[%OKJCIIK@
M1WN>VX`X!`6O>B0>OY.D=:V.4?LG$N`R8^,6!;>W,ZPLS74FANR!-Y(2.0)K
MZ05H#7F;@(S:1*0!UG("-06",DF&S0:VMV[KKKBX\9)]<&1P#$-P4S&+G&1X
M9),[ML1TZL99D&;9IL70U>@#4<)-1I%=-1<1N^'&U]%7C/T*_NDM=]%4_3IP
M#!]:=0DX'90VS2-A+2$MH0"2(XQ:Q5L`8$I3%()9M71AX,2T-$]0(-"!VD:0
M.`--'^Y>5#A<G9%0B2IL*8%FT1ZLWY6W6N3.X(.`.`8$I&C\4[O*M]Y-](\G
M-A`P5Z@7X)\.BL;6.+@&IC/Q8M](I=Z\B)XD<RQ@/K(-4QF,1\9ECMLY%]>M
MVB,]\$'`,!WC31:XMH.R;RL-'8\!D*)68"WT/=G"4R$LR`<R/CS&2C)?$R\1
M9MI""#R5U[GN29'"X".MI$,+QEH8C9\56Z'-H6G5*6B3^/NI&C*"14B%?D"3
M(!K%Q>NL;K^$5D%0&@,%CN1^OT8K\$Y*Y^*N4WTB<F2;1`6Q>M0X\&Y?K6?F
M9OX(.`0/MWH\VLZT9E;#6WI.+-S*-*1=4%((Q%97%@XYU7LZJYR@*3;-8Q*<
M,&D7L:6DP`1[+'@,7.3!&5NQY?!,H)>C2JC+U,\,EE@3C059-D46NCM/;#?9
M(=KE5UJJMLX31USHW54WWRHH\V2QA3;3?.5]\9]IG&?3Z>#)S>`>5G439SV$
MS&#$7;\>/FD5D,3?/Q2VK<HR9R(2[#NG8UQOHKH@_;(/-UF:VR:FJ3C1/?;3
M?&N=<@1/J#I^\K&:@)>3M%S+-0Y163*C50)O1SO)=`UIQ4<B/DDIG\XD;>$-
M(S:YO96)&B,C>[2EDP-C),'"Z?1/4:;W>L<DKVQTZDVN#(X!'/LOU^3[%PX!
M$E)8XB&`DD(G=G[=@_(9=H%Z]G=<D&.R`Z11G??&PJ>$'.K8D[*QDGLVP'E\
M6E<7(E@3T5./6^?D=CU\I#%$Q<I&?I/]*=7CR+Z,WF`OP++4)":T@E5QIH\;
M8+%]"!K,>@(QY(#VBC!$N8=NU688,-38BV@-SZWSYLSWP0<`@C:O1>,684GB
M[:7[0T+9DK.2.7BX_%62#S?218ZSDB^X4FW*,T!\E(2SK+'S[^4$!1G+Y.62
M9LX$[D\L#[<:57/T_DWX$G:CKQY6T7>""AUE(C1B3R26&B8D#M%0>Q*1$U7N
MZ`.,[F9#N%'MD,MT<M]S9)1T]U>$U7&%7^Z*0RS*/`'`'`,+T;20.B8N_BH$
MX>D#5\^!./?)#D5[VW916O815L:&I?!Q@IOLFPAM>QMNZ<JH*.B)74D3542U
M>ILVHK<^M[?S,T<$'`([W[UX&]A6P4'*)Q+PT*8L)0R/0@$G'-@4O6D8]L,9
MESGQ@$5>;%H<AJ0=PS=%QH.#GB6DIW&.Y-'XD6CXJ<?70R76L#0KB+?1Q(R3
MD*[B13*6%39=,<@])'9W+SDV/+Y:B60\<S::EY`\1',VK73#4<DU065=N$UG
MBXG\>%CWO`'`(6RKHS5TDG\[L5M)[)"&K/:(B9ZV2E2L@&'0#E&Q6,D"(-9@
MWD.P%K(A%C.@^JH!4:XC`N.1<?#E`(Y@Z9OA9?3#P^GSQ)8(R^)N,C=6\HCJ
M^QB1&H@(U1-C5<E99&]#ZLBBXW&CG;+Z1`$XI*%#01M[4D+TC9_=\V0U#D<M
MQ#T7`/#6=7X2UZYG=8R51ZC'[!B,AAIE<;NW3(MQLC%.A+MPPW>-GK+#QNBZ
MW6;>^LGK+*VFFKMFZ;Y5;J`K7,(TOU1B5)RYU+P<LE9=9VC-E,!":4::Q\<3
ML-6M\2-8(Q"@!B@<(R&U+!@$.BC1SJ"B0(>Y',6ZR2[3+`5N?#PGZW)3\$'`
M(]WKUPAO8!U`'$P)FV:=?GDCPYJ+^$[(N7*9J,G=7&NY,60<!S*+B*LQ[&3`
MEAI\8$+R@8/?-\'EET14X]>O4'IZ9J`73,:>Q]A(#TI<E"`L@4/2/4.D2?*`
M85$JZ!Z[M@`H*);X8PZ#1D:KEH.;X>NV;DFOK[R^6Q@&Y,N\$'`(9SWI)74_
MUD;5W*YN$%3!Q(74G%@U(ND@16(G2LKC.Z"CZ-/UQGT#E1AX<`IL-T4":OLA
M\L2D(A/W#85.+F&Y-XJ.M\VDD@F<N-VD5EDN.%I/)RC:1@A;<E(3[]P5-/T!
MC6+9;#D7A)VY<),6^<H--%-6Z.?9IZ\&E6U:WKF68<&!P!P!P!P!P!P!P!P!
MP!P!P"+O92HIS;)SK2I!Y=((!FN+[)3Z43:)_05641N-K==.P5>Z.0@^QXG.
M8H4<$I-/XV`>M'L4+KHB"Y(DRU8NF"9-D*G$\/FBO+3K7WTB,2GL'K^:S1"6
M$Y-?)BK+16LF'`X2"9V)>W9^>'R]L0.+(@6!RQ[*`SRM#,<.1FMR(N"R+=M\
M+2K1&+&F$J%FGRE7R25O&;WZ1D^95KW9LN1VG.<NK:K,$O[\2JBL1=M19L5'
MY6`]9H\Z&R$?!K)!QXSL];Q[L0\8@DK:BZ"3N6X(A[(KF;.(K8,-"R\+QQUO
MIEE@\Y_]?V-CBZ9KT;;B>4[$8`$F<DU4*JFW6RS9PX18*D2*YN4K*EEA.C!8
MPBI+YOLR**/&.9U-_=OI88&7CZ]>7!&8>`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`5)6QU'[2%B-I2^JK6.1^1ENTQZWJVA);-0K5:(UVH?2%16PR[E
M6LB5H;D1D\1:/7@#,X>,56S793:,.F2FS18:E0E&4/XIUT.6VA?>806)?1,5
M:C:`2@JF.AT:G=T0>63BJV#<OUB(G#U@RQ]-CR\@8'U8SV/5C32-R&P3(YE*
MP@-=I%@!E`'`0MSYWQP\-#OZ7J+N)!K<ZZ$Y?*)_+HKK5<<TOY:6V@M(XZSL
M%U![$4G&P9OI9#-%5SO83^$)C0F*;EXS(=@S(1NU*^9BST1F`-IIX8N+1:T9
M:3G_`!:'P9'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`*D9]T'NHF&%E
M();Y(%.1_9[MQ="8Q:SYN(@0V*7E'^V@J(-8HF$C:A6&SI?]=T-8R>4`TM'\
M0P[G<BBA`V8'A6YH;52TM"XVCPMZN=JRZT]R13V0-@,OC8>'3J94F791EU?]
MLFEZ'AU4]A_UHR>*Q(N1@#HA86UIPA\4CQ1N_>0H?'VZZ,`T<'(&&"^H)*\\
ME>5;.T<]<3T_6KJE?M)6_"3YJ>+R:`L*D!1F<8E-Y6Q91$C-4X#$&4D)Q8')
M0PK+;)NSQ<EE1!_.)3.FF[0NY*QD'#3\E.-V@-IK#/1+KKX<RS+@R.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`0'\GMF614'1ZZ)]
M44U)US88QW5(J/S8*Q`DBT=^EUTUU#BST<RDXDZ`7=Y!GR;='!000;)[K85R
MWVWTTSK'\UYHU2DZE-U_!XKY$NQ?WKG>O^&>E']I7*-I=RGK7]QYN8=0[>KV
M+'YQ/?,'W+A4,BHMV<D\LE;'HS'XW'@S!+9=\5-&BO5)J.&#VB.NRCAX\<HH
M(Z8SMOOC'`E.RHI;_P"_W&'>O<&8]L`YX]UL\Y_9^ZQD6?HC),K7RO14^XCS
MUUJMNR2-L&O5#)`5J13;.5!:[YJ@W*)-G*H]5RFW6VT%=L>S2X[:_P#8SN4Z
M37T$&$31GRU]X!0@0Q=E"I,@!Z1M&`X:/;J.WS]\[7ZF:(-6;-JDJX<N%M]$
MD44]U%-M=-<YP)M+N4]:_N/`UGUZEMT,2I.H?-7VML\<#?[BC+^`K=#)8S%$
MTEG394<1<@^J[Y%F^2<LGC=5JXW3737:.4=]-5$%-=0F,:*5\?W'JW74"X&,
M8?S5YY@>YC:'"A9`V3E:S'HRG'!X82DNN5*O#>W5+`UL.&HM7*K]ZLYT;M$V
MZ^ZZB>J6^=0E=RG]_P!QS2'2Z\1#L$/*^7+NR-?2@JL"C;-\'Z0-'1\TW"&9
M*N(#(+]3M%29)&.QT^=59,]5G*8<(5);)X:#W2R02NY3^_[CM?D2[%_>N=Z_
MX9Z4?VE<#:7<IZU_<<%3I+?2)%H(6\MG=U(L0:/W[`6H$Z0Z$7K`4J/0)O6C
M+;J=ARY:#5RPI%^Y12W19JDAZ;C=/=XWPH$KN4_O^XYWR)=B_O7.]?\`#/2C
M^TK@;2[E/6O[CJT>EMY.#1"-H>7'NTM(1(L.<*`T@W2!0N.#2!V<8`2SX=KU
M.R[:CC+Z,R-F+>KI:-W[D"80:J*JC7FJ(2NY3^_[CM/D2[%_>N=Z_P"&>E']
MI7`VEW*>M?W#Y$NQ?WKG>O\`AGI1_:5P-I=RGK7]Q@^^JH>=7(DTG78CS>=K
M*<B9$JB"%F9[IT9`H%S2Z2CA,2&1==3]79@EAJ@X>*,AC=VX08MG+Y9--HW7
M63!-/"BG]_W&1H/U,M>S8A';`KKS$=R)U!I<+;&XM,(BRZ,R&-2$0\T]=J2#
M&A75%T/(LU]?3ZB[5PHGG;7;3.<;Z[:X"5W*?W_<<6=]6;,JX(G);)\R/<&!
M1Y4BS$)&Y@WZ*QT4J5(94PP&I/BO5-JV4?O,I*^ZM-%-EU_9*>R3V]3;T!*>
M%%/[_N/P.ZNV,8@JEGB/,QVZ*ULD,*&E9^-QT/?0Q,0#W=IFB:DF:]5E0VC`
M0J/?I%'6SW"(]5D[2=[HJ-EM=`E8;%,_]_N/;_(EV+^]<[U_PSTH_M*X&TNY
M3UK^X?(EV+^]<[U_PSTH_M*X&TNY3UK^XZI3I=>*1MI&E?+EW93D3\41.,06
MX;I!H8>!1#L6P*EFH[;J=AVN-&OC89F_>I([-FCHJ.07435>M]5`E=RG]_W!
M'I=>+@V1C3?RY=V5Y$(%AS94$D'Z0*%QH:0NC;$"5?CM.IV7;0<:>QF1-!3Q
M=+1N_<@C"+5150<[U1"5W*?W_<=K\B78O[USO7_#/2C^TK@;2[E/6O[C@M.D
MM]/UR;5CY;.[KUT%?)C#+9H$Z0N%Q))4:/,I#R:*/4[=1@^4$%A15-HZU27W
M&DQ[[5/+5ZV54"5W*?W_`''.^1+L7]ZYWK_AGI1_:5P-I=RGK7]QU8?I;>4A
M9;$0/EQ[M&A^A`N)W?"@W2!^TT*1\L^`'1VSAKU.52U?!C@PB'*-<[^W8$V#
MQBZT2<MEDM`E=RG]_P!QVGR)=B_O7.]?\,]*/[2N!M+N4]:_N/DIT8["H^C*
MWEA[S)8V].-<J1WI-IZWH_S]'K=2\>GT>GZ_1P-I=RGK7]Q5F4[F=+@Q$B)(
M_I'78I`@*>NQS]#2.]3W.$7C%=1LZ2U7:]*%FZ^$UDM],*MU545<8QNBHIIM
MKMD;V:O[2_=]Y9Q'^FEWRL,)D4;\N7=PV#.BQYL.4'`>DKEH1$EFB3X:0;*I
M]2\X4:O6:Z+ANI]6%$E-=L?Y\&)7<I_?]QX26T+(8!+0T"G7FW[0PR;R-(4N
M`B4J(]!(_(C21TLX`@U!8<MU<:/WVIHXT=!1'NR"GQ,LW6',O;O$]T<!/_"G
M]_W&5/D2[%_>N=Z_X9Z4?VE<#:7<IZU_<<%WTEOI@N,:OO+9W=9.C3Y08&;.
MPG2%NN6))#2!E4>,16ZG:*/WR8@25*J-&NJJ^@T80?;)X:LG*J82NY3^_P"X
MYWR)=B_O7.]?\,]*/[2N!M+N4]:_N.KSTMO+!K6-Y\N/=K$AW%[G-0>0W2#X
MOL&3=Z,%"VH[Y3O>\CM'RJ;/9[A+W?5RIHAE3"NV-<AM+N4]:_N.T^1+L7]Z
MYWK_`(9Z4?VE<#:7<IZU_</D2[%_>N=Z_P"&>E']I7`VEW*>M?W$..W)",]%
M@L*/]G_-;WPKX;8A@H!AVPRGNM]BO#!,(P2)E4=1M9=')B19)LF2Z*RCHBU:
M-=O:ZIIK;J^G3`JOA11;6JI>=:/GU&*1;O4)G!KK!YKN^%@L:X*!PTS^)T[U
MPKIV&('V3H@'2R/LWHW#G[Y)\T9.U4W0UL\:Z90W36634SIIL#MC11?2JI^5
M;)52SI_<4#C9F8S?R_\`<^(1*.LE"1Z324=T;"`0H]'T85?%"Q'J@W8L&J>=
MM<;KN5TTM<[:XSMZ<XX)*[E/[_N.K@G5NR;1`[2FM?,MV\L"-)O70U4_#-.B
M,F#HDF.J6ST<L1#=57C5%^SU61V=LE5='+;59+*R6F%-,Y"4L:*?W_<?Q/JY
M9"R,4<)>97MZJA.PS610E9-/HFHE+@#XE%`[(W&E-.JN=38EV6G<)&-R(W+E
MHL_ET::)J[+FQNCD)7<I_?\`<>BQTMO+8TI&]?+CW:S(4A:)Q4'@-T@R73#.
M':[!`MN.QU.][U'+/FSAFD]V2PW4<H+(:J953WUP$KN4_O\`N/X;Z77C&QC@
MU(?+EW9!"&FS?5T4+A^D`X>VV=N46375=X[ZG)-TLN7CANU0QNIKE5PNDCIZ
MRBFFN0VEW*>M?W`ATNO$2\!#RGER[LCG\G*+`XVR?!^D#5T?,MPAB2.!(9!?
MJ=HJ2(H1Z/GCJK)GJLX3$!BA'=/#1@Z52"5W*?W_`'':_(EV+^]<[U_PSTH_
MM*X&TNY3UK^XX*?26^E23L,EY;.[JA=@Q'DWPI,)TAW),AI9<FU%$';'7J=E
MTW8DW04RV'NUDM$'JXDFBV4448.M4@E=RG]_W'.^1+L7]ZYWK_AGI1_:5P-I
M=RGK7]QU8SI;>1K<HF(\N/=HHH$*+`S.@\-T@>;B3+9NU=N!)'5OU.4RR(H-
M7K-PJR<83<)H.FZNZ>-%D]M@E=RG]_W':?(EV+^]<[U_PSTH_M*X&TNY3UK^
MX?(EV+^]<[U_PSTH_M*X&TNY3UK^X?(EV+^]<[U_PSTH_M*X&TNY3UK^X\YT
M\6O&ON[/;OK?9G9NV.RL,K^B.I=G0HK;X:HADBCIRU9/V8#S!JU7J2LZS'.A
MSUM6T7V23)CGKANJV6RDYUU7WUR#ATII).:DX;R5,8MZEJ'!D<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`K2\OW_I[7?_`/L-`_\`^DJAY'AS7FC5'O+GY,LM
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M)8+,!J?EX*+^?I-1[DGC7MXJ(B\1`3^LX;%(K6-B5JQ;@!&[9-85,HMV-B2C
M=9A]"\FVJ,A=W%%;!DZ0*=!(ZH=BBX,K#IF_;QZPAHJJ6_%/Q5IG*''RN2*O
MKIM8%N6T6G(.=1Z,*/$ID[B]DJ[2C>TJMWDO52U^NK.&P=L*<C!^D1'3"Q$;
MPP^TD@@C]*]CK+0=[XL&D@H1.%\LL9GCEA@<2/\`3ZQA,NB4JRK5#0$-G!61
MC:D;/IZO7U#H/B-&N]3%*[C4HLX)25QK4\T>NDB(R$BTC-U2O&NSN*IRZ)V<
M$K?ACF\<>JUP7+`$,\;EUQ)JF0>VM#IK,6=53ZITY%*VZ.[U\M,QU9IR:UTW
M0BNA;(9/+34KI81/$I"!L0AEE(\%9M-KKU"K1N0!M<E;#=ECAPC"R4V]%'/'
MM?0P`='[=@&(!T4JZ]*T#H1S)](=$WEHS&YIC";)%#Q*$0AB$TJD#84>I"/)
MQJO(:.2JYO*MQ.`>F\&B<+"5IH\N:S=\<<>KE-U+ZQR^@C,X/RN5#369E#H/
M&F$>%Y:+,(:G$;)O^:_"!#D1#JZCVP#5E<(UL/:@*^A0QH]'EL-(X/9*M-,B
M-SZW+CIJ38X(8CORI6]\TI:E+.I=+("VM*"26"KS:"/]!4SBJ4D%N!FYZ+DE
M$ETV)P;JXRZ&NMT5=47*:>^=-L8]'!4X:>CF^XHCK#PRW1T5NV!=H>J]Z2/N
M=/8H!G<()U9WXM(NT!CH]/FH31S+*AL:(U]-'=?3P>Z`-6!79Y#"S.41`F9"
M_$`RWLMGHVZ]I14DLYI7@TW?JL,SN^L?@F(5C<D$[/V+V]NT%9C"[C7825]>
M:'E&\:Z>")+([+,66^K&#P<P(T.9K!BX+Y!;8?Y&O3B"3HHH-#;$/AK,'VC:
MV841$M>U&]SB70]@*3Q>8FO`2Q\O'6$2M2-S\H\CTBD\1D3A@"%R%ELQ!2>'
MDPQ\(16<&&ZF'C,DVUW;(N6CC*C=RHBH,)Q/K-%;A'QG7`O@B$0O5L[`.():
M$-:E2F[EP>74FV;^V>FY1[Y&2TB/R&U2=PA)O=Q(=8L9C\@L*-%Y#M"3>CZ#
M,ZT%VMV<^7E%MWCQIIXW^Q,@`VB"8WX&<[3TT=<I&3Z0EP^5(D&MV:@+3(M,
M50[8:3B++6?&T,-'2<AG+U&""5HS?E?(BH:*B`JJ5K1;+BM^[QP=Y];)^@%[
M&T['T:V]'VPV67$VLW6+;;C73"7)+CNP#,DA+S4CJ66+XT9DK>@LF",9:$N$
MV+-4Z&2C4^AXE2O&%/";2MJE'EOW/3'C,A.NG4N:4Y;FU@RR51V;N6D*M6).
M["65DCFT++VL:SHC8(-Y/]C&[QFVTK0''-*UC>K<Y('3V-C@[A1X,:I-H\'!
MN5I?#)<..+,&#.@5E"\.';@C4LH<8850$D@8Z\G:(F^G5<0_LI%WEIW&^09.
MGB%@2"37K'+>6',V4G9(SFO&V49"D==!9_&`VK^I6%ETCAED=Z?Z-7(0CTRC
M^EK1\X:--Z]V=V\>W-[6A:(^('*(*DZSL1J9%S2O&,!+,JHF0=14I#K3;K-[
M/>9WA[=EBRQ=RA.%L/YOKGJL,<(Q26\;=VZ5[+H7&;.@#,M,RNTJ<SATR],I
M$S+]0%94_&3&KQ]`)`V>XJLE7Y0G#2,=8P";X0ER#J'3:I%8T_%S8-J_!1G>
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M9V,*#!2$PN4>/7EF;_J)Q6__`"4S2M(>;X7ZYY7:^/CQ(]3O&<:L\]UKVL[+
MZVQ<7$2S]8,R:2I'W2(NS3P3\+3;1\+EFK[8\_\`>M]]W&%M/8ZXU3]GG.[G
M/3Y)&*JZJXG*8Y_Z,M=@NM]F6O*KD;Q@[`Q,$[#=>(?UYGI*0:GW,NAH8$?N
MIV9DD*#L&FH<X<?@[C=H`=C)T*VCQ\(Q+N4#K7909L(G$;G/E]-_(P.1Z*6T
MN8>E=Y36LD9:F2*Y2+2<A8B<?N@@1TO+09;=O9#[MW[6RX2I:T1=@&$>7>)K
MK5@/P-FD/5Q6CNFA=KUIA9=,]>,^1<^.NZ=SDCDZMO123R5&Q)M.(:7F3)RZ
M2W+S"'=F8B'FI9O'HU'SXV75NTOJ.(QW=Q,9N?(CJT9"!]APH&XC(:#!M*$M
MT/P?BUNQF[Q^K'QZ7UJQU;,KX&U^FR<6IN%80Y0JBU'HVK#!49#[*LH0#IR!
M[OJ#E+4K;]7K#JR$,2UCF'Y149"WS\@9<AM+33POG..&Y:DD>J/5*;45*2,K
MELO$E]"$=,@V48$Y9JC8LD0>PQ?5H"5"0BLXV@*>.HL3DSYH'KZ,:_2&6%5W
M^IXSN6ELA$;GU_+\R>7!#^;8QMKG7/\`EMC.,_\`XSCT9X!IQ=P_T7>-1+%9
MR?QP*;*S!H<DR=G,>QEQOFPMU'B`9-$&I&'$?K`KLF^;$]GFQ#5TGKA1NHVP
MCG;T*[)VEPYQW>D=*JWVE+IK<)Q#5*>#G5>9\NGWZ+M'IAM:$E\D2OLI0\*Q
M9"KF/7*XWSD<U!,1+M&1*REQ(:O%Y4>.2'PW(S1HGOA-%)YA?U?61RHJ<N<-
MWI"FMT4JFAS$RW2EB])9M=7_`%2YN6EIM5`XSM'7$L%,12!O"CE-8;HU*C7V
M[E!=EG5T@[U19;ZM7*&=5&[K9)?7T>IR&$X<D99/TYDX>;BS5.S14>(EDPK*
M6W25L2:3^33.0E:XMZF9TH<9/%W)),X3D]<U,WIM0<^>QP.`C>H59LD58,WP
M!\+.O+!:_6>1'6O?&[:40C,&#MK(A,*VAE<PNN4Q,#4GZ0%RM%IGU"D$EL!%
MXD2C<E'R2UV/7"19FC(<59.4G4C!:;RHZ6;2"7%Q=I3A.=XWPLU:?5D=O$?'
M-83`0W7*V9'0<T`+UVA6LGC3%!0Y5@B.W-%+!FR8$O'HA6(!Z4F,:%RT!L0'
MU[$MUV$S?1R5_2O+J7R^;".KI=O?:-^''I:.A!^.*WF<2C\>D5APJ9ZL2NRN
MXV3.2:@6*$47/7QW^M>&-HM"H:.WL0RI3,N3(L7P!F[UUMT^Z,V),"6U@O+;
M!U*\6].V>O@L,LU]ANE=A7#:K^<A)A$!FN\I6F`64F59;]-@0??KU(Z4=T0Q
M2#J-FK:IY*<-D)]("C`VR-)/9I-6PX)H14:'%P3CUOF>.7J#P1?H7<A(9+F0
MJ?0*(.I?$I>&B)`0[G3I?K*D>/7J8Q!J.30^!,WT./C;7BD5DKTHSC3%L)KM
MKEC7[UCK7@&J@VN.7.(QZ6Q^;\UCQUVLV9OLM)56+EU*PL4!29N8'`R*@:.Q
M*>=D9@)@\?76IG:OR<28NKSBI=(:ZIH#'VSJK4!,3B4'?&HO-JT#:];X2UG+
M6;XO/Z[>/:_]@2J1*]1DE=/]*G6,Q4D],.XP14K6&OX;(A.5;$CENQ?`NY#Y
M)K>4_</:G(J9M6'QS58>?V42E0(-I:1CAQMA&&&.?(GSUBI.041`B,2DTQWG
MI@@;&%W<H<8(;$2SAE`(/#WA`NN3=/GKHJ5?Q1V8>.G#UVLKN1QE=RNXPJKN
M(W.[_;?S)&\$'`'`*TZ<_P#5>[U?_P`0>@?_`/?>ZW!I^Y3_`)5>5!99P9'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`*@//@Z<L?$7W0>LG*[-XSAT!=-';59
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9ZC9C_E_ZF[!P><<`<`<`<`<`<`<`<`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g887761g12j29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g12j29.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!L17AI9@``24DJ``@````%`#$!`@`1
M````2@````$#!0`!````7````!!1`0`!`````0```!%1!``!````Q`X``!)1
M!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E``2@A@$`CK$``/_;`$,`
M!@0%!@4$!@8%!@<'!@@*$`H*"0D*%`X/#!`7%!@8%Q06%AH=)1\:&R,<%A8@
M+"`C)B<I*BD9'RTP+2@P)2@I*/_;`$,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_`
M`!$(`"(`40,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&
M!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4
M,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R
M\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U
M$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)
M(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_
MV@`,`P$``A$#$0`_`/HK2)M7O+S5;?5K1+>T#[(7BF.XJ5'0[1ZGG/!JC<VM
M_P#\*YBM;83)>"VB1@VXN%!7>.NXG;N[Y-=/+/%%%+([C;$"7QR1@9Z"JO\`
M:]G_`&*NJF1A9-$)@Q0ABI''RXSDY'&,YXH`Y;2[.1],B\F&810:K&\#1))"
MLD9*;G,1/"C+C&,<;@.:U['3E;Q=>WJ6Q@B@B$*M@KY\CX=V]P`$`/J6JVFO
MV9BMVE6Y@:>?[,L<L#!@_H>,`<CGISUJ6+5X'U;^SC%<QW!1W4O$0C*I`)#=
M.K+^=`''E#9ZKJ_VB"\O8)?M$ER([21)HTR"BHX/S[N@`[>F#65=65X=.AF\
MMO(:*YEBLUMI72.X9D*0J!@K\H(#\<EB,9KT`:_:$WN$N6CM"RR2+`Q4LIP5
M7'WCGC`JN?%.GB-3LNVEW.'@6!FDBV;=Q91V&Y?7.X8S0!C>/+>[G:SD9&^S
MK:3_`+D0O/NN#LV+\I!!QO`;J.Q!K)O+;4Y)+[R;:\35&6Y:Z*;CNA(7RT5^
MC'&`N.00W3FN]U'58+&>W@=)Y9IPS(D,9<[5QDG'0#<OYU5F\3:9#<W44TDB
M"W5V:0QML8H`753W(R.!_0X`.*OK:1H;LP6MY_9K+=#3(TBD&R<K#Y9"]5^<
M2E2<`9/3-;&H?:!?W[74URL2W.)EB&5>`V9QGCIYF[ICFMF3Q5IT<`DD%RK`
MOYL9@;?"$QO9QV4!E.?1AC-6+[7["SG,,KLT@?R]JC))\LR$#UPHSQZCUH`\
MLW>/O4_K17J?_"1:3_S_`$/YT4`1:'H1TO4=0NC?75P+J3>$ED+!?E`_/CKZ
M4RYT`7'A)-&ED5BL<:[R#M9D(89&<X)49YZ5O4'I0!SFG:!-!8O$[P1%[Y+P
M0P*?*B"E3L3/KM)/3ECQ6E:Z>T>LWNH32!WF1(8E`QY<:@G'U+,Q/MM]*S;?
MQ?83W$<$<5SYLB1LH*#[S.$,?7[RDJ6'8'/-0Q>)Y``5M9;OS!&8EC"HQS&T
MC%LM@<(>_7%`#'\.W\.J7=[IKZ=:S,)FCD6)MTKR8QYHS\P4C/!Y..G.:-QX
M+FEL85_T-KL036[RREW.9&#&<'KYFX$]NO!&*U'\7VT=F)I;6:)W=%BCD9%W
MAT+JV<X'R@\'G(Q27'B=Y;=9=-L9Y!NMN9-J[O-9?E`)R"%;DG@>]`$GBC0)
M=6AMUA%F\L<,D`FND+/'O"CS$(Z,-H/N<<C%4+OPA<W)G@:\C%H&GF@8J3)Y
MLN#E^Q`.X\=<]L<WCXKM_/L83;RJ]U\O+*3&^YEVD`Y^\I&1Q]:;I'BR"\NK
M*R>-C<RQIYC)C:LC1"3&,Y`P>O3.!0!2NO"VH7'VN<W-HMW?I/#<C:Q1(Y5C
M7*=RP$2]<`DGI5^;0IENKN:`PD^?]I@W\G=]F,.T^@R%.?K4P\0ET#1:==.L
MS[+4[D`N#\V<<_+PI/../?BHQXF,THCL],NYW"C>-R)L<LZ[#ENH:-@2..G6
M@#CO^%2P?\_TO_?1HK5_X6IH/_/#4/\`OR/_`(JB@#OJ***`.-L;6W75[9U@
MB#C6+IPP09W&%\GZGUI^GPQ`VN(T&$7&%'_/"0?RHHH`QO&3M9^$;JXM&,%Q
M$EH8Y8CM9/EQP1R."1]":W;"-/L41V+DO9$\=P$P:**`.8O?D\=:%`GRPR!I
M'C'"LPFDPQ'0D9.#[U%=32P>--*MH9'CMS9V\IB1B$+Y5=V.F=O&?3BBB@"M
MJ$TL</CAHY'5K.XC-L58@P9=L[/[O4],=37<>'8HUM[,JB`M;6K$@=20YS^9
8)_$T44`>:_8+/_GTM_\`OV/\****`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g887761g16c79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g16c79.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0OD4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````G0```-\````&`&<`,0`V
M`&,`-P`Y`````0`````````````````````````!``````````````#?````
MG0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"4<````!````<````$\`
M``%0``!GL```"2L`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!/`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U195O2;*ZC:,NQKZV$[F:'<!NW5[_`%:Z_=_-L]-]==-E]/\`A?T>
MA5ET7/+*R21.NUP'M.UVUY&QWN3Y7]%N_P"+=^0I*8=/M?=@8UUAW665,>\\
M27-#G'16%5Z5_P`EX?\`Q%?_`%#5:24@R\NO$J]:UMCF3!])CK"-"[<65->[
M;[4L/+KS*1=4VQK"=/48ZLD1.X,M:QVW5-G_`-!R?^*?_P!24NG?\GXO_$U_
M]2U)3822224I))))2DDDDE*22224_P#_T/0^F:YN<_:1[]N[2#M<\?FCZ7_7
M'^S9_-?00\CI);2]S<FUK6,<1!)<(#O<VRTV^_\`P?T?YKUO\);ZJ)TUCAF9
M5AK?6;=I>7-@;@ZQNS<65^KM9M_25;Z__/MMW*_HMW_%N_(4E(NE_P#)F'_Q
M%?\`U#5:57I7_)>'_P`17_U#5:24YF?U%KFY>'3CWWV,::WNK9+0][!8UF]S
MF?F6UI=/Z@UK,3#NHOHL<P5M=8R&E[&;W,WM<]N[96]%Z?\`TOJ7_AEO_MMB
M)L_^G=-_X]__`)XR$E-]))))2DDDDE*22224I)4^JY>3A85N712R_P!!CK+&
M/L-?L8USSL<VJ_<_V_R$?'=DNKG*K95;)]M3S8V/S?>^K'=_X&DI_]'T?"JR
M69-S[Q8XOD!Y+?3#6N=Z3*V-ML?NV/\`<][%7R.C[:GV-R+6AE;H(/O&CC[;
M+/4][?H,>]C_`-%9D_Z?]&;ISZ1E95-5+*@UQ)>WEY+K-_N_/VOW?1_FG_J_
M^"5O*_HMW_%N_(4E.-TBK(S*G`Y=]+*&45UUU%@:`<>BX_2J>[=OM?\`GJT^
MG(P\[!`R[[F7VOKLKM+"TM%-UP^C4QV[U*F?G(7U;_FK_P#T'_\`;7%5KJ']
M.Z9_X8?_`.V^2DI?I_\`2^I?^&6_^VV(FS_Z=TW_`(]__GC(3]/_`*7U+_PR
MW_VVQ$V?_3NF_P#'O_\`/&0DIOI)))*4DDDDI22#E9F)AL%F7?7CUDP'VN#!
M,%T;GD?FM3X^5C95?JXUK+ZY(WUN#FR.1N:DIS:.E]-R\[J5F5B49%GVAK=]
MM;7G:,?%]NY[7>W5(]/P,/K&$[$QJL=SV7AYJ8UA(BL[7>F&[E9Z?_2NI?\`
MAIO_`+;XB;+_`.5L#^K?_P!36DI__]+T7I^+8S(NR[JO3MN`D2UQ&IW>Y@_J
M?^K/TBCU#IQL];(%[ZY:3#-'`ANW<Q[]^Q_YOT-GIV7_`*/]-ZBTD+*_HMW_
M`!;OR%)3E_5O^;O_`/0?_P!M<56NH?T[IG_AA_\`[;Y*J_5O^:O_`/0?_P!M
M<56NH?T[IG_AA_\`[;Y*2E^G_P!+ZE_X9;_[;8B;/_IW3?\`CW_^>,A/T_\`
MI?4O_#+?_;;$39_].Z;_`,>__P`\9"2F^DDDDI22J9W4L7!K=9<20P%U@8-S
MFL`<]UKF?2]-K6*>)G4Y;=U<M/.Q\!T?O[)^@DI#UMS1T?/!(!^S7'G^0]6Z
MW-<QL.!,"8,K,QNG]/R<[J5F1C4W6#):-]E;7.@8V)IN>TI68.%B]7P'8V/5
M0YS;PYU;&L)&UFA+`$E-CI_]*ZE_X:;_`.V^(FR_^5L#^K?_`-36GZ?_`$KJ
M7_AIO_MOB)LO_E;`_JW_`/4UI*?_T_555S<$9@8#:^K83K68.HCVN_,?^;O_
M`-$^VO\`PBM))*<C]B-Q,>UV-E98(;.UM@))K8VFN-U5GN].JMGT/?\`\(I5
M=(-]>/==F9?JU^]NY[00YS'5.=M%3/S+'_2K_P"MUK5224Y9Z*:Q<^G,RA;;
M[W$6-U>&-J8[W5/:WV5U_F)JND.OJQ[KLO+%K`+&ASV@M>YAK?N:VIC=VVQ[
M?YM:JS76]89;9LJ]1IL@;]@:UF[^<K]-_JO;Z7\YZGZ3U/YM)34S?JO@W-NO
MNNR+;G#=O>_=JUNQFUGIO:W;M^BRK^PGP/JUAU,IR:;,K%N+)+19!!>T>HRQ
MFSTW?]MJPV[K>10Z*6XSG^DZLR)#7C=<RS?ZGZ2CZ#OT*DZ_K?J-8,=FW=#K
M)'`?7,-]7Z%E7J^_^<_X']'^F2FOD]"JJJR<BJZY^19-A<[TGN+PQM+'3;CW
M?1957[=GI_\`!J=70<=QIR6W7UVM:2QP%=;QZ@'J-?Z=+/#Z#D9[NL5/<:V-
MR&NL'M<6MVL.S^;>W;N;7^E_G&^I_P">[(LOZ\X[G8];!,["03M$Z;VVGWOC
M_K?_``B2F%W1W44Y-M&9EBYX=8=KVN<ZP,;6QS6NJ>W=MJK]FW8ICHI>:K;<
MS*]:L&"+&D`N&VS_``3-_P#:8I4W=:?94;J*ZJRZ+0"'D#W?G;V_\'_J_P!.
MO124X^3TFS'Q\B[&S,OUK)L)#VDE^UM7J;75/;[*ZV?H]FSV(E?2#<*<BS*R
MV6M;+6NL;+=X;ZC';:]KN%J))*?_V0`X0DE-!"$``````%4````!`0````\`
M00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@
M`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(
M``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#
M`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`G0#?`P$1``(1`0,1`?_=``0`
M'/_$`)P``0$``@(#`0$````````````(!PD&"@$$!0,"`0$!`0``````````
M`````````0(0```%!``!"`8%"04(`P````(#!`4&``$'"!01$A,5%A=X"36V
MMQ@X.21V-W>X(3$B@B,E)I>Y,K75*%A"1%:6)U?7&=:8V!$!`0`!!`$$`P`#
M``````````$1(3%!40)A<8$R$B)"D:%2_]H`#`,!``(1`Q$`/P#O\4'K+3BT
MZ-6><>-*40F/.-4E@"88G++*&,9Y98BCPC&2$-Q6M<`[7O;^S?\`-0:7'9_R
M:]XV<Y;&99LNF@#VFR)>`1AND.:)!G)JGK-A%S18:=L@+6TLUY9W#*DIX]Q-
MBIE^S*)V"R(U*<MR//0U&N<8<T.R+MUCL[),ZAD93SV9Q!DV>E&<8OF^>YM@
M.'T#7%\WJ''7X.(7(<`R.P)713@E*Y6LC8D"9*XD71*'14$_HS3AI\-E>%,A
MBR[AK$N6!M86,>3\90/(8F0*NZ\+.*:Q5JD@FL*ZY"6ZP+?=RZ*QMRB^DYG.
MYH>7DM663:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#_]#O\4"@4&&MC/A[
MSM]S63_4A\HLWCANEWP=:G>&C!/LMBM"[U2]$*!0*#7AMEG3=[7Z)YWS+#<+
MZJS3!F%\=3'*=E4FV`RY%LL/D6Q_!E4PDZ6\-:M;Y/$$D@,&U+"$!/:(:8^U
MB1FGI^D&$J-22XFN65<!S'=*6NK6Z9UQ;J]#<</,6"\HG+$V=,KY"FX'1>2@
M5M")5&YAKQC1A`WF)#S>).`[#,*,""P"S;"N(-2XX5U1"@4"@4"@4"@4"@4"
M@4"@4"@4'__1[_%`H%!AK8SX>\[?<UD_U(?*+-XX;I=\'6IWAHP3[+8K0N]4
MO1"@4"@C;S%_E\;V^#;9[V)3BBS>>ZEL<_9[`_J9%_[D0T+O7,Z(4"@4"@4"
M@4"@4"@4"@4"@4"@_]+N43/;(]IE<AC4;:L(I`1)\6LCPHS+L_!L6.;H8VG"
M(7'Q.-1I@RR\CYIQ8BRBI`"-&&##SKV`4(!HBX5)"9(XRR.HWIVB3Y"'$\:D
MI3'9"JCK@N2W3GF%%*B7.)ODCC[DV.9`0*4AR=6.XDYH+'`)/L:061RR@PUL
M9\/>=ON:R?ZD/E%F\<-TN^#K4[PT8)]EL5H7>J7HA0*!01MYB_R^-[?!ML][
M$IQ19O/=2V.?L]@?U,B_]R(:%WKF=$*!0*!0*!0*!0*!0*!0*!0*!0?_T^U_
MM%%IS*LPS.+8OBDMD4H080BLH@A&,W/"$61PS*DOE&6F=-D+.H<IJF5;,X$Z
M'QAL+3IFXF5W(*:W42AIL>>@XR-1LQ2`.+2IBU-T]U!:<D!]TA0R$MS@EA";
M=,288:,E/S[7Y@1#%<(>2U[W_/59:HYJP9[C#!-";S+825+H_GC,<GC5SX7E
MQY4Y7L3B.+]AHDZO>ODLQ(Z0B!KWEQ<RFM00A-BI*](7Q%BU"<@"F-:.!90)
MVL(B&Q"N"LIH)"=CO<@>:R\[N>94>,!QURRR[K=>@XI=P,R^+2"0L>`;.*<5
MX^79"4"Z(ER,*."4`(TT;"M+O@ZU.\-&"?9;%:J7>J7HA0*!01MYB_R^-[?!
MML][$IQ19O/=2V.?L]@?U,B_]R(:%WKF=$*!0*!0*!0*!0*!0*!0*!0*!0?_
MU.SUM'BN29(V3F<>O"F3/3F##D#=FIK]TO4&;OV(8H_R[+K8UGHLF[$9SQN[
M296]O+6N$6A3H'!N:+MQ9QY0#'$7%1J;-MK.ELA:&I$$"@NR1N0I;%JPH`*@
M63IBBK`4@:@@:PJ`V!R#LFM8BPN7H[<SDJLOHT&&MC/A[SM]S63_`%(?*+-X
MX;I=\'6IWAHP3[+8K0N]4O1"@4$,;3Y>V*C>9=:,&:YN6%HY(,W),V/+[*\U
MP.<Y%9FELQ*PP]U(0M,?@N4,5+0KG@^4"L,\Y<:66`FUK%7N+G6+,:Y8>S3@
M'S*,ZX<RSA&7;!Z.-T4S'C.=XKD[A'-5L]I)"ACV0HLZQ%Z6,*MSW`=VU*\I
M6UW-&E,4)%1`#PAN828&UP"FJR^,UU<Y98!YH+$S-+&DSSH28D9FQ`U)3%.J
M&PHU!B=N2E)"!GC*W-)+$<(LFUQ7"`(;BY>2UK?DIJ?KZLCZ8YCS#EJ.9M:\
MYCQJLR!A78F>826O>)XS*(=#I&ABS!"WY"])8U,)MD)Z:E9P96(HT`W50`5R
M;"#S.=<-JE]%D40H%`H%`H%`H%`H%`H%`H%`H/_5[3V\V%%62\B.,B%B%-D%
M:VXDCD6Q&_-4!U*EY2#,SG*)P%!'<T+]A&9PE"*`+%+XPW9TS:99O,&L>+F@
MX\QNN(L;3T!`DR%$F&2D3C3I$Q`B$!=RD)`BB0%B)1%7L&Y:0NX>:6'DMR`M
M:U$>W08:V,^'O.WW-9/]2'RBS>.&Z7?!UJ=X:,$^RV*T+O5+T0H%!`F>?C[\
MOWZF[F^IN)*+-JONB%!`FB7IO>WQ]YB]GV':+>%]T0H%`H%`H%`H%`H%`H%`
MH%`H/__6[<>0M?<Q.$,V+PVPXRP/-(]L!*9Y)`9=F\S?VJ1-JB=7LJ:W:?PQ
M#C5\6261X6$:0WQ(;>^D".:F%K)XEG,)Z<$:S-*V%($QB)"B1FJU"\U(D3)C
M5RNX+JEIA!("AJU-R@%EW4*1`N,?-"$/.%?DM:U5E[=!AK8SX>\[?<UD_P!2
M'RBS>.&Z7?!UJ=X:,$^RV*T+O5+T0H%!`F>?C[\OWZF[F^IN)*+-JONB%!`F
MB7IO>WQ]YB]GV':+>%]T0H%`H%`H%`H%`H%`H%!I!\P/R^M'VB)XKF35JE@E
MNE4XWGTN8Y>_HL<QQ,Z2-FR9MAC%CR`UNZHI$$Q8AF+.^+$S@4.]P*2%)@!V
MO85[5&Y;KKPV=X.U/UHUG.DBG7W!6+\.*)B4U$2D_'D/9XP<_DL8W`QG)=#6
MQ,0-64W#=5(B@BO>P;G"O;\]5FVW>J#HC__7[4F5\GY#S?/<B8%QE+'PZ^,)
M2JE4A51E_.BN3$+0UJ7./N\:,8,-9^Q?/GQ@2.4G3GM0'EQQTM7D-:=6D+EZ
M?B0G%;.XX4,B/,))CB[/!A+,UE&.[\CLW/KH,M"0`3B]-X6]H"A=EPK=*I)L
MD2V*.$(/1%\G,L1JAR5B_+S9$<DL[D3G3)+6+*NQ2R)JR;OKK/'>=2'`[&EP
MC,4YL5(8T+1'&6;7=26M:42A8HX]B;U(.!"B*4IHUHX?D>);3M<(V!5PDAG:
M9F'&NX=\]2;,#!D@_'4Z9WW*SJ]8%%C]6VN[6ED#]&,%`<TJ,]&8>D9DBE(A
M6!`,`4Q(TT<\9<T9QQUK1Y5N,<`H\4BFVQ4"QUC\3QF%OE[G%8^VPW3J4YF5
MK0HH6]L3N:N6@QOP9?[418;J.=</Y.6PQO6<.!\TC_B?03_D38C_`,BU4T]3
M@?-(_P")]!/^1-B/_(M#3U<PTXS3F7+).QL9SLAQDGGNO^QCCA(]PQ*CE3?$
M)`VDX:PME5$\%(IB[O;RF7=)E4Q*;:YW1WLE"((;<M^468PX?GGX^_+]^INY
MOJ;B2A-JONB%!`FB7IO>WQ]YB]GV':+>%]T0H%`H%`H%`H%`H%`H-2^8-;<!
M;*>9DJ8,_P"'\?YB98QHK#G>.M60HTVR="RNB[/^0D2QP;4SF2>4D5J4A82Q
MC!:PA`#:U_R6J-2V32LV?^JSRW/]$&M'\IXI_A],0_+R[/\`U6>6Y_H@UH_E
M/%/\/IB'Y>7:6\%-C>+R*WMD$C3B:+:2[%-%FX18;H^JP17)R$#?T%[<SA`H
MPV*L#DYMB[<W\U."_9__T.[Z_8>G*IX=5\1V-R]!VM\<%3@KCI"#%4S0LYR_
MGF+#(BXY%QQ+7]EYRDRYA*54K<6E':UBDZ(HBUBJ+GT90A<6'#H^E8SI-*YB
MK*-5*ETFFCH2Z2!X7+E!BI6K5"0HFIE;RAG&WL4C;D2%N2%VL6F3DE!""Q'*
MZ##6QGP]YV^YK)_J0^46;QK1C7HGR#_U/Z86?:G2\>3<G59*"`])?M2\R7Q^
M+_P=:=5.VK_/L\YY^/OR_?J;N;ZFXDJI-JONB%!`FB7IO>WQ]YB]GV':+>%]
MT0H%`H%`H%`H%`H%`H($0_-(D_@$@GXB,BT7CY7W1"@TVX)^1^^>#;8SU?R?
M4X:OV?_1[A60,)Z/PC*$BE.9G[&K-+<YO"!V;8QE?(4<9B'"1-Z=*QNBW';4
M_N+:\]+(##T-G!$E./077!">2G(5*UABLN;PND@DI,22G(`$LD@HLDDL/]DL
MHH%@%@#R\M^:``;6M1'ZT&&MC/A[SM]S63_4A\HLWC6C&O1/D'_J?TPL^U.E
MX\FY.JR4$!Z2_:EYDOC\7_@ZTZJ=M7^?9YSS\??E^_4W<WU-Q)52;5?=$*"!
M-$O3>]OC[S%[/L.T6\+[HA0*!0*!0*!0*!0*!00(A^:1)_`)!/Q$9%HO'RON
MB%!IMP3\C]\\&VQGJ_D^IPU?L__2[26\+Z!OR'EUL8Y6V1UN7ZF,QFS[?(93
MC]C<)#KR%^SFE:TF$6V:QI[1N>52QJI80J$XJ6]A+*6-UE0Q&B(YD:C:;'G)
ME=69N61Y>2Y,XDI12)40J,66$42`)5BSCSQF*;JBN;S3;'7Z8([7L9^GRU67
MV:##6QGP]YV^YK)_J0^46;QK1C7HGR#_`-3^F%GVITO'DW)U62@@/27[4O,E
M\?B_\'6G53MJ_P`^SSGGX^_+]^INYOJ;B2JDVJ^Z(4$":)>F][?'WF+V?8=H
MMX7W1"@4"@4"@4"@4&O?*OF-8[PP<_"GNO\`N2VLC!+VN#F2]/K;,%D-='Z0
MS!N@45+8I(2;U>[)9=*WE$C:S"Q7LM-6$A!RW,#:BXSRS]A'8U#G%Q?F]'AK
M8K&'4")&L,79NP[(<7MSKQIYI`$C"I?A6ZW6D=#<9Q90;]$"X;BO;G!Y1CU4
M51$"(?FD2?P"03\1&1:+Q\K[HA0:;<$_(_?/!ML9ZOY/J<-7[/_3[6.U$/E6
M9)8[RO','?<DH&S'KQ!\4O\``H?K-)FQ'L!"<@91BLTCF:56=VA5)"(-'7YN
M;DZ<ML'U:`07P1]K*^KABC4;)(I&&*'L*%ACL>CD6;4H!&=311I1LC"G6*17
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M-5F026G))3E6%8H@HLDNPAC,%8LH%@`L(PP0S#!6"&W*(5[BO^>][WHC]:##
M6QGP]YV^YK)_J0^46;QK1C7HGR#_`-3^F%GVITO'DW)U62@@/27[4O,E\?B_
M\'6G53MJ_P`^SSGGX^_+]^INYOJ;B2JDVJ^Z(4$":)>F][?'WF+V?8=HMX7W
M1"@4"@4"@4"@Q9D+.>$L1JFU#E;,6+,8K7E.>K:$>0L@Q*%JG5*F,`2I4MJ>
M2.[:<N3ISC`@&,JP@@$*UKWM>]!K7\Q;;#5F4:P&-$9V5P!(G6^Q.DSI9L8L
MR8Z=W#JU@W6U\?WUQX)OD:A3P+*Q-BE:K.YO1IDB<TXRX2RQ"M*UXRYV7)[Z
M.G7^K'6C^>V+?_E55,7IGB+2R+3E@;)9"I*P3"+/1(U+/)8L\MT@8'9.6<:F
M&>V/+2I5MR\D"@@9=Q%&##88!!Y>6U[41$:'YI$G\`D$_$1D6B\?*^Z(4&FW
M!/R/WSP;;&>K^3ZG#5^S_]7O\4"@4&&MC/A[SM]S63_4A\HLWC6C&O1/D'_J
M?TPL^U.EX\FY.JR4$!Z2_:EYDOC\7_@ZTZJ=M7^?9YSS\??E^_4W<WU-Q)52
M;5?=$*"!-$O3>]OC[S%[/L.T6\+[HA0*!0*!0*!0:VYS!H3//,\A[=.(?%IF
MWH]#9TM2(97'VF1(TJSW@\?$<6F2NZ1800IZ`T8.D"&P^8*]N7DO>B\?*O\`
MW<]>_P#L3AK^6$(_P.AF]GNYZ]_]B<-?RPA'^!T,WM,7E<IDZ/2+%:1(02E2
M)99GU,E2IB@$)TR<C8O+)1)!!)00EDDDEAL$(0VL$(;6M:W)0N[]T/S2)/X!
M()^(C(M#CY7W1"@TVX)^1^^>#;8SU?R?4X:OV?_6[_%`H%!AK8SX>\[?<UD_
MU(?*+-XUHQKT3Y!_ZG],+/M3I>/)N3JLE!`>DOVI>9+X_%_X.M.JG;5_GV><
M\_'WY?OU-W-]3<254FU7W1"@@31+TWO;X^\Q>S[#M%O"^Z(4"@4$]YPVRUEU
MH41Q)L#G?%N'%<O)<U,72Y#F+-&5#\G91H2G4]L(<E1!BHE`8Y$!,$&UPA$:
M&W+RT62W:-*^SGF?'05AG^1,(>:SY?DR2%2YG#!\,`P6)^EJ6*R>?,S#9*OF
MJ';8BT@70>+/!C@M6EL2,M<%O-%8A(`S]E,^K4\>_%36$_,:P3%G]V69\\V?
M0_,4;4,]TS,QX_@3=A1R:WOC4IMG5:_N6R67BG5#9`6<3P842872&A,Z?D!<
ML;/JE\;QXMJ>+LJXVS;!6/)V(IQ&<CX\DW6?9Z9P]V2/D<>>IGAPC[MU<Z(3
M#4JKJY\:5*0[FBOS#R!@O^4-ZK.VZ0UWS2(QX!)W^(C'5%X^5]T0H($\L+X*
ML9?7+8+\1V6Z+=Q#\TB3^`2"?B(R+0X^5]T0H--N"?D?OG@VV,]7\GU.&K]G
M_]?O\4"@4&I=VU@V(F#]E1BQV]L.OSK-$^T[#E/,,UQ>QY:;,Q1K,&=ELFPL
MB0,<<R]`9&Y.F*L-JUC:D<'164%F+<;(BDYH`C`1&LQ\%%H#NTA(U43$;UX.
MN7IYR=TO/T8D`A*>3"4KP%;M=>VY(;/'\#3%6/\`8<)]/L6;_8#<H0S-=&3<
MIQ3S)\<8UGL]3[KZHNBV(Q%_?VMG?],G"`LSZ\MK8I4,T?<)O)=W@1^))WYU
M`2CNXK;\,DN?8PRUPAO:[4SX]/HP*$>8]-X1$)D5O'JD`,IC+'(+EL.DSQ+V
M4@QV;4RXY,U2IEW=NT21O3&GB+*7)?HZL`;&E_HBM37L_7IQ3&FGF^N*7S,L
M@C&].`#%^=,KFYCFMG31&2*TY4M.QWCO&(RV0LG=!*)"S]F\8MHK$F"/'Q(C
MA])S1A``9G3S*=/=]9AE;$V8W;>G``9;AENR,UQ`M)HC)"6@Q-E%N8&N2W>$
M8]T#CUIH$T;3\+<!Q-BA7'<5A\MK6&9T^[D^!^:3#L:Y#ET*VUUBR%,HK!I;
M)(E`5.ESI!4\XDS&P.#FPQ`^;/\`NP:PPXF2NJ4I$)U6A$D;PGW/.M<LL5J:
MGZ].0Q[&_F.R!@8WY/O1JT80]L[8[D&->B\A>FPPER1$+"QMSPBW<X)V0C`=
M:Y*DG]D>7R#!^B*U->S/C_RX#B[3W?7$2G**N*;TX`,-R[E:19CE?6VB,D6`
M+ELG:8ZRN1;38G=!)=&T!1QA-<HD=S1A'<=[F7L*U@C,Z8QV`\MG:O:*5XUE
M&<-P=>)JGQ6TY`:XY$C]'YTWQ!6;D4Z$&NCP^MC9O`D5N3RT!@B<MM-XDL"8
MM6KM<!G36N!@GE)PB78;R:SL:8JR-E=-?R[Y]+X['E;FQ1V;:?R'&#?-9,$L
MM)'XPY90G.^QL>B@GYQ&2C+6KN>44,P/*$7Y`W86>7NRW'/(\1HR2'J)3?0]
M*G=4)!Z9VCFA.1R"7)L5@*5I3B%[9OX$"Q"I!<!I8@C$6.W-%;E_)>F#\O16
MNONCV\&LN/18MQ;O!@))"RY?.I>V-;UHU+W@3$9/98[2]9'VA4=NN6>3&6)4
M[C2MB<P1IB9"446(TT0;C$^4MEX?77:>;ZN&<8ML$?O3@"T[B&*)[AQJ)+T1
MD@6`42R-+\;S:0&*V^^Z`E)SP!YQ:V63G!4``62(\(BQW&$0!F8QAZV=4'F7
MX?QPY35KW+U$DKRG=(XV-<<E6IHL3MCP)V?VY"[<V:S'=WJ)$K98X:M="TX[
M7,6\#=.7S1F!$%J3\;PRTFQ1YC2Q.0K2;V:Q*DBHDI2E5)M"9.>G4ISP!-(/
M(/*W>$6<2<6*P@B#>X1!O:]K\E->S,_Y8NPKIYOK@:!VQU"-Z<`&Q\,TRE.[
M#?=$9(O<.N\O91F6796#B4^Z"$K@2Y7.5H4A?1\XE)8HL0C!!N8(6R\/)NGN
M^IN<4.P(MZ<`=NT&*73#A!-M$9)9@O$G>7L\V5F&-_OH74B=[/+(38!UE%@6
M)N(-R[WO85AF=/EYZ#YD6%H("6I]UM.WES.E4'8T[),=5`8C;CV5[F3"USE_
M*EDUW?`S#48_@*MTD?5]K<0ZA:;HR;@-/`8%J3\;PS$DQ7YC"]*F7(=[M8%J
M):G)5HUB30J3J4JM*I+"<G4IE!.[PR3TYY([#`,%[A$&]KVO>UZ:F?'IC'"6
MGN^N`L;,N*X-O3@`V,L+C+71"8_:(R1P=+J9G,7^<.]CU:?=!`284%ZDBBQ-
MK%!N`BP`WN*]KBN,SH*T]WU*SBNV!#O3@#MVOQ2UX</)OHC)+L%HDT2]XFR0
MPMO]]"RD+O=Y>SK#.NHN"Y-@AL7:]KBN,SI\C.5_,APXRPUS*W6T[=E<JR;C
MZ%&H);JL3BDE%%Y#*&U%/YHVN<SWB*225=C6"F.$@NQI.5P=RFX29/<)I@1A
M:D_&\,V]T'F1_P"N76C_`.@DK_\`VY34SX])XB>@>Z\.UG5:GMN]&#CL6J\;
MS3%QARO1J0CE5H].4#\@=3P.Y>Y)22SF0&0'#),NEN`-PAL(`K6ORC,SG#__
MT._Q0*!0*!08<SQ"'^?X]+9HL%":_,V0\,9%;T3DY',Z)V'B3,D"RH>Q&NI#
M:[C;Q/Z6&C1`-NF-``9]KCM8'.%81_6!X,_8\QLC8)0-OM(%\LR;.'5"T+E#
MFSL*K)V3IADH459G%4@:CUK-$`RRS6D-NE3<],C!>Q1=KV!8,PT"@X!E2!LV
M3\<S.`/[,TR%JE,?7MA[*_$`5,K@>(JYR`EU2FEG$*F^S@44(THP!A1@`W",
M`P7N&Y9I7\8CB[E",4XQA;R),)XB&/87%W42(T9Z,3DP1MM:EPDAQA1!AR:Z
MI(+HQ"`"X@<E[AM^:B,A4"@Q7EYEDCW%TI45C,>E+HD>T:SA'IX[..;<ENF7
M(E#]!Y)=DD!3!.F8*VQS>H&G"&_-&7TR<1ECRP_#`4"><5X.P_C&0K&Q>]8\
MQI"80X*F:P[M0SXM'&YCYB`TQ`TC5IB0(;`"HNC0\18/2\,FY_0%B[LMT"@G
MG8?&[UD1LQZ='XXGDKI!IZKEJ,FV69WA9W:U*[&F18`2\L,U@"%Q<P*R+SFY
M"I,>4).-L4*C@A.4D)TJ@L9=@S=)V>$P]HFK^3*YDUQ:/MTME"9`2U)Y))T+
M2D3/S^0UIP@(;27AU*-4!(!:P"0F6!:UK6M1'*:!087SQCYYRK!TF/$`T0(]
M)IE""<E`6*!E6=,6-<E;WZ>10*<*<\#BFG[&TCCRY..Y01MKJIO881A#RAF8
M(0@"$``A```;!"$-K!"$(;<@0A#;DL$(;6Y+6M^:@_J@4$<[>X%F.;8Z%-CY
M42TRE9C?,V)37XV0M3.6WQK,T>9FIW)<6Y]QSD=`]Q\;G'&Y4L`D*;7D%D0`
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MC&%ER#'.$XSFEX695V(.PV^R5)(GG++8*+X[CP<0Y`32I[0$XH-$*YS@WEB4
M.:0F_,L*YMA)EE9XV]P7&U4B3RA^DT:31-LDBZ0/KSCK(*>*(5\+Q\X95FD4
M(EQ49/C+O-HGC]H6.*YH0JU*X`$*LH!8ST:LHD8KS$]H(I.,FXVQW'(K/;D9
M'QWEB?II)((;*(FE:`8KD6+&$]M6H9$R-YQQ4@!D\E2E6EF<*,DHFY8C@JRQ
M!&'!YSLQDK&F2LEM,YQ?C)JP[BC%#KG:79,09DG;Y,4^*6=3+0+7!'BEOUT&
M!QER9'$#SQM)#^8`5AA`2J.'R6N,?Y9'0[3XA5R!+&%"F;,SL=TJ5;9_QAD5
MF;V&0E0D_)78F2/*Z,%,[%/#<?)A/(&=2>!>)`,@RQ?TI)8\88Y<MY,4I'YA
M9TS'D499TCGC%.#WO'LXB3CCHB#8:'F^[P^Q^1QM"[GM\BAQZ,U`,``%G=.8
M#GV4I3TP1A]R+;L8%ED@01Q,MR$PJ7!2C1]9SC#V5(#&VY0[PE;D>/%/DGF,
M096%B'(X0V*G!(%6H)%S".B.L4>:G*.&*_<W<["06AH=".\]:JD,C8(S'8JF
MPKEFT\D"J70^73R(NK/!%4/32M9%I+&(&[GIW:R2S<4-N5%*#B#4BH!(PY3A
M78R)9XD$_;X0V/AD9A[3B20,<W7M;LULL[8LPXX:\F1]R8"G=K;517!L;RG`
MJ(-M92F-'8)Q90KV#<84)1"@4"@4"@__TN_Q0*!0*!0*!0*!0*#5=LWV9[RM
MCNL??&[O^Y&'^\YW,^ZUW9]V'4F2NGZ?MS_F5ZV[(];\?V,^G]#T75_TWDJ-
M3ABUZ.U83[53Y0C;I2\90()S.:)IGSUKY&\2N;.7@-U%(T$^D$?8)5M`QX.5
MQ.P"V96\MC@C3E"`8PICF8/1B&N)TQ7CH&K1>#O+Y!-S\[JA`E:("94Z),,H
M%2G8<.>2[3L]\0Y!6N63T4_.SI9R$O)Q:H42@MBN8%R,&W6+%<MSFML9'=![
MTT[ZSY_>QW+Z_P#)VC[,=0=FN\#9/L9V#XC^)>U_7W7G7/\`N_#=5=!^TXBJ
MSQZ)"F?<UWG3KC?>G[$]M<\=F>R7=QW9^\A[OF1N]GNDZL_S#]Y_=CVOX3C_
M`."^O.+X3]X<'0Z8EP9[D'10OI^O^Q'![:=XW>M[GON\<!VDU9[Q^\7NY_Z`
M]6=N.P?4_=U]%[1\?UQ^].MZBZJLS7[O'9O8'C>U_8_W`'?KONG[#]FO=XX#
M)?#=U'2_NOM?U7QO5G3?N/A^#Y/T.DJIK_M,69O<B]\O*?6_;;OMZID'>)W=
M^[]VS[:^Z??@>R_$?YS>U/<-U;U/V5_A#KGA.7]Z<5477#%6/?=#[-23L5[P
MG1]K)AVP[`^Y%U)S?=#EG;'@NY+_`*)=0=S_``_3=FOIW:'A>;^EUK1=5?R;
MW8N(=^V/>?U)WD8@[3=9]ENSW$>ZJ\=4=:<%^].R'=1Q'7/0_3NMN3AOH]$U
M8/TP]S'K'$O<KVVX_OTC_93A/=/X;K+W2]DNRG;OW;?W5U'W;]K.?UO_`!WV
MBX7K/Z)0N53:/=U75QW<YWR]D>XC4WD[RN[7JKANY-E[$=%V8_BKO%[LNI>T
8O/\`X<XCH>K/VO'54J_*(4"@4"@4'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g887761g24i88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g24i88.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X5LN:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*("`@("`@("`@("`@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0<F]D=6-E<CY!9&]B92!0
M1$8@;&EB<F%R>2`Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@("`@("`\+W)D9CI$
M97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@("`@/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X
M;7`Z0W)E871O<E1O;VP^"B`@("`@("`@(#QX;7`Z36]D:69Y1&%T93XR,#$U
M+3`S+3$X5#$X.C(R.C,U*S`U.C,P/"]X;7`Z36]D:69Y1&%T93X*("`@("`@
M("`@/'AM<#I#<F5A=&5$871E/C(P,34M,#,M,3A4,3@Z,C(Z,S4K,#4Z,S`\
M+WAM<#I#<F5A=&5$871E/@H@("`@("`@("`\>&UP.DUE=&%D871A1&%T93XR
M,#$U+3`S+3$X5#$X.C(R.C,U*S`U.C,P/"]X;7`Z365T861A=&%$871E/@H@
M("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR9&8Z06QT
M/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^,C4V/"]X
M;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM9SIH96EG
M:'0^,3@T/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@("`@/'AM
M<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@("`@("`@("`@
M("`@("`@("`\>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!
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M,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
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M<E0Y,3EC*W1C-C`O9CA!3#9-5E14>E0U+SA!)B-X03M.2&MB.'4O,#=95UIV
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M+WES2%%F*U=85V8K-$AR2"]:2FER=BM69S9$)B-X03LO=T%S=7,O.7=05U`K
M>51&6&8X04MW9$(O=T-76%=F*S1(<D@O6DII<G8X06Q93V<O=T1,3')0+T%(
M03E9+S=*359D+WES2%%F*U=8)B-X03M79CA!=4(V>"]W0FMM2W!X;S)S-F1R
M3VUW-FQP,&I3,F,O3#`S94]32G%O>%)G,&-Q;S9K37!&1U59<6IC5F1I<G-6
M9&ER<U9D:7)Z)B-X03M$+VY*1TUV*U4K<#`O665*=G1)=E)V.$%,6DLO2F%N
M,GA6;EAL4#A!-5)B4G8K64<R+S5-<FEQ831Q-T9867$W1EA9<3=&6%EQ-T98
M)B-X03M9<7=Z44Y7=61,.'-4,T9V<&0U<3=T<E=S>&TR<T)!6E9",5<W4$TO
M5TIB9$])-#`R87133G-664XU-R]!3V-H9%HX=&5:=$DP;&9+)B-X03M.-45T
M-D9E84LK84IB:5)8:SE.4F)I,VMU238Q52]A8F,Y:#%+<C`S4F9.3B]Q5CA,
M869Y,7%U;'AL4S,Q=3E&;4EG4BMZ*S1U6C-Q)B-X03ME,W<T<6]E85@X>5)A
M=G!$-EAC5'):>5!+3#8Q:6AI8T]);UAM44=2,&-X*V]Y0T]T92]J:7)!+RM6
M<R]M2$9F6$5K;FQI4V5X2#%.)B-X03M,6EEB93=":TUG;64V8T=2161F4TM,
M15%6*S!/47%'=W%N5C,U*S@U-F9P9&<W-DA,95A,-F%T-6-N,%IW-WI%4S@P
M4EDP-$E9=E11)B-X03MS2D=8;#9G;V1J:7%7>2]M=C4O:3`V8E5:4$MH:70W
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M-G):4DI-:V)L,%-E3T\U5DI65FEA0G=E=4975&IZ9#4V06]0260T05`X06PO
M,#,O<79G5D)A;'%8;4A5-4QE)B-X03M4569Y,FQU-4Q2+U5T;FUU.4QC>'15
M1W%L<&I49%%F;TAH:7%$94LX8V]Z+T%*5CAJ1W!20S%X<$IO<E)I26IE6&]5
M54PY1T954&0V)B-X03MB9#-.<F(R<"],1U=+,W1P-&)L231R>E,P1%!"24I5
M1#!M*TIE86=S4#)U*TMO3"]!07)'3E13+T@U6%1G>'=M0DQ56#)M0S-!6FUC
M)B-X03MV-EAR535L;DIR-#<Y9#A65$9,1U=.>3AF-51Q:D9':4I7-#!K9D$P
M66A+,$5V5#!X>'`T8EEQ<7E2,S!L=F(R,&XU5V,W93!34T\Q)B-X03MI834P
M;W)':S%F559!6G%!3EAC67$Q1D9F4E=P=%EF>71A2T%H:'=3-C!P9G0Q3$55
M;39K;75+;U<Q,&,R,6IB5U,O;%)Z:'1)>$9&)B-X03MZ=61+6G5),S-*;3-R
M,WA66$YN3S!,46XX<4(V5$TW<VXQ:E-A8W!05$QN*RLO82MR>#$O,58X0FEQ
M;VM6-FLW6$-F;%=&;F)M5$E,)B-X03MJ4U$S-W=Q6#,Y6#EO;W!0=FEQ8E)E
M879/,%534E)E46)T26\Q0V]I,RMM9TMQ:6=!2'(Y<T-P;"M8,FTV;'`S;$MZ
M=&13="]Q=#9()B-X03MU2DIR675K:%0Q<FE35E9,4FQK2C1U3VAX5DM(.'@K
M6C(O37(Y15)S<C9+:V=34EEO:7=19E5X3697;6\S1GI)-#1Q4#)A5BLQ6$-Q
M)B-X03MB9610359Z;V1R0E!(2DAB44]713$U3F)4,V%2,&]&0FIH84EF1U<V
M=$EV<T0R0W!H-6(Q0S4Q2%-)8C)E4T=95&IN1%!B<DI%<VM:)B-X03M(=W-9
M<$-Z4G0Q0EAK,WIX5E$X-#9"*VYV3#%Z<'EP0S`W.%=T,FY&55-21T)$9SA7
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M<F8Q:6531W%)26936C$U>6-X>%(K2%94,T1B67%Z3'EP+WEI)B-X03LK:C`V
M9E5B8B]K>75+<'!I<G-69&ER<U93>EAV2R]L,WI"86TQ,7948F9564M%2W1X
M1W)L83DP66IK<#DQ3TMS5R\U5C%R;6IF2#5-)B-X03LX>3-7;GA,.6I33E1R
M<59H4W1E0V5Q=W5)9V8X;5@V359E52]M5B]Z:T8K84AK+WI21&]D>G!M;5%Z
M,G%*2F1.2#8P.%8P2DYW,&)0)B-X03LV5'AR5&%M-416,T]+865X*UA0>E<X
M:38U1D%S97)7,7)Q36MA3DQP=#`O,64T:F1G0WEC2GA%>F-4=%5$9D9$3'=1
M4E5B9S1Q-T98)B-X03M9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&5T-703AU,FYN*U=Y=$Q*3&4Y:FM94$TY+T]R=5I95&-S67)1.&\S4W-Z
M)B-X03MD>%)U4G!T:%9.+U`Y+TA9-D0V.#%R0F,R+W)2<D\Q,4$Q>D1%:'(K
M.&%*849T-DPQ2%@V0T945'DX.%0V2EI34DQ':V-K2W5Q=W=T)B-X03MB>&=-
M2R]"17A*46(T<6U'2W-A,6)Z-7`K;C9J9&%A=&IE,VUO5S,Q44QB=WA);G).
M974V4G)#.7<X16)C9E-9<S-)2T]L9592:7%5)B-X03M.*V-/9SA"2VUM-FA*
M07AJ:%-:5G1Q3F53,C982S)91%1Q,W)E;DMT9'5(*UAI<D4O=T$O4%!I3BM5
M17I7,$IT<&19=6XP>64Q=6I()B-X03LV.%`Q9#5"8T%R13AI:W)*8BMN5E=9
M9D5$:7%'.&MF;4QQ+VQ7.&<P5'I*<3,K24Y!9VEJ9W4Y9F=S2EEO3DQU;590
M5'1:-VE.5$1))B-X03ML1T$U.590,G1U:7(S2$9867$W1EA9<3=&6%EQ;#)P
M95=V3'5Q6$U.,7%E;%=D.617,RLX.#EZ8GA44U(P3F9G6C%9<G8T67$S<E!L
M)B-X03MZ>2]R8U!O87AP=')Q359+0DQQ1DIG4&QZ0G`Y1TMS5R]W0U92849:
M<U@X=#9L<6YL="MO:C`K-V,R.69E,G506&AP-T)2:7)8,4PX)B-X03LT=$I"
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M:%4T.&QE:B]H5%,O4FE-369O3%--='I.935*;W95-S`T:6Y39S991E1R1E5G
M)B-X03LQ=GEB6C9R9E-8+S%Y-G-R-6MT56EU8EEW.&]J6GEY>7AS:7I25$E3
M5&-/<F,Q654W03<T<6M2+THW47945TI.4S%"259A3S132E=T)B-X03MA0SEI
M=#!T;'9+;3-,97(V8U,Q1F94+WE-5F5C9C@U0V%*2'!0;#=1=$]H2#916F8P
M,V5Z6%8K66QA4U=A1C5*;G%I4G`V=DLT85=.)B-X03M6440T2T-L0FEQ5&%0
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M.6)J3V<K575+=2]X1BMA5VIR+W59.'17*W57-C`U6&UH6$%75VYJ.51U*T)*
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M2590=DDS;R\T43!N,%9:679Q-CA!>D)Z5'AQ1E%B.6%"4E1P461-0W`W:7)S
M)B-X03M69&ER>D0O;DI#,G-P=GEP,4YR:S)Y=$,X8VQU8FYL6#%1,4%)94Q*
M*SE)2G`Q1DLW67%Z1'E$<%=M-E@U3C!E,3`V,FIT8F,R:TUP)B-X03MJ:%5+
M<&5334\W;6Y5<WAQ5&EQ9E-2<$EJ4GE+2%)W5F1'1E%19&E#1&ER03=N.'1B
M<E)R;5159DE&*TY#=4I'3'HV3DM';#!M-&(S)B-X03MG0G)!>"]N:'`X:FEQ
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M>4LO>3=F4$975V569BM56#!F+VU"='8X06MY=4MP<&ER<U99<#5L.&DS1W`V
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M8RMN869C+VUZ)B-X03M-=7`R:U5X9#!.<C8P8W)C;S%S;&]2>%@P4T)+1RLS
M53$O,DE"46XS-6Y&:#5D:4MM5E0Y86DK3S%C2F1R<S(Y<S-*5SE4=#A/+TAL
M)B-X03LX.%%L3B]+4#%8+T1/;4<Q3$=!,C9&0S5J3&UO,TQ'3#1#,65T3R]8
M9D%Q8C1Q;'9M4R]V.5`P1%5,*W=I:6UU-U=#4V%+3V1M4TTX)B-X03M&-4AK
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M*WDO3GI61V<P>EAT4C!&9%`X;#9X8TIB5U=R4UAA979'2FTT450S3G555EDT
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M.&,Q-V98=6=757I83VXK5W)M)B-X03M22#`K1U5K:U549TAD54IQ:4\U5F9$
M1E5D969L1BM75C-,-G(K5W)'2U=T9E5T;VAB3EAX<D(V6GA61$0X;W1"='EF
M,%9Q=75A4W9:)B-X03M,5%9B<W`P<#EI9#5L4%4Y4FEQ0C$S>4HK661V;VUO
M<&](;FI56C=L<F%55W1R9E$R56I0255B:6]U1FEH94UK-T)H,#8T<7AN>4QP
M)B-X03M/;DHU=#AT4#55,$159$1L<S1*,3@S>C,P13!#4W%94W%X5%!*4F)I
M9C9Y96%U<$Y"53%P=&ER,GI&6%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW1EA9
M<3=&5T%F;C%"3$XK53-M2#`U,V<Y3T%34'=#;C%&1')73G53=#A*.7%(,WA6
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M)B-X03MD4V=#6&1N3EI*9#)->G`O37EM3U)1-$1+,4<R,D)X5FUF;%@O;$8Y
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M>%8S+TMM9GDK+W=#5U,Y+S=I;7`O.6Q/2V]B569Y53AL4S9F9%)7558U8C-S
M)B-X03MK36DR,#=A;G%B0T]5<5%J;%1C145+,413;4MT85HK4VYK=4Q48E-+
M+VAU-3<V3T=.8G%:3E0Q3E9E5E5!9&Q!=49!0F%P-D1&558O)B-X03MY<&XX
M=G8X06QK=F8K-'!Q9B]:5&ER=BM632]L.2]Y>5AV.$$S1DY4+W=#>6Y&6&8X
M<5HO3#<O;&MV9BLT<'%F+UI4:7)V.$%L5%`U)B-X03MF9CA!3$IE+SEX5%4O
M=T1S<'A6,R]+;69Y*R\U6DPS+T%,:6UP+SA!6E1I<G8K5DTO;#DO>7E8=B]C
M53%0+W-P>%8S+T%#<&XX=G8K)B-X03M74SDO-VEM<"]W1%I4:7%6*U=0>4\X
M<S)M9U=.=')V,6TY,65+24QE,U5/<&%L2$A*24]R2W%Z>&=$+UEJ1E4P+W=#
M5DTO;#DO=T%S)B-X03ML-R\S1DY4+T%/>6Y&6&8X<5HO3#<O;&MV9CA!=4MA
M;B]W0FQ/2W4O-55Z*U@S+TQ*92\Y>%15+RMY;D989CA!2VUF>2LO-5I,,R]U
M)B-X03M+86XO04YL3TMU+S55>BM8,R],2F4O.$%C53%0+W-P>%8S+TMM9GDK
M+W=#5U,Y+S=I;7`O.6Q/2W4O-55Z*U@S+TQ*92]W1&-5,5`O)B-X03M!3$MC
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M/"]X;7!'26UG.FEM86=E/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@
M("`@("`@("`@/"]R9&8Z06QT/@H@("`@("`@("`\+WAM<#I4:'5M8FYA:6QS
M/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z9&,](FAT='`Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*("`@("`@("`@/&1C.F9O
M<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B`@("`@
M("`@(#QD8SIT:71L93X*("`@("`@("`@("`@/')D9CI!;'0^"B`@("`@("`@
M("`@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S(T:3@X/"]R
M9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.D%L=#X*("`@("`@("`@/"]D8SIT
M:71L93X*("`@("`@("`@/&1C.F-R96%T;W(^"B`@("`@("`@("`@(#QR9&8Z
M4V5Q/@H@("`@("`@("`@("`@("`\<F1F.FQI/G)R,3,P.#,U/"]R9&8Z;&D^
M"B`@("`@("`@("`@(#PO<F1F.E-E<3X*("`@("`@("`@/"]D8SIC<F5A=&]R
M/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP5%!G/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O="]P9R\B"B`@("`@("`@("`@
M('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y
M<&4O1&EM96YS:6]N<R,B"B`@("`@("`@("`@('AM;&YS.G-T1FYT/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1F]N=",B"B`@("`@("`@
M("`@('AM;&YS.GAM<$<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+R(^"B`@("`@("`@(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^
M"B`@("`@("`@(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS
M93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B`@("`@("`@(#QX
M;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#X*("`@("`@("`@/'AM<%109SI-87A086=E4VEZ92!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@(#QS=$1I;3IW
M/C8Q,BXP,#`P,#`\+W-T1&EM.G<^"B`@("`@("`@("`@(#QS=$1I;3IH/C<Y
M,BXP,#`P,#`\+W-T1&EM.F@^"B`@("`@("`@("`@(#QS=$1I;3IU;FET/E!O
M:6YT<SPO<W1$:6TZ=6YI=#X*("`@("`@("`@/"]X;7!44&<Z36%X4&%G95-I
M>F4^"B`@("`@("`@(#QX;7!44&<Z1F]N=',^"B`@("`@("`@("`@(#QR9&8Z
M0F%G/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1.86UE/D%R
M:6%L350\+W-T1FYT.F9O;G1.86UE/@H@("`@("`@("`@("`@("`@("`\<W1&
M;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*("`@("`@
M("`@("`@("`@("`@/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O
M;G1&86-E/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=%1Y<&4^3W!E
M;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*("`@("`@("`@("`@("`@("`@/'-T
M1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B`U+C$P/"]S=$9N=#IV97)S:6]N
M4W1R:6YG/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z8V]M<&]S:71E/D9A
M;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B`@("`@("`@("`@("`@("`@(#QS=$9N
M=#IF;VYT1FEL94YA;64^87)I86Q?,"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M
M93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`\<W1&;G0Z9F]N=$YA;64^07)I86PM0F]L9$U4/"]S=$9N=#IF;VYT
M3F%M93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1&86UI;'D^07)I
M86P\+W-T1FYT.F9O;G1&86UI;'D^"B`@("`@("`@("`@("`@("`@(#QS=$9N
M=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*("`@("`@("`@("`@
M("`@("`@/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y
M<&4^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E
M<G-I;VX@-2XP.#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*("`@("`@("`@("`@
M("`@("`@/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E
M/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L
M8F1?,"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*("`@("`@("`@("`@("`@
M/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.D)A9SX*("`@("`@("`@/"]X
M;7!44&<Z1F]N=',^"B`@("`@("`@(#QX;7!44&<Z4&QA=&5.86UE<SX*("`@
M("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D^0FQA
M8VL\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q/@H@("`@("`@("`\
M+WAM<%109SI0;&%T94YA;65S/@H@("`@("`@("`\>&UP5%!G.E-W871C:$=R
M;W5P<SX*("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`\>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7`\+WAM
M<$<Z9W)O=7!.86UE/@H@("`@("`@("`@("`@("`@("`\>&UP1SIG<F]U<%1Y
M<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B`@("`@("`@("`@("`@(#PO<F1F.FQI
M/@H@("`@("`@("`@("`\+W)D9CI397$^"B`@("`@("`@(#PO>&UP5%!G.E-W
M871C:$=R;W5P<SX*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(@H@("`@
M("`@("`@("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*("`@("`@("`@("`@>&UL;G,Z<W1%
M=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M945V96YT(R(^"B`@("`@("`@(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z
M0SDT1$$W-$8V.4-$130Q,3@V.3=%.48Q,CA!.48W.#8\+WAM<$U-.D1O8W5M
M96YT240^"B`@("`@("`@(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z0SDT
M1$$W-$8V.4-$130Q,3@V.3=%.48Q,CA!.48W.#8\+WAM<$U-.DEN<W1A;F-E
M240^"B`@("`@("`@(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#I$-C(W,S@V14,Y.#=%,S$Q.$8W-$5%-$1!,S<T.#$W03PO>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/@H@("`@("`@("`\>&UP34TZ4F5N9&ET:6]N0VQA
M<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B`@("`@("`@(#QX
M;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@(#QS=%)E9CII;G-T86YC94E$/G5U:60Z-F1D-#)A83$M-V)A
M82TT,S=D+6$R,#0M83<V9&$U8S$S,#%F/"]S=%)E9CII;G-T86YC94E$/@H@
M("`@("`@("`@("`\<W12968Z9&]C=6UE;G1)1#YX;7`N9&ED.C!%138Y-38Y
M149!,T4S,3$X,#!"040Q-C)$,C%!,C=$/"]S=%)E9CID;V-U;65N=$E$/@H@
M("`@("`@("`@("`\<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M1#8R-S,X-D5#.3@W13,Q,3A&-S1%131$03,W-#@Q-T$\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*("`@("`@("`@("`@/'-T4F5F.G)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@("`@("`@("`\
M+WAM<$U-.D1E<FEV961&<F]M/@H@("`@("`@("`\>&UP34TZ2&ES=&]R>3X*
M("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@("`@
M("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1#8R-S,X-D5#.3@W
M13,Q,3A&-S1%131$03,W-#@Q-T$\+W-T179T.FEN<W1A;F-E240^"B`@("`@
M("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P,30M,#$M,CA4,#@Z-#@K,#4Z
M,S`\+W-T179T.G=H96X^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B`H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B`@("`@("`@("`@("`@(#PO<F1F
M.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z:6YS
M=&%N8V5)1#YX;7`N:6ED.D,Y-$1!-S1&-CE#1$4T,3$X-CDW13E&,3(X03E&
M-S@V/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@("`@("`\<W1%
M=G0Z=VAE;CXR,#$U+3`S+3$X5#$X.C(R.C,U*S`U.C,P/"]S=$5V=#IW:&5N
M/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@
M("`@/"]R9&8Z4V5Q/@H@("`@("`@("`\+WAM<$U-.DAI<W1O<GD^"B`@("`@
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS
M93TB:'1T<#HO+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(CX*
M("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B`@("`@("`@("`@
M(#QR9&8Z0F%G/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1+:6YD/D]P96Y4>7!E("T@5%0\+T5X=&5N<VES1F]N=%-E
M;G-E.D9O;G1+:6YD/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT
M4V5N<V4Z1F%M:6QY/D%R:6%L/"]%>'1E;G-I<T9O;G1396YS93I&86UI;'D^
M"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I/=71L:6YE
M1FEL95-I>F4^,#PO17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE
M/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R
M>3Y-;VYO='EP92!4>7!O9W)A<&AY/"]%>'1E;G-I<T9O;G1396YS93I&;W5N
M9')Y/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z5F5R
M<VEO;CXU+C`X/"]%>'1E;G-I<T9O;G1396YS93I697)S:6]N/@H@("`@("`@
M("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M
M/C`\+T5X=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3X*("`@("`@
M("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?
M0VAE8VMS=6T^,34Y.#<P,30U,3PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E
M;G-E7S$N,E]#:&5C:W-U;3X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES
M1F]N=%-E;G-E.D-H96-K<W5M/C$U.3@W,#$T-3$\+T5X=&5N<VES1F]N=%-E
M;G-E.D-H96-K<W5M/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT
M4V5N<V4Z4&]S=%-C<FEP=$YA;64^07)I86PM0F]L9$U4/"]%>'1E;G-I<T9O
M;G1396YS93I0;W-T4V-R:7!T3F%M93X*("`@("`@("`@("`@("`@/"]R9&8Z
M;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z
M1F]N=$MI;F0^3W!E;E1Y<&4@+2!45#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N
M=$MI;F0^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I&
M86UI;'D^07)I86P\+T5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3X*("`@("`@
M("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ
M93XP/"]%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^"B`@("`@
M("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/DUO;F]T
M>7!E(%1Y<&]G<F%P:'D\+T5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^"B`@
M("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I697)S:6]N/C4N
M,3`\+T5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^"B`@("`@("`@("`@("`@
M("`@(#Q%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS=6T^,#PO17AT
M96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/@H@("`@("`@("`@("`@
M("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U
M;3XR-3DP.30U.#4P/"]%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR
M7T-H96-K<W5M/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N
M<V4Z0VAE8VMS=6T^,C4Y,#DT-3@U,#PO17AT96YS:7-&;VYT4V5N<V4Z0VAE
M8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I0
M;W-T4V-R:7!T3F%M93Y!<FEA;$U4/"]%>'1E;G-I<T9O;G1396YS93I0;W-T
M4V-R:7!T3F%M93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@(#PO<F1F.D)A9SX*("`@("`@("`@/"]%>'1E;G-I<T9O;G1396YS93IS
M;'5G/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@
M96YD/2)W(C\^_]L`0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!_\``$0@`G@#?`P$1``(1`0,1`?_$`!X``0`"`P$!`0$!
M```````````'"`4&"00*`0(#_\0`1Q```00"`@$`!@8(`@<&!P``!0(#!`8!
M!P`("1$2$Q05&!87(5F6V",Y5EAXF+?7,3(*&2(F,S0X)"4U05%T0DA286.(
MI__$`!@!`0$!`0$````````````````!`@,$_\0`,1$``@$!!08%!0$!``,`
M``````$1`B$Q05%A$G&!D:'1,E*QTO`#(G+!X?%"$X*2_]H`#`,!``(1`Q$`
M/P#[^.`.`09V9K=\MO7[<0'5QZV5W8\O75N719U(*CP5E?MT4%.E5P3`-D67
M$"<&3+,(7)(19`HC%C2G71YL-*2T1CBJ]3<<Z=HT'M_,M-K?"1>P\D&NY;P?
MM[=4W#.")LS1ASL'GJNYJ9MG98EFH@:;`,Z:A[+AA&:<()DDA9MZAV9JLW&9
M$%36F&$Y3OQQPL-8.:Y[TKB79#KF]YI5X7;(WO-=VY.%P"&_Y;O:'.O;U3&?
MK&@8!Z'A,G=$?%*<TP.J"/7JZ;/1WW:7?\CA9I]+UA]LX7WV[\T?QO';'=/J
M%U,[4]B:W"@$;EJF@T*U3@W9,O;=@TJ[[&#6_:?UVE-:Q*]M&`3I=)M5=-:C
MSKP?`)5VFA4BID!NBBR"33G&X)*II9MW8*R,+<==3I;U%VZ?[`]4.L6^K6/#
MB+3NWKSI;;ME%5YJ:P`&']DZWK5R,CP;)*:2(LAX1$U)C#&IY$A-;A-L(E39
M3^''W!FI0VLFUR98;@@X`X`X`X`X`X!INQ;R$UAKZ];+LV)JJYKRFV>\V#`V
M.B41R$J02<?*X@17'HZ),W,`>_B+'6^PAY_V;:GF\*RM(*VPA;&_-G9QC..E
MW9KT9QC./]Y.H/\`AG[<?_-;P6%FNO8_?K[V?^Y=V:_$G4#\UO`A9KKV'U][
M/_<N[-?B3J!^:W@0LUU[#Z^]G_N7=FOQ)U`_-;P(6:Z]A]?>S_W+NS7XDZ@?
MFMX$+-=>P^OO9_[EW9K\2=0/S6\"%FNO8?7WL_\`<N[-?B3J!^:W@0LUU[#Z
M^]G_`+EW9K\2=0/S6\"%FNO8?7WL_P#<N[-?B3J!^:W@0LUU[#Z^]G_N7=FO
MQ)U`_-;P(6:Z]A]?>S_W+NS7XDZ@?FMX$+-=>P^OO9_[EW9K\2=0/S6\"%FN
MO8EK5NQ16V:#7-@A1AH*/L<:4Z@/8VAC)T3)@$)@D@-*H"E#@?,R"1@2HSK@
MLP4'O9:]K#G2HZVWE"$@<`<`<`<`<`IIY#J].M?2#M!7AL,T0G%-0VEB/"KP
M>ZGS,E28R7EM00^N[_JVY3UJ;:7[1D)?*^YACVKDQR<.1+%SA:7%2>JR_::,
M=XSOU<'C\_@CZI?T(H7!:_'5^57JR[G!D<`<`<`<`<`<`K9W,_Z/^UO\-F\_
MZ7VG@JO6]>IZ-K,]L7#X]6B2'7>)4<`HF"+>V@^R2%CS8O?"&9:X3U..C!B0
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MFT2:&PMQJH?2EQ@++>FB^?,3590_R%"AD,W+M-?-.L%&AY*L`!-`;)S:[@"#
M%1S,!4T`Y#CVZ7899XZ5;?-.5:%B$,1%@MB6IT*>+9E_L^B7%^GBF5#R$RA:
M1BKR+9E2S5%+%2@^=18ZVA,<@DKL0$#>74,28T^4TQ6:_5/:QVQ:QR]MN%Y<
M2;+UL1CA]NN,?J;>>Y:F9'5WR#!W$CYEXJ5@!C:S&@-2XXVG-W`U+;N<5U15
M1\E!9"Q;A]%LR83S<RF2JC(#M(?]9-Q<5-6%F4<;.\<9MQ+`:)#]AQ$@LG=A
MVOEASU?JS06$%=:E8#'(,:0Q8L-$G1\<V3BE'%1Y>91\@3E8>:QB-F&TIYIP
M9LP^+`L=P!P!P"M/4#_IZHW_`+Z^?U&MW`++<`<`<`<`<`Y,^=&V7RC^)[N9
M9M:VUZCVP?0JNRQ9(DTH-GQ0Y39U&$6J$,(!EMD(14U5IYD(,D-K0TW.(L>]
MN,Q,OO-C?TXVZ9S_`,ZG`7_13.UG>G==TVWIS8.PC.R>G^B-)U0+7V;C,&DB
M6J[LX8$A=4TRG$GD_2E-6FT&NWV,BOONRZT%AU,6V.R'>0S$*CI]94J&E%3;
MXK'29@^V#@X#@#@#@#@#@#@%;.YG_1_VM_ALWG_2^T\%5ZWKU/W<!?MR.+1T
M=?\`7_76VUKZ-M/29FW=M[)H=A3:?>"6'H$0/3],;!%20:8*`[K!&18H$UZ;
M((QG1\6/$C39@*,6^"3ZRHY,YW]7]C>3DX1GMNUN9?V?JUUZ2VBGNH"C]9(6
MONQ<V594[-USUTF:3T98W]GZ<!QF0N1UDL#5S'M-Y%O`-V;#E%+!&`C35.<6
MN-FVRR&YJ43;V1U)M7ULS-)F5C(H07NUW7C[[`ZK%\%:[&V+@'[9P77#UL$U
M],\3DZE<$.8L@0&E^*J--+CQ>%2&&!FR=)Z%9'#G>Z&J=-&T^JR04\K<9D(,
M=AU`ML(",*;3/SZI%<6.W!5J.9?":T>`!G@V#PYEEU$PFNY'R4)H46%^WTW7
M6X3?IR-<-77R#Q(C$V10=<QHV=@:I`KA#`<DL2?#V=Q,2[&6W*]LVPR(]7JE
MRR-@,F)PJ--DZW)S+59P]8>#&7((?;A/Q\,.MQJQ[=?D0<*E:Y5^OP#%HS2K
M381$(P%BL5")*BW,(,J,0SL]&V%TYZSD@,HQ.+4D%(+J:%1H!ENQP2.2E<@"
M0L\;7V5_'HS*3CWDG>A7,`W1Z/'CN+ND*KW6$Y2)-IS'E"32J:1CB9&R!%>'
MR(5H='PY<@E')>K2&1IA863;6S`*6+]MG";XUPFU<GB2+M>X][1A@['U'JN@
MV6"BSLL@Y1^37QXE%7R6:CXFJGN[6A'C<MRN/+)$X<JJ4QT398JQHQ^SA?93
M)HBV<6^'SO,JZTTN^V?R(0IQ2HU2M4`O**T[<I&MW</3QD`8-+@;1&`ZWB%I
M%DW','BC!FH2XUP&0Y(@]%/VV4L*6CU2J@;"1AB_;GE.N<8WGK5/\AQ(Z+*9
M#T8'`%/SILFMX'5-P-8?A^LCTI02?.;V83.QH9[:A$4!K1N')COM50+$L-E`
M@22IX\B'VZQG.JTP4_(//#MGD?)5IY9/6.K*_;TUV%+'1(;H<O7,VM"S62L,
MP3QN$<46)1)9KV0,$>(Q\2`S"R#E@#&HT7*Q''">G):]+R]%"<N;M5&_6"R,
M9MS3I2*44&:]W&S&H9>?$%%8\7XB6]RR8#LCRK\#)*7F!(F.P\N^EC*4B$,]
M0/\`IZHW_OKY_4:W<`D6)NC6<_:)73$*S)D[)!P(Q(Q761)U:!L::.8+PT3#
M>!?T=8FRA4EDC'&++8)/0EYDMQ%-(<4D6'$X'HM^X]3T`I'"7?8]+JA:3';F
M)''K$+&2V8#SCC+)*:S*DMJ'BWGV7([).?B,/=DHS&1)4_Z&^!#=R9(K3K3[
M3;S+C;S+S:'6G6EI<:=:<3A;;C;B,Y2MM:<X4A:<Y2I.<9QG.,XSP0YN]B^U
M>X-07#8E?:E:=JH4,[5IU6L]K@6(V.@A9^ENS>QW&;?G%HI32S5GMFB0E8&L
M#),:,*@6=Z/'=L)OW%QP:236./JM'@[2`"?D-W7&S<%J:T^"<"U2[WM@,;`'
M'20.STXUV-%#.K!]Q&R(*9&Y[FQIH))@EXT:+*9<^F?N6NR++U>]T%V59?@N
M:3FZY3_4>+L#W8"9Z=]O[-V/U='W=J(+IL%+O=-U'2P9Z?KQK:A7<M.L6L=I
MAKSLEL67.Z:70JO.OQ6))!'V)-OBS(VO!C,:"XZ"3E;+AS9..36_#U9\_/3'
MR`:!\:G;GQ_Z+U/UH)Q!G:KH/X_*/V5-5J=\(DV?=N\1P;9]<W8-$NCRTK8)
M,0]N,\&L+4@F+D2XQ5RNUUR!%I`P02'6JEU4UU-^&JJ%?8L-+C[N.#SC@#@#
M@#@#@#@&N7"I5Z_5&TT2W#DF*I=:X;J5G$KD3(:2E>L8R4'-#E2Q\B)/BIFC
M9DF-F1!E1IC&'<NQI#+R4.)`@?'4C5>/LQ:NS>,8^S&,=U^Y7V?_`-ZX++TY
M+L/E)U7^U?9O^=?N7_?K@2].2[#Y2=5_M7V;_G7[E_WZX$O3DNP^4G5?[5]F
M_P"=?N7_`'ZX$O3DNP^4G5?[5]F_YU^Y?]^N!+TY+L/E)U7^U?9O^=?N7_?K
M@2].2[#Y2=5_M7V;_G7[E_WZX$O3DNP^4G5?[5]F_P"=?N7_`'ZX$O3DNP^4
MG5?[5]F_YU^Y?]^N!+TY+L/E)U7^U?9O^=?N7_?K@2].2[#Y2=5_M7V;_G7[
ME_WZX$O3DNP^4G5?[5]F_P"=?N7_`'ZX$O3DNQ-5`H56U?3@5"I4&6.K%;BN
M0Q40@;.V2>EMZ2_-D.S[!9R1BPF9TJ9)D2I9(R5GD)<AYQZ3*=<7E61"C-+E
M0G?(5MB$7^BS92.(;DU-AAK6[-AE"D:ITPV8)2_A^M&M@3IL&>1?'YG'MH2G
M1H.?`@10D>ODQS;@T[E\Q>L89<3W=BY!=[M%U^"U*S[+C8>:EG=@A:!L7=4`
M8TP&N>N(U5Q=:?KR@;9I[($T/+V],QR["M6#;)#%O,3=E?#A$M`D%<[NG\?R
MXZ$)2E*<)3C"4IQA*4IQC"4IQCT8QC&/LQC&/LQC'V8Q]F.#)_B]%C2,93(C
ML/I4MAQ27F6W<97%=2_&7G"TJQE<=]*7F%9^UEU*7&\I7C&>`?YY@0597E4*
M(K+DIJ<YG,9G.7)S"6DL3%YRCTJE,I882U(5Z7FTLM80O&&T>@"BODXJ,*U^
M/WMS6\PD+:.:ALJY34>$'D+D/-)B252%QS.S-,BI+^,1&U>N0V56D^AI&</D
MEMMA2(U3953O7RY^C.:5HZ^Z<M?@TZZ=D)^J1A'L=UQ\8'7C;.A]U4ZG5V5O
MK7%YTYH6D;5H4BCW20+D6&"(A7.OPII^OL3,BC`%^P#IL"3'*2VGAJ6OJ-38
MZVFI:33;3G@[\"./%7YX=]=X-8[$,7KH#NS8]LUY:!`-ZR=1A5$FZ_F,&13T
MYB$;QO7=.O<@K-$S#6_)B"K%9(S\`A!E/L@L+C-3Q:_IJEK[E;G/Z3.J'SG=
MI27VUWQ4=PG6\_Y7+9M;HE4/1C_RRXROMJ7E(_\`OA$=S*?_`$SP8V5YZ>5?
MM.(77[S6^1![R>;KTEVBZ?W^F=6:)*O4>T5G7FAMA[4V9H2L`O>&J+L(V?U6
MS=,[%#V*6V)8LIBKP#E8(0#Z[115Y!"DIGCHZ*-A-52WK$Z1$[I/I=T5VBZ[
M=F@TH[H+<VO=JQ!JLM&X=3L<&;8*Q+2YEI8ZWU5QQFST\LT[C+;XBT"!!-A?
MH2]$0K.,9')IJ]-;_P!$\\$'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`.8.HX
M\Z]=_-S[,JA$69HP=^11+4S"56)GT=N5"J@RF>ZG5#*R0+HN/Q3-G8#N$KX.
M56ZD\<&9K$V7<2.*T-39$?'^KN-LF4[U5%^_;.ZT5%HX2`YGE3TN*3]]M8T.
M))0+QIY<8O$EU/:6NWWKHF.Y,#@H!"%8$J"FK03$OAR8IMLL"<3RP_:=G\.C
M`:)-'AQ4`D4=-D80V#$(&GXT>&^7FQHK3,HH]$B)1$BNSWT.2W(T9"8["W<M
M,I2VE.,#)DN`.`5C[HP!Y3J?V#@%+/KJFP).J[8W)L^VJP*N>NQ",#75)D6:
MLF[#511:*MQ*(\5B;8!S31%Z')]=Y;*8SXJO7ZL9'WC/QA7C>\?J58PI*ND7
M5/"DYQC.,XSH>AXSC.,_9G&<?9G&?LSC@M?CJ_*KU9;FJTVH446H)2:K6Z<%
M5,E$5"*J#&5X6HA.7AV;.4/$18D3,R8YC#DJ3EKVTA>,+=6M6/3P9-DX`X!4
MW>O1KJOV,,Q;?LS403.S!B/0"W11IIK5F\JVM#>$,.5_<^M254V6+3'REMQN
M&Q9OASBFFTR83[6,MY%3:N?"]<G80-]0G?S0?Z7KSVH`=EZ5$_Y?3O>0*K%O
M:B)_2J@USM3IT(-M,=WUDJ8BR]IZDW"26AU/OQU2FO;Y%FEWJ-:>S?HUP*)]
MU//K$\?#%`KG:CHIOZB;8NY":N-7AMYU):]:F*F%5#:/VS7VV`%AF9MB1[Y(
M=';KMBI-!L*79;634$"TY&=DC=/T]J=FI-+1IVZ?UG9[KMV:T=VKUI5-K:+V
M-5;Y6+96:_9T,@[""+&ZZU81<4HR$N(D.3)/UBT#$ROAYVODU-3Q!:-,'2VT
MR(SJ<#FTTX:@GG@@X`X`X`X`X`X`X`X`X`X`X`X`X!1;48[5]/[4;7J%4?V9
M'MR(;R[%'LVRJO-J1&.9G2MPM*JU`<L+UR^"BSFZ+,B&;57H@Z&6FGPWO3T6
M`.7D5S">'Q91AF>CLM9-;UO;^BJU;Z``+/[C)3JLJQ$K1LNNH*R!9NH0!E*)
MU_7-%MPW8Z)T:V%RD$'LZ8#I<%L3.0]/9:*394,57-S=NQWW786EW&&&8S+,
M:,RU'CQVFV&&&&T-,L,M(PVTRRTWA*&VFT)2AMM"4H0A.$IQC&,8X,D<;<VH
M#TW37KO81-H-#F3%?"JAU((Z;(H?L)B&'8FR\>TC0!8<>N7[Z5+%I\"#&BL+
M9:>D$Y(X=-`K`>[_`&K:_(M$=^A;7F+J\.SV5:H,"@J09UI2I6W85MVJ&]ZV
M%%6[40DG2EP;6.GH'WHA[W5UB:=.0?94R-;-UJMWZ::HK#W^\AFMJ%T$[>;1
M;HL<C*K.H0DRB5+<+U.A5?;HG=1NW4/6%L!Q85H,.&0)DA3;C9H].)XKVQ)0
M6I2%OUP(N>/E\%II;J2UMC"+^6?4YV>+3R*;0T!J7JAI#M!:Z-M?02.LW7>,
M[O73&H-O1:_TOE7K6^LG>N^E>U&Q8]?*:G>(W*B6.OHE6I@O72=(/NPW+]"<
MK5H#6ML:KI3=35CVG8VONM<NE7V-/?<KH/J<X.0X`X`X`X!6OLATZZO=OQ=3
M#=FM':_W0/HAIT_4&KL'20=KY*4B.W/R.EM.1YC4$LW#A-FQ"I"A!Q$&"@O!
MFIA1<-"JIJYM3D1YLKQQ]&]K3XAVS=9M8"+</CMQ1FPM:"']-;/%QV6D,QV!
MFS]0RZ/L`>S%;;;3$9BV1IF-A"?8H1Z."JJI8O5.U/>G81G\D_8C6?Z7K1Y"
M^P5:AM_:Q0NT`6I]P=?8PU_RT;XW<FZ=V$:8QCTLNJ^O]Y:V\I7ZN76TJ4&T
MG?2MZ^U]NA&VY>TGD?ZBZDV;M7<G530?9BG:QH5KO9:Y=8=R6?6]A:&5,'-,
M39AK2>XZB=>B#6V8:IA%50W%?C4(<W*<@`#,MIJ(^*E34TDVI:2E3U3OX):H
MH[XK_P#2'-3]Q*C?7NX3.L^HMGKMU%@*;9B]B-B-/7R&<A29B!+5^N,5FL5V
MZ5M3$5LL&.VR,\:BG`Q('"2C,^+#&J_INEV?=ZKYN/HTKUDKUN#0+'5#P6SU
MXJPF4+.UXI!-!B496<X3(@%!K\F#,85G&<)=CON-YSC/H5]G!R,UP!P!P!P!
MP!P!P!P!P!P#FS2D!(GD1V8%'U6`*GCJW&L+AZ%JX&--E8-THE/1.@OW2/9W
M99/7\([4G"N;$[38A3.RK&2J*3D<:B8U91K_`)7=WVX7+YPPG=0^3$]B>K@V
M=(%1*_8C\0;&7[7<KDDVEK8^L3AVKV*)K*A6NOCZ]'<KH*WQ3^P"X`"N6$DC
MB,T;5FK9-D`KG_++XOY?V#J#P9-9N-0`7VN$:G9XBYP,K[GF;%;E28:W?<)\
M4G%]$F&ZQ(;]G,AQW<^S=3Z^$9;7ZS:U)R!7,QTFZ^GGK(^1KUD6Y:IA597V
M%^NL3&`5@>V3(LM&@)BG&L#J#8I&X-F/%:G$]D+4Y:LYB-1,5VH8KPLOE_.R
M.8_F0TA4]1=$+?8->AAT&%G??5D_<[+LA^W;`U[K;7VN-XMW<`S8JJF22G(T
ME6[:>(#B-5`LQAU:"7LV69;8&"&V(XW0YJMML<)6-MK//UNQ.(OCYZS=P^P?
MC5[/T/K=<]=`NM]OIG6,D<T;JO7KY-_L+=T=?=+0NRU3H._=BEZ3&U_N&SB*
M7##[>Q$J5SH0S>)@Y5*W;03XBRVB:.E=2IK3:;:F'-UKAPE:LK9BUWI'87KU
MN6%TVW3L'80+JGWQT=XX;7K2BA+`0VY6[S>F=6]BZZ;LLRW[0)ZMLE^V)OBD
M:Q-T,O6@%WV<"K12A&K;65'S.8D*&]<2XYO[DK:75+NA2M\)7S"OWV1WMU_L
M2@[8IP'86L+I5MAT2T04$JY<:6>&6:LG(#F<I3*%F@\F6/FM86E;:\L2%^R=
M0XRYA#K:T)'.(L=C-RX`X`X`X`X`X!_*T(<0IMQ*5MK2I"T+3A2%H5C*5)4E
M6,I4E2<YPI.<9QG&<XSCT<`T0%JO6%7JI"BUG7%"KM(+/3Y!2G`J?7A%5)2"
MF4J)OD*\/'1Q$QXBI"<SW9$-Q<O*4YD*<SC'H"7F4QL/B]ZBK,S[;I^K7#J7
M?2+ZI4JZ]/=AVOKI(F2U^CVLHY2]?D(&JKDY(5A*Y*+UKZSL2EI]:0R[E;GK
MC6V\8>])]7;U,+]4GDLTW]NJ^T>G.UU9C_[+%-[=ZQ^J_8V8C'_`CM[^ZWP(
M59=E.->AAV6:ZSEI#KB4RI$Q;CCV>!-#O3IUI<]'[CC9L#_2$^R6FO)O4>DV
M\.D8_7]+CD*I7MI1J6:V!OG:D#%GKL>SR-G:WDT"HPL7V@5X%/;/O@0^K)]L
M*A0YK"711MIT+!'3_P`:V'4JIRN2RMFYO?S/H'TQWLZ<]A"6:_J'LCJ6VV]M
M[$>3KW-M@5_9X^1G&,XCEM7VA8380=_.<^KADI6HCN5X4WZOKH6E(Y.EJ]/?
MASN+8\$'`'`'`'`'`'`.7FI5&!7D#W./L+X\I-*D#KT`_,+Z;L9YL6C7>K20
M:EPAH;2-%W/3A`>N31!-<TA<[/K-<B1\%DGK+L(K*GJ&GX5Z6ZVWQG@GP,[V
M\(%&>S/5$;\3J,(>1?)Y'QK'-U%E4N7#VCI>:76T"W*]$8+$X68];=J[^J)C
M>U1I5V3)&>IA$!J<"N?]R>7[LS.DW!D<`<`K'W1&F#'4[L(,`"[X:,3=4VYF
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M,*QC/V<ISB+'8S=.`.`.`.`.`.`.`.`8%VJUA^Q1;@_7`+UM@#G@\&T.AQ[E
MBAB9#F7I`N*;7'R3CCGWE*=>A,R41G7%96MI2LYSP"*]S]9.N?8L;@3OO1.H
M]QP4,Y9C(V3KZK7"1`3Z<Y2X*G'!<R<)D-+5ER/+&28DJ.[^E8>;<QA6!4VK
MFUN<%3_]6M3J'^GZN=DNW/4]UC]*/KE!W63VIJ:-*3_DQC3'9B#NW78X<OT(
M;D#:F'JJ%LH2VP]%4E+F!=K-)\(?-0^<G-SRF;5\WO2_K*JT]>]@:Q[0*DW8
M"#([#UUU,*Q.PFNZ_*BDY3ALU06;KM'4]K"RB$$>")V8;KH*D,X696JNL-S$
M%!(U0OIU.V:;,:E#?)1S.NOCOV1V1V]TJZ\[)[=TA6NNQ=LI"B&RJHZ$>K$N
M+,;.%X8$H3K#^$O5@S9JG%`V@U6W&8:@!8S-$9'CO<_<(PS4DJFJ7*P?SUQ+
MH<&1P!P!P#FC48%A&=^]D/UT7<+&(R23$L[YJX;G)TNJP"^L-;G\3@K-I&D-
M<P;HT6,3&,UVMV=H+"HD\7$K]9$'';/*?&O^5_,WQC]SH9/NH]&;W5U$0_<"
M]:E9O,EX$('W$57X]V+_`$]U`-E5Z1"G17WVG(U9+6$ZQ9,.L0VGQ3-(]*3=
M]`S((*YV3PF+';I\R.C?!D<`C<]N/4=6=F,V;:.O*Z\.M0ZC3VCESKHIR#=2
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MU,4%ZQ]JHD-/Z1;LFH'R$SKIM(BRTA:%+$VS0*9;JFO=`65YRSP/L>=+_P#I
M=UU,&[Y6]9$3Z==4/K%W=V+O,2`GW'8W7X5U^=I>TM4TD=)C0E6ZV?6Y:-<T
M,\&+S9"H%.7J^\["?O1"&0BT]DSD=.7'#8=\TQ@YE-Y63QF(QO+YZ5W=K'L)
MK2D[;U+:H-JI.P*R(ME>G,95&G_##,-J8PP6#RL-$PA:)AS,4J'*18I$408D
MP)T=B5'=;2(TTVG>B5^"&-,F0]<#E;#82PT"`!#II@V<,SHHL.'$C8SDPB4*
MDISK$(>.@1&7I4V;+>9C18S3C[[K;2%*P!%.D^QN@>R8`G:NOFZ=7[KK@0JL
M&9-:NO%=NX\080WA[X:4DUXA/0/F.QU(EQV)>65RH;C4R-AV*ZT\L5IJQIIZ
MV$T<$'`'`'`'`'`'`'`'`'`'`.:=$$FT^06]7T7&H,K7NQ`UE'BC\"-5I-G,
M'M6UG7>O=@979G+D[9\.5>VAH5+?IHJE+'MNC#I<X8!R1H]BWC3\*OGCPTMO
MF_A=M?9^3-F[FTZ<JQBPCUZJL%3$WTE73FQ*Z*&-;?V3KN/7PNQ7ZL_"#66C
M%A52LD@T&]<D2J]@=UJ7MS(36]I,S"P*YZ[L%\X3%L'0'@R.`4%VOTG<NQ#;
M4^GVZM4O&XBNPF;%$52%RXD6N[=TA6M0;!(1&19\&F1L%Z=7&[F,L\WVL>0_
M.*AS`Z6HHZ9CBS=I'1S_`#Y!2CR!==+YI;QY=Q[6"WN<IMIJFA*35=96W7]L
M*Z0G":IIVS[.,5A-]MJ[?EBP%+$SN4Z(N\9R0(KEJ6+%+8#Q9L_W9@;H<U4R
MI4VRIF;[(TX9E]?&=^K@\?G\$?5+^A%"X,U^.K\JO5EW.#(X`X`X`X!2GL-T
MYF;BV8"W9K#L+M_K!N"#KTAIVR7?4T/6QU5WU,0.*LS55.`-JT:^@(I:LV&0
M2-4:YA8`VQ5><</83((0B;L)`TJHL:35\.;^#7*YD5UWP]>,RO5&JU-73'0Q
MUVJ@18)-UL&OJ[-V58W!D-J*Y8KCL"/`AV:SVPNXTH@;L).>Z0(DGY$MQQ*G
M,)2&W5YG;A+BW"#(_P"J;Z%,?^":=L]-]'^3ZNM_]D-:>R_]/8?5_MRM8C^K
M_P##['V?J^C'J^CT8X&W5GT78ACL+XA]<["TS?*'J3=G:6JGC`N*[7:UM/N#
MVLW3H<T5#%1YZ!6]I:JV/MNVB;9KZQ2!C8.UBEL.2,A)\Q^$AR:Q'0H55M.8
M7"FE/@TI,#5NK/D<>WS>^VX:W],NLFRK!JW6>E7M"5FH[$[`:BV;5]7E[J<@
M6S8NQDXZW7,!;\S;K.#4QZNU,VS3:7#BB"2;0Y)<8@/GSY_$TPJ?N:3;FQ.W
M)6KK;H3Q\W';K3__`&?L_P!#+T;#QOT,G;'26XCNS-1>RC_:R0F:H.#M6=B!
M++C6%KR.K6MMDN1G4XCX(R_70\H2$[JN%2:ZJ5U7Z)MTIWRZ@]@S:ZCK#?-)
MG;#84EN;J:UOD-:;G&.J3Z?9%=.;*@5+9PU:<^E"LS:HRCVB5(PO*L<$=+5Z
MLSO7-6$QSM[Z/%[0&Z0)[DU4.W08@?%1&H9VPZC$V>5%^P<D_$AU!D%V[7-@
M9C,O2,2XPEV/EAIU[#GLVUJ2$.)AQG@2MP0<`<`<`<`<`<`<`AFL:)I%3N+E
MR'2K;*>9G6LK7ZZ7MIHK3Z>4O1%\M<2-6KLN2N&/F')TN;E#LCWWZ/0"!,'4
M4U\`4(BY0?.1D;-I36]OMX^\'PI&2?'KK[JD1;9<!%>-/5,JX<JC]MIH<_`I
M]VD5<RXHI6Y%P!''@4_#<H4N(\TTM`LNXE7@@X`X!3SR!O0X_2CLV\0MH&B0
MT:BM7M[99M@6S5@(+A43U$OD;[1G6+77FWEJ3%;>#.8?FOR&ACV%Q9LA"AJG
MQ+&VZ$^CL,-XSOU<'C\_@CZI?T(H7`K\=7Y5>K+N<&1P!P!P!P!P!P!P!P!P
M!P"$MU]:^OG9`(BN[\TIJ_<(AA*DPH^Q*37[4\)6I7KXD@YY:!)(`IS3GZ5@
M@&E09T9[&'H\AMW&%X%3:M3:W'$<WXLMV5UG9/6C3NN]$5?4>P.V5&[-T7O$
M0O1D]V:T!7ZA:Z#;QU)KU+N5`MQ:V;%H#=&7K?5-K)[:S3FM;$X<:T"%8A%J
MZ=?/GH;VE8W+:36S@YUP3TM3M6G0GZB_)94_T]-[]Z;V0EG_`(8KL#TL'R79
MJ?\`Z95CT1O#2C41ST?XO1JDZC*L^MB,E./9Y&9I\K6ZKNF/I=Y8:?\`I2FD
M.B&\H;7V.II6_=X:%L$C_P#)$#7'1NZ`2<^CTY]A*NK./6]5OWKU<J>0'VYU
M+@G^T5ZVYW0[M.[-T)UW,:7HW0,[O8[>(\;LCN*\:W[)ZURSKRHO6B71->5F
MG7W6Y"?LZUN+BK#(V/BIB\5<9;"0<;9BPM<(>*E3#<[48*S&]RKL++9:NO+G
M]">PES[)Z$D72_NTDQ:*EMC<VG)]_P!8,3HVK-N)T]LFPZ_8VMK:,1*'946J
MW1H&F>B!BP6&*,,(+C!YXQ`AQB$@2I0XT3AWJ4G#^<KBZ7!D<`<`<`<`<`<`
M<`<`A+LIBZYZ^[HQKI=6;NN=9W'X`NZM%GJLF5\#F>U^,-`GF"RX^8GO&&_<
MG4.8DY9RK.6L+3D%?VO(0\9WZN#Q^?P1]4OZ$4+@U7XZORJ]67<X,C@#@#@#
M@#@#@#@#@#@#@#@#@#@#@$>[/U'JG=M2E4'<VL]?[;HTV3%FS*9LVFUV^525
M,@J4N%,D5ZTCBHEZ5#6M2XDER(IZ,M2E,K0K.<\%3:M3:>EALU:K-;I=?#U.
MG5X'4ZK71\417ZS6A,`%7P0F$TEF$,#AA<>*.&#XC*4M184*,Q&CM)2VTTA&
M,8X(9S@#@#@#@#@#@#@#@$"]BZSL"STFK,ZVL%O!'@^Z]!V,HQ3B@T-(L-("
M[EI,K80`[/G1ER_HH_2,'B-A'!9X@F=A#,@7I<\*3+UXV*M<GZ6'*'L;?^YG
M6GI9W.W*-B>^V&EZHJTTT)[%&;;?:M;]@)LFWX&^"^J(X78[4ZG4ZQU2PZ?7
MK6"/D@J$&4)F0VZ(.G)/YR-)4U-+-M660K(FRV+9]<2_GC._5P>/S^"/JE_0
MBA<$K\=7Y5>K+N<&1P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P"FGD.K\^U='^T%?%Q#,^>3U#:6(T.O![P?,25)C)>4U"#ZWO>LKK/6
MIMI?M6@5Y`NI8]JY+=FCD3!LT6EQ4GJLOVFC'>,[]7!X_/X(^J7]"*%P6OQU
M?E5ZLNYP9'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`*
MT]R8@B?U5[`1#U8V%<Q#^K+:F=6-4F3=?V"89P+>5B/6C%<M-*-PY2'$H?DY
M@6@2Z\/9EQUNO,O.1)`JO7[NZD<^,[]7!X_/X(^J7]"*%P6OQU?E5ZLNYP9'
M`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`.?VU=_;-!ZG
M[F.&M-6?:\S7&RC>J*G3^OS%?*6CZ"630>M+\*MEF=V?===AY<D:]L&9*MBA
M$N-D5%7%$AA%DR+?/EA85EL2IMSEK"?F12[Q_=V]@53H;TEJ\/QX=]KK#K?4
M;K:`B7*GUGK)(J5MC!]-TP<Q9JL^>[25\X]7#S4=)4(Z:`A"S@R5%61$#9F7
MH;(W4EM5?=3XGYL_Q+<_/SLG[LKR,_A/J?\`F[X,[*\]/*OVCY^=D_=E>1G\
M)]3_`,W?`V5YZ>5?M'S\[)^[*\C/X3ZG_F[X&RO/3RK]H^?G9/W97D9_"?4_
M\W?`V5YZ>5?M'S\[)^[*\C/X3ZG_`)N^!LKST\J_:?F>_6R,8SG/C+\C.,8Q
MZ<_[I]3_`/#'_P"W?`V5YZ>5?M-&UCY19^Y=>4O:^L?';Y#K=KS8E;%6ZEV>
M!3NK3$(]7#D1N<**Q69_;.)-:8F1'6WFT2HL=]*58PXTA6,IP*Z4FTZZ95_B
M]IO7S\[)^[*\C/X3ZG_F[X)LKST\J_:/GYV3]V5Y&?PGU/\`S=\#97GIY5^T
M?/SLG[LKR,_A/J?^;O@;*\]/*OVCY^=D_=E>1G\)]3_S=\#97GIY5^T?/SLG
M[LKR,_A/J?\`F[X&RO/3RK]H^?G9/W97D9_"?4_\W?`V5YZ>5?M-$UGY1I^X
MZ+7=F:S\=OD.MM%MD1Z=7;%`IW5IB(4BQYLD>\\RU/[9Q):$MS8<F/G#\9I7
MKLJSC&492K(KI2<.NF?_`&]IO?S\[)^[*\C/X3ZG_F[X)LKST\J_:/GYV3]V
M5Y&?PGU/_-WP-E>>GE7[1\_.R?NRO(S^$^I_YN^!LKST\J_:/GYV3]V5Y&?P
MGU/_`#=\#97GIY5^T?/SLG[LKR,_A/J?^;O@;*\]/*OVCY^=D_=E>1G\)]3_
M`,W?`V5YZ>5?M+1]:.P-4[2Z3IF]*4`N-5KUT79X\>M[`@!AER!D*?<+!1CP
MP_!KQ^T!&)D0_6B;./AE@*Q76$LO-RL^TRA`C4."=N"#@#@#@#@$5[LN^-7Z
M@V?L-D'#/O5.EV*PI"S7O<AIB2/$NJ8C&IR8LU4,0[EIEHP1S"FJ@"$2).(D
MG$?$=8*UI9F$Z[V%)[5L"&BM5>HM4.S[#U`P"HX_X128L33&P+-JJ$NH!<8]
M0!7Y,.H,21]9;<E-59#JJTW/)($X(217?UYJ2;^"#@#@#@#@%=>S&UKWJ.DA
M36O*?%N9TO:'14J'*DB4X%5\53+E>;`=9&%K;2?I"_!%4Z0T@*./L$W$RESX
M\::T/D1G!5;C!%W4;>\+9F2E/K-+I51UI7*NDEJB%0X$H(.%T<%MG;VEH`@G
M6G8(^+7%2L:A:LX(=`A#F1T(Z0ISPS$FD/';&*U&_'?"?[+M\&1P!P!P!P"K
M79WL%8>O,*E6&'1(=QJQ?&W7;3(^D3HHV/5K;K[MG=H<77A+88BT6F6I_5\L
M(_,ESH$<(P][PF,6D266&!4IZ>J7[*]:R[.V:O[3F=>FM::MKX+45RU-KJVN
M:W00%UTO)WQ$O9JH$]4@D1680X33OHPTB^#B&9BYCY"QSQ\P;]%\QCPL63G.
MMV>^;.&<KI5P9'`'`'`'`(,VYM8]K6V:1%PZR++5?9%YM=5N%@G6#(N;5(@'
M3^R-F#7PPK(]^.<F%YM#R-D?$"P(<)'+F3G9<B3B)#>#/3NE^SFT'[]7#56K
M;Z5*Z%I-.=Z^B*#9-RZ>J[<>OS8A??Q,20K-<UQ.K):VTD[-@+N$/8]XMD69
M,BE1-J@,/B*_;EG(L$:V9:ML<P]WR/X=F.#(X`X`X`X!XR(X>7'SA):##*"B
MD.4.)C",5B:/(CYK"XTR#.AR4.QI<.7&=<CRHLAMQA]AQ;3J%MK4G('AKM;K
MM0"P*W4P(6L5T4TI@6!KHN"%"C6%NN/K9@"QK$:##:6^ZZ\IN.PVA3KKCF<9
M6M6<@9K@#@#@#@#@&KV^CTK80?->OU/J]X`9E,3<@[?7Q-E#YF1?7]VEY&&H
MDV%F5']HY[!_V'M6O:+]FM/K*]('Z"I-,JY*PF*S4:Q72]MFM$K65!`!0@E9
MR#'M\,S[#.'Q(\HU-9]YD^RE$G9+[?O#_J+Q[5SU@(0V-VRT_JPOLX#;RDN&
M9U56]>V@T,2L*B>:';+*'A%>:J<.::ARC4QJ979Z2;&68J(R5Q?8.RENJ0V*
MDW=G'^\S:!/97KT>=-L!=W:K*/5MDQ*/-0;U7)*Q4*OP2A(V0F):(*RT,&0`
M9R7+)YQ[@VR$,JS(_P"ZI_NX0\GR/``[4]:;5;OH%6=\ZEL%T^D,^I9K`>^5
MPB93:!DB?#G5UR%$(.NMFF)PDP.R-6E,QPD%-CFFES@Q./%"'?#@GW@@X!CI
MX@257!<*"QQ)P7*>G#%SX4:8L=-DC"(21,@JD-.9B2GPQ<L(>D1\MNNC"9&`
MM:HLV2TZ!I`+36H*O(JTRM:JUO79=':,,4J4"HU8$R*>Q852EV!FK/P!<=VO
MM'%SIJS#8E41!-4R4J;A_,A[*PEYWWDD<`<`<`<`<`\$T6,).#WB(Z!/>$S%
MD!;LV)'E.#2#D"<*<G#UOMN*AS'!9,D-7)CY;>5`(3H:EYCRY#;@$>"M':5`
MYKN0>G]6ALU!XU(J616OZF.S5Y%DCMQ+$_7<PQ+/P1X_%9:C&G1GNRRL=IMF
M<I]M"4X"7G?>2EP!P!P!P!P!P!P!P!P!P!P!P!P!P"I.U>FNJ-P']L6BV1D2
M;!M2JZRJF33P.MD"U,C:O,60T*FU`D2%2IHZ81E621\15[=3?HBQ5QD,N86M
M0J;5V<_[R*^$/&=7)0H</A;VV:*DUS30_K53R<<%KJ0_7NO0NE[+HL*E+8EU
M5Z*9M+(C9Y)_%^)M.S%3Z_6GEAU,XLL>RB[3R5\\>9(]?Z&5&K7365P`;(NH
ME[7-GMEE5@5"K(8W84VO<^Q=W3ZR4MP42-L4ZDDK!LHN$L5,/R[#6B=?@P7A
A`NMVB6>LID2?G".>I?+@@X`X`X`X`X`X`X`X`X`X!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g887761g24k11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g24k11.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0L*4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````4@```<L````&`&<`,@`T
M`&L`,0`Q`````0`````````````````````````!``````````````'+````
M4@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"&T````!````<````!0`
M``%0```:0```"%$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``4`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#L^H?7"NK/LZ=TO!OZME8_])%$"NL_N/N,_I/_`%7_`#BG@_6_%R\3
M/L?BWXV7TNIUV5AW-VO`#76-VO\`YO\`2[/9OV?YBS_J-EXF(SJ'2\JQE/4Z
MLRUU[+"&NLD^VYF[^<9_5_XS_#,6EU7K'2L[I76L3#R:[\C&P[?7:PS`=79M
M]_T'_P!C^;_/5B4(B7`('2O7??\`2_NL0D2.+B'7TL.B_6JWJV354WI67CT7
M,+VY=C1Z,`;F_I6^W])^8J>+_C"PK?3LOP,K&Q++/1^V.:UU+7D[=K[&.0?J
M7CO%>!<>MFUIH_Y(ED,D?1VAWJ_H/ZBYCI%+[JNFXO4<BQO0L[,L8ZJL`-&1
M6[=77>_;NV9+MGY_[_T/YU2##B,IBM(UMQ7^GQ5_6]*PY)@1UW\OZKZ-5URJ
MSZP7=#%3A93CC)-Q(V$%S6;`WZ>[WK._YZXW[`RNM_9;?3Q+SCNIENYQ#F5[
MVG=LV_I579;7C_XQ<JS(>VIC^F-+7/(:"!8S=J[_`(M_^8N<'N_Q<=3>W5MF
M>7,/B#;1JU-AA@>&QO[7_CGSIEDD+\./_F_*]]UKK%?2.EOZE94ZYC"P>FP@
M._2.;6/I>W\]!Z+UW(ZI=;5;TS+Z>*FAP?DLV-<22-C/Y3869]=,O%R/JID#
M'NKN-;\8/]-[7[9MJV[MA*+TMS.EUYV=D]>/6*J*/4?475GTPS<_>/2>[W6?
MS:8(#VKKUF1`^;^K_P!\OXCQU?IJ_P#I-H_6O!'UD'U?V.]8B/7ENSU-GK^C
MSOW>E_T_T:GUOZS8?1,O"HRV/]/-+@;VD;:PTUMWV[B';/TWNVKS[U<\]*=G
M?LW+_:3LS]K#J0I/H``;]GJ;?Z)Z?O\`]'_UI=)U_P"Q=>ZK]6M[=^'U&K))
M;.H#ZJWMU'^$J?\`]-BD."`E&_EJ0G1_2A'BXF,99&)K>QP^4I<+T>?UJK"Z
MKT_IKJG/?U(V!EC2-K/2:'G?/N]V[\U%ZIG_`&*D%NWU+)ASY+6-8UUMV1:U
MOO=736SZ#/YRSTZ?T?J^HN&P+.H4_67HG1>H@NR>CVWU-O[6T65;L2S^S75L
M_P#4K+%T_P!9FV^KC[!)MKNIJ!(`=<78^730YSO^Y+<.VEJ;[,1/'$ZV#(GI
M+YN&7^*F667MSD-P0`/\5)DU764863EM>XTY`O#'0;/;7?M_1U[*J[7;MGI,
M_P"W;$;`ZCF967759Z%;&4;K0"2^ZSV-?=A,<6O;T^FS?7]IMK_6O\'^B_39
M%BJ["ZOAA]3RZLD;@#M>QP^E78WZ5=C/HV5N5&O'INM<S!S;Z6W$_I:!0=^P
M18_U;<:U]K:G.KI]3U/YQ_I_X-1[V"*(_P":N!`X:-W_`,Y__]#K_K3_`,Q?
M79_SA]'[3&D;_6V_F^I]D_3>G^YZBL=+_P":/[#R?V9Z'[+]-_VSTYG9M=ZO
MVG_M1_-;OYW])L7SFDIS_-1_G=Q_LO\``8OTS\G_`'?^$_070O\`F%^TZ_V+
MZ'[0VO\`3]/?NVQ^E^G[?HIS_P`Q/^;KMWH?L7US,[]OKSKL_P`-ZO\`Q:^?
M$DZ7S?Y;>._S?I?R@@?+_D^NWR_R_>?HCZT_\S=F/_SC].?^T^[U/5C_`-!_
MUCT_W]_Z/>K&3_S6_P";K/6]']A0S9MGTOICT_YKW;O7^E_PG\XOF])-'RX_
MYSYO\#_J7]==^E+Y-O\`"_P_ZK[]B_\`C>?LW.^S?9_L&ZG[=MW[9W'[)ZGY
MW\YNVJ&/_P"-Q]BS_L_V?[)LK^W[/4C9ZGZ#?^=M]?\`<7@B2?W_`)[YA_W/
MS?U_W5O;^;V/\O[K]1-^Q?8!MV?8?2TX]/T=O^;Z7I+%P/\`F;'1_L7I1-_[
M'C?S/ZYZ6[^5_I%\[I**.TOGW_1V^67S?R^3C7G<?+MU\WZ4SO\`F]^W,'[9
MZ7[7VN^Q3/J;8=N^C^9_.;/5_P"$]-%Z]^S/V7;^U/Z-IQ._?/Z+T=ON];?]
M!?,R24?FQ_/TV^;YO\DMG\F3Y=C\WR[?Y1]Q?O\`5=]H^R[X$?M/[-]LV[1Z
M?JQ^=Z>W^F+I^B_9_3?'J_:H;Z_K[?4V^[T=GH_JWV7Z?V?[)^K_`,Y_A_77
MS.DK',?(-NGR_P`OD:W*_P`X=^OS_P`OF_[A_]D`.$))300A``````!5````
M`0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`
M;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8`
M``````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#
M`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`%(!RP,!$0`"$0$#
M$0'_W0`$`#K_Q`#P```"`@(#`0$!````````````"@@)!PL!!`8%`P(!`0`"
M`@,!`0`````````````'"`4&`P0)`0(0```&`0,"`@,%$0D+"0D```$"`P0%
M!@<`$0@2"2$3,10*05$5.'AA<2(R([46-K87=Y>WUU@9&I&Q)+34UE<8.4(S
M8W,E-55UU78W\*'!4I,TEB>8@6)R4\-$I&56$0`!`@4!`P4&#PH,!@(#```!
M`@,`$00%!A(A,0=!46$B$W$R%'0V"(&1L4)R(S.3L],5=196%Z'14H*2LM(T
M53?!8J)#4W.C))2T-1CPPN*#PX1C)N-$5/_:``P#`0`"$0,1`#\`?XTA!I"#
M2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:
M0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2
M$&D(-(0:0@TA!I",27K/>%,9/"QN0<K8_I\JH4AT(:>MD)'SCDBIA(F=I"+/
M2RSLJARB`"FB;<2C[VLW;,9R.](6[:+!65+*=ZVV5K0GNK`TCT3&M7C,\2Q]
MU%/>\EH:6I4)I;<?;2XJ6_2V5:U2Z$F(U\OK++9HXB<AJY@6VV.N7.0Q+9I&
MN78E>OE:B00C$4I.4;1EP-`-F7K4S#-5V:9FJYUB>L=8!L`B&?QJA18,MQ]_
M(J1ERC36)2XT'6'%S.P:FTN%4DJ()U`#9(QB[M>6,BQZ[LX_4OAY5*5(=+%0
MVV1L)TNK:2@E29@:5$R,]T4[>S9UK(IJ'R1O+ZUN%\6O;A5ZI"U!5^]<I(7Z
M(B5YRT6-*/6)ZC&G>0=CBT%%D3><^%,H+``-D1&7/./J+:+CCE"S1A-S2PM:
MW``)M*.AM$QM,E(69$22.].TRT;@JQ6^"WNJ6_.A+B$!$R?;`"I2I'8)I4D;
M-IY=PAGC5:8G*#2$&D(-(0:0C__0?XTA!I"#T>G2$&X>C?Q][3IY(='+'&X>
M^'[ND(YTA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA
M!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(
M-(0:0@TA$;^27*?$W%NH!9\DS(D>R!7"57J<8*3FRVIZW(4RJ$6P,H3RVK45
M">L.UA3:M_,(!S]9TR'W+"L$R+/;G\G6*DU(1(NO*V-,I)D"M7.=NE`FM4B0
M)`D1]Q#XF8MPSM(N>1UDGG)AEA$B\^H"92A/(!LU+5)"9@%4U)!K[H*?,KG\
M9.WVFT3O%?C.]W5@X&BK+1>1<B1*OF"@Z-85TPDR1CQHN`&==*$<Y)MY31</
MJP2U=3PWX2ZK?0T+.09TC8XNH`724ZQ*8#8DDJ!!DF:EI/?.)/5B#K*CBUQR
M(NMSN3^,\.5B;3=,K1652#,ZB[M4$D;"J26EB10TK:J)NU##O$KA[7DYQ*.Q
MQC?P4;/<B7B7B4K3,N%S^<X*_NMH=!+O5W:WU0S=-8$NL?H$BAL`1=<LAS[B
M)6>"./UM<K>FF82LM($]Z6&AH2-PU%,]TU&)DM6*\,.%-`FK13V^W@[%550I
ML/.*D2==0Z=:U&1.D*EO(2(]<\RQC_+]'NL%27-BL+*9H=J*WGDJ+>FM-?M'
M,0[9]4;>)&N,Z?+&6,O]`FV?*J*``B4!*`B&)58;K8ZNA?N#;32TU"`4%]@N
MI(5,ZF$N*>2!+:5-@#<3&?I,LL>1T]8Q:'7WVE,*(=%-4I84DIV%%0MI+"YS
MV!#BB1ME%2WLZ<6I'<(LD*+$$B[[D]>U#=0;&`K/'&(XWR_$`'8B[-3T^Z(Z
ME7SB'DNYM;0D[$VMKTR]4*]0B-3X-(T8O7*(VJKE^D&F1ZLXL:6[@W&1#EL7
MA0K;)8N=#%31+'_8Y)C6OA=6JENJ5>&R@D+$)@]9,#@`V\CK$$!5]8^HZC<8
M#DRL2.;"C3\@S[[6G7I#G9%>B<](<ZO/ZZ6G;&Z',+&G(1C!J%?*NZ6DZ=6C
M7IU;IZ=O-R3GLB;&_O\`A\_6FQL\+B9T[[4CCCFZIQ\H6,:;D##M>OU?QU9+
MI'SL@_MDY,/W$?'V%W4E(QP>OIIU^8?*-"-E$71W2K0_U5+K`"6%L7`LW/"1
MD===W:>ZN,+>0T4`(2A()0'-0US6D!4P4A(4-AD9PS=>*RJ+)C9Z2@;>MZ'4
MMJ6%$K420%%$NKU22);9RWB<,=ZKU$S0:0C_T7^-P#TZ0BHCGYW@<!<+'$IC
MZ#(7,.>&J(`I0*](I(PU377;J*-C9`LJ:3M&&7`>@XQR!%Y$4CE,=-$AR*#+
M&!<(L@S3L:YT&CL)/NRTDE8Y>R1LUCDU3")[)F1$1WEO$:T8UVE(R14W4?S:
M2)(/_P`BMND_Q=JN@0KWG?O1\_<W2+P6>75<.5I5PHJQJV&F*50*Q3$GE$3-
M;!]>O;T_E^)_,D_),H(F*D3Z$I;0V/@I@%F0V7;3X;5`;5U"BL'_`+8(:_D&
M7/$%77B;EUS6L(N)IF"=B6@$2_'EK/HJB()N;',L[GUPW+?DV+KJZ_6/O]94
M!8#>/B50+6!B[;^@/#6X#!\,#?9#%+=V?-X.U^A&MG)LB*]9OU9KY^V<_2B4
M.%.\1W`\*2+9=#.LQDZ&3604>5G,K=+(;"130/U"@K-R8IW5B18@B4XLY5J<
MP#N(B(`(:M>N#7#Z\MK'R&FEJ"-BZ<EHCIT`]F9;^L@^E&?MG$?+[8M)%V4^
MU/:ET!P'HU$:QZ"A#*'`_O@8,Y0R<'C/,;%K@K,LTY0C(5%]("ZQU<Y5PH"3
M9C`65R1$\)+/U#%(@RDNCSE3`DBX75,0AJU9WP3O^*M/W*U*57V9`FHI3)YL
M`3)6@3FD2)*T[AM4!$V8IQ1M5]6U17)*:2XJ,A,^UK/(`H]Z3R!6_D)B\<!`
M0W`0$/?`=]0I$I;X7T[WW.SD_P`-ISCTSX\9":T=M?(K(;FT)N:92+6,BO`N
MZFE%G*>WUV<.R!NG*+`(("F!^OZ+?8NT^\$,'QG,AD7TBMY?\'+.B3CC<M6O
M5[FM,YR&^<I;(A_BEE5]QQVSILU;V(=2X5=1M<])3+OT*E*9W2BA_P#7B]S'
M^G^,_$]A;\WVI\^Q#AI]7U?XBI^-B)OM0SC]MCWECXJ#]>+W,?Z?XS\3V%OS
M?Z?8APT^KZO\14_&P^U#.?VT/>6/BHX_7B]S'^G^+_$]A;\W_AKY]B'#3;_]
M>5_B*GXV/HXH9Q^VO[%CXJ'J,03\K:L38OM$ZY!Y-V3'=*GYAX5!!L5U*3%;
MC9"0<@V:I(M6X+NW!S="9")DWV*```!JBMS9;IKE<*=E,F6WW$I&TR"5D`3.
MTR`Y8M9;GG*BWT+[IFZME"B><E().S9OYH60[N7<XYI<6.8\YB;!^6&51H;.
MA46<;0R^/,;611.2FV#E>17&3LU2F)4P+JIE$"&6$A/[D`#5G.$?#/#,IPYF
M[7RTEZN-0ZDJ#SR.JD@`:4.)3LYY3/+$&<1,WR>PY([;[5<NRI`RVK3V;2MJ
M@9[5H4K;W8K(+WQNY@4Q1'/D4<`'Q*;#V&`*;Y@]%!(?]P=2<>!_#0@@6!0/
M/X14_&GU(T8<4<X!G\L@_P#98^*CWM0[^O<.K<@@[F[1C#(#5(VZL5:L8PK!
MHY)TB42G6HRM-D$Q\>H!(L78P!N`AN`XRKX`X!4-N)IV*IAP[E)>4K3W`X%@
M^C..[3\6LP94@NU#+J1O"FDB?Y`3]R47S]NWO58WY@6B-PYE>LL\/YOF3'2J
MS=D_</Z+?G**"[EQ'P4B^(#R"G@;H"9)@].H#G;H0<**B5(8&XB<&+GAM,Y>
M+94JK;&COR0`ZT"0`5I&Q2)F16F4MZ@!MB6<-XFT.1OHMUP933717>`'J.'F
M23M"N9)G/<"3LB\?4)Q*4+W=\#G=RAX:V/CI'\=\AM:.TO\`"9,>6I)S2Z1:
MQD7%=?4A"(.12WUV=49`U3F'`""`I%4\SZ,#=)=K`\$,%QC,F,D7D-O+ZJ=3
M`;DXZW+6'=7N:TSGH&^<I;-YB'N*657[&WK,BS5W8I=2X5]1M<])1+OTJE*9
MW2W[8A%VO.ZESDY)<X\+88S%E]C:<=7!/(QK!!(XVQA`*/1K^*[O9XKIEJ[3
MXJ8:^K3,,W5'RER=8$Z#;D,8H[MQ3X6X1C6$7>\V:T*:N+2F0E7;/KEK>;0K
MJK<4DS22-H,IS&V-6P3/,JO64VRVW*Y]I1.=IJ3V;29Z6EJ&U+:5;"D;B/2A
MN[52(L5%4/>/Y/9JXE\38?*.!K8A3;LZS%3ZFO+.*[6K.F>!EJ_<WS]G\'6J
M)FHTIEG40W-YH(@J7HV*8`,8!E#A#C=GRK,$6J^4I>H#3.KTZUHZR=,CJ0I*
MMDSLG(\L:#Q'O=SL&.BOM-3V55X0A.K2E75(42)+2H<@VRG"W>%^]'W&K?F+
M$]3L&=HU[`VC)=#KLVS)B7#K4SN(F[3%1DDV*Y:T-%TV%PS='("B1R*$WW*8
M!`!"RE\X,\.J*S7>KI["I-0U3.J2>WJ#)24$I,BZ09$#81+GB$K;Q+S6HN5!
M3NW@%I;R$J'8L"84H`B8;!W'DAZ$/$`'WP#][5&XM7"O7>7[D?,3B/RNK.,<
M"9194RE2.$JC<7<2O0,>6A16Q2MNR!%OGWPC:JM-2295F,$U("1501**>X%`
MQC"-G^#7#?#\MQ:IN=^M9?K4UBVPKM7D=5*&U`2;<2-ZCME/;OW1!'$K-,DQ
M^_M4-IN/94QIT+EV;2NL5+!,UH4=P&R<MD?2[+7<;Y?\O>4E]QKR`R>SNM-@
M\`VF\QD4WH6/:L=O9HW(F+(!G(&D*G5X216*E%V9ZGY)U3(&%7J$@F(02\?&
MCASB&(8M07*P6LL5B[@AI2BZ\N:"R^HB3BU`=9"3.4]F^1,<G#+,LCR*_5=%
M=[AVU,FC6L#LVD24'&D@S0A)W*4)$RV[M@AG359(G.#2$+#]Z'N.<P.(?*>C
MXTP#E!G2Z9-8#JEXD8IQ0L>V@Z]EE,@Y2@7K\)"UU:;D4B*QE:9I@B14J)12
M$P$`QSB:R_!7AWB67X]<Z_(+87ZINL+:3VKJ)(#;:I2;6D':HF9!.V(-XFYC
MD>.WNCH[/<.RIUTP61V;2YJ*UB<UH4=P&P&45%?KQ>YC_3_&?B>PK^;_`%,7
MV(<-/J^K_$5/QL1Q]J&<?ML>\L?%0?KQ>YC_`$_Q>_X'L+?F_P!/L0X9_5]7
M^(J?C8?:CG'[:'O+'Q4=V-[W_<M<2+!!;/L8=)9ZU15)]Y_"Y>I-1<A#EZBX
M_`P=11'Q`0'WM<%5P2X;-TU0M%@4%I;41_>*G>$DC^=CD:XGYNIUM*KT"DJ$
M_:6.?^JA]\H[E*(^Z`#_`,VJ&F+:`S`,<Z1]CR]WN%?QY3;9?;6_)%5>DUJ=
MMMBDE"B8C"#KD6ZF)9X8A=S'!JP9J'Z0W$>G8-=BDI*BOJZ:AI&RNK><2A"1
MRK60E(]$D".O553-%35%74KTL-(4M1YDI!)/I"$6K7WTNXK)VBQR-8S+%5NM
MOYV6>5^O%Q3B*0"#A'+]=:+B`?R-)>R#T8YB=-'SEUE55.CJ,8QA$=7HH^!?
M#QJDIFJNS+=J4MI"U]O4)UJ``4J270D3,S(``;I"*J5/%/,W*A]=/=0BG*B4
MI[)DZ4D[!,MDF0Y223%T'93[FV:^6F0,NX<Y+7AE<+HSK41?,:/V]5J52WA(
MI\I#7F)42JD+!,WSE)Q,Q3EN4Z:B_E`Y-OT$'IA?C5PSLV)4-HO&-4"F:%3B
MFGAK<<DH@*;5-Q2B`=*TG:!/3RF),X8YQ=,@K+A;;Y5AVI"`MHZ$(V`D+$D)
M2#O21LG(*YH8MU7>)G@TA&%^2%OL&/N/&>;[4WI8VTTC#&4;=6I$[5H^(PGZ
MW2)R9AGIV3]!TQ>%:R+)-04EDU$E`+TG*8HB`YG':2GN&06*@JD:J5^M8;6)
MD30MU*5"8D1,$B8((W@SC&7NI>H[-=ZNG5IJ&J5U:3(&2DH44F1F#(@&1!!Y
M81[_`%XG<Q_I_C/Q/86_-_J\!X'\-/J^K_$5/QL59^U#.?VU_8L?%0TEVE^X
M$'.7`RQ;R_9CGS%:C.%RJW;M&D8E.H21WIJS>XV-8H-F#9G8&K)5)PBW(1-N
M_:K`"::2B`&JQQ7P%6#Y`!1M*%AJ@5,$DG21+6T2222@D$$F92H;R#$]</LN
M&4VDBK<!N[!DZ-@U`]ZX`)`!6X@"04#R$1:UJ+8W^,,<C[=/X_X\9YOM4>EC
M;32,,91MU:D3M6CXC"?K5'G)F&>F9/T'+%X5K(LDU!263424`O2<IBB(#F<<
MI*>X9#8:"K1JI7ZUAM8F1-"W4I4)@@B8)$P01R&,7>ZEZCLMWJZ=>FH:I75I
M,@9*2VI23(S!D0-A!'/"/7Z\7N8_T_QGXGL+?F^U=]/!#AH0#]'U?XBI^.BK
M?VH9Q^VO[%CXJ'1>$&2[GF3B-QXRGD25).7B^XKJEFM,NG'QL2G(S,I')N'K
MHD;$-&,8R*JJ81\M!%-,OH`H!JE^;6VCL^79%:K>UHH:>K<0A,RK2E*B`-2B
M5'NDDQ9C%:ZJN6.V>OK7==4ZPE2E2`F2-IDD`#T`!$I]:O&P0:0C`/)GD!5>
M-&(++E.TG*N$:5)A`0A52)O++9I`%"Q$&R`VXB=P=,RJQP`?):HJJB'2F.ML
MPK$+EG&14./VT$*<)4XN4PVTGOW%=`F`/PE%*=ZA&D<0\YM?#O%;CDMT4"&Q
MI:;G)3KRI]FVGI)!*B.]0E2MR3%'?"["EU[@.=;+REY'J*6"@U.5*QBH%YO\
M`S4VUZ7T72(V..)R(TBH,Y`%W*0=/K3A=,%#*F5>"-I.)N36K@_BE%P^P>3-
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ME,9P:+Q[!/\`S(VJ0S)VJH+<R*17.QAV,F002)KF2\1J^Y,N67&Z9%HQ,;$T
MU/U"X-VJH<$EO+(EJUJ*>@F:CM6'\)+7:7VL@RZK<ON;*DI555'M`TK?HI6E
M>ULH2J>DH0%=*1)(FDY034:+MQ*`IJHJ)&(/B42*%$IP'Y@E,.HX2HH4E0W@
MSB6W$A3:T'<1**;NR3&-:+PKO;J3.G'L&W(O.TB]=./J"#=G!R,="NG2JA_`
MJ#5*!-U&]!03'?T#J7^-+BJS,Z(-S6Z;=2C9MFI22K9TDJW=R(WX8(128O5%
M9"4)K'R9\@20#/T$SC&7;!PQ&<CL[<C^Z!DNM1LC)Y4RU9*_QH=R+(3+5[&E
M)3?8^+<(@RJBA"2,S"L4(/UCI(L0(MWT=*;K;62XFWAW'[%C7#&W5*DL4E(E
M=:`>_?=(>"%<LD*)<EN.M$QU1+I8+;&[S=;UG%:P"M^H4FFF.];0"WK3R3(`
M1/>-*I':8_#N4\W\K9!R"7MU\#F[ZV<@+NDK&98N==7400Q/754VZLA&HV-(
MQ&<'+*Q[H!E9%10$XAJH")!%^L4&[ASA=JH*#[0L\(:QUD@L-K&VH<$Y$(.U
M:01U$?SA!/>),_F:Y17UE6,/Q2;EV<$GEHW-),@1JW),CUU;-&P=\=DA>!7:
M0X\<1:E6)VXU6MY<Y`MW;*R2^3K/$(2A:U9&Z6Z#3&S*124)7(V&65/Y3P"!
M(NUA\Y50H`@BWP&<\5LBRZKJF::J<I,?(*$,(5IU(YW2):E*&]/>I'5`.TJS
M&*</K/C].P[54Z*B[@A2G%">E7,V#N"3N/?$[>8"VK461(,&D(__TF1^\[W$
MY+AWB:,Q;BB2(SSYF6-D"1,NF8_K>.Z*'K$;+79ITEZ4Y]T[ZF<08Q@!)P55
MQL86P$/,W!OAXWF5W7<[HB=AHE)*AL]M<WI;,_62ZSG.))]=,1AQ*S->-T#=
M!0*E=:E)D=OM;>XK$O7$[$\QFKDA&M=>5L$JLY=+2,W.34@HX<N'"CF2E9>5
MDG(J*K++*&7>/Y!^\7$QC&$ZBJA]Q$3#J\P#-(P$I2E##:9`;`E*0-W,`!Z`
M$59)6\Y-1*G%'?O))^Z2?NPQ-PU]GVR5EBN15^Y37.4PG"S+-!_&8ZKK!B_R
M69FZ*BL@I8W,H"\/3G1VYQ$6:K=X\0-]`X204*9,*Z9CYP=OMM2[0XG0IK'4
M$@O.%09)$P="4E*UB?KII21M23L,3+C?""NKVFZJ_5)IFE"8;2`7);^L3-*.
MY(D<H&Z+3B>ST\!R0H19I#/"C\&_DC9#Y$A`F15VV%WZNG2B5X'&_CMZCY7_
M`+FHM_W`Y_X1VW]R[*?N?9*T^GVFO^7&]?8[B?8]GVM7K_"[1,_2[/3_`"8K
M@Y5>SJW>H0SVT<3<F.<G"Q15<&QMD@D-`VQ\1(!/Y4);V(1E6D'YP#8J3MM&
M)F'T*[[`,BXMYQ5+4O-TV6VP4P5L[9G4IM/2ILZG`.<I4L_Q8TV_<&ZJG;6_
MC]:7Y?S;DDK/L5"2">Z$]V%SE\;Y!:WX<5.:3:F^3`L:=/&@+0,FG<`M*STD
M<E7OL=.V"5&85?G*B5OY7FF4,```B.K'?*EM7;OE45C1M9:[3M=0+?9RF5ZM
MVD"9)B&C15B:SP`TZ_#>TT:)=;5.6F6^<^2-B!V[,:\E,3<5<>4GE3=$KGE"
M-;J&*8ZPR<O6:TJF@:"I]ALX.7!+9-0"`&25?%$0Z>E(%%P2!=3SQX@7+'+M
ME-QKL6HBQ:UG=+2E2O7+0W(=FE6_3SS,DSTBXF'4-ZMUAI*6_5(<KDCGF4I]
M:A2IG44\_-(3,IQ0Q[2_]LO$G_4>7/X_0]3MYM&[+O\`U_\`RQ$_&[W?'_8.
M^JB*).#_`!?'F3R7Q_QW+<?L"&\MK@X^RD8;X?".^Q6EV"W=/P5\(Q0N?7?@
M/R-_/)T>9U>.W2,]9QDXPW&Z[(54A?#"FQH"M.K6XE'?25*6J>[;*41/C%C5
MDEZI+.FH#2G=?6(U2T(4O=,3GIEOY8OT_9GU?TN2?B@/^<+4#_[E6OJHKW\?
M%Q*_V)5/U@1[T?TX/V9]3]+@GXH#_G"T_P!RK7U45[__`/CA]B51]8$>]'].
M&@,?58:-0J121>_"(T^HUNK#(`CZL#\:_#,HGUSU<55O5_6O5.OHZS='5MN.
MV^JNUU1X96UE6$Z0ZZM<M\M2BJ4^B<HGFC8\%I*6EU3[-M*9\^E($_1E"07?
MX_M#K+^"O&'UJ>:N]P"_=[3>-O\`YPBKW%SRQ>\7:]0Q'SMH\`&O<&R5D/'[
MK)KC&!*+1V]Q+)MZNG:1DC+S["$]0,U4FX/U4I0>^9Y@*'W$NW3X[AG^)F?K
MX?VZVUR;;X3X0^6Y:]$I(*ISTJGNER1A,*Q$Y?6UE&*WL.R:USTZI]8)E*8Y
MXGOR9]GKS-B#'-KR-B3+T+F@:C%/)Y[2%JB\J-LDHJ-2.Y?A713F[`PF)9%F
MF90C,105<B7RT145,1,V@XYYPMFNEQI+==K.Y2!Y02'=8<0E1V#4-*5)23O5
MUI;R);8VZ\\'[K;J)^LHKBW4EL$E&@H44C?IFI0)`Y-D^3;LA?6$FI>MS,18
MJ_)/H6>@)-A-0DQ&.56<E$R\6Z2?1LE'NT#$7:OF+Q`BJ2A!`Z9R@8!`0U82
MH89JF'J:H:2NG<24J2H32I*A(@@[P1,$'DB(FG7&76WF7"EU"@009$$;00>0
M@[1&RPX>9F?<AN+F!\TRJ:"4WD/&=7GK$DU*)&B=G-'IM+,1H0?$C0L^U<@D
M'N)[!KS4RVSIQ_)K[94*);IJE:$D[],YHGTZ2-O+%V<;N2[Q8K5<W`.T>92I
M7LI25_*!A<+VF'[;^(7^[>9_KIC75CO-G_5LR_K*7U*B(7XW_K..^P>]5N*T
M^R/_`&FW&_\`Q.8/R%Y+U)''']VE^]G3_P"8;C2.&'EO9?\`N_`.0_WJ@\6Z
MBB3VA[XAD!\H7'OW*9%U-WF__O`1XF]_R1%G&#R1'C3?J+A.KCE\87`_X9L7
M?=Q!:N/D_DY?O$WO@U16RS?ZQ:O&6OSTQL[R_2E^<'[VO,J+S0DG[13\>VF?
M)KH'W?98U=CS=O(:M^<7?@F8J_QD\JJ?Q1'Y[D?8]G#^._E/Y*EW_*Y@[7%Y
MQWD1:OG5O_+U,<O!?RIK_F]?PS$.JZI9%FX-(0E)[1Q\>/&7R5J+^5C-^KF^
M;AY(WGYQ5\"U%9N-'E);_$D_".17YVZ.$)N?6<[!A@N1`QF,%C&>R-\/C7!L
MX.0A++3J[\%?!X2\(*0N!MGF^=YP]/D=/0/5N62.(F;)P*QT]Z50&I"ZI+.@
M+"):D.+U3TJW=G*73T1I>'XPO+;F[;&ZL,J2R7-125=ZI*92!&_5.?1%U_[,
M^K^ER3YO_E`?\X7AJ%O]RC7U47[^/BXDO[$JGZP(]Z/Z<=EG[-.HT>-77];8
MA_5G*"_1]Z(Y>L$5"J=/5]\`W2)NG;?8=M<3_G(M/,O-#%5#4@IGVXV3!$_<
M^F/VUP4J$.(6;^@@$'W(\GX\-2@&P`'O``?N!JK$3\!(`1SI'V*)._YR62Q'
MQ":87B7@(6_D=8TZ\*9#*D<HX]IJT;8KL^042^@+ZS(*1$6HFIX*MI);8!Z1
MVG+@'C9N^8JO#S<Z2VMZ]TP77`I#8]`=HL'D*!SB<4<7;V+?CJ+8VK^\5J]/
M+L;04J69])T)ER@F$A=7@BKTHE-PFY`/.+O*K".<&ZH)L*;=F);.0WF]*])L
M*2]8NR'2B<HG5/59AX*.X&*5<"&$!Z=AU+.L>1E&*7JRD>V.LDHZ'$$+;/Y:
M4@]$XS^+W=5CO]KN:>];=&KI0J:5_P`E1ET\\;*&,D64O&Q\M&ND7L=*,FLB
MP>MC@JW=LGJ";EHZ04#P41<(*E.4P>DH@.O-Q:%MK6VZDI<22"#O!!D0>X8N
MNA:7$(<0J:%`$'G!V@QWM?F/U$<N8?Q2.4OR<\W?DTLVMBQ#RLQ?YQIOAD1A
M,E\G+_XD_P#!*C6;Z],3RQ2*)<<'N6=PX7<C*3FRKG6=1C-?X`R#7$SB5&WX
M\EW+0;)`K%ZR%]9*5JD]8G,/2C)-&ZA@,4AB&TW.L1HLTQVMLU2`'R-;*Y";
M;J0="MVXS*5@2)02(V+%LAJ,:O-+<V"2V#I<3^&V2-2>[LF.90!E&QBQCDFG
M9AQ]3\H8_F6T_3+U`Q]DKLLU,!DW<;(H@JEUE^F0<HF$4UDC;'16(8A@`Q1#
M7G5<;?5VJOJ[;7M%NL8<4A:3R%)D>Z.4'E!!W&+ET-;37*CIJZD<"Z9U`4D]
M!_AY".0[(Q=S#^*1RE^3GF[\F=GUEL0\K,7^<:;X9$8_)?)R_P#B3_P2HUFW
MO_/_`.G7I<GO1%(HV.7;1^()Q(_`91/K0CKSFXE>7^7>/._G&+FX-Y(X_P"+
M(]2)QZTB-K@TA"M_=3SA,9OY,QN#ZHZ6=U[&+EC4648@K_!9;)-@5;A-.S%(
M;I579'<MHL@*%W04;K].P*FZKX>;_BU-BV"U677!H)K*Y*G2HC:BF:GH'0%2
M4Z9;PI$YZ1+S7\YK,JO,>(U/A=L<*J"VJ2PE`/575NZ>T5W4S0R)C8I*Y2"B
M3:9GJ[1?;NX)UJJ4H6[&\%B8S'U352*FHHYO<ZS=RELN3D@B4ROJRI7\@!ND
MR8.3()"`$,4-0!B%JJ>,_%>MK[F5*MQ=74O`G=3H4$M,B<]\VVY3)TZE#<8L
MQFUXI>`7!2VVJSE*+N&D4K!`G.I<25OU!`E.4G')[@K0D[P(Z/:OXZ$QWAK[
M]UO:J/LHYV`UH=3<IYCF6:TQVZ%Y`LP=.>M8#6)3>8='*8!="X;^;U"@3IYN
M/>9?+>4?1BVJ",?M([)*$[$%X"2U2&SVOW%(EU=*I2"]O#YM&!?(&(G,;J%.
M9)>O;BXO:X*<GVL:CMF[+MUGU^ML'W,2M2U!$66C^3?2F^</[VOAW&$4&UU&
MS5KMJ?>)QPNK'96Y6<HN1>`J@X05\I9D:W<ELQM+Q8S[J%7*SK.'*?*O55"!
M]`*)`';J`=3E4/4U5Q%3?+BD*M5JM=)5+!VZ@W2L%I/+,N/NH3+IZ(B&G0_3
MX6JU4FRON->^PD\Q6^Z%J[B6FU&?<C.N<,C6W%U<QUVU^WU&-'6<8_'M?KU@
MN!40+5>,^+T(U)D.1[](MD#,FM[LZ1%'$6R-U/73E479DS"HW!QA++;Z:YU%
MPXCYZZ18U5*E);G-=8_,J[%L$S[)&P+49)"1H!V*EF+I6OT#-'A.(M@W0,I"
MERDFF:E+M%D`#6K:0!MF=1$RF>>^,7%_C?VV\+3TQ+VZ"83,H);#G#D+DZ9C
MXN;N]B656<KNIJPS+HI8^'1?.U@81Q5A*4RICF\YVNNNM@\FRC(.(EZ8;13+
M4TGJ4U*R%%#2)``)0)]8@#6N0GR!*0E(R]BL5FPRV.+<J$]J>L]4.$!2U;29
MJ,MDR=*?1,U$DXWXJ=V+!'+[DSD'CEBZMV]4E2A9RP5O)3DC8U7O,56I.,BI
M9\R8@"<M"M%W$JFHQ.Z)_"D/$X(J&(F;*93PKOV(XU09%='V1VKB4+9!/:-*
M6DJ2#ZU1D#JTGJ](VQTK!G]KR*]U5FH:=R2$*4EPRTK"2`3+>F<Q*>_ED=D6
MF:C&-\@TA'__T\2=TG-LQGGG?R)LTD\]:C:E?9G%%32(=0S1G5L8/W-09`P*
MJHH9-"6?1KF24`!`IG+Y4X`4#=(>AW"FQLV'`L=IT-R>>82^X>4K>':&9_B@
MI0.A(BFV=W5R[95>'U+FVATMHY@EOJ"7=(*CTDQ:%[/EPQK.4K]<^6&0(AI.
M16&YII5,81S]('+%')J[!G-R-H5;*%%NM(5"$D&IF/F=7D.GY')`*L@BH2+O
M.#S*IMU'18E0/E#E6@N/D;RS,I2B<]@6H*U<Z4RW*(.]\(,:9KJNIOU6T%-T
MR@EJ>[M=Y5TZ$D2YBJ>\"3B```!L```>\'@&JA18Z.=(0>GTZ0C";GCE@YYF
M^/Y(.<951;-T76'-/8Y$/'$&>0@W7211,#]7JQI$C0#-4WPIB]29*JMB*E;J
MJ)FRXO\`>4V5>.IN3HLBG`X69]0J&XRWRGMTSTZI*E,3C&&S6LW1-Z-$CY4"
M-`<EUM/J3ELG*<MDY;(S9K$1DX4W]I>^V;B3_J/+G\?H>K5>;1NR[_U__)%?
MN-ON^/\`L'?51%,G;.Y#X[XJ\SL49SRLI-)46GL\@(3!Z_%C,2Q3V3'-KJ\:
M#:.!=L*X#)S"/7]&'03<WCMMJ:>)V.W+*L,NECM"4&O=4T4A:M*>HZA:IJD?
M6I,N<Q&F$7BBL&2V^ZW`J\$:#D](F>LVM`D)CE4)]$-5_M`?;Z_TAF+\6@_[
M=U5?[`>(?]!1^_I^]$]_:]B'X53[W_U0?M`?;Z_TAF+\6AO]N:?8!Q#'\Q1^
M_C[T/M?Q#GJ?>_\`JBYFJ62.N-7K=NA_/^";3`Q%CBQ<I>0Y&-FX]O)L1<(]
M1_)7%JY+UEW'I-N&XZAJH8<I:A^F=EVK:U),MTTD@RZ)B)+IWT5-.Q4MS[-Q
M`4)[Y*$Q/ID81Q[^_P#:'67\%>,/K4[_`'-7BX!?N\I_&W_SA%6^+FS,'_%V
MO4,>U["F?L*\?<\9ML&;,G4_&$).XC90\/)W&8;P[.2E"7&&>G8-%G`@59R5
MHB=02AX]!1'70X]V"]Y!9+"Q9+6]5/-U:E*#:"HI3V9$R!R3V1V.$]WM=GNU
MT>NE<VPTJF"05F0)UI,ATRVPP)R3[SW!W$&/;,_I&8*_F+(8P<K]AU+H3>7G
MFTM/$;')'(S-C:QX5V#BO75$Q746=@L*'6*"2QR]`U]Q[@WG-WN-*S665VCH
M"M)<<=DG2B?6DDG4I4MP`&V4R!MB7KUQ*Q:@HGU4ER14U920A")F:I2$U2D!
M/>9[IR!A![T!L'N:OTD!(`')%3"9DGEC8T]L>G2U$X!\5*[.-5V4F&)8.<79
MNDCH.6J=M5=VQJ@X04*11!=)G-I@<A@`Q#`(#X@.O.;B56M7#/,JJF%!31JU
M)!&X]G)N?II,7,P:F<I,2L+#H(<\'"B#R:R5^HJ*'/:8?MOXA?[MYG^NF-=3
MQYL_ZKF7]92^I41$_&[]9QWV#WJMQ6GV1_[3;C?_`(G,/Y"\EZDCCC^[2_>S
MI_\`,-1I'##RWLO_`'?@'(?[U0>+=11)[0]\0RO_`"A<>_<ID7;4W>;_`/O!
M1XD]_P`D1;Q@\D1XTWZBX3JXY?&%P/\`AFQ=]W$%JX^3^3E^\3>^#5%:[-_K
M%J\9:_/3&SO+]*'S@_>UYE#<(O-"27M%/Q[:9\FN@?=]EC5V/-V\AJWYQ=^"
M9BK_`!C\JF/$T?GN1]GV<3X[^4_DJ7C\KF#M<7G&^1%K^=6O\O4QR\%_*FO\
M07\,Q#JNJ619N#2$)2>T<?'CQG\E:B?E8S?JYOFX>2-Y^<5?`M16;C1Y26_Q
M)/PCD16[0?+S$'"SD[:\KYK6LB%3F,*6BALSU>$&?D!GI>YX\G&A5&8.F?EM
M!8UIR)E.OP.!0V^BW#<.+^(WG-,8I+58T-FJ16H=.M>@:4MNH.V1VS6-D:[P
M[R.W8Q?'[A<ROP=5,IL:$ZC,J0H;)C9))^Y#)G[0'V^O](YB_%J/^W=5M^P#
MB'_04?OX^]$U?:_B'X53[U_U1^K?O^=OURNBV2D,P^8X5313ZL:F`O6J<J9.
MH?AP=@ZC>([>&OP[P$X@M-K<4Q2:4I)/MXW#:>3FC](XN8BM24!53,F7N?\`
MU1=D`[@`^^`#^[J%XD_?MCD?#Q][2$(,=ZODPIR'YQ7F(BY$KRBX-;(XCJ96
MSGSV*LA#*G=WF5(!!%#UMU<';EH90@CYC9@WW'Z$`"^G!/&ACV$43[K6FNKS
MV[DQMD=C2>X&P%<G66J*D\3;V;SE%6VA<Z2EDTB1Y1M6?162.X!&4.S#P$K'
M,6;Y&67)3!-:D5'%4SCJMNETU3BPR=E2(E(N+M4>0ITT7CNAP+1TZ*F<?J;M
MVT4])0UA^-6?56(M8Y1VQV5<Y5H?6`=[+"@HH/0ZN2>8I2L<XC(<-<18R1R\
MOUJ)TK=.IM,^1UT$!0Z6P"KG!*3%-=ZID_CJZVW']K9*1UFI5DFJK/L52&(9
MM+P,BXC'Z72H4IA*5RV-TCMXEV'W=35;ZYBYT%'<*5853OM)6D\Z5"8]6(UJ
MJ9VBJJBE?24O-K4DCF*3(P]OV4.2Y>0O!ZD0TO*&?7K!CI7$5I(Z=^?(*QD*
MBF\HLJ=-01<^INJ>[;-"JGW!5S'N``PB0P%HCQHQL8]G->XRUIH:X>$-R$A-
M4PXD<FQQ*C(;@I//%K.&%[^6,6IFG5SJJ0]DK;MD`"@GNH('24F+=-1/$B1'
M+F'\4?E+\G/-WY-+-K8L0\K,7^<:;X9$83)O)R_^)/\`P2HUF^O3"*11D_)F
M'[UB4M!<7*).QC\GXXJF4Z/)D$%&,_4;8T,JV>,U@'^^Q\BW<L7*9@*=-RV/
MX"02'-B;5>J&\&XHI'`7J6I6PZGE2XV=H(YB"%)/*"([]=;:NW"D54MR0^TE
MU!Y%(5N(Z9@@\Q!A@_L%<^S4FW*\*LI3O14KN[>2^"W\DN/J]?N[@ZCV>H22
MQR&*W874O6\8IF432)*I*ID*=>0`-5ZX^X"*JE&;6NG_`+TR`FJ`]<UL"'9<
M[?>KEZP@G8B<3!PDR[P6H.,U[O\`=W3-DGUKFTE$^9>]/\;8-JH9KYA>/$CE
M+\G/-WY,[/JM6'^5F+_.--\,B)NR7R<O_B3_`,$J-9M[_P`\=>ER.]$4BC8Y
M=M'X@?$C\!M$^M".O.;B5Y?Y=X\[^<8N;@WDCC_BR/4B<>M(C:X^+8YI"MUZ
M=L+HO4V@H>2F'!=^G=",9K/5@ZMAZ=TT1\?<USTM.NKJJ6D;'MCKB4#NJ4$C
M[ICJ5]6W04-;7.^Y,M+</<0DJ/W!"?G#@QLN<\<4S4^F#IQ:,N2U^DB+=*GF
MR#?X;O!U%=QV4$'S3J'T[B&O1WB8/HWP@OU-2J*4L6]NG3+80%%MCDZ%1Y3<
M)A]*^-^,558V%*J;HY4K"MH*D]I43V_QDB73MB:G>9MKZS\@\.8G3<`$7`4A
MM,D*4``R<Y?[.]BGPJB(]*@(QE58F3W#8OF'_P"L.HQ\V>WLV_#\JR-29ON5
M)1^)3M)6/34ZOTA$O^=Q<ZBY9UB.,(<E3,T8<'-VM2\I"ICETH9;/XQZ88GJ
M$$TJU3K-98$!-C78"(@V28;@";.)8-V#8@;B8=BH-RAZ=4SKJIRNK:RM=42Z
M\ZM:B=\UJ*C]TQ?:U435MMENMS*0&6&&VT@;`$H2$B71(1Z+75COQP;Q`=?"
M)@B$4?(64M&LKQ"+F:C7K-B.W<FZ50+/:#B_BL:V3-/(_(MDO]_E*TFH9[<;
M(M1F,!'TJ$8)J24T^>3*7E>IMWJR,O*;37TXU-N.4U0S1K>0C8IU%-1M(;9U
M[FV^T[5;[BI);2EI1.HH$16E\TCZ@AQMNH8=J4-J5M2VMZI<4XYIWK7V?9I:
M0)E:BX):0HQDW'$)R+K%7=TOAK@LE&3N<M(V3)'++F,9Y$7K(UTDB'-,9`>X
MAC/5\GSLZ]=G-ZHE/IUUBR0!-!NS*S(1(.C7/X]4U+==F%[[<LI"&*&@DIII
ML2DT'S[4A/X1;[5:C-2E%9*H[]&U>66%4V-6OL0ZHJ=JJN:7%K.]SLO=%';U
M=>E(W!,A*.$NTQ0LM69ED/G-F_+7,"[(%(NT@+-.JX[Q!5W*A$A>)TS'%"<1
M(0C-P=!,%2%>>2Z!$IEDC'$XFY/M4N-KI%V_";136>C4)*4VD.U"QR:WW0I1
M/,0!+D(E./T,!H[@\BKRFYOW&I&T)4HMM)]BV@B0W<LCS;918'CW#W'#`*2X
MXPQKAW$'K<>TC7[NHU2H4IW)1\>8ZC1M*2$:RCWDHD@JL90/6%%!\PYCB/48
M1'1J^[9#?Y&Y7"LK`%$@+6XX`3O*020)RY`-@C;*.@L=HFFAI*:F)`!TI0@D
M#<"0`3Z,=;(W*?C?B2O2-IR+G'%]6A8H$O7%WURA%70'74*D@@VBV;MS*/W*
MRA@`J2"*BA@W$"[`(Z_5NQK(;M4MT=NLM4[4*G();7N&TDDB0`Y22!'VLOUE
MM[2GJRZT[;:=\UIGMY``9D]`$8Y_6`<,/@CX>_K'8P^!OO;??<^$_AT/4_O?
M_9O][;X=\_R>CK^SW_)'J>_K_K_U'R.OPUDOH#F?:]A]&ZKM_"?!].@S[7L^
MVTRYNR]LU=[HZTY1T?IAC/9]K\M,=GV/:SU"6C7V<^[VG4T]]JV2C__4K3R(
MN^<Y`O3B4,L>27N-F6D3N-P7,^4FGIW9E]]A\X7`F$V_]UOKT[L&GY!LH1WH
MI&9=SLTRBBMS*C<K@5]]V[D^[K,.\=@=K&(=O2MK,")%=/<IY/<S1DRE*=23
M)*LV:1UQ+XG5"&:-"@(^/04H>@`U2OCXMQ7$6K2XHZ4TC`2#R#23LZ-15Z,X
MLWPB2V,/;*`-1J72KN]4;>G2$^A%UFH8B3X-(0:0@TA!I"%-_:7OMFXD_P"H
M\N?Q^AZM5YM&[+N[3_\`EBOW&WW?'_8.^JB%FZ71;ODFQL*=CJG6N_6Z4*[/
M&56E5V8M5DD21[-Q(OSL(*"9OY1V5E'M%5UA32,"2*9SFV*41"SEPN-!:J5R
MNN=8VQ1((U+<4$(&HA(FI1`$U$`3WD@;S$(4M)55KR::CIUNU"@9)2"5&0F9
M`;3("9Z(SO\`U'^:?Z('*3_T_9:_FEOK7?I[A'UNMO\`B&OTHRWT7R3]@UGO
M*_T8/ZD'-/\`1!Y1_P#MX_9:_FCMI]/L(V__`&ZW?XAK]*'T6R3]@5?O2_T8
MV,6#&+V,PGAZ-DF;N.D8[%N/V$A'OVRS-\P?,ZG$MG;)ZT<D3<-7;5PF9-1-
M0I3D.42F`!`0UYUW=Q#MVNCC:PIM50X01M!!6J1!Y0>0\L7+M25(M=M0M)"Q
M3M@@["#H&PCD,)3=_?\`M#K+^"O&'UJ=ZNQP"_=[3>-O_G"*Q\7/+%[Q=KU#
M%*W_`$ZFDRW$;XC.#W0_<#0D)&V4H^;X8([;_9+S%EN[5/*_*RGR6,<)PD@R
MGAH%F0^#KYDT69P<MH)]7EQ"3J=6>.$R`_5?)MWKAJ)DFZ915!TC7GB/QOM-
MLHJNT8E5"IO*TJ07D3[-B>PJ"M@6X`9ITS2E6U1,M)E_"^%]PN-13W"_,%BU
MI(5H5W[H&T"6]*3N)5(D=[OU!TA!!%LBDV;(I-VZ"9$4$$$R)(HHIE`B:222
M8%(FFF0``I0````V#5-22HE2C-1.V+,````"0$*:^TP_;?Q"_P!VLS_73&NK
M7^;/^JYE_64OJ5$5]XW?K..^P>]5N*T^R/\`VFW&_P#Q.8?R%Y*U)''']VE^
M]G3_`.8:C2>&'EO9?^[\`Y#_`'J@\6YBB3VA[XAE?^4+CW[E,BZF[S?_`-X"
M/$WO^2(LXP>2(\:;]1<)U<<OC"X'_#-B[[N(+5Q\G/\`]<OWB;WP:HK99O\`
M6+5XRW^>F-G>7Z4/G!^]KS*&X1>:$DO:*OCV4SYG&N@?=]EC5V/-V\AJWYQ=
M^"9BL'&/RJ8\31^>Y'V?9Q/COY3^2I=_RN8.UQ><;Y$6KYU:_P`O4QR<%_*B
MO^;U_#,0ZKJED6;@TA"4GM''QX\9?)7HGY6<WZN;YN'DC>OG%7P+45FXT>4E
MO\23\(Y%(&/<6Y.RY-N*SBC'-\R=8VD8O-.Z_CRH6&ZSC6';.6;)S+.(JM1T
MF_1C&[R002.N9,$B*KIE$P&.4!G2Y7>UV:G357>XLTU,5!(6ZM*$E1!(3J40
M)D`D"<Y`\T171T%;<'2Q04CCSP$]*$E1D-YD`3+:-O3&9OZD'-/]$#E'_P"G
M[+7\T=8+Z?81];;;_B&OTHR?T6R3]@UGO2_T8[\5PCYH)RD:=3B'RA33(_9F
M.HI@#+!"$*#A,3&.<]2`I"%#Q$1$``/3KKUF>X2JEJ0G++<5%M0`%0V224D;
MM4XY&<7R0.MGY!JY:A_-+Y^Y&RC+]*7_`.$/WM><9WQ=5/>CN1%GFUR%:\5N
M+&9\ZJF3^$:34'7V+H*E342>7:>51KE(:+(J#LLU6M<LT\\``1!N!S;#T[:V
M?#,?<RG*++8D#VM]X=H>9I,UNF?/H2J73(#:8P.47A-AL-SNA/7;;.CI<5U4
M#\LB?1.-:](R#Z7D'TK)NEGTE)O',A(/7!Q.X=O7JQW+IRNH/B=9PNH8YA]T
MPZ])FFFZ=EMEI`2TA("0.0`2`]`12EQ:W5K<6J:U$DGG)VF-A;VI.-)>+O"+
M$E/D(\6%TNC%7*V0RG-NL>U7I-L]1;."@(D3<0=5;QD8<I=@W9;C]$(CKSUX
MIY*,IS:[US3FJC:4&&OZMJ8F/9+*U_C1<'`+)\A8O;Z=:)5+H[5SV2Y$#T$A
M*?0A9WO]\:/O0<O&&9H5H"%3Y'UXU@5Z-P2;Y"I:49`71LF0"`4B;R.=1$B)
MA,(J.7R_@`%#5E^`&3?*^)NV5Y4ZJVKT#G++A6ILGN$+0.8)2.:(1XMV3Y.R
M$7)L2IZU.KN.("4K'H@I5W5&/Y[`O)4^(.8#O#4P]%&H<CZXI7"IG,D1NVR%
M3&\G8Z2_55.45"^MQZDM%D3)MYSF20ZM^@NSC_C2;MB35[:3_?+<YJ[K3A2A
MP>@="Y[@$*YX^<)+X;;D1MKBI4U:C3W'$S4@^CUDRY2H<T/`:I+%HXCES#^*
M1RE^3GF[\FEFUL6(>5F+_.--\,B,)DODY?\`Q)_X)4:S?7IA/;%(H<DO'`]K
MS:[.G%(E78(#G#$^"*U;L4/O+*#B6.,`@>R8_65$0$&ET9L$2HCN`)2;5HH(
M@F"I3TTI,[7A'&'*UU"S\BU=>MNH',-9TN]UJ9.S>DJ$B919*JQ-.3\.K`6$
MCY4IZ1*VCS]7K-_CR$I^N"=PG">K5S/TZQMWC563KEIJLTBZ;K$\^.F(&P03
M\BR*I>H$W+&3BY%J!@W`#I*I^X(:N&M%-74BT+2EVD>;((WI4A0^Z"#Z(,5R
M2IZEJ`I)**AM4^8I4#]P@P\-QYYRQW.'M:\C[++NV*68,>\=,Q4W,$*W%));
MX>3Q5:#Q=O;L2*&40A;LP1,X2-TE2*\2=MR;@W$=4<O^#N8-Q0QRC:0?DA^X
MT[E.K?U"^B;9/X39V'E*2E7KHM%:,I1E.!7QYU0^4F:)Y#PW;>Q5)8',L3/-
M,*')"+X^D?GC^^.KTH[T15B-CEVT?B"<2/P&43ZT(Z\YN)7E_EWCSOYQBYN#
M>2./^+(]2)QZTB-KC%6=2+*X2S"FV`1<J8MR"1OL&YO/-4I<$NGWC=8AMK.8
MP4IR7'2OO!7T\^YVJ(UO,@M6(94EOW0VVIEW>Q7*%).WI,(07,_`+YPJ5%-6
MWNH@#G-T@"M@KLU`($W`?$RJ\F4@![HFUZ)<:*5=7POR]EL=84Z5^@VZVX?N
M),>6O`>L:H>+V$/NJDDU9;[I=:<:'W5@^A*)2]X=!]`\P*Q.%*/\+Q12)J//
MX]`FCK-;V/0)B_2G(YC!$0](`8!]T-:!YMA:K>'-THURD+@\A4M\ELLG[H49
M'HB2_.R2]0\5;56H/75:V'$SW30\\D>D4;1T@PRQCFU-+UC^CW5@H15E;JE7
MK*T4(8#$,WFXEI)(B4P"("'EN0]W5(+M0N6NZW.V/)D[3U#C1'2A:D_P1Z&V
M"Y-7FQV:[LJ!:JJ5IT$<SB$J_ACV>L?&6@TA$>Y+BYAJ0GI^T(15QK=BM+U]
M(6":H>6<M8YDY1U)/59%X=T\H-XK:QR*O5SJ`3?H(8P](%UFT9#=4MM,K=:<
M9;0E*4N,,.I"4B21)QM0V#9/>>4DQA3C]K[5YY#3C;SBU*4IMUYLE2C-4RA:
M3(GDW<VR,6V+@#Q]M(JFF97D>[46$PF46YD\N7?B8=S;(R&;7C7Q]`_4]MA^
M=K)TN;7JD4%-T]NF-W]PHA+TF!'1J<1M-4"'G:P@[_[U4G\YTQ'&U=EOA)<#
MJJRS3-RBRV_F++Y[R9,*FW,)OHCV2<FQ.(;[?1;^'S?'6S,<9<WIPE+;M$`!
ML_NK`'I)0!Z4HPKG##%G)S15"?,^X?5)B,3'L$=OK),.%BJUGY&0$>YD)MB@
MO%WRJ&%PM!SDC".G206;'-@45:N7<<H9%3?I50,50/I@'6T*XZ<0+,ZJBK+?
M;55`2A1U-+G):$K$^S>0)R4)B6PS')&N4G"_#;W3(N%#<*_P52EI$EMR);<4
MVKOV5*EJ29&>T2(V&,%6CV=CC_<Z-)RV!.065XRRDEIF(BG.3653LE95=5BR
MR-=G4'B%9K=.E?*4=Q2Y$'*2IR^!5/+4*;;6:I_.%R6@KVFK]8*-=,4(4I+)
M<0N3C:7$24IQQ(,E)U)*9C:)@SC&CA)9+E0.5%EO%2ESM7$`NA)3-IU32YA*
M4$C4@Z5`R(D=H,>8_9PGOV/?!_\`61:_#7WI?@CX0^Q21^#?OK??0^R7USX*
M^&/,^P'[W_\`DSR?/];^%O\`*.W1_`]=K_<<KPCM/HP.R\+UR[03['L=&F<O
M=NTZVN6G1U)3ZT?G[%U=EI^7/;/!],])EVO::IRG[GHZLN^U=:?)'__5CMW&
M,3R.%><7)RCOV`Q[<<MVRW5]'RP(B-2R!(JWFJF;&#<BB)(*P()[E'P.0Q1V
M,40#T9X:W=J]8-C%8VL*4*1#:^A;0[-<^;K))[A')%+<SM[ELRB]TJTD#PA:
MD^Q6=:#^2H1>5[.9RDK\7]];B-99-%C+S\RKEW&B3QT5/X9=EAXN#O$#&IJB
M`K/VT9!LI`B*8B8R"3I7IV3.;4'><7B]0XY:LNIFBIE#8IWI`]4:E*;4KF22
MI29F4B4CE$2IP9OS+?A^//K`<<7VS<SWQTA*TCIDD*ES`\T-;ZJO$_0:0@TA
M'G!N%4+:DJ,:R09;HO"+V5&IFE&06-6NM7J,:XG4X85OA`T0C(.$T#.03\D%
M3E()NH0#7/X+4FF-8*=9HPO07-)T!9$PDJEI"I`G3.<HX/":?P@4G;H\*TZM
M$QJTSEJT[Y3V3E*<>CUP1SPIO[2]]LW$G_4>7/X_0]6J\VC=EW_K_P#DBOW&
M[W?'_8.^JB*V.Q[X]S#C_P"[_DW,'SO^"^0/3[_CJ3>./[M;[[.G_P`PW&D<
M+O+>S]Q[X%R'[]4(BW$'I\!\0'TAI"#2$(I]_?\`M#K+^"O&'UJ=ZO1P"_=Y
M3>-O_G"*J\7/+%[Q=KU#'P^T7Q7J/,93F-A*SI,FTC.\>FKJD65PU37<4^]1
MU]K[ZL3S97H%TDV2E6Z2;Y-$Z9W4>HL@)@*H.OUQARFLP[Z&7ND6K0W<%!Q`
M.QQHM*"T$;C-))3,'2H)5O$<'#NPTV2'([6^E/:*HP6U$3*'`XG2H'>-NPRW
MI)'+%2]SI]DQ];K/1+C$NX&UTV?EJQ9(5\F*3R*G(-^O&R;!P0P!LJU>-CE'
MW!VW#PU+M#6TMSHZ:OHG0Y1O-I6A0W*2H!23Z1'<B/ZFF?HZAZEJ6RBH;44J
M2=A!!D0?1AZ?LL<S?ZTW%:+IMIDSO<L8`0AZ#<%7CD7,C.5P&:J5$MKE14QG
M#A>2BHU1HZ64$YU7C%50QA%35%>,^&?13+':JD9";/7E3K<A()7,=JV.0:5'
M4!R)4`)`1:KAEDOR]8$TU0Y.X4>EM<SM4F747SF8$B>=,SOBXG411(\*;^TQ
M-U"V;AZ[$/J*T'G!LF/^%:O\5*JAOZ!$"O2#\S?5KO-G4.PS-$^MKI3Z$J@1
M7WC>#V^.JY-#P]$%H_PQ61V2U4TNYMQL\PP%\T,OHDW]`J'P5DP2EW]&YNG8
M/?'PU)?&\%7#3(`G>%4Y]`5#4XT?A@0,WLL__E^!<A__`%0:+=10Y[1(Y20X
M(U1$Y@`[SD90&Z(".W6H2E9-=F*4-OHC`DV,.WO`.IR\WQM3F?+4!L10/*/<
MU-I]50B*>,2PG$VDG>JL;`_)</\`!"?7&ALH\Y'\?FB0"*KK-V*&Z8`'5NHM
M?(!,G@'B/T1O1JX>4$)QK(%'<FB?/I-J,5PL@*KS:$@;34M?GIC9SAX`'S@_
M>UYDC<(O+"27M%7Q[*9\FN@?=]ECW-79\W;R&K?G%WX)F*P<8_*FG\41^>Y'
MV?9Q/COY3^2I>/RN8-UQ><;Y$6KYU:_R]3')P7\J*_YO7\,Q#JNJ619N#2$)
M2>T<?'CQG\E:B_E8SAJYOFX>25Y^<5?`M16?C1Y26_Q)/PCD=?V<[X\^0/DP
MWS\I>'==GSB_(:WGE^5&O@:B.'@UY4U?B2_A&H=CU2F+/0>G2$&D(53]H_Y)
M"(X5XH0,F3;J<9HR*S1$WFE.4CZKXY9+*D$"@F8JTXY6;FWW$&BO2&Q##:;S
M<<:U*O65OM[I4S)]);Q'3[FD'I4`=XB`N-%[VVVP,N;![<X!Z*6P>YUS*?*"
M1NA6.-?K14BPE&Z;19Q&O6K]!*09-)-@JLS73<))O8U^BX8R#,YTP!5!9,Z*
MI!$IRF*(@-J'FTOM.,KGH6DI,B09$2,B)$'F(((W@SB!D++:TK3*8,]H!&SG
M!F".@@@Q:R3OA=R\A0(3/T64I0Z2E##V%@`H>X`?^7X[``:BG[#N&>_Y`7_B
M*GXV-]'$_.`)"]2']33_`!41NY,]POECS!J<#2>0>1(J\0%8L1;3!(HX]QU6
M'T?,A&O8I55*7J=6A)4S5PRD#E5;F6%NJ<J9SD$Z29B['C/#O$L0K'J_'[<M
MBI<;T*/;/+!3,&12XXI,P0)&4QMD=IC#7K,,AR*G:I;Q7!YE"M21V;22%2(W
MH0D[CM$Y&(JT2YSF.;O3L@UAR+.R46U5^XU]V`B`MINLR[.:BW'T(@;ZD^9$
M-X"`^&MKN-"Q<[?76ZI3JIJAI;:QSI6DI5]PF,#25+M'54U8RJ3S3B5I/,I)
M!'W1&S'X]YC@.06$<79IK!RC#Y(I<'9T4B"8?4G3YH3X4BSB8`'SXB5(NU4`
M?$%$3`.O-"_6BHL%YN=FJDD/4SRD&?*`=BNXI,E#H,7>L]R9O%KH;FP9MO-)
M5W"1M'H&8]"/*\P_BD<I?DYYN_)I9M=O$/*S%_G&F^&1'6R7R<O_`(D_\$J-
M9O[^O3#EBD4;'+MH^/`'B,'OX+HWUK)KSEXE>7^7>/N_G1<_"?)''O%4>I"X
MG?MX#%Q5D%OS#QE$&2H.59@L7EF/9(_P>L9,72$[.R]"9_J$7?FZ!_.'RRII
M2J!S'.)WR1`L3P$S[Y2H?H9='YUU,@JIU$[5LC>WTJ:)F-Y+9EL#9G#'%G$?
M`*L9%0M?W-]4G0!L0Y+8KH#G+R!0/*J*5N-O)B]<:IO(;RJ',\@<L8DR'AN_
MUI9P*+&<K5]K,C"I.CCY:P)259EG*$BT5*4#]:!D1,"*ZQ337DV+T.3,VT5(
ME4TE6U4-+E,I4TL*ER=58!2H;MH5*:1$8V6]U5E76EA7M513N,K3R*2XDI]-
M)(4#T2W$Q''Y_P#R\=;*D22!*,*?N1L<NVC\0/B1^`VB?6A'7G+Q*\OLN\>=
M_.,7-P;R1Q_Q9'J1./6D1M<?.F(MK-Q,G#/0$S.6CWD:[*7;<S9\W4:K@&X"
M&XI*CKE9=73OLU#2I.MK2H'I201]T1P55,U64M32/IFRZVI"ASI4"D_<,(T3
M36>P3FN59-O-:V/$>2WC=L*W6FHG*4BS*%;'..P'$JB\:4V_]T0VX;@.O56C
M<I,NQ.G<60JCN-`)RV]5YK:.Z-1[ACQCKFJO"\RJF$)4FOM5Q($YI.NG=FD]
MSJ@](B[WN@U%CR*XQX2Y=4-$CYK"1[09\(\I')FU4O*+(QQD%R;J@:GV]D#)
M1,0W15>K]73T&U5;@+<WL+SS*.'=X.AQY9"-6P%Y@D#2#_3,DK29[0A,IS$7
M'\Y&U,9_PYPWBI8DA;3*$]KI&J3%2$SUD;O!WT]FH$3"G%SE(QD/M#<J8ZWX
M[4XX6V4(E<<?E>/Z&#HY2FGJ,Y<F=.(UJ<?HG#^JR+E3<@CU>H+)>6`D05$N
M(\XW`7[7??IK0,$VNMTI?D">S?`"0I7,EU($CNUA4]JDSSGFI\2Z:Z8_]GES
MJ0+M0:E4VH@=K3DZE(3^$ME2C,;^S4F6Q"B+J-5EBX$&D(-(0:0B,/*;,;G&
M=*CJM3EB.<RY<DR4'$<&F/6[6L$IT-WUF61(8%"PE)CG!I%XL.Q"@D1,3%%4
MHZW7!\<;O=R>KKDDIQNW-^$5:]P#:=J6@?Z1]0#:$C:9D@=4Q'7$C*W<>M#%
MMM"@K+;HYX-0MC:KM5B2GB/Z.G22ZM1ZHDE)(U"/16:=A.,7'5Q)N%#O8S$^
M/&$:R`Q3F=3;^)BVT/"M`*!CJJR-@F/(1+XF.=9</2(ZZ-#25>:Y<W3M(TU%
MPK2H\R$K45K/0EMO4>A*>B._<JVBX=8$[4N+U4]LH$I3/>XM"0VV.E;SFD=*
ME],>NPO5Y&E8FQW5YHQ%+!$5&$0LS@A4R`]M2K))S:9$Q4BD2!22L*[EP?I`
M"]:@[``;!KH9#64]POMXK*0`43E2X6@-P:UD-)'L6](V[=FW;&5Q.@J;7C-@
MM]<9W!JD:#QYWM`+RNZITK)ELV[-D9.UAXV&/__6O([]/`2;S12HCECBB#5E
MKYB6O*PN2X*-;E4D+%C!FJ]EDK"U012%=[(45PY<*+EW$QXQ=0W_`-J0AK#<
M",_9L=P=Q6ZO!%OK'`65J.Q#QDG22=@2[(`<@6!/>2(:XL8BY<Z9N_T#6JJ8
M3)U(WJ;$SJZ2C;/^+W(3]I]OM&/[57KQ2IV2K%NJ<PPGZY88=RHSDX>8C'";
MIA(,G*0@9-=NNF4P>D!VV$!#<-7`KZ&DN='4T%:PEVD>0I"T*$PI*A(@_P#$
MQO!!$XKG35-115#-52O%%0VH*2H;P09@B&MN'WM#U)>5Z%J',FHS$%:8]FDS
M=9;Q]%%EH&QJ(@FD62GZ4S\F1K\DY(`G<#&E=M5%MQ2;MDQ*D2J.8>;W7L//
MUF'U27:,DD,.F3B-YTI<[U8&X:I*E*9.TQ/V.<8J9;35-DE.4O@2+K8FE4N5
M2-X)Y=,QS`;HM9;]WCMQN(TDH'*.F)(G1*L+9>&NR4DGU%`WEJ1IJQZ\"Q=]
MA*!!\=18KA+Q%2X6_HL^3SA393^5KE&_#B+ABDZOEUON:7)^EHBMSE;[0[AJ
MJP<M7^)U1ELGW1RW7:L+S=HQ[6*!!.!,*9)$D(N=M:;29(`ZB-S%C$C"(&%8
MQ0$AI%Q/S?+W7NM5&4U::2A!VMMJ"WE=&K:VCI/7/,.6-+R#C#;J9MQFPTRG
MZ@C8XL%+8W^MF%*Y/P1ZD+#%Y@\D0Y%-^5RN5K*YSPUG2SR=X761,KN5,S4T
M'\$D1)"EJ*D6H9@:'*W+&^H&%MY((CT:LZ<)QKZ-JQ)-K;%B*-/9[=AG/7J[
MXN:NMVA)5J`,]@B#ADMZ%Y3?_#E_*H7JU_<TRW:);-`ZLMDI;(V`/!7DQ.\N
M>,^/<X67'$UC"<LS-5&1@I1LZ0C9%S'F*W4LU/6>[/'],GS`*\>LJ'7Y8B3J
M5`@+*4$S?&VL3R6XV-BXHJF6E"2DG:`1/0X!L#B-RP-D]NR<A;?%+X[D5CH[
MH]1J8=6-H.XD>N1RE!Y/2VRG"^OM+WVS<2?]1Y<_C]#U/WFT;LN_]?\`\L1#
MQN]WQ_V#OJHBD;MZ\F:IP_Y:8TY!76!L-GK=(:WAN_A:L6---NS6FA66I-!:
M!+/XU@(-WDVFHIUK$^ID-MN;8HSEQ$QBLS#$KCC]`^VU4O*:(4YJTC0ZA9GI
M"CM2D@;-\IQ%^'7RGQS(:*[U32UL-!<TIEJ.MM2!*9`WJ$]NZ&5OVD?BQ_05
MR`_[+'7\]M5K_P!M^5_MVW_VWQ<39]M5@_959_9_IQP/M(_%G8=L%9_WV\-T
ML=;;_P#C;3_;?E?[=M_]M\7#[:K#^RJS^S_3A@6DVAK=Z94KHQ;N&;*W5F"L
M[-H[\OUIJTGXMK*MF[KR5%D?6$4792GZ#F+U`.PB'CJOU53KI*FII7""XTXI
M!(W$I)!(Z-D2]3/IJJ:GJ4`A#B$J`.\!0!`/3MA'KO[_`-H=9?P5XP^M3S5X
M>`7[O*?QM_\`.$5<XN>6+WB[7J&))^S9_&0Y!_@18?=W`ZUCSD_)_'/'5?!&
M,SP4_P!;N_BH^$3'TO:#^%Y:+D6L\OZ+#F3K64%T*CE@K1$H-HS(+!D/V.V)
M<B"(>62WP;$Z"RIS=/KC`HF$5'(;\/F]YF:RAJL.KGIU%,DN,3WEHGKHZ="B
M"!S*YALY.+^,II*QC(Z5$FJ@Z'9;@X!U5=&M(,^E/3%6/;-Y>/.&?+&@Y&>O
MED,<V5<M`RXS*<P(*T*R.VJ;J9.D5%P=1Q3I1)M,)%(4%%?4C(`8I5C[RIQ.
MP]&9XG76]M$[DT.UISR]J@$A/<<$VSS:@K>!&A81D*\:R"DK2J5&L]F\.3LU
M':KNH,ECI3+<3&Q+9/6DDS:R#!RB\8OFZ#QD[;*D6;.FKE(JS=RW63,9-9!=
M(X&(8HB!BB`AX:\\E)4A2D+20M)((.P@C>#%R$J2M*5H4"@B8(Y087P]HOPY
M*7+BYB_+\3'B]^\UDT[2PN"%#KB:GDF.1AEY%0P^ALI;8>%:F`-Q%1RF/H`=
M6`\W:](H<JN=H<7(5U,-(_"<9)4!Z#:G#Z!B'N,UL556.WW)"9FF>()YDN@`
MG\I*!Z(A3#C=G*R<:<\8JSQ4T$WLUC&X1MD)%K*^KH3D8F)VD_77#H$7!VC:
MQP#MTP56(0RB2;@3D#J`-6RR>PT^3V"Z6*J5)JI9*0?P5;T*_%6`J7+*1V17
MZR75ZR76@NM.`7&7`J7(H<J?QA,>C#O>+.]MV^<@TEE9[%E\V+)WU)%:9I%V
MK5G^'(M\*!%'+)JX@H>7BIM-)81(15JL<%-M^DHCTA2*Z<%N(%OK7:5BS^%,
MA4DNM+1H4)[#)2DJ3W%"8BT5!Q/Q"LI4/O7`L.D;4+2HD'E$TI(,N>?I0O%W
MANZ+3^;ZE)Q%A6.EDL-X\L;JX.;/8&)XR3O%O&,<PD6^8PZIQ<Q,)"1,H^(E
MZP!7+D[PQCII`F4#6%X.<+ZW"_#+U>W$_+%0T&PVDS#3>H*4%'<I:E)3NV)"
M=YF8AWB/G5/DZJ>VVULBVL+*]2A(K7(I!`WA(!,I[3/:-T0P[7F%K#G/G?QP
MKL(R7<LJCDBM96MCHC=19I%U/%\NRN,FO)*)E,5JVE'$8A&I'/L4SM\BGOU'
M+ONO%.],6/`\CJ'7-+KU.IAL3$RX\"VF4]\@2L_Q4F-8P6V/77*K,RTB:&WT
MNKZ$-D+43W9!/=('+&Q9UYW1<N$D?:*?CVTSY-E`^[[+&KL>;MY#5OSB[\$S
M%7^,?E4QXFC\]R(N]I3F?BS@QR.NN6LN1=PEJW8L)6/'3)M2HV-E)4DW+7O&
M]F;+.&\I+PJ!(\K"HN2G."IC@H9,`(("(EVCBUAEUSG'**TVAUE%2W7(>)<)
M"=*6GD$`@';-P>A.,#P_R:BQ6\U-QKVG%LKI5-@(`)U%;:@=I&R2#]R&(/VB
MCA%__%\@/_!U0_G]JO'^W?-__P"R@_+7^A$P?;-C?_\`%5_DH_3BPWA)S\PY
MSS@[]8,/0]YB&..Y:$AYLEXB8J*<+.IYF^>LS,"14Y-D61(E'G`XG,F(&$-@
M'Q'4>9K@5YP2HH*:\.L+<J$*4GLU$B22`9S2F1V],;GBN7V_+6JQVWLNH2PI
M(.L`3U`D2D3S0L/[1Q\>/&?R5J+^5C-^K+^;AY(WGYQ5\"U$)<:/*2W^))^$
M<B%G:SYJT/@?R)LV8\B52W7"#G,16/'B$92RPQI9&2F;91K`@^6"<E(AIZBD
MVJJI#]*HJ=:A-BB'4(;UQ3PNX9WCU+9K;4LLO(K$/%3FK3I2VZ@@:0HSFX.2
M4I[8U7`\FI,4O+URK&''&E4ZFY(E.:E(5/K$"75/+#`?[2/Q9_H*S_\`]ECK
M^>VH`_VWY7^W+?\`VWQ<2[]M5A_959_9_IQ^K?VD#BXZ<-VR6#,^E4<KHH$,
MHECOH*990J8&/TW83=(=6X[`(_,UQN^;GE333CIO=O(2DG^>Y!,_S<?I'&BP
MK4E(M57,F7\W^G##+Z08Q<>[E)-VVCXY@T7?/WSQ9-LT9,VJ)G#ITZ<+&(B@
MV;($,<YS"!2%*(B.P:KZE*EK2VA)*U&0`VDD[`!TD[HF!2T(;4ZM0"`)DG<`
M!,D]P1K8.;?(>0Y3\H\Q9L=++'C;3;'C>IME53*A'TF#`L+462?41/R^F#8H
MJ'`"@`K*'-Z1$=>D>#8ZC%<5L]D2GVUIH%P\[JNLX?RB0.@"*4Y1>%7Z_7&Z
M*5U''#I',@;$#\D#T8L1[?/9:MG.;!KC.DKFXN%8)Y;IFMU&/<8K<7M6U1T`
M1HWD[(B\'(%(1:1Y)U1S'D*0CCJ79+[F+T@`QMQ$XTHPF_)L-':$5;J6DK<)
M=*-"E[4HD$*F=,E'=L4F-TPWAHYE-J5='KB:=HN%*!HU:@G>K:I,A/9R[08G
M3^S*N?TV$/\`TX*?GYUH?^Y:L^J37^(5\5&V_8BS]85>]#XR#]F5=?IKH#\S
M^K@H'_/]_G7P^<M62V8DU/QA7Q4/L1:^L*O>A^G"]'+7CE8>)?(?)O'ZRR8S
MS_'LT@S:6,(I2$1LT))QC*;@;"WBU'LGZDC*Q$DBH*0.7`(J"9/S#B41U8W#
MLE9R['+9?V6PCMT34B>K0M*BE:9\LE`\@YY1#6165W'[S6VEU>HM+D%2EJ20
M"E4N28(AH3V=/DN>X88R9Q@GY$BLMB&=)=Z*V<O!.Z/0KTY<&G&$>S.(B6/K
MEU14<+G+]""L\F`@`B&]7_.)QH4-\MF34[?M5:@MND#8'6@-!/2MO8/ZHQ.?
M!J^&IMM=8GE]>F4%MC^(LG4!T)7M/2Y%W',/XI'*7Y.>;OR:6;4*XAY68O\`
M.--\,B)/R7R<O_B3_P`$J-9OKTP/+%(HV.7;0^(#Q%_`91OK637G+Q+\O\N\
M?=_.BY^$^26/>*H]2)-Y@Q32LY8PO&(\B124U2[_`%V1KD]'J@3J,U?(F*D\
M:*G(<6DG%NP3=,W!-E&SI%-4@@<@#K5[3=*VR7*BN]N>+=;3N!:#T@[CSI4)
MI4.5)(Y8SEQM]-=:&JMU8WJIGD%*AW>4=(,B#R$`QKE.9/%NZ<.>0=XP9="+
M.!@71)"IV(S8[=K<*3*&55KMF8]10(=-V@D=%P4@F*@^;KHB(F2-KT7PO*J/
M,L>HKW1R!6).(G,MN"6I![DYCG20>6*99)8:K'+O56NIVZ#-*OPT'O5#N[CS
M$$1%W6UQ@8V.7;1^()Q(_`91/K0CKSDXE>7V7>/._G&+FX-Y(X_XLCU(G'K2
M(VN#2$+*]X/C@ZHV6XS/D!'J#4LJ(-8RT.$B',C&Y"AV0MR"OTE!%JG9*ZQ2
M51`/%1PS='-XCN-X_-LS5%SQ^HPZL?'A]`2MH'>NG6J9ES]DXH@\R5MCDV>=
M?G7\/G+-D]/G-"P?DNY@(>(W(JFT2$^1(=:2%#\):'#L._M]L'E)5D6,[P\S
M<+%_CG)/PFWI*DXL`1C66L"?JTU27AEQ%)&/M(G\]F(&2\J2%0-S*.BB3K<>
M^']?VU)Q*Q;6B\4>CM]'?%+9FV^F6]3?>KWS;"=DD&?-YM?$FVAFX<)LQT+L
M%PU^#ESO`MT:7*=4]@2[WS9V2=*MNIP2CGRSXH97X*Y=87RAOYY.BDGRR^,\
ME10+$7@'AU7"[2L3[M,5"-Y]DV*9/ZKLA)M@,<I1`5D4MWX=<0<?XL8V]9+T
MRR;OV.BIIERDX)`%UL<J%';LZS:N4=51C[BEPPR?@OE;%]LKSXLH?[2DK&]A
M:5,D,ND#8ZD<I&EU,S(]=*;5.)?=KQQ?HV,J'(A9CC6\-FZ+4;GT*$HEF42(
M8IGKI4H'-4Y!<"`*B:P"R$XB8BJ91!(E?^(7F\WVQO/7##T+K[0HD]D-M0T.
M:6SM4CD*>O+84GOC9SA?YT6/7YBGM6=K1;KTE(';[J9X[IG^A6=Z@?:YF84D
M=5-O-<M%;M\6WFZI/0]DAG:::K66@I)E+1KE-4@*)G0>L%G#94ITS`8-C#N4
M0'W=5UJ:6JHGUTU93.,U*3UD+24J'=!`(BU%%7T-RIVZNW5C3]*H3"VU!:3W
M%))$?6=.VK%NL[>N$&C5N05%W+E4B"""9?IE%5E3%33(7W1$0`-<*4J6H)0D
ME1,@!M)/0(["W$-(4XXL);2)DDR`'.2=T5X<B.Y9@/#22T#295OFG)JZYXV+
MIM#=%E&9)CS2MDVDS8F)7;!HH#D_0+=OZR\,H`D\H!W$)@PW@IEV4%%97TYM
MMA2-2WZA)3U!M)0V9*.P'K*TH&\JE$#Y_P"<+A&'I70VJJ3=LD4="*>G.L:R
M9`+=3-(VGO4ZEG=I!(C\.(V!\IV&Z27+?E,IY^:+9%J15%I!DU$HS"]'=&45
M"%BX]159-A,R2"VR^_4Y03.H550[APZU\X@91C]';F>'V`IEC%.YK?J-ZZY\
M#W1:I";:3WH`"29$`)2B/G"W#,GKKM4<4.)2IY=5-:*>FVAN@IS/VM*23)Q0
M)G/K)22%*+BW(\G<;Z3F/ROKF#J.JG*X0XW3K#(F;K"W43<0]KR!%*KDI%":
MK);@X:PLZ@JNX*)S).%VK@!*`M$S'R-NL_V=8#697=$:,IO32J:A;(DIFG7+
MPBH(W@K;(2C<0%).Y9`Q=VOGVK<3J#"[,O7AN/NIJ[@Z-J'ZE$Q34R2-Z6W`
MHKY%*2OE:!-I6H.BR$&D(__7?X$-PV'T#X:0A<#N$=ARJY?FIO+O$-Y7\97>
M4.[DK#B:4*JRQ[9I5<ZCE9]57C<JP460>+'$#-`2-$F,)13*T`#B>Q/#SCK5
MV-EBSY8ARJMR`$H?3(NMI``"5@R[4"6Q1.L<NKDA?,>%#%R==N./*0S5*F5-
M'8VI1,YI/K#SIEIYM/*LCF7A#RVP`\<M\K<?<GUMFW=*M"V).K2,W4'BJ0G_
M`,WW"!1DJV]\PA!.4".1.)/$2AJS-FS[#L@0T;7D-*MQ8!""XE#FT3]S64KG
MZ$0?<L5R&T*6*ZT/H0GUP0I2/RT@I^[$7A:.@<>J&;.`=@;H]5%%0'/7OMT^
M0)05ZMP]&V^MJ\)IR-0J$:?9#[\8,LN@R+2I]PQ)'$7#/E9GAVFVQ/Q_RG<$
M%%DD3S+2HRS*L-#KB`)A(6J5;L*W']0?1!YSH@B4!$/`!UK=XSC$+`E:KMD5
M(TM(GH[1*G-T]C:25G\F,U;L8R"[*0+?:*AQ),M6A03Z*R`D>G#+/`7L$5Z@
MRT+E/F>^@K_.QQVTC$81A#F?T>/D&Z_GMU;Y,G\LMT!(R9!-&(IDBU!ZB.#O
M43"F-:>(''JINC3]JPY#E/2JV*J52#BDD2(;3(]E[.>O=IT';$UXAPE:HUM5
M^2J2ZZ-H83M0"#L*U>O]C+3SE0V0R\V;-V;=!HT01:M6J*3=LV;I$0;MVZ!"
MI(H((I%*FBBBF4"E*4`*4H``!MJMQ)42I1)4=Y,3<E*4I"4@!($@!R0M=W_N
M-'('D%8.,Z^$</9`RFC5X?)B5A4I%<?SQ8=64>TT\<1^+)-3U8SPK%44^K;J
M!,VWHU8O@'E&/8X,F^7;PQ2]KV.CM%:=6GM)R[DQ/NQ"G%RQWB\.V15KMSSX
M0EP*T)*M,RB4Y<\C"[/ZMSGQ^B'GS\74]_)=6*^U#A[];Z'WP1#GT)RWZNU?
MO:OO0?JW.?'Z(>?/Q=3W\FT^U#A[];Z'WP0^A.6_5VK][5]Z#]6YSX_1#SX'
MS1QU/`'SQ_@WN:?:?P^^MU%[X(?0G+?J[5^]J^]&PNPE&2$+AG$<-+,W$=*Q
M&,J'%R<>[3,B[82,?5HIH]9N43;&2<-7*)B'*/B4Q1`=>?-V=;>NMS>:4%-+
MJ'"DC<05D@CH(VB+@6M"VK9;FW$D.)80"#O!"0"#T@[#"FW>FX<<JLV<X[!>
M<1\?LJY&IR^.L>QB-EJ-0E9F'5D(Z-=)OV9'K1$Z1EVBAP`Y=]RB.K7\&,WQ
M*Q80Q;[QD%-35HJ75:%K`5)1!!ETQ7_B9C5_NF4.U=NM#[U,66QJ0@J$P#,3
M'-&?.PCQ7Y(8!SSFV>S7A+)&+H6=Q&RAXB4NM7D8%E(RA+C#/3L&:[U),BSD
MK1`Z@D+N/241]&L!QYRW&<BLEB8L5[IZIYNK4I0;5J*06R)D<T]D9;A-8+U:
M+O<WKG:WF&ETP2"M)2"=:3($\LA#%');`=-Y08+R3@F^(@:O9#KKB)]=*F55
MS`S")TW]<L\>0PE*>2K-@:-GZ!3#T'5;@4X"0QBC7G'+[6XS>[;?*`_WBG="
MI;@I.Y2#OV+22D[-@,QME$R7NTT]]M5=:JH>U/-E,_P5;TJ&[:E4E=,I'9""
M5F[87/>MV.?KI>+&8YT(&:DX<)JO4J7EH&7",>K,PDX:3:H';R$6_!'S6ZQ!
MZ5$CE,'IU?6EXK</ZFFIZ@Y12MEQ`5H6L!:9B>E0Y%)W$<A!BI51@F7,O.L_
M(52O2HC4E"BDR,I@C>#O!Y1#??9XLG))+B\QP]R;Q-D;&ULPBJQJ52D[[79"
M#"V8\5;JFJR4>J^12]:<U!!H>-6*43"FV3:B;Q/JH7%MG&E90Y=\8N]/4TE:
M"XM+2@>S=GUY]"R=8Z2H<D6*X=/7I-B1;;Y;WF*BEDA!<21K;];*8&U$M)Z-
M)Y8LQR/CRG99HELQKD&!96>E7>"D:Y98&0`_JLE%2;8[9PB*B1DW#9<@'ZT5
MTCD7;K%(JD<BA"F".*"NJ[96TEQH'U-5K#B5H6-Z5),P=LQW0001L((C=ZRD
MIZ^EJ**K:"Z9U!2I)W$$2.[:.@C:#M&V$F>='9)Y&\=K+,6;`U;L>?<+NG3M
MY%&JT<K-9(J3$3*KHQ=HJ\8B9_->I-R]/PC&H*)+=/6HDW$0)JZ>"\;\=OU,
MS29#4MT%Y2D!160EEP[.LEPR2F9VZ%D2Y%*`G%8<JX7WFSO.OVEA=7;B21H&
MIQ(YE(`F9?A)F#R@;HI:EX&=@'IXR>A9>#DDU!24CYB.>1CY-4IN@4SM'B**
MY5`,&P@)=P'PU-+%?15+:7J>K:6T1,%*TD$'<002".F(U<IJAI9;=86E8V$%
M)!](B))X"X3<IN34VSAL/86O-B:N'31L[M;J#?0M&A2NS@4CF:N,J@U@&*)4
MP,IT"L990A#>6F<0VUK60YYB>,,N.W>]L(<2)]FE25NJ]BVDE9[L@.<B,S9\
M5O\`?'4-VZV.K23M64E+8[JR`D>G/F$.T]LKMKTK@-CQ\[?O&%RSK?6;(,AW
MQNV$C-DR0,+E"E5#UE,KQK663HP*+J&Z%I-TF198I2I-T4*4\2^(U;GUR;(;
M+-DIR>Q:GMF=A<7+85J&X3(0.J"9DFSN#853XE1+4XM+MU>`[18W`#:$(GZT
M'>=FH[2-@E:)J,XWN%'>^CQ$Y/YVYCU2Y8;P/D_)M4:8#I4`YL%-JDG.12$V
MRNF2GKR+4=LT5$B/6S23;J'3$=RD6(/NAJV7`[,\5Q_$:JBO=]IJ:K57.+"%
MK"5%);:`,N8D'THKUQ3QR^W7(V:JVVI]^G%*A)4A!4)A2S*8Y=HBF3]6YSX_
M1#SY^+J>_DNID^U#A[];Z'WP1&OT)RWZNU?O:OO0?JW.?'Z(>?/Q=3W\ET^U
M#A[];Z'WP0^A.6_5VK][5]Z&<NP+Q[SCQ_Q[R.C<VXIO&+']EN="?0#2[P#V
M!7EVD?"6!N]<,$WJ:9G"359PF4YB[@43@'NZK-QZR2Q9'<L==L5U9JFVF'0L
MMJU!)*TD`])`G$X<)+-=;/27I%TH'6%..-E(6DI)`2J9$^:8B&W?=XD\F\]<
MOZ!<,+X)R=DZK1W'*G5I_/TNJ24[%M)]EDK+TFZB%W;)%1)-^A'S#58R8CU`
MFX(/H,&MKX$YAB^/8S=:2]WRGI:E=<I24N*TDI[)H3`YI@B?.(U[BOCU\N]^
MHJBV6I]]A-*$E2$%0!#CAE,#?(@^C%*WZMSGQ^B'GS\74]_)M3=]J'#[ZW4/
MO@B+_H3EO+CM7[VK[T'ZMSGQ^B%GS\74]_)=/M0X>_6ZA]\$??H3EOU=J_>U
M?>COQ?;@YZ)2<<HKQ&STDFF^:'.HICR=(0A"+D,8QC"VV`I2AN.NO5<3N'ZZ
M:I2G+:(J+:@!V@WE)C]M85EH=;)QZKEJ'\VKG[D.K]T^7S6CPLR?3>/F/KWD
M/)V54&.,63&@0CN<DH2MV?S@N\X_09I*+M(X]09O8\JX=)DWC]`2B`[#JF/#
M%%C&:6JLR*X,T]LI5%XETR"EH'M:1SD.%*Y<R3%F,\7=!C%;2V>C>>KGPEN3
M8)*4JVK49<A2"GNJ$)2Q_;/Y]23]C'$XEYP:'?O&S,KJ1HLQ'Q[<SE8B)5WS
MYR@1NS:)"?J554$")D`3&$``=72=XI\/FFG'/I91JTI)DE8*C($R`Y2=PZ8K
M,C!LN6M"!C]4)F4RVH`=),M@C8"\<,+P'';!&*L(UDI`B<;4R(K95R`8/A"1
M;H^?.2YP,(F\Z9FW#AVIO_=K#J@N07E_(;W=+U4GVVI>4ON`GJI_%2`GT(MS
M9;8W9[306QKO&6@GNG>H^BHD^C&;-8>,I!I"%E>_/P'RIFZXX:SUQ_Q=9\D6
ML\1*8UR3$4N*>S4R$=&+'GZ-.*QC(J@BV0%_+-'+D2@)?X(F)A#H`MD^!&?V
MG'Z2]6+(;HW3496'F5.&29GJ.)!YS)"@/9'GG!_%C$KA=*JVW:T4+C[^DM.!
M"2HR$U(40.ZH3ES#FBNGMB\>.>?$WF?B+)LQQ9S]$T26D5\>9.6/0IUNQ"B7
M<I(I[(2QS-B@,;5IGU&;.'I$T87;?T#(7%#)\`RW"[M;*?*:%=Q0`ZP-8GVK
M>T`=*T:VQ[.--P:RY9C^2VZN=L-6FD4HMN^UJ`T+$B3LW).E?XL.$<I8.9M'
M&/D56:[&/)JPV3!66X&"AHY`[F0EIJ9H%@CHN,8MDP%1P\?OG*:2290$QSG`
M`\1U47&*ABDR3'JNI="*9NNIUJ4=@2E+J"I1/,`"3T18R_LNU%BO5.PV5/+I
M'DI2-Y46U``=).P1K^OU;G/C]$//GXNY[^2ZOW]J'#WZW47O@BHOT)R[ZO5?
MO:OO0]]P`I]IQ_PJXQTF[P$I5K=5\/T^&L5=FVBK"6AI5E'$3=Q\@S6`JK9T
MW4#I,0P`(#JBV>UU)<LSR:OH'TNT;M8XI"TF84DF8(/,8M=B5-44>,V2EJF5
M-U#=.A*DJ$B"!M!$2_UJ4;%%//>)[?Q>9>!PM^/81)SR#PXW?S5(,V0$9*[5
M@4SN+%C0YRG(#A:0,4KV*!0%!2D4/*2\HCQR89;X09]]"L@["X.D6"LDAWF;
M7ZQZ4CL3M2N4IH,S,H2(CCB1B)R2TBHHF@;O3`J1+>M/KF^Z>^3_`!A(2U$P
MH1^K<Y\>D.(>?-O?#'<\(#_^-JW?VG\/?K=0^^"*[_0G+@?)VK][5]Z'O>`%
M/M./^%?&6DW>`E:K;JOA^G0UAKDXT582\-*LHQ))TPD62Q2K-G3=0HE,0P`(
M#JBV>5M)<LTR:NH'TNT;M8XI"TF:5)*I@@\H(,6KQ"EJ*+&+)2U;2FZE%.@*
M2H2((&XCD,3`UJ4;)!I",69IQ!3<[XUL^+KVP*^K]E9^0<Y2E!Y&/D3`M'3,
M8L8!%K)Q;PA543AX;EZ3`8AC%'-XYD-SQ6]4%^M#^BMIUS',I)$E(4.5*TDI
M4.8[-LC&MY;BMHS7'KEC5\I^TM]2B1_"0H;4.(/(M"@%)(Y1(["1"=/)[C%D
M?BKDAU3+FT75C5EG#REW-J@LE#VR'16#R7S!P/41"2:%.F#QIUBJT5,`#U$,
MFH?TGP'/K)Q#L:+C;7`*E("7V"1K:61M"AO*%&>A<M*P.0A0'DUQ(X;9#PRO
M[EHO#2E4RBI5/4)![-]L'8I)W!:01VC<RI!.V8*5&QOB;W.(8]33P/S'B$K_
M`$!ZT1A&UZE(U&PKI128)E;QE]@UVK@]D:-SHD$D@3K>IB4#*D7/]5)"/$7@
M/5(N!ROAJ]X+<D**S3H46^OM)73K!'9DS/M6Q'(DI'5BPG"WSCJ/Y*3A7%AC
MPVS*0&Q4K2'#HV`-U+93[:D2!#HFL2FH+/6&;+WVJN/F?(\,B\2LQQD#!R9S
M*IPX.@OU)\XP`8[1C)MY(EAKKA(QMU4'1WYTQ#H\M+;;6L6;S@<SQ!XV7B%C
M;C]2V9%:AX.^!SJ24=F[/D4`B<YZE1MM\\V;`LZ9&0\+,N:8HG-O9I4*JG)_
M!2L+[5DC9-*NT(EITHY(KAVH.;5$EE3T6RTXHB)0+,5;(DQ7%EB%$?+%0%XR
M*=E,`F$0*`GV$?3K?W/.&X67:G:3>;74J(VZ':=MT`\LIK(/-.0G$:-^:]QD
MLM4\Y9;I1IGU>T9JG&E*2.?VM*AMVRF9<\93@>TORPR0*!,U9YB8R+!5(YV[
MBPV[)D@F4HE$QTV4BK$1P+%#?I_A?@8`]S6`JO.%X>V0J=Q3#%+J"F4PVS2C
M?N*D)<5+E[WT(V2A\USBA?PEK,LZ;;I0N8!=?K%#9O"5E"=0)EWXV<NW98OB
M7B)P^X(P9,BVJ4AALD:GTJY5RA)QQ7[=PH!]T:M&J`A&P[E85#)I%8H*2*J8
M@F997W85R3B)Q&XL5?R/2L/*HW%3%)2H44GI<(!4X`!,EPZ$R*@E,6!Q3A;P
MIX)4/R]<:I@7!M,C6UCB0H$\C*20ALJ)D`TDN*GI*E;(AGG+GME+EQ;R\:.$
ML1-,V5@478V3*:B;F.DEX`OE(2+Y@<I/-I-7;@H8%Y%<P/7'41-$J!S`5:3,
M7X36+AU;?ISQ4J&BIF2FJ026.TWI"MOMSI]:TD:$R)65`'3$.:<;<EXJ74<.
M>#5&\&WR4O5IFA79[E*3LG3LB?6>)UK!2E`0525:MQ2XTU+BUB:)QY7>A_+J
MF^%[K:#DZ7=KM+I%(KZ35`VYT62!4RH,T-Q\ELF4!$R@J*'@3/<UN.>9%57R
MN&AGO&6IS2RT.]0-PGM*EJD-2B=PD!9KAEP\M?#7%J3'[>0Y4GKU#Q$E/O$`
M*69DD)``2A,SI0D3)45*,EM:7$A0:0C_T'^-(0:0C@0`0$!]`AL/SATA'7%D
MT$W4+9#J]_RB;^G?_J^_K[J5+3J.GFGLCC[)J>KLTZN>0CL``````;``;`'S
M-?(Y(YTA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"/P4:MU1ZE$4SF]'
M48A1-MX^'4(;AZ=?0I0W*(C\%MM1FI`)Z0#ZL?L4I2@!2@!2@&P``;``>\`!
MZ`U\C][M@&R.=(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$
M&D(-(0:0@TA!I"#2$&D(-(0:0@TA&*<Q83QGGJF/Z'E*KLK/`/=E42N.I%_$
M2!"'(WEH*31$CV'E6Y5#`59`Y3"0QDS]29SD-G<=R6]XG<V;O8*]=/6HV;.]
M6GE0XD]5:#+O5`B<B)$`QK.68?CN;VA^R9+;45-"O:)[%MJE(+:6.LVL3[Y)
M!()29I)!7@Y(]H/+N/W+Z=P0_'+52ZU%DJ\Y,UC;_%-P\OI0,D86T39C$ZA^
MJMA;+'VV!M[HW'PCSD;!=4LT68,>`7#3M=2"JG4?Y2VY\RM2?XT4-X@^:EE%
MD<?KL)J?E.UZIAE1":E">;<E#LN=.E1Y$16NFOGCCG9W**#C*>%+:7H2=D06
MM%"EURI"<4R+>4>,6>MMCF$N_6D8IA$-P'4X*;PW.:%"W&K?=*&6R8:?`GLV
M3U:3S$2,^F*\(=SCA]<WFFGKG9[F#UI%ZG49#<=J=29;QM$M\2;KW<\YLUYN
MBU)F(9=!!,B2(3],HDJX*4A0*`J/U:V61=*F`-S'664.8?$1$=:/5<!.%E4X
M7/HX6R>1MY](](.2^Y$CT7G(<8J%L-#*NT2-GMK%.L_E%K4>?:3'V#]Q7GWD
MYT6M5O(T^\D)(HMDHK'^/*J$VY,MN4I61X:JN)Q%P(B/29NH0X#Z!W`-=57!
M3@_8D&OK[.VEA,R5/U+N@2VF86Z$QV3YP'''(W!;K??WE5"]@334K(<,]FPH
M9*QOY)1FK%G;?Y@<G9YE;.15JM=,A?#S9C*$Q*VN_N&0J)G5:Q%?D9%=W&@J
M!=@%ZJU*F(`8$C@`%'4[]QKX;8'3.6[!;535-7*0%,VEFG!&XK<2D:]N_0%$
M_A"<XW/&_-^XL<2*QJZ<0+M54=$2"55;BWJE0Y0AI2B4=&M2`#ZTR`B_KCKQ
M@Q'Q@J!:KC&OE:KNBHGL-JD3)O+5:G:)1`CJ<E021\Q-(QS"BU1(BS;=9O*2
M)U'$U1\QSC(LZN)N-_K2O23V;29I::!]:VB9ER3425JD-2C(1>'`N'&*<.+7
M\F8U;PA:@.U>5)3[Q`D"XN0F!R(2$H222E()),AM:C&]P:0@TA'_T7^-(0:0
M@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$
M&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@
MTA!I"#2$&D(-(0:0C$V9/M$FO^%OTS?_`(P?:%_?4O\`/?S?_E?X3;61M/\`
MJ--^M_\`K>Z_B]/-TQ@\A_TFI_4=_P#^W^K_`(__`!SQ6$Z_SJ;^Q\_OP_\`
M>/\`./TP_3_X3WM3\Q^K(_>-WOK>]W>MZ.:*Q.?K!_=/O/=Y=_\`QOG%B''C
M[4G/_`;_`#D/Q??M/_O*?_>O_P!A_P#2Z-0EDW^IO?ZEO/Z[[O\`C=//TQ8?
A"?\`1F/]&W#_`$W]6_$_@B0VM=C<H-(0:0@TA!I"/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g887761g30t48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g30t48.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X90%:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!44&<](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM96YS:6]N<R,B"B`@("!X;6QN
M<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+T9O
M;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+V<O(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@("`@>&UL;G,Z
M<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!P9&8Z4')O
M9'5C97(](D%D;V)E(%!$1B!L:6)R87)Y(#$P+C`Q(@H@("!X;7`Z0W)E871O
M<E1O;VP](D%D;V)E($EL;'5S=')A=&]R($-3-B`H5VEN9&]W<RDB"B`@('AM
M<#I-;V1I9GE$871E/2(R,#$U+3`S+3,P5#$P.C0T.C,W*S`U.C,P(@H@("!X
M;7`Z0W)E871E1&%T93TB,C`Q-2TP,RTS,%0Q,#HT-#HS-RLP-3HS,"(*("`@
M>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP,RTS,%0Q,#HT-#HS-RLP-3HS,"(*
M("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!4
M4&<Z3E!A9V5S/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3TB1F%L<V4B"B`@('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E
M(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.D)$.30R1C<T.3=$-D4T
M,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N
M:6ED.D)$.30R1C<T.3=$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z.45!,#8X03A#1C@W13,Q
M,3A&-S1%131$03,W-#@Q-T$B"B`@('AM<$U-.E)E;F1I=&EO;D-L87-S/2)D
M969A=6QT(CX*("`@/'AM<#I4:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@
M("`@/')D9CIL:0H@("`@("!X;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM
M<$=);6<Z:&5I9VAT/2(R,S8B"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'
M(@H@("`@("!X;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!
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M,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
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M-T5056AC*VA(8FED27EK3%534U-+46E/;UAF-'5823A65F4Q.'`O;2].3C57
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M1EA9<3=&6%EQ)B-X03MO,W8Q>C9N4#E3.5`V-39B+U9V5W(V9G$X5'<U.&%T
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M,VM$33-':3A13UA98FI#<60K5CE6,#-65'%T.7`Q>DAD,FMT-'9P>GA-1U4P
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M2$DY3%,V,E9A,5`Y,6A63DQ0>DAP3C-C<&)1=DPV<VQE06MT-31W84%S9FEK
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M359D:7)S5EE09%=/<S9H-7HX=W)B5S@R;'I$5')E,#`S6$1':E)Y170V<VA6
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M9EI)<4-#<DEV)B-X03M*1VXV;G`Y<G%.<'%M;TYQ;#E(9&HQ<C$P5TUV5S%G
M22M&96Q"=#%W2WE01EA9<7@S>DXO>#!R1"]J1&,O=T1%;V-+<&1I:$UF3%`O
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M<4UL:E!P>E0S65`Q4S952DMT3%="9FE8=%=M,6-#<VIX5C)+<V0X>F8X9$MW
M+S1W,U`X07A+2$-Q6%EO5$AY>B]W061++SA!)B-X03LK34YT+W=!4VUX4WE,
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M<$A3;G`T;V5L-'%L=6HK6$Y&,%HW,E148E9B95156C-U-S5W)B-X03MZ33!S
M.&I&;61Y-5DQ<3,P1%EB05EQ:#='+W0T;C%M-U=S.%)V26=N;R]'5TPR,7-G
M-#`V-VY&54AF-FQR<EAC3%=I,V-D=3AH17E')B-X03LP4FEK9G!S86=L<6XY
M-$8K+T-Q86%F<6)S66)E-&EU0DTY44HU65)'<D5!=%19:T196493+W=!>F8X
M9$MW+S1W,U`X07A+2$-Q6%EO)B-X03M42'EZ+W=!9$LO.$$K34YT+W=!4VUX
M4VPO;3,X,F9);FQQ*VLP;E9D8FDP-U964EI"2$YB,T5Y:%@S1%5I54)Q:G=F
M07)'-T0O;DE,)B-X03LX=CA!-C%,.60X,#)2=%DU3TU9:7-,,4AK47AQ95%9
M=$E&<$EX1S8Y=F9&6&\K9S8Y<$]V-E1B-G9P1G=,<E1R;TUB96-+-D)G<D9#
M)B-X03ME3&A7*S!P-FI&569I<5%J>5(U8U,V=C<R3WI5,VUO<S!L>$DW>45-
M-TM",#5B2V5045EQ>&%Z.'(K9FMM;"MS<'`P<U5I9U%F=DI1)B-X03M9;DAP
M:W,O1E)Y56M30V<S,UAF0VA%5TAL:GIF*VM9+S!H8C)$-F-*+W="-'%Y4RMP
M-DEK;$MK9$)Z0V5M5#<Y2V(T<7EE.#AS-E4Q)B-X03MT2TEB3DI*=W!-2U-V
M245-9TAW.&E#4T)8<G1G4W=M5'ET*UEO*W)X4C9B-69P44IC,T)E.$I*<D1Y
M:U9A<4)S6G%,=C!8>$EW,G)))B-X03MF3%!L4S=J9UDV+V%74#%K0E)%.6M:
M9V%%9D=(-4XQ<4%F:&]0=7AT574X*R]L>6UT3%I,<#)M-EI/,%!Q0C,Q3U`Q
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M36%F17`W+V1G5FTR2W5X5FEK;FM04TY.,$=3>3AV,E5C57EK)B-X03M.0TI8
M:UE%.&=787)&=FHT:C13,5)7;&1S2W!02#59.#AQ<GAV1G`P:F5O<GAZ0U-9
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M8C)6-T1!<3-%5FY68F1:4U`S=G!P<V]5=E4Y34-P.6ER<U9D)B-X03MI<G-6
M9&ER<U9D:7%!,7(Y3R]662]W0D1#,RMS*W1'6G9R4F-*-D%A<V]89T=03FQ(
M1F9N6$972TQ$*V)J86LP<'0Y0G1O;E)23&-2)B-X03M#9'`S-'%T27EZ8E52
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M0W).3E`K=6EW='9R-5$S,W!*.6%-5F5(<3A2>C16+UHU5G!G5EAX5C)+=7A6
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M3$9$5S=M0C`O,5A$6&M"2W5%9%DO9W1F5C1S)B-X03MG5W!Q0W11<D963F1$
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M1TMQ;4MU>%8R2W5X5FI8;E!Z;%`U86EH:VHP5RLQ651":E=Y:DUG47%Y<4$O
M14UW<GHV,"]J4E9&*U9V33,V)B-X03ME=%IP;3`K-C`R5T-2;S-T-WA!:VQ!
M>$-T>')89FHS2#-J9D956&]U<U(V<D)02VQT4&%',W5*8EHT<FQ!:CAO5S1L
M9T9:9U5B<7!R)B-X03MU3592*TMR5$MG;%=);C0R5FU597EK02\X4T=+<G-6
M9&ER<U9D:7)S5EE:<'9N-$IP970V<G)J<&)284M7*W9A9DA!>&YT='E55C55
M)B-X03MM;FEM6FMP.6EL1#%X5C-L8GHW-6(X,S8Q8C-':5103D9"85A(4#%)
M,FI.2D=T6%4P661X:7))2C<Y3$58<WI24U1%,T-):TU+1U(R)B-X03M,4E)J
M6E9Q84%F16992$96,FTV53A%.&PW95-R8S9H3'E4,7=P44Q#5S5R0W$X;2M&
M0V1J,3AC5E))=E9/;VUX155N25%I8WHX4C91)B-X03M"67%%-58K,7-44VY4
M1E52:7)S5F1I<G-69&ER<U999%IE8CE5:3AX-C-P*W-M,FAG,'%"-S<P-V%+
M5U$O5DM64C)N9#%R2E%(:VEW)B-X03LP.$<W67%H.4<O36)Y=C5S,6)4;TY'
M;&QK:W1R;C%*96-,;T%(=$QK1#1I2V9S+S4W,$MS:#%Q1U<T4SET-'!J8G9C
M4E<P4')+2VQ2)B-X03M*339-4CE$64949U9P=C$W-'$W1EA9<6=71G1C87-&
M4$-34WEJ<7=.1TMT37=+;B]!0U1322]F:7%/>%8R2W5X5E%V>F9#>6Y.9W-B
M)B-X03LS=VIB-G-K-TUS4FMP.%!.;$1-1G(Q;TU6659P,S5N,DYN-4II.'IE
M6DIK4T]7-$9Q9G%S1&]O;7!1;W%V3$UZ1&UR8U=*5V]P5E%C)B-X03M65&9Y
M9C5J,'9Z1&-A;G%/;4\X;'%Z>'AQ-V]Y5DU96D14:T)55E@O041/2W!N;T9(
M<VUU468X065Q5C5I0C)9+T-W+S1*5&EQ6EEQ)B-X03MG:&-7.&UR*VER+W9O
M25<U4C!04U)K3F$Y3G5)*R]&56)I<G-64WI1<FI7-3!V6#%33S-24')C>39C
M8EEU959O<E5I85AN+W5X<45N)B-X03MJ=#19<6UE2W5X5C4Q-54Q1S(P,U@O
M4#$U<3!S3G1P.71D<$ID5'EC;%)5.4MO<GE21EEC0TMK5C,R=W%N*VME679,
M;71A.6)384IE)B-X03MW6&MC5G!D97%B8V=G1FYT4W1A94LO-3=91EAE6#$Q
M2SEV;79.5&<K<%A.;S$Q2$AB4E1#94XT-4QM4E9K2C1*4FES22]W03ES2W-K
M)B-X03MW2VAO9FEV<FU19$973T4K4$I16D0Y1DI2:7%*>%8R2W5X5C)+=7A6
M,DMS2&=A>71F>E`Q<3=N=FY5>#961DQC=WEW1EE)-UI74'A,)B-X03MC1U%G
M:T976FAW+W1+;S(R.#%E53E9,513-&1&,4,R=7!9-VMT26M$1&M&3G!C,$Y.
M='8X*RM+;W!R92MV9DU59W51:V1T85A%5#)4)B-X03M1=3-Q3VM6=51*-G=+
M,$@W>34T9TLR-#8T1EI$:7)S5F1I<41S26]Z2F,S649(=5I#1'54.$U8-W1A
M9'0K4$PV8U92;4MP9$IR.6A()B-X03LU9V@P1FA+8BME,F4X4VM4;4E24G5%
M4$M51&=P-4XP2B]H:7%9-'$P-%EQ47`T<U%E3$56;V9';4MV4&9)=7)E5SE%
M.&IT8V%J<5%/)B-X03MM+UAR:4E81C=!8EIJ3'I936Y";FXU5EI72VUU-'=Q
M>4A1=&(P93EU9%EV.4]U23=Q,&E+1C-G25EC;S%B;5!N54@U.6-64C-L<E0T
M)B-X03MR2%)R94]-53E11UHY,F(T<%1Z4#)V;F=63DU643%R.&,Q>E`Q0F8P
M-#(O>4EH46EN=$E8+W="<6U+;VY&54)R,%9X3F]L.41B6$PR)B-X03MD,4Y!
M.&1V9%)"5$I(2S9L55I!=TDU8VE+8EEQ<C9B84Y:861A,F)43F-.8E%X=W1C
M4U5$>4=.479.=4E!<3%+;6=X5D59<3=&6&YV)B-X03MK-C!S3#-7+U!C3B]B
M>%-733$X<3-%37%L;VU!:E!)=#9I<5!C-V)E2C)/1E4V,')3=DLR;#8S8B]O
M3S)S-T\S*W`S6'(O5D9J4F9G)B-X03MA,30X=4<R>55P6'1G5DXY159H8D9N
M0D15:FI"23-O:U-H;"MI5&XY3F-65$A&54Y:9D8Y66PV97)-*S-H-F1)=G@Y
M3W5+;VY&6%EQ)B-X03LW1EA9<6QM:C9R9E@Y>'%59'AP,&QL1%HS3%<Y<E!)
M-D]T>6EQ2WEO14I+:FQ684XT9DU"5DTX5EE(6C)::R]-+W=!=S-&,T1B1%,R
M)B-X03LP>4M#9&YM4FUC8D9V5F=A:DMN06MC<494-#E10W%P;VLS-65V<3%K
M=FQ15T%N5S9!=E!Q4TEJ8V9Q=#%W-3A12S<Q+WIP:7)*=%`O)B-X03M!2&PO
M4$DS,C$U-VIV>6QA4&8U3&)P*T]"57EX5C)+;TA72C55=&QG:40K<F50.$%6
M,&5/=DM0;4176#119G-D9C0T<6EB4S)7,71K)B-X03MG5FUD67A25V,Q86QD
M:%AB<#!'2W%U2W!2;T4R<S-&>'%K*W`R,%9U;W4S9S`U;UI$25I,4T4X5651
M1E8T3UA,,4<K2W!V:7$R5GEK)B-X03M4=4)5<7!)0G)V458W0FHK1TMV32]+
M5G`U9'10>3%#*V19=%!85$5V6EI&4V532S5G1$Y+4D12:'E(<69&44-N24AT
M6$-Q6G!.<&8K)B-X03M(=DUB*U4U-U,P='I(>'1*-%DQ83-766AL9C1&2TQV
M251V5VYF<&ER3G)317=7<TU"8FU9:U9#=T9+.%%"5VQ45#<X0W(U=5AP4'A9
M)B-X03M),T4X6&)C03`V;C59<6AT25=69$]H33,Y-4IY;&%U-7))>&5H;W%B
M:FPO2TU64F5+<&1Q5V\R160Y<"MM5%A%8V0S9E-L<F5";4%K)B-X03MC5S9M
M6FEI;F,X94$U93)+<&II<G-69&ER0W1'1F@U9W503TAL>2MS-V-A66QW8F5D
M8EI40S`V,T5:850Q;FIC:W8R2DA(0W%!=E!*)B-X03MU;&5627)L4$MS8T]N
M,U8S65A3*W9E3DY017`Y4S%J1%!6*V9%0FED:C$S,S99<7IB4G)+4WHP.4DU
M6DAK;6-T3DU:0T134U5M4U%,)B-X03M4;W9.:E%91E)S:G!':E-/94M)0WI-
M97='-4]+;U12;V)Q3%195G4R-5A,8W!*5'0Y<5)I-4=W56)C=D1&55II<G-6
M465R87AP96M7)B-X03MB,W5P,U5D<&))0U1*26%62W%82W%/<DYX56M+;TI/
M2W-9;#@Q835R<65H;T=J,TQA6&5I,D-A*S!S9'-O=&)Y3FI*8S(V4V9V0SEV
M)B-X03MT.$Q+2VXR-G%S;C!B5'8P6G!.<'`U=4IB<S)S4U)'-G5#1VUL2VEH
M95)G0E9M-FLT<6I-5EEF6F%V1DHK665U84A*6E<V,G$R14XQ)B-X03MC6%II
M55!)6&]H4U9Y-35Q13A5.&-+=%,R2&MJ4F)Q>C%,5$Q7>'120DY*2F545V-A
M8WA%;&YD3G5)9U=)*T9Q061A67%M,VQ3,W18)B-X03MS0G$P4W-*3E9J:6UD
M;4QJ:VEX:%DR-%`Y:W-V>$A91W`S=TMN94MT3S9):D\U0V]O2EIJ,$%'-4]+
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M=6TY23-R5'`Y1TMS>E91<6A2,$%O34-O4%8U;S0Y4&U6>E0Q)B-X03ML35-M
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M8W@K<$$O3E`U<45D44-/=FE#0TU#;V$U3G9D6'-6;39H>$543DM'5W$Q54%+
M=31P6#DT1SEQ92M+;S=&5TYE)B-X03M:+TU7:W-$-69H=35Z<5=O>6I4,F)4
M4UAU3$IR:4US<S!R2GDY1&EO-4MZ52]747%N,FXR85=6:F(R85-35$QB>')(
M-C!Z8S58-&EN)B-X03M/4G1U5'0Q63EZ:7%V:7)S5F1I<G-664QC85@U-D@U
M:&5O='I++VPV-6IF,#=U23)W3G`V:UDU4F5N3$A)>F9V3&%-,4<S>"]00W)(
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M-VIP:6A0=DQ%=FXR.3AS6$8W)B-X03MQ.#`R;F%V0S`P9'194G194WAY37%$
M,#$U:45!9G9A>#!Q1'1V5$9+-C)L."]3955R,B]%,#@R=3(S<G@R;&I%.6=9
M<F=X='AJ:T0K)B-X03MI479+:%!%;D96.&<O35`O04%99%)2<FXO17));T=J
M.')$:4A-,T)J-G9O8V8W<S@K=F%M2W18.'8U:3(K9V%B<49L2%!E871+641F
M)B-X03LV4SAL;$=S66]7;$A0,%)52#=*;S%2,G)I<DLY0W5T575T2'1,:E9B
M45=/;WEX:')M,$1">$<O:'E"22](07%/>%9H+VTS>3-Q=VQU)B-X03LY93!3
M-'4W:E9I249T.4]%<T-11&AZ:&1L.65+5E%21F-/,40Q4'IW<7=V>FHK5T=O
M,T=I>#9X<%5E<%)E6CE384-F5DE,2S5T-V9J)B-X03M*2&)..$I):E9/2T]!
M=G<Y5#DT5E9V368U8V5B3%IR5F1',7)8<G50535M6%9):F97-G!B2DQ*17AD
M43!11$9+159!<E0V87%O;2LX)B-X03MH*V-D4#$O43=44W1B,3(U,&)M5S%'
M.$XU87)W06TY4E$V1T5-.4552C!)-"]$,#)X5EEV:VIZ*VYM<S9:+VE$6&XX
M=E-C2D@Q:C8U)B-X03MA.#%-66549W-::'%/5%!W24$W06UO1D%Q<S!J.'90
M348W-7AU:SAW,T=R6$=K861':6%89EA..4)01F-C25)#,W%7=G!C1#9Q=35F
M)B-X03MM1%AV56LT<7EN>3=:*V-28V%R85@P:SEL<#EK-&HP47<O54%S,$-L
M,%5"5F=0<#!73D11+W=!,W1I<4<P0U0X>&)N>35Q1C-Q>5A6)B-X03ML<DU#
M33EJ665P64]*;CE!4TMH9%E#1DAQ;FAV.5!I5E=O5R]-9'9*,S%Y45A395EV
M,VET<"]Q5T)O1DQ"2$1I,S1%;6DW9E0W67%Y)B-X03MF>7AF83=F85!&8V$U
M<#0P>E5785%35V%Y0U5+<751:#5+4TXQ<&=63F-696%8,VM45E)F=F]$0S<Q
M4'ER<7IC=%5N=5IR5GE$23@P)B-X03MP2$=317EF=3)34&E19"M8,T95:T@U
M45AC9FTQ9%!S3')73$AY-T=R>698;W)Y24HV:G5K>DPV3'AT6&M367A4;T\R
M,WA+;VYY+SA!)B-X03ML,S5T:3AY-GA:5&%X<FQL;VY*2DQ,53%U-U9N;$UC
M-&Q#.&923'%'5FEP-U57:$)&04968GDS-44X-#,Q-6-J>D1Q*W8R;'1P:DEU
M)B-X03ML2V12=#)&,'%03W9/67=W.'9J4FQ,0FEE=$-4>$9&5F)Y0C58.'IA
M1C51,4PP9%!K,'96;UEY8E,P4U-Y:TXR-E%"-&ML=41!.&A!)B-X03MK67AQ
M>FUO2&)&53=S12]-1S0X<7HS1GA*9%=M=G%Z>#(Y;WAS2%9G2#1O-TUS2556
M1S4K*VYB1E9,57!F>D9J.&TR*V]7560Q3C5I)B-X03MK.4PQ.4PU,D-I34TQ
M2D1Z34A%,%AE;&8Q67%U.'E0*UED<&]E;3-/:DID6#)Q6$12+W!#>3E3=U%1
M07A&,V\W44)70611;3-J=#1H)B-X03M65S@P6$AN-U-R:3!K,$-#8EAO:50Y
M66AM:W1)5F]58V(P:6E98U1X655B8S=9<7I007)S5F1I<5AA-6]';6$S8GA7
M,F]X=$I$1$HV)B-X03MY2W)V1V580F]Z56]63D-K:D%J,WA6:CA0-5-E4F]T
M4%=W87EE5S-J1$Q"-FMS:&%*6&IH:4MO-$E99D1A<'546')V.%)X5C!N-5-E
M)B-X03M2;G1)3%@V:S9X,GA:<EIH3DQY:F1W;S5!;&I5:F=+5G)J86]2=GE0
M+TQD<F-14'`X<DE!=T).,6-G+TA(-F(Y2D(Y<&5U2W!T;R\U)B-X03MB950Y
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M;VQ$2E)G2W%/=4MO-U)T5R]092LQ0U9T63!3,C!M>E148G-W<F)Y5S`S3R]:
M)B-X03M9+W$T64Y--V9#>793:DMP<CA844A&5E!2=%0O04]C9TDP3G)F-E99
M>4%32W%A:$PV1'E'3C=I1E1).&-.>F)O>&IH85IU0VAF<V]V)B-X03M*:5-3
M<6I'=E!Z,6IU-S)68DA42C1K84YB84$P5THT,$XR1V%*=EA%:7E38TQ9;C%$
M>$%F6596<7%P,2M89#$K66PQ0G%C,VYA>FES)B-X03M,:')L9C!F8E%.0SAA
M=T-&03-%>'1),WA3:#(K3FE25VQA57A6;#)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+;V)5<G@W)B-X03M/>6QU56=K=5=I1E)"0TMU,C1'=SEU
M=4MS2S!R.#`W,U5.571D4%AY:')+4&-)-W1+,%-):UE33DI">F%:;U953GI+
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M04LW:U4S2W`P9D]L-G0P,79*)B-X03LU83%62UA59&]*2U=R<51,1TI!.5DU
M,V]I.'%->#)(:F=63U`P;F4O.5=M-B]W0T-T9CA!<79I<G8P;F4O=T16<'5V
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M54=R,E0V:G`K;G93-TYK-$)K)B-X03MH:$Y(<#E9-#E6+VQP-V1S5EI46G!C
M<&%1<&133$YD3$=O;FU294-V24%!>DML5S1G;F-#<'!I<6]754U&2D%:=G-I
M=35P-%EQ,VEQ)B-X03M287(U=S`S5&9-96PK6#59<'!D43%F:V)54F5M449J
M1$TW3T=D6#1Q<45K:%-0<$E'2W%T>&57:RMU-F-K13AC<GAE=4I&4C%9<CA0
M)B-X03M(-&=$='5P2#!9<7@S>F1A5S)I6#%P<E4K<S9L1D9D-G9B4WDR>5!Z
M9T%71FM-46E3370V5$)+<TYZ6'9H5FU/;39H8F%J<#ET9C)P)B-X03M*=#=U
M2DIO:7=+='AC0FA52&]D.$-O;D95:3!Z>7-B1S!7,T]Q,S@U0EIJ2DI-4WA,
M1W`V9VXX8U95=DU/:U11-DAF5'<V;&5P3&)W)B-X03MV3V@Y6FA5>$0Q07`T
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M239N9D]V-6MA5'`O<7@K;E!A)B-X03M3>E!$.6%K:6M":')X271X8TMK=U!,
M+V9$57!7=F=Q<F%"-5<P4'DO-6=M:C!M,BMR<&-7<79+=DIM<7E&66=F:4HO
M6FI'1E9N;3-4)B-X03LW0V97=$UM;71O<%IG1553=6ES,4)Q1FQ18VE+,$A.
M=G9/2W-R=TMK175T-E):95IB-%AL,4AB1#9P8G%(;%!"0S!4>79);V1Q2U=6
M)B-X03M:-#)+9S%O=WA63TQ#+W1B*S%3-G183'=/5T-S5EI$5D=+34-R:%=&
M1U5J8UEQ<C1Q:&15,'EX,5A48FY49%%I13EJ95)T1&-W:VM")B-X03LT,T9'
M5W%K159(9V-6461V-54P0S-T-')E0S!#47=O<V-30C5+2W%I:6ID=7='2W)F
M.$EE6&8P<%IA;V)-1R\P+W="5#9N35AK4'`K)B-X03MS=D-3:6QU2G%V:4U6
M5&I&5T0K84I,3TPX>5!+<4Y!:W1Z97)C>&5S<E-P3D5K0T=95C144F]56BMZ
M>'-.<U940U!Y=&]7;2MB3&)5)B-X03LW2S%%5CEF9E=0<DTQ5UES4UAL4#)I
M869(33-40W%:95EL;6%#,%=">$A-,3%'27!'6&UQ<U$S1FET5C5!2'156491
M2&QE>#$S5&(Y)B-X03LY3'9T55A53$]Z,"MY4T9"8DQ!43E:63)F:W)-9FE%
M47%$-U5P=E96:W5+=7A60F$Q<#@R;S968S)-3G@Y5F4U5#!Z3G=%;$9B6GAX
M)B-X03M*2#)L<7981E5H.'-A.&QV1G%&=')M=G=89#5B,W,P4U-43$9:<W-A
M0E9#0D%6-4%.6#1U+W="1T95+W-.63!Z54I*:W-R:&)G=V-F)B-X03M56DML
M9FER47$Q3TQ$-%-+<50P=TMJ359D:7)!5&)A6&4O;6IR3VIZ5W%/=#-P06UV
M2F\U2FM::$QX=&I(2T9N35I0<&I9*VMR054S)B-X03LW:W%N=FQB43E-,%<W
M,4MW,#)!45=Q=$<T445N95%--U9*<51U,C-G3G-#;TQ6679-.$AM;UA6<G%-
M361H4$QP.$PR<E%";2MR:'!V)B-X03M66&U4.7!M2F]E,D976%E&535R83)M
M84YP;VML849G.%)D47A2>#!:83E$-VI&5TPK5T<Q-G<Q0DY+=3=#0S)T2C%U
M8G18:31G.&I+)B-X03MR3TM+-T%"5VU#<G-E4S=N:69H=W%Y>D%R<U93<GI2
M<&5P87)O9'I986)E<G`Q-4YW.4\X84E4:$],<7@O9'-60G%&<&ER96I73W97
M)B-X03LQ,69V<65Q3'%&=E!):E=%2W=*05E)=V=$2U=5;C%/5&(Q4%1&5U`V
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M3S%/<DAU8U99:WDV.7!F;D)4-G5N>#9D<FPS.6EP1C`S<%<O:'=&449I+VU0
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M1W`V8WI.8E-.1W$K;W!2<7AH:TY63S0S6$%Q=G)0:S=Y='%6-&PW9F%88GI8
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M<'`X*V]-8BM%4W!B*VYY:FHT=51+,W%01W9%56]D*RM+<U<Q)B-X03LY5VTX
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M,C$R4UA6,3`R6%1B=3%D;T=U0F-3<D=94T9D531E<$9*2T]F>%9O93,P67%T
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M0U='2719+U=&-'!+-5531&UF:"M!16YQ9G`W)B-X03MQ<58Y8F5A:#5.5RMT
M;V)X+TU4=W=L=$Q&,FDX6DI'5EI12D="46-&6FTS<C`W-'%U=3=B>E-02C98
M,79&9'0U:&5+171P9W5K54Q*)B-X03M)>7)+0DEW6E!G57-W<EAP5&9&5U(V
M1F1A<&1A4&%81W$R9W-D4FQJ1%A.;T=$:4XO1&M#4BM/0E5D:7)!;W9,;FUB
M44Y4,#9Y,&$U)B-X03MV<C-3-W%2:'%6-4Y,84Y*14-88TXK.6A:>GAR='5A
M,7`T65969E!/;BMC-&)85&TP2S<Q1%5B:$PQ2DIO:V5Y9TAP<4=.2&(P1D)4
M)B-X03MS4G981E5Y.'DR;FUM,#!7-FXP5RMU-R]!1DUC9G$Q<7=S54(U37%T
M.%17-$%O=%1V+UIG5E9G=%!-6C!.3'E3.790,'$Q;W-R-F%0)B-X03MQ24%U
M4%0U1T531S-P.78T95).3593-WEZ<$AM,CEI='16,7I58C=4.5%J:FUT<$Q!
M1WED0W9Q,5=1.%E3;DIL4F8W3VU&5W9+0V5E)B-X03LW*S-U=CA25%A7;'I2
M4W%,9C`R<UI"26A!6G%5='IS<"M'<$%*2%E(1E5(-54P-WHS1'$R;V%69GI8
M='1O,79Z*V]A;S`Q<&-035$T)B-X03M#;6MK57-G-7%3+WA(8G!I<5DS14AN
M6E!.5G)A4EA.>DHU9FQJ4#%I+W):0C0U3T1T=6AG<7<U2W%I;CAX*V5+=&%Z
M3#4T,#-73DMJ)B-X03LP<4\T,7)4-4-F,&Q,33EN14EX-FMA0V]72TIZ.$1U
M+W=N<79H5496;"M"6%EQ-T95<#AX95AD13%Q,VA85FM,45=R*W%P16I204=L
M)B-X03M0:4ML9'$P4'I'2W-D9R],=CAT;SE/:3`Y;&IM:&=,96<X='E426=:
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M3U%I2')"0VAQ=C<S;%%S5S)P-VY#<6,K5TQJ>DA0<%-Y95EB84<P,5`Q2E9E
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M2#5S=$1D<7IA4W-P35)S,VDY86QE445N35!Y;W9%13`S3RMZ9$U+;W%X=69Z
M)B-X03M(1W978T]O5VUN3F]S:V)F6$QM,DUN<7!)26=245-/3FI)94EO<#)"
M2C0W6494+U10*T]B868X04='4"]!26E-5E)/2W5X5C)+=7A6)B-X03LR2W5X
M5E-U=E$Y0G98+W4Y<3!R5W12>#0X9FER>7!3;3EC5E%8*V=F.'9N+T%%*UEQ
M-R]14"M8>B]P.'A6,RMG9CAV;B]4-6ER=CA!)B-X03M14#A!;#@O-F9-5F0O
M;T@O04,K9CE0;4MU+S!$+VPX+S9F359D+V](+TPU+S`K67$W+U%0*UAZ+T%+
M9DU69"]O2"],-2]W0E!M2W4O)B-X03LP1"]L."\V9DU69"]O2"],-2\P*UEQ
M-R]!140O04IF4"MN>D989C9"+W=!=FXO5#5I<G8Y02\U9E`K;GI&6&8V0B]Y
M*V8Y4&U+=2\P)B-X03M$+VPX+W=#;GI&6&8V0B]Y*V8X050U:7)V.4$O-690
M*VYZ1EAF-D(O>2MF.5!M2W4O=T)!+W=#6'HO<#AX5C,K9V8X04PU+S`K67$W
M)B-X03LO45`K6'HO<#AX5C,K9V8X=FXO5#5I<G8Y02\U9E`X07`X>%9(=RML
M-DME:E0P=4DY4&HP-#`R<#E'2W(X5F1I<G-69B\Y:STB+SX*("`@(#PO<F1F
M.D%L=#X*("`@/"]X;7`Z5&AU;6)N86EL<SX*("`@/&1C.G1I=&QE/@H@("`@
M/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG
M,S!T-#@\+W)D9CIL:3X*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIT:71L93X*
M("`@/&1C.F-R96%T;W(^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI/G)R
M,3,P.#,U/"]R9&8Z;&D^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O
M<CX*("`@/'AM<%109SI-87A086=E4VEZ90H@("`@<W1$:6TZ=STB-C$R+C`P
M,#`P,"(*("`@('-T1&EM.F@](C<Y,BXP,#`P,#`B"B`@("!S=$1I;3IU;FET
M/2)0;VEN=',B+SX*("`@/'AM<%109SI&;VYT<SX*("`@(#QR9&8Z0F%G/@H@
M("`@(#QR9&8Z;&D*("`@("`@<W1&;G0Z9F]N=$YA;64](D%R:6%L350B"B`@
M("`@('-T1FYT.F9O;G1&86UI;'D](D%R:6%L(@H@("`@("!S=$9N=#IF;VYT
M1F%C93TB4F5G=6QA<B(*("`@("`@<W1&;G0Z9F]N=%1Y<&4](D]P96X@5'EP
M92(*("`@("`@<W1&;G0Z=F5R<VEO;E-T<FEN9STB5F5R<VEO;B`U+C$P(@H@
M("`@("!S=$9N=#IC;VUP;W-I=&4](D9A;'-E(@H@("`@("!S=$9N=#IF;VYT
M1FEL94YA;64](F%R:6%L+G1T9B(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1&
M;G0Z9F]N=$YA;64](E-Y;6)O;"(*("`@("`@<W1&;G0Z9F]N=$9A;6EL>3TB
M4WEM8F]L(@H@("`@("!S=$9N=#IF;VYT1F%C93TB365D:75M(@H@("`@("!S
M=$9N=#IF;VYT5'EP93TB5'EP92`Q(@H@("`@("!S=$9N=#IV97)S:6]N4W1R
M:6YG/2(P+C`P,2(*("`@("`@<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*("`@
M("`@<W1&;G0Z9F]N=$9I;&5.86UE/2)365]?7U]?+E!&0CL@4UE?7U]?7RY0
M1DTB+SX*("`@("`\<F1F.FQI"B`@("`@('-T1FYT.F9O;G1.86UE/2)4:6UE
M<RU";VQD(@H@("`@("!S=$9N=#IF;VYT1F%M:6QY/2)4:6UE<R(*("`@("`@
M<W1&;G0Z9F]N=$9A8V4](D)O;&0B"B`@("`@('-T1FYT.F9O;G14>7!E/2)4
M>7!E(#$B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I;F<](C`P,2XP,#`B"B`@
M("`@('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B`@("`@('-T1FYT.F9O;G1&
M:6QE3F%M93TB5$E"7U]?7RY01D([(%1)0E]?7U\N4$9-(B\^"B`@("`@/')D
M9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M93TB5F5R9&%N82(*("`@("`@<W1&
M;G0Z9F]N=$9A;6EL>3TB5F5R9&%N82(*("`@("`@<W1&;G0Z9F]N=$9A8V4]
M(E)E9W5L87(B"B`@("`@('-T1FYT.F9O;G14>7!E/2)/<&5N(%1Y<&4B"B`@
M("`@('-T1FYT.G9E<G-I;VY3=')I;F<](E9E<G-I;VX@-2XP-2(*("`@("`@
M<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*("`@("`@<W1&;G0Z9F]N=$9I;&5.
M86UE/2)V97)D86YA+G1T9B(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1&;G0Z
M9F]N=$YA;64](E9E<F1A;F$M0F]L9"(*("`@("`@<W1&;G0Z9F]N=$9A;6EL
M>3TB5F5R9&%N82(*("`@("`@<W1&;G0Z9F]N=$9A8V4](D)O;&0B"B`@("`@
M('-T1FYT.F9O;G14>7!E/2)/<&5N(%1Y<&4B"B`@("`@('-T1FYT.G9E<G-I
M;VY3=')I;F<](E9E<G-I;VX@-2XP,R(*("`@("`@<W1&;G0Z8V]M<&]S:71E
M/2)&86QS92(*("`@("`@<W1&;G0Z9F]N=$9I;&5.86UE/2)V97)D86YA8BYT
M=&8B+SX*("`@(#PO<F1F.D)A9SX*("`@/"]X;7!44&<Z1F]N=',^"B`@(#QX
M;7!44&<Z4&QA=&5.86UE<SX*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D^
M0FQA8VL\+W)D9CIL:3X*("`@(#PO<F1F.E-E<3X*("`@/"]X;7!44&<Z4&QA
M=&5.86UE<SX*("`@/'AM<%109SI3=V%T8VA'<F]U<',^"B`@("`\<F1F.E-E
M<3X*("`@("`\<F1F.FQI"B`@("`@('AM<$<Z9W)O=7!.86UE/2)$969A=6QT
M(%-W871C:"!'<F]U<"(*("`@("`@>&UP1SIG<F]U<%1Y<&4](C`B+SX*("`@
M(#PO<F1F.E-E<3X*("`@/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@("`\>&UP
M34TZ2&ES=&]R>3X*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D*("`@("`@
M<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB
M>&UP+FEI9#HY14$P-CA!.$-&.#=%,S$Q.$8W-$5%-$1!,S<T.#$W02(*("`@
M("`@<W1%=G0Z=VAE;CTB,C`Q-"TP,2TR.%0Q,#HS-SHS,RLP-3HS,"(*("`@
M("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@(#QR
M9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#I"1#DT,D8W-#DW1#9%-#$Q.3@S0SDX040Q
M0C,W.#%$1"(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q-2TP,RTS,%0Q,#HT-#HS
M-RLP-3HS,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL
M=7-T<F%T;W(@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB
M+R(O/@H@("`@/"]R9&8Z4V5Q/@H@("`\+WAM<$U-.DAI<W1O<GD^"B`@(#QX
M;7!-33I$97)I=F5D1G)O;0H@("`@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI
M9#I"0SDT,D8W-#DW1#9%-#$Q.3@S0SDX040Q0C,W.#%$1"(*("`@('-T4F5F
M.F1O8W5M96YT240](GAM<"YD:60Z0D,Y-#)&-S0Y-T0V130Q,3DX,T,Y.$%$
M,4(S-S@Q1$0B"B`@("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](GAM<"YD
M:60Z.45!,#8X03A#1C@W13,Q,3A&-S1%131$03,W-#@Q-T$B"B`@("!S=%)E
M9CIR96YD:71I;VY#;&%S<STB9&5F875L="(O/@H@("`\17AT96YS:7-&;VYT
M4V5N<V4Z<VQU9SX*("`@(#QR9&8Z0F%G/@H@("`@(#QR9&8Z;&D*("`@("`@
M17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E("T@5%0B"B`@
M("`@($5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3TB5F5R9&%N82(*("`@("`@
M17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/2(P(@H@("`@("!%
M>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/2)-:6-R;W-O9G0B"B`@("`@($5X
M=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX](C4N,#,B"B`@("`@($5X=&5N<VES
M1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3TB,"(*("`@("`@17AT96YS:7-&
M;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3TB,C,W,#<U-3DY,B(*
M("`@("`@17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T](C(S-S`W-34Y.3(B
M"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)697)D
M86YA(B\^"B`@("`@/')D9CIL:0H@("`@("!%>'1E;G-I<T9O;G1396YS93I&
M;VYT2VEN9#TB3W!E;E1Y<&4@+2!45"(*("`@("`@17AT96YS:7-&;VYT4V5N
M<V4Z1F%M:6QY/2)!<FEA;"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z3W5T
M;&EN949I;&53:7IE/2(P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;W5N
M9')Y/2)-;VYO='EP92!4>7!O9W)A<&AY(@H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I697)S:6]N/2(U+C$P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I+
M97)N:6YG0VAE8VMS=6T](C`B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D9O
M;G1396YS95\Q+C)?0VAE8VMS=6T](C(U.3`Y-#4X-3`B"B`@("`@($5X=&5N
M<VES1F]N=%-E;G-E.D-H96-K<W5M/2(R-3DP.30U.#4P(@H@("`@("!%>'1E
M;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93TB07)I86Q-5"(O/@H@("`@
M(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0](D]P
M96Y4>7!E("T@5%0B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3TB
M5F5R9&%N82(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53
M:7IE/2(P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/2)-:6-R
M;W-O9G0B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX](C4N,#,B
M"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3TB,"(*
M("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U
M;3TB,S(W,C(V.3(S(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U
M;3TB,S(W,C(V.3(S(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R
M:7!T3F%M93TB5F5R9&%N82U";VQD(B\^"B`@("`@/')D9CIL:0H@("`@("!%
M>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93TB5&EM97,M0F]L9"(O
M/@H@("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C
M<FEP=$YA;64](E-Y;6)O;"(O/@H@("`@/"]R9&8Z0F%G/@H@("`\+T5X=&5N
M<VES1F]N=%-E;G-E.G-L=6<^"B`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`\+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*/#]X<&%C:V5T(&5N9#TB=R(_/O_;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`<0!\`,!$0`"$0$#
M$0'_Q``?``$``@("`P$!````````````!P@&"00%`@,*`0O_Q`!;$``!!`("
M``(%!0H'#`D"!`<%`P0&!P$"``@)$1(3%!46%QDA>-88,3A66)67F+?7(C8Y
M55FVN`HC)"4U-T%V=Y;5V"8R,T)1=92UU!HT)U>TV5)48G%S@<'_Q``8`0$!
M`0$!`````````````````0(#!/_$`#H1``(!`04'`@0$!@(#`0$````!$2$"
M,4%181)Q@9&AL?#!T0,B,N$30E+Q8G*"DJ+2([)3@^+",__:``P#`0`"$0,1
M`#\`^_C@#@#@#@#@#@#@#@'SU>.SVZO.MF]!]6>J-DV;6-Y6HTMJZ)%,J<K>
M<VQ-([7E/0$TE#8\^B5=Q6925D`N&[3T'A"\IT!KC`38>7=F%D1Z:^%1T^&E
M5VHA0H;2F76KA42;O,$L/QR;!@U&=8KT#U=#IG%^X?38\0HEFS:2160/O$8B
M,YB5=G.O,D38F4F6T)<'I2Z]APS;AI*OM#I.FB1P@GNL,!?#JU/TVJZ6:O:Z
M=3OK0\7R_P"K^[=7==$0U%V/"'?:?JKT]O#,?A$RB1N!6E?45B6LH=QR<RJ\
M%'<GQ'Y>7,EPP,)0\ACVD+0'#3UH-9-LKNJ"L)V6ZJCM+5*>5T7WW)HK-:?C
M$=R9M6G?"$-DJFZ]VM7W6B_+JHQ"/PN63EXO":LGD?%)6%!NPL:LZ=4Y:WM5
M?NRSS"ZD(KEN!F[P!G`N5@V91LY%V+,V<4[5E/"K5T7K?-VIGDF\1GL=3![-
MF2"45U<<TA'@@S/MKG,.F=HZ4/*IT!['P>*ALFZR;V"[BKB8:QXY[#,)JT2;
M2Q,N@5#!B0>,K^XTP5E.BHMM+"51X^2;,^@7<[L9?5]=GZ"[(1.E1!RF:\ZM
M6Y#C]);3E,21BG9:%2J5)1R2-YT0(/'$@B2\;U9J&QNHL<73=[[ZA6&4-<KC
M-JRDDU-7:3G1J[F;7.#`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!\I'7#M%I(^
MZ?9"[81XEUH%^E'4"&70DE$.Q-UP2;N^SUR1>`3$[,R\$JR%Q2*3YQUVI4/A
M4PQ*A11L[.#L99NHB2)C$R:0P=6HLI;*VK47*J5(K52^:FI"]W>,)VMN[IKW
MV`J/0=9RFO:%ZB=A*3O6A49'3$M<0^Y.R$!BCMNZ"-;VNT]'U"P!SMJU</9?
M#I*Y`DG[61P$0B3;Z;C5FQ9VK.-;5EIUJD]%CA7>RR<R\2GNKUN>^-!8YV<4
M):@CJ3=T""4U2\M'R<?)`P:?2>AH]'U&?N:3CGV]=,HC8A9>3/'#%\1<V>NT
M>"RS2-Y^'%7GE2*PG^&JK:57S?IW,Y[\^+9W)Z-^47.1_J?,;JKJF4KZN^JX
M9';4-Q5E`I!<\FA4/4`W+/+1I;88L\B;0$Q52$U3:LH>SA$Z]^!@\57$;;#-
MFPK3QAN$Z*L+"'W2JJG973XQG8FNNQEQP^.Q+K,0K.F^U'3FA]*U-D)RGV5M
MD!VGAD%.OGE:(LI1K'7$DA!"5.U]MMXJ3'OA#/9-9BT<-%'CT%832=9=FT[J
M*)O>$P?2#P<QP!P!P!P!P!P!P!P!P!P!P!P!P!P#3%XJG:.Q.@MC=1.YKB5R
M]QU1"2NPZ5[45>(SL\$$DK$@A8K3%A:L=6Z^P\A%;"C.0CTMKC?#IM)QHO?7
M3T]-\C=BSM;5E?51K@ZKDYX%%(?X@'>?K]2G5N`SN64O\OUZ=2.PGB'V=:';
M]Y+=(,R##S3:5P_J_6`>*R:#KAY2`A<ECX\AA\:*)1$>/>%=XP8664:8&G9L
MMVH3A6E823W_`#.CI3"\\*[\3SM_-NR%F6SH?J>%4PX\)2M>[L/ZR60T/*FM
M9`3K2P96]8P\PT,QM^?/.;!C2F3!G++86^IY,/AD`!RC9Z:W$=FREBWMNS.B
MC#=7?FC/-._G;94YX4EZWO#((W'=EJH[6=AP58=9K,N]LRD->17P^AO8.-1N
MPHH<5#QF93\E+="C8,!-AIU'X)L^%YC1HO(F;F3D0V5\Z3^F$VTOUQ3WE36A
M$,4\<_N"^ZPWEV/-TA0+D""ZAA>S=3O!Q=HP;,9.M;M;5](:GED5%=@I_/YX
M,$!;*8$%+0:@:;1'206ZC,B@P<@_&(+B_AJ4I?U.SWK<HNNKO.1VO\2/Q"0@
M;L#5J\@ZZTW:76#NQX>D-.6373&>.(%(J@[<!$9DTC\@2G!A0@U3`JK#P]C2
M+10&B;CRA76/,(L_T9D]@5FS1U:=BTXQE2L-U%W/IY@3XT3@T,)20K$SLB(1
M..OCYR!8=ZP8R:=AV;@J5AFK\@6?:Q,B^47=QW#TJ3=X#K,\.2#U;TW*@Y&6
M<`<`<`<`<`<`<`<`<`<`<`<`<`QKX,A_QA\H7PI&OC_,;^#?CCW$+^,/A#WG
M[[^%?B;V7WU\-^^?\;^X_;?=?O/_``_V7VK^^\`Q)*C:40'QH2A3]6HBH9+M
MI_#QB5?Q-,?%)YN]5([S:-,]!&&P*7;D%UW^TD%IM3.SU95UE[E=3??(2\SA
MDNOE"&IWM:1BD*A+6=N^CI3>QB5:PQ_.]R<0406B9':7N@JL@V?1=9JV5CKO
M)#+@(HW0W&J-MDD\ZBRXB7&4T.-%>N'7F"N9F\A-#4Q#GEC,GHVPG<5JZ#QY
MS.QQ+UGO%A,UQ`-HK*&3_P!<K[:U-[/D'7K5/7IJ>GMYA+S9ZA76KKD"$9CX
M2@*3#@=HD6@.P0554%'B-H*>/9E1R%Y&M`*+/,2,R?.9&6CF4?<Y$]G)AXS6
M(9]HXCS?>)>;S)"#06$1PR5D<>AL5`R$Z-`ASAT-'A`LR9$19NNSC`HJ48LT
M'Q$;'&CIRU`L7:ZS40W<+H#TFZ2RFNPAE7`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`*_@^IW5B+FD9)&NM/7^.R)O[=A`^#INNA)I#!-HY'DL(E6$<;OD_>#!
MZ\9/O07U]K:.W+9?UB*ZNF\A7PI++S?,]X;JQUACH,K&8_UQH8%&SPUD&.1X
M-4%?#`9D0--_$PX45$LH\@P(C6$D_P"D#)B\;K-6IO\`QJ@DF_\`[_RB7F^9
MW)_KW04KD,FETIH^GY+*YJ%8QN92<_6D+,R&6QT6_#E!@&3&B(5R2/!1Q./`
M"+$65<NV+1^##NVZ";@8R40"7FSW3V@J)M4TQDEH4K4MD2(6'=QX8?GM<0Z8
M&AP`@HHJ_!L2LA#$7S0.]5555=C&ZZ;)RHHINLAOMOMG(2U<VN)#$!Z)=:*]
M[`W!V>85X&/W%<<JB$P(2F7A(O(7L#+0N!#*X&:54_<Q_0S!&3R-B&6A=N-*
MJ9?NT_6Y432]!OH$N$L%[SW+@\$'`'`'`'`'`'`'`'`'`'`'`'`'`'`,5FD%
MA%DQU[#[%AL5GT2);M%",7FD>$2F.D%&#M%^Q4>A#C-\,=;LGS9N]:;+ME-F
MSM!%RCG19+3?4#&K&I&E[A&A`UMU%6%I!XT\T(QP58T!BDW&@"":>B*;X(QD
MPDFU%/$TDTTM'3%)!?5-/337?&NFN,!,7'C)*/I692`/+)?4%72J4QZ/DHD`
MDLDK^)G)`#BII@_%&(R',E!+HB,CY865*#205DY0&OV!)^S=-E6[QPFH$O,[
MMO6E<-58"NUK^$MEJI8.!57+-XH"15K86[!Z1AT-@*B;#7>',',;23CSAG'L
MCFZP-/02HGLPTU;X">MY'0_JKU>$[S145UOH08K9#;9G8B@^GJ]9;SUIN1;%
M]VLTW;1U/:4MMRS)F3V0.9?);$6C9[G7+E!)7467F^9EI^E*:E;:;LI34E8R
M5G9FD?2L=H?@45,-K`3B;=)K%DYN@1%.4I7I&FJ"#:/Z'M'^H9NBDB.PV33T
MUP)+SNN,Z"!`L9"B(W&Q`N/QV/BV`0"!",&@H*$"BFB3`6($"V"3=B-%C6+=
M!FP8,T$6C-HBDW;I)HIZ:8`[3@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@'QS]T+@O2,U'X]1:'65,1HZH^V?5L-")BV[&6I&YG3C"2$
MJ+]\@*H`"VKUD*!R)Y)Y2T/L1LSAC7*!4PEN.(:L4F>P[6$F_ARKU:FBA_5$
M\M28.[]A3.'S?Q^FL2MJS8XA2?3GIA)Z;:@[=GPY"L)+*8_+W4B.P!NTE*2<
M6,2)V(C:IE^$T9NRJF&_MJB_O!;#H2RE_P`=%6U:FBK$7FW[KQ(I_3D*A<[E
MM*7C/I)>A.N((J+I^?OKM@$+A80<[=1.ZI`[MB80A:.)RP9,MR%H$HF#<OE'
MXEB)P%.XC30Z7'._%4K5)=NAKEMWL1>]<A?''>0&W+"W5J/LET]A<9/OI86E
MSRA:BM"(4*A><I@R)UT6;0YK$(]-;0G2:PYNT%10FQ=G]6R"0+9-(;27_'2]
M6F]6FXGDD7&BLXUC/B;!Z3#=BY<EU[K&CM)"T@TLM2?3DC/^TUPD0D;:URO,
MYO))&7GXZO*<8A+8^3E\5,.XD3N$18>=6H99EN)&?RS%6[X40O=N_2*X5R[T
MQV_;?\4,CUNH6VI!7TCL;PGK4D43W5O:VJMB4`MQ+L-%8I$[R8AZX2,;%)Y"
M13QW[L:ZAQVTC%(/0Q0^U&86QD:LPK$M3%M8*JARI\B\[^1=_>YE(P[NVX>,
M*3NF/^'D4J^FY6><QN>`[,M>43NHJ(+#[>-Z"9<0B@".1.36)*);:P]L/9ZO
M8>$=Y!OHLX'N'"[SRN_R^;-E[-ZVI>B4M>ACTN\3+L.AV?K2&NVD8#0FNKH\
M2VM9:!!QH@Q3[/$^I%15?*:V9P)V8EC]Z&(2@G;!*OTHZT>RG3%M0UV\QH;T
M:M8P+%V5#<_HQNEN9NR3W,QD#XBESW1)/#GLHV$JP<*M\E8,RB;N"6A*<#M-
MWOA[3>V'XJQJV@EV$A[_`!"[,%R>*Z@+7RN[)#,A3[".UU-0Q'3@NRDK5](E
M17ZDJ..VZI;CPT/$+N/N)+U(O;,9JX3J9Z:=5.U\?<5N-E(?<.O?;BR!4D@Y
MK22R^78.:!7\%:D!!QE\/;I-2BHI^+?+-4RSD9M68NGZK5FO\,5XR^13[P]I
ME)CL[[(/[,LY\PA$+\3'N_6U.6+*>P%IR.1-K!C]RUI"J'H/:K')MF+DM/9A
MDGG#G$=3.EVFC`<Y,9;P'$::RY46TE2%78LMJ*72WONRXF<QWQ8>P1"NA*DF
M']<HC<P'O-UIZ<6Q$E@%A/8T(B_8.7$$8QV9B!%_8\?>F*BLJMS$/GE/O'/H
M-##0/+/;CR^C]MI&WVN&PIQ:V7:6=+UP<I]L\DZ^^)3VX['VC1U40Z(]=@A.
M<P/M),9))C@*R'4?F`_JGV[B]$&9)5*0RP-W#<%:E?%2YR'-#"\B3`3%AIH\
MD<FCZ2V5`=A)-U_+"E/ZK,UW7:Y(PJ(>+[V5F'72-=DA]#UR^A9S1I)96"AI
MP#.+EJF("A787:V&Y.A<W5&)?.2%-&*XK922O$3,#E!N-D[7,":H0^3[";T-
MA3$O%3<G=%8<37.L*:R8[V&\22UY"T)P>50AK%FX;LMUP=0$M%W%H1:-VU4[
M_N95=0M9I$[GKJX!CWWN&,/23&X*2G\4AIN)G$-(0=C\Q%9.E1X;*P>#FZC5
MANZ,?RM3G1H6GXT?8"%5!85HC*1@#9VRJ/MU:4>BLB'S'=_5CGJQW5#=66L2
MNI5M*1^7CZT@A1:0CWHE"'J1B3-/<R8F7#E5'S8-A3$_IX[5G:INNQF5<78`
M]M[.M/J;XJ1.;LX4WF'3R?=L*0%&8!F<PD3+A%:T#$;0!R#;#2>O)I#SJR$^
MV`O"<:GK1^T?!M9&`>@W:R+(>([*3L_Q)/FVO3(I74OBG7P)/T-7#>+U,\KK
M62>$-4174OFRY%9)`;X@-)$CA8OFP)!9A11V>KH['47C4O)@LG)3@6]<)'7+
M8UA21NQ=A5OGY\DOE>[I3`L9XM8UY`I'T5GT<L>THN6N/Q/NB%*3AB#M><QB
M,DJF(2"<)2F$:1H#(!(30-+]'2JTUWW9JO9&FV&MRSM=@&$MF0EBNTFE]-IW
M*^,[S#[#\0"P.J/8V0=1`B,$+PF`=E/#/IR'E;1-S616<:K;O).+*#64^>R<
MU/?;I&6J=*-,-8A)'K0AJD,T]DFR9Y]C8QO,>7K/1!694_PVGA'R^5*S&O&>
M[;"ZWED_2B76AQ[EZZ=Y+V'C-HC9>F=U^E?;-M02L==KZW!OZ[2THN]2+-':
M";;>&&D%7VR4O'KZAF]-;"F)?U65_=9F>%2T,E\5VY6DVG0P13T59`A5S=HZ
M.!!3#.2D):$S0'26-=KP-W2QZU/B!Q"M)D6,8C>0C01'5THN?BDB939R1=9#
MNQE65"K@GSM;,77KCCD<N+>(MVV%P?II:=J0"FG]7]KX52-A%I5345FDO*TD
M,OM'KT,@`>RH(5M4=,-`!B<3NTH>K;L'&SX)'RJ=7MY%"6&Q0BJ0#97S139F
M_&-JZD7)4;S@WI\&!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#!UZQK9SEYLYKV#N-B+K#XALO$P*
MN7[W&R^^'CS*C#;+IUC=TYVPX7]-7&SA?;&_FLIG8#U[596.^5MMZX@>^SA)
M-!QG:(1_;*Z".R.R2*V<CLY522V;M]DT]_2TTV01SKC&4M/1`R\<-'"&388)
M8,A8UFGA%H/'-4&3)JEC.=L)-FC9-)!!/&=LYQHDGKKYYSGR\\YX!TC"#PL6
ML3<#(A%QRYM%=N9781\2T6+MW6VV[I`FHW:)[OT7.^VVZZ3K971;;;;937;.
M<YX!Z0E?P.,L0HR-PF(Q\;&WKLE'1X2-AA+$`1(-7C%^_"M&#)N@+>O61$@S
M=NF*:"[EJ^>-UE-TG2^FX'/WBD64.I2E2-`%),CIZM&1[AQVQU)/+=1IZ"1?
M9MD@GI[(JJU]'5QC7V=11#R]7OMKD#];Q6+LUC3AI&P+5Q)/3^(EVX<>@L?]
M9A?&_OI5)OKN4]/#ESC?V[9?TL.%_/S]:IZ0'I:0V'L$0#=C%(VS;Q15PO%T
M&@(6W1C:SM%=N[6`)(M=-`ZKINZ=(.%!VK;=9%RNDIG;19378#K=:TKG1!)K
MI`(3HV0=EGZ#?6*@M4$7Q[.N3KU)+##":;LUG33)9QIKA8CG37+S=;.N/(#L
M0\,A\=<[/(_%(T"=[M,#]W0<$+&.=F&JFJN&6R[)J@KLTPKIHKAMG;*.%--=
M\:>EKC.`.G;575[-;#AI6\":KZZJZ:KMH?'D%L:+I;H+:842':[XU614415U
MQMY*)*;I[XSIMMC($-7ET_I2_!4"$RD%F/(UW;577.#7A#&-`W+N84V3T+P!
MN=V=1XH@8C8E^DWW4CSI#+!ZW;)#W.B@[*S145.)U37,GQG"H:.=!WP^)1EB
M]CHW0-'WC,"*:N@8=))=!(4'<(--%1@U-%TY1T8LMT&NB3E=/5+&BRF-A#@N
M*VKMVB_;NH#"W*!0RK(R:#B+`UD2,A7REE8Z_348[:/#*V44<JE'&JCU3*27
MIKY]7KY`>2U<UZX6)N7$$AJ[@T^;DS#A:+A%5BQ)IL[W:$":N['91^^:[OWV
MS=VZV5<([/7>R:FN7*V=P.0Y@L(>[G%'D.BKM23J,5I)NYCPA?>0JB_+(U4Y
MLJSWV+*#LXQECN_RXV:>6/9\I\`]K:&0]FS+#F<4C34>>V4W.,&P(6@S,[JX
MVU5W+-4FNJ!'937;;539YHMG?&VV-LYQG/`.M3K.MTMTU$J^A":B2K%=)1.*
M`=-TUQ:641BR>VK#&VBHY';9)BIKG&[1+;*;?*>F<XX!VQZ)1258:ZRB,QZ2
M:L<K;,M3P4:8PSV<83POLUP0;.,-\KX11PME+T,J823]/TO0U\@/%[#HB2+I
M2`C%8X_/H-$&")QZ#&.BZ+%JY4>M6:1)=JH]3:-GBJKM!OHMA%%RHHNGIJKO
MMOD#IL596.$\)8KF!X2PCNVPGB(1_">&ZBWM"B&-/=_HX14<?W_=+R]#9;^^
M[:YW_A<`[3:$0O9PX=[1"+[.G8+2+NW.P`3EPZC*>-<)QUPMEIZQ8%IC33&@
MA3;8?KC37&K?&-<>0'AK!(/IL$VUAL4UVC2FJT<VUCHC&T?6T466U5"9PSQD
M4IJLX<*Z[L/4;8476WQG&RN^=@,KX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`
MX`X`X`X!%]JW+7%*!6$ALJ1)QT22*-Q+9SED1([>O7^G=RN@+:/'#8:ST\MW
MY-PDFQ:94;-U5\.WS%NY"\C41V^H0B25%DYEI"5FKDV)(N[$9KP00+E<;+-`
MYR"D34FP.$MILQ5(C'VD<]LV>D0I)F:$X?C5-G.@L/++J6:X(.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`5-?=TJ0:FR0%D\DIQV+E+2#KKB(\MLP7E
MYU@2>P4(P>$%QZ3_`.4I4(;'P,TT];&C#L9ZQP:8#BL??EQ8?GF&5^A+-4WI
M4EV,R*U96!$Y81CZ(;:91D/(@A*65^^.M%G@\'8$=&D'A.''E-&KU/(DZBS=
M968/M$M5=6JNVHD-$L\`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`ZPT9%1
MP.5D!Q\W%A08YZ6+$G>_JVS`:.;J.WKQQOY9SJBW;I**J9QC.?1TSY8SGRQD
M"JN.\%#99!2>Q"5HC9`#:282^=1`PR2<QY.N!MMRPQNF\20=-6M<5\9$GI]H
M[;H.PZI%N!:-B<E]:&3%A\OVCGY!96&S>%V+'V<LKZ7Q>=14@H[282:&GQ,G
MC[Y5@Z68ODV9D([?#G*C)ZW<,W>B+G?9NZ06;K8T62WTU$,HX`X`X`X`X`X`
MX`X`X`X`X`X`X`X`X`X`X!&%F4K4ES-13.U:YA\^1`O$GX/>3@V)-T&=)$Q!
MC.XE\NEEZ.T=$0`5P009N$4">!C-$BDZ;HZI8"6KG!0+Q`.ME*0[HIW.DH6%
M:J'&?6&_G:+\_()5+=]C16,EY&1E;A*6'#;=Y.795HRW6GKM%>9[,F`\3@[@
M2P9L4!I-RMZR\X&TS@R.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`5WU
MZF=<6[MX]%U%%(ZL0)*FWND11>0YHY/;@-8PTD*C"*O`[',C"!<*MHO(,-L&
M8BN[(D8P^$$B9!VY%EYSOKW(/HZ+@(;WK[4QJ,"VP<((ZH=#![!BVQOMA-LP
MF_=]BV]<X6W5=/'&K5L@DJ]>KN'CGU>%'+A97.V^0=W%^A?C@@X`X`X`X`X`
MX`X`X`X`X`X`X`X`X`X`X`X!U!X`!E(A_'Y.$$2,"51]F)A#PUF7$$6_IZJ>
MH?C2"+AD\1]9IIOZIPBIIZ>FNWH^>N,X`@)KT_ZWL&HY@/J\8/&B&HQB*$CS
M$G8AQ@X9$T8)N+8!VAQ$8T$GX:V;1J;"F[1,?8(AJU9SIM(DVR&$Q9?GKGIE
M@1=T#8L1E:78.&LVH\>R[J]UV[-BQ;HM&;1NEV7L?5)!LV;Z)HH(IZXQJFDE
MIIIIKC&-=<8X#OX6>R+R\$'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`(3O6T)+4
ML58R6.0IA.UG1P8`]QK'Y`'+/")QV@-",@#*-P"P'YE^](N-$UTU&(UB,8Z.
M2Y(DV',W:Z`J4^>[1FM:S-*Q(#$)RBV19:RD"/,;L$52BNHYP[0UW=#=]C8.
M,F=5Q[GUK)TB7CH,FW<H*H/Q3!TFJV3$*N>)1_)\=V/JNW=^ST]P57K>NY=K
M@@X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!4^O^P\TDUZR2G936L6C8L/
MK)6HJ<@;+,2M*02"+MH>5*QQ*.D:MASH<]%@)Q'R9=\\(>Y]5WFH^/$),JV)
M*CQ8HG/"-_L6PX(4EK7^4'[>?5=Z,?M"[S\%P6]]D7:X(.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`=<76*-Q1)P#8,RAE%@[5$C"!)4.P($DT-]V3)Z61'&%
MAC5TXPFBX?I"B2C1+?9?1@[V3PAN!7OKGV`(7HR.N"T*0@[@>/BDD!MDC4B-
M:R>"S=`NO$YTQ6/P"!J)`I)[B*X#Z>SN".<#W>"S(0MHB@X%:CS+B_+I+*\$
M*2=$?X@7K]=ONW_:9LC@KOX+LB[?!!P!P!P!P!P"M]J]98W;<HTE96TNR$-=
M:"V@KW1578BV*PB^R;-5RKH\WC,-DPH-DHM[5LF[(^R8=.TD6VBZF^&Z?D+.
M[DGW*,]=.L+>PY+VG&RGL9W3>M*N[.'JTAJ:/;Z^&6P^(L*FIZ5MF+C=K,DM
MWZ^AJ7G7.SYYE9WNFY3;[*Y0;(::"MW45V2S9M'@4,9U[$0D-'FI?(F8-NLW
M1-3V6GIU+B&%W;AYLJ;EDF>D3IEQHHYV116(/%MT&B;=FCG1LW13T&3+^`.`
M.`.`.`.`.`41\19RX;=<E,[YCGN5:R*M;GM),9@P)@N@I.`N1+79[:XLM42B
M;R1:B&KIE9[?2+O6BRR"*F\AV!M7(U9OYX-]JG5F;DLNG>L5`&X)&`=DRDA&
M(*-UA,<C@M\A*FZV8N)W$PHI3Q+:L`>P@03=%VRD61/A'@4`^?QJ+)Q4:>*Q
M<2);EQ?7[.K[E*>ZW9R[)5TX[BQ@I5>TP`O.NG9(+DQ!HVO#]EHJ+:.H^)[!
M>UV98#`6WJ\B/?DT%(.+7E%D/748)'H=I+Q3QN.;"I*57%/[45^MVXWL<&1P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#5U0;PUMWX[%-WTGB*SS&YEL<#
ML&-3IGW3%L$K)S$T]/:;.*=@1PL6(>MUG:9*$HUP_,/'A`#@:B]'/"HT_I5.
M-?:.LG+>]ENVJ,I/"6-88(1H=.6@(-+->O-X,]#T)?0IX>E$[P'?'42`M:I"
MZ8YFZB[G"SRUWK]S"X&]]^"E#+D(6?59Q$ZYX7W'CT_FEB3WN+VH/V=7SRO)
M,IU9Z%)[,G>6[760ME)-W/?9E;..;$BAV$LR9!Z_;)PJ9+Z3".[CU61Q/9;&
MBZX.(4/%\+N#WHV><&1P!P!P!P!P"&KAI]S;C4$U;V[<M39".'R^[FGI6*BS
MHU[:FV3P@=5*1N18>-V7L^5&*:.C7**CESLILKC?3"8J<8)[S7N-H&>.NX,S
MI17N7W+^"`?6RL[28IZVC$L%,2J56A;43+;JD/DW\U&&PB'!M6[/U.,(N-7*
M^%-O7YUU&MJB^6S>\-QL3J*JG%3!B8=Q:=M6ML2)^\M2]NR89*#(W'LJ#7W:
M,=C(_'DVXS.4/:O9E&Z^_M2RZN%L:J8TU&6YP2W$M<$'`'`'`'`'`'`'`.$2
M]X9'O_=&66"WL3KW9DEJOL/P0]1O[%E_JVVT<[,L.?59=:M]M5\H>GA+;"GH
MYP!JA\/.0/Q/7ZUY`%D$,<MF(,`=%+!([5$R50D&T5(+OI)+1]`'E+*ESPEJ
M@'V=A;92&W.O@2\T-2%Z6(/?<8U:OKZ^M.5#NF_;_M*HT%K[4RSW>+H;^\A2
M=7V;HHV)CJH;RT$(9DU)+[O=I7W/=WT+KD]IMD;7GN_1*7IRPN2;,DPBSGXW
M'2]YX4J2KX<I<L?IJV#9Z*%X*9*=R.Z#XG#C[Z.DS4:>N.R=C*+ABA")&I%&
M'CY@IME!PX!'2PM533;9F_<HYU5V$M7YTL_]47\X(.`.`.`.`.`.`4FZ>_QS
M[T_79E7[`^N_!7<MWJR[/!!P!P!P!P!P!P!P"I';4ZQ6`1.LWLJC,!^4`F_(
MI3*P3C@!7'G7NC"4_!,FRP/Q0M)E)RKJBQ4A8F4QYV1AS"<R1=Z1%Q$C%Y$*
MN>F^GFL$A]8B.Y;KQ2Q-5^1**/JWB;G<D3?*E%W^ZHEMML[;%G#TFY,"'&<Y
M5`&'10JZ+`]AQ%R4)+N5'S@'>][(9\2C^3X[L?5=N[]GI[@*];UW+M<$'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`-8U#RP-->V&TS&2.(O3LUAEF$YQ7
MX"2I';8IXD%*UY&@T&O'"2+?=B":C1.7@6(/Q8-S7%H$YH`#O[&$/G$N:C34
M+&^_!^:7K`V<\&2DM:_R@_;SZKO1C]H7>?@N"WOLB[7!!P!P!P!P!P!P"DP7
M^4<LOZDU'_MU["<%P6]]D79X(.`.`.`.`.`.`.`.`8+9\VUK:MY[86XM8WK!
MX?(Y9L(;N-6BI+6/B793+/VS=%QHRT7PURFJ]V;N-6:6=W.S=?"64MP5:%0>
ME3<6*.7)'0EB16TQ(=M5F[.;5W(59-$#V[\&?5?$YD4W.R!!YV'?D$G3NVC#
M!R/92N)K5#,M(]&EY$X!#QIX4CSMEQ+\<&2DG1'^(%Z_7;[M_P!IFR."N_@N
MR+M\$'`'`'`'`'`'`*3=/?XY]Z?KLRK]@?7?@KN6[U9=G@@X`X`X`X`X`X`X
M!"O8&P&%9UD5E3^N#ELZHD@(]G`XX&3/ESI0J8:,13=F,4;//7.,D%F^&RGL
MJB;=ULW7=K,&";HFR%5]\&6U;)#<PKJ&2F2AU@!\]'AQ,N&7'$1&XY^Z0U4<
M-M1QC5,NU0TWSG+70LV8%=FV45"(P6]W7'-1"L7B4?R?'=CZKMW?L]/<%5ZW
MKN7:X(.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`5>C%[2>7=C)943&M),
MPAL!9$&QNQU$WBX`G)MQL8+,0V%\QU,.T5:C#.CS?5M+W+]UH7#I-1#]RRG2
M%?BQ2?,?;RDVAX(4EK7^4'[>?5=Z,?M"[S\%P6]]D7:X(.`.`.`.`4H[L6?<
M->!Z%!TI*XO!Y/;=[J5T4E,KA"E@LQ<<'T1>EK.?8HYI)HGHJ1>E:P##M7:Q
M;U;5D\?;X;++92SI4I<"83;K"NF,4LGF57^)^_/Y5]1?JG:_OTYO\/7I]S'X
MB_2_[E_J1LVB7=%K;YF[DNV%:_&AVMHS5;[7;JRCD/B+Q242R7"MD6'RV853
M)Y+3,QAT[R[W36:X:(ZMT]D-E%7X>O3[E_%41LN^9VMW\,8$D_$_?G\J^HOU
M3M?WZ<?AZ]/N3\1?I?\`<O\`4MSTHLZU;,KZPM;CD4;ETPK^YIE7?Q-%HBI!
MAQD0'&1HL.=*QO>0RC5D]3U/*M%]D2ZR2^K9);":6^V^,X:AP;P36*G//1%Q
MN0#@#@#@#@#@#@#@%7^MESR"YFTC,.JCD]31%`?&'L08R<"3"O"RI5Q)TI,Y
M5]X!P:'M2)85C=)L+0*C74>>1N7H2%Y\99$`16HQ\\]2T'!"DG1'^(%Z_7;[
MM_VF;(X*[^"[(NWP0<`<`<`<`I3V'[=2"E;/C=4P[K_-;JD!R!O;">N(W,ZX
MAX\&':R%*-I(N%9W(@JCUXY>J;;ZIL$UM$D-<;*;^EMZ.M2FB%$I;24QCZ)D
M0_=XWC^0;:7Z;>O'V]YK8>G7V)M6?U+E:_U(!H[LIV(JL]V(+%>D-@$D;DOX
MQ;H9(?==`ZJ"1!*MZPA28LG[3.$M=B2;V"OWF^S7*S7V5ZTQJKE;"VFC8M:<
M_L5VK%/F5%E:S;RU)^^[QO'\@VTOTV]>/M[QL/3K[$VK/ZERM?ZEYZ4M`9=U
M-5)=`081"!K>K*!6@(#&-FFQ80,G\5%2M@,*;,%W3'8BP:EDFKW9FY<-,N4E
M<MUU4?04VP5TH2;P!P!P!P!P!P"MG;5]!&=&R5.S!+T_!29.+!I(#8R2#0Y4
MN/)R46UW'J2NR#<6AH%!SMOKHH\)2^(O%?X+&/2)A)78?"PJO_?T(?EU93"Y
M:(Z\LZ!>LJNCN(E&#+(_FUYSF35^!W``"442A[L$UDH"Q'S=RV9LC9J4D5-#
M<*1DD7CYUBG8[V7!!5";GE'[->9%&NZW7'L'$NG'<22D;49QV/-NNG9(FN%$
MRZ665JWAA9FZ-C:,:#Y]'QHU:,"Q+$HNTM3_``"=BWDC=QH(%'QT<V<.14[,
MJF-GIC?GAI>;V.#`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!1Z"':I*=
MU[-8M8>DI<8N#/696<NK8"'"3.%,LUTH/CK6H$9#O*H*,(D2[A]L;-P8$',>
M[&!(-+)8WD[/1@+^55I-T/O=@1#MTQMU^5='')Z!AEGTRVD[R/"I3,24;]TC
M09\*_A@S1]$F3Y@!O<63C8>]EBJLE)D7T+WG:KR8'Y7H.B`LW*M%?<],[L.6
M<^?4"NI35O<7M1$I=8)FPB#/JST*]F6*-(\W8Q1BA)NYXW6%Q9<+'8^2)Q,.
M['O'(8E-5)!-7&A%70S(GJ2+%LR!N4J16UQNOPY);C9YP9'`'`'`'`*`][?\
MM=*OK9&O[&G;[FK'U+CV9+7TVMR_[63#>=C@.`.`9]T&_BOV'^M-8O\`5.N^
M<;?U/AV1Z%]-C^5=V7RYD#@#@#@#@#@#@#@&M_K7F!3JINPP^A(8'&2N1N"&
M)&K+KA'28%+[(.AR*2A>2NJ./G6]?"W&_J/>L8#L*[L1-ILMB05S"5G`AT1&
MG*:G",,.*A]48PITW[!;88Z,;-'"<-DU$U76UD3HL]5>/:G;0B-GO02A8$0B
MXH.;(/+"JV/CA(P#(GAA5N_T@[X4P+*!*RZ:S3?<\LVJ$E^'**-`Z:M@/(Y0
M\FIX;W'[GLR\M(#`X9[(R"'9.QDW)=T)C[,>$'KOE<;+J-!3)JQ0VWSHW033
MQKK@1W\%V1?S@@X`X`X`X!K$[#?AJQKZKC_]K"'-V+^'JC/Q/H7\S[(Y?.IQ
M'`'`)ZZ!_@(]*?JD]</V.PWGG/2[WO?<MMP0<`<`<`<`<`K+V73"O@88>XFD
MN!R-DA(I+'8+$YXI7.;?7;LFD,85\:E&R>68H<7G$^@35F06<LU&D@<A<J[N
M@BIP<]#S<6&""4@0<8&0=DWZ(MBV8)/3)%T7+.DVR6J6JY$H]45>$'BF-<;.
M';E3===3.RBFVVVV<\`ISXE'\GQW8^J[=W[/3W!5>MZ[EVN"#@#@#@#@#@#@
M%(SGB+=0HSH86/V/)Q#:/ZD%#;Y]25\(CAB`K"VQ)T\([5E["DR9)H++.'NS
MCV1-!+=?*WJ<>GP:V;675'.CWB!]4960!C(_/I61=21X,8!-M*3O9!F^<&%T
M&XW.A)U6B`Y%LZ4<(YU?.'2+)-+?"ZSA-#&RF`V;675%SN#(X`X`X`X`X`X`
MX`X`X!4Z@!4,(2N7RR$32S)_'EQXHRPE$RNFUI.S]NLYT6L)6')5;*BR47C8
MZ&0<K6V\0,IQ[0VL!D7NIZZ][##KTL*_*94OQQ+8\$*2UK_*#]O/JN]&/VA=
MY^"X+>^R+M<$'`'`'`'`*`][?\M=*OK9&O[&G;[FK'U+CV9+7TVMR_[63#>=
MC@.`.`9]T&_BOV'^M-8O]4Z[YQM_4^'9'H7TV/Y5W9?+F0.`.`.`.`.`.`87
M8[@&TKZ;N)-(BT1CJ44/[&Y4!?/!AR-B_=;G#TZ&(CDG#Y@5%-\J/A[QH@NX
M;.T$EDD5=M,:;`KT1WU^`,@T6,;,BTR.::RF0QW)J86M*+37.;PDR1BCH\W7
MDA4EI%URI(:04*QL;JV2'$$E&J^%MFR>^!7[803QP0I)T1_B!>OUV^[?]IFR
M."N_@NR+M\$'`'`'`'`-8G8;\-6-?5<?_M80YNQ?P]49^)]"_F?9'+YU.(X`
MX!/70/\``1Z4_5)ZX?L=AO/.>EWO>^Y;;@@X`X`X`X`X!K.\3(-&'<#JTP?E
MP2'NF5E1L".?$;_C?7T@II+I=#!:[QF?D%'W?DT*B!!(-84C8LQ@+(8?#])0
MH065"M=$1JS?P>$])6[C&)::#6%`*KI.G5)O9H%PP*1<('$S1U/D+#'RMTPB
MCL\[+-[$9QB(M):SW"AB9IQ,/A6,#GC-ON05'#-5TFV!,73IKD5.[Z7]4U@]
M%>ZL9BDH6>G<]4^PSE0:_C<K`+M%H_%3($Z%(9D(,4D-E0@BY:8)0X@HVE;-
MB^8%EPV@E^S>KBI.5O7GWN-GG!D<`<`<`<`<`TGAY7VVLTM:,E8=S[.K\0Q[
M!=EH''X9&*GZP$@D>C%5]A+-J^+L&A"84?)),_WUCT/&*/7ADX2>NGZCI?=?
MT=]$].EFPFDW./<S:MJRXV4Z*LO%)^IQ9O6_9ZQ(7+Z_EG?2\"$6G47/PZ2L
M$JDZBL57L?DXEV$,M$WK+KR@\9J.1SYRCHZ:+HN6^V^%4%4U=--\786O3V)^
M+%=A<W[G:`XAVNCH4/'Q/?J[FXH$+'AAB&]/]0%]D!XMHBR9H[++==MUEMDV
MR">F55=]U5,ZYW4VVVSG.6PM>GL/Q5^A<W[GO;2WM;7-AT<]-]P[(LR.2B\:
MW@4FA<KJOK2(#F0$P+["B*>Y2"TM%)0Q<H:*:N&C@6=9;Z+I:85]:CE1+>6K
M"2;J:LVU:;6RE1N]X(W/\YE'`'`'`'`'`'`'`'`-0?22#`(YVBN]4/)H7LF&
M)2:/LP4?$0T6YD#!P+K@YK)660%`5P_6%1Y8DK7JWM$W.:)$8JY;;ZD<-D%F
M`TYA3ZZYN-2]Q/MG0PA^H+>2\E[>F=)QC9NV@T^?;?$8Y[(QK<)C+.,+Z9(R
M8C$),P@:&-O.PG89TA!\GU-F^JXD/SSGEB0-U^G42L;O-VNE4*.-#P0AU7Z'
MJIN&_K47+11S-N[I#4>7&.TVY,&9;M7K7=^#,LV!@9NMJ@08M5\;)8!W+>_0
MV#\$'`'`'`'`*`][?\M=*OK9&O[&G;[FK'U+CV9+7TVMR_[63#>=C@.`.`9]
MT&_BOV'^M-8O]4Z[YQM_4^'9'H7TV/Y5W9?+F0.`.`.`.`.`.`13>P<9(:3M
MP";("!(<S6TU&$RD@-CHT#&L'T<(MW3\Q(B\<F`H"-9HJ;N'I@C$Y,Q&MTU'
MCH"611W8K@KT4=\.%6.1^I[/D&M@1\X';R@R2+IL+IC%N:19(.4E/O,N5<1F
MCJ0;QS24^S.IDEAV+.KFV9#!G9^CLHIAP-6E'[/U;W:%IMNW77K3##;>?[ZI
M%&8HB.<;1"=8:/!I6&-;$V)MW>8Q[,H-`0A\QDTX(85]CKL6]9KSQ>.9=(:J
M"0\O+N]V>!&'0IPW=US>#EJNBY;+]V.[*J#ANKHL@LEOV8LC.BB2J>VR:B>V
M,XSKOIMG7;'TXSG'`=_!=D7AX(.`.`.`.`:Q.PWX:L:^JX__`&L(<W8OX>J,
M_$^A?S/LCE\ZG$<`<`GKH'^`CTI^J3UP_8[#>><]+O>]]RVW!!P!P!P!P!P"
ML_9:S;#@`6-AJP`.S<QL5^0AH-TB+PY0C1@HV08AI0J_>J;@]U01-\V(?#11
MBND<'H$RS]^!BL6E1MD*HQ_?3SA+,D9UQBTZ@B47O5F[D1788@M+&;])F!<N
MRJHLB((M"R,3?;!U%<L2;U@0<1]PW"$E\J$PS8<R7:-&HFZAK^\0KJ'1P;HW
MW'E1",[34R+Z_P!]3MJK/]VDO;)VB^CC^1+6VBQ*LE6;&S$'H@,W$2H8BQ<Q
MT<(8,8XF)235]:-)N57%+A=&[O-3;KP9'`'`'`'`'`---'_Y%M/ZV7>#^V7?
M'.UCZ5Q[LY?$^I[K/_5$S<T8'`(ELS^-'7+ZTU%_ULTYFW]+X=T=/A?4_P"6
MUV-Q7.)T'`'`'`'`'`'`'`'`*6TO-.PUE6T4E$F8RV$4Z#9G(2WAD@K`)#E9
M))Q+O4HG83K:0R0C.PHY^,.C8Z!:QXA-HV:<Q4^3++Q!\X1#8&G"6N^<+LK_
M`$O)4DO6"DY<;4D1J*/MS"Q98^J\82^:!\J2#;)S<>?W1$2%DWV-1IS)Y"_A
MI+*674,*&7Y6+*"2*V'6HDM>><<\2MO7:N(-5O>?MM%X!&1<8#)]7^B2ZZ(Y
M#R=%2"4S[LC-S4@)K;*E)'(GC(:Q1)2,\\(G2N6J2I(@Z6U]9P5MM+>^R-B'
M!D<`<`<`<`H#WM_RUTJ^MD:_L:=ON:L?4N/9DM?3:W+_`+63#>=C@.`.`9]T
M&_BOV'^M-8O]4Z[YQM_4^'9'H7TV/Y5W9?+F0.`.`.`.`.`.`8=8<A?1*!3.
M4#&;P@1CL8.&V+`>#<R5\^=BQSAX@S9Q]F3"N3+IRJCJ@@.2,"MG2F^J62#/
M7;+A,"#^LTDNR9L9;,K<;%`HR5.`YV`1$@&CC-**`R.I5WN):&!>[21&U&35
M80+**2X`-=9*BWAD&^*QZ0#]!PKC#]]?/WX3GI70#M-@W7CIQ1D+&(!!P[:7
M2/(]F#4K]A5<D#(M-B&4L#9Y`!0R.SIMG&=9#H/:E5LI'D_>N0E^;Y[D;^';
M&8W#*@MV*0^/A(I%H]W+[HB0$:C0E@"``Q3+LI8R#,8'#"V[4<,'M$=-46S)
MDV0;():ZII)Z:8QC`._@NR+[<$'`'`'`'`-8G8;\-6-?5<?_`+6$.;L7\/5&
M?B?0OYGV1R^=3B.`.`3UT#_`1Z4_5)ZX?L=AO/.>EWO>^Y;;@@X`X`X`X`X`
MX`X!27Q*/Y/CNQ]5V[OV>GN"J];UW+M<$(WM29S&"Q?!R#U%,+K.9)-&7P9"
M#];QLSAFXT7V<&-B5IS6!1CV)CE%)-=#4YN354=(Y:,'">CE1`.,>:%,C?>&
MY(]/X)6)7P^NR#>962+FAB(#=;0Z<KHD1]?)1]:4K*D$>RF[%ALP3DX;*23U
MP@J]]IWPST7RW7PF+&JZ^Q9^G[2L^PGAMM8/6BS:%;C&S-<80GLSHN5-I&LX
M573<LQZ516M8CUFNPT3276W--!K59-QKJU<+K)JIZB<9Y^J1.W`'`---'_Y%
MM/ZV7>#^V7?'.UCZ5Q[LY?$^I[K/_5$S<T8'`(ELS^-'7+ZTU%_ULTYFW]+X
M=T=/A?4_Y;78W%<XG0<`AVQ^P]`4X38!;=O.G:K,E6.2@L38]FPJ#DR0S#A5
MIDBP82<V+=/&.'2"[;+MNDHW]H151]9ZQ/?7"4KW!8;N3([^[FZ3?EA]6?U@
MZE^UW)*S7-"'D^3)U@EB5_:4=;R^LIU#K&B3MPZ:-)1!).$ET==.F*VS=\V;
MFX^^(#%G#-QKL@Z13<[*-UM=DEM=-\9UY2&8\`<`<`<`<`<`I+6O\H/V\^J[
MT8_:%WGX+@M[[(M<5GL&!/5!IN:1,,11U3W68%9$''/4M5M-54ME&KMXBOIJ
MJGMJHGG9/&-]-M=]<YUSC/!"G,P[:6R&E!T5$J#KZ:1E@2<M0DKSVUIV.9D`
MY+?.K<ID"1;K/Q/M6GEO[$[5470\_1WWSGZ>#46?U=&0[5WB&VU;M?12RHIU
M8B:,=F(I,P(2.]OJ6#E]&BJBJ6N'XQPSRLS7])+?S14SG;&OH[?>VQP'9LIQ
MM?XLV)C+3KX@B/UWG$'1)O4VFNXM"9QU\LD_<ZIXV8(J-WWD\4T<;Y;I[H:>
M3C;&-DM/X>N.#)(/`*`][?\`+72KZV1K^QIV^YJQ]2X]F2U]-K<O^UDPWG8X
M#@#@&?=!OXK]A_K36+_5.N^<;?U/AV1Z%]-C^5=V7RYD'Q`2K^["D7C221K7
MP_30O9TV,`M3@3MZ@P-#METG`_!40X5ZQ/$F11IG;VQ@LHBZ3;.TTM]TE]=,
MZ;#T?@?Q?X_<H-,O[I%F14"JRA42[H1&0;$@#A$X3[[1>5,TAC*0"WLA';!<
M]-P?K5SL=;E0+-_[QT]R/"2!O#4CD=[M=C7X6MG^S_Z)7@7]U!J067!)8I0?
M;&;:!G"R^T5GOB!QXY$3&%FCAKZ@V*;=+QB[QNE[1[2CHD_;;:.T&ZOIYPGG
M38'\&<;*W6/_`*-X/A;?W14AXE7:X5U@UZ@*TOL4@TSF>LVS?FEBZHYB#5J[
MR,VCF*8@N=\$-7.VF'N#N/9=D\9]D<84SZL<[?PMBS.U.D1ZL^F#@XC@#@#@
M#@%).B/\0+U^NWW;_M,V1P5W\%V1,9;LMUP;Y)B'78^E@9-'+T:X\[7KE`J'
M?I^L:K>;0F7<(HD![C7;S;D&*Z:;E'U;MHKKA1'8(>3Y&J7M1-&-2]<[ELNL
M_&%MJ13^$P(Y((B#=SWP_3K8H;8-_6,F:X</UA9%"*:N_P!&S5B[;N5?O)JZ
MY^G@TKU_QJ]?K_V+0Q!]5<8E`&0DO%SG\Y8!BC0@\ATOM3H7B+R9LV5U45#'
MMHIUVBTEU%O],90=[`I(#*ZI;[;,B;-?&BVH?T):_/ZVFB[,6ONBYP;:QJ%7
M14\PD;_5QNQ`1:QH?(#;S1FV5>.]VHH28=OG&K5H@NZ<;(H;X0;(JKJYU23W
MVP,P\GR)8X(:Q.PWX:L:^JX__:PAS=B_AZHS\3Z%_,^R.7SJ<1P!P">N@?X"
M/2GZI/7#]CL-YYSTN][WW+;<$,!LP;:!:(OF-/3*"P*=J.&.PV2V-7)ZU8JT
M:INTMR2+R%QNSZ?*OW#MCJLV9.49T/3'N5$WB[0DFELR5!1C5:..L/L:]+&D
M7B,P"T^O-:X[&]-2N+WF$ZBFQG/1^YV68OB%U3,K-P^P/^<"=^^<D<Q+`7+;
M+T5[)A_DAZ]SEM[$X&OEK2U1?J6:7Z"Y%0QGM*$-$U[WN>B++CRPOU(<55/6
MZ>TL98&O:V^_O`B>E?:2]F149[#JZ;9$-XZ(=9=+-WF#6$FRC%V(XP36]I__
M`)18'@@X`X`X!JG\0NUK`F%4]J^K%?T])+*E4\ZYV5%(F#@[EB^GSTY*H:%'
M")6ZCAAP#&-JI5)37>,N);@ZH[:RF-&AZ0E]IHKNR&K*N<Q57W7]^%V)U7;.
MY#78.FL54OT0[:RL*:MSK>=F47F-35J]C$CKJ`=C:IL.RP1D:0M!ZP,,RU?Q
M62L-@;YJLR.[N-!#K7"#U3;4%1SM)7_JOAQ@1O\`(]T$_H/R_P"HYU@^U7!=
MJU_Y'SM>QXYISH%G;7?/@>E<[Z8VQKMGHUU?SMKC;R]+&NWQ3YXQMY8]+RSC
MS\L>?WL<#:M?^1\[7L>7R/=!/Z#\O^HYU@^U7`VK7_D?.U['=]<I,`ZV6A?3
MJI/#?[&U%4]B-:G=QR)5=1%0PL-F11D1*1\M+/8S&K&%C&K][[>$2R0]4HY(
MHM=,+;XU:):X$;E*;4M3?+I33>7`^[,-?D7]VOT70#][7!(6:Z^QKMK.97/%
M1LX:E>EG;S"L@OCLO88_V>"0%;7,=M7L5:-FQ39;/RH:>J>[1B7"-B+7RV]C
M?Y<M/6*^H];OTLVTDE4Q:L3:E6K-R_5@DOTDB_*S:GY%O</]'T!_>ER[:UZ>
MYG\-_JL_Y?ZCY6;4_(M[A_H^@/[TN-M:]/<?AO\`59_R_P!3`II-[E.FZ@?L
M.EG;S+>%7A6,_-^M@<!3WQ'XF>U(EMFNORH;>T/,-\9]F;>>GKM_X/K-/O\`
M):MIIJIJQ9V7+M6;FJ;6/])L*^[,-?D7]VOT70#][7.9N%FNOL?.E_=!=/\`
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MMTBDZ25T2<+::ZJ;#!V7`'`'`([M>7$X)7\AE0AHU=/AF@[754CHX5$AFQ`N
M/%OY2=2:*MW2T>A[!ZZE4A1;NV2RH0,_33?L-]L/$`7GG8UF5G;G9$=V)MJ_
M'70OLC.(E;W7WJK#`!^N)AT[9B2YVKC'8B3RH\,#6GVUKV9#8@7;W+&LQ/XD
M!C9,KAH82-@Q7LC)P5&H40[23ET:M:967D84'C+L_:_96S+K\&VX;3)6Y;T9
MF,,-3`7X9$XDPJ%`>NM#57@"6(RON6NY'[I3*N)D69"1KX@+T&&&1'#A$D2)
M,&0N"BVE_?F_X3-_A.HOZ"&>_HV\)_\`YR.!_P"Q?Y_ZCX3J+^@AGOZ-O"?_
M`.<C@?\`L7^?^I%%Y5:`F54S*-U;X)%@PRPR+!K\(RM&)>%O&UP)EF48/VY)
MN>C_`'"<&A3AOAKOLW>#4=W22WH9T]'Z=]05Z_Y%>OU_ZE\_NK;O_HV>[/\`
MOEX>?_/GP397Z[/*W_J5>[+6)V9N(CUY=Q?PYNW;-.I[P(V5),')[T":[NP+
MOK]?%5IM@V&/>`EAR5Q(K.C[K=N\V'M<!VI9SJ]V>-VC!];+AID=E--;=FJ6
M%O-/].AT'Q?VB_HZ.VO^_P#T%_YW.=-M:]/<Y_A?QV/\_P#0?%_:+^CH[:_[
M_P#07_G<XVUKT]Q^%_'8_P`_]!\7]HOZ.CMK_O\`]!?^=SC;6O3W'X7\=C_/
M_0R?K%9/9>F`UJCI5X<O;QZO.+IE=BB-@4\Z`NTD`9P'%!K1L0V?]X1FR)1-
M<&[V<(-]'371+=OLF\5WW4T2YVG+;.NRHLK;LT476]?X2S/W5MW_`-&SW9_W
MR\//_GSY!LK]=GE;_P!3^=,3_N=3QE7I(@\2Z9N=4G;YVY3U4OWJWC?":[A1
M73&^-;OVUQOC7?&-L:[;8QGSQC;./IX/5^+\/]72U['!_P#IR_&9_(U6_3]U
M<_?;P/Q?A_JZ6O8?_3E^,S^1JM^G[JY^^W@?B_#_`%=+7L;8/!>\+'Q//#N[
MO`NR-W=&+(D4$&5Q8,1<#:QN;IV<E6Q.5L&C4<LDPD_9>&BMF22B&^7BNYK1
M=/3.N46[C.<ZX&/B6[%JS"M*95ZM>Q]L=0W)8%EEBHZ8=5;]H!H.')O6AZWC
MO60J).N=W*:&P@4E1?8VZ3B1%-+?9XHH:#!Q7LR2FJ9/=WE)JJ/.TE^9/=/J
MD3[P0<`<`KWV-N8O245CTA#Q]E(W)>2$!.PYX\7:*O\`(N`S>;M(\#]0FIEU
M+YR2B+&OX:T5\D59-*AFWJB3A-N$*BI3YKZ*O`HSUBN^U:BBUGAI9T>[C;/)
M9V3[)VH)R*B]+/$?A:U+GF,ZB_M*BEYMLHD?<9ME[Q::Z*:-'GKD-'#C73"N
MPKC-7+/):&%]?"0:"5'%HO8WA@7V:FK%:3.3Q7:E^M1S=\X,2T\:0<*EG]P:
MO'RVS(BV]>JXQZS"V-T_2WQIC;(K<NEJ%_5[$S?*#6']%;?7Z`>K_P"^+@DO
M]?6U[#Y0:P_HK;Z_0#U?_?%P)?Z^MKV(KFTLQ\J'5^>5EX:W8V([U+=DEFTS
M)A*EZZ1DPM$#/6GL+5B;(<X$7*BN045F-D1!=P-6<-V^6#=V0VWW6'H(+!@Y
MM3_=FM"V?W8LM_(<[L_[ETG^_P`X)"S77V*76S9=SS3L<'M(-T>[?8C#&DW4
M`7P[CE+H$O?RT[3D6F=&FMX*Z;,?=^F?-QEQC;"_DEZG./X?-67#EY$M6=JR
MDK2HV\<MQ[_E/N7\A[M__NW2_P"_'F]M:]/<Y_AO]5G_`"_U'RGW+^0]V_\`
M]VZ7_?CQMK7I[C\-_JL_Y?ZCY3[E_(>[?_[MTO\`OQXVUKT]Q^&_U6?\O]24
M>J]_6?3W6'KA4<OZ.]RLRRK*&J"N91D5%:5>B\R*$5['HR;R->;WJVW=L,DA
MCGV-SNW0W7;^K5V12SOG37D=G$NJO>?L1?XA=JW?V4Z2]F*'J?I-W%9V3:=5
M'XE"W9H#38(4W/D,(Y8K/C#2\WCD<@GNGG;+M!JNHEG&-M=,Y^\+9A6DVU"=
M:/V/A1^91\;/\EF\/TFP3]Y/!Z/Q/A9K^U^QZ5/!)\:M51!97JE=2BK;;?=L
MJI9$!W4;[J)[HJ;H;[61G9+;=%3=+?9/.N=D]]]-LYUVSC(?B?"S7]K]CW?,
MH^-G^2S>'Z38)^\G@?B?"S7]K]CZ2O[G]I/O9X<HSM4S[8=.^TYM6W7]+N8)
M\(/*KG6C5.#M[22DOM^2UQB/=>R^TL`^S8;X7]MPBOE7*?LJ?ICE\5V+6SLM
M4F:-9:'U9U)99*TH\^/$ZHM.H%F9A83I';;&105(7Z2+-B[P98MHC,)HPW#K
M;/=F2*S@DV=[/&+[39EHBFBNN./&?-24^`.`.`1A=@>=R"H+-!U@2R(L0O!I
M,.A9'4EN%5:R-V(=(B]FYQ-%RH!=;NMTTFA[1J[W".=TBNK1UEIANH"*-;T[
M?SJV*_G4!&W17-7Q0E`-Y)6UB]@)++YN?QK-2"TT>"'#7L-8E:[CU`FP'60@
M)XSF"1^)H2-M"U8'83@8>V&I413&J4;L$_*S<<Z(0[M<;']4E30>TX;\E\0K
MJ*]E1$FMN(N']T$0V8)KJ=CA"'SN;8SO&Y<R/3N9R,R9B<@LF$LS%6&04K;3
MQ)6)@XK$.72EW3+#C2*]4K6G:5^G52;9C<`K6.6[>[QPH7NH:LX%A)/VWKVR
M*KE4U4'6H3WGT*`]>&T^KU.%OEY,_&[/L0[6(8CY!$T/"57<L/X?<N%UY&3P
M-$)6-L$9,AI'2WK@(@-IQ+!DS*O8-(;$D,D@ZC0N/ELP60$,(R7&A1P4F_8O
M`*(O(AN*:"F8[981Z9+M4GG@A4/MO$NQLU#08=UV?LP9:+GB%FE";^<%(8QD
M)>"CL*P&KR^031Z3*QJ:RTJT,2I@Y31C9./PHA&)(Z2929--<51CYF^"NU(:
ML37Q#<L9!F$*HMWC2=D6D+V%-Z6*Y+P\:E+99&24Z82UU'T1XV4IRR(U-/%(
MJ<WD\8*U(\FT.`'14_6V8B_+TK?1T6NKXZ&.(13OD5F`8B?.V/N''';+$^I2
M-4%%@!@&3EG7Z0P\O)XA%'#XH)#"``"X(['MQ,\F4^5*K-%9$L,BLN+A40^6
M.6<S7'E.$75+;==A78`0(=(WU)7$I*/XO6IC5T\;P%LH%FK^*::VC%!>M?@(
MZR6BP25-M5(\Y+-RQ99)^[QO(RS--GJS$<8:\L+RQW!"M'8F,3F0N*T<`@MA
M3"$!Y"><6%!ZJL?6K)R;T=Q<DRBI-I)=YY6*1`.`-JY4*QE><A4WJS\:?T3)
MNHRV'.!5XVI]^?N4_CM2]P($?.2M12RYH"-V.SE0N#";H>E9&#AX'M2:D6\4
MD:EJW.ZAA1Z7H<I'6D><P8A"!#H(&E,,LP::.M8@9+"RJ84B[2^BSSEW1B99
M,*Z[2F1/:LFP;VPW9V15<Y;];(0,N@0&F516`6U':D=#9H=.1@?5>7S?W?.(
M2\;3Z7,*L@P&40@$_B["3)P8F"BEU]:7K2F6ZM=5PK3K+M'))%V:+Q=K;HY*
M<4M;0RN-1-U,8ZBA*937%!C*@!Q02/M%F.K^75U/(Y;I.23!A[D9;IFW;T3)
MI5M+'#4:%*77UIJYPQH;+!SI=\/8/7(YX'<O&;5TX$$=QZI`6NX0T55'/U1#
M\H*4>,5-]FSK<83(C]UTM]F3]XVRDX4&3F<`<`<`<`<`<`I-=T%M@Y9\H)B`
M5K26/DZIBX6JGU<W,I7$?K:S&!>QUY9(+`C6EF5^I(VAEJ8KC=@\;A[&]J91
MPP"=@0+7UBLL%PPG5=J.,<B)*9@':BHC,;'6,(M*Y8W\/6Z!/KPVVFC@=HYF
M;'K-F#%6K:Z+V^/!VT>3AEO-R+A6<S,L#EL@DY:`N1$.F0F,QX5PYPNPWS=3
M+([ZL*[[1Q+:A=;'<6+.Y%'+[+%[+DH:V1KB+D:E,]>)7"8TR.1TI)H:C(&L
M"EIV#L)&@WB;QW-9S`9/?8V,BCLQ9`&@4K<J448SQ^TQ<C&JCK3M+%!53YES
M&X";\-;U7O9T@[NH;(<D&PZCLP^XYR04*VHL@4K.86:YTE$<KO7+EZ/7'NY0
MC7<<-OTV.0<=,M9YQ2>IL[X,C@&J.<1+N4.;7E*Z0B5X0NSIG.'@Z&HR*UZQ
MM*N(_`HZ/L9W&CT;A=J7=)0GOFQ)FM&7D^;MQE6*0N'2`(`B30]M6)!"PAI1
M28B,FLLEAQFN=,\BE:=Q&%N._:)_8T?KN42(X]*.F!NG)+'XP`5O3MO,\(@Q
MDV"RN3,9$5B,MZ\C&6[483%-HHU*QYXJ/>10`U&!2,)XY+[\2/HH5\1W>2PX
M),-)RR6-R:723.[<#UO6C`".#'?5%-M%K.E0OWJB1A;-<_V*8`GT&2B5TSP:
MR;'48L`U$Y1"`]FL1UOK=TOHM3;#P9'`-5TRHOLY+A&8]'E;.B=G9M"PS4JM
MR37_`&!M3<OB;UC;;B`M8]":O[`1.=Q82B_*ULW6$!HQ!W4.W8X1:_'`@.[P
M>&I6CHKDI5V:WY\#)W$4[?F8-.X+'F5IP:R"<TK"6U?=,ULBMI!$H:R$T]3P
M"9BY@)CTM-%)3AW)`MH-R\2;U5M"Y#)CWQ6-<`'+MA*PX4TQE5K5Q6-V,P=G
M(8#?;IQ*V@6)WBTB+ZN.EJ60"U]CB!I\^KFR)(3O^'QJ6.+;9EADP/UP9C0*
M23%9U%&%H$(R93+2A3#YB6(!2E5^;#-4PS)-ZVQ.\8E+=4+61GA)DMU@ZU1P
MA(3E@L);%]KB@BEFZ6CEB+7F9,TA(C3&60E([,D8J/:SIW%'3XL5768A<O0<
M89OE@7*X,C@#@#@#@#@&KZ9TGV3E;.1`@7RG1RR7MQS(\[MP[?$[WI8[6#RQ
M9,?@4>$5_6O82!SH`D(A;B%`"S`)'("1$KA3K5C()@U?OB$L&I5,LH4W5O7K
MRPYC&'=Q7E<S6NAS:U(C9SV2TU(*SO.96974MB,0Q&*4HF)SK67C@\N<R"9M
MB4TC-LDC4.3JMA%IV7D*IS#F'$3R<F`!2^F,J-7]JS*U.[.P"_U_B=D'BUW-
M8\2J?I0VR)6OP<6)+$ZOM^0FNQ4,`2EU:8LJTGDRJD\,CAB>Y3B8^S'@!UH=
MEK/;40^5!12Z:X9JF$49)O72)WE%)@-2M!O/GPW?K32D>)'#UACY=&T;2B92
M<[RYKH.7FQ4TK+'(.1Q9C(ITC&4D)P]C+I\5/OEFXE1X(XPS?*D%S>"$(W^.
MLQ>"(2"G&[@M9$$E$<FD?B.)+K&!=@,QK[#&70(V]=+(AU$)3""<E'`]Y#G8
M*&F6\8E+C*+@`U=("J,;BE)6O.]8GT(<RGUD'8Y%EZ>=J2R,F*3:%)LE&YIU
MG+3AQ&'D[T<2U*22=JP[,.)>"L5^WK]P%?0Z+1C&HUPN*3%^73'/7[75.5*X
MEXA+`(->Q:Q#;B2'(O4ZDQ((QRBI:5CDA0$]A5YX"A$,/&JEKUR#'RDI2.7I
M(O($I,7C^A)NQE!5<:FBQ#Y>^=;HZ3[&;L8?W+^5*#%Y//)L5KYA=+:1&@L:
M7H\0BV@S]3ME'%XX00^'@Q$[`!@1]U?./V#\D=GVCI:1%09-_*`R*0D/EC6-
M;Z??3@;`^#)%%YAIW(:BGX2LWS@?.",>=-P2S(PI'"*^^=D]GPT3)DO)6+FC
M`S5Z)"RA'9-6-%7K,XDJDHPU4U!>>>F)15[3'8IU:H&>UZTN2O:Q!,*Y'.:Q
MG]_R:43@D]<&+P9SLP.<-^P-@5CD<TQ(JJ*R$-,F\I=F(:*=9KPG#I_'AS$B
M-2H:I.<4PTG/*M\HR^-17M$?+]:#!,):$(!U_%H%&^Q$7DUK1!<E;)<5L*U#
M26/+0V<S9JFA!I:F6FEBOG4BAYNVX6Y^!3HN>M?98ZP"E>E+M.5V6ABS*M>T
MKMW3^^S&X!;6.6]8#Y;WW=0URN`A#[N-$[&$O;$V&6H9S8XDGU;0D-8`@SI2
M;D(T3RZ`Y$"A)K:1HA*KN6&D=Z\"X77$9/`E>$Q-BC)D--MK4NU\*^.Y:,FQ
MUS!I';\VE=<Y]_CI;,]]V(R!G8['V8TB63>`]`VP5%DB+8#55Q'Z+M7J3SP0
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`A2`1^ZQECVJ5GLVAYZNS18>O7$?#
M1$X(-`6*(0*VW3>EW\_D(_?1-RW)Z$&[6.L,F":_OY!8.W4R"P+2D7X^>>I-
M?!!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"(;P!VU(J_?BZ6E<<ATW
M5("5$B\E`E3S3(Q!\DJ1:-=!$LB#@>]72UUVU?JO""&S5-V/V&95?I$!X;_.
MC)0&)DDAH](P[8ORZ;%HF5?#!ZXD:\):()ZOG8\4Z)FG0QBX=856:#W)@LNS
M0W3;+$WZB>SI4#G<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`A2:Q^ZR
M%JUB:A4VAX6KP^I?%AQDO$3A4\<RX3TU1]@,LI^"&H^L1QAN+RZC)#X?(Z+%
MW7O]NYT#-@IX_L37P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#'9?M*=(G*-
MH.D&7FNL=-[0]"1+NFL?6E.!KG,?2.N6+=V];AE"V&FA-=FU<ND665U&[=97
M71/8#7W5W6WMS3X.)5X#NV)RB$QN0RA1X9(:2H$=.A'+:(V3'7;IJ2=6$1;F
M2ERC[#AL_3Q+G23^I+(V(`70TU%PD>;C4K+S]NN9%KCK?W]D$2DD6D-H1_=C
M(X';D:9LM;BMA#>+.9?3Y@7&EADD'(IR=\22MTFV?+OY^0M;:/PEFBE#GD;*
MAU-)B$V<LL%@_;**[Z6)@=)]C`MA,920GVHJ),)-'B;*#,YH5*,E`9(_<:]A
MMI=A2-M4YM)'4=D-4-6$B..'A!P;C!,OA\P>YW?%Q*8+R%ZSS+W\$'`'`'`'
M`'`'`'`'`'`'`'`'`'`'`'`'`'`*B]DZ=/VY,J4RG5U93N%PJ1N99)RLI,-P
ML\'$!1.-$8N"AY)6$29R-C90H/\`B"=;"3``B?3B0"'.O;(W(9#JF*G$WU\K
MXRIC?K!W.DJJ)ZR9I'W9,1(VY<0%B5SVD)W:C'%M]-9_+8V&F+T8]E;"/FFU
M)7'J#'$S!-%EB51QAE((-*$!<4%E>;K27='<V94'?,&,:F(#9>3CL+3MI$)(
MMK8,F7E$BM`Q6-U#`4>C47>!,U]D4,FKJART&>;1X4;8/0DS<%CBJ"_NF6!-
MG+'+">=TS?T+XT7&["BT$V%V434(&MY/+2`ILYE+^=/P,4(GWSN,1\E-BHH*
M2E#\8*51T7(/!^JC3UFH;1\90%I&R(CKTYDQ\$'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`-8!7K1VR#!Y&A`['#L'X@D1KJH]&<\D@/`6F8Z&M,E2!R3$5HD
M;<.I)"IU8L6'V-$$T"(BRX73\3=&S9G+@G!BHU*Q6_?*G*C2X-LRJ.];^PS!
M_*-75B.$PK:[1\_AH@M8<BFX1^)>=O9#;I\B:%R,`JY9.6-(OH[$8Q%&A3<,
M&F85R^'.V2WNR5("2NG_`.4N\G35W0O=9(?"-[+N[9P8`2,,1DR4>G\FP'/:
M;R_KUK.5D\+@-"#H6?A,;[#[@(\3<)BXX;L,.I'1D/091IG7(LJM/*_;E>Y<
MW!ZV0F75K0=15]/7*SZ:PJ!QZ,2DBM+S<]R5.!6*;`B72E<C;M#A1J6<(;DF
M>"35NX'M'2`SU*>C+37`R[V3;P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P"")EVDZT5U*5(//^P=*0B:)$F096)2VT83'I*F8)`OB@<*W!
MEC;0GJ2?QG_I$S89;>U.0?\`C9%+=A_A'!8;N3Y$OQV1`)?'P4LBAL1)HM*`
MXR11J2`"+,P!D``TR0)!S80N/6<,"@@L.<MGXTBQ<+LWS-PBY;+*HJZ;["'<
M<`<`XK]^Q%L7A,F\:CAHYJX?D"#]PBT8L&+1'=P[>/';C=-!JU:H)J+N'"ZF
MB**.FZBF^NFNVV`(WA=X4U8Q1J#@-JU],C3^-?&H\/&I<",E",+RZ8LDYF.8
M,'R[I_$'#LF.;,Y0S26!/5GS71H06V73QL$/(E+@#@&#R2SJWAI6+@I=/X7%
MS<WE*4&A@B0R@(&)RR:KB%)`C$(VQ(O6[DW*%@**QI(`-2<E5!*2I'1KLS3W
M6P$=*GA9-HUI3<0)6#;E@PJKH&&V;:F)K84H"0V)BMGKA-HSP2D4B>CA#'+M
MVJDU;>U.TO7N%4T$_254TUR"3=$I>2J92.,B"XAD?%$V!(&18(%1YA@[0=C'
MPQRAJZ;$&CY#=1LX9+MM]7"+E%3=%5';533?;3.,\`C/[H&B<U*I?FMSU9O1
MJ399ZI<24^BRM7ZM&QO>,N'.9VF4VC'J$)&FH`54]Y^@F:3W%[YP]UV0P+#F
M(<Y8G>!+<JJ2BIV=CME0(\$JT](XK9A</+@!(97DGA[!J5ED=F[YF_6;14Y&
M!;UF1D`DXHQ?AV+ML[((-VZZ2FXD'7$;RI</6K6Y2ULUP,J1]&XS,6=FD)I'
M6<#=1.:+,&\/DR$K<$$P:H&4N"@U"/EM'N6)A9^S28+KJ.$M=@C#$E/@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&I7Q!*=FDN['>&M+ZWK.0R,77'=32X
M;K/Q2-N7J`&-(TW(:W2ETG=,D,[/%TMW$5!:)I>VE\"6"*FK7W6)55;#=ETM
M2_RM+FF5[F`#O1$NYSJ)P8)?S/K:([X=:2\9Q$B#_%4ANEFW3$]'[8C`QNQ+
M:)MXX.[$L1*J\/8,-S0%VU;.PC%@$?L</Q5LQ6_9M?W;4KC!2!C$?%V94RB1
MU*]SU;6UZ?162;LWDLE#S._:R+]Z7+-F/49.""HC.5^J#M7$ACFN,0*8@-&Q
M*7,CLQ9M'J+S#ROD#Y9_+$QE39X8\5<6;MT7XL3E"_\`:)N;<^)'47\4';.T
M<)/V4>58DVL#^;(1I!#5R@R%S)HXU4R44C^C)Z/;M["TOA;4@[%Y<@MBDYV/
M_N?32[2SG;'I_P!A;N\(F]NO=;6-:LL[$W=6L:E6V;JF?E(]Y.N0@$LL.G&A
M9^R!(12,RUI'93"!P,IN@$![RYZT<$&,=\M60EEI6TX4)Y88/.<3W7E.>V%A
MD+<'4?UW,0>'!_#2N9Y5-F[5Y+8+?\`[2RC04-A_6F%E7$K$M7**I>,Q2;/Y
M-%8T4@R3F%!AKD\LT<,3'`L[-)?YU*P:Q;\QT96^R:S\2V'UM"E:KG_9F:&9
MKTCG$N&ZR&6:$)9#?$B-/NN+*'1V:)N&0A`/2C`0$M8FRCTM3?T\)+E9]B3J
M)LR4$8I"K8FL+YDM-BLYN;JWY8F=S>B?$^;]G7R4;M&7$Z(<]@(E*G3W2SY:
MT2S4_9.B#=;7/%P#5`NV68"NI=PQ%.Z*I%K:(D'N)Z!!I$&3-D045";,75CJ
MG*YJC*X&>IO8`C:.XL_6G8S<6V\=PUV/)SAM*YP8RGU9?]9YS7\9G,-E;65E
MCP9$0[.!XHJ]C614N#LU0C%FNGI#DOA@$TDZK_\`G%V.TJ.G'<3/>%9=S+Q_
MN?0M3=J0FS)_W7F]$1N%2>'E1^CRPSLZ$V2*RID\X1VU';.\QX'@B^D;]\FR
M):Z8?K$G3P@ENZ!.ROBRJ65:X0>Z3LN_&G<'>8PK[IM"DF/<GHSK'@6RLQ0K
M]/K"8ZRR07VP]K@A+.K9P'9VVC'=B;4N'6.1Z0(I$X.V'MW9)V\$^792I,6I
MSF:56G`UZ0;KYXE%6]0#U.P&#=D1&Y7I%-U&<`],H\#!NT7SAY"219K&Q+YR
MN#C10IUT,E#!I(7JRC1T/NFXE6SV1Z)^8U-EVE,1M=(5_'[%M-J![RPFV.RQ
MJHX]<L4'V]W.[XVS+F2!4PE7TYZV3'I_'(G4YMG'D2"@I*U2_8:,`V<"0&,1
M]LL4A[D@=0;5PYT6>B;5EI3#BS95U4]J7PV9DA4G07?D;4MV&D:U[&.[UG'A
MJ>%)!X@^'E2KH6UN:G)$\;]FHBM'LR/$1&&Q+UVX).16@#(QWDK(I0`TV0D9
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M\K..XRR:I&'I`Z)94Z=$@XL23"DI9(G&K5ML-"H:2!V-)3CY*7J0@EXD,`#,
MWL@L2#2B,0V/@H&<EY^(CYE<1,&TLZLI=<<2>L8564!.S"1@Q<!AI-6R#0H1
MLE`SN<I[MC4.&G)P*#9U\3A];LUE<;#0I@;(@PF0!G6KX.=&,#`I[HFJEJ\&
MDVJ3UBZU2<)I+IZN&JZ2N$UDDU=,;XU43TWQMK@9/!\=$#2(40^?HMR4C</&
MH1GOZ>5B*X\>X*O=$-===L8PV8-5W"JBF=$]<:ZZ>GZU5+3<#MN`=/(3X:*`
M3<HD1!`2`C@DB=-E'6=\-APD2T6?$7R_J]=U/5-6B"JV^$]-U,ZZ9QIIMMG&
MN0.XX`X`X`X`X`X`X`X`X`X`X`X`X`X`X!&]PS$]7E4V-/8P`8RD]"H7(Y4.
MCI(J[",C"H`4Y*[L52;`.?>-MET6JNJ&&XEWNNOZIMY(X6RY1!5:691.P>^$
MTA4DG`9C5@:3:Q%Q,U&;%B>+)F#[F+W(YJ-M7C5-$,^PG8#V/M];\722:O%&
MU8.$4-(\LQVQ.LC2LZ_M$SNPW\B>*([8";;GQ>HR45/B)H%C4DF3"6M&HUQ5
M-EPJ/689K-.95N=0/DBSD:4?#&9+#(P-:8;H%$M11:2CDDCCT1JDS^\26\X(
M8_&I.'EPYR5!N%'+)I()9&%U%$%FVVIB$RHS#)"WPFOIIOLFTD``FU27UURB
MZ21T=-]U&ZR2FP"*2@--8T$ET=<*/`,C&MC`5ZHW6;>W"WR>%V#])%QHFMAL
M^;;)NVBFVFN%VJR*^GGHIKG(&0<`<`<`<`<`<`]::R2V,Y2535QC/EG*>^N^
M,9^_Y9SKG.,9\O\`1GZ>`>S@#@#@#@#@#@#@#@$%7W:THJ&/!9%'(,G/4W3^
M2H%A:1=^.,:(!:XF\T')`6;&/'<%B)HS%A\=PW<*#DVB1=0@BH1=MFXA^*E.
M,?NOW*4O._TQ:9*):0VO7"(YQ9P]*2YDY=&,OF-:EAS4+9VJZ3!YE&L;H7?J
M0>MW[=R1W^4=IL);$)6VW7]B%C7S%;U^\4FZ="W^`OT?8BPJ(3V!&ZILEY5,
MYB5CBA`F0B96TAT*GNGJ]`1Z1C78LA%;`BY0>]1)>MW3?;H.FK-TW60T$:C6
M:T(7\0KNP.Z`=;RO8DI4-C78U&RZ'Q#$-K-JDL7T7EY3W:W+%'BZ3A(2%;*X
MU9X>;M7.71Q^$"IIIJEDW"`MFSM.)2OOT+.5-982X:ZBME1U@?$B94P4>(B9
M4)7!2,0Y:O'(TD*-B7.=E&1(829/&+I/&ZJ.RJ&RK9==MNDLH,W$B<`<`<`Q
M]S)P[25!H6LX4UD!Z/R63C6N&ZVR2H>)$8H*-N%'6NF6Z"C=[-8^FBW54U6=
M:N5U&^BFC-SLF!D'`'`'`'`'`'`'`'`'`'`'`.F)1R/&56[@N!#%5VCP60:+
M$A;%\JV(`W#EV%?-U'2"NZ+P.Z>/'(MRGMJL/<.G*S3=%1=7;8"MO:6%PX)U
M;[)/0L3C(AXPZXWXS8NQ8$6P<LFAN$2,N9:M%VC5)5NW+EM=2A-!'?1)^1QA
MZZU5<XPKP57K>NY+%&?YDZ=_V65]_5(1P'>][[G02+_".Q]3M]O[Z@PIV]BV
MR?\`UM6Q'>74"+&/-\8_[-90>]D;1MMMY>L14(:Z8V]#?T0P>]>I.7!#679\
MHG?=QP!%]6).%95S15Z#'UIR>8/I9%`]@SZL)"+.B:T&C1T?)/)]6*[#+&8R
MDAG01$IL)D-<K0N7&4=92B*;RTQ]Z53Q4/*^&JHV:<$'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`.,T>LWZ/M#!VV>M\[J)X7:+I.4?6);Y353]:COOIZ:2FNVBFO
MI>EIOKG7;&-L9QP#D\`I*I_*.LOJ2D_V[">#7Y/ZO0NUP9**.;O%]>^B>M\D
M]$W;YY`U+#CX?=TQ9JR>Q;J+K2.'1?1T3<LA[9S))Q.1@E9Z0=M1X_5VX(DW
M;8>T=NDE]$7&N%[T5_)(LA02D15HJF-X`<3D\%^2FO=8=(T\;ZZ'8PG$Q*8(
MMZ"FNJB>Q`9JV=;I*Z:*I;J[)JZ:*:[:X$=[F_$EO@#@#@#@#@'$?H)N6#UL
MLKZA)PT<H*K>>NOJ4U4=T]U?/;RUQZO7;._GMG&N/+SS]'`*7=&ZBS`ZKC,X
M5T@3%6Q:KJ1%D&KJM_DT%-8U'!L@)18A)!NTIE>YBPB0>9(HS(XF[8,G#H:U
M:L!B#=IA9P-6G+C)O&?%D7<X,C@#@#@#@#@#@'H<N6S-!5T\<(-&J&FRJ[ER
MJF@@BGK].RBJRNVJ:>FN/^MOOMC7'^G/`/8FHFJGHJEOHHDIIJHFHGMC=-1/
M?&-M-]-]<YUWTWUSC;7;7.<;8SC.,YQG@'GP"C_4+_.IXB/UX$O[&?3K@KN6
M[U9-O8+;7>'1-AC;7#DA>'7C+73;.,>LU"7E7\J)Y\\YQC&&H(`6?;YS]&$V
MF^<^6,>?`7H^S//K+KM]SK1;A37;#HE4M?FR.V^,X47+'8N,,F'2N,XQGUSL
MH_=NEO/&/[ZMO]&.`[W%TDX<$'`'`(-$_P",.R<\W7_OND6I.JVXG;'TZLUY
MO.;?7E"/G].,*O$()"UE4_X.^J35JIOC.JJ6<"X<7Z1ZDY<$'`'`'`/'.VNN
M=<;;:XSOMZ.F,YQC.VV-=M\ZZXS_`-;;T-=MO+'GGT==MOO8SG@'EP!P!P!P
M!P#7W(6$<9W>TC_8GV.=3"P$8RM5RD);3T(M6WI2,G&7SL,=>RMLA%LN/6Q5
MVJ7@#T?*</-B.#;';5N'.R0:K%,+[MZW[G.F1:JT[CKVBQ,,>S\LZ%CYA-05
M:QQ;.CDDN[DI@>5?CVJZJBBCE=50>!)K^ENHY(DG*";!@@2-/V+%V,I24H[-
M]TNOIOK'V*'.)<K%L$NODY;ZDIN/6B`5D1LBGYO):P#D2QS9HR9E[*BPA_((
M@/45RLY;Z-1)+`N3E0X)^-*RY5,>S2?)^07>HS_,E3O^RROOZI".".][V=`&
M_P`*[*6-LM_?,!*0IE,=M]_#522SN]E#J>F?O8W>Z1:-;K:_];T&3;;./1VU
MSD,%O?H5^L#LAK.^T*G2:'/OAI92(ZFK(L\:>W1DP9?(UI)GU4Q$(T'[/PTP
MD,!+A)&A8[@BS%QP"3([`E=YTT#II!WONI%TS=?2&6=J>C:AHH0^`4]7<7KH
M,379.2(^+C4QS=ZX&CFPA@LZU3\]EE&8MFU'M]U-MLI-&Z*&ODFGKC`GGKW)
M6X!4CLG>LSJ$U$AD69BW"DAB%D&Q0\C`9Y-'D\FL,;Q\D`JN,O(:18MH[))8
M(<2<@V?%VYO*;$`_*(A73$,6VT&DDYX8I1K6^*%M^#(X`X`X`X`X`X`X`X`X
M`X`X!`G8^'EYE6$A:-)NXAP08'.FY0@V@L,L#,E&"0SQ^W"N@,Z'%0CL=D@W
M;.GX_+1)P800R+T)#='*CG`JO^\=3%.JLCI*PH<0L2FJYA\";/GS:.F5(JK2
M3I4TJ-#!RS14L\HB;3Z,XW:M3B:;,4:.)R`1JHXSD6S&D&3HD#G%SS]2,I3X
M@]51`Q8(HK"+0RG6CF4;R,B@)C>C54%%+/9TR]D01-]*63DV-=62^1!L5&"*
MJ>Z2!79PLV+`#X48*K+>77*<O.1'M5W-%+>\10SH#3(#)!!^I,LB$XC!9%+!
M&-2(%V2WC[MDL]8+/0A)!PZ!/70]Z()OD5A^[95QAFY449HBM19_J]#9";+-
M0`4N=?;>@R"BWY9YMYXQZ+4<T5>.-O//T8\D4=\^>?HQY>>>#!3=>-:+=7.K
M51F6#1^1E"G6*).!3]LDY8OVL%0C%C3\>\1<:*)Y;N*]KF;(J)[ZY]=YX;9\
MO7>>!K%O?UI/!O`NJU:MF3=!FR;H-&C9+1!LU:HIMV[=%/7&J:*""6NB222>
MN,:Z)IZZZ:ZXQC7&,8X,GOX`X`X`X`X!"'8URX^1R6QYDNJT)6+D%40Q\W4W
M3<B7]P2,362,@0]5G"V^8QB5[R5;1#.%?91#C;7;3&NRFHJOZ\JQQN)I;-F[
M-N@T:((M6C5%)LV;-T]$4&[=#35)%!!)/&J:2*2>NJ::>FNNFFFNNNN,8QC'
M!#W<`<`<`<`<`<`<`I9VW;!8NQ$W#9AQL>JF%&:Z&[U*5A=)%@1*22B<XBKB
M0D)3<I".BP+EVE)0`EF5S-8FUBS)D8(Z;'GI9,5P59*]XUNX?<F2%2"L8=2.
M]CPV*!857:,2*V6K'XIM`=!C5@B)5-E%63F%'R%<K.'"#1198@%DS@`\=[*/
M=S.^JR[W(5G-^<2MP[Q#*\*--5F=76][9N_L8!H(>C(B%*?%]1MAQBPXHY8R
M"8"7(DD$B9-M*$%CJ(ED];ZN`.[AI+D?A_879>F%<*W>>AP>@T[BEF2KOY-X
M25P;C!KO`X]VD]6C]CAQD;U$ZC"7VN6A-JS>H[-R+!VVVPLV3]/9'*B65$=T
MU-Q'39W>K,_[N&'P*OHN5&J>@]%$+@.M\?3G&',=ZE]CS@QRIKC.,^K9'6`A
MUIOYXPF[3:9]+&^4_,6SCP_[(MV##L8Z$#Q\8GZD:#%CPX]'Z/[TQ&-$631/
MZ,8Q_`003U^C&,?1]&,<&3M.`.`.`51ZZ63%++G-_GX]O(5DS,AK*61=[(83
M-8;DS5!^HXDPAY\'K,H\`4*1TE-X[:Z;!VQT<:;.6;]QMG5H\'+.A6HCKOGV
M@M=P0<`<`<`U:]O>F^O;3NCTRF#:]KHK!'J`L?O.41JMY0X$`90N=)L8W7H,
MPTU413'/)I[HLH64DB&A1P[KT!-H$J.:IS-`Z)&DXLVE">U"KA%\<T;2N#(X
M`X`X`X!K5[+$!2/<OK<Q]XAP)M=G%U<NGSF!Y>R47BU!B.L?9L)Y;M5O-E6C
MO?91N^KD%<<J;JF-T7D.%*N(RSG(TKG?P]83ZQOOB]L_K&#V@Q&#9R$R;8B"
M"Q)FWP3,"]-E70HB"(,WV0Q`=N5"%PI8D*-QTKL]`'![M5H7&O4/1TU&;BGO
M9#K%1D,ZS]BS@"!-T28GKG:R#-<@<DYY/&`5238%'%W3,^;)LB#Z*QXN3C,0
M)$&[HA$HN^<1F-N18'?W=P:3<JN*[^3FZLM91G^9.G?]EE??U2$<$=[WON5>
MMFR9Q5T*[PVI7L<WE5B1.60R(1-GJS;DTA[/6GZ>),CCP,N7`[R(;"BEERF9
MD(NP,CR\I:LG$<!N$C)-IOD,MV[%X]))^ZU!3PJEX0_FT>*1JS9>):S:W&)U
M4<Y.;VE)6R#V:[$'8IV_8+-VA;U@B.MF3M0>$B(R/QT0BP#AQXYF#Z8;B=N"
M#@$&S+_&E]4@!<?_`&8>*W-9S;'W_P#'\<2KVMV.V<?Z,8!7)*-?3\_/&=]=
M?+.-\YU%P?!=_8G+@@X`X`X`X`X`X`X`X`X`X`X!A%F;[Z5Q/]TQR)A7$*E/
MJA#AJH^0+*Y!OL)"U6*)`2L]3(*9U:;,T2HU5UA;*"3]GNIJX3`J_P!"W1%S
M2*VY4S)B[K:5K93TE4QEDT?BD,1*&Y]S,WLT/2`T-&#U%-L(A<NT$&2RRZN6
M:3MVZ47%?ER[4+#.:/I9Z0>%WE15B[*D"3TP_).8%%5W[XL265<$2;MXJ*W<
M.2!!RNNY>O%E-W#MRNLX74465WWV"7F^95X)'8_$_$&#Q^+`P\;`C^DAG#`*
M!&LQ`EEAS?P]XY]D'#T6[1O[0[<.'2_JD=/7.5UEU/255WWV%_)_5Z%ANRRR
MK;KE?[A!39)="D[5615TSY;IJI00]NFIIG_1MIOKC;7/^C.,9X(KUO7<@"T9
M9:_W:76.M(W51$W3<:BLUL*42]D1B"+8(;?Q^1UP)+8;OI6.D+5""-C"(5X(
MT`/]9<RMQ4M'U5W58&F2H8/D_3GTC4O7P0<`<`<`<`<`HGV"IG6Y;_@H-#>O
MMM4*I-F#I675IB?2&":1VQH4ZB[V`EL2R.X@<IF:Q"4)LCZS,SC;2"+J(,7&
MPY9/`JN=_![[R]G!!P!P!P!P!P!P!P"HW>)P^;=>#J@UL_<//C6H<:+B7TA%
M%@R6]M0E%>2C#$5D$:.A7D;35R90,-2?LXY1GJX)-7@S5VWW%5_!]F2U3C5$
MQ2D&8&UG$G0(PD>R,;R8B[EC@T@\'X2>)G")UV6>',OFZVVCU0J\?*/4E=L.
M5%M5,^8@VZ^4)NU68[TE4>[)P.V#N&F]<0_9LN)W-ZR7<8LAL'RDJ/4D>FA]
M1FIILW4-::E-T]GVN%\"R\WS*_=0?\ZGB(_7@2_L9].N`[EN]61!XD$<LN?)
MU37%;2,?%W<J1,LBI1X_>BW2+246[USI_7860:")`FCOG6VUT#C9\#),S$/7
MDH'.C=<J@];"I4?2DX-W2LN<82GLI`:G-`0763J"UI+J)&ZR%8&FZ1"JG,,T
M<%E`Z+Y15ZD+W?X<;#TWBJCK1IE'5PINKC?;(R=MP!P#QWWU3UVWWVUTTTUS
MOOOOG&NNFNN,YVVVVSG&-==<8SG.<YQC&,9SG/EP"JG4&M8Q$:EBLV#)2+5_
M94/CAE%*1S.:R]:.5\Y(2:85=6XS682`YH&#5G&IXI%6+,/HQ;K^S*NG6KEQ
MOA;@K;G=WQ?&"UO!!P!P#II&=91>/'9,21)N!T=#%#K]`*(*2`RNR$,ER#I$
M2`"-'YHX340;J:,!`AB]*$G6R3(>T<NUDD=P-=7AC]Q:^[^UO;G:J`QF?Q9A
M*KC-U^Q%6+&7@4P)BM6B!(&."F!3.J@0\,>.W4AG;U&/OR36*2Z>2J(/G:Y0
M(\<N!NW9=EJRXNPU\C<D;+N#`X`X`X`X!0SLA,JRB-TU#$I0%NQT>N&01Z,,
M%Z_N6?P``X=$"J09)QK&H_/8X@>4C;)MN;F[V.CL%`T>0"9-.'K<P,8J#2FL
M12M5/HRY,AEL,@+$1O*9&`B8\B291H(H=*LQ*#XLNV<+,P[!1\NCAR]V9,'C
MK5LEMNKJR8O'>^NK9HX53&2J_9.Z:AF?63L8&B5GP*3%B_6^[GPL:"E80J^(
M,D:WF&VSIFV9/5EG"&Z0\@Y;JIZ;:.F8]^\:Y6:LG*R0J55O7<G^C/\`,G3O
M^RROOZI".`[WO?<U.]-NO%\4U7%F`KN[3S'M`<['>(>[,PEY,A:C)2*QFE;<
M?E)(+V7<%S&RK.40#KZ:<)@AZC&)!!VH<%'Q233+O+L:M--J+,19BE;U[OCO
M-VO!@<`<`@T;_C+LI,]G']\Q#Z/K5,-G'TX;;V+.[54E.F<_3Y;N]*QAF^VN
M/1SC1HGMOC;&R6=1<./M'=DY<$'`'`'`'`'`'`'`'`'`'`'`,4G0T<6ALF8E
M8@RG[)0*_64A1!L+=M90LS0W>-`FZ!K&1.5'[MN@@V4(^BT0<[(KK;IZI94U
M#H55Z2F@4SA,SF+&BFM+E$IV4ABBBR$TV-S`/'6(ITS-*O;,A4&G^@'4@6*M
M(X,+B-&2(YLF1'Z,LDW(L>*]\^;VC/BO<+KF$>R5@3L7#92'&I!'I0ZQ$YRN
M)!%HH;&1J1H$3C:,K!D$0\C-A`#U_E_D>F;-A17M67Q8<@Y#9>5_[^A!T0G4
M5L'Q!69R)D]B#+3IG)QCI)R/)A2PTF%[&(@BPTR`.LAIT(1'EQ1%@Y8EAK)V
MFNT6QE'T<8VR+^7^KT.'XI?5T'W&ZBF*!D4\G==#)Q;-`B%Y%7Y)%B5TT-W1
M"(PX1?M'**S0X(19GW)-4,[PF@L_'#GFRR6S'3?`6+6RYI1._<3E1L/;16>3
M8"-+GI$&J2K*`Z\MSTN);&I65,U_&Y'-2ADX6431W(ESL;M*!NSI3"*62IAN
MX<+:^DDFF@([EK+YT]"T7!!P!P!P!P!P"":I_P"DL[NRRMO[ZV(2QA5,8=Z?
MWM-Q$Z:1(#2B2K?_`*V'@^YI+<PU1TIY;.V+0;G37V=)#=05X+CS^T$[<$'`
M'`*,^(1WTK?PZ:%1OZSX19D_`.9]#8`@$J^-*'BB;Z6D<MO>!1ZONU!@1[-D
M@\W:+G"0](X=R(BHU7<N<9:X&K-EVG"BYNKBXN9&SS.4QT!)Q[<LS82,**/,
M6AX.3CIQJS+L4"#9N9CYMJQ,@BR"+C1(B'+,F9,8\U69/VK=T@JEH,G=<`<`
M<`K!W`?#H[1<LG#BG$KN*0K5B6!Q%)`WDTDY=$68MX5`/8F`DTT8$6(YZZ7Q
MM$A*Q5VEINQ578#7#XDR%5]\>8F55`5AL:HP/-=8:%IV+_#+V<R`.@@LS9!V
MB;58B5D!51Z(!&U5W8YK[Y?NY.$%RW":GH2@6/.(OF#<3'/`Q!/NAUO69)D$
M9V46;K,2A!MA&N+25=.T@>6"AMJR8)PK9\]+!QA0;)2H)HV6-#H6_9SEX/1A
MSA(YN+LOQKS[TO(WZ9$1Y:R/$*(BGS,F/<]WM-FSX>Y1>,W&NG3;IZEOLBY;
M[J(JXU4TW3VSIOMC7?3;3/EMKG&`=RW>K.1;>/B/MU1T?<Y],?'-(\LX;??R
MLE+@]ZV&W5QCZ?1393#K!!':V^VOH^M39Z8SA3=/.HJN?ET+M:9>3@R.`.`0
MCV.=.=*6G`5@NLS)SUL)J8,004W24$G+CD`FJ@AO*B><*ZI`RLQ:%W'J<ZK>
MSLE?5;:J>CG`JOZ\JDSM6K9DV;LF:"+5HT01:M6K=/5%!LV;IZI((():8UT2
M112TU333TUQKIIKKKKC&,8QP0]_`'`'`,)LN9)UU7$_L!9IL_2@T)E4P48:;
M8TW?:1D$_-;,]-\^6-=W6&7J--O]&RF,\!5H==3\!;U95=>5RW]CWS#(>`C[
MQTQ;)M$"95@-;I&C6Z*>B>-G9TOAZ8?N%-<N'CY\Y=NMU'*ZJFP-RY)'X`X`
MX`X`X!KO[.I%A79CKM*2360NH+@I"(]ERPB<TD8(#+2]L1T<,>FB3*OIG#XI
M[U5*C1J1AP=@)+.R>GO0L^'-ACN-C2N?F#U7KN+2W50\.O9E$&<M=FQ^T*E&
MTJ"O@&X=(@B_6`F8XOJBY,A361:_L!QRX'R`!J'ET>+-AY>,R(,0:X7W$3CL
M4,[,="Z;#=9NQ),H:L&8)CJ`D+U47(C`!N/*%:>HR>P:KBS_`'BL7C)+1W#H
MB;=!4$!I`>,-ZI-2,H'FRVBS]<:5IRL*X82T_0V`TR]:#:&JD@^73:L6%105
MZ\<K9]%%LT:PT6NX75V_[J:**>ZF^?\`1KKG/!EWO>R`*C9.G:'2F-ET%&[L
M11\FNTYKOCR=ZV+B)0*$/%2.,?2GN6^7.QGR^-\XPN0;;[)Z;^S[[(B_JC..
M%7Z(NYP9'`'`(-JO_#;%['EU?[\HE:49B[!W]_7(,%2E5E-&"6^/X.R;&4R>
M7Y4QKG/JWSEZCOY*)[XP*[EY67Z03EP0<`<`<`<`<`<`<`<`<`<`<`PRQQN3
M->3P/A5)#)6&2@;A9?++"".7P-\UPJMDFJ@-PDGZWTU,D%T66-,9]K530]9O
M@"F'AQ&F9&E96(;CQ@]U#[+6C)3`64U3,Q;Q\G7%;%]7[,_3?K8<OJX9%V>%
M6N7Y,TP735:DWVV4T$41JU?PUS>;;)8.=+.NTD)R,J:AA!XM+53WQ$WQ,)>U
M8DQ\FGSNV#815FS-MT4P[ZU'[RQ-FK?"*B4E<;[(+I"_(9@27GY$=B":_J:O
MZK\15YI"HVP%D)/TZ/GYA(MDM',IFA\AV%0)NS<OD:^NQ:1$MWA-]LW5).E]
M!K5?`T6DQ&(-F:(M]C^KT+6VW_A\VZ[@/^W0>V\0.%F&/I]:)B=26>89/UM?
M_P"7%3G$'<:[^?\`!(;CL9QGT^"9[J<UZ"AO\9![%F:WTOYQ==K/'F^O_8+-
M(+*75-1=RUSC^#NW=PBL8NZU6T_@.-UE'&FRFJN%-P?HO=]6R<^"#@#@#@#@
M$)=AK$-U95SR7QU1BB7Q,JHBZ"Y&'2FPD&R$_M>$P$BZ1@\))B)7*2+4;)G;
M@2%!$$7STHDS3T3=:9W:KBI2^?8ZGJTSD(^CXHPE*+K!QD6L!H[)D8=(:_*R
MQ)O8\M186";ALK=.Y``/60.T:3X\S)*Z;Y,21ZNBU9-5D&3<'?RQG"Z=+BP?
M!!P!P"O,W;#K(NFOZ^=-V18%5S+>ZIDR<)(/$$I*Z]X1&FAA1B[U4:N6[IUO
M8L['J:HJ/`LHK*)ETMVBNS%947"<Z>_IP;+#<$'`'`'`*?\`>X3L7ZU2O37`
MC?(R651(,H')!746&.]([:L,-JLEY#:[QA!!>[Q)CNV;N#:^WFX5218M'Y!5
MJQ<C5F_GGD\JF846C%;:ZM00<5"-W4-GM6:`34>6>!7K)X"-BG`8R)R3AR;"
M/$&+IHL[:IE8KZL*0:J:O@;E5BNU=*"._CY?ZF.YZ3]?LZN<^X91JY>.)<2<
MD$K"G+<CN?L%VW7G\I3>-SR2K:3S1FT;@#QMIE!XK%T\QQINS#JKM%0EYY=+
MO.-Y%_1:(1.!S7Q`XI!XQ'X=%Q?>%;8;'(L&'``;#8AU!ZADR&[,2*;M&+;=
M^3>O"+W=%#3=V_=NGCC*CEPJIN#<Q.7JR'Z4[04=V4\3F]X-5LW1E\@ZMU2\
MK"U`Z`8^Q;12PX[.=&3-34F5%,1A=XV<36V(:YW!O""3-T!*I.<I:+,5W@K3
M5E-XN5=7/6E.9MBX,C@#@%2K-LJ/F[NIBLTVDE60C-O;.)@7Q%S:\,2DB=+R
MV0PJ&/SFC/(W)IRYDT;G8Y7UNX\>M&F^CMTV+.!K=47#?=SO]/&6UX(.`.`.
M`07?G^-`$&@B7\-U8]N5Q'M6^_T-7X2-GD[2GPM]G[V692LZ\F@]5';^"[V<
MZ,L__<\%7;Q=8)TX(.`.`.`.`.`:P.Q<;WF'<>D4(]\.RJ1Q,S`Y*XC$B:UR
M6,A!@Z:1HA(C$<2F,VA,QB(03%6SF4:2>`1JW$Y!*&3H&Z;1(P&8MY&-*YWQ
MI/6GJC9_G.,??SY?>Q]/_CG/EC'_`/O.<8Q_XY^C@R5X[;[Z9ZI=G,8VUSG/
M7JZO+&-L9SGT*YDFN_T8S_W=LXUV_P#X=OHSY9X*KUO7<P21*J8Z*:L&JFZ9
M.1];`4+`^KVVT45D\Z@0Z&Q9LEOK_#T5=R(Z+:I[:>>^NZVN=,;;8QC(OYGO
M<[DZ]"2X<DD2OFW2S-/3(J)PBHZO0QC3&N@V1LMIQ84C8LT\8]%!%S&+"K)=
MQZOT?790::;Z^BT1SP3!<>5/N3OP0<`<`@WKU_?X$:+Y_OFTAMV^3B3W/TY)
M"G=USY*,/L;?]]!2)MP*;';Z/\7I--?+^#P'IIVKU)RX`X`X`X`X`X`X`X!6
M#N@\M=KU=N5M0\Y95O>)^*_"%-R]^!1DJ`^T9F2812"--!CIPW9INC<E,#@;
M,T0]J%Q=T11DY4:5&AW0QV+9B5-V.['H.F$%[%5GU?IJ"=L;1#7-V"C4/9CK
M(L0$-5'LCA;15;=LBHNOE->0/@PW=D$(3!PP#NIB\'+29Z&&O2CAMJ%IIMM*
M%@O/$6?X(.`1G<OHYJV<XS\284R`=X:;1'2RU#R9'/H8&+-4J<51M!9LB1]E
M5*(0E3!Q<3H^1;ZJ:;J)[`O/'0KKT41+(53*$R<^D5@)XL1YAB[FMK*6W/8]
MG6&0C0U&)F6V2:)Q@DQDVIQZ,A.188F%C!("ZDXMI+2A[3(U:ONBF"A>>*A:
M@G8$#"O\"C,VB(DIL^R,U&DY(&8/]B6!B!O(_#-T]2<9?8#.6Q?+3"?K\#'"
M#_*?LJJ:NPR4^$'0DF\0@,=CA@5(`A+I`47'&0A!H5%/T<7T,2RLR(,%EVCI
M+"J:B>5$%E-,*:;Z9SZ6N<8&OR_U>A+-A2@9'+F3F)+;;(2F.M]MS"8YUQZ>
M63.72:!/@#E+3Z<>T+CJ?L%-/?/H[^K0623SMHJOC`F&]J.ONB1J1BY.$TW5
M,1.:::'XY7<-$2'.F?2];(F4?'HGW*BF?X2R[LQJ]=.'&_FHX76474VV44VV
MR(R4.`.`.`.`.`4+:+V39_9K#SU=A'*IJ2^2K!GNHE43>F&[`=UM]B=EQSIO
MA"W91.8W<TF*Q5?1=T4B(,MB0M%QJ!^(LW@`:I&$QK-_*[B7TX,C@#@#@&J_
MP^NE(6C+A[F]K!UQ7'/U>X=TR4^SB,^ESP_&8K&()*)#%8\1$*K*[_$:A])D
MX(Q"1.=$<@ZJ=PJ##4W*`-X?D`U:M2K*A+96&,^5UE[MJ'!D<`<`<`I]W72V
M6J1%-J:M.-$LR4!LC(:NDMDPYZ)#I&!ZTQ<DI5"47<5CF<0Y,[[C.7"TVJ\>
M>U8['WHO*B+]`57^\><JY$P=?="6E)UAH7DC*8O\0X/ZR4L)>M/T3R66^,M"
M:LW67<8EKYTSRW4)R%MOH.*DLNW@MLT&JM&J(CO?[=#OGMNU0,]K]XV?7@_W
M>QT)O_;9K&VGL0U4YF,ID'?KR2?LS%228S'M':WH(;G,9$ZJ9?XRWX$%8NH7
M^=3Q$?KP)?V,^G7!7<MWJS`>H]>ULQ[8=Z[AA$+AD?+67*(*'F!>-@0PLN^E
M=:GK9KV0MY,]'-4'C\J2WBXN;N-B:BRZ^9>F4]+.Y-5545M[-E/"8W.'YN-C
MW!D<`<`JJ.KJ)R#M9/I<X:E%U8;":B+LD6TGE#:+Z648^5<&;-E8@V,I1(I+
MV==CZ_'-#)$(Y*#P;I@D@ZUURV]G%P6]^GW+5<$'`'`'`*>DKJJ2;]TXAUX&
MV/#S%E4W5<VN67UHT.L%)7%BLG6B4&KTX_$ZK9<^DXALGL_5PT3TW="QQX"3
M+(LF4EC:Q46'$YTT>+]"X7!!P!P!P!P!P"K%C#.NCZZ(8.N6P6+V?;D(I,:C
MJ^P)YD/%$9`".-6,</P:OU'0:-3::#IDFP)#"99G,9C%Y(Z#N`#D"FZ"H["U
MBBWT]</-3,+[I1U=X>!B4;"DD#3A%LUE:BF@)D#(,I.XK69AI@P!R%D9'N_7
ML?;!"3T6HV7;>ZI(V"R%5$EL%18+`G')KF:SKS\/]]!>O%\R%&XU@VX+KM)<
M>TUS!V,..(Z5U15DP]42#)%S<Q8AXU:>DBVE5NB=@[YQ))BV4-,R0YZZ;O!H
MTK4M4QSU6ZZ*:4)NM[LU0M,5+T+J*VK1C$`F?8F:=80U6C#Z[E):1OZZDM53
MHOJCL@V70:-<N64?C.2)-9@.1-2\"U4=86>))[B0V[32F)E\U/J2ET8/W3,H
M_<5B7#"<Q5*V+:>6;7S_``4B;Y,K`R49CL0C`YNG%39E-TQC\<@X-(1+'J81
MQ-P9`6>6!LGRI!1P(\LJ=7X[]'!>C@@X!@MD3QM6T54E+D"?E&<GX9&60",>
MX<&RAB=S,!!03=GO)SL9`HZ>^I&P4>N"1P>@W8:.5]5%54TVZP)3YD1OU4>N
MG'7FK!Q(.1`'8='=JTE0LJJ(</$)I51-_6LV5]K!%#0M^U>RR*&7P\BW)+[D
M1[EJ^=)M7CA=H@*[WSYU+!<$'`'`'`'`'`'`'`-3C*WNW]L^*'I6"=!QI]T"
MH^'&3;+L$TD[M-<AV)2CKB.O6^NR[#1E)7T05E,HKE_7`ALNPCQE$G-C,[^)
MXNC`QPW%E6)GYF[M/(<\-7MCX,#@#@&'S\<'*0N3-)!B2;!-1+IZ33B!R31R
M2K-!FGO)5N',0XJ$DK=VXPT]1A$44:+/TU-QZNRC9TNBH!A5%/*7?0;5>B14
M>#0S8FMNZ91V,[Q1/X@<,!KP@L7&K#1CQ60+-7(_8L]((JD5U_+5\Y5<I*8T
M!SCU*U33P_H'-"MGOGEBV#HSN`P>)S-DX^&R#E-&0&JRE#IK'BJ@1)XR5;'J
M@@K4<Y.?$J(V&L7418,FR&H0@"&E:B**GWOYOB8!4]/"JG\1,VJV-R(^>G/4
MV8S27/BDAD[F/[R&2=EUI,2^#H05D!F-5X%]X2![KJ)B;5CDCC1$C)WLBD6[
MPZ\%;FS_`%1R1ZNUT5G5RN+JK2MI6WAA^V)=0O5IV_7P_36<1Z*Q2;=B;'V:
MD&"VFXS#FN+)(H.MEV[UL;'"242129D9"V+#Q%AI+F_)7;UUG`V0Q9O(FL9C
MK67D1IB6M@0AO*"P4>L)#E)$B/;IFR(D4X=/W`P:]):N7+`>N^>+,VJJ395T
MXW3V6W&3O>`.`.`.`4V[8718E>()1*J7C9G-CE37%-1*Z--V%>YG!N%Z0P;$
MQ3.$5R6%D!^ATM+U]TY*>P]CZ+L&D(68.EB>N$AI).^Z5C%_[7%FH!$A$%A<
M;B8)JX:C0HILWTU>KJO";ITIC+DD3-$''^%ECY@DN[+2`R^V4(F33U^5(K+/
MGCA7<9,OX`X`X!&%T2TK":NF9^.^HVEONO4'!$'*6%FSZQ)8[;12NQCA/.==
M,HE9N:`#5=E-M$=-'6VZV^B6N^V`5_?=B91"8D*@,,B,%!>OP$A<8`Q,/[4K
MZ]S[KC@IH''^TK9QC*R_LC-'URN<8RHIZ6_ECS\N`9/P!P!P!P"#[\:U1I#6
MIRYV!8M!@Q\&@0%-UI8]CCQ22EF,8:YG,/CKO47,HFU=EF[HHPEX@_'12"6Y
MURP2R/\`:T!5.%_EWDF:C!L2DU;H!88XV`PLY$E`\==0C&8LJ%!/QBC!DXBN
M6C9KM'W`YJKJH&4:M4,C5D6ZB*.F4==>"%)AWAV0T"RU'`;,EC9JR?6:7"^W
M@(@[V&EK;;BXY*]E&HX4&#.@S&OP@N+Q*/)B68T$214E#G0N]PR9L1K:?;IU
MOOQ/;T&@X.MY3W\AD;6D;@*&[P./8E99,9=/C^WO#J+U&*N,/95.C<BDY%/1
MV^7T8(/B[AN(':M`PA%B&'CV#4&YC=@DL7D8'X9%,L@\<M+M"VG$[+/NU<\F
M$Z.Q0^YC#D",)_'DL(DG#?9A%AQ]1Z)F)N<QV.KO#[Q!"LVT(CCAJOO&6#Q-
MEIY46J.,O97<$N,LVE\&1P!P"#*4_P`9D+NF:?T,IC>$H3'Z;?\`:I)UE'HC
M1I73?.?+.-%9/5D@?-]?+77"#Q/?7&WIY44%>&B[U]2<^"#@#@#@&ORB.I?7
M9?M3???095$59W=/Y"6J0/8"3#1`LG#:P395U*7V6*>?=R$FE4^BTN2(3!%'
M8[((&QAPUP_T'(K,UAIVGLJS-%6-]?OO;-@?!D<`<`<`<`<`UV=FGR[KM#UV
MC@^0%![KVV&&GJ'M)--NP'(6H%VRO%]PD]CR8\U*-&3R+33:80Z:"CL)5R"C
M^HY5648=BJYN-.,/3U6!L3X(5Z[<?@H]G/J]71^S>2\%5ZWKN:\NP5<TU:@3
MHN.GL1@4CLJ$U2'?T`?DHX2^D<`ONRFU406K)%&M2&N[Q]J`9-[%N9^#&I.U
M%&U#*S%1KI\")/F0U,.U7&NMFLKC1<8-O<?`B(J!"1B/L418&."!H$(-;XVP
MW'"`[)$>-8H8VSMMA%HS;HMTL;;;;8T3U\\YS]/!@[?@#@%=NRH@3.(;&J<,
M"QQIE=5A16$$Q9=DV?BG<5#K.;*L)!\DY26PWW=UW`I6,#$$4O:6$G(`5VB[
M1WA!V@*O*P3='8U'(@&91R)``D7CPW"^HX%'13$(&88<N5GKG#(6,0;,6N'#
MQRX=KX003PJY7674])57??80[O@#@#@#@#@&(3^?PFJH3*;(LF5`X1`H2$?R
M.6RV2D6XH%'P8Q#9P^)$B#K=-%NW02US].VV=U%,Z(HZ*+*)I[`:P-O%>BTZ
M[J17IAUSI>97KO.::7M:.=E(^5;XZV)^@FT?8R1G@,7*,KPL<P<Z"#DT`-3:
M@VRR$=K;:/*$"K\J"&]B+.TVE6-G\W+RA!P+PV_$+N+JKV\Z^=QO$HEY4W><
M[FCNLY12L1CX9C%(29<INFP:4Y,`FLPVA9Y=%-H0IN%S",AX]%E3$5;SF0#S
MVVH@7:LIV79L*B4IUGTXQK!MTZX4LSZZ4/4M%,);)9ZUJJ#`86G-)DHR5E,I
MV#,]&ZQPZH/;-&JA$BMA1POOA+=;;.^,NW3YWE=ZX&&Y;<1+F":^"#@#@&$V
M6X:M*XL!V^3>K,FL)E;AXD-*J`2*K5$$_4<)L#B/DJ&>[HZ[ZM2J6?6#E\IO
M-/X2..`53Z!Q=&-TT:62C3J)_$<WR>R(6BI.$M-4]H'`Q35P.C3[K7U69,T5
MF8IO[<Z!UL^$E#.A,AI*WSM=V$CPU:OS_=ZON7BX,E(7:GJ?$706PFHME+I"
M64]4CKC=97T+T%;>K2USMKC93?R]%/7.VN,[9QC.V,9\^#7Y/ZO0I_X5G9TO
MWY,7EV;-TA8M$L87;,_KP3%++220-%)49#UJU*%7`_9LUW8O(I54`J&/)J:-
M=%&IN16.-T?$6:FCA46W9V84S1.>=.<]#<]P8'`'`'`,5F\Q"U]$STRD.[G`
MH`P4>K(,6^7A0BXSMH@/"A!VFVJQ60'2*S0-'PS7TGIDT_8"V2:KMVBGL!5[
MJ%UK*4.$P6DB-9CY9(ZIIF$2$36M>)PQ%N\K-";NE7LH/:RB0[6'*G;R>O6A
M2789QM`GL*T(-PC/4ALV;#3<YWN]Y]BY?!D<`<`<`U3=MIYW:+=Z.E],=?:I
MK:P.LC`XSM+MQ(9%)WHHW#V#=W(VU?J$DO8-TV+5B4`.YW7#8&E*"4ULF$L@
MTF1@,9%IGI(-)6=FTVW-R4<\>#WXW&UG@R.`.`.`.`5)[OX:*=>#K5X"=27#
M^;5"-:!6S)4OH\)D+8A;07[?'TJHO'>3"6[]5NZ*1W2J9@L58H+MVK48[RW.
MBA;-_/MO7<E3KZ`2B])UC'T6;X<F*B`EKJ/(MR3)TQ]%'TMFF1I:!58[#MVV
MVV46036M("Q",M&XD7$(\,9,Q;41WOSW[LF+@&J0786E25MXS=I;NU&'R=7=
M:4W3=HZ95<(+QCP^>K!EMLU1USKNN[RX9I:M&Z><*N'.R2*7FHIKC@U$[*SI
M_DR]_6ZO%*GH"F:X<L]&!.(UM$!)Y#3?"GI2=,(T5E+I5777359P_D:I1\Z6
MUTTU6<N55-=-,;8UP(ZMO4FS@@X!AD_FS*O8PM)GPLP<Q@O%H^P"@-1>3!<Y
M,Y2%AL=&,=CA4&&14?'SXUMLZ*F!H]HDJHZ>/$$$5-\`E/F1%G59\\)T;%7Y
M@&4C4K<F;$WL("86".7HJT\67,-;79ZNHX8/@WC!.R-93[I>C"[QJ]$Y9.M-
MT\J[()"N_E&Z*="PW!!P!P"B_B+]@;[ZW]6IM.NK%3,KT[&/%6<?J:JW&"KY
MY(C3S5P\+$A<5`Z8/3A>'QE@:F#R)"'HEV3%`W^V"[+1#;*@U92;2;A8O(G#
MJXPF@KK=1`RQH3\F\_'U-`F4T@NTD93%>+RAK&AR)P2\E0UJR82$@W(Z./>1
MAHWU0?O]G#C11?&_KU!'>\:NMT\">."#@#@#@#@#@&L^^2HNP^SU<#X=(G$8
MFM-VE6\3EFY!X^&LC@LJ5JRT78AHS&T%9N)./+Q.2;!V^CVUZ@U%2/==9[Y#
MTD#B@TG"KBI75<.I;3L"!L:1@X8,K?60MWWR@!71\[&Y?B+D(U&FS,IL_,:#
M]RP-G-E/7;-6#6*FR.\:U=OD9,>`S-G&_@B2"+TY^WE5>:T;RJ'NN*Z\WR\?
MV<F&9->NLGP[<360GK;"MAP2C+)&76()Q5*6Q)8^;M6PWP&:UE)E#6_R<QQE
MLP4;@QHS>J)0-)V95,<*8TB^*7^MY[*CI</VOOV.34E*YH`!=1ZSZX0IGF&O
M@:(>16(SAU8WG&<.G1./'-M#D&VDDJ&RYDS7'OMHW.P`S5UHQ+R!H[!TXNT\
M:7I\'K)NFX,#@#@%#XT]LJ<=K'<H;ZV`5A=:3NQ*MRY7:54E3@^%&JMA!\L^
MCKYMHG9YRPF%LQ\%%'[_`'>$1`+56P(LLU:.FA!(:-4C7K,OTW8%\.#(X`X`
MX!!/9SL/`.IM`VKV.M+20K0&HHF\ELC;Q0&\D<B>-FZJ#1LQ%"F6OGNX?$';
M1GEZ^68A1*2ZA:0%1`)B1*-!4G::2O9JID(&\/%^@O2?M?UE[+7-T@H.*6$-
MMK$=0#-$;+N86T46%&-I"'4U5CH9J">"C$;A;4V^LRO9\"E1F5GXHY8-(ZP,
M#5+#M*U95IQ&[5>)THS,:K\(S).*=OJX[P]H;I[NUEV4M(],(S!Y]*#T6!5V
M`)IH+LE<!XF7&@WTW&DFXAV*=,18Z#0][#8N:KF$0PDH6PY#;^EV4K+2B4JM
MYW>8MFT:D:1J[KG5,"I*F8@-@]9UG'D(Q#HV,PKND-&)J;N7&RKMRHN^($2I
M!5R7-E7[AR1-&7;PL3<NG[M=QN,MMMMWLE7@@X`X`X`X!$EYSP;7%9F9(8#E
M#XYT6A<+<BPPXP8)K8LJ;QRN$EF@>/-'\@,;L5I6F_W$`F;@R42:[L!2?M[A
MOG`)20)T7J\'55:3<1&A;B/@C5H/I`PC2]9VO6&@#TH-`@;AHU87,DA,Y$V>
M.0:I?XCREH*PX).(\PSMF/N-LBMMQ-\:9O(BFQNG]QSZ26(;%S"+5RYE1B5)
MQ\Q%Y9-5UHZR?S6,2<#83<)\/"%F]JJQ\')J_E)'26N5743LDA'PLE%P2$@H
M"5%32PGERQICO5Q6J3/I/TY[`7)8\DF"QIR(Z,6'(JYKAB."$X;7L@EO9M32
MM*FKI8?$HE*Y&'>2>51.'C4)0NXVROHU81EA$X_LRCK`:OLI)?F]+_7W+J^'
MAU;L#J+UZ%5=8MCL['//'0R6/W2,;=!G8(^4A\78S$0^,NYC+E)CNO+!)<XD
M=U]QM4_>Z@L0$%1Y@%%#AAN7/E[CI3[E[."#@#@#@%"YC'9]9_9=\Q%Z&R\+
MJ:;4:?</][`>#8``*,F)&3R6*%:Y20W8S":MPS^,3!BX*M'2`!:55](A9)F:
M$ME@HOKIZ\^48E]."#@#@#@$/W_+I!!Z9L>0PP@-'3].+$Q=9J%@B\F8N[1/
MHY`UH(4C38Q'W$AW-3DD!$HA4CP7))5YHUV+#4U-WJ`JO4W8[L>A5GPT*D[?
MU)ULT9][YS";'[/2Z<R:73R70MOGT78]=(8#B(T^401&A31D'&08X6D\C4;B
MP1J#;AQ&19$R-,2R2"VG9;^64L)Z]38-P9'`'`'`'`*:]S2T4,0H92TNA929
ML;:U?+IM6,-M&>,VZE?&8G)?,O'Z='OISAJKLHFHV*--V8UF1:M$"2^Z;Y-L
MN*IO6&[&<R1J?A#F-]:(A`!.^C]TQK/8")U,!)E6".ZJPMR@-9$0[[T9]#V[
M?*R#)QNMJG*62*6SW":1/T4]0=\Z[_LRE^O2&Y5!VNJLJ@K==8?-E2,?1DTM
MWC"[F:;@O8(*.]AAX38)5M7R<<9N*K1#,9L^C<J/(PAMENP%/IY)!967;#'&
M^YX8P[EJV[;0[MPK2O;3K[UWN672BV[7\49W%)#(#%80"6RBT8I'_#AJ.X4H
M*4#!(_&8<$".BD&BH`L7;`F"SB,#E$C9$B[(F,2%T-)J;+=E42I+2^N&ZS<F
MWO/J/&;NE!H]1[GTGF[%IN[V]FRR\W6R">R^?8]EW.S3S5SOGV;9RXRA_P!E
ME=7.GK-AS.=P!P"N_908-FL,`4X_'LRF+JG$<A+EJ_;(.6Z$:%JK3^>%--U=
M%=Q95A!(9(\1"0-T<N0D_<1!VT6:O<-720J[?L3-%(A$X&":1>$1D!#XTP6(
MN6,?BX<>!"LW!@F\-%G#86+;M62"Y0P1(%B*J:&JCTD^>/G.RCIRLKN(9%P!
MP#AD7:3`>^?+NF;%%DS=.UGI%75`>S2;(;K*.GR^ZB6B+-OIIE9TKLJGJFAI
MOOLIIC&=L`:K_#%!]\96)L^]?$+6K4C-Y;+"[;K>E!6F6&(AU[//L25LR2":
MI)_#C&6.<Q]\U;R/UUL.@<>C0RV7>QB-"AHH:M;-%9FZLY^<,C:YP9'`'`'`
M'`'`'`.&U'#V2Y%RR8LVCDP\T(EG#5J@W7*$$A[$2F^(JI::*/7B8H6,&:.G
M.RJ^@\<Q9:[X;-&Z:8',X!7CMYC?/4[L_A/;713/7BZL:;[:YWUUWS6TE]';
M;3&VF=]==O+.=<;Z9VQCR]+7S\\"J];UW/EFHKP8/%?VJ6A)^Y\19$3*HC=4
M@[,CHV*LNUV,0)M)3#8<UC^LB?,(B/,F9`6&"G\<+IEUG8&)P$T5BD>:N49"
M=VX.KMV)?R7I*L-J+\>JO=3:EX?WC#5]VO%3E[AU.YYO"&E.Q24Y!4]I&?A>
M[9JXGC>3PY35&8&TTX>X3C3)_#)I(EA`-UHS-BGY_,B4%AG`Q:L.S$XRU7"G
M7<7F&=\ZW(F7GIQB4L(8-L^0TX5E+A-%T6$3Z)5H2LF3,2<#$X)2AN(")!RL
M8?2'1!<4F>9;JZK[`E$S&PSLO2Z>$QCYQ(]M[O\`8CXHR!A\(;PNP%NODLOL
M%F^)?'(>*5B35JP0B1*-[0Q>RA$XD1HD^>*MJY6D,3D.4@"R9E8"U-!R3@56
M=:2E3[QV+^P2&"*]B(*&@]G:P\&R]1E^26U=&#)!=95Z8D1]]JDCDG(Y(7<O
MC\C+J)ZN"YPD0)N?-P[5VR,F6\`<`J-*N^G3J"]AW'52:]B*QB-\,X/I8;Z#
M2:2,P6[".+;H9;Z/SI39K&V<B=,'"1UK$'!=.5.(QOK)T0VX#;4CL+LVHF'$
MQ.IK/GWCT4[)(]$#?1JA;N[SJO>RP_KY8:%:1,Y'F%?Z/WZS0+)EC9D*N.?8
ML=)%9Y5>CE06",,AYA:82.$.&+=D0&_PW66K/RS5WEA@O3[N7.^_#[L9V$[%
M1.0=1-ZS$,X]TD%L"TCA,<LD;[Q:CGA-<L.`1^:J1]T[=3MK8QB-H2!_)"@^
M.Z1<8-KZ)2+(S-G9A+YI^K3TR]3:L-&C@PY@'#L&0H2*9-1HL6-:H,1PT<Q0
M3:LF#!DU32;,V3-LDDW:M6Z2:#=!--%%/1/377`R<W@#@#@#@#@#@#@'CMKK
MOCRVUUVQC;7;&-L8VQC;3;&^FWEGS_A:;ZZ[:Y^_KMKC;'EG&,\`\N`.`?.#
MXKO7+N!???WJ^?ZJV-%(LQZ_5&&[!VS!)=*YK%Q]M1VI>P$?G,>B*:<-@U@?
M$!#XI`#G@,>:"98BY$@'D37UQ06RV;#K8=E67M*9<*BI*U:CF3EX>_C90_N/
M%96^LZB;"Z_S@381B%1F!.Q4IDKR4L@3"2$2YO8X\B<:C@38&C%3+&0#B99)
MP,D`TL`2R^7&Z.7PS;L.SC*A.5KQ\4&WR-735LI:01<?.(VT(65%8_,X;&C)
M@<%EY@!)QV"@=TC%2+EN=]-=KZW&Z&&.5$5VSMNIC"K5?709AY7$H<$'`*F6
MW?H8NP?5O1DO7F%U.9(D(^&ZO6A9V7`14.G(85;Y!TK--]H!&E(D)P8!.7\[
M=,Q369O`L6UPO*2P<2\%6MVNZFO+`S/K;$95#H`7:3)O*$#9NR+,EVVTY=05
M_-G#&53,L:&K2E]6ZBT.7(:L72#9D@&<+M1()N(!H>S-Q:+%J#OPX7=:E@."
M#@#@%8.W_<.A^B]('>P78N5.(K7H0D)!Z;CA;LX>.R(ZON@(CT=",=<N2A9Y
MA%TZ]3KLD@U'L2!)\X:L&+IPD+9LNTX5Y1;J[)^[_9CND?["SIO5KKPS'541
MZ?=)E6#ADC-SAV:,-V(BSGXEBX?GT3Y2"/I2J493M<4VCT:G,49`XV,F.9ZQ
M"C3V5927U2]K+1+#EC-8@W$<&!P!P!P!P!P#QSKKG;7;.NN=M<9QKMG&,[:X
MV\O2QKG[^,;>6//R^_Y8\_O8X!Y<`<`^-GM#UQ\;&[/$7[ER7P_K,!5A24$O
M0>V820A**ZCR;:TCO7+J>1G+95L3%GYXLL3B4;KMBL\P+<1UP/2(`&V6K*1S
M%%R.R?PU8L[2EUE5SM):8F_JC?$JHFS,0JH8\6D]E=GFF[N`V53@05'H_/(O
M9]>1=P^MP9),3&41F##EXB5$D&A9(=,R:"SMRSUCZIM@K[=J.>R[[E>F\L,/
M3D7YB<\CTOKV-6<T7V%Q640T-.VSH[NT'[CH^;"-I`BN94PZ78L=V@YSJH0W
MP]6:-MDULX=*(Z>MR,NE#NP<A`2=AJ5C1P/(1FRJB&I$&39%F&RZ.<861U>,
M%W#?*J6<XPHGA3T],YQC;&//'`*<U';6+E[$;'7(X`V"A*FFXZM-0LT824LC
MA&UAX*SB$W$LQS70`Z.ZQZJU(:TT>E=VS9C-4UW*?M:>%QJ*<III*C=7H7>X
M,C@$27C>M3=;JKGEU77-@\"K:M0&TEF$B++;>K'#MW&K%BFBR;ZK/R)(T540
M"1\0/;.21XXZ:!A+5V1=(-MP2;<*K9J;O[L-VU[NC^HAWPT(S7MH]*K5L4=I
MV>M.QW.T-83.I?7JI2R$@&!W#>:I1--F+D\5L@H#B2\@4F#B/PT#E^P0L-NR
M&TK*VMN5:2^5+/R(KGH;O^#`X`X`X`X`X`X`X`X`X!KI[RO.SY.,VM`Z2A0V
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M&>V4A()&+#$9D[IYF3CK45VK%I0TTYF4NR=IQVXGE`K*\;+KM\GU=XZ,=`3\
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M"-;4K[QX.U77;MU2MYH=1^N<6ETOL$!#;%AO8.8UG*Q-:I:LG`35M)@U)6ZS
MD%-OT-5AY]U(6=2VQ,`*IX47V@S9TENJ"?P[+LM;3NF4HUI/*K2U)'Z/==K_
M`*Q#5S;;;I3U%L_M77U8;U)*NQ]N=^9P>['S,/H[6]E-RXZ#Z'R5CHWF0-H-
M>5V_>G"!UK3SV*QI4]L)T<M-@M6DY2M/9F85F%P6T6O%S#N)USJN52F"^'-T
ML@*TE=26TRM1P'N^<CTYL.WI4/7DA:-,V[+H<+@TIN2:%FV`#9929JC#1W1H
MAI*<A44B20S1OZG%TQ<EI,PE@3!M<WB$NPK8[&.H_3R;LW1$>Q0S%?$(L)SH
MHBX.MPA4GH_)=!18E5E&-=WQ0XB@15*Y9!R3,,-,2#V$(]$A9M</N8G.NSG>
M:`%8X%,=6>FBY$Z033>MF_B(3ADO$XWD>;?.;`E#:0=#0CMK!AZH-46^+C4"
MKE,F\9(ICU4</7#(5*R\7I\M[RO,[<6EXCJ1`2S;]-NI9!D2T>[N3;3O[96!
M@7#5%)5K@DF[Z`M2R_O7939!AL%%E]-%4M]B6P]OLDNJ)\N;Y?<PU?LAWQ;S
M]O`%.IW3WUZK%7*TB^<*GNL?8R;*@]0=7KW3?H7I(TIT=#/EI.%#Z1Y1N]C@
MHH0]X);H(MW(L68O<Y;.&<R9FC:'B/*EB(Y3IKU,;,F3$6[;'UN_EE["2R[]
M4FF[&CT6_0%<ZD]":,&JY-0J&&CEDC0S`9^672,HB1/ES?\`:O\`8PV&]C^^
M4V,RD,+ZG=/4=@!-)N&?K^(3/7;&PH_M'8J8<SR!^Y.A1=\1A(X[)7E>/RI=
MD#=HSR(2L9H.5&-A!DR+"S>M+KZ7Z298PMGQ%G#;=<IT\ZC1I3)@J):M#?B`
MV/EP_38$WK`>4:;A^@9=IEE(V;1,X&:KND#:0M\V2."`IE,@(8B?+F^7W+&4
M9:[JUZUKR4RD$%@%@RZ"B)E(JO83@3.W,2V(;;M7;5"0C68G$B$LBJ#D:A(T
M@@QL^60WTRT:.=56B0G;,F;@#@#@&&V*C+W-?3IO7KE!E/EX;)T8.\=>RY;-
M)>J$?:1IRX]N0<LO4(&MF2JOMC9PU]7IM[0@JEZ:>P+6XUA&JR[K0>QG?9AO
M:/7&*(,*[DU,Q6)=B`DE*2=./2*Z'DCK,1,;!AEM"8B_FA#1:(P]JY8;OL.G
M;M%N[>2,\HL5(#4J(AX.4]*TCU*V=NNE/9WQ8^K"5.VE;?3*.8'2@!(7Y>G(
MU:1J351:8H8DZDD5^(6EQ%HV:VU'21Z'.,28IP--,";"2-F:+O0`3:"V;2L6
MI2;OB71ZW9U-9G;SH%XHW7S,(A'5OMOU-&1`;6XUFO3CU>'U&>>/X6VU#UE*
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M`B;2SS/66DQG5A2%4DW(M)XD^-V0%`.Y(7NXW:;E20-"+P$.Q&7+G0T,NU8<
M4=_S)4HKM*+*$=5U0G'CLV-.NKFDSO#H&2BHNA96^O08Q<C+!*2`J34#/JQG
MLG;5=*FJAH_+HN6A<B`%ZG.Q6MF8XK*74A%;Z'(`D;!_AUA6KZ>U<)G-]3K;
M:??W1/7L#G!7Y7.B6)23[GB$ZE`D$1\5=S:FO4*%&D`BY:4D6P%G$36@OT74
M5D&[F^=@S*:.FE@^L0$Y?"_\4_FC9WP\^'(EN6._'1LF=7=*NO=X=!Y#31+K
M/L+J)Y%0Y5^';WYHZ=JJZ`MR,BDA<=/F[997=*0S202"FUQ3R#K[Q%VXVD"[
M$1?AJ)5J=JN[S"^^MQA=PZ>,Z@)Z>"I#WOZ*T-.86Q&R+M&W:QQ-J0W$EH@_
MCFDNG3*7'R`:<A]IANE$&@>OP=?A7=DRD3(QZ60@)FK&06Q\WRVFORU^U.M#
ML.LOA.]O*B@-FPN[>Q/6SOD%M66&I?Z?;ZJ[.MH=&$I4[4-2-"%BW-G)"`N9
MB<<;2.4D!K=')@FD-623:ZL$]E@M6TXBSLTBCOWT+E1.Y>Z1BQB=6`[D\-K#
M82W$@8I[D#62]*FID/9&24WKUO`A]Z:F03^NHHE!Y"XPMIND_#S=ENS;-T1+
ME189A1,6O+L,29CSKQ`HL(>GY+:O1,"$')Z*/BI:KKO8,&NJJR;='USIS>*:
M6FR[E9%LW3SMZQPY61;HZ[K*IZ;"4R?->Q'E26/W]M<2^<#[0\/78\*<K*%@
M$6CUJ3[W<`)%C24#D3DI'+SW:Z,IY&1:$H%:;)Z^SZNG8C=5P]#O]M17&3YQ
MOPP/;;-@>('5D?R]=69X?*DF()J_"D6DT<M:`_%#AJZ'-WJ#0W([RU8MM&?O
M-GA9RJGNAJ[>#!^VVCLHQT5!1E:C&'/H9S&R/?R8AFDBB=M=#Y(!?[.M&9@)
M6-VDASE1@\<#GZ*3MI>2J.RS$BT=CWR'I^M9OFKEFYT2<(*IZ"4R?/['5Q"]
MK\BML1X%>-M=)35:.F=ILI>1KDA(H-,8=)ZV##3CMDHSG%J2MN71&M'#]28,
MFP]![%6S9-Z56:I;9TR$)JB<TUOX*"^X0V'DH@:?CQ0>;!F&:!$27%.T'XTD
MP=)ZJMGC)XVW4;N6ZZ>VNZ:J2FVFVN?/&>"':<`<`@CL4PM@C7:K>G53&DF]
MX^FY2C9*-!Y,X9>YS"8W`0G+U4(XURSERD7*'=22^F'L382$<U2>OGC4<\!&
MMUFT[H];+-N!UK>'0;(^[[<TO"V7LX#6#''E0,BE/0ZIH0[W#+72/>E@4O<4
M/HQ:.LZ-<ZE]Y2136V$A'#5B-?*TJ6LE6]SNU->G8;^YZ+`NIW>DJA-F]?>O
M5H=@K3%6Q.;%JB+WZF_3+M?>#DX#"A#]S%`PJ.2T^7+3`X@R01*?$[WS'EF4
M:12C.!I?$B)4I*$FU[$#Z^'KW[E=Z!*YJ/NGT9<U&+I0C"8X[8@(NT/3.:#8
M2VRD)6B4":)2MNX>M&3:5R0O'BD;CLDC3J:E2L2E["93/$K&MJSLULVMJ:U<
M7WY:55^Y1(EC=$?&74ZRPR>6!;'31Q?9V>#/EN;6(,R]B4>A$KS7%>OBV1I9
M=YU[:R0;%ZYB*<F+U;5L9L4X.-S(5#I6;D[T2B3$VOARZ6MF'%8<[[XXY2BS
MG65KXRI6.=TQ\.L;PW1I5@@-8]9`T1!-I+D''E8*]8P(NQ?5W)MVL>CDGR,8
M&06UP:6$YWF:<N6W88AS-L.>"/8^6EK^)XMXKAP.['D_'\JXSU_E=IV5T-(P
MYCUO=@[-C4K]9%6\M[$O7C+($":,I'@2K^SB39-I[.=K\T`J#1$?8OI1?53>
M)."@?\=8VKZ/3SCZX<RIKQ_.P\*?%@_?+J+7HEEV^(S2$2NK(B]/)RBD@9YL
MQ1!)%A>"(US7\??L2NOR1RUDZF\E>,R<:LBS-6:>C14)^&G]-IK9SN>?E,4B
M*;.\.J\4.[Y?L=V-[9=4;^<S:GUJHNNKNP.9$PJ"'0IP!*:1R4%:D:6+&&+T
M0^*9191J-#VHX/%I8=)6PEHK(4EC#8-OY4DHARFKV\IC]Z*XW/P&J^]-60J+
M5Q7!7H3"8'"0@^-Q*)1NDKO%`H^#%H:-F`T8P:W7HBW;MT=-<8QKKG=3?.RJ
MNVZJF^^PQ*UY_8CZ+W)WCE5AE(*.N;PYG2>=&+6'/Q0FSC1:9R%LP,EYK'FL
M38WML8'.X:&9"#2RJ^7&A@0;V),=-&8IZMD6D7/G]B6C:WB#1H4^.R"TNBH4
M*,1RX(E2=67BR8,D,;:Z96=.G%X:(H)XVWUU]-3?77SVQCS\\XX)3)\_L1C3
M=I=\[D"."`.V/#P=E6>^7SP-$`5I6$FVBIHF8VKF5JE8U>BC74=8L0'LIB%U
MVTU]2V(+#-EG+H6\4X*X6%KG&_#`["VI[X@U61EP37LCP_%Y0^0<I0J)26-6
MO`<30\EENFV!,C\BO'4>Q5=NWC%EAXNFJW1=OV#=3'KGK9-4%LY/G/H9I&"G
M?F:@V4FA]N]#)/'B.SO1B;`UG=A46[4'O7(Q^D@]97DLW458DF;L>]2U4]8T
M?-7+1QJFX053U$ID^?V(MG]S=X:]E0:.&;G\.1BFFHY=V&[D`JS8N^KJ,9#.
M%Q$F?`R][)OR[,K)G$6C&R#7+90=\6#3;I3W?KC"XJAX6N?V)I<M/$49-7#Y
MY8_1QHQ:-U7;IXYJB\D&K9J@GLLNY<.%;PT11;HHZ;*JK*;ZIIIZ[;[[8UQG
M.!*9/G]CTTCV+F.A^;".QML]2G@5,55IBL)C3LI6`M)+K/`TAD)$>6CLPGTN
M)H>RQM&'2L$9;O$1QN-2C)9!/+!EN]V%:NA/&_EEXR]/!D<`CVRJY#6:$"!C
M6C7T8_8596,,<.!K4ENT,UC8$<GH[=IHZ^AHZ=JQ_(O!)#;5TQ;D'"Z'I[Z^
MJ4#[]:&(4'2R5&1![%4Y!\29=O8\KA]@1H$T38Q*MX'58%OEEJ0*>F]VC5>!
M7AM_[5HB2D+LL_9#PX]PT$,16Y\UGNS#;MZZ/[CF\*E69?'P@V"JB)`+#.X!
MN9?.I[%R1$C%)`4D3*81QV3CXM`J8C[N#$&CH._CDNG::"XV1&PDFBH)Q.OG
MFXFVM86C7%>0:OVS[<FA"8E'HJD14;Z,\OM`(IJ,U=X9)J+),4U\-O6),455
M$626VC5'?9)'3/!'5MYE7[#Z>:6#:9JRG$];B??.8^.6#,X;ZW_H\,;2I%^I
MN[5E.&2,^24EQ7X1L$*%".P+5;9"2B)XNB->C19\Y>W;C9J/657,Z)RF,PJQ
MX7)I%$';P/+143E<<D!V'%6K\@&=,Y`+8NR*X,FP+BR8Y9F99I;HDQCYBY;9
M7:.4-!(*?P/JS`^L)`/9$GO-76&0HT2/D#UIZ0R/N=S<EDU];#%3\^:YBX;?
M0H5[/2[!Q4J%<'9G-?ATODZS74?""@U+=(ORX8<%UX6DF06,WQ5;P;').!,1
MN7("GX>3B'KB0QQ_J).,##1PB]B,EC[PD-5>"M&[G<%*A#O9+*VC4JT7QA70
M9N9$?7FD`E!+KI.;83GCV3,1->B2![V9M*3QZ,%[1L23:&S2Q\H[FTM5+RN<
M$-4<HMR,=B8##%VF27%G)`^%;G"+W3@O0R;L-U\97RW@^'4T.PO,)D"YC=V%
M<E$-W+!X@DB1U0]W'@;=$RDDV3P)(GDI-'&::Q%(Q#I`W>>J0!.,//;R3(.O
MM:CZOKE@'&R@9,6Q=9"0(GP`MJ$C+YFX#"!@A>."&10VS9C7(,2+>+JM2SUN
M7+N2AU#9ND5T9-@?F=^.IC-NU!'+2("IPO,`(UY&/A8?"2)(6Q.1\/)PMQ0F
M;.%"*>AH,H<4/R&`1>%;BTBXDBP;*'Q@DDV?21]IP$X\T:]27:SC@B'UO7T1
MCY;)\#%H1%(X$.[+M76QH0$`L!@TMLY9?X&XR19M47F5VG^"JY6]8A_>MM."
M.M2HFW1YA\L<@MU.Q767$BE`$LZ".XZY?-VP41<^;S58BU%I9[N!R'>6(,!(
M^21X('9,XYJ;=$XR=GTH.3UT-;5(C/JH\]$7@,"VIP05"O\`3UC$P-?"WB><
M[8PHU(-E6CC3.=-M-\>DBMOKYZ;Z;8\_X.VN?+.!DII0_3)K2<P'2[-ANI0L
MV3(/7S=8"\9N%Y`\1/B4,#RQ.5R0B-A#>/GM\J0A=4IAS,&VLQP>0W66$9%;
MGSKA77%$YWG1T:OB+CXS(W"@[`TD_(L#3%DR7."E"D7D,1(*@GSQ-38,07$2
M1^A@BWUV4PGMNW526;+K);B$7TWU8^2FPGM@N)JS.NRKBQ#A,<-ANL9;ZRBR
MCXDJ:P'6Q)#2@J",F@,?H*@VVK[*<A5*2I[(7STAJU:BMRN2Y?N6ZX(.`.`.
M`8E.(6'L"-O(L<V=)CWK@:ZV68[-M'B"XHDT*-E&RKMJ\12WRNST34WRWVWR
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MV0<);^6V!DKI2?7JH:0ER`V&3J1&#H"%)1UE$)3,`LA*!PZT9J6*D#*J>1R$
MM77,AZ<KC198N1>"6.[!3W"Q$MB:K?85MN_R_P!R3KFI>+7<#``96](,&D>D
MZ$H8.A3&)KE42208T`U5%%9-&I$_B975B??X'RZ#KQB>!'&VJL?E0OUKO1T(
MG'GG4_:4J6,4Y$EHS%SIR2MEGS##LS(785V275BD4C-:"V*NT>$`A*?N&,02
M/Q[?5$8BZ57%+.RJCHPY?NUA6Y\XD663U*KJQ+/=6:K+YM#YV2%"]$'$4<PI
M)=->-.1:6AM'610V0OB*>K!-B%?`RK@G"4L.6YI*--9AJ/D;<)I'GFM^$Q0L
MS'P8R+`048#I;-A$?$#0(ANHMNLHD.$,4F+%#99;;95=1)HUTUV44VV44]#9
M3?.<^EG@A!6G7&`HSX+,DY%*-3S242><%AJA"/*IS4@^DQ&3!_B7=:/[GE1U
M;/9(V%P_4&5"J-(\TC4=DKF0BQ[!MP6<.6G[XDHV;7@:U809@<@</FH@VH)4
M=JC]!:RVWN8T..MVZ[,X,,A"8UXZ&(M#`<R))"3(E=Z*),G#)XNEL"<.2,Z#
MZTPKKLR4&0P[,"XW2+QZ(C&4J>`GN@80",2V2K>Q+B(\#=N'1^43B2'S*Y9P
M2PFZ>(L0B88*S:BT@;D_.PG62O\`LL-!!K!(RMD*"[N<+,XJ2'AMCK)R8C$A
MR(-OU1#\FN&T/0V-&<BFCUDP=%`XP@_;NWP@*Y&@FU<2G7D&9UU%TXRS+F3_
M`)G)?)7QJ09$>]R9N<R\[.)`\=:`1((.CA8[(B.S9L.$,6S5IE!OHEGU65-Q
M&Y\R(`L#IM6MA'Y'('TAG0-:6&?B(\PC[R+(#GAQB&$#HJ1TT)1(HZ:JPPL'
M1EH5%L[2:DY"Y>)S%"4QY1(`B+-RR];^=W8L/`X8/K^*"XF,>$22`[+]PN4+
M[L]RA8H7)O#1HN1]W,AHU-X6,$7Y%P@+&C1;95SLW&CV+%)!JD(9?P!P!P"O
M=L];85;Q`@9+F95'33\"C'<E8LO'T7#9A@)8,6?[HI'(X>9K.RT5L^7QUVN0
M:O<-F3MF[$IC2XYH23%3CSS(L`BDFW1201U]!)%/1)+3SSGT4T]<:::^>V<[
M9]'77&//;.<Y\O/.<Y^G@A5>!=2HI!)VPLC>P[/F4N1/[2@V5E[F`*N)>=1C
M5@Q$*]DJT<KZ-N%]8R`M"8BXZU&+"F@T0X!1[5'>,1")!`HLTB%U]]%Y)8N5
M@-I3'2L?P7(`L%6^&RA,6V!/7B*.54]W".&4F#2$"\;OD-%&+YJ4#/VSABY<
MHY2UWWT53$(`HRB:KZU.&D-B\X-/71")@HO&8S-)!%ERC8%&R\PDSQ8*V'!0
M1@HN:DTSE,A//"&Y?1%RXU9!M`H5@W&)"MS7KYNH9#?W6FL.R@8($LS25[-8
M^_U?C,QF9R.,:8WW)!2#U$@.%OT@II(@F#1%*J&A9!VR#OS;(,Z%^^R2C@$V
MKO0RVHPL5C,9>1R,3?>?*LY/+"\C/O"<9(F7$GELE+2H[[X3B(T*#'.=21=T
MD@.9!1B;5FD@CEOLKHJNJ(]T$,6OU!K:SYR6LLW*9;%Y"\CLB"J/8NC7(C#8
M?(X@S@<E>/7[^`D2L@66A*+X`R5F1.0M8LU/&7<80"/UF+M@*K32B]:^<2V;
M;1!-N@FV]'V;1%+1OZ&_K-/4:Z:X2]#?TMO3U]7C7T=_2V]+'EGTL^?GP0IY
M4O2VJ:BE(Z00N4SA3X=,A7JL<=/H:H$4<1BOC4'AK`F@-AP\FCF.1Z:R$SJX
M;DF1N52"3.Y/.R4K>N&ZV@KM3?'GG*B@M),8TTFL1E<+>D"HII+(T;C3PD`>
M:,#PQI(!CL4L0#/E$7.C$JT3<J.!KQ1LXT;O$4ELHK83RGD0CJMZ7A5=2R92
M6*$R2NIS"8Y*+[*@<1R#(+%R\Q)BXVU$AAY)JB:-RIT=<MI`3-[,4EF#./X#
M!$T6&P28[V$ZPUWV69QH=8CN1I#HTX=*HL@3D.W3?)O2D:+.4UU2H,PZ'.5-
MXLS':FHZN$D*`,G(PK<LB/D)-%<5-J[SR<24JZ@C2N8S\.-C1N2*K')3)29^
M1^YL&2YJ824K*C+QXG'@\?!H8V)&'*35L,"CVS=FFW2]5NKHHNJ(0%:73>O;
M7L9S:126V)'I3L!+`QV(L0BS4.&6D807$Y-(VH8O$#3`A*C\+$MH:^.2%$TY
M2CVK9JP]D6"QMP$%F%$*,=?/,9M2V&L6@U`.BV3R-;,4AJ317&7"7L*+?5KH
MV5POE3*R?L^N$M\+9WRIKY^LSMZ6?,0I:^Z%54_U#(J3*STVL?`+QD4U2)0O
MU;<.9I>,4'-&^RBD%4<K[SFNH<`:&W"R^ZPLLT4+0[>+K.G*:HUM/S?/<O!P
M9'`'`'`'`'`'`-:UA]"9G838FQ<WP"#L4S_8EW%T&-+)OLMXSV2N)Q<TL`33
MWY991M+"<=D+&(IPV2@FL$4#+`'IC(M<H4'+QX:VM,IKDH_>9,YC?4:1D(?9
MT0L.QY$[:2:XJFE,4(,)#(]#HN`5%:4:NM4=DR++@C0223VU%+4-(G@YW<Q"
MHI,X=&VQ,K\GK#58)K18>D>9WTDQB=^'X./*29E";(S#(Z>(:&V[4S'Y98,F
M3(N2L</G@<BF!NTVCZ<5O()>(,VB6@DG9/-3=NRL[+)8;DX`F;A9D%:\F/'A
M.5%F=]MT<T=59!ZR)68FXS$[UD-VEY*R@C8,1G#J7Q2>1Z5B9*U&R5%KN^.N
M[#-NW9YG[.GL)28@=PBOJEBBX3IA&ZZ[ESJ8*CT#.!91!4(Q9@UC!@C4J2-8
M<Q<IN9'2E`Y0ZX8O!V328LQ863$`%9R(&M-2/OC8"&*[Q]&-&QQEYLR$F^:O
M#KG.9T`3PU2S)B0&&^P;HVRW`LA`?5K6;<`N-?QZL;IKN"R)\J.G&=#YZ!+V
MP'DL5+D4??`E]6\52'DV:S(.0`"[6F>.;3](XG,W\.$CM*6QGY98[K'1$QUE
M`"')TB.08,636]HW>@Z/D7S6>MW1IBB=CFF[G#C5!IF2%3$N#C@;A^L+V#:6
M5<YTC(YS;PZ7R@!N`-WL2+Y8#SB;8Y\&D$)`:D!&!V[%(W+YV0<6&0TE<CJL
MM9H<M41%!L"<P<17\;!(+/B30/*0`;6G#"]:8I0S9QP9'`'`'`'`'`'`'`'`
M'`'`'`'`*]]@:H/V@G5#J.MH"2=UO9CZ<.@5E#GI2+'6!.HK7JY=BY;,6[I3
M9=HI9*!M'11'*+O42J/W69[/-'C<58Z^Z?H4B$=+^S-?-XT"C/8^>%@;1I5M
M991%RR3!PPV`@@FD`FTSVCA26>E$S^*J(2K:+M(L6F66][MJYL30>-CH]X%B
MXLIX:ZS,\<+\)1.\]Z9YET]LVU6L\+CYF>M",677[0>Z5C`R/[AJAKJH),')
M2:+-A]B)+3V&QN=0Y^4&2G<?&@D\UD`*,[3*/L2FX3=33K.ZCKK%\&$QGI[=
MH^RX?-)7?9R9Q^*R>$RU&'G)G9)$6U=`&H\1N+")O#"BJ:($.I)-,&)4[F+^
MQW3X2Y/MXF5UFQN?A.BWQY'#VCF8Z7V2WD1X^+O^:`]7MDV=.PH4!,[.C\9&
M(3NV)S:C)@[B029,(J479DI6R3,N'H9?0[[MW;/TUQJV&6!)],%E%Y$NO2;M
M!)H9#GI7L"<AL]3KLS%S_LECVD:D0<I+P%.>_#@:R'LA+D&))28UIF1R&,L&
M3R!$TM=@\7;1@J94L`6+M*M*4R5TY;_%0S4OTGO!TX9G4NP\E+R9%])B*CDU
M/[=13'.Y0^[":$W<062E9%M$2&8=9M;P8-NQ".`4=0@"!W$9-)CV4:?A*R[:
M7W3=QF*'11SHO?T;WP^V[$F)`^7(R<I)\/9U;P%W8"INMZ7K6/M9'*(Q)Q\B
M%*0?%1MIFV,QY9J_E!1PG&BJ+$0X*OW@2LHZQ?-'G-V!;OKU2$]J![+W4VN*
M66RK*6K;;=S*#<G(X0-H63<4G7,#A)HZ7#1=)Y#)Q7\.W"11J*#-D:]::MVN
M&>C!%L(W.$>+SB6;X(.`.`.`.`.`.`.`.`.`.`.`4VNCK9)+.M-Q+QI*",0Y
MH%0@MX5/`GY>:0UY1=O3*U4"D#V;K,VK<I)]I2B&3**E!RL8<C&YW1K(,IZ"
MN"S2-_6/;R\BVB>MG92M;%A.TWO2<S>%-7LIE\XU?SF1R0.2<,X+!(A`8(P4
MDAW22H-=9JM:=K&5\!LMB*#Z,1B5G)>0#:F7XK:>$71AO]%UI<=<CT*D<5AK
M-"N;@D`"R"+'W!*9>W*F8>ST#LAUG8A;D,TK;:)O"N]9RRSB,Y$@YJ[/MYH^
M9HAY89UT0!&(\&U+F-8XK.<%&!WT)Z@6D(?39W-;A?SE22USV"K@4\DLDF\G
M?!!UN-J<U"JIIF'^HOW>,*5Y)2FXE(?H0$M9$P&JR:7ET3\OD`3=3)Y73[^7
M+#)!TSOD%'33R"7_`&"3DR^Y+V8(XMFX1`)RP+'NP3E4*.2Q/L#X@R9A;%I0
M6/6C+46Y!,*0;-XWN-R0:ZHA*RRRG#31\SHY#T;[,.V,ATB7:4["BDGFLFFV
MQ4)*;)1=@\'HS5$4&Q8B\4-KOK(8Q&,0!W$HS*#SD#+&K#=L;?/23TJ3&-@V
MEE-W2>4O`[V;](;N=2&4E*X[$2J+)GVXEB-+.[%MUW+@+&,RSL%)XHQ=&2$E
M/YE@,-O<PINJ!,X35=?"[7+$Z&29#T<!M++RD[KGS.M0Z,W^%@SF%0[LH;B?
MDQ1$QHP*EEJM580D(B-51E`P/'-96V;29],$*\.,RXR3K.&<"1G3TO!'N"K!
M[K(@VE,PNE;].NE=-@]4P0A7,:?1I[)C<I;8ELP,`WDB/2*3F!T>D$B(&@\?
M=R"6%39\I@$U>ZC6ZSXFXPDU01:-,(,6[9ND,NI)?`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`-6=E=]2%<>)+0W60
MHYAV*,M^.V'42IE,JPVEX3MD)`0RW(:(.L\J;N!T-E%6/BT=B3C3.NTAL14R
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M0TG$D0V+U-57>MG:X4NU/VF^SG;2S.AW;2S(3K'[*[(5QV*[=4_3`PHC$H>C
M(6U5WU(ZWKN/Z[;-A436F;H`/:CP*I9LF-D$S4%H%T%6SY=#<&DG9P35EOBJ
MZQS9A]$^*E&C[B/CS0R^BTPLSLBGUQ6I:\JZB5.W-UGLQK0!^XMXQ:3`0&""
M9)$I4RA)TQ%YS'FA-3=H:%L<LW>6!%5N#LWW0E,IRG\R5,K[F2E3'BG,NPTF
MHR*4YUCMF8$KPZWUAVH06VE=5@64`J:Q[//54X)S10_+ASA=_#C0%<N<%PUK
M+"#R/+:N0;8D334$X!V-F9=S:WM0^S,`>>)YBUJVZTV+706:52PL'NI0_6RP
MQ3X7"9C*8Y.97<=C5?.J"L$02=(,8>9%JP1D]FTACY4I(HQ'YG$3L3'R%`JD
MON&S5J^++>*HDG*ST)EA'B91:;0J;2S6I9'''M87)B@+7CDFED9%NZCLQQ>B
ME(L-+&);9W$CH>ZPU=V3M)8TZECO2O\`80]0`.BY\4(7$V=;TFHQ42XU5T$:
M=4_$(.]MNXM5#((H7!=>;0Z!V+>>D!E0*.I28);E;]M6]`FG.YX<FX)*C]$V
M$A8H,\E51I!MH.,8'#GBBK?05V8LMXJTEP:;-PW!@<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`K'/>G/7>SXU$XC/(26D8."73OV)AR3JQ[00(1
MNZ<R`S*D9^).,9FU.-"K"02$V3$MM"7NH,L2<Z"1[)'?"6!4VN4<+H(]*^''
MTS-O3!`I3NSQX?.=A9(87WL6U]-GQKM:!:1CL,]4U2G2>FF;1`L6HXZ@CJFV
M;)I>L#HC%]U%=PVGGETN.0S\.WIVP*#C32HE42@F1T!+ASS%C6MLHUD?5J.N
M8G0)737><[)[+5K'WCD<(34TW;O=%<KFT2CK71?4-IYY];^9A./"HZ%:HBFZ
M-%K-$`H@,"8),;7NQAIJ,CMW%.Q\?2=:LK(0P2<`[N-F;"$/R7M9`<7+$F[1
MTB*>N1Z@NU:S[91VIN)]"=2>O\:K&5TZ`A#P17LVLHC<,C$L9S82!)U9Q:>C
M[0?S-C*])7B7`S"]A"V4NPH".C4432:CI!%++EUJL)+IHHX70=#*>D762:[(
M.I/7;TH;;VH&NM.8[6'9[2P\V;'H*M6(62+60QF;6>N-6%>.7,+2".)&K'=H
MVY<B51*C1PLGN&T\\(X'*ISI=UHZ_P`BBDKJ"M?@T["*=8=?XJY;S&?%6X>G
M1<G(3,;!$!9Z4E12HL?)RI`LR7=,ER;99UNDB^T;:Z(:`VW?BYXYG9GNHG7&
M2,1@TG5PG1D(["M^US-$03D<=]+L0U-*R-&U'ZD>,BU2TAU-K;$=DRN[T4JO
MJCZT?NFW0T3"7GA'#(X\\Z==;+)'R<=*JO'[:3&[81V0D+Z.G)7"#SN]:X'1
M`5";0;26$GH](1,JC["!Q1%J]$%&&BNPKU[Q)RX?$57@2\[E&=,J[SIZ5Z/=
M7>N\HC\SIRL<PV1Q6!2ZKXZ^TFUB'$1$`G=E/;@E<69C)++3(K0:6LDB[E><
M99;+,WJFC<>LT'(-V:0.TW>]>*4=BV'!!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P#JBIT("U9[&S`H/J1=;L1^Q4@T'ZOGJ3!\54
M9L\NUD<.728L82);MT?36T8#WSS;3#=HNHF!@V+LIG(]^6Q;=8Y%"HPYFQ0G
MB>Q7(\;#&3Q0<\ES][@K[,SC#0@BJQ<GG"B8I!XDHV5=Z+Z;:8"/8[J!617=
MJ`<2JL)["['C&7C@?B1P*4@Y@!R0::I;.F.#$>?$1^7C;5='9PVPX]<CJLEE
M337"FGF!V:DNBB(1>3+2>/)1MJJJ@ZD"AH;H$;+HOO=:R*Y;9SA@BJD2QD<J
MFHXUW3?8]DVQAQ_>^`9#P!P##9W8M?5<!VE5FSN&UU&-';9AO(YW)PD1`Z/G
MF=\-&6QB0/AX_5VZRFIALVRXPLOE/?U6FWH[>01-QW$<DD=F`(5*(B?"RF,G
M62)('(HX58FP1D<YU]-N_%%QB[H>19+Z_P`)%TT<+(*Z_3HIMCZ>`=UP!P!P
M!P#JGIT(-?AA1$P*'E)&Y=LH\->D&C5^=>,![DL^:!F:ZR;@HY9"F3PF[08I
MKJMQ[1R]6TT;(*J:`=KP!P!P!P!P!P!P!P!P".2EPU(#=+,35HUV(>MB!H0Y
M:%)K&V#EN5C8L:<D0U=!V2251?@0IH.6-,U-=7`L:6&/GR:#9^U55"#"9+VK
MZO0LI"`<Q[(4+$C=F:H;5P&D]P5Z`+3_`%=%<@6V84-+2%H\E.'!S78*C[C1
M?>M+8R-T\WN,H\%AUHZ7T=-^1+TCE,8AXWWS+I&!BP?VMDP]ZR,N/"#?;B3E
M-D.9>W$W#5K[6_>+)-&3?UOKG3E5-!#117?73(A['LDCHTT$C9$^%82*3)E5
MHX!>E6+4U($02+=P;5""UUTWQ5,,W>-%RN[!!?4>BZ;JN\HZ+I;;`=UP!P!P
M!P"&:K[&]>KU>R,=2-[TS<9"'99ZRYA5=H0BPGL5V(JOD!^)&UB)PNN#R^7&
M$D6>">C7+I4>^30]/=HOA,5IJ]-;UYF3-P0<`<`<`<`Q_661;:4JP;62@-IJ
MB`1E:T/U,#LRE*+N""XAO)%(_AS[VT`KE6SD8B8V:8'J$&ZS+1QLY2W3U`R#
M@#@#@#@#@#@$:KW-3[5+1=S:U:MT%!08ZFLO.HNDEN$D?L_P\9T44*:Z;"CW
MMC3W,0USEH4]J;^PK+^O2]((\W7G&2O.DUK+4I=&X:L5N)'7;=:ITK!B2EEI
M::A\2';=2":E\RE/76/YP<VVV%8Q@/G!/.?8LX7X+#B8<9X$I\$.G%2&/GEC
M#<&<#F5XZ65`R!`439$5@1U!JT>KA3";-=;<8619OV+M4<]U0>)M7C1?='"3
MA'?<#N.`.`.`1=95XTK3&`F;AN"KJHQ)=WZ<<S95@1."X/J"O8LE-`F906%X
M*[C<$AWM^K'U^6?M[+VC"?M2'K`ANY22AC.,XQG&<9QG&,XSC/GC.,_3C.,X
M^C.,X^]G@'[P!P!P!P#J%SX%J;&QIT;$-I&98%"H<`N29HFRHL&J-0-DAHI1
M;5\^8!US(=$H\:H*MQZI8:F[41W?-<*@=OP!P!P!P!P"'KFI.(WB`8QV79=M
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M,_$UEV2F].1J,RVOVS\#6J[35A`J^EKHP/A["0K3"(L2'O/#1=PQR-;;=M.D
MPE=6JOF_$WT0;J)#8K"H?&#UH=FIX<CD7``C,X.]K>S`\W,BH@4T'D9488`+
M;&`V120.VZQ9^T##F`ILZ=JHCV;9IHDCH.<Z+DO8RG[F.M_QE["_K<=KOWT<
M"7IR7L4.\27J!"'?4FS[(`6?>40EW7:-S+L3"GYKL%>,_#D)75];SA^*`DP-
MA6<;&:LC?MBS!=^)T'R)KJKZ(PFAJLY0<BV;5;E#HZ*Z=Q8>B^D=+T94M<5&
MTM*]I#I&`2(QB9W[27[$5)%NNZ<.U2+.,0NUP47&IO';M79%C'A#9BGKMKKI
MHHKG=50':;K3DO4FK[F.M_QE["_K<=KOWT<$EZ<E[#[F.M_QE["_K<=KOWT<
M"7IR7L/N8ZW_`!E["_K<=KOWT<"7IR7L/N8ZW_&7L+^MQVN_?1P)>G)>QK\[
M/^';U_FW;[PZ;E-&KY=2RJ[NFWP^F3[%W1+!RWN^GI_9PW"WQS,Y23%Z-I96
M\>6>I14G'4I(*W?@I:F>$*MV;0:5IQ:5(:4T6>[4W$<&!P!P!P!P!P!P!P!P
M"HMI]-*VMES,E#!^9A&5@/3SR5BXVM&&;1_L>'4RDKA#=]&"+IDHT.T3!Y6D
MY0<>T/#*L@2+[DA1;4>S%5IJ-/O[LTW=CO!MZX]L/$GB)*>3Z[`)>HZ9A789
MT7A\M&#GD[L&4]C[-.'%2VKT"1:Q,:LZ#H)LVE:MH9NPT44=(KY+9]YY&U;:
MLM)+YJ<$DL]<9+8^*'X=W7*_^L@>(6*O=942T[$]85&FC_L3=TH3:JS&]8/4
MAUPB,GTZF`#5VK";)E8]J^V#[/F"S[1TS<(J)YQN)8MNRY47/!93AN.EOWPU
MZSD_>;I18H^[>TD2;00#.&L?AXF^)L78#&L(:M2)YL`ETR?2:SX<WM>/GT8#
M:*4+G,?UD$-`A&+/W4_;KD7`*U\K4*L8>ESB,KS9?]S#67\^7S^M7VC_`'Q<
M&9>G)>P^YAK+^?+Y_6K[1_OBX$O3DO8?<PUE_/E\_K5]H_WQ<"7IR7L/N8:R
M_GR^?UJ^T?[XN!+TY+V-67AU]%Z9ATR[&MV/8[L!<*%0GX9U@@#%;L-(`'P=
M3M;Q`1.(DPRK2A.OWK[.Q^S9:-3R;</!"*`--,0-8D=3KI^-6FZ.$IK<JN=>
M%QM-^YAK+^?+Y_6K[1_OBX,R].2]A]S#67\^7S^M7VC_`'Q<"7IR7L8W(J4H
M.'Z-%9;8]JQ9-_NJDQ4D7<CL>$T>J(8TV63:;D[L:ZN-T=5$]E=$<[[)X4TS
MOC&-]?,)>G)>QD>.L599QC.#M\9QG'GC..UG:+.,XS][.,_+%].,\"7IR7L?
MOW,-9?SY?/ZU?:/]\7`EZ<E[%#8%T2Z]07Q93790$.L!>TFO4,"BF5DUM65-
MT57AN<R>$OR;[::2<^4*+YB(0<#:C2A1Y'!Z;=,FQ"-SR2!9(:=I[&SAM-W:
M(V[\&!P!P!P!P#TN6S=ZW<,WC=%VT=HJMG35RDFNW<MUT]DEV[A!779)9%9+
M;9-5)379-1/;;3?7.N<XX!0LGT`@CUJ$8LYY+1;..0PK"PR#9A'-]6S25TI"
M.O,T=[XW&8245)U=7X)L!;II(M8Y*%B9U1,TQ79@6`UM/UZM]V:J>KW@Z45*
M_$9[&]]G=J7TQE=7]D[.K8)!!EH3%F@Z%K47$XQJ[>VHD?UNK"Z+6=O]DD&L
M^;M_96+`#OKO&\+B%1I_$>PK,*&LLF\+L%AU-Y?W,=;_`(R]A?UN.UW[Z.#$
MO3DO8U9>'5X7=6==+-[PD&=O=@Y7M);V$`BFJ5Q6/6ZY0JT@X6VGTUDI"JY;
M$"$OF!HI>14*0*R1R1Q@3'`FS5%!^N8=D!JU:;5FBHLENBN%.]YM-^YCK?\`
M&7L+^MQVN_?1P9EZ<E[#[F.M_P`9>POZW':[]]'`EZ<E[#[F.M_QE["_K<=K
MOWT<"7IR7L:T?$4\.&"7*G3KH7<_86!*R%]*^KTFSM<=D6;J7K3M`2K]I.DT
M<6S+YEL'?,]:R"[LD1>S<*6V74Q*Q!_`X'[K&K-IK!?JN5]E-JXV4H=7:U01
M10TDO8;.B*2:6N<]N.U>,YU3TQIKG.$[FTTQG.,8\\::::8_[NNN/+&!F7IR
M7L>W[F.M_P`9>POZW':[]]'`EZ<E[#[F.M_QE["_K<=KOWT<"7IR7L/N8ZW_
M`!E["_K<=KOWT<"7IR7L/N8ZW_&7L+^MQVN_?1P)>G)>Q0:9^'Q0#GQ0NHW8
MA4C=3NP:ZZ]=CC@38_?=MS0<N_A4RHJ,1S1[O.I;)S>HEJ/O6?;D(X--#H[(
M'#@=F0BBC9JX;/!K:>S:5(;6"U]EZ&WO11-3TO5J:;^AOLGOZ&VNWH*:^7I)
M[>CG/H[Z^>/2USY;8\\>>.#!Y\`<`<`Z.224'$`KV0R0BB+$#]4?:'2NBRVV
MRSIPDS9,VC1LFN\($B+YPV'BQ;!NY(E"+EJ/'M7+UR@@H!CL&LR(6)H1Q&W)
MI)Z(RV]Z@I7$)?`)4-1?>O\`=[U]$9Z"C4H:C2>6CS4647$:#B>S)[HP=.-F
M;K"01'D]BL7B2_@$=M_]A4]_]G6X*KUO7<N48&ZF!!01L\(#M2HY\-V("'>S
M`JPU?-E6N7@Q]IKMNS(-<*^O9.]-=MF[G1);77.=,8X(?,3V4\%N+=?/#%N*
MGA?<_N5)V[*>,+*PZ+6BNUB[MW(;,C*CD42K]JGL#>MU-W*IM^\W<:NR,T47
ME>^R*BN!R8[*W-M/9LKADCZ7X1%TX/"XA"T3!Z1)1"+@(NE()20R7DYU,`):
M"=#$C*[)I;$SQ/5IAZ7(;))9>D%W#G*>F5?1P.)E'`*@]S^K6_;&O(/#$2]8
MCG$%MF,VHW8713/R_57)U8Z%E`3X<FM7?*!6.3XMRG)U"#??67L=F)0:/=^I
M=83RED6RXSNBCA\X?8TRE?"HUI:^NE4$;6G7%@(S=Q4T>*2:R>OCF4R^IE.E
M]D6#V\;M^I!AQ<^B?7"&VBY,*5J>A2#.>M0T>;-B*1(LOA9@J.FU*M.'2;G?
MM4^:E8X'TL<'(<`<`<`U:=WXMXC1[M#TA.]0H_U]+4G`YA/9'=3^W"IQ@2#%
M2=?2N&,'+E$/O@PO'EXO*#C$!B',RYCX\>"UI.T:Q-JLZV&[.S%K:;G",:KS
M<3GZ_P`1K^:^D_Y_O7[-\$^3^+H5IZ]V?XDY3Q*+NIZ_UNL^O66'=9J>L@,(
MJ_$K5D0V163++.C,;*CRTB&-#1%^;,U59S*9#3>^`(L$`@+J,I-RI*1*%16K
M.RFMJ7::K&"66]=3;=P8'`'`'`'`'`,`7M>K6TU1K5S94`;V,XU3W;P!>8QU
M*:KZJMLO4MD8JH1U.JZJ,]=G:>=&&V-VVN5]<Y2QG?@0[XIF9_P"DHO^4=G/
MU):J_;M<G!<%O?9'4>(ET$@'B.T,*H*Q[&M*L0`BS8A9Z)ZIS0\.<=DHD@99
MMQ)/4L,+CB`A5`ZZ?MT'#/;8=)!T>D"&=W`5-NN+9M.RY4.D5J45L_PZJSC_
M`(E/AQ6LRN;M07*P$/V#(LA4_P"P]BVH/>K0^+1IPQ0R[LLM*C8D::WDKI"8
M"`)08+DS!F/9/&:::3C9TCSRXTK7RVZ6<,+I>$&]O@YC@#@#@&G+KIX0<4I8
MGJ_/7G.%DA-0UQ3$>QUSWG?3DF2C]<E)<2:R2W3-,6UHZN2>%MI5E)[)9'HR
MPWRR469,$5"+KRD>)M=C3M3ABW6M^"E41;3[@^M/_P`Y^[/Z]G;;][W$+7F_
M<DO3DO8?<'UI_P#G/W9_7L[;?O>XA:\W[B7IR7L:XO$*\.V/+,*E.1*U9N9=
M3X\[Z>FVO:$[9/<46!BO;V65K$#MA5HPN6U%TZVLR#)Q%N^C\CCNVBA#+Q1J
M4TWT:,56Z/&V_4U9M1AK*H_E3>"N>)OB"#$P@80&25W72$"V`Q-=3&-5%DV#
M1)IHJIKK_!UW4U2QOMC7Z,;9SC'T<I@[3@&IB<]<?$G(^(Q,+^J_LQU[@W6(
MIUXCE<1N'3FBSMGGQTC&2/<T\8%`(.RJI)DG.2KL](&\[1M$8P1&F6<14KA^
ML-S),C:=C9AV7,S*<>CTPXX%C/DY\1#\K?J1^H=:O_[@7!)L?IM?W+_0B;KY
M4/B8Q;NM;U@=C.T-+VCU,.5/#0U?5S`*C+UPZ86"R=.-R!(;'"TTGI*&J#_\
M;+2$N1LRPM)VVD`)LD/C^D;8,XZ#=G94)JU+F7-.2[9YFS3@R.`.`8DO/X(U
MEC6!.9K$F\Z?-,OV4+7D@=&6/&.NBBFSUK'%'FIAPTU325WRY29[HXT34VSO
MZ.FV<`9;P"DO37^,'=?Z[5C_`+,::X*[EN]67:X(5DZ^_P`?.W_UFT?[-W73
M@KN6[U99O@@X`X!6/L[_`/9T5]9REO\`WUSP57\'V99S@@X`X`X`X!K0[#^&
MG'>P_="F^XQ#L?V4K@C4583&MD:WJNR2\,CA;24K:[ZF&106Y2)1?+A-=QB9
MCA2>Z<Y<!X&N]=#M(BLW/#2M19=F$Y:=5EYWS(R\)7JT+ZU)]Y?=MM75:&9G
MW:MO"VUNSMW,MAN(WNR32)-LN$4<*RJ0^^-]IK*U\9)RO(L![?Z.`[?TA;;G
M9HJ65<C;YP8'`'`(+[)R&6Q2EYA((.J3;289O'563X1J,4>BVRDI"-RYC*9U
M!:/;LPX94@3(ZR3=C'/=[1UDZ6#B\.BC0%?YYY<R,>HJ@D;6LF&1NQH_=!G0
MVYDQ"314^Z.PIR:.!F&N(XRF2#-]'U"(UX*59R)1@5/GR+M3%C31)O(YX[:[
MBO='GF62HBB_>'N2!EO2WL-'91")%"/E`ZX3`C#"FH^7RX5*')K8>WC^`Y6/
M090*@')Q:40V8NB<E+1LC'Q\K'MI``&Y:E'3$5*JC!J;EZ[^5#=5P9-6_C'S
MJQ8+T.LC>L("0G,ADTDK^-.G#8<L7%0@+M*QY\A,)*+9D1A5Z'\X^A$VJ8EQ
ML[3D<K`.'"61:!#=,:L?4N)&O1ONYW9OGMW;M0=E^J"W7V)`Z5KF?A0`\FK+
M_DW)G5EM1F\QL-\+B&TF=V\YS/A(D.(B+=M!WM"&45WQ9.6-B>PMJS9233FL
M;^%82SFLZ&Y+@P.`4GO_`/"TZ"_ZY=AO[/TIX-+Z;7#N78X,C@#@#@#@#@&D
M9'Q#NL4#\6WMK4<I.V`TET>ZC=48F23$TW:\N:Z'J]LGLQ-Y*U2Q#(?(2"C)
M&/=C*S<L3WN[$=).'A1DS+*NQFZ2HZ;+_#LO#:M8K'96.J9=[YQ#JI^,UI_J
MQ]H/W-\&(>G->X^<0ZJ?C-:?ZL?:#]S?`AZ<U[D'6!XQ'3"OKEZXT<])7"2E
M_9J?+5["W"="6['A(<KZMH@P=GE)Q$(J1=L29\L"CR>8D-D[D8X+IE9`W#Q]
MJZ*IBJPVFZ0JNJZ>=3:9P9'`'`-;4>DAZ6=@2^\DD,#C5)UW;4NBSB-/"P:.
MXE$U,OSV0^AP$LLA%YO(U);D+($"2;9X>%*+5VB*>8GVUP,VHN&NF"QFG#[1
M-J[NN4O47P\L-A&LY0*#YV6)L1\A5'24<,@D-)S%\2'A<1XFV*CU=!B8!5TY
M+AM6LC/Q06GJ\5.I^S@E?YYGS*>4)<H.Y?$!L]\-8&!A>+=0*VBTN'OHM8H4
M0.E(R^[H;F!,?D,_@<`TFJ(5ZBN(,E8V.=#1<A9%(\^70+BGS5(5J$M[RR63
M9L]X,FDSO_1/9VV^_G1QU3_9?:B0#.&W(F&<1^/J$)2)>C413JX5EDRK@E"I
M(C8,*(PF.1Q*2Q0EM!"D9(GQFRSDUOHB-V8V;5)NQY79.M]23/!Y@-^5_P!>
M[7&WM<Z=TOL=J.R@$4<<-#NIE`_6%QS.G+8-NWYLR3](;:EKUW+;H&1Q@W9#
MX4YL4M&!?I@V(AF-"W$T44752N2:7`VS\&!P!P!P!P!P"DO>3^+'7+Z[74K]
MKP/@JOX/LR[7!!P!P!P!P!P!P!P#6Z+7D<XOHX^)CH;&*#K>V9&,EVI.&16/
MM)S.2#@@QCKPH[.$G(:3EPLG&#7ZDO%NW,BPN;@HQC&Q4GVG#@.-4C-QG=?/
M2D;\(F;[E[/N*=E,@"/:Z('PD>B@67%)0()E'J(,69VDRZ;N2@PL1.GF([45
M7]D%,$`+*48;(0_;WXW!I&A3A81*?/OYA)&?066A)UKW%E<<W)*!2W=BT-F6
MY<`?BY';5I7M1,%O:04H&!CK#.'+5;">'XUME='";I#"K5=!90'2-WJR_P#P
M0K)U]_CYV_\`K-H_V;NNG!7<MWJRS?!!P!P#4CXHP?N2<^2Q/JR+N8@VC<`O
MJP&&:8!=;S:_W5,-<TZYZG,K+QV%4UU:5$]4>W'O,U8+CWTILS%Z/%--,,M5
M!NSLXQ>E6;G.TU&-T20O?%R^)S$.QM.0@NW6BC.SW5.@JMC_`%H;4W8U13>3
MB["E,J[*#[TE786$1BV(AJ!Z\1U8_'_DMU9LU-VJ^69AX?6U8(@MG9>+S<IK
M*$G%][9O6X,#@#@#@'YG'GC.,9SKG.,XQMCR\\>?^G'I8SCSQ]_'GC./_'&<
M?1P#3SU9\,SL;U_VOC)OQ1.VAK6W+[G-OCDXS$^KZNC%G+=F>VNA[-T=?;M4
M^)U?9<8+[0'>`03?U+;(B#"]L*[;N,<O5,W:M)Q\J4)+&L<5[ZLBOQ*.G_9`
MC0$'^&O$][GB'ZO:_IG%MU7@?JZ!0PG:_:&JJ70*:O*(Z\T++UWD/(V0PGHP
M:1F!"+DR44:,"\><*.&18-(U;\T@MAJ7\J?RVL\++>>-QO-&-%V`T>Q=$GIE
MRR8M&C@N2T8)D2J[9!-%8D_3%,A@M-Z^4TV=.M!HT>PU754U9LFC?":"=.9S
MN`1_:LQ?U[7$TG@Y@#)J0R/D)0[:2,V:CH?(8$CDE('+HM'(=/SB.[$$V(OF
M;89#S3HD^;-AFB+?#S9ZV!5?GV(WZTWHY[!0(K+2,3;0LB(E3V*D8\@8.'/9
MED`H`ZCNY<R*$5^20<KL)"TW68JQ_7#7SQILZ55RJD@*U'?#T;(&\12%0T1T
M>[:'Q,2C(LZEUMF<63-#@(ID63C+`3E1C'-"39HD\T!,]T$-V@C5;`]ONBEL
MBWTRGIG`*];T;`>"%)?$9_`ON[_R^'_M%B'!JQ]2X]F*R_E`^X'U:>CO]=^Z
M_!,%O?9%VN"#@%)[_P#PM.@O^N78;^S]*>#2^FUP[EV.#(X`X`X`X`X!T2$7
MC361D9BVCH)O+C`D6`+RE`2P1D90$#=$WH4*1.)M]2;X2'>FS+L6-<NE68]T
M7)N&B**K]UNJ!WO`'`.C*1>-'"4=,FHZ#+F(@0=%HF5*"6!`E%RKX4^!/B<=
M?.VZSH*0>!"9(.Z>C56SEP*(/AZRF[1VNBH!WG`'`'`-=RUJ2ACWNC5;&(A6
M95F8S*A(^?(4WJ(L$8*'5NYG[,6A83FXSQ%V)11?B0[HSBOA`H^8TD8@8*8[
M"WCUJ-1\L^OI'K2_$V`/@XDIZSWF+'$?6CB(=7VYDV=^L$E_9O>PM3VA)3TQ
MQ3V)G[Q9;>;9[[(V]I25]0EZ`R4EBH@2`\0J5A00L<%#C>CM3M!PD2R;#1@]
MJE>MR82;,F#-)%JU;IX^C1%!)-/3'T:ZXX+@M[]"]?!"C5][$=.XO2_<0BR<
M%M89VXV%H$G*[,<N1UA-=Y9(OW;5J^<M62CG"6CIRW9/%T$-E%4FKA375+<:
M7TVN'<U*DNL'BU]<NC/;DE(>UU6A#;->T;US%:M/+JI$0D]>%+>[9O(_=!GK
M3'I]5LWD\D,6U)*.3!1>3(5X8DT58/Y.\3C*IH@-38;5'E+Y6:;3E*B=:F\G
MJ6G<B'6:C$.P9B-R*Y6]:19O/I'%"I0V'D9=`:BBE(O>AF.Q-^[+'AVC(O(]
M\QP0UTD3PJD.::CDVF^XPXEQ=A)8;@@X`X`X`X!JR\2SJ#??:U&MTJ<>Q==I
M#X->##03*NS5_P#6EO%+GEN:O<T3V`$$*&@<[=3R1T63B,P?A8G*VX89EU+/
M:V1AJXT6VP-66E,XQ5).E956KZ5T(+\.2G^T$![3W8(NBPG\T1HX%85=63,G
MO:*_K:3OB>WA,:QOZH)^UH^Q8N&K&B]:OJ%T5KUX,KPB^24)GGS`?HJ":HOG
M`MIII1C6-E*,+U5S&*-X/!@<`<`<`<`<`<`UN%[&9C>_<&KR15O5I@W)=I*W
M"6:G2T493X./"UN4F#`4G9):\'<Z<X19[,F&Q8/4*D?*[ZR$0PV8X`R5_'QK
M\OI.N4=WZ%_#T)ADI1<MY/$8Q(V[U0<J\0/`11=%VJ'476$*.4B#1QHNH*5=
M.51VZNN^S%1PONVRELLIG89*F=-?XP=U_KM6/^S&FN"NY;O5EVN"'RXS0+XM
M\)IWQ6K,S=U4PD-%+&EUDR8%")00>35("SK@!,+7&4[:3RG1).L",2ZMH57&
MJ8)/P<N))V\-DDF,D![-1CML.BV7LJ&VZ<9I2:_-,W4/HBZW:7*E0=/H=AG,
M4?W>VKZ,M+0*0@@^)Q8U+V@Q!L5/"'1$)''>$CRJ6#"[3<,S2'O'K@>V]I;-
M47:XPXEQ=AY7N39P0<`<`T?>(QVFFU.=O.M+>.16&2/6D]8/;(.$DC1H?9E^
M&>PARU.K<AKFG6>!J<27DU?1LJG8+M2320./WW("&I1T)%K+%-1JRI3UIHHA
MU)?Z)^(=-^VMPRJN)+":VBV@.#S.6F([%96?.V13Y^,V>PA`ZLKR%N@R4:!3
MHW'R2,L;MHZ?+,E&;9=9@N_&K-WV0=F,=U+]56IMBX,C@#@#@#@&N+Q..K_:
M7ME2$"KWJGV"C?7N81R_:4M0^>DT12E#,P(JJP0,_#9:[;MGZC0K"IG'8U9`
M8;[!EC+C$0'Q(V3#`S!$@F-6&K+EJ5#5\7T[2N,D47UU/\3Z<3?K.9K'Q&H]
M&(Q75TBI?<85&@Q4,^-8`U&.T"`E5$-(9(E--7.N[@1K!SZX"-K*G])<J81.
MPR/)J"IV(<V:Q"KCTZ;KF;=.#!'%PKOF]56*L/&1HPX3ALASN-F)=N!BSIED
M8YU)ZG2KU)1@U'Z#<NU5\$E&`MQC3#4F8",%W!AB!6'P]&+9CUY3]F#2,+L^
MG4O)O49+(7LQ7?$B#AHY(%!4U5K>N`TSCSYWNJH%DT/UG$1)L\:;B+&E&='.
MS,:M7^+2Z7'&NARO$E_`([;_`.PJ>_\`LZW!%>MZ[EV^"%)?$9_`ON[_`,OA
M_P"T6(<&K'U+CV8K+^4#[@?5IZ._UW[K\$P6]]D7:X(.`:;^\],=WY[VKK*P
M>O"4ZU#UR!H=Q4$E'RRE65/5_8!&Y;`&=K"]ZP.8%0MLSV-RCKB3AL?"BZU>
MX>J+-RZ`QT%-JZ$L#=EV=ESK*K+I\L12^9GK<</NH=\1.JJUB]G2JRH65J""
M3[4]>C#IG!6M3WVO7'P!/QC':-2?LG;]D5VN-;6:1KIW(`R`-K)7XINNH**)
M(-G[$@(METQPETF5?"FZ39-U?87$+ZY4:-[".UW]YL:LA#6VWCMV`?NW-@H1
M]BG*57CZ*IIQIZ\V+:N?:G8#3`ARX]8L/SLUW2VV$<2XNFFXG;@@X`X`X`X`
MX`X`X`X`X`X!KI1CDO,>(,WE2@./3,'#8H^CI&91F+2L(5JO4Q%RYH7%IF=>
M3Z)0^0)'QYN.K-VC`/?$F;DW3<VK$*CCQAB>%#7Y>/GE-[B#8MP9*2B_Y1V<
M_4EJK]NUR<%P6]]D7:X(4GNG\-;I!_JSVN_J?6_!I?3:X=S-N\/X%?;[ZKM_
M_LGEO!%>MZ[DTUA_FUKS_4:)?^P#^"&<\`<`<`<`<`<`T;T;UG\2*&]E;2L(
M%/XW63*Q'MY%+0E]\9<]H*\M,DI:\7:=:W-=5#75PT!(ZL>0.@0JD1(D3,J>
ML\MD4Q2L9?/7*)<4-S9A2I=(BF%9;3F7DLZE[?@3Q'/RINE7ZAEX_P#[C7!)
ML?IM?W+_`$*-U4T[YC?$>80.W;(,S,0-DI6Z9:>@A]"O.MYKJZ9Z\2*JXA#H
MUUPD$QM.;QJPA_:=BPDQ0F_L8_EX/'$#B9!L.*(`FPT]G9HM%B]J9JZ)K9TZ
MJ7N_X.8X`X`X`X!KJ<@I,3\0>/R!<$SE@V,0XB+<RR(1"5"MJW;$H[+WK0+8
M\PUE<-BIA,ZS+19,3%W^E^&-32Z4L85_4PIXVEPL:_+&OMIORXFQ7@R4EZ:_
MQ@[K_7:L?]F--<%=RW>K+M<$-4/8S\#SQI/]5^R?]@2JN#=GZOA[U_V9M(`?
MY""_^4CO_P!&CP8.VX`X`X`X!HXH;Q"Z0KB\.WLGN<//*2AO8>QWU[T7,+#3
M@2@:SX+2-.4)U;F^`C6$S^92$0=TLFJY`[$AY@#C2I"*O0Q7UB#U<@*&O.1T
M=EM64H;LJ&LI=IJ^%<S83U8[C1CM5N?;B*GN&I2`2OZ>M5H-MUM6"3J25S>S
M*8/ZXE@)6K[2M%AHU*H0:0>UC#[T%(1FZ+?5Z'2PYTVX,-1BG5JDX;TBWW!!
MP!P!P!P!P!P"+KK4B^:IG(J8[8R`EH)Q`%VGH[J*EWUB[IP0+'VJ:;$GLH^D
M9N1#P3#3W>]TV>$4,*-E4_3UR&XJGTZ.2DIUOL0A&9M*;%+)&Y,XK=_.I9)+
M"FJ:+VNHB;B30^2L%G#M7B)EZ22E41PU69Q([`)-$I&/.J,CZI+@T[UAPCM/
MJYY%'>WDA[JK].>S3.;!\G(UI25P,31*?XC,%8/H"S?1-G&;'8)PJ`OS:-N2
M5AM8I%.HR:(*-B(RUB;&2FP4C37.RH5;,J,UGRKA=7.[3>_P8*2^(S^!?=W_
M`)?#_P!HL0X-6/J7'LSUU>LCOX@_<1'15/=5'K3T;]<EJIKLHEZR:]U]]/6Z
M8SG9/T],XVT]+&/2USC;'GCZ>"8+>^UDN]P0Z5E)(Z2,FXX./!7\AC28I61@
M611BZ,Q](XBX<A%38M!=1\*3,-VCI<5N_00U((MG"K3*VB*FVH'=<`UV^)A%
M+:L&C8?6];L+1>1*PK6:1F_5Z6BD!F5GC*:S6MG&-7L4"V0NA'=EUK:$50)*
M.]?6DF@(F559IZXPJLB-683<Y4OB95\<>)1_P\NPGB03R_8E5G;EO8HR71ZO
MRLVOZ"EJMI2.5Q#H7-&ID5UUEH&:PS.):]ET_DE>6*VDT;]I>B0I4$?8I-VX
M]D-<*,?VCW-6U92FS=<JMU7U=U%%)ORX.8X`X`X`X`X`X`X`X`X`X!JOW-0"
M:^(-7LPCT;39&A1.5P8M.U@PYP_-.@,1[)P5O#E-W+]N4#,GLDJ"W7X@XP:$
ME,I5828EV8<1/H@5D`U6'E^WNJ:S>68[/J=GD',3<=<E2BZJ,6LU,R"0#UEN
M$,R9XPCS>!.S4LG9G0I&MHRKF0FA8X%%3@N9OD](_*#,1:;L2BHBC'3/CYR*
MW]=U;J5[]VG\LR(O177J;!]8(XRNQS-WL"^Z+O+,;=6:RCXYA#!DUW%>Q>\&
MD-V<!_+T5-\,WV[I@V%<0HS?93KYSVD<&2D]T_AK=(/]6>UW]3ZWX-+Z;7#N
M9MWA_`K[??5=O_\`9/+>"*];UW)IK#_-K7G^HT2_]@'\$,YX`X`X`X`X`X`X
M`X!\\O:^)^*4Q[9VK;'62/WJL06DK"LHV3:,NDBM)8Z>,:+0E[C:#8GWM%NN
M^QS7L^3D*T=2L!OM`GC=1`<>SB(ZIX1'2SL;,-K/\TS..$;.5>)LF\.*R[9N
M7K<QM>SS5F28'8\F>3BBI1<@.E(W:$GZ^2R/QF05F?F0.@!XFN1I(HV)$G*#
M5H)&%TANS'4XR0(84QD9M))PHI?$Q.,34OIP9'`'`'`-7!`_"I?X@5:2:+QX
M6@0%D))"Y'8*X&,KER;@%$.Q$+9P[.2%4(344S?2ZO+6T!2H7;"PU16IY:&?
M1]F(EL>6EHU=9?;E7JL,5DR1;T/=Q1ME2UO4Z$F?090`44"9%QBN]FX$NQ@+
M):#)L74A:%G\L4L&WGJL?F"SIP*1KV"QXR^="1J9^.S]D"V8KZ^45<:QJCV=
M!UI>XQW&6GHV-B)9OW9M'WL.B)LI(XZVSBO:BU9X'&C,?BQ)[A0?AHLYV<@1
M^47BCANEJN@BDZ7$>$9>K+_<$-4/8S\#SQI/]5^R?]@2JN#=GZOA[U_V9M(`
M?Y""_P#E([_]&CP8.VX`X`X`X!`->]5.M-32283"L:&J:!2FP&A0?-S\4@D=
M"%94/-E%#9E@<>,&"*Q!B5+J[DR#-?;9L\>YPY<)**ZZ[8%EW2XR*J>&?2M1
M5%!^P^:NK6%5_L_[==FXD]WB4=&`]W46K6\+!CM>QQ=1@W1W5"0@$NN(BHO?
M;+($.76:#46Z*JFFPMIMM2YHNJE]393P9'`'`'`'`'`'`(2[',`+ZDK"4E$=
M&RB/A`Z4M+BBTLEL%:IL8628RUP92ED"!R.:!24;3"[2(.O&`STRL6%LF;+V
M=5QATB*KT1QTYF$(G-;2,]"((VKQ)2?/VYX`@YL5RIJ71BL0V8;*XM&!5Q*!
M[9C$5(N"`@4XRV`1F+!P,;C?LP84S%C@=]\\O1ORIC'B2_@$=M_]A4]_]G6X
M"O6]=R[?!"DOB,_@7W=_Y?#_`-HL0X-6/J7'LR#WOA.TC).VEG]M;"L^])X>
MM1$@W-5XYF(Z&0IJVW'PL1&F*)6L04(L0D)K\3"D&,%$'9N4'`LR&8D,-W!6
M5GGQ`-IQ%(YYYRJS6F61.'S=O4G\0YI^GKL'^]/@DO3DO8IQT3Z81/K=X@W>
MZ1P>R[2)`WT<JC92$2HH`."5M;,V-2L.F6D;F._*!)-:C813>%51O)9>67CT
M/DDE8/U2[PAJ_0&K3FS9HL;L(I3"M[S9NAX,#@'SM6+?'B`UOVQ[<6G35`GK
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M3W3^&MT@_P!6>UW]3ZWX-+Z;7#N9MWA_`K[??5=O_P#9/+>"*];UW)IK#_-K
M7G^HT2_]@'\$,YX`X`X`X`X`X`X`X!7?MC+;:@G7>TI;109S(+7"`6SF("V4
M1?SYZJY4,C&Q%RQA(MVQ(RI\-"KDB3,$R=)."3EHDV3PIE3U6XJANM$:Z>BL
MC[YUGU[C=.1_K=$[%K6CLCZ8IB>WG/)SU!M*6U'6\3B\:AQ>64F3H.TG@@AZ
MEDZ9;FE)&VQ(?8_>*80=IOKZ\6ULS,WU:4-)MW3)R^M/:KNA/N[)^CKDBJ43
M8QM:R#EBU@%I^8O8C6%9OG!<;USG`+M"52C(6S4;5+0N=,&V$8."4=.8Y(44
MA;+<*XP@#LI*4^U7BHPB5S@W)\&1P!P#6XI:,=A_>N)4V]I:K6ABPC\TD8RT
M`D+A8N5;&&-5%C;DH_+$IN/G1.1.XOLUCA"4@X";%$63XW'6YS*(*8XCHL.)
MFBPG-^YLCX(4EZ:_Q@[K_7:L?]F--<%=RW>K+M<$/EPOR_O$K$=9_%I&6=T!
M;PZ"VG9\\@D6LAI,I++,A:AL*!1JA)'<3FNZ\B4_F<VB%=5;&D+5D4H!H@F.
MWK"C5N(VV%.&&!ULJS-AJU+2EJZJEQ+A5=,<[BTE8^)SW)6N;H+4-N]#)M48
MCL/$6JUEO-8S<\O.#";]NZBZ&PA'%8QT/6.E;RH0I,+?"6H5V*1VHSX"2MW*
MN54W#\1V%%IJU,.EWORPDWU\',<`<`<`<`I)T4_B-?GUV^Z/]HF><%=_!=D7
M;X(.`.`.`.`.`.`1#V`,.@%&6^5'OAHXNWK:9I@')=P";#\R5Y'W[*--5E),
MV>Q[?9^><CF#=L98OQSQRY1:.F#U)?9JL"O4W8D#]#B41)T>0+Q)[&WK$A/Y
M02+D8Y[NPR='W;80[,O2"XX0%0<%G"RF'!%VLW6<+[[X57>N,YQMJ*YQGB8O
MXB$QB)[HAVN9@Y3'#+M[USG<@9M11P81<.P.[%=CJ;;(,W2RJXC9[C+/4DEK
MNSRZQ[/A;*O\#@*];UW+_<$*2^(S^!?=W_E\/_:+$.#5CZEQ[,NUP9'`-0$9
MZ9]\L]T^S%ZD.X+6I*;NS0<@%CE.B(),9>V95QL/C]-L'P2]*#FD:C*+*&O9
ML_GZ\9/O7DDFQ]DZ273#"VK)`:E;*456<\;GY!:;[F;LA_2,=D_T2=)/^5K@
MDK)=?<?<S=D/Z1CLG^B3I)_RM<"5DNON0_V%JKM?4-!7A;,5[Y]E9I**OI^R
M[$C<.TJ+ICOM+#\*A9J2AXUKJ-ZIN2.VQTB,;B\:L&Z[W.76,-455\Z:;"J&
MTH2EI8XO>?.M4G:_O?3)XQU_C?=IPXAD5EHQQ74K!TI5Z`?L7);BDPNQIW7=
M+)2OJT:.;6#7RDYF)>5X.NW@3#87NY$-F8H<_9#QT=E.L1G5T24)NN,9GU$_
M<S=D/Z1CLG^B3I)_RM<'*5DNON/N9NR'](QV3_1)TD_Y6N!*R77W/5MUE[+>
M>?1\1SL=C7_1C:GND^V<?_WVQU@UQGZ?_P"G'_\`W@2LEU]S\^YE[,?TCO8W
M]#O2?_EBX$K)=?<?<R]F/Z1WL;^AWI/_`,L7`E9+K[C[F7LQ_2.]C?T.])_^
M6+@2LEU]RLME=1O$84[#]<["@7>I_8=453*6,GFL*N!A!:]6D*S\PU!3)BJ%
MZ_4)%!4[%OJB?3(#&QDW,IM8Y.SPF<,\:/8PRU<"IV8<JK\5[I6_2F+-O/!D
M<`<`UTM"9S[OS9(@WG[@&7'K;Q5PZB-EIQ(8T#5^9"&FVQLQJTB`M-U)`Q9Z
MP]V-UA9W+YF48[JNS&"3X7#O=VO\T+]%I/&@+@>S.R$&%=EM2&XIJ6+,!S@G
MH(9[$2NP]!XX15>:C!^F[XALVU4PR9Z;.G.4D-<[X$*71(T&D7B$RPW'RPPZ
M&(](*J7'EPS]J3&/T/EXN;3US-^R57:.DO3TWT]8@KOIZ6NVOGYZYQ@7!;WV
M1>W@A2>Z?PUND'^K/:[^I];\&E]-KAW,V[P_@5]OOJNW_P#LGEO!%>MZ[DTU
MA_FUKS_4:)?^P#^"&<\`<`<`<`<`<`<`<`<`<`TN47<URF/%'NA$R!')1F?!
M"%$%P"5.7(")PB"=2Y#;4MJ*S75LG'6]82;2XWW8&3M5AP9JEZIL*CV!NR:R
M))0@-M?(M*[W:A-<([FZ/@P.`.`:]\&Y>IWR9-EMK,>0DB(W3![),K%VKH6X
M"0J9C#R)+;:ZHM!A;A<^-5W:;.Z)L%0LY5&OF<F8Y>BB<>&ORN[I.&D]2\92
M9P\&L];FY7&@[@:V8/"*!0Z+'K,&95THQ&.WJ3MTCNU;$7J2K-@NOJFD\=)J
M-V^RBVFVF!DJ5TU_C!W7^NU8_P"S&FN"NY;O5EVN"%8^['X&?;?ZL=]_LKE?
M!5>MZ[F!WC^&5T6__P`/9_\`9D!X*OIM<.Y=C@R.`.`.`=')V!$K&I"+#OLC
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MQ*\],GCRRNL!E7"E;)?%96>B1J`;"LW%C$%&N@%)I948>R4RQUE#=TBLI+H,
MQF)0/EENW8H2!35XJXT!WX\;_,J<"F'=GILI!>G79N:$+7DCD@QH>RB<F2@Z
MLVKQK84P(&])J^-S(2E9<CC#P*1*ZEWQ&)#XX.8+DY9*4V[IG$G8J'!14ZJF
M*X*Z+C=SP9-5WC/WFAU^\/JVYBO`)Y8OO4W7,31#P$1DL^8JE)T#>X,&=O2Q
MJ-!-TQ2C-0AMHKC8L_$#<)XW(ZJIC=A3:54K[]QS>IOBA1?MEVOMKJJ*ZU=F
M:A+U34,+MUY,;KK_`'@PQ^QF&D9RVCSP.Z75)@32VTF]*.ZO=ED)4UC,S?#]
MTFH'51\([,).4YP3-HG!D<`<`<`<`TD^)OW!S078CJ>G@!6)1OU_D*_:@H(F
M5U_)W8=IL)M7E\=0-*SHF!IUS,%[)L(8O=ORA*"]#`;9VTCK:-I)IJR'!L.R
MT]FO4W9LRGK2ZF=7-+B[GW<`+\FCNU^JS8__`,7@S#TYKW'W<`+\FCNU^JS8
M_P#\7@0].:]Q]W`"_)H[M?JLV/\`_%X$/3FO<?=P`OR:.[7ZK-C_`/Q>!#TY
MKW'W<`+\FCNU^JS8_P#\7@0].:]Q]W`"_)H[M?JLV/\`_%X$/3FO<J-</BY,
MZXM@57#&BOAQ#</59HBW[.6,8ZNVG*4;1MM:JD&5#5-(JEF;JZR4:4;[GSZ"
M,IAS=NUV39X=X5SNNF-*Q*YJD-3$U:=)-R?!@<`<`UL"!\_6[_X-D*\.5G$R
M;*8+*2$Q$8]88ZV%XK$&$/BZ@BP`]<;YI-8N)6(R9B#=725,GA,'(#35;QAU
M(E'+D:_+?/2*SG7EQH67OR@EKT5`LGTD"#HFP!340=CI*'.33@\ZE`YFR$$D
MSXV6Q<B.TBCEMN89A5L%0)$W[J.OQV3L7BQ0,(G&_/Q._P`I**J4-4251^(#
M9S%28S::%I#T]K,Z9(2N9SN2"F3A:^+G3:!H-'YI+Y@G`HB&'8:"AD="/\ZK
MHLM"T@?'Y2^,2`D*W*5U[N26"-G?!DI/=/X:W2#_`%9[7?U/K?@TOIM<.YUO
MB:6G$Z@Z#=K)/,"+(:R.4U,*Q"J$28T*Q=36XAJE501@^,F73(2%&O)A,`J1
M<\5=MA4?#Y?G2KA`:-=K)A94VESY5>^BN*,]2O&MZ[WA<?5KJ_'(A*HVZMVG
M6#MA*IP?A`IQB;MXZ5>1>,QN(B#Y\K,(R=8UO:38K8C!PT!QF2BH!&W;5VZM
M`"NV%=AI-WQH^N6%-^1O0X,#@#@#@#@#@#@#@#@#@#@#@#@#@&LI$>9(^(H%
MD!"MSE?,=@\P;H3";0V&RM"PU(C#-XZ#'5[/F50EGE=)R87)C,Q8AAW974^\
M!UU,&TIH^*+2DH4)#7Y7CSIY==BJDP7-U'(7!-Y'+U[#%1S+H5[!"MPL,D`F
M4P4@_"AP\DDB<NB=G1)>2R`O@%'W;1\=&+8#;0R"#4$G`,,=%2L$X4<YJGI$
M&*]!8NVAFO<6-,RLE-MAG=BT-4RDPD9>6R-U[57M1/=LDI"==/2I'9+=SL@V
MV=N5,MF:3=FCZ#=NEIJ#<QNPIBR__!DK'W8_`S[;_5COO]E<KX*KUO7<H!WT
M[NTUUO[[]`X/,OB`]*GS*V%W$8A34:=E[?6Y6#&JZC3'P[<JRDDH<V!8@8S%
MQ+:*CC*[-T*=N3&@]EA%=8:LV6[-KA7=5]"4ZZ\5RD;%[O"^CNL*L.`6`3A#
MPUHXM=BSK^0XGJ856=#*X2K0LOF9+J%:J&G;#TE_LR4;;LA[(-LLH5-,4N".
MRTIOW3==,W7TYY&TC@R.`.`.`4_[C]5]^U<8J80VD%>A"%27$WMT<TMBG&5\
M5O)7*=76G5JH*65N^F,$0*M4V-I/)`+>?$".XN1`0SW5LYPEMI@5.)U44<.]
M/T-/G:3PKA-24'U>C$<N-Q/GT>T@G2HBAV'B,BO>LQP?M-,:CI0S9E-U')K5
M81VC)=`=&V)!"6T3>O63)ME..;*X:M6K]*/SC3R_<S2M2VXOK2ETNN+G4^B*
M(Q].)Q2,15%RH]2C4>"Q])XJGJDJ[3##6P[1RHEKMOJFHOJVPKNGKOMKIMOG
M7&VV,>>:8,AX`X`X`X`X`X!X:))I[*[)IZ:;+;X56VTTUUV54PFFCA17.,8R
MIOA)))+&^WGMA--/3S]'37&`*3^)+^`1VW_V%3W_`-G6X*KUO7<NWP0<`K'%
M/PS+[^K'U(_:IW8X+@M[[(LYP0<`<`<`<`Z]V)%$%FSE^,'O7#/;TVB[MDV<
MK-=\;ZJ8V;*K)[[H;8WTTW])+;7/IZ:[>?GKC.`.PX`X`X`X`X`X!U[H2*?.
M&SMZ,'O'3/;7=FY=,FSAPUWUWU5UV;++)[J(;:J:ZJ:[);:YQOKKOC/I8QG@
M'8<`<`<`<`<`I*+_`)1V<_4EJK]NUR<%P6]]D7:X(:7>\W>6H.N'B0^'M5T]
MCEQF#DKA'8LHS<5E4DQM75)M*@H0,*3;1V`,)!/),03>PTKN6$PF(2<H%'K#
M2Q1FV&/,.TQNS9;LVFH_+>TL=:<VB:[[\63K1U^IZ?7+)Z][G$0<`";&G['?
MH9W'@.CO7+ILQ1;[S*X:2K>LX]JHY=HZ[$)A-X\+3QG.F'BCK=NU<`K#;2FS
M7^*R^S;Z%1W_`(H?5V2=R^B=M?\`XN-0EK]$;A<AXV(IFPK*L40<[/SOKQ9-
M00\S75.A+%F2TC/0_JS=!I;6/!CPAF+CHXRH6V!R,$3?"[+V;2I*M+%*EG:3
M<N%>TBV=[^++UKHJN"L\+0;MF_?:.AP.)1@]TI[=U$G-ID<=:,H_#QT\NVD:
M[K,*3+N=MO4K2>7B&FC=NZ6PJILCA'<95AMWV>%I..";9L(K>PX?;=?0>TZ^
M--9)!+'B4>G$./LML[-3,9E(IJ:"$D?/RVUU=CGK=;U:F-54MM\I*ZZ*:;:X
M&72CO1FG`'`'`'`'`'`'`'`'`'`'`'`'`'`*2]-?XP=U_KM6/^S&FN"NY;O5
MEVN"%8^['X&?;?ZL=]_LKE?!5>MZ[ECEQ@URZ0>N1[%P\:^C[,[7:(*NF_H;
M9WU]0NHGLJEZ.^V=]?5[Z^6V<[8\LYSG@AJ"NCM]UWI?Q48C&9Z1D.)&GU`D
M48V6AE6S^TGVDXEMB`YS'H3[!6$5F,FQ+'E:P"93=1A@1G0="QOO8DZ9LR@S
M#X:2>RWKGE2=TM+>6R^<(ZT_^/87]2WN=^X'@D/3FO<?.$=:?_'L+^I;W._<
M#P(>G->X^<(ZT_\`CV%_4M[G?N!X$/3FO<\.J/?^@.Y,VNV#TXZEFS^DS`ED
M]<S")F81M,0Q%8P`>RB*@I2V%2S45&['B,_JZ3-Y``"%@TPA1!)T/U'$P;XB
M*[+23>/3&O!IK0NYP9-3WBE0CM38`:H1/7@1=I8-'E9K9;[6B&_6%>1-K_JX
MI6\XZINI?CLVNB*S632=AY$_F;>'84-/DF3%D_26'KY;.!JRTKXRK-SF8C'?
M0BGK-9?B/D^Z#"LNPR\_;,06S^96O%@`KJVXZOAZ2EE72(13Y^!2X:)']H"5
M@F;UA$G''QYQTL#9(#2_F/0C^X-XX%>SLTC?\VU,U3_+='WJ;M^#`X`X`X`X
M`X`X!JA\4/LW544ZJ=NJREA52*O-J7GH!E*9"Y!"HB6FV8Q"#&M?BG3HUH;=
MRU4)9L-,-4-0.HA^U).&[`PZ)BRH]F-64VUOG@L=U"POSDG0/\L3KQ^E&*_\
M0X)#R?)GI5\2WP^T-VZ:W<OKDBH[6RW:Z*VM$D]W+C""SG*#?78EC*RV&S9P
MXRFGC;?"""ROH^@EOMJ&S:R?)E,J]\6'P\#/?'LC&&W:FL&RHKKQUK!XD!0H
ML)A)@O$)QV)D4G'QR<$&S>*R!T$&W'`-G:(LJYWW<%"#1KAPXCTAT%C3LVME
M.'5OT]GR+F_.6>'WEQEI]V5UR]JPCJXRV^5:)>OPWVWV3U7RC[R]9A'9339/
M"GH^AG?7;7&?2QG'!G9>3Y,]WSDG0/\`+$Z\?I1BO_$.!#R?)GI2\2SP^U]E
MM4.Y77);9LMENXU2M:)*90<8335R@MC0EG*2V$E4E,I[^COC11/?./1WUSD-
MEY/DSW?.2=`_RQ.O'Z48K_Q#@0\GR9Z6_B6^'V[;H.FG<OKDY:N4DUV[EO:T
M260705TPHDLBLF2V3524TVUW34TVVTWUSC;7.<9QG@;-K)\F%_$L\/MJELNZ
M[E=<FZ.N=-=EE[6B226NRBFJ2>-E%"6NF,J*;Z)Z8SGSVWVUUQY[;8QD-EY/
MDSW?.2=`_P`L3KQ^E&*_\0X$/)\F>E3Q+/#[24015[E=<DUG6^Z;9)2UHEHH
MX432W74T0TV)8V5WT1346WU3QMG5+3??;&-=<YP&R\GR9[OG).@?Y8G7C]*,
M5_XAP(>3Y,]./$M\/O9PHTU[E]<MG2**+A5MBUHEEPDW<[KIMUU$<$O6:(KJ
M-7*:*FVN-%=VZ^NFVVR2F-0V;63Y,]WSDG0/\L3KQ^E&*_\`$.!#R?)GI1\2
MSP^W&%,M^Y77)?"*RC=7*-K1)3"3A';T5D%/0);>@LEM_!43V\M],_1MC&>!
MLO)\F>S;Q)^@.FNV^_<;KMIIIKG;??:TXIKKKKKCSVVVVR1QC777&,YSG.<8
MQC'GGZ.!#R?)EQ@)T+*`8:31LJ//1V1"AQT"<$NT'XHR%+LT2`LJ,?-MU&ST
M>18N$'C)VW440<MEDUDM]D]]=LB':\`<`<`Q.>3`;7L'F,],-W[P3"HN>E9)
MH+3;K$W;&/"W19TU')/'3%HH^<(M-T6FCMZS:[.-T\.';9'TUM`5:&J)MW6Z
M\`.^U@2>>37%>(C>L,3JT\RDXTBJJ"LB%7Q<'Q1#G9&/MC@%V3%H+M7^5119
M^R<C7S%\W<J(N=.#>RX5,6^#B"TP_P`2GHN68,B@OL?!B0PDT;$!Q%@A(WC%
M^P>(Z.&CUD[;@U$'31TW437;N$%-T5T5-%$]]M-M=LB;%K+L>#SQ%NBB6=2K
M_L!!$\BD':VI)V.D.F1S;=+&SY75XL`QEHALBCC+O?"B>FR26,K9SIICR#9M
M9=BLO=/Q/>BHOIOV2+8ON.GFQ>B["""68$-)S#HV1FD5?QF.-!Z203"#C0H6
M.#4-7*BR;%%!QL\=N4622R^@JL6I5,5BL]YV%7=^_"VET`JWL$]L*F&AQO64
M5.-+!E]>+#)K%13&+I95U?R,I$O>X#`-GL];._(FFU8(Z.\:+9:9RIN&S;4J
M."?IB83XA'>KHI/^FU^PY:Q(?:,AD]=22.5U!VT*.2\[(+,D@EY'H,RB()W&
ME]G,I7-E6Z0I5EKJ]:Y46<(JI:)J[X"S9M)IW54N4J3C4M!'_$D\.T'"03R,
M]A:L`5ZV!"UH]L*&EPD58QU=LAL']V)-X\T&,!>S59MADDAHBWU2W2T2TUQG
M77@FS:Q1EWSC72;\H.(_^@E'_`.!L6LNJ]SAOO$JZ+C$,.B79"##VN7+)GAR
M]1D35#+LD\;CAS7"RX--/+A^0=-6+-'TO6.7CE!LCKNLJGIL&Q:R[',^<:Z3
M?E!Q'_T$H_X!P-BUEU7N<-YXE71<=JAN0[(09CHZ>-1[79VC(FVKE^]5U09L
MD,K`],+.W:^VJ+9NGZ2RZNV-$M-MLXQP-FUEV.9\XUTF_*#B/_H)1_P#@;%K
M+JO<X;KQ*NB[%1BB][(09HJ3>>[QJ3E&1(*$'_LKI][$RT5!Z[.G?L3)X[]G
M0QNM[,T<K^AZI!7;4-BUEV.9\XUTF_*#B/\`Z"4?\`X&Q:RZKW.&X\2KHNU<
M,6;KLA!FSLHLLW&M5T9$BX(+MVJSU=%BBH#U4=*H,V[AVLFAJINFV067WQJD
MGOM@-BUEV.9\XUTF_*#B/_H)1_P#@;%K+JO<D"KNX_6*Z9FC7=7W)%)=-W`0
MK(VL89Y)M"SL&#<#&IDDS;E!['VMN,7-"DWN6VRNS?V]MLIKKHIC;@CLM5:H
M68X(.`.`1/<=PQRDXLE*Y*-D!AJNX+HHCHTV&.2:J<>ALJL&0.\8,%@8[5N'
MAL*DQM?50CHZ=ZC<#A38@8>#QSH5*?.!K%ZS=]>F->RGMPTG/9BGXFYE7<BP
MC$91/3$:.4D`I>O*Q8(D`^'*FGO%JJ\`'&Z:S3UNNZ@DAC7.<-5LZ"NRZ4=V
M6K]RV#CQ+N@#-/USOM[0[5'*J"&%7$^#H)Y6=+IM6J/K%%M=?6N7*R+=!/S]
M-9=5-%/&RF^NN1-EY/DRJW>[Q..A(KI=VGSIVAJTX],4-9\2#!8N<^)3Q>13
M>)$X=&A@X.&2=OW"CX^=&M55]4<-1[=58B17:#FCMTB+9LVG:5'>L"QD.\4_
MP]9S$XU-`?;*H4PTK!"I"+2-2+0`828&&2+]JD5!&$F18,2217T3?"R;1L_8
M.=56KI!)=+?3`CLVE2'30PQ/M_X3!6P&5XI6_P!-R5I[MD%1UP)XKMY8&S10
M+D(V596!J/4D6S;>.K9$(;H%LI;!5<L$\Y8[Y2R+%JZ+6ZI*#?Q+N@#M/95I
MV]H=TEHNZ:[*-Y\'63U<LG*K-XWVW36VUPNT>(+M'26<X40<HJH*ZZ*I[ZX$
MV7D^3"7B7=`'"CE)#M[0ZRK)?5J\32GP=11HYV;-WFK=SIHMML@OLT=M76J2
MN-%,MG+=?&OJED]M@V7D^3&OB7=`-W*S/3M[0^[MNBW<+M=9\'V<H-W>[A-J
MNLAA;*J:+E1H[T;J[ZZZ+;M7&J>VVR*F-0V7D^3*+]6>[/A;P2^^ZI6+6AUL
MK>0S&[A!\)*V0>-09:QX%BD*2C,D,Q62(B!BDUBC&]HE:HB2.QKI\-:V6.E&
MQ#;!ITNNY>+4TU:BS1Q$8TJWPHY6CFXO0KXEW0!!1LBMV]H=%9XKN@S25GP=
M-1VLF@LZ41;)[K8V75T;-UW&Z:6-M]4$5EML833WVU&=EY/DPX\2[H`UUTW=
M=O:';:*KH-4]W$^#HZJ.72NB#9OILHMKC==RNHFB@EKG*BRN^B:>NV^V,9#9
M>3Y,I<#\2WK"-[=3^VSYPC&>N,XA<"ZS1'M"?(P!C11VWJ.<WQ<<X`MC^L[6
MD[=EB)V2$;!S3^(,QA,\R,"]7"/L[-P_<./E2[+C55C&'"+K;^)1T'3TV44[
M;T9HGIKMOOOO.Q.NFFFN,[;;;;;*XUUUUUQG.VV<XQC&,YSGRX)LO)\F>"'B
M5]`W**+EMVZHEPW<))KH+H3T0JBNBKIA1)9%5-7;11)33;7=-33;;3?3;&VN
M<XSC/`AY/DSQ;>)=T`>(ZN&G;VAW2&VRFFJ[:?!UT=MT5=T5M=5$EMM,[)+)
MJ)*:XV\]%=-T]L8VUVQ@-FUD^3"'B7=`'.5L-NWM#N,ME]VKC"$^#JY0<IXU
MV4;K>K6V]4OIKOIMNEOZ*FN-]<[:XQMCS#9>3Y,GNG.Q5%=A&A]_1]L06TVD
M5>LQLE5A4@8G/<+XBUV>CVI71HKNHQ5?---W#3#C33#A)-3=+.^$]_1!IJ]-
M;R9^"#@%3^R]4OI$`)'*]K:N9C-)2CI"9L,F4/$G6TZKLJWRD3B1MX1>LF[$
M&^(CXRN?>+(D%G0D"R8>@CLR&/1@L[_,23Z*(STI7;-W8N3BIW8U*$F;R4A!
MD:E)".(2$BC''\BCX9D-%B2;@3HVVRV:#V7IM,-'3EHV>N'*"8G0K7V14M4E
M;,4UB(67.0=>-8W-F1YK4T>FOPO(#9@E`)'):?(E8H<V^54554KGXR0*&##0
M:VA4CP#C,*FIB1'GT6&E=SSK25-;IC"_%%D:UJZ*"B&MQ&:HK.)]AK!A$-&W
M'.HM$HZTELA("`['52/&)NR:;2&2@(Z0359@&Q4R2:LV;9MAIMZ&FFW!&\)<
M30J<[5[#I]GGY\-#BJL35*`(>C-R4!AJ)M_'4+=CZQV`D)"B$;%&M7@JM)6)
M8T3+HDWFA&6:1Y%[.5)B8*4P*%I%\:<'7&K<+=6XO^?=EF`(T^`B=#YQD)(N
MPP)0@B)3-%F[-98<)W*N$EFXS0D\T19[$%T5466JV7*J2FB>VF1DHKU6^Z+;
M6!)MK8@.D&;2M]9LGEZ(V&PF/A)$98EZ^BU>SXB8BA&2JO9]*0(>5"'X=28G
MM&D!B,#>D]69-9(C)17&#R]97"G4LKV%?60.J@^ZJ=R38S;1_%\,7X>/M923
M:#?BD-F0Y9`G8LZD[7=Q_4F.37]Q&MA.SW!GW6\T';I9$6I&G4II9H.+$H=,
MH/I741A;41&H#"40L7""H(Q"DI0';5]"L1$<(#FZZBL`&UGF-21)CMDB3*R5
MIJX01&)`@0KCCCK=5ZS)B?=%.^"8^*1RI*_%V-'B868$9%'2XB/FAI2=1\]6
M[^KV!9"2A"@IF(');3F>[OG9.*IKFH$!`-)`F</!AQ$%&+C7G/MQ++5`^F!&
M!#W<YR44-[FIFDT=G!30&>)1)M-9"UK\R?"LF`EN)/FH&C&RQP;J&!*LBKUX
MW<``3A-40S$?GKU*K=E@%[*V$WFE>-RY<77\7]YPQ/2$5K+B(.QI=%K0CZ9*
MO%2T6S*!#Q!X$A\(GZI`T7%/J_O"3OT=XEB)>_6(THBOBE?OP+XHY5RBEE?7
M31?*>F5M$ML[IZJYUQZS5/?;77;;37?SQIMMKKG;7&,YUQG/EP9-:,$<]J<=
M@3LG/0;V-"0SM[#]Y0C!XL@H:J*)V1H[B$%FTMP!&'D(]7-?SFVYU7Q`8_*"
M3=@R)R.TFY]<J2BFHU2/WOBKRJTENP427]LI:6MZZGR\`]3\=H0J5+0KVAOA
MVW^+4P3_`'C?KVF4E\.D??.K+UK?*"V%M/23]4IZ7H9&5>INQ*>=3M;_`&$P
MEC*QX6A$(J:*6?+=TV$8`B!Y=4N<KQY7<Z(&!T2A1(O9%BMG]JO;1:D@`-Z,
M?QR.JD8%76Y%FUD8TXP;=U_&?3[DU]D=[D3C0O6I6C(PB];6,.F(!:.#CKP@
MR7J*?.HLLVW+O=!NJ24Y8QP?N&<"WFDC?EQ;!V_&!DRR1(11CIWKT(PZOK7J
M-D#Z&S&.O`-414$_!0`>YA\<B+`;!@#*MAU*N1S8$,$X;263`5;'VLN)X0T8
MP8M&XZ'&QN%CW#-*2`XOQ_>?3$NYP0<`<`X)06,.#"(4T.8EPQAB[%EA)1HW
M?C"@P@W4:/QQ%@[35:O6+UJLJV=M'*2K=RW54163W3WVUR!&%BQ^2QREIB"H
M=F)BDL"PXQM7(L2!!Y%H&F359\-#,@KW+./M\&'2>1J:SW7#!DX?^\72#G1%
M1!4%>INQ,"ZTB+)C(J51&7QYM%87$BB$:JZ-L0,'C0&-1<(J3%CHQ7H>!M63
M!M4X*+LX@U@F#C;65(Z[&&)??5%FP:M17UQO]<<\#M.S/R@.*XT#5N.D!$W)
M3K>-/]0X&$244S`&!)IL6(S<'.6!1L8A;-/*:A,&#8^_I,^]UQC0M%A!HQ+@
M`+R_T,;H:(3.44[((!V-A04H(<[B8NG!9/%*^4BKB*)UM`F\EC&D5C;#,5=P
M<78^)\!B38BP76>0X:"7<+E6RK4L_!Q-/*_L]YY]BHE*/DNB]<5)!F)6.O3,
M9A!^MD8I6SZJS51KJ-@DPKR=Q^7,7#,?7)>"*%P>[>+"L.6_^!,\[(C-EF+X
M%?77GAU,=AE/?="TBC"NZU71JUVB4E$'&$9N2%UP=6P0&1D+[05*1^/L5X2U
M(!IN]G0R)$`[71SO"DP+IVY=$'Q!\\!NORT_?GEQ.E['5W:$5IV!4[U.INJG
M%?!VR<<?U\^#0IM#`\2"M&+")1`;`SX]&)ZQ9-PML6?K-EFCH0E%F`P8Q4R>
M5*!`48OW_?\`?`LA3"\Z<5\/5L;8TI)=CTZU26DK.-CY&YBB<\DJ=?NS[&(M
MF,=9FWD!TC+HJV',6&$7ZRZ;E@R>ZN&J0.,-.U>I7OMX*ODXI"V%1@LRP$W&
M2LP>B+R(5>?"%)J!=Q:159)ESEC*OL1Z25G)`BTW@3-E'EV,BFC((@5D,;P.
M:OL`HQTSNQYW%DJG6FJ\!"*V#AY\3[*FL*J%&X=H;<!-#Y32).Y(TCR:`!G*
MGL2U!NY6S!MVH=K(UBC<:T:,DT6R0A5;LX.[&F;.@+*!QI,_4@Q6%R$OEM':
MQD)02<$FIB2E4V%XL,68V:SNOQPR`O*>8C&S?4M.)"L1(JO1$6*"7HTHC7RG
M''1:ELZN5F:]:U^M8R>R,_5AD:4FB2F@Q-9.4;AV>QW5RF%SL%2=8)9<8=I!
MMMQ";GUN@S?=CJAOD997+L1$K@/3..R*$N9`I&Z]:Q.0MQHZ*4O)B:,M-SQC
M%)#*ZR5L"'F3(:<1"DB%K($EU"R#,HWE\=&`F3]7:3"2XJC'URQXP6<@:DM5
M@T,5GZ#)M.U(G'5)JV&Y2V'-Y;N'9[2-!ALBLX1V9)&,O$VN4EUTLH:IY364
MT\M]A'I<4#["-.WK^[GA*OXON2@$0C\E)5Z991>G3DEC,T>UX+$1HU""4Y8.
M7K`E*I>=ED$GFCIVGJPJY.2.?0"^]P!AX-*(K?3/.J<<'[FR1'UOJ4O:,)X7
M]7IZ[".=LI85]''K,)9WQC?*>-_2]#.V,;9U\L[8QGSQP9-;EULNX2E]%CU=
MQ9N3B4<0D3&`RO8#4I`\#3DM3QQ8-&X\[DD=UD0N'2RZX\DUNA_O)2)%S'F\
M?6&MH0/CJ!XD-+9BM_'._@KO4V3\&1P!P#%I?"(?8`CW#-XT&E07VC1U[L.,
M&Y!GZ_5%=KMOZEQIOKY+LG;T<\3\O5OA;\@+>:+CW[QLL!6WLB*L][)H(3C`
MI(O%(NS^)TWPJ``9?.(!.$K'K&(D)Q#%)"A($EI.C14WNUH`&CHJNXU3T/96
MUD:[\6"3%40_,'ZP6#B+<X?K^%?*>$#XE[B.P\K,0NJ#5\('3ADU%ER&K#3=
M8@VSJ$E+;+D0Y2=.MFR[)H\:O-U44G/!,:>(@GM\!)S:N0]<MH<G/`EAR\5&
M9E&#E;B+-KDE$U$G3TJA:P$M')6IF$*X:)H[:!1#8T]D:D>9XE$(#*&I@%%6
M=T+.'PJJ^5,@ZL)3UE4881.P.8WD!H)!Q<0I%@$'7'QX=$HRB[$?"$69CH^`
M$QJ8_%D4B+04/;-'$'!1@BFH2]M]\$0<33RKSTJ2K+$%8W7AII#F3X3L%C*S
M./,H6%$NGX=NQ9>SLDXQ'W;5<0LN+;)ZY%"LBR+?.6Z+5`&6SZL2[$*H]0=;
MS&JE@MDPQ&&!EQ:TL+"V,0CD5CGRC39^RF<HE4:5!"Q#LT:M.8R2R)_:^#B&
M'X>;/D4]QP%P2>M78KKZ;KDN"2CN7;;#A[)8BY9L6;1P7>:$2R[9LB@L3()L
M&(I-\152TTW>O$Q8P:-T<N=E5M6`]BSUWPW:-TTQ#7M!'O:);L6:DTMJM"%L
M9'-642W+BHY`R"$GIN*QE,X`$S:>B7AN1^[J]/3F?$*[76(`ESDXD\U;K`&(
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M'&CC)<2/VWCP$:E(04@C3!F^<MFH;?=X!>M!X]PJJ@@DH@BJD"(2ZO`+0A+B
M=P&:,]$(M%?9$HRZ80B*0:/$S[^?6RXD)R.CXF.'L%TIG$=*RLB3Y3W)-!]@
MSF8BFCQANQ=Q:-BN*>9?=;DM[M6T'#Q^7FS!BS9;$'BI%_LT:H-LOB"VB22S
MYYE'33+EXJF@BFJZ6]-=31%+3;?.J>F,"&MOKBZ[5*6XD<L^#8CZ$P?1E&;G
M6T&BHI:3B@E53K>0J2V1L@`DOLZKNTO@*&5PURJFW?QJ0RO8&0MV."];01&G
M$4?D^JJ]8NN-F'!D<`<`<`<`<`<`U##N[-^P:#!Y41KN07NY+P&N3\D$M8+(
M:T>P6S2T7L>26'58HII&'HB6O168B"%"([JUQ+P#HOZPH_F#TW'@61J%G%7R
ME+ST18&07_=\[@JKJN*XD$6D8SL9K1Q;W7[DD3PFC%&11O8TEBSN9"A$72B;
M&8#G,:#2@^DGH21%D5E!XL@Y8M,!"Q>$]:)Q+NK3GB1Q(^YO8JKAJ@"9]<VL
MYG,1`,4IN^A!N7L0ZLD'1NO7Q,@R2>UVZ$(!)Z=ET@'UBV82DR3.I061,A[0
MM.\-JZV"$\84X\>U.>521C/87L$RC=6F`U8"9#(95=]FU?)(]AO,`@00#&WR
MI4\.E!4UM&#IH*S%19PWG)IPI'U&<A2'/-6#D4)?)%6(D:X3TF.="%I5WWO9
MO$3#-AUPP%L]>KOC0#%T#4XE)M9Y(8#7$K$^X`6U3@TY)K`'%DKIV(W*D(MM
M_P#AM,F@1-\_]-D+%A3?VS>NFMY(8_NK<AJ>3")!>L1)8/$BKU;:4D9'*6#4
MM&&5@8A&^!C-*LGRWQIEKHI(U8H84!N&+7;9J^5;I-M23X2%$SPC0A!WX@/9
M52-A&C;KFI\1(5F'E4SD3!K.L,$9/\F</-G(@*CK^$N2L;D1"PYNVBD31DB!
M<:YVCA5-%>0K+O?AX6%^K'U:[5\185#N%<;^7/X^-ZV.G`P.HN_-&59%-&VP
MH8SL/6%$(HJ@I4V63NU!X?=G-G4<9%%HSL"-AUQ\Q(C5=3#@2%$SPX3G=Y!L
M)X(.`.`.`.`.`.`.`.`.`.`.`.`5;[.W#(*D3J;4-.JJK-A.9^9C$AG%OQ\I
M(XR&'CZNL*9L$FS$98U8[X,%I!%@XIIE4^XRX1=NF3,6Y(NF:K<5*9O=,-ZW
ME8X-XC!61;H##U!GA!_;>LHR\&-)&]W>@K0LK681MC!YF)-0P(1A6K>V8V#K
MSWV]P3&[I3J.2C"V17M&O!79]>*456='/,SF6]D>P\/MJZ\J5Q%25#5=9$(K
M]&2ET6T*110G%;T460E!FQ?E/EY;83&9W;!1><N\]>P\;C58Q\R>UEI,_&-P
MLH"%"K5^[I$<JXKAU<`[W&;&L^`P!E5PJ*LY%+8..-EC\V=$MV\6F5-3*=I&
MV^0T4R+`N'LY%1>)5XPEY067LX69]^#`85H1$N%`=F)KGI5..-*GG'NZMDNI
M<=C).D&CT2"O2SJL=RMG*C()?(*'WK&ZW$G&,5<PV0)DEO@^>1<VNNI+AC(^
M6$R=1HG'A>6>K<(6>$]'ZIKD1$1\4)ZSAK2QVU3!"<;?0YP:&C!<\($4#!Y2
MOX9:+*.M[#:PS8`,DC&/'C<5.Q@H`3;M[%$)QQO+]W"Z"+P79K$]*Y3$W7<'
M)(,K[_R:*R35L4J($$BWG)=F1D]/3B.QY/2SYI5$&1379UPY:@BQDO7LDE<C
M8;)R`='*^6'2A0\NV;']1`FSZ4C27C@GQ=#%0_B029TCL:*5+'Q8<H+"F0S,
ME.'@I``S+=>*QO##:=S/>-OQXTD],2B35K$4!T:=-9=-/A$(D]$KOW[C0-FL
M3[WM47"N1=&B;V,7$4F@\Q6Y"O\`6.Z)$@FQ`LN1>&`#JQ;;KAJH:9+Q\)B.
M274A4)4N0CS5U(VC$-((XK@^Y=.7;5F(U&O[)^I8W@@X`X`X`X`X`X`X`X`X
M`X`X!16\.SDLJV\=8(P+5KD*RC_70TE`"@,T_M>QT+=N6PZ[L5]`GP^<CTT6
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M83A,E-L1QP@G'QYYXMG+[0(NOJUA@_'%+JG/,=^2D;6)K2.FFH4`D>0CXF1$
M++T8L=URDPD\3"E95N\@Z#&)`-L0F2F9"1P3.9CX]2->I0,J%RGPZ$9.7EPG
M/A=GD1X4\3I"-*210O5>2FC%^26"B`D@>MRI6/,*;A$V9%8L0>QY:.V"(D$V
M-'&`J2-240SM!7<2E",;?J.GR&!=B;LIZXY=:SD9%(_$1(P>6D(W,ZOCP]RW
M?"Q;8,QL`RZ+NUAUO7?4L[)#7CBN68\DT1=5,U-P1D12C"DI&D"FKE^*(,-!
M^XBLSYHFIYZG1B/$F)LH._DLLJE@1-AH3#)81C43E>[<F>(2BG(+/B<9JI@8
M%K.[)>P&0R(LG<"ZGPCO4L128E"C&0KMW&ST-G7R8KE.%\FQ.J9P1L.'8D1B
M/)18NUE=B0\J%;%E3K)`G7-A2FO2#H:8<!X^X(B2KN+K%A+IR$%N%!KYKEPR
M06]/3`RZ>9U)'X`X`X`X`X`X`X`X`X`X`X`X!UPD.(`L4Q8,6.##$5'2R(X2
MQ;#F*2SYVN_>JIM&:2+=-1X^<N7KI35/&SAVX7<*YW654WV`['@#@'%]B9^V
M>\?9&OO##7++#_U"7MGL>5<+Y:>U>AZ_V7*^,+90]/U7K<84]#T\>?`.5P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#IRD?`G%PKDT%$EW,;+Z'X\N3'-'ZP
M(ZFP("M#(=1TBKN-*Z#"I0?H09Y1=Z,B+YKJKA%TOIN!W'`'`'`.O$B10`4,
M!`A@\*$"CV8D.'$LVPX4)%#FR;,>,&#V::+1@/8-$46K-FU12;-6R2:"">B6
MFNN`.PX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!TVT=`[2%*6;!AF\G0#+QU"
M0[LF^QE`"Z>MR3L,@1V3RZ0&.R#-D]=LDE=&[ITR9+N$U%&;;9(#N>`.`=<5
M#B3K/W>:&L2S##L:0PS(M4'K7VX.1:EQ+SU#C11/VD:58LB3!?T?6-7S1LZ0
MVT713WU`['@#@#@#@#@#@#@#@#@#@#@#@#@#@#@$)D8^WEULRD87+3!`:%KN
MMWXYA'I[.(>S2>FY+:[<H[6;Q&0@TGCEV@"$H[+/='"B:3%+1'9/7*F-P.]^
M2**?SM9_Z;KG^WW`,,B0BDI\L>;P6T3DU7BQ+8+)T(EV5LR1K1PQIZS&XD\F
M'LQYN():Y25])@0U;NM?5J>:6/0V\@@S+-1Q/&,YR7L[&,8SG.<W=<^,8QCZ
M<YSG,^\L8QC[^>`,5)$\Y\L%[.SG&,;9QB[[G\\:[>>-<^7Q]Y^6V==O+/WL
M^CGR^]G@'J2JJ&N$T54#MDK).4=7#=1*\KD437;[8TVU71WTL#;55';55/;5
M73.VF<*:9QMY;Z^8'DE5$/7UVV1-V6MKHHJCOLE>-RJ:ZK(*;)+);9TG^<:J
M(JZ;IJZ9\MDU-=M-\8VUSC`'L^2**?SM9_Z;KG^WW`'R113^=K/_`$W7/]ON
M`5EL.^>A=12\M7UL=RZTK"?`<,-CD(L/O.4A4O#:E1K,R+R6C4DND8:'8)!R
M#`JPR\9(X>#7S-\W]8U<HJ[BJS:=59;6B;)WB$3J:P8P#FT!L"63B&2<>@7C
M<NB'8FU)+&)"*=8])L3!GPMD/118>XUQG9!ZP=N&RN/I34VQP2(HZ,[_`'JB
M'I;):J&[+3V74]4CKO>-RZ;+*^ANIZM+&T_QE13U::F_H:>>WH:;[>7HZYS@
M!K5$/WUUWT-67OIOC;;3;6\;EVUVUUSY;9UVQ/\`.-L:Y^C;.,YQC/W^`?N*
MFB.?O&;,S]&FWT7A<WWE,YPGG^/_`-[?.,XTS][;.,XQY^6>`>.E4PY3T_5F
M[*W]4KE%3T+QN7;U:V/1\TM_1G^?05QZ>GFGMY;_`,+7Z/X6/,#V_)%%/YVL
M_P#3=<_V^X`^2**?SM9_Z;KG^WW`/S-1Q/&,YR7L[&,8SG.<W=<^,8QCZ<YS
MG,^\L8QC[^>`8'6+.D+H@P*S*GLF76#7\GT?J1^7Q:_[@+`2^@LH]"$<L7[:
MP-D5O82XU^-=8USZ2+QFX04QJHEMC`1%'1F>_)%%/YVL_P#3=<_V^X!^:U)$
MM]==M2]G;:[8QMKMK=]S9UVUSCSQMKG$^SC.,XSYXSCZ,X^G'`/S%21+/I>1
MBS<^CG.NWE=]S9]'.,8SG&WE/_HSC&<9SC/TXQG'`/W%1Q/;&-M2]G;:[8QG
M7;%W7/G&<9QYXSC.)]Y9QG'TXSCZ,XX`^22)9VSI@Q9WIZZZ[;:_+?<WI8UV
MSMC7;.OQ]YXUVSIOC7.<>6<Z[8Q_U<^0'[\D44_G:S_TW7/]ON`?F:DB6,ZZ
MY+V=C.WGC7&;ON;&=O+'GGT<?'WGGRQ].?+[V/IX!X[5-$==M--C-F:[J9SA
M/7:\+FQMOG7'GMC37,_\]LXQ].?+&?+'TY^C@'G\D44_G:S_`--US_;[@#Y(
MHI_.UG_INN?[?<`?)%%/YVL_]-US_;[@#Y(HI_.UG_INN?[?<`ALQ*>L4?NN
M)=<#=UF!=[SN)FIS#ZI>]C+:0F<@BD?73;E#`\/O86%E$4]MG*K1#;T'A-H(
MD3X6W>,HS(7`P6'$PX5[P)D^2**?SM9_Z;KG^WW!#T[U5#$]_5J';)34]5NO
MZO>\KDUW]0GMIJHMZ.U@8V]4GMOIKNIY>AKMOIC;.,[8\P//Y)HA]_WS9GEY
M:;>?RX7-]Y3.=4\_Q_\`O;YQG&F?O;9QG&OGG@'[BI8EG/HX,6;G.,YQG&+O
MN;.<9U\O/'E\?^?GCTM?/_P]+'G]_'`/!*J8<MHFJB;LI5-77TDE$KQN5317
M7[_I)[Z3_.N^OE]/GKG..`>WY(HI_.UG_INN?[?<`_,5)$LYVUP7L[.VOEZ6
M,7?<V<Z^>//'I8^/O/'GCZ<>?W\?3C@#Y)(EC;&F3%G>GMKMMKK\M]S>EG77
M.N-ML:_'WGG77.^F-LXQY8SMKC/_`%L>8#%21+.=L8+V=G.N<8VQB[[FSG7.
M<8VQC;&)]YXSG7.-L8S_`*,XS][..`,U)$M?1](Q9VOI;>CKYW?<V/2VSC.<
M:Z^<^^G;RQG/ECZ?+&<_Z.`?OR113^=K/_3=<_V^X!^;5)$M-=M]S%G:Z:ZY
MVVVVN^YM====<>>VVVV9]C&-<8QG.<YSY8Q].>`?FU2Q+37;?<Q9NFFN,[;;
M;7?<VNNNN/ISG;;,_P`8QC&/ISG.?+'`/W%1Q/.,9P7L[.,XQG&<7=<^<9QG
MZ<9QG$^\LXSC[V>`?OR113^=K/\`TW7/]ON`>BL6VPPE:@),B=(#@-ALV(C$
M@D1Z4/63)W5];&UVB9:2DBQ7=MDJ6)/-$%GJB:*CQ;5#5-/.-,"O#=ZLE;@@
MX`X`X`X`X`X`X`X`X`X`X`X`X!&`G_///O\`9A47]:[NX!JT[.^%WV0O62W1
M)X5XJG<RI!]F)RI2.U5'2L>TJZ&8.C'#-E'&C9LS;2'$5;*JZZ.4F91L5RSW
M7PS>MW.4EM!M6TH^2RXQK/.;]8-%7AA?W.?X@O7BT+6E5D]Q#W4<4]C?P>'-
M=39W[^EEF;:GF!)-V;]^Q]B)'PMHBP4<LD"S'65JDW:/HL@S5%]J1'6W\6RT
MHLSC\RHN3^Q]7W5#K7,.O5422LK4[(V]V\=R26FCZLXOU0*4D30`9CL>`[P)
M'06R;,%HJV4#$"J35P@INH]DAC"VVZ*B>FHX-S@ENN]2NP7IM?D?>P9\WO`W
MYQB1-0!#6(V*;KHH9J:N&]?1RBDI/('%>6'M.GD=C\5G\FG5<%0X>)RN>7K.
ME4Y4U'"1JI(65E[3C"E1OO21QXETPO6OHI#(W&K?<O1\.KR)Q7`-]:]O#57K
MACOU.VFH"/S_`!@Y,:VB$I1HZR60Y*'ZIH1=&>M]@\<02>&VF@;2E[\E_%AQ
M7N9Y6_6*[X7;,*ESJT3C>OA)"8FR=<QVX93B/-2\KGEPRLDO)1<DK4Z[O-8T
M(L"'`G!:4R2OS0(G`$I8R>%2199NB#:<TRK&4<NN1L&X,D7W7`9%:543RO(E
M9DKIJ2RZ/NPP:TH-JRWET'?.,Z92/1_0CHJQV(M?0SA'#I/=+RWV]+7/!51I
MQ.F9HDI#J5W+Z?7'VK^(>L;/Q/!=P3RM)A%^S%YW+0\&LLHPCU*P6%D01Z/2
M2*&UVJ<?,!GL?$*-O847(0..=;(*J+Y749^<S;M)I0]B)HD\RR/A%^'[V2Z6
MU37&M\]J+<GBS:DQ\&<=8#KV)EZAIB0X+"">RD"-`$LNR7N5J,=`A[A9TNW4
M'F7V<YRIA/.H6[2M-PHK,XO>7TL6E"\DO`':'P54EHA-8G$(FF*M==V@^J=]
M&)P9E;Z>U?IK!YRS?2"5)&A6I\=NK!EUW]85ZMK*_0;>D*&)I%5NQT?CO*J]
M:^DUM=5ODV0B;JJK$:18)AF=][E7-5K+D)!4]+5U*,M6<%J(O&BB89]32)(&
M54CH`[+QLGU0FSK:1QQW*ID*VGIUSUUS,NAG3R?P6/1P4AI5LK)"^P58W.T*
ME"DF#*P",QE@BT?U)`-EXM+ETX37#--[#Z8'HK1EJV@!G<4<;-#;4X?F@3ON
M:WSB]^-]5RZN/],[$C0C1!H-IYX686/U>/H.MC1T;\0+=?K:EEC2V]S[Q&MW
MKAO>ES@Y*G"92P30*)HL66'+VS3S+9,*F$]GU5U]RP[&S;@R.`?,WW3\+#Q%
M48!G3K/XB7>*^S<UFJ`:>UM/;\@]70QI3QG0EM.FC([\.JD-RST7NG&(XV;I
M*I,]B>YE_LNB*P-)CJK=G&S93B^KKNZ]")>LOA2>("UN&<Q9O:G8+PTNHK^-
M-9+`JOZO]HX38L<C5K85&#I6WTC[R*,EF`&<,4<RC9PP0]-A*T#.7>KMO(&Z
M@H]%&A-I*RICXEJ:MIIQAOB[=&1]!T?H&RH;U+5Z[,[^GEDV&M$)'"E.P]MN
M\$[&73F1@IA_,""X-%@D^DT/CYURG$&Z>&#1P\`@&;]XS;;.GJ0Q-9A1-V&X
MJR]Z'W-O7)^J1]WY%0]C7,CJ2N`T7DEEP2%!8!)A?98;[E(5;&SGPBDC%A%L
MU'#8GG.YPB(CM+A'PLP()HLD=!=JLN^9=VG>'E>3T[ZZVX4JJS(6A:3J&D+,
M5*B%PS<\O8H`#%IJ`AT1E+M:;S"'L+5D\UBX)A+'L,,_$,8:F9`Z$OI6UV]<
M\V:B2J4Z:N*71=/0AC?J)V.B$21'0Z\"R&M>5E(:ZK>.P>53:%@5(PSC7:X=
M"0[6NL24?7PV0!M+,ZY@`TA)$UBHI&E42;>7"=D1Z>PJ:Q6-:;OO34QZ/=:N
MW\DA*9IS.#%72PX-DXC2('+]LJ02:!^=J]LCU;R`I:T=W/F+2UK:)6_5.XV`
MR0EF+3C$15!2QR$1#!MM196_A_+AA,/"F!P\==NZ$TE=D)/+%M2O(PQF;#4.
M^;]E2X%_:&C8W?RCNQ8THT`7:RJ0-[KF=5X:T\A#FD4+ZQ5K@FS%;!6C'025
M2YTK2ZBW36:R2D4ZH]AL./;0U[F%U=F#0B^;'K*M-\N\DZI&V,2]G'I&^7,F
MJP!S6(26O8;H]@.!ZD']P/Y7%H_H?9,MB@)K%=%I'*N^YF4W=UAEEKCJRTS$
M*F.N8Y3MQU@_86K-IS8^D$/VD0J=Z'LN*2V10LE,)_(X'\GA'V14N[KB1&-R
MR6[691I351;4$XFKO3II/+J>&.N_8N.O(.M%[H,'M\SB:O+.)32V;.VW>P\C
MV0K&RH4O&X[L.D4;P8`TM!Y'4A",C6T%CSK,Z+N,E7+%0@D4"56F%*:-=W.+
M,HZ2Q"^8=!9TROY&5H2!:<BM(_O,+1>6F3,AP]5UM'3DQ1>.9%)T8<PG-A")
MK+4:]'$]A<35+N&0[19ELW?O@M1-.BC%[N9=#@R4&[C]-[9[0'H28KCO-V7Z
MCM(F(*C282AW\>9C9DX(O&SIN5D.IH>]4W?"TV^[1EE#9/3"#E;&^,[9QG`T
MG'Y;+WSZ-'QH61X#/BH2WQ86#,K=5C2T0^."[9&>(R7+F5"(&$Q-\.9"7+A\
MD33)#KLC"+<8"`5L,*-M57*#(L)?L8`@\D`L=U\2QL7:;*S]M;^)]@74OHE=
M/6ZT'E@6!XB';+M."<Q(M&TZUNTE&'</:$")`.];RI!(.,:.\&Q:(MRP9;[*
MY1PU+/\`&^F=MM,ZC@[4_ELK<GZMG=W+U$D-FG[_`--HS3)AM=SAH]"VU*M/
M:K6J9BC445K%S!XN%+5K,`Y...7D;-R+VA26AQ.VME3$:1@I3*I)]*`3B+Z8
M8.LU_9W&/0SJ/;%=@[)KT8PI>;0NQ:DVJA4Q)C<EBBS##6SNR=A,I2\K6&5Z
MG'EMGVU],M2,0@TOK&.@GT<>(U]M#@+J/AXN$XUE.>BQX9/B>QQTTL9.,@8:
MT/PQ\]94+VUI(W=I8J:TM8^]OXB$*1ZS)`P91+#,[,W9..M)%9^&4JBP9_+R
MY<U$1P86@+C;<)5^J<84PT65]#.*RZU36$3^K)EB*T_'1\<EEZGC$=B)TMJQ
MKX':R`E-E#JSQBL@:)H.J3")RR38>MX"U6DI@FX;#'6R*3EP(WJ_??7E>6%;
M5G,D;T*6BI;,P6A3V&"(^WJO=O"OA=N48NSJCEYA36#Z2?5#?4DT(I+Z2[)-
M0JBJV>.5X^DS#HA-(CB543Z@6[O<M@60[M])H"NR9,3-L!X66GU<292-5S*5
MFE.`8_-H6=%&M5&=5$G\9FKAFO&/>Q1@%W](@UT<+\";EEZW];CWT?U0NN`R
M1T6EERE4WY&'FFAN?1N8%9?+34VDPCK/[W.LXG;4-E5?19O@Q3T^:.-V(TGN
M;#S1@^]@!EVB6!0LK!>?-KJCJ6W3>Y,6E.)R[N;5L$NJ8DI9;@R$&[#K"3>J
MBZ-BAJ>$!9K!3HDR7V"Q"9Q.)RHNJI%5R`FGZ_;ILWB*+E+4)I=NQ6$W[NK(
MP&]<N[$AE!D&<LF1Q]6-QJ1ZL[O,V:7D0*>3>2`W[&(GH=3C8V0&5[O46C[4
M-L]1$1-Q.TV>DI*:;R$V708!-F+LJ90ZUUZ'*EE`=ULRF/@(K.9D&$20=)T6
M4Q&=@YS+(SUOW4:VTJAJ1UFY8-,>RSR2O9+7RS)Y/(8IO`'439B8]M@`Y>/`
MX2O%$^BX7XF5$.G?8LO"I*)VON<M#;^#N(M&V<J[`V79@<6Y/M[Y8S%21.D8
M16@F=,RC:PZZR#7EU?%SD6Q"M&HDHG@,!<[A*E4QET2RU<8XDV'*#LZ3TUV:
MK22DPTF-6UK8K2+')19MB2B/E0\J.2XA&PAR$GX^0C]4"8]'S06(/AE=M)&.
M--!NY5VSW51:#N!*E:1@L(Y\2.1?4VWP#LM)X;+0=9;XDVT_A]'UK8ECPZDX
MH<2-T]E]#-T8R&`!S\5G,?KN;+2<P7JM9(5+[@ELB%P1^_3W>DPE8UPG'&N^
MJQPO%6UEVRCO8B-OK!)2*20?#J82^0S-K<QYW`!(@Z"D(X%1PJKWI(?B6N(_
M*2;29-+5-00(8V9^E%O6LP\9C;1Z$J.EW6<*4C]RYL#_`(U77_M-%?L:J3@C
MN6[U9)O!!P!P!P!P!P!P!P!P!P!P!P!P!P#7-V<[#S6B+MW3B(N+D<2BK(/N
M0S)&19YE'(:6VAJU]C]V&P^$\*8*./7^NPX]+T$?5Y2]'?U@N$ZOT]R#?G";
MG_%FL/S+*_MKP0?.$W/^+-8?F65_;7@#YPFY_P`6:P_,LK^VO`'SA-S_`(LU
MA^997]M>`/G";G_%FL/S+*_MKP!\X3<_XLUA^997]M>`/G";G_%FL/S+*_MK
MP!\X3<_XLUA^997]M>`/G";G_%FL/S+*_MKP!\X3<_XLUA^997]M>`/G";G_
M`!9K#\RRO[:\`?.$W/\`BS6'YEE?VUX`^<)N?\6:P_,LK^VO`'SA-S_BS6'Y
MEE?VUX`^<)N?\6:P_,LK^VO`'SA-S_BS6'YEE?VUX`^<)N?\6:P_,LK^VO`'
MSA-S_BS6'YEE?VUX`^<)N?\`%FL/S+*_MKP!\X3<_P"+-8?F65_;7@#YPFY_
MQ9K#\RRO[:\`?.$W/^+-8?F65_;7@#YPFY_Q9K#\RRO[:\`?.$W/^+-8?F65
M_;7@#YPFY_Q9K#\RRO[:\`?.$W/^+-8?F65_;7@#YPFY_P`6:P_,LK^VO`'S
MA-S_`(LUA^997]M>`/G";G_%FL/S+*_MKP!\X3<_XLUA^997]M>`/G";G_%F
ML/S+*_MKP!\X3<_XLUA^997]M>`/G";G_%FL/S+*_MKP!\X3<_XLUA^997]M
M>`/G";G_`!9K#\RRO[:\`?.$W/\`BS6'YEE?VUX`^<)N?\6:P_,LK^VO`'SA
M-S_BS6'YEE?VUX`^<)N?\6:P_,LK^VO`'SA-S_BS6'YEE?VUX`^<)N?\6:P_
M,LK^VO`'SA-S_BS6'YEE?VUX`^<)N?\`%FL/S+*_MKP!\X3<_P"+-8?F65_;
M7@#YPFY_Q9K#\RRO[:\`?.$W/^+-8?F65_;7@%U>G]C&[8B-CSN1-13(N8M-
M=-RV"H.VPW3497%;"T,H(OGQ)UKG=NS2W6]8\5QLMLIMIA/3.J>HKN6[U9;;
-@@X`X`X`X`X`X!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g887761g45g36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g45g36.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X5P(:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@("`@/'AM
M<#I-;V1I9GE$871E/C(P,34M,#,M,3A4,3@Z,C(Z,C,K,#4Z,S`\+WAM<#I-
M;V1I9GE$871E/@H@("`@("`@("`\>&UP.D-R96%T941A=&4^,C`Q-2TP,RTQ
M.%0Q.#HR,CHR,RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@(#QX
M;7`Z365T861A=&%$871E/C(P,34M,#,M,3A4,3@Z,C(Z,C,K,#4Z,S`\+WAM
M<#I-971A9&%T841A=&4^"B`@("`@("`@(#QX;7`Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR9&8Z
M06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM9SIH
M96EG:'0^,3(P/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@("`@
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@("`@("`@
M("`@("`@("`@("`\>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
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M8FY*,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
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M2#%P5S5G3%IO3U`Q6E-M.69I3F%(8D98<7DX=4DU5355,W`P<FER)B-X03ME
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M15`K<75+=2]2=FUR+W$Y=R\X05-%4"MQ=4MU+U)V;7(O<3EW+SA!4T50*W%U
M2W4O4G9M<B]Q.7<O.$%315`K<75+=2]2=FUR+W$Y)B-X03MW+SA!4T50*W%U
M2W4O4G9M<B]Q.7<O.$%315`K<75+;U!1=$(X-5=N;7)59%(Q6'I!3E(P835T
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M65-G9%5J9F=G:S5C4C!O9#A+<V=M)B-X03LX:5%19FUN;U=S46%P<4%&=G`Y
M-E9S-7)M4S5I258T23)"3G=:6DM0.5EQ84XQ4E1G5E!F>3`O.&QX-54O=T,R
M4'`O+T%&0W@T<7E4)B-X03M&6%EQ-T9867$W1EA9<3=&5T)F;#$U9G,Y33%N
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M37`O=T)59E%Q>7)&6%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW1EA9<7-N:V%+
M0U-256%6:U5S23!P>5EG5C1R5V=Q8U996BM5,FPS5VTK6#<R0S1T-7):6'9P
M6EE)6C0S:DEJ94]/;D531FYO5%AR)B-X03LS<G1H2W(O>DDO,W`X;B\K0D9A
M9CAM3&I!<DTX5F1I<D9V>E`O=T-53'4O*TTY;"\Q1W<T:%=5-'$X-3`O=T0X
M:S4U3"]W0EAY="\Q)B-X03M'5T]+=E)S5F1I<G-69&ER<U9D:7)S5EE0-4-I
M-&5:4$YV.$%O.'-+4UA34"LK=6)A9FMZ=DU8-'AW335I5W8X*S5.4C%5-%95
M;2]*)B-X03MZ>3DV<&QJ=7)L1'=J:E9!25-G5TI11BM(,#9D5D9F169$,$].
M<6IV>2LP,DA43'IZ5G`X36MK:TYT<7--8V)Z3GIC<4Y(,"ML5U!H)B-X03MG
M5FQZ37%Q5UEG2T)5:S=!05EQ.'9T=%HO=T-69"]L9&9E834Q=71:3B]D4'%Z
M>'I01W-I:E5:5D53:S!86E9:3U9"5W1A04192V],)B-X03LX="]Y:C`V6%)$
M-7`Q8C9X0C5V.'=1>5A5.39K.#!B=U!D,&M$2VMB>&A8-4%3161I4W9167%Z
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M4W!T<$HW,5(X34-J<TEL27(T5DY2=7)!<3EB,#)X:#`O5')7=V=,)B-X03MT
M1&%1>'=23DEX9'ES4VA&3$UD,F%G,TIW2VE-5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9A8TU625%G3E$X4U)503EQ:6]R.2M+)B-X03MS8CAH*UAR,WDW
M;U4Q;F9M3G!Z8U-Z:S)X;&5,9V%"0D=K;DM284EO2$5S,CEA1VA!0W)'4$XS
M;2]19%HQ4'EP85=--TYC=V598E%Y)B-X03MW>5)V1W<O8U0Q2'AG5G!55G`T
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M=E`X07IR;U=J85A0)B-X03LU44=N5U5.;T<X=U=58F5K9U5L63=E-$-!:V1L
M1W=W<3E"=TLW1E=,9FUF+T%-;UAD+SA!1V5Y+S9J66-1<DMC5E5B<7IS-W1%
M4S9G)B-X03MJ=45J:U-A3EI55G=S:V)":V-"9V%-<D-Q;G-C5F5084(K6F9M
M1S,Q8CAW-4Q,>59D6&)75BLQ,$=I;6II:FM%1G9(8716<&QI8SAL)B-X03MS
M>DM05%-2=FDT,#9->7)04$QN;DQ89%<P2W@Q3V9Y<&8R,&PW0VLO;WAZ,DUI
M<7-G-4I2<$HW9#DQ25!X4G%2,'A6368P+W%V+U5T)B-X03LV:B]Y33`W+T%,
M2SA69"MN.58O-FQV568K4FUN9CEL94MU+U0K<2\Y4S-Q4"])>E1V*WEV1EAF
M<"]69BMP8C%(+VM:<#,O6EAI<59A)B-X03M"*UEF-E<X-39L-5EL,&$Y,#97
M=V=36F)Q-593:W)%:C%%1%)'4TPT4DEL0TI$>3,V8V-65"]2=$9J,'%&;VMU
M<FTV-54S=5I43%-L)B-X03M4.$E/>6IF=&EQ+U=O=%-L,'4T:C`R45)8>DQ3
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M1#`Q65=L=F]&0DI&*VI#2DIY,T0T9E5!1$M!,V5V4&EA,30Q,GA62%AT>"ME
M165P=U!(1#5D6%1&)B-X03MT6FUU;F5A-D-,3T]*47-X44]"-%5&2V-U4G)X
M>%9H+VQ,.'E0>EHX,F%41$1O8C9$8V%X87DR-V%G>F97:T17-W-#>E5+0U`W
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M8U=Z1U-::'IP<W1':E9F:39B;D95;C`W6&9.=FQR)B-X03MY-V\Y<#5J=4Y&
M=#=X3%I0<F)4,U11;4].044U8U%P1$)*2&II2E5K5DYC2W-P.51Z<B]V:E1F
M*U)S+R]!1E1W2W1%;FYN,4="=#E-)B-X03LY34%C5SEA-'%7<65123E,='0S
M>%9Q93<X,U<X16LX-F%81$)#<&ML;&MN;59%4E)6;5IJ2%%!1&-K-'%L;FPO
M>EIR3W92>DYP:S)I)B-X03LS8E%%1U9B93=L;$MP25=-3$YX:E!(,458:T%F
M;#%"=W%M<VMV;F=2<UDW9E1':T%*4E108TM#86)!;C!J5#=S0W`U:7)S5E%L
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M0DI5)B-X03LY<3`S1F1G<6EN-6\V:WIZ3B]H5%4O4FIK6DEW26Y-<D)E:D9/
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M,VQ#965W:"]W05(S<U`V4VM3,W1*2EE)0D<Q>3=C9E%$0S-)3$LS=W-W*T%-
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M0V9H0EEI<#)'2W`O1EI817%"-'1:=5I%4%)L1F]W,CEX0FER1S(X.&56,6YT
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M5&=),$U38V9H,G!'-5@U8EE68FAS4$I536M5:U!L5U-/4T=68FE&;#`T9W)+
M;T%6)B-X03LQ;W5Z1&E..%94834Q,GAU65=G=61*=G`T6'!Z:6MS,V1443%&
M5EE%9%)G5DMO8E!Y9D1D5#-395=*:$YC.%!62C`X:TAG2TQ24W!6)B-X03MD
M=71"=FA62&%T<4]M87194U=.-W!E<%!B>49(*T<S;5)L94HQ;&ID2%=J2WE3
M27)+461I3599,4PU3CAI4S--.3`R:39X.6%U5&)T)B-X03M,4#A!-F%:3U9P
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M230T+U1+<49::4]S2VYF*T]+5UAF-&YI+S9T,F\O)B-X03LY26MN.4U#<U`Q
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M:6UA9V4^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`\
M+W)D9CI!;'0^"B`@("`@("`@(#PO>&UP.E1H=6UB;F%I;',^"B`@("`@(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B/@H@("`@("`@("`\9&,Z9F]R;6%T/F%P<&QI
M8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*("`@("`@("`@/&1C.G1I
M=&QE/@H@("`@("`@("`@("`\<F1F.D%L=#X*("`@("`@("`@("`@("`@/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG-#5G,S8\+W)D9CIL:3X*("`@
M("`@("`@("`@/"]R9&8Z06QT/@H@("`@("`@("`\+V1C.G1I=&QE/@H@("`@
M("`@("`\9&,Z8W)E871O<CX*("`@("`@("`@("`@/')D9CI397$^"B`@("`@
M("`@("`@("`@(#QR9&8Z;&D^<G(Q,S`X,S4\+W)D9CIL:3X*("`@("`@("`@
M("`@/"]R9&8Z4V5Q/@H@("`@("`@("`\+V1C.F-R96%T;W(^"B`@("`@(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(*("`@("`@("`@("`@>&UL;G,Z<W12968]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B"B`@("`@("`@("`@('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@("`@("`@("`\
M>&UP34TZ1&]C=6UE;G1)1#YX;7`N9&ED.D,X-$1!-S1&-CE#1$4T,3$X-CDW
M13E&,3(X03E&-S@V/"]X;7!-33I$;V-U;65N=$E$/@H@("`@("`@("`\>&UP
M34TZ26YS=&%N8V5)1#YX;7`N:6ED.D,X-$1!-S1&-CE#1$4T,3$X-CDW13E&
M,3(X03E&-S@V/"]X;7!-33I);G-T86YC94E$/@H@("`@("`@("`\>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z8F$X-S0Q9#@M-C4Y92TT83-A+3@Q
M96,M.65A,S$Q,3@X-69A/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B`@
M("`@("`@(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I2
M96YD:71I;VY#;&%S<SX*("`@("`@("`@/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@/'-T4F5F.FEN
M<W1A;F-E240^=75I9#HV,38Q8C$Q8BUB,SAB+30T-#DM.&8W8BTY.&-F-35B
M8SED9C8\+W-T4F5F.FEN<W1A;F-E240^"B`@("`@("`@("`@(#QS=%)E9CID
M;V-U;65N=$E$/GAM<"YD:60Z1CDT-#0P1D(U,4-$130Q,4$R,C1#-S5#-C=$
M1$)#,#$\+W-T4F5F.F1O8W5M96YT240^"B`@("`@("`@("`@(#QS=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^=75I9#IB83@W-#%D."TV-3EE+31A,V$M.#%E
M8RTY96$S,3$Q.#@U9F$\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*("`@
M("`@("`@("`@/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F
M.G)E;F1I=&EO;D-L87-S/@H@("`@("`@("`\+WAM<$U-.D1E<FEV961&<F]M
M/@H@("`@("`@("`\>&UP34TZ2&ES=&]R>3X*("`@("`@("`@("`@/')D9CI3
M97$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z-C(Q,C`P-C)#.3@W13,Q,4%#,C9%0C0T1D1!-D5"
M0SD\+W-T179T.FEN<W1A;F-E240^"B`@("`@("`@("`@("`@("`@(#QS=$5V
M=#IW:&5N/C(P,30M,#$M,CA4,#@Z-#4Z,34K,#4Z,S`\+W-T179T.G=H96X^
M"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M($EL;'5S=')A=&]R($-3-B`H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@
M("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@
M("`@("`@("`@("`@/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED
M.D,X-$1!-S1&-CE#1$4T,3$X-CDW13E&,3(X03E&-S@V/"]S=$5V=#II;G-T
M86YC94E$/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z=VAE;CXR,#$U+3`S
M+3$X5#$X.C(R.C(S*S`U.C,P/"]S=$5V=#IW:&5N/@H@("`@("`@("`@("`@
M("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@("`@
M("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@("`@
M("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q/@H@
M("`@("`@("`\+WAM<$U-.DAI<W1O<GD^"B`@("`@(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@
M("`@("`@("!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\B/@H@("`@("`@("`\<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y
M(#$P+C`Q/"]P9&8Z4')O9'5C97(^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@
M("`@("!X;6QN<SIX;7!44&<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]T+W!G+R(*("`@("`@("`@("`@>&UL;G,Z<W1$:6T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*("`@("`@("`@
M("`@>&UL;G,Z<W1&;G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]&;VYT(R(*("`@("`@("`@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+V<O(CX*("`@("`@("`@/'AM<%109SI.4&%G
M97,^,3PO>&UP5%!G.DY086=E<SX*("`@("`@("`@/'AM<%109SI(87-6:7-I
M8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS
M<&%R96YC>3X*("`@("`@("`@/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@("`@("`@("`\
M>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M("`@("`@("`@("`@/'-T1&EM.G<^."XU,#`P,#`\+W-T1&EM.G<^"B`@("`@
M("`@("`@(#QS=$1I;3IH/C$Q+C`P,#`P,#PO<W1$:6TZ:#X*("`@("`@("`@
M("`@/'-T1&EM.G5N:70^26YC:&5S/"]S=$1I;3IU;FET/@H@("`@("`@("`\
M+WAM<%109SI-87A086=E4VEZ93X*("`@("`@("`@/'AM<%109SI&;VYT<SX*
M("`@("`@("`@("`@/')D9CI"86<^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\
M<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B`@("`@
M("`@("`@("`@("`@(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=$9A8V4^
M4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B`@("`@("`@("`@("`@("`@(#QS
M=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@("`@
M("`@("`@("`@("`@("`\<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N
M,3`\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B`@("`@("`@("`@("`@("`@(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*("`@("`@
M("`@("`@("`@("`@/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;%\P+G1T9CPO
M<W1&;G0Z9F]N=$9I;&5.86UE/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*
M("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU"
M;VQD/"]S=$9N=#IF;VYT3F%M93X*("`@("`@("`@("`@("`@("`@/'-T1FYT
M.F9O;G1&86UI;'D^5&EM97,\+W-T1FYT.F9O;G1&86UI;'D^"B`@("`@("`@
M("`@("`@("`@(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C
M93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO
M<W1&;G0Z9F]N=%1Y<&4^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IV97)S
M:6]N4W1R:6YG/C`P,2XP,#`\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B`@("`@
M("`@("`@("`@("`@(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1&:6QE3F%M
M93YT:6)?7U]?7RY01D([('1I8E]?7U]?+G!F;3PO<W1&;G0Z9F]N=$9I;&5.
M86UE/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@
M("`@("`@(#QS=$9N=#IF;VYT3F%M93Y697)D86YA/"]S=$9N=#IF;VYT3F%M
M93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1&86UI;'D^5F5R9&%N
M83PO<W1&;G0Z9F]N=$9A;6EL>3X*("`@("`@("`@("`@("`@("`@/'-T1FYT
M.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@("`@("`@("`@
M("`@("`@("`\<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT
M5'EP93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.G9E<G-I;VY3=')I;F<^
M5F5R<VEO;B`U+C`U/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@("`@("`@("`@
M("`@("`@("`\<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I
M=&4^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT1FEL94YA;64^=F5R
M9&%N85\P+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@("`@("`@("`@("`@
M("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z0F%G/@H@("`@("`@("`\
M+WAM<%109SI&;VYT<SX*("`@("`@("`@/'AM<%109SI0;&%T94YA;65S/@H@
M("`@("`@("`@("`\<F1F.E-E<3X*("`@("`@("`@("`@("`@/')D9CIL:3Y"
M;&%C:SPO<F1F.FQI/@H@("`@("`@("`@("`\+W)D9CI397$^"B`@("`@("`@
M(#PO>&UP5%!G.E!L871E3F%M97,^"B`@("`@("`@(#QX;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@("`@("`@("`@("`\<F1F.E-E<3X*("`@("`@("`@("`@("`@
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@
M("`@("`@(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO
M>&UP1SIG<F]U<$YA;64^"B`@("`@("`@("`@("`@("`@(#QX;7!'.F=R;W5P
M5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*("`@("`@("`@("`@("`@/"]R9&8Z
M;&D^"B`@("`@("`@("`@(#PO<F1F.E-E<3X*("`@("`@("`@/"]X;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL
M;G,Z17AT96YS:7-&;VYT4V5N<V4](FAT='`Z+R]W=W<N97AT96YS:7,N8V]M
M+VUE=&$O1F]N=%-E;G-E+R(^"B`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS
M93IS;'5G/@H@("`@("`@("`@("`\<F1F.D)A9SX*("`@("`@("`@("`@("`@
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@
M("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP92`M
M(%14/"]%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*("`@("`@("`@("`@
M("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y!<FEA;#PO17AT96YS
M:7-&;VYT4V5N<V4Z1F%M:6QY/@H@("`@("`@("`@("`@("`@("`\17AT96YS
M:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/C`\+T5X=&5N<VES1F]N=%-E
M;G-E.D]U=&QI;F5&:6QE4VEZ93X*("`@("`@("`@("`@("`@("`@/$5X=&5N
M<VES1F]N=%-E;G-E.D9O=6YD<GD^36]N;W1Y<&4@5'EP;V=R87!H>3PO17AT
M96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3X*("`@("`@("`@("`@("`@("`@/$5X
M=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^-2XQ,#PO17AT96YS:7-&;VYT4V5N
M<V4Z5F5R<VEO;CX*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E
M;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS93I+97)N
M:6YG0VAE8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G13
M96YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C(U.3`Y-#4X-3`\+T5X=&5N
M<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B`@("`@("`@
M("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XR-3DP.30U
M.#4P/"]%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*("`@("`@("`@("`@
M("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/D%R:6%L
M350\+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@("`@("`@
M("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#Q%>'1E
M;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP92`M(%14/"]%>'1E;G-I
M<T9O;G1396YS93I&;VYT2VEN9#X*("`@("`@("`@("`@("`@("`@/$5X=&5N
M<VES1F]N=%-E;G-E.D9A;6EL>3Y697)D86YA/"]%>'1E;G-I<T9O;G1396YS
M93I&86UI;'D^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS
M93I/=71L:6YE1FEL95-I>F4^,#PO17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN
M949I;&53:7IE/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N
M<V4Z1F]U;F1R>3Y-:6-R;W-O9G0\+T5X=&5N<VES1F]N=%-E;G-E.D9O=6YD
M<GD^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I697)S
M:6]N/C4N,#,\+T5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^"B`@("`@("`@
M("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS=6T^
M,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/@H@("`@("`@
M("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#
M:&5C:W-U;3XR,S<P-S4U.3DR/"]%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N
M<V5?,2XR7T-H96-K<W5M/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&
M;VYT4V5N<V4Z0VAE8VMS=6T^,C,W,#<U-3DY,CPO17AT96YS:7-&;VYT4V5N
M<V4Z0VAE8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G13
M96YS93I0;W-T4V-R:7!T3F%M93Y697)D86YA/"]%>'1E;G-I<T9O;G1396YS
M93I0;W-T4V-R:7!T3F%M93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@
M("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI
M;F0^4&]S=%-C<FEP=#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B`@
M("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I&86UI;'D^5&EM
M97,\+T5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3X*("`@("`@("`@("`@("`@
M("`@/$5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93XS.38W.3PO
M17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@("`@("`@("`@
M("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y,:6YO='EP92!!
M1SPO17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3X*("`@("`@("`@("`@("`@
M("`@/$5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^,#`Q+C`P,#PO17AT96YS
M:7-&;VYT4V5N<V4Z5F5R<VEO;CX*("`@("`@("`@("`@("`@("`@/$5X=&5N
M<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G13
M96YS93I+97)N:6YG0VAE8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E
M;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C(Y,#`V-#,Y
M,C4\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^
M"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U
M;3XR.3`P-C0S.3(U/"]%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*("`@
M("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.
M86UE/E1I;65S+4)O;&0\+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.
M86UE/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R
M9&8Z0F%G/@H@("`@("`@("`\+T5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B`@
M("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`\+W)D9CI21$8^"CPO>#IX;7!M
M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0](G<B
M/S[_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_VP!#`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0'_P``1"`"Y`9$#`1$``A$!`Q$!_\0`'P`!``("`P$!`0$`````````
M``@)!@<$!0H#`0(+_\0`31```00"`@$`!@4%#04%"0``!0,$!@<!`@`("1$2
M$Q05%Q8959?7"B$X>)@8(C$Y05AWM;:XU-;8)"8R67DE-3=1M$-389*AL;G1
MU?_$`!@!`0$!`0$````````````````"`0,$_\0`-Q$!``$"`@@#!@8"`@,`
M``````$"$2$Q$D%187&!D=&AL?`#,E)RDL$3(D*RTN'"\7."(V*B_]H`#`,!
M``(1`Q$`/P#W\<!P'`<!P'`<"M_R-WE>5.5R+DG7@47DDIJDI&>P-GQ0"S"D
MBDWHROYW&&EAUB/9DRHXE@]8T6*R;$1<1=E(SCB211G'402F9&D]:E4Q$S:=
M>$9YSE/+7=B%U=SNR5;$[].Q&C6]B5+!*UZ_7'5<S`Q.9/%99`KGE*$&E2)E
M!,VBX4EM0*#9G;$J`#Q;!9:L`P9LZV!$Y!@NP$1$S$7MG?ELXY1O8"KWH[5#
M7EKE#]>U"RB51#NJ>C_8'&[?E;V:D.Q$D!QTV8@YABNR&.@$+07>'_;%F`Z-
MHMC\>UE]@Q.+"RD_("T;_P!6S"T9>IX1?!&YKY@^PK]L+9,Z/J;YG?N:B=RJ
MT"_ESP+=$TEPFE[BFN\,@,$/2`3.BAU_8U=!(OI!XY!9\9'1,J8DBQ]X2&9!
M8*T(VX3-KZK7B,9M;7G-M6"8W:&R[FG7C.O"^HI(3T)N&*U/?TWIY:C2TI'[
MRPVTC]@`*.<?!U$5#9$R60(1(^XKW1S(Q*=D)-P[0C+AX]FX(&4Q&G$:KQ$W
MMNO]\=FQ@QWMK>-$6M25*`(R^L6#6@!ZJ3%:RIXVL"9F&"=\VK8D1NU%.4(E
M=&'P.FPH:&S%-0LOLC%Q4M9C3RZ0IZ"<(&6B8O,VG'#"-46\4=83Y5>[A&-1
MB2F.J`25%#,'CLE7K2'0ZT(_+G$BEW3"_>P8V%LR)LS($6!0/<5,1FF7^SX"
MNL3(7!&Q6K$))1C!M,2M&G''*9B^K"J*?*;I7U)W.[66O>56U6A5U>QF*2(G
M>+J068=C%A)@9?#Z:/\`6-1L2KSV<CRB$(SR/V_<$;C24A=GF[B8T6?+M_?0
M.I@>')M%IGA:+QKTL^D;,VP"XSL6`\@!Z!X)V;)NMU_5=";>CTB:R0TV"T+-
MNO$N9#K4K=@HV(M$&PJ^V4NJQ5@*=.,+.M?F>LP2V$A%F[48:.J\3,<8F,)Y
M8[HPYUZS7R&=XI&[J>>B.O\`*H41A</MNRC-=L`4Z=QV92[?H7V.M5GUHL<6
MGG4H4F-4W;"*PBIDP+4!K$Y9-XL*$`A!9SL+)E133CC&R^S\],7YQ,SPNSR7
M>4CM@Q8O3$0HF&&!;(M>SALJXA-IJZ2",U@9Z@H0?`MVV/H:I.;)&7Y:28D_
MHU)C7B]2OB@025:#Y"/:C1C"\[(U9S%5^DQ$<TB*#[V=DK/N^"5#+:/CL<&/
M"5PMI'/G`V=1T+-AU9]D.P%)>]5HW>[G\#3C>%UU3]TNXT8?2-L9A%P:$F$F
M%A!+0Z6)F(B+WV8:XO$3CUF.,+<N$G`<!P'`<!P'`<!P'`<!P'`<!P'`<!P(
MW]NG\Z'==;*4K&=BZSL)VR!!H=.#P@V8C@(^?E8$&/4E6D:SK(!$2?+$<#)7
M+@NZ1.#1UZ3F;)9%P!T5T-C.,+[H50Q'OYVR@;NMH?).O+IBXF4SC8L\L;D%
MA74%6>$N\,&Z\V>7J2V46P!61U''JCF!"ZX.1E(%,J`CHC&)&X+1_3!K<J8I
MV[=V5-XB8VWPG>D#67:[O%-89UXL5W4U6O8W>=SV)4$@#QJ&V/B54ZU$-[-%
MP6RYFU+SA%%U!GDDKM@0EBS5-J[9QN=`]!&KQ5GDJ4,F*<<<HOG%IRPRV>.I
MA=-]LNVPT"(4,5CO(805"=^YL\G$@!67*#L6-];NTUA#@,<DR0EP_D2<5M>G
MWT-<T@RC<3DQO"*>S<,PE8AF';$1,1AC\.R,Z8F^S"<[VY.+U4[BW[V5[:T[
M]*8O)*[K]&L^XX*41YJ(D8B&RPO&B/2&64E,B0\TN62%G'$9LRVAL:RB<=:R
M(>'E)9GML@S<#01LQ$1/&FW_`-7\8A=7P@X#@.`X#@.`X&H][\I5.6?0;>T(
M3I*?BN(_D7L>8X]629=>Y8BNSW*OP[66;.\X0UBVSO$AV4SC&!N?X>"T[-_+
M:R"7V=`8"2C`B82@:!)3%]J.CC1YE?*A!?8H#!85VR@BMHQ'X/RB+Q_8J1V:
M"]#\GC0/=YJ5D`=H]#7S7M)U_=#PQ;YHQUF)D`LB=$EB^"(,6Y`C!JY=8_N1
M,L6#)H!=C6KQV&-O5VXN0I,"'P%V2V8/-4#;3]O7K!MB(3"-SP"UD\3*)%PK
MMP39)NM$7355$@%*/`AH8^8OT&I`85#&1S\07%$6K4B+)LG;!\V;NFZJ6AC)
M>`X#@.`X#@81FM:_S*59MF&QWZ6."#4PX/?"FGQ!P;8A,QAD>75]GZ%I`RC.
M<QIH>5UW,-HYG()%[H)S[IP,WX#@.`X#@.`X#@.`X#@.`X#@.`X#@.!KJ56]
M5L(>$QLNL&(1XF%#AY`5%%#PYL58!9$>UBT>).1FR_OZ;60R;;$>`J9;_P#;
M1O&PL9AT^TW0U%F('.SG7F.1BP9H9NBN&D3JJ,-YI8<@UE8IT+BD3=L\/VA\
MFY9N'&FHQVUVTW:N4/;:.=U44$?7<+));FVG"+9X1Q8GUL[I]4^X24P6ZQWM
M7]U:0!0&E--806V?K1K:3:EMH_L5;K(-W#9(S@$:P/6REE%UL*?Z)*;;M5==
M39IJISBU\DH.$G`QJ93&*5W$9//9U(1$2A4+`%I3+92??(#`<=C@%BN3,FBY
M%UNFW9#AH]LX=O'*V^J:*"6^^V<8QP/V'3&*V'$HQ/8-(1,LA<T`")3$Y0`?
M($@DBCAY@@4#&A!!MNHW>CB8]TW>,W*.^R:R"VBFN<XVX&2<"'W8SO\`],.H
M\G!0OLIV.K.G)9)@7TG!1Z9&=V94C'LD'8G0RBT;MG*N@Y4D/?L4'*V$TUW+
M%XDCG?9JOA,J*:JLHF4K09L/)@H>21XFR-`)`+'FP9@:X3=CBP<JT1?C";!T
MCMLBY9/V3A!TU<);;)K(*IJ:;9UVQGA+M.`X#@.`X#@.`X#@.!T$=E<6E[<B
M[B<E`2=H(.&8P6<QXP.--Q<ECKY49((\16&N7*;(X")(+#S(ESLD_&/D56CU
MN@NGLG@._P"!6\V/&'G?\M%B]A3QF&"/&+F*P)A.X6K6I4;(Z(56,BI'$$[E
M'R;<XY.@7,P!QY[29PC'OHR1FXZ0:1VPBSH&5^G+G:=O"WC'AC*NYJ<+VV2K
MO.L]7CT5ALBUDYZ%J1UD>"3@J/>AB$5?%\.'S';#B%/ASLO'&C[0S&])([&2
M4I'29B*QIP.,B;7PSU[$3TO&Q`LQ>:PI6>$Q<3M`3'@MA1J%0R'0B.J,("%?
M#*X3KZ.B&6P*M-`Y8H6F\J:!1SL7-9J:,DU!X4>14$:&Z66V/OG?;LC9&N6E
M"=)B:3\G/2<T,.G24TNJL._INX#B9>0BX_-'X\O24NCJ*<`^/D(H%'Q)[.SK
M*/ZM&BQC+#=NH>-G2B>Y-0J]Z*MTTVW9ZUR/#F<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`C?:G7EM8$S&V,$DB$3FH%I&_@KU>-I'A.Q:,S,-*V;
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M>$(%:/9!]#]-)4L,8):2)\*,+`U&NKAL+<J;^G0JBNU47BF?^M,<[Q3=]_&'
MX;*/A/2:C]+KL:[KEE$OAX*R!1J*]A^V-"`8K%;#CX>6!Z^'P*L>QS.(93BF
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M]B]B?VZ>]/\`J0X-*=E/T4?Q/JJ.F7V+V)_;I[T_ZD.#2G93]%'\3ZJCIE]B
M]B?VZ>]/^I#@TIV4_11_$^JHZ9?8O8G]NGO3_J0X-*=E/T4?Q/JJ.F7V+V)_
M;I[T_P"I#@TIV4_11_$^JHZ9?8O8G]NGO3_J0X-*=E/T4?Q/JJ.F7V+V)_;I
M[T_ZD.#2G93]%'\3ZJCIE]B]B?VZ>]/^I#@TIV4_11_$^JHZ9?8O8G]NGO5_
MJ0X-*=E/T4?Q?WX[O&A1OC6BUOQ6DY%94D:W)9Y.QSBUARU[(/A*>VSEO'8Z
M'8^E$8E@&(<88DI2NS5E\R731=RDR01'@F`855S7:]L(M@L4X2J9'!B[3R=O
M5#3"6$-G"^#P(HW"R`3'<`G5'2`5\3(#]`KVO"PZ/+I(P=M:21<=:KZ0D]:_
M>+M(0*P,DQ6KUMCOEEKSRMFX2<"MGL'_`!FWC>_H;\@7]5]8.%Q[E?&C_)9-
MP@X#@50]_N]W8OJMV2Z&4C275IS?H+M=:!J'3J1M"9)$A#`T?7C*YM8,T%MG
M"#1T%B9<_/BQV491C;*/1(CJXW22^(%0Y5-,3%4S-M&+QOSP6O<).`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@5P>7?^+;[:_T<-O[61SA5'O1S\I6/\).`
MX%9_EZ:]KS_0>[*^Z85P8LBZ[:'L:JU:@BD3&$HS`9LOL,LF4-<3`P#'O7>D
M-R6CPY)F02*L"DB8GFGJIAUU4RJ-'2B:IM$8[>&2APQC\H!JGQCT!H0N.J>L
M4VKN\.OW6P=$3U8A%[C*022SR)T/4\CE=J#YW=,!-A7<FF4,UE@1O5,2D[H$
M!)DW1PSKA87-CI_X].;1-46F<\,(F9PM$ZMJ2/F2)^:.F^DLI*1:[:AG\5(>
MPTNZ==::,E77^U*<K8`DG)#TT!SF5=MY@X<?%%Q249>,XQ#T";@86(83?@ME
M&^%3*-":HO$QLB9B8F=D_D2QDTD[&RSJOX@C';F!NZW[):]X^N0>W8P^)@2[
MM251N.71'%)0N[C)(L%34GC$4RG.XYF^5^#[2/(EQJBY9+(IDX7KMC%IMP7H
M\(.`X#@.`X#@.`X#@.`X#@510*5QPIY&9Q\+8BR2YLP71V,^VKK0N%(0FJFD
M"-"%F[BH#-A*XW(0YVY17$7;&QF6!%#1[%=MD2;4P5CHVM/C;;MMX<TG>U-_
MR&E252B(@;KG:56%(UV`ROIJ@L@7L!B(-0_Z2-HM)%9C%A$:=#(V7*IM5G;"
M7E34R+06/@(L8=$EV#LR(O?/#7&KEK0I7[^7TV`S$H,'5'.'D5C,>,PAG'(?
M,4/W11"0UKB7S1C5R>MC&5Q^.N)O;=A:R".9P\(-FJXYUK`3>%<-RM&+VQSZ
M<?FU9<V&C;JG-N>2WH6C)X7ON$C-:^1T=%KTC>\4:5+=;%C)J9C:3^NP+6QY
MS.QF0@N,B%9`ZE#1D`+O3:+Z#F9`(W6V'FVM17QHPUQGGA$+R.',X#@5N3C_
M`'_\KM`QS?\`?CNN/2V]+:<IZ?GQI+.P=IUE5D+<KXSZ<:9TB]4VZW:;X]7?
M.';W37.VF5,8*RHG?5$<HB9GSA9'PEA9.R*["GD(L9GL+$R=RHS1;1PG*0;`
M\X5([::#TD!#I\D054?;;Z:L]$V^VSG;?3".-\[8QD6UZF:<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`U$XOREFDLS"'-FPY"3:E,`5&"AEMJBA(]G.&>D7<E,[
M?"&LK4=9U02BSA\E(%5=]-4QNV=]/6-M.R=K%>TEMGZ3J`A.8LV".#VLKKV.
M,LR34=@$U0ED[CT=+OR"QN;5I'$-F`,B3=C?I)8L(#.S"0X<X/H+/6[9T(B\
MVX^7/R4>=\^[EA6MX_[S&EJOVDR-C5.W6/!*I8MLF^MF&TWBK,1)[X7GD[`E
M%(1;(]128UVN"A`V6LP&6K=2*2INJ0D0DNF+59Y7YX3EPRG[/25PYG`<!P*X
M/*C^B_#_`-<_QX?W[NN_"J<Y^6O]E3[^77^+([P_J[V!_5N>"CWZ?FI\X?'R
M(_\`>?C]_P"H]U^_LA;?!3^KY96/<).`X#@.`X#@.`X#@.`X#@5.06'5T$\D
M,U^%A*]C\C&$RY!OJT&5LRFLB5F]5M9K(I$Y7>7J'LE[NZ.2@\T6?@>OLD`K
M,A_NKR78>M9"\!E?ISGK-L^%O%;'PDX%;/8/^,V\;W]#?D"_JOK!PN/<KXT?
MY+)N$'`<"MSJW_OUWQ\E5LX_VMC$3W6+J<!(;?O]$TZDIQ2\)4P9;[?G3T0E
M?:)ZU(::>C7=\/\`W^-LHZ[<*G"FB-MZNLV_Q61\)>83LWXO*U[F>>2%W&-3
M&)POKU5M`W1V\9N\94WF5FM"=C#>O$2#*:CUU<$"`"N0+VS!S@DQ%*5Z#BVN
M&[@J:04T.L5S3[.8US,VX:_ZW\'I[X<C@.`X#@.`X#@.`X#@.`X#@.`X#@.!
M7E%I-9LNOTK,I3-6T9I6K;+G==-V"TY:QL=("!%Y*(^Q&2(0BT:1*>OLFG`O
MW1JLFD3C+/>",&9LS8FEK,&QN%L,9]=+>.>&"PS.,;8SKMC&VN<9QG&<8SC.
M,_PXSC/YLXS_`"XSPQ7!Y=\8QXV^VV<8QC.:X:^G/H_/GT2R-XQZ<_R^C'YL
M>GA5'O1S\I60<).`X#@5P>5']%^'_KG^/#^_=UWX53G/RU_LJ87YM;*A57>+
M7N.7G!QJ$:2.J",``86];=P8E\Y=-([&@8YJGC9=V\>D'NBBFJ.FVK,<W?E'
M>41[!XX1-]G$S73;;$\HQEI?NOW5ZA66P\>TJA/9RACP=3O9UVL%UNVMF"ZO
M`T.<0>S'>Q^1C53NA".,&29-@F45.-F&!3ITDT(>[.=L)<$4S&E>)]V=23_9
M+RT>/[JY7C2R9SV4K&6B'LPBT,0#5'-X99TM]]E#_+;)92-QJ1N'Z<>CS!%^
M?DA7;7&K(0-<ZM$B!=<8*(&115.$1.U8DQ?,BC)F2&O&I`<1:MWS!^R72=,W
MS)VCHX:O&CE#;=%RU<H*)K(+H[[I+);Z*)[;:;8SDERN`X#@.`X#@.`X#@.`
MX$$&]^3!YW-1HM.5@FP/W@C)]XN]4]SE2D/85N_&["<1E>M\NU$7%B,LS8?/
MT[.18O8\JC'DHTIA1)VL;A;*>-L,]M]F[4G&\(CQ^6F'[YFQR_>(CF.'CI!M
MEZ0<8WV;L6GMM]/>'B^J2NR+5'UUU<)[YTTVQIMZ#&`B;FI\_P#"_@5KUJ:^
M.*GD`OPF=1<C\76BK/0A)T1?N91;X@K'&"J;X\FT]KN'9J:.2&&Z.^N^1:=F
M6:!=QR&/RSR/>,^0Q8X'DH`I2WD%6&'`!-D9#D4=&'61#=5B3'+N63M+19)5
M'91NNIIJJFHGG.-]-L8+CW*^-'^2S[A!P'`K<\6GIDG76>W>I^=;LUVN[97N
MAM_Q9WC!Z]IG$*TV]K_[=/-40B"8;K?P9:X0UU_>Z8X55G;9%,>$7\;K'U54
MD$E5UU4T4$4]U5EE=]4TDDD]<[J*JJ;YQHFFGIC.V^^V<:ZZXSMMG&,9SPE7
M#XSDE9_5]M]O2:6^2W=R^9W>@%=UIM[XE2`?W"HNM3#VF^,?["YHRN87,$4$
ML:MTR,R+KIXRHZ6WW*JSB/ABW/.KQF7:U3Y,NM=P]\+W\>\2*$M[FH:(BY,9
M)N/AN(G*'V,C_IM%8J]2?J/'LAKG)Z.HR=FLT0WU=NC;=MHIB+%U4Q-,Q3%6
MJ9MZXXK#>$G`<!P'`<!P'`<!P'`<!P'`<!P'`K17E4^'^0"+QD]5%*%H\==2
MT4.M_2BCH:W&(L56#J;#6C&RU)=)QKT(Q^(!(@]/N4(ZD>--I4(%Q<9J/U6X
M5AHYSPO%L[9>/"V*QPP:#QT6]-R`L-!!1J&SDB7,/VHP6/;:YQC9P]?O54&C
M5#7.V,;*KJIIXSG&,[?GQPE6UY9Y%'RWCI[CBQ1T.3)AJU"J&!P\FR>OA29>
M11Q\)W)-&RZCACH498R\';.DTM7K7&7#;*J7[_A5/O1S\EF_"3@.`X%<'E1_
M1?A_ZY_CP_OW==^%4YS\M?[*F:=]O'E1'D9KR$5E?Q:T1D;K^>-['`?+";YA
MKW,I:!R@1D\(;*BS#)[E@S+OMARV['5\.775W8O&^KAVFX%-4TWF+8Q;&+J]
MKP\>_5+J35'C7HJM*LCIN,1OR!4[&]Y%8H&+S&>R8%)6EUR@F*F$K<@&KJ0C
M<D"'N[88[1P.:BQXD:BTU;#6NNA6E-4U3,_IGPLP_P`W?C!Z@W+U^K:QGE>H
MUW(JVO?KQ7PC6H&D;KP67`=DNTW7RFY_M*!HF.;('"0^(&B.T/?K^HK'RKE9
MUC#MLNY9+"BNJ)G']-4XXY4S,>.:].D:CC%!4]6%(0EW(7T.J6"QBNXLZEAE
M:0R-6/1$0U"!_C!E?1+=^\38,D$MU=46Z.N--4FS9NW3203(F;S,SG,WZMH\
M,.`X#@.`X#@.`X#@.!5[I!F8?OH&+Q\I:S@,YMHZ8ER$KF$I,57\S2W5J1[Z
M-HBR4FQ5!M.FD#?`M6@,I$A,:%P!(GJ&>(O!@%JZ*U<N><=<M^*<-MU$,M-:
MN7Z^XMB9K:P!TZ!&7@5,H08*MAI06_:AWFKI@^"KE&9+9LZ?CWB*V[73=MOC
M?17TZ$H#K^.*4$H1,*\(W8S1BTZB$2@RP[2.SR2[5M&JVCY@?"@M2%;`MN6R
M4(!)R*0G)#-0TB/R/5Z+)[P\&\$,&K<C@K2RFV5_'.^&SNU0]HHA4WE$Z,R8
MY8$EE,ALJNO(W)#D=1)%&E419^6D-*S!3-<P0@_*XC+M[],?<I88P27=3)Z'
M9&WJ#!7.K)`J)O15NFC[]L-F62[#AS.!'[ME;&M#]6^Q]V;+ZMMZEHNV+&;J
M[;8US[[#8*=/L$D_3_Q+N'K!N@W3QZ=E5U4T],9WWQC)L1>8C;,1U8]TBJ?:
MB>F_5>G%D-F[ZM>OE10\QIOKG5960!H(#:R-VXQG\_O3X[H1>NO3C&<N7"N?
M1CT^C@JF]4SMF9:I\ETWDD<ZDS6OX`04&VMV9.PWJ95#M#T^^#YEV+D3*M7$
MF:9QG7">]?0XS++*<+[;8T:L(:\=;Y]5'..&TVOCE%YGA$7MSRYIEP"#QNLH
M)"JWAH_03$*^B4<A$5%I>CV8V-Q0.S`@V"?JZZZ^HS&,&K?7T:ZX]5/'HUQC
M\W"9QQG.5$?B\\<_4$M=%T>3@#6!!I9\][@=L#M`2[%BV6NT'57L?D5)$C>\
M>>2]P#/:VD<$V;8[=S)AQ79J/L(<D$U'CA(!%@=*JZK13?"*8OA&>>S"V$<G
MH)X<S@.`X#@.`X#@.`X#@.`X#@.`X#@5OIM5]_(<R=$E5GI!O%"*:2T'CZFH
ML4.6BQO<4.M@Y6LF2/I*.Q>S5R`:=H`)6MW!UOAW3FXR9N@^C0K]//MN\IOM
MP2I[%U$]NJO6L3'%MQ;T7.(%-T$LFY)&VAK>$2D;(_@3\_#GH^4@DB&&.?<C
MH%S\2`&4AAMNW>[#O<7)D3:?7KU923Y"NDDLK/Q\W00,W4:PVJ6L'GL'M<CQ
M\)(7.O+;$BLED(J[!SA@;'O(7'RR.&$$C$77&[B0NC9OJ6:)-MF+@NF;U99[
M<;6B=;T6\.9P'`<"N#RH_HOP_P#7/\>']^[KOPJG.?EK_94L?X2KA\B/_>?C
M]_ZCW7[^R%M\*I_5\LOWRL?HA(?K7^/?^_YUGX*<Y^6O]E2QWA)P'`<!P'`<
M!P'`<!P'`B:I0==*W[\P<VB1ULI-)$OF,:BJ$S*M(V[5?)HCL3'>J-K\1B+K
M#0F.033LE/3(QL]`-7V@1NJ,3-OA;OWMX)9<,.!6SV#_`(S;QO?T-^0+^J^L
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M5T7?+JX]JX>/5UUO2JIOG@F;S,[9NW=PPX#@.`X#@.`X#@.`X#@.`X#@.`X%
M7>I@$2\@D7,0*S9DP:'3$A&V%"T9K8[2M9B5B5;6S76R;NO6-(I0-:;M)359
M5H(DTGN?3!T?34S;1UB4>P?48,*_3.'#PWWMCLUK1.$JX/+O_%M]M?Z.&W]K
M(YPJCWHY^4K'^$G`<!P*X/*C^B_#_P!<_P`>']^[KOPJG.?EK_94L?X2KA\B
M/_>?C]_ZCW7[^R%M\*I_5\LOWRL?HA(?K7^/?^_YUGX*<Y^6O]E2QWA)P'`<
M!P'`<!P'`<!P'`JW$!`IOR62PSH029+Q%R+U<QC&L2<8,RM7KRP;-)]L\(6.
M%L5@0:PV7NX9J""5Q+:Y5'--S2KY&8.2[Z)%?IX^5^%L]]\=B:MY6V9J%G!B
M@^':RL7(9JWC<B5T,;,"(4<N%,DD7(,4F,(;R4T]?#&XYJ)4<!6FB#AV_6+^
MW:-!14E!0GY&I;'@-DG2M51`CI3D8K^32YL!GY);$O3M^MDK%A;6M'3B)XP4
M2B23A$?99%^@EJQ&Z[288RV24T#ZE:.6.=_";>M^#5;J^'%M>4/HS%3,/D0*
M5UE7?D=CDBD#:+RQ.I9.Y%22EH:FO7-AF@X\)+'J7T+4>2^."7A$E7Y`FT!'
M5UE=VC]^5$6HJWS1]YQC/7AMM*[+AS.!1CWW[A52Q\H7BQZ-R=G--C[RW"'9
MDD\81S+N,.%\U%V$J:FA6Y'1YAZNLG8Y%_(3F[<8X&Q]D!%D2+Q+"N^[$Z4T
MSH5U1LMOSB9\(YKJ9G,(W7L/E<^F19J!B$'C1V7RHX]VSHR#1N-"W1HX5=[X
MQG.C4<,9.GB^V,9SJDCOG&,^CT<.<8X1G+PU=!NPOF1F/DKO7MC4G6N=6=3U
M]6RZ!695LPG3>$TO&@\LA,%D]6[2Z>,<S)&+6-3]1+U0$>+MX+)CD>%Y-Q`J
M+&G2QH3D[U11H1$S:8C#7.<WPO:TSE-\N2P/MQY:&<S\@_1;H+V3H]]UK813
ML]4MF=A\G++K2S6>TT;BB$EZK@@):!R9RW5@9&U',$F\T,3(#%ST?9,(L^>1
M\8R=ZK$3(H_+55$WPFV$QA^K.-EXPSQWP]6_#B<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P*L0<LA<0[Y"*G5IR*,C$EGUB24780F8FE5$96M5TJG[U;,1D$E8[[F
M/HO/RST@M&X>2AX$W;D_<!2J$@F-@.'A6.C>_*VJ^WC''#9";'92^8WUJIJ9
MV])46SY..#E,!0CHTPCB,CDKE-30(!4/D\;L`;5\[UQDD:=(N4@PI)\5V9O<
M,_=%C(B\V4X^37N['YET-OJ/D(.;0CUP0F1B*EE4%;3*V$R+R`VA&XG*W]E)
M0ZOE0=11!V6SJZ@\\D<H>0^4A%6SE^8C1<@*!/RZ:<>&=\,XG*^?#/B]`G#F
M<!P'`K@\J/Z+\/\`US_'A_?NZ[\*ISGY:_V5+'^$O,K^4!=]KDZ@6-T/#13K
M:G:L3S>,8O*)R=*6FFA"7VU6+@W&-:*8QP'#)"X;DCHFQ`AT06V=K.C&^S\<
M*"KJB':BAU]G1%6E^:V%LM4Z\X1M\T/FQ9`*!Z^UW".MUJN#MFS:K[=L)*WZ
MS[#4%K!CW5^WJ*[![Q&(.+?HF%L[2&F7\8*1D])XZY2WB8U)H>?`]M2XYJH;
M[/V=YF]46B\83$WTHF-4S;GFEE&?RD7KV3GW0NMI'5TOBA[M)'XB8O4G(AM@
MPZ,]<_F2-#,JV)B"]A5I#V]P0B43<S@4O84948PL='6#R1L#I]+*""IGX4VJ
MF\?EO;+\UL\IFTVB]L]3TE<.1P'`<!P'`<!P'`<!P*O$])@8\A84M(`%:1Z/
MQV0GHT/D<0?7F3ETBD&U(2,J#@TS.%(.-IU5Z\KPHWLIY$1NS1Q']F`C5O/)
M"^'*CI&5^GCPRO&^^?79KBSIPS://8>]M6SKW5RF\:^\()+^[.T?6PBZ0]KK
MM[%REC??":Z?JJI^MMZNV/6SZ26(LJRK<;\&^'5]"&'T<R?S'O<HF!:_`LRO
MU\2C(;V#!/X7F2854P?RQ]A\8]IO\1]X]?;TBZOJY@(.,>2#QG@(T&$QX$+I
M7R!-Q@4&.9B1(YO\-ZQ*>P8C6"+=FT1]????V3=%/3U]]MO5].V<Y+CW*^-'
M^2SSA!P*SZ7&CKK\D';6[WH]D3$=7(+4G3JLBBC1!SH+G)H&X[`]@2(EXLFI
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M!:,F>@=QH1PJ,T:-M66Z&$$L:"\Y7FS>_##@.`X#@.`X#@.`X#@.`X#@.`X#
M@.!6(TF'M/(UF/EOI>^U(H/%H,J\&3-2-AQ@BJR@>1-F3IW?<8CH5-S*`$E5
M]CIUSG:!9==(LRFB>3#=]%2OTZL.%\^%_&.&VS)ZR9DF;L<1:-GX]^V79/F+
MU!)TS>LW26Z#EH[;+Z*(.6SE!3=%=!;3=)9+?=-33;3;.,DJP/*]!H3&_'IW
M1D<=AT6`R&3UH"2DIX+'A(LS(4@<CCK(*D<*,6B#XLF'9[;-!>C]=QJ/;;90
M:812SG3A5/O1S\EI'"3@.`X%<'E1_1?A_P"N?X\/[]W7?A5.<_+7^RI8_P`)
M8%.*LK6S5H6YL6!1"<N*XFPBR8`M+(\+/*0NP0"+QN#FL8W)MG.P64!T2+[0
M8;'Y0(,L.ELMUT]M\YX+^."L+S-=>J-N3K1"I1:M3P.P))"^S'36+Q(]*HV-
M+EXY'+:[K];(19H(00=(;NF(F=Q%RO'I0P05T;&!>_NSQ-3377U2Z)F)FTS'
MY:O"FJ8Z-4]L>@W2=[W1\80-UU6HE8*],717SX1M6T8^&$(15'6B:'JWBQ%C
MJ/PV?A868'L2`!B\2728KM&^=,>JEIK@155HU8SJUSKG'KK7H<(.`X#@.`X#
M@.`X#@.!"F$4K/T>S!RXWD:A0F*[.I:+U*6&QA4^NI^P54(-QJ=?2^,0X#)*
MWA#Q\XW+,1DVMFX=MH>LWB+2`U@OKKH)-OA;_7]^'--;AAP*V>P?\9MXWOZ&
M_(%_5?6#A<>Y7QH_R63<(=%*)*$AD9D4PDK]$5'(H"+R4^3<9]#<<$!#W!0J
M_7S_`"(LV+5=PKG^31/;/`J[Z<V3&.L/C8<=Q.PKAQ%=K61LSO%;NRJ.%SGQ
M7L;,"EH12%,!FN^F[Z4L8Q*(#4L5C;?.';XJ+"1YHG[TJDGPJJ+U6C5:F-F&
M%_O?FH2I/Q069YJ+)G'DU['WE9O7]6;28&WH(;!F<<.O!8"O9$^>#7]?D33/
M76,0J#.6@"%Q*3!=EGUE2R*V';J+M&+V*&9NCKIZ$:$4Y9ZL9C7;U&$9P]H[
M5%1NV;(*N5GJJ""**CQSJAJX=J)IZZ;N5]6J+9MJLOMKE575LW00QOOMA%%)
M/U=-3@^_`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`K+CZLT7\@2KIY!I-4L:,Z
MS9Z[(2N-@Y8.N-_#88-@L7VBLT%5GN,KU8_'=59Z)$,[_DTM>Q>"%Q\RJ.!$
M"C_9$K#1VSSPQX\LK7G-9IPE7!Y=_P"+;[:_T<-O[61SA5'O1S\I6/\`"3@.
M`X%<'E1_1?A_ZY_CP_OW==^%4YS\M?[*EC_"3@5T>5#]$IC^MKX\O_R`=9N%
M4YS\M?[*CM/^G-XNOZ2>U7]U&P."/=JY>:Q?A)P'`<!P'`<!P'`<!P(0-)[9
M([N24@NC^;NZZ/OD5%`!#*3H<,W;TZS*9EP)IM3>_P`.J=8R(1C3DPG>.CS-
MSO20GZ$Z,B:KQT;JU7_OCGRRUIK/-'"C-TFT4PBZ4;+Z-EMO1Z$G&Z6VJ*F?
M2FKCT)J9UVSZ4E,>C'YT]_\`AR8IE8^/>^F,'-PL0:JV,>]Q0?&:VD3.3O%Y
M;0^!L3*L)8^`R.+4C7>U@&KW-F%Q5D2I\,A,A'PH<!:NW$Z<AF+)$O2C?MG?
MXZM6?)C0VF["J7R6="L2N8L4HS(:U\CQ2'4;%&$=7KBEFQ*34Q)-V$*EB,(A
MLR.(&14B!(DQL@0P!CSX)LRA@P6*55][-O>BOC1C.<Y\L/\`:\CAS>>_\H>\
MBD.Z==56M$/!3R12GN(UD=6F4(_+0H62PRF7*3$=:TL:!W>JY(HZ-QDJ1A4:
MSZH@.D9++$'TA;;B$Q94Z>RIFJJ_PX\]7B\K_=6]>F'D$\SU4)0I]:C#IS*[
M'ZX4A/B84C(LMYM]$G:<"VD%8Q9HHDVB%<.F(^&1E9=!-U(TD13NP(^QU)F%
M1&#M3$T>SF<-*+S&6%]4SMYZ[/\`25C,:C\,C@"'Q(*-CD5BH47'(U'@K-`>
M'!``C%`:'#BF#;1-NR'#![9NR9-$$]$6[9%-%+3733&,'E=WP'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<#1'9.*3";U&>C,$B$*F\E(D(Y[F"L0D]8PS5%K
M(!KMX7-L&C=RE*=`+5!4PPAI75$%*2K)B(-NV0QRY=(B,^V:CKR#]7[XKOHG
MV&*)61F(1^,5ONA/RKXBVM>;=C8TZG\8>PB(V&4.@@?T=)T[&TT8,-GH95\6
M/-M';EBS"#B+AAPZ4S&EEVC"<N.?':]'G#F<!P'`K@\J/Z+\/_7/\>']^[KO
MPJG.?EK_`&5+'^$G`H<\\7B]M'R1TY2FM#G&0VWZ@LA75J-D<I*1Z'$Z^L7X
M0+F19^FQ>-45Y#`B0*)SZ/K*ZKN-VT>."&30B\,-Q[@Z>SKBB9OE,<[QEURG
MBJ4[+>#";C.]OBMB4F[<3"U8`=WVJ20N20ES7LH`5[U6KM2QAPF.N8X>,;.B
M\ZAX2118A)5'0\F-)+L"BFQ+V[C9L5'M/RU_EML_[3CTSA[3N'$X#@.`X#@.
M`X#@.`X%5J+AO%_)J[;DHS%'ZUCN$MX]*VLRZX/)<$4&]=D_>1)&#N:_-=G!
M(UPA"BZJ1L=8T3@*OQ)FBJ!WW(.]Y@7^GAQV]->_M:EP@X%;/8/^,V\;W]#?
MD"_JOK!PN/<KXT?Y,Z[M>1?K#T*"QS%W33"=C6.U-)4Q4(1H]?S:VI(*V8-&
MT=";)-5`<<3)&2X<-I)YN4CD49.B&NSPPGJ@XQH933-5[:LYV>MUY>0GM'X^
MN_7FM)-^Q4&A]?2!-N9D#1[>4ULLM$*_D&ON^S,%3O4P,H#-Z&^M%'O$W+-Y
M<+D(P=]BK0+3V="#&(\J$3%G:FJFC"9F,,K7YSC[T[,J8M$WG/VV=8*O1I;K
MM2E6Z0.O*Q>PNLH:&D$$J9!1"N(Y+D@3)28LH=NNS8/7P3:4*%UV9<HT2,&=
M%OBIC&Q-X[WV.$S>9F\SCG.?-O;AAP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P*X/+O\`Q;?;7^CAM_:R.<*H]Z.?E*Q_A)P'`<"N#RH_HOP_]<_QX?W[
MNN_"J<Y^6O\`94L?X2<!P/$[YW_([VVZR^5'KG$J/F$0<B::AL9L&%1XA5V2
MCT3,[K9RVJ)R%)%26-6TLV,P=TF28J-R(H8&2)Z-DEVQ\6NNX>O7]._LZ(JH
MF9OQO&KK.$[I2O\`*)WV\W]3S_KKGKOUA3H"'71+`E$`H]*'-$=@"DOOJ5E2
M#J--'$BC$I*MH<%*1Y!1-!0PU&#VFX$R1=D5VVV^1A-%/LYOI3>T7V81YK@(
MSV=\@[.-Q]I*_&=-C4I:@Q+>2F!79OJP)&%CZ#!ND9)#A2EB/5!C!^1U<NF8
M]1X[W9-U4VVSE?9/*NYSM&V/'L[S]U-WG_Y7=B_M5]5/\]\%HVQX]C]U-WG_
M`.5W8O[5?53_`#WP6C;'CV/W4W>?_E=V+^U7U4_SWP6C;'CV/W4W>?\`Y7=B
M_M5]5/\`/?!:-L>/8_=3=Y_^5W8O[5?53_/?!:-L>/8_=3=Y_P#E=V+^U7U4
M_P`]\%HVQX]F'V%WA[A5;`9Q9LT\9%F#8=7,/DT[EA%MV<ZR%G+",Q$*]D!Y
MZW%"ID\*$UVHL>Z72'C6;I^\43U;,VR[A1-+86WQX]D1O!AY<YUY,679B/7#
M&!48L*KIXTF$/0C0<DR`_)2QMWV\2B[QZ[2]0A+J\)""0`^55RSS(&KL._9M
M7.[<J\V+]I1H3%LICQC/N]`'#FCG5-.6)"#98[*KZG\P:$)U;,C;P9Z+K)6)
ML8_-[`ETEB4>2.?+5I9^S>&@3@8:R;KSU=!NN'28I;N`2+=EDV^Z-6W_`%X)
M&<,879$X&5C7<]LHVV?/0U>PN4S@NS%Z(*$G8R)@WQ]^V')NEVK91\NU'JI-
M-'#ILALXW3U6713SLIJ(QP>+/\I,LA'M3+.E-3P$X-A=U5>7[=-K.B#V;*1[
M2*X9E:LBPYRA.]Q"(LJ(D[V($2P+V#=$B\$))I&!<?*;[M&IW]E^6*IG*;6P
MX]]N.J[SYVIT9LYVUZ_%S':RI^P)4_&6<;/1>53RSM%.O:P-4N?UAIXR4#O1
MQ.NG(D=\)#EZ]/*YTD,C4&_`0F$!I<L=8KC'":>%L=5^/%[4(O\`E(?CZKF%
MPZ,6)75Y4<6#G(166L*9UP-E,%`B%-&PM>10^=00\8AYVNX2(1U=*,V"[6=+
M#$$F@F!.WZ:[)N</PJIRF*N?G>TWGU*5$C\^'C#CEVP"C\WVJ8+3D6??NY<&
MA<N<0R!NQ+5L]$A9TZ<B&AP:4ES;=XH!2&`3"*&K'560+A&Q0.X?D_AU6F;8
M1;GPX:W)M7SR>,ZIY;4,1(WFZDR]NS!6)HEXC"9<1"P9%-IZ^LFG+A\(&.6<
M?4+.1`+7(-H>,8=ETGVXG4(.,$QXCV=4Q,VRQS?BWGG\9:%]I4)O>SC#_>!+
M3C>Q,PJ6ZUJ@Y2>>SQ"U2^PG!S$JW%:JR#&V([F-:#$LME)%J;WT$[#0JM>V
MNV</C(_/=XQ(];U6U'I?FY_>U`)P\QL".0^5$:\C*(Y+18*VDYC84W):+3+&
MA%..K``QYDFH-VW/.@K5^+<O!^'7:9MEZ\-;[QGSR^,Z3WA85'-[S=#B%?1N
M/R'><E83+F\`E.YC;T$@L6)HB7)AP5BVKH+L:^+`@[!QL933`/C6PTU\.'X=
M5HFV$X9QZ_UP<=]Y\/&&-OL?0;R_=D'Y&%XE2-B+0^5(UK@LJ2U9L8!DLJ*T
M-[S,@R]H8:))1Y2/J,T]6.9!@\N@'4'X==KV<BLO/)XSK0G5PP1A>;J-N:@D
M[.-K'97"9<PCT[3<,O7<'8*Z9"2+UX''&&Y2///CP^/D=WPS9^R'O`3\65>B
M?9U1;#/',C'GE\9THN^PZ/;WF['$*]CL?/[SDK")>W@$J4,;>@F&BI-$0Y+N
M"D5U<AOC7Q<&'8.=S*>D?>FOAIG(\?AU6B;83OA\*3\]_C#N_,X2%7[M#'L(
MFAV*Y'3R'RH4_DXH0X308S^,-AHLQNXA<BPIZXI8K@1(&VVF[<['P[C9!-<3
M[.J+89Q?,K_SW>,>P)E=4.1O5Y&<TH<0#O9#)X+,FL?G+78=NY?'8$J.#%"9
M`6)*-"D?>Z&18(FL_'>^#!Y`(0%E'@GV=41$VSWP["AO.SXU+[KY"P!MY.(!
MHJ:/!5XK8T-E0J5,5`I%9JW=NVX,7(1&S0V.]Q.C=V1EYOHP)-VQ'1B7;D!K
M,3[.J)M,>,,6@/Y01XP)[$K@F2=V&HT/IV0RT,^8R2OI@B7F@N+L]WK6605B
M,%E/B(*5(I+Z1UL85!2/WA'9$X!"Y4;[+#\.K"+9VUQK9S4?G*\:MLU-%[:T
MOU."M)""4,/HA.(A,6TQBKAGNX0+!#S(`#D`M4D,=M'3910"7-#'WL]'`H@_
M:KH+*"?9U1-K>+5,?_*(/&3(>NTN[#HVA+1S>);2A#>JRL!.H6F9?@B.6`8<
M('MDW<447F>BX=\!<NI<U&LFIIOB3OP#A@90&F_A5WT;<[X>H_U=N,?YP?&8
M0J9"X/W1K-F#5@^9VJ`>0J>ZS%FS3#[&'`-P%;QMPEM(VV-%!RC%J_<M%2*>
M4VK]PVV3=;F:%5[6UVSAI=_^42^,L?UH"]D][)F3A,TW$XUIUK`B^]NL2[\Q
M@,0`O6"F485J\CZJ1!Z2?(S=8(Y'#EEPI0JJZ&MWIOX=6EHX7XX973@J'R:=
M%;WE\#@%5]B(K)YI9WKZP2-[")@$)2-=..D)8JR8ZR&."D??TH\))E-V*RR3
MO"#!UC"65$MM.$S35%[QEGEP\T[>$G`<!P'`<!P*+?+OW,IL9TA[25W-BJ==
M*S`%+X/4Y^8EH\/&6W+JOLX1$['CL09I%W!K0M%SX]ZAAD8&CE30]JZ,!L/!
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M;[THY_BN#0K^&KZ9['UNWC#_`)]O6;[THY_BN#0K^&KZ9[/S7R[^,';&-M>]
MW67;7/Y\9Q:<<SC./_AG#K@T*_AJZ2I/\L/G>Z<0R?\`44!49)MV8%UA>4![
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MC%IQS/JY]&,^C/\`M7YL^C.,^C/\F<<&A7\-727[];MXP_Y]O6;[THY_BN#0
MK^&KZ9['UNWC"_GV]9OO3CG^*X-"OX:OIGL[+ZV#QG?S[^K'WSPG_P#K<&A7
M\-7TSV6"\).!UID,)D0<K'SXUB9!'1KX,:#DVJ+T:6$E&JK(B-(,G&BC=VQ?
M,UUFKMJNGNBX;JJ)*Z;:;[:Y"`4P;BZV[14/#XC`82V9Q89HA!E2D<+&YY(D
MK\DMBN^Q9*)SE\:V=#W4+Q7-=6)9A)VUD#R2?2U%*3O&K\V"(;%:ISWXX86M
M>/"%A_"6"SVL*XM-B#&67`XA/Q\8ED?G<;93&/"I&V`S6*/,$(U*PZ)9JZT&
MR$&\]*XPLTPB^:9W5U16UT65UW%[9<'4NJ1IM]98>YGE55XYMR/IFT@EF+0X
M!O.Q>LD#A8\>V92K+#XTBJ5CT<!`'J^KS"RP,4R$;*?#T=6W!><KX;'93"JJ
MSL(W`9+.X!#IC(:LDBDQK8W)HZ*-%()*E1KL.I(8H^(-7#@$7V&O7#;WX<H@
MOC79-3&^%6[=1(7F->>>]$KNCM!JF%H7Z%$TK&[[/CU**C=BV-`@I4A)0!X;
M)9(-JDO/"!^(I0ZO7DI%LY+,BA\^H):Q,5*60,6O-C4;4T-C'#&V=H[;=7/8
MPSJ.!A\RG">#E/TXT<=5H:QKZAC$;KE`>8Z_A2TMM:M#M$1R2$'15TUR!K*I
MJG+D%1B@5P6#SQH3P/0B4BC:&QL\9O.,XYY3?QG;BG0*JNLP=A2NV@L`APFT
M)V%C\<FEA#HZ*9S*5@HIE[F-B9#(F[5,J68A,$'6@Y!\Z6T;);IHIXPDW;:)
M$WFUKX;-3K#%(4U(;'&W`?JFNS=K!@;.,B+'+PZ/D9L,CXX^WE8X.PDKQ@L6
M:,!TF:MY`/;H.M-&)A+4BTPBZ]*N1><KX>H=G$ZKK.!R*?R^$P"'1.56J<92
M:RY''8Z*#FY[(!HIL#'F):38M4'AX@R%-$635R26<*(I>VRGG51RYW5%YG7E
MEN!55UF"L*66T%@$/$VA/`T>CTUL(='13.8RP'$_?/HT*D,B;M4RA=D#U?ND
MQJ#YRMHU1V313QA)NVT2%]6J%-$4GSBL.PEQR2M^K5;=?CI"P):T%FEJ%,1>
M7W1M(C],%4*N?2UNY`"I)8]]&S$\LW$B$HE]HVTB`9BX'R-I'S1PF7;",9G"
M,+WMGC;9$6C[QDN5BU45C!Y'84OAM?0V+2JV3#"06?(P$;$BC=@&Q8E`$-*2
M\FR:HO)`\8B6Z;%JL35<;(([+^S]7=TYW5(OX9;G]UK5E:TU$VL#J6`Q"M(2
MQ?&";*)0:/"XO'6A"0%79LV\;!P[9HP07)EG[Q^\W20URJX<*;[?PXQ@7OGB
MX$6I:H(0)G8"'U?`(R"M"0R:6V2&"1$$.%3Z33-+"$N.S$>V8IM)(4DK?&&Y
MQX72=K$V^,-WFRJ.,:<-O.&,X81NML=Y`J^@M6PJ.5O6\0CD%@$0$-P,7AL4
M#L0<;`AFFF=$!PL0/109-&NN-MMMDTD=?:***+*YW554WV,O?&<95[=I0D5H
MFOJ]ZYU70U/"NNMK.K&:V?`\5V*5ALC;&ST86+U9&(",=1L.<L"X-)K-#(0(
MFZ9D#CF)DT6#EGO[1\S*C'&\WV[-]]D87;7Z5S(K:]*$XY-8G`VT5!BX1#&<
M0C,)^C,+CXHU3$`,R^EG$3(/2S)5*JI%()!6I)GG1NDU:BM(D>%I20!(LKF3
MA.$[_&;>%I;W==;NOSZF1_75[2M7O*&%#1`@=3KN$1YQ6[,:`(-BP9HA$%F&
MX31,<5:-BC;/N?KZ$DM7_K9=9V5R+S>]YOMOCU;4=Q\"_4!JO@@AXK&'_P`4
MC2KL:S<*1XG@40!8(@]UD=]A+_X(7*AO>V&6[CX43(#_`&GNCURBJ8[?@.`X
M#@.`X#@0/[9UE4T?KB:/R,4KE@+NN51*$6M++51D9ZL8I%C\B1(F9`;CC6;P
MUF$8&Y`S')E-H_(X4T-SDL#D\M>F';'.CDV+[^6?E/\`K!*^I)6<GE55E.).
M`4BLDF=?0R5R&+JINDE8V<D4<&ERP!1)\FD]34#OWC@=NF\23=:;-\ZN$]%<
M;ZX,EL'@=(_C,;*F`,B*1\(2D$5V)[Q<Z_$L'AB-[FF7PTSN!)N&ZCT/L6'?
M[`3V'KM\OV7^RNLJH?O.!W?`T=V$INDKJK@@%OFLZEM"(15;>>CQET1$),(2
M`D498/UQ\J>,3K-X@RP*;K/='I!MJBYP'=$V>5<M7CE)4V)F,IF)RPP\E</6
MSL86-W:V-1MI0A%MV#D->.C$G@T9/!9K>L?8QNU(:TE+4(K;$R:5L0I.+U5#
M"LEAI324GV$!G$71G@VKYL;2C[$J8PUX:M48QYWG'SC%<?P@X'1QN,QN&`14
M6A\?!Q2,`F:8\)'(V)8`@(9@CZ?8L10@6W:CQ[-+TY]FV:-T44_3GU=,>G@:
M=O3JW0799W4CZ\JT!V&[HNT`5RU8L74)(;1:Q(WHOH)-)_#7S'!1FGE?"SN.
MFL$8V4<M!SDH(>+C!ZC8V)F+VFUXM/!$SR`W*2C:D-JI6D?F;#B[,_99M]*:
M^L^20M>:4[`+2OZE1@D[!VR`-J9CMNT)$I)+VLA/L'R`%<`W"!S&)`3+Q(VF
M,YO;5G&4VB?"4P^O%AF[1K!M+C[V-F'>TQL^.,Y)#F3D?%)>!A5F2Z&QN8Q]
MFZ.251,9*@`$:=142/EF#K+[=V*?N1*[%78R<_6QN[ACHW$9C;N1"Y@ZCX-S
M+08@U'PLH<"6"TB#@9([!OY$$%FU&^Q,>(/OHQ&WIH:T<HLBKN/`W+Y%=82P
MW;AWG`UA=LV.UK3%N6-%HXO,)-`*PGTVCD2:HJ.',I.Q6*%CHB.-T$EVRJZY
ML@P;C$44G+=111UKIHNEMMA34V,XOA%U;'5&_P"0$KJ5!,8_4#)Q>%I'I!:[
MF#QLLV)V89#5_:L4SV+BYYM;,_CA"N1HWKG3U*+/AB!$<1DA'4@_+QDR6&Q#
M4J8PQOA&&.6,3;*,<9GNMVX0^+AN@[07:ND$7+5RBHW<MG">BR#A!;39-9!=
M%379-5%5/;9-1-37;3?3;;7;7.N<XX$5OW!G1K^9CU0_9VJ#_)_#;SMGK*5_
M##@.`X#@.`X&C^Q-CF:JK!66@'T5%%5Y]34)0,3=JZ>Q4&C:%R0*LGQXPR9'
MHNY>-P;"7NBR;720A]'#EF@BL^01W4VX;$7GKY(>B_)'#!3N/QV:QAV5++O+
M):G)=7BS<A!?@]82:[&I>?#U"#[95O&G]=41*[43$[E2AW002""HU].6ZCN2
M(&Z/^IY8>,1YV9@CWS`2:#=B#D1@Y\9(Z9H,Q>$>83--NBQEPYO72,]&(YP)
M>JY3REH6CC.0BVC]8R`7*89'T`+Y8:F_&CE?7-N&-N]G'1[GRFN-UA%\5H58
MD=CK#X&;$M8U7F\GA!\I`88"DS2O9M9YTL,>)69+S$8/B5)<2U`16+:V4?>`
MQ$HCPAR9:^7CJSUVW,QHSM:2[,OIR%KL`Q@;H%6T)E@@Q.VKXZX:2*2V+=$$
M*B9!`&Q"%'O<!>M2H$FBNYL&[>I2)'*R3/1%#WP3%L_6$3GS:4SY$5ZXK>JY
M);]?%Y.:L"FZFM\@7JP%J-BHG-OPVY;&$0U`4;F,HD67P&(T/8'Q*4%%QL9=
M%MHKJY<`&!LNZBINCC-MML=UHV;W*=>2^)NK-;5W$ZPDLAV^F0F&KOE3`4,H
M1>S*>DJOKY:/:%56K$HB<EX0PY*KI$%&(:+-D":3TD4R7"`QHX7Y](O-]G?J
M_"'E"KD(-CKX_45L"EY$+8R)!AAO&RF4(T:C5*R$$36)B#;T$@X??/>(-G0]
MZ49;CM&![91=4AO%Q4H&C.[U?LD30G9Y>[[-M6O5:^?0;:KXG6IQWDS(`A0L
M[)3XY:#'=EEF"</F2;!B)@H8@B02(+^V>&WPY1)/X8FX>&6W[?MW10DWDR6C
MT$)&_E(3=2$8-LG""^"(C2('I9751Q^X7,506V.XDH1N^CLTBZ6)*["$FR#Y
M(VVU&./8LUES='&U_5]'UBR<IY)8VQE3*OQT%?&Y:[M_6K%7628X7%6+Q#L/
M'JC-Z.#B+PXQU7"1"1M)BWW6>MB!O&1CUQ'(X`D0U\F-'R^U_'%W<0\B<9E@
M"#.1-9RX\>GH5N[CH]B1A(A5\0'H!493DX)>S`@_K]BW)&FZ\9TD;ARO+X^D
M].1I0PQ:).'PT9B]YC#CRU)]0R4CIS#XI-@Z;I(1,(T"E(M)\FFB^3'2`6U+
M,4WB**SA))UHV=I:N$TEUT]%L;ZZ+*:XQOL2R7@.`X#@.`X#@.`X#@.`X#@.
M`X%>V.[9:,&BF)W7[$E'R)_L"'@P^M3VIBQ7ZU&]H8QUE;#B$4DVD<&/B<X*
M3`3(1.@:1[.M%&KV-#A)TPY%X=E6W[/&+^NK]'>22DR\=C\E%0NX7K(LTKTJ
M>2Q&XHUWKJ/6G##EC0B4V(]?3AL%CL8)U^"6F#X[H5?#XX'?"<2=<,^?:,M1
MHSY\[:H=K+^W\MAMOV=&%ZJ)2*M*JF#6)2N1Q]A*$RHY`A0\2M<1(/I$;""Z
MC<.#,VF\6JEO"W-@"9`.WD#.P3:X^&L2CIL9;+'/O;CX;LW&,>0&&-3@6+":
MGM1Y(2TTB<$RF8Q`@`%&3E>QC+KM+XDSDV\V?BY!-H.4^.RUZ`C>Y9D^C(=`
ME@XR&%VA34W1]<KWX2S>9]AY]7EM6/&3D&%R>#0Z/]>20)O!7N%+*DIGLE;D
MRI>&!-64P*1.#L-!$HB'Q`\3?2IHVU"%<*M]<N1NZ#TRU_'PB[4>GDWJ!T!C
MIT?55_[IRTF"8QYN6@X2.K.ATR<5D.@4Q<IF9:U<M8',C-M1`./E&C5RW'$%
MEVIY`6Y=`$#INCGC&''?NSPR?(?Y,JWTA:<XE-.W;'`C6%O)>?)MVE:2(:.V
M$BY\N6%#T`UE+RHTNF>K:2Q8:LA%$-2!'86_439`W;@HR&COB^&&.NV[?ZL[
M0AY%8EHK"F0RB[UT(S*X*RI;W>8!X7!<@9A8=G2B`*#C3`U-MI*B\$BH#.9@
MW4;QUP!+LA8@9B0L'IY++,:.>,81?PN_NZ?("'I)?L8S*U)-I<XHE?.-',6)
M0]L%((/J^J^11G20O9)(PQ<0XD4ULEK#D]H]')>D+:-])`2PBURX10$4WMCG
M_?;<X#+R-Q!L5D`F15)9FB@ZZ%Z=#N(WO!#:A%=`]6L2>2<L)4F[,J`C8.86
MM%(R<->P)B&SEXP=>_Z+'@XM86WZK^>'@X42\EU=DH,XF4KK2QPF!-?1>PY8
MS#8A1Q"*MYA6,NLF/1S9PO-!1*2&"Z=>S4*P>``:PE!V/8OI(XC0=XL2:C1G
M;&=O&R=%86*SM",+21K'Y#%5F4GF40*QR5?`,G!)R#2HO$3#=TK%CTGC[A%5
M^'6=L'(P\027'N&JBVS=ULX9MR9BWK:V'P'`<!P'`<!P.L-$]0H<L9V9$2>H
MD8_)[#@[7+XN0U8-57660MCKMIL\(N\)>P8M<;Z9<.5$D<;:YW].`XD:E$>F
M,>"2N,&!YR.2,6Q-@S`YRDY8DA9)LF[9/6JZ6VVBJ+ANKHIIMKG^#/HSZ,XS
MC`=[C;7./6QG&<?^>,X]'YOX?S_P?FX'\^T3_P#>:?\`S:__`+X&#"9+#;)V
MG4>;H-)"PALJQ"Y*D_9-7X1R?:!([*7#-ME;WAH2U$Z'AS1_OZF<#Y`S("U<
M:$!3G1(/M)ZW@TQ#D04AC(UX-+`%8J^U;IJ"WBL9<)+MW`!,H)48E&H=RU=.
MV;D<U>(-7#)X\9K);M7;E)4,A3!!$E2"Z0<4DL6;-F959,>TT5)LV:"C5HU(
M*:HXW>MFK955NV0<Y42004422UU3WVUR'(<#1SQTQ>NQ[)T]&;KJ#7;AJ@NZ
M'J.D-FKI1BX53V5:;N6V^[=?9ONGLLAMLDIG9/;.N0XPT"##:(IB`PD4FV;9
M9-]!HYFQT09[.%'>S1'5JBEJDVV=K+.LH:8U2RX546SI[3?;;('(`$\;ZLW8
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M^>JIH9S[+11XZWUUQLX5SN',0``FJRSAL%$MW#C5CJX70&LTEE]1C?=H-U65
M31UW5U'M%%&K'&^VV&C??=%#V:>VVN0[-))-%--%%/1)%+31)))+35----/7
M&NB:>FN,:Z:::XQKIIKC&NNN,8QC&,<#^^`X#@.`X#@.`X#@.`X&(!YQ'C<F
MF,/:NMD9%!G(9(T,>ZZ-72C&0!6AD.?'(;J97>QPAE8@%:FM$M62\BC<I#(J
M;NP+_5,,MQOIMGT:[:YS_P"6-L9S_P#3/`9WTQGT9WUQG'\F=L8S_P#?@8D:
MG$>`R2%Q)XZV5/SQ^89`AS/71TYPW``",@,&GZ&BGMV4?8),F@IT9W2V9-S\
M@C`991-X?'Z*AU&U/5'OB5Z[U;7.^L\?(DYSKM"(SMB9DFY#)=N0E>,C,XD3
MY`KML31=E_?%TB&V7NBFKG.5>&WG;.&3@CZ/J(;J432KV,.T2TG"3%=J9':2
M!FSD49CXN*QEZ"9'<D6D:1C,>#L!<;&1U$6*`-]'&PADS5?/U')C/G`$&\:F
MV+L,)=,I-JMK)&C@<S7:R#5R,;!7&IMNJCLD5U7#,V@E;#_1QA48U;,-_6:H
M)):AB>M253KEMG6LJ]URRCS6),\ZPN-XRTBC%^F491EMG`WTH1YF322(M0J7
MJ#6[]--VDVT<::J8%^[+W`4,[<*NW0D8Y=N,!]5W3A@U6<+8CQ%<P`PJLHEL
MHI@&6=.2@?&^V<#"+A=ZR]@Y545V##4Z?J5)TR?)5=72;T:=(RD<\3A,:T=,
M),758."TC9.-1F%6ITFN*%K$2Z&Z9!ZJ-8*.7"N[-OLF+SM=DQKFO1@MJ#&P
M.&#PK%GH.9"&,7"-!;,>G[W[-BU'H,4VC=FG[^^]1JDEHAK[Z[]73'O*WKAQ
MT:NK)N(9`&]=01`"-68N!P1&(Q](0P7&;/-AJS(;H/U9M5A^Q$ALQ4013W:;
M/WF4-D\NE_7#M",)AAC!;!:(Q@I@_A+!W!$`*>X-80U9Z(X+8<M%?B.$=!P_
M1+#SVWL]6+/73T8:H8T%W0;T_4BCT>24JVN=R(E5NN+?[PB,[/1J[159=JL/
M=;#,KLU6RSAPLW4;J)[HJKK*)YUW5WSL+SMSSWOJWJ2JFOP[W6LJ^;?"!A$(
M)]WAD<1^%AC##047$#O9C=?<AA06FF-(L&WLFKYAIHS<I*M]=4\!G#5DS8Z*
MILFC9FFLY=/5DVJ"3?15X]74=/7:NJ6FFJCEVY55<.E]\95<+J*+*[[J;[;9
M#D\!P'`<!P'`<"&]F=@['@%H%H\+@.TRBXW`Q%5@/B\T;DAPTA"C\B6LDS/F
M*1Z.M84'DXP7#38AM$G1]LF7<GQC@T\$ZQ4F5:+9^,;;6M/6_)&Q.5P2Q):3
MW7\?-=/I"4S7I!8K,H`'<9D!:T"\,&N2TDENM4%'4;;1YY)C1<Q@P),3-['0
M>TF-1>*,"HG<B/\`MACKV96B_P#6^6)!6-56BULF80OJD(A1NH*U8&$Z`7AK
M=.+V-)[!/R0)#R-L5(E'Z_C$EEE>IUY*"->ZNY$88-8[:6QC8_%C#G.H47F,
MYOCG?K:=6>.#L558V/;20"3\:].IS2*,D4B+Q.OZ^<!G;UK4LILLP29@`$0E
M!#9LL\CB42B0QI(BH:42TCM&=+!8+L<DW8Q^+QG;;=QX:D@8QV/.#CT-JV#]
M=EH-'LV!M#D]M1L@'1P%%V,EB(\D@,#AX$+#LI:R82<B6-A]B;2(`6@MR1$3
M"<;IOAS8R8UWQ]8^L=L0GMPPX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!I
M&\Y_**_#Q!U&,#FVT@F6X`R<+0V6SUA'A:<)FDD;O58U"2`L\]6+R".@XBQV
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M=5?`9E*0R,=D<GB@4X;!-TBB*`DD19).73!%(VT'F-$6RJFR:>"C!B_SIC7+
MIFU6SN@F2V+P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`X+08-8*OEV`]BR7*
M.O?B:S1H@V5(O?8I-_?'RB*>F[MU[N@@A[PXRHK[%%)+U_43TUP'.X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@<%R,&O'3!\['L73T4HNL+>.6
MB"[H:LY0W:N%6#A5/95FHX;*;MUU&^Z>RJ&^Z*F=D]LZY#G<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P(K5[W6ZW6V<L^.59-CUD%J7GYFK;21
M@E5V[+&T+L*/+JMC43+$@4$?#/BH]=%5-=-J\<)_O/6T5WUSC;)NC.%\+Q>+
MS$83KS;0^=,/^QK9^X2]/PYX+3NZQW/G3#_L:V?N$O3\.>"T[NL=SYTP_P"Q
MK9^X2]/PYX+3NZQW/G3#_L:V?N$O3\.>"T[NL=SYTP_[&MG[A+T_#G@M.[K'
M<^=,/^QK9^X2]/PYX+3NZQW/G3#_`+&MG[A+T_#G@M.[K'<^=,/^QK9^X2]/
MPYX+3NZQW/G3#_L:V?N$O3\.>"T[NL=SYTP_[&MG[A+T_#G@M.[K'<^=,/\`
ML:V?N$O3\.>"T[NL=SYTP_[&MG[A+T_#G@M.[K'<^=,/^QK9^X2]/PYX+3NZ
MQW/G3#_L:V?N$O3\.>"T[NL=SYTP_P"QK9^X2]/PYX+3NZQW/G3#_L:V?N$O
M3\.>"T[NL=SYTP_[&MG[A+T_#G@M.[K'<^=,/^QK9^X2]/PYX+3NZQW/G3#_
M`+&MG[A+T_#G@M.[K'<^=,/^QK9^X2]/PYX+3NZQW/G3#_L:V?N$O3\.>"T[
MNL=SYTP_[&MG[A+T_#G@M.[K'<^=,/\`L:V?N$O3\.>"T[NL=SYTP_[&MG[A
M+T_#G@M.[K'<^=,/^QK9^X2]/PYX+3NZQW/G3#_L:V?N$O3\.>"T[NL=SYTP
M_P"QK9^X2]/PYX+3NZQW/G3#_L:V?N$O3\.>"T[NL=SYTP_[&MG[A+T_#G@M
M.[K'<^=,/^QK9^X2]/PYX+3NZQW/G3#_`+&MG[A+T_#G@M.[K'<^=,/^QK9^
MX2]/PYX+3NZQW/G3#_L:V?N$O3\.>"T[NL=SYTP_[&MG[A+T_#G@M.[K'<^=
M,/\`L:V?N$O3\.>"T[NL=V/]=NSM$=LH&\LWKS8@RS(,/E!B%OSPP>=%Z,I4
M`38K&0;MC(Q08HW?CDR3'+E-5CIKKEQKKC;.V-]=1,3&$X-\\,.`X#@.`X#@
M.`X#@.`X#@.!YTO`;_XE>97_`*I_8#^ORW#I[3]'_'3]UEG:KR0T1U-B=SG9
ME%>PTD,4Q#STI*"XKU;[+$8@:6$1W,A;CF-V(5$O2#1D]3W;M7DJ?6`G%X^K
MNYR<)L]QSY%$FFF:K8QC-O>IOG;*]_#'4KX\;OY0+3/>F$6*<G-"7C34KKV2
MC!:X*M*KO[MO'B060-7SL*36EE&4.2VC)3UAA!J\!RL('RXPBB^!/C".Y)`,
M57[.:9C&)OMF*?"97Y`33&2`PLB&:$4QI\2.-#]#`8Q'"VC$HS1?--"D>D+`
M6?!$=4%T\/0QP8.,"W.%6)-@T>H+MTSFBS=O9<K3\S-0=>,#'A620F"E:/5<
MD72*<VEYVS4*PGPLRW;MEW#$!5"LPJB;2DJ/PY=YADJ.ODF2>(NY<+FV_OI?
MQQ]2CZCY0JU-#@<QA]96A(Z^^AD[L68$6[>!8-A:[B4'"6"VGP]'%AY`$`^T
M>>E5C<5V/HVJ%=#FXUS7FI$H,:O3='?&<1KUWW?UO9\8[UC4H[8[V+5Q+Y6^
MK:4S2(R.1HM@0VOX]((U8,^BC"/GW+N5[3/X@2#P50KH2"1(O'O;&@#=V4%O
M"N1K$13?"^R>4^MNJ6Y>N7;"L^T*4E=5LSE"0^/#XJ>;%#K0'H-DD8G&TBQ%
M)"$=`)#(=6N"B47)NG,7D^(Y/X\T5$N)3$`:9L3EX9,3&?KUT;_DTEC\+C<A
MF,M,C8Y%8F#+2632$P[18"`,?!,'!0R9*OG&VB#(:+'-7+Y\[7WT1;MD%5E-
MM=--LX,5WN_)O2,NML)4O7:6T=?+XG7$SL=\=&]AXA'!0-C`'(S,G&DO9AI)
MLW=M`19&4-U'>[-)Z!%RI^W]9O%3"J"\3E-U:,VO,3&49;;\&==6_(UU;[1B
MJW81FWZG86W9(U^3&4H.LZ.2F=-4F30J;]W5',L,2.2&D4&;R,H+<B61,`C[
MVP,,FKX8]337C:R:9B^$X:[2GEPQ$F'=I5I$!^9QBJI6!H8R&)G859XUQ]-R
MYH<TDXJ,`U#571$82FXE2P\%TI)7S>/-)JY7C+5ZO/$:^-Z-@+HVVK7KU>/K
M==BCWR#]=]RM<C8F\L2P-)^9:CE'4+I:[)!M'&A"%VE+1ZQ!B*KAZ_=2!9S5
M)X&Z@#)!2>"=M"!LM'F0./'7K,:,XZK;9B-G=EJO>7J_H@D\0L4@5'/=8W@&
M8C]<6I)`<O>2TE`!`$+`CH"$D@]@R9V2M&#,UXM"'I^2#536_P`4%LM1)O8:
M+3ZF-^>S*<W1Z]]>O39O,S9L[(@T.AQ9J'=RO:`6,3;-G&@AL_DN9:($PYX=
MK3$')K+QJ8XL4?&LQT^P?#3&6#QJX;I"TS-M;IF_D-Z\H;R7>4/)M$V\;>2]
MBJU>5=:QR2JX@=@=AX+)S2T9B<$//6,4:I=:Y])T9`NKLD@%:KZR!M'GS35L
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M*1F69)365F3.6L6#.F`>-92#FG4JFT32T$_&#8C7.$7MM:U<]\J#`G)-%)J:
M+1R61"/V),Y-'V,5FLM<1F&UIK-U)(7D;^.Q9V):K,=:YF+1YJ(?G0NIH6S#
MC)"7<R>';2(6GR\;=_6+^"?>ZF`YXT-(MYPQ'1@&Y>RIP^@$['R6+'TGT;PW
MC<E@K^+MI)'\OH[+`$N;'32`\+L","''O/\`VJRRJ-&=VK7&N_9CX;R(40;,
MD46>98I&4EPK>-'FL'L(H2L/,Q"]2BT%?0.+B(6_?E!<B<=P*X#.%"3D,6$O
M%4'^X5W'7)0W'C=&?5M^?24Q8#.HS9L+C%@PUZN0B\O#,CH1V[&D@SU1B^2P
MJGH^#F6C`P(?H9SL@^%E6+,B/=I+,WK5!RBJEJ2R_@0#[2^3KI+U)K&TK%L7
ML'59<E5291B4JV%6%"Y-;!:9#WB@E.`"X*/.JFTY4N=TP(>-B35BUCV^CQ_)
M70@4,)/6A44U53$1$XZ[3;CP:EZ,^8GI7W8H.-W$C;M:TE*UU-PT]IZUK.AL
M<E\$EK--'=\.3W.O@&TICKK1=%Y')@+'HL#0]?35PU$'6AD")-JHJIFUK[XO
M:5JW"$<'=WR\C:,I@M>U,YG<=K.5P2%VM*<30-&RH$]/`\;E&-(C%R['W68L
MH1"9C%YO/7!"4Q!9``6PS@S2?RQHZC"9MOZ]>7V11I[R5QVUV$3(M8+'W[68
ML.OY+56M+6:66E7NW8*T*YK6.Q&YUL0V*I5W9K3YC)2-"$);2/!L7$)OAD:2
M^"I+OC9I^^<6O:)G#''+QA)R1=F6<>[&QWK&M!C;J>S40WG4-((/VF(X5J@0
MFHVLN<OR&R/MA#NN9'D+%WD4RV>DCY*P*W=!W.X@K,B$!,MA?ES_`+CREJ1;
MO<QUCHR2YIZ9"6[=;L";GHF3FH\+D$%KCKE<8"G)M*5F(E:1LC$B>/I.-E8>
M$HDV6V\;82-`A(&,E&CH^;-MOV=9B\1]K_9)FI[>3M0Q<X?$-DL-7INVU:I=
M:2C81AU)-M:WK>R&<M&-1)$G[B","[''ZB6Q19N;V;M?>R8T4NZ^'-B;9;\5
M&OY,9^@#;/Z[/8+_`-!7W#I[7WH^6GR>BWAS.`X#@.`X#@.`X#@.`X#@.!YT
MO`;_`.)7F5_ZI_8#^ORW#I[3]'_'3]WH<+B!,@$E`!\6..`C@YZ(-!2[)L2$
MEQ))LJR(BR@YZDLS(#B#-99H]9.T56SILJJ@NDHDIOIDYM54AUTH3K3%WT*Z
M]TY6U+1,H8<R$I'ZSAP.'#"9QVFDBN6(M@;)GH^?Y;(-F:;EW[95!@U:,$-D
MV;5N@F;,S.<S/&;MS<,8F;@D,DLAATLD$7!F9-7CXP2@QXB.;.BT3?R`&\C1
MQT!?*I[+C52X`@\$D-FV^GO;%QN@MC?7&OJAK$/U<Z[@!94('IV!L!)L(>C!
M-@D#;Y;.(M)0+6+&(KKHIC?W>*K1EDTCS6--<H@Q81ND+%,&3+7"'#;SMG:^
MC_K#U\*&<2`C3\%>&,+&'67BX-MOLH^/E94:*DUD?1[NN6<D9W.%M"ZR*A-H
ME,Y:S9NF[.2&6[TR\[?7J(Z,N@-05A5K@\[KR#QZ(.)-NSR:5",-&FSMN-7*
M.Q8S3T9SAD"$.SIUV'C[##8&(=G3;H:/:KER*CD7NV1P-5W!2U;7Q%6T*M..
M)2:.-)$"DZ+'=V]8;?$03OVWL-W0YPU=J"#PQ8G$Y>%W6R+F$&D,GA4C:DHS
M(S(QX(F8R;4X#@0].]%NOLD8%`Q@9-GT<=NE'P.)NK*G#N'P5VO8L;MATI!H
MF\-N8\!;KSR(Q\GH,^'.A#`0S7A0D>/@A4Q&7YMYV^LONY(CI#0<;"#`D5'S
MF*X"2A&9!C4>LZ?#I.,D*`JR`>CYM)=#^QG?UP]LSL<Z1=/'"+YN9]#W1QNT
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M+!PH^?BSXE'CC11@7&I'XN3#R`:F08K+LG*HLFS<*-5UD/;8354UV&36%>]7
MJKK*?IV?'G-JDYHC#7]?HDIY?%VV:T1B1(L(..!*02Q+`DX)/V10&Q<L'N@W
M!`7C8@@-=-&Y@ND^-O.6'2(^R0_#&F;4H*M+E="2$V92A,J&#2*--#,*L6Q*
MR.*Q:7["=Y3%2)JMY3%"9:-'5009R^"$W3L?[Z+'D6Z"!%FW=)FWM_J)\VB;
M0\?O7&R8E)8VE&2<5<%XM88(`Y$2Z<[QV'%["C,WC#N6"*\WE24%W,"6E@R/
M85[0)IHU169,6^S=J(":#!I3Y>%M>>IDQ#HYUK+/6!@G$)4_DPZ0;2I":.[=
MN%Q/%9%L*3C^IE_.%9YM*R9%"-HMHPQ>$2[IP-C;$:$&J-!PL:@T%Y]1%NCF
M1GI/UHA[X"1C]>O&:\7;0=I'M%9]9!!F)2KEI03&(Y;,"4O=L<KL&O5ZB$7C
MI9NJZ.8@+;)Y8EL;D^38O/KGWE(.&0V-U]%P\,B`[X1&P#;9F)&^^/W_`+HW
MV75<;)^^$W3U^OZ5EU=_7<NEM\>MZN-L::ZZX,9/P(R]A^G76WM+5EA4_<M3
M0^1Q2S!3T=(G2((2/DJ+MTM[ZWD8:2-V/Q,7*!);5$V)-HK;.6I9NBZW]MK[
M5)4V)FF8F,X:FZ<>-OJ;TFH>)T-6%7QD\,`95(GIK.XY')'.9Y+7^B.#$OE1
ME<3KA8D_RW00;-&:+46'%M!X<4T:CV+=+4VJJ:IO/]1P3SX2T1*NMU4S*>8L
M0R.DVAM<C"S!T:'GTZC\.F!BN22):"EIM!@<B'Q&6DHT^;,=FKPX&>+OV8L(
M)-[E!`$(P'FWGU9AQCI?U\,1Z%QKZ+R`(QK^OJRJ^+NXI85@1,XTAM,3"*3V
MJ&+R0QV2C31A_7TKAPXK%#IA\^.!\E)@S9D4V,YF+8V+SZWYLA']6::8'1TN
M5#2(U.!,EADJ&V!)I[.9-/F+^!`S$:CC!K,CDA?R!&-)@I/,QI2))O\`6,GD
MI[/E38H@ZFLF7)B\^M_KRV0_B0=4Z1DVXO8I&2GH%R*PY'LDPF,Q%MS"EL3\
M3:%B@Y*W''6R,DB$MG8`$=+1`UH]CJ^HAJ(P.U!*/!;H7GR\,FX8]"XY%BTY
M.`V&S,G9$I:328N-G;QS@I(V,)AU=M7^B+IPL@/U3B,"BPS+0<FU9[[CMG^[
M?8@]?.G)CS]_DQGZ`-L_KL]@O_05]PZ>U]Z/EI\GHMX<S@.`X#@.`X#@.`X#
M@.`X#@>&?KK^E'Y._P!?"X_[1%N'>,HX1Y)H<-.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!+;\F>_BY"_P"LI;/]3P3ARKSY
..?>7H2X0<!P'`<!P/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g887761g47i54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g47i54.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"``0`'L!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`.JU[1-.\&_$?2_$*6=N-*U=FT^]C,2^7$[@!&`Q@;L$
M'\?6LUM"M],\8:UX&2PC^R:_)%>6LGEC]U$"?.4'MC:=OH6%=)JFA:?<:S=3
M:?864$?AVP80'[,K*+AAOP1WVJ`?8R9ZU5?Q9X@'P67Q<+RW_M'R1<%?LX\O
M!;;LQG/OG-=W8?;+C0+=I;L?:Y8`QG$0`#$9SMZ<9Z5R_P`-_%U_XDM=1M=9
M$2ZG93`GRTV!X7&Z-P,GJ,TWPOXJU/Q+XTU^U$J0Z79+&;11$"TJN"!(6)Z$
MKN`QT(JGX>UOQ-KFE:O<MK=E!<66I2V,"O:`)*5("[CNR"Q..*OZWJ^NQ_$;
M2]`L]0AM[2^LY9R3;!VC9.V2>0:QY=;F\6_#3Q='K-G:R76DFZMO.B3,<CQJ
M<2)G.T_CQ5SP1X@\)6?@'2K&6]T^/?:)]IA8#YW*C=N&.2>^:J_!R+3H/#^N
M7\4<"(-4N`)U4#]RN"!G^Z!SBMGP#XOO?$T^M6VI0+;W-K.LD,87!^S2*&B)
M]3CK]:7P=K6L:IXE\2V6H7D4MOI5RMO"$@"%LKNW,<]>W%,OM6UQOB8/#MOJ
M4,%E)IIO58VP=U8/LVY)Y'>NHT5KQ]'MGOYX;BX923-`NU)!D[6`[97!Q5+Q
MAX?C\4>%-0TA\!YHB8G_`+D@Y0_F!7E<TFOZEX5T[X@W-O*FIZ%)'&MMD_OH
MD)2X)'JY)^@2O2(;:33?`E[)=HYO;J&6XN%1"S&:4$[0!R<9"CV`KAGAN?\`
MAG-=)^Q7G]H_91;_`&7[,_F>8'!QMQGISGI7;VOBFUATJP@2UOWE-N!*#9RK
MY(6/)+97KD``#DDUQJZ%JKMX5U'1HYH9+_3ETC5M\;(T2!,[R"`0RX8`^N*V
M?#FS3_B=XG9;6XAL&M;:.WD^SN(V\I"&53C!Q_\`JK"\'VNC6\6LW>M:3?1W
MBZU+>VLO]GS&1D#!D*D+R"0>/>KGB"V_X2+XB^'GN[+4;>V?3)HYY(TD4VTD
M@!53(HP&Y]<9ZU7MIM1T/X=:]X.U33+LWUM;3064]M:.Z7R.#L8%01NYYSSW
M]:[3P-<)#X`TH3Q30O:6:1SQRPLKHRJ,C:1D_A7`>&IIX_!^L:-)9ZE;3:KK
M4BEC9RJ4MI67=)G;@#:&'U(K;ETZ3PE\5--OK=M1O++4;)K6]D=&E\DJ<QL2
MJX`[?G2^$-2BTOQ5XSN+VVOXH+R^6:WD-C,5E4)@E<+ZU2NY;+6OB?9:GJNB
MWC::VC&)O.L9'6*4R%@K87AMOY9Q746WB6[M[:*WTOPUJ-S8P*(89I/W3.J?
++G:P!'3OUZ]Z_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g887761g47p16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g47p16.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0[04&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````N````/D````&`&<`-``W
M`'``,0`V`````0`````````````````````````!``````````````#Y````
MN``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````##,````!````<````%,`
M``%0``!L\```#!<`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!3`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#NCTCJ_P"ID9I+\=WZRXNL'KM%M-VXM#MM%CJZ[6/V>SW_`&;^C(C.
MF=0:<=YNW.IQCBVL]6P-MEK=N1P_TLFNUCMEVVQ_I9%O_!K7224XC>C=5:QM
M;NHV6@#:7ASJWQ]G?B[@[],WU7Y#J\G<_P!7T[*O4_G'ICT_ZR5-(JZ@RR-L
M2P-+B-_K/][<CTG/_1>UGZ!GZ7936RS]%I-ZGT]P!;>P@\&=/C_K_P!\5EKF
MN:'-(<T\$:A)3AV='ZU9CMH.?HRZQ[7@O:[T[*<FEC'O:[U+'TY.13D,]_\`
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M_5$N<YF[TY]K*_2N_0V6^_?_`#M=?Z3]$47]8?>UAQF5U!X+[=X)+-Q]K:_^
M*V;W?^D_TB4@_9O6'-H-F=%E6]MFP$,L:[^9_1_3JNIVL_2^M;_A_6KR*[?T
M(OV=]8R:K'Y[76U;A+6AH.XT0;*MOIVMVU7;OSV>M^AL]3](MQ))3__0]4=N
MVG;&Z-)XE`P,A^5B5WO:6%X)@C;I/M=M#K?IM]W\X]/=D-;?7BN8[].UY#VD
M`#:/=^>VW\[_``;5'IS@[!IL#/3#V!WIR3$^Z&[_`';?W4E,6]*Z<V(H;`[=
MH'YO]7^3_P`9_I'JE]7#5C]!:X,VU569)#*F$PUM]_MJII:YSOY%53$5G5\E
MT3@VB0"1!D3^9JQK/4;_`%_3_F_TO\[Z,?JP2[HU3BTL+K<@ECHW-F^[V/VE
M[=[?SMKTE-SI_4<3J6.,K$<Y]+C[7NK?7N$!V^OUV5^I7[OYUGZ-65E_5UF_
MZM=.K?N`=B5`P2UT%C?HO;M>S^LU#^JK'#I%=K[;KK+7/+WWVOM/M>^INWUG
M.V>QC?H)*=A))))2DDDDE*22224I))))3__1]&S"\=0PS6-SBVX`$P/HM(_-
M>Y&Z=755@T5TO%E36`5O;!:6Q[=D?F;?H*&4T'-Q3`<6BP[(:28#=KF%X]KF
MN_EI=(:UO3,<,)+=@V[F>F8_-WUZ[7)*;B\Z^MSGM^HF.6.<P_M%^K26G^?R
M^["%V+,/K0(WYC7&3+ML`^XNW>G'[FQGI>I_@OYW]/\`H^,^MH</J#BAY#GC
MJ#MS@-H)];*W.:S<_9N_<WI*<'ZN]5ZCTSH/7<O`R'4Y%;NGMK>8L#0^V^NP
M-KO%M?N9_(70?XM.N]7S>I9'3\O)-N)1C&VJHLK;M>ZT;G[ZV,L=]-WTGKE.
MG?\`B7^L'_&=-_\`/URE]7<_,Z=C]:S<&ST<FK"K].S:U\;LFFMWLM:^MWL=
M^<Q)3[:US7?1(/P,JGT_)ZA=9D,S*J:Q2X,::;'62=K;';O4IHV^VQB\N^J7
MUFZG@6]1>WTG8^-@Y&:<9E--+7V5NJV>I9C4UV[6^O9M70?5/Z^9W5>O-Z=;
MATTLS#9:^QECW$&NMHAK7L'^B24]\DDDDI22222E))))*?_2]/LQV/O9D2?4
MJ:X,XCW?O?G_`-C>@](#ATS&#M"*VR/]RM/#G,<&NVN((#HF#^]"ABT#'QV4
M`RVL;08C0<)*7&1CDP+6$DP!N')C_P`DO/OK@"/J)0#H1U)\C_K^6NW'1>GC
MECGF()<]QG4N]\N]^YS['/W?Z6W]]<-];&,K^H&+76T-8SJ#FL:.`UMV4UK1
M_5:DIY;IW_B7^L'_`!G3?_/UR%TO_DSKO_A*K_VZH1>G?^)?ZP?\9TW_`,_7
M(72_^3.N_P#A*K_VZH24OT3Z'6O_`$SY?_58RT/\7O\`XL<+^I?_`.>RL_HG
MT.M?^F?+_P"JQEH?XO?_`!8X7]2__P`]E)+[(DF)#07.,`:DGB%7P^I=.SVN
M=@95.6UAA[J+&V`$_O>DYVU)#922224I))))3__3]522224CR+V8]+KG@EK.
M0T2=3'M;^<O/OK'5F9_U3IZ;B8.99ELS77FHXUS?T9MR+-WJ65LJ^A;7[?47
MHJ%D4-R*75.<Y@='N8=KM#N^DDI\@PNB]<JZ#UC#LZ9F-R,Q^$<=GHO.X46V
MVY'O:/39L8]O\X[W_F(>!T+KU.#U:JWI>8VS+QJZJ&^BX[GMOIO<V6RUGZ)C
MW_I%[)D4MOJ-3B6AT26Q.A#OS@Y0;B5MQ#B%SW5D%I+G%SX=_P`([W=TE/C_
M`$KH?7<=O4Q=TS,8<KIN1BT_H7&;;'4&IGMG9N])_O=[%<^IW2^L=+^LF-GY
M_3<RG&J9:'O]![X+F%K/92VRSW._D+U,XE1QSC%[PTNWRUQ:X'?ZPVN9M_.2
MQL:K#K<T/<X/<"76.G6&5-:W]WZ#?8U)3B]9ZK7EXU55&/GF,FA]H;BY+)J;
M8U]\N]*OV^FWZ'YZHV9C\*]EW1\#*8[T[&/:_%RO2W77XCWWOI]OJ/95]NR?
M;[['_P#"7_I.LR!6ZA[+'^FU[2PO#MI&[V>U_P":[W>U)]`?CNH+G!KF%F[0
MN@C;N]P<W=_924\CC]3Z_@5WN#\KJCWM=Z3+L#(KV._P'O#6M]+W?IO\+;[/
MH*>)U?KV'DFW)LRNIXSWG=0WIUU+V,VV.::'^C4U[O5]*O\`3O\`H?\`7+%U
M-6*RF@T-<\M)>9<[<X;RYY]S]WT=_L4685+,:S&:7"NP.!]QW`.&SV/^DW:U
M)3CT_6XV6MKLZ)U:ACC!N?C`M'\IS:+;KO\`P);&'FUYE;K:V6UAKMI%]5E+
MI`#I;7D,K>YGN^FFQ<&O&?8]C['FTR[>[<!!<[V_YZLI*?_4]527RJDDI^JD
ME\JI)*?JI)?*J22GZ-ZSZ'VS])SM9.WU=VW;E?1]#V[_`-S9^G_\#0+/0V9F
M[;])F_UO5VSZ]O\`/;/\+O\`H>C_`.>%\\I)*?H7&]/U+=L;H9NG?NG>SZ&_
M]'L_XKV*?2O1^WT;=V[8/]+M^C;_`*3]%_K^^OG=))3]5)+Y5224_522^54D
ME/\`_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`
M<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D
M0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`__``!$(`+@`^0,!$0`"$0$#$0'_W0`$`"#_Q`"4``$``@,``P$!````
M````````"`D&!PH$!0L#`@$!`0$!``````````````````$"`Q````8#```#
M`PH#!0@"`P```@,$!08'``$($1,)$A05(;46=K9W.'@Y"A<WMS$BTU@Z02,D
MEI?7&!HE5S75F!$!`0`!!`,!`0`#`0$```````$1(3%1`D$2,G%A@;$BD4+_
MV@`,`P$``A$#$0`_`.J7CBWKHZXKCH*SI5;+W3TFA'7%N5,SQ%G:(*8QUQ!*
M9F#:U:@<K;9%'G)4N>YDU)O/>752>2[)MKM";#4!'LEF1JXF$":Z[9Z+5=8%
MT<GM61H%KMZO]]T8W/UD-S(KII9R?3]40:5O_/B5WTV+'8B[G!SEY*J(J1:2
MN2XT`RU#FH(+,1'%Q,9QX6+<2W1,Y7:OJ*H[3L-<ZQ:E^P5565R7)%Z-.W1"
M%CK^OGIMCB0_RDNUAJF22HX)1JH:A:<,XLC1@M!+!IREFG5H.E+:N.&^H'-N
M-KRO>4R^$O\`+)9=W,-GFJ"6APL)AC<89T\SX^D)K>SMT:<W.F54E`_J52`.
MWEP2IR]*U6@^](BA<8S(UKUUUYU1RY8G8@(])+$E$64<P5#9?.SQ(8Y3LKA2
M64*.AH=25W32*.$.:6I;'T,'9[=CYZ2/R0AWVL&W*W`PTPOVR#A)+(R*7=?]
M)%45;SZTS)7%G2D_5HC?(;0_F1N,NBZQ*+=[\J*+>YNREZ:EY'O:".6,M9!.
MB4HAR.&U@.,/$JV>><))G_#;WJ(='="<[RQ^DB!!/@<K$T,1]-K<H+=?RJW^
M3[*=I'-D2>]9S3,V;E)EH5$./(R-`+),&G1"9G0TT@9^TAA8DE_7HHKZATS9
M[3L6LD<.6VF^RGM;J"DH`.;V$S0J,PUEHGD>#=)(&]"X1*F'%[W%I`T&*BRP
MN"-T=D+HM,T8K5)=$A)&-F75=ZH+M;KA0R*)\Q3'9=V1+D:8:/5R_0QLS+U$
MTW0Z.\@:"&J%NFY/"Z4W39Q#\Z&";->:X%>))`=!$:R68SJU'Q7ZB5@2&!US
M64HA\WOVWS@VM/YK($`RT;TCJ7?J'V[RY&W1N;FN*#97_=90R''N;Q[PK:S-
M-;.7H(U2U:6$0L\^&%=#=-]"5_9/K-/$1N5[CZ;BVG^1K?HE@<T;$]Q%J>9G
M7MBR^QHH]-#LA$.0L-GK8N0B&!0H$K:_/]II-1FZ!O3E9)_SHDJP^J,G<&./
M.:V@YE[XOMMOYR=F-.\I4,L)OQ3QP5UR=&D$3=FX@0(EL@>XT%W6+DX2G#_B
M3"M(=;483#U%7^K.P7))R8+7-&RZ56`UQM3+K!KM"IFC7/JZ;6.PZ@K^:QV1
MQ.7U/%G9#8<&'9*YR<&Q8!"BVW-B0TE>:%X2;`R>N'G]+O5S0SN?ABHFF_K*
M;X'UC/NO@39G9=QIKU'(]7G+ILEKIBB)IS$Y"1BB4U:MO?O1_GF+UJ@PI7HY
M![",(FUT:WJGU77Q759[S+:7"YN4"X>[(ZDD;R19H!+)6OX>OI;S[)H^6@U6
MJ!(VJ+6-9C7\A9HP1;48?I#M.H"'WO;)Z_[9Y'/5-7K[1CE?R2@TC,UNW0U*
M4$Z2)CM9PE+@V']!<FK>LJ[E+?&=U*QF/A26/-YK2](0JTYR-;[(T8W$`O9T
MR>O]>L>/5YC#;4#I;B6C9"O2*.8*DZR@S%N:MY"R15Q;5X'TJ@9I"X%QU6V0
MZ;M*DY`XF(_,<$IY:DTDI5L20XS&3U_KW78=W]&1!Z]/(A4VNU326Y.O':J+
M:K.KK"9YLFE4!)B5I.C,V-$XD;#7Z31\F(B;4ZE*-IV96@$I$D,-UH!HAB2:
MH:4IVIW?S3:3I#^V26NTGA##N*8_,(N@E$4CCC!7'IKIZZZB8INGW"8.\Q"8
M3=)$TT8"_MR)<U,AAR)0:C4;,$(:@N)9HG:[>IRTM%H6_6IM2!7"K*K.O[*;
MWQCLQHD""0&\B2&/-+_''):QQQQC3`XRYMDJ=4$A.Z.KI'U/MM[R@0K2S"@,
MIZZ9:NGGJMV)6L"8IS+N4F9$5+N6+'[&B3<EZ$TO&Z4U74>I60JR5RE-3(M-
M,\<06V>D`VB+-2%JV8?BM$G5%*`,DZY\L\7>I^:UM-IC<*4:2)+6-XN=/&,P
M;E1#22%-KE[72\>D;$4.`%3^0N;FF6HF=>SLD;>3671JAU4'[:4*M46R>KQT
M_JKLK[6LTMR%T9(9+#*=YJY]ZEO1$9-V9GF\+KJ_Z4FUW-HHE&3V=0@GZB+L
MD82(EAFW%J(-6+S?*%L"%1O&3U\9:FZE]2*018B(FH$$CJQPI[L;D".W43%]
MJ[-;YK2]Z4J\7(YLC/\`#(8-W<UHT)!J%6D0MICD4:A+.3"$!65[0D>VN'U*
MI'3[NU6^[QPF3PT'IKS#K[=8UQ:;!)*RD9R>\::BC>L;+!=:789HL?$T4GQ0
MD:POW=I-`I5$G-XC"TR[!C_;.C?5)>4]WV;S45S4\2B\*VDEMH01*`3]?)D$
MWCU55]1E@C/ACROK".G*IO)$5[(DY#.L2(D*4QO4C4.@"A)QFLGKYSHCGKU0
MK%BDT4SVYD:Q!64$NCU18NIC%2G-*XF60KB:):4-*"1LLO@>I'IY/^`&JT2Q
M$_M8#')>8)<$A``*8H8X3QMJY^NI!SF9/*<I^$)+,46!5;K`X`DO&++]=#T^
M<TQ&QYZR5K8;U%&=KADQD\8$^LR0QR;PFD%MIZY,8#9B-0"I,9U0O@7J-6@J
MF%/(HRTRY]C<P3]\2VU*\Z(:VVN;JJ>3\BPNL1J:`4.L/C#U&'-G97N<[/3/
M@4A[BY)A)_>S_>"5FUL7$U;*C'JX!D4.6/YE`@0/SC`/32D<#8?XK&*&N03#
MU(BW4$<BLGDPJR2@A+!5BQK%I<]^Z./Q)/XC+1ISO83F,GK_`%KVI?4+N2I(
MWM3<D(/L^+R[U&.S.32YQN?C)5U&Y066S)'SO6P$:6LSE,_:9BY1G463/*P]
MN6A6FIC#RU1RG1>#$O\`XM_^,7I_]<U-_P!:)A_V$RIH_]#NHW25/?31;8NJ
MP@H)RYKFMU=)47&&@MY=GEC!HMB?'986E"8Z/S$3KRT*Y1YBM&7O8"3`!WO6
MQFL&/Y)YI5('ML64K`EJ*1VLCO=Z*6LQ:T:V[F_8=I;AV>J&:H3V@7H`0[?B
MA@=!@+`$1X@@!K1<WEYA7+?/I#J[/955Q@#H_P!CLMP/ZK12S?QVUHVM;7*/
M60]$[5[3NLW8ES.D-1N:@!BQ,)*3Y9@?+!X#-?NIYCH):;7YZZJXJN/JF8OM
MA5LH7)3EJB$3N4/"B02281H]4H-.:Y(_/BP]6L6%"">H4*#AF"$(TS8AFO<1
M3GZBX-$GZ!0^GJTC<&E!+NDD<-:(3'4<6>V]^7NKH\-3DP%-^FI4S+W%]6G&
M(AE;2^VL.WHO7FC\29?A).>J3E\9;(;)JVC3S%FB9#L9"QK$I@D`;$,D)\N'
M8"DH)P/?YR*6*C77;NHV:X_$CC%7G>>8,P1<U[M_IRJI6\J)#)Z_BLA?%T>9
MHB[.SRSI')>_12..SA((_&)(I5EFFR6/,<A=E+BD1+]J4R9P/&J+`$\6S,)E
MAIG+7/!LC.EXJBA>I.?-)I8QCZ6V>4Y[GUC1-/`YW,@JBC`&%R260=(4SKE@
M=Z//:RPI1"V0'0-%S4;E/IK<_$VU&;5BJ)=7RN%ZIA'#D%>N4F@PHE&:2>?C
M3#`F8,0E+#&'""O>_,1+TCTSO"D+6N5I$BE,2-)I$,U(UDY3YJCAD-/9:+J]
M$IKLV4FP97J',QZV*?3A_42R8DL:U4E/5H$DGEJH;NN(`/1*EVW[Z,.U6M&Z
M&;R]@LYJH-RF,KL!UJ6$/$QG;C$'>;/KRRIWA3+G2O-'!KUPDA3GI4E>E=?Z
M4#^`C4%F"9MBWM'Y&\&:R%ZI2GI(\.TAD-70!\>WX"\#XZ.T28W!8[B=(>;7
MKDH<CE2(T2U8X5^>-A./,]HXQE'M"(6TN]E81CRGF?GI<]-4E<*5K)RDK(\.
M[^V25SAK&Y21,[O[>UM+TLV_KD:AW/VYM3`W)C@&G#+&G:T)>P^PB2A)+FLI
ME%15I-9M`+(E<.:'V=U4H>%=:RI<6:8\P93(D/PN1GQ=6$X`F<V1M'_!N.R?
M9VO1?\.?YA/]S"9:X#Q]RH69,%!/.E+IUE@,TYC<T<DM<Q5*[26.6<YGO-CQ
MUU=D[84Y*&">NRHQ0\(O-TE<CA[$H`9O>%S>7L$?+'.Z!Z0R-)44-)?FV60B
M>(7;X<(:]/-:UA9E<0&5@4&'#'M_B->G#8D*H6]G$-`MHPB]WWLO!FO+>.9.
M>7Z-2.&NU+5JKBLN0L;5)F'Z),Y#8],\9DKA-(ZQKDR9*2`UA8ID[K7=(A^1
M(G=%JE666%0H.,&,WEE,TIZL[&<X(\SJ'M<J=JP?BI57KF\^]*UT.E!*8Q$5
M)6!4-1YS?(2T1QA.EH-Z4^2:8#V_9,'H1&.2[F^B9Y)7>8S&K8C(I2_"@@GI
M]<F[SG%S%5SV;)JW$L/\P(CQ0.2'F.+1O?\`^/7&#4$^P:(0]ES7H0\A\MEN
MDE?$_/E0I'N8DV2FE+RA@4=0.S^GN/2;5K$.CDC0$+51-B^Z`V\A$/87`7M"
M.T,0Q[$,WEY;]RMSI*&MD9)%3T(>FB.5DY4LQ-KDU!5(FNHWDMM)=ZT2IS1B
M+!"'0AE1%J&WPVD.*1D`&#8"2M!&;R\1=R+S`[*3UCW0M6R!4IEB:=J%$DB#
M3(S3YDCB1<"(DQHWQ.X",>?H004T#/WXC,;22DP]B**+`$9O+STG*W-*!5$U
MJ2A*B(5P6!):LB2D,`C.SF.MD!.R&^"I#!-HA"BK<6(?NZ$SVTZ?9INRPA$:
M9L0S>7MC^=J+/2M",54P@E.PS>-64SA1L21`-!8$+8T<7ALQ)/0@3G[D,0B[
M:E:VI4(6S6YL2$)$^RTY)18"98&/B?DPR/$Q,?/U9"C">!.U5DQ_<=3?!RZU
M?YBFL)]@06_6_=?HB]3A$0ZJV_V?=E"X@LTP`A%@WHN;R]^LY/YI<GY3*7:C
M*R>I*LEPYZID#Y$VI[>3)F:P(8HJDOQ-U3K%@'=PBS6E;%1P1Z$K;TI*8[VR
M2BP!&;R_LCE/FE+*S9PDHFK$<M4/$\?U;ZCA;&D6KGJTF\3593DXB3I"BW%7
M/F\8RG@1X3/B(3#//]O9@]B&;R]PQ\YT+&(6T5U&Z>KI@@\>=D3_`!Z,,T39
MVUIC[\U`-+97QA3HTI.F9YCQ9WLMJI-LH]M"`&DHRM%EZ",UY2KGZC%RV(.:
M^H*W7N<`<)>[0MR7PU@6N$;=K!4%K9\ZM:Y4A-5)W.<.)(%3PH]O9SFL+`H4
MB-."$S1,L,9N.>3H[&I##V'FRCF:-2QFC4=D[2V5A#D)#^QPM1[Y"VIW,3M!
M:A>BAB[6E#.`P8M-:C6C4OE&:T+"YO+T_P#XD5HVR2+:A;7%:[J-FDX[*D5%
M0BKJPCT)F=SMTQC,[A]R.;LU11'+T$ZBLCC))VCDR\!2X/LA4`&$.]#&4J<(
M_]'OXP&`P&`P&`P&`P-=2NX*E@:M<@G%HUU#%S8V)7IR12N;1J.JV]F7*3D2
M)V7)W=S1G)&Q8L3F%%'F:"48:`00BV+6]:#T@NA:!#*WF!BO&GPSF.R2/0V0
M0P5EPO4K8I?+B3%$4BKS'=O7QALDDG3E",;T)Y(%2T`=B)`/6M[PN+PR2.VG
M6,OEDS@,3L:!RB=5R<WIK"A<=E\?>Y9`U#NGVK:B)G'&UP4O$7.<TFO-3A7$
MD".+_O`T+7RX1B3;TESJ\F/Q3/?E+.IL5FZ&LY.4VVG!EQD;LAT6C;&ROGX"
M5]-$SS=Q<BQ)R&E1HM><>'98"MBUO6%Q>&0DW)4"F:R&M4]JUN?8L18!2R5P
M$F<Q@V:QB+`-\@4ED,5`Z"?65@"?_<VL4D%)M#^3V_'"/W,MJJR8>JL(VS*^
M*@*$T9"V<&3..`AZ,XLP))A*J2B<M,J<T!PP@V$9^MZ%O6M_+O!AL'`8#`8#
M`P*<VK5]8&1<JRK(@5>&S>0IHC"RYS,(]$C)?*UH!FHXQ%P/[BWB?Y"K++$(
MI$DT:I,"'>P@WK6\#WD5ET4G3&CD\)D\>F,:<!*0M\ABKTVR%C7"1JCD*P*-
MV:5*M`I$D6IS"3-`,%Y9I8@"\!!WK09#@?B:I3D#3%'GDDF+#A)DA9IH"QJE
M`4YZL1"8`Q:$><%(E--V$/B+198A>'@'>]!^V!XB]>A:D*UT=%J1M;&U(I7N
M+BO4DHT*!"C)&H5K5JM0,M.E2)4Y8C###!!```=B%O6M;W@>JBLLBT[C;',H
M1)8_,HA)VQ(]1N5Q5Y;I#&Y"S+R@GH79C?6A2L:W9L6D#T,H].:848#>MA%O
M6\#(,!@,!@,#_]+OXP&`P&`P&`P&`P*HZ$J2Q*9O#U#VF[:OD]PQ?K&Y@6+7
M$G:FMHET=G=8O=;LL%%2LP4."X@F%ZK=M:CF_14D$WLBMM4!TA4'F"-(U&KB
MR85W=/\`,/4$RZC[JG;12\TL;G><=2^GM/K`JEL:3(_)NA:FH^J(M'IHIJ";
MN6FPY,]U?:+&G6'(0'(#I`A2CTF4@)WH2@LLQ.<)ZTX&QJ?[(]4N[5%,6O(H
M_=<DY'.HTAO@TI2EV4L@_.[9`I(`#@H9!EQ1G89<F&G7KG,L@!)`!'%`4:V4
M`TF\FK74KK"QJQ]1&,]FT]1\^=JCN*=?P,Z7KA!&I24\B?8G#5C9`>XV^+K"
M6QK"%B+?E\55[`!2L4QXP2M(`]8N4DI7DSIBL?[@Y9Z'ZTE5O2VAFF>UP\I^
M9.Q.4GJ#7'&JN8HY(DTT#&I##971$QCZAQ6E!OZ7M7L+W)P=S=$,X3M.*=F5
M>P0K$N-VLKEY0O5QY*]11*IK64RUZZ`Z!YZEU$5HEC8WV2)":[B?-46F<W`A
M"4?N+'*5$"=0;$H$F-,2,X#"O;]Z3A-+F9CHD3'@5)R%103@EJ22CRPJ4RA&
MH"`X`3`!/2*RB%:4[01?WBS0`,`+Q"(.MZWK*P_;`8#`8%9WJ0U].Y^Z^GXI
M@T,E,P)JWU$J-N:P!QEA='OZ+5G#(;:K5))4Y!;DJ@>DS<OE2`O1!>AJS_.V
M(DHP)1NRRSS^(QU!0O8596G:%A(F^8Q/GCHKU`[@N6>UE"W!J26HTTP[<^2Q
MCALU)3$.)2J.+K(OEM8W-X;&\S3Z0G]U,6A*UMT()BZ7'.&*-[+ZKRVNY&Q6
M4KMAOZ&0\DTY(^=Y;4[Y60*O5]'1VKK+;;C@O0R9:-7##7E\G$A9EAIZA,)E
M6C;R/@RL@1*@I0U7_G_#QY!5_72BT^9;P,8.J;`21JJ>SE0HX!<T0N;578$O
MI2B6^MX(7]*[2E3/(CS[#BLO/0/LA(4-YJI;[L,"EL"UE#&FKQFR/^I#,:/Z
M-3EK>@*SME'-.7[3Y$!(Y`^N;=\6::(ADAN"N+4=FIR=W9_KQYGD>?FI]1N1
M2)&I=UY1R%O;RU"=&G:G_.6UVP?:L[ET>/<6GH:M*H<.?*%>HC''=H3V`_DS
MIB_BPW]5U=>9SA-6!0;)Y8E>VCW)Y/1.B4U(W)SXZ1I;[29031.+TZ(),*PX
M1Y+KFP8ZYQ*<0>B*\BTLC+R1M,Z,3^R,"5`Z-BTGQ$'1R560(.]AV(`]:T((
MA!WK>[$[;U-#"&`P&`P/_]/OXP&`P&!6UU?15]V/<[+*:JT>W!1QFH&V*S+1
MT/\`=(._L=IRY[L-Y5.3U($TXAX!PQR0;V",-;A]+=$_"WCV4)9>]%EF&BVO
MF:]RUR10TT\[0^.FI65'6L342BK%0Z#M!*W\M)W2^%PV^?N2)<2O<J_D"@W3
M4:YNQFDRHP201LC<0&1<QI'HD'<W&_'UH7]4<CB%)N-+TO4:NU(Y8$-B=H_Q
MYM6#M,C:K=MMA5QJ;JD\?'9SC(63>W)TT!Y7?!!C6-Z<8PC,$Q;A?)#W-4]1
M*+/*[8!+7:.,CFL$6#19>U2]L2JE&RR];WH`-FF[\-?[-?)E99'@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,#_U._C`\1>-<6A6F-:9(L<RTBD;<D7K3FU
M"J7!)&)(F6N*=`ZJ$"0]1H(3#RTJD90-[$$HS>M`V$(:YZ-DSQ;C#6K_`&97
M4A<71YFT=4,"?FKHVF4C@XP!4]()B.MKAGK_`"^M[4.B3NUZ2')D!1!:TL!R
MLM42$`4XRX3IPA@,"M'UCOTP>T?N:<_G=GR79KK]1/NN?Y>P/ZF1?YD0Y4N]
M9GA#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__U>_C`\1>O1-2%:Z.2M.@
M;FU(I7N"Y6:`A*B1(R1J%2M2>9L)9*=.06(8QBWK00ZWO?R8%?=(01@:K=>Y
MM9,*DS2XOT_L=?3DJDLAH1QI=YW*IK)'J/+N>F2.V!+K3CS_`#^!&`?7DHY*
MA(<E052Y47H\DCRBU8?A#`8%:/K'?I@]H_<TY_.[/DNS77ZB?=<_R]@?U,B_
MS(ARI=ZA=Z@/(M1]$U?)I_8*NS44EIZK+1=H2I@%N6-6R0A>*/#>@GO#?!Y&
MQHI"(E>Q)Q%^^@.\L.AA#X!&/6Q+A''T>.4JP@W-'.G5#<[6N]7#<W,\.^GK
MG-;DLN;QU>=+R(M*WM6WPV4R9UC#*N.>&(C99Z5*4:03LPHL02S3`BD7M=;%
MO[R],T<:UKY(79L8F5M)VI<7=Y7I6MK0)P["'9ZUP6FD)$I.A"UK8C!A#X[U
M\N5EK`OH>@#C"R2;SITTTT82RBB[-A0S##!BT$!98`O>Q#&,6]:UK6M[WO>%
MQ>&XL(8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_UN_C`8$.:`?Z)>[-LQBAM#1V
MK;5KU_G+!*W5GKIA:!*64F:K&9C<_IJU,348I_B0P,C>^!1"WL7DCT'8C_=O
M-V6_J8V$8!);3KZ'OS9&I-*FQG>7;X7Y"95L_P`I(%^=MQ^.&/:\HDQOCA,I
MD6MMK2-P-2@=7+6TB39RC6RM!@;=U#0#L1'E+=:$<4E2IY)863V=KP&J%RKZ
M%;0'J2#419[6S.H;+C(D3BK"0WK029G$0>8%U;]J"XJ!OJH6G7MH>EUW*J@$
MJ;).G9JD5)EYK?L_00!7+&1>UN";WDDC:]C>T!FCV]Q3Z-0.!/B8F.-!K>]2
M[+U^HLZKG^7L#^ID7^9$.5+O6&]&?A[O;[FK/^Q#Y@F\1H]*S]-SB#\M%3_9
M1OR39>WU4S9]7\)M2&R&O+(BK'-X-+&\;5)HG)6Y.[,+ZVF#+-&A=&Y6`Q.K
M3#,*"+8!AWKQ#K*RH1YAX!XE=O4M]2R".?+%'+H;4L<X.=:RC"JO8^<RP1RF
M5<VH\2M=%T`T>R&A5(75G2J%8R=!V>:G+$+QV'63#=MQ-70[E8,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,#_U^^5Z96:2,SM'9$TMC_'W]L7LKZQ/2!*ZLSTS.J4
MU"YM+LV+BCT3BV.*(\9)Y!P!E'%#$`8=AWO6!5QZ>,&K2'3JU6RNZX10,J*0
MRO8(I3M,?AC*:C:D'Q.01V/V.XQ>LX.ME%L,*.0#;W8]>M=%"56@4%BV(0]N
M3K&JSGDLE4\WI;LC/5R+;.R2/H6/1!@<:ML!N88V!YZ$<%LX61V\'"LH7![.
M1SN31XMVTETZ/JUK]O9"8TLHI9LVI=ED.$0FOCD`=TV4[3DN>'1E/*X34=?R
M#:9$[FR1@CU66!8LU=/X?.J:2(&MB6VPQ6:XQF1&'H5`CV780>(P:$2(LN&N
M0<0SQ:Z.T@?K9BREYGD<:JYLG37`7YN;E->,Z"CVP!D,3'V$N,89>XIJ@7"V
MH4"5D)S)&#Q"H"SEZ<8N5>_JA<*L,?\`3BOV76-,7:5R*A^;JQKZIS8<Y3*O
M6@N*4B4_LL663]D1S)S0SM_>=V&Y'N`%>MMNM^[A*3:$3LTQ5ZW5?I7/\O8'
M]3(O\R(<K-WJ)/1G6_*?\%+VCO\`Y-\]_2#^%MGLOP+^-%<?&/C'T3?$/PGX
M9])/??B?OO\`N?(]CS?-_N>S[7R8)+F:(V^F9UARS$_3XXUC,IZ5H"-21BYV
MJ]K>X_(+DKIF>V9R21A"2K;G5J<9&F7MZY*:'83"3BP&`%KPWK6\DV7M+FZ+
M=B#R5))*E,<4H3J"BSR#R#`&DGDF@T84<2:7L0#"C`"T((@[WK>M^.LK*J3E
M']5GU;_J9Z=/])[FR>:U?F+8,K)@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_]#O
MO6I"EZ-6@/&I+(6ICTAPT2U8VK`%*2ADF#2.+<>E<$"D(![V6>0:6<4/P$`0
M1:UO05I<6/*ICD]ALTK61L!=?U7`T@`MUP2VVED6:&Y.O6N<94.#[?%KI')1
M$C#--SFM;V*,Z.<4`A^2:F/0A++6>\\U8^1OH6S[&9X*^1JNIT39#R8_2./T
M<SDRQ[F%AL<MCKY!5%7S&0S5<P/2)0\+5YDL1-3H::>C,-)]Y$J`6+=(GSA#
M`8%:/K'?I@]H_<TY_.[/DNS77ZB?=<_R]@?U,B_S(ARI=Z^27T9^(2]OOEL_
M[;OF8=YM&F\#NE]7[U>>K/3PG_--8T&WU,LC<VYIB<[>1V!$'F1.07L3T^1_
M8$2IMED?*(0^X,Q._+$4,7F;%OVO#>M:U:Y]>LN<J"H'Z^'<==7M?W1#`TT2
M.?=(MU/M=A$N$!D*F/DIJ189''(;N.MQ4Z3J6TTUOE"G:W9JA1H\S0-AT7H.
M]"F6O68D=AWHB=W7;ZA7*5@71?26#(Y?&.A)76#:5`&%PCS,*-LM;U/*T8U*
M)R?'\\USVZ359H9NC@@$5HL.@:V'8A6.?:271<;E9,#1-X=/\[\T)8ZNZ!NB
MN*<1RY0XI(PIL.4M<8)?E+.6C.="&LQS/("L-0%.!`C=`\=@T:'>_P"W6%DM
MV8147=/&]^S(FO*4Z9I>TIRI;U[J1$X//6*0/QS:U@":XKBVYO5G*!)D18]"
M,'H/@#6_EP66;Q*W"&`P&`P&`P&`P&`P&`P&`P/_T>_C`JHYEI%"\6U-PR:*
MS5.Q5]'VN.5Y(%T9M&NTZ%D(17%`@089L[H:EU-D(T$2L-0:!S-<)@8>>%,H
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M[(A#&6%8V+$R]*(PO?@87I0E,-*V,&]_+KQ\=?[<#T$MKV`SXM"3.H/$)J4V
M#/,;2I;&F61EMYBH)05)B$#PB6!2#4!(!HS9>@['H`?'Q\-8%3_H75[`4?IH
M<BSE)!X@EFRV$S8M9,4T:92)2K+,M&=)3"U4A*1!=E`!IB`%[T,[>M@`$/\`
M9K6LD:[;U<?E9,!@,!@,!@,!@,!@,!@,!@?_TN^]:B1N2-6W.*1,O;UZ8]$O
M0+2"E2-:C5%#(5)%:4\!A"E,I(,$`PL81`&`6];UO6\"L'BJ!4XZ3=ZD*2LD
M<2M^N#@GODGCZ+F-C9WQ<]$S.)/GP)THV3/]PS6`.RGWDW0;"6N7O3BA3*AG
M*'=`8>26L9Y4E5)QSK&WF,NPH4FF,YLCIA1#X.;:%7.T]0R35A0&/VVT3Z*-
M$9CLI:9-('"KVU=%TNW"0'+(VV*E2P_2D`\%V6VX1'2WNF()34YK>"2!,[.#
MA.QS!:[+6@@"E#7\7B%56E:0I++1:%YB<F1IZG<D#0E!K:IR4)U0R`#*0+!%
M%PTL3W,A*7*6=ZJE^9GV,-;;-++;ARJ-+@0BLGE)4*]NEA2M(,9<D="4EQ)]
MJVQ/HORQQ]Z"G4JO+:=O(PK^]43MBIIEZ:_34<F+@TU5*+;Y[A$UI:.2J4L9
MKG9\,N#X@\U\I8RDQH/"6*TT)=PN#,#SS$(T?M!.4$F%FBE:ZS6+PJY_E[`_
MJ9%_F1#E9N]?)+Z,_$)>WWRV?]MWS,.\VC3>!TN?N:OQ!\<_DVB/VVF66L=/
M/ZYH\C;MK]`CI."\@>COU7TA9;5+'R#U;UM+G60-4&0L[G*UB=UK/F&-)P,Z
M%_?8RT*#@+GHH8]'KDX=%!'O6]BUH(M39S[S/:17GV[ZD?HZ].6135IQ7C:X
MD<U!U;7]J].R270&MT3M;%*-,>E[=.X20)GO=[)<WR0.:YG-+3'Z;DI@$0MC
M5E;"$)DT63M/*]OTO_5H]-^UK&AW$'%_.]XT@3)/IU+F5KD$*KAB@"-8TL2V
M5214K5,5T3=\*6N:5I%HORT9H1G>SH6P!WL6K*SVZW>UT(Y6%3_H;?I3<>?4
MR9_U8G^2;-=OJK8,K)@,!@,!@,!@,!@,!@,!@,#_T^_C`KSY"WM0Z2PZ-L/N
MA[#6<;BQB]RL-[F\!7RIM?I>8(BD#-V-8J:+47HP0-(DH$C4J`ATA+TG$%,$
MI/&JR#FGJR:7+:D_K271:$LAT%=K1C2A3%),-Y4F/E4/U=,;RI5MJHPIT:V-
MY/L'0&X2M,F6C/;%I:A.F$4#1M2Q.S"-.SOG^F+,ED1G,YK:(2.70AS,=&*0
MN+"V'NP1CBLRAP$#@X#3"5NC,G9YZYB)1'C,3$JS@J0`">6`81FM>(>-J)0:
M:Q`:)<K4MRM.:I7.=DV`Z+Y&UH2JX3M\7ERQ?(U!\IBB--4,9*]Q6[.*/+:Q
M!/\`-TO=/?BY0$]4_G"G*V],7L@^.Q`E6K;*71I(ZOE2YQF;C$&:)'HVN(QR
M&.$J5.ZR*1R*M[BI*0(T(R"B/>CQ^&S#C1CEV7K;[1;;7/\`+V!_4R+_`#(A
MRI=Z^27T9^(2]OOEL_[;OF8=YM&F\#I<_<U?B#XY_)M$?MM,LM8Z>?US1Y&W
M4?Q+_IG_`%)?S+K_`)JXZR^*Q?OJY<,C:\7]NG^JS2'U,NO^D\KRS=GO\H!^
MHO\`J#]V_G)Z>_K;.,+-HAMD5]>;G/\`#W1/W-5A]B&/-N%WK<N$,!@,!@,!
M@,!@,!@,!@,#_]3O<DZU6VQJ0N*`_P!U7(&-V6HE/T;>IE[NK2H%!Z<_Z(1M
M0CD4J\DX&A?#4!Q2U=X>00,)HPBT$&^+6%XC3O-VL!\Z>XC\!CAS0ZR6O^RJ
M9CT?5:<Y`0*&1:KNN;BM/:9(F1E`."?&2&E`B3>2F,+&#:;19:QGE^8D/?4=
MZ)291,'A(I<;:1M;&]-3$SQV.;@=C1AO=BXX>ALF03F4)%1,N;@Z42MKUIM.
M(4(H\-K:@G,Y(NT6380P&!6CZQWZ8/:/W-.?SNSY+LUU^HGW7/\`+V!_4R+_
M`#(ARI=Z^27T9^(2]OOEL_[;OF8=YM&F\#I<_<U?B#XY_)M$?MM,LM8Z>?US
M1Y&W4?Q+_IG_`%)?S+K_`)JXZR^*Q?OJY<,C:\7]NG^JS2'U,NO^D\KRS=GO
M\H!^HO\`J#]V_G)Z>_K;.,+-HAMD5]>;G/\`#W1/W-5A]B&/-N%WK<N$,!@,
M!@,!@,!@,!@,!@,#_]7OXP/X,"(99@`F#)$,`@A.+T7LPH0@[UHPO1Q9I6Q@
MWOQU[01!\=?+K>ODP*X.55T_5WO8R"<.%D/XHN\]%1ME?)VVMC>E41,JTZ^<
MH\>S2!CKV!,=C@<)`X2$K>D8G!/#RF\#>'27WS8UI:LBPA@,"M'UCOTP>T?N
M:<_G=GR79KK]1/NN?Y>P/ZF1?YD0Y4N]?)+Z,_$)>WWRV?\`;=\S#O-HTW@=
M+G[FK\0?'/Y-HC]MIEEK'3S^N:/(VZC^)?\`3/\`J2_F77_-7'67Q6+]]7+A
MD;7B_MT_U6:0^IEU_P!)Y7EF[/?Y0#]1?]0?NW\Y/3W];9QA9M$-LBOKS<Y_
MA[HG[FJP^Q#'FW"[UN7"&`P&`P&`P&`P&`P&`P&!_];OXP&!`;G5K?BK[LD:
MYBEA3`Q.%Z((\C>6&3LC'5&I1<;7(5S(P2%S8&V/V:3>I:9/+-&H%C@&*$HB
MVS6RB3BO-+4^<(A1T7>,WKZQ&")5D],TKG9L9;YB52VF]OT8LAJ!W?P3>3SB
M1J5FG5J^D#<VE-$"1M0`+G*5`4^:G<6Y.X&-19$3&[LRV-N`6U+9\#F#>RM,
M>ED=E+8P1LA+>LE?V[E!<HI2/@2OBE,D5%J;U<2$`V_9CH#XHP:--6#;W+XS
M%Q$*_4-Z[M.7>FYT8QND$DEU(;,YPJ.4RN;5FTQ1)'.<9=:;<^/DXK:R=?2(
MM24W5N=&&[9>O85/I1;^06L"9L(#S"R:QT5US_+V!_4R+_,B'*S=Z^27T9^(
M2]OOEL_[;OF8=YM&F\#I<_<U?B#XY_)M$?MM,LM8Z>?US1Y&W4?Q+_IG_4E_
M,NO^:N.LOBL7[ZN7#(VO%_;I_JLTA]3+K_I/*\LW9[_*`?J+_J#]V_G)Z>_K
M;.,+-HAMD5]>;G/\/=$_<U6'V(8\VX7>MRX0P&`P&`P&`P&`P&`P&`P/_]?O
MXP/7NR54N:G-"A7C:UJQO6)4;F65H\QN5*$QA*=>63LPK1PTAH]&:#[0?:V'
MP\=?VX$5Z)Y@%2DH9WY`XU>WH&^M54`=FBKZB<JQ,G"[XG%7!EF$_7J+/FP)
M:_1P#*Y`2'J4XE8!/ZX?O/\`OC0FEMREQA'IU<>8%[BE>%S&SK'="$H*)T5M
MB)0XHPD&F'DA2KCB!J4X23C1##H`M>R(6]Z^7>\#R`-+46!,66V-X"T2T]R1
ME@1)@@2.*K:L2E>F"$O02%J@2\_9AH/`8]G&>.]^V+Q"MGUADB5)Z8':^DB9
M.FTHJ)X5GZ3DEDZ/5*'EG&>I.T6$/F*#Q_*,8O$0M_+O>\EV:Z_46!US_+V!
M_4R+_,B'*EWKY)?1GXA+V^^6S_MN^9AWFT:;P.ES]S5^(/CG\FT1^VTRRUCI
MY_7-'D;=1_$O^F?]27\RZ_YJXZR^*Q?OJY<,C:\7]NG^JS2'U,NO^D\KRS=G
MO\H!^HO^H/W;^<GI[^MLXPLVB&V17UYN<_P]T3]S58?8ACS;A=ZW+A#`8#`8
M#`8#`8#`8#`8#`__T._C`8#`8#`8%:/K'?I@]H_<TY_.[/DNS77ZB?=<_P`O
M8']3(O\`,B'*EWKY)?1GXA+V^^6S_MN^9AWFT:;P.ES]S5^(/CG\FT1^VTRR
MUCIY_7-'D;=1_$O^F?\`4E_,NO\`FKCK+XK%^^KEPR-KQ?VZ?ZK-(?4RZ_Z3
MRO+-V>_R@'ZB_P"H/W;^<GI[^MLXPLVB&V17UYN<_P`/=$_<U6'V(8\VX7>M
MRX1`7L'N:G*&99C7+1U%R54/3A#(RNL/CG3<O6-\12%N;@D-"OE[#&7IEF)K
M6N8BU7NHDAQ8A*?+%O>R]#ULLEOC12W5_K)=0RJZ;*KZ9]:^C!%H15$CK1*K
ML$]9?[<Q6Y'YE'44HDBFFW=9;BQ.YK8:4<:U+1K"`%)W<'L;",O6][F6O7^5
MT?TK?])='19?-Z%M2#6[$&J0*HJY22`2%ODK,ADB%N:G=8QJ5S:<>04YIFM\
M1J!E;W[82E)8MZ\!:RLV6;MOX0P&`P&`P&`P&`P/_]'OXP&`P&`P&!6CZQWZ
M8/:/W-.?SNSY+LUU^HGW7/\`+V!_4R+_`#(ARI=Z^27T9^(2]OOEL_[;OF8=
MYM&F\#I<_<U?B#XY_)M$?MM,LM8Z>?US1Y&W4?Q+_IG_`%)?S+K_`)JXZR^*
MQ?OJY<,C:\7]NG^JS2'U,NO^D\KRS=GO\H!^HO\`J#]V_G)Z>_K;.,+-HAMD
M5]>;G/\`#W1/W-5A]B&/-N%WK<N$4"O$'A<U]7+M8J91"+RTIOYRY(,0%R9@
M:7X"$:C5F!4#2`=4BH*89X20:'L'L[%H.O'Q\-9KKO3M;.O7"6?\":/_`/IN
MJO\`IY$?_P!/FW/-YJN;DSJYEX5I'MR5--//=G&37UJ;(H*!5E7RV.114?)K
M"K:G$D50MYKSM&PH$8EK6!,$`A$E@$<'>Q!`$6]<KO?UVWG77PB]=4X]5.:V
M8&8U>P>II7D3E%IO\FFL#%=/(!S3%*]?#WIS(AU2>2B&>WJ(ZM5I$J$;L8N+
M"W$""9[9N]#QZ]N%STYBRSBGNZVX?9?-_%W05"=4I)9=[I<((C?715C4C+7U
MZ-@4*E%M.S>[IJH]W($2U,[86W)/92D>`32MBV/81[QK-XEQ<V6(DW#ZIW:7
M54*KRT^"*FZUIB#KV*4*-+5?,G.MXL=H+]+RT+,J)?9+?,>70]"S.#2L2G[3
MHENS?.V/8-[)"`;%NT7'6:6ZO4<\>I%ZCU"(Y-;?=-6]57%7T>J5_>)="XSR
MSSE5L>KY\9Q-,D=YR5:#1>(I!)V",1ME=$^TY[$W^]`6:4"`4,@)0F.WF&.M
MTEU=,M56`VVS5];VHRHES:SV9`H?8#2W.FD^G)`VS./-TC0HG'20Y0ETN2I7
M(`#O+,&7Y@=^R(6O#>S#/<!@,!@,#__2[^,!@,!@,!@4.WUQ;VKT95-P45!Y
M3$*;8K7AI,+OZ37*@=9V1;$LW9-KOKE/*K(BDZ5F1DY8P.3(/2U:C*T)G.;V
MGW<KX+I&@C4LERW@SU/ZSK&T-;*BZ6X(VC:&Y"UI-G\^W`,[:9O3%)"-G##9
MP`C-V43KVMZ#K6]_[-8U,]>*H)F'[6CI:;RV4S1YZOI$+Q+Y&]RAU"B@LY(1
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M+VC/1%-]4\X*I]$VZ2M;63-*TL-[CXDTJ85\<<]JFY`]LJDTT+>XF;*WI0#0
M#/#>]"UKPW<)>\LQ8U3<'[9#JB[K:M&Z)EU=0Y4OMVQ9M9\K*98!/$+,7))]
M)7.5OH&E$>O6GHVP#H[&Z(*&<:,LKV0[&+>O:VP>\GAKK_U0>A/\V--?\E3?
M_&R87WG#H'A]*>LI"(E%H6S=+\&B9XA'&2+M0EM`6^>L$VL#8E:D(E9Y=ED@
M.4[2I`>8((`:$/QWH.O[,NK&>O%9%_#OUIO\RO`G_P#/=P_]T,:F>O%1?*X$
M]5(KH"SNDP].\7_Q#MF'5]!I23NDK5W'"V6M?CGT=&U-NIWI4D6C^D!_O)@U
M)H3?`'LA!X;\;+87ULDQ6SO_`!=]7K_,SPU_T'MO_N+E]NW\9QTXJ)!GI%^H
MV8QND>%U'R9[@[]P,WJ`J]ZJ&S=*-7LQ)X^F1)"C/I;[((%LN-)_;;]AVI%O
M8_!5KVM>&=<Y;SUQC'C"6_\`XN^KU_F9X:_Z#VW_`-Q<U[=OXQCIQ6K)!Z?W
MJGR6[:!OUQZ=XP#.>;U]E.->E)J2M4IA.46K`EM<R?4B;QSHQ0Y%EQ]>,271
M1Z?92CP&+8PZ]C<MMPU/69Q*]7SSZ<WJB<S4U!J+KGI[C8^%5\@7MS";)*5M
M-S?!IW%Z<WY1MP7)9NVIU!FESJ;H.PD%ZT7[.O#>]>.[+9,)?2VVRLLM+AGU
M7+>K*Q:GE?3G%1<7L^"2ZO)(8TT?:Z-U+8)K'W"-/`VQ6=/59*5P"W.9FR3!
ME&A`9X"V`6M>&WM;H2=)9<5%>_?1N]4CH>&P>M)/ZB,(AU60BDX50VZHK$F\
MH;6$RB$%TL+;'6P(&3,UD9EDN<$RDHA<N/3ZTI(1I@>6$)`-9G%Y:G;K/_E!
M%-^U*Z,1J"%:3KFH4JM*<4I2JDT/G1"A,H(&$T@\@\H\)A)Q)@=""(.]""+6
MMZWXY,+[SA<3S-Q!ZS7,C%)V)'ZA-/7F&3NR-V&[=,L=_70^L0D:/:/3=&'-
M]LA.:RM*G6_,.(+UL)AW]_?RY=4MZWPL>YKBOJ$,<Z=5?6-N\Q3^NC(FN3LK
M/2U63V$2E--1O#$:W.:]VE,RD3>H8"6(ER*-3@("<-2<0/0]!+&$59N/$3=P
MA@?_T^_C`8#`8#`8#`8$(9O1]H//7L6N)$<VN4.:&6ND;*>X)H8<1#D\?W<2
M6RVL8%\>.L%&ZRY#.VHQL5L+JE3K#B#BGD&TB!(0N+IA-["(B]8U@[6NW02,
MH:S^FC6I>5Q$HEB(Z('2RN(Z=\+.<7&N6^:2J(MK384@*2>XH).E4[=8L6(]
M6B`8>()8RQ^//E.VW7MR=&3NRWV/R9-;*J!NC2]-![J4<(^/CFB/X.!A7GJ$
M\=9HS&W%J;DA1(Q>\:3"4'#.5&J5!POA*]X0(G1H=&QR:TCXW.+<N0+V1>0E
M5(7A$K3&IU36M3+@C1*$C@08(DPL[6RA@'O0];#O>$5T1CF!UCCCS*S*:>8T
M_P!%/@ED6K9L&!!@.K9:QTI5SA\A\.T[2.,.]?UN?.7,U0ZJ&)*X*GB-)$L>
M&0-%K?EESNLC/*T>2<3L9I>CBC"MF$&"*.+T8#8-C)-!O0RC0^/B$6OE#OY=
M814DFXWO://<=U&5K6>VQV53Q778I6]-\O35X0X]DVW;ZZ0R&3R9&ZW`8Z61
M2$S9D6UT;?$CT)\9""W4\U*(9Q<:S$IN(Z&DG/-<26&OA1R5$ODL=<F5"X&Q
M(UX)TRU+6M?OJM:&`-+#"B$KS(X2J6I-)$9*I4G4!6N7_P`FK6`+J6YJ9F$,
M",'5=72ZUX="6>,[-7M3%9K))I[$"$\%6*IU#$T?E32)C1(;/8Y%72Y<RRAZ
M:W\@EY2B2&',H=!&4?Y)H"QN"J&&0Q6K:UB\N-:5$LC<`AK#)SV'1VF(Z0L\
M=;F]Z-9=*2B%&FDQR3F[3>8``_)V'V@ZWXZPC^K4;U3M6D_:D4,26,J=(=(F
MTB`.#T5'6Z:F+VI4EU%G)]/"82T-S[YONRA0(`PE$F"%L`_#V=A`"ON7KF9)
MWRI+@&-;3#JJL:R)G*J_7HVN'`C#M:L-Z,)L-XB43@<SG,'#&W&26+'T,>;-
MKU:QD;$)AAB@U4N=3U,:S->5GF5E`.Y>?'%ZD-TV*RT;6\ZE,E)KV!P5K=&>
M'K&\YD2+FV:3&TYBR/#O$$$]=B9F<EWIB='5*6X"AS9[*A'Y@U.%S_4OZJBB
M:"5?6\'1%R$E'#8%#XHD*ERUM<Y64FCT>;F@@N3N3,J7,[A(0%(]:6GI#CDQ
MJG0Q%#&#81;(BAU%SI8=FS%QE]9N@VYU=>9;EJ5P,=90MTTJ'"16)0$JC<:1
MQUT*?(RRII;'X9)F]R="VLT>PJR-+`*RB4Y)996E*=Y#M:(WY7MI.Z9$WM<7
M?WQ4RIBRJV;B([5RTOI+:>'2=!"V-N/*LA4YW>C4FHHP:F@0O=1GG$'N+>E6
M.,7.BU?*R8#`8'__U._C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8'_]7OXP&`P&`P&`P&`P&`P&`P&!4Y):L[&9T$*<XB8`PIDZ@ZOEZA
MHC;(SH[%8ZHL:][5=@.S5)IG8;Q`Y!*7NI),:9%DRMG2)$KJJ0!6^P42?K<:
MT9&H<.Y$3/*4:)HL1?I_=Z=*JMP7CJHZ01R','7%AJ;*4V1M*J0I$;W(.9'>
M-$`"`I8M.3)]^=[#L4XCRIHS:K&KKA@MRD4DP=[#E]?J:RCVK56R$VL6M*T3
M(^`2UVE;HXK&=.M,E83K*/;$`&IN;8XM;QB)/2+5;.0N1&#35K*(\Y7=7C3'
M;):1_1]^'-;%8;$C%2PR,Q^T7^J[`ODN9K9%()5(9;(&.P98Q,T9;P(#@I6]
MQ;HZ\/@&X(G10D"7%S,L+>XMW[+8Y8T8F`;-<D$HIES);R43Q4<0<F!W2L$%
M4,*$URB"EQ02^;R!:VNI+F)N,C)")X6.!6BU[+ME/`U/^6Y+FJB522V+1<F6
MIY$\S&3L_-Z>F;<)1QLHVMWB(220N,HDA\L<7MK=&%)%RE!*QS0$;$-\3^VB
M"G6Z4"3C$V:N=P>HB*O@&-AEJ:ER2/U>ID2$W^!)*U]M_4*NHNX6:$OJ<2E#
M#*Q-F@H0*..JQIDJ$E3HW2YK-;/B`PC1*CGH75!UFSM3=^G-%%31SX*!I/30
M=1&B#`V:OW6!L+=H\Z?'`)=5:((5Q:Q,HVIW[J8H&C<2UI2FIIC^IH80P&`P
)&`P&`P&`P/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g887761g51t74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g51t74.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X6@.:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@("`@/'AM
M<#I-;V1I9GE$871E/C(P,34M,#,M,3A4,3@Z,C(Z,#8K,#4Z,S`\+WAM<#I-
M;V1I9GE$871E/@H@("`@("`@("`\>&UP.D-R96%T941A=&4^,C`Q-2TP,RTQ
M.%0Q.#HR,CHP-BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@(#QX
M;7`Z365T861A=&%$871E/C(P,34M,#,M,3A4,3@Z,C(Z,#8K,#4Z,S`\+WAM
M<#I-971A9&%T841A=&4^"B`@("`@("`@(#QX;7`Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR9&8Z
M06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM9SIH
M96EG:'0^,C$V/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@("`@
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@("`@("`@
M("`@("`@("`@("`\>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
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M8FY*,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
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M>6-/1#!X5C9"-5$Q-UAB-S@P4%!E:EAL*S@K;#9*)B-X03LK:E`P8F%M3T92
M2#ED=&UM;'$V4G)),WA,.%!*:G1I<54O;5HU<S@R*U1F3D]M86M.43E8>6YQ
M-G1P-S)K:3(V0WIV-4)30S1A5#`O)B-X03M634YD,W%X<'8O:W)I<6)E961:
M.'HK5W)4>6Q(8F%K3&QR+UA.3C!V57)I94-0,5IO-VE1:55J:'=I:C5"86)2
M,4A9-'%K4"]!0W1,)B-X03M7+S!S2C9J-FHO:F(O0TIS=4,P.40V=%0Q=59/
M9E`Q+VER5VY(86YF1E=4950O35=V6#-N<GIP;W5P5'A45W5I4'`V,DEI:3E)
M0F)Q)B-X03LR33<Q<3!J13%)1S=D='%9<7A05G909FUA,#%Z.#%R4#E*,TEJ
M.'4V9F)81V=,2&%24W)"3$Y9=F1-6DA70B]H.5)!0C9P<'AR.'=Q)B-X03MN
M3VAF;7!B5VYL>E16,6QB=2\Q6F9+<V9M<E5,:4M/,U98:$-P-G=10F]6-6AN
M2D,X44M$<EA&5E=B.#=V3$5.=F0S3%=';VTR<TET)B-X03M.;G9P:$A!5FAJ
M,61683):=C,R+S)W1T,Q23DX5E)N+T%#=')Y*TQ#.74S<W(Y1S`V-G9,1SET
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M.'1V6E)8>5%8:C)6,TQ&8C9:9$Q$>6EV2G`W;#=6231(1&-E9G%213A82VM,
M4G5H>%9J,VU(.#)9)B-X03M94$Y(;'<R;#<Y5#!C6%=T,EAM2S%U5FE1*W9P
M;&]84TYP1T0X9C-H57%9,RM+;S8Y3594:GI&-2]K,&)6=DPO04]K;W)U>%,X
M<SE4)B-X03MV8FY466\W8316,7-95FU94%`V<7-J4G`X44-!:'$P2C)X5E-J
M+T\S>6HV;'1&8U%8='!.9C)T;&9A8D902$5$8W<V:$PV34)J2WES)B-X03MQ
M;FXY<C%#=$)V,#-X5E50-7`R.3$U:SAU-E1P9&LY>$9R1GAQ5G9D4W,P66%*
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M-4<U>4-.:$@V-DLW8FQ6:W`T57A62DIF>58X<E1A8G%6;%!D6'-J-FIQ<C8X
M;#979U<U=&(K4FQ:-6):,&A52EAG0GA934U65$<R)B-X03LO3'%#,3%B6#E8
M=&1B,4M(569-85<V86AC26)0:W8Q4TEW>$Y%1&)54F=J94A81E985V9Y-C!F
M5TY-=DY,=G)M-65X=3="3DY32W-.)B-X03M)255)8FQ$5TDP:UIK56QM<G5Q
M*T%X5E-V9GDS<V(S4F1!,&TT,6)52&DX=5A6=F4R9'=7=&I.2DQ::RMH-GI'
M06AG=E190W9E=4MO)B-X03MN+VQ8,VPS.4M#+S1316I5=C`Q.5<U1#!F,&@Y
M6"MR9E=+8V583&AV5&QX-6(P<FEQ=F]V:S9Z,&YZ2')E=GA8;'I09#8K,$18
M<U5X)B-X03MH.4I48E(K;$8V66II:EE55&)D:EA&571U4'EY,&UE.#@R,V)8
M.39S;FY/,VIT9%965W0K2U)X46TS5#!+=VMQ4D4U6#1I,VHQ,WA6)B-X03M#
M>F9L0C5E:W1B5T0V.69P.5<P5G9,8GEP2D-(;3`U9T(V8W8W;FIY1D(X4T)4
M:7%(;2]*4'DQ3'`K<5=$86AQ070Y6&<P>3)V04AT)B-X03LV.$Y(0VDR-&MW
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M1G0Y)B-X03M(3B]Q6#%/,S`K5%-W4%5T>5=H;'5F<F9).&]#1FM%=%!I44Q5
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M3#`V)B-X03LP,'94<'959U8T23=#6#%B95I#<TDO9DLS56UO22]:>%90-W)Y
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M3VTO;$HU93`Q9$)&<F58>4AY-4QF4V%C=VMI1&-.4UET8U%U4D5+;U-F:$EO
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M5C)+=7A6,DMU>%8R2W5X5FAV;F)Z8G(R:5@V,CEN)B-X03M"86TS;3`K-75)
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M1EEZ,5IU2SEM24E'-'AP8E8T=%`X07E,97I3.6)23D-I=$I:>F(R.#<R3F]%
M;$E53GI1:$174&DT4%!P:71Q56MF)B-X03LO3U!K84DX;6TK6&M744U6-5=&
M<T0X1$UR5DAP5E5G;S)X.$UA5S%.>B]Z:C9L-DQ0.45A13`S0U8R2S9D07EQ
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M9$56:%934G-E;4MV5&-69&ER<U9D:7)S5F1I<G-69DM';RM54'I)=5`K8VDW
M>%5T;FQ3-'9"8WIV2BLX=%<P5U=C)B-X03MH4D]#94Q21T]-;U505FA18C1P
M978V<B]!330S+VQB<4]U='$W5TUT<5AO5W-B3U%7.7)Y0S`U3$A'<7-N:CA,
M1&9&0U`K<69M3C50)B-X03MQ8DM6+T]F;#EA;C9P8TUS97)W24\P8S4T>#-1
M2&<O1GHT;D95=C`S+VY)>CAV8B]!33`R,VQP578W82MU6E5T:$IC,C1I:FIU
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M>39X)B-X03MR2WAT47I&5U!&4SDY>"MB0V<R,E5*2G`R=CA!-4U#5T]A6CE2
M.5I'<&(V,$I:=S1&>$U89C`R:&M00TM*<F17*T1B9F)Q8U9497HP)B-X03LS
M.&]B;E-,>6(Y1%AC9&=L.41:5U9S1&-T2DE9.4YK=DEN9V=$8VM23&)52C5!
M4#EL,30T<%5B5R]W1'E14&]*6C)T.4]T<&-U66]9)B-X03MF<E1O;'E),'0R
M:TM"*TEE55A+26$W,2LQ46<T<7E45&9Z63AJ5U56:G`K;'=8:VQL33AK9'1)
M<TUH1$UB:#1%-&,O:68Q8FQ7:5@O)B-X03M!0W5T0FEQ<$(K9&YL;')Q-D9X
M8EAD='`Y<W-J3F9017A8.3%'<W`U26],3',Q0EAV:E-Q:R\U,65453!Q5%99
M:F-35TU!<F-Z;4-2)B-X03M6:DMV>&MJ2C1T5U)6*TE,,$DO87AP5W9Z1#%I
M>C%J.'1:-S8P-6E)-FA:47-K<6Q(4U<S,65'0U9'53E#:VMB2V9L9U9N*TMU
M>%8R)B-X03M+=7A6,DMU>%8R2W9/9$5H,#)0.#AT96%Z=4102DQO9'$Y,G!N
M86(P-79R8WET1T9:;3E/:7%P-$-G1F$P,WA6-DYI<G-6951A<B]Z)B-X03MJ
M8C5+,4QZ;F1E84AV3"LS;75P;74R=#=E5EEW;#`W8WI.2$E&3'(X9GAG5BLQ
M-V)9<F%C;68X04UZ>6M#6C`O>')O568K-UE64T17)B-X03M):TAJ1T]-3C%1
M9GDX6%!V:7))=DMV;FYY>#5P:&MB4C=W4WIW8EAD;$E$1F-W3C`T>E%/1F1.
M.75L4$1&52MX5C)+=7A6,DMO1'I$)B-X03LO=T%C1%5V*UE79B]!2DYT:7)#
M9DDS-6=F;#%&-4,X=3)6.35K,&A*671,<V\W:3)N=F)536IP8F]'5C!:-FAL
M66)G:EDT<6]A,4HK)B-X03M1=7,V;D1Q3CER,FIM84PP9SA55W%W>%%40T-1
M>7=I-&AJ;5=/65)Y17-V3E1I<DEO9GI$+TLR06MW*UIT1&E,9F$T6#%O=&%E
M3DAX)B-X03M643%8>G`K54=R,G=T9%4X=V%$93(T64])<#<R>FM534%11T%:
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M=E`K)B-X03MC:61,+TTK47DR*W,V,4A:>78X05<W3V51>#)D>&),>55&6&MP
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M44MF;%`U=D1S.$AL53)S3#)S54=N,B]Q8617>78T,3`T5&%H4EIY)B-X03MQ
M*W(Y5FPK3TUM43`K2E)Y>%9M9FM/*S$K9CA!3S-Z5&)A>F1,95,R3VU15S%V
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M>6HK66Q2:7)03E`Q3%1T4G15=3E0=6]B>3!K+W4W:3-K5U=.=FLV)B-X03M%
M<6-64D=+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W9'9$]U=DPK=F5E6&)6
M.5-A26TT=5HY3$5T,6)/.%5M;3-X='A&26MK24U:)B-X03M:-5,X0W%X4$%N
M-6MQ>C,X>44Q<6)Y=F-7=6Q7,#`X<S5J16I7-VQ85D9L4C)5<7!74FMK4E=2
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M,$1E6#!T27A&2W-C;VI-87IQ,W)+)B-X03LX=DQL1CER.6YX=W%Z."M54%`X
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M;U)W5W-.1#,O9#<T)B-X03MQ:$<P>C@W9DPQ1S`O5DQ$>FI9;T)7,#%'4#9H
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M14)+8T8K>C`W;$MS,7=+:W5V*V)D33!+93%H=E5N2G5L=4A34T])=$=Q,C%V
M2F-V>FM.14(T471X)B-X03M7=DDK1DMK2W!%4'I7,'EQ>'EA4'%5539%;2MG
M8U=N2S%H<&)S2C5I='E62T9B,DUG4FPR-B]$=&ER>#,X*TY7,%,Q+T]V47(V
M.71H)B-X03MQ.7!A,E9L2&0V86I2=4IG8G4U67=T1U0X5%8T=49/,G=$9F%X
M4WIV.'90>70X=E,K8715.#$S2&Q.9$5S6D=T>F]E;#-I;UI9-4E1)B-X03MZ
M4S-,46\X<V-26FU!4F4S1W4Q8U506'-69&ER<U9D:7)S5F1I<G-653=I,G0W
M;49O8FE*2F]8,F5/4E$V:V4V;6]X5F@Y-RM4+VM')B-X03ME-&$W<W)"=$9V
M,DYF<FUJ>E,V9DE$-"\V3WE)9G!81E9(+T(O=T-9=6PQ3VAE8VUV66Q.57,Y
M9719-V](,DYX8B]6<'9V<FER=CA!)B-X03M&9C5L-E9583$U45A5;U90>%AM
M9S-A5$5J,G1B;U<X;C-/8U968E@X-%!)<GII,3%+-VPP1SE*<#E7,6U#5W=A
M=BMV37%X2#9(3TMS)B-X03MW=$QY,'9)1FYT2C0W:4)V<WEX37)O9FMY:VI&
M5EA&6%EQ-T9867%T:VIJ;&IA3U)1.&)G<39-059+:U5)25!52$98:W8U<2]K
M2#5D)B-X03LQ+U%B>6)Y='`Q='!8;5%H5$4X2$LR:&Y65%8T6DDT>4EV:C=-
M52LP0E4P<6-65V8X-#@O;&8U=CAJ869Q9C9F=4DP1BLV;5!426E*)B-X03M1
M:&IQ4%9-9U!%1F=A8U(W8CES5DPQ+T9867$W1EA9<3AK.'EA961A+TU63#9F
M4W)Y0T14;70T<F$U6%1P<&MU1U-:*UIM4'%X>'-I)B-X03M&5DU:6D=O1%5B
M-T%O6F(K87HV9"]G;3=H=C,T=WIZ5VE'349E56XK;'A%;W%-44I+9V)P*S!+
M:6]R6$%L069K>'`K:V%F-5AU<EA3)B-X03LW;#=M1T\X65-E<$%T<7E/3&5&
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M9$0X,5E%67%W*S<O2C-Y13@W6%=N,E5M:#-R1W8Q<E)P-6)"=V8Y5T)K:E`P
M<FEQ;79L4#AX=$M()B-X03LK-%AZ8TY1:%4Q5S`Q-C%38VME0G5B63(P;C-Q
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M<W1Y1'5O5'%.>CE'2W!N+VAV.#$O*W`R<W8K-$MV+UI8:7)V.$%$9C5R+W=$
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M.#$O*W`R<W8K-$MV+UI8:7)V.$XO;78O=T)4=%IF.7=69BMY=D95)B-X03MV
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M8GE0>FA&2'`P8VMU='I8.&-T,'5N4V],>C`S;4=S14LQ-SE85EEF5$YP5&HV
M-$5F)B-X03M#=D-M1E=39FQ6*VLO<58P3'8X05-::D5D;GE/<B]84%<K="]6
M>#EC.5`V-SAF<"MP5#=(-W5T94]"5V0T<3=&6%EQ-T98;%AM1S(X)B-X03LQ
M2EIZ26)R5G!N:#%E-FMT=456.#,Q:$)#;F]1=2MM>E=5:TU,37I"6#1M2E1U
M+W565&(X=51R4#98,4%8;C94<#968B]W1%-0,7HP)B-X03MH9697<"\X0651
M,U`W<C`O4S0O-WHO=39C8U9:+V=6,DMU>%8R2W9'.59L,4=F6$HS:FLX,'@V
M3W0K.&5Q4FE,5C%M;%%1,UI383).)B-X03MV1VEX=VDT34-);'0Y<%!I:TAF
M0W%A9FPK9DY0*TEB8CE,9G!8-BMB950Y3&DV*W4O54%V;U<S;V5J-FXK:65P
M>C4Q.5`T+W1C.3A6)B-X03ME;UE&9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
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M55)32%8Y5&953&1O)B-X03M"839M>C)X=4EO8F%'93-J9U0Y>#981#`W>5E%
M<VAC;'%L=59#1E9A3#AS=$5H.'9Y-DA&8WHO5EIR97ET6&573WIU5#9E;G=R
M1$A7)B-X03M/-70U;T-75D)Y-5)N9G!41E=1-D9O,7)O=6HR;6Q7<D\Y=EIX
M:4M*-5-'8V=E2D%69F]!04A957A62%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW
M1EA9<3=&6%EQ+R\R43T]/"]X;7!'26UG.FEM86=E/@H@("`@("`@("`@("`@
M("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z06QT/@H@("`@("`@("`\
M+WAM<#I4:'5M8FYA:6QS/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@
M("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@
M>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*
M("`@("`@("`@/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D
M8SIF;W)M870^"B`@("`@("`@(#QD8SIT:71L93X*("`@("`@("`@("`@/')D
M9CI!;'0^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F
M875L="(^9S4Q=#<T/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.D%L=#X*
M("`@("`@("`@/"]D8SIT:71L93X*("`@("`@("`@/&1C.F-R96%T;W(^"B`@
M("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\<F1F.FQI/G)R
M,3,P.#,U/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.E-E<3X*("`@("`@
M("`@/"]D8SIC<F5A=&]R/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@
M("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@
M>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B`@("`@("`@("`@('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(@H@("`@("`@("`@("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(CX*("`@("`@("`@/'AM<$U-.D1O8W5M96YT240^>&UP
M+F1I9#I#-S1$03<T1C8Y0T1%-#$Q.#8Y-T4Y1C$R.$$Y1C<X-CPO>&UP34TZ
M1&]C=6UE;G1)1#X*("`@("`@("`@/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#I#-S1$03<T1C8Y0T1%-#$Q.#8Y-T4Y1C$R.$$Y1C<X-CPO>&UP34TZ26YS
M=&%N8V5)1#X*("`@("`@("`@/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU
M=6ED.C`V-F5F,C,Q+3<S9F8M-#`Q-"UA9#-C+3`W,3,W,6(X9F9A-#PO>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@("`@("`@("`\>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B`@("`@
M("`@(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B`@("`@("`@("`@(#QS=%)E9CII;G-T86YC94E$/G5U:60Z-S`T,3-B
M.#8M-V4V,BTT9&(W+6(X.&4M-CDQ93<X,#<Q,S9E/"]S=%)E9CII;G-T86YC
M94E$/@H@("`@("`@("`@("`\<W12968Z9&]C=6UE;G1)1#YX;7`N9&ED.C1%
M,#DX031%13DX-T4S,3%!,S4U038U1#<Q-S-$,#9%/"]S=%)E9CID;V-U;65N
M=$E$/@H@("`@("`@("`@("`\<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z,#8V968R,S$M-S-F9BTT,#$T+6%D,V,M,#<Q,S<Q8CAF9F$T/"]S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^"B`@("`@("`@("`@(#QS=%)E9CIR96YD
M:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*("`@
M("`@("`@/"]X;7!-33I$97)I=F5D1G)O;3X*("`@("`@("`@/'AM<$U-.DAI
M<W1O<GD^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@("`\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@
M("`@("`@/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@
M("`@("`@("`@("`@("`\<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.C<W.3=&
M.#@P0S0X-T4S,3%!0S(V14(T-$9$039%0D,Y/"]S=$5V=#II;G-T86YC94E$
M/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z=VAE;CXR,#$T+3`Q+3(X5#`X
M.C,Q.C$W*S`U.C,P/"]S=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@("`@("`@("`@("`@("`@
M("`\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*("`@("`@("`@("`@("`@("`@
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I#-S1$03<T1C8Y0T1%-#$Q.#8Y
M-T4Y1C$R.$$Y1C<X-CPO<W1%=G0Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@
M("`@("`@/'-T179T.G=H96X^,C`Q-2TP,RTQ.%0Q.#HR,CHP-BLP-3HS,#PO
M<W1%=G0Z=VAE;CX*("`@("`@("`@("`@("`@("`@/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^
M"B`@("`@("`@("`@(#PO<F1F.E-E<3X*("`@("`@("`@/"]X;7!-33I(:7-T
M;W)Y/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0
M<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2`Q,"XP,3PO<&1F.E!R;V1U8V5R
M/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP5%!G/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O="]P9R\B"B`@("`@("`@("`@
M('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y
M<&4O1&EM96YS:6]N<R,B"B`@("`@("`@("`@('AM;&YS.G-T1FYT/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1F]N=",B"B`@("`@("`@
M("`@('AM;&YS.GAM<$<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+R(^"B`@("`@("`@(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^
M"B`@("`@("`@(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS
M93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B`@("`@("`@(#QX
M;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#X*("`@("`@("`@/'AM<%109SI-87A086=E4VEZ92!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@(#QS=$1I;3IW
M/C4Q+C`P,#`P,#PO<W1$:6TZ=SX*("`@("`@("`@("`@/'-T1&EM.F@^-C8N
M,#`P,#`P/"]S=$1I;3IH/@H@("`@("`@("`@("`\<W1$:6TZ=6YI=#Y0:6-A
M<SPO<W1$:6TZ=6YI=#X*("`@("`@("`@/"]X;7!44&<Z36%X4&%G95-I>F4^
M"B`@("`@("`@(#QX;7!44&<Z1F]N=',^"B`@("`@("`@("`@(#QR9&8Z0F%G
M/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1.86UE/D%R:6%L
M350\+W-T1FYT.F9O;G1.86UE/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z
M9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*("`@("`@("`@
M("`@("`@("`@/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&
M86-E/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4
M>7!E/"]S=$9N=#IF;VYT5'EP93X*("`@("`@("`@("`@("`@("`@/'-T1FYT
M.G9E<G-I;VY3=')I;F<^5F5R<VEO;B`U+C$P/"]S=$9N=#IV97)S:6]N4W1R
M:6YG/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z8V]M<&]S:71E/D9A;'-E
M/"]S=$9N=#IC;VUP;W-I=&4^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF
M;VYT1FEL94YA;64^87)I86Q?,"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*
M("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@
M("`\<W1&;G0Z9F]N=$YA;64^5&EM97,M0F]L9#PO<W1&;G0Z9F]N=$YA;64^
M"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT1F%M:6QY/E1I;65S/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N
M=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B`@("`@("`@("`@("`@("`@
M(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@("`@
M("`@("`@("`@("`@("`\<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,#`P/"]S
M=$9N=#IV97)S:6]N4W1R:6YG/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z
M8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B`@("`@("`@("`@
M("`@("`@(#QS=$9N=#IF;VYT1FEL94YA;64^=&EB7U]?7U\N4$9".R!T:6)?
M7U]?7RYP9FT\+W-T1FYT.F9O;G1&:6QE3F%M93X*("`@("`@("`@("`@("`@
M/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.D)A9SX*("`@("`@("`@/"]X
M;7!44&<Z1F]N=',^"B`@("`@("`@(#QX;7!44&<Z4&QA=&5.86UE<SX*("`@
M("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D^0FQA
M8VL\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q/@H@("`@("`@("`\
M+WAM<%109SI0;&%T94YA;65S/@H@("`@("`@("`\>&UP5%!G.E-W871C:$=R
M;W5P<SX*("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`\>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7`\+WAM
M<$<Z9W)O=7!.86UE/@H@("`@("`@("`@("`@("`@("`\>&UP1SIG<F]U<%1Y
M<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B`@("`@("`@("`@("`@(#PO<F1F.FQI
M/@H@("`@("`@("`@("`\+W)D9CI397$^"B`@("`@("`@(#PO>&UP5%!G.E-W
M871C:$=R;W5P<SX*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS
M.D5X=&5N<VES1F]N=%-E;G-E/2)H='1P.B\O=W=W+F5X=&5N<VES+F-O;2]M
M971A+T9O;G1396YS92\B/@H@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z
M<VQU9SX*("`@("`@("`@("`@/')D9CI"86<^"B`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y<&4@+2!4
M5#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B`@("`@("`@("`@("`@
M("`@(#Q%>'1E;G-I<T9O;G1396YS93I&86UI;'D^07)I86P\+T5X=&5N<VES
M1F]N=%-E;G-E.D9A;6EL>3X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES
M1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93XP/"]%>'1E;G-I<T9O;G1396YS
M93I/=71L:6YE1FEL95-I>F4^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I
M<T9O;G1396YS93I&;W5N9')Y/DUO;F]T>7!E(%1Y<&]G<F%P:'D\+T5X=&5N
M<VES1F]N=%-E;G-E.D9O=6YD<GD^"B`@("`@("`@("`@("`@("`@(#Q%>'1E
M;G-I<T9O;G1396YS93I697)S:6]N/C4N,3`\+T5X=&5N<VES1F]N=%-E;G-E
M.E9E<G-I;VX^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS
M93I+97)N:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN
M9T-H96-K<W5M/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N
M<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3XR-3DP.30U.#4P/"]%>'1E;G-I
M<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/@H@("`@("`@("`@
M("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^,C4Y,#DT-3@U
M,#PO17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B`@("`@("`@("`@("`@
M("`@(#Q%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93Y!<FEA;$U4
M/"]%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93X*("`@("`@("`@
M("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\17AT96YS
M:7-&;VYT4V5N<V4Z1F]N=$MI;F0^4&]S=%-C<FEP=#PO17AT96YS:7-&;VYT
M4V5N<V4Z1F]N=$MI;F0^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O
M;G1396YS93I&86UI;'D^5&EM97,\+T5X=&5N<VES1F]N=%-E;G-E.D9A;6EL
M>3X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.D]U=&QI
M;F5&:6QE4VEZ93XS.38W.3PO17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I
M;&53:7IE/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z
M1F]U;F1R>3Y,:6YO='EP92!!1SPO17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R
M>3X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.E9E<G-I
M;VX^,#`Q+C`P,#PO17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CX*("`@("`@
M("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U
M;3XP/"]%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS=6T^"B`@("`@
M("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR
M7T-H96-K<W5M/C(Y,#`V-#,Y,C4\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G13
M96YS95\Q+C)?0VAE8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I
M<T9O;G1396YS93I#:&5C:W-U;3XR.3`P-C0S.3(U/"]%>'1E;G-I<T9O;G13
M96YS93I#:&5C:W-U;3X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N
M=%-E;G-E.E!O<W138W)I<'1.86UE/E1I;65S+4)O;&0\+T5X=&5N<VES1F]N
M=%-E;G-E.E!O<W138W)I<'1.86UE/@H@("`@("`@("`@("`@("`\+W)D9CIL
M:3X*("`@("`@("`@("`@/"]R9&8Z0F%G/@H@("`@("`@("`\+T5X=&5N<VES
M1F]N=%-E;G-E.G-L=6<^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`\
M+W)D9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"CP_>'!A8VME="!E;F0](G<B/S[_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"Z`-\#`1$``A$!`Q$!_\0`
M'@`!``("`@,!``````````````@)!@<%"@(#!`'_Q``[$``!!`("`0,!!@,'
M!`$%```%`@,$!@$'``@)$1(3%!46%Q@A(EF6V`HC,3-8F.<9)"5!43="4G>X
M_\0`%P$!`0$!``````````````````$"`__$`#,1``(!`@,&!0,$`P`#````
M```!$0(A,4%1$F%Q@9'P4J&QP=$B,M(#0F+A$Z+Q<I+B_]H`#`,!``(1`Q$`
M/P#O\<`<`<`K'WIOS9TKR3=5^F(DT2H&I;YH+=N^[O9`R(L2P;-.T(M7ZJ`U
M8#LDF,_+KT"O_;SM]MKE8<@V8DTBNP<%QP')J$<&DELMYREPF7/E!!?R%]F.
MPO2?>G3BNR>PN^-C:XN](\E=\V[$UE0]-$=D&*]I'7`79FGV8HE^F1PF"FGX
M]JRP<GC8PIBV`*[@G;`Q1?UD>0-4TJI5.%*V(EN%+OGG[\SEM'=G>V5FW]X7
M:KLKL#6[E%[0]5>Q^T-^9T]"JJM8;5L6O*I2;/K>P#IJZI'*B7X\.WXQ:X=3
M?K(4B<CR8B!,<7&8A8!I17"?TU)*<5C/H;$\F?8_>75;8>ENR^N-Z3"G58UF
M[:9[*ZQ'B@I^)IEN64QKN)W$%30-5(722`T)L0T*#[=JDZP)`2IC]<$1(X<Z
M4EE(HE*3E1]6*W_QYXIF^-N;@VMJ_NKXN=-4[<E@NFH][UGM8YLIHH/UZ9F;
M4<U+HJ!<:):GK2(J@Z3&ESC%@67D-U"4!K!'Z<2F,(8@L+:D,XX^4?)$E%5K
MJ(QM>_;*Q^NODD[>[2U;M"R&[7*$';1XCMQ]^1!5NJU.0SI_=E"[%]@*.#IH
M8>6KLH>]6IE-K]1KK@"T0B[KK>LYIGY46@_;#10:=*3U6TJ>*A7]\<R<7:'L
MGO>G^"_';&I;*+5WL+$Z6Z+V^G9,`55GIKU]L52UZ4L)>0")@)]4<:,S#11<
ML=]@I'M)EJ3`C0_ACY9BND]Q*4G6D\-J((L;(\C^]^L_9_?-FO([:5ITYHKQ
M>:8[*9T)=[!J,',M>Q[3O1.J[#>XUUU^-V%)BMDJ_A,F&"GDVH&#,8@\Y7`R
M9D.:W2JE5*F(EU-2IT3S)77'RV%@6Q+-K&O]<81ZQ@>T?;#K%%?)[G=KX<@3
MZN=4`/;%^W/RX^I3\L>/NE8+RJND6V.(2J\:@M2<23T.:KZ,38M,Y4O#5[/J
M<=J[S$Q]ELP$XZ]MUXA:*5TCV+2(Q#=(1;16J=W*K?[!462C#E)AV23=*G-U
M]/$3=?:NK.VK79DE!Q*MCY+48ZP&!T1GG4L/#CVVC`!7G(&'JS1[X(ZSD5T>
MQ:<Z;;KLLPAMJ)#LE<K?;GL24ZS1Q8BOL:[GC[,=H=[%N%G&9-DK0ZS5-?UV
M"-?+I2#<%_QW:G.I8>&G:\S//(CNCM/4.[?4#1W7.[[%A-[TZ[=WBS]`HB-,
M-2#NSM2T2I%-/GD%MR#L`QC02SVIR2;CRS30<N.88C$@Y1MA460)2DZ:F\G3
M>^#F<.!H#27?SN/H;LS;]-=QFJ_MR;*NGBLZ\6AJF'`E7$ZCW5VWUQ?(=SM5
M)%P-?K<OE=,[#`0IMI@%;57H@*.R[+H[3L!Y`!+OO@5TTM32FOO>LJF,;VA:
M?V;IL'FJ!`*7O2UJZ]S2<O3.G-0;OCB@NWJV<&6VJ[2[)6SK7)$PKP"K)6D2
M+'6+)57C"Y-,.7^B%69#X/%Z&G`Y>)$$V,+XMKHI[F'N,@WSY7=G]:[;;:3M
M;J&+A6+7.L-);BO<.O\`8N(>3'HN]>X)[J/4UU.5C3T*'8K#F;!`[)4(+R*E
M#37#DL*0,"K"&S%(@J)NGBVL-*=IY\CA[[YFX6MM7[/OEEZ])<-Z7V#W+U[L
M.KA-TA2.')_32T4H-9YM"0_2(%]N`RY!K@LX,.RM:5NH4Z2(R%V-::JH]6B!
M8-BZ4X[.657.,=\N;+%&S+QY7158U]V7W<!T%9[AHSK%L2ZZ5NETB7RLB;1C
M<E=CZ2B5BNS=?3X.9\&IWFU;EQ7H5T%EK&Z"AU$E9C=:CA2P9R2[[[]B*G!3
MBIY7^/8B9V#\O!#6_9C3B9[D[75#UAM;O1UW[(4&1,0;UU<=C:FUYU]L>GK,
MYL]K6\VQ5'7\>1NT"2LEW<KP`?2V9M@<NL">$KD<C*&E1;5M4M/-)MIVF,L+
MY0;XNOD4N>F>S78NE$JB7V1D=N;QG:*KE+<VA6(&M:@8[G0+<%3:**='Z1B7
M*5`8LD6#+MS5QG6/)J%'B$ZKFH(1)KLP14REE:IX/]MXQC!.,-YR&G?+\QN@
M]KFC53K'?3&R;#6+1<=@TVIV"=;LTZLTWN>9Z:V4W5C$*@Q(EQ%@2U2NFT3,
MRT-:N;B4<)`@L?66RPCP:0=$8NW_`,[7NEQ9&VL^6+88ZI=9.P6_A12LU&PI
M\N-LM5)TL=`FJ]8J1TF-V^/7A%I$7'64>T3K"(#5+[-JA*J7ZEPBYOY;1<FL
M##*JI6A71=I7?T8ZU1OB+YI^[LIV'OS<MDZ']H=WJI3VA+;5]`[#V1INRUR_
M539T0]!AZ"@;3J.Q`4W("*U'CP;20G56=7;G48KTN;42,Y$(G5S8<C/&84I8
MWNL,XC'T>96%1?(KV,T="Z$VB^6:5V+J?93Q4V/MON&NVN?J+6L^B;1UAJS7
M%]D7>'LN7!H%4I5%VF<N\FF$8VP)\BL`"S8B56I(K#4T.5&G2OJ6$5[*=W*;
M:B,VHRON)+U[REW;:N_>M>K->:KK]<#6ONKVAZO[IE6ZS'42EC.OG5N7OJ(;
MH:RE#KL^(BP0K#7##GWM!`)40G6Y=-<0D18E7P.)LVJ<X4IKFTODDMTF\A`?
MN/>-CT%G6<B@&-?ZJT3MSZN+>0VQ*^8!;QQL"-$&P;17AD.LER%8,:X-0)AJ
MD&+O03\:1`)5BZ%&U2F(HE5,).9EM=(^<X>J+%^#(X`X!K#9&F-7[<<JTK85
M-%V$K12[Y^BV/*I8JW48W+A.C)Q:E7$))&VFHD"`M]\62EUXP->(BWWQTY<B
M$\XPH5-K!\=_'4Q63U?Z^S+3K2[RM3U!ZW:<CV>+JZP+@K^TZ.W>,/)OBP$C
M#V%1)-_0^\W?IGHN7>&G%-6I\NU^S@2[J7#B=\83PR,'KO1;J+3W*([3]"T6
MH.:M'V\3K)53BSJU^'(K8,M^??!E$P$G0$U`==)DE^1:H5?P/C'UN9^U6I6,
M)Q@);F6W.-\8PG@9+^4?K;]V3E*QJ"III]EUNUIZP55#,UNNF-6M399'[A$`
MR)B1TFKOS2):1,$N1\QIRS9_$U#Z3QA,X)>,N<3Z1O53KP'):9+B]55J`2ZZ
MB)E?T1+BX(,N:C`DH*!10+0,(G816118*U'KY<>,3'B%:W$A5PBU)!PHD!D)
M=[N^-\>.I]2>K_7QL/L2OL:CI<0+MH1-KNQQT$7B!&MU8)G+79RE2*HAK8RJ
MH%+)?;Y8"E38RS7"1N]W<K.&/SK?8GR02[7=KK=AAT71'UF^M^B[+I2/UPL.
MLZR;T1&!"JLSJ@I'?G4K%6!*CJ"5=8:1(<CNUH,F'"9$@'<+$#HL`?$APV8L
M"&RR$N9ESC.?4P^P]+NJ]NGV4I;-'T>T$KEJN-HZUSK'!DG)=AT_!^-<#6Q9
M\G*E.3:>/EM-%1P1]2H<`ZA)^&VR;Q]?P)>KQG'/7B?!#Z,]0Q\EB</Z^:V@
M$(YZY6M).$$Q$*.6O8E+1KB]VJ43CNMSYMGM]!;Q3;%89DE\P6K:G!$V:[">
M=96$O5]=\^3NCC5]`>ESOV#\W6O53V*NC6+-;0_7&GFP4?2T(N+U+$$M.N+;
M@0M=BK!81%2A1DMQ0HBQ6$5#9;'G2L:8&T]7GGKCU/6/\?G2P4&171G6[6`\
M$U7ZC5&A$,(J./;K5`NCVQZ*#;BM2$LH&4W8$B3=:M$2G#(&TR9!T6F*2?>D
M+#:>KUQ>=GY6-VV+1NI;;L^C;JLE$!F-KZR'F!.O;[,;D*L=-&6)'PV.!7IR
M7T*&1+&Q[(UA8C)0V=B,QHA9,R-%C--"2XC(P^R=3NN%ONI;8UFT]3#5Z.W#
M6FP3%IG0'7#!&[Z9:FL:DM4J5A]*G3FM6R1#%((9Q\]:S-E+$JBK?<4H67J]
M.N/4UL-\=?1H,#+UD1U;TZ,KU@J@ZBFP@^IQ(@PM3`][>V<'JT^&QEMB4!#W
M]]=J$"W4*ABRJ([L%J.B+&;9%VJM7:^.>IL;874KK=M@T;L>R]/U"\GK+5*C
M1;"7LT625GFZ?0;='V!2:X5DRI2W)PJJWR*S=0462IQ`VVX<L<;XS#[\QP26
ML&USUL_*Q@EF\??2BZ.%G;;UFU-9'CY':1@X^:K+!%\N6W:D9^+),D]*6X[-
MGWY\,((6*7(6X_-+C(!KY$%HK$U`*JI8-Y>6!F>.GG5K!"_D\Z#U<Y)VK7(=
M4V2V_4ADB!>08\"S5HD>T"GV7!9F4U68T:NY+38;I=T'%C"GISD&.RP@)=KN
MV%\.&A\I?IEU9L#45L]H^B&UQ&-K,8EEQSI(E,QO0:D-N=\N5FR'R1R=M00V
MR*OY(S+GD+4-C0X)F3+C0XK3(2]7EGIATR/BC](>ID1UE^-H:@L/,$=/EV76
MQSZ7&B?7V$Z.T7.0O$KW)DZAA/.Q]<.8SZT]"O\`P7T2L)5@-IZO//7'KGJ?
M0&Z5=3Z\2I!@+H'6HTMKB?;B-))1J^PF;7Y%^L6+A=419*E*=>A6BXIQ<30R
M8J2-G6_UM+T11Y2B&0EWN[XWQC#XX6`OI3U+"SQY(7UZU9#DB2.URHU#=5@*
MA0YF]&)$7<GP#7$+')B[,B2Y,.YC_I,CSL)YR'.BNQE?%P)>KZZ8=#,*WUKT
M13]0E-!UC6%7":;-A)M9+Z\@1GF:Z2K1"!@1,KDR-]1EU^OO!$H`?8KCV1C=
M>0W7VHJ`R$0<!+F9<XSGU,78Z:=5(]$L6LD:!U>Y1;9KP3J.PUZ55A\V.2U5
M7T*17-;.29C;\]FBUGWJ=K%4C2V`=;D*5*!P8$E67<AM/&7C..>O$XP=T:Z?
M"E#UC^N.IHZA>Q)NVH"L5$<YF/LDG3X]`+W'&7FW/D-&Z=$C@3TAWY$G8C6%
M%VYLC*GE!M/5W4/AB9)I7J7UJZYSY931>E*!JPC/J8&BSYU.!L"9,VH58@8*
M5NORWFLY7)'`I9\KD4T]E>8,:2F#'4B#%B1F`;;Q;>=WF2'X(.`.`.`.`.`.
M`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`?&1(CQ`^<6+3H
M8P6+AR2)(D0DLPH`\?"97)F3ITR2MN/$AQ([3DB3)?<;989;6ZZM*$*5@"-F
M>Y?6[Z$$43L5;HRS4^)>0)-BF7^2.)A"06TV,1#CSX]5=B?>XZ!I-J+U_7RW
MD7T^/#29(:M3FUL*>%A^<98X>YX9[G=<,*PC-[)X<5.4"PUG7.T,/9NJ2DD-
M^%OPYI?RXW0LE#DQFM)91^+;WPK>:I:X_H[D(??KPWX;S?M/M]=OU8#7"J$,
MDZ^?AIFCI;D.>-D^SWK9?C3Q1:+!+ARD"4T_`*AB\&"7#DHTH:4@PY\61&:$
M,EX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!`LOT#H16
M/7AZ=@7L>+K4,!/'1(C566ZC8=.JFPZ73MBYES`$I:B`4'L@E\X!U#M<)D*_
M5)4B`VU$/1;&-;3OOXYN8QP_LX_/CZIREI>SL^]_,G=N>TWM2/J&(WYHL%YI
M9O:N&<@LO?9+29S@K&NU255U8QB-A;BB*'B+X;6[*.7>XZ=?]HLSM7Q_=U^M
M%]ZOW_8FI;+8M$O6:T[AI9]FJV?8NTG-CW%JXD[2_6&QKDG!0.FMH(UB7'31
M98M3(P:!^&*80Z._Z255+VDG>(:P49=R7L^&W^T`ZJ\@"*YU^W\V(U)W!Q`F
M8B1VOIQ6L]S)'*B(:>U],(%GYL*^RX[STXGKR2TI;K,*:4JTTG"1-&`AS_4_
M2=%U>GS7'Y.Q_P`'(<`<`<`<`<`<`T%V:O=PUSJ*=8J%,#C;9,O6FJ4+)G@[
MQ\6+3LS<U`UN1)OA6"@5PDX.%VN;-AQ?M2&VY-8C_,[EG#B%"K'KY*3@OP^[
M3_ZE-?\`^W+_`)BX%M'U7P/P^[3_`.I37_\`MR_YBX%M'U7P>*Z!VD;2I:^R
MVO4(0G*UK7UTPE*$IQG*E*5G<>,)2G&,YSG.<8QC&<YSZ<"VCZKX/3%I/9R<
MU\\+L]K>8Q[LH^:+UY;D->Y/I[D_(UN5:/<GUQZX]?7'KCUQP+:/JO@]V*!V
MESE2<=EM>Y4CTPI..NF,Y3ZX]<>[&-Q^N/7'ZX]?3UQ^N/TX%M'U7P>7X?=I
M_P#4IK__`&Y?\Q<"VCZKX'X?=I_]2FO_`/;E_P`Q<"VCZKX/%-`[2KQ[D]EM
M>JQZYQZIZZ8SCU3G*58]<;CSCUPK&<9Q_P"LXSC/ZXX%M'U7P$T#M*KU]O9;
M7JO:K*5>WKIC/M5C_%.?3<?Z*QZX]<9_7'KP+:/JO@\OP^[3_P"I37_^W+_F
M+@6T?5?`_#[M/_J4U_\`[<O^8N!;1]5\&JMUS^U&F-;'-E_CMKFT-UF=5ER:
M^_H-X2V6A%+<"!SXF"<?;4MV`ZN$3?S'EHBR?@?2VXJ.\E*FU!9Y/!YZ*="=
M_!!P!P!P!P!P#I6?VB5?::=Y-.C`/7/5Z+V$UV7U02K52IA#6L2R!]PVJYE]
MCTK<^O#-SK@<?L`5"'ZQM0.0_%<NL<10$F6=F`F0);)0PZ._Z6SL535LN=8B
M(:<<>N!*NQ?V5WK]7.SFN=_=7NR>Q.N=?UL2KMWK]`>J$3;9,5M.EDD'JC:0
M]XN%NBN(`Q3\$*2,54]7;&X2:@3H$4^+9*M."A/\SAJI)S;2V>'RBVI/<;>W
M5920WD(U5$C4"*I,>-W7ZY!;+:]!O1D^C;9'=NLU*/;2ZVRG,J8P0+SL[$U#
M#?==>D[1#L)3$:'.$_M=]'CR>#\GHC?O67O[TV[DG]@U;K#V"HFXC^K9#+-V
M&5=XFA\<Q(DO0XY<<HL-&LV:M2);"XS%JJSAJM//J9:;+*7)CX=!TU4Q*:G4
MF#P9'`'`'`'`(L]R/_HE%_\`WIU/_P#ZKTOP58\GZ,SS;>KI>Q7@;L;=^W-0
M8$M$$+9U@>I@5D]]8J&K#IG%LI5N7(<'?393!5!7`2TF;*Q(3(RMG+(G*>OL
MT5$^/7JU"&P]^8">6_M-V1^\VW9NRHCC1<16<5BJWA$ERK2(J-F`-AO7$#:T
M"";X?9M`=KNK+Q@1-=I@1G`PDO(W4\/H2A1S6.$9Y.Z+S#DH7!"EYQS#60L,
M60E&,/QE3&,BX\1UXAAZ(AI]<IK,1#WR1DLO*?1ZM):<RK",C!5*7U'IY^&*
MI-,[A5W3,"GR*85:J&<D=?1IAZKS\=E/MUJI_B;0A!87.IMYIIFRDX0&8:A*
MIP!<NYP1P*Q4Y8U?29SQQLO-=V,BJE?UOKVARAQ7O_4K58EWC&PS5P(7C#9>
MR`7A]TCUZHS(]3W*-MQ:`-@6D'FIMP[,MN3.I=8;0')PO_$*%NW:G*$HW[U&
M./;.!1IB!6XK3ED\DA(C:\K$2ZVLGN`Q3A#ZJ1%E72QP'@;6Y9T4A$,P2PHQ
M:9DV$9F#JXW#DSFIXEQEK@DSA2HW+7?KIO,.8T[0[<`LXB9Y%`699^HQJA>G
MH.P[0]#D*((B6[$H$4L.^W9QL&JF62.`&RS4NU0E@+1;<MRF9,X'%HXL_P`=
M_.RTUTB<-9RM>J:;%%UDU7?(C-UM6+74[AMV%7B%V*5Z(3KNZHL*>$NT$99]
MMC+37:U%FJ6\-:7):C1%$2K8)ZK6F5-.Y$W;.BLM,=>]4;@U<G4E!V6FU3^\
M-/M,QE+-1(T%W;^55K)9D?8Y4^`FNV7<5R4FQ/.$0Y-4XS]LW9`ZJP8DX].B
M.O/("\86QF/?XA$@Y';SK%'&ULLO>>N'85LD5*.&S%LD*9*]UYB-$*NZ6@1%
MO3ZY$)CGL$?KK%&%0X0]N1-(/Q8T62XT)#T?0RJ5V(T)$A29[FZ=5N1HL54U
MSZ2_5::\N/B*Y-3F-%AE'Y,MQ^*TX[%9BM//2L)](S;JLXQD(>CZ&C^V-VIM
M\ZH[1+T>VUFY"HQ"E#I).J'A5A'QR#=\H\U<%^:(ES(S4Q$.="EJC..)>3&F
M17\HPU(96L$H=]'Z,FGP0<`<`<`<`<`J8[&2:7GRU>.>(SL:3(V*C6':>21U
M'F\-O0Q-+=U_.:#;&3K;ZG+HV383C)ZLJO&8;;9MJL(`IDO*KZFF!M?95;-7
M]BV?@P<>6%P#@HF$*QD3!9@?,%DH;BEI;EP"$9R),C+4VI#B4/QWG&E*;6A>
M,*SE*DJ],X`Z_75_^S]4#H;=-@;CZ3=M=Z:LW-8TR1%;(7T#K;:.M&-?2"4<
MQ(UCL"A/UFN%;M72!&`(D2SHBZ4FY0W@@F4$.BY"">2PZ5?J.I14DUNL^,R_
M2-Q-YGO3LKKHZT"\B.E%:;#MN(BL=L=,+/;1ZB&,J5AMN=<R6!V-E]<7'UK:
M2^UMZN.4`>ZI;+.WC'LPZH9V9^USN?W?#Y7W(L:K%IK-VKXBVTRQ`K=5;!!9
M)@;-6"X\_7S8V2GW1R`@R*D2QI*#(3^YF7"DO1W4_JAQ6.#)SO`'`'`(J]T7
M/IM"2R+C4ER(%VWUIL11<6)*G.0P=<[*ZC.GBCL>$S(DYAB`HZ>4(.H:7B-`
MAR9+OM:96K`J]GZ,UMM#8?CPW<X'>W0,T+MUZO-3V:^]L_58N^N@F2BHJB;0
M9RU5`JL6V15!@JG(@J83+5#BJ?PYF.SE`)M8-J<8<21UIVI/%36U(<M#>O\`
M=SXRL5/7],E=AJ\YNR5K;5]!P7Q1=7Z]?OM3+.5NFU;)\RN*AK+Y\N]/S(M!
MX\_#'.0Q=NK)QK%IWN";\OMSU@G19,*9M*N2H<R.]%EQGQYQUB1&D-J9?8>;
M6(REQIYI:FW$*QE*T*RG.,XSG@R1QC/>.>+';8398LAUDB*,,%"-VW25L#!8
M!7<5.ODV+*3-2[`R0KU?1''5^:T33)!I@"Y`MR)+%#I$467W'?>\X6R#?'59
M`%Q"N7ER%,NE/F4N;9,W#:A\\-'RK6U?\313EQD60<V41L%AN]29,T;-;-V=
M<^?9&#*3!IDB$M.>]/3ID<&<J7CK-'(91.SS@@5DI8#%GJ(F\;,9KMYE'JVF
MJM1K-F2F6<;"UP6C&:E7:Z:``*W)5(=%#8R9Y-N:+M/XMA_W-G*"JOXP09,<
M9#RPXTN(9K3`@I$N&Z&2`ING#X@VJ9&3$F_J(#M>9AM21+\1QIZ$67*.,N)-
M3ID]\27Z^>)SML_Z<EXKL:HV:S,D*M&IH&@YKK=\W<."SJU6`[U?`M&1HL["
MB'C`P*^L;'M)IJ?:?IL-8<-+4PPIL)?O@O@_+"OQX6.15WY-RCP6ZN:LAA,0
M18]E#HQUJW:Y@:LL8&Q_"OYR=;,5,)6XY$/A]B/.=KL)$OYX)"Q0C82XCNSD
M]HASQR`IM7GC+#`:>I)JN6"I-OW#<DZ%7R=5=<DAUC!L\O)'QH>)RTE"@I,7
M[*L!B+`,6"$3*#H$N,$OKPS[Y9'#`P7C*K+)2/6R(JOL'`DVLF6@ERW2*05K
MI-SYBH(CB";8^L$&)/MF&!\C+D8M.;:FD6Y,IEIU`;3Q]EWWO/FWALSK&WUW
MO&L=)6*#--6HAJN$*JX5BXF"!697"&KZ.&9C)(Q9C^50*72``Y64NH0M@0HC
M-R[.?GS9`3>^C\T_=EI_!"'-P[([1K79>FZ4A:"ED]=V8E]ER]N.'[VS)BN)
MKX(TJ8*K8S3)NCDAF7S4V#E\QN.KSH[%&V&1E"V?L>M0KD+%IGEV_;WCE]]=
MJ*YI.SBZ;*GZ>'G9X*/9U+W!V'UOI,<Z&D$"0U*`\0RY8;H6)*DBI6&G5TH?
M4GLX5'Q<$SXT^%#!*=>2;_KS)%U`]*L]:$'YH`A6)!2+]2L(3GUXI+B(RZXA
MES[2JAJPU^=%FLH;GP)0XO*0]`E1G'TQ92GX<<0Q"Z[NU)KHVJM7;8%:KUD3
M1K-LO[O3)Z5GE4*GRQ8^Q6EL/&2^1<%0")H4,0\W&4J>4G,#1R)<Y68^`B?3
MJ8!GMYUTPK#:MEPTO9B*<^F4!MB9F#*";X7-"5#4`Q*3MO)>+)&ITRIG&V%S
M([\=%,4XTM*18??KPWX;R*FZ;)6+QWE\6UVJDZ&9"V(7W#F"C,=EQI<H>[I4
M&XAEU$EEB=$>CO9=:EC)S,>:.G(DQ)T6--9?90*OMJY>I9[P9'`'`/6\RU(:
M=8?:;?8?;6R\R\A+C3S3B<H<:=;7A2'&W$*RA:%XRE:<Y2K&<9SC@'6)\PWA
MX[!;)JM(*>*0@YH*:8OY0]V"TOK[<MMT=K781"4T.74-EC:.,/#-5B;149[=
MB<L4L2'!FK1BPPR<E9HF"B)2.M%=*?UJ='";6N_UY7+`]-[-\E74_4NLZ+V@
MZSQNXL*CT6JUZR;XZG[<'VC;9E\*%A"YAR]:6WE`U03M%B>DQU231K7^P+>5
MLKSKQ=JIQ9C[T!`P]ENSV;X/#DU/"ZYDFM2^1?I_MZT,ZZ@[:BZWW`Y\;;NC
M=^@+)U^W4U+4O+2X<;6FX1--LQY3+V,M*F5>$=%.J]%Q2$AE;;JQ'2TIBVJN
MNJL3=X(.`.`.`.`.`.`.`.`.`.`.`.`.`.`5*6A%-#^22`2/H$SC=C+5Z)62
M46ITDQ)KTD#K6JCBHH];;+UJO-TJ<G,N[TO,2/4NQVM*W*7L&HPV:C#M%F.$
MMBC5]GO7CN>3=M,,\[^F)/WATR'9REX;%<MDPZ,-+K,*MDGS$6!!K"FD;+[!
M]8:%93$*4-,(^`3L2Q76L-SXJ\4O[#M<HS%"E3/>'!-K%9+CD6-`DJ0$#H4W
MAI2!0]*FL)93AM28C.,MX3'GE8Z<(SCVX2P4),X]/1J?,1[9#@R:(WIUV$[N
MFBBLFQ2JV5!4RZ5@1+B#(Q!+1*QGM?6D&<F-//QE3F:O8-=C)F`JGFHY:-.(
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MFD>MG8,]$#2YKC>,25Q*7V,L4MYS#C$`&I2VF4A%+P;3TJO_`++W2XFP-:^2
MCI_L*T1-<F=ER=&;@EYPVC2G9VK67KEM1Z7[DHS$"UK;@RK(NJL>]"T3*!/M
M@J0TK#T4@^UA2\!LO&)6JNN<8<X)W8SC.,9QG&<9QC.,XSZXSC/ZXSC./TSC
M./\`#/!D_>`.`.`.`.`.`.`.`.`.`.`4]D%D-H>1&!9M?D(ID?K*]QZGLR,G
M5?P2*HZ`I;HX'%LEN9T`;+/2F5D=H2ZL7G;SIT2<,V0%R,C9KP`N"V*-84WS
MOCKNGAD\.FQO)86#1`VJ0I2XLU>1:%;+"0F#US&4"FS$3*V-BSR<JQ$NS/5E
M+UTKL:5]93`35VLF2$61:2.:;E85JXT\*5,]OT?.W]S>T'1)>M-1TZF3+@6O
M?V4P5D0+&;E/3B+@0V>*GJ\&7.?/6=<Z-5@1,=5A\Q!V?'E#PT5^(IB*XS&9
M&7<W!P!P"F[L0"'H\T/CTLR1#R"DG0W90$\>_".)%CR!\&JV0A&$8WQAC$XZ
M]$D$)4S.HUR5Q*FW-3<FF&GKHZXZ-I_14MZ>/M[ER/!@<`_,9QGU],XSZ9],
M^F?7TS_\9_\`C/ZX_3@'[P!P!P!P!P!P#7^R]3ZMW/5Y=(V_K>A[4IL_U^MJ
MFQ:B`NE<E9RA2/>\%L<`B.6YA"U80[F/\B/7/L4G/`F+JS((Y\:M;UCG,[IA
MV([#=-)+&<NPZ-2KGC;77A;V?VK:D=>M[,;!I`$<ZS[6'(NK'M8RD(;95$(Q
M76DN<&MJ<4JIU4/JH<\9/S\2?)KHG]FR]"Z:[KTN'Z)<N_5VU?@1NG,&-_FS
MI^@=[6$GKHT1?C_WZF*SV0'+D2D.QQ]?1AZ,S@(I>#=/&ZZI3_KS,QH?DUZC
M6BRP->WZZGNLNV2*_AC:D[:TRP]<[K.E^J<8B5M[9,,/3[^MSWI5'D:VMEQ@
M2D9PY%EO(_=P'2^.^F_IAS)]-.M/M-OL.-O,O-H=9>:6EQIUIQ.%MN-N(SE"
MVUHSA2%ISE*DYPI.<XSC/!D]G`'`'`'`'`'`'`'`*Z];ZVK.I.T-G;`;_N)8
MW;CMGF676D/340O7QT.][%VGOR'5[+LVNTY^+7)8TUM^Q%`WWHLL$TNNSPWO
M:6T68E$AIN:<.<\%AR@VKV9(5<&:I*G9&^U7:UL%QH<3I;8H&FI)`JREHB;6
M6C;,O-.U7AZ,HW%0U,0ZG8LAB0O(!UP2'+/#!%RY_P!7]B35.!CZY6`P<7]N
MX@Q8F'&?O-9"]O/^Z8XN<_\`:UE.F;"5,3?J)+ORRY)LGC.?[N/*7%0QZ"&2
M\`<`JE[((%-^53QRS%;+).E4Z][7HD:D=-5C[##"FM;/.L[+;`H%(N$8E8)*
MI59E&IQUZL28=7BPQHJ(4A%IDP:7VU<K\^AP%:\V73:W8N=KKP;L&2Z_ZZOL
M+7-Z[;,Z4L'Y9ZJ?*_8^!$PM>\RL&FJP2S8J\XW;&JF]7H(^P`3I@@-KQL46
MF)_O<'0UC$XQ*GO=CS.7V5W(WOV>UU?J/X]>N>VK!/N5*M-;J7;3=3<WJ_HJ
MEF+`#G"0>P*:K8-=G[JVFNM$I+9P6JE:8E5,RZ.9:;NT6/)3,0*DE#J:QNE=
M_"YOD0AZN=1^TE=V=K<WU1T>4\:)&F:%.4?MM=NPHZN=D:EVKW1+*Z^>!%A=
M%UUV5%$=A&*U+";"L2NS%MLM2M1,?=D5E0(NU/(Q:\*W3>7MW^F&TTKZJV5K
MZVSLH^XOEC'?MB]F>@EF0G_!1KIIOVNON>G_`.2P_=HJPWZ_^\IC.>F<_IC.
M,>F1GZ=*O_9?B0>[-C^X+&U=6I[[E-G6SJ=BB;,^)?BHJG;RH61&_,DJ+^'2
M]W#-2WJY;UD5K[O)NF=?NULHC7<>]9C8V.TO/W;>P*HAQ&U_/9B-TJ)UF^F9
MM_J_VN[L:9T%J\1V\Z-=L[W)@5O#?XRZZ(Z@W/L(G7E3IDBG2-SZB`76N[7#
M[0BTIP%!V"Q5*;??K+E$+RLR<2IKD9@*E2V]FI<+KHW;JU8E=0?)AT<OQ^/3
M,]@:MK78<GT0C6&_QUEZX[/5*]V&W84>@;W"Z\M)&4P[ZM.)%#)[><I4MIUU
MGT=R)LU8Q*U5UU4HG-'D1Y;#,J*^S)C26FWX\B.ZAYA]AU.%M/,O-J4VZTXA
M25MN(4I"TYPI.<XSC/!D]W`'`'`'`,/O>O*!M*M3Z7LVC4_8M/*I]A2J7NLA
M;=6B*/:I/LG@C\(@+EI]JUI])$5S'HI6/\,YX!`1WQDZWUXZX3Z=;FWYTB*I
M<5*CUO2UYQ9M$/S,JRI."'6O<4+8FF8D!6%9:>8H]8HL]3/IB.6BN)P[@:VM
M4JN./50^LGA]\/*#HC]EQU9H?O92HGJC[RZ//N]8-^*B-?OS+F:EVR;MVFK2
M26SA25X$;SUXQ(D8Q](%82M+/`^AX-T\?J750UT9D=2\GW5&=8!U&W"<NO43
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MDR7FH\>.TX^^^^XAIEAEI&7'7GG7,I0VTVA*EN.+4E"$)RI6<8QG/`-/*[%Z
M!0U!?5NG5N&2=&%[,&._?JMY;(Z].,L20ET@*P1SB96S,>5&?$EHV789)F0P
MY"=?0ZC*@AZ;N>AUB?[3%:ZPD'X_-K5'8H6G5ZZ6O9(&V[DJ:L$IAG1)<)2I
MU@'0"]?6ERXUYT.4*FH%*E%ONW=7G9%9>C%?O,X&,#M^DON34Q$+?,=_)S7C
MTZ3US91[>76'KEW=VUN_Q/1V-"[(-/R-:TB(G8^RF9"QY7KP,W:]4@LXM60F
MNM0:7E;2(:[#B'E1;!]TY3E:L1,].GB5U8-TI5WUPUB7J^X1VPN#D.`.`.`.
M`85?=:ZZVH`?JFSZ#2MD5>5[OJJW?:J"N`"3[DY0KYP]A@$1SWN1G*%?)'5Z
MISE.?TSZ<"8P(,R/%IU:KS[Q'K^[N7IX9==<>^HZF;JOVH*OA;B\N9P_IZ.5
M+Z&(M)>S\J6"^JR#&%8PG+>6_5&1K:></BDWUQ\ST_@UY*=5?NU?W"T_V0"L
M_P!VQ5>W>BF*?<'(S?\`D(_&KK//I09B3[<)9>FD.O5@<=_=)<0X_G/N":7^
MV.#MT<^J/W\XG:O6?]WV*\=VX,0&<?'(OG46_P!%[4T]3C7^9*^Z,I>G]^IC
M/(PIYF.-TP>DH]R8V<O.X]Z@A95+FFOE>9FU`\E_1S8!^/3$]@ZIKG84CT0C
M6&^X-CZY[05)]WQN0V-?;V"Z]M<^2P[[FG$C!4YO*DJ6TZXUZ.9!TU)3$K57
M752B<D>0Q*89E17F9,:0TV_'D1W$/,/LNIPMIYEUM2FW6G$*PMMQ"E(6G.%)
MSG&<9X,GNX`X`X!CEMIU1OU?(U.]5:N76JF&<QBU:MH,98Z^4CY_Q8(AC$68
M.G,Y_P#;4F,ZC/\`[3P"OR9XP-*TN5).=2=A;NZ,6)U]V=B'UJOBH&H)1!3F
M7VG#'6K88^^]>9<5+ZE_.V+UL#(/L//L-E8V5H=;&MIO&*N*OU45>92CV7W)
M_:*-(^2#1NI-9C2':'KO'D4AURVTOKG5M;ZDVY5"$Q$F_HW9?I#E\'Z@O`9I
M1&O?:D&\4T7\(D#:*Y2$*/2`Y0=$OTG0V[57Q=T\H5I7)O>=M)&5*0E2T^Q>
M4IRI'KA7L5G&,J3[L?HKVY]<>N/TSZ>N/TX.)Y<`<`<`J)+A`%]\B<&ZIKNU
M`$#7]I8JTF8?USM033KI;\T^OH^\0>YS^I)`1#%#':T$!!(T/M!5JQ8%P31:
M`!>`[*)KV4-?MQWY:\?;TMLCR(UY%D9U=`;LFRZG*^EO$M!S65?WH5FQ6Q!"
M@&I#5C)]:I:=M@:\7&CRM6>(J%&*+!<LF31B.U<0VOU.!3R\O>W>DE@])RI5
M,J*E&LV52JP!RJQ*8D15'U9%1,Y-9C2WI$J/DKG_`+[+$F0_(9R_\;SSKB5+
M4,G-$AHXR.GB#$"$5$E84H:4%DHK$X<2'3F%QIL"?"E-NQID*9&==CRHLAIQ
MB0PXMIUM;:U)R!6RKQ\FXX#5%9&;A$M"M1V?KSMH&J9K>=(G$MU==-54[4-<
M($WX^PX;*-5'Z[3(,\SK^'&9L+!N7+EP-AMLKQ&P-;6-L97)N>N_R.NEWXQU
M/ZW^4`90?)",WIO?J]`Z2E=IUFIQMA6P-J^%V/O^SK&O8=ZU/J<AN*O1Z^%(
MUT*Y6TUNC'2$D`<0/L-FAE)F95[ACI3M.GZ;/:C?"5E*5\\>5E;L[>,R9L\E
MT,ZQE=P/6]VZ&=<LG&D;"D29FP8-'-&2Q750B_3YS;<\E>`FK9E-$6XH13]H
ME+#!)$""W)DE]Q0YU6J:66F&^.9.K@R.`.`.`.`.`.`.`.`83?M::XVL`?JF
MT=?TG9-7E>[ZFMWZJ`KB`D>].4*^</8H!$<[[D9RA7R1E>J<Y3GUQGTX$Q=6
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MJ1'D-H>8?8<0ZR\RZG"VW676\J0XVXA6%H<0I25ISA2<YQG&>#)[>`.`.`.`
M.`.`4Y3*G3%^1#-AIFI68Q]O:@Q\[>6>M%A'0(SK6LH\6[2R]T(]6IC9VPF9
M$X1*&;<#]CJR`CP94(>AE;T`L#VZ-98\IWRK3Y1ZVSOR3U2D39VF+-8*'0+N
M1CNVD%*@&JZV[=70A.?41PV4'ML+K1V5.CZX-N)H$'(UU@)6H1ZQ72K^TS)*
M1H`0L%.>.6=K3_*GN2S&HS8)*J5@B,D1I8V?7@LT?*AO9DPY,&4-C/Q)$60J
M",5(C/,.-N,/9&C\NM*2O,&)E7T[8R9#P!P#K!^58SU[@^8?QD6G;9[7#U?T
MX)L5JWBBPZGMYAK5=`L([9HW5EXVMMI^:5U:#U_8-JL115:KYBM!355LPR7=
M3EI>KY8,@,.M,_XZXM,1=7:B4ECAC>(R.STA:'4(=:6EQMQ*5MN(5A:%H7C"
MD+0M.<I4E2<X4E2<YPK&<9QG.,\'(\N`.`.`.`.`.`.`.`.`.`.`.`.`8/?]
M8ZVVP`?JFT]>T?957D^[ZBMW^I@;B!?]Z<H7\P>Q0"(]WW(SE*O?'5ZIS[<_
MI^G`F,"#;_BUZOUQYV?U]F[KZ=EG'5O8=ZG[LONJ*GA:U9<]'=-9)GM"3VD.
MY^5#)354YG"L>W*,M^K>1K:;QA\4F^N/F>K\'O);JK]VLNWFE^RH5G^[9J_;
M;1B:+<W([?\`DH_&GK00J@!F2I&$LOS)W74VMS]TE:%O*5C(32\FN#]G\E<N
MSO(IW*J#O9G85[V%UIT-L+J/M#6^M8WCR@,.;=N?9]FU`-<GF#%+VN<QK#8\
MR=NAR_3J_H5=(U&R-&'ZP[`M\&U/,'4#QK95DI<J=K",<5@HB7+P9V.4*]Z$
MK]JD^Y*5>U>/:M/NQC/M4G_[58]?16/_`%GUQP<SRX`X`X!4/LBB%+]WWE?=
MERS5>36[3K@@1V.&I.+64!%1^KER&A(J]_DVV@`I==)!C4>,=U]:NT6MGIBR
M!(XNFP`>Q42=FC7[>]>*GH_C;?D,JC-_%:OI.=45_?,PTYL18W5-B&#FV$34
M5J&-:VJ.M12NV"*.-:NR8^<75\Y&+MDFQ)F()0U5?$R*%.=XWX\H[PC,L!K,
M>=$K=>BE)2YI.,#$QR,QP?$$N2YS,".W+E+%CW7X`U;\A+CJA\)YZ)#RO,>,
MZXRVA>1DYS@#@%$W=+3VWL=P#&D])[5UC5:]Y9=2VS6F^L;&UM.OULU@)T'J
M8I7B%UU5D;>:M!EOW/6]LFUJ'7+P(,U@)<0[=K:=F-DSH&4-TM1+_9=1G+S_
M`*_LNSI53%T.FU*C!%3%A:960-3$+(2<S)ZQ==%10X]4Z6I*%2IBHD-K,F3E
M"<OO96[E*<J],#!DW`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`,`,ZGU98KK7M
ME6#6M`.[&J4=<6J7\S3:Z4NM8BNJ=6Y&KUJFCGSH6.XM]]2V1L^,VM3SJE)S
MEQ><A.61G_`'`'`'`*F;C7C!KO5K/=%8L5?51RVS3>H94^%7*U%&E+%KBHI@
M%*W8+:;U5.LLJS@S8S;X&.Y6ME1!$^P0:;2P\-DG7]J_&-91G9^>DZ1EKE!G
M/?ZHB-P0<4S%/#;.>TY22>X;A23+%L"J#CK-@S7:)>0EMJVI-MDSQP,0IUY?
M;T\)`N??Z#!ER+#ER(&#@+4"<;IM-N:ORN6"TA;3M+J#K!8<?8<JX!;)T/!C
MC!!II8F(ILL+&Q%+BCQQ)&<3(,&,I4>)&>:895EMM.<C)E'`,?.6VJU=N0]9
M;-7ZZS#"E;)+=.&1PEN+702X+9P](7/DQTL!0SA08V5*.93!'+(P4RWV52X^
M'`*U]^A*`6\CGC)VN`$4\G8K-3^V(-C90>`%FFK!08^GX-CK@=FXPFG)Q6GL
M3SY0\$'H(OA6Y9J>4@LI>)2'WAI?;4N%N9:1P9'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`(XC>M%7&W6/9<7?94RJ#KX?VF$T_--@G-9A=E6<F
M;.F[?'0S66+X2=DV.R'K+"K-BO9NB@K"0;,5^J"IHH&Z+%G_`*<[LOKKK#;)
MK-@MK%VBE)->9J!IVD[5VCK1FV5*-**SH=9NL/75QJT.XA8$L\>>&PK(P22-
M38+%&@*C0[$=CD03:[3]3=$.'$'1(H^!%CP8,&,Q#A0HC+<:)$B1FDLQHL6.
MRE#3$>.RA#3++2$MM-H2A"4I3C&!#Z>`1"WWUF<VAL.J[4JZZD)MU4J480](
M*#7&9MOD57L%UUWY2:X>L0^)*)1Z@W.TM9:_)SF,76"_$$@;%!I[WU\`@*G%
MN\&O?R*@44/86G/-;T/UF=VK9K;52G7/L;M)6OY$P:[K[7M_MH^\P[-$U:/^
MUV+&*J+D87!C1(INI_O<C/36;3(5,<JM7&\:*G$0TO\`MK]>1V.^#F.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`4T]A_L[_K3^/7"
M3`19;\`>R7RU]!/8JK'''?=BS?`8D!I!A>I6`DR3]1"B$Q0"/L65/@38M@,3
M*U#K,*"-K[*N*[U\RY;@P.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
M`.`.`.`.`.`.`5>]D!5I3Y.?&V;<M;#M)>JO;@5"HV*]%;DPK3&U6Q+)VM5L
MQ-S-E,%!,L2'17ECFXL!P0X2;FO.DG6&!I?;5R]2T+@R.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`5<]BZ;35>33QK[0AA1:[H7J/
M;6FR+<PG"R$^FBM41["&"YEH6IMX7$+'RY.(E.,XP^2DN)7E+OIP:7VU<O4M
M&X,C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&-W"L"[
MI5;#4C<1N>(L8>>&)0'WI+$:=#GQUQY$.8J(XV\N#*;6IB;'PK+4J(X]%D-O
M1WG6E@4H;9Z/;J?[">/Y<3OS=]0.:\UG;*.U3JO.ZP-3:B7"Z#I=!+R>O0+:
M&A3]QV'$NQD)+)7M5X5=)->'D<3`4>I1EQ(4,;VE%7TIR\?JUSBI<H)=_DI[
M)_Q5>[7\@]#OZ..";2\%/6O\A^2GLG_%5[M?R#T._HXX&TO!3UK_`"'Y*>R?
M\57NU_(/0[^CC@;2\%/6O\A^2GLG_%5[M?R#T._HXX&TO!3UK_(T1V*Z[=J=
M;ZPM6:#Y=.P$'>MAJ]H'=?*IN$?T!J=6V%M]`=_-)J,E;O5`*4(PRMD?#P"<
M<%,;)HBSL98>CN.-.X%34J:%&<;>&?[C8]&ZP[JOX%HW4_,%VLN45EY0PH4I
M('Q^64''/1&6%%!B"`OJ'-91(AN/H]\5Y[$MEIUE3[:<N)SD25X*?]_R,P_)
M3V3_`(JO=K^0>AW]''`VEX*>M?Y#\E/9/^*KW:_D'H=_1QP-I>"GK7^0_)3V
M3_BJ]VOY!Z'?T<<#:7@IZU_D<:5ZA;[`QF9ISRU]R`T.02#A8\LK4.@@Z,^8
ML1:$!KXEE^9T]9:=)'#I(<%#P$+5*)EI\(=":?F2F&7`E>"G_?\`(CCK34G8
MF5,V7$VYYF=M!'!_8:QZGU>Q4I?CRD2B@AN*)Q4:U;F9_5J6N)N><0^\#!:E
MPT0YR&XD3Z<*VO+JG!6U:*%A+^_\L"4'Y*>R?\57NU_(/0[^CC@FTO!3UK_(
M?DI[)_Q5>[7\@]#OZ..!M+P4]:_R'Y*>R?\`%5[M?R#T._HXX&TO!3UK_(?D
MI[)_Q5>[7\@]#OZ..!M+P4]:_P`B,%IU'V*%;KU/71OF7VVSJ.QZ]W@>OA`_
M*\><+8J;112E+CTU-"$_E98C%JI$@C]W+V>2=&SL5R531C3DX3E@JU(%E0_H
M4RO'$.?Y:Q',D)7.IV\+@$@66H^73M_::X5;6\+/URK=`#80DRT\[&<=@%1G
M4"5!F-MR&7F%KCON)0\TZTK.%MJ3@25X*?\`?\CF_P`E/9/^*KW:_D'H=_1Q
MP-I>"GK7^0_)3V3_`(JO=K^0>AW]''`VEX*>M?Y#\E/9/^*KW:_D'H=_1QP-
MI>"GK7^1&O?&J.Q.O:/M!W5OF*VH1W;K80&-HHNYI/CZKE1'O$"U?:'L[/\`
MHNKX`]60)V.;@Q84QX@%7-E&`[,.;A9&+ET5-6FBSTVIY35!;Z!V#0K29-5R
ML7>H6.PUR,)F6$"!LH8N9`PS\3!`%*-"Q\V1.%QC4!29HE^<PPT2B*Q)AJ>9
MSA?!@R_@#@#@#@#@$6=J:`.W[:@2Z#;(('5^6K2'WQA$!TV4=C(Z^[E?W=4<
MTN4Q+9A156X[+?K-WP397A0!J!)@9=EP_IGA4[=8YJ&2FX(.`.`.`15[&:`L
MFYCFNC-6MV*&2J;)X/*MHLWL4%<@X2RVK65D,YK2JA<@=5/-DHFN?L0E5]BU
MFS@9[I,656ZT,!':E?!4X[X]V@Y'J[HVP:+J)T)9SX$\5,3:0A+E8%30H6.,
MU[IO66FA+J(,Z9-=20-P=;-60@VES+(C)ABKQY):-7F3I4&Y\_5OW),\$'`'
M`-/[JU*,W!7:D(FM!L3:;M_2VV01(N'CEW!!+5.TJI>93H;+N,.BC)FOA3=4
MCF(;K3\.-89B7,OPGI<20*G'1KJ03>Z`WIPT1)IV34L,SM!E.H^&UUTTJ2UI
M4O<C%Q?V*F1@OC&-Z1G"N![#V$?=M<EB0<6^AV?]FPQ=KUVN?QGY;RTS@R.`
M.`>F3&CS([\26PS*B2F78TF-(:0]'D1WT*:>8?9<2IMUEYM2FW6G$J0XA2D*
M3E.<XX!6';/'Y82(IZLT>_5[786;7;W6Y4RMQ]AC$YK9F[]B;E5]>EM=BKZ.
MU/;=>P7-Y#X<B"4J,$R&C5@V@,4?D66JSM9#6UNGCP2TG+TTO.C2E`,:XI,D
M+82`TB>-WO:.PC*@C4ID)!([0V3:MB2`PC$Y69<B$$59OLG!.0U#>./PWSCP
MT6Z26-BC+OY>2@VUP!P!P"!5XZR[7MN[".WLGM7YS4#PDWI,0L78!T0+$Q.I
M4Z[B+Q$%I0V?+;$EUELF6O#LDA-!S*EJ^.!`1XE?LOWN%3R[S[C.7?"/IZJ=
M03?7!RA")MY%6RM:FUQ?:!39<4'-$V.Q9VM:-=76W%+I\Y0C!1]WS6NHPNDQ
M1KC^6:X7?BD)'SP&ERA6YG>_10O>2=G!D<`<`<`<`<`<`<`<`<`<`<`<`<`U
M?N^981^E]O$*DLDU:X.K[_,K+@=MYXNW88U4+/!5BFHZ''W22"2(RH+;+;CR
MY6&DMH4O*4Y%6*XHK1QN[N?1K\'3?X]1J=7L.I>M(\G>4UC;6Y]?:W=+B^UY
MZY7BT5B#$U67DW6P62E:EUJ:A1;%'AA';M5"Y*3(PB*+("VCKHGEQWGNF=W.
MUDFOQ1,/2<"M;;(,4XB[5[!J3<!<;50UJZQ:.V*_/..QC5>;FJ#[SO.SM?+B
MI,!IDR)KXE7<18UCK%G+<"%*OSE:OV1)7KON_>%OWEM[4NV!8&8-H<66H#;J
M1JJ[TNN2EB+%]@+P=+WB]%RD,]9HKC5B!UMNHHKTP*U.-4G96R*XT@Q@1I1*
M[S\L_1$X^"#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
5#@#@#@#@#@#@#@#@#@#@#@#@'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g887761g57v19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g57v19.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X5:,:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+VUM+R(*("`@('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(@H@("`@>&UL;G,Z
M<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*("`@('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(*("`@('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W0O<&<O(@H@("`@>&UL;G,Z<W1$:6T](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*("`@('AM
M;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O
M1F]N=",B"B`@("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O9R\B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!X;7`Z36]D
M:69Y1&%T93TB,C`Q-2TP,RTS,%0Q,3HP-CHT,BLP-3HS,"(*("`@>&UP.D-R
M96%T941A=&4](C(P,34M,#,M,S!4,3$Z,#8Z-#(K,#4Z,S`B"B`@('AM<#I-
M971A9&%T841A=&4](C(P,34M,#,M,S!4,3$Z,#8Z-#(K,#4Z,S`B"B`@('AM
M<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*2(*("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X
M;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.D4Q,$9&0C(R.41$-D4T,3$Y.#-#
M.3A!1#%",S<X,41$(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D4Q
M,$9&0C(R.41$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240](G5U:60Z-3EC.65A8F(M8S@S-RTT,6(Y+6)B-F$M
M.#ED-S!D,3!E965A(@H@("!X;7!-33I296YD:71I;VY#;&%S<STB9&5F875L
M="(*("`@<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2`Q,"XP,2(*
M("`@>&UP5%!G.DY086=E<STB,2(*("`@>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD](D9A;'-E(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#TB5')U92(^"B`@(#QX;7`Z5&AU;6)N86EL<SX*("`@(#QR9&8Z06QT/@H@
M("`@(#QR9&8Z;&D*("`@("`@>&UP1TEM9SIW:61T:#TB,C4V(@H@("`@("!X
M;7!'26UG.FAE:6=H=#TB.38B"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'
M(@H@("`@("!X;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!
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M,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
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M04UT8U`O27AF-C1Q-SE*-F(O>3%W+SA!27AF-C1Q-SE*-F(O04UT8U`O27AF
M-C1Q-SE*-F(O>3%W+SA!27AF-C1Q:W9N5#$Y)B-X03M5.'%A<'`R:6%R1%IA
M=&113DA:6&8Q;&]04VQ0,E@Y4TQL2710.&M9<7A585`K63%Q:VQP62MD3%DR
M:7IE<&)81G<P33`V>&TR:U!P)B-X03M/6EE:4S8O6$=4<2],,%)137)B:W%S
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M>5EZ1&I*53`O8D).9FUF131Q9W14;'-03'1R1DYA5V%*8E=K36]J=&]G23%!
M;&YH1$)A06=B=%AP:7%F-'%X)B-X03M,>E4O-6E*<E9U+VQS5WIA6DAB3S%Z
M2&-Q2#E39&TT>'%Q:&\S*T=O8R]V1D9!4G54<W%X9RMC=GIK+U0V84\R9S(P
M4FU"84LU3G9*)B-X03M*0TDK9D8S9#!U=4-I23!O1TE-;TY117!1;%A*-6\O
M4&]Y,GE3958W0D))-49Y>5`V:7AR.5E#:F,S161A43$S<%%N-'1G3TI65$A2
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M;G)L854O-6)99C0T;U)'<2MH6%=Z.%=X,5DQ,G%$-DYV>7`O)B-X03M$1E5Z
M;#AY,S)N-G1D4FAZ3D,K;S-A3DA)4S%)-V941751:UI**T%C,2]%-'!484QZ
M9D,U:E)O5U=6,C1%04%Q1TYP.6,V.&=34%1")B-X03M&861C5E9D3C@P,E=O
M:%1$2VM294LS;55407@Q1C-'6EE60DIO5S1Q86=(8D%Q6E)813!Y:&]:24I&
M6E5C1D=,07$T<4<R-TAT:7$T)B-X03LO<$-M,W!6,B]M*VY&5W8Y>610.3`Q
M<"]L.6$O,'A6;R]P4VAP-D9E,S(O2"MM2W1(.4LQ,CE#;%14-V93;G<O,C1Q
M,2]U6"]!3UAF)B-X03MP+VPY868X04Y72W1(.4YD=G$S-U`K+U!$-'9X-EEQ
M,2]U8V]0.35A.2\W>6Y8*VU+<F8Y>B](+T%).4]64#A!:7EN2W8V=4]+=2\U
M)B-X03LR1V@O,VMR=E0K.#EU4#A!1W5+=$@O15!B-G`K,3$Y6'<K2"]!26)R
M:7)8+T%$<V8O3&XK>B]V,W<K3"]!26)P:7)2+WA0454K<%9Q)B-X03MT9C<R
M;$XK6#A+67%T4#A!:7)J=#E2-3AF*TQQ8W58-G50-#1Q,&8X5CA4>"MO8W0K
M3F97<%AK2U8O,DYF<'A6>F8T<G%E4#%#;%AP)B-X03M8,75L4#-F-"]A>%9R
M+VYB9BM81'`O>&0Q-&8X,2]H:7)2+WAJ,B]2,U90.2]W1%-N>"\X3CEN1E9O
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M1VYJ.#A52U=G)B-X03LV3G%T=CE113EP2V=I:#`Q2DMO5%%W5T5S8VY4*U8R
M0S1Q<%(V3G$T1F@O;V-W35DX=CA!<69!9'9Q:VMH=4\S-T%B9D966%),2%@W
M)B-X03M33S(O8S--5'(Y5U=10EAP=R]337)Z06=B9C-$0W9T:7%A,BMO96)+
M2C9Q5&1$>E!O1'(Y9C0Y;"]W0U=8+T]U2W185W)E8F\W959R)B-X03ME,VMK
M;5='.&%*5V=/.'$S65<R1W=8<F(Q4#8Y.%5Q.&UU*UI)+W)N2%0R;#E-,UIT
M0C9-;S5I4#`O<310+T=4:R\S67%M165U>F@W)B-X03MH6G10=65-8W-I=TY(
M13=C-#!J5G=X<49O6%EL45!B07%-:3%/2U1N5T<T:C1(:CAC36TO=V<Q1D9/
M,CE0;FEQ+W=#=G=F>7IF.&E:)B-X03MV*V%C5F$O4T5(.&LS+TEI8B]M:D98
M9G!',R]K;2\U151F.$%.1TMR6#%7,5%62UA"1E%.<F$T8G%A9&M/2V]*+TXK
M9U)G;#4U1D%6)B-X03LS3F)E-"MZ2$E);E`Y,S)K4$A';&%K.#,V0D5S<E-4
M4TM)4DLP<$YV8V9#24=#>6LO=2\R1UE!-'%T9GIN-61J95)(;FM$471):V].
M)B-X03MV8V9#,$M#5U%(.3,K>6I":FEQ.2].,F=O-5)P6F=W6F]Y4'$Q>CEP
M22]7668S9F%-.'9L:7$R4'IJ;T5N1#`U<&TU.&5&3&$U,S52)B-X03M'6F8Y
M,3DT>'DK5TMR22]/+VQU46]Q5'I-6D)#54%T8FYC6$E*:'`K-R]B0VUM2W)L
M.#9E6&U#1EI::4I04C1%5W0Q=CE92E=(+V18)B-X03LW6E4P>%9Q4'IT-61K
M0VU/861G+T5,4S!U="MC<&A8+T%(5C-K2$@U-'%P=#4X.'-+2W1034)X9"]W
M1&53-RMZ1DM)6%`Y,2MZ2650)B-X03MZ>%9F2C4S.'5X2S=34S-#<D=S<G54
M6C-E>7=/235#9C-8-TQK031Q,E!/=FPP=DUN<E1+,78V=G(X<E<V54PV0W$X
M9TIA269:5C%0)B-X03LP-'$V+W=$375J4U)Z,DMZ3TQQ6#$W6DDR:&U8.3=(
M8FUD:S5-9U55:2M,8S1Q=T<X0C`W>50U9T]L*V$U=%=N=&)X3&$U85<Y=4DU
M)B-X03MB5U=#-DUC<U1Z=$Q.3$%7-F1653`R1D='1EAQ9&=X87AT,DI*3%))
M86YL53%59&595B\K0T9F2$%Q0FLX>BM61FMP3'$Q:4I&2FIO)B-X03LQ>$1Y
M0DQ"0W4W9GI55VYJ=&EQ2T)I3CEB3D5636)15$UH5VY%:&UI3E)4>'A61C1Q
M-T9867$W1EA9<3=&6%EQ-T9867%W;CAW=D]8)B-X03MM8GDO4$%M:F%3,G%#
M4S%U<&I(2$10335L:&I,4DI74&EI2U=!<G5X+W=!:V1C5E-'-2].8GIS.#`V
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M3W)0-FYG34YQ:$Q8>3-R16-6)B-X03MO<E%I<U$P9U`X83=F535:2&TW+T%,
M25EF4'1I<44P-U)T5F=7,E-7,6M6;$YQ5V]P249.6&%9-VEO,FI022M!>%%K
M.39J<D=W6E-P)B-X03LK<#9I8455,D]T4FMF94U65$16=CDU3E,O=T-98E=F
M*V\K4$961S@O=F9-6"]'5%8O=T1Q1G1C5E9T4R\U4U`O04QE,2]W1#DP45EP
M)B-X03M3:3AV8D-A>#@R5%A&=TY*:'-D6E%833!-5C!82W!C3C9B1GIC4FU0
M.31F5C5W=D=O<3%2=6-54%9,8C9T93961E@Y.6)834,Q-6-V)B-X03MJ:FM4
M=GE,3G5$,TYC0U=03BM6+VMY45A+,TYM.3)L,U580UA-,'-O66-I>6<X;5`Y
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M)B-X03LV5G!Y="]';%`W-S9C5F%/;UA90G!P;'ED<3!$5S-J4VTX,S`O=T)U
M2W1(56)W35(K:7)O9V-Q3GET84=G,B\S9E@T=3,T-'%T3W`S)B-X03MT869O
M;3=),S,U5W1.:%@O04@O,S99<3<Y2C-T45`P5&0W;%)8;&%B8VA5;BLO.$$R
M96@O0W5+=$163#1K03909&ET2VMV86)63R]3)B-X03LT-V0X5E<O<&953TYF
M,$IE,30X=5!/>7)8;%1J+W944W10:3A+92LR2W5B5CE10EE$4DPP:&$P265Y
M;S%/;$LS4&9T6$97:G)';V@R)B-X03M8.4)8>$$U55E063!0159&4#E*<CA8
M469J5$97=C`Q<5A+;C9"=G%B9D9Z<V%B:7`O=T-0<75X,E`Y3CA684=T86Q5
M1#E!,S1"2T%N)B-X03MN63!!8U9*+S-Q+UDV3BM&8U97:EA.5$E"4&PW54)6
M86M'5%0Y:GDT.&1R=G)4-'9#;G9T:7)483=Q:6=K95A.4F%I.&="2G`K-34X
M)B-X03ME27)D:F5N>&5&4&9B1E5S.'DS=74V:G!.,5E7+VQY+SE343!34G!D
M4$-(,#-6=V8Y-BM8>#AA3'0X-EEQ>$169%@Q03(K;TMD1791)B-X03M$8C9W
M0S5E>6]!8GE.-FUL>EA:=F<V9&8X;C1S2T9/8E9R.34Y941A3&520C,Q37-Z
M=EIK25I,5S(U2S-'-%DQ:7`X6$=O+VPU67%J)B-X03MB=3EU6E!-<6@W0V5!
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M<E`U;FTV;&I8)B-X03MY<6924FTT4TYQ1&EQ<6]9069V9"M48VM",BMZ>7!2
M:%%Q:$Y.,6(X,D<P83!N8E)O<C8V94)8=5-T-'EG5$AI2%)3;'=Y,%5S96YH
M)B-X03MI:$57975F;5$Y,4LR<&581S`K,V=G=7!);U5V6DQH-VE73TIN:6E5
M<DE'<GE7;G=+95A88G!I;%%I,78X,C=L3'%N;&=746AK:$YV)B-X03M.2F1Y
M>6U72&MF5B]C:65.;&-O;TE(3&)L5&1G4FEQ=#5D,5@X>C=Q>'5*3EHP4F),
M55E9-&QJ<WAE3W=:,VMJ5G!726Y01F%'56=6)B-X03MO94A81E5)=FUN.#-"
M2DA(3#5)8T]Z8U8T-FQ)>7-1<DY1=4AP1414:'EB6456,S5!67%I2F1E+TYK
M5W-S:UAK+W="4UE80WA7.%(Q)B-X03M*,#5W8T]45$U42V5&5U`R5#!P5&5O
M3TMS-3!+1S=U.4ET3&I5-V57>3%#5TU.8S)O=5IN0U`S05!,-F-#;W4R:456
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M5&%&<'1T9C95)B-X03M5:%<P='`R44%04T5Z3GE6:VLO86M!<5-$,3(T+T=Q
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M161X<#`V83ER-$]M<$5K4SAP)B-X03MG<VAJ9C%#.&]%635->D=T9'0X5F5H
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M83A2:7%)+U)M;2\X<VM0+TET9C99<3<Y1V%B)B-X03LO=T%S:U`X07E,6"MM
M2W4O4FUM+SAS:U`O271F-EEQ-SE'86(O=T%S:U`X07E,6"MM2W4O4FUM+SAS
M:U`O271F-EEQ-SE'86(O=T%S)B-X03MK4#A!>4Q8*VU+=2]2;6TO.'-K4"])
M=&8V67$W.4=A8B]W07-K4#A!>4Q8*VU+=2]2;6TO.'-K4"])=&8V67$W.4=A
M8B]W07-K4#A!)B-X03MY3%@K;4MU+U)M;2\X<VM0+TET9C99<3<Y1V%B+W=!
M<VM0.$%Y3%@K;4MU+U)M;2\X<VM0+TET9C99<3<Y1V%B+W=!<VM0.$%Y3%@K
M)B-X03MM2W4O4FUM+SAS:U`O271F-EEQ-SE'86(O=T%S:U`X07E,6"MM2W4O
M4FUM+SAS:U`O271F-EEQ-SE'86(O=T%S:U`X07E,6"MM2W4O)B-X03M2;6TO
M.'-K4"])=&8V67$W.4=A8B]W07-K4#A!>4Q8*VU+=2]2;6TO.'-K4"])=&8V
M67$W.4=A8B]W07-K4#A!>4Q8*VU+=2]2;6TO)B-X03LX<VM0+TET9C99<3<Y
M1V%B+W=!<VM0.$%Y3%@K;4MU+U)M;2\X<VM0+TET9C99<3<Y1V%B+W=!<VM0
M.$%Y3%@K;4MU+U)M;2\X<VM0)B-X03LO271F-EEQ9W)Z>35P,7IF5VLU=')B
M,#=B,4-5849'2DUI.$YV1#13=WA6+R\Y:STB+SX*("`@(#PO<F1F.D%L=#X*
M("`@/"]X;7`Z5&AU;6)N86EL<SX*("`@/&1C.G1I=&QE/@H@("`@/')D9CI!
M;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG-3=V,3D\
M+W)D9CIL:3X*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIT:71L93X*("`@/&1C
M.F-R96%T;W(^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI/G)R,3,P.#,U
M/"]R9&8Z;&D^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@
M/'AM<$U-.D1E<FEV961&<F]M"B`@("!S=%)E9CII;G-T86YC94E$/2)X;7`N
M:6ED.D4P,$9&0C(R.41$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("`@<W12
M968Z9&]C=6UE;G1)1#TB>&UP+F1I9#I%,#!&1D(R,CE$1#9%-#$Q.3@S0SDX
M040Q0C,W.#%$1"(*("`@('-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#TB=75I
M9#HU.6,Y96%B8BUC.#,W+30Q8CDM8F(V82TX.60W,&0Q,&5E96$B"B`@("!S
M=%)E9CIR96YD:71I;VY#;&%S<STB9&5F875L="(O/@H@("`\>&UP34TZ2&ES
M=&]R>3X*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z
M86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI
M9#HX,CDX,49"-D1#.#=%,S$Q04,R-D5"-#1&1$$V14)#.2(*("`@("`@<W1%
M=G0Z=VAE;CTB,C`Q-"TP,2TR.%0Q,3HR,SHT.2LP-3HS,"(*("`@("`@<W1%
M=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@(#QR9&8Z;&D*
M("`@("`@<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N
M8V5)1#TB>&UP+FEI9#I%,3!&1D(R,CE$1#9%-#$Q.3@S0SDX040Q0C,W.#%$
M1"(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q-2TP,RTS,%0Q,3HP-CHT,BLP-3HS
M,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@
M("`@/"]R9&8Z4V5Q/@H@("`\+WAM<$U-.DAI<W1O<GD^"B`@(#QX;7!44&<Z
M36%X4&%G95-I>F4*("`@('-T1&EM.G<](C8Q,BXP,#`P,#`B"B`@("!S=$1I
M;3IH/2(W.3(N,#`P,#`P(@H@("`@<W1$:6TZ=6YI=#TB4&]I;G1S(B\^"B`@
M(#QX;7!44&<Z1F]N=',^"B`@("`\<F1F.D)A9SX*("`@("`\<F1F.FQI"B`@
M("`@('-T1FYT.F9O;G1.86UE/2)4:6UE<RU";VQD(@H@("`@("!S=$9N=#IF
M;VYT1F%M:6QY/2)4:6UE<R(*("`@("`@<W1&;G0Z9F]N=$9A8V4](D)O;&0B
M"B`@("`@('-T1FYT.F9O;G14>7!E/2)4>7!E(#$B"B`@("`@('-T1FYT.G9E
M<G-I;VY3=')I;F<](C`P,2XP,#`B"B`@("`@('-T1FYT.F-O;7!O<VET93TB
M1F%L<V4B"B`@("`@('-T1FYT.F9O;G1&:6QE3F%M93TB5$E"7U]?7RY01D([
M(%1)0E]?7U\N4$9-(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT
M3F%M93TB5F5R9&%N82(*("`@("`@<W1&;G0Z9F]N=$9A;6EL>3TB5F5R9&%N
M82(*("`@("`@<W1&;G0Z9F]N=$9A8V4](E)E9W5L87(B"B`@("`@('-T1FYT
M.F9O;G14>7!E/2)/<&5N(%1Y<&4B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I
M;F<](E9E<G-I;VX@-2XP-2(*("`@("`@<W1&;G0Z8V]M<&]S:71E/2)&86QS
M92(*("`@("`@<W1&;G0Z9F]N=$9I;&5.86UE/2)V97)D86YA+G1T9B(O/@H@
M("`@(#QR9&8Z;&D*("`@("`@<W1&;G0Z9F]N=$YA;64](E9E<F1A;F$M0F]L
M9"(*("`@("`@<W1&;G0Z9F]N=$9A;6EL>3TB5F5R9&%N82(*("`@("`@<W1&
M;G0Z9F]N=$9A8V4](D)O;&0B"B`@("`@('-T1FYT.F9O;G14>7!E/2)/<&5N
M(%1Y<&4B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I;F<](E9E<G-I;VX@-2XP
M,R(*("`@("`@<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*("`@("`@<W1&;G0Z
M9F]N=$9I;&5.86UE/2)V97)D86YA8BYT=&8B+SX*("`@(#PO<F1F.D)A9SX*
M("`@/"]X;7!44&<Z1F]N=',^"B`@(#QX;7!44&<Z4&QA=&5.86UE<SX*("`@
M(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*("`@(#PO
M<F1F.E-E<3X*("`@/"]X;7!44&<Z4&QA=&5.86UE<SX*("`@/'AM<%109SI3
M=V%T8VA'<F]U<',^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@("`@
M('AM<$<Z9W)O=7!.86UE/2)$969A=6QT(%-W871C:"!'<F]U<"(*("`@("`@
M>&UP1SIG<F]U<%1Y<&4](C`B+SX*("`@(#PO<F1F.E-E<3X*("`@/"]X;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@("`\17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*
M("`@(#QR9&8Z0F%G/@H@("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT
M4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E("T@5%0B"B`@("`@($5X=&5N<VES
M1F]N=%-E;G-E.D9A;6EL>3TB5F5R9&%N82(*("`@("`@17AT96YS:7-&;VYT
M4V5N<V4Z3W5T;&EN949I;&53:7IE/2(P(@H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I&;W5N9')Y/2)-:6-R;W-O9G0B"B`@("`@($5X=&5N<VES1F]N=%-E
M;G-E.E9E<G-I;VX](C4N,#,B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.DME
M<FYI;F=#:&5C:W-U;3TB,"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F]N
M=%-E;G-E7S$N,E]#:&5C:W-U;3TB,C,W,#<U-3DY,B(*("`@("`@17AT96YS
M:7-&;VYT4V5N<V4Z0VAE8VMS=6T](C(S-S`W-34Y.3(B"B`@("`@($5X=&5N
M<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)697)D86YA(B\^"B`@("`@
M/')D9CIL:0H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#TB3W!E
M;E1Y<&4@+2!45"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/2)6
M97)D86YA(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I
M>F4](C`B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD](DUI8W)O
M<V]F="(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CTB-2XP,R(*
M("`@("`@17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/2(P(@H@
M("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M
M/2(S,C<R,C8Y,C,B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M
M/2(S,C<R,C8Y,C,B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I
M<'1.86UE/2)697)D86YA+4)O;&0B+SX*("`@("`\<F1F.FQI"B`@("`@($5X
M=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)4:6UE<RU";VQD(B\^
M"B`@("`\+W)D9CI"86<^"B`@(#PO17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*
M("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0](G<B/S[_VP!#``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_VP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1
M"`"N`>$#`1$``A$!`Q$!_\0`'P`!``$$`P$!`0````````````8%!P@)`P0*
M`@L!_\0`5A```00"`@`$`P,'!0L)!@4%!0(#!`8!!P`($1(3%`D5%A<8(2(Y
M5WB6UM<Q55B2F!DC)#=!45)WMK>X)28R.'%VN='4*$)38;*S,WF!E\0V5H*A
MM?_$`!@!`0$!`0$````````````````!`@,$_\0`.1$``@$!!`@%`P(&`@,!
M``````$1(0(Q05$287&!D:&Q\"(R<L'1`T+A4F)#4X*BLO$CDA,SPN+_V@`,
M`P$``A$#$0`_`/?QP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#5!\5W<>V],".
MATK4=QN56E;6^(]UFT+L`;2I%>8*7G5FS<71-OI3+UI2V)'3S2@(QL8>21!3
MP\A*E1SXR/)FN+&["3TIPL-K:H+2=;NZ7;?6^RH'3WLGJD_N;?3#X;:Q<Z!(
M`6;!0^M>Z^Q%RU;J&3=\Z^I<K6=GM6JJG67[/N<\+L-9#I`-0(U7F[#O2RL)
M8.RHTE17;TDW$UC*][$5C5GQ7-C[*I/7VWKZGA`*NVFR;AJ7KM#=[%1YD.QW
M?66>P^=D0+Z6?TZ+^@(\%.B(35)D1X-L<NTW9`"(]'K?R2R/0`T56MU73"FN
MM]<HUG<L/Q9+*&KO:RQ1>HUTF1^GU;VIG<+4F^ML1JQL;4?6NC]B3U--6,70
MCM.C@3:K+8-9U.W@K'9R!>V55DN[3(-.L@X^P&C6RI\T13!MJ>4Q0M\:^*UM
M^R6J@Z\J&DJ12+=)[W=0>MET<+;.*7,-.UUV9ZXL=I@YFOE6]8UM\597:QCZ
M(LT6;72\.NS,RI@`A85RXA$0&BKYE.RVJ9./RB63/C$QHQ;:8.'UQ+6$C0M9
M_:@&74=J!;<#,U^+W$F]13\TY;JU5"E1'A:C*:B;/N%@U^=VO!JU:BW*MGD#
M[K1C`1P-"Z7$_$KC=6,,RNU+XK%QM&Q*[J5OI_>W-B&A.T+ZFN@[2>,++:9U
MGVBJ_6I>T:1*F:G!Q["+LL<E:-NA%6!5*K<C7X.M^WN$HO?!<.`&CK6"WM3%
M^%SR?.Z6ZMZ[+)_$UZU=,HY@M1-+VSK/N7L):S0)Y08YMBX4ZU5RE`]8#[8S
MAHR!&4^&==V'8V:A/%GRZW*]$GDVZVDL+-")>!VHEZ22U7N==T5,)>T'=3L!
M\/SLV?69O)OM7J+6?0;?'8N]4RSV"HZW)S%0.[.M:E7"(\I4M8G(,^]:NUAL
M/.N(`I4&JA[JP+P6LY`2=<<(\&K-E6EDW:25[^UYO%J=1DELKXLX_7>TMG:S
M^Q!L\Y1J+W9MH,T,VV'(0SQ/I51-<[!L-=/R:Y4;+7Z=.N@;8*&&Q";+8]@:
M^(CHT78NO@"CP[P$5B5,XV<,+4Z]6I/!D/JOQ?SUA9)1)G5](PW$M?4H9[N-
MN1\I0`50[===+%V"IUPV#<?LB@E*@H#BMN:W*#(-.LXZ==SU4C#[(J*96["$
M=E+'/"LIPXKOV27,Z^_$YM>]]F4_56.H^RZA;%4?K+>-T!2!8R^=TB/[0UO:
M%FK+QT>0UR`A2Q])8H]9&WY\X7IAB*7N<Z'6J]9<4PH[-%=F%,J]I:XCKASB
M2!;6^(1;=#=L.U%'13;-LV)6=K?#+TK6*E8-IUVLT.O2NY179%01;ZHR)TB0
MM8>5!/#1\R\B[+9[VQ8(L6#+K$VG^RD!B@:,I/-6W_U4PZQLA;9,O^N>[CG?
M'JY`V$,S8.N=BE;9N=(L\>FV0?=)XR5U]["F*+>PU<MY>IU],X#L>'KLP%;/
M2*<#."P%K>DQ(,$W`C2D#+4.+Z)\5*X2:F.EO?3>H#5?5O9NU[7<M\F^R.\^
M^'7F4(LMK`56NU^;H<WM_86L;8W'$:Y)S%R(U*TP2UL4Q$E1&WFK)$L\R"9+
M#'T$!NU94VDJ:*LO%WZ*=[SM3R+KSOC>E&:;1KY`ZK0Y@"R]9NE/9P\U(WRY
M",`ZWW*W\OKP-K0B&C2\R%8C]#M2HYF4[-*5D;8:^N0XW*"$6&H$H/\`QWUN
MM6K-WZ5.>.^-9,)_QH(HD/LZ,0ZZ/9V!I&!\0:Q[3KL':^7ZE'J7P\[:$JE^
MGT2\3M9#)EO/7]RQ#)=-KQ>G4QJ&E!!JQ&1B6QL@L)H75HW92IC:F_9%;]1E
MCU>[QW?M/NG;5+J&A(`?3VG[;!JEAVT5VSG%H>?MFF-7;JUW)8U*]KB$\C)\
M+LGY/8XV;NXNI%0N<MN6&,0RY!$=F$JU<TC)M7[C7[?^YG8W4N\-I4G>X[<%
M9%'[1W.M/5/?6G;12;-UVWS0=<Z8W59JCH"U)GUJT+Z_;QU`-J;Y])B?3+"]
M<;YJZPN6!FPUB8T/<&M%-)J+E*=Z;:\2S3NOI.9.Q'Q;Y^L=:Z758]0F=G"X
M?PZ0G>K<%^=V\&G[%J.IQ^A*C:PQC8(05J"ITR;LS<FVIY[6U0`@Y]9B&WZ[
M9-C."*C56HX5D-"KK'CT%E,X5;A8SJO,I+UW`O=G^'IVZ[(/:PO6F2VL=&;0
MN]0EA[.Q#)6FN#=#C]HC-DZFMEYU6ZF.N/DS/!`YUTU#(@8NM0GNN!#55>'%
MB8SH^*RKY:W5B'#Z/F6)J?Q7#47:]#TP4T6Z7!/[@Z3]?#FTB&X8K]PDV'N+
MUOE;OIUQ=HX[3@.OD\!)`F37[Q&C62LL^O+:.UN$^PI=>A25SC?>5V;ZYN(I
M1Q?.7QK*UWQW+VVZR[[^\MJLC8MJ]5=,ZIU_/[;]8!(L;,L[NN=@VC;(L_V"
MT\5;B-6%F\:?A:_&&#-/^:X"6:IJ.2$8#3XCY95)92=+G@YIL>W/,Q7OG=/?
M&OJAJ3=A0MN79'2?9'6OKO+>[0:,,UL]L3J_M[8LDC;36R-]Z3.#1A6_:TV;
M3]AZO<5/]MEG7-3`ST54)7[D79+NC2LJJHK2=JCF+26">::<9YT,MNJNT-W]
MS87Q#K!9-S6S0]ITEW/W=UBT[#K,:O-!-1T+2X6H)#V:TU6P#9HJ]%-F*-SK
M?:B]P40S#`%!\?6)6DY@Q3JA+22T:3-E-ZY^+MLR2+H#O2^6_;/Q-F-Q;2+G
M:GHON\7TWJ]BTSAL<72J)BDZ_,AJS!<CPX+A"3*LMODPXDTP\5/3ER!PMN8]
ME+#*Q+225F%?9EWYOX([T$VAN_NMUZ.=B[QN>V:BV,YV[V*"<I`B-745;7&L
M=+[ZS4'>NYNH&AC\&5.NE/JTB%:;V32G:,4_=GB%>L@D/#$5E@6TE9<1316]
MM3/%W*E*EJN_&V.X$7OI6.O'5V\[#B&-A_#S[&;'H-+JQ'5H\+%[$U*VUZMZ
MGOUAE[28P*Q501`\RFX!,O%898/AQ:*D9(-I2H6RK.C-I?>D[[H;:48DLD_$
M]V7JBRUWKGM+5E-N&^Q5(VK4K5?ZALJ)*UZ;WSH/I36NT5TDS0M;JIA%"J%P
M-.VRN#JH;LD7;E9&PJW:2VM&:O=`!'@FC-9BZ%&=J.E9N=TRC'JL_%DO.NXN
MC]I[U!V(^5V5\,GI-OF91J/;!#6H"6R.T?8<'J&#9W`F--O["IYK!"W0R-ED
MP;C=*^(J4/-9KM)L]HB0SIX5V*M+"U:6N$F\XPI12[VL+\[L^+Y>-'3C4*V]
M/"HI^E:*KV_KX+M&W9-6LPVH%^WKO4]]JN5]_4!!9J7.RX*VQ3$V&;2G#].+
MQQMB8H]A:=@\:N\?@BL3C>X4*<)SC4]=TE+7\5_8FM!/96[;?U`"G:^UKWMW
MKUB$7.O'KJS2=5TK4.OJQ)#6O=9:NZHOI^M`;;>)XL9*V$_7Y%/KA.]N-V@A
M50M>"9LH:,PE?HIQBVW6-G>)O,;<;>;;=:<0ZTZA+C3K:DK;<;6G"D.-K3G*
M5H6G.%)4G.4J3G&<9SC/!@^^`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:X:WW
MK/7XM!JU+UL&CW*];%?JVJPE[-WZGP"=*B5W?MG1L>T6"1JN3!9@G(/7JU#X
M(BDM75P,;)"8I\C''R8)4D-1ROVTI?A*R*=7/B)(E.UPQ=M.6B@4"]US5MWI
M-H(1KF:DSJ5>*J(L=A-J%`-?D%61RN3;+4*LW$US(NV8]CN("'=7:0THC(@!
MH\:\NVZQ<9J[$WCK75E5!W6WF#":S99U?&`2=7I5XV!\UGVN9`'5B)$A4"MV
M8@MZPD"@V`%3F)CYE-G18D/UI#[;:AF]QB6]^]UJ#^:.P']D7ME_!/@L/5Q7
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M&\MEIYY-OJD!&C4HK5D^<E2Y-1H'F`0<F&#+SDA2BQ',D/%?-;ITE=E><95C
MX?!PK=S97K)8YA/95/AZ_P!@R5]"^R:/K.ECP.*I#K=D9:T,W'+#&*EA-1PQ
M,:=RJI(16%J4!0@?@/%2MUWB5-E3K/C?AX2VY;<SK%9IJ)]JUY>)V)O1'LS-
MS,N.I:[BGZTLTI4K13JGS5)J&/I*O$'5*D#ZMG-=:7\F5F%D/%G_`'+;GF6,
MVMUY^&ML37UEHM=Z\W/5SEI>!I+GJ/T,[,AB)((*W;6M_D:?/EAM)ACD:JVG
M8M8BDS;57/U:Q05S)LZHV6KFE1RL<5.U,S/]2RC/!/YDE&G]8]#-5B:O$GZN
MW9L8K1+A9[CKHQL'J3W0O<K5B[?#KT4]5-9%=C:TO5SKE"(2JR.L,FI$;E8(
M#MJ>FG/,ES(^.-$FUFJWU5=M=VPR8V+M?J?MI=9D;%UCN*TD:24D'*2<F].^
MV;-EI9F7"<&S2M.L\'2\2PU4A/&//BR,L`3'OD!C[XZ8M^$\ZPL%*F&JW^)5
MYEN;7&^'Q>FWFKCUGM%E:DT"9JJ4T8Z(]F)K4O6I*TQ+P4HLMM[12D2ZL7N<
M"%;#`60EV"6L<2.:(LR2+2)&`\2QU^9;,\BA+J'PV'3IZT.=4#*[':7]C2;(
M<7T*[+**G7MP`XE:VJLM.SHG,B?]HP.%''75,EQQ%E9P\HNF6[*E./!XL[OW
M+"['#`L]O+07P]]R"*L+B:?VA16ZY<J%;R#%;Z5=P0<:Y8U;JNZZ=UJ#LY6C
M:TH=_;%:[I=Y)0J.BK7VLN!&HD(,ZHA4W2E;)"IVD[[_`-RQ<XMXEW-/@^C^
MH$:X+1M9[QN>QM7U>33*OMV_=0^V]NV?$JKEE,VH95E7>PZ:*6F?6Z?/.SH-
M"@'C)N=5`J6(<4J_*5.(3A'+Q5:PFDISB8P)M9R?1*ZVH]>+9U^O=AN-HL&N
M;78[,5Z0=HI9HY9M/JEN:H/%)[FCLR)A;6KT^;(HLY]:Y%6DRY$D*N$^\XXH
M/%GG]RQOQQQS)UK[</575%4DT;6>LMOT.H3"EA.2*[5>FO:T*+<-6TC*,6<O
MB-!TFRE!*P&)TXN7G-^23/+399*2ZY-DOON"0W>T_P"I?):)H'\.EFE@M<L]
M7;(U0JQ=B.R*Y4&^B/9I%>`WPS$*CSEK$"TZ+Q%'F3\$Z<A6"7%;:6=BF2L<
MO[UHC,0\+XL]7F5V5YUG*K\-MP<V'^Z@79#M5*FT)D1%Z"]D88IFDZ[M*+Q0
MJHR-B:'9A,@*9=6\7"L"VV$Q`EI4Y81S4<N\[,6'B_5K\RQH\<J%:E-?#]FP
M"(R7UMMTB`8M-[NAJ*[T7[.K:-V7::HB]I$C:<Z,\3.-G+@0%[&@D\RAU[7"
MB*M40MF.SE`>+/+[EA=CAAD7,INX.JFO#]]M-&UAMRJ6+:)R+9MC&073+M4/
MGW6Q0A[(F&;LC[&D4J*E(HF-%$QYLKU)#(N'"'-K3#A16&0J\;KO$J<R$?.>
MCF<%VUZ-V<_#.2-AS9XF5TT[9R@.".W?FOVK%X%?DZ8="!S>S$G3C=_-B!\$
MM<6C)5FPS"+1&8AX*YK_`++5&.$*,B.AA'PZZ_-=GANKM@'R9`"KU27Z'0SL
MK[>=6*12Y^N*972$)>B%0R`2I4`J4I=;%S6'X0.L$B`0:S&'S),=P/%GK\RQ
MJ\<R6`;+TAJ^H3&@:]HC8(C2MA#SZ\?UA#Z1=HVZ:<`DQS0>>$,!?L.S%)B9
M01B.!='34/P\@(T4'AG`F,Q#;#Q3,USTE/&2.QXOP^HIB)88_6RX-'8%EUM<
MH9=/1KM!\QCVW3E<=I^J+,U+SH[+^#VN*H^_6J45\^9M;!/.BA3T6"XMC(>+
M/5YEC5XYU+SM=@NN3%M+WMJD[P3<#]?&U4W8/N@=LU$"E;#2B$X0$FN*TKE#
MXT9,+EY4"*M&6HD@N6>82A9.<J0)#U<5\EJX9+HJ.Q$:&Z&V.-A0Q-$`8#C>
MEO:X?7YH'5J8N-8@C-<AZ59!'PNMW(4:3011L<0@4V<WDA7(XV<X[(6+7//[
MEC?CCB5@A<NEQ2]E=F3M+[/=O-A6#=M%@1TO[61W[A)J[:6JM-NL6-I1D?<R
M%6;0TBL$+3$+S:ZEB/@,_!]NQZ80\U_V7SQ(Y#5T%'FBMBA==[S'-'MDA]R'
MB#?2+M+ZIW;5>)0#('9AM.=(Y:+WL*5%"R`JU$6Y)H?+'0'XLQI<2/EL/%GJ
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MK+"+Z"]DGALC4L`^FV#]>NQ7M#N-*JHZU(19QHG*?;#[&A!R&E@HA,K`3:OT
ML9\ROSO*@:#?#LLD9V'8.L-G-1I%'':UELE.B?9R<F=0!-P9V&/J!#W.C',S
MP,>_L-7GY?,R^R[<<*L[R7#:W)R@\6?]RV9Y4.\^W\/^01O!=SKC=$E-FD#A
M/8\]CH[VBC2K]*M`\:*M:;F]&T>TNS0[<,$P8%M&F<S1MIB(?CGXA%J;-3(#
MQ4K==XE394R.QVYT_C&,8#[_`,8QC&,8QU$[98QC&/PQC&,:3\,8QC^3'!(>
MKBOD_OWNM0?S1V`_LB]LOX)\"'JXKY'WNM0?S1V`_LB]LOX)\"'JXKY'WNM0
M?S1V`_LB]LOX)\"'JXKY'WNM0?S1V`_LB]LOX)\"'JXKY'WNM0?S1V`_LB]L
MOX)\"'JXKY'WNM0?S1V`_LB]LOX)\"'JXKY'WNM0?S1V`_LB]LOX)\"'JXKY
M'WNM0?S1V`_LB]LOX)\"'JXKY'WNM0?S1V`_LB]LOX)\"'JXKY'WNM0?S1V`
M_LB]LOX)\"'JXKY'WNM0?S1V`_LB]LOX)\"'JXKY,;/[L-\.'^DJ._\`VVW)
M_#O@NA:RYKY-E_!D<`<`<`LG,ZV=?"$:UQ)VDM62HUZ,L6&XLO46MK193D:>
M9*L%3&,CO\-G-E;)92F'WLJ7DE9K+/5G,NPF'IHLO-\256?4FK;H)>!6W7=*
ML@9\2)`.BS-9#D(.08$BR8"!TQI,1QIL8)*QXY$=!;2F-#FQV)+#:'66UI$+
M,]LU016L=?J5F(-&CNR?43QRK+,.#!A1>R^J<?CG/IQXT6,RCP_]QIEI'_NH
M3^`J]GT9?NG7^B;$@3RNO[K4KT+%EY0`F2IUD#6>`./068TB<$GS`DV='B%X
M;$V&]*&R'&YD=F7&<>90A]I2Q"6\`<`P<NG>&LZ^W+8M;6C7EGBTVK[*IFHC
M.UHQJIR1L&\7C5,#;XE#E+67CW:=7HU;(-1RYH`)-R!4I$@A.%,5N`6.CA8I
M.J8U7$Q']XNL)1NM28.PR3\"V)$RA)C.M=JM`6`=A*0`=9N-@/OTAL+4=>VP
MT18$4_8]LGA:';23)&#6[&4DB"S4(-%]M=[CDF=WNL(Z;989'93PUFJM&Y$\
MX2HFR!]0)QJSL2IZDLTJG7:93V:?L&+6]EWJITFPR:&<LC`.P&8\$HY$6U*R
MP&B^VLIZ'9=[I=;(<E^.7V!.K;4(60)ERMNU]LRGURN."=?3=LDJ[;+3:*:(
MK=1O4+5P^7L1_75F*B;ZBDH19_IOY-(CS'0A]]\[BI1^VNDY$NL#4S-ELF[=
M(*-"*U-T%OT=;&((676()2RV*I3]91K+3J/#EW.L,.7^W"@=(4LNQENP+2W)
MRR$/5Q7R<E4[4Z<L8<@0EVP8'G""E1%%0^5$2$F,_LC;]JT;K/VZXXM&2GUW
MLFGFZJ'P,:E)0=@3ADE:'(;KF0CO=/0E&M.P>H]OF"P+7UHDFB`@;&.IS+JU
MPKHZPUJ80FBHENH9JS@`P;9%*DD!\B(S=-?S[+57'51,)+Y20@9DA#7?<&/E
M<[NQ")-E^SZ;O%/UT>W7NW0-*VM(/4DQ5R^Q=)7W9^O)@VR"AIU5PIL6[G-3
M6ENE%95=)!I#ZA(LX2!F#86`1%=F,9HFU7%)^Y/ZWW.T(>#/%WK5.@QP]%!W
MJX&&:=?RE!J#)O75:VHQ7BNTX51SKOZO51[=7+%#IN+"W<B8@V'G0JXM!2&A
MT1IKIMPIC>=LEW'T"&JLF[%C]Y&UH26.!K=/G:1WC%=UG,K8H%8#;VXQKVN$
M%=+"8%;LU?M*SVV(-,!NU,O!M,<B]7WL$N!#[:Y9[BK3.UNC(+]V:?L]@5'U
M^4D5X\9C:SVE.K,VUQ;D,US(I%+MD*ER*SLF_-;",C:&N@ZZ+6FY?6<C-7P#
MR<8D06@A]QWO+J:]V)4-J56)<Z.3?*`9<XV*RN:'-UTJ/,UDV0K=D!':W9AP
M>R5RP5ZPB280X!/B1I@04@2H)"%'D,K;P(3;@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'YC_!Z#].
M#@\XX`X`X!:VT;PTQ26;'(N.VM;59FGF!E>MJS]WK0G%7/&02+0)"V'WQ)G(
M8J1K#B+-#@$<1I4BNY^>-M*%X5+P$/(J8[:^KRYLG6A6Q:.2L04F("EP4&U`
MY1<:7/QB<L&,FCF)RY<>>8BA#3XR(XTE^<V&+*C(<P,F^@!CEWQ_Q"C_`/7Q
MU?\`^(O6/*KUM748/TVO\68;?!)_ZOO8K]='<'^QVJ^:^IY[6TS8\JW]6;E>
M8-#@&,2NI&FW=B;SVU+K@R=LK>L)D25ODRO5:1<:<#;U<#U2Z!I-I<!J/BPD
ML.#P6EC))";#>-D23ZFO:R,14"S1+!$!M_1ZGVEH.-C;'V%7*[(T[J?0>T``
MI%-DQ]N:MTN<.V&D@CTXQ52).M3,2[==QIDQ2)=?F$P%U.0TYBDXE8-5P-+9
M>WL;_P!*^>IC[3N@-[E[3EN[!N\H7HK7\6VAM&4H/?:]>C0D6?[1Z1[*0<+>
M^[?J0C4A4:=H2L`YE<LMTWR5^5G9`D;?(+M:^H[>+I4HKXF_)K-S,MS2NTOG
M8NA&L#6Y]B;I@EV@QW:$HB;LK<G4G7N\$XEJGZEBZ;R:K=RV5J.YV\,/^F!H
MJ?+JBB\VM$#<&1B4/S7K%;Z[80TG"66MYSF6X@?#&UK!%U`2SL:UP8M1V%*V
M('2!H^F*V[2)TO.O<2`>C2`C7$<WU\K)%K6XE)T%JDL!&'91NV&)T11XQ'*C
M0TGW-;[Y=;\9PP+PA^C>J@]ST9=VS=TD$-%%-H%1HYV>)0$O3^QK6?NXQO8@
M]@,U@^UJZUV8Q8-8>BY`76S4QXHI<R:ZX\H2?;=2*;5?F=CJ[TJUKU.?FM:Z
ME17`K=9@TNN07-;::KIT35!DS$H8+.;!I.NZSL"_/#&&H8R,1NMD+RYL2"P1
ML*CMK=G6:6#;=7WWJ*/7>CU?%E/+8-Q;6N5#%[@W9O2G:I+,:U&TJK['WC==
MF7LT<<F5_7PJ\6GZ2-;:N"Z,,M5P*@Q+KXLL0$E[%7Z^9%"NU."N2FLPDEGD
MJ[\RU1?X6VF+&C$`[=+F\';T^`T[Z0BN:BKAXN'J^NZUKRMS;Y:@^MHY7:[-
M8351EPK%:VIFY585<$I==$SJT/"5D4&D]5\XY[=U*QB4'8GPHM2[-HJJ(>O4
MP6-F@]O5XNU4M)=8*V&7'W#7J%6RUAK]3B:576*OLD(.UT'B@MJP!CNPH@TM
M8@R;`D7FJ1:B"MM.=COM83KUD[V%\-?4NSKEL^Z6FV'\3-D38I=X:&I&F`X+
M%@%;0H&V*Y8KS7XVM,@-TFZD8UN$JE;+;>$V\FQKHK;ZN6FF9-J)FE!I.FJE
M[R:SI?A!F!I+4H?2.NQ6O`;PZ3"'3CA)<@32-?Z['N3#YF<;F>UJ6L:O4*D.
M9:?G+8:<CAU%)K;29IXH:-/SBLL9;FO?,NQP!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#\Q_@]!^G!
MP><U@=C>R'9_7FXGJ:!VC\/;1X0@R_+U32NR%OV$9VQO`,&CAD6.U)33[%38
M&I:S$L)?%:8G(KNXW8Z68QHHS#?)-UV.-))X6GLPRP<\C8Q22-I+TRI%KS6H
M=,NI.M`B%OJ`X^W:A]6L\P9%D'Z[`M#0\2W8X04JY*&Q3J!0Q)=B,W/2/A8D
M>V:&23\`UIL=`['4"1P[K_>9$N5E[$B["#M[>IM:LT5LK/TEN+2]OFV670XF
MM3%L.6!.Y"=SF&S,Z20(E0,.`0D9<,F#:QJ=6$4>N<9.6T_#TAPAHS.D]EG-
M6V8%2*S6A]B;)7F9)FV(/%L(J3=YF!]Y%?3Y9B#9CY`9&U]]&L$BUTV:U='+
M0,OT^-"#2K6O=W2^;E$%P._`-N5I&H$))$SF77]\]9W&TQ2LX</)O2]]:W&O
MK."8#\<88;PA]<J+&(19$>`02Q.AMLR8[#J*KUM1G!^FU_BSS16XJ4#?"@[7
M3@Y(@)FM]V-U>G,&S)$&4W_S%U1_T)$5QIY'_P#BO'.SO^ML./\`*]3]S=*/
MVE:`OQ@[!6S5[M3&LAG5#:EGGU5TZ=DU./-%W;4K;)GZ89D/CUD(467,:C26
M1ZYC34J2VQG&)#B5\XFS9A5G)3C\'1.':FZG,VD:<WAJSL!4Y-YU!;8UTJL2
MPFZI)+Q1YD8VU8*Y)3$-#51CHX7-RY!D*2VMY,;,9WQPJ.\ZC\KF6FG#O-%U
M^0#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'YC_``>@_3@X/.><OXKK
MVGR?>SJM4KA,%5L],J-1.V21;>Z>INK52VK3(^Q[A40FL55F\:<VI=-E$8B[
MKL'WH;7Y[5DXP#N\L"Y82<J1!DU4=+">C:?#PZ4.^^:7*]-'HTX.8X`X`X!A
MGWQ_Q"C_`/7QU?\`^(O6/*KUM748/TVO\6>7?8'YI7MC^NQNK_875'.SO^ML
M]SC_`"O4_<VI7C\[AM#]1W=_^V>H.9LW6=KZ6C5K[_Z3&WK/V]V+T\^'@J\:
MZ`TNP$37<;;M>F1;K!.382(A2]!X#KT9(*P5]]N2VU*<4VIU]]KU,(RII24J
M2M;4VOJ/+X++6@LX]C>\SW4TKG>U_P"O<QRU#+IK36A;;-I)RP&'JPQ40UAK
M=:FNQ)HV<0+3"&"-I&J:A-A<97%3*=RXE32&W<:%JD5TJ+;$XETE75>2RC]M
MNM6Q*#6=GUO=%&:HUSLABGU0Y:BOT!BP6@%:IM()`A0V^M5HO+)(M8^4%BQF
MH"EDI265#?=L2HKKTAUI=>652M]QD5R%'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`/S'^#T'Z<'!YSSG]Y+1MRG]UZN#L%S(U2KFK(-O%&AM=\Z_291770Q
M51CVHK.TN]T#VU/K-1"E!AW$<;,W!$CFUMV<@S:!J5SDUT=+,:+I+N\LQ?<]
M-9Y4/1AP<QP#3U:M];NE-WTG2ML[TA:VC;2(5F&?*:-JY':]<P%U)OPM%E#Z
MXSH2.*1KC86W:]K2G4B*>J5BO,IP7EN98(N=L5>".&J:KLW$RME;YK'`D]AW
M1W8TR8?M6PZZK8M8DAZ_?"--HHO_`/IE,N#M3,?5^)L75,HE")6J4NH`AN8)
MK:))=YULS$*F:*"W<%>!!%E]\]VN*/%HR%[X.SE:>IT;$-C`*;V#ZR-V,LY,
M6D@"A8[`ZV<8E0`R(;K9U]R8EF*]$65$)89=7*3)D*:Q&=JO6<HSGEHVJY>%
MGG)V6#UJW\*KNI'AWXY*$P>WN^Y=9).T?VTFP'6*7J](T//'?4CWR*)/91'=
M?+>[)>Q4^MKV,GT?.YUK/U)6'BU;,ZG*G_'ZG'>PV<7P=44_%6L,MJS$G#A/
MIEV!CW,0JN>2)51+%VT?@83&%?FROJ:000^26^.]B&]AF`PCW4KWWFC95UFF
M+QU._MTYU_?/[>^XW8:USH77&/AJV**B]FUA!/=/:S]#+YI7DE7(FUL*NJ@P
M"XKZB5]),3'O%IV=[T[[5./5]L__`-#E<Z7U*;:W4>JO(.^QE2O#`V"FQ5(Q
M\2/LK+;MQ59POTCVPQ?0ZJKY(E,%Q]O:&^5D!!;YTKZND$<2"GN('L07L,CH
M_P#A4KW_`/@M6E_QT432N,+V_P!BD6]N6O:8)Q0>LT=`NJT=B_G7A(;NK=W=
M>DET7TI-WF([FV#,>*9'?4J_HUM]S*T+D^[L'H83A?HN>;RI86]_1?["\UCT
MKHS<@)[KV8)VG[":_/6'%PHVH-+JV,5IL*DP:Z7JT]%Q%AHR1MO48DXN2"`Z
M9-]2/+@@T078C*L//9?SY<Z*>BE>\=RS&G";>=V2J[^[C(G47=_3^WM;Z8VI
M'+A:!7=[%E5V@B=G6NO5:XF;&F\E=>,@1@%N:38+E"EE%+B@H8TI(DE/=PFL
M,L2WE16\Z-][B:I4IKP-3==53?6[9[EV!V]Z@5EW8./M>J9MBU[@._<@43:]
M=D3:G"-++M09EL:;9S(K+4Q\/+9&Y*QF4$7(I!+#GF'OIXB[S5_;TK432?#_
M`-J<8)V#M<^RPP1JO1*V>K)J)%F(L02WQ"PUQIY2DO.BY,&`]#+QFO+GTI,>
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M;/\`O<3'<^I']IX/V%/FWP)<>7=)VFSNSE$@[#NOP+8N5'AK-$$WOSR!,AWS
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M>69`19&L:VP$FQA[EB+(V/ZTL'*?\_S&/"%_2+?SIN!X(]%_WP[WOFS_`'J/
MY?RD68?B<X+1OWS[";4^6F>E[1[E&8MN^EB2<E_3509,1Y@QH4+1MWU8Q&%(
M01R5ER"7T&W\O='+8&ICQ?9ROF&)[ZO6B^Q\)*+$^9QB]'A21-J/+7+276"H
MQK-N9PS78LK558CA)T4:Y92[>SO7E`9;^%?,XT$5]&-?/&Q^<(PQ(]Z-]]YL
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M</5F'+TY4HU>GPQ;MI-M[:]Q,KLV0A>2L0>&^A6OG[0U>$)CROF`OYAA>5>A
M%\OE5(5:[HO)XI5%&->^^5`CWGLRL"7F2-`41BP1IX9D,$;WGZT,H.E-EE&Y
MTDQ]FK?RUX0[&#MQ87L)GS5)22Y[B%\M\LQ"SG=\L2_TQO*NS<.P"CU3AO:5
MIS5?)0@[MP-IW!ZLRKSI65X-0QH?Z!1]2M"L8;S%E?,!'S/SYQZ$/R>*E*UV
M4OY]ZRUI3;6[EWJ(_'OG:)8`O,D]>*"Q88Q$(P&!HWUZT(J-EM&5'9\HS]F#
M?RQ\.]%"-1(/R^;\V26E.>Y@_*_)-L6?U<F2;7Z>:*RS<^PZK#483VCJ6U7"
M4`,]<3R-S>K-JQ"5ZGSN","?9ZCZF9$^#?M9GS$/\T\^<>WA>3Q5*9YX<,<=
MA9>7/\>Y'8VP.UCE=-3976_7L>R1"0-@&!;[!^X@F!DMDVH\0EF_LK:^5/AG
MX@)F)`^6S?FZ#$MWW,#Y3Y)UBS^KDR3:R6&/'$K3%U[(+L-/A/Z(I#-;*#PC
MUT/(W9ZLZJ$I>'/GL$6$^SEOZG8#YPW[2;\Q#?-O/G_!X/D_*D+/E^?SJ$VL
MLL>)'(VQ.VRZV:G2>M&N6+-%*`8X.OM]BO7@%Q,Q@ZNPDI9W[)FOE4@)(B`&
M80[Y9-^<H-3'O=C_`)/Z<]"SC=\,3:_3S7>17&;SV879*;`?T#16:P4&@W[O
M84;S]6?4BDO#F3P\4!^S5OZICAE8;Q#G_-`OS?"U9]M!\G@I"K7=%XE_IYW$
M<A['[>NUD_/F]8M;Q+3")U^/7:ZUV/\`=#S@J:T;58R,T_\`9&S\ED`G8@)N
M$/\`E9'YTDS+<]T.^4^6<A9SN_(FU^GFBL1+[VD<LE+@S.N]`BU@J-#/WBP-
M;[]S/J).5ZWSP>)!?9@S]5,"/*S[2=\S"?-?55_@T+TOR[%F'XG."T;^=.99
M>6US^".0]E]R7*K8",WJQK*+;816NQZY6FNS'N1QP3.:.JLI.;8LZ=9^2R`#
MT,`U!'?*2/SQ)J8Y[L;\H\D\U9PM-_TQ[B;626_X16XNP.UCEFI$"7UPU[&J
MI8:%?O=B;[!>X(4XI*P[\\'B`'V5M?5L<1E+.(D_YH"^:^JK_!H/I_ER%6NR
ME_,2Z4VUNY$;A[/[INU2PD9O4_5T2W02U;C5NLM=H/=#3P>>R>59RDZQ_8PS
M\CDUY^'7FH`WY02^?(-S7?>#/DWD(6+/ZGKBSPO:GD)>7/\`!7(FP^VKMII`
M^9UIUS%J186#D7RRM]B?<D::6EI>R>&B*]]D[/U;'#*2RF(0^:@OF^'5J]K!
M]+P7(5:[%%_.%W>)>6URB+PMI]X':A8R<[J+JF'<X)BM1:U56NU/NQ9\+/8/
MKM!6=9OL28^1RJ\_"KK,`7\F)?/D')KWO1GR7TR*F;X?D5R7'\$B@;&[>/6Z
M@#"/6/6\&FF1M??V):F>QWO2=')S4NYL0\+6?LDC_6<<$I+*84[YS7OG6'5*
M]L.]/P6I6NRG,3:R7'E<1"'MGO<[4K&2F].=21+A!+UB-6:NUVU]T-L`8@S8
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M]3+,5G=(]-P[N/-U2)5:BUW(Q+%6,$2CV==O,$+3]W^/\@EUB2/JK`T3\E*?
M4;=C(/\`OA'T_P"F4M,WP_()0.VEW=?O&N1!/J1JN!0C@>MRMF7-CM-[XO0#
M4]AU=G%`JC]BL;ZYBUY]+3,`I\^K7SY#BG?9#/3\BY3M?D$(@;H^(P]2[45(
M=%M*0KP..U"'4J@SW4]X*LU?)Q;4Y<S1&U?=WC_3LRJRQU1C#`_R0M]3-V4E
M(]^'^G?2+6F;X?D4^:?GX)7#VOWI=N^L!,WI[J:)0[`%JDK:UQ:[8>Z+ZX.$
M<O?5PBO5/[#F?M!B5C"6,CBOSRK?4?JKQ[$3Z7BN"G:_)`X.[_B5/46UF"'0
M?1L*_CK!3850I;/>'W@>SUTI%MKEV.DKA]V^/].3:E+&TZ,*"_("_P!4MVDG
M(^8A?IKTC`M,WP_)DQJ*Y=AK,2]#<FCZ9JL7]GM*-_,*SN7[3)'VD%5$\7JB
M>P^SZG?\B4],<4H3=O=?\[,D9"?IP'\O\90G?=3\YO@]!^G!P><\]GQ8=;W^
MY=L^L12G]7=O;=&!&J/8;A::,8V\,UO:*733NV95JUOM3.N8I$4\8A?48*M:
MQ#G&("3V-^7^4:G2=?UBZPLCI9N=4KUA-8SPOG8HAGH3X.8X`X`X!AIWPQE6
MAAV,8SG.=\=7_#&/QSG_`-HO6/*KUM748/TVO\6>72_J2KX2W;/&,XSE'=K=
M258QGQ\JOH/4RO#/^;/E4G/A_FSC/^7G9W_6V?!Q?\+U/W-JEX_.X;0_4=W?
M_MGJ#F;-UG:^EHU:^_\`I-8)K\UX*_7DV5_O'KW+:\WU>\&'_#W>QL3+_G/>
MYOZB&Q?][NF>:LW?2]7_`,HF%O:NI@`._-W=&/UX+?\`\:%BYEW6]_\`BBKS
M6/2NC,TI7_7F^)/^J;#_`-X(_BSYOI=X(YOR6N\+1C;2_P#JU?!0_7$UQ_QN
M&N9?EM^I]4=%YK'I71E^1?\`CE^,1_JRT%__`-;>W*_.MGR9^S^KV+;4";,B
M4;X&B8TJ1'1(O&MVI"&7W6D2&<W$WXLOI;4G#S2O'/F;<PI&?'/CC\>1^6WZ
MGU15YEL7^)GY7OB%[XBN?$-GDXM&.Q^L$W4Z-;CI@&9#CN,W"-M!XTV??%%H
M,PCE2JF(Q%6V_%S'QB3_`/B9?_(NA9=J%*6BW?-5(TW&;E\HRVER*3\2NVDW
M_AX![%J^N22?=#7M(M%I*!3Q,7!IA:R:LF7X@D`&G1#4B<.9GPU0H<4B<]RB
M([CUY[SS>77,:-&YN<7?DVW#C#1DN2)^)]J1ZI]F;J>H&Q!@7J_;1%3MJ!::
MV:)'GBXB87:F@8TDV#C899:A.LNM3IT=S+BVLHRI.5^G="L)X3W>-*DM8QG\
M%\0/=_19Z[Z`UTF99A=N[*4)G8NMQQ4#Z3.`#FM9NUWD6(G#F310>="J0Z:Y
M*;][*BXGL9B,3'\+:=7F'">#<(LJ6LJF1=-V/KS8J#;FOKY3+TW63"Z]8W*;
M:`=G17S[<2*0<!FU!)TY(HPW`G09JQD_+$U,29%DJ8PS(96N1%Y29\`<`<`<
M`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`_,?X/0>TW:/83N>'^)57-/54@.SUHFF-7"2TJ.YH1%0JD8V*!
MGYP[8)P]:E[IB;7V+B)LX11Z*%K4!DG!&ZRL-9R8@R=B2Q`Y)+1EWUB^:<HS
M>W5.OGXKI#0.[.\>O01=.\W;_P!=K?I2J'[%%ZZQ=H:8UE7O>UV\[0N8VQF-
MSZZ@LG@@[M/U>*W26*KEP/5N2K5\QBI7D#]6AA[OOOW-6)2PJGC#>2N>3U7U
M3/4SP<AP"T6X-OP=1#ZFZNH6Z^GKU:I-.J-/I&*L@\;,CZ/<]CDFV9-TM%-K
M,-F#3=?VHJMPE8(69+L!D;!3)(SH<9T5*3':I?$+Z[V\]+#QB94)`9SKY^):
M;3(J%=K<P+L8`>L@FR3)!*VLD*H#B#0"E/2+R-J\@R\;J<>GQ+,[:@2)H:+Z
M\J=Q)4>]Y09'TW513Y&`P4/=@.LL<&->F1VYYJ1%[`ZVG26!,-;B9!%Z/"9>
MF/M0VWEM16G9#B4M-J7BJ];43-8Z-JG]+/-1===;!<^%?VR`MT2Y+.$.ZFXR
M<`,BL&U%IPV3K_4C,<A#')@YF28+[L>0TS+996PZXP\A#BE-+PGO::TOJUOL
MJ.".3_@[7U?RC:+=:U8U_%9V6?0`-K!/]*]TC&3214Y0EXE)N&IG8P]HCAC,
M-R=(;CR'&(B'LONH8>6VVI+2\IQ9NL[7_P#17]_])K2,T*\J^&@+!XIELR:3
MW6V,34'Q73&2B1KVPP#S1!0_$/W>(+K*%.MR\L^W6TE3B7,IQG.+:\WU.\&'
M_#W>QL`+UVP9^)3W!-X!&<AB/1_8(L>7P,FY&3B;NU]/R&AT.?Z'M94YUB/(
M>;B,.KD+98><2WE#2U)U9=/I^J?[43"WM74P-@4JY)^']TF$*J5FP6&=TK83
M)#,@2N"`\:YW$L!%LA.A9B>YB05CUHGHER&FV%0E)E8<RPK"\Y=UO?\`XHOW
M6/2NC,Q)5>/_`'V/B*E/D9CY:9ZL1(`<C\LF^Q*S\7T>[F$-E^A[>=+PUC+F
M8T5QU[#>,KRCRX\>%YOI]X(YOR6MW1F.E/JEI9ZY_!JA.UL^U,K7;C7A&Q1'
M`Y%$H`/9[GF23LXU'5&PZ*AM#E)GN29R&&40E)E*7AC.'.9^VWZGU1T7FL^E
M=&7O&`CB=O\`Q<9*@Q5,>PZWT4P`?4.F89./Q"N[U2F0[N6?(3=C)E1LR&X2
MGULXD,9<PG#S?FK\ZV?)G[/ZO8MA3*[8&J7\$MMT$9;<J]XUV]96W!DU"ZZT
MS;C#CSIU"F,*$MM-J2MQ<_$=*$*2I6<8SC/(_+:]7NBKS+8O\2L0@1Q,'XP&
M%!BJ<V.;H;->QD=,QD[B)!W?B5D-C+/_`"IB-F5&Q(S!]?T<R&,.>7+K?FVO
M/.&@UU,X+:_8^:6$-,VGX'JW1!1I%7U%J^/9EN0):$UV0QUW,PWV#JE-8P(>
M9EJ3%=:(9CK;DJ2PM.'<X3S#7AM>KW1MM2Z_8R`K!'/L$^+'$^3%?=6#;E-D
M`8WRZ7[@W';IAUIQ\0SZ/J$F4.*2VMV$EY"5J2A2L*SC'-??_3[D?D6WY,@J
MW`G-]N?A/$'(4M$"O]4IX\].7&>3#"3\](KL+Q"+R5(PR-EY).M#L1IJV7LS
MG$1,(]PM+>9'@L>MOH5OQ6O2UR1BD[!M([H]\22.-AGX)\KVO,D0#$&.1C%R
M4)>H]?QDSQ#3"$3)D53[3S"94-+C676W6L.>="TXU_%MS=#_`!S1,+"PESQ^
M&9Q+,V1/?7JH]@J<Q6$=1+JR==]]/P!2<SHQ#<9HLOU?E^"N9_\`>V$3,XF>
M[_(;QZWX<S'@L9Z4[O@K?BM5^WG",";)9]M#_AI]Q_E5@V)"NWWSMN.UO`\K
M98UI^GE:ITOB`X$Q&?06^39FI(8B+@_X%F4F;Z.?6P_S;2T[=%$68RPF.^@5
MUC.>3;-G%GVSM*-\2"0$@;*OK6KT]4-I$D"(]PL&*"FY1LT?Y/-2/00S74V1
MA+L_(U]+."37J3%15)RM[.>:5+-/NRPK[%GSUYXQ\TY&(;_:WMB'Z#(N`_;F
MRU[83VNO]=R3FRI!>V?0+%L!L#82F2D:;,R`8@O2VX+BF<QD1E.X9<]-/Y.M
M'ST^U:-,7D9TGX:TI/%JK[1LRG]VMN1>X6\M.,HI#FJZ)UPMNS*:<6'F*?(7
MX1>-?`A8A\^V;0.)QW@]A.R%B8C+,^0N,W):?0U$>2Y-!19=:WK=.5,MQ=+S
M74B./,L/7_BA;YC=7=';<L&OM?&-A[%WY8]96RO11EH#1P=/A;N)T`98F1/S
MT@3AOIJ4>,7=FSWG!LI[QGH:9@N>ER:%]])C7&[$NDYLK.)WFUK/:SKYBS6R
MGYV:'38*.%^HK-#7!.H8@B,S&X'NHY-0K`HLOW3J$>T#SB$WR9R_[?T$J=QG
M1M4I>72LYW`/VOZXG052LL#<5+2'O1502J2"1%01\P638)%6Q!:'&F1Y*.\X
M?BO#F,3(D9,A>$/,*<C/,O.31>3+*S[OW4S+L?7U%Q^.;I4\8_[QA_\`UG$/
M)\&)6:XH^?M`H6/Y;O4?VD#?^MXAY/@Q*S7%'SG8=`Q_+>*?C_MLP7'_`/-X
MAY/@Q*S7%'S]HNOL?RWJF_M.$_\`7<0\GP8E9KBCY^TC7F/PS?:7C/\`WI!_
M^NXAY/@Q*S7%'\^TK7/_`/?]*_:H%_Z_B'D^`E9KBCYSLS6^/Y=@4C'_`&VL
M#C_^?R1-PE9KBCYSL_6B<9RK8=&3C&,YSG-M`8QC&/Y<YSDA_)C_`"\L/)\!
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M>$CP]#/U_4_[]YO^CZ7_`"M_?/'_`">3S>/^3B'D^`E9KB?.=YZ3QZOCN'5F
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MSV&T!AM3N=Y:>PTA64+=SLREX;0M.,94A2\F_*E6,9QG*<YQG&,XSG'X\`_N
M>PN@DN9:5O'3Z7<(RYEO.RZ7AS"$^'F7E&37FPC'CCQ5X>&/''CG\<<`X<]C
M>O26_55OC3*6LKRWAW.T*1AO*\9\,H\^3GE\^,YQC*?'QQG\,XX!_<]C.O:7
M%-*WOIK#J$9<6WG9](PXEO&<8RM2,G/,E&,J3C*LXPG&<XQG/CG'`.'/93KG
MA"',[^TIA#BO(VO.U*+A"UX7Z>4(5D[X*5A>,H\J<YSY\>7P\?PX!4P^^=&V
M$CD0`W/J<X6PQ(E9%A]BU`F1Q&B,KD2Y&84(P_)PQ&8:<?D.Y:]-EEM;CBDH
M0I6`.RK=NF$"7SZMN:P2"BD7A$DTJ_53`F.6CHCNR!;Y');$-DBPW+BN/0G'
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MH1.U$*U"NB8G&.?,W*\&!P"V6TM2U/;PD,+M*[!#=K9URR5PW5+(9J=C`F9-
M;L5-GS11H'+B3(SA&H6^TUN7^6O&1IV:ICT)R(<R*"<=R06]]6=+[#K@>JG*
MY-BAZS3A=!J3($Z8".5"J"Y(][(JL/09C:A#91@.%&G'F/\`""XP('AS'7$#
M(>619?N1CM2(%Q=:ZNALP(J8PCLIU!AC&U,H=]C&;[):IA):CK=PMQM/M/\`
M!E9PKS+9RI"\J2I6,@K]UKHS)O(4-F/F)D2,S%4ZI]4;,"+F/E]?E\[V6<M>
MGEU?E3YG,I\ZO*GQSGPQP0Y\CQ^9#DO,&'F4ZRJ.[)S&9S(<CK4A2V''O)ZB
MV5J;;4II2LH4I",Y3G*4^`'!\E#^@B-\I&>V:=4^W']A%]!M]2_54\AKTO30
MZIS^^*<2G"\K_+SGS?CP#F^6#LO/2,CX69$AK+,A_P!HQZS[.587EIYWT_.Z
MUE:4JRVM2D94G"O#QQC/`.+Y.(]*.Q\J&^C$=]:(S[&+Z45[ULR/5CM^EY&7
M?<9R_P"HWA*_6SEWQ\^?-P(.3Y6-\\AWY=!]26C#<MSVD?SRD)SE242%^GYG
MD)4I2L)<RK&,YSG&/'.>!"ROO/C`@2E,5"18["(*L+A)Q"C83#6E>7$KBIPU
MX1U)<SE>%-81G"\Y5C/CGQX!_?E0O&96<#1^,S?)B;GV<?QEX:\_IXE9]/\`
MPCT_4<\GJ^?R>HOR^'F5X@$B12?:>48/3[#"<0?+"C8]EA&,I1B)X-_X-A&,
MYPG#/DPG&<XQX8SP#^?*!/EDI^5CO+,RE4M/LHWEE*1A6$*DX]+P?RG"E83E
MWS93A2L8\/'/`A9'U@4+2N(XD;`2Y`;PU!7B''PN$TEK+"6HBL-^:,WAA2F<
M(9RA.&LY;QCR9SC@'Q\F#^E(8^4C?1EN>K*9]C%]*2[Y<(]20WZ7D><\F,)\
M[F%*\N,)\?#\.`<GRP;ZS,CY?!]>.WEF._[2/ZS#.6\LY:9=]/SM-Y:SEK*$
M*2GT\Y1X>7\.`<.0@7+#T7(@7F-(=R_(C9@1/0??4A+:GGF?2]-UU3:$(RXM
M*EY0A*<Y\J<8P$?)SY&CLOXE9@0LRDM*83)S%8]=+"TX2MG#WI^IAI2<82IO
M"O(I.,8SC.,<`X%`PJHZHBA`M41;BGEQ5#XF8ZWEXQA;JF<M>FIQ>$IPI>4Y
M4K"<>.<^&.`<^1HY4A<M0^%F6XRN.Y*S%8S(6PYE"G&5O9;]13*U-MY6VI64
M*RA&<ISE./`#@^2!?01%^4"_;-NJ?;C^PB>@A]:_44\AKTO32ZIS&'%.)3A>
M5_E9SE7X\`YOE@W+STG(^#F1(:RP^_[1CUGV<JPK++SOI^=QK*DI5EM:E(RI
M.,^'CC'`@XL!`V&H[&!(S#$1WUXK.($7#49_+V9'K1V_2\C+ON,Y?]1O"5^M
MG+OCY\^;@')\J&>I(>^70/6EHPW*=]G']22WC.581(7Z?F>1A6<JPES*DXSG
M.?#QX$''@*'PB*W@2,PW!<P["1B!%PB&ZEW+R7(J<->$=Q+V<NX6UA"L.YRY
MC/G_`!X!4?(C_13_`%<?^7`'D1_HI_JX_P#+@#R(_P!%/]7'_EP!Y$?Z*?ZN
M/_+@#R(_T4_U<?\`EP!Y$?Z*?ZN/_+@#R(_T4_U<?^7`.&1$BRX[\65'8D1I
M++C$B.^TAUE]AY&6W676UIRAQMQ"E(6A6,I4G.<9QG&>`8P;#Z3]6]G:TL>G
M['IVKC]<V\[/M%HK5)1,UW'/60H/@"B)XI)HDJO3IAB8,%#($@F])5-7$'06
M,O\`IQ6$HNE:6+KW[DA4U7'2+],-/EMX.]@U.VN+L%6M[)JV/A@Q%57XE:M#
M8IN>ML4\,===)-)#Q,194F>\AO&7O48=RM.472<)90^!-%5USS,6#OPE=.EN
MNAKK=&V5LJ%5S^V+)MV>>>35YI])NSN!E3!L3*`D.`R*82%CIBI=B2).,NOJ
M>D/)RVA#2=;JC1NK=/62\1CHB#(]E=F]F(^P2;%AV+H>XZ+S6'P,-\&)@V^V
MT"VO6'$EN>Q-FS84B@Q(;<3/MFG6"$AQ;R5LMX4TO+*G1[_.W(:/FKYC$R1\
M(PCGK1KGKU'WM"6[1]Y6#<DFVOZ[?;P10<V4J_8K[`9NYNJCYB,YP+R0<*NX
MD.8]W[-A&?;XKMUM./-RH-&J<W)(D!3H]NW[U?:[>+#-1F5';W78EK"F#HY_
M*#[MGE7:L6!E9"),@11T`?F`'EX7+646M+ZF6\,J2M3C=TEX-2?0D.+:CS.R
MU=K^3&<+\/;M$-ZY_#MUL_2@R[5U][0B]G;4:9N565$"TYCMX;VV]-BS5E&V
MS;[=&G1R.1XK$N6J1E0U#2YJ?1XTEHVUBW39#0AS9>5F'P9*7NNN\!N[OB27
M*5JNX*K6SM0Z^":\GPP[I/-N+BSUVD$8(*`-]V0F28S,^"\ZAN)X^20TK&<^
M/X)4V*X.=5,21X;5/NI36KN9B(Q2[;K[7WP4J=?:K8*7<`G836<<]5[8%(5Z
MQB7G]^E);+)8,6C1"4%QZ+)CR6VY<=I2V'V74IRAQ"LOMM^KW0^_O])(`Z4_
M5'QI?R<>&`75[*/PQX8_*[-^/E_S?CC\?#_+CG1WV?2U_=^3/V?U>Q%:1C'D
M^!/^&/RQ6K?/^&/RO^9AC/Y7^E^/X_CX\R_):]7NS7W6M5FFJBNR*2PE.-9_
M&+\,8_(O>I?+^&/R?^;NR_\`H_YO_P!/#FK/_L7I?N9^S^KV+Q4I*?O(_!"Q
MY4_E=5!'F_#'Y7_L!WK/X_Y_Q_S\GV+UOE:4&GYK?I?1&-4I*?NA?%9_#'Y/
M8^'A/X8_)Q]F@O\`!/\`FQ_\L<GW_P!/N9?EL[^IET.0C[]OPY,>5/@KIS:,
MJQY<>"L_=),?CG'A^/\`^O,KRV/4NK-/S6_2^B,(;6E/]R][\Y\,>*>\VW<)
MSX8\<8^Q#0/X8S_D_ES_`"<T_P#V6N\@O+8]7NS/PRA']TZU,GRI\N>EFT<Y
M3Y<>&?\`F#7OY<>'AGD^RQZV2U?:V+K9-=MV2G^Y3[=5Y<>;'=W;:<*\,>.,
M>2@8\/'^7P\/\G\G-*_ZOH]AA8VOJ;-K&A']UG[&)\B?+_<_=V9\OEQX>/VO
M==\>/AX>'CX?A_V<C_A>E^XPM[5U-;4A*?[F?I;/E3X_?EO>/'PQX^&=_-XS
MCQ_E\/#\/#_-S*?_`+-_N:_1L]D;`2"$X^(WWQQA*<8QTML><8QC&,8SG:&O
M_'.,>'X9S_EYK^5Z7[F<+>U=3!RN8Q_<_P#X7F?#'BKO'8/-G_2\?B'W[&?-
M_G\<8QC\?\F.1W_56$OJRKS6/2NC-J72[\ZSWDQ_DQI^@>&/\WC>#7CX?]O^
M7CZGV['U+8N>T\</.1ZSVS4KI?T4$=PMHE`>U-C-;^$[@UGNZP:ULUU0@'7Y
M)VS[KW?6Z7K8;::FTIS6%NV]MS9>Y[&#H)\C*1LC#<.:;$!XDJHRAQTK41A5
M=%T22G#B8I?%3J]4F=X>O%^,AAUUB:ZUE3)>PDV7K9=]Z5#0]%-;QD-"MPF+
M"`[,Z1CZ]59#HV>!P0!4;;!_+%.>+F@#H4'!:P-67X6LW2L2XN\K]MIZ)^#F
M.`.`.`8Q=L?\7^O_`-9WJ+_Q-ZIX*K]SZ,R=X(.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`:@>X=K+4WLM#L#-OL&R_+6]2#*WUGK^Z>SG7_8D8LW=+`X7M
M>F(VIF96M.P!6T1C0I-FJM[&1A@F)2\A;A>P=,-D618TKM]\)K?-W="Q=S[7
M=CM0:CNP@'MXA9MTP-Z=ZY4!G8]08C5^OC=8;JV'*U#J0Y+B4^[6\N9VK1R]
M-L.E-?5L!",W;7@Z<U4+A5ZX"@DY`J4O=9YI5^6Z;2@[)WMV&^6=N*Y5+N;)
MF]@K['.S])C:=8W+EJZ@K^'I(OU;V]5;HP078`46/O@'5-=UKV\>)6YQFWS@
MPN`]>D_-&`40J95_JNX5SC49I:K["]BK)V](:MLLK7];HHFY6FJJUJ<29B[!
MFZU"ZNS8JEMFLMIJ"WCLBT7!$#W]DDW%O7,6NEB5,:@1]G59]!@2%'OKFZ_+
M5.-Q9/>]F/Q-S]Q6ZCL'L`WV<"W/42.H.N:G?=XS*$8FR-)ZJEQ(9O4`DO+T
MF0U,8V%*LT;;=NN526.KH61:CTNQ`BP:$7&@KE11C=F\;YB[D5^#V7WO4MH:
MVK,V4ZW4;7V/WM47*0#'R;-MH]'?[[;CU:#.S1.TR69A#38[6`ZM6"<6U3:6
MR&I*ZT9N;E*=U7`J5<;"%#SA;+EEGK5;KZEJJ?W?[5$M7S+#L"PT*HV6UJU"
M.(#QD5P9-ZQ[,M6;H1O-/W7*LNK"L#6E`',`!E,$2K4`V1L-J]/1X:6S\"[`
M)H(6%-+JYUBE,ZUPID=T-WG[?J@:Z,RZN*NEXLG74E90FCM;4Z7\_LNWP.L-
ML6>0_L6KWB-6-EUK7ELLU0J(FJW&@.$H@$L<14;M5X!0G'E#Q(5=L2\*X8.E
M\QJN,[^D&WMJ;;KM\G;(NNN[_#%EJY]-'J/@@T2A+*5]N59:S;H3E.J`P40"
MFFUN#0J8S]I`C"#0*[Y<-C?FI@1J,UM[[P,Y."#@#@#@#@#@#@#@#@#@#@%/
MEB!4^1%ESA@^;*@.H?@R9<*-(D0WVU>=MZ*\\TMR.ZVO\I#C*D+0K\I.<9_'
M@$:FZVUT2C'89&@TJ?$M"8R;-%FU8%*C6),+W.8:3K#\!QHNF)F;,]M@@F1A
MCW<GTO)Z[OGLN^7)(5T*"UAWJ=UWL-AU7:9NK0$0OH]Z'(U)@"\5K`6AN#XC
M\`>@'5ZV1%5A$2%$D.L1H$D/(@M-Y2E,;'IM^5+B)ID&D]K4&".SOAI/#=4=
MNPVGK=*L%Y[3E:V:(1KQ(@AZ^!EU@=88,1F!*%#)$O#$CZ@?7)5*;DK\66<-
M8;\',N=+-M*WI-4AJE3#L^&%6LD0`=$-["-R?#8NTA%.=!=4=&P=>[1<C6)Q
M4ERP1.JUIT^Y],QGAK"BT%=P*P\-29&1RLC%+G.,MY;4QQIK12QTIW-I\H*T
MYM/.S&^AB3>>DG9JF=5_B!5^=K`J:L6[]T,7+6]>ILB#=#1P`U1H`A4I<"LR
M";L%S)!AYA,69Z,G/D\_I8;6TI:5I3--'9CK,M/1LTNG7>RX2=;["%]Y>A$T
MA1K=$@4WJ?;`%L(O5TM@;6S;75LR&<%&R.(F80V?@MCY9B-+?:=5/RF(E.7U
M)1F+RV?5[LK\UOTOHC7Y?!!41\+_`+XMEAA`6Y,[M[9GPT$84F$N5!=TIH9E
MJ9&3);:4_%<=8?:;D-84RMQEU"5Y4VO&-?Q+6NO0+RV/4NK,[3/YSO4OZEFT
M?]@:]R?98];):OM;%ULFNR[?FIMO?KO;<_\`IH'-6;_J^CV&%C:^ILWL?YVC
ML7_^7YNS_>]UWY/Y7I?N,+>U=36U(_-G:5_7FO?^_P";YE?Q-_N:QL;'T-@)
M'\XWWQ_4LL7^]'7_`#7\KTOW,X6]JZF#=<_-_P#PN_UXS_\`XB%^Y'?]7;:Z
MVBKS6/2NC-J/2[\ZUWD_U/Z__P!N#7'U+K&Q]2V+M_LCQP\Y'K/6?O8:69^,
MSJ>:_0M*N'IAG5<BF'#.INC<^03U<U2#$2]V6T;?NI5GNX"W>`LT:8(U'7=8
MP7*7,`PJ\VZQ,@3KE(&-<;SFHT'_`/J=D1HQB\>1$>[F_NM][^)/K6G6`A\/
MRV6GKI!JU1+Z\[H['*:4V/6-E6>[5*\U>WZ?F1='77.T$.5Z4)D`J4;NS5<E
MV=0LU!KX6;'39"P64]%^:LULJ5$0TZJ-N1Z/^#F1"U"[016&>KM@CBXH^:Y*
M/!9(6&3;MPWT,X^09GRWD*`)DN?D+*1X\UQM#F?&,O"?#(&HQ?2C;IFGS\(T
MWJ>@G;>C>:V:+6SU=B:UT+M3:%;T#6=5;RU`,%5=MB'.T0#TZ6;^=0((385F
MN=OL]T!QJK%N9&N`AN5FW=7-2Z.<]^58DO2OJ3N+4VTE7+0-H;=`D]M*N)(7
M=9M6D*]6^QW\[,L<N,Q3(L:8PS&&5*K#RZLR=T2`LC867-@RT66(Q&$E1580
MO;K7=2AD1V]A3WZ?JB5&,28,.#VBZH.$1;44>\P;;?['ZOCQV)4F3&=FPTPI
M3C4]I8U^*X\]'0Q(6[%6ZRL17[K71F6/!!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP"&WG7.O=G@WJSLNB4W8=;D>;UZ]>:N$MH-_SI\B_6$GX)"`[YT?DJ\\=7F3
M^3GQQ^'$Q<"R&QNNVEF39_>[-"&L[8!:XM55#VYJ88;>&UXJ)3&GBH@I!%(%
MF,_'B1V<>47ZC+;>$L.-X4OS:3?A6":IO,6DH;Q<=4>5Z[?FIMO?KO;<_P#I
MH'.MF_ZOH]C.%C:^ILWL?YVCL7_^7YNS_>]UWY/Y7I?N,+>U=36U(_-G:5_7
MFO?^_P";YE?Q-_N:QL;'T-@)'\XWWQ_4LL7^]'7_`#7\KTOW,X6]JZF#=<_-
M_P#PN_UXS_\`XB%^Y'?]7;:ZVBKS6/2NC-J/2[\ZUWD_U/Z__P!N#7'U+K&Q
M]2V+M_LCQP\Y'K/6C>J^?"?&D?.NQP\4+="FCG8#HA7P[9A(CD'K)P7/D6IK
M<EJG]U14UIY*(@YS2`"OMS0\>"J`.G98(&R0Y_9AC^O/"/#Q,D^]??FK=1NS
M6EM<3-`T2[VC=%:%C:_=+`<2"O5P.2+%98M8U9K(;$U[9Y]UFCB@UQ9UIVPB
MH]2-;&USY1DJ-;RA<&)9LZ2;F[5<LW6GXU&WS@P.`.`.`8Q=LO\`%]K_`,/Y
M?O.]1?#Q_6;U3P57[GT9DRK+OEQY$MY5X_CA2E8QX?\`RSA.<_\`^N#+G#F<
M2\S/,OTVX^4^57DRMQS&<K\<>3S8PWG&$^7S>;PSG.,XQC'CC/CP6OP<"U%?
M(CTV8&5^*_4PM]_"<8_)\F49PQG*LY_*\V%83X>"?#.?'/@%<.L>S/A2S'J2
M,)CCLM82OVJE29&%K5YL>GA].(V<-XRCS97E"G/*K&,)PK&?'`'76Y8\,M9;
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M$&W3YU,9MC&6/9JB.I`+=>=<QF3[E#S3*6LH9PVMW"UY1?#^[EO)XLEWP.5R
M3LO$PTED12E0&VIF:\ZX<-)E2GDR&\0$EV4@U-0VW8N75RU1'9BF7TH;:2\V
MI3B9X:7SC=R+XJW1A?S*>],W#B%`4P"UVHBIZ7@FT[9+$B&S'2ICV2H3R*TM
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M-#(T5"XF`ZQDIND.RI;\AM4[)%N3%BHC*;BXCN2<.NY:>";[4844Z\1XH^V=
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MZXL]#$>,B4PXY(;4S?#\EK@EQOY4YE'F%>V:0@)R!2=`NV)R26Q98LK8=^9#
MQ(:'86`C@6:UKQZ9.D2&5$%$VYL*"W%<:AIBN2DO/*9OA_=&XGBI136?8J4@
MGV;P:NC<6H:277H\4SG7TI^]75LN4F-D(Z`#=NAMT5R&&CRA>93Q9T3,,N0Y
MR&(\1J8PXN0W/#2_7=R+XJW:K^90I9?N!@,"<@T7KPY8')A9-EBRMD;#:$1(
M"%C_`)&X%F-:V=ESI4E"BF2C4V'!:B*9@XBNR\/OY8>&<8V*>I/%^WGWT*M(
M*=I<';PW%INBUUN/%,YUS+?OUZ0:*S6R4=%?;N4)%!<A!8TH3F6^7=#3C;D,
M@B/'B-3([CDAMX:7Z[N0\5:+44"49[EI!@'(5!ZX.6-V8839XDG9FQF@T.`V
ML?@"Z$FM:S=F3I4EM13)5F;"@M1%LP4Q7I>'W\Q[X?W1N'C_`&\RKR"O:_!R
M]MQ:5H1=;C13F=:2W]A7ULR7FME(R*XW=8+>O7(8.-*#9ER#+H6<<<A$41XT
M-J;&<<DMSPTOG&[D7Q5NC"_F1^6:[KI!UUR!K[K.Y8W9IE-KB2MH[+:#0A[;
M@[`!T#-:U<],(2Y+2RN2S,^$/:B.,0$Q'I:9#ZHZFO@ODCTJ47'_`%TIK*Q(
M+=N<'[^U%H_7U=8BQ#JM83']B[`;-F)S9:*BMMW>`WKER$!BRP:ID@RZ$GGG
M8)1N/%A-3HKKDMIX:7Z[N0\5;M5Y'9AOO&D'7'(&NNL#ED=G&DVR)*VKLYH-
M"'-NCL5YT!.:U4[,(S)3*BJB[,^".9AN,P$1'YB9$A<>^#%VHI%%OQX%KJG:
M_@K$XQW%38K^T-H?75ZJ18AQ6L)LS96Q&#YB<V1C(KC=X'LZU?@`8LL3F8^9
M="$#SL*>W'CPVIK#CDAN>&E7K4+DY]@YPC5/^O<CTP[WO2`K+L#6W5AVSO3C
M2;A#E[:VDR$@#6WAV*\[79[6I7II*9*865678(0!K,-UF`B(_,3(?7'OA_=A
MEO\`P3Q?MG>5F>9[GILFP61E`ZW/5&+#.JU;.F[.V0Q8#,]LI$16F[T.8UB^
M/`19894U\TZ"(GW8))N+&A,SHSKLEJ4S>NB^?]ZL;6MT8?FG>LCLP]WZ2`JS
MH_6?4]VSO3C:;G#E[>VNR$'CFWQV*Z[6Y[6H'II.9+C+++,,DH(MF$\P/1#?
MFHD2%QKX:UM:J)<5+ZCQ9+B^5/8K$XUW;39MCLC=>=97:?$B'U:FGS=I;,8L
M)N<T6B(K#=_&LZM?'UZ+,"*G2#;H`E878!-N+%A-3HKKLIJ4S?#\BN2X_BF>
M.1')E@^(0FO51T?J_J*[:GIQQ-VA2]Q[<9`CQK<@;BN/5D@SIMZ>4FRXBRZS
M#!,>+9A2&![<-^:W)D.1GAUZKM^)/%^W'/=^2MD#G>=%FV4R+USU=>I\2'8%
M:AGSMK[0CV(Y/:,0VZNWL(:QJA\=7(LP"J?)..UXE8W8!5J)$@LSXCSTQE37
MP_)JN)&"=A^(NBJU%X/JKIV_=7YUD3>AY'=.X8U:&C6GA.*D]5BD;2TDD6FS
MF%FU6!@H,$LCG8PQ$!\BB7)7$4S?#\@KI`[WS3:=G,B]:]5'J7#AV%6G"$[;
MFU&+*>GM&H+=6:V,+8U&^-K,2;7E$91UZN%+,Z/+M0X<%DA#?>F,0%O[K+^)
M">UJ($"]6]-$W0^BY"[]'G;KW(U6PPI[Y;'J,NID6=)O$C4^7&>-NV"*6&!V
M![T88V/DD42Y3D2JC3UD:E0>?SO/UI[3=2.H.WM77!G1=ETY8-\WC9U"NM?M
MMY;V*0FVHS6(PD?:J9/I#-=`1?D@E4N?D7<+$]$)NIA,.SHR<S>=;+G_`,C4
MULUF'"C"JP[K3#26@M??,N1:#7=_'Q%-MS6=>=8E;J?Z7[ECWZON;3V<G6HS
M7V=IZ-5)*52SIU6JR%[<B<@&VR'*U@0)<BR2;JS#;L6,U*?R]E-:K,U[UBGC
MOB5.=[,%)Y+LKCHO3(D6I:67J./VVOC^NCC]XN:-@E;Y]O,3.!MPKB*.NOA:
MKE_,E.2X>QFBN&D,K^4>=:T(BCQU?#;KV]U+3P7\,(OOY<S-1!GN:ON_V^DF
M:#UOC[-D=/;\G8(@;LW8\JDBQ3=[IJZX]4CDG644T8GRSB1L<Q'+`P\>$,=F
MRH<B;*88BOJ_\=USC6M>3O)X?'YHE8*;W..=VHQ+A$>R*.CG09L)4],R*U$[
ME;#<U!+)W:Y131VP-=V7Y%2B["@QJ3*A5L3.V+(V**L$RO3K)+'4\53C0^&2
M,&C`4+7$_5VOWU;<?S5&E8O\JPPAXS[&V#H//W^]\6SN"BXUG4T`0[KK#=M?
MKEPMA(A!KL6]%?LOE5^,1IXV.1,&$Y>S>(1"2.A@5);P#FGL*5E.;<Q8F+G=
MM^9+9B'$WXQE7V@\HO.9ZCU?"-BZ([7_`!!ZO<+!=-TT2^:;[4[(UN&U?6^C
M#EBJ9NW=:[[L_20LZ6[VP^N#LR+4+Q%KB[4<JZMO-!JS@J[KB>33+%R59'.M
ME8.;*^Y3%I)^72OK?%5@=?XNLZUR.U_7>C`>T=BU"C8%0I8B/7:-V?[4:4M=
M`]MNG&+7M9S7?7VAW2O[0CWVFSR6K@*KL6UZL(>'>ZCV62-:(I%A8N?AG^E/
M"ZMVZ=AO2T+7-E4[1NF:EN>UPKWN"K:IU[7=JW<<Y(?'W#8X6I"!MWM$%^6-
M#2I$0_98Q,K'D2`XA]]J4EUT6.6M4-D8<-N**7"R1(;M>&J1'@27JM=[,U-<
MEH<32:S,M$@>B'$<F+?GPX"LS$MO);RQ$1&8E2)<M3<9AA;KB4Y$-5TGXA>X
MI$/8LA=-J.O2.O5;PMB*SL?7^T0QRT"M6Z_ZRWFJZ''-VDQKUU&[=@?;V7#M
MV</"M0&%/IOG`T*W"B4<N\-Z.^ZZZK==E-6XO#'[D[4UYM!^C=@]>BJT+>V1
M-!CBU2BP"+R*I9&I:-88=PC9AJ/-E$FP%TL9DJWF!=7`E=&1$:*#OW`*12)"
MBCPK?OPV7TUT+[=O2:HE/U1`P,*2TE>T74]I<^'':<'BL1>Q^KYF'2SRY#3D
M9J5EG$.(IEF3ER:\PTM+:%*=0(K]UKHS+'@@X`X`X`X`X`X`X`X`X`X`X`X`
MX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`
MX`X`X`X!K$^*IUQMG9SK[$UW3K5KNI%Y-C&YCS]D62160S[[\Z#'BPF9<847
M==ERY+C49AE$;*EO/,MI\RG,8YNQ:A6Z-S9:IA1WF;5]G;WTZ$+OW4[9@#N-
MO3MQ.G5)6L3?4G9^J80^.4(N6_%CL-YU1:H$A\6L,T-;%)&T<PB3(2:<D-RG
M(#;<1UM]YV/5:3=A?I37)F6FE;UM=?R:/I'YL[2OZ\U[_P!_S?"_B;_<N-C8
M^AL!(_G&^^/ZEEB_WHZ_YK^5Z7[F<+>U=3!NN?F__A=_KQG_`/Q$+]R._P"K
MMM=;15YK'I71FU'I=^=:[R?ZG]?_`.W!KCZEUC8^I;%V_P!D>.'G(]9^F%7:
MM6:A!EC*G7@=9&SSUFM,X?7Q4$/"F6:Z6$G;KA8944>Q'8?.6NUFS-FL95U"
MIQL^6)&"3\DA.DR'1YS0/\5>X7V@=P.NMOHM'V^Q'0%U?2;?L>@[^[$ZG$FX
M]VV7L`G5]<*IFBZ#:H&PIK<^B&<3F+T3&`\%+W0JX^N$S:')JATLW.JV.RGD
MIENEZSNF*'H6X.8X!29@`$06PY/"B9SD4K'.Q5S!T.2N,;B,ICQ#+"GF5J9*
MQ8Z4L1R#>4RV&4I:;>2C&$\`^Y84//4TN<)&35QR44RPJ7`BR5,F(+:&H)5I
M3S2\MDH;3;;<6<C.)4=M"$,NH2E.,`8Z]L?\7^O_`-9WJ+_Q-ZIX*K]SZ,R=
MX(.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`6GV]IJG[L`CJY=,DOEHPV-/L)&
MOQ6'%S!DIF2VV_F5#FMNQGT-NQ)+.6_*Y&E/^7*)"8[[%3B=="-3&IR5K940
M0O6URB%FIZ@J*L53-9%+0V0S`8@N*<:A.OQYC+3^6F_*V](CNL-9_OC^,-)6
MK"S>MHM7/OON3S>=LM3Z^HW270E;T4%V>]4Y_9IJX)AWT:4D6E,VR[:A'"DC
MU,U"IL31/^$MNQ9@D9-#,)R[!CGS2H3Q![:^_P!MYG&QL?0ND1_.-]\?U++%
M_O1U_P`U_*]+]S.%O:NI@W7/S?\`\+O]>,__`.(A?N1W_5VVNMHJ\UCTKHS:
MCTN_.M=Y/]3^O_\`;@UQ]2ZQL?4MB[?[(\</.1ZS].#@\YYY.XH_<FRNV.Q]
MSE[3JJ=ULZ;V_3NG+%7L=@>_&J)=+M][D:MV6[;+!5^O]8#46^W!(';%,38F
MIYN[4@+2Y-:7:W*^F+:6FQM7)15S%++ZRU=JZ'H;X,#@%@B/9S38T:5+.F[3
M,'C+C*U^P^$U;M:Q*M%P'(LKI@)KM@!22<C:#]?8IMMDV9_7+5IA5F+6CDH_
M)&QQ<QQD6'VUSRWGW5^SVBKJ>^FJIL"$=+N2*I%'-CQ%C=A6!RZBI1T$NIE_
MDZ1%PBX#09Y4[-JT\Q#J8^!.EVM\*S"E+:"'WPZD<[8_XO\`7_ZSO47_`(F]
M4\!7[GT9D[P0<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`XW6FGVW&7VVWF7
M4J0ZTZA+C;B%8\%(<0O&4K2K&?!258SC./PSC@%@MO#]R054.+HN.%'0$6N&
M_=(SL8)'A?)9=D$3"#V&)68[N<2'WILNQ*&*03D5AVW."<N7%ZM875$.;\.?
M?XDCF5%V/+O\P:]=A]2-DT;L%VZ[5&#%+>U[?^M)[7@40.)&G[>P8=N-7LB)
M1*!(KT0.P-]B$E-*=CG9<G$IR.WB*II3C[6U:EV%^E-&&H5IYM=33O7/S?\`
M\+O]>,__`.(A?N5W_5VVNMH+S6/2NC-J/2[\ZUWD_P!3^O\`_;@UQ]2ZQL?4
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M=WPJ;;L*I;/AYZ7+U$%5ZKA-*D5C7U"U\,.PZ\`GDC,?7Z*R+$'+^[[0>_>3
M;-3JT:I#99"3%4$$FK6V.RVW9)[&05I[:SWUVI$T[45$0SKS22Y>)A<A2NR?
M42.%,EIK\HKZJ^PFK`<N?.D)4TW/GD(#KZ9LB0RK#KS[KZ$-N92I(BOW6NC,
MQ."#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%BNS?\`B`VS_P!S"W_V
ML<U8\RW]&9M^5[NJ/+#7/S?_`,+O]>,__P"(A?N;=_U=MKK:,KS6/2NC-J/2
M[\ZUWD_U/Z__`-N#7'U+K&Q]2V+M_LCQP\Y'K/TX.#SFBS;_`%CV[V&^)1(+
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M/F%9;8\7$F]L^RD622GO19\UJ%`8?W,V[,ENPQ126W&CH<>7%&SWTHRU#D+;
M"7JX+X(G?]+]3M5QQ$K8]^V-2V#Y!8L*JP=N.RP]12<S&=G2FH+3VY,.R$P(
M##Y$F^VA4<6-8?($'8T)EU]`2\E_U7P0*4)Z#PF;5(E;UL#+5)-P*W:%+[G]
MBO$4>*F"U<%"%HQNG*Y,XI9@)ZK#8\),E<^T@C59B8>.B2`^.+7+^U?!;P?8
MND)O:+&M*W8-UV2,Y4:?<WMDB^XFVFM<,#+V!-6RLL1YQ7LV,M)Z5.J(*7:5
M/U:I'A+`5QEUXHF4B9$B!6,-FBIZ:R0.FOANL_*LJ[,/K2='PBP5QCO!O^2T
M6&%)IX6&G#GHV[76ID8\7K!\+776%K3838J4&"YGE$IB*#Q9?VKX)K!J/1LE
M/J`R!N>T2YM]KL&V4]ECN9V*7@]7"D(N1%%H;N-T^CB,6@5VQRQ/KN,N$V*W
M8W(#<C``O[(27DO^J^"DZS`]+MN#]JGZ/>-MDZ=ITA$A6V]Y[7=CT4U<>30P
M6QW#0HTC=SK<D!#K-AA2I):4U!C+2AZ7#S+%*B$I0M5%%7]JV9'RS`Z!R:[]
M71MZ6:15DV!^KR+%'[C]D7PL`W&%##S\<J2:W(N((CH`&PEA^9E'8@M5?-A3
MJ)JA)8?,DA6Z*^E?!0CD[H$$O$#6_P!K]^,7:>;MU74!`=O>QA20)M=)]^V=
MJ]CD-[M1"K)YF8,G#40#TD<I,Z.XB2J,RG+V`K?%/2O@[)]CI-7@9<E)N>X)
MQP)0QNR)M$$]L>PA"XN5<E`K!),L9&:WQ@&;]E!N58DD7PIX@/B1SHB4J<J*
M5&O2PKDJN/*O@N3>-5].-9&`M>V+M6X48Y8QILR!%6SN9V'`SRP:M)BKL9>#
M&)[LC./BJ^W.ANG"*$YAB693#T]^.VZA61)>2_ZKX(T+K71<W,K0X3N.YSR=
MN+R`-?%1^WW9=96:7BR0T-Z`Z,^V'$\<][NQUN,U\SCPT2'[+7&HZW5GA"9@
MM<O[5\%"AN?#Q(UJ5<!W84M/K,2:%@.&8/=3L1+B.2;&(*6`%[/,?=+CA".5
M`@;$;AS8"),-X36;01Q(]G63KP\/%E_:O@J[P7H1'.V&LO[Y,M'*G7Y=JLL!
M?=CL#A0.O0:T%N<LJ2?^V[VT6,Q3[&!MB\N/8<^F3`\]A&14IJ6H/%?']JV9
M9E1A4SI&1G5$7$VW>%D[WE*:H.<[>=EX\\JXX=)U:,Q[.3N)J1!DSK2%,U<;
M%)-PY!.RB2=?'M22\"7#:"N7]J^"]'W0=+__`!]U_P!J/L__`!AX)+U<%\#[
MH.E__C[K_M1]G_XP\"7JX+X.CU-@9"5[;]89+6<L*JG83:-?KZK=;[5>2P\)
M$D"GX@O%BNAD_89,.&N4_B(S,*2$Q6U^BQZ;*4-I!X;-F+,J^"#@#@#@#@#@
M#@#@#@#@#@#@#@#@&IN)WCW,-W-NB$9"4\[IS45]WI6K7AG4NTM<,Z]JNL-=
M8L]/MUB[/6^X%M&VPM>+PL-KO.NP5:"6F&Y;F;.WZ@NG6"/+&FE"OJD\'5Y*
MC[@N=KWO]+V@=`T.G=<MH3MFSB&WQ]BJI0@"H\.HM:<1U\(F3I&9LU5%LDFO
MG`'9+7Y*NKCTS!^<^Y);576Q'E/8!V<9I3BYA4G)XP0/6_Q!+B4U%K79.R=>
M@*_9K]U=T!NP?KP845EFQV3=MD@U\?#JEFBD;,;E*(JEO206N(6O[#=%MPTQ
M8Q4\6F(&,@U6)I+4ZEWLW5+X]9.V,SLEL0\R.KA*I4N+HW7US:K5I#R1=W`;
M#?WEV;TYL<*<Q)<:=3#&E-(1(PR+*%C"37EE2B,2')FK&#Q&HUU?1-=2"SOB
M)!!T,24=TCL2:-V+[2;HA(H[0'2NW0.>RNF.KI`BF&4L@<?1)B;MOS65A##;
M@8@MDJ:?]X2(@#@LX`$BZ+X7ZJ-]$^%)+R[DW%M8#&ZWTNG@ZKK[:?8W8LJB
M*E['CO7ZMZP37]1;)W%9ERA%-M51^OC[@O6TNN`A0JZU^$J24>M#Y"6,K<L.
M4$2OU5IM2]\B#V+M1<=*&Y=`VI78>TS.O06L;INK9VL0S.M:E4J-O3:EUUEJ
MPN*U[<M@WRRG"D251+)/OPP9;)V1X8$^:!9)%#0BE8%B=[A+8JY9TS9:\K\2
M.8*%';0[UDV,JEA-<[?W2NQ_7.KTK?U#U]N^*/M^S_)DV-PDV<'RY(LM2ZFE
M#TJV"9SGS,A4B<18UT-&Z&I<4KBI6';SO./=WQ!#M,IFX)]=U,;K_P`@1V>I
M6K=C6,I5SE;LNV^M8RVE#@TE3PYM-F'5DH-I=D(!BT_,5R8^`("Y\,3B97YY
ML$JWY<XU:RG;*^)/-@0-OHU1HVY6B1KX]>*G7;58(9,=13UHU/N\#I38@PX5
M1"BCJZS(+RK3+U]-;L!/-G9J!3)2+7);@H<6",VEUKJO_P!E[JCW8B6G?C6A
M_L=V)'FP+2C7%RMP^')/5BF;';U)&V^1@DR@T5D.JDC1\R)27+JX8B2I&PYH
MX3'JRZ_/CVE0D4F5VXNO+/;2[E;;IW<Z)H`!]"RJY*OO7*EB:F6T[M59FW1=
MKQ[,>V669['Q[S!TO1S^N=?U6S[!KNNK'4"5IV+%J4^LUY#A,W`(#Q842]>5
M(HJ8R^!V8'Q-*\;K=CN%?T'N4O4VH8HQ2K6U73*:N:K)+8@77B[/<SC5?DQ:
M"'B8/CK\\XSBVR&];I*'I+$4H`/U\8&CK4S$3WLVDN'_`!!0,V:+(-ZO+3M8
MH,]?ZW<-M5G8.N;A4@)OLL\#$:TS7D5TY-GWP#FT66OB+`?",LQQT(S",P6"
MS48W%#!%^_DI>RGN4\3\0M!B%2FXV@+\FS[;$Z4MVG*R];-?H7;Z'OU-V^A[
M"=+Y-_+J:1#?0\R1?:[)65D!H)42NLS+H05/&0`T==TSNB[BLO<^1WQ(*0X9
MI,&RZZL.OQ1^JFS9^PW@^!""X=@J5LVI2KQ0]>SLJ?$[<N%&-:AL,VQU^LEH
MM@5635..`0IU1UR`/"+\;HA9Q&R9IO1>[JWVJ8[-Q;)*9U9L'7#08)1+6-E6
M\5,9%'J[L9BPR`D:&8>'P![]Q!)K4M-ZK@9XX-KF"=;DPK.>@'X4S(C48K<3
M[LW_`(@-L_\`<PM_]K'-6/,M_1F+?E>[JCRPUS\W_P#"[_7C/_\`B(7[FW?]
M7;:ZVC*\UCTKHS:CTN_.M=Y/]3^O_P#;@UQ]2ZQL?4MB[?[(\</.1ZS].#@\
MYA+L[H'H[:%\M.P7[-V'UX2V$_#D[0!:5[-[WTU2]G2(0N$":F7&GZ[O@`$Z
M6?!#H04D?"1`EA,"HS$(L5G,QV$M#2M-9;[*?5?@RVIM/K&O*A5:#20L*MTV
MD5P)4:G7AJ%-#@-:K8R,'!!H#:E+6B&,&0XL*,E:UJ2RRC"EJ5XJR,NM7>RC
MWV1L./`C9U^(KY=Q6)^#+96PR*^79B)@NJBJJJ\URP!Y9QV9Y&F&[$H:'94I
M#TN2XREQK(&F:G5SO#'UZ["/3.P1DLFN7Q&MS,(SM.NS/O)R-4]98FJI=^!V
MJ\'[<SJBO[&&=AFKS]960YU_LLZ2]8(=>BUTM3H+8V]&<,.$N>4:UN9DVL-W
M!TSM)4@:4M.]*$4VVJ7Z)'ZF]NVSL2,^IZ'Z;MJ*R@P.A"`D:"R31B#ID58-
MAR"#-%$S*.T[($H]5.B][ZUI"O,B>WOSKZ/U1[#(OY5]Z+JA\]Q,Q+R0RQ]X
M_5_L?E.6<XC8>^8^W]W[S"D9A>MAGP?\F>"*_=:Z%4J7_7*W]^K5U*_WG=T.
M!@MKZ(D>T>N>G=LW_4FSM@@Y$^Y:9L[=BUT3;L9P0V.,JBSXZ&EP8!*+!GH>
M<F)E.L.QU/3'($2)*<D"LS1TL$VI2QO*ALW3:K]:Z)?05_MNM;O0!]PKXRQ5
M6%3BRIM2V`Y5Y%NKI`5>:Q:PRD3I])J1:`4C0(Y482`QD(E2`TTV&+!._O46
M0JO1VCUJPUDZ]?\`89YC7Q:MNZR"DLT^/`HU8K-U.7V+3H[XFJ#R=@'R3!E@
M?)+6><6L/R&N5Z*R4:*YLANR@W--<[7G_HMXYUHZT5$^*T\0VX>A7&8U3+-!
MKDTS6T&G(,>N[9U+5I#S2*ZEF+'LKNPKA&$(E>@\>.UE;03#[80]%4++F8OX
M4:?^R_;O5"B/$1)-1ZV8>#UWJM6XZ,2`_I+A]2-A779%"?=QD-E>95@,7DI"
MMZD+0U)&1H+89H+*1(E2!)]^=&6/D?#4T7+*S)DN>6(CSU9D5BU0#=4U18"9
M-ASZS;8(@;D<UX0NM"*-P;M-'.2:4?"IPP)"S1K0LU\\*G!=)[,H[CC),077
MN!`U[VLU`+W49V9M3;=*2/MA>]QJ6-D5>0?TRQJ2A.2@^N:?5X4`-)#5!@E(
M<R+G3YTYHU)C+1&S$&PQ)JG%WLYUYELKS\-6H;4JA4+LC<NS+"8MXJR";V5D
M!=0SAQ>/8=;T/64&0(JI36$JI`++1@&OH.*'?8`!%UKSUHV`[#+L?5+2`XJM
M-7)*+K\YSUF0!/J;6),&JQ!-WNH!ZL;-W[L54R&BJS734?LE:[[;-DTXBT5K
M<V.R!7,OTV*!G#&H%D%1A(KS&I;N23A`2?;EWU,<BOP]=&@K4-*VC;=ZQ+MP
M)>G*;&--:SR;=Q-UY4Q"ZT*N#M!S=2$6.!U`NQ@:@X?55@DR3;9L0(I#\)`L
M72>6,XYOYY(RLW+HO5NXS!H%?CTQB7LGK]N70LBK0RX>#,,Z]V._4<WPN(AS
M84LA(*@\#PD=N>RB4*&8,(P5'R53(?@(G'%/A,%E0G0&A@SFO;&/O!D&9H=^
MBW]96@:ZT7J@O8I46?0Y<@"5.:PU=4C>:U:X>N*W7=C!U$7X=YJR7Z^1:8'1
M*\T!%TGQIB^K?>\B.I/A^3:/1]/23N^+]C>FK-;Z5U^,V/7!>MW!==":AU;M
M'6T*I5RN&-<J#EJVEK>&T2<,S;0Y"XR"!`!))%'(07`5\':OHHKGBUKU(GT?
MH!IT;1XVO0Y:T1JP.E/NC!AB)2;F/:@KZR5GJHT#*"+I4#X6R!$Z\JH^=)A6
M$<1R1/OSGIKKHYYL<P&DYGYSTNI2*?\`#SUE4;C0;TY<K5<;'2X]9B2)^Q:W
MJO8<LC#I&VM@;FH\$`5N=`.'==0J99]D&PM6;H18)(!4T;5!8J5#-U8-98H:
M3KKVK",'!G_P9'`,8^LW\G8']9S;'_U@^"NY;/=F3G!!P!P!P!P!P!P!P!P!
MP!P!P!P!P"V!/2^K3-1V#0R=*#S*CM4B>,;`".)D8C64O9FX[9HK*<1(1)C$
MI7M(CS4X>_$E09<6--'NQ9D=I]`2Z:KBA:[ZYZ7U27;L-%H\438T)MWJV266
ML-AL<YV_,ZX8NLLM8+*6+F#)&T(U%K?)HF6FS2$YVI#7WI*G\RG)`LMT[I,<
M)9"6>E_6B-68U0BZR9B`QL*OC`"(=JO,0I4!=1/9LM1%T2PQK,U8:$,J)?.5
MU,?3"@*'68.<A@;$`-G,#@2^^'/$N5K;1FI=/Y6K6E&#U%;@1FN..#?=J<<"
M,6^[7YH>XY+E27'&DW'8UXL.5+4IU1"RD5K<4A;2&A)[X+V1$!G4_KP(,&#L
M'5X5!$U8`]H=S(F&Y\(29!;+$;FA.U,5/*R15'A/;9`A=CF`]-A`0]AN8R'8
M3\`F293(P++SSYJ.E-A<79>JM?;AKK55V/6HEE#Q2PZP#/4D3QA4#8A"UN";
M)6+"&ECK#5K(,4Z_@?8*Z4&&8;<B2U'FMM27T."7%JF>GG6]B95"&-90WIU/
MD0)4"7,L%NGR#4D3;I.P`DB_O3K!(7M%ZOWV;,O%<=V5FV+KMPERK,$S`-R'
MIRQ9??MEE3"A+97732,T%,K,K7%??`D*#L35TT6M$O,:1K_;):.=V-5G,8E8
M7D9;2\2-.*)PO#RGF4>@\RGQ3D):K.7*[@6OK'2/006;LTJ?J[M^*[6.[B)V
M*5<"A@G$AB-W6F99KK6:X#61^05B"12_$#$R-=&"C=@%"1K5@(DE1FU)"7PC
MES)D1ZH=?BLZ^S9^O(S[>S8UE8NH7!^V,U,K)N4AJ;;#L6EQSS51!6VR$64%
M3=TKX05;21C"C$LTZ36Y+4$NFK9U*I7NM>FJI=1^PP%6(0;?`CCFG"V;K?):
M#DT34F:$.LEQ&3K-)$7J[1:7%B5=N_7.`>NV0D.'`6?4Q$C(:"7=W?,:E-85
M"OVC2&I[IFX*M%&"F';[)I,ZUR)*9*99(EK:<V4U^7:F,2&I0PU2RK+!6L&A
M#T`J%*QHI.!,8G18\AL)>?;OXXYD#;ZCZ!C8/I&TXL!:L4Y\F_'K.Q-F5:*#
M(2SJK.0ET6)7;B,C:V>+6!;A<TK7K58^=3GGWROO%/O><)[A=LBE*Z/]?Z-L
MN5LL55,N2HWT%FG5=\B5^BJ0_KRL.5@"4&5-!#%?+V-AJ1,)Q;791ABSBRT^
M=/%EXDJ7(><#2?&_E\$UI75#KSKM]B33]8!1+T(M53`E:IIPGFOJHC=A;HH6
MKX+%9Z:M3:0BVVG%.H5=P,I%6S8C:@5?@*)S,O`VW>^\7K;A2[W!RM]6-!M'
M0U@3KV+[D`2GFQPE9RT.4_)XC8;';'["1H3AQ=(-6)BR6ZQF1A\S7IY@+.*O
MNAYL'R,8:"7[=LE.JM':PTE#(#M8UV16AI%D3"^6*L=I.#!8D"W,9`UZLCK&
M;+PJC5@3)":R%JE68#UL2U(<:'BXZ,X3@29[[XE#[-_X@-L_]S"W_P!K'-6/
M,M_1F;?E>[JCRPUS\W_\+O\`7CL'_B(7[F\?J[7_`/1E>:QZ5T9M1Z7?G6N\
MG^I_7_\`MP:X^I=8V/J6Q=O]D>.'G(]9^G!P><<`<`<`<`<`QB[8_P"+_7_Z
MSO47_B;U3P57[GT8J7_7*W]^K5U*_P!YW=#@8+:^B.QV$T18]T2=9R`.VKMK
M=%&V#7+=.B5A=33%*1@[TIUQ]/U!2K3(P>8P_AH8O#\<6EM;^)L.0K+:T`G&
M$]]]"C=D=(V?:<+5B10>A;2%T0X7G6;5^YSA2O4?8"25-+5P6?-DZY2;NWFQ
MT\M,9L`2+*H\\2N8_+F0\U\Y!`&A@)Q\J]=]Y/%A/1#81JSF5VDEK?Z4*;#S
M8;L[#+VLL6[&5Z;VHJ>\X>-TAI];'CXQ+6FLZ^8TG30J35[!&ZW<30QZ33Z8
MP/I\<6>\J-4VNKNWE9H_0L]2[5&MT(K0HIL?$Z^5@:;'Q"31^'KS3._MX[*F
M4EHSD6@@FOR]?7K65,%!?=Y&>>@1H,QIH4(!NY#2]^+LI3\D=$_#9@QJIK@&
M5^A2I&GZ[Z85PN4F.62?**6[3>WE6WLU9D$9S#I*1(WYK5V3KPD1FO8)VL+.
M(UBY>G6"4^/(#2J[ZNT^*IP_T=:-T(VV*V/3S0S80EJEU-Z;!H\,/8HE:):+
M!#>P.ZME5AC6\<CI6\F2`R?K/86O]8VFE5C8FD@\^OZTBTT^6N]&D"10`)67
MYHKZK&LUOFC+L=8.IFP-/U'=(DIG6VKK)L[7&OJ3"/Z:+V&S3$V^FTFR5<MN
M<^4L]1HY,C>[4;-LV^=F>HX44284@Q;S\WU#,H+3F+W5WZ\*%J'.C^U)4*B1
MAE/Z]ZY?`#H@;W-.N]](*U[;8AS612?V:U[F3JL&Z7W7;8%0*@SPH\\'?S$C
MALD=JV2,?O`\N$WU?#"M'6[9PN*T+^'G*&6$?<VIM&1=8MJUS<WK0W\]R9>L
MU2[;SMT&[%F>J'[A9XII:=(T]'+.*]]D#(E49Z0U07W8BPTL-7LDN:G_`$6J
MU;T3WF6!`;"1(U?KY9?:,H(/U2P';3=#=E8JG8ZLQ-TW%QRO5T9&VH'^U^K1
MP0R&3L*(H&M/PIFP9T2/60X(5VEM7Y5-E.=Q6ZG\/39`AFHDY"=8#+@!C[>`
MP#S5GA'7=93=J:[UA56MX:@0!ZWZJ%U[85;L.L1]AS34`A[]C*3I5F.;F>L3
MTMV8#M*M]>=]'77?R+WZSZD;(JG4_L?HV07`56[;DIE[KM?)UVYI+54%8+-J
M*+KV);82*CI'1>*:Y),16CQJ$%JQXV\01)LL^X6*REITG`C:E/*-M^UR0?8/
M0FT3]KVH[1YXR)K8M23X*F"!FR'-5636N3NI;G0S=-!F0VB=A7IZJ7"UV>;L
M(N6$[9J30VYV,A<Y=#N-DK`1XF"M4X:[G.:V787Y6OK_`$DWPS<Z%7#%?U(R
M)J06GF!&S0Y""`<T_-"=C2^QY2=9`-=Z7UE4+3LXU2&&ZY8K&.H>A`"X%@>9
MG#+3`>L@NR"RM>-,Z)*:^[W%PM?=`KFR?I;.TWM7GJ&`+Z_^TRNQ9]ELD?LF
M0I6O>RM9/;LVV#.UD2&^U'9]BV_KXQ;JW)<MX_,>A*9*7ZUQ!]/$`1-+*?BJ
MIL4<[B%K^'[V$P,;'0-F5$>7<Z\ZGUC:+Z3.MW2SW6QZ[H>HZV>!C9MET@[=
M]=4'8DO7YX;<HTO:.T:*;&V@S;)NAEWRT60I(%TES;XS6^KKJ>LV*=9M6F=-
MZ@"4,ZU#BD(!BVE%#!=EAVL*'9L5I+GV10$D,U=I<1%"0T$?*,`A=95,+6XR
MD`1$!P<.C2GQEU??R^I0.LW\G8']9S;'_P!8/@.Y;/=F3G!!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"(7^"2)4JT00P
M^`5+R@LYH8.*QH4L;+GJ95[1F=&(M/PGXJG_`">LW(:6A3?FQX85X9Q5>B.J
M??4UGV?3T`V!ZAT;>/6X8?+B]I#;(U"UN5'TD)KJP";-+O<"RO"JG8-=TQ;J
M[-#58R(]U3[9*&T1:BP[O;IGR,MJ:6H=,L6KKW7O`SC8I@^EU"SG2[\ZUWD_
MU/Z__P!N#7-?4NL;'U%B[?[(\</.1ZS].#@\XX`X!C4=[.4Z`6URNOQ<W.AW
MX7M$FK8=>+#9(H2O5M;FV0F,9&>91,P0GL#2$=GT&XT**[$6E^;E]QF,X!C/
MGX@AR(+,.%=)CH9VGZUMN^+R*C;3?(#QFCJ3K[1^Q3QJN&DZT859-DI&;T!#
M8.O9@RN`I92OV#S;'8'*"3S`UHZ]5V,M9W4OY%PZMWA!2=@2M?[)H)K4LY%\
M/U:&0LR[#F(\%B+;A50Y+3)I0IV)+N)9!IF(XSB?KF.+I]T+1=IEOIU^$\)&
M5:3\\.-50E'=2W@:GKG7[YR1,9;QV+ZRF58A!S)EUL35.P&MK+9"+K`4>0?:
MAA@(V>6GR'6T-,0HC[JE>",\!7QC#IC<RS]XV%U<N&QB6T179G;>M[.;I=1H
M9W&O(ID:,,@J,;O)^LYFP3VK;'C$X?/V-:L>ZB.Q<R(\UEJ0VY[5A20BUD^!
M1OKC1'].CLW_`%H_\">!#R?!CZXT1_3H[-_UH_\``G@0\GP8^N-$?TZ.S?\`
M6C_P)X$/)\&/KC1'].CLW_6C_P`">!#R?!CZXT1_3H[-_P!:/_`G@0\GP8^N
M-$?TZ.S?]:/_``)X$/)\&/KC1'].CLW_`%H_\">!#R?!CZXT1_3H[-_UH_\`
M`G@0\GP8^N-$?TZ.S?\`6C_P)X$/)\&/KC1'].CLW_6C_P`">!#R?!CZXT1_
M3H[-_P!:/_`G@0\GP8^N-$?TZ.S?]:/_``)X$/)\&/KC1'].CLW_`%H_\">!
M#R?!CZXT1_3H[-_UH_\``G@0\GP8^N-$?TZ.S?\`6C_P)X$/)\&/KC1'].CL
MW_6C_P`">!#R?!CZXT1_3H[-_P!:/_`G@0\GP9<W4N\^J>H*\4`B-RV:S.G;
M2=N9VPW,-;RMA,6"Q/MO$9DR5`HXF"E.<,LLL,1!T9EEEI"<(4OSK4$6LGP+
MH_?*ZV_I)1^R=Y_=G@0\GP8^^5UM_22C]D[S^[/`AY/@Q]\KK;^DE'[)WG]V
M>!#R?!C[Y76W])*/V3O/[L\"'D^#'WRNMOZ24?LG>?W9X$/)\&/OE=;?TDH_
M9.\_NSP(>3X,??*ZV_I)1^R=Y_=G@0\GP8^^5UM_22C]D[S^[/`AY/@Q]\KK
M;^DE'[)WG]V>!#R?!C[Y76W])*/V3O/[L\"'D^#'WRNMOZ24?LG>?W9X$/)\
M&/OE=;?TDH_9.\_NSP(>3X,??*ZV_I)1^R=Y_=G@0\GP8^^5UM_22C]D[S^[
M/`AY/@Q]\KK;^DE'[)WG]V>!#R?!C[Y76W])*/V3O/[L\"'D^#'WRNMOZ24?
MLG>?W9X$/)\&/OE=;?TDH_9.\_NSP(>3X,??*ZV_I)1^R=Y_=G@0\GP8^^5U
MM_22C]D[S^[/`AY/@Q]\KK;^DE'[)WG]V>!#R?!C[Y76W])*/V3O/[L\"'D^
M#'WRNMOZ24?LG>?W9X$/)\&/OE=;?TDH_9.\_NSP(>3X,??*ZV_I)1^R=Y_=
MG@0\GP8^^5UM_22C]D[S^[/`AY/@Q]\KK;^DE'[)WG]V>!#R?!C[Y76W])*/
MV3O/[L\"'D^#'WRNMOZ24?LG>?W9X$/)\&/OE=;?TDH_9.\_NSP(>3X,??*Z
MV_I)1^R=Y_=G@0\GP8^^5UM_22C]D[S^[/`AY/@Q]\KK;^DE'[)WG]V>!#R?
M!FH;JANC7U3^)#W`V999Y\+0+CJ^DB:O;2%$OK`0Z2A6\M-EPATQ59\C\B/%
M=;?=;3^*6UX5GG3ZC3T8<PG.]F;%FTDZ.\\M7V8[7_0_N/\`_:/8_P"['.9Z
M3]*O@\XX`X!`['K*DVVTU&YV$,LC8Z(HFNJSLE349D4HS$5`*Y^6PR,<5.]_
M!6N%)P1A3,.Q''(RL>BXM"@]RV<3J;UT@B!H&)JBN-"A)A9J)%\Y1?G=<%UT
M$H40?<(+DEZGD!3J;7L4@L]-IN*]3:@!2!P(JP"$/%EY]]XWU>9.;9I?5MY)
M1S-MI0<V5BG@5E:(RTR,3%%*U#F0`J9$AB0TY+%0XA$BUFORE/`)7S(BN8,D
M.3Y:W@EKO,N?P0<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`9_\`
ME^&>`6&US`NV-D;?ES[@.FUN+>XL1ROIJZX\QR<]JC54J+,CFU6"0F)%C,/9
E9=')%.XE2<NS?=,*>4SC3B+,99SB]2,J9<N:Y:E_HOSS)H__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g887761g64s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g64s23.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X=RB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*("`@("`@("`@("`@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*("`@("`@("`@/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B`@("`@("`@(#QD8SIT:71L
M93X*("`@("`@("`@("`@/')D9CI!;'0^"B`@("`@("`@("`@("`@(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^4')I;G0\+W)D9CIL:3X*("`@("`@
M("`@("`@/"]R9&8Z06QT/@H@("`@("`@("`\+V1C.G1I=&QE/@H@("`@("`\
M+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@("`@
M/'AM<#I-971A9&%T841A=&4^,C`Q-2TP,RTQ.%0Q-CHP.3HR-2LP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*("`@("`@("`@/'AM<#I-;V1I9GE$871E/C(P
M,34M,#,M,3A4,38Z,#DZ,C4K,#4Z,S`\+WAM<#I-;V1I9GE$871E/@H@("`@
M("`@("`\>&UP.D-R96%T941A=&4^,C`Q-2TP,RTQ.%0Q-CHP.3HR-2LP-3HS
M,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@(#QX;7`Z0W)E871O<E1O;VP^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4
M;V]L/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR
M9&8Z06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM
M9SIH96EG:'0^,3(P/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@
M("`@/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@("`@
M("`@("`@("`@("`@("`\>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"
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M03MQ8FY*,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%9
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M1W`R<'5M)B-X03MK.4%1:5I#-6PU1D]&2R]A-4M6<#0T<6UE2W5X5C)+=DDU
M-U@X-F1-.#8V,7%7:S)4-FAP3GIC<W1N8EAT-FIW<D$V455K:&=.=T]*)B-X
M03M2-#5+3"LW;T=0,G%G2U969%)U+WHQ,51Y,65732MJ,CEH93-&<&-+='I9
M>G!&37,U<S1M:%=*=G)B96Q3-F569E4U3G-O*T9195=")B-X03M6.'9M4"]N
M24E)6%1Y=G`U26AH65)C-&E4355T=E=136(U4E%02F-C9EI&1F9I<FEQ2#%'
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M9C!M2EI#3C9Q-#1L4W%L2&YB>7HK6F0S<C`Y,V]'<%AD='`X='=O:W1L)B-X
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M3S=85'`U)B-X03MB,EI,57IG=$A)8FQ&:5%5=6)E='9*8G%'54(Q94YG,U%(
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M4V$V845'.41P1$Y-;T-Y-TM1<6EN-$MS>7A6:C`O:T1Y<E!Q63%+5WI,6%%M
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M<$,W2#=94W)Q94AX2U)4=&ER1#5D2G19:W9:;DUK.#`Y.652>G9+-TUR:&19
M<WAV1G1%2SDK2T1#:$8K5%%6,7EX2W-W)B-X03M!=5!30T)M-#A"<'AB:GAR
M>'!Y,S99;%AP*T),<U9D:7)S5E-J>D@U;'1.0F=3831G;75&8U-(:D%)>5%)
M:S5S5#9J>&IO35949D98)B-X03M9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M;&XO041J+T%0.$%(3C@U+W=$9U8V;B]!35)H>%8V;FER<U9D:7)S5F1I<G-6
M9&ER<U9D)B-X03MI<G-69&ER>3-Y8W5K,E`U:39L;V5M<T5E0U,U=3=I43)"
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M;BLX,%IR>38T<7%A<G`O2G18=G98:T)38E4T+W$O-W8P>41B86AU9F<U,2\R
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M2G5U-C`P;6UA83ES9S!P8E,S:6IU04)Z3$Q9451M<#E5)B-X03MN<DM2+V0O
M5&=3>FI!<G-643)P+SAC,C<O=T--36XO151I<D-8+W9R:B]J0S,O2FY3.$M'
M9'=85G1057=42DQX<'DT34=P6'!7;4)+)B-X03MP:7)S5F1I<GEB.&ER>3!S
M.48X-C-.,U!(8E<X9FUV575C,')+:4Q544%66FE!2VLP>%8V;EHS=&YE,C8S
M3FQ02&,R>C%#5'=U<VE-)B-X03M667$Q1U5K1VI!9RLK2W$R2W5X5C)+=7A6
M,DMP469.;FPU3#(T<S5B=U%3,F]*;F%D2&AI6&DV4FXY.4EQ>$4X-6M'>F(Q
M>%9--V$U)B-X03MT<G%"3&DR;%-E0U%6:FQJ64]J1'A$3%5(1E941EA9<3=&
M56PP9GED-60P83EM=F1.=&UT-VEC15-N,7`S4F=4>2]U,V1K-CE.='4R)B-X
M03M+;TQ8=DLR<C9L-6IS3E-T=%9E=W1,4#`O56=I371:94UV3F=Y."]3;U9(
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M>%(R.&)")B-X03M.='I7,%`X07=1>%95+U)0;6@P94@Y1C!.,7%6>'%G67I*
M4DDS:CE-4G1T<SE:3VYS8U923FQB*UI495)4='!"4F)H>&0P85I!54,S)B-X
M03M5."]".71N-#-9,B]Y5&EQ9#-/<#8W8U=8<')O>G$Q,DI)9T=M46-+;SE'
M9F)99D14-E)I;&IK9'0U:6YD;FHP=TU*5VQT5%-D1'=A)B-X03M.3%IE5%5'
M>6LR3%4O=T):8U5+63`O>DU59&PP=FQW,&=A1U9%>44K<U=#;51P.6=C<6XR
M>%9T,#$R2C):.5!50S!A2S)L+S!I4')*)B-X03M(8W)Z+W="5698;'(O<71I
M<3%.3CAW5V)16$5M;GI*1%EI-VLQ0F]B,6]J8TI,5C1&4FM:83A.:%1&5F91
M6#@W861Q16HS=VTQ1DEB)B-X03M%=6)0-GA'-%IJ=T-'33`U=3,W<#8Q+VU(
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M6F)A;G)T=EIE;3)J4TTQ;TDT:GAM43@V)B-X03M):$Q*='50:7`Y0GA3:T8K
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M03M7579*2$=95VA7,CE/;VQ)5FIY6FA135`R844Q1D966%5,2DE.879)-#12
M330X;'AW8TDU27='5E5J57-*;"M&9W%N<GDV9EI/*WEQ)B-X03M&:'5D5&@Q
M;E-95&)'468T6FXK<5)647%124QK3E-65V(T95%R<T-A52LQ55565&9Y1G`K
M<7IA:C5#=C%T6F)I>F=H,4%46&M82F]O)B-X03LK8S%W2U-%4FA63E-O,V5P
M4&)9;D9,,C5Y5E5K2U=)0DE557%F659)1T)8>GIP5VM8161H-5HK<FE&<G58
M>DI*96U#2S5I:S11>4=%)B-X03LO6F=E4TAM9U5+469I<'DT:D-H1S-E9S9H
M9&%:<55U;%%.<6M-,VU5,VI0855D4T-R;FUH:%=D6%9),C9L;#-.0W133591
M4&UR;D0O)B-X03M!22M7,VAA5V$T,6EZ-4Q'9TQ!9C92,$9+2&QX3S0S*TQC
M9'EQ=3%M,FAS2F90.$%B4W)3,'-R8E0P9W1O=T=B,$9E15%2:#(U-V]/)B-X
M03M.3R],9GAQ<7DO>41$1VXU;C-1161#;FPK>4-Y9D-0:%I984ME3S-W.&%F
M2VU*4VQ0-6%P22\U9"]M97-9<34Q>EA/2U569WA&=D=E)B-X03M*1$%G:'5H
M=TM5;C`R5W=G=69+5C)X84\Q1V=A:$UL=S-%=$=R3$].>E--14AN56-V16UT
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M:VE01S`S:V]E:DM*1F<T9W=U<F-P4E1O5%AK>C`S24\R)B-X03M+1W10=#E*
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M;V-A9'`T=D1E:3)I*W5%)B-X03M!1S4T3#9P04)59DA4;'-#4C%X5D59<3=&
M6%EQ-T9867$W1EA9<3AS+W=#8V8O.$%J;2MC+W=$=TLY5"]!3TEW-'%Q*V9.
M4W59=GI()B-X03LP93)(<EAE;G996$U6-7`P36A+=C8P8V<U3D98:CA&1G%X
M1WEM=$1467%N4#56>6%F82]L,5IZ,G-%<T9T1W,X:E(S13AC,&YW4U!8)B-X
M03ML3GAG:E`R9&I1040U6491+W=#4VE82RM3*U4K-U!D4W-S9TUB231#<7!+
M3D4P:V)+<DM50E9I3G-*5FYU0E=0,U!K:E-*634Q:6UU)B-X03LW9')M6C4U
M,U<T96)K,'-B4E-!3&-M9$9$>'564$92-U5X5E`P4E5255=V1E%!2VMK,$<S
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M8E=C53!D)B-X03MV27<U03AK;&Q)4E=59T=P+TAP:7%9*UA.36<P<E%.4#`R
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M03M69&ER<U99<#5T,51Z-5HV=G`X9FQV4S1T4W-P3&4V93DY6FQI0WIX*VTQ
M=6=K3&EN<69'=C)30G-C5EDU3#4P+T]92#DQ-4II6F50)B-X03LR:F1)4&DT
M1'%#=TY/6BM91S(U=W$Y2W1:2G!,84=395`P6FY25VQH<GDT35)6;'%/=$1T
M9U95>%8U6B]Z:B\O04UC,WIN+S1&97`O)B-X03LX4FAX5C9*<C`R<E$V4F-Y
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M:C`S34QW>6-A:TXX3&IC1$973&%F-48X+W="=75N;30X-E0S16QR3D4Y>%=%
M0EIO;&QK95--,5DO85(Q)B-X03M7<#=$-F-+=E%-0W5X5C)+=7A6:&8V4C`V
M1U!Z2G!D-4I,8GDS;'I/<5`X058U-4)W;'0T,$1G;VA6:#E/1D-2=D9P.'1R
M1&%T*VI9)B-X03M6:F5":F-1-E9D<DY31U)8<7)C9&U01')I<2M,4F9+,$YZ
M2E!$-6<Q:45Y6%EU,E=*2C!"<%1L1S-'1#1G>%5&;5!X1VY8<FEQ<G!E)B-X
M03MN95=.4'1(=&LQ,U9:,6MV23<V<S!D=S52,'%75TPY,2LW5GEX3&-D+V9&
M530X=39N-5HP4S-U65ER,C9U4')6>DID3DI,87HX<7E5)B-X03M&4&AI1F%"
M4G8Q4%4Q2DIX4W=7-#AR,D5U;#-';FDW<W%44GE20S5B4S=S>6HQ05)Z2G`Y
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M>&UP1TEM9SII;6%G93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@(#PO<F1F.D%L=#X*("`@("`@("`@/"]X;7`Z5&AU;6)N86EL<SX*
M("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(@H@("`@("`@("`@("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*("`@("`@("`@("`@>&UL;G,Z<W1%=G0](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B`@
M("`@("`@(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-3$X.$1"0S8R,T-$
M130Q,4%$13!!,C1$14$S0S5$.40\+WAM<$U-.DEN<W1A;F-E240^"B`@("`@
M("`@(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-3$X.$1"0S8R,T-$130Q
M,4%$13!!,C1$14$S0S5$.40\+WAM<$U-.D1O8W5M96YT240^"B`@("`@("`@
M(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$
M0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@("`@("`@("`\>&UP34TZ4F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]X
M;7!-33I296YD:71I;VY#;&%S<SX*("`@("`@("`@/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@/'-T
M4F5F.FEN<W1A;F-E240^=75I9#IF9F8P93@V82TX-F,W+31F,F4M8C9B,RTR
M8S(X.6-A,#@V.#0\+W-T4F5F.FEN<W1A;F-E240^"B`@("`@("`@("`@(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-$4X.$1"0S8R,T-$130Q,4%$13!!
M,C1$14$S0S5$.40\+W-T4F5F.F1O8W5M96YT240^"B`@("`@("`@("`@(#QS
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q
M.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@
M("`@("`@("`@("`\<W12968Z<F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]S
M=%)E9CIR96YD:71I;VY#;&%S<SX*("`@("`@("`@/"]X;7!-33I$97)I=F5D
M1G)O;3X*("`@("`@("`@/'AM<$U-.DAI<W1O<GD^"B`@("`@("`@("`@(#QR
M9&8Z4V5Q/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z
M:6YS=&%N8V5)1#YX;7`N:6ED.C5!1#DY0C0W-T$X.$4S,3%!,C@W0S@U,3$T
M,3(Q130Y/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@("`@("`@("`@("`\
M<W1%=G0Z=VAE;CXR,#$T+3`Q+3(X5#$Y.C(V.C`R+3`W.C`P/"]S=$5V=#IW
M:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*("`@("`@("`@("`@("`@("`@/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#HU,3@X1$)#-C(S0T1%-#$Q041%,$$R-$1%03-#-40Y1#PO<W1%=G0Z
M:6YS=&%N8V5)1#X*("`@("`@("`@("`@("`@("`@/'-T179T.G=H96X^,C`Q
M-2TP,RTQ.%0Q-CHP.3HR-2LP-3HS,#PO<W1%=G0Z=VAE;CX*("`@("`@("`@
M("`@("`@("`@/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*("`@("`@
M("`@("`@("`@("`@/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.E-E
M<3X*("`@("`@("`@/"]X;7!-33I(:7-T;W)Y/@H@("`@("`\+W)D9CI$97-C
M<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M("`@("`@("`@("`@>&UL;G,Z:6QL=7-T<F%T;W(](FAT='`Z+R]N<RYA9&]B
M92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B`@("`@("`@(#QI;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R
M;V9I;&4^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SIX;7!4
M4&<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*("`@("`@
M("`@("`@>&UL;G,Z<W1$:6T](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]$:6UE;G-I;VYS(R(*("`@("`@("`@("`@>&UL;G,Z<W1&;G0]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*("`@
M("`@("`@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+V<O(CX*("`@("`@("`@/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@("`@("`@("`\
M>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(
M87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@("`@("`@("`\>&UP5%!G.DY086=E
M<SXQ/"]X;7!44&<Z3E!A9V5S/@H@("`@("`@("`\>&UP5%!G.DUA>%!A9V53
M:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@/'-T
M1&EM.G<^,3$N,#`P,#`P/"]S=$1I;3IW/@H@("`@("`@("`@("`\<W1$:6TZ
M:#XX+C4P,#`P,#PO<W1$:6TZ:#X*("`@("`@("`@("`@/'-T1&EM.G5N:70^
M26YC:&5S/"]S=$1I;3IU;FET/@H@("`@("`@("`\+WAM<%109SI-87A086=E
M4VEZ93X*("`@("`@("`@/'AM<%109SI&;VYT<SX*("`@("`@("`@("`@/')D
M9CI"86<^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=$YA;64^
M07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B`@("`@("`@("`@("`@("`@(#QS
M=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@("`@
M("`@("`@("`@("`@("`\<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z
M9F]N=$9A8V4^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT5'EP93Y/
M<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@("`@("`@("`@("`@("`@("`\
M<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N,3`\+W-T1FYT.G9E<G-I
M;VY3=')I;F<^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IC;VUP;W-I=&4^
M1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*("`@("`@("`@("`@("`@("`@/'-T
M1FYT.F9O;G1&:6QE3F%M93YA<FEA;%\R+G1T9CPO<W1&;G0Z9F]N=$9I;&5.
M86UE/@H@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@
M("`@("`@(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU";VQD/"]S=$9N=#IF;VYT
M3F%M93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O;G1&86UI;'D^5&EM
M97,\+W-T1FYT.F9O;G1&86UI;'D^"B`@("`@("`@("`@("`@("`@(#QS=$9N
M=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*("`@("`@("`@("`@
M("`@("`@/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^
M"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IV97)S:6]N4W1R:6YG/C`P,2XP
M,#<\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B`@("`@("`@("`@("`@("`@(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*("`@("`@
M("`@("`@("`@("`@/'-T1FYT.F9O;G1&:6QE3F%M93Y424)?7U]?+E!&0CL@
M5$E"7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*("`@("`@("`@("`@
M("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N
M=$YA;64^5F5R9&%N83PO<W1&;G0Z9F]N=$YA;64^"B`@("`@("`@("`@("`@
M("`@(#QS=$9N=#IF;VYT1F%M:6QY/E9E<F1A;F$\+W-T1FYT.F9O;G1&86UI
M;'D^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R
M/"]S=$9N=#IF;VYT1F%C93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.F9O
M;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B`@("`@("`@("`@
M("`@("`@(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@,BXT,SPO<W1&
M;G0Z=F5R<VEO;E-T<FEN9SX*("`@("`@("`@("`@("`@("`@/'-T1FYT.F-O
M;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@("`@("`@("`@("`@
M("`@("`\<W1&;G0Z9F]N=$9I;&5.86UE/G9E<F1A;F%?,"YT=&8\+W-T1FYT
M.F9O;G1&:6QE3F%M93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@(#PO<F1F.D)A9SX*("`@("`@("`@/"]X;7!44&<Z1F]N=',^"B`@
M("`@("`@(#QX;7!44&<Z4&QA=&5.86UE<SX*("`@("`@("`@("`@/')D9CI3
M97$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*("`@
M("`@("`@("`@/"]R9&8Z4V5Q/@H@("`@("`@("`\+WAM<%109SI0;&%T94YA
M;65S/@H@("`@("`@("`\>&UP5%!G.E-W871C:$=R;W5P<SX*("`@("`@("`@
M("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\>&UP1SIG<F]U
M<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7`\+WAM<$<Z9W)O=7!.86UE/@H@
M("`@("`@("`@("`@("`@("`\>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U
M<%1Y<&4^"B`@("`@("`@("`@("`@("`@(#QX;7!'.D-O;&]R86YT<SX*("`@
M("`@("`@("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/E=H:71E
M/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO
M>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM
M86=E;G1A/C`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL
M;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N
M,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G-W871C:$YA;64^0FQA8VL\+WAM<$<Z<W=A=&-H3F%M93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM
M<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M>65L;&]W/C`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,3`P+C`P,#`P,#PO>&UP1SIB;&%C
M:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.
M86UE/D--64L@4F5D/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA
M;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIM86=E;G1A/C$P,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C$P,"XP
M,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@
M("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@
M("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D--64L@665L
M;&]W/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P
M,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM86=E;G1A/C`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXQ,#`N,#`P,#`P/"]X;7!'
M.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA
M8VL^,"XP,#`P,#`\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@
M("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#35E+($=R965N/"]X;7!'.G-W
M871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXQ,#`N,#`P,#`P/"]X;7!'.F-Y
M86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^
M,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z>65L;&]W/C$P,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P
M,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z
M;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIS=V%T8VA.86UE/D--64L@0WEA;CPO>&UP1SIS=V%T8VA.86UE/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F-Y86X^,3`P+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X
M;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K
M/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@
M("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA
M;64^0TU92R!";'5E/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA
M;CXQ,#`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.FUA9V5N=&$^,3`P+C`P,#`P,#PO>&UP1SIM86=E;G1A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,"XP
M,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@
M("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@
M("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D--64L@36%G
M96YT83PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,"XP,#`P
M,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z;6%G96YT83XQ,#`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP
M1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L
M86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@
M("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STQ-2!-/3$P,"!9/3DP($L]
M,3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C$T+CDY.3DY
M.#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM86=E;G1A/C$P,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/CDP+C`P,#`P-#PO>&UP
M1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L
M86-K/C$P+C`P,#`P,CPO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@
M("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,],"!-/3DP(%D].#4@2STP
M/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO
M>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM
M86=E;G1A/CDP+C`P,#`P-#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^.#0N.3DY.3DV/"]X;7!'.GEE
M;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^
M,"XP,#`P,#`\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@
M(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3`@33TX,"!9/3DU($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^,"XP,#`P,#`\+WAM<$<Z
M8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT
M83XX,"XP,#`P,#$\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z>65L;&]W/CDT+CDY.3DY.3PO>&UP1SIY96QL;W<^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P
M,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G-W871C:$YA;64^0STP($T]-3`@63TQ,#`@2STP/"]X;7!'.G-W
M871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C4P
M+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P
M/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL
M:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.G-W871C:$YA;64^0STP($T],S4@63TX-2!+/3`\+WAM<$<Z<W=A=&-H
M3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,S4N,#`P
M,#`R/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.GEE;&QO=SXX-"XY.3DY.38\+WAM<$<Z>65L;&]W/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP
M1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@
M("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS
M=V%T8VA.86UE/D,]-2!-/3`@63TY,"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIC>6%N/C4N,#`P,#`Q/"]X;7!'.F-Y86X^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM
M<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M>65L;&]W/CDP+C`P,#`P-#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K
M/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@
M("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA
M;64^0STR,"!-/3`@63TQ,#`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z8WEA;CXQ.2XY.3DY.3D\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM
M86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL
M;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@
M("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@
M("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^
M0STU,"!-/3`@63TQ,#`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z8WEA;CXU,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM86=E
M;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^
M,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STW
M-2!-/3`@63TQ,#`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M8WEA;CXW-2XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P
M+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STX-2!-
M/3$P(%D],3`P($L],3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC
M>6%N/C@T+CDY.3DY-CPO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIM86=E;G1A/C$P+C`P,#`P,CPO>&UP1SIM86=E;G1A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,3`P
M+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F)L86-K/C$P+C`P,#`P,CPO>&UP1SIB;&%C:SX*("`@("`@
M("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,].3`@
M33TS,"!9/3DU($L],S`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC
M>6%N/CDP+C`P,#`P-#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIM86=E;G1A/C,P+C`P,#`P,3PO>&UP1SIM86=E;G1A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^.30N
M.3DY.3DY/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z8FQA8VL^,S`N,#`P,#`Q/"]X;7!'.F)L86-K/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STW-2!-
M/3`@63TW-2!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N
M/C<U+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXW-2XP,#`P
M,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@
M("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,].#`@33TQ,"!9
M/30U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^.#`N
M,#`P,#`Q/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.FUA9V5N=&$^,3`N,#`P,#`R/"]X;7!'.FUA9V5N=&$^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXT-"XY.3DY.3D\
M+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@
M("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,]-S`@33TQ-2!9/3`@
M2STP/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXV.2XY.3DY
M.3D\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z;6%G96YT83XQ-"XY.3DY.3@\+WAM<$<Z;6%G96YT83X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C`N,#`P,#`P/"]X;7!'
M.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA
M8VL^,"XP,#`P,#`\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@
M("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T]-3`@63TP($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^.#0N.3DY.3DV/"]X
M;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA
M9V5N=&$^-3`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL
M;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N
M,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G-W871C:$YA;64^0STQ,#`@33TY-2!9/34@2STP/"]X;7!'
M.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXQ,#`N,#`P,#`P/"]X;7!'
M.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N
M=&$^.30N.3DY.3DY/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.GEE;&QO=SXU+C`P,#`P,3PO>&UP1SIY96QL;W<^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P
M,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G-W871C:$YA;64^0STQ,#`@33TQ,#`@63TR-2!+/3(U/"]X;7!'
M.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXQ,#`N,#`P,#`P/"]X;7!'
M.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N
M=&$^,3`P+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIY96QL;W<^,C4N,#`P,#`P/"]X;7!'.GEE;&QO
M=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,C4N
M,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3$P,"!9/3`@2STP/"]X;7!'
M.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXW-2XP,#`P,#`\+WAM<$<Z
M8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT
M83XQ,#`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P
M,#`P/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3$P,"!9/3`@2STP/"]X;7!'.G-W
M871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXU,"XP,#`P,#`\+WAM<$<Z8WEA
M;CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XQ
M,#`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P
M/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL
M:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.G-W871C:$YA;64^0STS-2!-/3$P,"!9/3,U($L],3`\+WAM<$<Z<W=A
M=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIC>6%N/C,U+C`P,#`P,CPO>&UP1SIC>6%N
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C$P
M,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z>65L;&]W/C,U+C`P,#`P,CPO>&UP1SIY96QL;W<^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C$P+C`P,#`P
M,CPO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z
M;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIS=V%T8VA.86UE/D,],3`@33TQ,#`@63TU,"!+/3`\+WAM<$<Z<W=A
M=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIC>6%N/C$P+C`P,#`P,CPO>&UP1SIC>6%N
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C$P
M,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z>65L;&]W/C4P+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P
M/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL
M:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.G-W871C:$YA;64^0STP($T].34@63TR,"!+/3`\+WAM<$<Z<W=A=&-H
M3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^.30N.3DY
M.3DY/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.GEE;&QO=SXQ.2XY.3DY.3D\+WAM<$<Z>65L;&]W/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP
M1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@
M("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS
M=V%T8VA.86UE/D,],C4@33TR-2!9/30P($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.F-Y86X^,C4N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,C4N,#`P,#`P
M/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.GEE;&QO=SXS.2XY.3DY.3@\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB
M;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T
M8VA.86UE/D,]-#`@33TT-2!9/34P($L]-3PO>&UP1SIS=V%T8VA.86UE/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.F-Y86X^,SDN.3DY.3DX/"]X;7!'.F-Y86X^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^-#0N.3DY.3DY/"]X
M;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.GEE;&QO=SXU,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXU+C`P,#`P,3PO>&UP1SIB;&%C
M:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.
M86UE/D,]-3`@33TU,"!9/38P($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIC>6%N/C4P+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C4P+C`P,#`P,#PO>&UP
M1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY
M96QL;W<^-C`N,#`P,#`R/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z8FQA8VL^,C4N,#`P,#`P/"]X;7!'.F)L86-K
M/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@
M("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA
M;64^0STU-2!-/38P(%D]-C4@2STT,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.F-Y86X^-34N,#`P,#`Q/"]X;7!'.F-Y86X^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^-C`N,#`P,#`R/"]X;7!'
M.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE
M;&QO=SXV-"XY.3DY.3@\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIB;&%C:SXS.2XY.3DY.3@\+WAM<$<Z8FQA8VL^
M"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@
M("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M
M93Y#/3(U($T]-#`@63TV-2!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIC>6%N/C(U+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C,Y+CDY.3DY.#PO>&UP1SIM
M86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL
M;W<^-C0N.3DY.3DX/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z8FQA8VL^,"XP,#`P,#`\+WAM<$<Z8FQA8VL^"B`@
M("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@
M("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#
M/3,P($T]-3`@63TW-2!+/3$P/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z8WEA;CXS,"XP,#`P,#$\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XU,"XP,#`P,#`\+WAM<$<Z;6%G
M96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W
M/C<U+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.F)L86-K/C$P+C`P,#`P,CPO>&UP1SIB;&%C:SX*("`@
M("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@
M("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,]
M,S4@33TV,"!9/3@P($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIC>6%N/C,U+C`P,#`P,CPO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIM86=E;G1A/C8P+C`P,#`P,CPO>&UP1SIM86=E
M;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^
M.#`N,#`P,#`Q/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8FQA8VL^,C4N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STT
M,"!-/38U(%D].3`@2STS-3PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.F-Y86X^,SDN.3DY.3DX/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.FUA9V5N=&$^-C0N.3DY.3DX/"]X;7!'.FUA9V5N
M=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXY
M,"XP,#`P,#0\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIB;&%C:SXS-2XP,#`P,#(\+WAM<$<Z8FQA8VL^"B`@("`@
M("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@
M("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/30P
M($T]-S`@63TQ,#`@2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.F-Y86X^,SDN.3DY.3DX/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.FUA9V5N=&$^-CDN.3DY.3DY/"]X;7!'.FUA9V5N
M=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXQ
M,#`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8FQA8VL^-3`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STU
M,"!-/3<P(%D].#`@2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.F-Y86X^-3`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.FUA9V5N=&$^-CDN.3DY.3DY/"]X;7!'.FUA9V5N
M=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXX
M,"XP,#`P,#$\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIB;&%C:SXV.2XY.3DY.3D\+WAM<$<Z8FQA8VL^"B`@("`@
M("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@
M("`@("`\+W)D9CI397$^"B`@("`@("`@("`@("`@("`@(#PO>&UP1SI#;VQO
M<F%N=',^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@
M("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@
M("`@("`@("`@/'AM<$<Z9W)O=7!.86UE/D=R87ES/"]X;7!'.F=R;W5P3F%M
M93X*("`@("`@("`@("`@("`@("`@/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z
M9W)O=7!4>7!E/@H@("`@("`@("`@("`@("`@("`\>&UP1SI#;VQO<F%N=',^
M"B`@("`@("`@("`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@
M("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#
M/3`@33TP(%D],"!+/3$P,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.F-Y86X^,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,"XP
M,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIB;&%C:SXQ,#`N,#`P,#`P/"]X;7!'.F)L86-K/@H@("`@("`@
M("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@("`@
M("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP($T]
M,"!9/3`@2STY,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y86X^
M,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,"XP,#`P,#`\
M+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIB;&%C:SXX.2XY.3DT,#(\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@
M("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3`@33TP(%D],"!+
M/3@P/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P
M,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIM86=E;G1A/C`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY
M96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K
M/C<Y+CDY.#<Y-SPO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@("`@
M("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,],"!-/3`@63TP($L]-S`\+WAM
M<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'
M.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N
M=&$^,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/'AM<$<Z>65L;&]W/C`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^-CDN.3DY
M-S`Q/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D
M9CIL:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3`@2STV,#PO>&UP1SIS=V%T
M8VA.86UE/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.F-Y86X^,"XP,#`P,#`\+WAM<$<Z8WEA;CX*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6%G96YT83XP+C`P
M,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIY96QL;W<^,"XP,#`P,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXU.2XY.3DQ,#(\+WAM
M<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@
M("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z
M<W=A=&-H3F%M93Y#/3`@33TP(%D],"!+/34P/"]X;7!'.G-W871C:$YA;64^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X
M;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.F)L86-K/C4P+C`P,#`P,#PO>&UP1SIB;&%C
M:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3`@63TP($L]-#`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G
M96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z>65L;&]W
M/C`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z8FQA8VL^,SDN.3DY-#`R/"]X;7!'.F)L86-K/@H@("`@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@
M("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA;64^0STP
M($T],"!9/3`@2STS,#PO>&UP1SIS=V%T8VA.86UE/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F-Y
M86X^,"XP,#`P,#`\+WAM<$<Z8WEA;CX*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@/'AM<$<Z;6%G96YT83XP+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL;W<^,"XP,#`P
M,#`\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIB;&%C:SXR.2XY.3@X,#,\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@
M("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@
M("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3`@33TP(%D]
M,"!+/3(P/"]X;7!'.G-W871C:$YA;64^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P
M,#`P,#PO>&UP1SIC>6%N/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIM86=E;G1A/C`N,#`P,#`P/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.GEE;&QO=SXP+C`P,#`P,#PO>&UP
M1SIY96QL;W<^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L
M86-K/C$Y+CDY.3<P,3PO>&UP1SIB;&%C:SX*("`@("`@("`@("`@("`@("`@
M("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`\>&UP1SIS=V%T8VA.86UE/D,],"!-/3`@63TP($L],3`\
M+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X
M;7!'.F-Y86X^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA
M9V5N=&$^,"XP,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z>65L;&]W/C`N,#`P,#`P/"]X;7!'.GEE;&QO
M=SX*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^.2XY
M.3DQ,#(\+WAM<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO
M<F1F.FQI/@H@("`@("`@("`@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z<W=A=&-H3F%M93Y#/3`@33TP(%D],"!+/34\+WAM<$<Z<W=A
M=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,"XP
M,#`P,#`\+WAM<$<Z;6%G96YT83X*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z>65L;&]W/C`N,#`P,#`P/"]X;7!'.GEE;&QO=SX*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z8FQA8VL^-"XY.3@X,#,\+WAM
M<$<Z8FQA8VL^"B`@("`@("`@("`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@
M("`@("`@("`@("`@("`@("`@("`\+W)D9CI397$^"B`@("`@("`@("`@("`@
M("`@(#PO>&UP1SI#;VQO<F%N=',^"B`@("`@("`@("`@("`@(#PO<F1F.FQI
M/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$<Z9W)O=7!.86UE/D)R:6=H
M=',\+WAM<$<Z9W)O=7!.86UE/@H@("`@("`@("`@("`@("`@("`\>&UP1SIG
M<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y<&4^"B`@("`@("`@("`@("`@("`@
M(#QX;7!'.D-O;&]R86YT<SX*("`@("`@("`@("`@("`@("`@("`@/')D9CI3
M97$^"B`@("`@("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3$P,"!9/3$P,"!+/3`\+WAM<$<Z<W=A
M=&-H3F%M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,3`P
M+C`P,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P
M/"]X;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL
M:3X*("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.G-W871C:$YA;64^0STP($T]-S4@63TQ,#`@2STP/"]X;7!'.G-W871C
M:$YA;64^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/'AM<$<Z8WEA;CXP+C`P,#`P,#PO>&UP1SIC>6%N/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C<U+C`P
M,#`P,#PO>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\>&UP1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X
M;7!'.F)L86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*
M("`@("`@("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.G-W871C:$YA;64^0STP($T],3`@63TY-2!+/3`\+WAM<$<Z<W=A=&-H3F%M
M93X*("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIC>6%N/C`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^,3`N,#`P,#`R
M/"]X;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX
M;7!'.GEE;&QO=SXY-"XY.3DY.3D\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,#`P,#PO>&UP1SIB
M;&%C:SX*("`@("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@
M("`@("`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIS=V%T
M8VA.86UE/D,].#4@33TQ,"!9/3$P,"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`\>&UP1SIC>6%N/C@T+CDY.3DY-CPO>&UP1SIC>6%N/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/C$P+C`P,#`P,CPO
M>&UP1SIM86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP
M1SIY96QL;W<^,3`P+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L
M86-K/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@
M("`@("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C
M:$YA;64^0STQ,#`@33TY,"!9/3`@2STP/"]X;7!'.G-W871C:$YA;64^"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@/'AM<$<Z8WEA;CXQ,#`N,#`P,#`P/"]X;7!'.F-Y86X^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#QX;7!'.FUA9V5N=&$^.3`N,#`P,#`T/"]X
M;7!'.FUA9V5N=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'
M.GEE;&QO=SXP+C`P,#`P,#PO>&UP1SIY96QL;W<^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#QX;7!'.F)L86-K/C`N,#`P,#`P/"]X;7!'.F)L86-K
M/@H@("`@("`@("`@("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@
M("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G-W871C:$YA
M;64^0STV,"!-/3DP(%D],"!+/3`\+WAM<$<Z<W=A=&-H3F%M93X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B`@("`@("`@("`@("`@("`@("`@("`@("`@(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\
M>&UP1SIC>6%N/C8P+C`P,#`P,CPO>&UP1SIC>6%N/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`\>&UP1SIM86=E;G1A/CDP+C`P,#`P-#PO>&UP1SIM
M86=E;G1A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`\>&UP1SIY96QL
M;W<^,"XP,#,P.3D\+WAM<$<Z>65L;&]W/@H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\>&UP1SIB;&%C:SXP+C`P,S`Y.3PO>&UP1SIB;&%C:SX*("`@
M("`@("`@("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@("`@
M("`@("`@(#PO<F1F.E-E<3X*("`@("`@("`@("`@("`@("`@/"]X;7!'.D-O
M;&]R86YT<SX*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@
M(#PO<F1F.E-E<3X*("`@("`@("`@/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@
M("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z<&1F/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0<F]D=6-E
M<CY!9&]B92!01$8@;&EB<F%R>2`Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@("`@
M("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z17AT96YS:7-&;VYT4V5N
M<V4](FAT='`Z+R]W=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E;G-E+R(^
M"B`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@("`@("`@("`@
M("`\<F1F.D)A9SX*("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O
M;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP92`M(%14/"]%>'1E;G-I<T9O;G13
M96YS93I&;VYT2VEN9#X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N
M=%-E;G-E.D9A;6EL>3Y697)D86YA/"]%>'1E;G-I<T9O;G1396YS93I&86UI
M;'D^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I/=71L
M:6YE1FEL95-I>F4^,#PO17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53
M:7IE/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]U
M;F1R>3Y-:6-R;W-O9G0\+T5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^"B`@
M("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I697)S:6]N/C4N
M,#,\+T5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^"B`@("`@("`@("`@("`@
M("`@(#Q%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS=6T^,#PO17AT
M96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/@H@("`@("`@("`@("`@
M("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U
M;3XR,S<P-S4U.3DR/"]%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR
M7T-H96-K<W5M/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N
M<V4Z0VAE8VMS=6T^,C,W,#<U-3DY,CPO17AT96YS:7-&;VYT4V5N<V4Z0VAE
M8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I0
M;W-T4V-R:7!T3F%M93Y697)D86YA/"]%>'1E;G-I<T9O;G1396YS93I0;W-T
M4V-R:7!T3F%M93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@
M("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@
M("`@("`@("`@("`@("`\17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^4&]S
M=%-C<FEP=#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B`@("`@("`@
M("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I&86UI;'D^5&EM97,\+T5X
M=&5N<VES1F]N=%-E;G-E.D9A;6EL>3X*("`@("`@("`@("`@("`@("`@/$5X
M=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93XS.38W.3PO17AT96YS
M:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@("`@("`@("`@("`@("`@
M("`\17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y,:6YO='EP92!!1SPO17AT
M96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3X*("`@("`@("`@("`@("`@("`@/$5X
M=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^,#`Q+C`P,#PO17AT96YS:7-&;VYT
M4V5N<V4Z5F5R<VEO;CX*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N
M=%-E;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS93I+
M97)N:6YG0VAE8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O
M;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C(Y,#`V-#,Y,C4\+T5X
M=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B`@("`@
M("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XR.3`P
M-C0S.3(U/"]%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*("`@("`@("`@
M("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/E1I
M;65S+4)O;&0\+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@
M("`@("`@("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@
M(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP92`M(%14/"]%
M>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*("`@("`@("`@("`@("`@("`@
M/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y!<FEA;#PO17AT96YS:7-&;VYT
M4V5N<V4Z1F%M:6QY/@H@("`@("`@("`@("`@("`@("`\17AT96YS:7-&;VYT
M4V5N<V4Z3W5T;&EN949I;&53:7IE/C`\+T5X=&5N<VES1F]N=%-E;G-E.D]U
M=&QI;F5&:6QE4VEZ93X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N
M=%-E;G-E.D9O=6YD<GD^36]N;W1Y<&4@5'EP;V=R87!H>3PO17AT96YS:7-&
M;VYT4V5N<V4Z1F]U;F1R>3X*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES
M1F]N=%-E;G-E.E9E<G-I;VX^-2XQ,#PO17AT96YS:7-&;VYT4V5N<V4Z5F5R
M<VEO;CX*("`@("`@("`@("`@("`@("`@/$5X=&5N<VES1F]N=%-E;G-E.DME
M<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE
M8VMS=6T^"B`@("`@("`@("`@("`@("`@(#Q%>'1E;G-I<T9O;G1396YS93I&
M;VYT4V5N<V5?,2XR7T-H96-K<W5M/C(U.3`Y-#4X-3`\+T5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B`@("`@("`@("`@("`@
M("`@(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XR-3DP.30U.#4P/"]%
M>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*("`@("`@("`@("`@("`@("`@
M/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/D%R:6%L350\+T5X
M=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@("`@("`@("`@("`@
M("`\+W)D9CIL:3X*("`@("`@("`@("`@/"]R9&8Z0F%G/@H@("`@("`@("`\
M+T5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B`@("`@(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@("`\+W)D9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"CP_>'!A8VME="!E;F0](G<B/S[_VP!#``$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0'_VP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`#1`<$#`1$`
M`A$!`Q$!_\0`'P`!``("`P$!`0$```````````<(!@D$!0H#`0(+_\0`41``
M`@("`P`!`00%!PD%!`8+!08#!`('``$("102$Q46$1<X>+D9(3<Y.EAS"A@B
M(WF8M[C6)#%VL[8E='5W-4%1<;&T)B<R,S0V5'*5U=?_Q``8`0$!`0$!````
M`````````````0(#!/_$`#P1``(!`@,%!08%!`,``@,````!$0(A,4%1$F%Q
M@;$RD:'!\`,B0E)RT4.2LN'Q,X*SPQ-BPE-CDZ+2_]H`#`,!``(1`Q$`/P#W
M\<`<`<`<`<`<`<`<`<`\[&C_`)3-_7/1E/7^V"^KH=65O>_OORPY-K,F&]?B
MQ&N/+R[$5U:35G_HOFMLF\&N]7)_CVO:-`S.Q@JE\B&!)D(G*]?'1T6M+>S2
M]>UCR+K`/ET\]."]J5@2=<;Y<(]XONJ]>ZQHAE_6D,S&7W7J=VW%K:U^*FMK
MB5<;5,K.O&L:7H%#]-E1V8?$)?@"OA>HV[`FPU.%DV^3A]3*M/?)YHST?1UU
MAH]/WDY7MCZVU#LLI^!(02_<TJK[W:'!(0C6V*7YJF[HPTCZ*USM5A4A=Q*L
M$"9L1VY`O7QA"^(Z&IF%#:XQ$QWHIEY@^;54)>3$_9_J#7.R:FV:/G72GH-Y
MZUNIH_Y1<$[>7H,QYO6F'6M&YMJT2K5!&QQ\0IC".DRV?@J=]F@E`\-DPEY)
M\O%P6JB*FEA+5^$WMT+6K?RQZ08'2R@3:=])A6BL>]>)7X7*EH+20N[)\4!J
M;)N/6@01KC:+P=8V^ZN$1IA`[7A91<<>[]<'48:[1U."AI-G>LGGA5R[SX2?
M+AY^L#ZLBSK3?3RQ7_1X[RK12$\%K`DR7-NG]&3^A%4=7LVMM#U3,6SHE:>K
M4O?F;J8(T0S`G&FLR033QALO51L[4WPF)PG'<=9Y`^0@MNWTUZ8\X.X66%W1
M]Q3PH"#7K):[L+7.D(=(Z+?R3!ND)?V%G:LV0NP-N]:]SNH])CDG+XQU(J-R
MF&.,,(.F$GDUCE.U4H7)3<@KV5[A]I:M]G[N\Y>:5<+M`LI^(=9>E-/ZSZU"
MSNY1SVDT>@+VI2B,U,2L>"X+2#;6@MTQ^:B]Y<KK!BUF1)L5D-2Q"V'KH6FE
M-)MQ-33PLH3\S*?.GREG;6T]PZ:]'ZW<\F^MZL]::=TY?U,I!VD)<%>8M!(F
M^3^M"50:XSOC1M'I?+-72^3`Z\A6W*2H)$5+-$_:PH6`V+2FL$W.4N-(CF2C
M9^8WR70H$K!6IL4&0%[76M,613#%K)=KQO+IH>+T(G#;3L=V@.U@'L,RI/"K
M#`[`]B&;'964B3?`T2%:W)7#8J\)SPF-)\.J+':3]VZ/]`;B=-+:ZC<+QU'-
M;@7"#)8$#.TZVP:(<E=`V6%C(#3I(J&("VIJ@H`X6\*L].]0,S&TC)B`@KI/
M$1TM*7G'BI7AW9D/)OIG=(_Y.&SR/L8RLS:M8O,$^ZM6Y9Z>>T8E;=0&Q!0!
MH4T;9)$V<3MKB5!+85TGL.YU&OF![&P`_P`%#PC.SHX($+9G.4L4\4^:P?K'
MY_(7Z1]2^8+NJMF:$U^%W-K1/#[!V3Z?U%&)LV-HG=)I!;7`1D8M)DZQ*G6R
M>TN#86;=*L&*EVDTA@%P?3G'D>HL;X4I-P[-X/*=^[@5$V%\J1531]6>A:#"
MQM7B+:DF_+DOK;5.F)=K"=,D0S2JB]#1[N0@EF-H#:AL!(MB];+.#Q=5UM.H
MD>J5"*#:IDHYA=C%85*+-I3K#UPX*<2R'GGUUMOU5Z1]*Z(1W/7ZT$\G:6\H
M%K>R`2U(Z!=U;<]-:KO[8IM8ZN1)A\XM#AP%4;'0"A9%]S;;!:S<J/ZY4H0U
MK(.E)4OYG5;1)QW^&YG:>;?1OH]K]][\\K;B-H-P)I'R]YDV7<Q2EF<?U=VE
MMBB>J;#CK&B-Z>Y82AYQ7N6$ZG*.I%X:!#"(S?(2U^N^Q&DJ4U-W5W*/N?'3
MOIST!Z\<?D`%:/.H6LH_*.XS7FO3=-R5+38*>]GJJ*&8F9VVU)5,##':"4.L
MHP2F#$&\M$AXL;=92Q=MZ)5UP<#26S,W4OA+5M\(RCVGZ*W/I[T+\>^IM;GE
MP*#]3;J>=6['M%U:)BOCQRYJE@?QQ-6EE(4(J)'LH"QH6^K\)*I8&VI.HJU6
MW'A9X"2:J>B4<VD5BUY\RJPF:KWXP^J==M=0]YA]%>I_/VQWO3:CWWJIB_S8
MF#7%:\X!I'ATK_@1MO6-I"#H74T;8X/!+\F[(R7HC42YW#D-.BZCXDFD\5,[
MM5C$76I8<=\E8.L\>J`S7IG9$"?YX]"IGGP4T*\:L;A82C/I$3N3)M;+Q%L!
M!-;JLL!2N&'&7&^'!XW"JB+OFX&QH[6!`FQ9.5=-]SB%FWP1>+0>[$CTEI35
M>_=:R%)4+<"*N;!4^S@_\*-1A&8;`3IURX[[ZSA3)U<)_IKT$-JW7PM12]5K
M=JO]U8D&6FFT\58ES@@X`X`X`X!X?KG]LRA_Q:O\+C#@]'X'KYST\;U]2.HC
MW+Y;\0(.%-;RW-K?<.ZMC[+NCH2A8,CZOC%BA*KKNB0^^`?FUE:C5><P:8AI
MX>`5Q=F&NNWR1^F4`#BE[KJT:2XO7DO'')T\]K^X?0WB;=7D5.W!MO5X#5FZ
M,_<AK9VQ5_2C6SV%C7OGG44>T-3GJBH./&S4)O/NW6&;=QAS*A2->I?,+?:&
M/S[S&BTTJI51,K9A2KMM)XK/+3>?WK'W1[!:MG_#.I;37]9ZT(>]-5^F'S?J
M>IUJS=1&2:6UPO[)UW>UFUQLIR`2+V$'919!AH7[[E,+%W(A`PO7+4[)JR+L
MJ/:--O9:CFXO;[$F?(C[!W[XJVKH38>)="N>.MME"^C7TC=H#1K9I;>S11OC
M=/[$8FPC?MCI=%V&KNJ-V;/VLRE4/NGD7^M.1DJ:I()32JE5CM)2MZ6//2]R
M8MI>@]X::];_`!T><;QY#=5?TM1]'UMNM&2,2"--H[I+2L^P!Q!,ZHN5L&N@
M31V]5QF!70S$4JCQD-;%GMRV[5C)G''R^Y$DZ:G>:8CFTK^OWH!YU^6[=>[D
MYS8<%5$%EFCXVMK_`"%ZK@*+QJ^&3<]:^A=OZICU>VP#6@)?9:)-07-<7,B4
M!<*6P;<=@%8IL@))?5U85T1^94MY72P\?2O<+:'L'<J]\-M;W:!D4J6\>O#N
MM_2LL$Z_/=1IG@]JQ7>S8SM>E+8W\%NV1)WJ=>I@=Z(4J></V2<LT/<DHE-*
M=:IRF-Y3F?Y$_>RJZZ0E.ZAIL&EMM>G_`![J!"<9=9W-<NVY16[/,.U-L[P6
M5%?V,[*8N,AKW8R.N@4G9EV9512H<\1&VLC]@38:(!K9IO>Z53?*I)9:.ZQM
MR+JKGRZ>8F58\YND"QNP6I^G>M(P:_8#J0#%#*IC?&SF33ZVMDK$[CWB<8%1
M[7<*&R:&NNGOI)&,BBQD9LE]@J$NAG8=\+3-]%/BL-;Z'$J_,+Y*)`QQD/B]
M&;!O8C5JL"MT<M88-E]Z15G:3BY+14!?V?2N(#`OKFJ21"=9VATCM!'-K01P
M((5*-$-*N&Q5W7SSC=OZY$L>Q]R[WH>/27H#R*SH:\Q1:YK[34!NUM4.;V8V
M==+!1Y+6>E`2"):T`X"<]NL!<.FUR%N<R<!F;],#11BI<QB07PI2VHJG&'&6
MKSPQ,?\`9&WO;>N_/>DM@^;M>Z^9?09!@7;VQM`,O=HF->!8C53CL[:&L4)N
M&$*\PAYDP1RH#7[#+&8$W2LU6$@,LQW(K%8%LRTYC)J.3<Y:X%-[ORLFW+20
MOUCI@#LW:'F:UO\`&)&Z(]5ZO&-WH+S%KVGY\$MC=V;UI--9G*'T;?+*%5MI
MD;0@[`IZ]K6[@<(6LDA39F+L7V6X;4J<&YUWK#>2?Y[]]-WJ/TMJCSAK+9J`
MQI93Q<2]D-'HM#3"%#K8U!FW81U7JU00DE[FO?D*N+IC2!/:\#14:#XX]4Z0
MA]H03I%&'L'3";<SM;,/)I2\,<;=YG"WZ(]3@OD?TSX\VBT:P*K35Y&W%Z"<
M;R,C$0O9%D3=Z5-?IE9?E.L9Z^O+Q%&80I0^"O660K29Z=NM3;K@S+K.42%L
MNI3VDN]-OQ1GBYZAV/N_WGZ<\DZ]*!M=*?D_3^EVL\W6EZ%J.OVSM[5F(\M5
M(:UZ]5&PZP3UQ>^X:*`OJBVLC$3[J#7-/@#2?BP1%-+U;[E'C<Q7W)Z+]+>7
M_/?D`_6.:XQW)LOTUY+\[[KOCE.\30[,^Y3=)2V8:0!)8Q$8$842^5PDC]F"
M93Z2G]Q6.U2V?>6>(4I-U8PE4UK92IMWD?K'R?W-<[8]I:0]#(AMJ+>2MO:]
M3J>Q]-*L=%894;;_`)^9_0R*3>\G-RJ*FO6(2'4".OCQ0F[#EMFV(<1QJ^."
M6&ZJ%IB[/9:S6>J<.-5GPG0RU$^51'?W;9TZ]J/:!K2:/YA\;>D03XO"!AAI
M9`_L,L>A7,;B/@>@)K@55"U!I9I-DL>AZU0#;!/M=T"L+P<LQ".F,[[55+7T
MQNW]"[OF7TIKKUAJN';NL,#D"YVY;$0;E)BKBH2H]GU>\GM?-5.24`885\C5
MP/+MZ086`GBXDJ+EIWZEW/&?O",1J'#W>*GS+`\$'`/C9EDAKSS15Y;DL4,L
ML52#*#">U)'AEEA7ASM35ZV$L^774<>5BQ!!CGEUW--%'UEGB!K--_(`V@X@
MN=S2X6*T0LU%<D.RV3;SS&/;$P>F%Y:K87(4.2.ZET+WF^YVW-F->*R/'-%D
MN/`W(TZ[2,#43GX8Q&_?9$L4?=^J09;7*5M<9L%,?-C;%,:D$6E_3F]'S3L[
M^-W<\:#&B)-]`-6R:J7;36Z(EZR%"NS,L,54,6!7BXNI6*4+5P39>-N]3A.$
MSX%X."#@#@#@#@%#53XU/("L?Q8L]=E6RU%O79OIJ`<]O#FX+<.^]PCIA.P]
MG_E4P;G7++";'6;=:G'>%VA2S]9=L*@X':N69Y1K:JUR2R5E@K'W6?CG\S**
MAI-""T-F=*/G'98C:NC093<>S#]'6;&MA&M95Z*W$>926,2PM+CPT@Q*W:ZM
M#.AQ3"*[#=R%AI!P;3N]5#LK_NVI;Q/CJ'XW?+&@R^OCNG`#[KTIKG5M?2PR
MPN;8V-3Q8=:"VDRZK*R^0?F/.N]0J+*PFKRY>9HB)*K4)7`-NY>7;$HC,'4W
M,WES@L=UK<B/(?B(\/5TRKK^%#<XU.GIQ"T%6&8[6V'^F/5.L-U6/0J(L=7<
MF#N]WVO[:M3LL)C*SV;N12=A"1&Z"ZZ&]!M58SG."QB--#(F/XLO'+;98[A]
M,<+L[8S^HG$YGAL]^H]VF+V4GU$3T,0C_#SU7NIT[+5&K3K5*G<-%6FB[N*E
M8+:EFED#:?3)989?SF<Q/^,3R6BEUP\`7M@=%E7=.OO0@>X5VWL4Y)'MS6.H
MX]&JC79Z,,-W"Y]/K3JPO7`]K&4%>BMYYS#?TU!?0\-JK7)K!8-SIK<RVK\>
M_F*CO?KTM15F6CN?K;QW=_3E1?&ZG;[=VE"!:P9X<H:Q:*#-.9$-76EXZ@YX
M9)I6,`()70DQFA7)8";3B)M$1"PF>^6[XWQ)6I^8M34?31CUY7H'^MX'M4C=
M($CN;2=E"2ZP$'IVH<KQ*4ES);KQU6>U</8DX!L9G*_<M8R$<Z<V57@2XC*9
MYX%>V/XP/(#8:9CYU.;[1)OV%Z'VD>DAV<_4,++MZHU'AHG=Q:#$>>K=T,6K
M5<>*O3I4,JU)8QZ_%E>N(.=_B?!=IZZ9+)RN-]3K@GQ7>0`"KLM)IK;_`'%?
M<BLL)>T@A_:SZTCG994]9K.GQ(TO1931:GCE!KY0`!:A"A!2)@K`T><5[H(^
M)#$QH;3LYPF,HF^6^Y8?2WD_3'GMJV0T:C%LRG%M-O.[`9DR![<KFMX'EL['
MR.#8`U[?-650`<:[0NG?-6QHR'O*]V0LT,:.9HY^)"-MQ.5E98+?B<W5_F36
M.J#\+2'E>VID&X;`I*Y_:.R'?:9M)`;19`C:\*B>8?#9TH%6C9Y97+4P["W+
ME'67P0J*?`2'&T:H-M_LDNGK'4DXDA!2C\K;'L6C<;`H+[4KBX*IBW6"3!G2
MRO73U<J%CRZHE)9[JFN6JEJW')9'2BX^J$M>.T0CMB%:`W@KSLHA#ZMKT*S:
MS4&L%LI39$Q!;2P%0+*6WG9JV%L%<_+74E@.*K%6AU9+(<J!J"65&I%+@C7Y
MU5%W+M2R++U]*%Y([^OXNT0#>*VQ=>AF'4+7WK-.TR<NZE;#B+6;M5Z\@EIH
M2>SC15KH=>_)(^Q:%)[95K47Y6$6[(E?;!HZ7*MP)<1C>;WO^^:P>9CI;P3H
M$F^[:V97_6<NN>[]9JFG=CFE+;FP%FV7ULD4+HQ661]@2=K6EOH34)$<(S2W
M8%,=B2]:GN&+$\N4G`VG"6EU96DRRMX[TH'?WW8J;2;-<EMLP+4&VQ6NG5C3
MUG9<B>(C7ULDQ@Q-Z&O1/T`,%8':9U/):9#P6G0#LI8R,H4JD`3:-,-UY]2=
MONCROJ/?;GI;8&P*C/VU^>F0RX:D)K3@PJGY69CX&PKE"_58%=I5BEB9?MVQ
M449>*]6J5[4^=2""QG]_T";2:6#Q*W[&^)[P]LY<&JAW6+"-!T%+=:;;@6=I
M;-`76@?Z&,A67;A1[,4VS\9?6EP9UX,PEVMP(&CY$E0@_$[]ZGC]'P55U+!Z
M9+*RRR._:/C+\F-[:7=BZ]L;`\=V\A;W)R"=U[:"4[&TM=ZP_4V&:OH!+A3J
M1D+VN?LKQVQ'%C.3QQZ(931$^\KF0;3B)LDUE@W+7>6DT1I+7_F_3VN]$ZJH
M$16N-6+-%03!A8V58R`\"-ZSQHTIS1NU<)WNJT>?W,.5JS)W#7PBKQ?8@ABC
MP$;;;;Q9+7!!P!P!P!P#P_7/[9E#_BU?X7&'!Z/P/7SGL(VYYOU=N=JUCL-F
MH%Q.T-+D#Y'5.ST\Y>6G=)R;1>(1N&TB5//NF76VL3'!38U)G'G54OW4&W;@
M:4D)%7:0X2U._'UYD?.OA_S]L=\TMLI^"M#DW:$BVC"@WF9Z:CE67#=JY(G[
M;C;A1,G:%N]1[49<E4B+:*A,0+7<80RT/!CZU:"():F,XGE=$<)/QF>5]<3^
M<K*0+V4`E\D4-JB?.>6&W]B%>]6A]U5<1^Q0X;(\?*YD!1<9'`*'4&'(Q66!
MM6I25HPT-:''$5U5.;]J)PO&'K/,S)C\$>>'+7[AJURH/3BC/FLG+4K.$;MD
MN31W?5=BN<FP7ZY$1/%2!6@XN#A+T<.O="[6<+=VH&FZ-1YK2UD'$VFG,W5^
M[#U]SM:/B31]%C\N-O76PKI_QL!8%G0)$OLMR,V%D,UK4:4R5SLQ0K;E>YC"
M;7J+%F^\2,!"$;4@FI6JI/N8A*&T[_\`;&RUGE?0ZL!X"\O*@/9:\KH=E=&[
M4UH=TN=Q$,)JI9"Z?9W;8.QF'6B3;QM]V$Q5*NFU7\U+7`24[U?HY2$T+]0$
MHHXM9#:>N$/FH7/#/S9E9GQWI!@\GQ^)RXIDM^>8M8A],XJW;BQPF>]8`1M(
M()4<W*O?B:\Z54$.I!>[N1;LQ8'0=1VB,\LDTT@2T]K.9RQX8'.</)NG7M;\
M\JS+19;HWRV\)NQ],R1MQVI?7W)`5S*6IF2=ZM;BG9LQ:RPFA>55BR)4;V!"
M6T1K6[N$%F()=]]GSN56!_#[X:6L$.(&D;"&UM:#M1#$^I7W7MC&H/@T5MX[
MN_5TEBOVV]QD[*P_,Q^[6G)8V\Y:A.:O-]N6&I8KB[=6NN2S4/+2Q(Q7XU/*
M9D]1=;:TXP[,$,^M&T+MP3L5P`;7%E=1K3<FI.73Z"*#CYCJLIO[NNF[++:.
M$VP2QSU6D@8Q%KW8<-IJTVO:T7W89<LB4O0_CW4/IY704_9Q+<%4'K4EV95\
M==[WW#JPM^+8A9%Z`F<9-?.B\QLU^J'L7ZE>VPEB4^/XJ6L9YYVB-J:015-3
M$7W)]42/1T@CB0>DEL1VQBPOGWL/^KBE6:#6?<&`)%*:W'PL=NW;M7FZ+I.-
MEQEGICLD<KD]^0O:SE-0TR%83S(W&>.=)JSHQ[%UR-/:J=&S9CKN!@,:Z/60
M54QL/8R<@HKV?+K,\9!0-_FH'K55LEQIM?)"IVFK,]8THW>7%AB%EX9?:>>?
M=;`Q\7X.\XJE[5!W6ZR;U2X:726/6B,]:[:305MQUXXGNFQN3&LA:LDJ[^"8
MG#K)TN0/5)BGJ.<UEN$6!K%;M$I@EWSF_/7UPP.<4\2Z1)[?7]\QY[)%;85M
M2G-'@G,7M5[B+4];L[#$V,@J6Q:-V\[Y8XSP0G2#<2RMMV9*/">(Y%]C''H)
M<1E,Q"Q/P;XCT4N,R@[H]9XU\\J6HEO0TCHG;!:A[,YZE4?L9+ZKL8I<($97
MJZ*GZL6QCRP8V]C"+A$Q:#N`^<P3SMA+<IYN>;S]6,HWAY.TSZ&2M:Z^V6,9
M+ROJ/8"#M)$K"71I"7QCYJZQC<0V"Z:H%(S)RROWL>K^$1R^0K$KW75HS"1F
MZZSZ!-J8S33X/$B=Q^-_R2\UZ6)Q$8^BD6WCF]#+4,V;L@6[..RV5`,ZM.'7
M1SIM,3*R0V=>GB">/%7B?8M97>ZP53J`1=2O3C%VGRB(A1$SIK<P.?XF_&$R
MGVEQJFQ:(+/47GS2<\`O=.U!DEQ)\LM'3?HKZ[*BUP1WC2$8Z[_#2]N*:?.A
MED/GQDJY=Q\#;<S;%O!8NS[_`-\;EM]`>>-7^9$HMKW48TT)5C+_`+`V9<IG
M6ID<;G;9LUH(.3?;C+M1,N6ZKD&`K>O8U<[LD<<MB:7OO.Q//-*(VWCN62PL
ML";^"#@#@$>D-2:I+6NKY366O25[$0>`8W""6MW+70%JS)RLX3JQ8&R3="&.
M0T9D/#>L_HS&98GF0AL97[7<H2]2@/R7M&KO//G71;HQR@=::@U#[!\B-#!9
M'!^Z2ZF)"EN->+%[E<(O4)<X1PD74LV?H1(V67[N+O"K5DD[QCR&Z9;:5VZ6
M6*T=[H\M^CWN[K+3VRK3*]CU(B]V%PGKW9Z1<[4A)@$ODS=61]2UBI>JT3#.
M`H6<*-BQ8BE*5LLH?NN\\\!F'CEQ3Z%MN"#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'A^N?VS*'_%J_P`+C#@]'X'KYSW`
M\'G'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`(C>M\:CUH<P7'
MIV'+A;(!<:)8KM8GG4H@Z0IK.?6EBE6C8%!LB`E#>+P*F5NT[S)"FM7Y?K$\
MU\MC4%ALTE?Y1&XKCW\0.UFA6(=D0MQ\1J>,TM(@+MU2()YN`3HDH)+U:!<,
M:`G1A((<"EZ-(J&,#[PPG3JWJD\$8Z>Q[?)D(*/O;0R;ZU+;]ULQ"/00K4WA
MC;=0ZL:I:%F^8F)OOJSQFGK@WZXD2I!1LUT@6ZGPE*WZE?Z6G;S^]Z^[YJMI
MNVARHI:I::CWION3-AD7RU`%S/8U3;WEC?6N#:$-T20H*PPQIG8S&\2>AMND
M=)H%%:C5-F9@X;6;R.SK$<#I\3W6IR86\.I<.\>LXTU9XE234IJ+R[J(4O%+
M(MCY=]GI?J=CVJG@]8[FU4U:?JZ_(-(#<:\H@KU@=LO!NS6+X7)0>GFI<KR?
MDDYA<^ILT9J^>%;K&*;J;+*.;LQDFFFG.$Y<4BX?!!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#P_7/[9E#_BU?X7&'!Z/P/7SG
MN!X/..`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:V_1[E>#8E':W[+
MVL#&Q[-SU2KZP\KA_*X^<<XQ""S'DN[`9O0ZUL6AB[BP0(T6*9,#SK)4GJUZ
M@B!*M'KPF$P-+AOESPM$6;W/B6S\YFC;3J!,<2>R\MN!G<$"=4-YO)%!!9RZ
M`UKX@XM2.X<-8C7;+=G#=GL$R:TN(P2:&Q3JUTT5-3LSWA'W>O6O$B/T#XN3
M/0C_`$W]@:3(,C23(U&G,*%@[)D#E2';0'TR:@?)U+<ZWT5_6J4S?1?54@/?
M(%9$&E(ZXT'>JF03A1ZRRY=329_E!OE?62/\9FPMF7ZMQFVX%=JN7Y]F)'1,
M&?>TMT/.T&RG43J)K)5@%],^QV?`)A?H%S0X/+0HV3Q*Q1PO9CK[)S7&4=$D
M3S\PG])U3]R9Z_B#_'#P<U@_7PU%4O3'].SW_A_$;_$R8^=*NW3RZF*/Z57&
MK]!M!\#_`+8WNS_Y:>,/_P`/2O,5=NKA3YBGL4\:O(VY\A1P!P!P!P!P!P!P
M#5?K+Y8=7[/=]5JE'SCZJ6%W<NS[NI47:K6`T;!KN^TT\VN/&2U^`[\8'JF*
MN9IAWJI:D1N['?W,/=FG6ZFZ^S8<3D:A2UM*4I:BJ?&E+/4VH<AD<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`<`<`<`\/US^V90_P"+5_A<8<'H_`]?.>X'@\XX
M`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!I)?:2"R^M-L3>G/2^DM6A
M!8IE&+U8UL+6VI=H5@](^O$=96*B(_:#1C3QK]<JUV*8_;VUMGT_H9V:LJQ]
M61PV><8Y)&[PH3UU77'DFM3:[I382ALG7X@RD/$&S0@V*LO?K'&!,Q*T\W18
MP?W;9E&Y5H4U9D72.=CK*$\A3E$K(A@1$"2/<XB]2I#+48J-VGGWDL\$-"O^
M4H?U46X/_&VL?_4F'!U]CV^3.B^83^DZI^Y,]?Q!_CAX,+!^OAJ*I>F/Z=GO
M_#^(W^)DQ\Z5=NGEU,4?TJN-7Z#:#X'_`&QO=G_RT\8?_AZ5YBKMU<*?,4]B
MGC5Y&W/D*.`.`.`.`.`.`.`>3[S72WM@,^."VQ:0[7M0R>Y+?Y?VQ^LE-+?C
MUC*WZ.^BK_D2A)VSB_K,NKV/WMW#K"O]%^F;]'5F'FI]U+3/O^YO9]^NJ<:8
MCDN61ZP>9,#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'A^N?VS*'_`!:O
M\+C#@]'X'KYSW`\'G'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`-?W
MKCURHZ8>E#4UO5ZAL?8#4&$,6OQ^Q'=<0%>V8OMW8N]8_'#"ZWDAZ_KU"`;'
MVMM5U$+!B/7RDGBL;E"Y:<Q/5<:5,J>GK.4DLY+?ZCV'1V[JC6.UQ@L@$&[.
MUZE[#'A2_4/1411=%L:R5!9/JOG)!T0H5R4=2[U!)G#U9BD^[SRP^SWV,NUB
MCOK'5WJ]OVW*=TT3:?RAWI^%?!4@6PK".*$MTHK?,#]=*25-DJMW!H8Z9_3H
MS6I>-/;Q0=A$7#)RXIR!PK(-&E&>ND\.6N$ZY&GWYW4_TVO_`!6.WYE;DX/J
M.N^V9R6KWA597W?-3`WOW8QO5];K>U#>Q5*JB5C61772]=6IM?O=V&R!*UJV
MPK=>U2D'#I[*-NV,8S"P4VB=<RS_`,PG])U3]R9Z_B#_`!P\'-8/U\-15+TQ
M_3L]_P"'\1O\3)CYTJ[=/+J8H_I5<:OT%WO.GH#3WG'TY[9==UO`]#632SXA
M3A)*_2+D>R3.5H^J"(\+2I`QQ0A8NVJ(8I:CPBJ98]0T9\LLL?L]?IQ5VZN%
M/F6A-T4QK5Y&V31OI/2'I06SF=(OX]\'IA^%7:LZ8XZ*L`F"P&&L-<60HL`L
M1?AL3@S`LI#W]-W%+3O5Y<),NL^0K36).7!!P!P!P!P!P!P#0OJK]CWXI/W\
MJ/\`^=]4<'1]JOZ7T1OHX.8X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!X
M?KG]LRA_Q:O\+C#@]'X'KYSW`\'G'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`
M'`'`'`'`-,OLH5LZ'U-&)1]]OPB=QTS(<Z27S>/FK2VGUY>KFLU(Z/UMELKQ
M]Z-9VPZ?EM=6]C0=UH,A(\DO5R;+.',K"T(&E=83P3;YPUR_DVL:C$R`-4:Q
M!2W;9*4+KU+$RD2#K=V5?OR#5L;3SNW=C$J`LB_V[64/<]EUOC!UUJFDS.VJ
M%.>_)7C&62%P#0K_`)2A_51;@_\`&VL?_4F'!U]CV^3.B^83^DZI^Y,]?Q!_
MCAX,+!^OAJ*I>F/Z=GO_``_B-_B9,?.E7;IY=3%']*KC5^@DP/\`MYT?WJOC
MM_X)?(OS%7;JX4^9:/Z?YOU4F5[\<=L"O:V[]?:QW-L+2=/:_NQ3!NK!K/I+
MP92057^*?5+R,&1V7A.=A5:MVP+PR>SE$'^IEACDAPGCZD^UTI4M(U4XI3A.
M*+3/_P`C636IL=^,QXV:X:QWL+VEM!QV\5UOZFV9K=?<7W!8Z:)5(&MZ_)"A
MY*506U()8SJ6C9'+">`'5DSQFZQE[S^QCWP[-K>9Q5+B)I3M._5LV0<@'`'`
M'`'`'`//PJY]Q^%?C(DQRSPRC]IVL^LX^\^I,.\(_6&766'<?^GUGCWU^G'O
M#_3ZRZZ[Q_G_`$<'1]JOZ7T1JK\I[074(%X'V?JNQOX9NS_-CW*\OS/LI<]2
MPH+FUK_QS[D>\B$9;;X^MJ)^KR[$%4&:EBHWRM,I#6P+A<I@F/5OK3V848VG
M'2X][:]HJG[LQ3>EOMJ,+]F<<,'>"[3?[E]Z:AUUB\FO12]L&PV>$?3F_@PZ
MYHW7RW`J;#U;KK7#6IVXIA'6<ID=7(.=S"V-(8XUKD-6#&;'O[6771J$GJ8I
M:J;6S$5)8NZ<_8V!^2=S>II/9.>CMT[U'[D2C'F5XVO0PQU.EZ[OAFA8VGJU
M0JY87%;O*6_3G$N!7J6M:RZCZF^XEQQ[RCZ[Y*ELM+&5/B15*JEN(:J2Q>$/
M4V_<@'`'`'`'`'`'`-8GH'YEOC4\L;C;?/\`OKTX,U_MY%D`1-:=/K7<Y^83
M(T+85O!8YEU37)U>M?7KK"')8]T"UKJ#&[C6M=P7(;%>$:5%34JEM&SO@R.`
M.`.`.`.`.`.`>'ZY_;,H?\6K_"XPX/1^!Z^<]P/!YQP!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P#1G\GC>#CV[IJT9S#M*$/K%5PH/1B/D.V]CV&:^
M1&.%9FQ]%D:I*E^$"20`AKK$+8B1A#A78[FX:^4/27AD-TY_ORB-^.[#,VXZ
M!Z9>M$:4Z<YE2PX=:DUOTUSHGX3^1YF7I.#='9DW\!PB!_E20I]5FN_@L<8G
M\(RI_AV&%/[G'H8>+*S>L/:$_G5R4TD0E9GK9M;=6`L=.5F4:LCLQ>K=MNZG
M1J'*06T&M]2DM5$YGV?,I#92U7.B2D&WLC]*6B-)3ZWI>=M32[\^7H\@[_%]
ML1%/Z\?+)^UL>^)O[,4D0QGHSN?4OH#8^J9<[#?9)$H5HTT=ZZ[9*2;<(&K@
MJLQ"1_9PQUG&3LCI[)17.[#.Z3],L?\`,)_2=4_<F>OX@_QP\'-8/U\-15+T
MQ_3L]_X?Q&_Q,F/G2KMT\NIBC^E5QJ_028'_`&\Z/[U7QV_\$OD7YBKMU<*?
M,M']/\WZJ3MM[_UBK/\`[0"M_!W1>6CM+GT9:^Q_9_M9G'FCV9GYBPVD@!]&
M;&WHX;G]H^KBP4-K\_K);[#B]5I/G'(_=+D-GNJ2*[QGR?1,=&O1O6K4F4-K
MO*#'##'+*--U-+5DML4MN$J5KFWHF;AO)_I$?ZKU!AM>@B-6M)8'W:>MS22Y
MW5DBP`F?46Q676;16M7TXVQ+=V'L^K$,Z5H49O5;%/*&7";O[?('QFR<\4GF
M64X`X`X`X`X!Y^%7]A7XR/WT[7_E^L.#H^U7]+Z(BYXZR[^.3X=>L>^L<N_$
M.P.L<N^OM=8Y?R-V]_T=]X_IQ^UUUW_/WU^GK]/_`'?IZ_[^"_'[3C_LI*D^
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MQ##9I11=P2XS=R1`E3915+4S*C/+9\S=WP<QP!P!P!P!P!P#P_7/[9E#_BU?
MX7&'!Z/P/7SGN!X/..`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:+?
M>%;9BIZ:IPZ[<]OM$CXK(GV-<C*OAU70T4FZNA)#5YE\[OCS)MP^=+[!=ZN(
MXW<(?>2`S)1:@-N&(,XL@P8THB\=U3PN\&M3;#YB*"S?FSST:"73)(*7T=J8
MH((L9O\`,K#?%WT(!;H73K'^#+GX^9M5)8IRAO\`+P'\5NR3WOP87]_]#`(\
M7Q9,MT</(X81D*-._''W-E''=K0VL(\K%2R/L=X8SX9XX]ST+MRE-WCUUW+4
MMV:V?VH9Y<,Q#0E_E'8H6"^)#:08(-H!Q`QLU72&BA5.N/&CZ5=ACCKU*-&I
M'#5J58(\<8X:]>*.*+#KK'##''KKK@Z^Q[?)G!^83^DZI^Y,]?Q!_CAX,+!^
MOAJ*H>FP3(T;U>UM.,@UQK/Q_$<'7#[*`OM2^%.$ODP9:8DH;6A;&H$3XH>0
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MSJ)W,VY1)_JC:%`>=([UWWI^0(&QT?JS8%\<'BK:9KF*]YQKAI[\YFU7H_4]
M#Y\8,\X[_),TZ5$J<=:=$[RZ<9M&C,A&?*_ZW?M?X[&UKIOSG7#@_'GGOTXW
MT7EMV=6)Y%=SZI.;+)JZYT#"7:\H\)^`V1M&V4EK6+/WT$D_777V\L:E,O05
M)4U)-N]3I4)9.+W^_#7>MJ)TL[(U1K'8EVE`-N/NO$MTMCJLDDU8?9:5L:<G
MI5I9>NI98*LM[."&27KJ3../'+/KK+OOD,NS:T)#X`X!Y^%7]A7XR/WT[7_E
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M3]$8<\;<'W/>$N#;40_>O/:4.W!OJ;-N#(X`X`X`X!H5]*?LQ_Y1E_\`&G+^
M%7X_X.B[7LN7^2H_'W]B_P!\?[4./_F_\]\!=JCZ5T9OKX.8X`X`X`X`X`X!
MX?KG]LRA_P`6K_"XPX/1^!Z^<]P/!YQP!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P#07M#>J;?]1DAWIPV5V1K<IO3<?GI_\[;!\HC-C:A1O.-#5Y)T
M3'X.Q5=!FW,Q===RZLUOVQ8$-E-*B=LN`Z*51I9IRK<`CHDXE:)IIW;GCDF\
M-.)O23[2Y=4E>ZG5ZU11MKH2TK5*8J4%3K+E@96E!UZH2>I0F#UH1F=6.`5-
M1I2CXL<:DE2MG#W#@.9&FS_1&I]-$81VQC9I?^^$V#/XG&CO1E?BKP"FLU%3
ML,@%;)@H#A$<D-$@==D(='C%D;$/&CK)$L$JDA8G^4:5/\H7>5O8WP_[6:U2
MW;M"+.Q5`3W^("2P$E3,*NQ"2HRB"04[2'%QA(&R!"P8C3O4H)H;M"?#[.6'
M6&>0Z>RM7R9V/S"?TG5/W)GK^(/\</!A8/U\-1`NTOVMI?\`Q/\`#=_%&,\U
M[7%?V_J,^R[#^JK]!9??/]9P/_>*^-K_`(,?))S&;X+JS2[+Y]:!6_K9[?[^
MQ#^#`H\I7V5]'^QE?R7[<5?]ZCY,O_07@GFJ.TN?1F*_Z?Y?U5$"Z,*;$%[O
M4Y=<:(VEOLG)_*EQWE_5=_4@\L'H=_)B0R[,D9-O;2U4&S'8V,(*7>`PL1)_
M4W*^70[NKC9LUZG%3;W]2NG:]FE*78=]KY-R9=7X=\[<KQ5DOC+H6]G\?FGL
MK@<EE0S("[7?N7Y$/OQ][,7=)#<[=.7[5>QD/(7J>4L>7=:W8A[PESP;J4)+
M2IK_`/6@IAY(\NZ`WKY0W`Y[;U@OO+1KGXE_"5M),E\R6-I=L?YI&R2?WM'J
ME?J0]Y?7C*%G_7Q3=?>5H_YOL_:QR&JFU5;.NJ?S&1/WH_Y:5G47IC87EQ\T
M6%\Y^)/.VD[W8UV[#PNM?H)\?NA?0[?]"#LZ/>.W'N:XZD9QN%_8BEU;DEP!
M?;#UJL9>02*752GC4W-O^S2OM+HXQO@>K&A+)/1IS3?H^^FJ5Y9?L_\`[/WD
MD.&>?V?YL?YOM=]_H_FZ_F_^KK_NX.1R^`>?A5_85^,C]].U_P"7ZPX.C[5?
MTOHB+W;^KF^'/]R)_P#X-^]N"_'[3C_LI/WY(_V6?.'^RA]S?\`_-W,U?^:O
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M+_XTY?PJ_'_!T7:]ER_R5'X^_L7^^/\`:AQ_\W_GO@+M4?2NC)<H^T?9,XM?
MW%.K>9>M$G?D!N>.<04.&T_UMP+53W49\:=MW=[,KVG9',_P?-QZK]5OH.OO
ML:GW/^CWAP2%A>=E/*+T[1N/X,#@#@#@#@#@'A^N?VS*'_%J_P`+C#@]'X'K
MYSTA^[]I>[AFZ_,FAO")KS.NN&UT?T9L%U+>FE_8)M:P!Z:(:%%#:8"375V$
MI3*VK6V[4D^-NC;IV:]7'_M%*2OCC;'&E4PW5M6:2B,YQE;B&_/_`,H5Y4U4
MG*_L4(?=/4<KEZH6F^CY*T;M)[0)AWG'U3LSSC:8Q-&M$>.APUZZE4,JLC!-
M!<O9V^K4E2CG/W1KHG`5))VM3:-II8TIQEJ9N[?-7XB0\==]ER&V;.>S]2!-
MV+<`[5AS*U"BL#D_H0V<U5O34)Q);)DUFW59P]B/ZRM%2@L38886X?M!L/<K
MQ=YPGYFR73^TU#>>IM8[KU_9N7$/;VOD[9J7<(T9AA"TJ/:\/9UZQ>&V/^T#
M[<PDI4DLTI_]=5FRS@E_T\,N#+4-IXJSY$C<`<`<`<`<`<`<`UD?+!%-?\Y:
MZ`=%6$2/;/6'EQ38,UAF85`I>7&';8$<;$]'E4H&.TZI.C-+5M_0DJTDD.>6
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MJ%P?];5^]QMB(8\OOL?NI)/T9?HA&FG#)EZ[Z[Z_3UWUWU_]O7\_7!#]X`X`
MX`X`X`X`X!6;<GE]<W>VUF9LV!LFD/I(AY'H)`>5`D3QLS+4.#RSV(A8]?L+
M`&V-*/,PC(&H0Q49J@@37"UJT0<VYT6@5.,EZRX&B#_*%O*&BT?XT-@;._(B
MZV;I6VT33'[S;EI2M[;QI;'VZY;&<!T36(7@GX6'*MNPF\C^`@:0@%4P-6JU
M(;7KY]Q]CK[)MUQ-HPEQ;`G;Y?0M5CVJ,7KLY"M3.>+7,1;L"2%H24@K$OD,
M^-^G/,.*49(;HZ]'%-EG5O5)HK-6?K":&3"3#'+H8H\_*HAW>7G=,\W^P>E1
M)9-J,H\T>^&YAM6]L;3=MKFH+LOREG!N5<>:>2Y@B/%XP#8)(Q=6>.E';EN6
M\8NI[<^><J<XZKJBJ-BR2]ZK!1\!/6^?ZS@?^\5\;7_!CY).,WP75F5V7SZT
M"M_6SV_W]B'\&!1Y2OLKZ/\`8R)@6B]/^A/?5=#W=KI6V>FQ^G?DZ-X+;>,B
M*B<2X]$\!Q4B.-6;_0ZM5H[5G"&7_OPQFDZZ_FR[X$M4V<3'6HS7XTU!8U_Z
M\((Z4#'+*@H`_E765A=$5\:HL&`!?*=^%!Q`ZMA_HUZ(T=4K4ZL./^C%!#'A
MU_-CP6O#\G^.D[[XH_Z83/[C.M/^?3Y&.!7@OJJ_300;\=_[%/I7_9'^$O\`
MDZVOP6KM+ZZOU'.%_P!6[\V?[L:Y_!8\G\$7;H^I?K9Z1QO_`-'4/_<JO_D1
M\',YO`//PJ_L*_&1^^G:_P#+]8<'1]JOZ7T1%[M_5S?#G^Y$_P#\&_>W!?C]
MIQ_V4G[\D?[+/G#_`&4/N;_@'YNYFK_S5Y&<W]:ZLD+YB"-,1L%A+$9OIQXO
MQ'F1O6/NY9?N*=+Y"O#]FU-]U!A)-)]U!%GG]W#')+G]G[,>&6??6/=S7!^1
M*<_7PU%2N]MZ]W#ZP_'M<L/3&)&O7Q%B+MOH6:%?<$,/D2<;F5?[@X.&69/T
M5K=>3[V*'.#O[S['4G<F&>..ZVF[:$]G2Z5=1_4_QEJ/5^M=?;?^1##7.U$I
M7V*@L_J3P-58DQT"#V-9.5JWDOY'R%>`J%*U[5"]%!>J5;<6%B"3&.S7AFQZ
MZSCQRZR;3BF5;W7XUTKHS[ZVHM_G+U3OGRQX@K:*\U+>V_D$KJ_>-W1TKLC)
MX1;^*3S]O`A@N:V3MC:;JP7V)K#69+USIBBBPG,D2,E.W:ESZD!J:4W+BA9_
M_94LYR+C:=]^+^KA.QE3W+O/5U'8BSZ-W%J%(/)^M6]#&[!7-4KVJ3!8S31(
M6?;I(99$3[.%5R\DK5<K?H(#/N\L,Y,L>#+IS2<0F\\>[0N*J>P/+3HEKFPP
M>_M58)S=.SU5HR><0ZCB9L);,236R&C2;+(0E)(O-0<F!*X]T\>Z9*G-6E_1
MEUU^D39<Q#G[X$[+[&O-H:@QJIT,S+Q6'NP+/+Y2D:#$H,9,X<IZ!0;/9HW(
M<9HI(NY*\\F'4D>>'>7VL,NNA#N>`:%?2G[,?^49?_&G+^%7X_X.B[7LN7^2
MH_'W]B_WQ_M0X_\`F_\`/?`7:H^E=&!W[$>O/]N29_CJO'!'VO[%_C1L33_D
M:\3/S>`0U#T$HFVIJ,D%Y;&P#VF",V:%4RQ"^-&DK@"N)M6:U($8M9817LNL
MX1UK./O/J+O@SLO1V]>9C&G_`)4?CPWZ\C]::>];ZA>WDF,8#-->$F;<5K,0
MJ`2+0R$IIB-"E2J40B\))%R-FW9@AK4J4\LF?76'?7!714L:6OWZ\BUZAN_2
M^P2WX`A;>U>[G?HYB'X*H/ZHREOH*V4.%B]^'!BUVY]'7SL0836?N?N8LIX<
M9,\>Y<.LA(:Q3)0X(.`.`>'ZY_;,H?\`%J_PN,.#T?@>OG/47MO^L>\1?NR^
M^/\`UAX@X.*[%7U4]*S3IH;1;SO;U*1"(N[B^D+H4C\K!6Z9$(B<]RF:LGR_
M[RJ=#):3C7L5*4>$LL=KJU4QQL=Y0]0]]_=9Y]<J;6!JM)TI-3V,X_#1G/QA
MZCU\YL^(S9B6E;/L*WQI>9*U`B[)BV>SAM=^N/DD@OWZ%4F/NUQ,I+*E7EM1
MC^H8\NXH<._M801?9@K;24./>J_305UT?Z6]BK?D50':?]"4M7)?FKXQ_$#N
ML*7ZGM=.O1LR8\<B7HIV5.L]&<M'!:)!8H,8H9,L8()I.XNNLNL>N:2E-Z$K
M:5:43M5U)W?S1YF<;G]>_+I;6O7>^=)O.M:NB_,M'7^)+HL/UK4+U;W?COSG
MO]YRP6RNK6$NQXSEMMD+U3N)Q"X9Q6HPE.(?&,PMV,A*GW=^./S-8IK*,C;^
MU_)7KA3.OM2QH;U`62M:;GKZ'<-P!$)(M:N%O=AR7D+[/96ULRDP2B(&5I"T
MY[V"SW+CC:^]PJ2=8=]<$V;3*PF)N;&^#(X`X`X`X!KC^35+4-CZCT,AOZR#
M<TEN]O>/`#2ILPRH:7F$(2W6N5B`DR)OQ3TB(Z[7SSAM5+4,L$T666$F&6/?
M?7!JGXOI9JJV%Y(\N!_<HSSL)\]:<&Z%/^X_)%\YIREKQ7K:U+W<_CP^0HUG
M;(IL0W$%<L9%QU`GW+/2SS[O4JMG[7WT$>>(W+V9ESLN^?;I^[))T-JS6NE?
MD:L:UU"AJ6L]>K7R)[GP7TE&`#5A7"XE?AS\LGB>(L((KU1]+J^:*DRUOJO!
M']00OW+<OVI[$N>0C<T*;^ZOUU'3(.B-+>A_D'C1M[ZIU_N%,I[(^7IEJ*NR
M%0,X@*S".V3\:`Z@;@%':EVE&4IT#):G6O80]6(:Q*]#')C'9FQS%;:ILVNQ
M@XRK.?XH4-BL+.M>6M0^AMJ^4],I$OR4N8E7\_*_GK"'*XK_`"L;YURLB/L;
MCT;N"F+7`"G/B-%!UNF#@K1UZN/VLH8<8N!5&+2J;V,6_D3R:.I0?E9]')JA
MK/7Y+'SML)M'>9$O<[EM+TGNW+2+(^$W+<7I+7E<>!6M>:;+*U^X)&Z+JVS$
MXVDNU,;+'0CA&182?;Y4IS2XN#%:2RJNVDJ5,0J7F\]JQO:\S;;M;_\`-_G[
M>]T)76KNZ](ZIVW;7*=Z0I4`6MCH@%QL!*Q*:M2E(5Q4IG.A#>EIU9+<<&,^
M=:#*3N+&$:AM:.";N"#@#@#@#@#@&A7_`"E#^JBW!_XVUC_ZDPX.OL>WR9^?
M*[_3DI_NA,G\1;XV>#-&/-=*A[R_;G#?_?\`#3_%;;.1X<UU15V%]5?Z$?N^
M?ZS@?^\5\;7_``8^23C-\%U9E=E\^M`K?UL]O]_8A_!@4>4K[*^C_8S^?/\`
M_63P_O$?*+_Z(^/O@C[*Y=:S]\!_MS.G_P!_RV_Q7;'!JKLK^S_'2?+XH_Z8
M3/[C.M/^?3Y&.!7@OJJ_300;\=_[%/I7_9'^$O\`DZVOP6KM+ZZOU'.%_P!6
M[\V?[L:Y_!8\G\$7;H^I?K9Z1QO_`-'4/_<JO_D1\',YO`//PJ_L*_&1^^G:
M_P#+]8<'1]JOZ7T1%[M_5S?#G^Y$_P#\&_>W!?C]IQ_V4G[\D?[+/G#_`&4/
MN;_@'YNYFK_S5Y&<W]:ZLFSY3OZ=Q_[IH'^)!X4Y<UP?5$6#]?#4?S[M_;Y4
M_P#^[XA/XF&S.4M/E[3]!^[I_K1%_P#>K\&_\G_R4<%78?TO]=!^"?ZU4Q_M
M(F;^!YIW@OP/Z%_E9_?G3^LVL?\`S;^5C_\`)?&)P9JP7"GI483XOUOKO97K
MV<9L9"2W\;0_EB+]$<ZJP-JHT[W7S%.=?J[5J':-^O7M]5YYX.K$,>$W4,TL
M7V_L29X]BU65K=C_`!HV1_%[4J#_``YIBC0JUZ5&E>VW4ITZD,=:K4JU]W;(
MBKUJU>''"&"O!%AA%##%AA'%'CCAACCCCUUT,U]I\NB+^<&30KZ4_9C_`,HR
M_P#C3E_"K\?\'1=KV7+_`"5'X^_L7^^/]J''_P`W_GO@+M4?2NC`[]B/7G^W
M),_QU7C@C[7]B_QHZ)&Z_3X<^(SKO^?KOU1CUWUW_P#7_P#J8]B\$>-?/]2*
MOO&J]8*GQT_%>W*VN41::VGP;M_-G9U]17PK$Q9DOARWX3(9G38T?6)EL[Y+
M_P!H7,[]JQE9O==6YN\['7WG!IM[=5_B_P#:,F>]+Z`^,\AH'U!Y&T!JO7VS
M:WQH^UMH,/>`PU^#OK&AJWDYD`QN45$Y1(VZ&!,T9DFP&D1EGO$I;^ZLQ998
M98#4NJ:6VU_R4KD]HO=M?V;[,\H/YE3W6$\T;W[N:0'[$1A&IP&S]`RV&\SZ
M<\_^=189F;'-Z]!0U%_O/=V1^Y=&IMB]%^"X01Q2]3Y?H;O67W,)4U1$J]Y:
M>3>E.AS-J?*FS^4K6VJWLWS2-U]WK1.\\.0_]1/H)8W#&QT?1.SMIZJ7H2!;
M<:1Y35$_H`?U44N&KQAEF'8"2-6UU9CSAFB[<?7@B*F8AXMJZ?PI/!2\RP?@
MWY']+_(36VQ8U`K/2S^IXFHBV7IQ,Z78ZEZ9T'%R0K,$<TAM[<*U;Q@@"V\"
M5>X:H7Z<V=?#*GEU)EE@%5+IB<]S7ZDF>8.Y_;,H?\6K_"XPX.WX'KYSU%[;
M_K'O$7[LOOC_`-8>(.#BNQ5]5/2LH7\=G[8[G_[K\JG\8[=7!JKLK^S_`!TG
M6?%5_2`R_P"S@\T_\X/R7\"O!?55^F@H)YR\N:WW=XSWH_.)W<(PWK?XE?"-
MM?J:^WEMO62U<EK_`!]2F(\6I30G!?7'*#NW1ACEKM`PK#-1SLCY<,Z5JQ!(
MDU4_>5D_?JQI3^+*4XY%JZO7V?C+^9OKK]/?770_K]/??>7?\WQ1^!NOY\N^
M^^^^_P#[>^^^^^^_Y^^_T\'/.GU\3)D?_P!B_P![?[4&+_F_\^<%>*^CR925
M,^/KS`)!:6][TE1JC]-G?F,OB";GGLW8DP2<=A\JK]JW&KTARLN:1%'^21%`
M5WU&!Q_3G%E>[_3>EEL9#>U5V)]W_CPA?_'.FI(VI_/>@=6^<OBX],(ND=5+
MV^3OIR[:9MJC4D)1>6KJ33WK,O<J,K11K53I>F1O@A$Y""R0[^IS'U,\LNI*
M\.>`S4W-2EQ"M+C&G(L?C[4][Z_TCY@]`[%?/*CV`]+^8MK[LJ(2CYMVGKTJ
MD,BOXM=_4"J-MN97U=L.LTAJY]<'K1Z*!06+I@5G;M4+H&U+#U7CRW_9OR#I
MIFI+:]VI*6TYO'RKJ6JTGN_V;3W[YC0-^O'FA[2/2GG[;^W*L6HM#[/U0TII
MK6V&B;5(=8-N/I3<HI@&$:^W[<%K&);"6L)@]>>*SUA9DKX4R]F&TJE=8M.S
MG1*,-YM$X,E"OD!__E#S)^_KXO\`^.2SP:I^+Z64*VI_6E*W[['D;^&[\B_!
MI=A_2_UT'XJ?UJ+'_M%=L?P7?)/`?87TK]=9_7E[^LQE_P#%OS#?\5?B^X#[
M'Y.E8^.7]JZ[_P"%/E%_C([RX%797]G^.DAKXZ]6ZRV08VE)L37*(^R`/CF\
MMS`I'107VG,++>]/?*1W=E$Y'!][(=)<['T.[6=/N'*QW2J=R]Y_30_8"MM)
M0X]ZK]-!&GGM>>GCQ-N1TK^B?3.OIO,GQD>-V742WJS=K>@I8(U'\>J[L&6[
M:5PEF(<1DN-(^"_>^_P_[5UW+%)WWC)EQ$_RUT#Q6%ZG-DY]XMJP^T/=8C1_
MKS=>OB_EZ37_`(OIJ`*=>V9K';K3LK9-FKY&\[>A&$N2=U_>:FOT+A8CN:X&
MJY8IDWTV`J.Y;^NEL2=<.R;T#5*A15+G-)+WG2LFWAJ;*3'O[P\O;(M:>.^N
M/.P?:U)MA0KFN26W4BFZ57:P1A#P*<ZY.9P*Q,,Q6Q`.C$9UNKV=V:.MC#W+
MGCAV,;-43LN,9AQWEN^"#@#@$9;K6FISTWME/12?X*[->LWM;3S'XC<#_A32
M<5R@P`2_%Q^$I`5]$5M5+/XG1CDN4/N_JJN&<\4>/8+%&J3U!\9VW?;'G`CY
MT:?0'^;QI1D:F1D[U`,U4L[(85>IWMAS<4L;3?L'P?1$U1JJ771&:>"K%5I7
MR&R!%TQ>"5J.>(W35LN4I>&BPT]<#`S_`,??MGU8P-[;Z$]<"D<XHD]@Z118
MPWF1.[@;M,T=T::W"MO6<,&UI_H[K0UZ32KV-:7+J<>+@*C)<.^R74T(;5*B
M%O=WC#6F_OW6/D'\`>U/2!;#=^^?7H;7NW*#HEANE85YG2[M&-6\@>O]@;;\
MWLTO53:\L?7;Q+5"/IVEE)C)((8?RQ/]/./EGX&TDHB5=W>;I2>2PR\SI$GP
MM[:W/06/6.R/6Z\I^E9X=1[)8M8"?.:,7#+NR]'J.Y`"*J37:.V9JD\.-+=C
MA`5SZFQPORVQ-KON'$=UC.#=."4KB]W/(XN'A'WY@HR^UL/2XKOV/DIS>F<]
M%_YMZ5V%_P`Y.;QL/T+GJ7\4_6M]#T-["#JJ3B0[F^EZ.]YM'WO<6?5;H7:I
M;2B%A,OL[4Z;^)V3;X+]PZ@%LGJO5OJ\*Z>CQ<>X-C+VLK_FU)'!SNS/0HG3
MX=X4_KK6UXZ=>.U-J=.'@>\YOLT[4=_N/NQF4PPC>+(G3@U;B\IW;SN"7Q]>
MVO-Y._O+S_ZV%[&VR4=&0-;627F1.J#ORKZR]@*.W?0[/'W9VM'#A^2,S;0_
MA*7WG<GX,M]+%?[^:W'8X&TG9J%&3S5,++.$CYAOC\]J^3KZDW>??70AV-,<
M^I=`.,)WS,FQUE;24N[]H[+97GKZK:]?"V13RV[GPU+!'E]05'8BQ,,>.=+J
M69X^O(NTG,K5J^;26FY&,4/C4]>^<5=*U)IKUV.:M;;J6=<>3=W&C'FY+BN:
MU\[:C\W[H74UYJ3V=JP=D379B)40R/=;#.>Y=>8F#N"*`//'D&TG+:NI:OFZ
ME.7%G)9OC4]B`1;GYN6O6]$_HOV@GMJ'Z:=<O-2=5*(@%7\L:_\`-R1BO]2;
M4^^QN-B2@@0'=BO%9[J'X;AZ3#]%SJM&"JIQBZNKN[F?`MX2U?\`)L,W!KM&
M$>O$DEJHSK7:!YPV9WY*38NU!U4C^I!FNDOL/EN#ZDCV_`VO9!GLE%_J1?>O
M/IY^OMEJ_!GW8=G,J+Y7G+*V.I],=9_)QWNF9+R]>I&.JL-75FB+9_\`FD)O
M?WNP96RV)G0_P7]<'U./W"Y%68?Q3_\`<9?4?2=?ZS#O@>[&#F=<NZ"K"S\=
M_M6,TN>=;GK8:,T#YJZU7O+1^R<_,J=8(MNX&]@]+#MD)Q>GCM7JSV/U^$**
MQCJ6:.&$K^LBG7@D^VO6/O!K:IQB[E.[PA1EG?N.E!?&E[%:Q*YYS<?6U)<T
MEX]20&H_,[?'YJ3K!78*0X^4#6@':R<QCVIW-^(+2LY,*Q'8LPP963E>NQ11
M=QQ]5\A-I2W%ZKN^'O;4*VY`Q\:7L7T@%<-9;P];4DY+TVO[/\J:7(BO-2=W
M=V+YZVIIC2`]I>;64.U)LZ!F4X)+)P_ZB/&>A93[);N"6(Q%AA(GN:[QM)7B
M9<N7G+T2,A*_'_[6]5FG-R]`^NA".R+1IYTBJU0GF9-D@9-/*>_=>;>1'B6.
MMM>?JA?<3>HTD]E3FRZL414I`1-']JYW-%?7KN&U2K*G3/<T\M[/X">`/:GH
M\L+WSOGUX&UYN0>S(@V12%>9TR\/I@O*7J/8>T=`FYNJFUY8\OS;8FH.9JMW
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MD'DRF[PH=CR_V<I_Q7KJ`3:I=FH419Z3&6^/4G97/C\]L^;[T.Y_/OK@5L?9
MUUZ8EVTO$O,B=7'PI/L+VNL[M])N&.5C:T<67Y!G:W+8P*CC)][V"68U2M]1
M-;BL]B[2=FK1J\53"[X2TS)0&^5_D*\Q:TU'K#07KI9>5J+;`E?8("_E9.P(
M)Z$_N)YD?GV>[/MN'\5Z6+9FS;@%11XSV*\T5:+O+N'[60S-+;;66N?=^Q)^
MP-9_)POM.EA:9Z]2'!>=-F$5K:I__-)31_ZL$*OJ;:#91>.JLNX/O#7UNR%C
M7^O?PRM_KH_SW^+9?Z@9/P%LPY3PM?.5NTEWT*P[;^/OVRPE]O:AB];BF'4O
MOZSLJUZS=JOF1.&6D3.IYQUUH];R5ZTFULYJN+8KZZ``\.J^-O\`#C%>\;E[
M[PN?<1C2J5G%Z8B[O=OJPR_'U[:O,QWS[AZW%WM![V,[(]0[8V9'YD3J]]=W
MZL[G\_N:&D#:'>UN[.(AWSKM;%WE%A+`-I:^LBIIOMG(),`VE$Q=0E?*'.4:
M=Y_$'Q_^UH6<=YSZ]=",-"!M@=^UQ6R,O,R;V4F]+6_8AOTU?2\QW>U_JY%R
ML\$NF;[O[KJMTO6X5KZK[<?U60FU2[Q>-G%X;,2?%/\`CO\`:L!9/\]W?6PT
M3H?RA^JO;7G[8DGF5.M$7'9C11]&I^PEDW4PVKC9SIH*XR!KOWD\<$16P^4>
MX,_M`9L9`FG&+MN5-DK-9:SGD8T,^-#UV[A`OF)W]=CUW2?DE`#Z<\VM,/FY
M,F-[!0G?R8;\^/5HUA'M7NSB06E1U8EB*U8@@RG.UZS'''W''U6S%VJ9VHNW
M+4N%=.UL\_([,[\;7LGTO1>T7>GK6BG*FJEC;ODK4!$3YH3_`*G8GG;<.K="
M9-KQ8[@VI-D.-V6)3MJ0SNQCC..E4+Q+[B:(S%U&&VE@KRJG?XDW&6_@=T3^
M/SVSZH,,3WZ$]<"D-K5V)VU"IT0WF1.SK,6HD+TN@[AUJ]R85]K3]5;3P7TI
MK]HDIR9=3T1%PF"FP^W9RGA$VDL%HYG.(>6]GZ`^/OVSZ".#/0F^?6XK6^YX
M&37X[-4'^9$ZZ,K`?)GI#<CYY_.9=5MK212?FN-PD<SE?[WK.<<?I@9?IY1<
MDL@;2B$K7>.#:2>6XS72/F7Y'JR>V>F6/U,L)'I7>.JM>%-H:CL>74LR-"N.
MMU4]77$D:2AVWA4BSBLG+@R\4CDEAN220V?T1XQ?HR!NF4HLFX<Y3C$3R/)N
M?S]OU/\`*(+AN@P`R/O2OH?-]H0?JY7X`MS<D7Q19.U34?Y*R;^UV/JQ9QCT
M_P#CV39])C:S_.W?Z,NOPW@[^[_Q?]9\/^3AY'K6WMY<^1*M$N>G$GUBL[#]
M"Z:U?L)4UQKJ'RRFA!1>+<A?5-]Z#$+$^V\JTEN#/62_,-(22QXU<*1"/&.7
MLAUW$."=-TTTFYQPA.,MY'5OX_\`VMYEN3;G\_\`KH/L+99?8%U:*@"WF9-J
M#JR1ZO\`;PG<WH]QQSM;7AAZRUW)L38.R`P_[W[Z4(KUU&O]_8L16,A=JEV:
MA1J\53"RW)'Q7?CW]I^7"2(<\\^N1+W8<Z.H/-SU*5\S)N5=0T&OOF\MER/<
M/4NUX<2))?9-UMF=G&#+N8K0(B*T46'0ON2<-JEXTZM7>+26FY&,U_C1]>>?
MU5/T9J;UT/9=3;W4$KRAOEA+^;TR`AK'S]IWR5M1"0G"E+9VK#F0-W2"\C:[
M(YUH\YYR3Q^9LZ\5<7/%P-I.6U=75\W4I\WR.2P_&]Z_'#GCS`K^O1C'HGUU
M&\8>GG./S:EPF==D%SSEI/2*/1$Q=[6RLUIG%$UJKU/LX0394B-2V?DQ^Y,1
M0X"*JG'9NHA2[W;?4R9E^/OVU?9SWGW'UN+O:"WJ6V3ZAVOLR/S(G5R"[O\`
M6=T^?7)"1QM#O:W=GH.[]PMK'WE%'+7&TM>614\WVSL$F`33$Q=0E?%0YRX=
MY\*7@#VG18P7G#OUX&KZ!3'4?[#5]DR^:$SLG<])$_6#IZ#*(\P_O:_5N8$/
M;"43+C']UU!*#*0KN-CO.IE9R#:4S%XV8G!;*ITT."M_'7[,D)*OFDKZZ%B-
M#>7:NL]J^?W_`#\TIE@NZ[$:1WHQ)V4MEJ6.UNK>=+7JVU`[F4\L,,)&UL`=
MW%GUD#EPF#:5W%W9WRM&6XX(_P"-/V+L$/4\\OWK:DM:9\I)E;1WG!KK^:DZ
M8IL76C]Y+CTB\E#'4>U,IHB:^(<&I.KSV(H<Y30F%DCBRBSPKY"NI8Q=N7?.
M6]"5M7^-O?)O9`QU=O7*^D$/+-O8^A?/1#ORVG$Z;YI1X3-#WRCT8HP[9Z[P
M(7F%&Q7:=>Q)#/2[5R%SN.2,Q'U$(W3$)8PW?!J=V_>35JC6?R<-8EMM[&]>
MH^OB(G:.SE=;']>2$TM^8M?+#H7"H#Y][!N#[-3\]*M,8S_A<G^O&?B/T4_^
MLARX(]FT3@IOGGBM>1&(WRO\A/I/5^N[WH+UTLZW:T[=%#:`].&>5DZUF/-Z
M7VV6(:M+6R=;;<L5T<QB0"XU7Q?76&75<SF,EECDASSZ%FE-PG#48]^1!2MX
M1]V[%`J7L%_]2A57U7A50-[F-05?."3?#`=VZ[T!MO4B^AS$*^U\J5FC"O;I
M<0UV?J;&&V3L"C/WD>%#J&8-I*5#:NIF)4ISA;!>9\K7A+WD'3V7V:L^H`QK
MUW^"-OJ"II+KS@D=!2/I<SXW2=!R:HZ*_K7^@K#+H'72LEPW,YOI:QW.XT=R
MY16OIL!=JFU+7NV4S>-IO3>SOF/P%[CTQ,;]0Z8]7"M@>A*GZX3`S7UOS.FT
MQ),MZA<=!%=QT_OI]K85X,!OZD5,@$[RF_10A%%ZN'=C(OUE`&TG9JULWDG'
M5G(M>`O:?EVV.V[H?UZ%>7FX^6$T\+.>:$ND,#:T]4>V*6[O23]G+=VO!!E^
MK:38>P-DBJ/WO4L@%:KJM?[Z:6.SD&U2[-6C5XJF%WPEXG%`?'=[/\PS+%OS
M[ZY%O6.S:.G/-^R)BOFA-RB4-"*C7Z!V!@]U.YMK0]7B0!AWNX=6L:_><Q6D
M4#0QQ8=".Y)PVJ7BL)>+NVDM-R,=_DV/7&EPZQYRU=Z_%L^L?2:,)\V;Y+$/
M.*5"?UUH'3/D=RU6G.8>&?:T=LF0LW@VM=;&+5*O-E&;V!58[$<$</T^8;5+
MNUA=7>+J3:PPB>[&3L&CXX_8<$+[YJ7/7@MCT;Z^_/5CU`Z0^;4N`OKPPM^?
M-'Z81AXB#O:V5FM(Y(NN5RM]B.&;*B0HVSLO7<)F*+`-I.&U>G!39W;<VU>I
MD!_X^O;5QF,^>\?6XNWH'<+$\^KMD;,C\QIT-\'Z%6_0.D=G):/0H][6[M=!
M6TA68V3O[N.2O1&)%@-+/]LQ#-@)M+1RE&.4.<C9Q^JWU;_>O6?]W$!__P!#
MX,%K.`.`.`<,AE?QH7LA45.<IC3LY#82$\U6A-?ZAS[IQ7K5:M<L5J<EC[O"
MS/!4M30P]YR15I\\<8L@-3_@Y$!@MQ>J'?7ZJ$%6&8E])'>G9]?366DD&:60
M1+;<ZBJB`-H#"-?(3'C+CM"`NPUB]IG(V>IV=B;210:>"OEOMW^7V,0\0ZW4
MU+2?I=G7D6NHZ^?$1,DAZA9TLM@QZZH+SG;.,L5?4Z.M[(&MYP(QGF";!_H6
MW:PPEJ8NK5`UQ>8FD*W=0Y<ODY5KMKNL??SLD"$[PYZ[N8J@E>67BKMUQ8Q(
M9PTA8'=K9W4T5D_?7K.CPI]*%7)JV=G\.J-(:^0IUL*(^Y%VFBEL+3$QJ6ME
MGKON?76*:D(/AS?*B&!HUY1%[7)4SRXLL:.2U_)U`"UUBH@EPPL:MJZ\80!:
M:%"%.';NN$A!"N3=;.XC4Y#%L'0@YE3/%X\;MWQ\C[TE&MHKXM+RW.O@%(0&
M.C\2ZH?Q4]@!YE@YZ!#_`)A7H<M,Z:VBO2EVQ=OD*`PT#U`S7A+49A:#L=<Q
M6*,=,,:K7WJV6]^9]GM11K?BS7N(44X#UVUM:F1B6&YK=MV+FK;*C59=>%AY
MJAO[SWN9W*((XB$EI?EDUHF?I6V$P##E'I$I#>FP($O:QZ*<\FEOQYO`[CT]
M6#&/)7DB8TOVEF07<UZ;C$DT=49J:5+)HM['156C6E7REMD;+5G[N3*HZ%?\
M]H>*X>(#;E:BH1C\T0J"Q=]>=^*XXX&+?(HK`G?SKH>5KT>[-^%E4BI1C@P8
M(P7$,J;I:\N5`-H:$\_;J4Q)\F0%P!NV^!%5E$(MCG815*08,HI28`I</%+I
MXM67&=Q_'O"8>R[\T>LFZXWJ%;PFQ$_BSWYZ`U25]@G2ZTZ[G%LW>R>Y1.P/
M"U@?IDD]0GM4)S*.W`.BCRII!@""F']GOW1W[UA,[EN#(X!J87!':K\E!>"U
M6)LIEH.$"]QJ=L?//XS7`E=#=9K?6O)@_GD/MJ!-6Y%$NA&%^+;^%FM=[$M1
M29CA;&JMV-?#_.N=XSG#=D?UKC7U:G\EVVG.EIEU"F^TVYEGLTJ!S@7V*L2I
MYXTXI=@S:*%PE0WUD7>/2H&WP[DZL%]&QNKGT^O95W5(?"E.;MZ?E^_7>.%[
M75;V]Z=*+E4)4>Z_ZTLMC1")QEFUF?;MQ4R-JZ5.SZC22S;7L=KM<:O0+S]L
M(%KN@$M+KG76=B&24)`'@KZ>"X^2F9P,V\.:YZ0][>H+-99;*8YALKEZHQF:
M#0)&3YUS+8.E!8]M/F'SY>;"L>-*)CN-G;7N^:_>8"Y<DTTCK*98]C`W*7KS
M?1?:+/CUUJ)7=3^E1P_1NPM?=&E6NMET.U4KIIF^4"6-Q"K"P$,6=/:8),+@
M3I6Z3*4VO8MM*Z6+/X\8JF0H9.Z$4A:G?%/TN*Y=\S)UGEA-6:7BKV\)#:G=
MDL8TD=Z5;:D/7Z:059"US7.=(E@CK1/S)JJS5M%.\L>UV4WI)[QL![2V)B'F
MJ(C'6"P(\5?2_IOG=>9W'1OM8\'LXP0,JA:EO:N("F<!C=*:Q&DHL.P[-"_K
M`MV1_&2!(%6"8_"ZTTW)"EP-!T]SKVZSNF2UCF8.[_E__P!:Y/N9RP*SKJ'X
MQ:J?=8QFOU0FW6H5NZHF`;C%4M]>B9"J]04,]%'-VU"-W&S7JP4,%4LVLHRY
MAV99;])RI'3%(+[6KWV6%\8,"W(RZE5_"NBXG9CUIK=0H/SH<&4C4RK>$370
MCF[K\<8S4IW0NX:!)0R[:9\,D;K2T!C3YLDC";`%'(K=B=9%4SK92^2WK3&;
MFVS14N$^D=.3QUZ=2.;5>O98Z@_)5SH5<)%$1GA7HYHHT,DY4X<>^HZV2<'%
M*N4..':\-HB.Z=6(9>+X^L;DJ<$-3_R+Z^H.NT/+DUW33SLF2F5>:@UC6%_\
MR54TI8H"KE/[F271VWAJ6RG<J&89>>CY_5H1:,WA+5.>L6U*FTZW&J6TG#C#
MGX\\',<G\/2`CL![KTPR6ZY-JNLUG258'TW8^><EA8!#]FF@1\5K;)I\\-6S
MAK6'+,X9X+9A=I@#C6)*$81)X+81EN&,5=E\YQS6<.(MI;/$[[9B0--?)!K1
MINA&ZC8`IZS1J&OPMIM@6*<GVWG*D`QG$^97,>N8A/R3?[O`K?I76\)2M*S8
M6%:$*RM/>Q1/A?'UGY/[8GKYNUJ6^2YPI!6S7#+L,CU=),@8)9UDQ'5L>%U,
M.2X[@]M(:%I/5(;E;5^P11&7M_7C%%LKN!"XD1*U=AGB"^S?EZGCEAF<_4J<
MNC_DTVTP5]1N"TQ]H#!8O[`OBX81)\22.U+&,\S?9T<$[8*<MN;"S7`B=_.O
M8@670AQ5<^TE1`M0`^RK\O3\EG>]\'U#JE!E]-[IW3`D_D9MTNV>EGI:-D5K
M!8M,LS"Y.<+#;=7\QY9U.&94EKMD8W%8MTO3#Q;`*/8T-(7R7+KE-.*W:,9C
MUVGT1D7QT1#K3CZ*/JX>E58#`S7.!>L9V)ITXPUIZA-XI4`3[7U"ZOC&-9E5
M;A'+<MYPI5Y+U@+)=BNEG4ILUD-"/!<XLUIK!@7@P!JH-H#U7/KF`555ORT"
M!.?02]B,EJ5:2JSFGB[F04M)(3:PO&0IM-,%%^&K[RKMV=Q8$:P<+RDOU8!0
MM4RKRYMX)9M91EA<M#\:NMZVO-4[*EII`S7]5XW`:>:X$(9U"7#=QG%E5SZM
MC>M,+JRMCZG?<7=2D/(C\C=(93'T.Y<`U,-4JB5.7C-M_FV>9:Y_;,H?\6K_
M``N,.#M^!Z^<]4GR$A@['YB<5]J!#V-1-&$$86#WCH]?Q*7K^R4VD!$S$#ZN
MT*E,:4(6/I+Q-E@H51>>=2V/*"#'5`V*'&GM*-_0J9MW6PFSX*T5K<FI`2=4
MP6O5`RGB2U-F/@=V,:_7*M8!+@KU?/PX$N`2CL75J]D:"6%DD#2QBG#*<IAZ
M<X3=M.._">^^?V.N]9KT*3Y2\:JME3[.?E"CJ995E+"'2K/8N'<M77T><81"
M/.G-HZ3NUQOXF$KB"*J,$6L+MFU(K6AZG7)UB(+%N=7GY-/UJ<_Y$%-?V?J/
MS?>DU(T;-&E%0]7!E4T&+8>ERRQKR&8##J5*IH_;BVN$GC\%C"4=AW%U:44Q
M<B:>NKM:P8"Q0A3:;Q$6UZ8:9DO3G]&!_7VT%E_8MK*CFU[)$,H:8;O/=*`A
MWY5W3/EP&K59T5(;UI'8,G$F6-"Z\AT2;E.RH+2)+6;HRA7$C`O&[AO>?\8H
MC#U\-<DOUBL;6`([%N$M36]1WU%:-KJP5!4\P6P6?\:7T`P$\+;\=4ZZ"K2S
MOC87[VVGN3+T:%"4GZV\O@*HD%AC&/']2Z1KF<_92P$-_(]Y[;R.DWJLUVEF
M(O0>Y!=2U6%=8K/?XJ$D;<M)-(Q=B&UH9<+R[1W^DE"$2\_Q4%_"B\34=Q@N
MR[XY>GY/+2W3(E@2U?)27/W*`+\P#FP_'4[E>-!3DX(0VC;Z=.TJBX)WTQ[=
MQ"-P>(`-8QN6MX,[=Q9!%V$>`Z5I/H`OL[N#O?6(MQUU,NT#KH9C[JV]M#+7
M-Q,V+@J/2P9ND!;9/39+5MF`L.5ZIL:WY8413(J7;I'O%?[B]!-9.-:'+`>T
MC4,D>F`1P?9QS]9^7/7B^)R8B+UAZ;#5`.%2S<;-XW9&.4=J/ZDV:%[EI6GJ
MA4/`-.(&WRX1>87*H*%ROS8VCL*L4`^E<*V!.)"N#P7[Z6W8<.9MIX,F`;8&
M?C6K-EA_P0HS?BR`Y#/RV$)1!C3!]>ND:OX((+S820BBA;[WZ"@2ECSBHV[$
M5J3#+&+O'L%BLMYJ:\Y*:\M^%?96&.O2.N4IC9MXG686>4_R+7M`[>I0E5@*
M*B38T/JFP-!QSTLAH*FX:Z.5+8`?!T4)7PV&"P%&GBL\.N&+ZF0)&M!&L?CZ
M>ULEKX(*5;;S$1)Z_M'M8?ER$76*)XQ4`PS:[5V36TH`F6!*8ISR>*,](P'O
MN#9MIAN3D6`M="7M3,[^5]'/\+(QOO3&03XUM6IX>H=H@U;8U8N725_/3+VM
MD1][T%=+6+C?$J^9=\++&NK\EJ1HMBD;3EJU9OQ]],L]*>N6:Q`3[TXY3=91
M\R?>S@;&,'W+Q9KL8_ZPLZXKJ.SJ28M*4:#$P4]E3VM=7+RWA1!V`7CY8$)^
MT`K,U:CN+]_7:K#BV':8*2JM&J]S.@&;O,K6,_[L,>%^/8^I\15;R)XICI*]
MAB%U1NFZB&L6`NL;1,F1,:D(JL%$XF;?UOO37%?NG4-!L:?W%Z=B'$[%O$8S
M2A*9B4P"[3YR[^4>LC-_;.9<DF>3MA*A5<5P%=;88IWXX0R3E16Q>%-)C3K+
MIL8:JYHRAJ^=@@$764?T42RK.0%JHY%A)1UB87($L4YX?M*NN<7E&=VC^C`W
MKS9ZUL%AVLJ.39L@0QAIQF\]U:_1+V2]IGS$$6()T=';UE)8,F\J4-":\IT4
M;F.3(C,(*VK@L?6$C`O"TC3>\_4&"^ARH\3\A.E+1-?KDRDZ_IP=*1^AU,7H
MK2^1W"[KZ<1BM[%TP>=03&=:60M2MUM5;*"%+=$51O30TN@^);(%V7>,=;VO
MGIJC;=P9'`'`'`'`-5W@$\0[V]Z@1?TA8`Z.VV*%8&.8E,I,KV+;$;)SA\<0
MK*?+%JM<B0,!NR]Z@K4JV2W%C`(K6RUM;3AJK"G6-_#U'VF-?!C/0':]]'C2
M>Q1U,Q-K:EL$5?%UDUK8BR2:EVX8&[WQ5`+6XYT+IV.Y&-RT>3BI2:^C2PPF
M4(/K-M6ET#5U"SCG:V7?G)_?E#8`L9Y(]@UB&TNA;(J!=GNEFLG.B>^,NM4Z
MUJBH:565?9@.\WBJ9MUE_,9>I6;VTUO.J4I0Y%2`DE=N.9P'VE;3*%.>2YV^
MQUNG=H)-+P9N-(-[Y471I0B"P@L->B]JS,,PN%5E"'+RJ%9,MX[*^@#;7P'E
M;!!_O[-%R*C@>V2Q0V%:1%N]B16KJV.[>\H6&G#$DQ>%;$5_C?#C)^Q-O8>3
MDDP5PT-S7K%3*&3/HQ9BB3@#$NAO0:9T69;%S((KM]H$;P5#Q<<:O54?`%U,
MM"6VMU]<(Y/CF]YT&S4[6]OQ]YZ,'EV)25M<OQ179$H"P(0'H/\`?%W)0:DJ
M$8RA?.B2VE1.P1(ZM.$@$*52N6#V&X$/<K"X.KL89N,\'#XSK=<?,Z;T8M@H
M?)WB0^2.#5`=5I:T4;A2@RC'=,CJ'=,G^U^+Z2]N)8J;-[LG:H\,IV1VWC]B
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MX1.`&!E*;7JWT?:\&IQ^6RB1ZA992UXW;V6;,7##-0'WRQY@:`5^_(%6"OX-
M++";=R1F7@S\(K:^VYI,H"=*M'K5"I9L8&-(DM>T5:@142E`IJA@;UK0NAXW
M%X30A%=MSMM]HOF=BC&.%C2_PN$>PD)`JUMB]]LGB[8V,(T*HHKKXK]F#4IB
M4CPG*RZ%J#ZLF0VOJ95FJZH$L)LDP_7[)/T$>>ZR7CN;/=.,:D*LB3=_*M;6
MU#\,Q!AG3CE9\>'D9\H+J&<\/;$M*'40)*L;:7'5#NQNURPP?0V"FL;:^0P%
M:<VP8'P;!LU[&$:%KT&XT@FP&+),.,"R*M/A<+$&=[OA]^KRX(^`[6;4[_',
MM5GE#M$'\*\=-,RJU62Z'=(V(_0.%\Q=O6&9Y4B(DT76OQ/`,V%G'`]W4)X&
M((^K1>=3R"VUC;6SRTPXDNS#U5^\;:M[S>VS0JH*+W0C"77+;LY3@PPNZZH+
MJN''@"QW#2\&H]]$[$&R2#?^7DUC"+C#<(7:`RO0N"9ZZ6[G'ER+HZ5Z"1ZA
MUG47-@T=L!1B,LAJ.RQQF!AJ/6`414$R-$9JN6/1DLS$].6[/:[-EYLYY9?J
M"=Z?J2S(#Q=HW$G<$-6OKU6HS>K//QUC::4HNPHMU<(#<>]&4P``I4>-39S=
MJ=O9?FG;)&R:8^NXYB%8>[*C-^D54[7+D=;&W*)&E@[=='C=>I,!VX="[']]
MJ"D7I(JP747C7=4>X7VH[28[`#4%_7VR0JI>6Y5`@/-D=I..[S--&'!&A.@J
MU]<'FAD.-?0BJ@3`IB<5?QE-\DO'F20T2.3)[O4AIS7[/JK7W5O\;G:F2H1;
ME'=++JR&*GK'`:4657!>UF?MQOKF548+^\I#)D:E&Z#IHSK,H,(9!"V7GAR\
M;JVD2U<E:193Q/LC%E.>D30$_>OP6$O0C#,Q)X1@Q(ZMQ668<CXFF(:L;4%W
M+D*Z]%(U5<8)4ER"W,.[8@H=:.KXF6'/G:=,UE)"&O`R!6^1C9M)?+IYERM)
M[M<:1$]*2BT)\-R-2(!X[O5_95NZY`"%]M:B?<`]1%PT?S1U#;FQ$#TS!=%G
MW>?+/UXZG3^$E9<`^CM[UQSW4<"JW;VNHW8[(_5`!JKV1^X<:)W,V*2_0[X]
M7AD)<)C65+^P]/IL]5=^@R%$1,1F<4;!X+EK&'".,,E7PO=-V3VVZHHCF0U-
M7HKG>O/J7*\9M";&;'L&(F&HK5_UKZ;_`"R''4(0<-2K85]+6*<N$H7M3MUQ
M>`M4$>6N?J%YD,>*&KL5Y=WPV/?H`J:L+BB1#,S(R?<NTFL#$>#\U3U2&)3=
M&ZJ;8V`[#U4`6%VD475TK26E04'5(I"5J>\*\5%/+"5W*,)YD[_&X$8!&G7.
M8]"-H1&=GEBP$.(;DA]H"UR9>6H0<.#:F/NP?Q:>0;!5RM9'R=`UU/CG-9HW
M.[/;$="K'EI$[X/,5<_MF4/^+5_A<8<';\#U\YZJ?D/FMT?)&S#8ZJ.L$EBX
MAM0R8J3&"Z8XHM["5S`PGG*7-+M*WW3OU*TF(GLW1L&/T]C:>!&W:A$D!QIQ
M7/H53]!NHXKXAT8,F<%K%D?'"OUK\21<-=!JVTZ:]@Y$15VVT7MCI:RG5L0U
M8*^&ZM=VO0434%'3YC-K[9K(TX"5\/VY0YC##?8S\UJ;T":7_,=Q4AUYLY&5
M=*ZC&D%+8FW<TE88[>*XP"=N_F%*44S>>N=C57-#,+H\$3G:&@>FV!96XK&R
M-(]>-%PE2YQEY=V,-0^_,X_R$]91#M*OD`@AG85E?9-^K86]<A]S`2=@ACK*
M:AJZI3,Z"W2*72FR"=(?13-J6@:Y27\PEFC8P)0M'X5B%.>%XF7%K[UW$O[6
M;V'8!\>KC-C[(3D5M[1KG8.#Q#Z1)FX:=BZ)*2U[VT\*8L`GVK^</W)7%D`T
MYTR*>Q`QU(I*=G[(FO/-=,^6)@WJ4#<9?3_G^"50,FQ(1ETR6K3#M?B#N!<S
M2VY.?L=8;*BT,]&=8_JL'KM;93!2*;;UV/V&M?4K:[7ZM8LA&058.^N>[2;S
MAA;'0Q3<0O7]?Y$M)6<RZK;V&6B#31)Y6#,:R1`,`;1(09E]AO[%&U[D>=U1
M6,K2Z,3+MF;%6EC'Y_=EW6JQ!/NM7A9Y8JW7/R.O[A&:Z^1+&-C:$I$!MC=8
M:$P6^N.UJ][9Y1QTW45#5C7\+_-GK&V_K+MT.7A(+5I.2;\B.;..+`Q=\8*Q
M*!C3AQA+RO$8SFD<70AF<_[]?K3:-5AS8&6-O5ZI!5"Q]!;H:P_@UV&E"[9^
M9]/'CI*"37U^F>HLFV=JTY6%68Y0%"2FNQGA8/LKCZS>NB)(\]T<;'IAM=$_
M>7GS9P]NQV_FVCU':1AX?K:E7V?9*(/=-=Z(%UE(K:FL'?R(P#E&(&#82C,2
M86;HBV=4)>P>&#6EK;[YSCX8&R3@R1QN,?B6U%M07D%),F)+7#P/R70]S\.+
MGL;BP4K]A11#Z(E]"2*=2?0T;GX<0^FLSQ3_`$5K['W$@JQ7%&K?46R551\;
M^L%MK:BBY65`[M%AL4UH6CI-;)]&M4+\<-,2#FT_YK2[C0&-9WU6^ODB/YKO
M61&)NRPKZT6`5%\6\TY[IG/B\KG8H*V4%_&N\T3<H.S:$]B2<V>#EK]@#*LJ
M5:0,R3ETX+VV&\2W6AY5:([=M##6Q@QLN<N6$6I87!_X#9A"VU;[3/2SB>9D
MZ^R,3Y\<RN7^DP-$VA@S@BMAEQ.W!]$#_7.3Q[9)T<<@;V'-6:ZNU<RQE7#)
M!YDHY#KD=[-((#RQ97#"K^5>-6T\=_>=7L06WA?&OF](2TFT(@/,>-*7JL4;
M%;;(.Q$(>6T0>TT%2?+6Q"R@8/QC[[%4JU=/:[N:I0K%H%`L*/=.Q16@42\^
MZ.<M=7+S>?:6]6>AVL)H!K5#RMO)!FU^B,/2YM_>C:+!$H&RB?GVD"+CR>@R
M4^Z@9_7K$)!I[5MM8&/2U$/OD;PP83-&,,PM?)SDERSM?0RCU>+;]L;#\^K6
MI636"YL%.(7)JT+;0@)4Q;!L?6S>?2V?7[/+IK9E<C831&J7X_\`@4D6NQ+;
MA0$5B+30F[&#+8+!S,6\,<UJM25][%6TZ[2ZXCV<Y*JF9LJ,-P6M>/\`>C]G
MC#G?&W;6$&]567-`$=$,X>XK=^W4SKJT$TW1GKO&M-ET(M?-=,?N8Y6UWO@=
MZL+O[.&U>Y:IO&<OHYFO<INR<3H+.2.$U4?2-7EM2DUY+8UO[O<(:;\LNHBW
ML0@^]3%S5BU1JUAHMHW[EQQ<\,K07[X,C@#@#@'6FK=\>'+7Q0F8\4I#;]L:
M#KVZ="<U?K599J8F&\1E@'TIB-C".G';O3PTZV<V,UJ6.##//H#7IXCM[#%&
M=XP;0!M&F@ZT3H_ES3C?9V`QA%`%<H8-AQF7MOM.(;736N8,1TZJ1B];KM4&
MH0J/^F?,B"8+NF*XM%^[IESQ(8\;GM<C]0;M>K>UZP$KWJM$_,!IGQ8P)5,*
MM0UQJP[#[:-\--U'H6MDL/TU.NLHK'#H@>:1Z6"^1MU2MF?`5J^&;POAE:/O
M?<?'SP\KUOQYZ,=$78M/,47*'4H0_P`^RIE?I"FLI"^I$&BJW;BWN]/BI(/9
MIK;;7%N3XBRV"66!%)'3B2XC9KV#45*W+7N2Z?8[-,I=;&\(/C*>($[8RGL2
M)_7)(FULU6HU%]9M)_<N>N73:&VK/1+7Q<?4.F:-\AN>IKQV-'#=&BX*ZP3B
MG"AFK1W/OMCRG<V8E?=10/XQ:LCF9UU2P<G\4-RSD92K<F;!5KWH41.XD4JR
MZV]TFF]4+(.#">`W%7IGFN)T5=J51:=-G7"K`1-7+NM;"(AQP=C[[SA`E?&/
MFB^L/*0`TY(5OJLPV]3,+BM=P,AFP4N7Z&T;6XO'37J6H#I#V!7ZDB9@M9MJ
M-DB)972U4Q4K6P4R\95]_=#F;/QD[#V+8'+_`)A\4V/S4GJZE$[:4'AS*[W>
MG^@<+2GW(CLBEL+OUMKM<IJ@ZQ!;OF)V':NTI#`C.%@'G3EX-DS9BTS+UO/G
M\+Z&*>NY*K,E^<-3)UT%3Q+Z&4.QEE@TCO@.O*:`3LJ5LL3-[#3]M0QJ]<MV
MAJM<-J*FL[3V+&5`QUV(I222YEEI!2IEXWEW6_='.5NP)_\`;$'0S<WG)E@J
M";TH$*VUL1S+E;G[8*EIRU3/.NZN'?@QGIDW)=Z&Q6@:U:**490/2)7+S!E7
M%23BA%@^6'/'=YP;.>#(X`X!J3T##^;O<I[;,-RO`%<T=AO`")#K>,G;M".B
M`T[GZN&)_P!"Z^UHV(XVZ<N=U2:<X&RC`GB-9G5K.JHT6/\`,@TW[L?;QAS/
M+69=SFZS,.JON+UOD&K5S6U]?*/I)KTYI.S$.)X!X'39EQS&78+8C?K$QW:&
M_642IN9`>R:X0IZ-^[*`3RX$2&L#;@MH6^)?"VD6PL^),GEL9K1$CW'LZXB[
M*T;U!V:R9I=N8,RTB"]9H1YI%(C&-(NDT=`?#^JI?5"K-#,0SK*=:&&K)@+D
M[+YWQ'-ECPC%XX;RF_FJP&UQY_\`0=L0JH]?6^"1DIF7(5DY[HV#7$B[]N8$
M@[+\O:[?V9JK7#@C9[=712B3Z);2%];[!6"59,5Q2\$I"N[B[E[ENQ<::(R/
M6*^YTO"_JYNF;5Q;(E[&UMAL-/\`(SDP9_DO+75@@=6'):=-R"XA[N6QM%SU
MNVB;TZ7%MAL#8:FR#"\+FJX@[5+'+'PRW9J=QFZ0MKN7QXOX0%=5C=#(F-I=
M%D-QO/H++I>*((4),Z.%O>'J0K<4U<&#!C7J6Z]LN8'5`&Q0KIG8P73!71/B
MOW/'ROIO,&V1L$K1\2ZV7<`=?L<5<74X;-ZS!%F<&5AT;LVT]"AFK(NM9N(1
MCCVV47*$*09?=?RIK0"L7K!1=M0E:L70J7O6R[[KBL,XN3=Z"LXL^M?/VH=9
M65/8UPK`Q[0$W=]"$-5UTSI.I\0ZD5$.25BCJX2V5S*;75[28M!T!:&5R:[`
M<NE`'X/7G)"+-O\`>7O>&%W=ETM`75D_IS7#RK!Q@BCLQ)3]DVNABX+4\21!
MR5@Q><M>!!B)H>/(W(9J_P!56KG#D=7[O"I&9)PUX[DHCQC2Q,7!#4G[HA_/
M^Y=7!Z=RO7AU@2K1LQR[UO&ZE(\>Q+2M4&'&LBC:%>-:K;95'_CQ$'@][`""
MENSAKU]=(;*59LA"8TK)O=NOXS&NMT;;.#(X!JM1"U%W]5D'9D4-5EM;[QV*
M=2T:R:")#AM^JR:.5+F=.D6M8SU#"+KRZ5T.=VDE5L9G*Y58IX,CHU*-FXHA
MXUE%[*=T/SOC:VIC'E:U,Z^OMC;+QOB)%L:N/0R&3O4^\M2LS2P=-O5TJ:`)
M#GL;80[\ET[Q5KDB)%JZ:<;6$]>,`4.\L?E5IR!J*5QW/++PU6^3M]*B-CO9
MKUI<TLTST1[H$]$4DX[)N0P8U^D;7=7"^:UB16DZGNG:1K6QHA7,D'+<E5IT
MAKIE4W?+.BE`9`MDB%X#CW96$<UT>%KX8EL/*FM-HZN5F-7V4F:V#=='F*^M
M'E3<;[N9J-`3C:T'A2^]->QM2:^:2<R6'*C``Q@,'7(J;@BL2W<AV5>/ZX1Q
MET2Z%-/,"ID]>=O1R0T%9++X+UNKZW+K>+104+VHX4U38R"3I_+8*OO;<D@V
MEKHL2(X4VXMBI.&-:_(PLE8S]94DIBO%:8SOG&Z6ZV!-OQPWY"FM=ID(_P`$
MMB;&X2V(,TN.I%]#DQD"HI00U8V+]:>X%&\96^\.UATS0&[%5K/HAJ%4Z%WL
M9VW-859</62\;GF.N?VS*'_%J_PN,.#M^!Z^<]5_N^[LRMHV]'J_3#/N(W7)
MT6?"-1=[J8=3RB)/$Z*C`.C7AAIX9[<S8$#BL%E,%3$"D%VS`0M4!&=VQP<%
MC=Q^]NF97WT_2ZJ>4=,.1_9M$H=4BTD,VQG]\V7YF$6)F98:P>19I4SNY$!X
M(Q@V*5?M$]<,#R1>^AH@KB`J%6R&H)O"K']E5Y>O$BOU0.6X?,7CEK?$%%H$
M%A3UT*/6-IJ%0F0!4W#5=^K^31+AO;S[[#*#S/YF#"^F%?:!,[G=[JT\S.P9
MR<<D+.*L7&_#CN=/K(D#W@/U^P5_/:47CUQ=;(5PN-LI&PGJMK-2KI3Q46P<
MG;LTB30`SK@+;/K5/M-;!F@]EX5WI3'0"5!8O#NI8!*9O$\E/K&]U9YG\^KD
M4=N7>'ER)]U&3B?EZB*>;$X[HSL6GKN\/>!HN:,825?*^^(0F4V=\G?$NY5A
MT+&0['A#F1&%A1:E_7@+!Z>MZ\_&]KF3S*>.;%-G8'E-J:]:MSZNWRQ`+FJ9
M2FS^GK5%9`@!UUW;'>P:8H2N7<-;`J%VJ4UBQ'ZR\7;UT0S#:!4/^7!)[X:Q
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M?K+T^`J.+@0Z5WK>`+-)LX5J0!8%0[!1F0#(:6J&P&"HO6+!-R<^M6L-A3`&
M=CIN3+G<FJ"45?6@@/!89<[7_?&'Q9M:X,D7;NNJ%'3^S<WXB-%IUM'9!!^V
M6(51='*B=%V0O=+*[=.J]>.P4FOQ#*,>3("DM7K=:K`6H3S168P4S;$U;:76
M/Q3QUZ,%X@$@*!.UG!XCV&I^@KZP4GVF'75V*2/<-*D[!I=&OAFY2$L3$""^
M@'=9+=$"Y)BV,IUF2I5X-/%8Y8I8;M=UEP,BUK=>67Q$4LJFJK6VLW#:0PS4
ME2-Q/<D(L(.J*K?6VBI[&96O<+'L`6@MZ[5&*1#31(U'LF,0':%=>52)H^&`
M!GC')=T8=^&#P)WU'KK:NR])^<MEY;"&4-UJ`=YF)6=S:6V"Q#!5G8EN6NW+
M!77#ALY*V*)=T3&CAK\8Z3O-.Q.$A;Z\03%;><Q-$+)M9<5UCPX:&,^E-1A4
M+R_J+4%BB*?J@W8HRI@N=:NA9+3-?[`[":+(K6"=1TGZ.I:_B!3_`%9-<J5=
M>E*2GK9>OI5)D$8S5S6`)W;W:\,;KKB5_P#4VHD-)\P^01'ZM=*#6BN31U2S
M1J^?=6BX>K;JJU_U@PIRYL/3V(+6&;*<CP[NQ3Z^3R:\0N4&"^NS8J9'7I\5
M8O'/-Y:P[PO69L+$^?O/.V5O6+_L+3NC]LM<6O$:$7L-DTNERDYQM4)W9%R@
MX3X"R55@_79HK=$+D4M>,!$8NTX8(,IK/68S+6$K=)4[VUK91VCZ,\XB3"$6
M93BQ'$Y#6>D(8F:-/CI.P07C8KU%_P`O>@^U`E/@3(6Z;22:]+T^[PP:8K,=
MTPC"CJ(*L'P]9KH_OU6YA:91^0_4Q&5-UO`:=QFOHZ)&^D(U#8["T(;&YR'&
M"`^P^4=GM#2.!JMA0@%7EC>>KK"Y`'O=S6Q]?.@6P!/W7C;NOAFL]S-L7!D<
M`<`<`<`X]NI4(5+5"_5KW:-VO-4N4[<,=FI;J68\H;%6U7FQSAL5[$.><4T,
MN&<<L>>6&>.6.7?78&IWP>Q(\Z9Z'-Z\%7**ITCK1L)K`'VUO7?0FE;W,#'L
MH*(Z^%B,MG8<*QV/&:YAF4"8JBLAOKZXJ\Q]510U5E..;B+VM;&-=YE/A4,@
M;ST[M^FWK2FW+A#<N<=H0/&?7:MK'DL"J#*Y/7,I)M?+]2^+-@\349FFR06Q
MY_&HQA:P2]:^]S!VC*W.\XV7\%M\/*VF,M:!-1$0S(<1E)FIMR-`<V`^$6A`
M.C8Y8Q5Y*V+*Q];'`6A/5LEB*(56S\4'52Q(94O1")\1\8DN9]=V!!>^L@GG
M#S:N:>#V-F-5"B(MT@![$AWD>UYJS55+!O.&C1I+V?YQ<R:[K]%"0KM?%5>;
M.SV6OD.C*5M@36&7LD"N_5WW-7[N!,ZUYK"2ZT1T;:K*T;'*I<C3)69JCQMI
M6L31,K!;,1#I;6>T&!O,T@`[,8N";+L[.)S\/$16;1B:[<O2S!-Y2\$_*/`@
MWTUY]WTZ&==#M+E.H-=J(%:`V@EWT?LW55S\.I%[4+A3NPB=:[5I/!)G3L0X
M<"ZM>?;GK8R/G;D`L`<[,315%36?1/APOE@\"^8"G(.!!1\M?Z26B)'4Y:OX
MN08/II*U.&'.O^/%HX2IO[G+#N/\7)Q1$"7V?K;L>%F:3'H9-9OI/0&W-E;\
MO.8O4*NQT05%1Q3'"Z#TF='F!@ZVMQU$%OJ[!LV&N(-.XL3P[[9*B1=8E0UM
MKM!$Z;)S[`9FP7:&DTECQQWX1RC?C:(VD<&1P!P"N:+Y3TSK@HOEEBGL?O-2
M`$%=4%LV]][O:NK@28ZN'LCUQ->MDL:D#CP$58!="46%JV!0[#Z(9-3K9YQY
M"RW_``ET.%H3RKKKS04;.M1$&8$D-WTUNUK.]<&&UD2=J15JV)\,;)"9M@]W
M;=.&2N0K'G0\-E^\CFITJ$T664P-MXDO[-01VTD%IU\6)F`H]J%RC)S"_D*Q
M-B^\I(YH;XO\=%'0N5RI8ABGAC+A2HV;+#[JZ/MULY(,Q#$=9Z=L:_96YR.;
M3V-MAJ<0:<LW3>PJFKA\P]?1;[H4!"Q=+5>M-9B>H\2+^RV[5LD.)$;&5FO#
MU=CJU((,16]T=_FWH9ZZ)2]L`#.M-$!&P(LSUK$T0L^P+-SN6I+U-!W@66"@
M<M%AU)CUW)%%>PBGQ_3'/A)'WWCV(4\]/Z$.6='!-::3UN.V!!WL.)BNKC\<
M@;JU2_05FHBDL5TEM=IDL?EX'M^GK0@ZUA)*VR?JZB<:Z6(N,=FA7D%6,MQP
MMTW23+Y703FL=-"4H\!C7;`AJV3V.I9"=>A"MQ>O;%:""V?9AVJ:E'7L+4R@
MK5!@8<UJG5@G)$IYR%6L8D(UX@=WW=-Y*CAK;76POP_I_04IXZ$?5]BNG!6!
MLWX9]?\`3?7?A_XU0N_1?6?1U/J_IONOJ/I:WWWV_N(OLB2U@X,H&C1P8=0$
M"*%(4)%4JHT6+&U8*(X:.HP1U:5"A2JQQ5J=*G6BBKU:M>*."O!''%%'A'AC
MCT!S>`5Y=O+>GMA,#*RLM;8W5QSS&R-XM=WIO1*3VC,2)'`JF3`@I>QU]&,=
MYA1(T20_$%VQT7'4H*97ZV##[O@LOTEUQ+#<$'`(]$ZDU2`9)7(%K+7H5PGG
MOVIVL2EK8YDFLE?OOQ2Q*=IC82DDY+ZB?Z^;.UW)<^_F^HRD^\S^T$O4SZ;#
M*6&6/":2OG)'GAA8AZARF@RSQ[QQFBQL13P=R1=]]9X=3P30]Y8]=2128?:P
M[`AO7NAT37K*0?HLV-QV>:!Q+9S:&P&&^TN1`'A>Q*2!:,EC*``G+MDKA&4G
M4M?@5)0R(PPW8P$<\,6>`LY9:>O,S]W2UK8R@RH3D-[,*C>&OK[$*ZO$1O9`
M03KYU;U/Z\3;H$ZG4\$F<?<]&[6LX=9=]Q389?H[X(5_1?'VI4K4S;H.U@7=
M](LQ:8O0UPY=A;%!/SLG\VJ2DMG`(4`T95ZK-C38@A$^9.-($U2@O#&2'*"E
MA3%ES.9*VHM2A-,+A%16#SD87+30R-(RBZ'\VR^OSMI:RQ'QU-G)U\V\Y3OL
MY$TQR77@^V,7XB;O0?COX3",&#A&Y/&C<_MF4/\`BU?X7&'!Z/P/7SGN!X/.
M:]/D-`:[R0E-R?AHJYT.MLJ&*FK1L2Z]R5MA!H[+.$7=KKNV-69("T574ZY>
M=QYK\Z!'6,&"%?DEK/5`"T:&J9O&G\6AY_RB(_1[BV-&@_,^RZ^SPVMQ+*I(
MQ$/L8SCK%NV%>8]AZY-#F4!8'/;QH#5S#7<U$WW);-+0Z`I1GI&R:TI!:<]`
MB!!8M1.*SUYO(GWKR?=V,E2]&-W/"-6?=)@=*.8+28K6-9"<-7K\C]73LX8-
MPZ_W8]KI2VG;"O4S'0G9=W"O:GR^A+D)ZL1VX$Z+.5.MM(66A'7L1:GM>A_/
M+5!KG!UF"U\*4$A5#"NL.>5S8J7--01;9+SYN'I8>J%>OFP7+]Y]T@+E"4(+
ML[+;J@R3-KD%@[QSX[U/<^&NR_@R.`.`:=_,MH)?]2^D=NW=@H9LDI@VP<$6
MTH*\6H;@R8.G[/9M@JHDK:^O*4K3B\M2N:%3GC7<C*)OTU>5?IY]"J(T^RE&
M^=]U^Y.'DV%Q!;*J3O["O-A??6H#GH$.;$`S]0G3@8=@"C1U.*7KGH_<B]$$
M2H=@J`-#C60,`,@N0]CP[5>@4+?XJ(^$1;'RA/(V,<$(YVOK>IM=+L)MID94
M_+)A1FH:T*'2UFQ`S^O'E<V&M$!T3BMMZQ/W"PJPSZJL96RU.U2[LU\J^.<N
M$T0)QZU*O[4T*L)6B=VEGU[,;1ZLL<6_FUSW`J*I@R,*:V2%82,OJ-/2??FJ
M!6.KH7702TK-8DXOG`1N.<M98NJ_?7=069:RR7/C.M]QVO@=L#-7G1:C7/QR
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M_P#T0/\`_P`G?_\`]3P9.\X`X`X`X!@^S(#MK7CO75PUEB9)E4[&``4W4AK:
MR:,9#;'0T7#L$37ME$G.];^YK=-(ZI:N@NI.R-:M8FKX0Y@O6?AF4O\`).@]
MMZQ0=MU3-DYK78^R6@<WRD23%1VLF!#$V/<9/%0"$V4TQ6>I:L&,;$=>G$J?
M:S5[(W'D&%U!:H$%;E[ETY>1:;4^MVE$LO1=SV)/L9A>F`::M$.UJBICQ=<2
MLAEFF,&AZ%XC%A'W$([O6;&=GN2>W<F[^QACCC^D'&2CG),7!#`M@:JU?M@=
M2$;3UNA;+$C+O9(:+V`GKSD.'D>X):O=^E28AQ*M4N]UIIJ_=J"*.?[B66+[
MS[N3+'L)C`[]755=(`#51+6P*@KA8<JP=;5PXX``$U\YI+&=<:'$UZ@ZC#E/
M--/E%5KQ1Y32R2=X]YYY9=@4$^0O4>3\KHC8-TVF;+9$EFFS'D#2^D,I8>&+
MJ+L)9*%D.]ZBVF,(+V=6_5N5J<%6"?MHC$D<\)8!D@XR-4N'Z^Z+G:7["Y:=
MU/DM2RSKF6M$3L!//>D)SS!>U<5V*EF)35*$I"62C]QG)>EHTI+>??<^=2OE
M)W#@,O?B27P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#P_7/
M[9E#_BU?X7&'!Z/P/7SGN!X/.4S]T7!WZF1JX1"6V/%W?0*Q5!P,=I2JD;.(
MP^Q]QE3T6]/.U*G0AJ+UJUU&6V74I7K]>C0K!S1FT*J<&J<>7[:/H4-VOL-8
MVEXM\G%[.;\>HKK`BA&5HG.U5G<V1I,U9^;![6+O+WK1!KW^BUL:O/+?'%O+
M8V2^,CGO.%:9A4S198%B*GZQ<?*^&'[[FDVN.J)ZI5$5Z=0366P5<75'8#XQ
M]8="+JQTJ]&,3=)"XZ<-;&*.K@-(D!^,&.&-.[:K]1SR#!K.]DV*,WI#3AKK
M7FP&3+7U9?C*%Y]*$W%#S[9MD)<=`>J.C%Y,W>FK+A3[EQ)EF&CM33%6*E#2
M'G6;&47^8];C2P=\=_[KH^&NU7@R.`.`.`8`DZGU9K2R?N:XUH@:_MM=S`BT
MVDE-756RRD(Y+,N%\_."'4)3-S"6[<DPM$<K,^,ENSGUGUE/+WF$MXN3/^`.
M`1#Z!8*:GHG<S00PO245[5KX9N1C+=P>1SK#5@G;GPHD![:@WJ%K*.++J&]5
M>DR:G)WC8P:U[N/\6J`L5Z^_1E3OCV=`LRQL[4%.%F&EM7MM4K,NF2@QB!+2
M^\1D*X<4EM%#?OH^P<"9FTYM)6^R6P\K`HZ0*A(0P:H.A&U!JI8/7UHNAL/X
M,E3O57FV]Z/%I`JK;TE0B4FH"V26MMZ#EW9>SLK#HENPX8O3Q[2UQBLAC=M/
MP$/5/*(S(T@KL=*"P$EH]6+(J<:\G&XS<]YTUD]@4L=L58#$R2HI4U">5&R:
MM7+A,']%2@+J.2RL-V6=K5I*Q3PDBU8V&G!7KTL*]&]@7S@RN3A+]7Y\=^).
ME>O7IUX*E2"&K5JPQ5ZU:O%A!7KUX,,8H8((8L<8X888\<8XHH\<<(\,<<,,
M>L>NNN"&K#V;9HS>B]-FOU>;`9<M>4Q/1,M-I0FY(F7;+L5'PH#E9S8_)F\4
MM:<J_>71$BPTMI:8J04H*P\^SXY#OS)K@:6#^_[ION?W[7T!16Y_>^D+;&)L
M=Y0INLJ0<R&/5J]:6_8VNX%JPG:(:]Z+U\,["UV-?4BVI);FG-AD"KS$RQ*T
MA1@"UP]`%@[ZV[L+:-S?#<;0.#(X`X`X`X`X`X`X`X`X`X!KG]F)76PGI%7G
M;S]LC=VKJ\*Z1^TB'W>C6`EY#+%1;"1(.N[*41-LR-7)@_:U;N`[I'K`F=JP
MD>ZTLM/`:3A2G#X<-W'P-@0"*O7!!8*E8A2JPB1T5:F6DGF*U*\=.'"&L3FM
M6+=J4A!'CC%<DLVK,^=G"3*:Q-)WE)D,G;<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`\/US^V90_P"+5_A<8<'H_`]?.>X'@\YKR^1VDT?J
MD73(&Z2S$CF$K"X+M:5]IAV!>P4S;/GVQF47;^I[`"D,NJ-2R+OR]LI`JR2A
M4L71JQMI+.R-4_Q/\/7SX5KW!8WP[ZC\K`DE0V`46;&DM9M]_9RF$VDR[(A:
MF77S=@T]SO&MMY:K-PR3345$<QU#%MKI["BV419)[/UR=!?F"R;EZY6QX/'P
MC>;<]?Q68$)(AN+U-1N0J*W%:5!\>$5!8LQAJ6$Z]1BCRSCCIA9>LAM:./++
M#"&MACCEWCUUWV,OOWE:=K^1J.Q]X:[WU"_ENS^NV8.P#$+886CLW4=;*BNG
MU:]>5U.[:`FT1NN"V":_79%AMJ#HVD2NL9M88YA.-2<5.S6O)_OZN7$X(.`.
M`.`.`.`.`5W]856*?SMMRVIG2JXPA45F.#R8:NPW"./0X)?EO5JE%9?-:DK-
MRX-[N5ATOYP%P"R<E(WEW+*+AP[%6*XD,?'?:N6="6<2%:_1O#G<N+G$7#+"
MP0KF4`=?N3JM$FU-;T?C[7"%^^-9`1!Q/3*S[&X+4N0FP*G`"0>/'UHL<<%:
M"]_!!P!P!P"G>V?(U'9.[M=;Y@?RWY@UTRB&`6A;#"T=G:AKYT5\^KWKZTHW
M;0$TC-]L8PS7ZS(KMU.A$T"%UB-+3'*(QJ3BIV:UY/\`?U<JYLBMOQJ]F"2M
MG4S)915I\UF$%71:KLJBI,J@N/B60H&=A,0S=M#7;A$B8.&U=L)-HWJB2RF.
M2Z&$UOK[-F:P1%41CKT>ZTV3AW6)MGX,C@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'A^N?VS*'_`!:O\+C#
M@]'X'KYSW`\'G*S;ZTMLO9C)KQHUIMX3JV^E17JY*`TA'GJBQUIMD:9V74KY
M1`=IZPF'Q=WM.PK9N.>P6C,J#>S"(\!DUG"[P5-9J?3W/7P+#AHB\`<5`PWA
MI0_"-HQ'"8<59!"")>.K%@2O"@=TPQ7`PVW=ZFL415M@.V1U62*I.8)RPYW9
MQ#LN`.`.`.`.`.`.`.`.`0KO76+3M-3&"4I]KZY9@K!@>&,5Y;(-@_'O,"?7
M+=6X$%.")?L?:HL5FW0G@9:7T)>F.NR178J\E.85>O5S*=7K[RJI09>V&X`'
MIA$5H!_;*NJ!=*JWZ%*M!5I9W0YM[V+=E+Y80Y2DR7YB^YOV)<I8A]'KKO#(
M3@2#P!P!P!P!P!P!P!P!P!P!P!P!P""EGTMI5L8&)9&.,M(FKY["Q(RM2LY(
MP2[%J9HLI>SKJPS.J\OK3J*0&>K((;BZ<6.BP,\E.4C<KUK]&>P+#)!BV1KN
M>1<A@?4N:5Q%VSBC%$T@Y)&H)0J]7KYA<PPO=Y'!=*CWU<MD!G5JI6J]]6)I
ML(>_M\$CPQ,0S]#:'C(#1F>X]9XVC"D5?1.>3JO]422:"(3"S3+1*?7_`(9:
M$BB%:U6(6X;F>%3.I<[G^QA4LY1"P]'H9]0<T\K!2LBVM:)5B58/<'6*!T7<
M@(5&'&UD`M4I:]J2.U6.8T;N0>>#*2(GC3M=TLI^J\OV!#H`VVM;,A]?6EIS
M!,I1J`N[*!R7+F!\7?#ZX.)JV[38G1'U@."R`./ZF.M#K)&$E+.3D^EJ3X#B
MF=((9(G`'`'`'`'`'`(9==^:XU\^*>M6;M^Q;7G+K!5K`=/;@<`Q63'&Q):B
MQ;4]$.J-2895K3$#<5\[5D!"L<2QG&B-EBMYBQZE&5#-IZP-4:90/L=#+#"!
MG)=H$1C>O7Z-Y@PMTQ^8*G;JD9:]DSA?(#Z60R&3.[C;O4ZW<'4UF'#,05MJ
M:PN]C^J>QT.WV79+:8*ZK."]/V3<!_77=]4']1$<_K62EUWUW;!5OO"E;KOK
MN:KA^G@'W,;*URO4:10^_I0,82Z!]CB)AJ!#*-_IG^N_+7=*W=OP5[73#^&$
MOP/N"23\6_#[WT'U'TD_W8&:\`<`<`<`<`<`<`X1._`*'$"EG"U+6&TK=^Q'
M1I6B-Z2"G!)8EPICZ$-B]?M9QQY8UZ5.">U:F[P@KPRS9X89`0@N^I/.[,K#
MG"KN/7XD.13%K87<+<RBTDZ)37"JO7%D\S++;8#,2K3,P-JMW2_,8P7+)(Q@
MX>X^IRE*.86'HS);>^=&T)2D%[<VJ*4X-?%MIN&WL10K2AU4YD&P"LQ2.8QA
MF/7R^;&O8BS-OJ$<0R/!L:EF7LI1ZG"'H^X[<!MG5;6P8*:OLS7[(TR+E!PC
M6@#FN&&#-2*U1ET6TX!AQ*R1R7"5(T'MT#>-;L9<JEAEBO:DBOU<Y1(>A('`
M'`'`/#]<_MF4/^+5_A<8<'H_`]?.>X'@\XX!!;=Z1U$CL3"KGC#/(03Z$9%S
MO+NLMH.2NDPS!<V2&!V=4Y-/)R<2E7NH#D8=E.BRV8DD$(=4NZI\)*0%AO\`
ME+J?V@>C]/;-N4!BBRDY3!(N8`P`F!(?4EA@+`E)6?2%,FONRPO&@V7:6[J+
M0/E+T:,!@&PBB(>6]7M89]A#]0^AU-SU=Y_H*KNZV]B58EK6JE?=]@D/P%JS
MD2P(MF9DPATS#HP690,>JM26W`)%&_2A;?Q-9.UL0>68NY]R$,R"[Z"U(.V`
M3UC>:+%5M#=6XR6,JPW8K=8I03(-CW%CMZ_`>T:5WKZ]LPODB)`QR.72;G^9
M_P`"["8YW<1(S]>MYGR,ZK&RDE.V*DE<#J8_*R^ZJ)N.M=I1F%AJ$U#H`KA3
M)5J1&I@0%7ZEO&L0IU+L'4W45JM!/A)%B#M9XHRG@#@#@#@&![$V6GZJ!5F)
MTN%:P^\:%+@Z`"K-;J<*'3<_=86*$K"2$864K=MRXY?8A'";.6$<<DTWW<,<
MDF(8GS6=K:V<!*T;77=<OT'!3C>EOK(G7HWRBAG%'-FP1B".50M".J8RX1D9
M;5&#L99^U4(XU;4<D.(>1_*_MK5[6RR)ZQL!/86:-7#NWX,%8!I.Y,I'R;$%
M$,53&G8FPNBKA538J&-NIG/'%9%SQV.XN\H?O18>AT^N]X:UVM]1(CF"Y&C'
MB.F'&B:6\*RVUTR^!*865U^SMBX$7MD!"-81>NTSJ"39`]@=A`1BO94;M&Q9
M$B/7J#+L7Y%RM6:.+HIY7:0NN<N4\6,/W:J!+GTOTABS7ZN?>P"[7UU'Z<A+
MAA4G^LJ_=39?40_;`_JN]I%SL)U4<E6UVS#KAA<ZKL(B?M@$#HL9R!0)]U<R
M_%1U"#/":Y>H??UJL66,D\N&&77?8&'V-[Z<KG":S^L=5M,`4>L%RX883B+D
M!@=P:BB2",WZPKJY)5#2,X0N,)%YNL!R_P!CK=Q@LBZ$.=KH(S,\OM2N*L5*
MI1D`C;1`Q57J%:^8'T[%T_>JX7J0.I#8L1R63%RE)'<JC(<<[MBK)A8B@SBS
MQS[`[[@#@#@#@#@#@#@#@%`C'AG)HJWQS5MJV2#A-@[;V?J8-22!E`:I.&V-
MU7-W7+[UA9-%+.SJ@@M<LIV`/"TEKQI#*L`PV(MF2`X^$&IW90[Y1'K&YUV7
M@:K.#V8N6MG]=C-YZ_V$F;=GIH=.D:QNO[EZ$V!,8T^8Z8YY=7T1C-Z0<HX@
M):'8>%I?$@1N9*(G:;3S0&UA;!IKE&.N&X_._"I>K0PE7]P1JS41#LXIM9!"
MR_V+1[LT[J+U6L4#9W=YG9:_)=N*?X"[6Z^S+AP^L,!VJIF]=F^Q#`)$E::>
MHB/#OO/7C_CE4XXD[HILUEM3J2=N!$PL#0]"A8O@-[%=O$WR:8F4N,+#VQB?
MUJ]U]7M=LY?8-<0BV&L-OWAVU]JCVT7:W9I]R7!<?V1+>A/)-'2C,%<9W#MC
M8!0+98&Y9@'M-?`_%L*GYT%1E3%AUV%LDYD8!A/-ZL*BZI&Z8'.K?EKBE\#1
M&T:/`;GPTWZ):EQ.#(X`X`X`X`X!&+EK.JX.NM':0U?%7=:3N=@?#1AJR?6R
M.2I;59I,YK6$V,$@V*WW>J=_3V(Y+$6$<\6<7>778:[_`.2GVG/C[`:Z,56-
MUV2:VD?@O,1',H8'EN[V1,[JK7>H\&&L6;'%]8QK55`Z[IDLC-$[#!"7+DL%
M\:N`HAP2D*W.[+QG<?F/@K&QGIF4QL@80_4X&H(U$>-2&)-7F#7H0AJ<HO8%
MUY'VJN#K>Q1=_4*]:S;"F!='M2R1X_JGKUP"K7!B[6._KW87_?&>O??CM$-.
MO7[7H#<3BLT-@/#43NR9U[\D`C53`H/BL$T:'KJ30B7?R!K:SLAL9-=AR98D
MMCRQ*6NR*S4&^R,Q#:NG'\SCG=YYFQ$71Z&#!PWJ;.QT/H4Z/4\O\TD_52O'
M7ZFDZZ[[ZZSDZC^WG_/W_I9=_P`_?!DY_`'`'`'`'`'`.O+5+!`43H5+N0VW
M='W*E8CA!#:S'V+-:2&&[A6L=95[&563/&?&"?KN&;N/J.7KO#++K@%&1/@1
M'#ZC@UA6V`ZYWQ[=J)X%.N<02N4@-Z;TCK_0B]!>H#J%"D1#%4I!CR-T.\JU
MG$JP&"0(B#N1")QHNT_!KO;?F<++X_5&"(Y2$;';080JBZX48E0/0$ATS`SK
M'K3F"ML2ZK@<0XR38:[6TFLCTQX!QK;HDC+Y`>!9HJPI*P4@GUW_`'PP\9S7
M6_C8?K_<"SN`CN7;6R#"@EU$T+!L@J,9;W5?K7*#KPO<N,4XW`QGV=RU_7>"
M5*A*-IW=@-CRRD\"4YNC$&"=RUMS^Y<[@@X`X!X?KG]LRA_Q:O\`"XPX/1^!
MZ^<]P/!YQP"JCCYM,G36Z.UK:I!12_0T>=O:RKVHA&"_:8N]7@M09F%%EOV8
M)%JL425%/'GQ-T4Q1SS+^-]>MJY$H6N7!9PU6'?-_2(\7?$V.L2X0KI7:%E(
MP7V$XSC!K,GU=@5H2K@CKR.Y_?$+1\$Q$JI:!17R@B(V<*V%::.\!#VL$R-8
M654)US4:9SZMXG-M^+*F")Z93P6T#U"]ZT6F*EN`V6!T3D-QW;Z1)88]B`1&
M-X7T&)SZVO"];B@OU]L&)74+7$O5:V0!L%EN%G"<L,O5[\V99!YC)Q[.SVA-
MLGJ8CDV][AQ#])M>(5AOW+SG3\O9N_66)_(ADC]:UJR20ZWRN=VL&&[9)2O$
M\&-2C5$G[<IGUT)=T3K2UIC36L-0V6/%MPU>CKB`.8OP?$#,3!J`NL!`371D
M9$K%&2P"4*$).Q!;ZKWB$=F]7J#X;.%"L([MO4EC@#@#@#@$`>D-&0>@$02G
M3752ID%>E)YKPO2+ULE-*652_E=B%,B;^95',P-N?;RZRPB81\M>QA7LXYR?
M==PR"IQT*="OC*5!&><.;W7:0UM`/J%D`[!-A7@H6P9UGLG550<A@E+=:0LJ
MNL`*?LDDL`4&\!93H!0BG`K.Q0-N_P#C=07:Z[MV-L;8Z]Q8?0OEN_I%NZ;I
M=@U7:X1UU40&.8RHD,S<D(+:>X-F*F:TV%GAA8Z`L5AN@\KEJ[K?V*T-(]>4
MBI=TR/53Q!A$;ZSZ[MW#2OE7S&OZOV``KQ>D]/ZWVB7<%=OU'K(8EX)J`5*K
MM?9`(\?ZT';W=GBRNS8"V8;&'V/5]S7`V6\)7;MM9N1BNQU@6=S>KGAG%L,Y
M(LZ^,IUH*SJMT7?69.,9-J^CJJ<L@68BQZNG:#\NZ1.%MR'*IG+(VOW:NDF0
MA3U0#&4!TUNX!OD':66O4K`0=4Z[[[V[6WX\2;.OCN'RSRYV=E#XXV.;,T\?
MA6LZ8RYBSP[7WQN8?GJJ]^;+4FL$^5MW^TB654LX.]ME21M`#,RT219M8&()
M]<DKZX+2]S-[/A%&[M"*(VXJ#$F'7GF)!/JD6M1/69BOYAW"3VT$DIWZAFB-
M%BGR1A/@'L%:7C75^+,(1HD:.8J]3-B3Y^*AF"Y?'$O8CM71S[/.M1M%R>*+
M0=?87"[+L@&W$-21BY6&#7^R]9R3N*.F:*U:B+3`:N,B]8$KTA!D1SQ:>G:&
MB[6-L?#'6;7=O$V5<&1P!P!P!P#K3)D0NB"K`P%1H(`"&WC)LV9O51@@,(&5
M9;I(J5)798*0X:.I036[UZW-#5J589;%B6.*///H"JG\H-X(_OO>0O\`>4TS
M_P!:<&MBOY:ORO[#^4&\$?WWO(7^\IIG_K3@;%?RU?E?V'\H-X(_OO>0O]Y3
M3/\`UIP-BOY:ORO[#^4&\$?WWO(7^\IIG_K3@;%?RU?E?V'\H-X(_OO>0O\`
M>4TS_P!:<#8K^6K\K^P_E!O!']][R%_O*:9_ZTX&Q7\M7Y7]A_*#>"/[[WD+
M_>4TS_UIP-BOY:ORO[#^4&\$?WWO(7^\IIG_`*TX&Q7\M7Y7]A_*#>"/[[WD
M+_>4TS_UIP-BOY:ORO[#^4&\$?WWO(7^\IIG_K3@;%?RU?E?V'\H-X(_OO>0
MO]Y33/\`UIP-BOY:ORO[#^4&\$?WWO(7^\IIG_K3@;%?RU?E?V'\H-X(_OO>
M0O\`>4TS_P!:<#8K^6K\K^P_E!O!']][R%_O*:9_ZTX&Q7\M7Y7]A_*#>"/[
M[WD+_>4TS_UIP-BOY:ORO[%B=?[(UWME6HO&JWU+V8E%);D`UPU^T@W)6(S#
MK<U`A#18%R\2$VY:-ZO/2N1U[<F=6W!-7GZPFCSPQ&8BSLS-.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`1EWI33?>QNMP]ZEUEWMSK]'?6T^T-5[V-U^@'^6.OT
M._8K\S?S+7_Z/=?^T_Y@?_LG_P#@/^S\"7A-M"3>`.`.`.`.`.`.`.`.`.`.
M`.`.`.`5#-:EVX%VMMMK1!FH60-NC+7Y&TQ[&*LM1JUB50%V%>&4`BV(3S=)
M]5J5NA$[K@J9WUO97'5A<B4-V[D8CFKBRH6-IPS^VF=BM>G?$V^P5>QAL3<Y
M"A]+1W/:3*BOLUO9*J.YO*/Y?"(;)!4%)&DE5G'I;KJC<#Y75S*5$)K$]D5I
MY<3IRXP,&;GR[OW[RRLEIEQG-M8JY:OR1IM[TCKDRL;"/D#YPFV]G<);>R9]
MF5*U?\HJ(&QT))6-3Z@D!U2A8$38KX'(";GD/F3+*1;39AC(]UQ'#PZ1YLM+
MP0<`<`<`<`<`<`IY\AW[`'N7]SSTS_P5=N#5';I^JGJC@>=?-_GB[Y]T5<N:
M%TO;MV]-ZQLVK5G5R//8LV)TD)+/8L3R@LI9III<LI)99,LI)),LL\\N\N^^
M^`VY=WB\S7^ODM[;JV#Z)&^<OCT^-@GK?1/H)X\_Q'-QOS"D.;"90QJV0(FY
M%Q.\F;!#4!UW!EJ?1QX,EBQCE'/%-'UU%A/.+A$UU2U-E/\`Z70^;.3WUI%X
M\^5O17QY?&J/UMNWT-K;S]:-:>V`Q.CHO%=E2E(AQV!=</)2`%(41WX5/+<A
MD9*L\GZ8H8<?];E-`&,Q75*4W4?^GT+_`$X?Q'3,-H^_I#4PP(ARF*KEL0IH
M=>&:J6B*\,B,'QYC95]3KJ%'()0FQQ*D;!3`'1+1VEFP5C:*5T+7&9JU?>?M
MZK\>0X69,V@GD/$<OCP)4M9P`Z?SCJT&J+*96M998T^\<X6;''+H!+AWE&7D
MQSCHY3YX9XXBS5_V\3NTA,\0;&KYR)FL?.;!?KKHAI(KPO7.NB#2'$'!\!,;
MF76J(:R:H69ZUF'KZ*:GU9ZL9XU>HNY\L(\@FI9OO>1]@^NO)++K,1MA7\ZZ
MW9%9@"CCP.L+\_`^F@E1*YPQTL,%.^I43]&YWE8P[N4RM`?.*CQL2EL:,56U
MG"$U3$OO_<R!'TSY.V,EJ.P5'1>E22H\K()P62,NG%`=+>`,@NJ9#W)!Y)9J
M$:,ED?<KS9T[]6M<K99]PV8(9L,X\1)JU?>:N?4&T2*!ZU.^8?.7@?P]L#%/
MT/K'=#0V[D)8ZVR[RV<[[84!X(&+3?/^R^K>(['5T]VW<O6Z'>>12.**'+J'
M++*JEO`KJ22=555VTDE."3SJ6I6W<GH[T9HW4^R-RN'QG?&/?5=6)+*_,=)>
MVDU6CUL*JB;1DE7#UB'CX91G)2U*<N%.*X0I5I)^\,9K4,?>4F-=#2FQ*:Z:
MJE2J_:2VDII42[?.S<S@L>0_S`M*'^;;KT@TG%U):"8]8\\BFJ@GB-@WB(E7
M(-9H.E3#Q`XD7#&ZF%NSG']'3#%#Q>$8OT+A2#)9JQE]_P"Y_5.C\>!&"M:'
MC/'%VG<"EV.I>J"],6*%D`OT290Z8AO15LZD@T,+"FB92WC-W#1'!B]ZSG%5
M%WI:X>]_V\3^40;X%V3*%JJ"/YB)DV6\XTEL+TCZOC.,/2*U.::>OA!&8OZ\
MF+Q,Z]<^Z%^I!)7(T%PP0JY25AE_.L$U+-][]9H[I-0?'[R?V`KB-`ZIJ&]9
M$*=!LJ'-%JX3"IB2Q(2#+M>V06(:=JF0@%7;<'4<_P!9&/ZI$[=2L-,!;9$2
M7J^\YNL-<>.-QJ,+WKO2NDSZI:--8&D8[TPJC8;]U,:3"<:GH1E%:E8N"LC0
M(A^$&:\4@H^+^D.!+=\.0HWK`34LWWLKG\4HP:%TIZ*#AQ]$2($_(I\B0P4*
M&5(*`T8-H>N]JU:(\?1JQQ5:=&G5BBK5*E:*."O!''##'A'ACCT-5XT_13T-
MG7!@<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`<`<`<`<`<`<`<`<`<`IY\AW[`'N7]SSTS_P5=N#5';I^JGJCL/.6YM/U
MO/>B*]C:VMJ]BOIK5\,\$STKQ30S1)`/"6*6+,ICG'+'GCEA)'GCCGAGCWCE
MUUWUWUP&G+L\7D41&:-V]K38&_&'SW\I/GO62+O7>;EOFVC-GGO7VT"2ZS.X
M]?'EZ,+E/Z*4Y"8_")<I=U>L@-#N+],G66&>7>4F0NDT-PHS^Q\S.B]P[0=]
M$F/07RF>>MDH>D=[:_WW"CJ?GC7VLB;&QZYD(RAALKE!Z+:I!="?LG9QMY8@
M2&6>'>/V8NLNL<\0UBAJ5&?V+8-&J/&S@W7VTUM12E[O7FTW&`AVDF0A13(^
MKTBNZ'@<_4F3((R:!4LLIM<I,,2008))'*PK9N6>1_L3WM'ED\L.[]L#JBFE
M/&Y)[:-F1[G#"7QG,3&NF@3ME'KF`=F[@P5RD(N_-A9M7JI$8W-@&.)IE8\P
M"X?D7U*5>$!E>H!#WM'I@_6G'.;F8ZC2/(>C2)\EK;9FNP4IX7F,R[_.VM;5
MP=]5)!;*W*IZ:ODT7YS!6M`9MTV(Z<#52.&6084+JRS59`>T\4^XXWY#\F]Z
MPAUEWN)0ZSK)^6O:VR(=@:TJ;6@1)&")BL)N+E2I5I,U>]/%T.*@9J,@LT)D
ML53%6_):LSS![VCUP>.I/*UM#2:ROA%VON;75ZL#%T1-:W<>$."U-7H5XZT&
M4T`>84*@RZBCPQ^Y'#*%*+KKK"O4@BQQCQ$AZ/N9K%]-^8N]N>HR_IW2/R'Z
M9T.49])ZZTPT*K!K5$W+4(T];..SF\.<H%;6ZD+,5-8EV<0I6J'0ZYUWB/@G
MZN]_?=P05-K`.F4DZ6X;:Q6,3EN17+:W@S<.YM9OVI'?Y>O/DR=LI08$=HA&
M>6]>#B,H%F&61!6.C?Q]1394[>=.U-C!9ZBD[AD[QDZPR^S^CN[56O@A32J6
MJE15*:>+R<Z&T]I1/)KFPI#0>V\FR%$W/45F2&KLA'Q%,E_13+><M6$BM&_(
M2D&$E1E+&[D!91MK9HJ.-$5EB)FE>7$-ADL5://)YX^!AK%H/Q`T6TNR6V<K
MR1H&IJFFE>K'MQ4P[&JE!!?=:4YZQ3*SF?J%HE/9#/7EEH&*8Z^2R$'28NZ9
M`A[U,/>T>,X<_)=QD23J_P`?HFPP&U1NV4HH_!8V7NTS,3YK$R6/7VIEVBW$
MRUTA/0QO`[WXWN;8TF,2/941=B@>A#$AU\.$`T1@>]H^Y^LECH9'@H^/2!EU
M8'EZU+M4J]948"4^S6C6#/"/#"JS12$`0U'NO3H5:HZ@ZM0W\6LUKC84%F,Q
M9YB+#Z(NM1#WLDUP3]:&<ZN)^6],KEU2UP^:G6E^^U-KE.-IOBIC!^..I^\R
M&YH\>BO74<.5\A+'3KX]?=TZ,56E#UU#7CZZ$BIY/N95[XJ[M,EIGT>1'6ZM
M\??^1CY%;M"_2GBM4[M.UZ]VM/5MU+4&<D%FK9@DPF@GASSBFBSPDCSRPRZ[
M[&J\:?HIZ&S;@P.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`52]X?L.^R_W4O1'_``A<.#5';I^J
MGJC_`!M.#W#@#@#@#@#@#@#@#@#@#@#@#@#@#@'^H1_DSO\`5`^?_P#QEO/_
M`(Q./!X_:_U*N7Z4;\.#F.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.
;`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g887761g66h73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g66h73.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X5N/:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!44&<](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM96YS:6]N<R,B"B`@("!X;6QN
M<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+T9O
M;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+V<O(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@("`@>&UL;G,Z
M<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!P9&8Z4')O
M9'5C97(](D%D;V)E(%!$1B!L:6)R87)Y(#$P+C`Q(@H@("!X;7`Z0W)E871O
M<E1O;VP](D%D;V)E($EL;'5S=')A=&]R($-3-B`H5VEN9&]W<RDB"B`@('AM
M<#I-;V1I9GE$871E/2(R,#$U+3`S+3,P5#$Q.C4P.C,Q*S`U.C,P(@H@("!X
M;7`Z0W)E871E1&%T93TB,C`Q-2TP,RTS,%0Q,3HU,#HS,2LP-3HS,"(*("`@
M>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP,RTS,%0Q,3HU,#HS,2LP-3HS,"(*
M("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!4
M4&<Z3E!A9V5S/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3TB1F%L<V4B"B`@('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E
M(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.D9!,#=$-T1$031$-D4T
M,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N
M:6ED.D9!,#=$-T1$031$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z.#1&.4$Q-45$0S@W13,Q
M,3A&-S1%131$03,W-#@Q-T$B"B`@('AM<$U-.E)E;F1I=&EO;D-L87-S/2)D
M969A=6QT(CX*("`@/'AM<#I4:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@
M("`@/')D9CIL:0H@("`@("!X;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM
M<$=);6<Z:&5I9VAT/2(Q,3(B"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'
M(@H@("`@("!X;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!
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M,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
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M;'19-TIK:F=.>$5I5W-V,6PU4CE64U`Y-6-E)B-X03MN>&]P03<X5C59<6HY
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M,4MQ8B]64$]F+U8P,#<O=4A4+SEL,DMU*W%E8R]W1'$V860O)B-X03LS1'`O
M*WDW1EAF5E!/9CA!,61.3R]W0S1D4#A!.6PR2W!48TPU.%AZ6G!L<"MM<DE7
M8S%T9%A&>$-L9WEQ9G$W4DEO*TLT:V8T:F-G)B-X03LW3W1/4'9I<68K:#5J
M+S5B<E`X03922F8K>6Y&6&5H-6HO-6)R4#A!-E)*9BMY;D9896@U:B\U8G)0
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M661V:4QR2#=C=5$S6$9745EQ-T9867$W1EA9<3=&6%EQ>&8O=T%Q9B\R-5`K
M>'9#<DM-0W-$=%DO>D@P8GE4)B-X03MQ57-W,&]A>$5D4799;%5Z=$-$3DY,
M8W%$5V@R-3166G)P-79J65=X=GA'="M9:RMT<D%366A.>$AQ0TUT.%A(;%=L
M93)"5F9&6%EQ)B-X03MK5W)A3')&>#5H,#=68D151719-U-'94-A0U=)4W$V
M>D9'<%%&1S-A3E-4>D9/27`Q87%Q33E$>D@O>3-79CA!,&E3+SEL3TMU.41Z
M)B-X03M(+WDS5V8X03!I4R\Y;$]+<%IR8V9M>$<P+S!D5F=H4C=U2T\T14YQ
M1EIO;G%'2$M:-V=!*T9&*VY#<DI-0W5X5C)+=DEV>DDQ3T\P)B-X03LO3C=Y
M84=V;G1&64UJ,C8R-WHO5V8S<7-%57%R1DMD95$K6&)#<C`O54Y",%A56D)*
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M)B-X03ML469H46)$<'0P=V]:+V=3;#-M6"]L2$Y6+S5G-VHO:S`R2W!J:7)S
M5F1I<G-69&ER<U938GI0<"MT6&M&;BMI6F\T6C1,<4]757DO)B-X03M:36$Q
M1&9S=G5+,7`S.&-65EA(;5IK6E9A>E)I0T%W.5%K2'@S,GA68C55;3%39E%R
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M>%8R2W!B-6,O-#0Q=B]!3%`O)B-X03M!2D].:7%:67$X;B]!1$1A-V(X,B]*
M:4=,5&QT,6M$2DY,>FMV:BLX2$E1<5EU2VEU>#1S>'!U94$S=W$Y67=+:TXW
M+T%-<#5O+SA!)B-X03LR>715+W=#;VI4.%92;FU46')0>2]O3CER5C9S:C)T
M:$,P.'E1;UI*0W$Y;%5F-U$V;F)&6&57-%!2,$MZ<E5Y>E(O5TIY>7-H33%W
M)B-X03M43DMX4G='5W-J<V5*1S)+<&QI<G-69&ER<U9D:7)%1$Q9*V(O34U5
M84)P3D<X=E-I-&M:;&MI.5A59U=73DM-<6MR8F]'6F@P6FY8)B-X03MS<'%Q
M>2]&6%EQ-T9867$W1EA9<7A,.#$U-U=(>41Q,S%M9%E)-4DQ4W),2DIY*TY7
M6D]%5$I+,595,4--1W!59VIR:7%',%!59&%L)B-X03LO2S=3<C-Y-V%W+UAM
M=')C,C%Q<UII:3E0;6]93$A,2S=*5T]T3V-H239M=E1&54XU6G5F359X*UE"
M9EAB84\Q=2\P3W=#4FYB:CEB)B-X03LX05A&06%G2&QU3C9$0VAN*T)+5BMA
M8F963&YY,W%L='!34E-A;%!A>7A7<51S56E-:F]62$IL0DY..%93>GDY<79N
M3V)Z1F0V9')L)B-X03MT<#A.=&(V9EHS2W9:4U1/-75,:'!5:T(Y4E5(1&QB
M=%1U0E1D<6UI<DHX5F1I<G-69&ER<U9D:7$R44]9,D5B0DA)25)Y3U%"<'-A
M)B-X03MB5GA69S%Z9&5F3D(X;',W>%=,6'1S.51+2EA0=U-454$T96QX<E(K
M=DQ#:&Y30G=I:'E'8T%C;4%O0V4U<'9406PU+S5Y=G)#,B]-)B-X03MN>7%L
M,UE7.35*34A3>FYL;FYI;'0U5V-,-FM52W$X52MX;V5H6'%31G=Q;F9M<GET
M<E=S6$AQ5U=U5&%B1CE834%G:E4X4DE:56LY)B-X03MB:VIX='DT<'A(.7!W
M2V=.1C!A.3!N>E)O5G!E6#AM;WIP<%=Q:')I4W4Y8G%W3F9I3&UU*RLK2V]Z
M>C%C6#=T;VUK5VQI,39U<&%J)B-X03MB9EAM5FM!:'1,5U9,:5=2,5EJ:V@Y
M34EW+WEV16=&5FQ/2W5X5C)+=7A6,DMP3#5R.'A,;VUN<3!56FTQ2SAC5S)L
M=V-(6DI,<5%H)B-X03M9;&1L,E9E4G$Q5%AI1%-P1TMO;GDO;V1R;W5M<%IW
M:WE3<U1,95A49C-L>&-047EZ>68U8VIB;C=H=&EQ631Q-T9867$W1EA9<3=&
M)B-X03M72&9M='%E;&%:-51A.#%,4R\P=VE4>$QB5UA->',Q=SE6:#1S2V17
M4$5I=31*1R\R4W%N2&MX5UAY<G!987A/;75,9$]D:7AK3%).)B-X03M4-&Q9
M>D%31G$Y4S%46'5E<%912"]L5"]!4'1Y9CEJ949755E&9&EQ4S)N+T%#;65Q
M9CA!8D\P-R]K+V99<6Y72W5X5C)+=7A6,DMU)B-X03MX5C)+<$PU>#!V5715
M.'4S5FIP<GAP9'EM36]:<3A#1FM6:4149F]-5EA70V5A:'$W1R]L=&TP<U%$
M9TE1=VM-.5%.*UA9044O5#=9)B-X03MQ=W)Z=EI'-R].3'ET8S(X2G9(<T=#
M6$MP6E-8271X2DE(16I80VM2,GA+:G$O561-2W,Q,3=Z6F]M:$UG,4]74T98
M4G!&8U)33VQ&)B-X03M)0BM*1DEQ2S%).%!O=TMK<V9M6%).43@P-E)Q9'1C
M9S)+-E)Q<VI43T=J05%83F=/4D1!161-5F$X;%(K8V12,6TO.'@K65EZ<#%R
M)B-X03M/;C%84TY$8TLP;'9#:C%A6G!&<'90>%9M5FQQ2T%D:&ER33A69&ER
M<U9D:7%7-G8U:#!V4UI)27)X,SEE-C5F5EE9;W!*6&M+;%9+)B-X03MJ9W)!
M2&Q);S-P,7A60658-T178G`O,'`U:VAI6%5%2E-X=#!!-%%2,$%:=T]C=SE3
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M>&)!<7<O6DDS<C`S=TLX-C!J>60U<'9.5C%()B-X03M79DI7=#986C983&%M
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M-DYW46<Q05!X,355-DHP=W%P83$K65`U:F%:)B-X03MD-G1A,T9Z-5AT6C0W
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M-DA4-VTQ:W%&;&EV;FM7<6UJ1&MT=5%A2'=X)B-X03M60D1Z=EAZ03)G5C`S
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M6$9V,W=*,S(W,'A6;&5+=7A6)B-X03MJ2&UJ>6AP1V\V<'`R=5,V62MO86I9
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M,F]J1#1U4%1P,&%M2W!0<%!M,SAK9DMD.7%T.7`Q-$QE-&UH5V$V4#A!<$5N
M355M8TQ%2$(K)B-X03M)<F)-841Q079I359D<55(-4PK8TY79VUV<&UF5F(Y
M;VYJ:#E7-6I9>5-*1VM226I0<&AG159A+WIB2&9&6&\R;V%&<%=O850K:6)Q
M)B-X03M!4'`Y26@V04Q+2U%S<F]+<5%D:6<W-$93<GEN*UAN;%1Y<$YC>F%*
M871"3&1G3$]Z>7E3:S!.9C(R86QE.5!$1E9U=69L=C51,7DU)B-X03MU<FY5
M<DUY,T8R1CEA45-Y2V%P-EA&;$-S07)$-G-M-#DO131Q>4]#1TM#1T]#1E%K
M55-H23!(44MO;T(Y,DMR.%9D:7)S5EER<E!K)B-X03LW4G8X43)F;6%04VYV
M=%5I;DQY4U)Z8T=51T%2:'A'-W!%,41$1TMF5#)X5G4O1FPU,#`Q3D]M,#(U
M9E%,=VLS5GI*2CE6+W57<45#)B-X03M+-&YR-G$P25I12T$K,DMP=#5B.'1A
M4#5C,'%04W1):$U&;$=Z37%&;6,Q63DR8VMN=TAT:7)"=E!E;F544$LS;4<P
M.#54854Q,W).)B-X03MZ3R\W>C9Y,%@Y>F)T25)(16%P2DEW:2]D>&=66C9B
M-%95-2]Z;"],8GI"65%7,7I(9'E73C-D45)F2$-55&U,;%)!>G-(+W4R;&I0
M)B-X03MZ0VUO;V0Q549O=C5M951F2E9L9392*VAB-U1T2C`K-79O8D\T5EAN
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M6&%74VYQ5$Q!2DIK4G`V,&M79VLY3&=F9TA)8C`T.$1I<C$O6&1",')8=$UK
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M941-0U)6;#5!949$=FEQ-C4O)B-X03M,15A,*W$O;5!6-'!P630T-S`R.7@V
M851M2T-+04TV;%<V*VE73S4S6G$Y8U949GDU-5-/:EAL>F1V<3$O<6-L=VEX
M,'9P=E9#2W)S)B-X03LO=T%'=W`Y=D95.6MI:6LT*V]I=G=93VY)03!99$-+
M.3A654DY3#`R2S5L=5DW5TI,:6-2:6%6555-=VE*369),#,T1FI4=WA65V%'
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M5E1(,3EF+W=#5T\Q+S93<%`K)B-X03MY9D974#9V-4QI,6956F(K+W="36AL
M;FUI5TIG3E)U:VHK04]Q4T)%:%9226EZ3T9F<4LW6593=3DO2UA13#5R9')Z
M4DE,:C9O=V$S)B-X03M%;7!88FA$=U9'2VAO:E%U23%,:V)S4E4T<7`O.'%E
M.'9&<#)K,&%/6G)O3TQL<$Y5=DAA47EX;48R6FI&56MX<WDQ-T$P1DU65"]Y
M)B-X03MV-5E0;&5X;'-D1C!Q,71R86%15%-*.6-M87-G:6IG<CA50G`K-VA5
M54<R0E8S;41Y>D8U:',W:3`Q:E%T3W9)<FU0,'!':VYC>6-E)B-X03LS1U0V
M='I5<61W461J:7%L-6(X;U=V;'5X=&)04CE",#8S4S!8:D9-2C)->$I&1UIP
M5&)C>7I6,TYC5E)7=#9.9F%Z1D-L-5I22SET)B-X03M*-G1V4&(V:&,R.#!B
M1E=J8FI*1D-J9TUJ<W!&96AX5DI0.$%L5S%G:S-R5S)M<&%-634T<$9T=%1U
M-%9D8G9H-B]-2D-+;50P62M2)B-X03LV+T-V:&A6<5@X<W1,;4E-;6Q2;C`T
M>$1B1#E*,UDY0T5+>4=+0VM8-W5.;S5':DMR='A.3592.&YL8E5)=$,Q<E-R
M1S)G:$=S:35-)B-X03MJ>3-S.'=34S5J35I+2S!(=W%V6E)167%Y-T%R<U9D
M:7)S5F1I<G-69B\O6B(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<#I4:'5M
M8FYA:6QS/@H@("`\9&,Z=&ET;&4^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/C$P.3PO<F1F.FQI/@H@("`@/"]R
M9&8Z06QT/@H@("`\+V1C.G1I=&QE/@H@("`\9&,Z8W)E871O<CX*("`@(#QR
M9&8Z4V5Q/@H@("`@(#QR9&8Z;&D^<G(Q,S`X,S4\+W)D9CIL:3X*("`@(#PO
M<F1F.E-E<3X*("`@/"]D8SIC<F5A=&]R/@H@("`\>&UP5%!G.DUA>%!A9V53
M:7IE"B`@("!S=$1I;3IW/2(U,2XP,#`P,#`B"B`@("!S=$1I;3IH/2(V-BXP
M,#`P,#`B"B`@("!S=$1I;3IU;FET/2)0:6-A<R(O/@H@("`\>&UP5%!G.D9O
M;G1S/@H@("`@/')D9CI"86<^"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF
M;VYT3F%M93TB07)I86Q-5"(*("`@("`@<W1&;G0Z9F]N=$9A;6EL>3TB07)I
M86PB"B`@("`@('-T1FYT.F9O;G1&86-E/2)296=U;&%R(@H@("`@("!S=$9N
M=#IF;VYT5'EP93TB3W!E;B!4>7!E(@H@("`@("!S=$9N=#IV97)S:6]N4W1R
M:6YG/2)697)S:6]N(#4N,3`B"B`@("`@('-T1FYT.F-O;7!O<VET93TB1F%L
M<V4B"B`@("`@('-T1FYT.F9O;G1&:6QE3F%M93TB87)I86PN='1F(B\^"B`@
M("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M93TB5&EM97,M0F]L9"(*
M("`@("`@<W1&;G0Z9F]N=$9A;6EL>3TB5&EM97,B"B`@("`@('-T1FYT.F9O
M;G1&86-E/2)";VQD(@H@("`@("!S=$9N=#IF;VYT5'EP93TB5'EP92`Q(@H@
M("`@("!S=$9N=#IV97)S:6]N4W1R:6YG/2(P,#$N,#`P(@H@("`@("!S=$9N
M=#IC;VUP;W-I=&4](D9A;'-E(@H@("`@("!S=$9N=#IF;VYT1FEL94YA;64]
M(E1)0E]?7U\N4$9".R!424)?7U]?+E!&32(O/@H@("`@(#QR9&8Z;&D*("`@
M("`@<W1&;G0Z9F]N=$YA;64](E9E<F1A;F$B"B`@("`@('-T1FYT.F9O;G1&
M86UI;'D](E9E<F1A;F$B"B`@("`@('-T1FYT.F9O;G1&86-E/2)296=U;&%R
M(@H@("`@("!S=$9N=#IF;VYT5'EP93TB3W!E;B!4>7!E(@H@("`@("!S=$9N
M=#IV97)S:6]N4W1R:6YG/2)697)S:6]N(#4N,#4B"B`@("`@('-T1FYT.F-O
M;7!O<VET93TB1F%L<V4B"B`@("`@('-T1FYT.F9O;G1&:6QE3F%M93TB=F5R
M9&%N82YT=&8B+SX*("`@(#PO<F1F.D)A9SX*("`@/"]X;7!44&<Z1F]N=',^
M"B`@(#QX;7!44&<Z4&QA=&5.86UE<SX*("`@(#QR9&8Z4V5Q/@H@("`@(#QR
M9&8Z;&D^0FQA8VL\+W)D9CIL:3X*("`@(#PO<F1F.E-E<3X*("`@/"]X;7!4
M4&<Z4&QA=&5.86UE<SX*("`@/'AM<%109SI3=V%T8VA'<F]U<',^"B`@("`\
M<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@("`@('AM<$<Z9W)O=7!.86UE/2)$
M969A=6QT(%-W871C:"!'<F]U<"(*("`@("`@>&UP1SIG<F]U<%1Y<&4](C`B
M+SX*("`@(#PO<F1F.E-E<3X*("`@/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@
M("`\>&UP34TZ2&ES=&]R>3X*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D*
M("`@("`@<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N
M8V5)1#TB>&UP+FEI9#HX-$8Y03$U141#.#=%,S$Q.$8W-$5%-$1!,S<T.#$W
M02(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q-"TP,2TR.%0Q,3HQ,CHR-RLP-3HS
M,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@
M("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@
M<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I&03`W1#=$1$$T1#9%-#$Q.3@S
M0SDX040Q0C,W.#%$1"(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q-2TP,RTS,%0Q
M,3HU,#HS,2LP-3HS,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA
M;F=E9#TB+R(O/@H@("`@/"]R9&8Z4V5Q/@H@("`\+WAM<$U-.DAI<W1O<GD^
M"B`@(#QX;7!-33I$97)I=F5D1G)O;0H@("`@<W12968Z:6YS=&%N8V5)1#TB
M>&UP+FEI9#HS03-!,C@Y14$Q1#9%-#$Q.3@S0SDX040Q0C,W.#%$1"(*("`@
M('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z,T$S03(X.45!,40V130Q,3DX
M,T,Y.$%$,4(S-S@Q1$0B"B`@("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240]
M(GAM<"YD:60Z.#1&.4$Q-45$0S@W13,Q,3A&-S1%131$03,W-#@Q-T$B"B`@
M("!S=%)E9CIR96YD:71I;VY#;&%S<STB9&5F875L="(O/@H@("`\17AT96YS
M:7-&;VYT4V5N<V4Z<VQU9SX*("`@(#QR9&8Z0F%G/@H@("`@(#QR9&8Z;&D*
M("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E("T@
M5%0B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3TB5F5R9&%N82(*
M("`@("`@17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/2(P(@H@
M("`@("!%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/2)-:6-R;W-O9G0B"B`@
M("`@($5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX](C4N,#,B"B`@("`@($5X
M=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3TB,"(*("`@("`@17AT
M96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3TB,C,W,#<U
M-3DY,B(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T](C(S-S`W
M-34Y.3(B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE
M/2)697)D86YA(B\^"B`@("`@/')D9CIL:0H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I&;VYT2VEN9#TB3W!E;E1Y<&4@+2!45"(*("`@("`@17AT96YS:7-&
M;VYT4V5N<V4Z1F%M:6QY/2)!<FEA;"(*("`@("`@17AT96YS:7-&;VYT4V5N
M<V4Z3W5T;&EN949I;&53:7IE/2(P(@H@("`@("!%>'1E;G-I<T9O;G1396YS
M93I&;W5N9')Y/2)-;VYO='EP92!4>7!O9W)A<&AY(@H@("`@("!%>'1E;G-I
M<T9O;G1396YS93I697)S:6]N/2(U+C$P(@H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I+97)N:6YG0VAE8VMS=6T](C`B"B`@("`@($5X=&5N<VES1F]N=%-E
M;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T](C(U.3`Y-#4X-3`B"B`@("`@
M($5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/2(R-3DP.30U.#4P(@H@("`@
M("!%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93TB07)I86Q-5"(O
M/@H@("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C
M<FEP=$YA;64](E1I;65S+4)O;&0B+SX*("`@(#PO<F1F.D)A9SX*("`@/"]%
M>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`*/#]X
M<&%C:V5T(&5N9#TB=R(_/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`+<!L`,!$0`"$0$#$0'_Q``>``$`
M`P$!``,!`0``````````!P@)!@4#!`H"`?_$`%`0``("`@,``0$%`P8'#`8+
M``4&`P0"!P`!"`D4$1(3%1875M0A.%B5F-D9(B-5I+:W"A@D.75V=WB7N-77
M,D%15W%T)B<I,3,V-T6!H=;_Q``7`0$!`0$``````````````````0(#_\0`
M-!$``@$"`P<#`@4%`0$!``````$1`B$Q05$287&!D;'PH<'1,E(BDM+A\0,3
M0G*R8J*"_]H`#`,!``(1`Q$`/P#]_'`'`'`'`'`'`'`(WV\_8ZPUNUNN%.0F
M1%48JJZ'AI$B,QYO.WJJ^F+T5(-6N%+$C`UE`P;#&C6FGQ[O??QQ^S'OOH$I
M,9]#?)]LU+\!L.WM[I&.R=R^/_15?S![=SENW]5$%4$/V()5)O2515N)!8K?
M`RZ\:TK:A$!*%6H[0J9MGJ%:<:_+A(.CH6U"PJIVJ<WA]/646@7OD58FS?M_
M0*SYP8CQY66]$MNP2HMJ+ST4]8]&U-MD]?,UC.76L%')?""T!1EV/.6*`2P&
M^^WABH%?)D<G(3&73"F<9C?$3WMZP5B@^91^J^5T;UDT>1EX"B[5T?LS>^M`
MM7T^(.MS"MZ?U>7V,^";:E5U#7<JQ&G*(D$P&0*NTI08?<',VQFG7U&WA5X-
M;'XG3.#B8B[<+/\`?1,DAL^6ZZLLS?W%Y6?K^M$`*Z.;BW9LUB-K$:U1_'8;
MU[<V9VEC$,V"[3&*F6ZT\FE;FQ!\)S:V%8%8S%]V9>J8FQO6FZ=ITX\I=K*Y
M;[0F[7OV1H9O,QI[IYINMBTM_L\?Z%C%EZ)K^RM3I[N-V7K>TX)JG-?R5R[8
M84,<F-(A%669*MEQV#"K$1ERZ,M0\9_G#S74RATY[)W=KMQ]!.KWL+8FW%W7
M'S1U/CZ5D,TSKP8-4U#MX;JA(3[Q*Q"AE")HQK1W?<7.O9[MC"C%2Z*`BIO*
M"47F-&W2K;_Z;JG>MIZYI0=VT_-X=!:[Z?!WE,64RIZ:]O[G-BKGH"T+QIB/
M#?H##2+L(&7XM&%.RA!SJRQM:M+9HB(*]GO)<+?30X_J+(-A3&UG0L/O4ZY$
MT@OEIE-;#N:6[\_1U-O6?1TNB%8;^U::9`)BNO)4?L")W/O7>L(22W=_0TG2
MS94*R6P?=;<L<:#(2!QW#%09V;3-MF?_`*V8QU]#I/*/R=,_LK9RDK:=\W1X
M:_*:0\U[_<'APW#"OLJ:B>APVT^^HX$"/6Q&JSG$QOUC*NRTZ+M3IL0@W6::
M!&GA5R$6!:J=E7=YJ4)6_"UG._3<<5Z7W-OSSU\AB@@W7MU/:*]S:!=-:>=`
M,>,?Y1J/VFEV:%B**<D('UBE-2=D,IBT_4GB1+L->5&F<'#!1CGJQ`DG2W%Z
M6F[XTOGE[D?^@?E&[4M?>@-3I*X]"3"A;]M>7=;[XO,](B^=^A?(GCV3T+??
M#Z5FH1"XE<E8K%Z8T_B:)X7S`2C<)I]599<^Q(*G!VRJ:O@ZHB>G)XGWM1_+
M$SU*FGM8N.H^W-LG:?C#TNU;)EV3"*G96'WGI&9\FV1(L5-;9U*,R@8"W8B:
MO6*=5CF)'JW0,!<8.A^4G'<TNL?(=.-_N?1P1M<^=AFHZU-;0L>1`W801YSW
M?Z8[I0^C;<A.=*\[>M.O*&RA'W)-`PUHF:T:L4&Y'K?42C#HV6V-/%%&S5BM
M7*:_MWC:S2PS=.TL^3-'=">ZL_0F_=IZG3])N6*#J?;6W]'LVWY+=S(:'V'J
M1=U:>RI,(FPM41`\>\?KMDK*,H5T9C'X"57)G00:BX"<ZPPZ82<XPXW.>T7X
MF@'!D<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`J1[B.;]`><&VYY>P7;^],
MS^O8TI58VD6CX[#IP/ZV1>M9+[F;K6Q2FZ;$UQ1;U!+9;M?+`&REQA.*:E9J
MPWZHM,2ILM8F-'&<.[6AEMK_`.6N=1!RU[6F-VWV@T7]N77#5'HAL'I>PO-C
MEXS\T:TW4>T9D9$ISAALQ/<AIZN?1]J6R<ACH6Z4K!FL?L5INL9NW/TCY-.C
MVAJZ:;B?VU+.ZI^13=&^MC6-?Z;\GK3%(+\V>8/2)TBQ>C<5/,>%]0ZLV0ZK
M*[6HY:6+X$;P%S0:B.1NQD(<+(MCB<HZ=?L796IJ3924MYM8:1OT?H1`#^25
MGWZ'^/+9:BCM6M%[?_IVEJ$XLB]G"8I\-C4=`;@9MB:IVC19="E;91.UT[K?
M:J5))Q148KCJO2VHNZ$`.<60%V8VINTIY.I)/%0[S=.WIV*E\KYMFU`.V3<\
MZ"UQBJ;G9O-^P]>%=XU\#6O-])%W><3CKS*//6$#!L"\$%ZJ2V+NGK-3;6R=
M<V\'9\D^NJ*;0P5PV;Q.4JV*LT\86.;RUL?-X,]I.?K?U8^GZ]]A!Z6>_`_B
M3TBC:F.3!R/6OVS=!3=$3=C"9HCZUR_+9I*B_1L99V.A\\@SLC4&#;%^Y'D)
M53"WJJJEOAL_+-B^#(X`X`X`X`X`X`X`X`X!\'=FMUG%'W8@ZSGDEBAP[EC^
M_-+!UGW/'%C][[9)(>HY.Y<,.N\H^H\^\^NONY?8!_,=VG+^!U%;K2=V?QOI
MOPYXL_J/I^^^I_P/NY]_B_@=]=]3?A_>_#[Z[ZS^[WP#[/`'`'`.:9DY7<HP
ML30$HFXUUA%M@/&]%W)T+90F4N8@U3[ZRQ[B(#I)I9*D_7?WH9,OOX_9GUCW
MT!&M?S3Y^JWMQDX-.:\Q(>AZG=#>]O-7%RS;@I=C;87&KL?*:#/]7P0AKUP/
M5C-]7,:@FS,-J]0TL^X."R[7=L-W#0^\Q>?-'-NR!VX675"&:VH*6\D\?L*\
MMC96^NK_`%5F]""Z._@=$)!U&]=O7A5>6>3$/>OW[@OZ.S=M2RB3ED1T8\/^
M/6%-0M>'?-&ERZ)JP*ZK>ME$@@+UI>15W8XWL0^`%45-2RIA`C8.[PK'!-"*
M"A>Z@J22U^YJ522$7:>,N7BY=RN8#XLO/*UOLAO4+&1#7K[<+9LP*[>95@78
M!B-7A=1T]4FEL`UC]5,FINTX".&W`!S55UE+5*\-0RY$H(_NY"[3B)\F9GB7
MFU/IC4^B5.!$TUKM1UDG59?QJZVF!*0(1#GU%%7BZCJ4HHH\8JM2"M0HP==?
M@T!U6H.I1UZ-2M7B$;;NW)',OCORS,#>EN70>KY`>SGT7M380W)4&]UW'9X4
MK2-BMCL'^2^^1?:)8:.(5W"?/)AQLT*>?YCW]-#U@$NUW:ROAP/%[\+^->QG
MY+AY?T;7#?IMU3LA%36RO2%R*NRC&#!L5>F'U!T-2<0^'(X2SE1FAS@9K]>M
M9-879:T&48;3U>6;RPZ38Z3KR5YGQA.PQ:/US7[9F$(W';55;I5"1!K6U69$
M!,TA:MA$3B8!B+8L)%8S7MQ$<4ZQ85LK.0*>6AF$O5Z8\^]SL$W1.F-=-5YW
M0=7(R4V$DU4UU=.*JV,`W)T)$K?1I"9EV,KUHL5A/J]R5U@'''@.`PV+<8NO
M5QN6NI@EX2XQ.W-*2NQDE0P?7Q!DJB';+0F$25"M<NJS'<6SZ=:-@;$\><HP
MI856IE7IKE3**>00=*4,L^Z]R;#,0BUA\R>>FPTV,+-IG71TR]CV08XW2:L+
MMY,E5R6!"0XY%HI8,J]NZWI*^`2VLG)%V39$\"$5C5NZ!$CQ]<67KYCWOQ.5
MD\5^1IF!>:I_-NF++$IU]<5EDO:U\N6;@+#3U6W0U3*+SGH2=4[NMZ-ZQ12"
M$..-]9I91U1%FI7KUXX@EZO/-YX]<]3S,O"7C3,-(N9^8]+9@)D]CU]*%R0@
M.0N5$<';'9+<G24.ZG=:19:=@X8.S&$SC['&VG#$Z3KVB6/5CH-IZO7%Y67I
M8E!7\_:02=A,>V%'5*(N;,<*H^HU/0A<&TF=AC%C:@:E*8+0P8VR%Z,/0'B9
M"5F20A:&#AU"U:FJ4*<4(DO";:$P<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`<`
M<`<`XQ[UXD;."1+C^L"6P)7,!F*H/,5NK,5%A6R$!A<8!^?VXS4#JZ8JU#(`
MQ3D@(A3%.F5&6:I"I6L1`1*T^0_,#R+%AG;1.LW*D',.+#3[;%<>QWLSVQ`T
MR]L`T1+&8[I4R4>0D^0QOOE[MZTRU(ZL1F6[U3J?@"JIK!M<]+HZY!\_Z0U6
MPW6S6>J$%`8B"<I:\NE4]9%+MBPB(-7NBC)^>(JM5AZ6TZGE+66`^,>-$%!9
MN1C(*V-VWU,#;>+;Q=]^/7,_J[H'21&1'ENZJ1)\]:/[#M;7W>2V,QQ3-EMI
M0Z;:'Q;PP@QP$MC`5:&:\7.T\8B%^=B.=V9Y.BU_JP)+UW<M#RW7S-YXV/2H
MC7W2>L7`>.V-8V]2I,*8"*58=H7:5P;?>_P+=*2*1F(C2%X<3*2XYV"0^Y9I
M7LK%6:2+(67J],<M#_-5>9O/NC;V)/3VG-?:U(X)2]KCJ\G+0X':[0E*:U95
MU#*>E#')FOK]F^0LB!F>65:A9(DK%:..8A=SG!MO%M\7).7!!P!P!P!P!P!P
M!P!P!P#)AU^/[8)16P2DTZCK\,Q_9UI>?K)YJNN^DZC3Z];O1==@UY/<6R!1
MA;=CIK#00=J6;[<HV^K8F&W*?>J.<\,XTJH]+:VB_M9GI(?B/9:_M'M[F`:/
M4`QAXTFTAUQ+/';<7FX;I^T(L.(32/4NKENN6A]+0C+5':OW8]7QT*IF]]?A
ML.3K/*T$\<^<Z\,L>1./F9IVAWZ-]L:I>]LMFUEG6CEJ(KKJ5R!:R$%4\1L[
M7DC@53Z5K6:!K^`LOAB&>-4#:9ZAUICH188%F0O:REMR`XBEQ$S.-XSNWZ%Y
M.#(X`X!D/N#Y0M6)'RJ>;?CLJM;`,9FM3>"NR:N*97O+A!J9%,8<THH?J6>.
M8M0MV1])J8"5P/6@%032JXPD3G^O(UA0VJ7L.J+2ECOO;HC7C@P.`.`.`.`.
M`.`.`.`.`.`5-\@[1==SJ>W]BM!:,DM7O3?H%-U+!$.&T8Q>L-.;!):1'X13
M4:M:P6KGVG7#<ZU"Y:2[?M4VFOA#;_*(1=6J*[1P7JI]RV7!!P!P!P!P!P!P
M!P!P!P#._?VGMWE-BNS`J8[2>M<L4.KKQ)(7-N5D\H0MAT/U0N$PZ-E==$2@
MGTP3NT^=W@MG@;`?G/:]<+PV69A&2BK0TFHRF^*X;N.IEY[^U!\ARMX2]0'%
M+=CQJ7:*T`IL;+M`5L9IZ*;?)4/0#(R*E;2)M&W$M$=*6*.M":HA,Y5J4JH@
MZ'_^A4J;?I#Q#\K#5+IVE*E::6SLYUQ^"S/Q_P#E_P"7?2'E76J1N'V7H4QL
MW+`TPM^&]=([W]6;&!WV(S=)5EDONS/V_K2@S8KXN6@,CK`4L8`#R03C1EUD
MB@[:#05.AMM4N-S5*Z;+[_!<[]GWR6_TLO$O]@3=_P#>-<&9H^VK\R_095^^
MDWYKQOH[X^Q^I_:_GD,K;)WR2UR;J(&B'+4"S.;&(3?NF]+M!*:]T;\*;35<
M]7:@V/#7#BGM"ZZ,8T1,<%4@=JMX`;I_MQ5-+M3*ESG&247:O#^=5_V>_)5_
M2S\4?V`]V_WC?!B:/MJ_,OT#]GOR5?TL_%']@/=O]XWP)H^VK\R_0/V>_)5_
M2S\4?V`]V_WC?`FC[:OS+]`_9[\E7]+/Q1_8#W;_`'C?`FC[:OS+]`_9[\E7
M]+/Q1_8#W;_>-\":/MJ_,OT#]GOR5?TL_%']@/=O]XWP)H^VK\R_0<TYZ7^2
M1U3VQ-L>S/)B[`VK1U9G8$WP_OI8;P4)X7:%2&51D'?([@07F09A;RN@SE'/
M&X)*05;];+&>OAWT"="OLU<ZE^@SR^,/1GR4C]>;;>+7M75ERU=W/LW1<R[N
MW7GK[UO3J6/).T=B^?S3XJG-I_("`OI1#;#8J,K@U@`U/L/)]]>QH]#J`^B!
M#C5;HGZ7@G9TTXI/!4Y&F_[/?DC_`*6GBW^P%NO^\=X,S1]M7YE^@?L]^2/^
MEIXM_L!;K_O'>!-'VU?F7Z!^SWY(_P"EIXM_L!;K_O'>!-'VU?F7Z!^SWY(_
MZ6GBW^P%NO\`O'>!-'VU?F7Z!^SWY(_Z6GBW^P%NO^\=X$T?;5^9?H'[/?DC
M_I:>+?[`6Z_[QW@31]M7YE^@?L]^2/\`I:>+?[`6Z_[QW@31]M7YE^@?L]^2
M/^EIXM_L!;K_`+QW@31]M7YE^@Y1[UE\I)!(<*"7[!\7CG"ZKGJJJ0Q\*;<#
M946.P+M1!;>)<I[MV$,%=UR6=:7HB00G:E2[P^IM*;%!%F(MA-'VU?F7Z3CO
MB0U;\@.HO)HY5^1C9X[96Y_U<QW@7>1"-K;U9)L6_M'@GC8U0A9'/)26]U?+
M#+%6"20"!(#@-DR2[I1T@PM;I;_`H7F1J!P8'`'`'`*&^>?Y['R&_P#*GEC_
M`&(<&G]-//N7RX,C@#@&9^L-6:TV[\E'J3T:8U\EFFGS:CZ&\MZ\>+JP&NL:
MPZ64YLWGMB\%8YZ4A*H2)H_H+5"K;FIVXY:0L:1$8Y80E2M>8:G\*6K;[)=(
M?4TPX,C@#@#@#@#@#@#@#@#@%2_;/HAR\L:"-;I3M?J>P/T\S)0IHZ>]CD=6
MIJ*HMK,/52VT6UI#Z\V@5A4->S%Z+&Y8#U*W9J*-0Z:ZFBC$282C5*EQQP4\
ML5B1?\57;3E\>7E#-S6*RNPR:K'37?I#EY@KN6-B^1GK;:BN%%5+*4XMU5I(
MMN0`BB[1*+==UB`E,K)`=9LRA5]3B]_%B\,,303@R.`.`.`.`.`.`.`.`.`.
M`4-^3S^89Z3_`.98_P#UM7>#5'U+GV9?+@R.`4*]@V:\._?C!CFGABDE]PNG
M<6$DN&&<G_V?'NFO_D\<LNLL_P#+V:T/^+UW_E;$$?\`Z<L?60U3A7_JO^Z2
M^>>>$>&<DF>,<<>.6>>>>76.&&&/7>66>>67?6..../7?>67??77777????V
M<&3Z8PH,-4*I4,1HEA=V/\:D2&6Z]^A;A[[[QZEJW*LDM>Q'WECEC]^*3/'[
M<>^OM^WKO@'WN`.`.`.`<XXMJ^@*+4]MM_L4JI2X<;68GC3OD<AJ^MC+1@S?
MQ'BJMXG>[ICJ=FQU3'4K=^UW'^!3JV+&<<68&:?Q1[WUEMC5.ZUE**GK!]<]
M4>M-J%A3"A;`1KD.O/2_KOT/N+13;5C>E=;_`#,3L;6148XAI1G=R2N*(4_S
M6(?9L15\AJM77^M*YJE)]'8U/X,C@#@#@%1S?NGR^N;UZ\UF-@&JNXNW93UO
MDO1ZLV]<"1/3RJ5WI45[&P:*%9US6*F4^U&QUX)VR/J,3':MV<X(Z-WNN-;+
MB<L<5,*V$SZ%N.#(X`X`X`X!4'U]0(SIE4P?P1[6FE/&1@V4";!NU&*5NQZO
M#A(U6C4=8,`RRWTB4)0AC@JEE;:,!XW^3PC]?&CM414N"KUR^?(SN>YYP3//
M`^L8:O/VK633H?*6=<)J%C4.W?-RS;N8X#"DAFMI9^4]<@[I#N.2K6PV"+29
MK5C'HB"P8I>ZY2A"#G._1^OL=7MOTKIK19<"'VDV9JTS",)&J]Z8(>O!QP<4
M0$"+10\8&#;@\'2R+GPXR"4E8K_C6KV.6&/TU>Y8K@DWAYC\'@A/6NE#S`/5
M*Q=II,=HN'`%Q!O7CX"N)!IGN_EJ4,V/@67:G6OK;_>[CJH6#;D*Z<99ZO0'
M*]U:K]RA#\]M=\89D/>=I8I?:_R']Q21R=8%_+<67<>>.?6,D>DN\9(\N\>^
M_LSPRZ[QSP[^S+'+KOK+KKOK@K^FGGW+[<&1P#^<LL<,<L\\L<<,<>\LLLN^
ML<<<<>OMRRRR[^SKK'KKKOOOOOO[.NOY>^`4/^.+')A\W9;PL8]Y7O5&VMS>
MG8[/?7?7=I-VSL,X1TS]F7?7WI,!^A:6K`T4V7??X\0S";#K"+..+`:JLXT2
M7-*_K)?+@R.`.`.`.`.`.`.`.`.`9\^NQP_T'MO0'BNW1IG4IK*2^C/2H>]5
MA("+^C-(&P]I00F"E9PSIV:6WM\WM?C[80AA/1;-=(NVPMJE;HXWL,!I63JS
MP7%Y\DGS:+_U:M6C5K4J5:"G2IP0U:E2K#'7JU:M>/&&O6K5X<<(H(((L,(H
M88L,8XH\<<,,<<<>NNAD^?@#@#@#@#@#@#@#@#@#@#@%#?D\_F&>D_\`F6/_
M`-;5W@U1]2Y]F7RX,C@&/WR,_$,E_(GO?RGO%EW[M;4=KS(:DOX`D#O#"1CI
M9,@1IQF6F#$H-OZU<\2`.M#V\"H#5WZ.(=C$/AMB*%R,;IKV54H3VM24-T?&
M#KS<FH]EZGO>D_;HNGL='94NR1M^M=V-E*G"Q";0O.>^K,S?>7F4?AU9_P"'
M@#56888I_CCKF/4-C//$150TX5G."^"-O@J\UB/,?QE^=%T0X,;CULY=@WN2
ML,&4<=<$5VN-%'K2PM#XI)L!BZ(QQAQCA_'ESOEYC!V;\"8O)5@"M[53<1^Q
MKUP9'`'`'`/CEBBGBD@GCCFAFCSBFAEPQDBEBDQ[PDCDCSZ[PSCSP[[QSPRZ
M[QRQ[[QRZ[Z[[ZX!FSK/XBO`.N@Q(63\^)&W+Q`^1)Q-.ZP0/8[:)7NOP1J3
MK<,=,"_J1^N-3I(Y>UOK-9CZRC7DI9#T9K!`CU?*7AIU5//I;B^+Q;S9(W^#
M+^/3^A;YK_[(T[_PO@DO5]6/\&7\>G]"WS7_`-D:=_X7P)>KZL?X,OX]/Z%O
MFO\`[(T[_P`+X$O5]6/\&7\>G]"WS7_V1IW_`(7P)>KZLK(J^./-.D_D^TO?
MT_J-3UA2D\C[VV%,KHM#!93+.QDK8VG]:JNQ;2D)^F!6'L)KO>^VD>DTRTLR
M^"NZE0^5G*I]-A`+M/9:G/OE_P#*-?\`@R.`.`.`.`5;]LT:I/R=OP=>($!E
M2[KHU5L6QH?L_+^%-U%AE5N".WK5\%L*0ZR_+V+ZW9>O!D`"R2LE7E3&PVCU
M`58KSV?*SX'$^$1S"-U8S0LBL-4KF;]=EA'C*R_5@L5>UQ:PQN9QKGKKV53[
MDSEPE@^]+L=>L_<@PQR2J<741T^+4Y>,^<%V.O\`07CW5/I8N+)[(M,^5>@!
MR6;H</.N0U2P3(W4/YT\2I59,-BEE<MU.J9VWKEC2KK:"ER7'&RP`H*(^F(F
MUAY\\Y/,"^,T<6YV7Z_L#:3,S,;,@M^SKIVUKZ./;Q_496$UI^X[U@&NP<(W
MK5Y"K0E7(-<XH4!3$?5C=8VS#J;J8)_;=./7?.XA_P`D(*+KKV-\C0;7R6IH
MH<DX^=&DB*3EP.L#2#,S:@F+,C%=HA*=&K:.L!6Q8)FR\\4A`J0GFN7K$]B3
M.3(5N::9WKU-'N#(X!3_`-^/9W7GC?T&74)_IGQA0;6K=9S?>RQ^YM?=1`?I
M[57V=8=]29]][$>EG'J&+O&:;OO\*++&3/'+H6E2UU?!7?H6,UNB`M6Z[0M9
M*T'TRSKE+5D1<K?=QQ^G!*`.BOB(/NX==88_A#Q]>/[N/76/7W?LQZ^S[.".
M]SM.`.`.`.`.`.`.`.`.`0CZ1W77\XZ(VEO>\DMVQ!>J%$B[&E)%P#R-)``%
M_#LG[@W`^5"BN\`0;J\?(_4DH,^A0N[W4CM7.J]2<5*6EA-KX%,?CE=BWH(_
MZZ]7-Z.63F5_WU9TFIP$&!(;Q532_G$'36E<"H-VOV9L66(33V@R;H,LQ`87
MFI0[,8'@%0EOB@(TG<%J40MT\W^T<H-/.#(X`X`X`X`X`X`X`X`X`X!"WH#9
MC/J#61=]4U`"]EQ=P31JJ1QR)(\K&18"$"\MK:V4&H[[W<<&IO*+JHLB+XP6
M+O%#D/=]A%0P]YRBKRTF6'R!>MZ9/RIZFUEM%.L:I8IZ]!.0QEJEMLR4>;]7
M9$R]=.4YB.DE-,Q2K-U5LW03<"=VD98"E5RXS]I]YB#"KPU2KIJ_2UK9^;S;
MC@P.`.`.`4:^,G_B\?%/_5FT]_J2(X*\7Q?<O+P0<`<`<`<`<`<`<`<`<`P;
M]'>[*^A_E6U^,?-4E*:FK:GO:([8*C)T8:#:QZ))Z[V]!O<%K-=7#;41U8@6
M_.NQM<MA"#K*>%WJ#QOV09F0N!,;5,TRG=WCA*B=;IQH:`?X2#QY_P"\IH_[
M#]^?^6'!-BK3U7R5=]+?,KH72,*?.@+)W;=5@K[!M,!<U$WZ/7$Z-$22#U7J
M7F#9FO*=`H;<AP0\,3P0SN0B;9*-)=HQ6#!T-2MI2Q*J'G;U]S577;(:<=?H
MS<R*!37S"TIZTQGD(W:JW3209-AJ1,FHE[E#_@-LHMW;,P<A9I]]U9[=.:2O
MWW%EAWP8=F\]^IV/`'`*Y^K$TQL;1[IKT<F,+P/=!TH%A&I9G78YZIBK$><T
M15.&;?K_`+)FHK2+0#<K"QL@J'428G(CB5R-11_IHT*L?Y]K]/W(^\@J[LC!
MF!9*ZK>4-:G)63V)79PWRFE-)`W9K!1T-`0C^0Z]]$M`XZ(ZU9OL[:8%M\=_
MND*KBBX7*"T$!WS[^]RYO!!P"AOGG^>Q\AO_`"IY8_V(<&G]-//N7RX,C@&>
MOKQ@`O?H'PSYBC-B)3+'O[#T0\+'YE3S,QZV\T)3?L-9,RANI_KNJDGH.KI:
M.C<F@QJ9Y#RDE>26R-RPP&EA4]%"XNW:30K@R.`.`.`.`.`.`.`.`.`4N]^M
M1X3YJ:-?)5^0=LGT:;5O+^MKM;K'*Z)9-\&($,HXTH\^N\,\]8HY)OVM;ZDQ
MDPQ%HU^3*&QUA^!*+3CN5WP5_7`L5J#4>NM"ZP1]-:D5AR5K;7"]05T]7%]2
M?1B0X_#O&*+\6>2:S;M3R92V[Y"Y-/>(W[%F_>L3V[,TV8-MMMXLD?@@X`X`
MX`X`X`X`X`X!YIDM3`!RITC]9^7A1MXM?_+QI(S?^C'59;EKZ$.&J7RY6Y^!
M#G],-%4;I*]-]RK1J6;4L4.8$1Z]]#:TV@>S6E+'8_17`?8)Y?JK2.[->B_I
M:LE>*;[I[8&O5@#G:^_9B_"'X$LK]C#\62O6ECKSYQ"QPZI]B5C:^$9*E>@?
M%TB]*H8`L%:K?@PL00FU8V/9%PI'')UWCU="'Q0TP-G^S[]4C1JVHN\98<,N
MA#.?Y%-6Z[2O%?KEJ4TX$`87)4JVV4J-I806BD]G8-`]<RS[Z^W"O@0839MC
M)0T\*\!)D-F6&_'8,E2%ZP-4_4N?8TPX,C@#@#@%&OC)_P"+Q\4_]6;3W^I(
MC@KQ?%]R\O!!P!P!P!P!P!P!P!P!P#C;&NT.V_B]K64]<GV6$4S"&(?)1%+-
ML');`6#G3:M4.=P_F$((F97PI2V-QGZJR7AU>QW'^)CEED!V7`*&?)&+&EO,
MXBH5'42=7OU?\?\`WW6(5*]VOW^+[R\W59?MALQR1]_B5K%BOG_B_P"/!/-%
ME]L<N>.0U1C_`/FO_BHOGP9'`'`(']/'2ZUY_P!KG`#9&DFAZC>E&,671C\>
MO;SSAAB'C95U:=&.J;/=R_D`"\NICBP4#9,?="*;*4@J!+PJQ\\[<45[^.HM
MN,SI0E:W/9V'T>J&UH&/%;/$;GI-0Z%<U5KH"?OS%=Z:MU2XGZK8Y#F1QCMP
MC6<97LG;=?\`5]DIT37EH*HFWG1O#`^SZR]FD/,Y_*"'7<K4LK&O:VR'XU+;
M(TL*XX\X=(*BO!)1PLOGV=.M/>(V&2:A=K1E"2S2*1!ELJQ/:4*E.=]//.=G
MXX+V*_2;/9=9L"$F?4ZJ>]((FS3*\SFKE(_9]&L-5?02FJ8K@*OF4IITE^M:
MV7&<DJ9TH8".(N23NIUE()&#U3],?V]CR/(CL+?/8OR.%A(MP$UQSKYW6I8'
M5&<-?DY[B[J*87<OT`[L%`E"*]=G@RL`66E3F`L8W.$H#(7Q\\-G,5_33SSG
M/=V-(N#(X!@VK_'WJGT)\T.X/D1_5>P:-SRE^S+38D$.,5NU5RW;AI&Y*^V)
M9Y*>5^JGJ&MMHZP#Y+P2W#7(;%B=NS5Z2.$F"D'3::_IJG66^$V]5/3B;R<'
M,<`<`<`<`<`<`<`<`<`H8T__`%R?(%KA3Q_X4H^-]1%MTG\?_P`2M^W#T1TR
M:FU+UUGW_DNB2EI];]!6"53KK.U7J;05+^?=6&W6^N&L*7OMR4-^L%\^#(X`
MX`X`X`X`X`X`X`X`X!BEY)UYKI?]][3F'&Z7>S@]#<A%QJPZX!MC&=Z;-DQV
MJQ1IWOK_`&WLQ?4JW:YDF5HM;[86=8[48F(&8;E(&&4R#6KPC;F%R[:-*>*E
M83DS:W@P4-^3S^89Z3_YEC_];5W@U1]2Y]F7RX,C@#@#@%&OC)_XO'Q3_P!6
M;3W^I(C@KQ?%]R\O!!P!P!P!P!P!P!P!P!P!P!P"C7R)_P`VX/\`]:_X_/\`
MO\^:.#5.+_UK_P"*B\O!D<`<`KYZM1S6RO..XT-=B*6#;2CE10VH'K?67[]B
M;&/+H;A4Q<M=SV:Y+'#*A?AIOR41DH6+.`UJ`$.ZQ2J"Q7GSV(;\(6S,25LY
M6:%HVG-B9M#L4?6V')PR(TY"2"C,8ZSADY[]]$W9J%\69J35;0MTHAI),;->
M('`2J%+MX5Y</=[EV+>G41(:"P`\S)JJQ'%22[*K&3J\(+EEJ4E'#$1D`$2%
M.Q<#R$(JU>.[F.FK96HZ\.$_<F,4?6(AX(?36H%Z12F`:JUN#E0<C62+*'1E
M@9(E9,F4N;%DI9TA<&2YD>RGFR-=A^Z?93*:7N]^/W)GWV$O7'$JKYY_GL?(
M;_RIY8_V(<&G]-//N7RX,G`[6V2KZ:U?L;;KO;^@3=7(K9L)JN]?=[SK+J:"
MOL)B6/'/+''.;`>.L=PQ_>Z[DE^Y'U_+EUP$I:6MB"?#NM6C6GF?7T6PZGT>
MV]BY,6\MU0Y?>SEK;AWHR%=K[$#]SR8X2STU-B;+::#_`!,(NJJZNAZ$$%6K
M4@JPBN[MA@N"4+L6TX(.`.`.`.`.`.`.`.`1=O`U16]+[<8"6R<=-T`FLWLI
M<V[E6%7>M75Z*N4LR;#ZI':9`+=S3,8^V*.D7'WQMO,=C7O4K5:22"058JTW
MPUW&5_PN(WJK/5>Y_1OK>398C8GIQY2V.!*VQFF6G"I1UKK5=UAWL.Y,KZOU
M5;7*.SNE^"^N:V(`I:J6G@UNY%;(LC.WGSHU7%DHM.$Q=S&+F-<^2-H>#`X`
MX`X`X`X`X`X`X`X!YI@7`<$%0MJ<E5JEQMX79LARI($7KP$*TM2:<4<#6J)<
M,2BCERDHE15VF2'6<8K=&U7M0Q2X`9M^1@#MCO+9C&$7VXWH:\;VO(M;4);?
MV8"4[+/GLBY5-*BSYU8-T[A7CG5$U48H[^U>P&CJ]:V.RJ*B#>&G+-RD-/!:
MVM"TQFW2^]R:4D"0X15SO%2%(92CRPQDN$+4%*K'E)GU''CG8LR1Q8929Y8X
M8=99]=Y9]]8X_;WWUUP9*'?)D1'W?"'IR"G>IVYJ2:(PNPUK,,\M3.RRK-NO
MA:CBSSSKY3U9H;,.,O6'<M>6.;#K*//'+L:H^I<^S+_<&1P!P!P"C7QD_P#%
MX^*?^K-I[_4D1P5XOB^Y>7@@X`X`X`X`X`X`X`X`X`X`X!13Y&+%>OYN"_CS
MPP_?]7?'_P!X_BRX1_>ZB][>:99>\?OY8_;U''CE)GWU]OW,,>\\OLQZ[[X-
M4XO_`%K_`.*B\V4\.,/=C*:+&#J/\7N?*3#J'J+OK[WXG<O??W/P_N_XWW_O
M?=^S^7[?LX,G\U[5:WAW)5L068^LN\.Y*\L<V'6?7767>'>4>66/67766/?>
M/??V]=9==_9]G?7`/GX!5/VL'ME/-^R)X"[-2I!0=XN;"+P75)V@YAHZ-JG<
M6WBIM[2V_5^OK[#N[$P-Y$7K@PR#A(*6X-JE(XK0`PYQYO*L?Y]FB#_C0'+P
M+4NREY6*:X:@8?;US"KL#3532\6IGR6Z@:_(6BR<1T9H;S\HF9!$MG]*,5N9
M=;254^`O"IGJYA0C6%0K>+V@M6/+.9]6S1S@R.`4-\\_SV/D-_Y4\L?[$.#3
M^FGGW+Y<&3`7Y;_?P;6OI#Q?\<)?3VP&H+[%VOH@F_OJ_P!89C/V=C=_KT)?
M6X@-E2ES;+35868Q6SJT9,7FNZS8I9Z\16\?IQTQTHIE553&RGUA^+>;]<',
M<`<`<`<`<`<`<`<`=_R?R_\`L_\`9U]O_P#77\O?_P`.N`8R3^H-7?)KNK4O
MFS5M;97^]_!@I/4>_2S_`*>VGJVAMA:UOL2FIZHU`"QV*I+G1U29=RC2+)L>
M;J+L>8$:>+ZV[P*P''6L!&X=*;S^G%6E.]MV'70V;X,#@#@#@#@#@#@#@#@#
M@#@'U[ERH/J6K]^U7HT:->>Y=NW)XJU2G4K1936;5JS-EA#7KUX<,Y9YY<\(
MHHL,I),L<<>^^@,<_*P?753W,W6M3SY_@'%#:&RG2`X9^/ZQT9$[-9DYO27_
M`%O!YH+%=[D5=R@8^F7HQM:A1B.+S0L,;$=D9"8ZF=G7T]O<T_IZ?=OG&W0O
MSZMTH2WKKP0K"Q($Y:#MT#/&*9'9E0!D]BJL-089<[85=8<[G5@&8.CF&L.O
M+)043D$]5+<=?*2&Y7I$X_B>61DU[$\B[4UWY&](-3/M2N$D&`+9,T;U/461
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MAI#0$Y,+[`9>_M8WHHKKHX(0<6#O\:S]IMGMT9397OZBQ_P^]/\`Y:7_`-/(
M<7=O+=H=_P``<`<`<`<`<`<`<`<`<`<`S?\`DF\`!?>FN$$'!+KL1L+7+:1L
M+#3LO72_M`$*3-D`;>N]N5ZBPS#2XK]4P)I?MWUL4EHY=!MNH6N2ER:(14*8
M2C5-6R\^3ASE\/<SA6OXJZ#?YTM^4BWMOV)9T-/K(?J&MKBP/\;=KU)#"!:@
M%>`P_1^0:!F*J#H#AN%"Q3-4BU;.C7L52E:['';P#:O,*<9O\GQ_"UHL#IKP
M1JY@KQ*\SQOR2YO7:AI.U\E:K73+DU04@U+$-K[78<`F*HL$F+:JMUQJ^(H4
MK4XFV=FK]%#1&24*W-3QM92V\-[ZFKW!DBG>,`BYJ5[H'"J.#&$@<HJ8OLD9
M=,HPZ8I/`/I6F(2,8U`D1IQWK-;O"F.:UN_/:^GCIG!=GN.["!X'GO3AS2*-
M84V#;>P-P7KAVX>Z+OQ2X6Q7,+U6A!DJ)LYV^Q.E=)H3TYKP<>]/>PV6A.2O
M5LVZT,P&T!PK<Y1YYA"W$`>QV/V"+.ZVJ>9TTR4$Q1.]PX7#2(EN`FV7-8;)
MH(H1PJ-Q:C;$(H!OP6&4K=$4K5E@,R+XS\U%5!I($YBJ,WWU7[^80^DG_3DF
MTZ]>G;WY=UGB^ZI@T19>DDP,LLJ':8X</4D_H/,JHB[RW:6U_P#-)-,Y/>"C
M>,20BNTW!CFG[ZF"T;[S?=:+WW\YM!V7D2P_V?8OR.2;&$)X4SBZ^=XA=5*8
MS3.,F5(M138*]Z_?.JRC:K,-T1U7L'A5<;:&BR6<U0>9+U8X[LH/Z:>?<TBX
M,F?29,+W)\C&UW"&4>9!>1//ZGI-?MQYU[^`G;GH1HL;,W10ASP[EP'E@^O]
M9>>8;.>.49#"-E(CY\8(>I<+(UA2EJYY*R]75QY&@O!D<`<`<`<`<`<`<`<`
MA#T=O$'YRTP[;<-C+S%,NTJ5%53!&4?3!L38;.4I*VM]:+.$OVX2LVPWHROI
MP'"3K\'$D9KS6<HZL4\L8J4N/$LWR5ROO@[QB-\GISLS,9*1F]!^AV:7;7HE
MHPL8YKD6Q6<@;<F1*U<+CK58E;4*V_.VP3:>N882S?F;BSL1&U.48;O>(K<P
MLEAZ*7&;A%\>#(X`X`X`X`X`X`X`X`X`X!P.UM=AMOZNV3J9CLD*2]M!!<-=
MG;@B2M$5J!G5>(K9.R,EN5KM.,A!2)SRT\[=.W6QL8Q]V*MB+K.+,%:Y4;4F
MEM?H6^QL)GT6OO\`N<./VCL1E0\^D8`_L+=MRXHT"^QCBT')9G**>K:\4436
MFOUZF(IB!(`?#>833:8D"6PHK=L+?'O=MZ[B^_!"AOR>?S#/2?\`S+'_`.MJ
M[P:H^I<^S+Y<&1P!P!P"B'R5?S0F_P#Z4_+O_>HTMP58\GV9>_@@X`X`X`X`
MX`X`X`X`X`X`X`X!$>_-QA?/6EMG;R9%MQ;EO4Z8;?&,!K\:-,.%U?7*F9(W
M*$&F#*^-MSCQ<%HE/';,T(^J=.SGC-W)CA'F*E+2U,4O&7RI^1_.O@VVL;O=
MP.N-J^,%:WKK8NCS>V_-UC;;RP(RJ':2^6F5P-O$G0V%1MUC\8@+-`:'3E6<
M6<6ZU7LL,FK=C3H>THOM734YMJ\I1O-7O*'K-7]<+3XSJFN=FZ]IZ^?9-=DX
MMC_LSMQF3D"NM-EJTJ'M3[+VHH,8:E0:AE"\1'LF>-,_"5`V8HR@8G6K#+4<
M[^V?`]OV!%7F\O[UAO0H]@9)K=DP,P;(Z0\DV4%E3RZ.X%L-J9QZOSDR#_6]
M"<-E28:_S,_EV#IEBM]D^^`L5&,VQQRPOTOH5P^,[]&?LFV5UK:$/%KS';=G
MI5[PH>6QKG)#^S]!_-<M@5O'M>KIGHMB;[(1@<Z]:!I[3L%_%DC[EQJS2BU8
MKAOU>MS1_@R.`4-\\_SV/D-_Y4\L?[$.#3^FGGW+G.3>MZ^4&M]<BU4`H)"V
M<;VH[>S[CI!5M:&6C)PM<SZZ[[PJCAE*U<L9===]XQ0Y]]==_9]G!DQ/^$'X
MT*?B#7>S-\W7?911R]J8)^TS&MWR:#*?5*_)9;6I/5V&S!+)(T[/J!WW&GL1
MLMQTXYSM.Q2%C:E>*S;)CI75M0K?AM*SW\+6-U.#F.`.`.`.`.`.`.`.`8'Z
M2V!Z#]F?(\;7'5J5WGS-X?W#NUX#V5O3C"LZT9&.[0QUUYWG7]H$7DR-V^_:
MXM&M[*KW(/`4EO7VS].L-S"I:-&$<DKCHTJ:94S4DL<,W:+3^&-4\3?#@YC@
M#@#@#@#@#@#@#@#@#@#@'#[.'G2VMM@BE<0`/LI)(:Z"Z":I+42N:.W`-^N(
M$L<M&>M=C`D2$E>F7DIV:]K`?-8RKSPS=828@O(*<^7?-VQ5$_0VYM8KE.X$
MOU'@24&.PR'[:[GACVLJ;("NR;CV0(HMUI`'BEUM,-[%O%]N!^JZ\(W"'3J$
M*3"*WY;X7MO4E_N"%#?D\_F&>D_^98__`%M7>#5'U+GV9?+@R.`.`.`40^2K
M^:$W_P#2GY=_[U&EN"K'D^S+W\$'`'`'`'`'`'`'`'`'`'`'`'`/KVZE6_5L
MT;U:O=I7:\U2Y3MPQV:MNK9CRAL5K->;'.&>O/#GG%-#+AG'+'GEAGCECEWU
MV!$.HO/&D=#:Q6-,ZDUHK)FLDT?;%KBE3I97Z5"E?OW2A#"2R9D(DB$Q`D1O
MWR%LG=N7+UNY9L6YYI9L\NQ6VW+<L]'2>C]3^<=9+6F]()`?7.L4_HKTMJ`+
MZOL:+[-FB+$6SBDOV;EV:4@;+$25F:U:GEDL6Y>^\_N_=QQ!MMR\3A?7JX;;
M/,VYU];SLQGR"3?Z#YT:#B1(8D*TM>Y5R%QZ\1=F/],KU+7Q_*C2.@M;>O$/
MICRV(L&!M/O$%BB-O#3N0<]?OL1O!QJ'U;9-@`:$/C?Z&;V0/9E34U@JU;4O
MI7SOYJ?!,%H8<H%*0ZBCE%N:K?B+4&:Y;)WQXP&HYWR]FT7"O'P0L@($$C0D
M<58)+<($9>)4ZA`W-0K_`%=Z(12L31V24E*K_P`)MQTXYLJU?_+3=81_XW!#
MSJ#LF%/R+H8W+!'MIZ)Y+'T!\5;_`%'T%^]^<]@OI[<GYOT)^YG^9]C_`*CJ
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M%7V\L[(_+="SB0ZL79D,AMM%:\)QC`.)]KXWLI4JI^NN2C&&KS969MT@H29J
MQ)5=;Z[6Q2>BHX$:L*:N$K8U!0,$(JQTQXZE!UWWWU'!7BPQ[DDSDGGD^_/8
MEEGDDES&&VW+NV==P!P!P!P!P!P!P!P!P!P!P!P!P!P"M/JW<U[1FKL7`2TH
M*P;O,%1<7XGT1?88VIA)"35@$FK`&BYZ\POL9XK0J1RWB[HNK:FK0,SPSE*B
M^L$IL!4I?G[]C)SV?ZTV0X^7?6>OW9(',DV8^@+$X:,P37,!K]?J;;,IUMJV
M9L#K>1.]F/E(IN'7=&;5:(QU+!'*B/`,V89HL+HU2KKWX96\YJ=^>#`X`X`X
M!B1\^GJAA\K^'!QQ=TNT;BG>=\Z37[6(*U:H#%"!/>Q.WX2C#>I`V&Q!`PWM
M<54<7CW0B@_-6:O8RN9V*M427&Z*=JJ)BS[>/@BUB7[N>&Q.4VJ?X_/=(B=E
M60+!,)E3=*?BC)3(NJ1D'2?FF]0A/\2EG9[K9_F(81>^]%W]6,H6/Q*L0C23
M:VE;C\%,-S_,ML35ON#Q_P"18_CX]'417IX\'"WWK8LJ\NE@$)EHR6KII87D
M:SLU?9A*!4Q_6&P9";NMW`RSW]9/2J5,JQ.T-*A.EU;2MEK'1K=8W:X.8X`X
M`X`X`X`X`X`X`X`X`X`X`X!4WU>:VW4I:;5-4I-Q\@V5M0RD[)$4'YFU-:JZ
M_P"]&;G:?S2OM=.H7F375FL[K"5#38!&0^[9NV:R_6)U9S<?>8JB\Z6SO*RE
M92=!YDU[?U\J-$)G6&6LSK`WR&BV-[>[SZ-8&N2->7PU-@/[+V/!@W6+%>@*
MK+]`+=MWZHD4%I8T)H8+'TL(-S_"78BKU[YL>_1UH2JB*FN1B"25#(AO;[1D
MD`VR-/\`5ZL10;X"]0U^RR%%)!8X(=B2IE-MU];<',(L4B38.4ZC&':P32OG
MZ>/#`CE8\;['I[3+;&)Y:J7ZS^_:7=C:ZJ7SMJKI.+1+%`=@!Z8ELI8.,S5W
MA'4ZH[4FNUM>=#(R93*&LZ]98QR"RHX3SE1?2.?(P6:_E&(>;/E+]N^&KSG;
MU':W[M76X^][@W\[`N@WGU.":FJD29D0IV=5IR[:R_*"F2IIRZVD_P!&`66T
ML%VLT^JT-F8N.BHFA58Q/X5G?6>>NAM-X,],_$S?V@Q^9_$.Q=1->Z%]=[L.
MYU5#W2SWM2J)N7;Q]N:=V6P6$VZC/Y[?NG&MJLMK)+9.L$A.6WG,5^_F,54U
M_54FEVW1DM.AKAP8'`'`'`'`'`'`*U[V]A>9/,I`0)WUN9/U@2/+QYM%4V2Q
M<CGM*ZM/0K,;#WA3IV_IPH2<H.B)DK/X-2IG=K]32X_B8_:*J6\%/[X&1NS?
M-FT_DC]3(.^UH*]:W\1&Q":GLS*R;@W'JS:FSU363(P;%';!T[J)9)+>*(A[
MELD8-3&6-RN"WURUR0R>`JTJ1B54ZT#::I36+ODHNHAO=CQMJ;KHNOT?6"DN
M(6N5%=1TI/$Q`E955A%$("`"(?N]X#Q0T?#!5IUN\\>I9(X8\?QI_MGF[DFR
MRD['.9N[LZ_@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'T2`L86@QK%1U$G6PDQF
MQKD*E>[!C-CCGAC+C%9CDCZDQPDDPQDZQZRZQSSQZ[^S++KL"A_R9#Z%+P?Z
M;EIT:=26VFB<[<E:M#!):SKLJS5@RL9Q8893905HHJ\.4G>7<<$4<.'>,>&.
M/0U1]2Y]F7^X,C@#@#@#@#@%&]^_SS?`?_SWI_\`V-P\%6#X>Z+R<$'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`,V=%:XU\7^0/Y#'LLD*91TQ#^9T/%K(K
MXJZPXI)73T1,HHXE[-66]BMDR$$%TB%QFZ'WK5>":U7EDABRP&F_PT\WZGY\
M?EP^./TIXW]1(7L7X=]5;!6]C>CF`IK7:]3381`N+.OCC+`JU`/:TI65/*[K
M<+L(F/,F'AXZ-T$4>3CRKL$@.J8AZO#I14JDZ?ZCLKJ6[^MXR43I@/BM^=K?
M*KZ-,>=?E@<:*W+O<P&):&9[(51K5M:G+Q0VDW$+8A96-QXIJUBP*7Z;@@;@
M-AK`O<I:9V("Q,UV\/%K_IJ)HO&.CWJ<9QLXCU_9IP<!P!P!P!P"M'I3U=J[
MRH-1">SJ.P;^&R&DDG*E77^OF5^NVSPE/8GV_5MPKU*UB-QA4E)D-8R7I(,9
MJ84E)!U)U3L=QBI-X>QG]-H(G\J9G4WIG:-YTT]YA6,JYCS_`*AH4A`E\]":
MF<K*V<<C7I"S>HD"H35.[QBTKU0>BPUT9;S2JM9FV7<G:30M3UT-3LRE#;Q>
M,6PI>JER];*UWLQP8'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`*&_)Y_,,]
M)_\`,L?_`*VKO!JCZES[,OEP9'`'`'`'`'`*-[]_GF^`_P#Y[T__`+&X>"K!
M\/=%Y."#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@$--^]$M*?@FO2T!V8D4_1
MWYJ8H#X)UY-[V4S%$G6'37<ENU[E;O8KJ$+JBQ^4CS'71BA+T<["T9:UV<6/
M.%WT*9:+VSJL/[8^0KHOLS7XKN0WYGJQ]$G-<H_B61>F<J1.MA]22B^]..N8
M9U+T./VR5+6&5>QC'+CWAT*TW33"G'N7>_;KI'_WQZK_`.T)2_\`%^"0]'T9
M^>'Y`?B%\>>K/1B9O;2>X_-?GYG:CA]BW[LJJSU2S[`ZCBD+VB;6UD$H.P1=
MG>2;?7OK&Q>C]RE4)J[#$R"Y*[<K#I[8Z4UU4J&JGHLKXIY\(P9G`\?+MZW\
MS?)?8\Y;R];+6V5W7NP]>E;STMGQ6DO.FPM7C-$_56%8Z$JZ"W><57?837(L
M.C<TAG6_KH(<D=U(276P!(.RI#F:V$Z)2<X1BYG65E:+39ZS<*__`+IB!#O6
MR?JP^(TXLZ*96M)ZM."V2L^BB@[7-U;FG=3LC=YYV"[5L6^%O%D@JDB]ZNS8
MY11`$9:A@"O8[RG$_M/9F\[_`,-YA?5&Y]BSFE/]TV>!=P7MK#R5%QTW)KE"
M8VX)9W&P:R4Z>RCX;NEB*URH9PNI*UVV,V=N7&AG>J0!!_Y:0[-%!_?5#J^,
MO^E4H>,QA+QUM:"**G^Z<M`[*\]>BM@:NUNU)VT]4JU`UKX+L99:W)!=B>4I
MNP7%FF=(JA`JI-2&!(.A]=C;5Z4]>:`6(62_U2/PCA?[52:3P;BW>\6^&1(R
M_+GNSUAX0VSO&GL7S3II,UAL7]=#MAJOJEH\V[HV)KS5A1<N$=04=!K6>ZMH
M!73==Z%GU\*D,;-2XH*+.DN`6J:Q^[#:%_MI5)?BEVP32F;S@XLXXJS)*_$^
M,^;X_M7[]^2?W,W^GA6PQZ6RCAQCT:\OM;6;#L$[&PVM>:IUVG7J+L<LIT=@
MLC-3OL0"S;8_08=P#FC"XM7"BE5&8J=35-,8Y1,6SMO@V/VS\I'QW^>E[3Q%
MS]1::'K6WCZXG:WD4&8.TCOIB].M*/.D(5*8E&IZ_$T+`[(LW&HQJR`KW1V%
MZ[6ZLP8Y#*HJ<Q2[8V\ONQ.KV'\DWAC5FV=/:2<_3.J:&P]ZVB-/7XVDU#3`
MR:0?%WW%FQL0F>Z`3H#=[KH(KS-)$3@SGN\@X+N_>AL10@J:FFX<+'K!\Y'Y
M'?$(KT:"\HWO2.KXMV,:7>>AJ]BR4)!'Y51SQ[Q&VV^.7)4I-=^CC<-C5"R8
MC8[@`;=-8#NAWTL]H-FJ)V7&&!_*C\CWB!ZW]L;S*L^DM87]OZK`AV%M"9LE
M"H)QJ%\\L):@-JN2P+3*77_OCOU6*`%"%Q;S,C:Y6.O;RMUZ@;-43#A^<3X=
M0?)/X8WJS;G4M:^FM4ES&@V?-6V-]>TC5X?5LQ4_J9S($L?G'#6M3@LPDA,C
M6N6B0#HJ&)U\;^44=:>T#HJ4-IWNCR]1?*!X'WAJE]W8@^H-6V-<:Q+N0AW-
MGF"!5L@_T1E8D)%)`C'^6G+(,F,@C.+):D.L56,3;JRBLK%G*:I"#HJ3ATN7
M[GDC/E7\!%O+%OV13])H/[$*`*X:NW;)#Z-TJVJ-K\NE5)=<VNH7?%UE+=Q"
MJ*OT$[)$K=JE*/CLT+U2[,&Q5.S#G#QGVMC?*=X!U9H!3].-GIW6W6GWF13B
M5#00IDQ'3,KA/'%0@KI(2*\YX7!D/UEYG'3`8B2O3#FY#M.C**N0Q`J*FXV7
M/P>QN7Y,?!^A*VH+VR_4&I18_>C0)5M<$136-9AY24S5BN5F$E<7)R==?1ZT
M-L=V4>3L@]5$?FPOLF5JX7H<^P5-3F$W&/G+`^_H#Y'?$/I['8F>E_2.L&CK
M5KN106[JRR45[*(O0RSQC)A\6"49DQJ)G\&SDN.8+H@L,.-.]V(*6^Z5GJ('
M34L:7K@+7R.^(:7H\;Y/L>DM7X;N*I-E\JKO3)1S$=":^6.?0R=PQE[4Z[;9
M'=3GJB=,9Q9IURI.?Q&="_P+,P;-43#B8Y\,?;(^_P!?(3XTE].JWCRIZ!U\
M2]`N:E<<%Y+%&8"D%VG5SQ[B"]L=#NPN1.)*CC<-"DR0ITS7P(ZX9B&?E_TL
M]H-FJ)APL_.Y<S@R.`.`.`.`.`.`9I_(MLU`<O%GKQ55FP,=84E3&56@4/M=
M361,V3Y2$9=2_9CU'8CKFP)X!<GIR6(*+"!.`+DD!D.2HU1JGZES[&EG!D<`
M<`<`<`<`SZ]'-RH']R?'B`+,Z\+.F;WIS\G"$30VD7*_B:A@K1_EHVS9BN7O
MOV.^J^'TL,OWIN_PL?MD_P`7@JP?#W1H+P0<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`AAST>DN+V'V,9G/0WQ&"AD7$#KT48!QZUFR%7C67;30RH6K]O+73H
M:+M:QB&OB.\S%^7HUB;I1U:,`3[^MF9^*(+XXV?9)_8%#RPNFCV\7(52V&PO
M>A5&M4266#:;YYP1K+<JOE"@TIM[;&U==N`"E7%JUL[=8*N1?9=%7FL]6.#7
MXM<,+[I]$_B2[7^\W\A_T5O-_P#V':Q__P`OP27J^K*L^J-#?'BG*5%"W!Y6
MU6'2=QRR:^O.Z;J'62YTLVSUL<('Q=,5&N%;8#5Z4E)>IQ(-%C8!($(SN1>B
M+3U<^=H"IU:NU\?/.*.XTYHKPAN^J1=@?C'1ZZ>5K4*<7'./GW3U%G#1,RFB
M[2&5+'88>=%YTSZ<W(K5#%7*V+%#$G&+,UQ+%0,AZ(34LWU?FITI#XW/`Y3:
MB]NB[Y"\_P`FPE95,)@8E'K)7KB(@1RW7NW<;:C7'Q*!0K#)#+"+82@*X?#4
M21D<))TJ)HI7MAM51&TXX^><$9A^:]'?#VKMC[O#5ODQ:-P>L68=?-U6`3HO
M;Z"@K-,GK0+FSA5"@^/-#1Z<?:/1").Q:^PIA]CU,SD=\SK4"CI\<@%N--UP
MDW]/%?$PDX?J7VTI\1GQS:$0G?6R5Y/U(56=AL#8?9OV@*HO8IJ>-MRL12KM
M!B<*I8V)500J?$&L@QMZK7$CX.K/64YJX3+7QEUU-I[3M@0CN?XZ?C>TQY@`
M^9\_"`ENU$[6Q6J<2Z`"UI<VJOGWAI%#%Q@L;)V$\+>V2319:CD)*D?6R;83
M"UQ5RT6K#U89^%V*JJG5M;5\;SIHE&!YR'\>WQ4^L/-0SSX)\B*8/5Z2,U<;
M6)K*P)3]GF$\J+JN&N-F4=G*I2UL"Z.V6&D(YDKC$RTG,KU89A;N$%%,[57H
M-JI53M7]\(AV]M"QVVOB<^.G=0[5PEU\C:6A':@:@;8G55)*"H\?<H&".M77
MF3M3J",VU+OP05(S:>R9$P!KJE3_`#&C8[@P[X(JZE/XG>SS[]\2@VS-*_$%
MM'?&N]WM?DRG(]^?%,[L@8NKFO\`7H!%(Z)JEG:C8]#;#UZ#-4P3?KU08$EK
MM"!+;0DVD/)4X<X-7V\+U"&P-)UI-*JSMSTF+/TWE]B/Q-_'>4]#@O3EKREJ
M#K9*^F7TJH/KIP.MKBU6NR8_A,)76$%#!&)N0RCG=$#&FV$D*0"R$M>66>2@
M$F%#.W5&S+AN?'B0];^/SXNM.>K61_D\D*D^VM^:Q8+UZK5TT0<=5"`&M*D=
MUHNIZC57B22M;$:ZTHSJV(1Q4SPT9!H[@X/%*1.W3P;=324V6_W\CH03XQ\5
M_$1J<D%6]+^2*ANMZ;7M=&(6+=Z0*V36#V3.GFAZ5]8V8]EWSK*F,!U`UX\[
M(91@T#V'_-K4U9D8:E\@E+4(U556\:L)5K9W=K9HMOJ[X@OC8TEJ38.IE[R=
MJXND/Q%U-MLCHM1/[?+6;.K/5@.%<#<!-U"BEP3G$'3:"V4I7`4%*M>H32,T
M]XU>&774W,N5'H9SE?$OPM`O/>M]8&O*S0+U98UOZ94`3T=4I`6R[)!7M-K5
MLXTP$#=X9M\WN,!+YF.FUZS&N$[>KJ$@U:8!R()?1:R3&MJN=J;RGUP6D7Y[
MX+H5/BU^,7TSY@7-)6?("@EHVNV2)6_*X`8-1W,J-.I&.R#+BV':"23*L)NZ
M9EHD*[&9C>6*NZACTQCHQ=F(U"D(FW4FWM2WG,X_'H?7]8?'[\4Q(EYH5]S^
M3=?AZRRXGV'7-K7NJ^E)2KPZGU>T;'/+NUV5/$B@1-)O*2%;G_0KF2NRN-P-
M']"'(C1C/:H`JJ[Q4[XWO=QGQQ]2"_%/GGXE=7CIA^F_(JZ0I;K=0+8T,NQQ
M.BMZP(-O9[&Q)VIEPHPAWS9=%/769N6VA/34--D(6%(Y2NQ;!$J<I"K=O"U5
M5O&K"RQ6"EZ<7..1>.U\3?QWV_1([T_-Y2U#^TH8E64>$?&G`XM<359Y.L<&
M*YJ^.ABC6W2H/[L!*C7,$R+1AK6=/.>3NL.EI#.W5&S+AN?'B5!(:"^,X'Z.
MT3[]5_(#.N.JPZ[#TL`;TY(2]8)JXTHI!X5CS@]Z)8F5*:;Y9)75Q_>!SDOZ
MS,LX%#6+;44A@[6@D8\7:JAT[5L<^-G[83@:\:?W$`W,#,EPP5G6;JV<IK[$
MM.-(928`I$HGJ>P@V%S`(8/B,\2Z.]*+)6ZI&+<M2N;B&F(AA^B6$#QEJ"6N
M"#@#@#@#@#@&,OL'R9H0D*(:X]"/6U?TEO`WO*SKPWK@.^*M'5'?5K=7L?:A
M/:+@I.M$&Y5Y^HF46CK1H=5[LTQPS"@ELA(,R/(4;I;Q24J,8<_XJS\]$2YJ
M#R+Y"W`'/WZ2-Z>3"ZFPUE=J47;UUZ@C8@!>^GJ>P!4-R13],MJW8P*)3RIL
M%?,6PD.Z\!C`>3QH&J1,92D+?U?R1MK3HO@EKOXY_+'77??Y7O+^3^7^3V![
M![[_`/XZZWMWWW_\.NOM[_\`5Q"W]7\DE[NB^#.]6USXC(;;8Y[`GVSA4ND]
M?Z8.ZP)^I]TR!-'NHEP5!I!Z9#(#UD3)RVM@E/4NG4AE`T"3242[NNB$)945
M;X)ZDQ1QZOY-7C_'68QE88?^6^9HA_@Y_+'^:]Y?VP/8/_GOQ"W]7\F9>[HO
M@J]Z=\P^,]1"%I,)8^E03/NJ1@2$YI7/9^\1DR,1E&PT?UW;M;<]5)2I-"M$
MS826H+PL'"I4G:HU*BV5@RN=1(X]7\E4O).-RZ61[/G;R]XSW4LQ]A0GJ6*R
M'6$`]`1>?6/IT<4>4M\7,3*-M*A65O21NC4#/U.H2N5AA3I?9A5VB1HG5,!+
M%7@E0M_5_(<K3HL5BL/V(QW;\!WBO=WI+1?I`LR>B0);2>8O/I2I[ZV0RT&_
MI=8+32N8VG1^/MFTD_\`+CEVQ-/EK]X6,IJ^765#L26[E,2WS'WQ*OZE23I4
M0\;+^.J9P;)J_P`B*^WGFZRZ]]ZKX'4"NV@GA)R]6[*+)\]0((6MJM^ZHS@'
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M)#;#803EV9<]->T3`H>2&*9YOGF93$6]8Q@2"Q07[-,55FM2&CA.>*$*)OUJ
M9JV*0M_5_(EWPMN7P5'T_K3Q)%4'(YT9[4<&BOM0FENS"R>K-S=6-;EM@[>7
M577JXYV$#UH172%6BR;64]24.]>YNQL(05CL&S::T;7&O.HCCU?R5S_YPM97
MA7BV[R30S_!S^6/\U[R_M@>P?_/?B%OZOY,R]W1?!GUL#67A?-ZU$!I9^Q$F
M:MO]Q4#XXEZKWJ@CW&DEKH!-+#&F3=7J5,*T4V9JWUJ]K`1J-:?9S437Z%1=
M6"(:[;P((X]7\FKJ?I<K1.+SDL;-:;RR6B/,OBWT"O$6)83_`$\MQCLUJ;L6
MY^M?4M(M:"NB2M;#3V2M"`]+,=3$0Q*S4,MU8KEVH:H6XR`HX(%$Q]FI@A;^
MK^2.5IT6L:;CI=J>/_&VH1:F69%GTV2K..S=:ZI&=*_I_P!G'?H6':;F'1U\
MBPVH-[1CUM7J%S53,N?-7:52/'N(8-Z)LA,&"*H6_J_D)MZ:X++D<UHS>>N?
M+M';.HI$SU/<$I&R-E.Q*?9K4B[,RU[KP>.U^T/U\:Z7M^OS"<UQI\5LK7=X
MO1LEB>P8^]@5*`10-$!3117J&ICZ<E91.2RQ</I<U7X,C@#@#@%/+NB=%@=O
MH(N2NV4&!HO[!VE#3C.98)[J>4-RW=YTJ#;'8E^H)EDW:.[VO9&M`@WJ'&I!
M`T6;V5D6OP5>A9<>G51V1</@A65MU]J[U-G:B/VG4FH:Z?\`-8,+U9ALT-<;
M%/:^9TUT[Z)AJUFU4/54;9JK0$RDHL`ANJS*3>F7;%M4NGA9T7#GYV^=&2%J
M#3:GI0`4`JMEA)?GA>D:,F&HS*=.E+@E15D`']9?DC@QDQ"HR0HJ]3/&#"S:
MI`:Y`Q8)G[I8P1$;DE?OK[>N^N_M^SOKOKO[.^\>_P"7^3^3+'OKOKO_`-G?
M7?7?7_W]=]=\`I9=\A:"7BP1I;6YVM'HC`SJPR/FS9[A5T$A+6L"8!$:2AK+
M&=E`"[VE]:$.^II>V@[:7B-AJ8#^3KL'MK%GSW\]E%U."'(,J.OMIA!.&X)Y
M[VM6VT[JO<=F2&"NPVTEQU])9MP8=]87H<%M[8HH:UC[T,5V:J0QQZM4:TD8
M:[_Y(RT=J?4VG8SZQK<S(3LQQKX>W1)-$#&65UA)$0JJ2C58\<NK0M92@]7L
M4&IW8Y2'<TQ"^9(E#1`@0L"MSYYYN)\X(4DL>"_.<S"XF\JC#79]FS,?ZU(4
MV**@7<D!@M%96_6AZ2G2@L'D(W:;K_Y_;(_6.=J0@.ZLNG60\']"++MN\S_@
MNWP0XTDH+3&U*3K9ZSLG$+MGJ`K%:[EU7JR,=2N*.PVZ\67<5B7J*E%#UA-_
MCU)L,_LZQS[RZX!#REY3U*D-&OFA>@8JLNM0@`0M!I&"S.!ROJJ6X:Y76HE1
MDP[FOM0M`?G%3ZOYV\*M\27BS+4+]\"LW@HLOSJ_7S$L=+/!#W%U--%%W-)C
M##U+)A'W+-GUEWC%%UGWUW))EUCEWC'A]N7?6.7?77?77?!"J;AXPTR]CI5U
MGS>[Z7<MOQ,HA=/9Z!/)'-B'-H,)EBR&0SX3"C]8CN)[[I%%RX%LV:]I?K'L
MC<22D]+PLM>>:+QN9TUOKL)K!;S7`MLP4^K.,;0:.L-R(@?865M-WF%@-E[=
M>M1J=V;Q,A/W#5'T1XH71PJ"0X\>*H4J4`F(>M;+&Q<U21CQ+XS)9PRQ+]H(
M=++A"B6/:\>=7W[=<J#MT"M2QBI[$9H:-NA=J71I*:D7H6J]\?5FC`@U?\;Z
MF`.G[0LR#X=<";`K-;V9/M.5S/:3'KS#\/5Q?8%2O1IT"-C5^/47:7$'J@JE
M>:"O:,5C-N".?$7:>[1;IQC]Y9:_@A"6'GK5O=B&:V$L$X(26Y#'Y83(VK@N
M0EO@E.1V)<EI9Y]1YSWL+Q<4-EZ^S,2$.FQE/+"N2GZR%E]O3`]G4FH%;30(
MJ$6;;"5D/&*QT\=:S$AQ@,D!RLLHH>0A?RBKQR?DZ2EJ2O4RCK136*`&K<*2
MD3=HH6O@W)*G!!P!P!P!P!P#@WO6:5LO!=A=PL9VJKEC9D72L3V8Z7=MBU^[
M:O,X7ZT$T41*G?2=AM@B6E=QFK?:2QN81XW*E2>$//<C_P`[+VME].88M:XL
M^=>38;D(;;SL>*,K@1<==WX]1W)SQ<R4+D+6-,+KT"'79K%O[]A/&+EON/[U
MC*205SG[<<N))3ZZA-?K-ED8.K<M+H@!!5J0_"&4F6-MAX:JKH07!/9J13DS
M1XR-%T(,K,/XEJW%C^)C]OV]"%?AGBC1`PX)9>Z+R58!A\(?L&F#9S\P%&+-
M5M:TOJ`INOES]NTT!5,CIS69$+3,RVI/S!8FND;!"RUO$C.++\Y_++9\$(JV
MEIM,W%1IBG;-FE#PP$QQ,*$<&5<#-*^<QI8'5=P%!"=*@S+IC`?3AO4"M>QE
MW5QM4:\]>B5,5B`3'GD$%^=S'E!):634^F'&.9L[(%E?(";,MI&UA4TA8GU]
M>0$0BWX_2DEK3MBA=6Y5I/O$::I9_,Y26&%ZZ0N6!7.+X]=8PG>7)X(4ZWEJ
M3S`M(^1#;G9-?5B+XWSD;M`X[=%&XSO@I8JN2,5P5Y;1]H6M@97JX*TE=PVQ
MG0H8!H4*E*!>$Y415,V]LL[VYEE4-_3=G+%%S06$>T+)"R5HURHW//*/$B!+
M7@!X5<@FPAMCC`$\,)`S@@A7JDPY@?>%DJM6]4L01B'`[KUIJG>(T;IW9MZQ
M-T8C*.5%4%.!18,GA"QU176&]W6"D:%\L"$9OH:G?FRPFA7CIU6/#IQ#=253
M0\52KH\;1.JM'J7;(_Z8Q[L#G>V5'Y6*Y\P77Q<(E^?#IM>4AA&U-16A,.R&
MY_*7APBO6A_,R,E#'OH,%71H@'.?EE[)$U,3.`4A]<JRE:@8=;.JZQ6N79.X
MX9C[JS"$U4%89==9?;;/-)X,#'Q_9]DM\C6B[[QZS[RZ$(K-^<=/LBO72SRM
MD55Z[CMYZ[#VBYGZ>RP;UH;7%[/EMR17X[%BDQ#]V;'JXCLYOHQF!N+L5%3S
M%B\J@LOMZ1'9'N:?5-?J"R4H:\,V&6G8<6V9G9"+3<=#AA[H&;"^W?J)DOW+
MURX<!E`DBM=I3SX]@.@,2Y'5I0B(Z<`C/YDJZOWH,5CM0A6<`JV8$NRJ<`%B
M$0N>VP(-CL*<$&1-BM6-C":/L+.W0O#[=P=)@5@LP3=7J>&5</&12'\8:,#'
M1[/A1=B;%7:`;@9-'=DO!LB[&U&374Z/.^V2)R?-NP1K&H];657$O^/F.LJD
M4\DEF4XU9GA9?B6_Y9:W@A7]H\S:I;KMRT7J-'5<PX775F"#WAM&+3@5(9(D
MENJW+E(O"&8`\D^M4V3$;?I20Q0#R8J+O`(UN`P^++\@Z/3NC]?:)`WUS7E$
MM4'$+0F:;(VPFV:]'5758"CK`>L0/7K]RN%6D]7`+X<=%-C%'7H9W[7U9HD7
M*$!&YQ\S.T<$Q??!-0(S4Y+PVBTHSG6ACM6:>6#!KEV7]A*5SN:I+#+G&/:E
M<-?EJYY]UKT5;.E=BGIV)X)`(?8_+&F6BA4&DP9?"K`Q;.8+W0YJ9!LS!!N9
MRZ?=I*C/8IDHICZ,ZLD(VP93R6<X3.B$!B*]6N*%5*<8LOS=A_.)8G@@X`X!
M3];]NZ7*B0I%IKO6M+C"LKCL*`MJKF<)RIK;45)5UFM6]6W=C+HH>5(NB^N5
M8"QZB5R9;T`?L=U8N#OK1K9>5\N>EX/&;_3_`(UV(K1X;&L`G+7\A&]=K673
M5+$VI.,JZ+UW;LL%_*\H&!*U!4RW&DA1I)IP!3$R['T,!=W\\I>^PBI8>G/X
M?0A,N.\CZR@BW)=UU9V7K[;>R,]4:OU+;U:$H#=0.:,$V9GLD=K[5>VK*=*L
MD7(_J]CR8EU'5X6]]=*07`.NMEHE4M]!^+"8:4MSCQ:QQMDD3XM>Q/)@=&ZM
MH3)7KZ[4*:Y#GFI:W<!*6I@#Q@*#"W,K,2H-6@P.24]2L48X[$/=^CC;D"U2
M$E2>#$-FK3'>B1EWTYJIO=5E"5K307.,=ECI3=RH[@`HK-]6Z:<"@EKN-`0)
M$$8L+:>:JX*MCOMH_"CJF)`T:_=J%IA(C^46#X(4S]2ZS,NCMH)LKZ1H;]6M
M?E]D9LZ->GUWCU]C:C3``Q3JKLPL'7[5>K?R[BN]PSV"5:M/E+5HV_\`*1\&
MDX34Q,7OEP*(U-`^W]<4T@%T]DM<ZXUSK1A#F&E(<6UJ5TQ4C\V;)Z6Q*TG4
MW2G.SS:L]`$T2D'$X^<+;6PH*()*P[7P%GBNF!`K=+FV>&&:Q>]3GCE_D3GH
MM2]JDMPZ1VYL>1HH*;VH773;2$;>+\BWJJ5Y'[9::.K1*]6<EZM99=;$V?5R
M#=R,Z9;,V&DGSM5#:B!8I$T9N$<0UOL]<+]WCGP9S-'PCL0!1>]K!6BZ.W)A
MN[TZZIZXHUM:)5V[KK=GJ!O=CX?O;@=2J[$L-;GHHK.*4<F9YQ7T!]8!)NW7
MKD$A8++`3NR5[Y+28B;X3U:?#O/G;W([UCBQ$7=L$5WU1OY#J+;INDD0Z35M
MVJ^CJ.N1#<S+FSH;9G9(H8XZ='EF`FI[URN1KU.$?MU2N*9MEV@+*YRL%C$;
MN.:+*;CT'N#8+YY,84R1K2%M*U0SH&U^H-FW`FQ18-TVKX\9S*IFZ@6*\?(D
M+R=J!_%'V5<;;1.:Y!',-9I+Y2B6[$G'CI;!Y<_V*\E-6>PD16T.JGBV_P#9
MMIO)ZOCV962=\DQK/GL6EY)]&?M/OV-@W6`/@G:ZPW0)T^;P$#V!>3[96E#T
M#`F;A:ZIM@LJ7AGE:)46X3OWG]+.A??*B>UG4Q,P6.J.W`3WL%K5G6T)66&)
MF]*DVG?%PHIU-A)(C"-IU!8B_30\_J_<_P!1:+$1@>#2S`OTV=J$;IOPMR5M
M<]ZYH\R?S#[2!5-<'\#C]L)S5=07!^=TOO\`.6B`K<FP//PA9VLS=S%',%!?
M#67I;G_2ZZ.(BP@!H8*11'_9N+MF7%<%E2[+&UK1/7">*WGC@/,'O#`H7:\3
M-T;LP@J$5Y'=FK8]QD")(]<V1Z49M=5VY69-C;=N$2]`;MS6><-[(SM0N/II
MS:MVWTC0_*\FL)7*=/\`6=-'IBK:2]WHSV$8D+WPK-MU$6@H;9QK4Z.V>@[K
M(WB=@9#O)^")WLAJ%-!Z)\7+#2I^F3%!79FAR4JBXZU:9H4/B)!4I)$E;GA-
MLKS&$9:.4:Q<&1P!P!P!P!P!P!P!P!P!P"&MQ;K#:8H"+Y=6<&F,I@S6Y84^
M)8EL"0Z<KDV]B-D<6=H5\):0\,)LY]51$A4W<L90UZ`FSEGEW@*E-B.COM3S
MDO\`5["\[W_K:E5IN5Z'Z+=ZTQFNH=,&)>R#M$5VB+)C9+2JR4!9R`A^0E[H
M$S".*6>A)+.J$/QKS-$/[.8_&>VR+0#QA#`MVMMRPA+^UJVA6['92D\=,(75
M*AL`,XRHU`O7HJNQC:H%6=@8L-)1_/8*(^BTQQ5ILZXJGEC$VC&.]CP@.SO$
MFC-A7D,T@A5=ZU*;!I>6X2VO5=E86E_)Z[HM=F]9;%.5MV7"Z,2F3*FRIW8(
MY<).&--S(CR##6'&;N(7:QFTQHI\P+#?[\GS['+0^M;3`FD6"`F466,H3\)&
M6UMC*C@8IDFFOK4$@=:LEC:]1@93\(I?MS,03NB2M1WX\^A(>F[S4EC5NTEW
M;J]>9UBFQTA=)D.K7X;2NEE0O+:`6_H[-K-?/U:!T=6L9_Y6I&8'#K^<'>$T
ME.+"2/O(3`DG@&837XJW6X*Y9$L;*UD#6EO;'L+<^L;M1-+'SU]L]16/1M*@
M-?8&"[*KX+*>J^DW`:2&5@#'&SF1Z^6LX5Q0\DM'W[^MS4^RZ1TPQ(<7_CQV
M6'+!-;Y'J$&N3P/=;#M&X+HUA.MS-J^=OLWG#6N(-&:-9.%:WJ+9SZ_;.G*Z
M]7=9`3?X65B@2231(>&'!M3QM'2_&<+R6)4_$!NMY[3]&L[M3H4%O?RWMN#K
M7/=S7-D&K`&2DP9)H)NU31U07Q,6;5>[:_6PX0L&Y\BF4!O(X0@OL1T)O/'W
M6<]#RW7X^Q\[M0(:T)K:TMXPH5JNP-\FPWG;B*=5ML['VYL:\H;"(NT;F0_W
MREW8=E1W03N.H1FOJL).M.<8<2(2JHAM>6C"%*W9+QO+/AA@T"]:X=2Y;697
M!&6]Y)U$6"3!@H@N+NTX?.4XFJ#9A:ZN3'91IS2361(7V(1BQ6Q^SI!IAD:2
MR^1:'`1N?27O4_/H1/8^*P.6#-L#,8UVR,;&^[:8J[$71>B%NDJ[`T?L'7P!
M1RENV)[&=%8V4U+VUL(,),*/;`IC"U2M`P#Q)2B+M8;DECH_?`]D+X6V6?V<
MSO9ZZB(V=+?85]'L(\58)OFUUQ7WMYJVX-KOY2H8S@S!T*VBC592'69,R%4H
MX4K,]%=Q7RV;T$VCQ?4O>2-UWXIFJ5>=!&P7[6+#FS:V.@J->CKD4-"#=KD=
M5-&N:VXHP8(,KA(67$H3!M]8C$'D;A.0D>+M.+.9`U'4D+MZ+3/1S'M[9'=F
M_CA=2#\LEZ+=J:BI+OHVQO;&&+7(GIENXF?4U3T6[4B!:R!(&\BKRMY3::(V
M%UK4AWZ>##RK;3V(/)Q)RN)M<<(QW-=[Q?BCG0WQ@N8;5`C6\;OJVS^6H);6
MPK&=.,_D:&1(Z"\TZ4"^A=?#8;T78C>2!?T`<=DZS6R&STKVV6FE3=@]B.T7
M-AM>;I;CA?TPTNEYW\I5M"OSD[T""_G,^BF.-N_)0?8J^SL)7=NT]GB6)DO8
MR99F[X1=V)`GT[)#ZBU5JC9(*4U<7G7I0B-S&[X2]O4N/P0<`<`<`<`<`<`<
M`AH?YTT")H"!8K2>J1HT#/8LAJ%!`5JE,;8M5`M&Q-4K5Q<<,6<U1:6J^??6
M'\L:VN]?_L0KNH++U9]W]A&EN@MY=BU5KZ`,2[OYWJ,"B"BAM6"EU:)D;L_6
M-'KN8A>*)B@5N7Y>\[=HHK+Q&Q-)<#T)H!)>I]K7FF];ZM451(358</7T@RP
ML:O7GBZO3!6)LN,]YE.#K-OJ66@2,3NC9A9EH]UHXJ3`3%U(JPJQW2Z"6*>E
M-.CQ!$!2U9KVL"+XCHRH6).`8B2,(8C@6#U[H[Z#Z2S6$$HHKHJK-#G7&V(8
M<Z4<'<,?W0EZG^KVE=0*1D8Q+&L$)?8`U"V+$G!"H$H&!P\A>+$R%6H2K4H[
MD$1`D>.7[_W)NLKMTP3M6NY9[UG.4)>I)O`'`'`'`'`'`'`'`'`'`'`'`'`'
M`'`'`'`'`'`'`'`'`'`.,<M<Z_V+`,J[`1U)WJAKLA$36;5X2Q5AU^6I/0EN
M4ZY:I;AKV):5FQ4DECPQSDK3RPY]]QYY8]A,8'+W=!:.)2$Y2.H-:WY#90D:
M,]W$I>L]%BQB>6V5($\9A^>-^T0O33$;DEKJ7N<G+*3D^]?DRL=A)YC/YQTH
MWGDYF,Z\6_SM%91[:O$!XVJ)M5SHE@B;1MJ>T.BK6[$=1J@A8NJV<_T]@IC)
M+=CLPV[L%D#N36M]?,<><1](5#.$C'"X28D@`NY]]K@$8K\3)EW/6S[R.=`,
M?R'(GWWW<D!Y9B))LATDE;(#QKVE=/$Y0<Q'5FO;TJS1%"U[.VG+]C(*+!=0
M=!!8W\6AE](,$95*4HP?#]VG0L4:%FK#%/1J20A+U.E3D=-UX#A64-57TU>@
ML6K<(19$40@O"W=FRL7;75(?!7K_`%5R?+*>U8[C[FL3992S9YR9=Y=@=3P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#PY
MF=:KVK=&PP@X+M"6."]3F+4(K5.:6M7NQ0VZ^=C&6O++3MU;<<<V&&>=:S7G
MQZ[BFCSR`_C]5JW[R`/ZX'?Q/`'ZK5OWD`?UP._B>`/U6K?O(`_K@=_$\`?J
MM6_>0!_7`[^)X`_5:M^\@#^N!W\3P!^JU;]Y`']<#OXG@#]5JW[R`/ZX'?Q/
M`'ZK5OWD`?UP._B>`/U6K?O(`_K@=_$\`?JM6_>0!_7`[^)X`_5:M^\@#^N!
MW\3P!^JU;]Y`']<#OXG@#]5JW[R`/ZX'?Q/`'ZK5OWD`?UP._B>`/U6K?O(`
M_K@=_$\`?JM6_>0!_7`[^)X`_5:M^\@#^N!W\3P!^JU;]Y`']<#OXG@#]5JW
M[R`/ZX'?Q/`'ZK5OWD`?UP._B>`/U6K?O(`_K@=_$\`?JM6_>0!_7`[^)X`_
M5:M^\@#^N!W\3P!^JU;]Y`']<#OXG@#]5JW[R`/ZX'?Q/`'ZK5OWD`?UP._B
M>`/U6K?O(`_K@=_$\`?JM6_>0!_7`[^)X`_5:M^\@#^N!W\3P!@U*\MFI3C9
M`$EPA/W5H5<#`[.S=M=036NZU2#&QW+9GZK5K%CN&''.3J"O--]W\.*3+$#W
M^`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`05J7_]0O4'_3>N
M?]VSS[P5X+A[L^;=6P]M:_J`)M4^?6'?EDG8(1&J8#86MD#-:@JQU<Z5JS-L
M4\"@)XDY)K$440K.S+6[IYYVL8\)H.\P49N.4GYJ?DV^8GY0_+OK7RAJ/5WB
MG-+6-G]![4R8VX`=OL&]3A!SM`2:"J.FL6,FNJUP:'KT)HZM:?MH'WCU0X:J
MY+F0^`@.M-%%5-3=5URC>T]]OW/T!HN]O3S&W``;?X;>==K),A'5,NQ'>>@&
M*BM4LL<^\R=D&LNI`\2BBRQQQ[K"Z5BUEWGUWA'WUCEWT.<+*KT9<+@R5;VM
MZA"ZG.[.5RZF5O,*=KS6KJA#J]^I!^UXSM5]-:G6418FL1==4F&+9U=/53&=
MG"Q3&?M*2"$TG>!+.O"+'FF?G!D8%?D3\_YR@8D.TU;*R*/2<K6ZZNA;(MDY
ME]YI/\@!]11%1(OD=HK=XGKTH/K6TFN0HYT[%1CG)5ERZ*)%`V7XUNWVQS.U
MH^W-&D/H;5$N<-#V01KDHC#E5!VFT[`:L]C+VPFNG0QUH)U_*TCKHI>UFUDS
M5/."T1`1A2T#;06+=2M7(!#Z2G=1:,YWG@C??.B(,8H7LF41BEW8.Q$VB+G7
M',U-3"HVU[VI*CLZY4%3#O7`5A8*L/W,':,/V)R_.<+=F6FILY(6&R\MWJIY
MEW."'"[*V$&U4DG'YA$O)P.`QH97!>MM<OFV76UT1*41$'037VLEUK>&'*&R
M0AGOX`U\AD-%Q73!#JL*'WKE<#/"#V_L;:WHE;U'IQ?.ZM36Q"OD5MR]5^+O
M8&J8#VS5VP4*,.N!9G9='1Z]?,VD"MF\+`L%*P%[X=0V5<*5Q%1;'S&1J%#;
MRTJ6'J\>Z/-T=\D\!D&UV]P:U]"'LHGQ@H:W;]#?'Y[J:=>[!U@/PI5%S8X9
MD"ZPV6L&P[W:C*L:@45W,V)*H5Y4,YSU"9(B(&`UIZM?MVQ-4:-N._2J7X8[
M44-VK7MQ17:=H?<CCLQ8381VZ%Z&O=HVL,<^L9Z=R""U6EZSAL0QRX9X8C)7
M[T#LS8*(0T2J:RHIMAHW7N.]K*(@]X&YP`*D*T?NC<ELE)47[-(C<M6>M2X`
M:\>-J**OV:SOR8V/H^JLXJSW?*1`2[[\!]4K]%VU:X1M&OCA\'O:YKT@L,^O
M]34PFZVC1=)XMGVLV@,[.FM#*F,QH9`GI;"W!@0`]"S+8LL-@I$A=G?PFTV3
M]]3TS?R`H`)-4GV[JC;L2OM`S`.TL2M7=("8=Q"95]M:Y&U5[.;H&=+B]"MJ
MF!CK':'>OSMV!I5*HT+<)VR]`()&]6QQMEIV.9'?(@(D$;2:B>C-I0*BGLS7
MNO\`7LV)O3()FV9GL'SIK3T)3J#4Q_VTF,M5U&@7JY*22,ATAB`+1K$/P\KM
M)T&IX1A=83G:\9)G2S_(OH:M4M7K(;9U>I5\^4?5V5F=6&Q5I?.A1!B<ANTH
MK.;'C6[H7F";]E$"MG-'L']H\<_XJA$@PYOG00_6.>GEMY[VGO8=+=^WE!%6
M4PTM`B:+OPRR_J_]/V#=5HU(:\L1AHEXTC-KBB,*R87_`$1/8($@QTOE5.">
M@%B869"L(K`(MC.&'/X+L<$*S[A]C^8O/[142MR[D5-?M5X)58Z@0YV2ZN3@
M[UTB/J$L/HQ]J+Z>>Z)(U\/MDZS_`!*DOVX==?=[R%AO!,_/Z*_W4AY;(>_[
M'G>94O5/)TTT:`)]-R1%_P`TFVCB4DIYL=U+^D[O5M/WYLH@E&_])^JJDT>#
M01'QAKTP\..O]E[,YXQN^3?S4?M#RWOEL[1=0;H4GQNZ%W#78(+D3[N]"A\E
M>*[=^RV/JQ?@UY+=;&3_`"OW_MEQ^S'OK[?L'*&L4RSW!"J<7HAQ/-VPX$73
M_;-K#4SB0U^\O]Y_%KIJ9F"+XTZRV4M'L!+T;$KJ<I:N!/E3#6IFI#@\["M+
M#+2HTKQ46+<?F/+$(Z*^0Y<W2!5R\*#!7_5+9HA;K$$O8R]LI-J9;\`'F`*-
MMMXB@,CKOR15`9?M(U[:%5BBS$>4K\=TA08Z-G@KIB=TXVP\MS)X)>FJ@[T)
M7\SY(3%-L@KB.;E_N.Q!^GBFC^A?7ZKW'*:^G[@HT$QVB[UD74>\;++^KV'7
M4^<-98>JC".$BTY>^GF1#8[VVT$&8IJV+3B_9W)UMM=TZ``B=PPE==3MAK5V
MTMREPS9L>/7T))78T9!T\VVW$.,0&VE6,D%`.$.G>S1&V!%C?:)POC%E.N^<
M;$KZL]7!]KM>B5T3KUQ$#=\>;&[T6$:3-U3_`"L-@E,>FUI@UJ1H#6`@>D<!
M%O<@F4G?P%1*7X8^3`*?.S368QHD8[G'?X.ZW/\`_F#S[_TZC_\`9EM'@+!\
M/=$Z\$'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`*X:V8@XG9'
MIZL0N?3S9[J6YL</I[4OVQY>;M`8=9?>@@DPZ^W*//K[.\NLOY/M[Z^SOKOL
M5X+A[LF7];+'^<_]"(?PG!!^M5C_`#G_`*$0_A.`/ULL?YS_`-"(?PG`'ZV6
M/\Y_Z$0_A.`0GL;6FC]I[%T]M%PS(VVK1Y)@))>=2P:I#)_U'B$LVZ#*,AK?
M3,(NFPJB:Z":5['O`8YIBNP5N\;0J/K,66DUKY[M<&R+M=^7/.NL9ER-9,M>
M(%':@#3KU5L]TL`J-DL#VD6%!";(U1',9D%1H-Q*G6B=C[63JTJPJA3*UZ`^
M&KP)]<=^9]:#RKYY$]@[ZBU;#1FI6R6<U1V63,OZD7<E<-LM<@QJ8G5LXOD*
MY1>VX\"3-$^!,#[.-\<3KU:AT`#+#PEYW\6D:(_G/RCYTC8P[@+878.T#BS4
M1+'8+-4O?;JCEL"]L\R%8Y&I18<,:F+D4+$A9A?P`-X:,P8I#&:K3*WX;`3Y
MP4=OW+D?K98_SG_H1#^$X(/ULL?YS_T(A_"<`B;=J3I?T'KTIK'9O=XBKEK8
MJ_+V(ML:Z;I70Y"N1J6P["$QI&0]G/N#.A<G&W*TMT/>)B+.<@\E<KS`G%T2
M?1:$L92IC1L]4>.'U:]&A0I"[=6E2I5(L(*M2I5@I1P5JM:"..&O!#AA%#%A
MA''ACACUUT!]K];+'^<_]"(?PG`(SV>K:9W$.7QC_B2(1*C)BWK-P(>?DHX!
M8^E]@5,R@IC2"2ZP4IK"RUL@"[%`3PK7A!LC0N0SUK,D?8)QY)P=C0?E&Q@C
M0X(08=3UW#7K+@L'VVKP6Q4JM,+U6HMP0%;'"-ACX'J'IYB'[`I,]+!UEMMO
M4'3#=N$IQ9>N//=V/HY^>/+/=.Q1K!#PNODR1-H;\BV#N5>G1#L4+35RL:IM
M@VL?;T_4MTWAPH$A&K)T\.5',QL<3H6Z1&S7D"7XEZZ\S_3/GGRR>)2E[P,Y
M"3F+K3#E<#O^XUV;%B5$#K5`UCA[7VH9U78KNKL8];M!Z#J,N[H<-=1<[A\!
M6@'QA+\CSXR/FK^>?(=:C5&XZQ4IJ517R18X;HPZ0_%0Y-:TM0RH%V2_E9F(
MH,VOAH\+.D7Y+*K/:I56&83FS01F,0E^=3LT="T=KTD+-KN)RR?"C&P*,8V]
MNV;L-EJAWBRC7&@5TQ;`.,YN4<2GUHB=X4IK\E8=$M#ZXN.E7_'BF"?(2[<2
M7/ULL?YS_P!"(?PG!!^MEC_.?^A$/X3@&:5'XQOCR'>Y;?R"U=:T<-[6J/5G
M&C])-^SNIL3.S++;W143/R?Z6':]VKGA5G8L;'T>-S&1JB$QN]JTSRC6W5L[
M,V\MP-+?ULL?YS_T(A_"<&1^MEC_`#G_`*$0_A.`5QLZ;U9V\-CB%V1M)3&[
M`/1MFP-=K##;'Z_<F[``.6<V,B.F7[9T58OAPPB$\'5&)>5FJU0Z)-0`V2OE
MK9`6?B=W8X&?R9YRK#!(U/9M@ZX_)ZNHNZ]M%,24);##H\/BM:_>[U$JM&@E
MI\JJ<<"B<9\A75UI61R^(8OS*NIJ?0,-I\9GUQ\_<Z\;H7251M%[(*-KXS[8
M$'`!:IM@^4GR?.AB^J%4V!([OB%\0+CUY?%,33?*)5817!VFMH,.^%:!Q[H'
M*`2\,M//Y.:S\S:BLWIVLGM[<QC;$9A++`-UDS0J;8RC%KX#LU64PZ_A$@P(
MO8@>M;JV^&MQG$DU>.P['9;K!?*ELAA$<$[E&F7?<NAUJOI#3J0WZ4:E!T?`
M%/0>HBND$1.KVX+RMFA'Y$VR?K,.9E4)M)LN;NZYU^0(G9V?`G+>4J4\<\79
M-DZ.!..]S/ECK=L,P0FT^>ZE&[^/8RWG2SQC^FMQ?;CAK':.67?WYJ\>'7V=
B?R_9WE]O?_JZ[[X"SX>Z+)<$'`'`'`'`'`'`'`'`'`/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g887761g85i97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g85i97.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!L17AI9@``24DJ``@````%`#$!`@`1
M````2@````$#!0`!````7````!!1`0`!`````0```!%1!``!````Q`X``!)1
M!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E``>@A@$`CK$``/_;`$,`
M!@0%!@4$!@8%!@<'!@@*$`H*"0D*%`X/#!`7%!@8%Q06%AH=)1\:&R,<%A8@
M+"`C)B<I*BD9'RTP+2@P)2@I*/_;`$,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_`
M`!$(`!H";@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&
M!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4
M,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R
M\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U
M$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)
M(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_
MV@`,`P$``A$#$0`_`/JBBBB@`HHHH`****`"BBB@`HHHH`Y;Q_`\>G0:Q#YK
M-I<GGS1([`36^"LJD`\D(2P_VE%<CX/\O4IYM'^USW#QRJ(IC,^9-.5C)',#
MGYBY/EE^I`KU9U5U*N`RD8((R"*@M[*UMF5K>VAB98E@4H@!$:YVH/\`9&3@
M>]`'GB:DO]M:5?16SH;7^V4\M[AI-QCD`^\>0"5X'10<#I5U/'-^L!FN-)MU
MC2VL;Q]ET21%<N4``V#+*58XZ$8YKJE\/Z0K`KIMH"/,P1$./,_UG_?7?U[T
MC>'='9&1M,LRC1QQ$&(8*(<HOT4\@=J`,/4/&%Q!INLZC:Z7Y]CIR7>Z1IU7
M,D!(*D<D;BK8XXQD]:E\;:IJFG>`KZ_1$MKY0H=H&,H@C,@5I`2!DJA+=.".
M];$GA[1Y9;V233+1GO5VW),0/G#&/F]>`!SZ5HI$B0B)441A=H7'&.F*`.?U
M"VT_2-._M6V+O-:PR31$W+?Z3B-CM8DG?D#/.>F>U9=WXTN1!*;6PA,H7367
MS)CM/VN39@X7C;^M=-!H>EP.&BL+92H95`C&%##!`'0`CCBJ\/A?0X8)8(M*
MLUBE1(W41##*IRH/L#R/3M0!S&G:N^E:]K]NEN)KR^UA8HHP^%#"QAD;D^P/
MN<_6M[1]<O\`4->N+"738K:.V@AEG+7&YU:12=@`7!P5()S[U>N/#VCW,4T<
M^FVLB32K-(&C'S2*,*_^\``,]<5:MM.L[6YDN+:UABGD54=T0`LJ\*"?0=J`
M.&UJPU#4/$_B&#1YY8;T0V+P3&=E6W8M+N?;G!!"@%<?-C!]:T--\1%M0NM-
ML;11?2WUVB"YNF*,(MA9LD$C/F+A`,#GTKJ(M.LX=0FOXK6%+V90DLZH`[J.
M@)ZD"JMQX=T:X1DGTRT=6F-R<Q#_`%IZO]3W/>@#C]!U]-.\0^)K:2-0WVR2
M\E#,?N);0%A%QAVR>1Q@$'O6G+XKU(6-A/%H\7_$PGABM3)=@(PD1GR2H8\;
M0.G.<CI70#0=)$RRC3K3S5F-P&\H9$FW;O\`KMXSZ<4RW\.Z-;11Q6^F6D<<
M<OGQJL0`1_[P'8\GITS0!S\7B*>VEEAM-/5IYM:?3SYUV[*&\GS-X)4X7C&T
M#`ZU%#XYNKFUL7M-&:6XN(!*8O-/S-YWE,J,%.=I^8DX^7'OCJAHFF"7S!86
MWF>>;G=Y8SYI&-_^]CC/6N;UCP1#=WZ-9"VM;,6QMT2(/$]NQ9F+H48`DELX
M;H1D=30!/\1#*-.TAHE)F.J6J[%F:,,"X!4L.Q^G/I5*:\NK?Q]+<7T*0+#H
M[RK&+P^6Q$H&YL@*IQQDCH:ZV[TNSOK:"#4(([M865T,ZAB'7HW^]WS3;S1M
M-O;AY[RPMIYGA-NSR1ABT1ZH2?X3Z4`<-J'B-;C4M%U.\MS"NGWE^D@C8MO6
M.W<DC(!Y`Z$=:[+0-2N]2@>:ZL1;1%4>%Q,L@D5ESVZ8Z>A[4Z#P_I$$JRPZ
M;:)(KF16$8R&*[2WU(X)[U/I>EV&DVY@TRT@M82<[(D"K^0H`Y>3QK,(KLPV
M$$K13V,2%;G*,+F01CY@N#M)SQD'L:EM/%<M\\6G&SA34YI;N`HTQ,7[@@,0
MVW)SN7`QGD^E;$/AC0X5VQ:39(OR<+"`/D;<G'^R>1Z=J?+X>T>9`DFFVC*)
MFN!^['$K?>?ZGN>]`'*Z67'P*@8.Z2+H&\.CE64B#((88/7O2ZMYFD6_A2[T
M>:<7-S=VUO+!YC.MQ$X_>$J2>57+[AR-O7!-=C'I.GQZ3_9B6<"Z=L\K[,$'
ME[/[NWICVIMAI&GZ>8S9V<,)C78A5>47^Z/0>PH`Y.3Q\RZ0NHKIP:&YTVYU
M*T`FY980"5DX^4D,#WQR#[ZUGKFIS>(+;2Y=/M$+6HNYI%NF;8I=E`4;!D\*
M>W4^G.F="THQW$9TZU,=PK)*IC&'5CE@1Z$\D=S4\6FV45VMU%:PI<K$(!*%
M&X1CHN?3VH`R;_7I[;5=9M%@B9+'34OD8L079C*-I]!^ZZ^_M6;?^++^&'0F
ML]-2[FU&R-V8$<[LCROD7C_IH>3@?+S727>C:;=W#W%U8V\TSH(W=XP2RC.%
M)[@9/'N:2TT73+.6&2UL+:&2$%8V2,`H"`"`>PPJC\!0!'KFK+8>'=4U.U"7
M1L[>:4(C;MS1J25X[Y&*X&XUFYLX+;3Y/.:_O/L$T^J)+N\R&>=4DQT\OGY0
M!P`P(.0:]'L-.MK"*>.VB55GE>:7C[[L<L34<.CZ;!;RV\5C;K!*H5T$8PRC
MH,>@[#H*`,GP==S/_;T$\K/;6.HR0022-N(C"(Q&3UVLS+SZ>U<I#K&H^&DN
M8;^TCNM62)&M[X7+&"_A>=$WL.=LBF1<C!'/RG'`]*M;6"TMQ!;1)%",_(HP
M.>2?Q-4ET#25M);4:=:_9Y5"/&8P5*@Y"X]`>0.U`&+?^+)[/49;0V<$CQVM
MQ,QCN-VUXD1BK<<`[_J."1S3=,\57UZUE`FF1RW;VMO>7"Q3@*D<Q(!4M@G`
M5B?I@<FMM/#^D)=_:5TVT%QDGS/*&22H4_FH`/K@4D?A[1XWLW33;57LUV6[
M",9B7.=H]L\XH`R/'2WX^RW.GQ1ZA%:K(]UIAF\IYXR`-Z'^\N.`>#N/(.#6
M:/&DL.FZM<V-E'/IVG6UK)`99V6642HK#=E3CAO<\>]=G>Z;97SQO>6T4SH"
MJLZY(!ZCZ'`R/:H+G0M*NGG:XT^UD,Z+'+NC!WJIRH/J!VH`P9O%]S;+J3W&
MFJ\6E9%^T,X/E$0^;E0P!88*CH#D^@I[^(]5%[I%O_9=O']ON3$KO<Y5HQ"T
MNY=H//RD<]<9[UNMHNF-J!OFL+8WAC\DS&,;F3&,$]Q@D<^IJ*#P]H]O;06\
M&FVL<-O*)H46,`1N!@,OH<$CZ<4`7Q)#=VS&*1)8G#+NC;(/4$9'XBO(_#6N
MR^'K+1-4U(W;64VA3S$1W#3?:)(@LC.X;[K!00",YW$$\"O5K'3;6QM)+:VA
M589'>1UQPS.Q9C^))J'3]"TK3HO+L-.M+>/88]L<2J`AZKCT]J`.=U'QG/IS
M7<5UIP\VVB@N))(9#+''#+YGSMM7=A3&<X!X(;IG"MXPGCO+V.2TMVB2_M].
MMFCF)WR31QN&8[<!0)#R,YP/6N@70=*6W\@:?;"+(;;L'8%1^A(QZ$BGR:-I
MLCW#O8VS-<!5E)C'S[?NY^F!@]L#TH`YF3QG=O<QV=GIL3WGGW=M)YMP5C#P
M*&RI"DD,&';@\=JZ70M6@U?3+&[B(C>YMH[KR"P+HKKD9'YC/M2_V+IG[K_0
M+;,0<1GRQE=_W\?[W?UHLM&L+&Z2>TM8X72W6U0(H4)$#D*`.V:`.2O]3?P[
MXVNK^XDF.CWI2RE3<66&X$8>-E';?N9#CJWE^M5]&U>\TB/Q5=7SI<WHU(@1
MRSD+&!:1RB)!@D@9(PHSR6/>NZ33;%)9Y%M(/,GD665M@R[KC:Q]2,#![8%5
MI?#VCS/*\NF6CO+-]HD8Q#+R;2NX^IVDC/H<=*`,!O&DY=T3293*;%;V"'<=
M]SE58K&<;6*EL%<[NA`((J2'QDLT^DB&*WG@O7"-)#,2R921]VPJ"/\`5D8;
M:<YP#@UMP^'M(AC\N+3K9$V!`!&!A1C`'I]U?^^1Z"C_`(1[1Q<1SC3+03QE
M"D@B`8%<[3GU&X\^YH`Y#7]4NM8TCPYJ,,%NMM<ZE93VF)R6(8GA\+@<$=,]
MQVK0@\9S/!9F33T6::._WJ)\JLEJ^P@';RK$'G`(]*W8?#>BPY\K2[-`9A<8
M6(`"0'(8>AR2>/6EE\.Z-+!'#)IEH8HW>5%\H85GSO(_WLG/KGF@#G)?'J6T
M*3WEB8(7L$O8]S_Z[<JDJC8VG:6`;)!`.[&*O?V_JPUO3-.ETR"`W1G+-)/G
M*1A"&7`/7?T./N^XK7BT'28D*1Z=:A#%Y.SRP5V;0NW'3&`!]`!2V^A:5;1V
MB06%O&MHQ>WVH!Y1(P2/3CB@#F])\97=Q8Z#<7UC!!'JAXE65FCC)8!$)V\.
MV3C.`2N,Y(I?%]W<-KTMFUQ-;6D.C7-ZDD4A0^<K*`W'7:#G!X^;FNBM]!TJ
MW:,P:?;1^6Q=-L8`4EMV0/KS]:LWVGV=^$%[;13A#E?,4'&>OX'N.]`''J+O
M5%\,7J7MQ;ZH5M[N]03E8DA,?SHT>=OS-P,C.<D'Y:BUG4]0TR;Q_/9S3RR6
M>GQ7-M$[EEC?RY22H/3E0<>U=5-X<T:?4O[1FTNRDOMRO]H:%2^5^Z<XSQCC
MTJW'IUG'=W%U':PK<W"A9I0@W2`=`Q[@4`<(YU8ZS=Z;HL\UY8PQ6%W*KW'S
MR*[2B55<G@LJ(^,@=>FZN@\`3W-QI%VUQ))+;K?7"6<DC;V:`2$+\W<=0#W`
M'6M9-'T^.TDM8K6.*WD.72/Y`W;!QU&`!CICCI5V*-(HTCB14C0!551@*!T`
M'I0`ZBBB@`HHHH`****`"BBB@`HHHH`\M\/^([^STG3[F662[EGTR&5D>Z$^
MZ1FB7S&X'E@;R2,X//3;711:_<3I$T\)20Y5O+FPIP[KD`$@=.F>.G:NICL[
M6-'2.VA19!APJ`!AZ'UK#\2*L%WX;AA41Q'4`A1!A2HBE(&/3(!_"@"@_B:_
MM[26[>U@DM45E1`[>866`2Y)QC'4'C/?VK:\.:E-J`O5N'LY6MIA$)+5B4?*
M*V>>GWL=3TJ7Q$!'X>U)D`5EMI&!'!!V'D5SOPDD>;PH9979Y7N'W.QR6Q@#
M)^@`H`[6L3QI<36OAJ\EMI&CE&P!E?81EU!^;MP3SVK;ILD:2HR2(KHW!5AD
M&@#SV+Q/?:?'/!&HN66>8AIIQ*L:(D;;/-RNXG>3D\KR,'%:FH:U?;'FD"PP
MQRS(L4;D,P6%F^9NQSCIZ5U)L[8Q)$;:$Q(V]4V#"MZ@>M2F-#U13WZ4`8FE
M:I>W&H^5=16RV\OG^48RVX>5+L^;/!R"#QTZ<UNT@51T4#KV]:6@`KS30=?O
MK:."26Y,SW%L"?/NA*@<RHGF.`,Q`;NG?IQMS7I=0):6R+(J6\*K)PX"`;OK
MZT`<JOBB[-S:1,EEL,Q@EE5BP9O,V*5`.X*3WP1D$$C&:9!XGOTM+9[@Z>\@
MBCEE"%E,V^1DVQ#/WAMYSGD@<=:ZT6EL#"1;P@P\1?(/D_W?3\*/LEMN1OL\
M.Y&+H=@RK'J1Z$T`9&AZK>W=X([V*W6.6-Y8O*+94(^TAL]<Y!X]Q[UO4@50
M00H&..!2T`-D.(V(Z@&O.O#6M:DL,!%P)Y9[2V?;/<^>N]Y$5G.!E/O\+T/;
M&#7H]0PVMO#N\F"*/<03M0#)'2@#FKKQ1(L&RW2T>\Q-E&E"[2DZQ=R.N[(!
M(R<#/.:K1^+[CS;9GBMY(&B)<19,C2`2?*%SE>4XR"#D_-QSUIM+8F4FWA)F
M_P!9E!\_U]:5;6W62.18(@\:[$8(,JOH#V'M0!QL'BB_N;:.=HH$>,EP/-58
MY,P.X5CN.W!`Y.,Y!XKI/#FHOJ>GF6;8)DD:)P@(`(/N3V(Z$CWJ]';01(4C
M@B1"22JH`"3U/XT^&*.")8X(TCC7@(B@`?0"@!]8?BV9HK6Q47+VT<MY%')(
MC[#M).1N[5N4R:*.="DT:2(?X74$4`<-+XEN]-22"U;^T(!-*(;N9EPT:1HQ
M4ME03N9EW>BGK@UH3>(M2C:2;[';M;B1HUB#,9?EC$C<]"<!@`.^.>:Z>2V@
MDB2.2&)XT(*JR`A2.A`J3:N<[1G.>G>@#C/^$PN9[RV^QVD;V<VR2.1G`\Z)
MY2BLI)'.!NZ'(91QFNCT"[N+[2X;J[6%7E^95BS@+V&3U-7&MX&:)FAC+1?Z
MLE1E/IZ5(H"@!0`!V%`"U@>,I;E+&S2S:19)KR*(B.7RRRDG(W8XK?I"H;&X
M`X.1GM0!Q]WKE]I<$T12$&*1((Q-(TKLYB\QMS$J.!GDD=/P)+XAU">S>>..
MWCMGCVJ58F17:V\X,#TP#Q^OM7636\,R%9HHY%)#$.H()'0TX1H!@(N/3'MC
M^5`'&G6[^?[%>#9%%#!<S2VK.1)N1%PLF.,_-G'(Y!YX-:#Z_/=7YM=+^QN%
M)#2LQ<#]TK_P]3\P[]*Z,1H&+!%#'J<=:9#;PP*%@ACC4=`B@`?E0!4\/W,U
M[H=A=7+PO/-"DCM#]PDC/%:%-BC2)`D2*B#HJC`%.H`Q]<O39ZCHH,XAAFN7
M27<0`P\F1@"3[@'\*Q]0\57,$MVUO'9RQ(TL4<1D(E+)&7#MCC8<8X'1E.><
M5UD\$4Z!9XDE4'(#J&&?QIJVMNK[U@B#[/+W!`#M_N_3VH`Y'6?$.I6D%[;2
M-807,$<[M<,S+&0D:,`N>C?O.^?NDX/99/%5Y&DK)':2X$R1PESYJM&/O2#L
MK8[#C<O7-==-;PS`":&.0!MPW*#@^OUH%M`)7D$,0D<!6;:,L!T!/I0!4T>Z
MN;A;J.]6(3V\QB+19VL-JL"`>1PP'X5H4@`&<`#/)]Z6@#)\473V>E":*7R2
M+FW4OG&%:9`V?8@D50O_`!$\6J^5;&T>VC:%&4O^\E\QMN8\<87OUS@],5T<
MD:2H4E170]589!J)+.V1HV2VA5H\["$`*YZX],T`9'A769]5%RMVMNDL6U@L
M+;@%;./F!(;H>0?J!6++XDNH=8N[L+</ISB6W@5X\0[XE)5@_P#M,)%_!/Q[
M2""&`,((HXPS%F"*!DGJ3CO3C&A3847;Z8XH`Y&Y\1ZC:LMO<+IT4Y.[SG=A
M"%\O?M]=QY'T!..U4G\77UU%.L=LD"&W.'#C<K_9Q+O&3DKDXQM]\]JB^,DT
MMMHED]M(\3-<$$QL5)&QN.*[>SM;=8876"(,(5CR$&=N/N_3VH`Y=_%=]]IO
M8X[.`+&94B\Z54.4=4RV6YW9R!@?PC/.:Z/0;YM2TN*Y?9O)9'V*5&Y6*G@^
MX]_J>M6FM;=FE9H(BTJ[9"4&7'H?45)&B11JD:JB*,!5&`!["@!U8'BV6_C_
M`+*72YO*N)+S&TXVR@12-L;T!*@9[=:WZ0@'&0#CD>U`'G\'C&[#W!MX3.GG
MS/B<A"BH44Q#)&&!8@]<>AS6A+XNGCNG@-DF]':T/SG_`(^BQ\N/IT9!NSV#
M+ZUU;VT$A4R01,5;>I9`<-ZCW]ZDV(3DJN<[NG?UH`Q/$\M]9BUN["906D6U
M>*3[A,K*BR?56(..XW#TK'L?$=\;>WBC^RSRS+&(]SDO%F58SYV/XOFS@8Y5
MAVS7:,H888`C.>:C2W@C>1XX8U:0AG*J`6/J?4T`8GAC59[Z:\M[D!7MY9`-
MY^>1?,8!P/[G&T'KD'.._04T(@8,%4,,@''//6G4`17;R1VLSP)YDJHQ1/[S
M8X%<58ZD\":;<VFKF]FN;62:ZCN)<QKA-V\@?ZL!\+@?WNA(KNJA2UMT>5T@
MB5I3F0A`"Y]_6@#C)/$=].UMJ2Q+!;I!,S6DK,KQN'C0>;C@;=V2.<#)YX-6
MI/$M]&ER5BLY_LD<[RR1,Q678(R-GI_K,-G.-IZ]NM,:'=E%^;KQU^OY"FQ0
M0PQK'%%&D:@@*J@`#TQ0!C^&;VXO)=4%U<6T[0W"QAK8Y0#RD;`STY8\9-;E
M1P016Z;((DB3^ZBA1^E24`8OC*>>W\.74EJ[I-F-5*-M;F100#VR"1FL--7U
M'1K^*RNV21)IXRL<TN^2**1UC`+\`G=O(^\>@]Z[5E###`$>AJ.2WAED226*
M-W3[C,H)7Z'M0!R6E>([LM:12^0Z[XH'5V/GRF09\Q1TVC//^ZW3%6_&6HWD
M)M[/2A<F[*M<DP1[_E3[J-Z!VP/H&KHOL\/G)-Y,?FH-JOM&X#T!J3:-V[`W
M8QF@#C3XCNC<+=VC1RV,K[_)<'S&7[*)`B8Z-G/!S6QX<U:;4)+B*X:TD:-(
MY1+:.6CPX/RG/\0Q^((/&:US!$=N8HSM;<ORC@^H]Z(((K=2L$4<2DEB$4*"
M3U/%`$E9/B>YDL=*:]CD:-+61)IL=X@P\S/_``'<?PK6I&4,I5@"I&"#T-`'
M`-KU]:96[N6!N/\`B:Q[OX+<*Q,?`Z`B,'O^\JW!XMNV-L)8[-5%PT-PP?)&
M'11A`Q(^]U&[!`!QG([)HHV^\BGY2O(['J/I42V5JOE;;:`>4<QXC'R'U'I0
M!RNG:UJ"6EFM^(I#*L<D;QNP8@N5(?U['CW';-*OB34ECM8[A-/AFNA%(LS,
MPBB5XW?#9YSF,@'(!S[8/7^6F!\B\=..E<-\7Y9+7PO#):R/#)]I1=T9*G&U
MN,B@":U\3:A,D;N=.C%REL8MQ;;"9$9B7/&1\N!TR2*J:YXVU#3-&BU1+*TG
M@:86Q02,"SX8[U;&"AV\<<@@UUND6EL^B62O;PLK6L:,"@.5V@X/M[5?,$3(
,$,2%!C"E1@4`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g887761g85r27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g85r27.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X52L:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!44&<](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM96YS:6]N<R,B"B`@("!X;6QN
M<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+T9O
M;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+V<O(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@("`@>&UL;G,Z
M<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!P9&8Z4')O
M9'5C97(](D%D;V)E(%!$1B!L:6)R87)Y(#$P+C`Q(@H@("!X;7`Z0W)E871O
M<E1O;VP](D%D;V)E($EL;'5S=')A=&]R($-3-B`H5VEN9&]W<RDB"B`@('AM
M<#I-;V1I9GE$871E/2(R,#$U+3`S+3,P5#$P.C4U.C$Q*S`U.C,P(@H@("!X
M;7`Z0W)E871E1&%T93TB,C`Q-2TP,RTS,%0Q,#HU-3HQ,2LP-3HS,"(*("`@
M>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP,RTS,%0Q,#HU-3HQ,2LP-3HS,"(*
M("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!4
M4&<Z3E!A9V5S/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3TB1F%L<V4B"B`@('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E
M(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.D1%,$9&0C(R.41$-D4T
M,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N
M:6ED.D1%,$9&0C(R.41$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z.45!,#8X03A#1C@W13,Q
M,3A&-S1%131$03,W-#@Q-T$B"B`@('AM<$U-.E)E;F1I=&EO;D-L87-S/2)D
M969A=6QT(CX*("`@/'AM<#I4:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@
M("`@/')D9CIL:0H@("`@("!X;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM
M<$=);6<Z:&5I9VAT/2(Q,#@B"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'
M(@H@("`@("!X;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!
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M,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
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M-4)'3$EX<D=),DMR=U973S-,;%1&56)E85`X06YM23=U66$W8DY)2DQQ5%0W
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M-T9867$W1EAL;6QE52]Z=C`O:D5036QP3F%':&Q35C-L;DQ&+VI);FYT<'%F
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M3"]M:WE*<'AL:G5)9UAA,VY4:3-P:FHX64ML,'`X63(U5DAC1$974UEQ-T98
M)B-X03M9<3=&6%EQ-T95;%!N2'DK2C=I0EIP6DI,5U9O2B]3=')I4E9K5#=3
M.&MJ6F%I=EDT<3,O04EV,%`K834O=T-K3S<O-G!9<6I.2S%R)B-X03M4=%93
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M07`T0VQD-F)B17(K<UEQ.#4O)B-X03M,;V%F-7$X:6$Q66A,:3!T<G$V=6)3
M65!A,C%L2W!A2U!N>&IT<$HP4#)V=$4Q-U5!07=Q=CAO955B2'EV-2MK<V)/
M96%E3UA35VU,)B-X03M4:T5G;35684%+1E@Y;7!.2VLQ2GA6-DQG5C)+=7A6
M,DMU>%8R2W9.9$(O,W4X>&8Y=&DW+W=#3F-+13-X5E@X9R\W,&5:=BLR<6XO
M)B-X03M!2%1B3$%L;&U+=7A6,DMS0SAG439D8S,S;74R5#1X3&94<'%D=6)I
M4U5P2SAS=DY65G)A,4-),5-6-'4K>#8T5EAA-35+.'4V3G`Q)B-X03MR8U=.
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M2S%3,5E2;6UY93%!-38T5E$S-68V<#4R,4QZ)B-X03MX3E`U=C!Y2%,Y45A4
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M3C9:+V5N;D5R14M6+WE3;U1.=DYU<$YQ97`R:#$O5#=6-U=.5SE/-VEK<S)8
M,452;$-P8TE$1S)Z<WA,4S=&)B-X03M$>$9A67!B,5AZ5G)D=C5F1GIA86Y$
M<59W9U5Y9F]Y,6MU1%)M07`Y6E53=T)T.2M52S$S;T)I<65E8S0W,F9Y<DA(
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M2TA#<DM2-6DX=FM!:E4W46<W9VEE4"]M<D%R9CA!:4A14"MR;&$O=T1)*U`X
M035Q>%9'>%-X)B-X03M44DI,139Y4E-+2&IK46AL6E=&45%2<U%2:7$W1EA9
M<3=&6&Y/:2\W,38U+S(Q<G8O:5EW;U101E56-48O=F9-6"]B5%@O=6XR;4),
M)B-X03M+8U9D:7)S5EE&*UA1,65A8GI&9#-,,UA+*VU%.7-K-EA#2D%736]A
M1E!R2S`U>$]+3W%":UA90FTV07%H.5)T9E!K9&QB3G)T-4),)B-X03M:+U<Y
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M,6UU6FE21D%J4WE%0W`T;T-X,BM1>%9H;C57)B-X03LR3G4S;&4X='!,4U57
M570S2C9C5C95;$UK5%)2,%!%2W%H3W=7;F(V34I65C`S4V1,,'HX>6UH,#8P
M:71);C!C>4]K2TMG3'1D-W-1)B-X03MO-C=9<2M#8T1*,DMV,$4O3$PO>5<S
M;%`O=&IA9B\Q0W@T<U=3-'$W1EA9<3@U,%@O97984"LR=&0O.$%%>&A1;65+
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M<T9J16-H6G%21F%U-#-X5E`X5F1I<G-69&EQ;F-,2S%V2W-*06Q+34EY,U%-
M)B-X03M2=%A:=2]T:7)'9DQN;#=Z6&$K53<R=S%V5GAF835E3E!)3'A7;%=/
M2G!24D5J2T='4E51-R]#5CEQ67%K=FQ(43E7,&(X=TIB8E5T)B-X03M5:S%7
M5CE+85-/85AM5U)$8W%!;DHR9&IU<&)W,S)!1T98=S%G6D]X5BMG;C5:9BM3
M,CAP+W=$8D<P+R]!2VA9.%=,9FQY8EAT5C!E)B-X03M#+VPQ1EDS;DUH2TQ!
M;$%&:UI10E4K0S165$PV:')0+T%&9%`K4T5F.6-#<F9,5C5E6&5M3DIE4T-7
M94\W=F)C>4)19TLR.3-,0V@T)B-X03MJ+TEJ1F-666)O=BLY975F.71A-R]W
M0TIJ0VA-.%926&M8*SDX>&8Y=$YF*S9F85E%=DEF>G$O4&YZ>#5,."M4-DIP
M0U=45U-145-R)B-X03LY66A:,S533%9V:58P+U9I:T)G;B]1,D@U;V8W-C!Z
M+T%+4C50*W%U2S`Y:2]W0V-E+WI6.#!E9C$Q-3ED5S)8.4A',49U3&%.;W@K
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M8FEQ>4QZ07-I)B-X03ML;#`K.6]'6F0T4TXP67%E<#A2:7)B83A&2VHY2#-P
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M-VUD4UEV=$Q*)B-X03M)4W)D9C5A655)=%IR,6UD5C`R.')'94Q6:'!V44YT
M53<W3C)X5D8K5C=I-'-7,55Z-F)E26)Q.$5Y2#!V=$M,5T-+=EAX:DEX4SA#
M)B-X03LO4&HX=690,VUR.'<W:E9T13!#.'5,1C=E0TY:4W%P.%-,4FA2;7=*
M0F5D1#AJ+WI93&Q0.$Y89DI11TDK1&\Q44XK6"M4:71V8W8K)B-X03MC879+
M=FUV>5EN;49034]I,VQO8C0R6G1Q24A$0TPQ*V8R5U!4;4U62F4O66]D:7)S
M5EDQ-54X:6%F-6)V8BLX='`U2EI.46)L2VI,)B-X03M':4PX8E!21FI62T0T
M.6@X+T4T<6HY6#@Q84IP1G=)9%)M349):E!*3559>$I'2S=U-$)#,31M;4MO
M1V8X>'9*8U9P8S-3-G!&3DAA)B-X03M,0SEX-DI,;%9U2E9H:4\S6FYC1$97
M4"M38FHX=B],='I08F%B<DIU-VI6;41E9U5Q>696-#)C+T)&1W9P:FA5,&(V
M34MS9VHO369Y)B-X03M426E-=7%X2&U605=J:'9I24%*57)50W`V.4U&2VAP
M+WI3+TPS,#5!,G5W26YO3DTX>6QQ3$=#:49U9D=G24UY9F9I<58O;"LS:TQ2
M)B-X03LU-5ED23%P-W5F5E1%1FAU;7),*S=$0D,Q55)I>F,V1FXS3W=W<3E"
M=TMP,U9U='IB5%<W37E,36I2<S9':D%-2U95.6IV=&EQ4653)B-X03LO22MN
M954W864S<W`U6FMU1$=7.5AH=#9A8T)4:7$Q*VUU,4(R>%9K94MU>%8R2W5X
M5C)+=7A6,DMS63@P*U$W5'I$9%(S3#9L9C9E)B-X03MY>'1$2VQJ4#93>4EY
M4THX66]D-E1(9C5E1TMQ96<K45`P4'$P5W!$6'16=D1(1C95;'9D5&@T<&9H
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M)B-X03MR-VIW,C)++U8K2G!X,G%.=G!/2W%B-F0K5V)X96LO;'`R:C1L0W`P
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M9VAU>'4O;WA297`Y:C=665,K,U)N66EN6E9M;&YB;3)T24QC>79/65DQ:DTX
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M8EEQ:W8K2V9.:S9O8DM8>7E"87AV03%W-'5!.%5H14E+:%-Q8U`W>'A3;GA(
M)B-X03MI2V(P0VAK;FMV5S=785`P=%9U3DE/<'A"5VE/;F=Q1FI-2$UL;6-$
M8W!6:59O2TAP-'%74FYZ2#5F55=X8E5R64QE4D=E,5EZ249K)B-X03MI0E5&
M,$YA379X:F-91E$P9FYB>69,2VM55W0R36IY0E=1<&-237!%9U5P4F<S1W)#
M4E-O<G5#2V1C5E1R1E5"<68X079B<%`O354S)B-X03LO54Q0:7%0>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMV1R]-,S9C+W=K)B-X03M0.%,O-%0O46XQ1F5(-E(K=&974'$S
M06-A8V9I.51P+V0W.'9S-S!W<74X;V9P9B]!03%(+VAR+T%!6"MH9G%:-2ML
M.6%R.59P.&8Q)B-X03MJ;"LX+W=#36YQ8C%R>3-X5C!8-E5R2#98*T-0<WE5
M-"]7855Q=G%C*S%E6$=V3&5T3RM+1E12+S`Y.65J+U)0*T10<G4O<"MJ.6(U
M)B-X03LO=T)Y9D0O:6UV6#EN1E8K<2]P,R]1+S!P+V=B*S=G*V]F5U!7+W5F
M5E@P4%,U9G-E<G@T.&1U5DU5;T13+U4T>"]O,R]!9$]).5`P)B-X03LO6#9E
M:$94+T%*22MN5"]*<&ER3G8K47IF.2LU+W="4#)"5CEL+WES2#E.85@O:4@Y
M12]59EAK-&9O+S9Z-G9Q+U9P=4YF5RM(:E-T)B-X03ME+U1&5UDT<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M+R\R43T](B\^"B`@("`\+W)D9CI!;'0^"B`@(#PO>&UP.E1H=6UB;F%I;',^
M"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^.38\+W)D9CIL:3X*("`@(#PO<F1F.D%L=#X*
M("`@/"]D8SIT:71L93X*("`@/&1C.F-R96%T;W(^"B`@("`\<F1F.E-E<3X*
M("`@("`\<F1F.FQI/G)R,3,P.#,U/"]R9&8Z;&D^"B`@("`\+W)D9CI397$^
M"B`@(#PO9&,Z8W)E871O<CX*("`@/'AM<%109SI-87A086=E4VEZ90H@("`@
M<W1$:6TZ=STB."XU,#`P,#`B"B`@("!S=$1I;3IH/2(Q,2XP,#`P,#`B"B`@
M("!S=$1I;3IU;FET/2));F-H97,B+SX*("`@/'AM<%109SI&;VYT<SX*("`@
M(#QR9&8Z0F%G/@H@("`@(#QR9&8Z;&D*("`@("`@<W1&;G0Z9F]N=$YA;64]
M(D%R:6%L350B"B`@("`@('-T1FYT.F9O;G1&86UI;'D](D%R:6%L(@H@("`@
M("!S=$9N=#IF;VYT1F%C93TB4F5G=6QA<B(*("`@("`@<W1&;G0Z9F]N=%1Y
M<&4](D]P96X@5'EP92(*("`@("`@<W1&;G0Z=F5R<VEO;E-T<FEN9STB5F5R
M<VEO;B`U+C$P(@H@("`@("!S=$9N=#IC;VUP;W-I=&4](D9A;'-E(@H@("`@
M("!S=$9N=#IF;VYT1FEL94YA;64](F%R:6%L+G1T9B(O/@H@("`@(#QR9&8Z
M;&D*("`@("`@<W1&;G0Z9F]N=$YA;64](E1I;65S+4)O;&0B"B`@("`@('-T
M1FYT.F9O;G1&86UI;'D](E1I;65S(@H@("`@("!S=$9N=#IF;VYT1F%C93TB
M0F]L9"(*("`@("`@<W1&;G0Z9F]N=%1Y<&4](E1Y<&4@,2(*("`@("`@<W1&
M;G0Z=F5R<VEO;E-T<FEN9STB,#`Q+C`P,"(*("`@("`@<W1&;G0Z8V]M<&]S
M:71E/2)&86QS92(*("`@("`@<W1&;G0Z9F]N=$9I;&5.86UE/2)424)?7U]?
M+E!&0CL@5$E"7U]?7RY01DTB+SX*("`@("`\<F1F.FQI"B`@("`@('-T1FYT
M.F9O;G1.86UE/2)697)D86YA(@H@("`@("!S=$9N=#IF;VYT1F%M:6QY/2)6
M97)D86YA(@H@("`@("!S=$9N=#IF;VYT1F%C93TB4F5G=6QA<B(*("`@("`@
M<W1&;G0Z9F]N=%1Y<&4](D]P96X@5'EP92(*("`@("`@<W1&;G0Z=F5R<VEO
M;E-T<FEN9STB5F5R<VEO;B`U+C`U(@H@("`@("!S=$9N=#IC;VUP;W-I=&4]
M(D9A;'-E(@H@("`@("!S=$9N=#IF;VYT1FEL94YA;64](G9E<F1A;F$N='1F
M(B\^"B`@("`\+W)D9CI"86<^"B`@(#PO>&UP5%!G.D9O;G1S/@H@("`\>&UP
M5%!G.E!L871E3F%M97,^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI/D)L
M86-K/"]R9&8Z;&D^"B`@("`\+W)D9CI397$^"B`@(#PO>&UP5%!G.E!L871E
M3F%M97,^"B`@(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@("`@/')D9CI397$^
M"B`@("`@/')D9CIL:0H@("`@("!X;7!'.F=R;W5P3F%M93TB1&5F875L="!3
M=V%T8V@@1W)O=7`B"B`@("`@('AM<$<Z9W)O=7!4>7!E/2(P(B\^"B`@("`\
M+W)D9CI397$^"B`@(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*("`@/'AM<$U-
M.DAI<W1O<GD^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@("`@('-T
M179T.F%C=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN<W1A;F-E240](GAM
M<"YI:60Z.45!,#8X03A#1C@W13,Q,3A&-S1%131$03,W-#@Q-T$B"B`@("`@
M('-T179T.G=H96X](C(P,30M,#$M,CA4,3`Z,S<Z,S,K,#4Z,S`B"B`@("`@
M('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R($-3-B`H
M5VEN9&]W<RDB"B`@("`@('-T179T.F-H86YG960](B\B+SX*("`@("`\<F1F
M.FQI"B`@("`@('-T179T.F%C=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN
M<W1A;F-E240](GAM<"YI:60Z1$4P1D9",C(Y1$0V130Q,3DX,T,Y.$%$,4(S
M-S@Q1$0B"B`@("`@('-T179T.G=H96X](C(P,34M,#,M,S!4,3`Z-34Z,3$K
M,#4Z,S`B"B`@("`@('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S
M=')A=&]R($-3-B`H5VEN9&]W<RDB"B`@("`@('-T179T.F-H86YG960](B\B
M+SX*("`@(#PO<F1F.E-E<3X*("`@/"]X;7!-33I(:7-T;W)Y/@H@("`\>&UP
M34TZ1&5R:79E9$9R;VT*("`@('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z
M0D8Y-#)&-S0Y-T0V130Q,3DX,T,Y.$%$,4(S-S@Q1$0B"B`@("!S=%)E9CID
M;V-U;65N=$E$/2)X;7`N9&ED.D)&.30R1C<T.3=$-D4T,3$Y.#-#.3A!1#%"
M,S<X,41$(@H@("`@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED
M.CE%03`V.$$X0T8X-T4S,3$X1C<T144T1$$S-S0X,3=!(@H@("`@<W12968Z
M<F5N9&ET:6]N0VQA<W,](F1E9F%U;'0B+SX*("`@/$5X=&5N<VES1F]N=%-E
M;G-E.G-L=6<^"B`@("`\<F1F.D)A9SX*("`@("`\<F1F.FQI"B`@("`@($5X
M=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/2)/<&5N5'EP92`M(%14(@H@("`@
M("!%>'1E;G-I<T9O;G1396YS93I&86UI;'D](E9E<F1A;F$B"B`@("`@($5X
M=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93TB,"(*("`@("`@17AT
M96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3TB36EC<F]S;V9T(@H@("`@("!%>'1E
M;G-I<T9O;G1396YS93I697)S:6]N/2(U+C`S(@H@("`@("!%>'1E;G-I<T9O
M;G1396YS93I+97)N:6YG0VAE8VMS=6T](C`B"B`@("`@($5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T](C(S-S`W-34Y.3(B"B`@
M("`@($5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/2(R,S<P-S4U.3DR(@H@
M("`@("!%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93TB5F5R9&%N
M82(O/@H@("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F]N
M=$MI;F0](D]P96Y4>7!E("T@5%0B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E
M.D9A;6EL>3TB07)I86PB"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D]U=&QI
M;F5&:6QE4VEZ93TB,"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R
M>3TB36]N;W1Y<&4@5'EP;V=R87!H>2(*("`@("`@17AT96YS:7-&;VYT4V5N
M<V4Z5F5R<VEO;CTB-2XQ,"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z2V5R
M;FEN9T-H96-K<W5M/2(P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT
M4V5N<V5?,2XR7T-H96-K<W5M/2(R-3DP.30U.#4P(@H@("`@("!%>'1E;G-I
M<T9O;G1396YS93I#:&5C:W-U;3TB,C4Y,#DT-3@U,"(*("`@("`@17AT96YS
M:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64](D%R:6%L350B+SX*("`@("`\
M<F1F.FQI"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE
M/2)4:6UE<RU";VQD(B\^"B`@("`\+W)D9CI"86<^"B`@(#PO17AT96YS:7-&
M;VYT4V5N<V4Z<VQU9SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$
M1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E
M;F0](G<B/S[_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_VP!#`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0'_P``1"`#3`?<#`1$``A$!`Q$!_\0`'P`!``,``@(#`0``
M``````````<("04&!`H"`PL!_\0`51```00"`@$`!@,("PL,`@,`!0,$!@<`
M`@$("1$2$Q05%A<YN`HA.%9W>+78&!D:-U5T>9>8I=4B(S$U05AVM+?6UR4R
M,U%768&1E9G4YB<T87&A_\0`&`$!`0$!`0````````````````$"`P3_Q``W
M$0$``0(#!`<'`P4!`0$``````0(1(3%!$E%A<0.!D:&QP?`3(E)RDL+1,C-"
M@K+2X?&B8D/_V@`,`P$``A$#$0`_`/?XP&`P&`P&!\=N/6UVU].VOK:\\>MK
MSZ-N/3QZ/3KS_DVX_P`/'/\`DYP/68ZS]J_(T5%3[L`G)C5M4-UH[!>3`3V(
M0L=W2T<`2FJ.OS`KK0<#@"\5C"EHC;)9'0VS=[*=HZC%G`=<DZE*TB>:"&:9
MTF*<-)FFBV><YSCIUWNL+-?)K;H0EUHN:6TO(Z[@]C]1>XG:B'U<!NR"2:.V
MY`*CZ[41>P1Y8KU>D7$IATI8;3@Y$(\.C!]DT''6!LF?UET>(@>41%$3>(F_
MO4TWQUF8W\+NVPCS#OY'8$*AL@ZU(QX=*;IZ65*_.CKHXD#D.U[W4LXN&G9&
MV#KU6`2*NXYHP?1VSP*I@2V!*\,BD3D,Y2<N63`FS%L_BT^&;;]7'D?-2$'P
M*ZYEQUY?/WM/UUUMM+0*(MZ-G!LHC78CL(;ZZI,!TZ!QDG"'QZ'2D(J2<NH:
M:G-?GF2BC(?8+<DP(-VPV,8B^=^Z(F?'6T\%GFG>>V`/9"LNK=O]9PU;67<-
M<D;"K=1E>7$TCDN^4+F80*SXT%+LZH$:N#U?U46$WZ_:*(H+.X@12"JHCBC,
MPN,)LX3-\(FV7"\7YS@BGR:SZ^Z/D_3R5UG?LXB`6_?(;TMZQR:#APT!4!,J
MNL([,F=EZ,WAR)&SO,DFFO`]-4YP41V!-`HU./-AKI4L]*"F(F\3&5-4WQSB
M+QPTW:SPM_#OD0+]>K@D/5J70T]<)JM+]Z$4,^N$W,P0`[+&7?N93X!$Y>5C
M("NV8-(O5>L5;LY$-&[CF,U3WY+#EHLKML(U+LWB\87BJ;?+$7[4"G?-\;"1
MV82?GJ>R=#XO67=6S6^FM_;I."0[HI<C*J;88+)\TKOJ/7D;5\C(*^5TW?\`
M!-]PH!D2,7::\2/8NQC:^M,9?%$S'ABG=[Y>H+\REF(6GY$_BB%U6'UN!2,E
M)T114G=-?=2Q_;5TP)Q=O&R^P:OB,=?;0I*<MC)M^WDJ'Q#>'JQI74OJ38GK
MM>W#:V>V^F5M=$X5=V?M7LAT7F?95>L5^O2,TZ[-+CI,D)L@%8YQZ#EE&B[+
M$2%TGO#A#./%XW(RCJ.J@S`HNW)<`]2^_K,2O`]N28V9M>]KQ.%L8F8WLAK7
M[[]RH7T\L^I25K&07;[IMW+K&B>P=R-8;"47M@5=9?8"MP%+2UE'G\3<0X+]
M.]*6EK(4"(@/JX'$:UDFN@\9P:8J)FXIIFJ,,*J9F(OE,4S,ZZ3&4[^"[-O^
M:NI:+VL=]*:EG!*#P*PNY=+@9`.-M74IEUH=(Z["3>>#R,7<!6K2.1J7K+24
M'%)>I)BOKN03`F8"C6,C1^'F8HF;8Q_&>JJ;?C!%D"\FEQ5K??9J"W'$GTXD
M4I[6]=*3Z_4[&I$K(H[7+RS.D`OLK)@>MC1ZGV<QDXQV2'G=!.[FO"YC8\<%
MA&B+*+L7AH<78B8B8^&9F=]JK:S:/6JX_1OL5;5W]G>^D>G_`#,([$8!OTV.
MUU44[$Q\;**9VN;JY%K/GL%-K!V*3QT88S$N]2+IE"IS4>0;KLQ+Q,8FBEAF
MJ(B*>.U>=)M5,8=C3_#)@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8=6;W%NZE
M.XA&*7ZQMB.]<K"["14'UM[)THC"[&H]V+"140.EO52^85J/WF5>SP[8T3L+
M5E82:ZT@(28N*!#R+&"`2H-T]>O6K<4Q,7BUXC&)PGA,3E.GK%W.N?+<M:4;
MZ^D8QU=G#0YVT>1S3K<G*Y9M$X)/6QNF+.N@BQ)6(9A#=H(E<485FI$#PD&$
MF$=WETRAJ(69%PKHV9`C8M>\Q[N=L;3>(\[^5WWFO+F)CQPZ'-=?I(%WC]QS
M;K.3;DYX(5,C>QD!ZCM^V4AAY%C'P$@%<P%J/V=UQ])H.0'M5I2S^-,XJ[A[
MA$YR-CCIM?T[6S?SMNXH\A'FA2FH^)#%^N"P2>VRIXZT*A`ZV_P^CAGCR+QN
M92:%*SF8IU@W?03:MAE>3!>5?"8C.^"?NX1('LL^,*L1KUZ\2:+:X1M7_IF(
MFV..:':2\N$ZIKJ3$I[V$C;Z[)=\V=F"<LD#2;PH/)FD)@'D"<=7H^+$PJ-Q
M7@T9UBL<DX'?YXD,6@5?$E8^/CQB>MY[,!K!P6:8F<)TIWZTWURONO,\+0MK
M*/)?<0V(=WK*A_3?Y[KKHW/[IKV>%V%]CQ\CE!2EA]33`NXC\/5JYV^X;$JQ
ML8[,4O0\>>YD8"2C"FRZAL.64)LQ[N/ZHB8PWWC?OCUC:]$6EA7M!1XZ8P"9
MO*Q"S>2"#L&L&!/1DI?R:J@%A#2*)P2K*XBD)8L;E@X5^S8NM!)C<1%YBT/A
MBJQ;1HLU,Y3C'5-XQZIOA/\`O<QSZF]WKTAG2T9W2NVPYK??+GM1.NJYBN":
ML"AXK5"7=V`]"UA8(LE'J[3>IEZ[`+\L"H5535A,!K]=\Z<L3HY)V0-U4QM3
M3$6M3?6<J-J=>:3IQYG245#%GXOK$U-D`;?R7O"+)Y=^X5EPU\9)44A9.[8B
MG4!A==2QQ!'=[!TMQ:'#0JBB)/[LF3A4\T)%%]?@_P#<7CLU=_AGES8S&Q6E
M-IT*Z'6C*KHZ_P!5UV.7LG5>(&!/8?JV][:1N5R^6(P#WN'OX[7PHH"DL7%Q
MJ::<S+1@S`2$X"<O9"+&QK?"TS.&.%6SZQAS?6OREE^VUD4[#J3ZV/B,<LCK
MG3'9Z42F56N)BQ*OJ[LRRK+J:4MN8OO#2*<LD,!EM9%%V[(7(6;*91QSH58$
MA;S5L(?$FFT3,S_*8C#.T1-^N[J_9+M3=W5#R`5L?DDKD4PZ:W`SUZ]%ZR0!
M1YTK`NRLJASN?46>BQ5F%1EKQQ;I"&22I-010XYC[:1'0#E!JF\?Z;HEB(JI
MF/Y1C?'+7AA>_*$(]4?(?=,47MR!7>1(=@;KF?DO[L=8ZE9.'D?KBO8;`^K=
M0O;B)LMSL>@CMTT%,Q8$R*CVY&/R.4G7Y@0F6)),1KU^T+-,9QA$44S.N-5O
MSIAADZQ)/+Q)NS)+K,3ZMA))6,!W[@^-.!VY))25"?,LE!=RHXE9)ZIDX"\A
M<@'K`AL&*!!YFQ!TW"EN)$NNA$6;D6@H=7+L6OM8^[7,?TWQ[8R[=SN5@>4.
MR+PK/K)9U$P>R*<KVR.[G3^#C;-?CVI6/696L_[<3.@K1JPSK*82T9A98I&X
MJ.D)EK$'DD3"M9DP9C)VA(HX:;IDBB(O>;SLU3;=[MXG#GKV/8"PYF`P&`P&
M`P&`P&`P/YMKQMKMKSZ>.-N.=>?5VVTV]'/'HY]7;7GC;7G_`*MM>>-N.?O\
M<\<\>G`@N(]9:$@<`GU5PZKHQ'JZM-[*R5BPX<@Y2!3(E.T%6TW(GF?+G;5\
M0F*"RR<I>J<^]2#A53DLJ[VVYVY+>9QF9NX8YU$ZTR41!@)^FX:7"UG6\KIZ
MOQC]HX<,XA5<ZCS6)3*O`2&[KG1C#Y/%6`Z-'`"7'`XB`&"P[E!0>,8-VXO.
M^<<7$-^DO4YH^9DF]#P%-^/.53)F3K@:MLLWD-%QY>)4R:3VW<[?\I5?%W+B
M/P9WSZ58V'65'B]F[7?9/D7G?/;OS=5%>.SHX"`E(N%ZO5$)CIR-1R'&0HZ,
M(,QQ6*P^<.+)B0`@U0W32=BHQ.W.THC[1?7=(.508+#]6^HT=HU&U5.L]J66
M]**+WGK<LGF+B7-(U&74>J2&EHK%-?HG5DC$$PL$D#FC<=I,3*LW2C`;=VF?
M)O%&&VYA!)TNP?,F0D7PM;K]<W/6K1E27@E#D+9@H:=(U[,1-B09,WPZ4UB=
M@1_;;>/3@#PW<H?#9?'=U%E(])&WJ&0.[EWN)>,]G;GE4E[9<G3YKU)ZS6-8
M>ELSRCZYEMC:.8$_^;CL=9ORRA2JR9(Q6AI?=;79%R>@)(P4<Q`\X15,1_E^
MZ2%O6R*NR?);S:UYMNOOS[==[J*O0[IXX8N1;CKU7*XYX%LF./&*XI59J[`7
M&73D%M!G2*CG;1P,LTZBB9GK);C=O+"B2;\YH^=::J\"\[YTUW9=FFYW/GJC
MUQY*N3G-.0CDL[$/`KA_\+_OZJ)&`M*J($N>?:>KQ)R%8,&-<OICKKQ+7D$9
MM8DY-J`$$F&HO.^?6/CB[N'INL(_4[2BP<-$B*A'Q+F!,*_'<.6D>80CW/8;
MK$F35%QINTCB0O?D0@';JIL&X?C42@@F.TT;:DOKKG=U&<=7NOEE1TE%)_4T
M0EP`V6AA^0,#K'=_S)#E=LF+"!F9.[56Y?20I$&PL9\NOSKD@Z%.!S%ZS52>
M-$'"8O,:OI(]5.N!DK*C1NE:].D)P+F`>7;G8ZR-MI"SL0``BEAJ$QY31V/<
M$;"C,5C$?GIGEKP8F@:.`QLF?%&@EBD@6\QK/K'Q=)UZ'=.=09>._L=:QV''
MI-`YL74W`Z*%WLTJ\0G'Z\F&\B45VD*<JAX+3D."D2)1,PQ&+.V*;SW9Z\37
M&U5G>=>_/M3)`Z2J6KY%-)97=?QF&R*Q4XFE-RL?'Z#W$E1@8%.+0I$GJCSP
MBJC%(RBA'H^CJEHD)"-VPIEJBQ;(()DNE+`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8$,M>O5,,Y.I,$*_#<'%9L]LS?E50@Y$<V408.13NQM8TX>JQO2?J"7
MCD/K--!.LF1$*\BD"B8_71MJ+RC5#HKT]:0UO7K+KG5;"&L)P.LD,!'1EJ/:
MQF<!WI8@'D4/49>P=0YZ'=GY"H(TBRXAL+UD4A18(-T#Q9-X7:JG6<K=7'>[
MB_ZK=<B1PC(W=,P'8P5&OQ;YTB";--%4BD$1JP@^3:-.$&38\\K!NWK9>3-6
MZ,C4K]NA"^2ORTBD,U%YW^L\^>//'-U!#HSU$;#7`AMU_KMLP<"*F!<(MQ.Z
M&[(50RW#BD6HEPDXT<A/HC5]IM6ZX=9BYAG#E[I'UF&CYYJN-JK?.O?GSOKO
M=;?^.;HH3'M13SJE2>XUD%D,=;,DH2,:MD@DJFC6QCX[V;5-'79`A/V3>:;<
M[^LHWD_"AMIN@0<.'"HVIWSVN[R#K'&6,0L&-T<1:4$1MJQ&MBVF=C$.BDL2
ML(B^7&-)ZE*([.!YH$]>6'$AJ</.2))JVD#<6B+V9O\`7@*/03%]^.%N2=8Q
M#HW#(;'J_BPQ(%$(I&1,.C@88HNS0#1L$*;A1`P>J@KHY:I#AC5NU:*(K:+H
M:(I[)JZJ:\;<$0BRZ>=8!U1G:$94G!6U-221:3`Q6Z8W?Y5<2U.1LICI*$!W
M*_.@^1:R\<QE>IL;RT)<25JB=]Y^*Z<.\+>;WO-]]\<K>&')P'/1'IU[KRQT
MZYU:@QV:6XP48M(X@S9K,K];),KN:+M6NR+==O;+-NU:6$DLGOI+&K)@W-</
M$6#/1`;4[YTUG3+LTW.=9].>L([XKN/I>&,'9E[791\48M7;0YP6J2*[06LC
M#$\W=IFA1J"PC=6&QDP+?LR0J)K.(XV=:!G"S)07G?/_`'-V^$]=J-K:5L9O
M7U6PV$R@76T>IP83BXA`'\-JB(N%7D6KH>R'>[CV4-CCQPZ>A(^V:)#1CUZ^
M>,VZ+E\[56%YG6<[]>_FY]Y4%9DCY.4%(<(+G#!N'25\],)K%N-I#7KC5W!C
MC5H16=,AY:*.M.'`(@/;-70Y;G=1NKILHISL1&#7ISUA9##XAG3$/:,Y18QN
MX#NS9!\B0?6Q)Q!*/2NROBZ;W4LVG<NCI@M'9?*V;UN;E<>)D`4A>DA3QPS4
M+>=\[L]+WMVX\WT$.E74LI)0$O>==ZFV/Q;:LU8Z[0APEDW#.J8;N651$&`M
MD@W%(%*Q'O'(N!%M6/Q**"%>1(1TR&ZZM=1M3E>===^?;KOU?6VZ4=366CA)
MC0-;#T'%H#;J]V'@$F#5K:H<ZYE0N<C&K/=%N(.L)6\=RMJX%I,TTI4X6DFJ
M7!M39_R+SOG*W5NY+180P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M*3V9V<G4$LIG!4PW6T;N6DL>C,9CEC]E2\1M*6.9<_.BXBX;0^.TG/0H'29O
M8P;U@R127+[2)1%L,**1,ZLL+;%M''JB_G&6JVS]#F0Q-XV)BC+/DY'7"!`&
MU,ZB9"UY)C=TW8IM((\:0U&&4/;J,T3(.1(ZLGVNKT8:3X30?<$9M3FE.PH_
MJ[5D`BB=XDK6#$/I1FSD1<>A1N4G\R@]N/G=6$Y?+;WA\Y=T_`[+,1,4LQ82
MWWEO$4(1S&B)YXPE)J.&L+SE;ERQM:8O,>H2P&NF_P`9Y!T^N,U?U$3IJ9]5
M9C?,)0B\(F`>RHG)8%8-*5V9"2F:E;'.1J;!2S^P9&6%KB:Y@CT>S1#L'?Q!
M=L\>OB86UO?''#&^EL,M\KWX0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P(/OTM982*PTC5Y!NQ(_3A0`F6H[Q-26/2E:2:YH3%K$'B]-7[
M9&/./E8V0?$)8Z8'$P0!B9708,'^[.2@2Q;7=/;;!FV1[#=N42!Y)$A/-$6M
M?&)0PT3IX8NGQVN:F)TV"=/$UN*]VX6JTJ-%1IQS,=]]YDY3>,WS6Y6S:2B]
M4C5J>&=L]-_/U9=KJMV7E/8`KV)B4^J'Z&I[UQN=K4$HCR$^'60-+;EJGK2W
MP<B&2(:!CJ6J+^-V<(2<#%!^ZH]XV<);NU]N>=$C,Q:V-[Q?OF/);K"&`P&`
MP&`P&`P&`P&!0#N'W1F_6ZT*"IVL^O\`M?,ZO>-W7+F35Q:@:J14;!4BO5#8
MVL[*%XQ)]2+LHO;0?5BT0;MO9Z#WNZBN_KIZ\6(OA"VBTU3-HB8C*9SONY(.
M_9Z=U/\`N[H__3,A7_"3-;$\._\`";71_'_YJ/V>G=3_`+NZ/_TS(5_PDQL3
MP[_P;71_'_YJ/V>G=3_N[H__`$S(5_PDQL3P[_P;71_'_P":G-UEY";K-=B*
M'H>YNGR-/M+_`#%@1Z+3@3V%C-G)#S4`JR7VLZ;DXZ-@4<=:M2`>&OV*+S0C
M_>'KAOSNBHGZ_HS53--KZS;#E,^2^[,3LU7MPF-;:M5<B&`P&`P&`P,>K]?Q
M`9Y`X]\=A(.9)$XS02;L^YDMQ1_FNE4^P=>L$>%!$/0<0:6&S\R*4R5UT)C]
MG*(:,M&%A2!E7KAFPX-1^G/6<,-T]>5_+%L+ADP,YI!];?4O\G-V'^TQU?PN
MD\X\):,X0P&`P&`P&`P&!2^T;QNR#63.T`T#9G:MA`^E>-%V\7>O#I\S9,_9
MQB0-&A]*P&BB&H$([Y+<<-*U-,F&C=9T5,\:^H.V+:+<<==T<M_XY=1%]O+,
M?6O7M9EJ>AL3XD$M@P^5F75IEI"S#1B<U6?FS%U[8;6C)*,2;F5IQB"Q^.6+
M\J/YY(GKX=%6SH;LC*&Y;1:\3U6MKSYSAE;%XLK[96/"[&GP?>/PF7QR-3OB
M'JAD&<IACZM@+Q>KV`>S[9LM5W-X\R@[U[-RZ[O9""A238*'=G1B!T/&I<_&
M"T6CU?/"-\Y<-,)<(Q[\RM^4%BD^N)=HX)O:VX42+V;&@*@9A/8T[/*L)$\-
MAQ\>!6,@Z9N1,;J<E($)M)-FC@B28Q-B^C*DD&S&_?INY::S.EXS:1X9,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@9S=+?PGO*Q^>?6?V"^GN&JLJ/EG^^IHSAD
MP&`P&`P&`P&`P&`P,>N\_P!89X\_R`>0;]-]*,W1GU><%7[=7S4?<E7.KSF`
MP*S3'\/7QC_EA[(_8QO?.?294_-]M3KT>5?*/%N3G-LP&`P&`P&!A7V7<Q05
MY)ZL&SH\P.2E]O3$BK34M'NNXRQQ[#6^((&Y@U9?,5-R*PYW"F;J0%9K)S32
M:!3L4'1V:J15PU/M'$H%&XOLS,<8G/=>^$VY8<VZF&#`SFD'UM]2_P`G-V'^
MTQU?PND\X\):,X0P&`P&`P&`P&`P&!%-$69O=-'TU<:@;6.;VS5-=V9O'M"'
M);0#O.X@'E.P;4ILS'<DM1?)7ECJ0Y'L.7G"'#CEFUY4]AH)PF8W)6P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P(;L^Z@U8F8K&-HC84\EDQ&R<V&C%=1K4^3^`0Q
MS&&4E.OUWI`.''#QA":15AZKLJF^>.32'`]D[2;$%68LEIBYY>LF;S9LZ9;.
MVK=SRS?)Z)/6G*Z6BO+9XDFHLFFZ0YW]DX3T55TT5TWUU4WUXXVY#[_:I_?_
M`+YI][?A+G^[U^\ISZ/0GS]_[V_/K:^C3_G<^GCT<??XP,Z>EOX3WE8_//K/
M[!?3W#565'RS_?4T9PR8#`8#`8#`8#`8#`8&/7>?ZPSQY_D`\@WZ;Z49NC/J
M\X*OVZOFH^Y*N=7G,!@5FF/X>OC'_+#V1^QC>^<^DRI^;[:G7H\J^4>+<G.;
M9@,!@,!@,#)ZW'RZ_?>+[DY.X2CG+>AVL.9+12[9Z(<GVEAS4?+F04O7U\UO
M7E=$>'R`H<?WFU96.UX=(M21QP;&LW$+$FHB]-[;]V&'*\\KM8<,F!G-(/K;
MZE_DYNP_VF.K^%TGG'A+1G"&`P&`P&`P&`P&!%EX5HXN2GK,JIG-YG6A"?PF
M0Q<78E=R(S$YS!2Y4:NV$RZ+2``0%E1YF.DMFI9GRW?()NMVGN;SA9BX<H*%
MB;3$Y^N*OWCPZPR_IUTXHWKY85F26W;`@D/9M9K-I)*Y++DUY`YX]X<Q^)/)
M2Y6?CJ^AB&S:'P(,@U$M&46!#-_A#%ZX>Z;%JF*JIF(M$Y1ZWYSQ74PR8#`8
M#`8#`B>&WU2%B3R?U9`;@K*;675+A!I9M?Q2<QF03.OW3G?9)%O,HT*).C$<
M6W6T4;^H69M=M72:K7?C5PGNGJ6TQ:9B;3EQY.BRNE[?*R$O(8KV^NB)(/WJ
MCP="5X)UGD4"!);^CV8MFFZHEE8KP:ESQ][DI9;PMOKSSQN6YY]&W`O&Z._\
MN3ZR6!,;*JCDY8#@"^EX"T+]JPT5C(9Y'0IY6DK[LNFFLD:`'YN2.0BDE8P-
MJ>>B>3Q5$>_(NFK5XHU21]",>_NFQ.?9WQ=/^$,"!NP%O;TT$KTWP0AC!O*[
MIJ>MB/,R*<B^%1=@3$=&B/,=Y]Z9Z.Y&P:/E"K9NNKLW38CR#U=!PFTV1W+$
M7[)GLAG_`"WR`6<"93Q=#>EF/RZ4)[:/3`R0[L(80'B.WI-.DISJWL-MNYMM
MXYZXPL5P007CFJ+JT4N4*_(*-@#62FHIB;9Y1Y8\L9[.RVUX]MA]*$R`XC%A
M:RH2HUK9(CY#.6<1D9YMLWE_.D<K4$N$+:SLO&EX>Y?6FIR1`-*ZBA<%)EU#
M>A#@<F9B+]MO^[N"N;GR#RM%9M(N(#"_E#8"V)+L-)T.=Z<K?&+/CKDBULML
M\Y`N(YN[A(P^UT0A[F:JA73H"A"W=@.&D42+L_\`+8Z:=?+#.V+1FM)LPLJN
MH%8HOEML-GD-C$R'\L]B^[/EG)@K(RVY:;GP48.J-?9/=/=U#,:CY11'U-WX
M04ZV58H&9=VP&!E!Y+&<,D;BJFDNAA.>"(UI/_2PB-:4?-9^#FYX?$_DDPR(
M]B:ZG$&%UXFR:27BPDH[SI+R+[:%IH"),%9'P:IJG=EEK,>$Q>=S2NMTR*-=
MP)(Q\!Y+)0N+)E.8LP<"HQ\1T!L=7ORX,=HMW0X#[SPK\(8.6Z#AF/\`=VZR
M*2B>VFIED5SX\KMX7LM95:IB_P`]Z3I%DD5DC[1"+V#.U+06;]BXYH,J1CNW
MF5=KS(2M!1!]636:UT>RIJ4["E&XJ&ZM3>U&'#_6&>4ZX=25_'+%I)"[K\H4
M;EMD2BW)`/[J0K=[8,S%0@))#B9#I-U.)L$2(RN8K"8:WX!CGC2/,M@\8&;.
M1PIHZ)>^EUWY!V2K*C"WN_=5ONU2PR8#`8#`8#`8#`8#`8&/7>?ZPSQY_D`\
M@WZ;Z49NC/J\X*OVZOFH^Y*N=7G,!@5FF/X>OC'_`"P]D?L8WOG/I,J?F^VI
MUZ/*OE'BW)SFV8#`8#`8#`P>L6.N8QWQ@K20%U71(W=46EXD#H'C;EW&8U(;
MK,_`DB&[WR&CB@YB?68D90,?BZ!?M';0NHZ3KAW)49#!&)N\VGEY?+Y]>K;B
M<S(!74)F%@RMWLPB\$BT@F4D?:I[+;,P$8$NS9AWJCKZ-E=FXYBX6X3UY];?
MG3U>/O\`.&$`O>W=9#ZEC%Q.!TF<QV6/Y:U&C8\K"IJ8T9P(),)1-C*KF#S.
M215<;&(Q`I29(I#),0+J*CTHP/%/IN1&QAV6TWMZ[^?J%='LCCQKR]5LP#G0
MY5\'\<U\?%V0XDR>O!/Q7L7U<)"^";5LLHNPY(CU4GS'AVFCR[9J:.4.%$=M
M=^1_&><>;3+"&`P&`P&`P&`P&`P&`P&`P&`P,V^R?E=Z>]4NTM1].[9D<YUN
MZZ1H,A$`D/KR131DFI+SI*+00036`(.R'QR=2<4[!1T6(&%W'#SEJN:X#CGK
M1\L:BBJ8FJ(PC/'UDL7[SV/M3[S-HRZRPM?[VSTIK&;'OM\WV_N=^60ELM(*
M9K1XFIIPNR?E7U[ZD6"_L"44C)+3;5$F$<>Z/S/<JQU`\2/5GI3V<OKMM5!.
MVC=N=AF1IA,G%A3,=(0@M&5RP9.YHI'6+"-`W>CJ7S(../EG)\C(%6:[?W*/
M\A12SE@L:JKFJ(B;6C*W=V:-0,,*I=-/WH9A^=;WP^W%V(R1EUSXRLY]4>$+
M6Y45`NWL;*J9LC1HO#PY^JA\0@9>7F="4@:2^/D)[:"E;#7P4*)B\G2F`]H\
M=BWAL0GN"+#A"1(F*4DA#W*.N"Q%_+=AC.*'*_[]EY^`)RIC30GY<@XB12VS
MS`:W64K8"H-&G,9<D)!7KR/P=TRL9ZA%I-I(W<>=.860:KAC<9]=:0-6[-V7
M9TOGEASSW8X..->0UT+=R1+FD&P]L$B<,F&NLWN6#5^=68S=O79L*9>Q22,D
M3VL691R?MFY<V!:28NE8\9DE9!(R>,LF;U\-GCK;"+[]<O\`6+P@/D,+/CD8
M$O*U@Y36:SO04"<";;TBS@5"W@BHC(ER;&VI#H,1TL&4B+80D,!@+MN!*3>.
MQJ3N]=0#P/LQ<BV?"-VO5IAF[U4W=96=TI?%YF@D!'1BN',<6BP,1-WY=)JP
MD-5U[,DH[9TJ:119")3`7(9BX!3MJA'"`>NEFSE`L4),A#\YN)BTQ'K.<HZL
M-[J+?R($%(NQFB])MVT96;/A1(@G:C(@B)F[*,W')%O:DA<+>1AU4C-"ESRI
M6VVLCW]Q#E1$A;PP@-Y><MALXVONTTFV/?DM_P!;[/-W%5+.?']8CP_?3BX`
M2&\#,N))#W(6$7#/(-&GP"2.F@]22,2$<C@I]K(M1@IN=4<*%F@@2T>(CFQ)
MBT]G@G7",<?*D&%`B-5V=S*(;`B'RW,(40E4HL5E&R+X0ZFM4/W\8C</DW8.
MD(K*-]HAS/I@1T;(F9"3+0N'13@D#'G/:K&Z<ICROI/"?6]J33^BJ=2U<FL-
M$AEM*ZA.BH<`Z%/@0E76-#-5!H5\"XX"/!+';CEJ-=!^.!3AFDBL/XX:;HX8
MGMXI%P,YNEOX3WE8_//K/[!?3W#565'RS_?4T9PR8#`8#`8#`8#`8#`8&/7>
M?ZPSQY_D`\@WZ;Z49NC/J\X*OVZOFH^Y*N=7G,!@5FF/X>OC'_+#V1^QC>^<
M^DRI^;[:G7H\J^4>+<G.;9@,!@,!@,#*2TB:P?N&YGZS&W-&/J5:!<Q@.T[T
MQ]5Y]'4JE;]^:!Q_KQ$"U$WB).AS[!^V2G3\YNT:ZJ1BPG88%JK'`1K2V&N[
M6V^;QU0TV)C49K#B`<FF?C[>6QIV-((M"6P64A$3PM1J[3;&`3Y;<2?&Z.U-
M4208DKLP(HZNASY3E)%QR95T-=/J_D<8=QDW+K*?<E#TEDQL_J9CK`\:-SL#
M.8A8;UVJ+BC$8T^>83/B<0+-@PH6T#C!,8)PM"+2D"SD/!=J?7"UNR8OXJWJ
M0F&1GS!P4Y&XE&8^;EOCJO):5F0H(6++2=8%V&ZMA@BTB),FJ#PVL'#H(BA:
MI-9UN/&I)L6FR3;35+@?QGG'FU`PA@,!@,!@,!@,!@,!@,!@,!@9RFO)QUL-
M=EYAT:I&7,K3[G1CVC1Q56S&31Z*!7C89P8.OY59KR/J11(5!A*B129#XP[D
MLO2UYV"!(V7D:;L8S-;,VVIBU.__`%GY<4G!NC%"DK-AO8FZ8-#[R[30YQJ2
M$WQ,HNT4-Q9[IRHH/$5H'<N"3.OH/$5EW.\#C3%P0>`';DA*2)X_8DAEDVD(
MVIM,1-HG3UW_`(P7,PR8#`JETT_>AF'YUO?#[<78C)&77/C*SGU1X0M;E1%U
MQ3P[7$'YDD8BS.9R!U,:RA@F/DC[N+#%WMDV9$:Y2(%#["-3!Z,%@>95R?)+
M-8T66W8C%T4V^FRO"Z0A6ZL^W,PLD7:;Q.B28G>OGY(=QL(LZK9B]%<LN9LB
MHYLF'[2:*3:!/V#B(M_B$6W!F#JVIYGH)3(;,#6XPLQ;7NY93C=U*.=T+*)N
MHLN0H<0E$SI4,)7D"-DG$Y(AH\N*&4@2*<PA6I]QK?W:3SD3(FPW>?K:*PQH
M;(*ED2`YL-)BT;\;7RPROO\`)%H;R/R`]$8W9#2N8%K'3$3..FK1I;?OT(.R
M9^OT^=Q%OQ>+^"@HS%4Q37L-,8M+DS\;X#M9["EP.TG:<MW*O!=F+VOW<].J
M.UV1UWXL(C&PLG!TK$XR#D*=5F!IRQ;/,C&0X%)9EU,$S[B;:,*TW8Q'@`"[
M/<K!S[4[*&'MX-(3!D8V8L^!CL;/'''".%\M^7>X$_Y%9>XCQWD-4D/A)S;>
M0:QI[/KJB[Q/VX1V.9<0@W%(L)*R4-V$=;D]7C&AI$E'5R(X/+5V4[57B99J
MF)IXWPTCUAQ[FK>&3`S&[Y2)Y$[9ZXG&L^C%=Z<PWL`)6,2N\"O78<[X>DJ+
M>)C=;)$4K=:KM97D7RZT@ST4`''O=/C^Q=8A#QH]R:IRG"^6E]_&):.1=?ES
M&8ZYV=(/N7`(0OR];%=CK9YRJ/;J<NFYO=@+W,(..=O:I%=Q@[8@GOJ[V8-.
M5N6Z9E4[3OMUU79GB3(S)R@J-$SZ!8L(B!@H,;QV(CR!>8SW9ZQ270TAL2$C
M5"IURMLB:;"2,6*H`W(V=09W)"[,^N[M_.Z;1/T=)#BW9/RJ/Q3]D38K=T:Y
MT2>CW2#UHKNVZ)=06KC1-RV441WV0<HK-UM==^>4ETE$M^-5--M>"U94?+/]
M]32;#)@,!@,!@,!@,!@,!@8]=Y_K#/'G^0#R#?IOI1FZ,^KS@J_;J^:C[DJY
MU><P&!6:8_AZ^,?\L/9'[&-[YSZ3*GYOMJ=>CRKY1XMR<YMF`P&`P&`P,X+9
M[/V)6O<,550XZQ*5N?!4V[/#R=:CB/$'?2JWH[53YL+F36VX9(EB,S7LJ$N6
M:*U<3H-'OAA(AP6<+;N(LF:B+QROK.Z^Z8[X:/X9,#.:0?6WU+_)S=A_M,=7
M\+I/./"6C.$,!@,!@,!@,!@,!@,!@,!@9']=O*M4WD.E]JT[T/?$W\JJ@O\`
M#;(M>S(O\)A4*C+E\^%#)I#8ON92D-GDI.^&%&T.!KHQ84SX&/C<[)A4$X['
M)P;FB:+35&>4?G=ZYQ8FFO'!U"HZ^CW:V)UCN5[0S`*_$3B^I?)I+(IM+ES2
MB2TC.O!CDHG`@!V1*):ID74(AL5;H"_5C@EH,C*2`9(DU53&S?",H7GPR8#`
M8%4NFG[T,P_.M[X?;B[$9(RZY\96<^J/"%K<J&`P/CMKKOKMIOKKOIOKSKOI
MMQQMKMKMQZ-M=M>?3QMKMQSSQSQSQSQSQSZ.?O8'@BA0L"+&@P8UB'"AA[,4
M($"VB#`8*%CFZ;,>-',6J:35DQ8M$4FS1HV230;-TDT44]$]-=>`\U55-%-1
M9931)%+3=5557?5----/7G;=13?;GC73337CG;??;GC777CGGGGCCC`XF.R.
M/2\$*E$3/!I1&CS%`F#D4=*,38(R-=:<*-B`HN-7<CR+%PGSQN@[9N%D%M.>
M-DU-M>?3@<S@,#.#M6Q&799\%JL>\`<G`4F+5MI%K2B\ID-9EY;9-2G+ACM@
M,=()8L---)E642IJ9:1HL]Y;*MW4I+C`I$"1*-)..-1-K^6?AE,S"_\`$@KN
M-Q6,QT@=)RE^`CX4*]DQK;3<Q(G8H:V8N3I;=/CA/8F760W(/]D^.--G3A7G
M7CC7GC#*ENWCOI#C4PFU/6,.1-1LA6SE`<1AK1)*CRZT[7,T6APG!O6W@A9:
MQI,H[D#S9W;NNZ@W=I9S;<0.V;FMJ?5\]_/#EP19X]8%!:QO;RC0BMH7$Z]A
M8;NE`U!$0@\<#Q.+BE"_1_J2;*[C0`%F/%,=R9HD1+D-FK1+9Z4?O7[GE5VZ
M754%4WBB^/N_=4U%PR8#`8#`8#`8#`8#`8&/G>;ZPOQ[?F_>07].])LW1GU>
M<%7[=7S4?<E/.KSF`P*S3'\/7QC_`)8>R/V,;WSGTF5/S?;4Z]'E7RCQ;DYS
M;,!@,!@,!@8?=D$$!?D=JM"3N9;+2KU2I9+6:I450+62!M=KJA``_":>+K]0
MI;:/,"%@3LAF]E;`[[C4C<@H]+64G<QN,JH314U'Z9_WNYVX1AG9N#ADP,YI
M!];?4O\`)S=A_M,=7\+I/./"6C.$,!@,!@,!@,!@,#.+R)>0^I>D582!BXFD
M8_9%2R%2)Q3%>$'(9?C0WRR=,`4_LG@Q)X<$A=-Q^1;-%)7,9?+8D)>(-W,>
MCQ0C+G@P,[-4TS5RO%Y_&=YX1$\GK:>+_P`OGDKAT*LT)=-46)Y!Y$A*A%DK
M0F#P6_W][U[!KE$ZSF'G6$DKSKQ8E/O*^G6CLJM7E?S255H7A*0,S&F[A@*&
M-8K&'_>W%TJIHF8M.S&5YM:9B8B=;X:SC$Z;YTS[!?='=']?J2+36<]0>ZE:
M7&MHY"PZG[RI_BL61:9;"2#U@@7GBALP)&1?5TQ]F^>MF;Z6^Z;[.F,+=:H/
M?<C,=',S:*J9WS$WP2+#ONC_`,;TWIR(SX!(+2,6W->'@\%U6CE9R"57H\E#
M%^L/4`)(QY(A`4DW7"6ID:5(38>V<QUTT?+I-"6ZP5`3T5<7PPC69B(\7.R:
M]N\G9"*2$AKT2[+Z1]U'BJX"NB,[IKKY5F[E4:ON*WGDA/6&5['W1QRKZJJT
M53IBKJX.,7:\6F%>S5+A$JL2T1_*.R9GPM';,Y9*'^,R)]C>J5C,377_`*>]
MH;'0N'K.`F_<F'W'1M+='187M,@9AW*[2F921ZXT2"G@4)\8LAB#@[Z:O@[$
M:2=GFYG1QRX7(FZ[3&,Q%IF*;3M7CC[U5LH6?@GF&OPA858?-U4TV;#V-VK[
M'=;BO4RFY'](/?:LM*20[!:M#TMAX^PW5;DN=7M*->90_!%E8ON-D'!&-&B3
M38:N],[$8XSA3$WG"F;[/7J^5R>8R[(C-;V<QRLJGKJ,T3+.O<<XZ\=D'9.$
M=TK>2N%S#$2R]7P(5/%XN\49:2E52/[+NG35PBST<E%FR:BR:`BB,,;S-\8Q
MB+;VBG[.:W'?]R%\9'D#([[?\S=ZTZ;QEOSZ?\'KJ2;N(*72]///'_/:\>KQ
MZ>=O1Z/1AG9CXJ?_`%/A3+/SQ]^2^\>RG8&AH!-;OZW3I:VH'V%D]M=>JZJ,
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MV_:O&H<N\'-W2OL7_"7M'"3;17?V7'"?K;\^IQZOHP]$=%3:/?\`!U7]UE=Y
MO\QVH?\`RM__`.?@]C1\?@?NLKO-_F.U#_Y6_P#_`#\'L:/C\#]UE=YO\QVH
M?_*W_P#Y^#V-'Q^#PR/W5_WB?CWS%7I!4:23UFY:**:\6]ZR:;A'='??7UG_
M`*OK::[\[<>M][T\??\`O8/8T_'X/7OZ2>4+NQX^CJ3[KA<IH1$57W#XY44J
M]I+J@DN^^_&[KDE!B:_N8U\]XXX3<R**KQR5^RXX20/(:?>PZU44U9QCOC/U
MS?I$^);R*7?Y#*;^?KCZ9V;UN7:#F3@?81/EOK3=K\..=-/B-8ZR5V)L91NO
MZ57?''RS(XFR;H[M=;&)D_59[GEKIBF;15$^,<]._J:VX84YOFN^A92QHN[[
M-5=U@+V1,@)QQ%I3=M9UP5*%PU?J!&10<UG,WC[EOJN%TG3#8?'5C:1)R/(&
M7H8<Z'"Y"X8%C:TOQM?UHMJ(1$MA(MN!2'H`VXYDB&0$:-DA2(E)LEH.2&)L
M^-6B8]-GJCHRT:\<-M&W"6J''"7&O&$<C@9S=+?PGO*Q^>?6?V"^GN&JLJ/E
MG^^IHSADP&`P&`P&`P&`P&`P,?.\WUA7CV_-^\@OZ=Z2YNC/J\X*OVZOFH^Y
M*>=7G,!@5FF/X>OC'_+#V1^QC>^<^DRI^;[:G7H\J^4>+<G.;9@,!@,!@,#(
M"^Y&$CGD0@+&;E:V:IRAGUS;UNQGP$9+SRY?BQYBP)\UTZ?=HZF)0(LZ)+B6
M_*C&F+18.BJ(PRUXDQ-,G#VIJ/TSGKE?=&>$^.NC7_#)@9S2#ZV^I?Y.;L/]
MICJ_A=)YQX2T9PA@,!@,!@,!@=1GE@06K(B=L"RYE%Z_@T78J$I',)F=&1F,
M@F"7/&N[LJ;,.68Y@AQMMJGPHY<)\;J;Z)Z>LIOKKR+7PC&7JUH_=`TV[<=\
MY9TBZ3*5%`JME4>+BH#W.N06?=L(4XKB*3Z=6_<*4%6?C`4OBSJ,1Y-O5`J5
ME(.-;D`2LIFI$F%/_*H@[>SB*=JK._Z8[HX3OX89N"A_CAJ/L\%NYU0Z+^\W
M]T1&;1R_?,MWM8/+`1+,3\;*1J3[](J>7)PP.63##'Y,9';G8N857,&`([L8
MA/;20'I,&0V[6OALVM13AK?WIF_7&,S.=LT@]/.JOC-LJ56;9K*2]5O(`1,1
MFO:@!47T<ZF*T'"X\0K$K8)4G+;'@`NZY;7SXO8',_8#>+<N@Q!H"['1,4-"
MR1ZHX5UY),UQ:/>IM>;US>=,IM&[2)QE:KLAX.*%[D4QM6)*I:"Z+"&)QE+H
M0TZI5)`-;'9R!F-+@TG%LV6C'HJRF85_'I&7;&*SCP-BQ8G^6I36U)BF-'+:
M$CI)IF]YJTG:G#JUSMCW/)B_B^<>/VE8_$.MT3T[J=?1P_1WV)Z:]AVD1FKB
MTCJB.O$GNOKR_FK)6+06WWR>GK%:B,[-JIL8:U:#6;V$2]'B3&GJ2:YJF\^[
M.E47CJGAQSYICI#J;TDNNM][9Z&S^]NL/.CLL(*1OK=<,\IQO"9V%YYU+UU8
M_6&>?--,P>;QDEMPR,QB7TDD0%[*ZJ;MEQ;EHJX),S$VJM5SQOQO&,WWW[U3
M^B5">=:`22S.+7NBL(R/G/\`^4I`9['`PO:%`_<Y0GL'.1V"C:.M7KXK5%;Z
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M['Q3/53'G,]RL/CYZ+=\^M7:^\+X[&7Y4UPANP@$AK;I,`^FB4KG4XBTC22I
M&7MX8XA4:@%>ZP2KUR5;$0T2<J#R@O4*MLDJX$(+X]>O4%4Q,1:+6M;=&&/.
M\XW;;8952Z:?O0S#\ZWOA]N+L1DC+KGQE9SZH\(6MRH8#`8#`\$HSY(C2(_A
M3A+E\Q=L^%>=?7X3Y<MU$.%.=/6U]?C3U_6]7UM?6]'H];CT^G`PLZ`_<\O0
MCI!\$F,BBO[)Z\AON[KZ3;F$CGX`(51]7?WN!59Z7T2C/L7":;L:1-<S"7BG
M6GM&$L1UV]GJ=*NEJJUM&Z/RW@XXXXXXXXXXXXXXXXXXXX]'''''WN..../O
M<<<<?X.,.;^X&:'D-8(EW-0"UAQ:<>V&VBY;5=&3_::)R9\_1X@#9E:*)_J+
M3=U6.N!K95]\",Q:1`!==GGME@GAPJH=!1<60-1KU8X3U8S';PXM`:_:DF,#
MA+(R54.F&<1C;4J;5`*Q14P2;AF23XJK%ET&JT:4(.M%7>X!9LV5#[+<CE$$
M=VW*>IF6:)'R*R`HZNSF'PH"/'U&3L:0L-)HWE3`Q,*ZJVH(_8RPA4:Y0`;Q
M>Q;1)/S.D):K;&MHQ#A7QR4QEX?2(Q1B:MEQW:8S'7$=6>&]Y7CEG'%CW7Y0
MIEK$9S!>"W=2%)<1:R([O%)D.^$])NIP7VA8"HY=[LDB?([XL(WY<;^^A'PX
MAQPGPZX3T%6$4:^[I\U2*.W_`)\N@/2'L#-NL]W$K>TLZOF\6<21&)5MN?!H
M<3&)`YL&3;%]S8_5VIL`D0M=S[)#V:"ZRC;E395%3C4U3T=547BUN:L_[JB\
M57\)]@_YG?\`[1A?8U\.T_=47BJ_A/L'_,[_`/:,'L:^':?NJ+Q5?PGV#_F=
M_P#M&#V-?#M:4>/SRE=5O)@VM9UUE>SYUK3*\*0FJ4ZAV\351YGZ<J4CFXWT
MD2*9!-;B&'=77J*)[M=D$/::>JY2VY,54546OKDT9PR8#`8#`8#`Q\[S?6%>
M/;\W[R"_IWI+FZ,^KS@J_;J^:C[DIYU><P&!6:8_AZ^,?\L/9'[&-[YSZ3*G
MYOMJ=>CRKY1XMR<YMF`P&`P&`P,5+=786)VYB$T;`9*%B(J[JNK*5W(&4EC6
MNB4NKN]MQP^LN3);KA,&[IQ(Y8,K2-2A^'F46C#2X84-K4%943.(RLA+3<9=
M4S;G&><<;9X3>S76RS"D>KB?GD2!\2L%A4I+(E(I$W4\E`U4<#?.TG\;@S$>
M6>S,\SW1U<!XHT%$G,A()MQ"#!XJ\U;J&&;DKN3LEQUHA\EB\FMA*QMK`E4D
M+LGU,$>+,(5HY!721KJJ3#@5UBFM>B[&)&HU#(Z=D8>KN8P*)\M`S*029621
M*16(:M%].W#3'._?YV_K(Y817S(1AI+8$)B<6&>.RX_D$\UF^LD,S!H1OGJN
M^DBDBC24:%-H2]CD@4<`6[1K(I>W.MF^II)^/T6X'Z##9ZXOW]O<U8PR8#`8
M#`8'59O.8;6D3/3RPI2`A,*BPY8M(Y5*"K((!"#6_''*KPD4(+(-&J/'/.NF
MO*JNO*BNZ:*?&ZJFFFPM?",9>NO:WW23UUDT$'<]'X*9NRQ38[W@Q(+K>,NO
M%`41LX=/&3-:[[1F[YB,Y++ZM?BH2#PMX3)3%MSJ&$GF4C<-ANYUCHIO[TVX
M1[TSRB/%7NN*%[!=XI<!NGLA6UF>2:;L7R9J"!;::2'I5XEJ4?*\<IMWT'KN
MP8VZO?LUN.]99#2=.:%D8"7"=.&A!^Z4T8'>1,Q3A3[NDSA57/9A'&(F/&U$
M*8=U'8'D\%](+-Z<4_<-_55VX['7A?-@T_+21N%WU`R(B[YI#.ML=KRR(]$(
MJ(@E-2BT*]><"+(L)"$BA=0O0:*I]^N-#EW5QZVIOL;5YB)B(B)C*<(F<+YV
MG'.;];W$WM/6A<H!Y&KKD(BNZL+"'$?(452#YZG\8C3QGN,=QV<W2\&`90Z$
M/1W.FG(>IXU4;D1Z[H,YF$R#;\[KG&\1EVS^/S?J=-Z,^.KJQXZH?.H3U=AI
MB+"K'E:<NECJ0RHW+BY!ZS:[L`P_4B;<KJH!P#%5=L)9I\<*:^].W3YP^?.G
M#I0M54U3>J;Z+R89,"@O8CJ=(/G<EVKZFRD=3':A@(;IRKEV**%:B[,QN/(*
M;CZ][#P>.I[DY`NW:\*C83:<5;<VQ7NR^B(1S(8[P[A!8U$Z3%X[XXQ^->]1
M'QQ^>V@>\,]L*G[6A+GIW<$2D?`"-0ZWIB/083Y\S18L9'&`9\\(A7*=FQN2
M[$&Y&M'0E*2;`/AQMFB[42DC".&JNCFF(G.)B]XTY\)TG)NTF4&+$G09(BQ5
M,,63$D]%)NV^Y)F.*+D&PP@Z8ZJ<NF[(BY$E6[%TJEH@[7&$$FZBBC-SJF<W
M23=0U-)I(WF4CJ^NY!+V:C!5I*C<*C162-51>^J@Q1N<?C%R:"@Y3311ANDZ
MUV:;Z:[M^4]M>.>!>=Z1,!@,"J733]Z&8?G6]\/MQ=B,D9=<^,K.?5'A"UN5
M#`8#`8#`8#`8&;'D%A$M*NJDL.+`BLITK\/;#8P!:CH\2'\L9$W@I'DPHF8[
ML=*WJ1H?K$568C=A(9XT48ESS<@`%.%A13DU%L8F;7MO\HE?&M#3"25S`)$*
M6X<"ST)BIH:OPV79\+L"@)@^9K<-')8^Y:\*-UT]_=G!TTNAZWLE2Q%379XL
M9<D6AL0/[([G8I&S6[<X,DS?8L#%DMD)(%2U;AY`CL\:K<I'!*&FB(PMISJ_
M8):ZIM7"6FO&O`4*Z6_A/>5C\\^L_L%]/<-594?+/]]3\^W[I'^N4[:?Q#K[
M]FBG\/3T/Z.N6&6'4P&![Q7W&W_BWR(_Q[JE_J_8W#S]/_#^KR>[=AYS`8#`
M8#`8&/G>;ZPKQ[?F_>07].])<W1GU><%7[=7S4?<E/.KSF`P*S3'\/7QC_EA
M[(_8QO?.?294_-]M3KT>5?*/%N3G-LP&`P&`P&!FB=K_`*Y`+QYJ:267V,CQ
M%S;,)OT%7[B2RE2G)3/II>).XA:83X8'(#]FC>X@RI@_'"A(6D/Y?,-5M.0A
M!!3DMYMINRB^7)I=A#`SFD'UM]2_R<W8?[3'5_"Z3SCPEHSA#`8$#WGVBZX=
M90?S'V$O2JJ9$[H;N&JMBSF/1=T4U3];C9,(,*/T"AYUMMIMJFR#,W[Q;?7;
M1)#?;CGC"Q$SA$3/)EK3WF>7[!Q2P"E0],K9=&:\?(%I*6LVT*9I6EXE5,S1
M5D=)VA/[5L:3B#0!I:M=+B)?K'(U6<Y*15XX-1I\J0=1Y=\[-31;^4;L+S-\
MIBT;IBV?'55F6]]O(+V8<.XUU5?L;'=*++,-TO'_`%HWEU7A7.V^VCAC)O)3
MW,$`^N>V[5#3;3A:H^L=C%.%_;*MO0JDAKP6*:8_5A\V$_1&.[.J(SQW9D]W
MO%!VDG536-;/=WMZ,E-RQ2!2"S:EZ80R1W'VNL^S'46;J%FX0B<E$G!EXX@Y
M;-'@.4$.O=2PBO12I%P<W5'LQVGM3=-41,;-.MMJ;1$=77K*7/N:3J-)7U#3
M[L8'ZUT+#Y,;M?>.5U=-]1"4SF<1`?#8R#^-%:PBCQJ%)'`<D.E7#`F>"6S5
M[5F=C[T6FQD&X=?E$G2U8VVIG?$81CIG.7*<WM7?L;1DJ_OUX6!/KQV4^^M%
MY(30BE3<)J?W;D2M4D`;QJ)3&/[+^A1HRMY*T2K331)/DZXYTY4W.5]T6\>W
M\6<U"^K'6BN++)7+7M`4W!K8+QEE#"5BQ"MXC')@\B@Y)BW9QY8\($LR'(E!
ML+%->&7"_".[02(:*:[MQ8])L)F9BTS,QNF9LGK"&`P&`P(IE5$TC.8S,87-
M*>JZ60^PS"\BGT7D<!BIJ/S:1.630:XD$K$$!3AA(#JP\>P8[F"J#LELT8LF
M_O/LFJ&J8NPR@?@SGW6_N]9/<;IYW.DE0,RT69B:ZI2=PXQ:U:CV;Q0C\=J:
M>#^+`AQ,[1H3C04YJ^/A"X0Y`WNS95F16YB;'8\=/:1-,4S3>VN4\)B<<=]X
MF[[+E\PG;SJ?W%H#J7V/Z!')4WL9I(R,AMOJL]LBZA<WBXX>U=\S>EX!K70N
M8.U:^XT)/KAK8GR=D\=$>YOP)<ZV<!W,B$44S3-459:56C'=,WUTG"\[FLE1
M=]^F]YF_E*N.Q-;/I[KNFDM5\F+J5W;K157_`*--_4=C-HI98]3;;^X]1]%6
M^W"O'*7/'"G'.O!B:9C3KC&.V,%D@TYA4BD,MB4?E\8.2J`N!#.=1D0>%DC\
M,='QFAH$VE0=FZ6(1]<T'4T*"4BS=IN1'[</&?"S?^^81VG`JETT_>AF'YUO
M?#[<78C)&77/C*SGU1X0M;E0P&`P&`P&`P&!0FTNLEKVQ<$\D1&54YO6^Z$)
MW@$;MVB1E^<!R[(&JSEI2.I'9W&VT)X).DQNCUL.';J%U623]R\WVT222+$V
MW]4V\EZAR#EJ/8-GCA!T\;LVJ#MTU:?#VSERBAHFNX;L.%W7#)!97791)IPY
M<>[)[:H^W5]3VFQ'F8&<W2W\)[RL?GGUG]@OI[AJK*CY9_OJ?GV_=(_URG;3
M^(=??LT4_AZ>A_1URPRPZF`P/>*^XV_\6^1'^/=4O]7[&X>?I_X?U>3W;L/.
M8#`8#`8#`Q\[S?6%>/;\W[R"_IWI+FZ,^KS@J_;J^:C[DIYU><P&!6:8_AZ^
M,?\`+#V1^QC>^<^DRI^;[:G7H\J^4>+<G.;9@,!@,!@,#'?LFZ%/^_5<1OVT
M33/<+]9R[>23!2J!5B05@A:\B=*#*#+S'LC74WX!VCJ(>Q2U&4,IR:;2%ER0
MC?+FP7KA"$1<U'Z9W8[[9:X3U7F&Q&&3`SFD'UM]2_R<W8?[3'5_"Z3SCPE&
MO>[S$]9/'Y;<9I^W(M<<H./(`)N*>E:W@RDD!U;39V322O1-@R=[R]:<+-G5
MFAQ$,W%LN-G:"LE'D-U.>/8LWAJFB:HO%L[1><YC'PQ4TV\[<T[!;<L>@W1N
M^+?8.^>=&%GV!!;'WB"B''/HY*C0E*PVTF#ANIMZB3-C9MF4:JY44UV7>L4=
M=EN"^SM^JJ(TM&=XYV[8NJ+=?;3OA(Y$G!;WG\XB\X/I[+ANK]56I$NNL]?(
MN.-/4TXI;HT)\AW?`FT5X438-71&\Z9';[J\.S+F/Z\J^Z&HBG2(M\4WF.VK
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M4IJGPEL:E9Y;VQN5GE]/_P!L](R!0R]WVV5=OEE-]]^29N_X#`8#`8#`8#`8
M#`^G=LW471=*-T=W+;5;1NXW23V70T<>S]XT15VUY42U7]DE[;73;7A7V2?K
M\;>IKZ`BBW>O]%=@`GRW>E-5;<0'A-1-(39L"B\X9-N%/3SMNR1D@LCPQ7UV
M_OB;AG[!PBKQJLDKHKKKOP6)F,8F8GA@S9Z+>&7KYT$[5=ANSU1SBS7GTT,D
M@46K`M(B?RA646=.&)<T"54X*+.;%XU.L4ODY],4UW,+CJ:(=MR2*<NY&[-5
M5S53%,Q&&ML_QU9KXRSN1U)@A\O$I?V<H,!,0#Y068A3^VX)I-AY5+T>T$N(
M;H=WDW!;7T\<?"]16S_GGGCCAOSSSAFTSE$]CA.E^CK>D'Q5P-,BVTKO[M[/
M0*)\(7CA-[#[$[;W?.H0>W"GF0TPR9R:'R$'(Q7#]BU77%%63GE'71;7)'G/
MC).?5'A"UN5#`8#`8#`8#`8&;G:"'WA<]IJTO&@YA"L"8@#(BS^4M`QBNBCZ
M/:.C*?"'S!1\\@P9(B39#HF00FYJVGR)5PVDPKK'NT9I6N.-1:,?^^-_#=M:
M+^0D-M'(9$8]OJ]TW`Q@`&WT)&EY(1TV%BFC';5_(72+=R>>Z\H<\.C3AN@N
M47X4?*HI*+[::F63LBB/;0\O99F*!.SD7:$7D^%UW#BMNK."`ZS&PB8)4_<Q
MV0<VAPPUKX[)2*CB>5`"03JF+A6M8MG%?R+W*8/DC5XPRTO-M-=.R<\)X.[^
M.5&RF]U^4)&WB,&+6%IW4A7QPA6X4_'H:X0VZ3=3M@/PD/)S\H-LU4HYL(0+
M^^''VC@VD1=,_=6*[9FW%65%OAY_RJX0]";[I'^N4[:?Q#K[]FBG\/3T/Z.N
M6&6'4P&![Q7W&W_BWR(_Q[JE_J_8W#S]/_#^KR>[=AYV;5O75W)D'<N3]9.L
MSWK+&`4$ZSU)>DAD5ZP>TYH6+%K2M&\H#H&#:0"S(&S'CA+.HFSW;9\V?N7+
MDLOQPNFDBFGP:M&S$S?&9C=E$<)WN4^">67_`+3O'=_,7V4_6)PF&Z>V/P?!
M/++_`-IWCN_F+[*?K$X,-T]L?@^">67_`+3O'=_,7V4_6)P8;I[8_#C*9NWN
M(&[EC>K_`&:=]:9*(E/6.?WW'9)1,)M&%DAI*"VI5=>J`S25@65/&K]B1:V(
MX?Z*,4&"Z"XY'7951-7?3"VC9F8OA,1OSB>$;FDF&6/G>;ZPKQ[?F_>07].]
M)<W1GU><%7[=7S4?<E/.KSF`P*S3'\/7QC_EA[(_8QO?.?294_-]M3KT>5?*
M/%N3G-MC7YP?(];'C"ZI0"^*<A->3N4S"_XM4CH79C>2.@#0(;KVT)BZ)-T(
MM(8R1V*)O(*/:-^5"7+35L\><J-E5?8;)&^CHVYF)FV%^^/R]5W]UZ]\_P#-
MUZB_^A7+_P`8<.WL(^*>R#]UZ]\_\W7J+_Z%<O\`QAP>PCXI[(/W7KWS_P`W
M7J+_`.A7+_QAP>PCXI[(6;Z6?=1?<WLCV[ZS=?9G0W6(/$[LO*LJLD1:,"K5
M:R(6(G4N%1MZ1"KE;/,#="+%$CLY:^_#'K;=5+715';3;GG@E70Q$3.U.$3/
M9#WF\/.RP[!<3J)=PH),*S.RY;69G.O,8GT)BT`D,@92*/#K4>`C1<C*=>ME
MAQ0&E%XY(3Y&1N=[?@9!J`"K^_$8Y[F**<&HRTUYWMSCPEJ?ADP,YI!];?4O
M\G-V'^TQU?PND\X\)>O=]TC];Y39?=/H6_A77]2R2M^,VO7-^8=7XXK@-/\`
M4/)I5)`]/OP3-X,4BC1@O-R$W?64^W,L'RFHL'H/;*!EVDB.W13:FK&UL<KV
MTOY->'L$/VBYWB/8_N3;?8@N)U2"E.I7CE"'J<J6/NT4M$=X59MH0F3&;6'\
M[-T]&.R]S]G*CBAQMHYW=1=KH\V:IG/+*+<:L9YQ&79$S&]:^D^O,NK6.J12
M@*7H+HK79%3AR11BT9"V3=LBX6YW]J0DRH3@'6T>GB6^ZKA21'I+V89D5EN5
M'W#A3=7G"3-\9F:I[(_-NQ.@WJQ5:S]H>LI(_?<L9N$WS:1WH6TGR`THEMQS
MH8BL!49CZDKLKZO&J>[VLZ]AJBR>O&JWM.>=N=B7ZN7J\];N5.4!1O7@`5BM
M"T_6M,QDX>>RDR`K"%1Z#B"LC(Z(I/#3\?'!X]L[(JMVS5IPY63W429-6C)'
ME-HU;HIB9F<YF><W2[A#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8&<W2W\)[RL?GGUG]@OI[AJK*CY9_OJ?GV_=(_URG;3^(=??LT4_AZ>A_1UR
MPRPZF`P/>*^XV_\`%OD1_CW5+_5^QN'GZ?\`A_5Y/=NP\[.B(_6T]@?Y/#J+
M]I#NKAJ?T4_-5X4-%\,F`P,XS_UN=3_R<?83[3763#4?HJ^:GPK:.898^=YO
MK"O'M^;]Y!?T[TES=&?5YP5?MU?-1]R4\ZO.8#`K-,?P]?&/^6'LC]C&]\Y]
M)E3\WVU.O1Y5\H\6Y.<VWJO?==7U<=(_GJU]_L.[#X=N@_7/RSXP_.HP]1@,
M"_GBH^LSZ`_GA=>/]J<8PS7^BKY:O"7Z_F'A4\K'JS)8*4)&'/8>YM&SZ[;<
MMC6!1\E!VE<?#K%NZ:6LTBBXXE7K^3[C]V$G1%2;V<HT</7FQ5<4^'(+L]6I
M;\(RB-=UM]NY;`T:$1L,6D4@)L`@$",?FC9DJ[08"Q`@6U5?$B9)\YW3;,V#
M!D@L[>.W"B:#=NDHLKOJGIMMP1%K_L+2XJ#C;(*V"%&0LJ9*QYJ9(ZOF/J'(
M_H>6DPM^.=,TBHEY$V<5E)*8(E6++:(B(S(C$D^%BP91XT+:?7KLWZ*EG_K;
MZD_DYNP_VF.K^#2><>$HY\@_B`ZX^1^V^NUN77*;-"$NOCU?5O'H:6#-H[/(
MXY.C)(O')(U,A"Z['18F*317*Q]<82<"7K]BLHHOH'?!S5-<TQ,1;'?IR_W=
MJ2"``HN''1Z,A1,=`"&J;$2#!#F8@.+9(\>A)H.&#T6[)DU2X^\FW;()):<?
M>UTXPPY;`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Z5-;(@
M-;MA3R?S*-PUH<*IA!#F2%V0A$@44;N'GN;91XJEJINDR:.WSK?CGV3-@U<O
M7>Z+5NJMH+7R4;Z6_A/>5C\\^L_L%]/<-594?+/]]3\^W[I'^N4[:?Q#K[]F
MBG\/3T/Z.N6&6'4P&![Q7W&W_BWR(_Q[JE_J_8W#S]/_``_J\GNW8>=G1$?K
M:>P/\GAU%^TAW5PU/Z*?FJ\*&B^&3`8&=$@XX_;;:CV]'W^?'1V*XYY_R\\:
M]E^KO/''_ASMMZ/_`.^<-_\`YS\\?VU-%\,,?^\?''/D)\??IX_P=>_()SQ_
M_'/S%TBX]/'_`(<\\?\`CFZ,^KS@J_;J^:C[DH9U><P&!6:8_AZ^,?\`+#V1
M^QC>^<^DRI^;[:G7H\J^4>+<G.;;U7ONNKZN.D?SU:^_V'=A\.W0?KGY9\8?
MG48>HP&!?SQ4?69]`?SPNO'^U.,89K_15\M7A+]?S#PF!T.TX"PM:L+'JXJ^
M=C!ED0.7P$B2'ZH[OQ["81XC'GCYEJYT4;[.VC<BHNVU73W1Y63TX5TVTYVU
MY$88JJRSI_))A#GX`C;0EJ>-RJR)<<D(ZM%TV:Y*X(995;S]N-C[ZPGZ8X>G
M!YL!0A*:Y(D[`2:'<GI&\FXZ2$HXB:B;:<L>,3'?&//1]=E>-OJ';EG.KEG4
M*L=Y9CP`TBN\I`=DNS,%6;QIFS!,M`(L9`K?C(,*'<ZQD$[)C0PQ@R+EAJ!L
MH@[,>T?;B*ZHBT6^FF>^8NZ]^U;=-_Q?OG^FIW6_6$POM*M\?33^#]JVZ;?B
M]?/]-/NMS_\`Y^R$P>TJX?33^&?(?K?T:3NH_N<CO>88,?C:Z@+RGSW:/L,U
M&4^:2D426?6[)I`)[;/I%IS8+;LY2$;+PIR_)R6%LXEL:>P0"BI)2/)=JK?3
MA>;[,8X6P]VW\9QXVNT&_:M>FWXO7S_U?AI]UOUA,)MU<-WZ:?P?M6O3;\7K
MY_IJ=UOUA,&W5P^FG\.!&^)SJ$P,2,HNIV6+MCSH<X9`B7=/MUP'BB;$6U'+
MLXYR.NH>6Y:E7#=0T2^82I]S\5>.N&#E@,X;#6PVZN'TT_CMWN>_:M>FWXOW
MS_34[K?K"8/:5</II_#@I-XT>G$:CIJ0:P?LE(-PXQX13!1[N9W,<G3*K5'=
M5,8)1?\`9$:/Y?OE-=6[;<D2&C4E5-5B!!BST7=)#;JWQ]-/X4NZ]]7.AD[E
M3\:W7[?3H3:MGFV\&.FNVG8UI$*V,MH"5/<4&.-P?M21<S'AO'ZJG=I!K$9-
M97"SP21L=1UDDVY"*M'99JKC=%H^&G*^?Z<-UL^"]W[5KTV_%^^?Z:G=;]83
M">TJX?33^#]JVZ;_`(OWS_34[K?K"8/:5;X^FG\.!CGB=ZA`AZ[)ZIV7E:RQ
MJ1EM"<C[I]NN"#9J=/DC3&/H<1^Z@##X+%&;]",1SE=BN9V`"!NTA,'SW)(Z
M1'M*N'TT_ASW[5KTV_%^^?Z:G=;]83![2KA]-/X11=_1SH%U^JZ86W/P?8SF
M.0X.]*N!X'N+W7+2,VJT:K.DPT=$\=BD/B!=[J@I[%-5PT8M$$W),N_&!F)`
MDT+%=<S:\?33^$7]=^AG3`KKM4!YQVSL&:0EI+V*]LS/MAVCB[:WG-=V(:K.
MQ3``-#.RJB8S6$SL=S$BS8M'(I[WMN,+`$#H9_J8W$UU<+;MFF;7ROAK"T_[
M5KTV_%^^?Z:G=;]83">TJX?33^'B/_%9TZ>L7K-$7V#&JNVCELD18=T^YGOS
M!1PCNEH]9>_7V]9>]M=MN%V_OC-VUY63T]X;.$O72W&W5_\`/TTZYZ:ZO'"^
M*7I\)#"13IMV,D#H8,8#W)\UW3[B<&3:[)JDW5+EN`UYAQ'!,DHGL]?\"A(L
M;PZ75]Q',FOLFR0VZN'TT]6<.3_:M>FWXOWS_34[K?K"8/:5</II_"J7:'I%
MT?@(X+4:!+LI6UC7V`FL7K>S`_=N_4=JQ-:[1>(-;$Y:7%VSBD:DK^)2BQX>
M0$0MBWEAV4O/0P91,PCJZ1PL559^[,1:\;-.,;L*?^-0J`NV+W9$=RD;'S`7
MJ%;133="=-A+4^4#RJ#QJ<Q*5^S#&SS?9A*8Q)!I%'AV[:F&;[XD*."11<<\
M9)&)BWKJ\D[80P&`P&`P&`P&`P&`P*T]C>O;B^1;0>QF:,,46A]GUI(7+J-*
M2G0A7=Q1MO')NS#MDY'&N`DQ31'"W<7E3M4Z-#+(/42,3/M2&Z*)8FWCUQDK
M>U\3G3@>;ELD%I=GPYR>GN)1-"87OIWH#NY3(=!0T"B9/+#>Q;7<J1;`@P<$
MU=ON5UVH40+$M]TQXYFV1+MU8?IPPB]-,X=B#9W]S_>*>TY22G-G=?)Q8TV-
M:LM3$PG?:7MG+Y26U&L&HH=J2D$@O`@6?:CQ;%D-9<.G:O#5@S:LT/9MVZ2>
MAJ.DKC")M&Z*:8\E6AOA5^Y^2"899Q1(B/)'HW#I,.4F/8SLM#=-T)ZZF#*-
M!5-I-<HOA*7.GE?S9L\A^W/S()7C!=,J,9[-N>.2^TZ3?OTITST1O!_"3X$7
M9N;V&0&P@W64I9!GT3BYCL3;L2'TSM$647"304?DREY-#JYR3GYY$2;H--^&
MI*/."C`6P;I(/4=%A/2=)EC?E&/=P3;"/!1X$[%).P4.H2/&I&Q6DVCN+M^S
M?8KB4MV\0E#N&G":L;WNO4UH%0D#/EH@9V9<#'J;D>Z:.EFQ%DJN/:=)&O='
MX6MJWP>^..C=3FM*5E<M/:R?D;M)-:M[D]S*_P!9#L&X?<"-CG$3OT1P6Y%<
M%"?`WE_[QRQX(ON&OLO>W'M#,])5.<Q/.FF?)+7[5UU8_ASM_P#^X?W\_65P
MFU.ZGZ*/\4<3+QD=$*UU/7#)%^U(TM\'C<0*RP?WI[^DYL<&<2)RWA,&:J!N
MPCR523EQ,)B[:0^(,M7ZCB32IPB%';$S:W#DNW5E[N^VS1;GEWHC<]>O'L-D
M@F)'37?Z-G2:T(:.&4B[C^2X3L#(618LCJB"L3?O5_Z\MOF>>Q4P&%$6O#P(
MY:Z,Y%J4XC!%@9<#:JW4_31I%]VYX&_2SI?I9M12C:^^ZW$"O>I@G-25!QW&
M[_*?/4ED$B`%DIV(EB?8/>4<&0L.D+!22P5ULV81Z%:FK&,-VHF+24J(&U-I
MPIO$XSLT=F7K)V,;UJ\<Q;<#RQL3NDHTD!.1"4"BO>#R5M!(MU')Y*:RVWDI
M!Y?2#:,LY#.H7)8["WQS=BTFCP;MM&5B;=PT67%ZMU/T4<]V[/=JD2"^,SH?
M:+&)WE%%>UQ%R>AZ[",38EWD\@069)0LX_8%7H'E0]V!'RT&+(E`PLB4C3])
MAZQ,4P7)#M7S!'V)-JK+W>6Q1GV)+_:NNK'\.=O_`/W#^_GZRN#:G=3]%'^+
MK!?Q!])9`;"28\-[,&Y'&F)L9')`7[X]YR1L`-DJ@A61CPA5[V+6?BF)]6/@
M5#;1BN@@54""-WR:^PUGRB-N?_GZ*?\`%&<J\?7CA@\W#5]+9'V1CTA.1233
M5ML5[Z]\V8-G'XDWV?%7)N3+=B-(_'UU1;0^:$LC1)B[-A(;.RXE%X/A4F<#
M+>=\]LFU5NI^BC_'UAO=!E_CG\>*%CQ-TEV?M&%`H$VG2MGU>\\B7:)PYF.B
MSUC!Q3DR9+]HM)%"-*^G?"H]Q\*U0U*2,AI&3G.KA-!KRO.^>V5VJOAI^BGG
M\/J')#NG/B@*.":+>Y;312%&1\<7?$O)5W,$#7,A*;2+AB%%OBG9QF@6(.DH
MH>=M4QNSK1ZQ'N'K%1RU16537G?/;)>KX8^BG_%."OAYZ-KF8_(UPG9!:0Q-
MT_?14ZKWK[QJ&8T]*BG@(F\CY3?L3R^#.B(0B0#/W`Y=LJ\%/G@YQNHT=+H[
MR\SG-TVY_P#GZ*/\7;_VKKJQ_#G;_P#]P_OY^LK@VIW4_11_BCJS/"UX_KJ!
M-(O<D*OJVHR/+('F$=LSNSW7G@)D<;,WP]L::")3V"*CVQ9NP)DF*!%%OH\2
M9D'S9-;5%VOHH6*ZHRM'*FF/)FR2\1O@-&`HY)ENF=G\@)L4#LH$:4L;M<-"
MSL<>A\[G@J2Q8V;N46&?!',5K>5%]M%R#0XV9)`WCL*@RET2<FS7M.DQ][+A
M3PX<7&S7PE>"V1UI#+GB-9&*TJN.VM"59],W4\[,EA)Z'D`2)7B(23B46FD0
M@D?F&THB37><MF3<L!*N1X[;EER\?;H#VO27F+WG&,HS[';I%X<_`3%-RS0[
MU*L!B9!!86>+1Q:=]SM#[1C-X=/["8Z:#U+*TV?/0T*JRP#TG8#=WKH'\KD`
MCE+F3;-0C@>TZ3?W4\.'&$Z5)X+O"V5E<@/U'USEH>64M8@\"I*P5_=O8D4C
MT['1R)6`,)PZ2<6\*<O.6`N61T@.ED5>N&")/E=LR*?$1;Q-N2>DKMC.$\*?
MPO(S\8G5YBX3=-SO;W59+U_4YW\AG?I37CU]-D]O3IOV4YUY_N=]O1Z>/O<^
MCGC[_'&&=J=U/T4?XM",,F`P&`P/CMKZVNVOK;:^MKSKZVO/HVU]/'H];7GT
M<^C;C_#QSZ.?1S_DP*CQGI-2D790X>W5L`JWA)IX;&\G[`D)5P45)3&&6.4:
MRIXLYU=RQ`Q8U?Q.>'',@6?ECTE8$'!HF_9R:5LCA9JF=T<NN/";+=80P&`P
M."D\>9RR/&(T0=&&+,TP78+O8\;*QLXSU7T]7AT)/!';$L*?M]O55;/6+M%=
M%737;C;G7UM=@@J"]4:?KN4BYC'6,C^-##LBFBG)*6'"(\M9$M^>-)+9Y@6N
M[Y'O)X99V5.A3HMHW0;:AY!L+;L$&0B/(B"WGRZL/QZNLEA#`8#`BJY*0JCL
M#""%=W%!8Y/HH_1*::,)"+9D%!+PO'3<3=&X^[<HJ.0$B3CTD.BV9\2HT*LF
MI5\DU=):.5N-Q$S&3CZ]H2M:NDAR30P2\&N3*95NV&*%G[L!%V4ADQ";2=A#
M@CA;=A&F4HF15[)CS<<DGJ^);-$_2F.%"6#$7]=R9<!@,!@199=/1&V=@:<P
M7DZHT,MMLXCXN5G0T:D[+<O'CVPJ8Q\>]1%24?\`%XJ#<:<$6JCM)HD5!HNT
MX[*)8(.A]%04G`Z.!/8[`FI9%@_<"-U=SATI(GR3*.1<#"(N%;OR[ARY1#1J
M(1@$"$LM5/\`HF2I-^H^/%#)8B69OZ]:I:PA@,!@,!@,!@,!@,!@,!@,"HDL
MZ/=?)DB81-1A9UJ>L^46L3]]W''M53DX%.Q$R$-D)2+/-1L</HDC#WED+09/
M@1HV7/10F`,O=WW!;SW6_'8^U;I93?!:+R,.K,XU*H1'$XQ#I0#D?&A:.L>&
ML?'+.6.A)@2%+$'8B.H!W#DB-?:\LB!3=%)%\N@\:B\X\<9XN6K#J!2=0V6=
MM>%A'B$ND;F5DBCXHLQ,O%S4U>"UY$9YD)$:O,MUWC,&&$Z#%Y,M'6S-AR[;
MA4SA$P8)"9F<_75DM!A#`Z?/8,!L>*D8A(]'GPY\N)?HNACU8:6$&XZ9'R2,
MR$,1;\\*L#<:D@@3(`KS7C?AJ5&M%]TEM--DMP@W]B)4SN1-)S(E)9,++8N(
M6\8VA)SNCZ>#'<'F$[F+'8"6;,&36+#3"ME3&,R2,Q4>$B1>"%EH5N`2CVV[
M'<MYZMVGK_N;QH]U!K@(TK%N1D=B2UW232/CZ;,2*0#4BM9L(_L%1X;1E6,@
M(XVWV.!`+*(2=^;:&"D@A#H]#R+]6/RB2L"POGI?/U-][M*?6BM$9*(DS?60
M-UQTH-2\@,3+^D/*31&S99<@A62ME6RCAVA"[*F\EE,/;L78[0>\(<H/_BC%
M!!JF+^MR6H7$`L!BP:'QU-=$*!:\LQZ;IQNZ<:([+*K\\*N%/1NKM[1;?GUM
MOO\`HYXX_P`'&$=HP&!7F>]6:2LZ9.;"G$.:R":K:1YBVDKWV:A<3'(^PDXE
M2&B'G*7*S"(R,-.[!#2T*EM[*0"Y[*F;W?E-^C[J6)F/7KJW(B>>/F@7VK#A
MU\XOMAD:'QQHL?*A9HYVV9\@G#TV4=3J.2=S(B4D,1P;*)4PDBIB+2"8+'I:
M0CBLAELM(G!>?6'AV<L,K.?'=&J,'MY$UYUFY)&2Q;>&O=C,Q(%7J8%>#6%`
MGB.A5YHH6>/GXVU)V3?&##\H6<'3FSW=[[!FP9MA>?7KA&&6"XF$,!@54UZ9
M48Z$AHU)1)Z=PV+\-F40@D[D;^3PF)1MC!K"KD;$P<9?\[#-`P^)VA+1:3M\
MB_DKE!0$W(R!ZSB46;!RWGM_[Y.HRGKUUSAPA")VS.I`5@=D3`"DM7MJSQ,I
M$["G#4$Q$#^3B!-NF5E9%ZH%%R)\@8+/6+J4C&!YPWX>HH[<B\Z=L>L.[#!)
M<MZM5E-6+=N?<S5T2;Q&'PCB4?.!;>5+@H='[3B*'+PVXW7</"QR*779P&1G
MG'"AI^C*%BC=^RD(X09'B\QZY?B$Q1F$1V(/98_`,]F2LU.CI$<3X6WW;;$1
M4-BD"8^Y-]N?9L6J$:A8!IPU;\:H^U;*N?5]JX5YY([9@,!@,!@,!@,!@5C[
MB+RAMU]E2L1VL+4E\SU,F2VJK2;J6!K#5[@@:%A;1OBMM=I]HXX@2DEY=K1'
MC@\W'>^+C]TUD]5-2QGVY\IMFSJE]^=I*='3C7K_``:]9]73B83F24VE==-]
MA[!EA8#"*VHIR4@KT]*^5[N$#9;94EM!*O=;)C+XO)^`LL?!IY$ZUA<:^835
MHG.8TO:8C?PME:^,=<NWS'MKW-9.Y-M&JY&DAE66L;IR7MHW3UCV!+)Y)8:K
M(I&O(($+CA12,:`)Q7DDIIT'$3"9P%FVEBUAQ7:RFIH$V'K$M&_/&,HCE/&]
MXPYV2];=:=DK'[<2?Y"/2>$U_&JYZO%0<]<7+=<2BP`XWM>ZRUJLX[2D8$J4
MW=YV0PT-%0$I9V&;9?+[$E%G#ALY:N6B*PPMQQTC=%L<XU0-)NVG>H?!5SXF
MM%W!M!G6QF5".>KM\+EX=+S\:O,A8='0P6V<+L;9?P>00NJAXZ?*G(-`)JWE
M!(<QL:/F)W7JHD6IW[]8X9Y6O%]\\$TG)CV5VZV3<PSXLPE:P3O&`:BA*4`D
MP&0M:9X[F0MXU!^XCM5]I7`OH&?\_'I*"=O(ZO"W)D>1)[\AS:^@PO\`T]^S
M^42'NS'>ZMZELVT9T$BCA*&U[8!9%MMUVL@&S$E@W22+]DF,N+:\6,1?DHT$
MN<A(:.WCK;D>[)KB%X\K).)XV<;:%M3>WG'Q6W;L7\,=A.X(^320T,CM@&`#
MG4)`X),].N=M,(J<'<R24E7M@R"JW+AW*X"33Y9J5\H<^`RYR8T8Q>3#H,I'
M9P'<#"6C#'??&.'5.OA?!PIOL%Y"I52Z\R7AA"OBD@C,':.8U&.NUGNII!B;
MOJ)2%^3F4LDR!Y^;*^XV\>M2DV<8VBNC]J0'HQGWI[/H\];OBVIOVYSA.,Q&
M4886G/CD\>0]EN[4KL`H)80N?Q^MP]FH;M"#/K=<("0$(^W/7/"-86;W:KDV
MVHJ1;MJG-:3&,2EZ['(OMIV1YB,:-M@,>)$4X<>,89=F%\)Y<7?&78GNZLO&
MHV&KUP/-%I#74/.!S_7ZXR[*JX@9LN@H=]*S^R"<J9A[.<%(9.;$EYR,-RS8
MK%N!"O,C(LMZELMY(!:G''OC'">&&Z^NFC16AY%84GK5B_M,=H.G#"4V3%2F
MR4>)11`VQ@]ERZ%QR8-8\5>$78QG.8R`#S-FEH0?,%&QY)P*=N!:S-;<D\.'
M@F'"&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!
M%<[N:!UQ+:YA4K(.F1JT'IQI'.4F#AP/;IQYJQW?$#I'37W4,.6+&HS%!KAU
MOQL3ETMC`!DDL\+(ZZBW<CZ8W#U4D"P1.;3VJ37,>53G0-8L5$$6H=<9#'=@
MM3S=[MLLS:*\P1L3E@[;=?3<D`&%R;%-TV#D%&@M.Y]2G<7KB@0)L7MGQ\8D
M(=$&#TD7<:B6'Q$9%*\F[I@QX);-7Q=PC&;.C)!YL(8OFXA3X@..+C";35FL
M6T[O7J%E&[A!V@BZ:K(N6SE%-PW<-U-%D'""VFJB*R*R>VR:J*J>VJB:B>VV
MF^FVNVNW.O/'.$?=@,!@,!@,!@,!@,!@<,`CD>B@[@/%P(:-B>'I,EP+`"V(
M<=P0-$G1DR_X9#D&[;AZ6+OWQ4FZ]E[=^2>.GSK=5TX65W#F<!@,#P28P::'
M/PY@>Q+"2C-R/)BR;1!^.(CWB.[=XQ?LG2:K9XS=-U%$'+9PDHBNCONDKIMI
MMMKR'G8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8$,3_KW3]HR5C,9["ALEE05M&4(Q("&[E0M"UHE+-)R&*0=[PMP
MO#3GS0W%DR9J.;C21SD#'6IIR_9`!3=J6)F,O7/>AUST%ZN.%8TIK`B3/6'A
M);'XRBPF\V9I!1<V;V8R/MA_*)_55MHX&6_/1"*:*NB"(H@$8:I<H0J#ZQP7
MGU;A^')Q[H]UOB[D,Z#PPDWW`:RK@2AM,9<HQ8J3:$QRNY2JT&[&?A[/4I$(
MC&PZ;)FU;C!#<0S^!,1?J<^D;4[]W=-_%:84,9!!8T,-2Y0'"![,8P0Y446Y
M19,&Z;5JERJMONLKRF@DGIRHKONIOSQZV^^VW///)'(8#`8#`8#`8$.0J(BR
MT)B)HJ8FRKXI%X^2(.MK,L-MHL]?BFCETM[)"4HMD.%7"V^W"2"22*?K<:))
MZ:<:Z\!5'NOW)Z8>/F"QRP.T%M3B&C)D<6CL.$!YG<DNE$H*,VZ;PGJ)C\=D
M#][LQ#LU4'!<L\X:"1_+H>T</=7Y06T>&J::JL*8OV>:<J%L#K[V<J*#WM1U
ME22>598HK<O%).PLVU66CUNW>NA;]LZ&E9*Q+"2@DLP?B#`@JQ9DA15B\8/F
MJ#ENHGJ28F)M.$PD`\.KJ+D(P+D$FF0IY,RA$)&M75F6EJ@3+"HR=F1!AJ]U
MD^S)JX;Q:,2$YZKUPVX58!B"B/*G+937@B*W=P=61P4/("5XZBQ)I*(KIN"M
MUV"+5$-IY'7$KA[J7,2$N;/X.U/@&RK]@XF34$CMQ[-LINF[62;[EM.Z?^.;
ME$[Z]0L28,RJU28-F%9RL@LB_MRRT2A-I!XZE+)4M&`G,JY,S#4-'7"!5Q\J
M,3/*C99+W?A91373DEIGUO=]""ZTDSLZPC<W+R!]%R6X63,@EU3@J[CIA+G?
MA02=;,)LX6$$D^4U.-V!#1NZTYTW]9+CU>?0'8OH\`?PA.?YS[*_WMP'T>`/
MX0G/\Y]E?[VX#Z/`'\(3G^<^RO\`>W`?1X`_A"<_SGV5_O;@/H\`?PA.?YS[
M*_WMP'T>`/X0G/\`.?97^]N`^CP!_"$Y_G/LK_>W`ZM.8:,$0F8%AQ:=-B`N
M+2`BQ<<698RO*#QD)=N6JW":TJ414]DNEIOZBJ:B6_J^JIIMKSSKR$Q8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`A+2LZ[N*@X[6UL0:)657LH@<*;R2$3J/BY3%#R#%D%+,D2X`TU>#"
M*;0HP8D6VCILKJB]9MG*?&JR*>^HB9C&)M.^,&$WDX\./BEN<#7U;I,8/T?M
M(6L7F4=D'7.CPR9&41910>&.M)S$H3%D=9$!0>\#?@S]^_&N@1?97X<[W;$B
M[!^=:.DKB\WVH_\`J?"\K0=)_%1XF`77N)P2"=?*'[*)5RY)Q&56Y<U+PF46
MG(IIRMK)3GSH0E,+9&&KQ+B1M-Q(91HBU"QI8(-'\*,FR"RA*JZ[S-YB^D3-
MK<+2T:[-5_34WILC%[EF;6K*^0>@_3,TI5'X`K'>=7&HOD<-E$@15&!$I4$>
ME($3U2T2>/HS)C0@:X9.WR+M`Q%[X9^O#-`T5IKJ*]MLI.(O=<;/2(9+6EC<
M0X;.*?+M(B0M%1CLVU;J,X^M/&,:L0O)P102)*2ER,*$2$6;QW30<WC0UJ7&
MUK>.-N[#EYOBPZA]?HL#EL)$75+@`R35T5I"Q!NTMJEV\/1L/6K4=L++*GH*
M2>Q\[$HH]VF2CB-;1QY_RSH8DR10"@`:#"7G.VMX[?\`25Z0KNAZ,F$L`PRS
MA925V<,2L!M%3LCKEQ)FT"TD<TD;!['^`@0+-#L!9&)I)>1QF4$96BWY6<*)
M&??W9IV2$WG3AKGX::66B&$QIL:/,AB#$N'+L6A,45&.V[\:3&OVZ;IB0'OF
MJBK5ZQ>M54G+1VV55;N6ZJ:R*FZ>^NW)'G8#`8#`8#`Z39?[W$__`-"95^@G
M^!W;`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8'0Z\1U<5C!F^^ZR>J\#C*.V[=95NOIJK'V6G.Z+A';19!
M;7C;GE-9+?15+?C7=/;7;7CG@*#-.J\_ZP6VZNFB96O9``E5+F"333N?W&[&
MRU:-[HRUC(F!6)R:>A[U^"BW&FB[4R.:J1MLY=:L72_+Y1%/V)J]\)STM3$=
M6%G;*-Z:'0UL6%V)M^9V`#L^<V^XLE.MZ?[1=A%NO3!@E7\*@C!@:K)T[KVO
MIF1<ZQ5P5+NSE8\<.5W;%-;=ZH*;.N!,X6PMOM%\[YYQVK.W+5\AL)Q5<@A\
MG!QB7U#8ZUBQU:4Q=Y,(P3<OZXL*KR0PR&'2:($]>-@%CEWPLF-/M'(TTQ'+
M+($AO)`4^)'C_P!5(-="Y.0E\BL=E=@QO-I0<!R%XV(5N;)UV"?A);UMGBB4
M'A.ML,WD58'Y/UP!ZR5MI*2"I8"]$,-G216+)GC!=K"UM^N.O#B[\[ZC2DS8
M=FVS(;(@I2:6I49^G9`+UIQ5.O$@9`'&VHHTUC#RQR1OYEX.!7*DT*K2]12P
M86W@,%-:H(51!3(XE^>=\\?#LPPQWO"C?3N4!9-`S9"RH>>80X7&2+T4\JXC
M[(_8$5ZZS[K6T<./;V2]21K(A$IVL?)5\JD\*[R1DY40FZ;(RX;M2WSX_F^[
MO68H6N"=.TE4M2%Y`-E3ZKZ[B%>[203'G$48&FT-!,HZ/()1UU()2L)4<#QS
M7=TUY/DD^'7*^Z"J2&Z;=$S.,S.]+6`P&`P&`P.DV7^]Q/\`_0F5?H)_@=VP
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&!"'$<ELNH*.QV"V(4J>5DH'"DP]@A8_%Y43C:J#(*Z<KM0$T&&
M8P1V>LD'(M30J,=)HHOE'+?5-X@W63'>RF[0=8.\<KD4-K693^X.[O6(P'+G
MK:@W$8Z:5*R/2X.5#*UQ%BOH(T])R<;'O$B<U.IMRRHUT8!PH>HV(LUCB#6Q
M;7&%TFUJ:M)]["-=_+M2CUOH+R.'*Z43MWN;=M+F@$E/1N,1@[5W3*R3)&NA
M;A/B!'S<J"1N><OY&O'568N5.2TE?%2DH$&3RG"3(NQ3UBS,;H_]9Z[M<L,E
MT>UE.6C>E7C*JKZQ65<<FCK1Q-;`=#BY`R/%``I<J`=1H7&I'"WG)[6RVD',
M\\Z244-3%#"K5Z@49.MPSXD3:;^NOJ03.:Z[[2"-RQ,9.8,-)$D8GO%1PF62
M4:O&W\G`;G+/Y7.#14?=E4(-:#00%J_=RZY:\U0[D7,F!2@RFQCA,ON\?67=
MGW.GG:&[K28BLZDLZ8&$&,R9&QG#2PC<?T<I%J9O:$FVA0`P'*P@S#0DPFM6
M$FD=UBL8W-!HZ>3D;&3R,<VE<R%Z=WJ\=>43KRS6FHRN[TALC>DK*GV\G$%Q
MLW1=@^2J;T2$=H6F=>5AI%A^@`5H):,ZG?#Q,BU36YY=F6:&J_#[ADV>\$PW
M;O#'O6FPA@,!@,!@,#I-E_O<3_\`T)E7Z"?X'=L!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0AQQ97-!1W
MBG]H-I8_R'"OEC:R4SZL(X7]R"^_?'DXNHB>V1^$^_\`#3X>IKOP1]SY6YY;
M<+<<B+:Y<'K+>?FUO,_674Y@TCC2IQM.2V1LPEPV7U#XM9"SXTW=.FS6.1@Y
MO)':IJ.0F9%W3=@\DT1]+EX2191`T0$CI`F/E1VZ..CFK&]\XO:V&,]G%I-T
M2=^:\EU.I5Y?Z?4@?9JL1:<E$K?8V[]+RPSC=3B/N[40A+QO&&4^=!/<59$S
M8)ZNT7>W_+Z322;&&38S5[/:FVU;A:W4TB[")V`H%K#4(A.746^D-#Z;F]2O
M%A\W5@'-?3S5M\M.F;T?+4FNEJ<UTJ6XA;YO+=H\F1U1V4%\F4%3$?\`.=XZ
MLKYX*:;-.YL:G\ME#=I;KZL7A2O](N&7D(:7S!R#!RKJX5D?S3&METAT1,(P
M07?0I-2`O3S"Q#)Z6)2=4&3$5K\REPZ\=_&WEZO:72)/L:8L>TI`-;VW'*6)
MUC*W59-DQT7YGP.YODV*I++<QHFR-.-X1RVU<<5H*/L"&J-I)6PXE8]Y&2%+
M\M"86C??CEZSMI:V-W"Q=?LP[G];%3^ENBQ6T&BRDO<-D!2@5A#T^OL^3F::
M\:(:$1KR[D^R7$&?,>%X^2(NHQJP;">7,5WF;!4LVQMU=N'5;OST2Z&,]D$^
ME<6)``&Y?L\WH,0@2&V._0BY1:W!\!X:&'K_`):1N0!71E:;-5'35EN.9QDS
MNOIML2'"5]5^"87X7[GP[-H]K)%549CM`L8M&K>-FN21XWO.';.'Q%G%0AJ3
M"VNLJ>5V5)&6,HG8R$1,T)VK]FL<A)J9M-7\;7T;G&PBU\<O'U''!#=EVUWK
M;1><$('2>O!%DX!\5[HNF%4?FMIE'93/&R4E$HD9(LQ:5N[0@](2G5FBW^9I
M>8/3!(]"H8/5D0@MHW\\/6>?#BZC-YIWU*OYA\.BQ84.#F)HVCC>*1YILPDR
M1BM+@YA,??<DG8B4"$0TK#UB@=F@"0%Q2A65MC0R1A$^#L.@0PW_`.L8\K_[
MPE;VG"O81W-YRE;+`2C"UUI4K"-6(1`8Y#MPMO61&HVT=D$Y$86.[R:K!M?3
M%=TX9C]FS\H\UU30X<<C!Q)MIZPCSNLGA#`Z39?[W$__`-"95^@G^!W;`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8&:$1NJS6<4C#-M)?9MVD>"MFZ?P:/[^S10&MDDM/74%;;[>KIKKKZ
MV^VV^WH].VW////.%G.><N?WO&T=]>==Y-KOKSZ.>==P4;VUYYUYXVXYYXY$
M<\?>VXXYX_ZN>..>/O\`&$?+Z<[3_&C^I([_`&1@/ISM/\:/ZDCO]D8#Z<[3
M_&C^I([_`&1@/ISM/\:/ZDCO]D8#Z<[3_&C^I([_`&1@/ISM/\:/ZDCO]D8#
MZ<[3_&C^I([_`&1@/ISM/\:/ZDCO]D8#Z<[3_&C^I([_`&1@/ISM/\:/ZDCO
M]D8#Z<[3_&C^I([_`&1@/ISM/\:/ZDCO]D8'6)M=MGN89+FZTF]=%Q&#Z*NG
MP6/:^NDJ*=Z*:^MH)UVU];7;GCUM=N-N/3Z=>>.?1S@::X#`8#`8#`8#`8#`
F8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g887761g89f77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g89f77.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X9V\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+VUM+R(*("`@('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B`@("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*("`@('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(*("`@('AM;&YS.GAM<%109STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W0O<&<O(@H@("`@>&UL;G,Z<W1$
M:6T](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I
M;VYS(R(*("`@('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O<U1Y<&4O1F]N=",B"B`@("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O9R\B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G13
M96YS93TB:'1T<#HO+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O
M(@H@("!P9&8Z4')O9'5C97(](D%D;V)E(%!$1B!L:6)R87)Y(#$P+C`Q(@H@
M("!X;7`Z0W)E871O<E1O;VP](D%D;V)E($EL;'5S=')A=&]R($-3-B`H5VEN
M9&]W<RDB"B`@('AM<#I-;V1I9GE$871E/2(R,#$U+3`S+3,P5#$P.C$W.C4T
M*S`U.C,P(@H@("!X;7`Z0W)E871E1&%T93TB,C`Q-2TP,RTS,%0Q,#HQ-SHU
M-"LP-3HS,"(*("`@>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP,RTS,%0Q,#HQ
M-SHU-"LP-3HS,"(*("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R
M:7!T(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D(X.30R1C<T.3=$
M-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-33I$;V-U;65N=$E$/2)X
M;7`N9&ED.D(X.30R1C<T.3=$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z-3`S,#0P1C,W0S@U
M13,Q,3@S-S!%13-$1CDP03(X,#DB"B`@('AM<$U-.E)E;F1I=&EO;D-L87-S
M/2)D969A=6QT(@H@("!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(Q(@H@("!X;7!4
M4&<Z3E!A9V5S/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3TB1F%L<V4B"B`@('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E
M(CX*("`@/'AM<#I4:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@("`@/')D
M9CIL:0H@("`@("!X;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM<$=);6<Z
M:&5I9VAT/2(R-38B"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'(@H@("`@
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M<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%
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M1E50<%`U=F59.5IJ=$@P+U-R3D)-)B-X03MB5T-95#-$-U0S9#%D5V=:1$5K
M:6U.5W-I,U4W1V=*-C1Q,W!N-74V;&18.$U-<U9N6G!E3D9382MN.4<R:4EH
M4G!)56Q#8VUL;61Z)B-X03LV46)S1#15>'!#6F5D+TU0;6)1=DU:;'0Y4S5A
M6$AP,"MQ4U=$47<X94YR3F%W=$=:95!-2W=U2&1M-UEP45`O04-T=E=R=2]K
M:3!M)B-X03MX<V)M,%,U:71O-VPW:51J2CEA,5<T,'DS:U%X<$EP5#EW<VI(
M=TIP:7%N3"MD1V]2,CAS<F%80C9K3FYC>DYB:61J33!T=&(S17AN)B-X03M2
M3TER86AR5#`R9G%'640U<7-H.#(V:C5S="]+=&IQ:TXY1G!T.&)I,&EU;W)E
M3F)I2FQV8GE',TA&<#%$07AP3%@W3S4Y<U99-35E)B-X03LO3G)89%1U4#!2
M8C(Q<F,V:$AQ14=N<F934VQ9<$5M9W4U4%9D26Q,2DE$64=Q1E8K,3!81E5$
M8V9N,7%%9')C5'!P=&]W0G1M:EDS)B-X03M(1DQF-GE,;'91=D=92TDU,2MQ
M:&5(:50T54Q3<71V*V)N;4E8335E3S!N04XV,$9I2D%*159,;7I3,T4U4E<T
M+W4W<S!:9G1D9#AA)B-X03M63DY,+TYU*W9.8C`S4S5R3S!T-5HW;C9L9%)T
M3S-Q>4]T>&,R-WI7:UI51C1K83`K26YO5W`R,U9E;31&9&ER<U9D:7)S5F1I
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M3$U%5S`W1G9G<GDS)B-X03M#,316*TYT-E8S>%9-<U9D:7)S5F1I<G-69&ER
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M-'1P<V5N37AK861M158W951)<D8T-&=Y:3-U63`K)B-X03MY3VA&04U#<&)D
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M2SAH)B-X03M5.7-65TYQ;6U,8V96,G4T4F-65F9236E"-G14:4].83<X,7`X
M>&EQ-$Y96#EO4T1&9#)C;%%45EI),C1M:$AD5%%J1EAL6"]!0W)F)B-X03MZ
M9VUL,FQV;S$U85(R,#EL8G!C5%$S37-3*W!"3F-30U)"2$523#9S9'EG-45I
M9U1V=&A69E`X06QT-6ES-7=T:G))<W)I-FQE1S)-)B-X03ML.61-6&EB4U-S
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M3S%S)B-X03LT6E5N84-V<65T03=+;G`W;"LU-G%V65).1VI247EY<4HU1E!"
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M4GA*)B-X03M(96-H83=.2#9456I)8C=86'A643,O2W)0>D9L=G`U-715:%=-
M,WAV;UEX9%A$:7)7.35$36EN,#0U26AC0V%*1TED;59A:TU3;T=+)B-X03MS
M>3AN-D)R1G0U:S%M-W98;%1426E)9$IS;EHR4D1D2VQZ96-3,5!545154TYU
M26]!44YS5EEN<E`U565C6G)'83-S3#)"1&%/3%!2)B-X03M'13AS1'AA87!M
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M,%=X)B-X03M':&%);')C,U)M:G1J2U)/.61O,FQ:-#`K27-F9U)G9S,W649D
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M,4M+2U-)9FEL2$M-9&5R:F1F2$966DQI,VML:VA35D=L:'`V,&%S0WEC:%9E
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M3T]3=S%I>%E2871O=#!/1GIA>3`V3W!P>5)U<4]U>D0S<4%Q>5!&5TPK8C=I
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M0V\Y)B-X03M-9U5)2G)8<E@T=D1&5DQY,V\K;&%X-6HQ3TA78DLS,5`Y1S)L
M<$1B1S9I4UE)2&YU:3554T)G3UA"83`X0FE5<VLX;#)T=&%A9F4R)B-X03MT
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M;C`T>G5(1WI55V]O1#0T<7$K5SE:,$QY+V1A:G%7<#-O=')E-FET644U<7A0
M3THU)B-X03MZ5#1!,658<D-M07%N+VMB5TQ#+UA627)D<$))=#5.8SA*65I9
M4UE,;59Z1$EO;%9/4W8V8E5).$1G4V\K9&9*9C5D*UI.4S!Y2'I2)B-X03MP
M:V0W9GEL,#`Y>4IL8VE)1U9K85-%<CA!1E1X9'5/2W1F;41P5FA9+VQN<DM7
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M3EIC6$]U-FE"45!,4VEW>&5%34DK1TUF5%%6<&EQ)B-X03M3;#`X>"]M+TI,
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M.#1L=C$O3#-Z2U5"9$I,1U=.4E=G+V5$:"]W06)91E13,C!84C1R1TPV>G`Y
M=&-Z6$I.,4DU5EI&)B-X03M6<$XQ4TIZ6#19:T-O:%=M=T9+6598:7AT27)Y
M.6IM:W4U4U=I:VEI93AU:6=H:VI!;U9-<$<X:V-L86HX35982DMD1'5957-,
M17DR)B-X03M7<7131S!H36-F<#-32U=K<'I+3%-31TUU9"]T265P9D95-'-.
M67,W>'I!3U5&-&=*:W-P>'=M54%G1G5**S!L5%1M:$MN<U1G5D=K)B-X03MG
M0W`R07A63'IR*VID23=U3V1U=G`R-3ED-E5R6&A&>F(X3592,%5S8W-A4WA-
M2&IK54UJ<6%G<5)514@S>%9D:7)S5F1I<G-69&ER)B-X03MS5F1I<G-666PU
M;%IB=EAR4WAM2D5#<5=)<E%->$))*RMG1T9#5C9R<'1R87DR>&=(<'9),T9O
M>5-15C=T=G8W2$953D)P1C-F=RMS)B-X03MH4DED,6E2>69S:F)A9U`T-%9E
M938Q;UAM:E-*3&UW.&YA86149S%/0S945DY(64%R84M3<5-83F]42D=59&I.
M=$=O66-H>4%W2F5P)B-X03M26#-M:GI,4%E1+V]R.494-DIF5S!U;S-6,5!(
M>45G:%8U-#1)-V-Z8W959W53;TQ/=7IB-S%81E=7-C-E,TYJ;S$O9E=S0G5R
M;3%T)B-X03MP<#1,661:6&IJ3$Q'2V9Z155W2RM9=GEJ+U!F.'ID8R]-<E1T
M33%+-EA59%`Q5UIO-7)*65EK14MC1V)N17E+<D%2:&%M<$Y11%AF)B-X03MF
M1DI$-DHX=E<P8E,K6F)",7)%3E-K5CEQ8VAC,G-%-V1T+S<K;4M'4&515#5M
M9GDY<$5M<7IQ3D]30DE5=&E!2FU#>#`Y4FU!879")B-X03MX>%9F:'%.>G50
M:4M%,C%+1U,X=DQF5#=/,F$Q;31Y,U9V<D5P6&UG=#-I1&5I<6QM+V5C=W`U
M54)&87%W,DML,$YV<4]Q3'`P5W1Y)B-X03MQ,&IK1%5,3S):;',S26EC=7%Q
M94UJ;WIQ4&AK3$%I=3)+<DHR:3`V83)J3W-V<'1T1$)*6C)L=DLP2$9I=C=X
M4U!66&LP:V-C6D$S)B-X03LK>E5K2&,T<7<O>7`U83`W>EAR;#$U<V%":S!+
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M,2MI=%-U9$ME-FPQ960W=E=,94YN64Q(13!59D5T1W-$;W`Y2FQ-:"M-<3EF
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M>%8R2W5X5C)+=7A6,DMU>%8R2W-2.#57-EA/;U=S)B-X03M%65`Q<&M.1"MZ
M44=U+V@P3RM%2VMJ,DTY;$Y'6B\S:VMT4D<V;7$W1#=/*SE4,#9D355,<F)5
M<GEY:3E"5$4P9E=%>59R4G1X.6MI)B-X03ML83$K3$95=SAL,FLV*UID46UU
M4#<P,DYT2W`R3E)C>C-!8F-';B](<T1I57!L;S`Y-T1P,G-A:%HR9C$R-6XQ
M3S4T5WEU:U)C47EI)B-X03LP63@S3E!H5T%N9G)4-5E&6DQI<5@R6&PS>2]9
M,S`K;U=7;5=L<F8S4"LY3C-$0DA(3DI8*V525D1..4IX5FAK6&YL3DYU-S=8
M2G1$)B-X03LQ4392<D,R571J8U)247EI4G!+=TMX.4]6=E1$<C926#%#<#,V
M03164F9L<6)5<E11:D9Q;6M85G9$.6-M:W-G1$)Y4S-U-VQM:%-5)B-X03M'
M555D9E5O.4)29D5J9D9#*UA1-$ET4S%(5V)A4V)38BM70E-T1SE9;59%;S5M
M:4AQ>&M-:V-A.%5*-E8K,5$T<6A,3SAI.#,V86MB)B-X03MA:D)B5%=C-E-Z
M4S99.&=K5S149C`S9%-H5DM%<7I2>55K2%)G=E93>%A63E-U9D]N;4(O2FPQ
M<61U,FI737-X=7(U;U%K.2].8G%!)B-X03LY<$-&9$MX<C9N-SAP43A+3'HK
M33!66G9C5W5S:4I,<W)B869A861#,S%E2S%K34US=$YT,4954E=#<G=J3'5O
M4#)G,C-&47`V<DHU)B-X03MW1VXS,2]B3D9)<7=I4%198G5&,&Q,13%%<'0T
M;7$W=E5,=V)G4V5Y8FAL3$<O2E9P<3)U-G!F961R5S185')J5TQS5U5-1$EK
M<U@V)B-X03M,<T9A2D=:83%:<'`Q62]$2CEK:6AP:7),3&DQ,70Y4BMT1%5H
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M<4961%`O>5IT.5=V)B-X03LO=T%Q=V9.:T5S1'AU.'1N96A04W9F5&@T;3-L
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M:30U0FIE=%-G1D]/0DQW4"]N25`X,'9Z2S!,.'AP=$PP,U5*.4LP=3!I9VMS
M0D-!)B-X03MQ>F@T=WIY35-$>G!)5U-H,BM(<&EK0C=L6F$Y<C`O-5-X-GIQ
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M<'!T)B-X03LY1D)B;39H5&10-W-+2D=6:'ED4C1F6C0Q>%=M6F%S13`V4TQ8
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M:6I52W9O6#AO63!")B-X03M!;VML<7%J;U`Y,EEO4R]Z13)S83%P53)L>2M7
M8FA:8F]#15A4>3),=WA+-TM(9FPV-&PR5W`K1DLW9DQ#<GI(.'A.3R]*:7@X
M-G`V)B-X03LS;4).3#AW5U9V4#E7,#!T9'1!3#8U*TM+4S5U1D5Y>$E/6'A*
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M4G`W-D@V>5I&:59Q:49#0V1L3D\S45E&571(,$I0365R87)P;7(S3C,Y5'-R
M4S)J)B-X03LK<5$S16M58DY.3&-I575%234Q15-J9G=X4VYF:W923&-Z,W1Z
M8S-&-64S1VTV;&11,E0S9#-C5&E.04]!;VIU62M14U)L-6-E5D0Q)B-X03MX
M5FU/0EAX9#5V.$%Z4B]/3T0X>F(K1U!5-RLR,4,S,4(T3%12;T,U9V]S:%='
M3F):9F=L1$Q3:$MN;C$S>%,K=G15,'@Y83AT6&5L)B-X03LS:$YQ*W`R56QR
M8W1%86U->GA&2$M(+THU8EEO9DMO+TQ:=GEC.#!A6#5O.#-A;$9C5VQV8T\K
M;#)E;6,S=7)Q4TYA:FM*4D-K56$X)B-X03ML.5$X>C1!1W1C579B1B].3'DO
M-3@O2S-Z3G%E:#9E8C(T<TQ/8C9X;S$O16HO=D)%6%1M9TQR26YW;&QO86YJ
M5%DT;V5%+S@T-&5D)B-X03MV359L*UET<'!&<D9&3'`R<W-Y-FI$1F)X27=#
M4G5Y4V@T,$1+23(S<%AJ4W9Z0VMO<C@U-V(X,S(O3F4X83)45EA4,6PO4517
M46Y-)B-X03M1:&]05#E(,'9H1&9Z.2M6831Q2#`Q-5,X,6%89C)6:G!T>')&
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M83%,,#)'2VQH4#5))B-X03ME9E!Z4W8X03@P9$]S-716,415<F%74C`Q4S!V
M6C5:655H-&MU>%=2:7-B25(X1DMF1E)E.4-Q6'-N;EAZ>6QH-39U.4]T3$=+
M-70T)B-X03M"6DYR9UHR4S5L84TO5TEK:35%>&A&5FMR5E!J<58U0VQC2T=A
M955V4%9P<F5G=G%L,T@Y46MJ=7!B5C=5;C%(1$$X-%552GDU>4Y#)B-X03LV
M3593=3E12S1&4S5B2%AB1WIT-VDR;C5A9EHS13AL>&]A=TI*4#A!56YL9&M7
M2C%K-65Q9UEB0G%C4E-N269%54I:<6YK-WEP*UE+)B-X03MZ-FPU:7-V6#`R
M16UZ,%%*2E(Q5D0K*VQ6-&Y+;FY*.%!8.6Y&3&9L>GE:66558B]!13)X.'1W
M,TYZ;V1M,#$Y9#)P34)E2V$T:F5")B-X03M:4U=-56MP64MW+V%+<71",4%X
M5FUT,35L,#9/2E)B:S-..4LS<#(K;F=&2C-K24I!84YW<E)J:4]26F=!1C-W
M2S$U93!(.4=W2SEW)B-X03LO<C-V16]'1E-K35)9=71V041U<V%B2T\W549E
M9T%65&9&6%EQ-T9867$W1EA9<31G145%5D(R27A69S)O,C)R84Q.26QU;G%7
M:W)&)B-X03LT;30X9W!06'`P=V]11FQ:,SDP.&@U05-L,6MM36A)2&-J:T%$
M.7(U9'-65E!7,5A40SEQ<%@P5G%Y4T]+<4%E-%`X041X>%95.&I8)B-X03ML
M<$0U:C%N,3=Q35!.6C),175W57-W;79/5D]60V%65W9Z>$M5-#AI6#%L9$QR
M9C%A-&EN<'%T,'@Y3C%F67-!1#A*4&14:592=FY0)B-X03MZ:&\S:R]Y-V1A
M+W$W3TQ/,31G<$5V2U(S9&=Q26EK9T5K;G5A94]"5T-E4R]W02]V23-M=4Q6
M<C1733EN939$6E0V:$MK>5)V2S%P)B-X03M#3U5H:&17,TDW<G0Q1TLP>G-A
M>C5H24(O=T%0>D0R3GIB9C@Q-'$X."]/9GE39E!/:C)),5=X=71)9E0U=TED
M4VIE,G5&:E<V9$EN)B-X03LY4T@Q67DV,4-K.%=Q2V0K;49B5E!Y>CAO-DHK
M6&5M:E,O3%8W8BM:9&(Q<3956&QW,#1T-&QJ:&AK:U5K47)D;$925EE+2T5S
M>F1A)B-X03MD071S=3`V0UA32C5R;3(X;'<R.7IC9C<P5&%5.6M(:U!8-&UL
M3FU7*TQX>%97,4166CEA<W11.'92=UAM:39V9C)&,DQ+83162TM1)B-X03MO
M:$UI>5%34W)73C5K8EIQ*T=+=FPW>5(K5"\U:RM74'I$,%,K,5!46F)3,G-T
M46A9,T5,>'EE=45R2S!56$(O:3E72TYG83!!2#)Q)B-X03MD355K<W@X-V8X
M-#=8+VU0>FAE835P,$8O63)M<'IV9#-D=F-R66MI4U$X,SE.,74R8C0S2C)A
M4#1F9G!I='!T*V18-6-E8G9-96@K)B-X03M69$,P<7AT-U%A6#9T<G`Q;6(S
M,4=L4T]"94EB;$1#9V19-$-6*U!X-EEO0E%0-5`O;%!P;'(U53AY85@U:D]M
M83=Q,39Q6%9V;T56)B-X03MY;'<P1#)A4TMJ=DIB='EJ9#-U3THT3C`W-S!X
M56PV5C59.'(K5G1!.'$R8W$V>4Y+,$LW:E,V14YS,%=M5S<K<6=93S`Q5W5I
M,T5G)B-X03M6835*<%1W=W%P-FY"-51U=$]U4#A-85).<6UT<V]K,"]6170U
M6F8Y26E94W=-9%)U*TM&4DEI:S!M3TMV3V9Z5B]-=GE(6G9:-E)Q)B-X03M-
M5C-F95EE3G9C87)Q8U-W3F,R<$)%:E<P8GEG3$519&YJ4D%V63=K-')42B],
M,FUE5615:$XS-5)A8E9R3U-W83<Q:4IR;&\W;U!*)B-X03MB=DA$8GAZ4FQ0
M<3@P;VM*9&9H6#163S-81E=D>%AU<TI&84I&66E$53E2=#-E0TEY*W%T<U8Y
M34UB:'=O0CE0,60V5G%244AE=4M%)B-X03MG.',S3FPU85<Y,'$T,6XY33)-
M9#-);'9B>6=1,V-,.$5K;$,K<7E#9$1*3BMX<V]:83$K26A6.#5A-W%N-7=0
M*UE5.3E"2G%-3GA*)B-X03ME57-I1VM7>D5,4V9U5C5!*V@V4$9T-FYJ,7%E
M=4Q,6CE:6#!2;74W3W=S,%=85DQE84\V83=P.$9P1GDK3&MW,TIM5&MG:D)Q
M=THV)B-X03M$9D9$2G-#=7A6,DMU>%8R2W5X5C)+=4I!0DHR038T<3@O=EI.
M6#%I-VQU26U)9VIC<$5/9D5#;E-N=FA1:%ED4G9,2C5(2V=Y;'94)B-X03MU
M5F-(9&PK>7AO4G8Q>%97:$1A<&5X<F1(,'=Y1U%O;G=K,$Y!;W)8='8X069I
M<5AE84Y#,'%+-S!L<&])-VTS92MT1FMH=5934E%J)B-X03M835-35C5#;DAI
M.60O1$9765!9,D]N96-T2BMQ5SA6<D1C5TXY07E1;W-96C%K='!9-FAE23)6
M6D\S9D%L6#@X951.23@U95=R<E%.)B-X03M6-7)A,U!&:$Q%44I)-45936IO
M4T-+9VIU3VU+=D]V3"]W0U%8;%AY4#5E.'HS4G9*-RLT=CE+=3=/5S1L-%)#
M2S)K:4IK5D%O86I')B-X03MG<7AR,"ME2S)Y<E599E!L<&(V6$E035-M83EU
M3&4S;&AA=VE"2'$W>45F1G1W544P4&AH5DPO3RMN*V1$-61V>F(V=V1815%3
M4CE/)B-X03M3,&EI:V1);E8R-'5V2714:EAI<3%046(P>%%W4#AT;T=V4$Y&
M<$AP<E1+4D-':S%#>65&4F)Q5EE"<$).1$]J*V]#5E9+8VHQ-D%K)B-X03M*
M5C9V6E%E6FQH=&]M.'E-9%)D05HT<G4P=#5&-6EG8TMS0717-&AU;2M+5T(K
M8R]-;75#85DV:G%%,6QQ='$W-F9P6C`V>75R84LT)B-X03M74S9G931*=6UK
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M0C!A4C-#2VIJ<G=:;4%::%-G,W)H5DID2'-,,WDY6C-F<GIA3G`X;C%P>$9,
M=V%*)B-X03M*,FM:631P<#)$4G%S,&@R2T%.,BM);D98>G`U-R]/=GHW<#-N
M-7)M,U,R<W)M>&I73F5D<D,W>5)4:$QH9S!J<5I"1S=%1E96:'14)B-X03MC
M;C1I16=08W9,.2MN;7)Y9$QA*V%.374T=%%F,#4W;3)T8E=98V9R86DU:6UG
M8FHQ5C)/.51X8T5B,'=O5E!)554R;%-83VQJ4S)H)B-X03MV3&Q!;D%,3$A)
M.&--:FQB>60U,5=O:SE8:3E'<4-O5E4T,&]O5&4V,$MY.'8V3'%$84):,E53
M>5-#.'99,5`Q96LX8DEY5'%F<U!W)B-X03M-64I1.&58:C)+;&E8;DPX,F1(
M,&)39C!T0G%D=D9:-C%9>5(V4G!C.&)3>E-T5FQ.,#!L=4IF4U%':3A'0C55
M4#)455EQ;B]!2DLX)B-X03LQ87(U<3`P-FY:<G`X:%IE3G!R:#E1.%9:5DIJ
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M6E-&)B-X03M!=DMI:C925$-H3"M6>'`W4$=::DA)<FM)549A:F]443`K16M$
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M0G`R*S!O5$\O=T115WIL=E!Q<3-C5G-Y>7DR.#(T0W%E6'%6269E36=0,$HR
M,C-P)B-X03MI<D4U4$QM:G=A>3$Y-6\P:V%J25AK;6EV,70W83AT=$]I:4A.
M25EN0TQD.&0K<E(P1&1+67!E1"]M=G!8-7)A<BM:,3EC5U9J<6II)B-X03MA
M5TXY3%<Q5U%I3TAI16A.65-5:DY%,V%V544Q-S1%:#E'5W5I95E.5#AU-E4R
M<V%Q='!Q8TYM.6QQ5GAA0U%34U-S5E-C0U-.-&U5)B-X03MR2D9S5C<W.4YS
M2T52<F5P-EIA6$57:%-80W@V>G%2:2]1:79Y0WEU:DQ*-G%N9BLU6D]B2U1U
M04]V3$98;E@U>69L2D0K658O<"MU)B-X03MA6G%K9&QQ34YQ=')C-F4X57,O
M1E5D<$-T3&1:2%8P859G>3AD+V)!;TQ*4'EL.'1A5F]F:TIT0VHQ0U):;W)U
M-E<T;G5%83!:<$,O)B-X03MP;5-&2E%R:&%)3TI)-C166DY:87AO.7)O;'!B
M9G!:2S)P5S)K83=M5EHR:UIX2$@V:&9H>60R64-O,EIJ=%A&551*82]83F1H
M=6)#)B-X03M',V$Y<V]8=&)Z57!O=E4T:&ER:49'56\W<W),5FQ$0E(S*TMM
M2W`U65=K;'1%+W%Y*W1.2S=3>7E5-&ER8E564U=O;T%!07%C0W%T)B-X03MX
M8E<Q>D,P3GI%:SA,9F%J:U5/<'!U2VAQ:D97<E<P=')31EE,84Y9;VQQ47%I
M;3='<D4K2EEM<$HS2GA65GA6,DMU>%8R2W5X5C)+)B-X03MU>%8R2W5X5C)+
M<EI%-7AS;&%C9U)8-6EM2W90:%IE661/=5AT3&5/46AM*T5H07ET,C5$:T-"
M:%%L,G!*3VPW26LO.3AL1FLS<CA1)B-X03M!<G8X.$MT,G-S:TUB8T9%:E0O
M07-B3'E"05!7;FI8<&EQ<$(U:VTX=4,U=DDY3U,T=F)O,FQR-E1Y1S)$5FU+
M4C%):FQ!;S%Y4V9H)B-X03LV649:1#5D=71D,&DK='1%,65Y=&M857!T4G4T
M3'$P=7!,:6IY6$185%)U:W-%0D-H6GE!=UDO6C9#=7=3;RME9GEG.&DK9'(R
M,W9T)B-X03MD<VUE.70P.4IB:4=2;VYA345K22]%,%E!:S`W:D975#9.;RML
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M.7)B4W5X;71%-%)855)-3'%$,5--<6%R2#!!4W`R039K5G=+9T):=%HV9DAP
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M<SEX.5(P>39-8S%X23`P-T9)2%E&-4<U37AX5D%E8W1-4F9,*VDV3D=G95)R
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M=$QV-FI:=WA71C`W96M*8F=Y:31E5E-*1V)G;U=3,4<S02LY831Q:G1'9S%V
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M8DM7-SAA67%Y1$95;#!$+T%)-G9M5"]T;W@O.3`V,'A6-3,U571D44AL;E(W
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M4'`Y:5E%:C!K,S`Y=WA73T,S4S-$559E5$U433A+54@K=%A&54HY9&LO-FQ'
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M5'I23&I13F$P+S8O6E<P6G0O5W5,97)X2W`U,G,W,CAM,4]N<5).5#)W2VHO
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M5C)+=7A6,DMU>%9$-FPO>'IR<B]J1$HO=T%23TMQ5W`V4%IA:W-1)B-X03MU
M9E=5=W-8:64S;FUT;D))2VXT-$AJ86A"-E9P:7%#+W=J<%@K+SA!568X075+
M86HO=T)L1TMO>E1D13`O5%AL:W1H2S!S-%):6G)I)B-X03ME935K2W@X:6DX
M-3-K64MP9&E!1%1C-'%P95E03'5M-CEA4E=T*TI/145Q,T5,=WE0139Y2W)+
M0T=19SE(27A62C4O>7<X;GI10T8W)B-X03ME8FE#-4Q,8WIQ-V5R3E!024A:
M6$):6&MU-4-Y;EDQ.6AI<F]F>7<X;E%V8G9(8E-Q8EDO=68X05-*=FAI0FE+
M469B+T%,;$1B4F-))B-X03LO<W)X1DU643@O-5`K45HW:31U2DY08W9D47E1
M6$%%.'=$<DQ%65A*;R]8,'IX<FEQ3S!B.'5V2U=J,S@Q.5DR8D,T=4DU-%I$
M2DQ,)B-X03M+<&EU5VIA5D]$<WDX5#9#9'4S=6-646PS*U4S:W4X14%U-$QM
M-"MR07!B;5<W=5I$2$510C9+1G!$4TUC4E)F-FY&5U-A4G!';C92)B-X03M:
M9E5R0U`P<F(Q6G`K0EIM+V5837IZ>6UR16YE4U)J-UEQ:DU69&EQ2&LO-#9-
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M=C$O,7)N-GE*=E1-5E`S15501VI35$4O,TYA;'4K2W-S>%8R2W5X5C)+=7A6
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M>#1N;F5315%V>3112T%)>3=K:F]W<4YT<U9232]K,S@T:G`Q;%EW)B-X03MA
M=DA',%1O=#%0.$%7:C9C:T%)5E5%6#%D:6ER1%9(*TEL,V\Q5C-X5C9.-50P
M-C<P>GET;S)M,VI"<GEX<V)A,G5756QL37-52V\U)B-X03M$1VA)-4PQ=TMJ
M6E`K3VI"+W=!65IV.$%I55=+;VI&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
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M+W9+8V5(>&)B5DY+<%`O04TU139!:VMK6C!Y-$12,C8S0F(Q26EO,VI%<6M+
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M+TU657=60G%.3V-%9TQ7:TA10V=(,BML1&ER6$=+;%`P63%+055P0C!8<"LS
M,GA69'E(3&PK:FXU1G5:8CEX6&PP-69B-C1Q-%!2)B-X03LR:T=N>4-2-F,S
M+V-64$AP53@Y-F1S5E%D.7!/;5@Y>&)81C5O-6YM=$I05W0R8C!F:&LR*T]N
M<55*,C<T<6U(,7%F+T%*635V=F@O)B-X03LV<5EQ-S8Q4"]W07-C,S-W+W=$
M5E1&6&97<"\K5T]B-S1F.$%Q<&EQ>$103&5X>4Y!.%-*2$EP3&Q$57-Y154T
M<S,X<'A6+R\R43T](B\^"B`@("`\+W)D9CI!;'0^"B`@(#PO>&UP.E1H=6UB
M;F%I;',^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S@Y9C<W/"]R9&8Z;&D^"B`@("`\
M+W)D9CI!;'0^"B`@(#PO9&,Z=&ET;&4^"B`@(#QD8SIC<F5A=&]R/@H@("`@
M/')D9CI397$^"B`@("`@/')D9CIL:3YR<C$W,S(R-#PO<F1F.FQI/@H@("`@
M/"]R9&8Z4V5Q/@H@("`\+V1C.F-R96%T;W(^"B`@(#QX;7!-33I(:7-T;W)Y
M/@H@("`@/')D9CI397$^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I
M;VX](G-A=F5D(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C4P
M,S`T,$8S-T,X-44S,3$X,S<P144S1$8Y,$$R.#`Y(@H@("`@("!S=$5V=#IW
M:&5N/2(R,#$T+3`Q+3(U5#$P.C(U.C0U*S`U.C,P(@H@("`@("!S=$5V=#IS
M;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(*
M("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@(#QR9&8Z;&D*("`@("`@
M<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB
M>&UP+FEI9#I$-3(W,S@V14,Y.#=%,S$Q.$8W-$5%-$1!,S<T.#$W02(*("`@
M("`@<W1%=G0Z=VAE;CTB,C`Q-"TP,2TR.%0P.#HS.#HQ-2LP-3HS,"(*("`@
M("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@(#QR
M9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B"B`@("`@('-T
M179T.G!A<F%M971E<G,](F9R;VT@87!P;&EC871I;VXO<&]S='-C<FEP="!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P(B\^"B`@("`@/')D
M9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@("`@("!S=$5V=#II
M;G-T86YC94E$/2)X;7`N:6ED.C@U,#%!0S<Y13,X-T4S,3%!1C@U.$8W0C`U
M13-!-38U(@H@("`@("!S=$5V=#IW:&5N/2(R,#$T+3`Q+3(X5#$Q.C4T.C`S
M*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T
M;W-H;W`@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O
M/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B
M"B`@("`@('-T179T.G!A<F%M971E<G,](F9R;VT@87!P;&EC871I;VXO<&]S
M='-C<FEP="!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P(B\^
M"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@("`@
M("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C@V,#%!0S<Y13,X-T4S,3%!
M1C@U.$8W0C`U13-!-38U(@H@("`@("!S=$5V=#IW:&5N/2(R,#$T+3`Q+3(X
M5#$Q.C4T.C`S*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA
M;F=E9#TB+R(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)S
M879E9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HX-S`Q04,W
M.44S.#=%,S$Q048X-3A&-T(P-44S034V-2(*("`@("`@<W1%=G0Z=VAE;CTB
M,C`Q-"TP,2TR.%0Q,3HU-#HQ-2LP-3HS,"(*("`@("`@<W1%=G0Z<V]F='=A
M<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB"B`@("`@
M('-T179T.F-H86YG960](B\B+SX*("`@("`\<F1F.FQI"B`@("`@('-T179T
M.F%C=&EO;CTB8V]N=F5R=&5D(@H@("`@("!S=$5V=#IP87)A;65T97)S/2)F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA9V4O
M=&EF9B(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)D97)I
M=F5D(@H@("`@("!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+W1I9F8B
M+SX*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C=&EO;CTB<V%V960B"B`@
M("`@('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z.#@P,4%#-SE%,S@W13,Q
M,4%&.#4X1C=",#5%,T$U-C4B"B`@("`@('-T179T.G=H96X](C(P,30M,#$M
M,CA4,3$Z-30Z,34K,#4Z,S`B"B`@("`@('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@("`@("!S=$5V=#IC
M:&%N9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX]
M(G-A=F5D(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C@Y,#%!
M0S<Y13,X-T4S,3%!1C@U.$8W0C`U13-!-38U(@H@("`@("!S=$5V=#IW:&5N
M/2(R,#$T+3`Q+3(X5#$Q.C4T.C,T*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T
M=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(*("`@
M("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%
M=G0Z86-T:6]N/2)C;VYV97)T960B"B`@("`@('-T179T.G!A<F%M971E<G,]
M(F9R;VT@:6UA9V4O=&EF9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](F1E
M<FEV960B"B`@("`@('-T179T.G!A<F%M971E<G,](F-O;G9E<G1E9"!F<F]M
M(&EM86=E+W1I9F8@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<"(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)S879E9"(*
M("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HX03`Q04,W.44S.#=%
M,S$Q048X-3A&-T(P-44S034V-2(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q-"TP
M,2TR.%0Q,3HU-#HS-"LP-3HS,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N
M=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB"B`@("`@('-T179T
M.F-H86YG960](B\B+SX*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C=&EO
M;CTB<V%V960B"B`@("`@('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z135#
M-$8Y1$5%-#@W13,Q,4%&.#4X1C=",#5%,T$U-C4B"B`@("`@('-T179T.G=H
M96X](C(P,30M,#$M,CA4,3$Z-30Z-#$K,#4Z,S`B"B`@("`@('-T179T.G-O
M9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@
M("`@("!S=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@("!S
M=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(*("`@("`@<W1%=G0Z<&%R86UE=&5R
M<STB9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM
M86=E+V5P<V8B+SX*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C=&EO;CTB
M9&5R:79E9"(*("`@("`@<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A=F5D
M(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.D4V0S1&.41%130X
M-T4S,3%!1C@U.$8W0C`U13-!-38U(@H@("`@("!S=$5V=#IW:&5N/2(R,#$T
M+3`Q+3(X5#$Q.C4T.C0Q*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%
M=G0Z8VAA;F=E9#TB+R(O/@H@("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T
M:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I"
M.#DT,D8W-#DW1#9%-#$Q.3@S0SDX040Q0C,W.#%$1"(*("`@("`@<W1%=G0Z
M=VAE;CTB,C`Q-2TP,RTS,%0Q,#HQ-SHU-"LP-3HS,"(*("`@("`@<W1%=G0Z
M<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*2(*("`@("`@<W1%=G0Z8VAA;F=E9#TB+R(O/@H@("`@/"]R9&8Z4V5Q/@H@
M("`\+WAM<$U-.DAI<W1O<GD^"B`@(#QX;7!-33I$97)I=F5D1G)O;0H@("`@
M<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#I"-SDT,D8W-#DW1#9%-#$Q.3@S
M0SDX040Q0C,W.#%$1"(*("`@('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z
M0C<Y-#)&-S0Y-T0V130Q,3DX,T,Y.$%$,4(S-S@Q1$0B"B`@("!S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z-3`S,#0P1C,W0S@U13,Q,3@S
M-S!%13-$1CDP03(X,#DB"B`@("!S=%)E9CIR96YD:71I;VY#;&%S<STB9&5F
M875L="(O/@H@("`\>&UP5%!G.DUA>%!A9V53:7IE"B`@("!S=$1I;3IW/2(X
M+C4P,#`P,"(*("`@('-T1&EM.F@](C$Q+C`P,#`P,"(*("`@('-T1&EM.G5N
M:70](DEN8VAE<R(O/@H@("`\>&UP5%!G.D9O;G1S/@H@("`@/')D9CI"86<^
M"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M93TB5F5R9&%N82(*
M("`@("`@<W1&;G0Z9F]N=$9A;6EL>3TB5F5R9&%N82(*("`@("`@<W1&;G0Z
M9F]N=$9A8V4](E)E9W5L87(B"B`@("`@('-T1FYT.F9O;G14>7!E/2)/<&5N
M(%1Y<&4B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I;F<](E9E<G-I;VX@-2XP
M-2(*("`@("`@<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*("`@("`@<W1&;G0Z
M9F]N=$9I;&5.86UE/2)V97)D86YA+G1T9B(O/@H@("`@/"]R9&8Z0F%G/@H@
M("`\+WAM<%109SI&;VYT<SX*("`@/'AM<%109SI0;&%T94YA;65S/@H@("`@
M/')D9CI397$^"B`@("`@/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@("`@/"]R
M9&8Z4V5Q/@H@("`\+WAM<%109SI0;&%T94YA;65S/@H@("`\>&UP5%!G.E-W
M871C:$=R;W5P<SX*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D*("`@("`@
M>&UP1SIG<F]U<$YA;64](D1E9F%U;'0@4W=A=&-H($=R;W5P(@H@("`@("!X
M;7!'.F=R;W5P5'EP93TB,"(O/@H@("`@/"]R9&8Z4V5Q/@H@("`\+WAM<%10
M9SI3=V%T8VA'<F]U<',^"B`@(#Q%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@
M("`@/')D9CI"86<^"B`@("`@/')D9CIL:0H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I&;VYT2VEN9#TB3W!E;E1Y<&4@+2!45"(*("`@("`@17AT96YS:7-&
M;VYT4V5N<V4Z1F%M:6QY/2)697)D86YA(@H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I/=71L:6YE1FEL95-I>F4](C`B"B`@("`@($5X=&5N<VES1F]N=%-E
M;G-E.D9O=6YD<GD](DUI8W)O<V]F="(*("`@("`@17AT96YS:7-&;VYT4V5N
M<V4Z5F5R<VEO;CTB-2XP,R(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z2V5R
M;FEN9T-H96-K<W5M/2(P(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT
M4V5N<V5?,2XR7T-H96-K<W5M/2(R,S<P-S4U.3DR(@H@("`@("!%>'1E;G-I
M<T9O;G1396YS93I#:&5C:W-U;3TB,C,W,#<U-3DY,B(*("`@("`@17AT96YS
M:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64](E9E<F1A;F$B+SX*("`@(#PO
M<F1F.D)A9SX*("`@/"]%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N9#TB=R(_/O_;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(
M`2D!)P,!$0`"$0$#$0'_Q``?``$``@(#`0$!`0``````````!P@&"00%"@,+
M`@'_Q`!)$``!!`("``8``P4$!@<%"0`%`@,$!@$'``@)$1(3%!46(2(*%U.5
MU2,D,348,D%S>+,E,S=UE[2X&31"45@X4E=BL;?6U]C_Q``8`0$!`0$!````
M`````````````@$#!/_$`#41``(!`@0$!@("`00!!0`````!$0(A,4%181)Q
M@?`#D:&QP=$RX2+Q0A-2<K($(S-B@M+_V@`,`P$``A$#$0`_`/?QP!P!P!P!
MP!P!P!P!P!P"@'8/;VZZUM;:HN@[,UGKFI:8ZM@]]3\;*I#MBK=@+3;7M@<1
MA6D_%N-1)5FN,B->PV_LA<I4@:].E%'F23<9`Q\4DK8MMQ;IMN8:=\1IFO`;
MU@CI*PPMCZZT==NR=GUJ3M#`LE#TE4^O83;L*YJ(2*\KV<GMEV4;U];%RAS$
MB+=`>Q#$=PF+HTF.1#AWM*4[S'[QPC4X&T/$+MFI*YM7%FTA6INSM,6:^1K?
MK6J[,V7<<F*'K[26H-ZGKU2[#5NM1A:XXFN[NH]>L3FR0.KZ2`N$YD4[L.7&
M)@B!4%3.=M;8MM1CL_H[RR]X=JM6XX#H77JFV8"S;-CTBL'[/ODG3)YBP:QU
M6'W$==-@1VD+JW709&J3B`T%/A&K,2D6L?''DP@@$079X(0HF<IPWC4Y%,[M
M6K8UQGTO5VN!ELLUC+N6*H#=B7Q&KZX'UJ&ZR=0MSV#,VT`J+L>?-MF3?:.O
M#Q%?_#\A$]MJSDI-B$A:XRET(C%^7-K;0DWM&=WI7;KU\BZKVP%HH/:FUQ^I
M[`+*ZT%W1^/F10=J7MVS#B4PZ*<:EY73!(A(UUAV&F.N7*]>7W4X;&+/9?*1
M&+7?(B_0=9%@&KF;+<-BZYZUVL6*+WMJK"\&NP^\!&B8$`V7@4ZR/BH-?,DE
MV(L1@5\J\["C21D`*N6VA2QL;YU>BDZ"#X@EXBQXC=QT!7@1FV$+33]<0`NZ
MY=C@&-CT3MYK#I-;1-S*S-0UM5+I;>X=MU8S7KD*'W<P7ULR8/DJ-7K1$BTB
M?D]\G'N.'?=S;)U:Z+:Y+&I>VMWVULZ)JT;IL",*UQ-WQM\S(VN_*!5.10=L
MW'4):/07F-;(G;*R1-53[8*X4@:Z3@3)FQ;%BN6,2H#,TQJ%,\K;)_)'>_MQ
M;RTWOM;6-OU#&K6]36/;<:D&M:ST3"94-M#4VMZYK!JX4T9L*[.*O!38B14*
M=6=87&W.&I8J"`JYB:\U!D`E*ZKRO]:G5"O$2/D*ZX??T!(@?@NE=F]B;HAS
M+T<'2Z;5^K5W!U.Y-4L0>U0$MEYM%DA'HQFI5VSU?5RG'F)(>P3P#OQYCXWA
MWT2ZJ=?L_@SX@M\K9QS71KK^%F;??LXL.(K5!V/L[:U/F"B&H6MP.3IEGUQU
MHLESBF&!$N`,;%#M6&PLB1(=**MD<#%=)<#ASFT3EK&NVI_H;NEN*78+A.MF
MKP-0HXGL+1=:5D8FQD<[/8%V7I-2^T!*K[,K!.H9"!3PPC9GQ\XO7;7+5#F9
M16DAI,<"[;+5FNS^$Q%L;Q.V,8_H[2K=\-A6611J<YH6H"-K[6=T^2UP`F;S
M(KH#U0W#I[=>Z192\[!;TM@S5K$%KG7W8PHG5Z[KN^1GSRJL@=8Y08J9,UK1
M&]E,VTA:[K,NCH/:;>\]&Z<W2T&_#C6V]7T/93=?P32:P#1=ZP,LB1&#"((Q
M)7`[!+$3!)(V!B;AK$G$*+ASV$"79M:$M<`<`<`<`<`<`<`<`<`<`<`<`<`<
M`<`<`<`<`<`<`<`<`BRY:,TEL6T`;OL'3NK+U=*JW%:K%ON6OJE9[17&H,]9
M6$V!/FQ$XL';AE''"45`^7'3'GK7,:PB0K+F0EZG\R-+Z])778M[/`HMG+;2
MUW6=36^#98L`T`GZXJTF\38E/R$F0UPG0A.;L:WR;%$G(FH._9HBD/>@0!\2
M,!QKSU]T)L_+^=E:1U%L/,HTY9).;QK:FVS,FQ/5T74'CTC[X+/]\T[4P82K
MN%'?5.77@XH*I_(T=#C,C9>K,L1KK7S;F'FZ+34/8GE"N'45@(ES!,X&37#1
M'"TP<*Q/+UY"`)29C/R"`9"1<MQZ"G#&!AB-AZ\Z!MP5%;M>CM/V>NMEAQ]L
M!8=9TLT%;.B*H-H@DT@62"28*2PNCA@]-'$4L8F0JH*&UZ,\T(@Q8;0V7JR2
MR0((9>$2"X845?KQ1!P`^2'Q)SP,VW!GBT&!#DIEU8TH@84)CD$(2F9:8)&?
M$P]B/+D-N#",Z[UYT#4")PO4]':?K!:SG!UGLA2O:TI84C8;('L>+B(L!N:-
M"QI)4V*MR<6D:5GNOSH-CQ@W%?:)XQ*X$O4[TIJ#4QP=,#F]7Z[,""(^Y""`
MLI2:T0'3A6Q;#$MNP1DR%+&.QI(^]6N!!LUQA/-+C6>PPHAHVW.)1V9*`GOE
M@<ZHZTUQK^,/AT.@4FDQ!(;\.BHM2JH*N1QE?P3F&OHA[(>!#;AA_N2!`M]9
M'2W"^SG3)_L?*DONK"3^K;K?7=^8(Q;U0J7=(I>ND:@5CVRK`[$P3J1>7!GE
MJN0:,09B)E=)SA8R:0"R$N#9LL=!DR8SCT2.ML).FK.F-2T84@-0-:4'7T%@
M380D!NC4NKU9(H;:YD4E8XHQH0)C1HC!LK!@%BT9#&8I,F/@SB+$I^*RM(20
M/J_H=UCUI1+%KR1K"E['KMKN4.^GX6Q]=ZK(B)=F%U^-5@Y"'2JW0JMKD$X)
M`QE0XKE=I@E]]^>9+$GIQHZ9(SAO$]?5DXL:*TC%-*LD73FJXUB7""C5GF->
MU%DTL=6PC]9KH]11L0F<J$`K<J37PL7+^6!020^)@ML0'G(ZADO4PS;W6#4^
MXJ2]1"M?"UH7(33(STFOT3595]T/K[)3--KSPS85`O57?!UK[HHJN0WZ\ZNL
MO3I,NM/AYCJY"ALO'[S)5UU0:MJK7]&U?1QV1%+US4*U1*B*S)DS%#:S4@T,
M`"@KF3'7YDQ<49`BL+ERWGI4E:,O2'7'EK6H89EP!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"G^QN[.I-6;0V+J6V";VS8M=ZG&[@=
MGQ0X5VOVP'++)%$0%0(O6..[*N-=3(&%BP0W#`HDA">"5>FG6@UH2!&PW&[C
MJ9V1[8=;@\ZZCS&Y:,(>UXJ8FX/E2R1HT1]5;1-!/+P8FH8$D6JK>CP6F7-X
M5-G-4NU%A]?M:PY:6Q$6$/0Q>=WBZGCB&1$S=E6;+^N!'0)1'.2"CY0K4!FP
M!5=BCHPEV;+MI6B%X=R&4^,P[:"%6Q./0Q#PL44E0PAV<6>'G'N9!8.U^B@4
M2(^S>1YN0<H$S8]+9$-RWA^P`,>AE]F1&*7:78S-0/&"]&!%;2+#0SRR<FO0
M9AW$7`B'*FLC([_1UFW>SL?4VH*MNMO3FV=EU*Q"ZV7G,:[D:B9+U2+;5@(P
M#)V+LO:^MV969Y"Q0QZ<5F38%QGF93\]$.$EJ2\-B[4JTZY8Y'],]L]9"F"2
M-FQCFG;`)/PJU.I=SETJS6YDM*I8J_R6UC--W':;+<0+5S$(J>).S&QPB`X@
MI+E(#R(9&2$==[QZP9H+[%:4-'2-<&;""RBHNWMT%].&R+4"3<U'256>K0@R
M_";#'BH^T!BU9,1@D\@H)8ALX&8S!*17HB!D/YZ'P?[*Z'CFJW7G-GUC):V$
MFA`:,S(?D-J(RKJ4UL+BDYL>.[!KZC^Q`A>AU==@DC&[5<ADZL5Q90U&=A)&
MPR<>#!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"GY_M]"J>YR6GK5HS<M<BB(`0
M]/VN5,=>F=81ZC9;D_0:];E+1OIW8/UABTLI&Q!.-??B]*Y$9<FLQTNX\AL6
MG[YZ&=7WMCUOU>_F/L#<5+JKJ)=QB2,%"#C:8'[NW*LWL":4<;8=:$AJ-B[5
M21<#Q)<0)681R$0-$(4%3DAL$F\%)ULCN/UAB5UNU2]RU&(#6:.@7I4IPA'?
M&S:N+$';-*.#7H*"@`#7:]8:Y93MI-PQ]9$5FR5NR$"\<'8`\^:$/3ONW.V)
M(8'=FL;?9KQ2*1;1-VO&N42$V^H5N=$E&`I!AJ,\@*1=E2(8@:9EHG#UQH14
MI`SF.1@SWW&!LA$S@R/7#<@6C=S(EL,6D98M`;LU1"INS@6G3]CV2>ZU,`HV
MP[`W2YL,!'73.Q%T*3G$!KV&-N2H8IZ(_$:GP!S\X^U'#2AL;KUWVV[1GT3M
MWURG"0QR%M`7+&V*:_$`.QA-E??-QHH\26DV(5!;"JGD*1'%'P1-Z_Q8SM(:
M'FP\U=@3&)PG7PA_/?UB9G/W[I<5"D$26RZE!@Q86T2#\J44:9:1$TK>1>L]
MJ.84OR]Q=(V$;#TTTPWZWV[$3@BV&GY4EIM00].W<RRA[!IVS:ZU:J,<CGP;
MDXF+<D-,S(<F"7"SWQ9D,7%DH\(L%-"",:1!*!R\&$3'RFELRXK+F/3P89EP
M!P!P!P!P"E_8#I#KGL,Y=YMFLMN`&K<5U,9'GJTZ*CE*A-U:BVBGD@G9PV:T
MJ+?:7?+G0+I&(,RTRJM9"3([(XAF,0C#55&F>.\>T)HQE_H35)Q_YQ/9MXFU
MT':[K;=>53X-5C,4J;L_LKKSM1L2,Z78#)*V:,4V)K<0*KWVKR7:W3IQ48XL
MR6<B'883WTC[)G_T:JM^\W.T?OCV2W^D?_I*X'^0[Z_%I_T1?]#SZ'']S^3]
M#^"?.S^?O?8_BC.<?,^I_N'`G+:/6?<J7`\+C7$(AK-YW9]S*#]54.I4:K),
MUO7I2S#X-4ZQE>K2(`F[S:R]9*S32M7*R;\3H=9DB0<O:LTU:92I,4S($-C>
M*S6N..L]O0NM<M&@+II&)HR<7,1`$,-10J#$3X7W"F*&3KQ,>ZKWHSD+WIKM
M=C-S?*-A'MOO^PEI7MY0,F[>L^I`V\.C-5W3/O91R_V6GE;]=8=U?/@PM7=M
MU(*Q=45C439C5%TD#,6K7%Q@@:RW/$6L$6PN.2)$$%QAT7\0=%&JJ.]YNL'B
MT8\_T#%-V:\W*O[@M]3L-DV'6MGU]FMUFEBJB#NE<V&1V(NU6&APA4>JW>XV
M"07)UVSW.:.%64^"F/RR9"3;7I-H?&<3^.D1'+.-3K@'APZVK]UHU^5:W+=8
MZU^&L6(IL;6.G;P2LRZ?N[8>^P)4-,*49'[N;(FY;/L\><8I#`QO`U(:6"'5
M^S`A-BB#>)X?>B6NV<FQC@D<`<`<`<`<`<`<`<`<`<`<`<`@O<'8S5VBDE%;
M%)E!N1>H=I[N6V.!%#3\^D:<DTJ%=D"(XN/)?*65F9L.H1`M6AMNF[%)+(8"
MPYKK$E#0U)OS2ZO`PFR]T^NU0`76WV"],CZ9KP4^9MUO=B/?0C8+&G!.^E?%
M>_*8<F+UA8*Z?8&`(10E(58`\%F(N7-0U@(>G<Q[F04KMEUUV#L&=JZJ[@UX
M4NS;HS%?"1[M4WYE_ADZ9!OB2^N(L8V_-NX6%79WR"90%%E18+L(DAY>&X3S
MN`AXQW,$;;6U!K3>NVMQTEVZVRO;):Z\:<B%\B1XY<*JU\QMS9]NU9=!CQ<9
M,'%C35]U5:/L@LS,J`H8&ALSXC39=MYP):6TOVAKR96F=JKJ,0USLVTWKNW1
MK`&V;5>UO7^[;4E;&TB"KC5G[<BM3F+J(@2QBXM6%VNK!=+BIU+J\AZ41;`R
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MQC'6*%$#P`=AG62I*"T:66L^2Q>K2AK]8'B!LO&,>;G&SU_1ERNI77'<4.RF
M$]JH>P-9V![;2J()!&=)GJO3K!VK[<:^[$))QS+84S%O4F7V/U'"KU$`V_[F
MM6`?'G:\(@++/:)OS@EK*_7)1[.=<Y@G?JYL?K-K_6=#JX';.H0)?9];D;P#
M4UV!J32-G)5FRC)A]VR-:EJKPQYB!%"`",DF;?9-2EM`B\LD>D,#7?AC'-]K
M-WRMB3SJ_LEH3<U$`[+UIMR@6JFV(#3+'`*P;.)0J.-V%.=$4U)J!(E,D*^1
M/GHTVM00YN+`*KM`XE6E0TG!TV`P$/0_TAV7ZXB6RKI7L!I(8T"/1JJ;=(;5
MHD)L-:)K1&1#K95<D\VD<>EL!RST8/+RR0?:%D7&HZD0I.6@AZ/R)MQGS_/'
MYXS^>,X_V\&#@#@'^9SA.,J5G"4IQG*E9SC&,8QCSSG.<_EC&,?GG.?RQC@&
M)4J_T/901-EUS=JC?ZXN2[#38*59`UJ"*ELMLNO14E04V?`S)::D,..L8?RZ
MVV^RM2<)<1E01&)EW`'`.`1*BP[+$@L2@"X\F>-%1GR,R/!9D%#$Z.+$#6'9
M+C2'9Y4G+BCAL-M2I$Z=)CQ(K;LAYMM0'3A+M3+*6L8"N6ZL'SM.E1X-N"A#
MPHJ6JTV9B0J)#L8Z#+?F`Y4K$25F/')LQ7G\1I&6D*PRYZ0,GX`X`X`X`X`X
M`X`X`X`X`X`X`X`X`X!6CL-UM&[^,Z)-2;1+JDG2^XZWLR5\$6R25=ZT$5DB
M2UB36_,BI@5ZRV093#I>4EN>IU50A0E07&I;KC0U.)W4?LJU$\-0)%T+C1^-
MME7L+@=B@DJXO5"(HI*KVX]+6'KMK\<Y"_$'LJD:9TVYK^H1"#TE]=Q1KV/,
MEL`EF76AXWBO,:9[IOS<\I)OB]4C)"V.[`N>Q016Z$MW:DW8<F5?74JKA)!#
M5FL$:TP`$#"NP+B6%#C<?Y)-,B98S3XKYTN!Z"*'G)*AD[91?G)S=D];]@7'
M;VR+U6]K5.L4?=.D=;:)VC3RNKK!8;BY6*%8MYE9)?7>QA&X:9`I=C,BM['!
MT68;U_>HH0D$$&L0B;2I0AP)VP<^V*C8K2SX=6Q(E#C5&#V,@0IZG:\*L9AF
ML]CEL7ZC5?7]OI`&M7AJ7W0E6>>H!*MC]D`#`5SK>K8L]M]@EJ<QAP9("C>*
M^'M;TCS3>YEVK?#FK6LK>:MTV_R-@1;G01NH]DTRT5-,VKVW5,/K/H[09*O@
M1TRV/(HEJL9C1HBW'[<!D-1[57#B]=WT#;<4[7%RICM]]YAU??66^N/=R<^H
M6A#>H>N%=H>W"$B][,N(UVP;S.V:5`L1"UV^Q"((B>+L!6+$B#;,S5:@-KNL
M(95H?$C%ZW3A3RH;.'5-8&-RY5EE&7+W*MO>&S;XNE6-2A>SAS,L@9L2+U8K
M#5[NN)?:5C4X#1FKJ\?$Z\WAK$V2*ZNUC2J9$;FGKD?I%UN+-LO=HUJ^:LT!
M-9&\5YCO%Y/%]5DSO'_#PL>9QA0S>[%>`R1^MB<*K!J/?'JR>V;J.SZ0M]'V
M!LZFV+?5AUU85(*Z3@#+7#UI1M,V2\5.PD@5HNY!]AHLZ'%MKY.;*V^K,_L'
M43;-MOT>Z6'>.NDQSYWK/9MHAJ]H0\'_`!$9ZO;\/[MJ"J-/F[Z.?@2#8V"L
M"L6Q@]"V1,D2QCUE&D1WVCH.,$K36+ZJ-#!JWX?%M`6OK]-?[$3CE%T)'TTL
M/3"=4N[:E$]3UPQ7ICM=8'[OA:SKT*[X*8*&9)G4MSN\::AV&U>I`%`<.$#B
MQMC/KTGU1Q@/0'98*O:WJC78.E/`ZIK3J1J"WJSH4TV6M5'Z7;;);1U*L!-S
MOAR%3[6;;.FZ_L4U.%W$0;]^"5K58IRH+@^85K"<;:YZJ-#O+OX>[1ZJ:W#5
MC9T<$7H3G9.`0<)`-D1ZA=JOV<OT78-T$66NZ>WKH^T3I\(B'!CXLR;L*>!)
M#?Q&@U5)TDY"D`057QIDHS3-AP$2P!!A@<;#28X42.$QTL(>:92P.ALPVL,M
MR),Q]MK#;*<-H?ERGD(\DN27UX4ZH2=MP!P#XR6O?COL>KT^\RZUZO+S]/N(
M4CU>7GCS\O/S\O/'G_AYXX!K9I_A\NZ]&Z'A57:,J22UU%UQG8-FL\0Z6-V*
MPZ]_<,,:ME%3%LX\;29Y/7NC6]/J&.0BPZ-0K@8;>^PS*N8W80KBQMC^_ESV
MHZ7_`-GA88?X.C#-QOK&@>OP_4YAF3!.QB1*Z(U[L2F6R^,6&)8U6'+.RB=Z
M@VBV!B12>Q(,5$-.-XMTJ'6G*B$^\^T+#+Y+11>NYR;U]J6ESNU;&&+UQ34B
M1;M70`^M6"R(A`G,A5HE7*S!'AU4Q<2=%#V,#7XM4AV*)`6J%&K$>;@=#&3>
M?>_OWS.SVMI,U>-4:SH%?D:X"EM>7[0EWBS'*+,CU*`O2=XJ=V^%2:I#L+LJ
MG1S&:KBLBF46`JJMUHQ-@YDE\M^<D)N]Y]3H-0]<SFMKWL>TD;D,+#K'^\:-
M4H0P%,%$8$/9V[MF;S,O6J<^:(,FIP4UL;\.5Y4",,;8'"2!>1E<NT.P`H-R
MH[P2^"O8KP[&(0(#79FQ43Q0"!&<A0U!S2&6K8L#U($G;E'QFV+6P>L$WKUL
M@N1))7DG)G;TL\J5.D3G;#+M`UU3WE>WKZ%Y]1:^_=30XM(P4;)#Q!^]30F6
MXRX,0)5;!>K+9:I48$5R5*3%%46L%Q5-%M,NMQ&QH&+B'$'P\,P8PEW[[Q.J
M8[`Z9DV#%89V"!675(^*A/KE)'N2?7[>&6C:HR0CKBG/T(PV05[B\X0CU*SC
M&:X:M.^6)/%3J3%R2AP!P!P!P!Y^?YX_/'`'`(;WOM-.HM>$;.RTS),2)#`>
MO19'GEAXO-0\XVY(2E25KCPHL>5.=;2I&7\1L1L.-9>PXG:5+CS)J<+T-4X_
MLINN!8$V'-],3GOD8>>%SW</@)"/5ZEQ5!,8;'QX[B?-O^Y,Q7FDY]4=YES"
M7,=>%1$??F<^)S,_7D;@M9WF%LFC5VZ0&OCMFH/N2(GK]S,(A&><ADH7K\DY
M6F-/CR&FW%)1EYI+;WH3AS&,<FH<'5.5)G7,-'`'`'`'`/C\F/B1B)F0S\O+
M/R,1?=;^1ECUY;][#/J]S+/KQE'N>GT>O&4^KS_+@'VX`X`X!QG)D1GVO>E1
MFOD2<0V/<?:;]Z7G*\8BM>I6/<DYRVYC#"/-W.6UX]/Z%>0'],RHTG+Z8\AA
M]45]4:2EEUMW,>2E"'%1W\(4K++Z6W6G%-.>ES"'$*RGTK3G('WX`X`X`X`X
M`X`X`X`X!Q69T*3(F1(\R*_*'N--$(S,AIV1!=D,-RF&IC*%J<C./176I+2'
MDH4XPZV\C&6UI5D#E<`<`<`<`JIW$NL^HZC>A"WW(TRWEXU;=?94I#K0QR+,
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M8N&O:9L8#0+7N'0)`;97X)AJJ293#9@%,E)>%SXSJO[1M^*A]_Z@IE'JS"F/
M,QY#4A.&UX>84_%=Z-*I>S.2;3+W;G[3@==@JT_58D>S';@%B6(4Q)=<8@#P
M<YOUQ"!1+.<2%N2EX<98'LN,.95'E+?DQ_9;1(YTTRW."MU.CKC"_P`%#=O=
MA;#NFL"!=@"BADH`8<(^^%<F(B2VI<1R*GW8,UZ:ZRY$7CTX?Q-<0Y\OT9::
M5C&7+5*6!#J;Q*Y\HDW$=-H<R+HX0[*PM+<\Y8)D'"_/']S^=\3S3C/^"%2X
MDI>/]BO5E6//"O//*O'H=:,.OT6HY!8X`X`X`X!0C>W38KMS=%TW@'OCU/N$
M30M7H.G)HID+#GUO9@!CLU$1;C5FQ4)M^$!H36\@S\")0KL"04E"B2;0(,PX
MPV+(%)PHWE^GUH1W/ZV;\FC+:"D]ASU7OIT-39.KZ8#[+[@EO5BO5W?EXNVT
MP_XNL0F8:M>+/K"S4C7$?:]EUM:+'3W6DPQXJ&,$`\$`E:3=Y+2UO.TDU]?-
M*;TUKL<N<ONQS=RH\[6U3KS$"X[INFUK#%MP&N4$(]-&Q7-?:HHXH=(77[-.
ML1Z76;%=KS93.;6LK3HY0S4%@VHZZ):[OO4E_4.M+Q0B%RGVG91.S";).9EU
MR@X67*5S7[2)!!^7@9:+P9MNPCD\KB9&C3D2+&(HHZ('&L4O7--PLMDJ)[[[
MZLI29Z7;.-U*+6_I]*!VX]K[;)#PHEAL$T90('97<]=VY6=TTM*M6#\,[ET[
MD89$UX"Q#!Q)DH_-+1=G`D/RQT@5*]O10UR?:)+U-U<V9K>N]@X4$Y3:S9]B
M:JBZZI=IJ!0XV3*VX,<WR?B[TODUNL@98;8=IF;=!+LK(E=NF0I=.3/8N!KY
M4*&,"5;9S?I;T_1UI3J+MV:?6VQO;9<>BC+74R59$M=A>PL4['K:[=HLQLP0
M=/Q+6V:LCQX%5-UAZWFP&S.*TC8`J,`DUZ-'PL*$[9:+&\9<O+,N3J*L6>E:
MOH-0N=A?MEIK%4"@3EFE$RAJ6=GBH+4)PG,,G,Y-F)DO#*7994PMTJ1DJ=F$
M'GY;SSRQ+Q9(O`'`'`'`'`'`'`-?O8_J7=W]CN]M.GEG#:L[90A(P3;Q=B^=
M^Y;M13:\UE`G6W8`*,2N0V2%Q,N#]=[F`QEWW6_O)AX_$=0^34WA2>55UZJ<
MU]9DF]6>W=-[+P;37)==/:@W_JJ3#"[VZX[`7#9V-JD_+:RY$D+S$6H?<]>6
M9M#A'7NU*JN;3KR%RB6.EQB+)0.,&-1NG@U@^\UBLRVO!@X!2[M/V*,:Q>'T
MND.1V+21@X)DB[[#,SZ4<ZZZS#:B19"'8KA&8MA]Q2I;3S<6*VVK$=Q<QIV/
M=-,W>&A%5466)K_MFYMA[*KS57N9A-@:A$VS8J2_!A1R+$MJ-*B.Q$/P&(J'
MXTF-+><RS(:>>S)CQ41G6TY6R]T22PL<VV\3X3=O7C`;-6R4;=A-15"Y4I<5
MA4^9%PWF.]'7+PG"_94WYLID(PW/=:_6[*]QQ7EIA9SKSV$JNLM3V(/^'B)2
MVMW.HQ@5<@SX,;\6GMJ76EZJJ\2,0*NL1A$6/:;%7F#LJ8[+4-#O2#$=HBJ.
M[`3SK6#Z'3PW_CS?DK^Q::'NK9`BZ:YJVS=*MTP=L^TD:37["#V2%NC<2RPJ
M+<MA--&AB0M>F1A<P)1#L5LC`43>9+NBH[P],*5*(C^9TUV_HLMP"N?<+_[)
M':7_`(<]W?\`[9V?@U8KFO<PWO*0^HZMW<M[7O\`UAS4)#V<+]KWOA;CU[)]
MKW/2OV_<]KT>OT+]'GZO2KR\LZL5S1FO_&K_`*LI)LK=X6V52170@LFTX4S$
M^?(*-Q&D16XLMB=Z(F(TN6J0XM^,VCW7<1\(9RO.&\K7C#?<\YBFL@H>Y7(5
M`M<U,UB%7F40!;TA]G,IR(U'5#'H4GV\KCM17Y$W,>._[BU1W,+;RQE[&0,J
MW13:I79]:37HC,&>:>>A3@T5Q:D28BEQVV):(ZEN?%<3(5[;*TIPT^^A#B6U
M.17LK`AR[!1].MEAK`HDR?:!%IHO)M<)++<QR$^IA[V83KLMEMMMYM;67?6_
MEU;:G&'<,+3A1`V(=0-ZOVB.C5=@CP(\\`'2[6)D&,U!;GBX'MM28$J*PE$?
M["(AQ$E$AAMO,V/B4[)1\B.M^5SKIS\SI15EY%[><SH.`.`.`.`1#OG>>MNM
MFI;KNO;9SZ"BT47]@3?9CN3RI.9)D,CPE:K8>/YS3]LM)J7`KU5KHY#I$\?)
M#Q4%IR3*;3D:DVTEGW_9YA^C]LWMVU\4OKQWY[!AY5)E;0)=\M/]?M1_8MS1
MNK="=9:_3:3,CIEP<Y'G[/8-L[*O,2\6-MR7$('ZJMP!)8K+@<?&'6J*:'2L
MN%MZMSO-DK<[W/6MP<1P!P!P!P!P!P!P!P!P!P!P!P!P"FG:;I\'W[.JVU-?
MW$EHCM7JJ++1ISL548$:8<!QI3N)<Z@;"`/KCCMJ:7L\I",6W65F<4/D>M9>
MO3*[:&81Z,*3C=/%?6CW]U8QGK+W!,W6[SNL?9ZGC=&=R:B'>,$*-%GR9NN-
MW5"`O$=W<W6FUDT,/7C7LQ7H=.UN5A%_U81?57;X+:RU`.F0:M*O3A.:>C7<
ME\>"35EM]X2-[9&Y5Q0U]8\/".!WIK>'(,=S\,#&8TEY*TJ;3':F,D$8?6G+
M469Z93BF4LJ>:[4?BNONSC7^3Z>R(]WI8:,077W`\L>3.Q9:GGB`1Z+)0Q`2
MA.4,RY4;U,RE9DX;7'C8E)=CX1(SZF,/X]ZB3KM$D:8$+'EG)@V$0>1$<`DR
M[L>,QF!ZI6)28\R4I$>++4OXZ9"%.I=7EM3+6<^S(3D"-]W&JZ2V_IN74GF<
MQU]C>HD0M+'^3<0B1SVCU=F4ZA3>$MR6U15PV'7T^IM]UA3B5.>6'5S5^+[S
M+\/\ERJ_ZLVK;X_[0>H?_$D3_P#3%V2YQ.RP?+Y1XI.R_P"U9=P*9VYOX74.
MI-,1NOFMMDV"EP:1>0%GDWN[5^K'I02>7L-NAV:#BLV$ZB#(G#H@D$L?5528
ML`E$MBX$J43'=>"G2FVY:G*,,,&>R:W75WM'X?EGV+KRM&\O]B>G)NZ4>GR&
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M28+43`BLWP'9K/&DGQH4]&(.C(\]I<V;B!(P[&]V0[B0WAJ.XTRX[&D90Y,2
MW\+U1T/.2XQX:!$M:./5$:1M"[-.%P;#)FX=8)&'8\=IV-E3^9;<:=+REEAU
M4E7N2&\NM.2DK8RG#V(ZO:`S_5\H(7[85*72<,*A-1RRB\J`C"($F0BMG4SY
M+7MI2TIIQ#L2.MY"?;D3<*?2IS+N'G)J_%]YE4_DN\KFU7G$[#@#@#@'`*E1
M8(62.&R,$.%#0)A4N7*2X\`8+%CH[DN>1(SY3C46%!@Q&79,N7)=;CQH[3CS
MSB&T*5@#SI]F=L7_`+/469W1&CY<?6HJW`=*>$EJ8[&D0E[I[4;F,8U71>\M
MWK\QE#JP-2D'R%KZ^!3,=#P/6M;MNZ)$<>4L=9=#CJH7\<'?C>E*NZ5SSWL6
MPKNDJGU\[N>%CUUHN'%5?0G1'NT)@2'_`$)F%?KSW2.I/6,I^IQ;YFQ$7RAL
MU*6M;DPL3FRW'7'%NJR)F::GK53[59>VAN+X('`'`'`'`'`'`'`'`'`'`'`'
M`'`'`*X]FNK6K>U=(@5383!H.>JIAFW:LVK1RBZQM?3.P(*%)$W_`%?<XK:Y
MU<L0]6<(?1Z908^.5(!684:`S9HR0-3:PZK)K1KO:YK+-^(+OOJI<Z_U&[90
MZ<1W,76B/J'M(.@_3ZG[%UW*7D"&B%6C26V-7]B'6HDG\3ZRED<ULS)B/6#6
MDDN'))!`JI2>+VYOU\C*IB:+Q^2Q=.^ZWY3O_.Q=O$-N,M%;8)&Q[<%'Y@1#
MH1IR(R0$/S$8<@%H#[\E.7HJIDIR!-ANLI0B3)COPWE.,RHG5*,,#@W.)*]3
MT;2BU*$SYDB<\3,"(I%12/,]#<%Z;&2_AEB+C^[+;A*7AA],G#CCCK+WFXQZ
ML):TPJDXW&3'2RZ[G*FILYEF8SCW65MMXB^E.49]*_CJ6M;Z'&U94C#CF?8=
M4[^@#(1]=KJZHY=LND+/<M>;DZK62J:\"(@PREPFL=H].X;'`R%@(A0F395_
M+-9#M6(E7*W$.'A<^QV4("8G%H45NW,Z>&IJQR?JFFWR\]#81?=EW.W;?ZB!
M[!U]V]JP?CL#8)N+1?#.AB(-R3%ZP]C?8#ML:PW9L>QI)$,.+7$=D`(X9#<6
M2F87BRECXD_D=LG=.V^JU143<W[/MX8>]^Q9;LM>]-'\6ZTV5VY7FH5V^'Z[
MK2]VJ7+S/*'+%5ASC;[$DY.RJ:?CUPL`'&IKTN:2A299`B_+%+Q*TH3M@K*4
MC<\+%C0@P<%##X0D.(@Q!8H4-BL01PP;`CMQ((^!"C(:C0X4.*TU&BQ8[;;$
M=AMMII"&T)3@<RO6C\)KVQNS6O5XQ'2/VP-V5786<8]U51VW0ZP8EEEN?DIQ
M!+;P;<3#.<XS[2!OQDJREG&$C7ER]K>T&NB[TPY3YMP*`G_B2-2;YVA0R4QE
MUIED7'O1I78S7#$5MS.4*'0-<;M!5'XR$NL-)KJ("F<X?3'QTH>*ZG/Q5=5:
MI>EO6'VR/K+=;7>&XK!XXQ-'#UYE+CQ&&(+;2DHRA<M<9,:(N3(RVI;;*_2\
MVRIW+3>&,2%8<Z'(L8(TM0BM.BD92GOL"HILL[8$$'TMPWID;$QQ;4;#N('P
MHBW%)RB1'4]EEK.'7D.^I20*YU37U@V`VZ\$:92J&K+$Z5,<RQ`]3;;/L9P^
ME+KRI;Z%_J93'7C.&5R'7D9=PC(%D^JJ'->;XQ43XMK!8^`*C8\]SR5B.XTP
M@XTX,=2M3;D2=&%2&7'E)2^XZIECT1%,26GXK5N7]%4?ES_LVL<Y'8<`<`<`
MU)[6FS/$BW19>L-4ERF^C^A[4T+[@7@9(=98[&[6".QR#74"HE8RDX?UY5'O
MA$NSQF`\M1-Y8W2L9Z.J9?<PQ2_BD_\`)X+1?[O_`,^>DY27A0^P?B2T6@C8
MD5.GO#AUA'V*8&PH[3`-7:+L)72M.U0"P/2E,+#VH^O+%YLK,>+'3]2O<].F
MM*9<;B82&%.]?LG+\W'DSO[7_?O%YT4TKSRBO>'/VDG)_P!7R0_9.R74B$C/
M_P![];("3C_#&,>C\L_J5C@+\'_RI]JS9)P2.`.`.`.`.`.`.`.`.`.`.`.`
M.`.`.`:@>].EM9[8VRQ2MZ5P?9]4;#K8=LM`+9>8AY4.5,B,+CDXSL::%(C"
ML4>1C&Q<R"4!O/1BD"?"E--26^M,.F.:^3E4W37*</)KR[3Q-=-UNQ_I,L%J
M;L$>9V;U_*D80?3/;=Y8M5TUV/F/-P1^MNV?US<=N5%9R_%BTS?J8[(:PS8\
M.%L!D!8GW#IQ>EPY:R>FS^^UK2K4TJ*EC1D]Z/FGJM"Q$2PE&Q:@XVUEVA$M
M*LY@M3)<<)*0_CU+S[;,U32F96%>KU.14-O84E<CT)\U)LYDZ:0'4]!4X/L:
M1#YH9[+8]HFJ'(BN*6N1@I)&Y>4[$DN(RU!90^TIQ68S:9<-6&9,G*0(SW4_
M786WM/(I;D1B+([$]18IQ`C+:1SA!WM)JS,J.VB/_=<H^,@>N0VQCVT3FW%*
MPF4AS*9J_%]/=%^'^2Y5?]6;4M\?]H/4/_B2)_\`IB[)<XG98/E\HL9(]_##
M^8N&LR<,N?'P_E:6,O\`H5[.'LMXRO#67/3AS*,97A'GE.,Y\N##\D*X[.\4
M1/B($91BR]BF._K6X'1\8(,FVG-T:N63BEPZW7`#;KD%S7Z\>A@.!B1G=?RJ
M5EAIF._5',>L>U*C@5EPQ-_?GZGZ=-BOX71^\J#?]W6ZC:V'[;ZYNU/85JM-
MD%5:C0-C:5LHRSU:MC;#8IL(<F08'[FW46@1'I:)4L/3I4M*7VX#ZV!X\<,G
M99W_`*7F:W]G;OTUV`[EV*EZ*W=0[P"M]+U],G1J[8HLP#)VS74[*@6XD*G-
MY3"MY3&JJ]0D2<U:0<2,%UIO,YV`F?&^5T\-J_>OL1XE+BEP\^BM'*\F;7S3
MQ2@1!YB,68.1'IC4)_'PU#W&'WFW5H2XTJ7*;=A.H:>:>>4^UA.%)2XWA#F5
M)Z'$C?)>6Q$?"1[(:2'6XYCX#;TK`ES"EYSA;D7$UM"TJSGU.+S!]><^I6&E
M9\L9`DJA;/>UDY/#N#FC8N3[$G#D67\969:FO5\^,ZN.[AZ-*CK8:]I]IE[#
M4>.XKX[J7XR@)NZ]2R^VNQ0NY+'_``A=0$3Y;K3:U/-PXJH$\8-BNR\MM8>E
MR2)9R3C^S:RXTS)]MK#;"O*:_P`7T*H_)=39F_:J^P^[$22;G38[BVI(\.U)
M.$8RVU>AS$D<'9G38R6U_H<6^PVAM?DA:DJSC&>)V.6,-CRRY3414M#\/+/R
M(Q`83$2T(D)6J._B(6API+D1_+3[;,QII<5U^-+CH>4_$DMM`=MP#6[VXW/L
M?96Q1O0SJK9)5<W3>:]%LV_=V!TMR4=1^OI:0_`D6YI]:7(G[]-H8C$JUH6K
MO85)C3&C&SR[#5;IR?MA5*2_D\,EJ_I9OIF66"@-%=%NL$F""'0M=:$ZWZOL
M%BFH:4I]0VJ4T01L]G.DILIWY9RQ%LL%#QXR1D/%K)89\XH2E221!]]P9=O=
MD&^&SK>VU;K>SMC:8QP5O#MM=;/VPW(/D>>9=?L6X5PR-0U\[EQ.'FV]2:G@
MZ]U2U'<6YAK-,<6C./>5C@VIJ86"LMXSZN7U,:=Q\KQ?(2O+S^C\-PICS]./
MT?BOLZ(SY>O/Y_VGX-_U4X\L^UYK\\X1Y!_A_P#;X-D?!(X`X`X`X`X`X`X`
MX`X`X`X`X`X`X`X!#.[M-!=SU9(>:]@::&N.S*Z<2UAY8^6XA*'F'V_4A3XZ
M<E#:)C"5H5ZFH\AO/NQF\9VEP_@FJGB-4NU^KUVI=0M"MA`*X=I!*/BM%$*D
M0C8@U#,/H8=B31$UG#KXV;'2[&E,D8"&74O88=;7AWT\ZJI.WH<VG3?"]FGV
MS4BN#=ND#BY06/8]E=.D+4Y.KK"2%EV/U@AYSZG)]9;_`+V9OVC!R?-<ZN8^
M=<-:CD*E`LGJO#6)$/QY>J7RO8JU>U>N"KYZ5:/!X.'=[(Z5BH;)U*YM:MW8
M&5#1'JU@3*&2FRD&X@[9&GR@DRN$X*I$66\P@60<<4ZXF+D6VVIM]MV%B/*V
M;K>7[?9$1C9K)XG60&P3U@I$TLS(CP:MM#4>P%2(OJES,)UGM.F[%<8^,M^(
MQ*>),59T2TK"XC<1<],Y3<G,5,5XU*:-I?"YQQ]4U\ET;QW+HFUGM-[1UOJ_
ML=:M;Z2VU8MG[`OV=$7NK4QG6HC0^\:L5O5.M-Z@58%M(!$GV<5(C*U;/N9$
M]`<<D5@>;6A+*^!Z(:G"ZM=.\JSC##.(S-H\>0Q+CL2HKS4F-)9:D1Y##B76
M'V'D)<9>9=1E2'&G6U)6VXA64K0K"DYSC.,\$D24S9(>[;2VY2VM:[(KAG3L
MBGA)&P;EKZ77J5L"-<ZZW:F\ZDO$K*F;X)KOK^HN"QOM,@+,E0R2VM[T.J&Q
M9.U_/KH8-V]99?T?-0^TV\C]YF@/T.MI<3^>_M9(S^E>,X_-"E)S^7YI4I/^
M&<XX"QZ/V9$OB'EIP'3NOS0QQ+)`9V"T_)B/*;;=PVY]W):7YH<2I*DNLNNL
M.ISC];3KB//R5GFK%<U[DO!\F5!MI7<UWJ\$P8I%CCU.1!9+"R0BH'LA)S,S
M"&XIATFEH@QB)*&2)+D.2[+CP7(TQ+K>/4^QG/7BIU.7#5H9QI3J@5V_2)=R
MEVQ5.:E%)0ZMH=KWWC4^*+6N(2*R8_W`.0EO)=$D9&93);\_JY4G*G69D5;<
MNN':Z[S*5$J]GWD3/3^N5&A0ETK:\T:1P/GGGP&Q0L@U548:@RQD*=5IBC0S
M`%][)-XE/B18IJP2(CC9EA+K6&'W'<XW-O+'Z-X%F_C[+DT*D:[U75GD5%@<
M*`>RLL2-NSD2/FM1V5..$R1E]U6'8[#"7'$KR\B%%9]S+#;+>58S+;>)226!
M"%UW_0Z.,HU=,[*J%$N-W?DS45>W6`54+C)+&).":Q0VL6=\8?=RY/(R&8N&
M!ZG9#3#/LK<0YYN;2DW?HC*N*)2>[2F(UL9^!N1B=``VY0`S-@QWDB9UAB1V
MG&C(,A,2SDB@:PK).4+%NJB$XQZ)`F,/1V2:XJ&A!&4:3CB7&!JF%.)$W;SM
M7*TG5*34-,A!6V.SW84E+IO6;6*2&<B;">:A)F'-D74@.4Z^'TMJ<,]BX[,M
M+.<);%-0J\*?59;,`C2<+I4XV2Q>G[>2^$S*NH_5\5U@UT1%3[+-V7N/9%AE
M;)[";N.Q68UFW%MLVQ':-66:PSE306MBHT>)6=>TN`OZ>C480$K8U*\0Y$R8
M,;EZ+):+0KAX@V?WXW'K!T''Y^5#['['_>9OR,UGUIB=4>MA`!?MC0"OL^I^
M*/VGL23J;2ZO6EMHD)O=D82[E$24E(VFTU:*W-X>2E]#8C+LK7RGA0&(H^7C
MJ]F3'BNI8&"7/3C.,'#&6W8PY2/6PIP=';GG\QWVY<4)*BX<=0)-<E3+/N>+
MEMW\2H&B)E:\-[1JE+218<@RQYCLOV,DRC$)U];$J/`;9KT1!!N=%CK@36WV
M5.RX*!Y0@*_P7_)^RZ&S:$0@$F?DCIT,A']2D?(A2693/K3Y>I'NL+<;]2?/
M'J3ZO/'GCSQ^?!)S.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`0YOJ=0(^L+)!
MV.4P+`F8F1S3C3>9)%PIYXE#<BH2/[29/BS(S4UMK]+*4QU.2W&HJ7G$U3,J
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M^QM-$`TIO#K$2H!K$1F:T#O-N8\G8KFD[#KMS"%HPVN-,2A*5-92I7&I0WWC
M<[S*3U2ZN(;\TR9.H\R6KKQKBNDI#TTQK"(=T<=(2'%.O%C^@[2<TN<-K<7G
M*UX/%*'+--+5G/N,SVW,9RE:59PUX\[^=RQ_!A6/N#(8AZ&-D)CS46`+OFCR
MY.;)<0Q$'"A.\]<$BI.=)=REF(/&#HLF>0FR%MQH<*._*DN-L,N.)&K'H_9D
M1=R-CZ;)5/4`HYM;60T05[%:H'$Y12WU?XR1TN84:((2J45:CLRG(.9"(4I[
M+C4&7EF:Y'DMQUQW!B4Y3L3P?MIX<69$5I3$`/'C0HX*(,A0G8DB`J*UB$[!
MQB.\RY&6UE"8:(N/C-LH;;;1GT*SGI332Z9>^>'>-SE54U5R[OW;U,3?[':[
MJ5MU]U]?FDQNU+U7+'(IZ8-4MYNF_74V8"$FCY*^("R:B*=BHL$`PR(M-@@$
MS;V)`^$Z1DN,RI<--8HZJZ;65GU]\,C.K);"M2)1ZX$8:C#1$2"Q'3(:5*=G
M-_':5ZW'G59<<QG.<M..H5A]U]#SCKRG59]-TTIJ6]>G>)SJJ:<+^S[NQXS5
MDLDI]#/PXE;JNPW::TRTRF3;I;IT>X<+J2I3TYN`U6`^($=4=$2&5B.FW\3B
MC(EX3$7C>)+FTQE,'F[L(_JV%V?WL!>)'T5VCV=VKN;<5VO>H=DU?K/L/?T[
M8FD'(`O&F-5Z>VE3PIQK2\W6(6/FIEP!"RZSCB3<5ZV$2Y"%8/GLJE$XY^6T
M9\CI354U2Z:J4E3=2DU5FVGBGD[Y+(V$Z?VUMWHWX?VB"7;TU;'MCZXU91*K
M/JL65F\WVWW8PID7KO3H=</*E;,VH0<G5_7B%Q7I:C]HC2IRY^(7R23=I4\,
MO]SER[DY535XK5%DW;))9N'9+%G\=<(E#USL3L9VL[C;0U<"[>&@6MX^UM;B
M]J5L+`Z<:MO3LVS:STK]G#+"90@0;:DBB%TOYA4&)N7;<$Z6'-S@P>H,082G
M;5G2IM)*E-K*S_DUB\_TK:SC_:SQJO#OZB;GK6FML[KNHFXX>BYVO5*@)V->
M7Z4.(!9<^K$;-9P#TB0-E>J?"GOU\%)G6.8#G0)I02W$CA69QJ&T***ZZ>)4
MVYX\I@Q'IMO/6G9+N%LKL3'UQL*]:][-8/\`7KJCMP33#YRCU'1?5W#TNU7N
MT[!GMH>IA??>]+7>9-*FD_08L0G75,8BRL.`F$<1:;^5O/J*K139-0ZE-YJP
MA8N*8G)2S;]B#<7J5($>A>38:WV=@^@=EIK)1J:8GFAI5AJ*K"4-EQ9889?%
MMJ<<@/SUP75/NP7'5;3$WP.=2;5L?(U]Z6`3[)XG7;-FU0G9#%-ZC]%,>N=G
MW9D.*G:'=ZPQ1L?.5YDQU$I4O*9;&?[&:!^W#S49AE<LNY5$N,"E_P"W3/\`
MNKQY4FPD;:15KLS$<E5!+F9BE1XA'$=*S,3VT+<8<P0PG$AM3?I\TN15QG(J
ML^\TYC*/SJJB%,\R%7+B#'7)]<&#0<`L!S<2<:%\,R];RI.S-LE!4E\,7Q`_
M$3YA++CQ(=+4N3&0REYOVE*2YZO2C*:>*\P*JH<>9(@\FS4OA0Q(`E,!VE#9
M*J!P<2"S@<0>CJ(&PV7)LH4%%Q5Q\.V(>F6093(>_$46,K"V!,"3)9G`FP"S
M*GF(KRVI\5*%3A,YEV"7@X<RI*%RATI+<E##JD+Q&FH0Y!FX0IV#*DL^3F0.
M[X!QI<R'`87*G2HT*,WY>Y(EOM1F$>K.$I];SRD-I]2LXQCU*QYYSC&/SX!Q
M()L,4<6T,+C"+K:,.N-P9\66M#>5>G#BTQW7,I1ZO)/JSC&/5G&//SSC@':<
M`<`<`<`<`<`<`<`<`<`U@=BU3]L=@L:\<)+'@Z6'CI\DX]S^VF#X9DG*CL+4
ME"YLK,Z`/RM6?2TQ"2_Z'/;4V[VH5N9QK<OD5^VGJMG738DP*)OSH4J9\534
MY#6)4>6VWF2TK#C&&VWV'D-.X5CV6E,J;3C*G</?V5$D>1@9P@5E!*R/(39$
M-;R9*1[;BW?-IS+;KDEYORPB.TYY1VLN+0PK.$J3CWGU>L"FFV>NETJ-ZM^^
M-'%P>L]LB@!BU;>IFP)TROZGWC5*-79I\NU?E,Q)CE5V$-K`J4NE;:&CY)%C
M+$8#9HEAK$MMD=+M_)=5K^]SI2^***KK"EYTMZ3BM:<\FF78\.SQ-^L^R9V[
M3`:H;OTW5Y,S1X:=1-@Z@OQB]-]@D5^1JRSU;$+7==M[!(^9J%1T>^$#PG5G
M3CI.5(CAVU(D-,\6YN=G0Z4E:TYXK&;QJYTV-K76U)B1.WY8UU2V5&D7?=:[
MEK:#=`<JI')00GJS5\*U$_P>5]JR5V&7V<+O1I$:UC@)^5.)D9;P&)`='S20
MQY<K^;^"O7BM]_F/#7Z<7+LHS2D;"M35@K="U_4YDR0."$+K;GI6($FRD8C;
MLR*`#C1I<U.:AI;EE5#V`<:8-?*()PQM%/'4E,&E+P6?V@S;GB*=E274OM#I
MO4X4M=:9;[%K^U:D&6L:">_"\!14[3[K6+I:KUF7%(UO!23"/1#,%A#PQ`>:
M$G*,(GPAT\3PE2I3>C3_`%!OBZN:#T979>[F(VE]3Q+M6.QNWHYBSQ]=5!BR
M2XUR.-;;J,>89;#H)/,!:)LBK`0C+DE30^OBQ0Z&EJ%$CM('-MVO:%]/UDBS
MIULS:":`1U"FEP9='Z_WW:^E9>R%/X@Y#T?4>P+5K2N5L&"1"9B6&R#P];'N
M,*C$8R8E9:@O%!TXS)%M6?8PC/+O4EXN5;':&I^;ELIH:@U>.1-&SJK()BBR
M4]8`,-DG",P4W'D-S%R1H;,Z9)'H;P[&ENKBQQN5JPT0?98<6RNJJFU$1J13
M2DY3E&"M[5V/5=KSM4G=0FY%0B49B^53>9HO320<=,,7<^):U!+KH\^JWD[/
M4ZU`&'$6%2808F,G,BYM@E&QKIJPXDWA^N153I23<3.&=L'?KU)#PW&'/XVP
M^5*'34J=+K8W,I]4.$]4T86Q+KV`\+$<1$C8L`^;8X922/)6-/E%%3#$F%E;
M;>*EMQYAM)3BO>2"*_:[W1=*;'*]AKYI]8I1W:DZQ7H%4)>O1P#3\A)HL(@D
MADBQ2(#,ND5-^)!-7";:$QYN&9!-T4V^PK)'6GF\%,RX1B=-N&F)M%I;B_3V
M->O3'0]%/`PO;V0-LVINING;!L*U=#-&VV9'<=KL>_2#![8_</;SEY'F9N+[
MLY1FR$=60C^53=4ZG,R)278MBO)5L)B5].YGR.E54*SFIPF]\.'"T1?)QL7_
M`*Q"ZS=G-4%[D>J>I-W:WWNS529[8+=>I5I:VL+!X7*H;MFAO5Y86X!:FS$P
MP'Q)Q(P"FMM+B`H<WY4]-1#M%4J>D_?4YNK*KBH=+M=II[:'C*\;/P7=LQ^U
M]B[-Z8NE9L^J^U&\]:4NNA+,^>BWP/N#<$QH)]$V/%U\K$(TQ!$78[!'L#KX
M=P,""&A+XAW(D&0M4.9OBWAN\CU>%XM*H2_VTN^32]GEW"]4_AV]'=5]$=-Z
M^!UB.6N>^*5H\=K"S;*,6NW*IQB-$MUNV,5F#M>R;`Y7PT*!;+U8&P>1@ANS
M3Q"A8<F>@1<S2,2G2UGC"/-5XBK;<63=24+9<YC+";XEOJU8=I6/<!RDC==K
M@:^<UAC8&=YIW&38,F=PQ+:.$?NX+:JB"FF&P\^H1XQ"1>HA!H?!AI:JPNLQ
MTPH3S"JGAW6IE-2J6CTVUGT@H_HD-)/^)SWOW/-V;<*[/K.HNHNNJ]69HVNO
MC945?[W[%*8N(R$!8+RYT7X[D>3"A$P[8UBU$F)Z)5D#5<\%Q)O`NII44SFZ
MG[;[::7-HF3LAI$"?5Z4(%F#6&T?;%YK+XMIY\X%!OJ&QQ"W)\Z/F482XKY:
M*M(5"1F0J/F0ET<DV\'ED2DL4L2']GT78I%&LPH+9H"HG@.W`5SV"1&T>#=9
MFQ-:NGS5@N>HLA3)^LMTZ5;\EH\(7L(//-&@2F/>AU3+<QQ3>KB2M,<A_";W
M>5\]_IX^C['=59V'>0E',4_9UOTZ3H>WJZ8M,&H#:L542IU85+43U6:_$0<R
MV/K^Q!\L;*+VD`@1:&1:Q30`J,A3934]2I?KSV,J?"L)M&=IP=M"2G2[LBIU
MDF>C.2"[=N@-@2&&4)*NMCUI/R(L%_S9?^588(6?6&667$)+O38X^9[D65(5
ME4DG;^A3,7Z<CD$)@&NR&HYN797[-(Q@@<E`;$<BCV",Y692O9@Y*1(,J-"P
MZW$%,3H$I2`L0="F+?0SA&2I;O[AU)./8_SY+`D4?NL=#5A(3['B.$L)8>,R
M18A1A8T+(_7!'COCQ620LJB.RVTRAQ3R9#F'/D+RYB4N&*G"E0<D=:"9&N3[
M;*8;<GTQ4J=E3&8\-)41B)\@T(4Y*?C1$//0V</Q/D38(])>*$E$'FXL5Y2M
MJ4,4U<6.*S)4$&(!R"V0'.K<97G*%MOL/Q)D5].,9=B3X,MMF9`FL95A,B',
M99DL*_2XVG/ER2CL^`.`.`.`.`.`.`.`.`:E.VT&?2]ZOVP`4]B<9#A32U1%
MI5)%R&XJJ^IJ6SE*T89G,BL.X2^E3,E$AUI:%)_)?:C\>7]_)QK_`"Y_T5X+
M7"TW25!EV<GF>R/4O,",IB-"C/2LX2K$=B/!CQV7'9+K;3<E_*/6AK.$*>1Y
ML-JHDS_5.R0M&)V5@Y'E9B&WX\M@A$:3(=;RRJ4XTB2WE:''([[$S#K2VO4M
MIWU84RI+ZEL`8#N<XWMVTU^$"A28X@]:]1:R)2'VT(>=![#VY5:`6F3FVE.I
M;8D-7E0W"%..*6PXRESTJ=RRW-7XOO1%T?DLHE^2;-KG9)EHC&TO4D--_)O'
M8_2R<J2A.'GD:KL$C??IRO&/6M,9C5$I_"<YSA#>'\XQC"E^?$[+/D_6WR3'
M'V+K^9?2>JHEYJ$G9P6L#;J8UU'L@=Z\"Z<8(3!`FUD*HW,4=AUPD5'SAL$U
M(@MCI4Z)(B,R5OM*1@9&>6$D9]G^L.ENXNDKKU[W_46KGK.]Q8K14;\N2-(P
M)XV8P2"GP!B"XU.#'@A.-&GC2$5S&4N-*C2VI8^3,A21J;3E6:*'^'SX*72#
MPV;O9MGZ)#;!M&S;*'E5I%^VY:AMK/5NL3Y4::1`59@%6ZD!$Q23\*#B<14%
MDV"3&B(@K,_!?F1I(JKQ*J\<-%A]^I=W4_\`T/O;M36W?^O/6K5.X&?/_6^K
MM>HJUJ6-Y8_A?9Z#-^E7^UWWT^?Z/+`G)>7K/R1]IIMPJYVCU)!4TPYKSLE;
M9XMS#^%PR4;:@*F[^)(PXA&/;?B67;!R'/CXP]\66U%<?<0J7[3.IPTS*U*6
ML3U4K;0Z_8VM=T39-&!TG=-8H0@F5L@W9>J2%-&VHEMFL6*KS0<**/M:C4(M
MKK\(2'I=QG%`0HS(.Q!*0KK@]+N7^;4TXCO^B:%"<J[POA[S/;)9,F`!VVNU
MV[0RM6M(H8L@^Z,;DG*\1K:):&HQ=LLT-0L?'<>DJC^Z8@C6T3FYPYAXBL>M
M[!5-60=*;GS(_!3=Q"+'MR/MFJTB+UKC3:N2T,2!NG8FUQ@]\5,F;!D[=Q.?
M?J@]MBS3,N4]]G%:8$TIMUJ[2Y%C2XAW$VG/>\]^QKII=*5]_B.FIK!QIFI=
M\>RFV3%;L6ZBOA_5.V4UK<N+%:;%8=:;W[`:2AK#M:QU;K0LXA%8T-KPSA!'
ML22KH62.W/NH`,JI)M5:H%N?*I<R[]X%_C2DDDXE-8I59SCQ1:G1.=#<('(`
M)T%P($S%L.OYDA`F,Z2@$8\4J86O+#J@]F@C?HV1KCL=$,3@LI.3Y6:W'%DV
M14@+]HES.9SX5$.Y%.V[5K[2NKKD5CT:UA:AI&F$+(FIZ\I;EP/FFQXM$E56
MK`"J27QL4VJ+$A#:O7)\\;-L$R6PR%AM"FX\\AJJASCEI'(.B82LYS=KZLI,
MR2QV&[V4@C60TVS:<Z(Z=$WZ_5^Q1IU=,8[4]FJW9!-.KTNO/024A=ZTSH,S
M<5EZFF.LT'/;J`C$)R?1Z(N-RY+2X:&IGB<3LKO#5M1RY%Y[1;3]3/ZZK&N=
M(WFTSMI%R5<N-CM9"N5FO:3KN:_.+LV*R8*S&OQ<P5F18H&.+H.;:4B$)C62
MJ(N&EPY>NIOI>Q"II4N<L'GZ98WT,QG+-O4(VY0!4JBD)(\@G[^S31K<NP_%
M;E-CX--)I*98'?BAYGW!EK)PHJ0XZ3%+KK$B4ZU'@9+JWZ?025.TZLTUZ/VC
M:*=M/Q4.S/8&J@M.YU-I_K;=KEHNIE(NQYE;FZKZBO[6OX"N[2%R1U:O4S(<
MNQ@?#@!X3B)2)<U^;)A.9(+VFKAFW:+JIXU0J7BZDGDTZDN[[&A#I?\`M%Q)
MSO.@K>.IFHZ=KSLYN'4@S95FU\7VF6VXA=>BO:VUP?.RK%=#%(L^*0&/IS,$
M4S6^O7CV(:)7]N1;2Q-EN7)W?@Q0DJFW2G$X:N._(]M56L^L=P6/81W7FU*7
M:A>LKZ8I6TDBC+;Q775YK+,.;9*5;8.<(>KMA"L2XRIHXO\`"ECVW4_)80MM
M2,VJOXQ&4>??]'D=#XI=D[WQCJHC3*#SV>-WX[.ZO#OWM4]+==]6U/%[MVNP
MNP+2>W`()E0_X2E6"QAJG(&UP#9PDMH\86%L&9B2LF#,#`V0C!B#++RE":9!
MZ?#\-5IMMQ,*/VGJ7J\)/Q&&_%BZX/WJ[BCNL]R:VOKU0,,@Y<&52(EW&B!-
ME`W2IL(%CY+XTD-)XB.UFU23K@]QLP,7.D,38)65L6G3$Y^(O].I4S,J4^L1
M^S:VMVO&E?)O;,L/<(,^,!)C@:9$V#8I^'V1\2?7_;BRY4D9.<=C-.9RMIX"
MX[@>==BNQ_ENZJFE':.;I3<]L[&5!.-S'856G5<4PZAWW-<VV;DM$*2)#V9+
MS[DB!F8_4YOGZE)BB7K$+?\`>^Q<%MS<2,R)OCZFMK!YY/O8A6A6_>=AU73C
M.X]9474EEGE#!;\(:XN,O8]:BPH=AF+I<R7825/I^5FW@C0HS,'+#90/,J]U
M+_S8:8XZZ4G,W>[_`&36X:5.&5H<YVOGY[EBPKTZ85J<MQI4`Y.%DI]H4VCV
MFB`2"E0X4R1BIQE""$HA.'DA4I;33S<0:=AQ9#<9V7#?EQ+C`I3"G$D_F&C@
M#@#@#@#@#@#@#@&K+;SHAGMF<<N3C+0O`\)].L@I*!N',U<7B-\E3N<,XBYF
M?88\WO[O\ST^]Y)]6>=J/Q77W9QJ_)D=[]>J#ZZ\L"Z*>L_R\I>6)7&<5]?A
M&/93/5%SEOW<2<L_"P_GW<-9?]']CG'*)($4Q/E3U"P<.7-DLY=3C`Z*])GJ
M0EQ2LLH^.VN1AB+Z_8\T9S[GEE2W%-98:9`[\!LD'0Y`()?1F!00CN#2QVU7
M9T21D3JD(UCL(3LM.3K4&-)EQP<D_50B")+,/&(#_P`66:D(%,.RQT5IM3IE
M\G3PW#>Z?MWS@N?LKN'U2N.T.LN*SV-TO8&J3MV\7"T?0[&JQJ57VH'7_;E#
M0..CAA*40#$Y1;9P;$4<2BQIS_MO>S'7AIW+?([).'9W5K/5,NU#QJA27][C
MD:_7@U0ATB3N*`U7G%F-80695J$..WZ,E3A&C1&",VQ#/45>!,HGRBT3"<2G
M7W!)HYU7^TP>&=MOLB'ZY@RVX@B;1;HM'J.Z;70Q`?3=CL!(@@4%PV0Q;Y5[
M!B3I%^+%'FK3000^-F0F4>="P$.3$CH_"K2FW)._UY,W2=B[@5U_H+=%TKZ_
M19:UJZ\E:JGSSA<BV1ZV1S5H3.,?J5)GV'(V%%;3^MV3(:;1^I6."%=HH)VU
MZ1=5Z?UC(Q:UHK6@J]Y5I?557O`6IB@%DEVZU;%J>L:19;;+!,#UWMT)8KLY
M8WQER381121*,-$QQ",8*1Y@U5.;MQ=OW<:89%OHU9U'J)R+2:/IZ@@Z^#0M
M+<,=714)#*2BFR4Q$'"(2O;0\ZXVZ]E>5I>?1C.4XPVA7+5$J9.55</75][&
M%:QK&_7-9CE;.&:G8)YL=D?KL'1S5CC!UZW=FHSK27;&K)E,F7L;\+_%;O+P
MA3]<;/XEJKZ_K'6U94-*9Z>IOB*8X9C-;_.UC37VY[W]D:AN`D#K[ERT0,U+
M&CV'X%RKD]!?:X&,Y9A<*PW&!*CM2)NJ"4<;;H-5J8"?',J3))W0F8'7=RJ0
M==ZJ4Y:UMWOIIZ8VTE2U+:NY6>2T:F[>>T\4SVC>NY>X#0[J3KV#L;KLN6*`
MVSOW>9[#D$[UFU'-<D+BT^J6":F"F'M+=S4?)6B'\P(I2GZB9);6M%>#R&A`
M"9-;XHBSOW=?&9=%/!+=U;A5FFXOJHISO=J-U?W1_6VP]=(I?6%;LARR:T&W
M"67TM2)0.JB*SIO58V(#AUO5M2:`BARC0&K+A*F_>VUTU<2Q8U)EGS!,E(S,
MDZE3PWCV:Y8OO#$BIU.I.(>;4WOB[PN5B6;+MD8-#&"FU;*-J>N!;#Y.XFI7
MD*CB!$5IW./<+MY3,$M?8J@XP1CN)*QWDM8'3(DQ;4A&U4)*TS[F4U-N.?V:
MZ!GBZZ9<?VM!OM9_=!I.L@;38J=8BTA,9Z]4>M!YAFT0CL1<6"NB7:R08)4C
M7:^_*ES3$&>V/61&WMM8=><,)M^GL[=^4TFVTJ;W2C/FM=],<+DK]%-7[*U_
MUWK]TMH)\#L;LZ>*]HMF`@D7.(`&S;=Q`+5K77L0V$L)BZ<UE!U]I\5!SA<6
M.,H,-<1.&W/4K:>&+Q._?JO@>(ZN+^,NFFU,9I9]7++]'J;8;.\+.QY$*5@B
M)%K?S\E*&H[N8C67%L90E;;D1U:LR$*CY7YJ=7Z493Z5K4U)2LIMW8FJEN'G
M%^^\-32OXC_8'=H,G6-`UV#:];4(/-M;\O;E>NE;A']C&PA<*436*XFIVN5>
M*!7:F/L=5DDY9H572UP)/O@X"H].#%47O*8;>_MI/<^^U65+Q:M.,6W5VXZ<
M\,+\*RRV'M4.\1\9M:J(NL6V=A]95?9Q!\-7L`[G4JMUHT=0",!%?A%ITAJT
M3@\61<B#+08<#)R%+A5\8M4DA4@<O%YY>5CJ_P`?#M'\9A3::JG_`%FL#D:R
M_9P_#^T;V!!]F=6"=KW6'6;`S>*)KNUWP;9=>4:R!IRIXN2-%1ZM`O%@5624
M9F0%'V>V6E]N?";9*Q2<UE&%;3PYS\=^@K\7Q6N%1#4-I0]YO'5)&Y78^K`U
MGUX1"5-N4.$7\':H=GMNKYTJN7!\Y<8R8I^VC[=751[$/M+DIIN;"LL>6DJ(
M,C!\EM^/,'0O:VGAO/2?LY5<4TO&+Q$W48JZZ&LGNOX3G2SO[6NLU:W1(W`2
MV5J2C)HP78^N;FDANRR:AKH^2U#39;E?`ET$;#9A69X'),V*QQBA:*=M1Z8H
MS#*6$E\R7$VP.M'B5TJ;7NU%IODL/UL7.Z6]/>LO1;4W[E>K5&M@I\++FGYD
M*[9*ERIN^'7'JXNUW^X#A3P=^3)=KB(<V8,?6.%``[.`(=J''&17$N(R_KZ)
MJFJKCJ<O#*$M(Z^9:6>Z=J;%?LLJ6-M==K+TY^PP@<=2IH1\A'=9EVOY")+S
MYN9$1-+Y,O.,0&GV",XBD/#QYNB\$G'55X+$M-XEVP'&IV9#1_!^401%:^(_
M(3)96[+D^U"9PXM:&_DN2\8\UI5A'N9]G'3C7#$7B/@Y\#F9M,]Y'9P;`L6L
MVRQ9$!(<NP$9M>CV2J$)"W(1=N,7FS'X+3U?+1HV+,0.QHF2*HJGH$6.XQEZ
M-ELA+A)O!%MI8LRFG,F63=DQ9B@@X<?AUV6R4`AY8$5^&W<%VA`]H9,/61[$
MB,48L4U^8HK(S*038PGVF668L?#20^`.`.`.`.`.`.`.`.`4O[<:0BW4*K9`
M\D/#F:@'D8+J)*<:AE0,53LM#?O,M/.()0W79&(*?97B=\KXBE(6F-G%T.+:
MD5J;Z&J]J5%C/)4U%]U+><^EYUUQ$GU>6<)>;PVK,=E:,^3K2%LRL-.8QA:Y
M&,>>>IR)YT[?*M3B%@^_<5"9/_%F02WQ9$KVVF79F'H$EN(U(EMYP\[Y84TR
MIIQQA:W%>W\9S(&*[4MH2X7%TL!;5\&(!4/>G+85'40?2B>A,S+3B4/)3GYT
M6`UE]"'LH8;]2$(]"4@73\->9C/6X@`SY>_5=Y=@8<C/EC"\YM.VK3LN+[GE
MC'YX'7N%A&<_GEG#7YYQY<X5?D^?O<[K!<EZ*/B#-M%T(%LKILO1]IQ*S6)-
M5W#ULL30^1\2:V`J-FO6CRT:#)PESXDJ..!/QXKV&U_'=;;5AO/H]/,*>,YV
M?G<\DNF/V1[;U2[2U@_LKLQJPYUBI][%V;#M8&W*+N>Y5T$89*1JW/K4T&Q3
MZA.-,14#2)V#?;.@2F0[/@BR#B&XF!W?C)TPE=KI]GL0[-9R6!:GU^S^<W9'
M8;2XV.C/YM/C]=6Z/OJW0Y*/R2[&(4/4-J@/LKSZ'6Y66UI<2K+:QP6?)^MO
M=D"]^+/;&3'336]$F@H%BV/VXI3DV;90,VTA`M:HU2NMJ;LQ&MCK%4Y9EL-L
M>/K)N'%18A2$%R`R4^\\S'<AR06?+W:S)H):Q['&)+4LEMOK[*D,X2E#J^LV
MPD9RE.<Y2AW#7:]"7VTYSGR;?PXC'GG&$^6<\U-K!F-4N[I?G^KD=W/7O9;7
M]-V!=PVZM+L3@8&RW)J".T!LL(+=FA0L@@Q&^H'=JTU_+;OP&F'7IH,B[(]2
MWR&)[N5Y7AMM'YKZ-5GB5=&]M]F,JV3UXWCJ<3V`W9I[4-5K^H=K/@QI<MAV
MSF9%GN"K/^(AN,`:[1[G/9P.KVI3Y24FHM1H$625++DPZ532:7F%2FZ75,4S
M,>B\]RZG7_JS:.OP_1G7@5>61FU+9KG:W8?L[NE$2)M<YL[L6/L.E`).W/2=
MFA/A1!%V(76VRFOK:M6SHT'2J;50)`(`KK@^9)K<R\L$M%>,-/MN66A:U'VX
M"NP%UWLCI^1!"0YT$2)/]:SREN0IDN/,P/GEQ78&&TW%CXAPX,10\!&S#'1T
M1X[:%94[D9;1^?Z(\W8/VD8J`.F]B=+]9-@:WNVQ]74RSEQ!4S82;QNVW@'7
M*@9':9V)J<O6B#02[$@!XTLCM7,\-51YTB$>DGH8WUA"RF8TYVF>>1Y!=FZZ
MVA4-D];]`;8T)<HRYNN[)NF]CMCZEM)FORJ)UM!#=JV`?*=ACGS`<?8[C0JM
MK2W6Z%D6*C4K8-A&2[D"9-JE9NJI-)+KY:F^'0TZZG&BNFYJ<6AZ.=9BQ[70
MFGNPK8Q(H_VCP-81*(R&Y&JM)TRJRX[1`C*((@P_WHE]Z08\$8F5@<*C?`<1
M$&1HD7R<RS[BX,MIYOZ@ZF#U%BX7+78=^[^L^)TG$I]31+4^M)B',1V(V$PS
M.C-1:I/#D8:CM^7UY2*O#V7I7K^5(?><"=E[^[:-;6U:WUX[*B-&Z5V%WBTU
MJS?NK[WV+U:&J%]MM"L&V=GL#=TE==#RDBI$]CTJWE+$=QJX>664;C$9%D(E
MB,UUEZ8\I_FIQ="JB5=5<-G:RF-8:M+(PZR]`!'0#9=PH?8_L<*MVB>PN_=E
M=B(DVZ2V-:ZX<(U#6.O]=4C7-D65+?"S>K`?VE9+8##S;8;7(@=<J):*Y[%@
M%6%QC,;ZE3*I25Z:53OG?O5FWG'6(1B(Z3U#OK>5$&V!$,A+B1]CXW-3K3AA
M'J@*G,;PB;1),!7V/CQ)L.B66G(+!H\82_+R/:::0)G9>4>T>I$&\]@[LZK:
M],[.V3=.O3VKHY*FUBXWT=BP]?WZI%O=MKVM0AO-7LQC;M*L)T<2LHCR,/WK
M6$+V6D-RXA"(/'",#4E4X4SYY3DD_1E7/&6VQ;NG?7+;7='1VM:D]V*U3J\/
MK/66TI%)"GCU$I&P=@5$5:9*)<P?+>D`:\])Q8\@)7R`&"(V#+,CGA#A5$BK
M<._=^7R31-7B4T-Q0W,:PGZY:QA<\I_@W>+/XINY^]53T,[M-OL/$[(SW!5[
M&;J1(4+JE>K`Z=9;!>@5BJ`)1VJRZY4!9^&+%1V7*<1E$(8XF'2YD<0'2G#7
M,]/B^'0J'"C)1G-LWU>=CWW"0YW7[1,],CM2W5,,B!0:+.BMK.FBLZ+"$0\/
M2W8T2.V].>:;4_)=0IAMQQW*/0A>,W54FE!XZ:6G+Y<SC0J"%'(@#GB]?"6.
M`[!GB8$9O!.#%-,R&)SKJV2GDR*@GY\=$DJ&ID2EYDL2Y$)<R>O$,@U,/&'!
M4J8FYV1<!`M$J6;)%&:M,@9BP[.-(K:<0-E)0VRP]&GNN0FI`X@WAI8N:IIE
M$QM6%*:CS<2A\6E7"B"71+F3F#IN1D$39YEC@"(5CJU8APQS8*7*)Q!X]L@0
MB8:ENDGFWIK31[+$R9(")C*<9:7B"RIS+.92=4YZE-JE+R,[#%%_/^O?(J*1
MB4+!>ODW$16W)<1G#$<G!=3"C18_OCI#L64EU;$9<B,53';8<<%3G\X;C=&5
M\`<`<`<`<`<`<`^$J5&@QI$V8^S%AQ&'94J5(<0RQ&C,-J=???=<RE#3++2%
M...+5A*$)RI6<8QG/`-<O8;L_0;]1[#KVH+.N29\P:C)R3`9B`YL0>28FO(8
M<5-R42E]<5KVE2!;#;B?5AW+:%>K/2FEIRSE54FH4XFO-QM;2\MN)]*D^7GC
MSQG&<9QA25)5C.4J0M.<*0M.<I6C.%)SE.<9ST(,HB1:XNLR7BI4G".-D6U!
MA\(4Q/C3X+S643Y$V2\1'Y'IC/1F$1E-IFJDK6^W\=M+:GT@3+I8OKJNHLA"
MR$P@W#,>.^T>M$B",B1(49$I^>EV00=3`%*0E#4AS*YCN)+32ULRW$Q93,=W
MWW^GN3+U`[%]=!I'MDUC=NF10F-V)'E82U[$I8X8H9/ZW]>432D-UPNQ$>@R
M;1&L;4B?'6Y&=+,$FU/9E-OI3QJQYP_0]%*?#39X/+_Y,LKT^,ASVJ+*3KI4
M=8:[/[!=I3`&S!)L8J`L8BT=C]HV^$5`EX+KX\L,RU8,0DSX$B1$<DPI+:'<
MJ:6E,FO'HO9%IN#"!SUHZS;M-&]%V*T:1VG9P<ALB?U(0L-'M]F`S@[V'&"A
M&E+FSS04@'DY2]%).CHDP9)]#S$B.]A*\#;J]^9@Q[J'U_9COV">UL`5(KD%
M4L)97]V[B(2-;0QQD#;I<G7R;!>C`O7T=TC4`,HW'JHX7!.0!#`DY%(A_<@+
M"7AKHE\(\="_VFG5*>Q"JVG77:U?6)-JR"_>=CM,>QM)59Q/^-^/TZ[S3?I?
MSB_](XHV;5B=F/Y-9LR9GG&P/1_I./\`&=.&W*9]3V.*ZTU"ZUO+<G<W8:QU
M*VA,H?CYW7:V8)ZNGH'I=9S)'K@$6HA09*4C+\&9#FH9?]R-)COX0Z@<.+:G
MR/S/_$.Z=>(E`\2'<(BV:BWK:]I6_>AE_3MOJ]8MY,5::V[97OW33-76H=&6
M-B5P)660,$!#&DHB*#$%)!SV@<H!,B0AZJ*J.!7225U*MK/-^9^E'3M(X*]?
MM!F.U]B/1=VZNT#4!&X-HT_<.PM12<V:-2JQ*V[-,W;6-UI+Y*JR[97I-AE(
M-$I(%AR(DNVQ'5A3W!Y9NXP;LH3Y9%6]`]F.E/9+8AC4?4KQ-KS8+^%9G27J
M16]HTC:!4@/%^K)&;69/8C6>SYUR&CV\>_-+U4J<8C1?1+?G)CK2\H'34KU4
MVW37M'J713H*[D;'1YEX[!7C8U3HUNA7J+7++3-6"2A>Q!AY2*`^WL-"IU,B
M+$BIY-![$"%7(4J27$B%+)(@LS84\9.T<I[[P/*EWE_:?:!0NT&X^OE9Z;5W
M<>EZ>2O'7K9UYL=^F5*][$`1B$ZK;&@4]P56IN*Y5Y$Y@HT$;($23QUJ/$-O
M)KTB6B/`':GP6Z4^*&[KX[R/1+7W^M)_J4*[J6'<79Z5I"9H6+V)<LIGLEOR
MIE!.LUT9-^?63KNLM@U2`^9'@?6S,'8A$)[Q-ER$V_+DKPIT<KSPPIF,%C,:
M:GGSZL>/5X:O9/M/3>O^P.BQ@!4MH7@50-=;HWA;AG8$D]8[*3:#U-=_K=_@
MV"=3HAHG)A0)145=[L@/*G-/D7,"FIQ6*.K\*JE-\2M=I6P67](\\?<WP@/$
M<K/>C9&N!?639EV<VANVYR-3;#H]16UJ>Y"CYTQ8Z[*%72$U#H-,1%K2<3IU
M:+%0+M+A#Y4:7"@01F%I'6FNC@3E*%=9_;OGF?I+4VZU;J9U.T8/[F;XUG5C
M5-U'JW76S-J[8O\`7JC6+ELD+11`>UD%6.[D1$0E,LQL<6)H;D._.((>=>7'
MRK+F,#R1+?"GG"5W'0_JKZ'ZF[-!0-EZ5B546$MZ'2\#9?5G81368^YX<><2
MHG*MNA+-61M\CIEMN9S]W*/CW)#2VWV7<)<;X$M6?JICSP(7`4RJ=E*93307
ML?L??.E']JSAL:E;4UU0H\$K;]46*QA)<2?)(:AH%C,`]>6.L%K@.3;A]C5:
M;A1ZJ29LQ,(X[$/#7*>$/;?DX+F2-8M$*\9J9VW62UU@]#GBR=?N,"BVD5."
ME(N89($39+TR0\;#SV')34N&=D$_?8F/PEN9@88BL"37#TMZ3:4ZB:945K&E
M.OHK?).Q7,!MO9VM]+`*._.9<NYXV'`,CG7["X%%B`TFM"Y`<64;JCI0;F>+
M##&'1\`?5"3</3D/$K<*[BR2;F+%;/$VM6\^IOAZ=Q^RNA;]MBP[>(;`H%JI
M23YB!8JQH\?,DTVB6F3IS7S-?CB!(2OUA!ZY2HK\,RX-L,\S=Y\W(\>0BY5)
M)[8\C?!:K:55DIG+BQ=WK\1J>8SP$.]OB`[O\1S7FF+EO#<F_=;;3A7PCMJ#
MM&V679#%-"`:@:/1KX++V684D4M8^R0P89"84J`&,+.1ZZ[$<GD`[D7%4URT
M>!W\;PJ.!M))J(:MG%];==S]!.O@(5X>5>GCQIW$N29##VH:!0UE`,%8[".&
MN#2K`9FV0DD8JOF2I<.PQUD/>0O"D0\M1D8><Z&V:Z;'3JWD23G1@#S<>M.Q
MS9DV=8%3<K2BOOQ9)>=.D0HQ!:G`<IOWW<22;U:9C1V5.3Y#E4U<,[DU4\7,
MS@(-;FL@X`UU2PM5G*E).^7I=*%VL2V)4<1CS4C`[RFSHA*;GW6WF77AD++B
MOD3(N-RVS4H21(_,-'`'`'`'`'`'`("[1/SHVA]A.#U+0^J`+8=RWYX5\&58
M!,8DG/E^?H6/=DMN_P"S+2EXS^7GRJ?R7>1-7XOO,UQ:ZT:)M54BV$R7(QWB
MN)*H#`WXB6HK4>2_$PN9F1'D*DK<=86YEEE<7VV\H0IW+F5X;['$BINC%B)L
MY68<@4I^ISYL:>6)%1H08P,C$,CW)TF85EQF&8[4U37MM)=>EK7/PPVT\XE#
M?$]XC$S'6NKX=_)V%90D_%&@GV(*6QN6?E2%+^0U']#\AE]MJ.RQ"QCUN1G'
M)&58].<90[G@$=;@H$&F;!U#5GU,G@1_L)U*6Y%)1V'\/C9_:/5\-^`3C*0J
M+)2I<-YM]"F/8EPW<MK:1AUQ"9K_`!?3W1?A_DN57_5FT7>M(I<78O3^1%J%
M7C2&^RT_#;[``4R\CU=9^Q^%>AUN(E:?5C&//TJQY^7Y\XG98/E\HM[C&,8Q
MC&,8QC&,8QC'EC&,?EC&,8_+&,8_PQP80[V*K6Q[IU^WI3M.6)-1V[;-.[-K
M6K+6N2Y#16-C':4;%TBPJF-)6[$P&LLH81S*;0M<?XWO(0M2,)R-42IPE3RS
M/S(ND/AA^*H'\0'2X\'UT[#:@V%KK=M4LEIW!:Z=::]1Z6."V>+,M-J([.EQ
MT5"S!Y8=HJI,8,?.)V%"?D"0[!]!3X[X]=5='`[IIJ(6/EBO@_4[?88E,/1I
M++4B-):<8D1WVT.L/L/(RVZR\TYA2'6G6U*0XVM*D+0K*58SC.<<'C/%7W[\
M`KPU>@E;VKW]V%<-[6;0>O#@FR#.H@*96H+-MM%HM@X55M51-GR!TD^)UW//
M%H@\H^X+FVH-262,ANR$"L-N1('>GQ:ZHH42[<5],><>I;?PGOVD,;WP[15W
MJ5L_K@)TD7V`/L.-.V&E767:0*YU1KA.T.TRRC"5="+'*>JX$JZ)/C9'PWR,
M*,&4`B?8,2F1E?A<*XDY2B;1MKJ:0_VH+6'=:P>(8\=LU7VE;NN4^F4"#UG>
MKP:QG:$+3BK"6+\%BH$L2Q$#8,O9#=E(%X[V&[)/`RZJ\O#H=`5#(Z>"Z%3D
MJKS..-ND1U/0!U`ZS=Z>TG[/K<NIN^W[]J_L;<Z%=Z/K0EN61)'V@CK]LV,M
MNM@US>S+)6@37SP7W=93V[./AV0-5?<C3*_(A0X?V(Y5.E>)Q*Z33<:YQ[Z;
MGGA\-WP@>[W3ON7K3MQW+KXKIMUNZCW.-L[:NZ-A[(H3`:<.!J=AQZ75LUBT
M&Y=F7L.;,CU-Q<-OZJ4*,S(34J:9F"0!@=:_$IJI=-+XG59))]_)[J.I_B*=
M*>\DFSP.JW8.F[:,4QEN79:]`BV.M6D8-=D)AH,YJMV!UJQ2@&9CC,/\001D
MD*F6_&BJGX?DL-N#SU4U4_DHD_.D\478OAF'/%+W`<I>E>P,W4</=5E8[!?@
MC<%*I\:]WZ#9I4;:!_48$[J:W2*T$*69@T00T6MCS-F?DOR`:=>#Y<+$,>FA
M5\"NL+2IA99KVMN?H362X=%\^&*S8K<4!T/P][/U(K89MXHHF*A!NO5ZUR+K
M%8`1V8WV-B:L#M:-B:\%%CTD;6]9GH0T:U-/N1VW1YOY<>M2JYW3^SPZ=3.D
MOAMV"[;ZWETJ[G;-[*[WZMZXV%V)ZR]4=C=>Y.M+-=KGJ@5,M5%+33\LX4'[
MI'U`[`%6,KK^L52G6&W-C$PYX2$"ED8JQZ*JJX2JI5*JA55)S9XK:<);:*F^
M'IWK[X;H\3[I>=N6U=I]H;5([*U-R/2-K'SFQZR'@W&6NK;"LE5JIM^=7]<S
M*YKXM8R<2S546#:I,,8DDWF.)%NQLBJJ:515"2MRY)O.^3Q/0=^U0]%.Z'8>
MY]?M[:0H]VW-I36^MS]0M%$H<278C&O;G+LTPX1OCU/@Y=*S1EQK[H$-.-!Q
M\]`G\"L-G'(#$P8N2.7@U4TRFX;B[^RU?[+#J+9^E>INZ:_M*[UK$JX;1&7N
MIZ4@WJNVBT:X`O`$@"%IM``$7*.TJ1?BXA<)L$41!)MKICLDA"C2I2FL"?&:
M=2C2[C'^CMR_B6]KZ1V#VJ8FPH"T,&K/##==]RU:15)^MJU-<@QJIB/,%#Q-
MU#DRPD!73)TH9_'M5-S99Z72X\8::C%<=%2FE>_>7>IP=7"[T_QR>L8M/!KI
MI?$W-]+^R_[Y>L.M+M>3<4MLV/!+4V_MQ6!HL@7N=`E20QRS.AFG8HRO1+9`
MA0;\EI;L,$&%6@<W\MB*J/G,-0VBIFZP=_UT=CKMKZ`U=V&K\ZG';+?*I:'-
MCPMF5P_0-D[%I#HVRBB$(C])@[3SU:F$:M8\CU#[6'2P.B&Q\AOV?,T(`G8N
M\+B8L8JU-LY5U;U\U]V)K@SYUDL62%BC16H6J1[\@H%'LOMQTW6=&R]%C/,2
M,RH3CH\*ILO#0E];T2*7J]ABSLL'7X4&5>QKLIZD53ZOIF:_;K*SJ'5M2NQL
M<W"_>'!!A*R;5(F36QXU5GN(T7',R!,.>53,DHE/RHBTX>0N`_E[TYNJF+R1
M36W9],8\O,G^LV%=:&A0)QL*^KXK>(DRH$'#3;[#JE.194D<J%"(K?(H=8<2
ML1&+)FR7)4Q34")EO'(C/(J5A*D[*5\/9"9XC^R?IL63F`=;=;QEVQ2FDLR5
MB,QWD^Y%!X;=C/R9#C:'C;+S.(&<!W<3"0TD%IIIAIMAAMMEEEM#3++2$MM-
M--IPAMMMM&,(0VA&,)0A.,)2G&$IQC&,8X!].`.`.`.`.`.`.`=+8P`ZU`#-
M;+M9>&'1LP7.;3G"5_'FL+86MI><9]MYO"_<8<QC.6GD(<3^:<<)PY#4J#3E
M>P>XM`SB%240)QJT])D*#FH\)EX62BO*SE+P^<_&D*%S5)SA<R!'DQY,:4I;
MGDM+C4E[NFFO='!II]^A&53IEANDZ2*&H;^>_A,Z9)(O.--18B%J];\YSVWG
M_5*E/Q_80VR_)?RAUWV\,I4[G3#)C`W8FH3^'X4Q4-XTSA29@W"9XR<YA7G(
M94U/B9:6Y'D+6ME$N+A]IAY#B<XPZO.0(])%(QNX:W.72PKE%\=B.IN1?]FZ
M\F26_P!*?3$=J,\ZTRW`A08H]R?);6POXV)$=AIM/I>RO$U_B^GN7X?Y+E5_
MU9MW[`.MM7[J#EUQ#>,]EI^,9<6E&,^GK)V2=5Y95G&,^EMM;BO_`)(0M>?T
MISG'$[+!\OE%F>##5)XH/B]=;_"QKE#>VV'N>P=A;167<HNL=?M"?N)8FOJA
M-FK-8"QLA`&UVNQ9)"&/C2%_/)E23RV!0B9''FI@L710ZYBR6+9\.DGC"]:N
M]W6[8/8#4E?V##+ZI/5FH7[3!R+7&-A#+5>2,8-0(8^7^(&ZC/#7HQ)S`KUD
MF6`2/;<@E<GT@_JYJ6@JH=+AQ>\K#?>W(NC^]W=W_P!)]_\`_$W1O_\`8/!,
M+5>OT5[[5:^)=RM`['ZV[RZ:[*-ZVV:(8&FFA>V=&#38R8-(PS8"PUXFJ^2$
M#[!7#XT::$27XTN'\V"TR1@SQKTN#(&JS352E<_HUH>%KX)W17H_9*UWKJNP
M=L;(N$G6TFU:W8W%)HPM_4P"[5%U9EUX%2HV(A*_(JI4G69Y;[L@";BSBF`L
M%2I,8I@77XE52X7"6<9Q\&XZG;6[4VNHU:\8Z[:?:#VNM@[1&#Q.RUI>N,*&
M?&12T8?,%ENM0*N)+0V9:(T]E-QS#3+:=PQ->9]+F1S<:OR_9D?[\-HP_P!)
M?J'OI/M?^]3P%HZU'Q*4X_Q<B(7OX5:)S>/\<(15&Y:OR],7.?RP$+5>OT:R
MO&"ZO;`\5[P[;5K'K,1G`=G4G<`:V_N]O[4B@RK-8]:M6`,>U7:'2WH@B)C[
M-E;LE=(RWWJL1,":Q+R:CA"&#\0515P5)O#[S-`/@9^%OW5Z%]X`>^^T&I;G
M0GF]7;;$4;3]*-46]7K:J/.HURRDR:ZY<WJ+5]?TV7;ZW.E$;M<P4TI:)E13
M6Q!B`V8*A1U\2NFJF*;W4O"/.[Z9%I.T'[.%KKLOVEM^^Z=0NU&EZMLZZDK_
M`+#U47+]4T@7K!8R3I>TJH]\`[QV$<I`TV2DS"*!I'6=V:"R9LAH6AL6U!#P
MA*\5TTQ_%Q9.\QEDDXZ&R'Q*>FNXMZ^&X.Z1U_66E]%ZW&%NL^J=3E0O8*_7
M>749@_8E"UEJ<19JI(ZZ5R.<K+I8J`#VV<S>I!0&-?EW0?&MQ@%&K9P314E5
MQ7;NW97LYO+-0'A`^!GN?H)WKU?V6[K[NZ^:JQ09%E!ZAUV%VP.G6W;U[V-7
M#6K!$*&T3C5YI`1UJXRECQ\1^=93]A^H!X`-,2I*^#I7XBJI:I3O$N,,_CD>
MFNM]<Z)/[/;[DU$=5.O-G%1*$6?+Z#U#I&F[#VA1-DA9CLBR[(VP6UO9K_-F
MEMBU'95>99JIFH/PH-4A$'2$XG.=D1QQFRSYNR>RY1B9=:ZKT5U;8H,+:I.A
MV[9#'MD:\(W9>3?8+<.'&U(6VNA5O99W8FQ6W%.+0XU`HHMM'J4G+$-*<)Q@
M/Y9>EEUB$=>;M!C8V\].WZB:^W)7-:UNL[!UOLJZVFED-/1WJSL(GKR8#A"*
M[?<U;;^"0RY4L(A9F)0QP4'3B=U)1+6.GJ@)FC,$URP<_K/63S.]UO'4\-+:
MO:*EZ9N>OMY6C0N@;]::[^/M;R*U6:6>*DWXP"QVAJ,*>B;:*5."N(3S$+5"
MV4XJ6@$2I-->LS[H=2Z32UG!NWU\HO\`T?$:G^,8I.9=L'E[Q8]!\#7O4B^Z
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MF7.0F00P^S9H\"2E\O`>(ZVWBSIX"HI;LE5DV\M%+]B<OV7'5/:P-UPW<6W>
MU:JAU_8O=0F:2A;$40$R!BX(D\0VN6K(TXEF8-I<]$BC.PY:$1:[(,Q;'.@*
M7+P8>=VEPFM?+<CQTG72Z8E?DUS498XGK1KB)4\N7LZ([HL29BCH\(?):<8F
MDLC\R<(LI"(YAM0V3.BOL0H\1YG!10J`-R84P^U'$")(,UX`X`X`X`X`X`X`
MX!T=GL$&J5P[9B>58@`!,\O+PCR]Q;,",Y)6TUC/Y9>>PW[3*?\`XG5H3C\\
M\)2X,;A-FEVS[3W1LPT0M3)*Y?%C25O,1*PX::"UYE.?=9CL(&Y2PPIAKT>N
M7(_O<CTX?DO+5GSYW224=OF<6VW,W.AJVSC=;L)"WNI2:F'5R$61N8ZIM9"5
M(?\`FX(XDH0K,>9(>]Y2E>R\UE6)6<M8P^TEC3#E7._F-FD1;:(3`K#CWT@F
M&W)6]Y*)/1?GKE3%-LY4J0XD:SG*6&FDQ4.(RTK*G5K`[W8G6R`Q1C#I":.M
M4)(YS%AKYD)&?$%!RTXQ.8S'ENRV)+#;>597%G1UMS&4J\_:7Z6'`F+JS,^\
M/;J/U#L'7]FRF.K_`%[+W=.U^P`NP6`WI[7QJPN-P=V[#CUN*^8*5^603#C4
M6178PN`B0B'`#*B0(<=B(TAE/"I0W;/OT/2JFTKO!9[*?4O5U$DRE]9M*"R$
MF1,+4ZAB-;'I<MYQ^7)L>K4N:XLC\MYY2WG)3IVK$%R5O+6[E]2_<4I?JSG`
M\7S-6WC/>"G7?%9@ZLMH#;'[F-SZAAFP`@\3KCULJ5LIQ^7%(R*]81L4J)(C
M)8DK&61!GAC\K#*2!B`1#DDS8$P,+\/Q.";2GYD8]./"'KWA/="^V+0K:'[V
M-WW(.#W/9[E(K+M?J$DSUSR0V'JB@BZN@W.**KN+&@G".$W#L<R=19);D5`7
M,8?'C!56ZZE:%AKC9W-G^WK3W0UB`"6`?:.K]DC%-BZCH$IB;K+:U?>AYVMM
M2FZN8+1_8W!8&YOTDJX,%W8+BH/SV(3L1$R*X\AY`E0\GGFLE.AD\F1W)@XF
MHD7SJW*G0X,J:V%#ZNV;..S_`(\=<A$2`/F[P$M.3)7HPU&;?F1F5.+1[C[3
M?J<2)FG#/3B7T>0XJ)UR4NXVUV^KF((0#LC3D.YEIM6$UW:$&NZN):YJNPIZ
M1$HG((5>SP8E/LCD:ISSZS@*8PW7IDA92,O"^J7\/WOC.WQ!+?\`ZN-FXSB6
MHPO*G:^5F>L+6T;M)FK4B<)WKK=FE'*!$L`A&Z.KI<=L8)$C-A&80NU#J-V`
MUW7QA+$$G'P2A?0C98PBVX/?%Q7VW8T?D7_']IVZ6P.VO6W^R6I:><V%8A/5
MV^:[JP]XE9[LK:5_T<R!@1EIQ,+E1A/7NZ0HP(-:7B8:*%;Q`A`QJ)!0C);'
M1)$ELY67F%PO">E_KR@T]]@.W^T=?,Z>9ZY=K-:2).QY78G>6SU]?S.KMTUJ
M*O:&RJQ9]3AG[5<J.963@!Z26)"A9-ZH4^89^%+(IA_"^!$&W32G,]R36W3E
M&"NHP5[<\397J&W;RVEJOI_V&I\"J[BVY%Z_ML[.BVZU0]3AR,/>H+7UR+.8
M*U>BVQD99Q-@US5WUU^+0H0J6)(.3F"`YOX$<A#Q96J?I?#KA?5DU/VON:5G
MBASE2T;J=\U.3"AR)R[?O0:VMM*YDU+\L2?T=)0ZR'BDB,7#X^)'F.0?K\26
M94J/A06W?DOLB(Q9'-NWNN:?L_=GK+;+&#VJ"FS-*:RK@?75TL]\T2>IVZU5
M#YEDV]O.R0255P&KMFO(('6\V.-4IK4K,NK,S(QQ`3HJL,7,7E:+?/$T0=Z3
M8LUW#[`V&E9F!;M*<K!0\2-U,]4)==V54(4N@B&H#-F`U\S8*\#$:WI-C"7V
M`/DUFS2"DR=6"Q-F*ZXUTH7\7OGT.==G0],KX3/*\PTGE<V_==[F+[Z$[+?]
MZ=?]Y:9'AJX#$BG#-GMU=H&]Z1+AS+U6'8-JJ$360C<U2CASA`S%JEAJTF1K
MP]/N8YYY,PD<B-<XO!TF%*<YX*4UCK#ZY$J72RZ,ZXZ&W):M$`^JW6ZP4`3-
MEUZZ[`F!M=Z?%['DK@#JR*WA:*Q!C&8@>P%SX008:<>D&Y40W%CBU,DGA,I-
M.GA6//GB334ZVDT^EW$Y+NZ+-ZR(W>?&;_>4]`=<565?O$;;>F.TZ*2P,Q@Z
MV-<--L.-!D3_`)3<7$UJ,_D2E69C+>4.I1M40HB=N]2*9XGC%\5Y<NG[/&KM
M7]F$J)/NZ"J=2W)MD#HO;J]D;<%UX9H<Z?)4.A`+(+3&U[.W`9LHK70NTE6+
M`RW6V[M)&V1@)$S*(@39YM0R;![%XSX<$VH7Y8[QC_9ZBM?:UDZE?J&G.O,;
M2>L].`"E_(;SUP1H%L!;7/%'A`.!J*9JYP!.2#*)=4'DR=BE;'"N)0IC$-N,
M53.Q().ZG#39YZOY)RWQ6B]MY^,D6<J^"+<V$`@>PU;&R42U0A!Y10&\.`C/
M>%'3&(LH2^[-8+QS":RVIF,MEAXAF=F0W,&1V\[4TX@FE-8]]]9Z7BA#?7CM
M#1[Z0@V75?82A0;#;Q%YJCP88?IQ2R:UM3V;159D6RK*B7Y%?L@/VL29K$N+
M$*PHA5GT,IC/(WB?#$;3D9PQ5^33QWAZ/<GVP'K%6:U2AT7#@Q[(`<F<YEEM
M;J)<6%$:=A>;J'$(4ROU9>QC'J5G*<85A.%84HI3F<LA74U$>9S/K!A(E1K>
M:#0)1XPS'"3VU14?/EQ1[\PL")I0E.7'X@.>IPB]"5A(YG[;[M_&9@$-AJ79
MN"DVTI[WZDS\PT<`<`<`<`<`<`<`<`B'?@N:9TUL:`/2M<I58G24-MXSEQU`
M_P!!"0RA*?S6MZ/%=:2C'GE:EX1C&<J\LU3:I=XV)J_%]X7-;^KMOTJN4N$%
M,*DCIXK,SU(CP7I*2>7Y;\M#S#C"5)2^I+R67$S'&$X6WC*'<,Y2EOL<2%8H
MLIL&QGU5D(VY]R:EE6H+BFV6(,'+\MY:GI/N,-L)B_-B-KRVXC#KKS;+#2_<
M0SD#@6>K62J/MCC,'`Z7&\R(_,-;;C+\57H1(DQY3"UJ><BN1XZEX6YF8PA2
MG7DH:;2I(';EMJWRT!LUV>3:7!<;;3.?;B,1WY4=E2,^<^4VCSPUA24*>RRA
MG+^?)#OO>YE"P-A73,()J"-\4X+.1.%1-GTJTA7VL*2S-$W/KCHPC--1FUXP
MMJ.;O$:[S/:7C"VY7RFUXPM*L8X57;YGH7XT_P#'Y;)'ZR8Q`J^S:NY_[Y5N
MQO8O$W&/\$XO>W[7MX2G&/\`X<)KNQ@R<8_P_+SQC&,^6,-?PO:/<L?P85T[
M5_WC2Q,)G_JKE>]*ZZD__+,/9>[->:_FX7C_`&MYB65[#F/\,MY5C.,^?ED:
ML?-^2DZ'M@=9&@])!'H\B6JY=G]$!XL.,C*W91"NW!O90U"LXPKV8S<^AQY,
MV6I*FX,)B1-=3EJ.O@+/D_6WR9<FEV+%M20>>%)?40R80C)96%.^F1F5B,A7
MP_F^7Z?85(P.]I"<*6E"DIPWGIQ+AC.(.7#_`"QMCC?O#S->![5W6?8?>L?8
M)VNKT+WU8:46VI$!O5DA,U\;>U98A.JC6TB4QA;%)DVRJEH@L12%SI;5LL$/
MVKJP)*1!>NB]>FFJ-^^1;I;4JW^,YPY<*^>?E-VGSO$_[SZ4Z.=5[/:]@-[/
MCNQX<2C5!=2&N5ZX6"VW^`=0*'5$E8ASPH,6C_0%[<DU8X&!$2#3C$H*Q:R0
M.7772<-MYSADW[&T^&Z^&E-6AN<(6J5]O1N\FJ3PKO'GZ[=F(-*Z;;"U7V`8
MV08?I=0'6*ZS`^_AE_KP-$-HW;]Q7`#4Z*T%<FL#\KO!LK0F*BW]NF:2)1!K
M9!Z-C<QRYG2KP71-7\8=X2B-E+<[=2^O?7H<.&CR/8*HQRM4%5&&'A;.K^IM
M7G-GV:VTD?F!7PA+7>HZ-'00*[%JX[`T'$C-MP`SU/C-)/S?JJ2%0S7'"4+*
M-N?W[V.*HEPW;)SALYM$W\WG!=?1.@=8:&Z_6?5.E&9]`7;KG821.4C+8O9%
MED%TKJ@F\NR9XV.Z5L=B"5\,>CR6!'T<%QJ4"#B8(4&@%!Q-3-3Z[]X=#:IB
M%%HME"ROZZWQ/MURU'<.JNESE1VGO?>6]5M6A=KIM^W<]7SUS%,MPQ8^+0UF
MZ56@'FT07">9:FF1>"A239C#?SI*'F1\?'CC._?N;,_XJC:GWO/EL=<]K*K:
MR[)ZF/53K'5-A(-EMHWG86^Z(#U\Q8=*EB%!&B!UOL$1R$W?[98-R#V8='4J
MA9-622$"MN'$R:W`91C75*PC7O>WL2J<9J<*(IO=)RLX4-MWMCFR#)^P.D??
M(V+UML:E71XH"+[IL=5N=TT[MRD5=RN4W>DW7MC"O[(-5JFQQ'W]HP-&S*&3
M.,CKK`EQ8$F!8$R$P&<3CN.G7,JJEQ,KS3Q4IQRF'EGC>Y]?N]P/[5.:7$:;
MME5I6LZU3;H!V?>W@@*N;<DV5P]%,`*4U"G%[@#<J6&F&KC@W2&ER(E@0"=:
M!QYL"88-MN<PDE2KSC;[YR=./T)J&FIV76*3I"ITTYO>UR;SM(H:#5*P5,P;
ME)&,'-A&(TATC$/G<)`"DUJ+9Q$4@<,Q(9&0,^M%6N6,2_-SU&$.790KX+1%
M9]C7ZY=&Z<8)AHG8#N7I8;'[1]C-BV&RFZ.2,Z6@:^H9+:E=HTXX[-JIDQ1C
MAZ`JMZS!"*!:RH\@B;/LUFF-1AT69C36*@U16\:5@K9R\=.?]QY#^N_[2]WI
MO7<O7DO:`+61O5&R-IU:J3]:U"G2AI6I`K38H0.,Y1['@G,L)$V$:FLO,Q;'
M),PK`IA^`J*.60;F0=3:MBM.[G>K_P`>ATMIM5)2G.FWT>^&X6T]6=;.V*N#
M9Y9^9(M1^!#%_`P3+1)D\P>!C1RRLB&,C$#T9^*S%<)3(45AYW")4J*CW'FM
MI2;OI)Y*VU$6G,@734O8E[L&K^U.RIFY-8PK1H:5K2=UIL4&@%1E.N%BN`2V
M9N!A=2@&;A*V!\4=BHR?H+&0J;8(8W/*@A9"-,GIQXZ;:=_V6L(L[O\`DINL
MH3A1GAUR,CUD$V,(V-M*=>`>LTZ3@2Z]%T8;H]HFV>V[3>L-?G?O!C7&I/5\
M:&KDP?:79,$6P,/V1LW"^:3,NBD1I"UTZI341/\`;)5$.EIMN\RNBB[G>8+#
M#*M88,>3):)LJS,G?8-5`WC)JO!X^(T9EH0))+Q]P-<3\5*OEH?(!1[TR=D=
M651\166X*,J#AG(CKI0H\W..S&\-2)2$J3&A1?5AQ`H2TOS5''LKPE2U9\I$
M]].)<U2EX9:C@9!P!P!P!P!P!P!P!P!P#BSI4.%"F32#S,>!$BR)4Y^1E*8[
M$..TMV2\^I7Z4LMLH6MW*OTX0E6<_EP#0U>9=>*6RT$M>U^4/J.2<F1!:DL_
M/5%AK7GTK5[D?+0Z(ZM+C\6&K"G8C#B8KLN3[.%X]"F+XGG<3;`[G6VPGJ61
M<GX%X(QY#"1LR#$RF,ZYAUU<IB=&PAI:,2FG&G&GT90EF0PMAK'LK90[@#M;
MKL-J_P!MK;D^!)`@:_(2Z_ZUY<(ICOR8CT^2XI#:,,N.-1H[,1E*7?0[E*L.
M.J?2VD#.NQ=<U].TS+!#\C1TJZEZ/KNK%`$WX9I\MLNYU[7XU0TN.D-E),IQ
MRRXPF8B4[*C84J>R^S(8;DM359/OO^MBJ%-2FZQ:V5^OT3-N[J'U[IHZ@?@*
MD3Z64MV\="UF2*J=\V-7JH?KP^_CR%E!V2BB+;$IEF%.:X9O@IB"=`$8XQDO
M,F#40YB&Y+?$]";\D^EM<KE]Z91:5KBOQJIK^I5ND5B&],E1:_4P@ZOAV)1*
M6]/)2T#A4:+$Q+(SY$B<0E9:S(FS7WY<IQV0\XXH28._V(Z_QMGM:2D[ST['
MW._A&6-1O[-I36SWL.L8E-Y:H+AM-K<PY&SB0C*!.<+8SAU/FWGU<"'C%M3^
M]YT.Q;&U_@#4IP6!9!5ZU+L`/FQHG9!3YVJ-KTO:#`0H^,PX0'Q#ZZ?@(LO#
MC$'@^9Z2F!)A,10J8-7WZJ"F/VW;#L:=UU:V]+]=:R%Z]=D]AS<)(]D]E%)]
MN,T"F[BT1)6X"B]5X#0,>BS7!VY`5R#Q*3/&@!#CT8>X:2Z,&V4W=TLN3U)9
MHQZT;.KM(V<Z!F!I]YQ'D/!A!H>5E5ZP14S/Q%6X!<LV`8GN526&-P(Y$B.#
M-$6Q*7LCHSTIL=SIQ+AC.(COS.+I:K>DS/J2E:/Q%'2"$`Q!P$(&C8L`<*9D
M-2);.(>/BL8D.AR)1.?3';CHC>]-=<RA.7%9PZMW&,HX;S$[P*VTU#R-2?B-
M=(V.S'3:7I??UJWOV@M>RMP0K[JVW:?U[JS.R-.OF+BV/UBO\,PY]*"6K4VE
MZAL>^"KK8B\UP^4J)XW.=GQ2^0DH9%IVGO0[T5.EII)-4W3;AN+ZQ+PRDUJ:
M`\%'J]X3VB>Y?;/ME8#?;*O@NN-_J\^H3J1(U97I%?/.B\/5@:-B72P&7[9<
MB4(366;+BT"XM?AE9>$1$.R,$6J:2P<\BO\`5K\5JE4\%UG+GR5E>2`.AO[2
MG2ME=@M9Z*['=0-$Z]TU;)P+6]0V&`D/%;-07,LL!JI(OY"UCWQUM@RI38\:
M:-P8U,P/7*6;7$=C,.P^257X7#2ZDW4U>,VLXWS/6?LBZ7/7&2"M#Z?&[GL,
MTWK@.&K8NY`J2S1==V<HR!V'81<Z>,*PT,T%H:FZS-?0(<&5:7%QXD*6F6M.
M(+U."AK&+6<3>+&8P9MK9!765,5/=%P@4^4602C9(9<8A.H=,Q(,4BS+BO%W
MQ#16+$9E19<#$Y4?[.%*CHS&<NKAA1$[:=ZG.B9<SUUL>4_]HI"]I.G?3'K_
M`*KZV;;WX=ZU6?9NX+9N_9#UF3)L^7[F:'V35E"L5RI`>M/YU9"09MHX+!)^
M_#FK%52*>(DY[83UQWWZ^1ZO":JK?%$PN'?*IJ_+S<6,4_95+OVQN(WLS-OA
M"]7+KU1@=<*ZV,WN4?-#1FUIT@H)*C*-/-.R(<J&W6(TB;98D%;SH"=!#('N
MB46:R,'M5VEO`_\`(A)<,*J'/);=7&N>!ZIZ!=]A;(W!=*)?M:'8>K]?UFMW
M*H[6<LU:P*OEK-**035=AUT`58MXS\%P$*Q.S8!B!!Q1YOXN<M06?E[4HP4;
MSB>>ERIF7I$1I>R<^D7)$!.U*QEY(=FC5D.LK%EQX10>&'-DHN6&7I+#CS[<
M5M2\MY;RZC+:F\-OX3G'GC.5XUTNF\S$&*KB;63\^^[D6Z!J=ZH=$*U[?FQ:
MONO9\/\`'0&Q8J.NWZNS8A9&P%)E?BS=;0R=Q>&C,4^37QBI<F?+A&H[K)F:
MN(HEF+C'5*2SS9JIAMJRR6/-S"SF.<%5=&^`[X7O7_<`3?%'ZU#'-BUN>R=K
MGXFN%YN%/J]E:<Q(:.UZCV:Q$ZQ'(#Y?IE`GI@V=^'93,2<"2.GQ(\IN3J_$
MK:AU6]^;Q-K":I&'M^W7'D@X^$I1]-\=,VL*0GRPE"0*W&&QS:/-UW"`$D*E
M^6Y\F?B;E/HR(.6,$/IE9+&'&))/"7&(349*\#PT%6<8^(.0YC"\NOI0VH@0
M=2F1,<QAM*(T%F+"8`YJ0@=!-1I`H<@PMO+3A1$..F>XVI#;>4N2TMX?<QAM
MIMI/K6K*6DX;3G",Y3D#M.`.`.`.`.`.`.`.`.`.`.`0'VAG31^A]A/P,K2\
MX/&07%-YSA7PB1\4.(8SY?GZ%P)4AMS'^'MK5ZOT^?*I_)=Y$U_B^GN4-U%L
MFB!:/%$%"$<+/'KG+(-/QW\_8*D27GD3&EL,N_+6N,MF,IKS5)1\?#.&O83'
MRKL<2L=FFPG#)A81E4$61GRYS$=.,->F#.D+F0(F4(SZ4,1H;L=/QL>:$/X<
M_4XE#*D@?>IQ'+&4'T]V?%@M'YT6!"G3_P`HPXF\XMH<MZ3A*GHHU^6^E@E[
M><L(:=Q/=CR'X$;"0/YBZ[-$MC:J"QU!R;H?L1U]+S%!SH@RA<.G[II-OG3H
M:1LR4Y,A,0:[(>D2VD9CQ&O)R4XSGR0J:OQ?3W+\/\NE7_5FW3>*O>V7U!'_
M`/6)?["V*=+C_P".%0Q/5[L=+9D.)_VMQ#GT:TJS^2)2HN<?J].><3LL'R^4
M6+D(=<8?;8>^.^MEQ#,C+:7?8=4A26WO:7G"7?:7G"_;5G"5^GTYSC&>##\K
M&U>#;XO:^Y)6BO\`7S>E@VM.VO*-H[+1A]B3J\H;DV995O<"M^);Q61K<F4I
M-M5+EGHUN@/+^.^'9L;61B1[%XGAJE724?CGRCM,_4YK4(L-K@`<?*8.'8`0
M5"-&DL)BI,%HL%A@D4Q%1^B-@A,;>EX81^EG#WMI_)..#QD`Z0E1@EL[<0)#
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M$_\`/:*QF)V6F<0(>(<1B*:55,Y0754U$$8"^INHW>N%9ZPV5JW7'0%JJUPU
M]*IVP+G8KV<4FZMG)TE9"X68@0N5G@YBS+#'&9/ES1*M)GC)PJ9"C@8$T'C4
M-HM5-Q5GCI?;X-6'6W]GDZ%],-S?OZ"#=Z;/V'6YCLK48?8-BK-CUE4K(46H
M8$L(Z,)IE7D.%@TTBQ@5#V"?.NC'<QY(A-G/CXA[F'2KQ*JJ>%Q#QC/U]H-S
M'9';M]U-5K/9*+0K-L@K5:VX:#:YI::^U9[W.:_U`P5^S31@=#R_++:&WY['
MFEI_#*)4M46(Y:2X6W?EEWU.#;XDI5*M=X<WGT,.OT#M58]T=;G]9$M5TK1M
M@9DW7M12]A#C1W:F9`P0,76ZW0V:VZJNBE3BCN(=L.E+0^)CS*P-9%C#K!<X
MR3@Z*(<S-HC!:S\%ITU5_`W(!<X>[7T_(8CP7P3$M^..==>S'&8<GRY@UV)!
MBNI'1DNB%9^$PRVYZUX6M8PB:IZ5O%2W+>-CQ]SDB=%L5&I%*J.F)^OZ*.JN
MO<U:6<G%3(TU4Q]9L9R3891C+C4(W,D0*^G[%H:RI!+&(898==?Z)4573Z)\
M8C"-`H3C#,F.]&9JKOPIC4G*%KP\C-@S(9<P\TR[EV')CJ>RTVF6F2VTRAL"
M&=;5W>H^\;=_'874XFLD;9!_<L;U_BQ2BP37BZV*R<;OGXI*OQ2E[>MN3&!'
MX=K0"L10>8:YR2+T5R'/UMO%CAI4<*<Q>?@L<-&1!,1$.$VI#:5+<<<<6MZ1
M)D.JRN1+F2'<J>E3)+N5.R9+RUNO.J4M:LYSS`<_@#@#@#@#@#@#@#@#@#@#
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MIFF*7V"$7#8^Q;3V`-V.B;@L=<IDG':GLV+15(F=:Z_C'6@K(?;8]MI)8H4L
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MM7"]_76\Z(:!TG<F-)@YARB[7JMR9J5E*$V-5EB-@@'8&O3DV`3'S]>!<)K(
M@].2IHNYB,_&@PU$-I_)"I32X=TGC:RO:)WS/CJ_6FOC5"@$IX^.7F$69*B<
MUV5(0[#?:==0N*U[+[6(.8;>$9RK&$NNXSB2M:F764I[GG.?UOLM!I[>X8EX
ML2?W?1IHIJ+$?<6]'L3ZGK##B82/A-+F%'I,!G$G$>+_`'9.66YDIOTQ([T>
M*TW$;\NI=#B9_?0ME1]SZZV<3Q7JT738I<?#LB#6+Y!7`+NL,)]3R@-@RU+1
M/Q'CM^M<$JB:7EXPY(F%&HS3CC<.FJF_JBTZ:K1YI%@Q0=UN1@N6]APNJ/F-
M'9CYRH>"'KRVK(H3ZVVLY2O+3*B1);+,DO(996XU$@1!8H;)1W$V##)1784^
M,S,B/X3[L>0VEQI>6UI=;5Z58SY+:=0AYEQ/DMIYM#K:DN(2K`&+O`C,'"5!
M2,<DVUA68D"VI?)YA.JQZ4.PCZ,J,X2VXM4J2V54:?F^TU!B3@S.??:"#N@X
M=L4TZI;[DXE-6E\H4D)3B1/D)3E*<^E/FB/$83G+<*"SY1X;'Z&\*6IUUT#N
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`:F^V]ODW;;J:E60_
MR9E0A)#.31D)<@V4FOH;)3(_OQT*E9@"\O9CM1TXPEF3]F\M2FW\81VH4+G<
MXUN7RL5;=38`I%F*5C$!I@>Z@B/^QC.L3H\EG*'V%)3*;PX\Q(S&3AA*L+:R
M]AM;/Y*>2]1))UFWM8;37GJZD1!@O$FD1"$R*Y(><DMK4GW68<5SS^-\GR]I
M>%NS%>TM:&\I<4EQ`%S^A-6(4ND;EKA5M3).%ODP_.CKQZ7(DHKK'5)=Z&[C
M_8[#7.S%=Q^>/<95Y9SC\\\:G+9Z%/#3/^WY9*O4[_LKLG_$=W'_`/5[O+DF
MO'HO9%B"8L8:@OC#`Z"6&RL(3*'DXD>?!DX;<0\WA^)*;=8>PV\VVZC#C:L)
M<;0XGR4E.<#"O/;M/S>OEXJ^?S1LJ=0]-.IS_@MC=NQJEJ-]"O\`\CC-U6A>
M<_EA"E9S^7GP:L>5_*YT?<02.MVN:1K4F[F/%V1O;20E]]+B6EL0*7?Q.X3K
MR'%_H1EFN:S,.K<7^AII#CJ_TMYSPL49D\OXOU4?)J?GX@BIQ46/+RBHY,R3
M%22@Y=@PB45A]QN/,3!D)R\\T^TE,EMJ2J.M/N>UGTYQ[N?0><S_`%QKEN_3
MWH.2:X0H9$1/D2FF$+ERGYSF6&X[+*W/0PEK$1:'5N9?]MUE:FTNM2FEH`R-
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MK>-B5R-`-S!@*V6B(`=DU6N;%B7:BBK7FP$*^/9ED*J:A-"B1.0*&C2<*%+:
MBN4L;9]Z'3PX=3E9-KFEVRR]IT5;]7;2U/'J_:+L3!C]A=PW$=LJ3EW1\AXU
M:8VA;3;0QF&-=T@JN5Q3`O2C(^2S6P8F).P^Y(FL/SWU2\\CM,S965L=>>YJ
M]\>ON_OOPI>H>C:AT_D2Z_9-R[,V$/L&\;.*%78S7)K[LO8]NGX8/#)555L#
M:MMMIP_B=,!/"AT,=:T5^OCUX%O@Q?ATJNISDL-<N=B"OV:_Q7NXW>BW[[T9
MVH/)VVQK6C@]B57;RZQ7ZV;$K(6)NO2*)9W*F)"!#."Z)*C=8F2!C)QA`&RL
MS2!:*N"V(&^+133#IM-HN^M_7H>EOL;6;9:=?B6*?7W+80KNU=*[!FU:*3$A
MRU@$ZQVS3MB3!P$A8)@ROM',JK#$@<P<+!A4]V/D?+,"T2L36!R6/FO-04;[
M$;)W1OY^N5O4W5'?*CVB=T&6ME-F;/U@#MC9%FZOW$1'#09CG8]R$7E2Z_V%
MJ![Y`V3)A16/F17I39>$]!:U.&F^^V&OXM2KJV.JVV9A^G=84ZZT!!@^$L`Z
MR?>7.K6$43FQ(Y.IVJBW`]1+17\_0$R]>G2`=CKA,>HE`)6`(5<CY(""$X3)
MB/.=DY4GG:X7#[E21`/+EZ`=*-UP_%1*@DIH]IW&6W8I*"E];+F9&'&WARFY
M'Q(<AK#CZ5QU>>4.-/8_+3"WG7'6]XV=?AFVMA-26@-55AVOHE1,06RA6.I:
MH6!L1+;6/KQ<E:I[Y#&,XD3V8\=+LE29?QHKJA1F_0NA2YR1LPYR.HX`X`X`
MX`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X!73>/7&L[H5#*.$'Z
MW:1\?X;)N+$;G-2X.%K=;B$X"WXN928[CCJXKS4N,\S[SJ%*>:RAM%4U<.Z)
MJI3V9KVT\'J3%KNH^U,C'3XXD[#@1C2(RFL)CS)S!)41B7ZF5S&WFV,._DJ0
MRU^<?R1F4K'8XD4[V;KHS9FNB5+1#Q"K>X.NURM#0GVL0(L:F;WI%JM:HZ8W
M]V91&J@5Z3*;9QAEEY#_`+F$.8>2F:OQ?3W+H_)=5YTM&U;L5_T<5ZW6]7_5
M4[LI3?=5G_43^\FF;#T8QZO]GZY>UHS3?G_B\MK&/SSC&>)V6>Z]K_!F6]NO
MND^SFNBNI.P&L:AMK7)E^-+FU2YB62@])"#E>8)8>XKT3`YJ![KWP#0B3!*P
ML//8BS&L/.84";3E.'L8AUGZ?]9.G%1)4;K%I6D:;K9L@V5/1JF.<21L)%AI
M;$698[`2D3[#8'X+#CL<>HR5G?7QW76(6&&G7$*!U.K%M\RR/!A6[1O_`&G=
MR?\`B1J__I"ZJ<&O!<OEFI&,W>Z_.W06:Q:1-7,]C.UBH4QE92'7RSV>S&U!
M3^$OLJ;@2I#*V9:<M^M3[;L3U*3Z&_+/:C\5WFSCXGY=*?\`JB4A?7L^3K4<
MTDQ#9)S8+<^&%5&<4E;;[27X[#Q'WTX8E.-J1A2/AN--.J]M;^$X4XFB"]G2
MNVSK!JJ4%(O./N4\](%05N*RI:!$J-'(0X^5*SE6<1I#TYAE.?TM1D1V48PA
MM*<<JU>=?@ZT.S6GR7!Y!8X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`X`
MX`X`X`X`X`X`X!KC[#]3[8=N!*[:TB12S-BD*GF*^N="&S(99[]4V9#>(OQ8
M4B(0=]4MY"Y3<EF8\]AMMUA:/9Z4UJ(>1SJI<RLS[:NZ5NRJ=L"!M2:^')7N
MDV*CCVZW*'R3%/C64:^-EV6$0DQ28?\`$\%+V'0N%12@R(MO+DUJ?A]45C*J
MILL#:*6G+RP1/CG7^WV:4`<VCV#V->@X&VTZ[9I$*JZAI]-*GJ!:!-VJ+Q%P
M7KR3L%#`>W``AS$89L,<R0=&-CRJ)X641&S8.DZ+WGZ]"S7!@X`X!30)=IFG
M=J]DTVC6VWBL'8NW:U?J>:HNM;+?@I6N-==]$:\DNN$*G$*H%D(ELU_9Q[XD
MNF`2PS$C$D17!I(?+DC<4L++5+-ZF(0M66NV=3;:(EUDR"LY3;_8/;E<K9N*
MB(?R&N?8[:>QZJW/&(>?='%S=#M,*3@++4T4&SB#8LK%A$H\R&Q5+A^G?N3X
MBE<H]%#*40]UWP6`366GH2,18WUS!%Z&[]S#CM(]A#"'<R$QL.1VDX9;=>A.
M26_0E67?=3A?.QP-E'4&@$J1JI,LU&=AD[>5=L/Q'T9;D1ABHL6&*;?;5C"D
M+?9CN$$I5Y+2U.;0XE#B5(3RK<OD=:%;F6IY!8X`X`X!A"%`Q=8C'[$;?%#X
MXF'.*%RUJ)C1\5*X[*G9,R9**L1(K67%_J6XMMO&58QYX\\8X,CGYO[,+_>Y
MH3_\:J!_XPCO_P"4\&\#TJ\ZOLYXO8^ES9"()"[9IY<J0>3&@#!>UHQ`A-D+
M_P!1B)"B65V3)>7Y9]+3+:UJ_P!B<\#AVJ\ZOLD;Z6'_`!BW\_._U'@R%OYO
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MC;A$]^KC&$W"VDH0?M=IFH0=6#=D;B?,F-&7;K%ID9:"`#2V!971/[MJ9LJZ
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M'N3%RL9]29;CBF,^[,2K&%)EN85(2K"<I=QE.,XV7J_,SAIT7>V!GG,-'`'`
M'`'`(2V733=[U,'"5R'721F$<T_;X0RV3Y8JO%<Z_P!@TJ^/BR1.""L\H<@E
M%K;T)B:U7R_QI3[#RX3K:%XP-7WZJ#%_A[O_`/I]ZU?^.%N__P`J<"VK\E]F
M.6>B;BO$,0!(ZBZ_U`>BZZ[L4^Q@MKVFPFA<.F7ZM7&4X(#/]=:FQ/)/,`5Q
M833UD#M(DOMO.36T-YPH++-X/+51J6XX,-<6Z.N^XK'V%VEMR@-I@G"W7IVD
M:;O"7=0N?N_V7'I6Z1<8M)=N.M;/LD$A9VY51YJ30+4*%3?87^*`QD9&FCR`
MI.T;R^5M]LS%-AZ![FER<`36MC.$1M9/33NJ[/:+YEZ-4B,#86VS(LILT$W6
MLSMGNJJAS3(NNPY[I-H0BE6O,UUF=/P_:0M[3OAGEGYI<NM)=:>T%QL0^?8;
M3=(-<EF=>LAADK=3A4_KVM4K=&D]AG)%GG1!,41>+2937-J$Z>;8A$9(.(1J
M=8GJC0H26X(R4O)KW7RCG&=#]W#I6773^SHARAMQ&X`3UF,_(E5T.<**&"+S
M,=DQOL;3(2Q5[,NVP*A-/SW83@:;;A4!)D9;@E1AWE'KW$<-C0_=B=:*V$+G
MJ?$UD%BZQP2'C+'.:A&GJIL'3=ZE3TB$Y^J%'H$VL[-AJ17JI6XL\*2KB2!Z
MR2"TX=3QLK):Z9IKGIG^YRVWIS:QG:>P;G5*A1K;9#M%KX_0NT+B=;;SUQN@
M(7:6I4UJLRP1=_(P@?(A[/+F5!,@CL'W)5)OL>!6*W7ILH8GY9K7OHES9'&J
M.OW95G;>L]D;0L3).%6#H.43AD3[THI`$"Z!VDKLH;&_Z6ML@S'59-NU0E`D
MFK84(N#W)6%Y$1@@NO01LJ([_P`?K^\39;P2.`.`=+,_SH+_`+DM_P`N+P2_
MRIZ^QW7!0X`X`X`X`X`X`X`X`X`S^?Y?_IP#1Z:[P[]U]`L`"2\JWV[I^H?J
M/LB0-0:6"%6B_P"YM_5K4_7;:EOFEBVO*F'#KT,/L/96\UJ!<]9@_E;#UN)G
MVNDUJ:HI'%PO/#:%+6>=D[X-P9P/\179\4_J.!<Q>B*X.N==-*E.CMC:SO*K
M/;8>SMX4(/'E2-;]@;M+TI6"P350*UR+=@!V"HE:+';]0[M?:I-T^>/F!G#9
M[:VTU5\=M;S!&4GQ2]PHI=9P+J>IBVP9D_;_`.*IQ8SK&@ZNKIS5U`T3>QVG
M,[!M?;)O51D_<X&Z72</:="W+L)D94*<=LN-,E)0NU`:J-X5?'+6;S>(FT:*
M^>NSCJA>[1L*E;&-6PC)(31_8?L#61B)+T&2H57*SM.QAZZ!:DCL?#E1@@F+
M&&QI++CZ7V8Z7<2'\*PZH2_A>R+/\&#@#@#@#@#@#@'4@/\`(@O_`'2._P#)
ML\`[;@#@#@%6+?V\UG1]U3-$'Q%V9MS4#4T\828%!GJS8L;:V2.U?%A!)^;"
MB>LC3#)VN%KG")"AKV*X>C$*CBW21MB@!1L-J>?HI]<C_`O=;K38G:VP%V#/
MG/6FU3J3`91KS9S3HVS#3>N*Y,'6]M^F-+H*&SFWM9#4$+SBNC)$BZ`_C3'4
M2<K0$/N.?7#(^D;N?UOELBI$:]E'6#*'ID1U.N=HX;8`,,T62J[%E*I>,`-;
MKA[+HT^/LX[]=KV4.L40C&LST)J9(C!#[:W^F8X+[X=<GZ&[L&RV2RT(1`E`
M8AUFX:[V$.?`IM"K4BOFIK[-7DCY%*+.TBV1X6QADR=KUZ<`*#<6C[&&]%0$
M-]=T9(3[E]?!,KX<JR7-UY5B,51A0S2^[3<::<!W89K6;%&S0VNI\,I'=V,8
M&4$23'/RA9^Z2T58%-)'$N04!#[:Y^Q]L]R>MZ9P@8O8CC1*Q:_"[.K8]ZE[
M`9G6:I6(A71`-59B.U5$BQ60H;ME>`1**%;G7IRP$V@/X<P8:D0F0A^L=_>!
MS1W;GKT4N,G7S&P,Q;M"Q5DSJP9J5XKYB#)N5@UW500R?#/5H:Y"-JL.V=<B
MBX*5[)FM2;8,_$L$2W\A;`0XG+OZ,3C=X=!2B!MA!6TLA@%D@UR=<IM*L@^E
MRE$>O\[LE'(@K#-@,1;*UC7H]]F0$`8(V^*?RU`?K3<1^.1=#A?>.,=+ZG:6
M?N/I&KEQ%7F$;8U=C\:MD0M*.:]OM&L)$18K_7M=?9,,[`K=6C>8DQ8XLTF*
M<E(.H#QY9&.,?8:PI0<+[Y3D6HX,.EF?YT%_W);_`)<7@E_E3U]CNN"AP!P!
MP!P!P!P!P!P!P!P#CKBQ7$R4.1H[B)B<HF(6RVI,M"FL,91)2I.</IRQC#.4
MNX5C+6,-YQZ/RX!QF@XAA<%Q@6.9<&1EPQKC4&,VL?#<2A+D6"M#6%1(RTMM
MI6PQEMI24(PI.<)QY`?/`('B$R-P&%8'1Y"9;$#`Z'B$Q+2^J4F4S%PS[#<A
M,E2I"7D-I<P^I3N%>YG*N`=FA"&\9PVA*,*4I:L(3A.%+6K*EKSC&,>:EJSE
M2E9_-2LYSG.<YX!_7`'`'`'`'`'`'`.I`?Y$%_[I'?\`DV>`>97]IVZT=\^R
M&BNO@WJ+7-B['UO6K?=Y.]]5:L7/EVBPD"4.J(U?8IE5%/)*7`#65PKM&D0H
M4:=D00/#BLB`\TC$\2.WA.E-\6T-^OQY&PWP.M2=M](^'3J'7_<]^Q-;5'$[
M9*!5RY%\G+E2-93BN7J14+015+GNI(#HORY<(1(G2)-8`D`]6D-CG@JQ`\1X
MCI=3X</G,VY\$%0METWJ-LC<0J@[)%!;%MJ<9I-T%C9CUP1E-DU^!O9"E)24
M&OL5J#8H=3(;`+L5)Z?'+6"JI,&)P4J$'_+C#5,6POIG'72YC6J=2=-GK&;U
M_KH23,6&@3<2"7W=DW/8<(DU>T:J!/(&7.]&9\"VQ:E;NLFLZF2B`SQN#5S&
MM'J>19'/N685/&MU8O/EO]OG,F%;!ZV]<-6V?5$8-KC;=V,$1UVJ%8U#2-E6
M&2[;0;0_4Y:>BUE-B[7J@F1JZ@@-+5&OPM=V>YM:Q<;/-A4TLL2,1&<A+<W7
M./:%C>=2(YQ3HSLFP3M>V73.SPQ.H+J&C5M,7D@*E8&E]JXZ]XIYA>L]W2[`
M(!Q+?VB-CR\+8$<&B]5\M8R]79OD"DX6%#^2SQOZ3IMEAL63GR>MT/99W5*M
M9W.9?-9CI6U)@@?&L$Q<6IQ]B@>PPG84!;%ERDH#M6]1*8%1A(2^8L%ZIEUJ
MT.OJIU1MV8`R\3D[>2B/+W6J(0"UKI(6N6O(074FT&U[4HFIK:)L`^[WF%6J
MG)N5$E6'4>)8N%MILA7]L.5OK>-0#N%+K,\\`*U6I8=N0PB5%2)HV][JS?O?
M+#^6#UP+`ZVT7URV[0V=D@*YLZ()VQ`JI^<V?VQN@78G2E.-TTM7+,1CHV0^
M\'V*).:RJ,]ZZ0I3-U?F"'<DSLE94X@@,EJUK3DMYRPO@96STPZX,"4`4T,D
MX%;ACHJ!<G8FSID)+XK5IS2L(YAB7<WD9MR-86(C5'KKG&;=+CM!R$LV^8KM
M?(C`E]QK/N?7'3GK\JR8MTVKVLU8<E0YYXA9-N[CL^)E@`)K[(>P$8EAOQ."
M2/08=4K@QLT0C22:@P:"%<E+$M?#4$OM+ZW+/<&'2S/\Z"_[DM_RXO!+_*GK
M['=<%#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'4@/\B"_]TCO_
M`";/`.VX`X`X!!A[KEJJP;$,;6?%GA5^/UE^J%K#6+G;ZI,D07016LL$6E5T
MV-Q`L8\&9FP1ME'?$.1,-B)*)V9E;K<@0-EX:=]HPJ@=5JY1-I;%V?'M-I6]
M=3"2PFM#+)>15?K*I%[M.S3^$P)%W+Q)/XNNUN)E;4+$1:U3S;:&&IM2=DND
M)LX)LN]EEDC.2&AJJ?IVLZS:3]_.G-608#(#93=[M%=V7*)-5IRK&C1>W5@F
M')$I-L'R);ME@RG'0Q">\P1R.;GB@TD>$X[Y9:F&$.F^@2#+Z<5FPCYTPG'-
M$3XG8FPAMJ,%H&QJ[ML03/VF+9T6"PD:_L6K"[37"!TB1G5^<\>;#R(<.UVF
M,9"7W'(R:%UIU3`-3;4Q"M*[L3"&*T1OLJ_7>9>9U=-UX%6Y@*3:I1YXPZ':
MC5H&6'#,ROA"K9"<N0YB-:B)4O."7VEW^K8'6@.J6F*R4UZ7$";.S-U?4JW2
MZCF1L"\SF&`],!W:M4M\K%FV!^-8#51!;&NHZOG3;4\M";.)?S+=F!J])$!+
MOOW\$I:SUO6-24H-K^FI,-UH"F4@6R=L)RTD6&I<Q^<ZTLS8IY,M(:3(DNY8
M;D3'4QV\I99PAI"$8&8F><`<`<`Z69_G07_<EO\`EQ>"7^5/7V.ZX*'`'`'`
M'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`.I`?Y$%_[I'?^39X!A.XT[C5
MK*X)Z^NZS8W+D6G\`.[CCVF5K)!GY<;U9N$>DR8=J<%Y@_,PG`62U+Q+S&5G
M.6<.I4-43>8VQ)'8][V6?DY:S(]IOW\L87AG+WHQ[N6<.9RO#7K]7MX7G*\(
M\O5G.?//!A]>`:Y=V[O[):W['%55:DW6ZZ6K-%%3GZ^(K0:8&MEJ):XWT:&4
M\26@5PA>X-\M>Q*GJNM!3SY+.M0T(K/!G8.;;:Z<F6*236,.?K[?<D93.ZO8
MN%#8M+6GY!0$3BA`K$F(&BIK`&9(D[+(R;K9'56SX@F-(>K-9UI-"N;2EH"'
M;`+L#N5D9+E(<!)9OG^M8QPO@LF<X_WSW3`D;-Q`T$9^#22(..R],K17)5IQ
M4V_B[`!$A7K.*:V`8D$*G7I-3]1G6IJPU:ZCK(`I=DD2*77]@A"M=>?+[T>'
M..NV5W>[#,4O=RJWIUZBG*X?NE0IARQ5JP68@#)"*UOZ=6LE*76E'R!LK=B&
MJJ`U1)9"-60I0AMX1#;$V&(.JLC:H)*U])]/OT?2;.RFW-R4BX@X>OR]F:)X
MTA8[C3*(*ULFXAMO[B@6"OP@6M[00C5<D;K@PS$ER(L@J&L]):J\>;(MY\HL
M`!G-H&*,_P"L;XY:9X'T?[5[:`E@8^TZ>3AR];#(5:B#Z_$NQ"=)!B.S52TG
M/F&Y;]>9'0"F->&2NY<YDK@!(P*&G&"<P-`)6'`1OEZQ,8].9(W4?L!;.P-9
MO96XU>)4S%.MM<KTD/&#70"^+DV'4NMMG3ZX6@WH6',.'*;.OTBGE238Z#"+
M2@:B;(P,Y+>##P:C>?MKXDMIP8.`.`=+,_SH+_N2W_+B\$O\J>OL=UP4.`.`
M.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`.`8R()L11(R,_&+(?CCX3#R/
MHC:O0ZS&:;<3ZD#U(5Z5ISCU)4I.?+S3G./+/`.P^ZA_P2W\@._T[@#[J'_!
M+?R`[_3N`/NH?\$M_(#O].X`^ZA_P2W\@._T[@#[J'_!+?R`[_3N`/NH?\$M
M_(#O].X`^ZA_P2W\@._T[@#[J'_!+?R`[_3N`/NH?\$M_(#O].X!C-4"T*AB
MU`Z/31],"KF22*P]4H<BNBU$)F4JF3E#Q`.'$5,E*0C,F3EG+S^4)RZM64X\
M@,F^ZA_P2W\@._T[@#[J'_!+?R`[_3N`/NH?\$M_(#O].X!P_DIG&!BX[$_#
M<9@EEYR2-(PFT>ZF*AO'N38L="EK5C/DA"E+\DJ5Z?2G.<"6KTO29\C(N"AP
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
*!P!P!P!P!P#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g887761g89u83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g89u83.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0E,4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````J@```<8````&`&<`.``Y
M`'4`.``S`````0`````````````````````````!``````````````'&````
MJ@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!J\````!````<````"H`
M``%0```W(```!I,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``J`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T5U4TU"EK:7M:-V^@O!.V.&^G]%W\I1&/?NGU&$1$?97>//T_I;4[
MZZSCL],/KM8V=K*P"X[=NQYMIL;])5A7F!T%EI:.X%/G_P!UDE-ME<4O%[&6
MO(.TLH<P?#:_U$9HZ@QHUJNT`@AU1_+DH%5=0H=ZK7OL</HOK!+3'T6NII8C
M-Q;W-'K9+SH-S6!M8_[_`'-_[?24O]JM8)NQWM`^D]A:]O\`T3ZO_@*!5GLR
MZWWX=C[ZFVNIBH-T+/9;_/-_,M:YBL#`Q`X.=6+'#4.L)L</ZKK2]S5(U6[G
M[7-+7F=KFD]@V/I#]U)36.3D[0X4Y1![`4SQ/[RF,ES`VVYSZ6;]CA<&"06[
M@9K_`)7M4?V5C:_H,;7G]%Y;?WD=M-@],2P5U'1K6D:`%@:/?[>4E+?;\+_3
MU_YP3.ZC@,:7OR:FM:"7.+P``.2=59224Y9S;VL8]SK';V[OT5>^.#^:/Y2B
M.H6EX9^G!)`DT$-!,?2?MV_G)LG'8VH47%MY;M(J:UVZ1I6?YQK:]W\M1P*'
MO#2^NK%R2R#2TN>S:V&CTGS4U^UNS_`L_P"V_324Z>)8^RG<\RX/>V8C1KW,
M;_T6HR%C5.IJV.(<2YSB0('N<ZSQ=^\BI*?_T/54DDDE*22224I)0]:G<]OJ
M-W5_3$B6R-WO_=]J1NI#=Q>T-\9$)*9I*O9>]EEO'ITUAY'<D[_SIVM_FU2N
MZWM8\,K'J@'9N%A;N)V,W>G0]VQS_P!Q)3IV6,K87V.#&#EQ,!5K+7O8;'..
M-CMY<1%COZK3_-?YOK?\4JN/F,MR6^HPV6S`<X.:&S[?T-;V-9_T_6V)[^H,
M^T->YA?4T!U(U().X>NYK&V.V^W]!_VXDI(<8>F-S-AN.RNKDM:[^>>]WY^2
M^D6>I;_UO]^RXSZ6/OLJ=(WAMM;AHX/`])SJW?R&MJ_SU1=U<.O9::R:F-=#
M=MA)<[;ML:6U;=OI[_\`A/>CUYXNRJH8607-<3/!V-^B]E?^%=3[VI*;--SP
M_P"SY$"V):X:->!^<S^5^_6K"R,W/L#S596TLW'TW[FM,L.WV.MNJ_2,_P"_
MJ-'5<G975+;[`-KK!Z?N+6R^UU=61[?WMK&I*?_1]522224I))))3A]=JI=?
M6S[/N<]KK++3@G,8=NUC6N=7#V7;?YI`P,;#?EUB[$K>'RW=^S'T'?`L;;9D
M6%[:_P";L_-]]EE:Z-))36I:YN5>'NWR&$2`(:=_L]OTD"SJ>#4]S'LVEA(,
M[&\';N]SV^U''_*#_I_S3./H<V?2_EJD[^<L^A]-_']9W^O_`!B2F-G4L6RX
MU.KVTL`+P#7N>?=OJ+/4W^E6S8^S_3^IZ?T/65W&S,;,<0QDP/I$-(T/&YKG
MJF>_'^OBK&!_/.^C]`?UN>W\A)3=].O]UOW!9^;G8M8MH#8N#26:L9+F^YA:
M;',_POYWT%I+'S/Y^W^:^G^?Q]%O_224EJR.GY%@'I'?807`.:X!SOWO3L=^
M=^<K?V'%_P!'^)[_`#6;C?TBO^:^F/H\_P#G2VDE/__9`#A"24T$(0``````
M50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`
M00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))
M300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("
M`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`"J`<8#`1$`
M`A$!`Q$!_]T`!``Y_\0`L``!``("`P$!`0````````````<(!08$"0H#`@$!
M`0$!`0`````````````````!`@,0```&`P```@0'"P0,"PD!``(#!`4&!P`!
M"!$2$Q08"2$5%A>76-@BU5:6UC=7USAXF#6W&5DQ(S/3U%5VMG>XF;E!46,D
M-'0EE;4V9F%3LU1E=28G*#H1`0`"`00"`@("`P$!```````!$5$A,6$200)Q
M@9%2,F*AL2+PX?_:``P#`0`"$0,1`#\`];/(7(7)KWR;R\]/7+W.SN\._.U*
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MB6'/)Z56D5$1@L],I3'EA&68`01@&'6];UO6")FXU6_KG\WL#_R,B_\`X(AP
M3O+<\(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8'_T/;#Q=^QUR=^[11/\UL5PL[RLOA'5AU);-NPKIPLF-S>?0ZM
M8A'N-7N62(G<&4TG`6&P;UZ#:K4D-Q,RYI<[$<&N8PNO$3`G6-GJR%D5GD+U
MJYJ1E*W$F-1LCB2^\NE+-;$^@+.573U'1(I>9#YB^-C/%45:;B'7G/W*#\^V
MNU,W0%@S5RB$44WL=(')6\L=9B$WQE3Z`(RE!JEM6=6#;^R;+@:Q"[+IW#;:
M*4,?>3JIF[4M>VZGT6JZZYXPI^/3%6RDS&8B05O5T>N9T<G#6WE6>V-3>L**
M5EA,-'H4^5@=9WV\V)\1-MU5%'(='Z5[RCKI,(S#78$'NVQ:B,Y%<H:YU(\K
M;7]>B]@-J2U7]F2)RG.1%-SPP/X1D.FP$B;!7#<4/9'0-806M(?.AUA()7+X
MMRJZMELGMJAIC<5CMWUI?4@4J+(;;!NF&-$FDQ$HYS4LB=P,E\63O#E*$`BT
MQ:D`6]:*BY;87VC>0RIZ\OQ=(PB+573%#S"6."%"KMA2]3V]G.T((PIXLYL-
MQPZN4\-)G$6:5@U2Z1%HDS8H4$K7)(``W1**V0V#WE]K.<=9QE.'/$$>&R&]
MTO\`(Y!8A12F-S:1\ES#GAFB<-A:6`]`2N/L3M8C==IQ*K2:53#:)2W"-3Z5
M:"-+L4N]473=B6->;K1;Q7J6+2&"DO$^LDY:E=RPM-33%DC3M0.D6AJ3"RIE
M+G*2NK.OV:,:;XQKN2>C*)+&@WNI6EKP81"?2VU0><>@!(2TYJT-)VKM&4K.
M,3I3%6H(_;3EJ3R2%)I"<9OAH8PEF""'>]Z"+>O#98WA2Z%=<=1U]!HJ*V?=
MSW:O8DD7CI"64<TVC3'0"-4G"V)"R5ID6?I+3%F@*.3Z";L!#`J,!X[#Y=[U
M\,68CQ+;4GO3N,4"TAGM2=S3FV0G"``;'U'3EM<][3C,'Z,O0I%9\,C\)4A,
M'X^42=T/!O6O'6_+\.6TZRN=7MN53;C7I[JFSJ]LYE$#1@7>O9I&YHUB+%OR
MA,TX1MR<DFP"%\&M^?PWO")"P&`P&`P&!5"4O5UR_H&;5C7UD1BNXW!J<IN=
MF#<ZU#.G)Z>[-FU^1]>`:HZ7QTI`A;$%3H]DE@*,$,Q2;L0O#0=:+IAF/F[Z
M?^LK#?X>T?ZT,%Q@^;OI_P"LK#?X>T?ZT,%Q@^;OI_ZRL-_A[1_K0P7&#YN^
MG_K*PW^'M'^M#!<8/F[Z?^LK#?X>T?ZT,%Q@^;OI_P"LK#?X>T?ZT,%Q@^;O
MI_ZRL-_A[1_K0P7&#YN^G_K*PW^'M'^M#!<8/F[Z?^LK#?X>T?ZT,%QALW.$
MUE5A4[&9/-U;8X2DUSFS*[N#.UC96YP.B<]D\3)7IVDQ<YB;_74C(6:,KU@W
M03!BUH7AX8)W3CA#`8#`8#`8#`K;TW9D^K6,P/YMCH@CD\[M*/0`IUG$<>I:
MPM"-T9I*\JW`R/,,P@C@Y*=`C^BBPZ=$X`;-V,7G\ODVC6:,RA+Y:]B_I5YH
M_ADM+[7V;Z\L]HP?+7L7]*O-'\,EI?:^QUY.T8/EKV+^E7FC^&2TOM?8Z\G:
M,'RU[%_2KS1_#):7VOL=>3M&#Y:]B_I5YH_ADM+[7V.O)VC!\M>Q?TJ\T?PR
M6E]K['7D[1@^6O8OZ5>:/X9+2^U]CKR=HP?+7L7]*O-'\,EI?:^QUY.T8;SS
M%<]J6#.KZKJU5%?NSG4;C7(&N15]$)'!D+LAGD442`PA?'Y'8-E*"E;8H3;+
M"<6X:`:`6O$H&]>.\S%336\1*XV0,!@,!@,!@?_1]L/%W['7)W[M%$_S6Q7"
MSO*R^$<0]`A5!5@5(DBD#@DT@7A/3$G!6H=:4:TB5A,`+2E)K2PW7HQ^8']M
M'\'W0O$,9\E8QYW$?R<8?.[IU:1V'\3M_G=$J\E*F7)G$7J_BM3K4Z(DLT!G
MF"8`D`1:WH(=:#DIV)D2%$D)6=J3$ITBE`02G;TA)1"%9ZMZXB)++)"`M(J]
M2)](6'6@#]$#S:WY0^`?'<:CFT3>V[C[)MN:1!$U(-M2#:)L$``RP";TOH/0
M(A`+,$'6RPA\`BWK^QO`Y"EE9EB8Y&K:6Q4D4IDJ)0E4H$IZ8]&B,,-1)#B#
M2A%&IDAIHA%%BUL!8A;V'6M[W@!,K,),J1":6P2-:WEM*U()`EVF5M11)R8I
ML5$;*]$H;RTZ@PL)(];+T`8@ZUX;WK8:,LINKW";P^Q5<+9C9=`(M,X7#W#1
M1Q21CCM@O-;R"6HTS$2<6P&J7)VJ..FEJS4IBQ'INT!,:26<I`<&P,\'C##*
M)C,VQM]%)YZ-@W*'<Y6M5J%Y$7:]M,?;R-*U!Y3:TM:<P\PI(F"2FTJ5J5'D
MV>I/,,#;,"&NC/V>[V_T-6?_`)D/F%C>&Y5S^;V!_P"1D7_\$0X)WEM:M(E7
MICT2Y,G6HU10R%*1626H3*"3->4PD\@X(RCBAAWX;"+6];UA%-Y_[NKAFS'$
ME\D_+--II,G'LPB90R((JTG9)F_#RF%3NN/DI,`#*WKQ+WI;XE;WO8/+O>][
M+<Y1X;[OM=$BSQ4#VIVW2`RQ!&S,JRXTG1$':M%C\Q*/49ZFC-SKAM1(=[UH
M@EQ3;%\'F&+7F"(7F("X)[T.OA&!CG0')71S9HKSD(KCI2?4/+-GAV+04Q\X
MJ*<6#%]E&!UXC.##M;\PON2@Z!O1C4_YP_>NJNPX)HG=R^[JL1V0%BV2ODO+
M-VU%>K<6,(M``M+BU@+Z`L8U(>'Q-$6F:%AI(=;!_;!^31@J,FO>E<@,0])+
M@D=F\TNP5!24]MZ:HBY:03)S%!FRDXOE=-80@K]:G4&Z\`&I7<\H6MA%H7E&
M6(2SK*X-;7;3%RHA.506[6%JMP2=*1+ZVGT4G*(*<0@`"H$JC#LZ$:)$,P.M
M#\WEWL6M>/PX2ICPD_`K1%?VQ;V_=HY._G2[1POA.\L=5#%%I*^)`$F*V:/O
M+JE+4A&-.8H;FY2K(`>`HPDP1(C"=:%H(PBV'Q\-ZW\.$=<<&[3LV!<_^TAU
M1&1-U:$MU2O,G?HW3RNL"H+'[";G$I;*D+<NZ#O=WM-D;Y4N949I20EE<$:-
M8)4!.NWYB"(U6M0D:0=U,\+L:L8+-ZW?&5-.QQ5HE3LSKG&;CI^9S*(NDS8H
MC92F'Q5X@C*YJ&I(F\"]R'UQ3I8`]&F5(]!4CJ5;XJNVY`5$ZNDB;GR9+E=\
MMZ244NQMKR9)E[[!#8:?.%T@F:>!QB8NL+<&IJ-;DYR,E&[%;7.Z8`%(B"UB
MA**19:G>=FGQET6U#04W:%<5N/@N&2)79BJ+Q)W)UU19G,8G.M'""/BX,EC4
M]!!KK4LRX2XD@AC=O*;LTW91I946N6V3WWBS%6\3(D<DJM^&YQJ26:QW)#(\
MZN,QD]:M=7S9LAKI-B2(;#Y`A=H*Z!</74SLZ'QY"`OR)SS25>S4Y(IC(WW5
M9I14G;Y51FI!*%O1G05050V5POE+R&0Q6C9A-FEYD4Q1L\3F;W'%#4UL+6F,
M.3)EI;DZ.P!!3H4A9YA`I--==@$6%;S!5RBJ9E6>Y'%HQ(FO=Q#U6TX=3))5
M#/:YZ..5Z_H"E$G^2*=W,8W\I$O-=69_;'$E2@`E2"6"J5INN;A%:.0OS#1_
M_+*Y/YZ+!PL[K+X0P&`P&`P&`P*==C?R;S_^\A#O\R;'RQO!.TN'G1R:!.;"
M0P13"DJUD?G@R=2Y%"FL3(%D$6C=UR)>XD&.>W=[9Q%(=(6M28(9.CQZT3L/
MDV(0`B+$7;#M5\4<^JI2B9+EJEY6P9`[.LV2-5B1!P50YK85A[<^.4I3I'@X
MV/(&9P3&$*SE>B2TYQ8@&;"(.]:7&2IPQ;?TISH[KFIK:K^I1S<WU":YLC<W
MVI!5JYX;2#I*G/<&I(F?35#@A)40QX+&:2$981M2P.]^*4_0%QDJ</H;T=SR
M1%T\X/OFF"86L=36-)+S;1@Y<75/9"`IT/9T\@&^::3W4EL4%J1IPG;."0,)
MFP^3>MXN,E3AFG*ZJ;9Y"]1%WMJLFJ61MD52:11ARGD50R%AC:)K(>UL@>F5
M2ZE.36R)&544L-5GE%D%I3`FB'HL6A;7&2IPQIG0="$MD:>CKOJ$IFF;DX,T
M/=C+*A@&R6.[2O3M3JU1I>)ZTE?7)L=%92900E&::2H-`6,.ABUK:XR5.$OX
M1HO(_P"TCVK_`-=YY_FU=,Q[;NL?QAV%YD,!@,!@,!@?_]+VG,O&E*QMF:8[
M'7/H1@C[`V(&5B8F7L+KMJ9F5F:DI2%L:6EL0WB0B;FQN1$`)(()``HDH`0`
M#H.M:PMLG[)U6_A5TO\`QH]B_KVP6>R=5OX5=+_QH]B_KVP6>R=5OX5=+_QH
M]B_KVP6>R=5OX5=+_P`:/8OZ]L%GLG5;^%72_P#&CV+^O;!9[)U6_A5TO_&C
MV+^O;!9[)U6_A5TO_&CV+^O;!9[)U6_A5TO_`!H]B_KVP6>R=5OX5=+_`,:/
M8OZ]L%GLG5;^%72_\:/8OZ]L%N&X\>4Z\-Z]H=WOHIU:G5$J;G-L<>Q^OES>
MXMZX@:9:@7HE-YFIEB)8F-$6:48$0#`"V$6MZWO6"UF$"%(UH438@)"F0MR1
M,A1)PB&()"1(2!.F)"(P0S!!*)+T'6Q;WO?A\.][PCEX#`8#`8'X,++.+,).
M+`:4:`19I1@0C+,+&'81EF`%K81@&'>];UO6];UO`HK?G'ONZ74@V=W]2/,\
M44!-,&*SWUHAM42=.?Z$7F,)M%J-B4G1J"RM[WH1;D`8/A%K>O[.%B9\2ZAK
MUL;D&'5=;[;P!WCW!++2C5>SP5?U9S38=V]KU0HEZ>,NBEB8GUSEM>]*Q>(1
M`]Q``2Q2D>FP29(88H*-T+0=[GPUKI<0WSW`-B=(6;$+#D?2+];$K=O9^Y51
MU]*;AA+3$Y$^UR1/.N_B16VO2>9R>267'/6!'Z1R1Z2M:YQ+_L%J"0%JCD'O
M7AZ(5J-*XHU;>N(`I1+TQZ-8F,UO9:A*J*&0H(,UK>M[`:4/8=_^S>5A!45Y
M=HJ&)&YN9(-YVIH<V)X:69_DTPES(V.48;'IGCJEO999('MJ1_$J"0*M)@%D
MA+*,V6:$.C2"!E%N4'$0#A2+K:MGA$:C+#M!:2FGJT7Z2SEO8FZTZ#36%$/5
M1-`O11]`YUZS50^-25^<4X""VAI*2D+1(O4BQ"Y;@^4/QM$V`M@?FJOX@PHG
M%CDK&G6SY;%PQ`X#1-4T;'`5FY0WJJ]9-1W4A(1(V,QO;_BX+@265ZN%0#0N
M6TOE5<N.3.M@#VVU]IOM0V!SH;(*3A;W&8FTHCA[C`)@TG)GM*\JQ5\BKQE4
MI5Z(S7JH&PD[8_N=BV+G=H$TH#C-P9(#&)!7T;D+2X&DQ^/(V=Q?W4Y[06T_
M.THVY3)6RO0G"81Z7RQ*M=3'%\,7)U#L(]9Z3:D9ANQJW!)1_*5KCESVPM$+
MF`W:=$2R1NL*FJ\_XIL="UNC:>_-BR)R0O4)EKBT2184YG-HD*IS)6FZ6;/T
M:+Q%RDAGH>IF&8H)ZUP].3*&E(D2-"TYS?%R-HVABJ6"IG%I8U[HI86M^!"T
M86G;D0E+<!MPC$XCME&FA&+E+N$=3=`]&='12N-QV*>[\OJSXXTV%<Z1HG\:
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MPGL]2\R9$B1[+5O$44R6*K%:<X1*P@L1`3+Z[PGM$1$U/AV5YU<4.6S7<KGR
M^K%D9E\>BI=?64USYV)?84Y2\<B2-S4\,XV1O.;YS#`QU0>E?#Q:6&`<0@,T
M#?JXM!$$98FK5R5\1)5,7C3&&P2"W.(H[Y$R/0X.2>7IYN'IVK^GVA0X-PY-
MH2U@C4CJQ&W.;;I07\H$IHQ^G0B"$.2E[<-H>^6'V>J.@W2RK(9G!ZO_`)\@
ME!.*R!5ZLA2:,(H+([^?$TC;4SW/Y\L7FN2>[2"3T9ZKT0ALVQ[&(M5HA*K>
MR]JC:4;S3BVR)G"'.-'WC'FMVE2N7#GJMMA]Y_)B;@D,)C4.9'>2,R_K%?-7
MV4PHB.^5N$ODZIBTD.`68TC/2IU05<KVB[K_`-^'&=>#GIP2NC6BN4N,,[BQ
M0_2E%%8Q8C63)9W7S56Z6(SB>,IM[+8,Z+$[C7"<2TYD98X_.#?HA&-W#HD9
MRA7)VX;0JX\E2A5&'U'9T6C,Y;'M[=)%841B5UM<P?DC^XP,;HU@=7/J-\-<
MT+DS0-(G5(Y5\KF<Y0G2'A0%A2B(/4=N%\<K#1>1_P!I'M7_`*[SS_-JZ9CV
MW=8_C#L+S(8#`8#`8#`__]/UX<Q<_1"P^:^>I_,)WTN\2V<T=4TPE+M[8W6S
M?\:2.30)@>GMQ]0:[M1-B+UUS6FF^A3DDD%^;RE@`#6@Z+*<?9.JW\*NE_XT
M>Q?U[8+1#8$#YAJ^;U57DTL?IUKE-S.SLS01(7UWVTN2JU+-MF3*SW9R0W6H
M;X\WF/,F:6PA0M,(*/=79$D+$(Y06'8U9-MK;DMY>9/'&CH*RW60PA$].,T8
M6WWAG3BYYB+?&W14QR)?)VM+T6:N8$3"](CD:TU6`H"542,HW83`"#H:X85F
MA_)<H.C.X9=MRSEIE1TJ3(91"^_NG)-%DJB&,J20OY#B]-72"A,0<B:5Q1PP
M@]((L!@1F:``01;&KZF1/C`F$H;+.Z:FY5<.;H-C;;`,]XYTB"$N#V68<48S
MH96+I'3$K=`&IC`[3EJ!':$6+6P^(=^`UPS:JKN4T+ZW1=;?=HHY,\1D<T:(
MZJ]X/T^G?72'%(U[B9+&YH-Z*`X+HR6WM:H\2\HL271*8T>Q^4L>]#7#$I89
MQLNBK_.T/2L\60B)N:=EE,R2^\9Z4416-/*LQ$2E:7^0D](#:&9S4FN2<)9"
M@XLT8E!>M!WL8?$:X?E\A/(L?.;V]=?MIB?GR'*I]%XL1[PGID4GF$02M*Y[
M^4$29#NCR5D@:%#8VGG%*TX1I1EE"'Z30`B%H:N?&ZVY7E3^W0YGNVX3Y\Y1
M9LF@*Z]O[J$RP$L:=F]$Z(W=9$4O1:AY);Q(W$@?K&BA)]Z,#L(]A$'>QJD[
MV3JM_"KI?^-'L7]>V"T:73S=!8E3ELRJ/S7I=O?HS6<[D#(O]LGKM5ZD[LT6
M=7%M5^JK;P4HE/JRU,`?HSBS"A^7P&$0=[UL0MO!%:E?!X:N6GFJEBV*1U6K
M4GCV8<H4J&A&<>><8+Q$,TXT>Q"WOX=[WXX26UX'X,,+)+,..,`444`1AII@
M@@+++`'8AF&#%O00``'6][WO>M:UK`II97O$N':F<],$QZ@J(4K$;LD,&ATG
M(LNPQG?<Z"4"O*V!+9L,PW8_`L.D&]F;UOR^/E%X+6IPC7??DIG(])>=N'.R
M;C$I\!MLHE]=,_,5<*T@M&"`XBDG2DBK:3C;S"P:,`)(PK3#"]_<`$9L)8A6
M9@^,_>HV69YD,6XRY18%@/1Z,DLBM+J^R&S01>42D;1'6_GBO@*C0Z\P"].K
M@47X^40C/#S;:G_/+\@X>NN=;T?T%[PSJN<:V'T8XS2`J]Y1@^R#`E>LD:W5
M$6';`]&#`+R#-F!IQ8#!!\^_`(@B\0VZ$>[,X2@SSN4%\VP.>3$7E$9.;NV]
M]`S@2C0]F"6@E]WNU@2!*M&9O>]F$*"A:"+8=>`/N<4=IRNXWM+4T-R=G:6Q
MO;&E(3ZLE:V]&F1-R9/OS>)"=$F+*3$D[\V_N0AT'X=_!A%=8B663V#>9))8
M"BBN9>2RRBBPA`666"T.T`@++`'6@@``.M:UK6M:UK6%\+-80P.O(7`\/,D=
M<34Y!"U$SC/5]TWU,G]2T+%1\N@]J.W02A-`SB%`S$ABA"T6ZVI5(C2]IS@M
MIFM:WH8<+:L;'QY=K"P<NN::+,=BRZ(]AR-[VCN$9&V6ON7:LY1ZXH7F-CEX
MT1LE<59S0W2AA<U.DH%JKY9RI:J$`DL1HD\6]_A+$7]W_,H1\@F=HEE>O;0R
M@Y(='B3NS"ZMLQB3ARG.C)^7!:B*2Z=$T;JJPU(`M9:$U7YXZV+7+6@NFUV@
M$"W)@'`<U@2!(V([#AA@-W]5_0H'%/%%B11#%T822LA\IB`MXU:M*AHB%*78
MDZ",QIG_`&*!8XDFB,T<$S!<821QORC9'/T^MF>6),&&3+K)K*@X0J"QR"P'
MS3G*JA>+Q7RFQE:2:JS6N'FV$7:2$6F%@(2,S5MO$626+Q],94F;IV`80P*T
M<A?F&C_^65R?ST6#A9W67PA@,!@,!@,!@4Z[&_DWG_\`>0AW^9-CY8W@G:7#
MSHY&!UH3NM+\6R-X=&QV=3(89W;2<N#!T\'4FNJF$-,FJ(U\E9,O`^!-+BJ`
M#:K/4ZTA$0$I,<$0O#S"U)O_`"W<?=(_A]`ZMM76[:CKAIBT+9I#WJ_*T=R\
MS+'".)C)CTG73[4@PU]937#=-SL[56KUMH7>B]*F;4BI`#0-E*"B95^,K=7K
MCRM/U+&YR\\S=21AZ2G/+6]UE)6&J([2C):">P3'%>V.;=&F9R!!G->]N8%;
MV>V$J0H"$S;ZAZWIQ!MN$?H-G:68JX1]++'OA(WLZ>O6FPV2/!JFAAQHXNE9
M&Y+0N#U,IE'NA766,[[%S9&WO]05>SMSXP,0TR!6\.A@$Y1#SM3I`6U6H_R[
M!BQ;&6`8BQE"&`(A%&;+V87L6M;V6/90S"MC!O?AORB$'QU\&]Z^'*P_>!HO
M(_[2/:O_`%WGG^;5TS'MNZQ_&'87F0P&`P&`P&!__]3VP\7?L=<G?NT43_-;
M%<+.\K+X10[H;C)YOR8SR>CN.20=_P#F_A$6IE/'4#:-FA,HK^8FVTP325D.
M"54YR(W5OMS`YFI6]6T;&GC:,'IO2ZT:66)KPC6:<'+5%4R%I)D8':3)W?O6
M<I01F(LJAVD2_K'H-RZ)9886@EDTB,>>D36K3-C$XI'1Y:D#\2FT$Y8VDB](
M1%O5HB?BZZ>AV:QI/>3TV5+*[&E-[J#&=OAS+M2E:+.Y@J#G=H7.<88+EMJ,
MI_4'"M#EZE`7+'8MY;CP>E,;C5)R)&+K9DK:YGZ)CKJ^W="],UBW9-7RPDSE
M#(56\0/JIDCTVIZL*I&O&U6;TK2KL"6`15$A,^/B7A>I`G<%#;\6C2ZTJT+C
M9E4GN^9,80\I729Q%6WS2(P,]Z2N0;86*H79D-YGB_.H7.')6*T8G7[RR:0Q
M(E:0<ZQTQP+$N7EF#.)/(*3"VU2C@QU5*:Y?8A/F9A?ZOB?,[2SI?BN9,3(^
MOE"P'I&KW)>\KJ\G4)E[<E?8AT&$3?Z@XDF-ZQ@2>G]<2[,3"J6X*K@R3$JT
MQ$.G,.K=A<*R-@4U;8@W6PK0RXCY!6%&&UL=HQ.K?FL25IV"13<MQ0/?JA<C
M(2)?4/61%>A,)BVD>C^2I?3MGM$L1V`S$1!/&6M%*HNPH9P$FPI4SU?!*P:I
M6\,DJGLIA<2?&]KANO2KXZW-2IS("G)5>.@'B45)E>S"(:Z,_9[O;_0U9_\`
MF0^86-X4@@MT^\8GT"AB.K>+JJIY`*)QO:&9]2]((5*D:(MH1`+4:K#GV(6<
MJ,.7D[T:42IDC<84'P`>$LS8@EQ=+FY;5OG'O>R`!W;_`'ZDK)N7:V%UBG'_
M`#Q!X(:0G&6((T;=9-]N70DF`;HP6A:5IT2`[[G6M!#K8O-4N/$/H#W6W*D@
M&2KO`-S=4NA*@*D*OI^^K6MMHT8$S9OE)KURDZ*JD2?8]_W).PDE>&O#0?+\
M&*.T^%RJVI:G*:;A-%05-6=5-(@:*$UUM!(M!FX18?)Y2Q(HPU-:;8`^C#X:
M\OAKRZ_XM82[W29@,!@,!@4B?+BJ.GNO[;4VW:=<5:GDW-O,9$;/L:;QF$$R
M$YAL_KTQ\)8S9,YM@'8UF`^(A*PD;,VGTL(V9Y?2E^8OA(WMH\=?6QYH^G:K
M?RJP5.#VT>.OK8\T?3M5OY58*G![:/'7UL>:/IVJW\JL%3@]M'CKZV/-'T[5
M;^56"IP>VCQU];'FCZ=JM_*K!4X/;1XZ^MCS1].U6_E5@J<'MH\=?6QYH^G:
MK?RJP5.#VT>.OK8\T?3M5OY58*G![:/'7UL>:/IVJW\JL%3AQ>-5J-SYXB#H
MVJTS@V.TBM9V:W%">4K0.36Z6[.U[:Y-ZP@9B=8WN*%06<0<6(19Q0PC!O81
M:WL3NM#A#`8#`8#`8#`I/V\]LT=C=$O4@=VQB9T'1T,,7.SRO2M;8C+,AMAD
M%C5KUII"5.`9QH0:V,>M;$+6M?#O66-X/$HN^?FC?TSU1](L0^_&='.IQ)\_
M-&_IGJCZ18A]^,%3B3Y^:-_3/5'TBQ#[\8*G$GS\T;^F>J/I%B'WXP5.)/GY
MHW],]4?2+$/OQ@J<2?/S1OZ9ZH^D6(??C!4XD^?FC?TSU1](L0^_&"IQ)\_-
M&_IGJCZ18A]^,%3B7[XGDT;EM_\`:;Q%9`R29I&Y<_)P.D?=D#RW#/(K9S">
M2%<VJ%*81Q(MZT,.A>(=[^'6<_;=TC^,.R;(&`P&`P&`P/_5]L/%W['7)W[M
M%$_S6Q7"SO*R^$,#K"Z^=[#CEG6/):0A=B&W&T<8V7N`3>,45*IPUD6'N6QU
M3%6Q#*5$"?Z\>)<!K3N&T[0H4'J1E#&7M/L)^@F1J-M<M/DM7]-2_HR"QMPM
MB[DK96UPWJU03H,FJJGU(6J`RKDNC']M$]*!T_\`,V^-F[?DDB:TJ[3`E&>%
MOVW;-&M2*%`Q<5LKVI4=%RJ>TW:MKLE_5*:DM&O)M+IQ3O,RZ3S.*'R?W9C<
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M7Y-(RV]4-/4FJV=AF$,"&NC/V>[V_P!#5G_YD/F%C>&Y5S^;V!_Y&1?_`,$0
MX)WEN>$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8]S:6IZ2[0O#8W
MNR(0P&"1N:-,O2B,+WXEF;3JBS2MC!O?P;\/'7_!@:Y\W->_@'#/Q79/\!PM
MSD^;FO?P#AGXKLG^`X+G*N=U6QSO2[LRP<RO&VR+HEZ0U9`Z&J^#QV36K+DI
M1VDQSQ\4FA;V>'0M$HWY5<DD2YGCJ(6O(<N`8(`!B+GSHZ&.V(!?W;3)-8*Z
MNT4J*KFF=0ZCWBO:$0M:J+/%_6A+X]!H53*^X-(8^^W?(:S<9.7(K&6("6:&
M1A(U',H$KLYA5N;-&XFEG^3JR#P1%+.:&R)J;6YBHZ][0JN[X(Z,9DXLCGMJ
M`Y)+(JZ\:\]>2N<DE5=.]!V-%7&<QHK9ZA&I-/?V8O8#%S>:29OY=WL?C-/R
MUA9I3%H[7$CC4C:T#Y'Y`QLT:=69[9G5*4M;'9I<T28]&X-S@C/`:2<4,19I
M8M"#O>MZWE9N67^;FO?P#AGXKLG^`X+G)\W->_@'#/Q79/\``<%SEG6E@8F`
MLXEB96EE*4#"8>4TMR-N+/,"'RA,.`C))"8,(?@UO>M[UK",M@,!@,!@,!@?
M_];V;P3E68UO"(;7<2['Z;0Q6!16/0N,H3X_R$N.1Q^+-"-C9DIRU7RD<K6&
MIVY"6`1IHQ&&;UYA;WO>]X6^&U?,3:7UT>E_Q5XZ^R=@^CYB;2^NCTO^*O'7
MV3L'T?,3:7UT>E_Q5XZ^R=@^CYB;2^NCTO\`BKQU]D[!]'S$VE]='I?\5>.O
MLG8/H^8FTOKH]+_BKQU]D[!]'S$VE]='I?\`%7CK[)V#Z/F)M+ZZ/2_XJ\=?
M9.P?1\Q-I?71Z7_%7CK[)V#Z/F)M+ZZ/2_XJ\=?9.P?3!R?F:>3"-2&)/W97
M32ICE+&[1QY3%QSD!,8H:7M`H;'$@M2GY0+/3C-1JAAT,`@C!O?CK>MZP7PM
M`RM2=B9FEC2#.,2,S8@:DIBD0!J#$[<E*2$#/&4626(X19.MBV$`0[%X^&M:
M^#",G@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#49W/H15\1?9]8
M\LCT&A480F.4@E4J=D3(Q-"$KPT(]<Y.!Q"8@(ABT`&MB\Q@Q:`'6Q"UK84W
M'8G1G4PO4Z,0//-=$J_.6IZ#L:)^BNJ>MAI8=@5412\O0:+A#8M*,\4\FG2/
MTVO#SIXXJ(&4LPND;[HK%`V9CELFY$X\.>8Q-7P;/(NT>M%CLZRNU8DUNJ!`
M<D0*[/DJ5[6S+IVRXX?OXD)5*1)X4QG:=O5B"=,R!=%YEOIM<0=NZ4Y1YDK.
M.I(Q5')U92SHERC3.#936V2!]3.]%4,B<]>G$I=C9`0_V.]&J%?IC#WAA+6&
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M@,!@,!@,!@,!@,!@,!@,!@,"G,]ZR+63!ZISF6%CZ*NEB4Z;9<!K>`L-+TRN
M,]'O6KQN$*!X;(V[$D#V:&-,Z5[EQX=!%ML)2CVL++7F=GX@O)VW68,5Q]1S
M,'0URQY9\;PQ,I91QVC:5<1;-WH=*5`<YO:%L?$I9OHM2E^5OLN&'0@E."5,
M9ZF`7XAR^@KLF(94T<U<[G-:WHJ<LX'QTD+@F3O$:YUJP]?\5.-V6`UC.++<
MEPCM')HC'C!`,E#V2(&_1MB)U6)!&9V3'2-*PF@J^;*\@Y+@<F(4KGN1R9_6
M"=YE8$V?#]KI98<]D!H`*9'-9>[#&J7K#-:UL8M%E`*(+*)+)N@3D7?R_DW3
M/2)PCCR+=NMX@<!4G"^X!3_-NU5.1TMO#Z8WS,S]9;1,I*C.^XTH3R()H0^C
M$#>RSXA]>O\`0H8Z\R7\2;I,73G1D)8I:<(>P%**WZ'+6<Z2$AP%KPV%H8Y3
M93!(U`_,`!'R?`<9O919@1"/,+HX1UZR^`3#C:2OMR4*P/TQY[D;PY26^^9H
MXF.='*&K7948XR&\N;&!.`1Y;OZZ>>OE4(2:]!(M&'.#246]:-3/)=]]UX(-
M.8?9D/C=@5_)&>80F8,Z)_C$G8%I+@SO3.X$A/2+D*L@0@&%&`%\.O@$`6MA
M%K0M;UHC:L!@,!@,!@,!@?_0]_&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P(7NCH"K:#:&QQL)^.+=I*M,:(+!(XUN,LLJRI
M$$@:@N,5S`(^G7RB8/AI8-B$6D3C+3%:V<H&20`PT)8BU<`P#H[JH7K=U+G[
MF.@E@2S4E"UY*]I+[L)M.V69M/>MRP]P$56K6J)#Y#HS`EXEO@+85,E.*&:@
MT-(^5QH!7L$JF'L=?UG#XW`H/&DGJ+!$XDS(&%@:4VS!GF%HFQM(3I21'J#1
MFFCT'SFG#$8/8AB$+9-T+]%WTXU<3&*^K)@26#T7;1KBU5!7:A0:2U@^+@IM
M2&SK'5I!A5QVG*V*7D*7UP#X''#.3-J+1KFO1$&EB/PS?/-#HJ,BCH2Y2-PL
M.TY\\[FESVV^$B(?;+GZI$E0J77:':M<3&HLS-Z,EN86)*9M`QM"8E*3H6PF
M&FB9MQ^L+3>*8YTMFP8N1I9.D$8''ZP;1:*$%ZMZ=KT4"J!@%H[>B_"06;)F
ME%OQT+P]8^`(M_<[$;PW:DJM9Z0IVKJ=85"A:TUC`HK!DCBL&:<O=M1IE1M1
MSTY'GFGJ%3H\J$PU2HXP8S3E!PQC$(0M[V2=9F6/Z"JTJ[Z+M^H#%8FXRR*X
MF$.0.Q8O1GLCN^,2U"R/Z0W0![(7,#N:0L3F:#O99Q`1:UO>L$:3;@\UVH;=
M_/\`3=M*TWJ#O/*ZBK])6@6B@G1^8*&E,7,XRK`0,P@IPC$K*6-Z@!8A@`>F
M&$(A:UK>RSI*;L(Z_P"=5K.^499(KVYR8GN9U))WMPE70_*D?3IE*A0M=3`*
M9)>7.#=HHHUMM,!H!K9!$RS@MDTT(Y0E+3OXQ&N1=])7,KJQ8/;<'C-DUM)F
MN8P:8M9#S&Y(S'[/0.2`_8@;WK0PEJ$JM*H+&0I3'@*4I%)1A)Q99I8P!(W3
M`8#`8#`8#`__T??Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,#@N;HV,C<N>'EQ0M#0UI%"]S='-6G0-S<A2%"/5+5RY484F2)$Q
M(-C,,,$$``ZWO>]:U@4;.Z*M3I`PUCXQ96Q-`#1F)7/L.S&9:IJ?U;S'I51_
M/\(+6-+[T"\I3R]^@=A'-4'UO7I2G-TV6-",M5NF2E^8:]IQU<YR:J?[/NN3
MHBT4UOFT5B626C)4H=@-VS)7(E$@:81"2E(/2IHW'4;3'TAF]C*1A,$,P0F;
M^%CL(@OH"]F2AH:C>#F9SFLZE[R3"JBJR.^.Y3:MDN2)<M9H@R;T0J+;DWJK
M<>M=750#U!C9TBIP5B`F3&"PL1;3^<J&?*^-D]LW"\MDZZ7MH"`VS)FW%"^(
M8RQMIJI1%Z7JP*I(D7-525UI><!&$T`%;NXGJG9=KUQ:8$L3.-EI,(I3T%OY
MR>CN3J()$<<U,LBE/5=D)R1>"<R-T:D;V"M&MT,],#T0UUZ60P/:$ORC$H%%
M%&PZT`DT6BQM,KK80P*7<E:W");U501NA$IZRZ#D=@PQ/LH))0ZYZ72I[V3J
M$8-;\0-S?:TKF+.0#7W!8&CR%^4L(0`+/B5T<(8%"+$JRPN;)I*>A.9&)=+H
M=+'@<JZ-Y5:"TP?EXL-`(+_<E"%GG)DD=OD*<(#W1G\Q37.PI_*9ZL\"+7'%
MWTE;JK[0@=SP.-V;64D0RR$RQ#Z^RO2#TQ>AZ+.-2+D"]"K*3N+.]L[BG-2+
MT"LHA:@6D&IU!11Q0P!)LWW`8#`8#`8'_]+W\8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%6K?ZLB->2L51P*.2&^>B%#<D=$E&U@
M)N5/[&U.6_(VRFU9.YJD</IB"J1>(BW21+$8EX2S"VPAQ5!"E$6(_".V[EB8
M7:Y(IEVU)6.QBDRHAR8.8H2-QUS!"E*14%2VJ),@>4C>^=$RQO&469\9RE,2
MRE*0!/;V%N.#Z40NMEYBRRR2RR22P%%%`"6446$("RRP!T$!98`ZT$``!UK6
MM:UK6M:PC]X$67/<L$H6O7JRK"<%"5E:A)$2!L:THG23RZ3.ZDMOC,'A+`2(
M*V3S>7O)Y2!J;4^MGK%AP`!\-;V+0B+03S_34Y=9FX=1]((D8+WE;,JCT(K]
M,L2O$<YEJ5:X;<DU81AQ3"-1/$_D/HDJJ<R1/ORO3FG)2)MZ:FU`'"SB-ER<
M(8%*><]_.1?W6M^&[./:R)JP<M5P>:+S)AQ#G1.Z#GZ]"4$XPA.I4=#V!,6A
M8(.M&G@CJ7TN]Z*+`46=HA=;"&!2Z6EZKKNRIY<'8D[/TE1\QI!_,T6+0%M@
MT8[JKEIU"(>O$L9OR"F%GG_=>480IM>7S:V+R%\+HX0P&!1&S:DL:AIW*.C^
M6F8,C32Q7I_Z+Y?(V0C;[E4D!3$K;0J)4I7M[1".C$K0GV$_1_@T3<L@E(XB
M2K`IW8@N^DK3U-;,!O"`L-EUH_%2&)R$I1ZLI]75-[BW.+>J.;GN.R)D<24K
MO&I5&G=*<A=&M<20N;EQ!J=046:6(.B;)'P&`P&`P/_3]_&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!'5IVY6E)1!5/+7FC'!HJE4I6
M_3H]JO1"<'=P$(MKC[$WD@/=)%)GD\/HD+8@)4N"X[P+3DF&;T'8W5.`X].=
M6"UIF*EG'?/2KR&:D#BC;BNL;6:32Q:V6S1YS3.C-S7&7,DW6_6G(IPG`B][
M"%%'E80GZ+I'RM'4%)U;0T4^1E40]NB3*<N4/#N<28L<G^52%;H'QE+)O*WE
M2X2B<3%X$7H2UW=UBUR6#UYCCA[^'";I3P&!J,]GL-JZ%RBQ;#D;7$(/"V1?
M(I3)GI1I*V,S,V$#4K%JHW>A"V$LL'@$``B,-'O0`!$,00["H5,02<7W8;3U
M;?,?>(@VL85X>6J!D)2E$XU7'G(ES:E=Q6FS^N&H1WY94>7>0M&:6(<)83]M
MA8@KU;P,PNVD+UX0P(EOFUFVBZ5M6XG5,8O25K`I1,`-2<`C5CXO96E4L:HZ
MW$%B"8J=)$Z%DH4I(-Z&<I4``'[H6L$:S37>6ZJ<J3Y[J:M7]6)RF#%$4:RP
MW@1H#AR"T9.:?++3DQAA9AQ8C9-8CXYKQ>48@Z$IWX;WKPWA9UE/F$,"F/=W
M_P"-4BWWF3H0%G+=FUYT:H5A$:`2*"P-[TWWF8$1(1F!VKYXD<N2^/@((?6/
M$>A`T(.RQO2Y@1!&$(P"",`PZ$$0=Z$$01:\0B"+7CH01:WXZWK^SA'ZP&`P
M*-VM3EC5#/I#TMRJTI'A_D@B%_0'.AZXAECO0*=L2D)2IE"UZDPEHA'1[0T(
MP)$;HH]&UR9(62W/(R]$H')M+?B5E*<N.`WQ`6FQZX=C7-@<S5R!6D7H53/(
MHQ(F=48W2.&S*..):=WBDTBCNG-1.C6M**5HE90RS`:WKX23%)0P&`P&!__4
M]_&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!JTVG$+K6*/D[L271F!PF
M,HA.,CE\Q?6R-1EA0!,+)VM>'UY5(VQM3>F-`#0SC0!V,00ZWX[UK`K%KOGE
MQ1LL3/,YK+$AWAZN[0.BK]L%@5^8>P@]2D4(K"0,2STNM:&#T2@?G*&`P/B6
M8`0BU*X"904K3D*B-CV2I)*4$[,*-(,V4<`)A>S"#P%'DC\@M>(!A",._@WK
M6_@PC[8#`8&FV)84*J6!S"SK'D3?$H%`8X[2R7R5T$;I`R1]C1'.#FX'A(+/
M4G^@3$"V$HDLP\X?@`L`QB"'85(<.OE]PK5</X?CK!?;L0,Q$^WDZ.RMOY9K
MA7H)>A@<;"9R52FW)2B]+YA1R'>NF@-+]`YN#+YP'X6JW;S57*+%%9DFN2WY
M>\]#=!E$JR$5HSI"C0M$!1KP"*6,5'UF@,/B5/,!J<>R#34(5#^Y$>`75U<1
M:T/!,^(V6PPA@,#B+UZ%J0K71T6I&UL;4BE>XN*]22C0H$*,D:A6M6JU`RTZ
M5(E3EB,,,,$$``!V(6]:UO>!U]0=M<.XIS'+MF"!<@Y*KM^22+G6O7A(I1&7
MU,F5288T=*V"Q.;:D5E0)D4!"HKIG4;$!4/0)(J+T=\3A2%VT\NQ#"&`P.JG
MM_I^F!=+<C<!RR4KF&:77;M36T_H5+(^!9'VMJ^?)Y-HFP))$C3#;E;I++UI
M^/LRYL$8'S-*\X:C6TPA!'&HC29=JV5DP&!KTNBS+.8I)X5)$FE\=F$>>HL_
MH1>&@K660-JEI=$@MB"+6M*$*LP&_'6]?#_8P*X</2E[DO+U7-TM6#7SNL43
M[0]C*SS=&*UMA<_R=ZI>9.RO7CO8!R%]@QSD7_9",A868`0RQ@&(L[K8814^
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MZXBQ.$7:W:C^C$2^:/JB-1A,.%1`8G9\2QF13%0WDB)L$PLDPN-1-Q5;$;LL
MO8$P@Z%YQ`")4X-,O__5]_&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!
M33N\(1TA"0#"$8!]D>[I"((M:$$01>\&YAT((@[\=""+6_#>M_V<+&ZY>$1A
M=KZ[1>F+<DK"L&W/D=K"?/K,X%@),,0NS3%'9>W+"RU!9Q!@TJQ.`>@C`(&]
MA\-ZWKQU@AURFCD<6K1%8UA]A7?%6!)&69[D<C?)96+.R-OKZ5%YSU2Q76Y2
M9(4:M5A+!K8OA&,(=>.]ZUF^L)VFZB(2`&"6$,(1!Z@Z)$$6M""(,@KK81!W
MKQT(.]5GO6];UOX-Y>L)WG$.-\D)UZ]\6^U)T5Z[ZIZ]Z'X[K_\`Z+Z;U?TO
MI/FP]%_=O@\OF\W_``^'A\..L'><0BB^.16CIJM7FGKRO'H>>5I(E+4K?8FH
MG$=9$#N:QN*=W:@.)T9A3*O5ID;JC)4A(&=LG9Q)8Q!V(`=ZG6#O,;1#.U)S
M291=<1*HZKZ`Z*BM=P5L^)HE&]3.*O13(TZ4J%13:F<)#!'9W,1)3%(@D%F*
M!A()T$HO02@``%U@[S/B$A&06PBBQFF=0=%!`6`1@Q?'U>;\``UL0M^&JRWO
M?AK7_!\.7K!WG$/DDAD]7I$JY+U%T4:E6)R528WX\KX'I$Z@L)Q)GD,K$!@/
M.6/6_`6M"UX_#K6\G6#O.(3/Q\^31=[1L:F4_E5B@KV_D44BSQ,A,1KXACCA
MSOS]/C6@U5'V*/IEA!,HFSF>6,TD1P0J/1['L``!#F8J9AJ[B)7(R#KD=#A]
M_P`P7Q=N-\_#5=R,]MF[PG-3G(NP+#C+B`*N!,BE.><!?S7`WE&,F1*=:T5,
MWDC;66(;0D<0N1=OE7>IWN<K.;::MVR>M;Q8C);5M1R&0+P.U;-3.&26`Q1D
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MEA4B*--*\_HC3`"=83O.U13?S8_+2&U$\*.K^@DS:XG,R=$K52&O$Q:A1(EJ
M)M8TX='UD6,*AT<7$@@DL6M#$::$'AYM^&.L'><0RWR"L3ZS_17_`']7?ZL\
MO6#O.(/D%8GUG^BO^_J[_5GCK!WG$(:O]3<=254_V'%^F;U4/<;=(6<C3/CA
M7;FT*@+YS&VE:E<4'S<$;4I52!>:6(.AAWX"\=;UO)/K$1*^OM<Q%0MY1A>J
M^ZDZ\J7>AD-DS<*OZIAY`M@TC*36=%CZHL%K:=!WYO\`FU@T6H?%X!:V("N5
M:,\?*>`(<-3M"Z&$=;T;_/QV=^\)"_\`4_Y7S?KM+/MX^'7U%NR+5BT/D,AL
M5D6#=%S5#W.$L<^(A$+T_'+"K2<9<^1V4-3LUP='6.T<7:$3;I[<29,D=C32
M5Z;SKV0E;;7K%Z-Y)ZRG4NM"O(^UHFB*,CZ8PE/</2.:=TL=*GDZKGDUND+\
MG=HL:G8V`(;0="4NRR=Z<4R/TP3B31["B7JG727.WUI.7_Y-_%J.OXNE7N\7
M)=W(Y\6O:=`OF]=72_)Z?<#%36TE,]V0F15T@3N3:;H0MJG9$1LDL1^RMK.K
M[JNN+,C:1.TOU91E7(D+\<R.;N;/VB(1-R,25+2%GDH43W.BHDW%/S\*WE"$
M@H(S#=_$*I26D-!HTE,LZQEFI3UA.(8\5*A?:_BX_G:L9GB[2V-\P$2XI8H]
MVU7=3ER`P^1H8X-R?VD<S/>5C2U(W4PI$E"`1H"A"6A7L==]6&9^RI>YL3.]
MH:]B\O2RK4)CS`Y5[+G&3,39:5J,#FM@M>3)U!'BBV$]E?6<M))E@M>1H*?F
MH[98M&*`E+.O*P5S_G'Y)_>$DG^JGTWEGPS&WM\/_];W\8#`8#`8#`8#`8#`
M8#`8#`8#`8'7C6_O+*2LFTYC415<=(P625DV-3[;CI:-)R"`Q&G(\_1E_E[#
M([7D[XH*;8(P/;!&%IZ58O$40:$@6_-X:WO1:\K)O757+\:B7R_D?2%",$$^
M48(?\M7JX*]:HE\K3&Q(]%Q;Y1KI$0S_`"C,9W`A6%#Z;UG:8\LW0/(,(MBI
MPYSQTOSC'IM$:T?^@*28[&GZ%G=()`'BU8(V3:;-DA&<6P.,1BJU^(?9(A?#
M$Y@49R,@XM2(`M%[%O6_`5.$:5WW9R?9F[1"R7C7#5NG[0>ZCFFI7-8G&]II
M2RKTK5I2BTXOA>UL>>G-5ZLVKM>4E>>6865YA@%K0J<)(B/3?-M@/,3CD#Z#
MH^;2&>H7YT@K#$;8@<D>9HV190N22=QB;6S/ZU=(T,<5MBDI><C+.+1F)S0F
M[!LL>M"IP^+7U)S*^$SQ0R=%T2\)ZK-()L\]KMVOW`FN#E2[;6F*GAJ20G`A
MYJASUM.6%PVGV,_7H]>(_@P5.$:V)WOR)6L4C\Y=KZK!\B3_`'7$>?OE!#)W
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MFPP=U?CY>`P[9*IR1R)2>:>!"J=DN]^JI]F:/)E+<WMI_P#6$K[GQL4Q=<NE
MTTH6*O;S.UTP,K8F'1QUJ0M&6O3$-C3(:\;[14-ZM,8WMY3CI$0]J"4+YHA2
M%2HTF]&8K19GB6CJN5$#E+446-LJNQ0=D@#"T'6B\%,0IW*'1AI:O*>)C#BZ
ML=I))*ZUZ_DQ-0N>6@13,/SJE`4[D8)5Z1/*.VFVJ9=\MU!MB:6Y):<`CCRQ
M%,:1AE,6"?J011$BL&UYO(2(;(9K9LZF$>^5":TAHC`?&IZ9-I)_:B?5!E(4
MUJ$[3ACXQRS6T3.JY8R6K3K*X5Q8(IL)2V,;\[IUZ-;NG2W]C96>R[XLACB2
MB0I*C*)&X$)CCV\1Y:EM"A6@6*G%1VF;TE)E(5#!J8F[E+4EO5VYIG:#1R*.
M;<D:F=O=75WCD?A,;3R=PE;S-)6\)@;:X6`L+2V?%K3_`&_TAI!ZDH!^()F9
M\+F<8N+>ZOG8"UK7(W)&9T^S!+5H%1"Q,8(OD?E0!@0'IQF%"V`8=ZWK6_@W
MKPWF/;>5C:&O6G*)+UC84FYEJ1[=H[3<$<P,G6MV1U:O:G!2X!+:G,WF"HI*
MUK$*I/.)`SK=?+5]1&['$VD\*!.,#TNT:TQK;7RO'&(S'85&V"'Q%D;(W%8J
MS-D=C<>949#>T,;$S(R6YI:&M`F`6G1M[<A3@*)*`'00%@UK6O#6$=*%6IXW
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M`"$QZL]0]'IG5CK/;=\4M2YE:B@.&SS2%1Y(1C5R=IQ+]Q[E&L$KO-%\RMVJ
M9HW35W:WUS8E,3:26A:^-D=OE@^4KLT.]BR2/#DJ[YYDAQQK8A:4.AQ\KT20
MH:C9A*MSM.'Q'RA6YS,O9EMNU"^#<7B,/SE(W^,*#YM)E3*Q0YG<62;S1DN6
M/R.10I2JBH5[>UE'HOBU4F:_,<J*;?1JE':<-]Z'40J*<?'5ZT2V+.(HLQT[
M$D!+:_'J]J@1^90-I)]3+?Y3+I.>`9:/6P^O.;FNV'^[JE!OG.&G^,GK?:U\
M[W__`%_T]R%<)8/(@E3M9?*LS/`5_:R&FVXRFL^"N[D9Y@:V!%9M%-S(CWO0
MQE*)2,(-:"<<+7-OQ,+H81UO1O\`/QV=^\)"_P#4_P"5\WZ[2S[>/A''3EQR
M:FH_`%\6;OC!7,)XYQ9;LF"R.RW-&W-E26G8XU3/"(M(XJ[OJX:R`$D#"%:6
M$E*<<<+6_1ZRS-)$7:.V?L%6ZD+BD-6NTG<&:)Q%2ZJ(.Y+93'#YS*JUK^SR
M6-@D;3'5S%)XR-BL%/ZJL:5;D]KMDCVF9SBQIS#UG7ES&[K32TMF<BHN0L8'
MR:MD./?212M/'XJM5M=3[]1=W,J(.K]IR<WZSO5T9CNRQE`0-`<F<%"-6),6
MJ6=6K'=M@B[#62F;0YJ5ODVK&.V`](X`^R9^2,7RKA-F3.,Z$Y.D!:(T2@?B
M*I<R0@/=@.!)P=Z*3JR2AJ-KV7K=U*4D?2*T^8.,`5P(A!*XPZRD$R3'35O&
MWMK!$HQ2$P<5L?4A:=.,I?S62_V0):$*-,D];(6$B7!T%(-;;2N66H>;Q6[(
M3&7\BMMQ1HAI\<=ZX1N:%5I(E:'6`I]QM_C/QFR,1I&B(S*5+6(P@@Q'H8#]
M(U2M*(I28C4G2=W,N?\`./R3^\))/]5/IO$^$C;V^'__U_?Q@,!@,!@,!@,!
M@,!@,!@,!@,!@=9$[X.ELNEWO5)(FGL<1D>\'YQKND8<F/;7,9M>NL+I"V:I
M5/DF&6+R.C>M<+%)5EEI?`P)*88=_="#C*W_`!X5LN+W0JMYA/'J2DI/7-=2
M'G*I9E5MBQ%M;IO6$"N8VSZQ@E>V!-54AI1]ATS:).[E00DM8:H`X?';8;I*
MKV#10=BE+'MNB>R_<Z=!SS56QHJ_*^05E5D.Y+:8/!DA]Y-;!63CST^H7"7-
MD6CQ5A.#98+5-DJ$OU%SFPWYS9]%`)3!*'_SO2E[1A-4W]UQ9LN3W+!#)K2)
MU663WW$.UV[:R"ONIF%L1S:(RJ65-)P^MJX\ZL9B1@4IT8PE^0T:KS'``#S`
MVI.VWPP,9]SF*.V,RS-NE]=Q@A!VWV3T@:MA4.VPRM#5?2]?OD'A]:,#J0D`
M!`XUQMV`>7K?BW%^A#H@O7AK6*.W^E>VWW&MNIJ)M6DW&X:L='![Y=*Y<@%J
M*3K[7OVHFV7G6%N,@G>"R2QY)7L%9"B(.K">V,:0\6W)9H].J3D"/3&J7M&G
MRM=9ONK)(ZSSI*;5-)Z=A*&QNH>(.FZAKY?`EH(%%7?D^.,+9)XY*6./#:TP
M$=G.[48>H.;0!,&6;L)VA#%L6E)'ML[D8T0[I8Y'TK^!D+?DS(U$/9<:(4I8
MX6[DH""W($?2K1F+$S(%8$>DA9PA&@(\NA;V+6]Y654>[?S)0?\`?)]W1_O!
M^8<+&ZY.$?%2F3K$YZ1602J2*B34RI*I*`>G4ISP"*/(/(-"(LXDXL6PB"+6
MPB#O>MZ\,"(/9SY[_0337T80C[QX6YR>SGSW^@FFOHPA'WCP7.3V<^>_T$TU
M]&$(^\>"YR>SGSW^@FFOHPA'WCP7.3V<^>_T$TU]&$(^\>"YR>SGSW^@FFOH
MPA'WCP7.3V<^>_T$TU]&$(^\>"YRK'9;\H6S!7QMQX@8:OE*TI!*>@K5@<;9
M6AGYT@[\6VEE*$"9*PJ(TY]&6>P)_0Q9O5EF?%R`G;XO`-(E1)'(<RM_5-60
M6DZ]BM6UJQ$QV&0]L`VM#>6:>K4F[V88I7NSPZ+##W)]D;ZY'G+7)R6&G+7%
M>H.4J#3#S3!B)ND+`AP7.O/HQ"&.BJ<$,0MB$(58PD0A"%OQ$(0MLF][%O>_
MAWA;G+\^SGSW^@FFOHPA'WCP7.3V<^>_T$TU]&$(^\>"YR>SGSW^@FFOHPA'
MWCP7.3V<^>_T$TU]&$(^\>"YR>SGSW^@FFOHPA'WCP7.3V<^>_T$TU]&$(^\
M>"YR>SGSW^@FFOHPA'WCP7.7W3<^4(C4$*TE(5"E5I3BE*54FK6&$*$R@@83
M23R#BF4)A)Q)@=""(.]""+6MZWXX+G*+^X(D]ROERUE,21A7SRNFYEO&MTF]
MF`&KLF@I,RW1`F\!Q.MG$A=Y3!$J,W8?'0B%`P"T(`A!V(W6*ALM8I]$(I.H
MNL"XQF:QMCEL=<`Z\H5S%(VM*\-"P(?'?E"I;UA8]:\=^'FPBC#[3W4#%<5_
M2R`PVA97#;7L:,3I@5R^\;"@DG0E-=%TY5SBVN\>9>;[%:B3`O=;JCR3274_
M1J505L02S/.6&Q->$F(FM7S.@'8:DQ(<HIOEE0<WJ!*T!IW3MHFF(E8TBI`-
M4D&/C40DR@:%:<3L8-A%LHX8/'RC%K=[<)UC+4CJ"Z(4&GGJ.9N+#SE+0='U
M)QU\SDTU0PJ5`U:AD/,'Q0(9K0>K,$:-,+>R1&"V+8=[WXX[<+7]I<O=(]+[
M^)?'G/C??R;5$+8[X]!3[?Q`L2I4B%*K9?\`^*_^RE29"@()+,(]&,!1!8-;
MT$`=:=N#K_9Q-4%T0%4F7!YFXLTM1Z<PHUFKYG.E24+V<I4O(4RC7%'I2-.R
MA:<8JT'>O6!FC$/S;$+>W;@Z_P!I99=4'4KHI3+'/G_D)Q5HWI-)$BI=T58B
MM2ED2)(G0(W],>HXN,-(>DB%(424J#O1Y910`!%H(=:T[<)UY?1CJ;JJ,$JT
M\:H3D:/)UZX]S7$,?1UCM)*UR4^72EP5E(.,$X%*Y1H&O.:/0C!^&O'>_#';
M@Z\M5F](]IRZ34]("ZVY=0@JZQG.='I1]-6P>)Y*<*DM*L]-I)H>/2M(C"C[
M%`LV:()FM@2B+\NMF:&%VVT7K&NK_]#W\8#`8#`8#`8#`8#`8#`8#`8#`8#`
M\_SG[75P^]SZ5A,#FD\<J*H9SX?>))&$W4L^IAA@<>L*+.;U,%S'6\;A4K8K
M7.D1$65J%38O5LQ!AJ<)(CMA6FF$3RUIUUW5C=_>Z7'9CKUC`T#G7<\I]]Y!
M]X58%='$Q8VEK5@KUS='90B:VZ0)JVZML:TV=G>S$BA.!:[HJ[DRP)!3HU@1
M@WKQ6O7:>7\A/=5S<_Z[0O!`ZM[VVQ:H?<="#';.?;"EE:5U'KZ@2YDMB1(`
M.D[`\,YQJ1YVJ.<U;F::I6)R#W$Q8,(MC%1-1\K&N/O6.AK(G"R&\U&<JRMM
ME'O&#^.ZJL9X;IY+X$[5N?S^*TFV>*W:#V>F*DSMN2!$'2MM,*;EC>'191(!
MCTKTLZQ5S@B7O.^L'#MD'.\JC-#LC9"^H(5S58T4='NLZ[>Y%&Y!"VL2B[ZP
MW9'4S5>DG<)'/EPE<?CC76+VUGQ;0];?5#@G4;"*BK>A'*PB6V$5ZK$+1JC)
M-4L<<RU:GX_%;$&F,U0K$(B0>J::`P^PX"H;E9"@(O2;.VJ`:`>O+HO8-^<:
M>75W=K'WTW2JI'3K"<\YS7EHKIGDY(ZL/-4:F%3V'JP5G454HZ+>I`AMD=W%
M2&%M=TGQI4^(VF0QY?M`2=HLX\OTA!L:T\;NY[*R8#`8#`8#`8%1^BKREK*_
MQ_GJ@"&A^Z7LMK/=6P3L4!RBM)5T4M`V/=[VHWDK4:LR-LZ@8DS&U!&4HE+]
MH"$D92<MP6HBQ'F=DH4-1D0Y^@14+BQSF].+@YKI5/I_)C2%TZM.PWW99TIL
M:?/!"=*%VE,B5EZV/82RDR1.62D2%$(TZ<@H3-IHPA@,!@,!@,!@,!@,!@4O
MX3"",4R^44+0"C^7+8LCGI(B`9L?Q?!(D\AD-')1@%K0TXQ\]R^)';+WXZ!Z
M7[C8B_(+99RNAA#`8#`8#`8#`__1]_&`P&`P&`P&`P&`P&`P&`P&`P&!!W2M
M_0[EBB+.Z%L%MDSQ"ZGC)\JD39#4;6X2A:WIU"9,,EE1/;S'FI2MV8J#O03U
MJ8'AK?W>M^&MEB+FE5J:]Y#SG8+OT*3-HI/>6Y1S\R51([@(Z(:ZYBZ@N,6L
MTF.%7O`)/7M@V1&'<IZ3G!(1HQN07'UA0`DM-L1FM;EK/K.C>W?LG@J,P!)<
M+I;E-M\%F$FF45'*0HB#-K)6VEA^<!ED21(T&O+8[(B-%[=RW(@@8`&$[4>`
M32O-4J=F=D/7/$,=?H3!7RZ:/+>KMC<)<X<QD.K$ZESB(2X9;96SB,384M0#
MC<J,4Z3L)RP9:5P%L1:39FPBUH5.'UCW6G$CU-9S7T9NJBUDVJ9%)9=-6)M>
MXYI9%TD!1[33-]V<#0$IXX*B+]"[FI3#3&D.M%J?0_`'!4X82.]P\!V&3/;(
MC71O.TK*I"-M+U.YPBET3<!0.,28P(6=0=(=F",(0N[@H"E++3&C\[@<!+Y?
M63`E"%3A8&G+RJ3H*)&3NF)XPV'$R'A;'U3PP''&$HGQO(1JEK0O3JB4RQ`X
MIDK@0:(DXL`_1'EC\/*,.]DV2O@4V[M_,E!_WR?=T?[P?F'"QNN3A#`CVU+2
MA5+P5WL>PESLWQ5D4L*%6:PQ.73I]4.,HD33$HZULL/@;%)IA(W9ZDCZD1ID
MC>@5*#3CPZT#>O'>@J[_`$B/.'^)NK_]GYWS]FC%3B3[C\P?TB/.'^)NK_\`
M9^=\_9HQ4XD^X_,'](CSA_B;J_\`V?G?/V:,5.)/N/S!_2(\X?XFZO\`]GYW
MS]FC%3B3[C\PJEV[[R9S9^8K-6<7U[U-,.E]DQI/6#.OX-[$:VP"Q3,(^2_N
MCFIL&@&.+#1-$3$O4")//\Z@182BP[&/7@UPL5>LQ7RP'$'5E9UE4VY=T!$^
MEO:LN%:":='2EJXE[_F93[+B]'HV1G:G@[E!D(9H5"H]LIO9&!"4-M9$P1%%
M'K#3%"]6J<+/$Q7S"YG](CSA_B;J_P#V?G?/V:,5.)9^X_,'](CSA_B;J_\`
MV?G?/V:,5.)/N/S!_2(\X?XFZO\`]GYWS]FC%3B3[C\PD"J^R*,N.<I:WB!E
MPMDP7L;S(VUOL[F3IBDD3HU1X]J3O1C5(+HJ*`1UT6MXWM-L:1.K,5^C,])H
MK8`#$$+28#`8#`8#`@>V^H.=Z&=&ACN6YJ]K5Y?V\]U9FJ721`TN#BV)E&D9
M[@F2*#-'C1@5;]'Z3R^38];#K>]ZWX%J91/_`$BW"WUJZ4_'9L_OF"I/Z1;A
M;ZU=*?CLV?WS!4NJ.LO>!H8O[U.]43O>G,;3Q99]4LUGD6(QR0"TZ4V3#&^,
M5DR1YT<%3R?J,ST<?5%>OD>K>KN#9&TQZ<POQ.(U/+5?\\NUS^D6X6^M72GX
M[-G]\RLU)_2+<+?6KI3\=FS^^8*EOU9]A\M7++$\%JN^ZPGDR5HESBDC,;E3
M<X/*M"V%@-<%*5"6;Z=06B)'H9GDT+8`>(M_!K>]"I62PA@,!@,#_]+W\8#`
M8#`8#`8#`8#`8#`8#`8#`8%:.Q^=O:TY@NGF_P"6'R`^=^&J8C\L_D_\JOD]
MZPK1JOC#Y._'<;^-O)ZIY?1>O)O'S>/GUX>&RQ-3$NKMQ]QQ!6B&WE4]/76.
MHJ;MV34G;K#!6>L?7W&MN@:75-QJ>:M$V36*Q2%UKJ6$(Q[5Q4P1!Z!8;ZPV
MNZ+>AEF2E[;36K[/'N?+&<ZW:H$V]1Q:'HG:V[KM6W(Q%JHNX%6VJY7%5E?5
MVE<Y=&WKL9WL&53RN%\$&ZL[L\RUP;S%C@+:IK.+*V2>H[</JP>YLD<5DG,3
MW%>H$D*6<_0*@JZ?YQ7E7V1`K;L^)TCX>OQ)[?([TXFJU=#K`](:$Y/(X9*E
M[8G'M.G6B(%Y`J.V^CG1CW.+@R)(G"7'I)*Z5'243[?CW.$=3TP!NG4.7=R,
MLL8YFY6E/`6<H06HBA*.:+_BY&B9HUM4,18CSM>@*T%1VX9N0>Y_1O4;9(\;
M<$+>T;7[N_FC@EQ9YS1KP_1.3;YYMMBL\VV7EKC%XP22)E<M(9]HDJ!N>D+G
M'U0BG!*]#/3E@Q1V_P!KR<0<ORODFFU]83"[)->CDOG\HFB1]D&I>!OAS*_`
M;$[16D)(L"Q;;G*>#0Y&V!+0A=I(\+A"-,&8?OS:"&I,WX7#PBFW=OYDH/\`
MOD^[H_W@_,.%C=<G"&!4[M;\Q:3_`$^\A_ZV](8C>#/PJA<UH/L0G-=0AMF5
M=UHWRZ+6=+%\^LIM.>&<"JN%-?;30Q`@^6<!2_&#^U2YP=#CA.`S26Q@5^C3
M_=#5HNDL1&^B,&WL(;[8SM5\5B,;E3RE7`;660)9N[-$:>%*";'0.2C<@K8"
MI=V$#6[IC=DB2D/"1;HH?H%1A6@'F+7KI;A)^UDRZO\`5B(82Q`;S&"D5:>.
MNUE)6Z9'O]YM-6N\?*`Q$Q5P#N#LY=J)R5KWH[:CUA`K"4WF!+T,2SKK5IMJ
M>X9/:+EH/R";(ZPH(VV+I"XJ)V0\.B23.NSM$L3*U-$=/;7EI("@4".<#W%O
M/+UL@/J>S!GEI:S,4K17?5UCN\D9XY)5%2JW=WE,0+<"4S@U-,#;H9)8Y<QA
M+_#;8AUEW,CEB=XE=<)$344],\7=58M'B-0I_72"F^1+4^L,BC[D<G*K7:T4
M%0IQH6N'2&R]-I]E(0'JX`P5RML4PX`DT46JDDQ-2H!H_BY0G*0:4[UL#D:#
M1@BUZ6==:M*DEZ"D;94L[EQ[%%H?*X);$1JB2G.[VLE,`BVI--Z^CSI8*UV]
M5@*]VBT+BL^T]+BSM,VM^H'DB5$$ZTMQ>B5K#4'_`*B=8:\)H(4?"K;>2F5,
MX.\]B3HWQ)F2B>Y._P`.:TZ&,+'Z6I7IWC+NPBW($_QV@-``PK2,@U2>6A"M
M>MZ[,G&>GW,4QA$-D[$T`+FSZ<RI9,%Q=$I13B:00)K8D;&T1Z4F"<E@@*#?
M6'94QMQA8-ED*3U`1D:6G7=9!G_:PH'_`"`OW_X589/;PUZ;>SL-S"F`P&`P
M&!0:S_VO5?[M\2_G.GF:]?*>VT?*F[WV._,5F2.!+:I4@:8[=D?@BF=?&;F.
M-?-VZ-4=(<Y0-45'3"OE\U3*0%IM1PL9@CFK>EX5/CH:8.K3KI=^&V,'8#9(
M2R'KYG[ABL0)K^Q;#>7NQ&*.0`Q"P0-DKJ1%O*,,GEC>VN\==4$[&1M:F5&`
M2K4@@'Z+)\YX%\)UY8)=W)$_B!U<6ZK+:0NJ9DLM0W()TT1:`I%<JK0J?[<X
M,);))BC&ME)VX`:HVA;2W!82W+4RLTHLD9@BE\+UY;I(NMHK&9>^05?6=QK9
M*P19QDBU%'8W&Y24):T-,%?G2%E+8Y,71&";H&6PV]8:B.&4`*$0E7I?51$'
M'+3KYM\F[K:'+3&)5\G),='I3,6R&-TE1J(&=%8\Z.+-6K@0FF$U#/S(:F7.
M"NR22$*5&M5+EYZ%6G3)SCR-`-6=4X#_`&DN7O\`[_;'\T,HR>VT+Z^78GF&
MC`8#`8'_T_?Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4V[M_,E!_WR
M?=T?[P?F'"QNN3A#`@;I6N)7:M2K8G!Q1[Y5)9U3DZ9R)6Z.3''W`ZJ[D@-H
MG,[D]-##*'%H*>DD.,2!4E-RW9!AX1[)'H.P["M:^M^LW4D*=TIKEMR3@-`H
M`0OZ0LI82`\OS:+."4HX],`$TO0M^46M>.O'?AO-=N&>O+\%UGU>4K/7E4OR
MP6O4C`8I6E]'62!6H,+"`)8SU(>/-'&C`$L.M;$+>]:#K_BUCMP=>7X%5_5@
M_'STGRJ/Q;!LN_-T98XO%F,\OI&G?CQYO_LP?EUXI_[EOPU]SCMP=>7+35]U
MTB*`2CJ#F!(2442G+*3=*6:0460F+T2G)`65Q^$("B"@Z"`.M>`0Z\-:UK';
M@ZQEP@57U060J3%TARD!,N5A7K4X.BK&"0L7`.+4`6JBM<=Z+4*PGD@'HP>M
MCT,.M^/CK6\=N#KR^A=8]7%`5EE4KRN66O/5J5P"^C;(`!:I<`:*7J%80\>:
M"I/6EAT$X8_,(P.O`6]ZQVX.O+DBK[KH92DD50<P")6>D]<*%TI9NRE?IB]$
MG>LE[X_V$_TI6M!%YM;\P=>&_@QVX.L9<(%5]4%%H"BZ0Y2+*:O3_%A8.BK&
M`6W>M:$%3Z@`/'>@H_6`BWH?H_+Y];WX^..W!UY?;YM>L?64ZWYF.6?7$FC@
MI%?M'V3ZRE"I"$"@*<_V/?2DZ4`#K0]!WKSZUK6_'';@Z\MFKBH.@3KS@5D6
M='*<BD;@L1L9F`1!+8FUAO;LY3<41`ET-%(*.J]`WH4)4=-$8;I6>8(1@0Z*
M\/$6I,WX:B*M>G(&`P&`P&!1:\83<1%^);)@-7FV/'E]0-,'6:03*(QE<U/+
M3-)&_"V>GE+BVZ5)52%Z!Y!DB'X#`+0M:^#QL35DQ<5:-!16YQ^F\_&X1^L2
M%-+5'FGU("]/*T7JGJ<G.\7_`'Z60I/4"/1+1>*DOT)?E'KR!\-=HPSU_LT@
MNB7\I`!K*]WO!BFPM.Z)"VXMSYR`@`D?&HEB>DH$@7#2<*=X9$Y:-4#0?*H2
M@"49H1>M!U.T86I_9^TM&R-#H@*+W?4)1Z2E/9";25UYS3Z3D24+R"1DD:*<
M0:)*?P2)PTM"'PTJTN4:-\WIC/->T8*G]GY+HN0E+#W$KW?$(+<%3:%F4KRW
M3G,"Q0T!2LJ(+4>J"XZ/.;0HXVW$Z($+96BD"8'E\I!6@NT8*G]F2!4DX+*9
M2"^#8R`F-N"5WCI()%SX$IA=4);*2B<V4L+MH#6X(RHVW!*.(T686%`FT$6M
M$%>5VC!4_LDV$PF]))>E-RR64VIKV*UZIGKF[N[G/8+(#%)D@@KO&&U"A;8P
M[N2T9PUKD$8QC"`L!8-[WOQ\-;DS9$5>KL+S*F`P&`P/_]3W\8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8%/._/V1+E_9[_DR,_M2_F6_P#/,7_EO_U9
M^"?_`*N^+,+&[SK59_Y@1?\`^CS^3#_V=_V3?[B#_P`C?\A_\I_R'HLC<_3U
MLLO\C-/\I_R8@_EK^6?^BE?RM_\`4_\`W_\`ROFRN;)X#`8#`8#`8#`8#`8#
6`8#`8#`8#`8#`8#`8#`8#`8#`8'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g887761g98g61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g98g61.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X6?@:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+VUM+R(*("`@('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(@H@("`@>&UL;G,Z
M<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*("`@('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(*("`@('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W0O<&<O(@H@("`@>&UL;G,Z<W1$:6T](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*("`@('AM
M;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O
M1F]N=",B"B`@("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O9R\B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!X;7`Z36]D
M:69Y1&%T93TB,C`Q-2TP,RTS,%0Q,3HS.#HP,2LP-3HS,"(*("`@>&UP.D-R
M96%T941A=&4](C(P,34M,#,M,S!4,3$Z,S@Z,#$K,#4Z,S`B"B`@('AM<#I-
M971A9&%T841A=&4](C(P,34M,#,M,S!4,3$Z,S@Z,#$K,#4Z,S`B"B`@('AM
M<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*2(*("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X
M;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C,U,T$R.#E%03%$-D4T,3$Y.#-#
M.3A!1#%",S<X,41$(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C,U
M,T$R.#E%03%$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("!X;7!-33I296YD
M:71I;VY#;&%S<STB9&5F875L="(*("`@>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/2)U=6ED.F%D,6)E-C(U+3=C-V,M-#DY92UA9F-B+3!E93DX.#8U93`V
M9"(*("`@<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2`Q,"XP,2(*
M("`@>&UP5%!G.DY086=E<STB,2(*("`@>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD](D9A;'-E(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#TB5')U92(^"B`@(#QX;7`Z5&AU;6)N86EL<SX*("`@(#QR9&8Z06QT/@H@
M("`@(#QR9&8Z;&D*("`@("`@>&UP1TEM9SIW:61T:#TB,C4V(@H@("`@("!X
M;7!'26UG.FAE:6=H=#TB,34V(@H@("`@("!X;7!'26UG.F9O<FUA=#TB2E!%
M1R(*("`@("`@>&UP1TEM9SII;6%G93TB+SEJ+S1!05%3:UI*4F=!0D%G14%3
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M6'`W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N
M2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$
M8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#
M1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*
M:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P
M8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6'`W9D@Q*V8S3T5H66%(
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M;UI,2B]I*W(K:R8C>$$[9THW<5-F16A54G`Y<"MF:S$W95<Q,7%D<$5,9CE(
M<DAC1T]*64I13%ER979%+S%D,S503W=D95-5*TAJ4DLT<6UU9RM74'I,,'9Z
M0R8C>$$[<FI63$EE5VUV<G$U;C`Y84Y),%9Z8UAS>"M),GEU6E`S,70O=3-Q
M<CEA-W%P6$(K6$AN;E)D9G9,-WET4'!M;5=L-W%,5'IX,'$W,B8C>$$[4D9K
M<7A%=&)355E,8EA'=V%L6DLQ<FEQ='!U9V9N.4AP=G!8,VU85%IB-'%T6GA%
M:$%C1S1R>'!A4FIH4C=C:T935'A90FMR6$97=B8C>$$[34@U9&5E3F0X=F%.
M1'%/<7=85W8R549W3#(X:TM#,F579C!H-F8Q9&)12DQ$4D<S-'!)=3-&='IH
M5C-K=GEP*V-U:7AA5%DS*W1A9"8C>$$[3'!6:SA55GAB=VAE4719;S0Q-%)(
M-FY&*S!J+T%':E=J1#1G5G%W5DUD0CAS9FU,<'5V5F953$IV3$PS9#=C5#9A
M3C-D3'5E.6U(2B8C>$$[,G1U6F8Y.6)6+V5F<W8Q<G5Q=S=49GE6.#EE6'),
M5&(W>7AQ5FYA96%)3DUF5#=U-&UK3%=Q>4=7,C1.1$=,4VI!>%%Y8S)K6&QY
M2R8C>$$[-VUL47%N5&53+WIJ:'4W,B]S3F-S67(K-D1*-CAR;5DK;7,R;U11
M4B]V3%(K2TEB=3)(161K96A',DMT,UAL,R]N25IT4$M7+VUF5"8C>$$[63<T
M24%K:%--;UA63%93>D0V:61M6DQL<41P>E1E9S)65B].+W=#6&9N3%A03F5K
M-C4Y83`Q,3`P06-E33ET2GA&,V)806I$:C9W828C>$$[:C!(<DEP5&QY-#A!
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M47AI5#9I,'I)4'%F2W-J,CEX5W`V1T]L2TA&55IP9FQ4.#(W>B8C>$$[>7AR
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M."8C>$$[,#`K375%;5IY43)X6&HQ659X5C9*-6%T.69T.45T669-1GI&96%W
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M:&LO-&EC5E-,>3DU<3%$5W!T628C>$$[=$9T23=7-C`U;6A2:3=Y27,Q6%5*
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M1"8C>$$[+UI267$X+S`S.'AF34YZ<G1T67E25V=T-7)L65=+>'EH=VI0>#)9
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M8C%T0DA+-"M':%IZ>35":%=O3T952E`K5V9M:28C>$$[83%)6'I89%=L,G!I
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M2$=M2W)99DQT,T=L<W`Q,U5:1&)Y*W%Z3S%T5U5F1"LW:W!!4&<K2#EM:#-/
M*TMQ1V]A0F1,<%9W<#%R54=+="8C>$$[2F-&:3%V5FPT9C-"<$0O9&)D4'1F
M-5=+<&(U1E)R6CEF.5,U=&)Q.4XS3%!D3&).>4-Y33AG6D=B,$DU9&U1<4%Z
M4T913TE.04)H5B8C>$$[3#<W.'E033A&<VPQ8F563'$X:45D<DQ.1D=817%P
M8U<V>7512&I13C9B=G=)1R]W=%5$1E=8=S-Z6$XU6E-R87I2<$Y:=DU054-)
M>28C>$$[.#)I4'!U:&)K<G(K,$M5.3A#=DET1$HO>%99;6QF.$%463EV*V5O
M>5-'9&9M;WI(44Q7<49F.$%413-.4#DY4RM"3T%+6&9L5WI$428C>$$[3&]"
M0S,K;5!U2V8W-FDX4TU3;UEH<D]S-C!N;64X4DY1=D5J5SAD5FA7-&Q#0E))
M449#:"M.4&)#<C),,4@O,S`S+T,O=T)C:6PS<28C>$$[4"]V='8K1B]R:7)V
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M4&55,F-D>'!6=D0V5%=36$UW:6E0<2MT8E`Y8DQ$-GE1<7=Z:&5,<"]W0D<R
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M:&QB:GE91E58-%=0:E-L9&=R3%ED1VEH;3`K0U<U=6)I4S)S;28C>$$[9TYX
M2E!+2DI05$U1.5-49WE+6&)Q>E4S>%9$>&519DMS3GET,4AA3W,V4#9I3TQI
M-'%'0G%#4#-N:FIA;W959DLK:F%J0W-&.4A.4"8C>$$[17)",5)R:31O1T%)
M<G1*-$4T<3=4=DLK:F%D0S!&:DA.0D5Z1C)28FDT;U=)07)V2C1+3591:W9K
M2'EP3F-T9%-7:G1/-RMO-VTT=28C>$$[2VQI86MN.354<FIA;S8K.'4V5F97
M<C)T,G,P,79*>$QX=&-81D1X64UV.$%U>G-W0GA64C`S>6QO5VUI45=%571U
M2F%'5&AC6$<O1R8C>$$[=$LQ:S=6>%91=G9)9FQA+W5*3&DX=$AM;6QO2DAA
M-'5+=%%"4E=K;F=+63)Q2S%4469R5FA.8C)T-6,R9'A)=$DW;%HW:&EH<E=T
M4"8C>$$[5E=V,S1Q;'9L+WEF<4]N5'EY86AR;#%Q8V)P>%-*<$QI34MA,356
M33AM1E5N.#9A1C5V;#%72G1#82M.;4E&1"ML9DY'4%8U=EA:-28C>$$[:U`R
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M87!A>%=6.657."8C>$$[8E%C;5=/-G5!0S--:7`K4#)X0W-Q.&]7;W4O3&1J
M8UA-.7I,3S9-6&MA-6Y*3DA98B](:55S0CAK6"MQ6&YM87=T-W)58C)A0U@Q
M4"8C>$$[56IE-W5#<'!#-T1B;C1J16]4+SAZ1W5D4%14=G%.-60R+W%M8C%0
M5'5R9U8T.$M6*U`S>$-P=C5$9V$Y.'$R9'ID,T8Q3F-/,#1E5B8C>$$[-VTT
M3$AJ8U-+=2]0<T%":6QH3G1F-F\S;E4R:#%'.4YT*VQ*26923C-C8V941GE5
M0S`U.4]/,DM&9CA!-7E*,4Q64$QN-65F<$Q23B8C>$$[474W0RLK=7=2*W9&
M8WIC=41"*U,W=5)V5$%L,R]/3S)O-G`U:B],>CE)-C-Q1C-F,WAV6C0O6&QU
M6G580D%N1F1N03)R:7%%,7I5="8C>$$[5V@X>C-C15=P6'%1<&-L16I&,V-"
M46]A;$MC.&MH:V8U,51896EF;&IR;7%A5F585G!Q1G-K2F=U23=M9FMP831J
M53!Q-4<V<U)K528C>$$[<THO-7AH.'=E65!.1VPV.4XU9S%3.#%'4S)N9U-"
M<&)M8C1&6DA,06-72%=M2VQ.9GI!=F14<W1F=C1B5%5R-D-+3D5+2DAE6$MG
M128C>$$[>$LR=T5N:6-+2&](;2LQ1G`U8G9R:3)N=5EP-#!8:$ET>D]#2W5O
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M>%-7469M5GDO>$IQ6$E!2#`P,D)R+W5H9FQK9WAE;&5E1$PO:%A52W%O2$)A
M,%EN.71F8D%%<T(O3#=L.6,Q5&E!9CA!8V9.5R8C>$$[<'`K,'9S8TI1>E1Y
M=#5I=4PS579-54XT:&AG,#8V65)Y>4UX0FI$4U(X:'E!-'!30W9Z-61Q16A+
M62\T>#AQ8VQ5-G1A0FU+<4%::R8C>$$[0C5-<%E+86Y9,%AP9U9'=DQ&*VPT
M665A*W%,959Z2%5C9W!E34)Q9&%61TMO=D9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T95:C`S>5(U6C!Y.6EV8DLP84LU
M:#5E;35M;F-$:W!5+T,W<W8R5U!B1E9V;7)Y;D8U9U<R1#-$5S5T:35"5E$Q
M928C>$$[9$LY4U`U8TMO,WDY;WEA3'!%1VUP2UIL:$UH.5)H>$HY4U)P1'-+
M.4]E0EAL1G(O04]406(O='-39CA!55<R4U%R9C@U5B\K4W(O-R8C>$$[949T
M*W`X:6M/+S5X52\X04I6+SEV0S4O56U+;$-E678K575V9BM9='8K2C5*1$MV
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M46%B63)L-UI245%Q;V=S,W0T,E!X4#955%)"1DQT5FE"-VY&57@Y3U`K569D
M:28C>$$[<G94:B]L2#-9<3<P-"\U4CDR2W4Y3U`K569D:7)8<'@O=T%O*S=&
M5R]4:B]!2E(Y,DMU.4]0.$%L2#-9<3<P-"]W0U5F9&ER=E1J+R8C>$$[04I2
M.3)+=3E/4#A!;$@S67$W,#0O=T-59F1I<G94:B]!2E(Y,DMU.4]0.$%L2#-9
M<3<P-"]W0U5F9&ER=E1J+T%*4CDR2W4Y3U`X028C>$$[;$@S67$W,#0O=T-5
M9F1I<G945"M59F1I<G94:B]L2#-9<3<P-"\U4CDR2W-1:2],;3%J,30V=#EC
M8S%U;790431#;%=K379'=&5L5"8C>$$[5'!H=%5,*V-F-64S,VYR>68K9SE0
M=4EB4V8V>D9/6G!W,TAJ1T="2'=!;7`U649D*U1N-64S,VM8>65D1#%#-&AU
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M-4]+=6MT+TUP5R8C>$$[8C!R*WE6;6MR8FQR3U9G:U<O=W5"9$QZ8G`X431J
M+THS,E9B;&<X>$4S2&\S,6UG67(Y5D0R:W(X0E@T:$I3-5@Q2VIP5&I4,WA6
M>B8C>$$[=V59:3`S0RMS,59K55<T83!L67!)2V-M8VDU2$Y4.%9&2$=M,C5P
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M>2MP>3`Y2"M3;C%R-V8K6%=N*U1I<F-T=C5L2WIE;&8R87,P;&)C=%IY<T5I
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M6#`K8S,Q9SAE3$-L2D-34$1P,"8C>$$[>%9(959V2VUH*U9T2EA39$5G3G19
M;S=30TEU>B]'-7%X<359-RM(461S5E1F1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T971BM:=GDT3W5A
M;F-8=S%(-G5,:%95>"MJ>G!X44HY<C%%.%!$1&%%,S@X+SAO<'%(*V]V+TIX
M8R8C>$$[46QG2#5E+S<R87`O,GHU=BM*3&E54%A-0U9H:&A02W%+95EO.5%.
M>'8Q*S@T<6]U04Y29T$R06AM+S1L1FEQ4U1$>GID,FUQ=TDQ=B8C>$$[<#`O
M,6A&,'$V54)J.5A%+WAS-%EZ<5A-23(K16)N;TU64VE+1#@U5FQU>3DQ<$1Q
M<VEP659J:S1T17-Q.'!*;$A&=E5A3&QS<D)2:"8C>$$[5DA7,%`U;FE!0V4T
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M5DUR5%10>G9N8W9.<3!&=&)Y4U1C23)&<UIO-'E#14IP8D]J2&Q1;U`R4EAM
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M=5`K:V5B+VUN1B8C>$$[6&9P4T0O9E9X+S!J>F8X04Y/2W4O4W-(*RMR:B]P
M2&TO=T-A8U9D*VQ94#DY6$@O045J>F8X,#1Q-SE+=V8W-G50.$%P2&TO-7!X
M5B8C>$$[,S969R]W0CE82"]34$XO>E1I<G8P<D(O=G$T+S92-78K86-69"ML
M65`Y.5A(+U-03B]Z5&ER=C!R0B]V<30O-E(U=BMA8U9D*VQ94"8C>$$[.3E8
M2"]34$XO=T$P-'$W.4M19C<V=5`K:V5B+T%*<'A66DQF,F,P8E)45S`P:U1I
M:F\Y=$MY:V5"0E-M2V]+4DY*:'1,;&)(5&UG;28C>$$[;6AD2WA7:GAK,4=W
M2D-$=FA64$U#=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8O+SEK/2(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<#I4:'5M8FYA:6QS
M/@H@("`\9&,Z=&ET;&4^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/F<Y.&<V,3PO<F1F.FQI/@H@("`@/"]R9&8Z
M06QT/@H@("`\+V1C.G1I=&QE/@H@("`\9&,Z8W)E871O<CX*("`@(#QR9&8Z
M4V5Q/@H@("`@(#QR9&8Z;&D^<G(Q,S`X,S4\+W)D9CIL:3X*("`@(#PO<F1F
M.E-E<3X*("`@/"]D8SIC<F5A=&]R/@H@("`\>&UP34TZ1&5R:79E9$9R;VT*
M("`@('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z,S0S03(X.45!,40V130Q
M,3DX,T,Y.$%$,4(S-S@Q1$0B"B`@("!S=%)E9CID;V-U;65N=$E$/2)X;7`N
M9&ED.C,T,T$R.#E%03%$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("`@<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED.F%D,6)E-C(U+3=C-V,M-#DY
M92UA9F-B+3!E93DX.#8U93`V9"(*("`@('-T4F5F.G)E;F1I=&EO;D-L87-S
M/2)D969A=6QT(B\^"B`@(#QX;7!-33I(:7-T;W)Y/@H@("`@/')D9CI397$^
M"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@("`@
M("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C5#,S`P,S)"1#0X-T4S,3%!
M0S(V14(T-$9$039%0D,Y(@H@("`@("!S=$5V=#IW:&5N/2(R,#$T+3`Q+3(X
M5#$P.C(X.C4U*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@("`@("!S=$5V=#IC
M:&%N9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX]
M(G-A=F5D(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C,U,T$R
M.#E%03%$-D4T,3$Y.#-#.3A!1#%",S<X,41$(@H@("`@("!S=$5V=#IW:&5N
M/2(R,#$U+3`S+3,P5#$Q.C,X.C`Q*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T
M=V%R94%G96YT/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@
M("`@("!S=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`\+W)D9CI397$^"B`@(#PO
M>&UP34TZ2&ES=&]R>3X*("`@/'AM<%109SI-87A086=E4VEZ90H@("`@<W1$
M:6TZ=STB-C$R+C`P,#`P,"(*("`@('-T1&EM.F@](C<Y,BXP,#`P,#`B"B`@
M("!S=$1I;3IU;FET/2)0;VEN=',B+SX*("`@/'AM<%109SI&;VYT<SX*("`@
M(#QR9&8Z0F%G/@H@("`@(#QR9&8Z;&D*("`@("`@<W1&;G0Z9F]N=$YA;64]
M(E1I;65S+4)O;&0B"B`@("`@('-T1FYT.F9O;G1&86UI;'D](E1I;65S(@H@
M("`@("!S=$9N=#IF;VYT1F%C93TB0F]L9"(*("`@("`@<W1&;G0Z9F]N=%1Y
M<&4](E1Y<&4@,2(*("`@("`@<W1&;G0Z=F5R<VEO;E-T<FEN9STB,#`Q+C`P
M,"(*("`@("`@<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*("`@("`@<W1&;G0Z
M9F]N=$9I;&5.86UE/2)424)?7U]?+E!&0CL@5$E"7U]?7RY01DTB+SX*("`@
M("`\<F1F.FQI"B`@("`@('-T1FYT.F9O;G1.86UE/2)697)D86YA(@H@("`@
M("!S=$9N=#IF;VYT1F%M:6QY/2)697)D86YA(@H@("`@("!S=$9N=#IF;VYT
M1F%C93TB4F5G=6QA<B(*("`@("`@<W1&;G0Z9F]N=%1Y<&4](D]P96X@5'EP
M92(*("`@("`@<W1&;G0Z=F5R<VEO;E-T<FEN9STB5F5R<VEO;B`U+C`U(@H@
M("`@("!S=$9N=#IC;VUP;W-I=&4](D9A;'-E(@H@("`@("!S=$9N=#IF;VYT
M1FEL94YA;64](G9E<F1A;F$N='1F(B\^"B`@("`@/')D9CIL:0H@("`@("!S
M=$9N=#IF;VYT3F%M93TB5F5R9&%N82U";VQD(@H@("`@("!S=$9N=#IF;VYT
M1F%M:6QY/2)697)D86YA(@H@("`@("!S=$9N=#IF;VYT1F%C93TB0F]L9"(*
M("`@("`@<W1&;G0Z9F]N=%1Y<&4](D]P96X@5'EP92(*("`@("`@<W1&;G0Z
M=F5R<VEO;E-T<FEN9STB5F5R<VEO;B`U+C`S(@H@("`@("!S=$9N=#IC;VUP
M;W-I=&4](D9A;'-E(@H@("`@("!S=$9N=#IF;VYT1FEL94YA;64](G9E<F1A
M;F%B+G1T9B(O/@H@("`@/"]R9&8Z0F%G/@H@("`\+WAM<%109SI&;VYT<SX*
M("`@/'AM<%109SI0;&%T94YA;65S/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\+WAM<%10
M9SI0;&%T94YA;65S/@H@("`\>&UP5%!G.E-W871C:$=R;W5P<SX*("`@(#QR
M9&8Z4V5Q/@H@("`@(#QR9&8Z;&D*("`@("`@>&UP1SIG<F]U<$YA;64](D1E
M9F%U;'0@4W=A=&-H($=R;W5P(@H@("`@("!X;7!'.F=R;W5P5'EP93TB,"(O
M/@H@("`@/"]R9&8Z4V5Q/@H@("`\+WAM<%109SI3=V%T8VA'<F]U<',^"B`@
M(#Q%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@("`@/')D9CI"86<^"B`@("`@
M/')D9CIL:0H@("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#TB3W!E
M;E1Y<&4@+2!45"(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/2)6
M97)D86YA(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I
M>F4](C`B"B`@("`@($5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD](DUI8W)O
M<V]F="(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CTB-2XP,R(*
M("`@("`@17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/2(P(@H@
M("`@("!%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M
M/2(R,S<P-S4U.3DR(@H@("`@("!%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U
M;3TB,C,W,#<U-3DY,B(*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C
M<FEP=$YA;64](E9E<F1A;F$B+SX*("`@("`\<F1F.FQI"B`@("`@($5X=&5N
M<VES1F]N=%-E;G-E.D9O;G1+:6YD/2)/<&5N5'EP92`M(%14(@H@("`@("!%
M>'1E;G-I<T9O;G1396YS93I&86UI;'D](E9E<F1A;F$B"B`@("`@($5X=&5N
M<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93TB,"(*("`@("`@17AT96YS
M:7-&;VYT4V5N<V4Z1F]U;F1R>3TB36EC<F]S;V9T(@H@("`@("!%>'1E;G-I
M<T9O;G1396YS93I697)S:6]N/2(U+C`S(@H@("`@("!%>'1E;G-I<T9O;G13
M96YS93I+97)N:6YG0VAE8VMS=6T](C`B"B`@("`@($5X=&5N<VES1F]N=%-E
M;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T](C,R-S(R-CDR,R(*("`@("`@
M17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T](C,R-S(R-CDR,R(*("`@("`@
M17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64](E9E<F1A;F$M0F]L
M9"(O/@H@("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S
M=%-C<FEP=$YA;64](E1I;65S+4)O;&0B+SX*("`@(#PO<F1F.D)A9SX*("`@
M/"]%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`*
M/#]X<&%C:V5T(&5N9#TB=R(_/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;
M`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`1T!W@,!$0`"$0$#$0'_Q``?
M``$``00"`P$`````````````"08'"`H!!0($"P/_Q`!R$```!0,!`08."0T+
M"0,'#0`#!`4&!P`!`@@1"1(3%"%4%187&#%!45=887&7M]4X='=X@9&2E)8*
M(B0U-T12=I.QTM36(S-"596AM;C3X?`E)S(T.62SM+8H5J09)C9C<J+1&D-%
M1U-G=8*$F*.FP?_$`!@!`0$!`0$````````````````!`@,$_\0`-A$``@$"
M!`0%`P0!!`,!`0````$1`C$A05&Q<8&1\!(R8:'!`W+1(D*RX?$S4H+"$V*2
MHM+_V@`,`P$``A$#$0`_`-_B@%`*`4!$#ND&H>;X5U-[FPPXSE=^,%A:A)DE
M5A3`@,&/(YD!PNA#;D8&78A602[NB^1%\@M%EHN%AB(@6+%A28HW1(OD"'<V
M7&Z4G36VE*2:F=?1YEM=)FZ)ZBFZ!'^FO63#;W=^K=%+1HK38+&[7(J9YF,C
M4),[UC^$'*[6W&">OM'!71&BWD]]SX:1%!NM-A-<WT52L559+K321`=*Q:?Z
M<IS:2;B?;6Q<1A;K62>;,9$@J&F60FHRY8G]+TGQ&[%)^QR=0GOJ,4)[=T&F
M66(73E,9X-UM(X;.5I#4'JJM"P8K7(*2>DHJFYPT=&70=$.)LI=[1/>\2U<%
M(W3(FH3$D0,=TTS<ERFFDH.&F%H@)?34J1(+J"?CS8+)/J'201<Q!59R+FS<
MGV_WB<4&V0:D9.!$<=BJFL@N)K(`GAPF5#F,IB)OQP6,OJ8MY[MV078;>4B-
M33@X$M9PTA:Q-4<9`.]]H0K><^6C.3%B+)':ZZ*W21U91<#:LFV5VV=N0OFN
MD\#:<:";V?%%(R-?^/%2_P!U-.'_`+*4_P`_)?$?=1RD8)6FI*FV,C1=SS$W
M]'`2VKMMSH^94ZX-6RZILI)7&`US9<NL.%IL1T$4<643:EDVK-0N\T).;UWL
MI6X`P,^&9C+Q?_G':Q02_NW4.-(A(SG<T-R2FLF/(OU'2FH',#J.,\R2;IRG
MSK:S[=>+'&P*9L-U2/)YE(PCL@MKN9,XV5+):7E%!,IYU)#%\#<)-2VEU4WS
MA7T>IF*X-9ZDE:1-6&I7.&7PA+VE]KSHJB,=TH[D1R$AGHAC\5_)BRPEE=;K
M957-';P(CII<D[@6XGX@GL'`F7*7.H!K?B>']24K%K%8Q+C'U])++:>E34_,
M.B#3+JE-ZGEPF_))@]`U!2HBD6+%0C'4$V2XB4WJ28[)3AV*<46GG&BZX6V"
MW%,TK+@ZT3:APA(&+J.K8RJ2"J%54HLVE?)_.?M!BOHEW7!WN#3:Q`]0\?/%
MZS<E:$X8UB+KZ33T8H:1)S2D:5%N&EES*2>B8-AL1F`V74B'7&O`X$1"I2/2
MIQPA)P*L7Z5Q1JNA)X.%XG3&+B(?.Y>X/=@FBKG&.@,Z#G*\'6\9XUCZ<;$D
MY\MTBW@)"T;Q\KR8YU=-<JJGE+K$>O1K)5CC;<0B0EKP-S.(1MH9&,,0!1/`
M\9<0D\4[-Q;7T]SJ@-VDC-;0XB7FG!LDJ@$K1SI$?Y-,6%1%0%T7+63(2O&+
M$0F4F8A*W5$,L=S(AX643Z.8)DV\C9%C:3=P*&1I*)AX'CBL'4O3]-YTG+#%
MZ&56E77\S=6SX64&/XRDPHQ@\)ANUY:/MU7R8JT8@^8186=:.M+=D@%!;#E<
M*X'DZH];>*\MJSD89946E0NVE1'44``1TQ>^$KBI7]X1.IB*P=TH<#6>+\8R
MLV9"F]T/;=.]0VBV/4U54HR9)%@+$?1&@R>WVVF*:,@).*Q%9<@75\`G8Z0U
M"2BYL^+8^4<F`9($$5TV>"7A53O-XZSE,&;\$3F;U\Z084U!PDZGII^)S$`T
MWI<W=&83D>J$A(3PX%[LP(%V(#T98@K@P05AJV<`J"<'+)*EDMI0*6LXDQ2(
MC7AJ:<.,,X^&1/Z)-?NHBT::=9IU#2R])M*:@=<TZ:`R+(LU8.92&AO`U)2Z
M/"\FFSC)BAK./BC.9<3/EK.4J"NG2ZT(\4U5S;IQ13`SI0;JI2;2412JIQ>6
M*OG,\B]XN[:-8>*&/*B%IM?*T5>FG365J1NC=/K333*$U-#TFK<>RVGJ)LX4
ML$8.JY9%S7&1FF!'!%48V`D*Q-"PQ'50A%]-S$J]*S_<L/[T]2XZ)NP<7*BL
MXVJ?B)^M]Z92?H:C&,F^IK+:,`/Y0W09`-.:#%!46$<PIE68$BHB2XU23BV8
M3AS;A)"&LW17BH'"*<,)X'_+_P#-_P"C\$G=<"#\>$=1I"^F*2)<D]^A:F$P
M=D)#YCEJFFX]M)$I(<93$VSJT^E9NMTZG99+I1R,9?**G".5,&*E5-%;)\4P
M"3$=,8MI+"'CCXDVML="JMT;U0SSI;>,0/Q!CZ:'WI/)-&3;:E5?3"C,=Y3E
M$C@.F&CE$\J*+(>",OCK,4("<ER>*X\4I.#)V4`2R@YC9E*1,6PY@I2<J4GA
M$S#U6&;P]^)8R)MT5$17)+;D5IA59XBJ*M".CK4$IOYPDH_BJ+#37>S1DI;?
M<_<*D,C.2$=QOL=IB=$XLR1E_!*5K-M!:J.2-JBD01!72\,(FJI0I;41ACIQ
MQS+PQQNL2'(#ABEFY:9IR2'P^(W@"6GTQBB08=KMBEBZG))6&#%RPMI352%.
MQO%)1DH.3Y:X^9;H$<,$[8;C#A<A!5;I('1$XJ[2]?"I?X5Y>!^NK[74H:4M
M4;L!6!GRY6!&6YS3AJO5XH1`F$3;+KRB^56`CJZS=SJ2",^4Q])R$JFTQM(P
M"Q=CK)=2-"+(26HE2Q_,14RLL:E3..:Z1[F1&DO6LDZK'C/T=8QPYHP=T"WA
M4XLEE=:;SB+*K;U`Q(CS!'BNGJ"/D,5`5@F\K7)N-$'!-EDE7*W"**BV4&L/
MB#41C>>J<,A8TYZLMT^F)(7'(R)0=DD(,::P->45SNYWC%T#-AA,#3]$*(?(
M12M-];1HM:!QQ3"E.8`IDAIB+TYI:F:S,9R2V@V]<(7`::I66+II:O=Q*X>^
MAE#IWW6TZV--.B%8U'(#@?#_`)NBW1R>>LD%AV*V#KM=>J9Y*\:!.5FQTWB*
M:35$5ANY.2#,J"EB;*2FXGO!N!-<JY%0UT&Q"JC&J++Q8>B4WX6O;'4Y0-T8
MFN0WM'H;A(]2M%'W8&5M"*4EQLH-IV@OE$BAAR"0R;TCF7VR+'D=L+[B:)YX
M'GBQ!B#N*&;(Z`G)8:?@=.B">&/7]"JQPB8M%WC&.&?H=TT]W!8CECE7DHUI
MUD%#1P=(.HG6$V03+R:)T=SM'2[+YJ()2:WV#@+FBKXJF6NJ,\PH`W(KA>PQ
M=2R;]\`#!H'0]5YJ:?\`Z4K^RXZ]NO3/159\(H4%O-64&1+FA*)QBQ%V-L$1
M9.:^F>GNV-%),$40")0/)JV5TQ+=Y)3-$`,30AH=+5#I4L&(9#P/#%8JIY_M
MF=GVS]8IW7^-WH^6&TY&B5SPTBN\]K<;:N_7`\&HN-9GNS0,<`&G'%6S2\@3
MV3(Q;)BRZWWEF5)FC@Y113CC8(E@"RN=!T0IF?+S52P_P8RZX=TX*,B?-S[D
M2%]5#PQT03U$NOEY2TNP+&D:R\;72^F!@D3R0YV>,XHBD)T%1FL\A5TLZ\RX
MP38`)-\4TX`4](3EE2S&J:)5<K]2\$2VO,_1Q8N/!.Z@2@P-,^CTEJ<89R>=
M6TTZ97YJ@=J/IE30'>268F:#R0DQ#4V>FL$HY$QV2>[&F^&@:+L]J6)-`ZY4
MQZ`XN9LD0&^55!ETJ7#BE/PIO#''UMAQMA>&H[=7F\=C7421C12=D6/73K.T
M;1O(0*:.R<YY:9,[JNCJ%R"DI0K+C/R3KL6;DUP666>\DP=R)&<9+@ZQFMMN
M1BQ!G9"JARIQ34J\6;NLU%L,?3$]K41NPP;8A[52N0@P&V>E73;*3>A]U,22
MGF8;;Y9:H[-2#9T[M]Y/",!FR"O=+;MQ<Q238W5D-07FDY6<(6Q5W,AN7`VT
M<1%1+4S#3::M@FXGECFGA!E`K;I`W&YJ::FEMR1<JI+Z>C[?T7((O3@BG;].
M+#T^$-0EUQ422I'-22HG=Z/=P--EO@R'TPK#D:ZIF-'Q%(P$4`!/"X=6B3]X
MZ_#Y&"+SW=6ZII@E67HQTZK*`]B>@H/7%$!217BAG&XL,\W+X\$G@'6&U`CI
M]/5FN\+!N`HWP!,@WD@!X$QE]FGC(HA%WWT-+Z?ZDF_W>%QPG"U_;0S'W1G5
MU,^F_3)IX6&`416O+NIO4EIMTQW=_`@/)!ATQ."F8#<<A%RJPE$$MP"MY,25
M$DW+.!'#1,G$J(II91E(@`.C'AFE)MS94NKU<9=Y%I9@UJ3AI(USO#3UT.=N
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MXPQNO3>9>EC2K(,JI,G29:3XS@MT+DGN[.+F@^G9::I\4H!`/(<>L4N4;JXK
M,!PXH2W)A5-":*"@M5SM41)57,YE81(H:=#\36"Q=I:4*;OTMZZ&1S`W4]L/
M74@B:?#<)O!"!7=7FHK1:5D*SI;:HC=5?3S&!66U(]T##Q*+O2HY6L/F"24Q
M``3:>L7*$QD\R6&-'B`SX'$S^U5<FX/>5]1TJ2;NJ:WH@170J1?%,2:.B&HE
MQ*3<36YF\Y1?+WDDLR$$B&K.E"<8"9'S(2P31TP&WR*>K+;R,ADEA6%;R>81
M%4(7@\6?BCDDG[R>C.6NLYN?3=(-G4:,Y9S/)06#V6)6`Q83(6G&Q).U3AQ,
MQ6^TV,AD4I->#\B=K/IABR?8JFL)M9HI,%>3E,RN.$NWL`5/BMAZ8NRG'1/+
M^FSIC&ZW,)$F]6BIWP\[FZU6_JYDG1VNRI@Y4!52"#]84&]7XNX,&T`$`XC+
M75&8$9+J0_`!&T15Q+`%2Z^$,8&)!X'$S^U5)8V;\.Y[I+=6FX9C^"I(.P'(
MJ&UM6#BA%"TOKJHKHYM%D7JW(,DO`F$X\VP7<;A9:\PV=&AM:?R$1;#QQ)&7
M6RD=`5'$=4U2Z(+X,6I6$SZ0TLXP;>#GC!4,<;I(ORU.+*@UD:09OZ8%Z']/
M\\/C!Z*C+C5P0W&TVN=R,Q9,2(R7XIH+AQ=,7+S65<W$U&R$X3BTB@746\8-
MF1"J89$\,)N5$M*,9:2>$+.</>#$_7-J4UH-7="77IJTX2A)6`2[N7LGS[$$
M4,>,(4=V2GJF0Y5NPXX$57"^8P7%))8BKGF4*O"[F>:*V29<48P`LHAP4EOI
MFUZ+WG\&J53X9:_>DWCY6L<_B3(UH;HT[&"^M/&FK4M%@*5J+?RQ%$)OXVU'
M0A9H'5[>6FSJW*CA;[;+#+!XO!9IQ(SOCE/>AI7S6.G!O+!5*:JZWDH9QYTS
MX9EJREKA,8^MG&GK@8AQ9NM#T<#2T1ZC9[LJ17'\MQWNG\O.^/XJ":SX:Z_'
MVD3CZP0#>!YV-=*?*6XF.V$80LU^D):*%GZX+J"DZRZ2G'2""GQ.<4:\*ETK
M'RI-X8MZ:/UQ1E@5W5L`^2@JY+3'*G134++T;0_'5E8W=KM9>4I=T_C3\S7(
M@O1U-Q%2G,V$@DG+S#D@\@!'1FD]D$X`BEWDCFTE64:9\-\5@FWZ0XCC9Y=2
MRS(W9!9E)UQ,[V)`"\?A%T;G/J/UONIM%%&Z[.AM<A*64.+1(Z93<2$T9"63
MH*P1<!)-M=9!N\,7(EJF0K5LV!DMS#3HB<<56J?3'-DI>E/4PR=6L3%)CCI3
M:*ZS5-8.I:*O,=Y!/1`5PR!1.&-#8&A49LN!#42)TZ91EAKO%K-EU(JHF&PE
M%&!`$)F#(PU#C'FH,DZ$%`*`4`H!0"@,>I<TL0?.DBPG+$G-=:7'[IU<BF[H
M;6DZ0I(:0+/<:T1P3%55Z",YVH"`X!CZ9AT-,!NA+6R^:<*8(\#8J:,A"BIM
M)I6=SUG)I/@]TSTDZF3S=7TV9DQH)[`..AJ2%(;+*.YEHR\,YT)M2&V&DZ$9
MJR*D(2\9-**04>J*N!D\C9HKA:Y`P*4R"7$97LKVY%M+[G;I$M`.>F4&,U8&
M(0Y/,S6CI5I0EDPZ&E+AEYCR'U1&1(YU\&I%93G+O8V=<9(ZV'2EX$SR@IX`
M`X%%11+&A?$YF<8BRM$0U9X:E5@:*M/Q66V_.I1%?A25D)E)<>''@6FB90#[
MX:*$OG'2WTN50PWY8I+/0!P**@HHQR1B[E.D;G!B81BR=8(F$)+B,IF,+^FG
M(M*B[E?H5;Z`1:Z7#*I@WTV(YX@HDDGIAG%9)!17J:<"LZYQ:N8*U)*A@9Q?
M;D6E!:,JYJPZ\CG\RXS<5$?B)&Q87QU:YIV5Z<%EDCKC>Y1:(3RFDK)J.WX,
MJ(Z;`J:`=RG^?^%-VTRN,PZ8145FUI-M@N+;#5#9O!'6UC`ZI@)YHPFAF<"8
MV85P\=6NN2_=?+,L)$VY1C(*J_4.89NDJ5H7EH.;BDVPDYY-=[PB*72,P+ZZ
MX2^*<P'.2R7(8.-!76\EM)66]*+V=5E4OAD7<Y+A3`XHKJT4/"'9J/58.5?!
M$G\;0RQ8LCL&+4$)RKS0P(B)AH&2WN\I:5U9/%3"Z,(16W')BZZUY8(Y)!0N
MF6(*"B.1P(!6*AEL`;YX9#%_\1[+`M-'VBN`HN:A:/F4D/A+C5*)+Z<U8TSE
MN4SK#8Q!S%E(HJ$V0W3CP&*-DJ6`5S^#7+IUPP6!@-B''^#6!!`##%;;<N_!
M9=\\RQ)[<CM`A]G=(8D,KP;;#@]CZ<294*;I[N838;C25PYP8+23#P\G#'".
M;4E,+!V)+@`&Q<X0ULDP19%0Q!$S(7QU7G.;*[4::<BJTG<R-&2,NI[G*1P[
M\U])E":YF358W.D]G#I63-13*ZGDT.S(<Q)@F9Y2?;2R,)JEFIW.XEASI]53
M<22N=,GA`\3UNDK*RQ2Y&*[CW)7-O2(WEK35/4Q:;V6P(BBR(8=18\FN2;$8
MP0XU67FLXXN9FOS*2TZ<"9\=XF@RR6MN=@DRR8'DC*>"X&,*>S%\>J3ERY2Q
M;B;1'Y)%(5TH0AIX<+^<,0-U?:-I(=3G>[@;&$@R$K1Z0=+W5`5UY++/C9<=
M"DPV(:="V!BK+-V<WD3`R<$,7QP#",CA"#+;=\8X3UN6Q+[G7I#*NHL]BT;.
M$!SD]1[QU<%E0*8YNPN#J'?S8!9CMD;$IC(UB/&%5K%PT2S=N5NT2!*XV"8@
M$LS`^8@OB<1Z>&RM,Q;7$OG!6GN)=-4,M33]";;/,J)F.F*2.TVUB[7DX3:&
MG*JBH*QPN4=+J<"X[[WZ(*AXP5&'7AC"?<7`,@*6!+E@PA&VVV[LQV1MS1T;
MMN+FM#C=CATHK$8\]%M3K,*DYJG$5?:DY@'5<\(_VZ]#TCG'DC*!\9PN"RD2
M3EXNDGL%M2N.0R%,<)B+XJIF<HLK:'1$MRIT*)[71664A]?";#?BB<X024FT
MWS]<N6B_4LL*#@G1KY97E&XHX<C+:H>5%=4'$$6BAL7$1&44RP!?$(/'5KFG
M97IMED52G;F[HV2#*^H)L4'@59PY:;3!E9-29+"PK)JII!*!$=-R^VSJX^%,
M1KN2+"H5P$MP-[H:K+8)A0!=IMP`JBF&;#Q5:_[LE^Z_7VR*I8FA#2Q&C\B^
M3F1&IE`?<.IDJ);%7BC]DB]R^$X.3)X2Z?<24([LT)[KL@.C+%<<+A>J6X%L
M<^7)9@'RX9`B&7$=3:AO##)98+A'H72?D!L*0G<&^U<R]TIU8LA3C892:$AO
M5H!G6.M'[*2LAGTMO+9!(."&C>.`A-?'(9NAO96$$:RXA#&CHAD3NW?3/,QC
M=6Y8:$'FG.-%7(.%LW7:P82BQPM5%E*96NT%*.=.1X)4AAE"-)L2&D-L%NLI
M2!Q4`DTLE@EUL[D*9<N*R,.-F(->.K75V3Q=\LRXR1H2TU($J-R:T-LOA+DU
MO(JRVAG66FN:[GWDV5R1%J5QVU)_#R",'*C>(/YQ+2VA(<AX.5+;Y8]FW$8J
M2:P8"($)XG$9<%I&FA[DX:&],6H]VN!\S''ZJZG,Z8*=FFA?/%)+E5IEU&$'
MTMD7$[V*(DLQ[MY'!+KZNFIYH^M%B`+ESQ)ERN"S@3#Q+T"J:L\T[*ZLRJ8;
MTH01`+KDE[Q2T59N.F7DB+T.0U<Z_P"1G6*X4Z&6.6C>-0^`>+M7R:49;3**
M%D3%01"Z:H*N`.!U<-*:EM.7!MN)RG)9XLZR'-'&GJ`H[E"*(H9Z\VV),KF?
M;RD5(-R?*KI-+;JDT`4!]KQ1?=SV7G&W%)QV&S'.#MA61KA';XJ!.Q8_A@9Q
M!MO%Y0K*RL8X@;D/H&)!-\LF1([$DDUV[![612"9/&H`H3`2-.#O,OB%;&P<
M)/OT746`NG#=T)96<E!7+)YD9-Q.V)YY!4+XZM=<EFH>6:+EE]SDTA%G7B]`
M(Y<@*X#J:6=8A"Q>8II*(R3J-<)59*+LCI+:)R$7;B>96`W&X,U%"+I6+8."
MK)W(=%SMP&(`>)ZY>&RMAA[(I=O[E=H3;#?)M5'A90P;J?"$QZ<2B.HR[-RZ
M0#AF?W4IOB7&8(77I(4L#.#N=JN<71%PU89RHYVQ.[?6$D)-3@BH>.K7-.RO
M3@LLD>2?N6VB<A@=OE&ST4CBF\]/TA*JLLSYJ#55=4>6EE)`1(#6SRB<E$0R
M-E'2<6``2T[?XI!NQ<KT63U#$F3Q+AXGZ9Y+]U\L_P#!6K`W/723&#^8,GLF
M-5I*>\8/N>)+8ZR9EB9%P-%>VIOB5YT6\DE?D!41%7J@9IQ,8ZG+*<H)248#
MR,MXBD&!AQ!`=5334X.%9?MMEA'H7"DW21`,Q3-$6H"2&4?<LJ02EOA%BU:$
M?4AIJ*W$B3$G%`D)-,L5'=:<P7*3>:'@$C.,NZVPN!JB6`7(FL1"Q<$/`26D
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MH"J:Q3CDM(M:QT2;N9.CE'DT"7TQA/<H_2THKLT%E8.=9WR+@2:ZHMQAIU/`
M-)%DC-*LM.B/@RZ*XU"Y.YM<XH4,J0YD8L#EB+XJFHG"(LK)S%M3H2>Y-Z!R
M#-'C\I"2EBTA]-ZII(Z#FI@G!4`!T_*S[,R8980%U:2#^87`OLV(XD]S6RN[
MDPS@6*)Z\632A8D$'CJF9QF;*]M/Z,IWOIOAJ2X8PT_R*T1'U%V!%#)XI+K<
M;J6U[`PV3I15;S@#?AY;%?H+R1%@@27$I\`.8-WIZX5`62BV"I!8&K"2TY6#
M/!CZ<HI8<CN68R",HK\NNYHHD>KDFO5?6GB\1(_;9PVI(S&3%%>.G`V\TBZH
M>-K)Q";I9*(KJ^8%<;A"5G`)FIY!+L60=.YP:.'<RX/CT]$PR.SM.:7)*%$"
M*R7[(\>A-="F!L*;.D]$S,L5VMTZLI+X;ZPHD7"16S*@`>P-FK"8[TV<P,"^
M*K'&][.<9S]2IXBT)Z9(*6\'+&+*<K?<&$`L+3!T4'EB75L2T(Q>1'3F$S@2
MBX^E%-)YM@L;.="W$0(E707%-F1<5FV8V=[@ZF[ZMV2Q=W@BP5MQVW/D%$16
MT0AUUI+?;[`CR,4Q(2I[U"$BN+-B>534U1PG'L@I2XPL&F=(QXXNH*NL#GU=
M/P,Y)A<]@F!%R@(>.K6[;LKM0\M"\J#N>>D=LR(D2NBQJME7ZA:@9&U2I:V)
M+<S'0@)XEIJ$V/(;\$1C\@F4$WFY&D1+H0S=.)AAI$"/#8I2"0$-&A!@\541
M.$*FRLG*RUSN72DG3#$$H22T)G6T=;09B8K=6&8W)28+O=,?O<-CN`X745EB
MK"PTE9*NZF4=4RI=7#:SJ!6D5-70@W"CDTY>##4L!):PRO%]RPTN[F+HRG-7
M.+LE1RZUI54XR1(B6S9.:IM0A7(R6W+%YS0BSLR0Y#3[NU:39:$,/L)U.6ZJ
MYAW":&/G%8R-8'((555*S];+2,-,,,,CO/\`R<NCO)ZWD,:+%8XZ\]0*EJE'
M.J,L3*ID#<ZK#+QCI5>YY`4)!,M\_@H,;"S6-M8ZECLP9'OF5S;M[""7R#Q.
M(RB+*TS%M<3IRFYFZ/4^)FY"!!C/@G'##D1!E6*D<"<YRQ.0H^6LJ*ZPVUB$
M%[*1,UV(L44XOK09-/8"B@)V2:I&$8T5,H^(!`$/$VYG%WP6/'7F7Q9FE>$6
M!,BKJ!;+;<`,O+T8MJ'5QXJTDR<YQEB/FBIGUM!251(<[Q6$`^HEEI55E@TZ
M324*[5555E505EP\;4CHPXDN(RF;*[.3FE>#S^I=*U?FFNLYZA$2,S,-ICWP
MD*2`$\O&1U8NX3;1R81=VA1R83S*]?%:&%,M(8\(JA%S^1NYDL7$""7'ARF8
MPO;B6G5=SKTF+,XF-19U@N6TK&9I9VH897)RU+J<@WF!BL,S&2`\\6,0?)9C
MX'>D8V*W58KBWK)Z\GVQ`6BA["^>.8OBJB)PB+*8F8F)OZE/M?<OM$+0*QXG
M)</J!I'B@C/R/'K><$JS$YVJVF[J@)CITY-0LTG"_P!2;!QIOI/,F"AEM*B0
M>1DO$<R91"::>-FS0Z,LAXGCZQ."RME_G,J)!W/#2JWVW!;4+M.05)&TT/5'
M?\%!.&?9^<1J-U]M-U1:#6+HA]9DTX=%;+5:BNIMYN,Q3'/M%)35`_B51,3!
M\\8,!XGC;%0X26')%.-/<P=%C"+QF58T:.QGAQ!&[[B%A"MV<9Y35%*CB2'P
M#);J:QU:!DNRVOD17\7!=J.*OJ*F;;"\"54FT8232>FB$P=53F7=IO!76$V_
MSF961/#$=0DDN5'CE!Z"@/1\N62W@:'/J"JIN=^N\8N,XG0LJ*F9-FC2DI<4
M)@YWX3```J3*%"H`!<N&'B,W+I4`H!0"@+0SO+Z7!,7+\EJJ,L..R:H-%NI#
M=02ALZK.!VR"\V]'C)0BA=/)J1__`"P\74A)PXQ%,5#A4L9&-%4M2'!#(CBI
M2X,8B>N0$V?0,2K`35Y"+`1$3DY9:KR7C!QHO"<)FD;3\RV8UVL[HR9#D="T
M@RS&JLV)03WFGQ2NL,P<`!Z`KBHGKJ6E!'S')3M:Y[\):ZV1*:TVFLZD8G%[
MF7TRQKB"VZ.')B*:NMMQ$9R$WS2LWVN?<"@K*2T<;CA_R0F8L]^)Z4RSECYU
M[,@XO`U$WO%N??H99OR3HXBU*NNR4_&@P$6W![Y7>3B2FVF8\*;*)X6^/JYH
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M@()@!@.=<H`68^080HF(..=Q,@PA,[8WQ#SO8(>CZ,RMH0I%],5K22UU%FO)
M-$5&^J")ID<`NHJJ*?*J"(JD5Y"6$=<0CJ8NH"^WUY,3%UON!"4DY;05M.(*
MZ0?)*)(L9"`M`D:3(#0EIK.%,9:@$K-$<`Z1''?<B'@%M4*/)X2,077\0/NP
MRGR@Y$J0Y!>[]1W)))5V+R.]72MNM+42B\?&4,A9??3EAH5$NZ=H<<KL3WRM
M,_C;J377T[`JV+@=)3,TY,3<:GP#:P5)+98BODR1^'(J/IR,NE5%$3#T?M4X
MGIQ8RCE!0PE]\_RRL9$^T"?^/47^DQHU5?D]F9=N:W1750HH!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`@K^J"O89QG[YQF>BN:*&Z+\OE$ZE#`H!0"@*
M%D3[0)_X]1?Z3&C55^3V9';FMT5U4**`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@(*_J@KV&<9^^<9GHKFBANB_+Y1.I0P6.U)&',5A)^&&<],H\<81-*
MR(/+!/4U+H)ATP)-CPN8*.W':H%@32=<V0,*X+<5@T$`V(N&BUBB>.*&*HG&
MW3\$<[:ES4DO.6,@2AV8FNI'PH63F&W%M"/.YJ2(GJNI:=61J-?SK<JC%+&.
MJ*$EP*W8_EQAX+Y*.U9O(2JP;B)X:L\%!/5A86^/)-9O.5UTPK.+Y4U91)([
M)CZ94E9E=)/+%H\S<J&:5C!`PYEES0D5=#DP6\HD1<GH3:J<_#3N;X>96.DQ
M%:[7U'I)HRXP8N:A\Z#\+MAVXS],;Y1<D&E$9=#3V\&G)R2:2Q7S'/1<X=6C
MA!0(WPD=H7)63DT!!4BZI8P-M#-7,JR/Q,*UA0K'L[W!M5GP>S,/+BMT7&WY
MWFY7M??@OP_>/=['=\78O"C?G>;E?G@O<]H]WD\G+XJ#OO`;\[S<K\\&[GM'
MN\GDY?%0#?GN;E?G@W<Y/O'N_%;EY>Q0#?G>;E?G@WZCY?\`%^0!OSO-ROSP
M7X/O'R^3Q]H.^\!OSO-ROSP7X/O'N;?)V.7LV`;\[S<K\\%[OM'N?S\GCH!O
MSO-ROSP7N^T>YR^7D\=`-^=YN5^>"]WVCW/Y^3QT`WYWFY7YX+\/WCW/_AR=
MF@X]^R&_.\W*]K;]F"_#]X\O:V=C;XMG*'?>`WYWFY7M??@OCV_>/DV=WE[&
MSE#OO#CW9OSO-ROSP7N<OWCW>3R<O)V*#OO`;\[S<K\\%[GM'N\GDY?%0#?G
M>;E?G@O<]H]WD\G+XJ`;\[S<K\\%[G)]X]WD\G+R]B@&_.\W*_/!OU'R_P"+
M\@#?G>787*]O9]F"^+9M^P;[.3;M[.SDY;[=M@&_.\W*_/!>[[1[G\_)XZ`;
M\[S<K\\%[OM'N?S\GCH.^\.]!OSO-ROSP7N^T>YR^7D\=`-^=YN5^>#=WVCW
M/)R\GCH!OSO-ROSP7X?O'N;/+V.3LW`;\[S<K\\&_4?)_BW*`WY[FY7YX-\/
MWCW?\6[%`-^=YN5^>#=SVCW>3R<OBH!OSO-ROSP;N>T>[R>3E\5`-^=YN5^>
M#=SVCW>3R<OBH!OSO-ROSP;]1\O^+\@#?G>;E>W]^#?!]X_'W/'0#?G>;E?%
M]F#>+9]X\G;[O:[.WD`;\[S<K\\&[OM'N>7EY/'0#?G>;E?G@O=]H]SE\O)X
MZ`;\[S<K\\%[OM'N<OEY/'0#?G>;E?']F"_#]X]SR;?%V:`;\[S<KVOOP;X?
MO'XN[XJ#O\9=^HWYWFY7YX-^H^3_`!;E`;\[S<KVOOP;N<OWCW>QW;<O)V*`
M;\[S<K\\%[GM'N\GDY?%0=]X#?G>;E?G@O<]H]WD\G+XJ`;\[S<KV_OP;N<G
MWCW>SW+<O+V*`;\[S<K\\&_4?+_B_(`WYWFY7M[/LP7X/O'D[>WL[/'MY`&_
M.\W*_/!?@^\>YM\G8Y>S8!OSO-ROSP7N^T>Y_/R>.@&_.\W*_/!>[[1[G+Y>
M3QT`WYWFY7YX-W?:/<\G+R>.@&_.\W*_/!>[[1[G\_)XZ`;\[S<KVMOV8+\/
MWCR]K9V-OBV<H#?G>;E?G@WZCY/\6Y0&_.\W*_/!NY[1[O)Y.7Q4`WYWFY7Y
MX-W/:/=Y/)R^*@&_.\W*_/!NY[1[O)Y.7Q4!!=]4$9&KZ-(SX0$#''KFV;RX
M&1,[[>I7,_)O<BH=MG^ER[Z_8MR7VWWHW]._+Y1.W0P*`4`H"A9$^T"?^/47
M^DQHU5?D]F1VYK=%=5"B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H""OZ
MH*]AG&?OG&9Z*YHH;HOR^43J4,'%[VQM?+*]K6M:][WO?9:UK<M[WO?DM:UN
M6][]B@+7%)RA0^H,E)(R_%YU4DM*NNQRFE'^U#)Y_HE@#1KHPRB@*MF.Z4OB
MQ$\8LH(89XI<`D;%L+<,L-E@$>USN6C)T:O\JEGF)(3(>I-<*K1Y%-M-UH3B
M++!)MG4Q-<)Q+'2#YP-0*H*BM(Q!9,%,A04LXKIA4[F`,?*8"A!Q(GV@3_QZ
MB_TF-&JK\GLR.W-;HKJH44`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`05
M_5!7L,XS]\XS/17-%#=%^7RBZS^U):O$:=W!'2/J)W/I"D8DIE3C.T9N)GR^
MM/APLMQKIM,CO%]:DTB22"='+ZD0N$1NGX!:>7"@(*JK$4P$J]2N9):5@243
M%7JU$?\`S&*_Y+D273#&0,RQPO1P>=;J9)!S="@E=59N;=NL&$HDKD%-5;8^
M#J;SH0CK>=9(F.V'6FGD0R$KMA55TO:!8[<8,83@P&9.@Z0FD2CYG*3[:[R9
MX#>TR(\@KZP7Z$NLD'I;G.4YO;Z2ST%M--*:ZJB/O.1";!5K'AVF.U6VCJ9_
M$)ZJ+C%"3AJ;\_=1_?KZ%6-S1.\(NE!O.R')`$:S3+.)$)JJ&I.QZ+"CA'3:
M6(E.DB!DVKXK0CX5U=MMB7&"IIZ^=24DJBR2Q%O$TIN""&2,<#Q2L>W\9=/5
MF9\GI?&B+<4>B*H6Z&OJ./L`J:L$G*'&I':`7^4RUPL[FN+[.$*[!`^"%O?+
MZ[L55GP>S.;R]&MU<N=4-"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H""
MOZH*]AG&?OG&9Z*YHH;HOR^46;F!4B)9W;YF("B*QFRZ6HIQ<;-M5Y:O7$SC
M<NN]U,)NJ22_VEII18/=))Y.!H$6%':07`6)H8R<IJL<MI:46^8Q2DPZ>F$W
MQTGX[]BJ?!QG]JMQF=<F;'%4YB@%`4+(GV@3_P`>HO\`28T:JOR>S([<UNBN
MJA10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!!7]4%>PSC/WSC,]%<T4-
MT7Y?*+1ISPFMG[I:VXWD.:[$"23)94\,P4K7'K!>"<,SW\[#XK")NB,;Z.R4
M%W<RH$\V@6SC=9FH@`WTY;99/-7$2SS7/K0L+PS_`-4L4L<?'/.,<>!L$/18
M6F^U5Q;;R*2<*PF$1#9)(4UK-NIQK(++&XN2@MA)*\83B14OPILT8*H:P=L`
M`)@23#QK,$L(.9A`V=?"8Y`FLI@18L=+QD"+PGVJD7.04C3>5IKFF28`BTLT
M$?%++G'PGK\B1F>NI#*EV(OMYM.=I*)]KY+8KG;+6&H^8Y*=K1,\,2I8/UU1
MM+RJVFXL`I4=N1Q)=SP)!=>:-F3.'U171$EHH+6.'@$,T\5=:-J*LB+1='3+
MW:#U;AEH*W"'%QI&W`#I:GT[GT])NL3)23UM%(D6ZCG5=+)JRT^HXZ#I9I0*
M%U%6XC([0&.]#20PN!D]Q,'+$4UQ4(7BX5[""[S&]KU5GP>S,-Y9RMT7.J%%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0$%?U05[#.,_?.,ST5S10W1?E
M\HM]/;*>9C=E8;>`&EP96;2$L-50493..F9`6@YTQR-J-6>W':E-!O26!$BA
M*S&7DU]J#E6WK&9W!(8T&1D3&-C.E>C)7;@J:\#Q](PG-Z>*+6=V\DR?1UME
M/>+?46VJ''"0(J>`&(QQJ.MS,AP`7+&@#H.:<Z&<K(;B3,^'+!XC]#U0OB=*
MW'3SV)E.-FRHXYEB4;2%`2`LM5>3&FM!*+2&('2V1B1)(4"KA5DE\O.3TAP2
M$GJ#M-$)-<J3)4B/B04QQ2$6<RT2>SG4W07/8+60!T`66^UI'+!05&OZ;(:<
M[Q3W\LM0R9=:<[<7O@J!NEWE..N$(]%JJ6&5R11>!(+">1582B533D13*FD5
M/.L%`%))X%@S6)H)??/\LKJ1/M`G_CU%_I,:557Y/9F7;FMT=P['<TV&WE1W
M/ESMUF--$!P,K3G=BTFMUO)!<4<(J&.J+2P9)II`$0R.`7P%-F0L,QQ@@<<K
MB"88WA2P?7MZ,?"ZTP^?R*?VLH6'H^C,BT5:1W(CI+B;JLF+[?7TP@M(2ZBG
MRJHCK2.J%0CR8K)*F1%')**8HDAP#A`^3'&*G"HP1@N*($)AG<0QU8NL*`Y"
M>:NPD9SKJ4O)2C)J6`8>C`?[":[F-0W)0,/R;9D/AY-I$9;XLSY(-$FNK8-5
M?5APS:@G&0P1$\^4.#"M->V:S4HO*E2=&RZM)S<0Y"8ZRX5="NZ$E!2G8@J*
MTJ-G$QD5NXDY+**`QXZA6-89EKJY8`5/L8PR!N8X3&^-A#KB$RQ`J)ZFK)DK
M1LHI:*=,IJPI$'RV#:>DJ),NIFS:>IG"ZH(7('2I5$63)DJ:$"'`+I"F,*'B
M&0-9!!#T/<O*L7V-N8A>2&%8\RT<NXGB2N\&]8VTV^<*V/%%US%NB/#(*.:)
M98G"ZFJ8%20Y6]C`0^05[9T$>]CTP9DB,UDU@R4H1Z?'?1(XHL4JGO-N'C;W
M(I]A..FF:5*J0H[H!*W!%P'$0PSV`>8>6&=\<L;VL$>USM6S(3.=C=170D+I
M'H6N@MW,GB?&P3%``VZT9)<""C*:8?R`/I3@/I"ZD'`T%0`+JU@U$I>Y2W#A
M;X#W6H]V8^R1Q28[N;#R3DY4.(:@?:B^E.$D06D^^%CZ0<-)!LX`55"-Q0['
M$\<3`V6N)APP6&_QV@8T,W71IU?22(LHJT_29,>.W/*S;S=4-2ZR0Y!8C/3<
M%=PK,7''>R41-DP9.3!2Y\=%8YY=7@B)LD>&3`R1PJ8%%\+^+KM&0PDG1L"L
MN1NC2"R`7"S$;IC>"",ZT$)::;?X`(S=<<R5F?Q/(*/8L,"/=350"A*P(H8M
MQ]YGCE<2,\CKPYDB`6S+R"E6-Q,9(RRPCO(-\MC.S]SP&P+YX,N^*I>SIRP,
M"A`98H?'KXC"8!7M;//'&X0]+7]#]A9;BD#-YACR;'H(D<X8"2%@*]&V'FPP
MQ+97P$>>.:E:[7PSMCE?#)<L1QRMCELO?9>@CWL5DDJR4O):>MH2FGK2*KDR
MRBE*Z2=+**6IIYP+$<H?3SY,08H=)F@,\!BQHL*(`.%GB(%GEAE:]P.PH!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@(*_J@KV&<9^^<9GHKFBANB_+Y1AL[ES33.&[&QY*J&S)S3'RR=2IR
M-7E*+KA6$U=DV4F%FIP0P6ZP'RM20;E%!8R]-FEZ:FN7<C59`J@05STE`.%%
M2$=ZM5XEAK]2H:E8TS$O/%SA$PT[K*]C:=H<A0"@*%D3[0)_X]1?Z3&C55^3
MV9';FMT8>;J![":4?QM@+^L5$]%=<5N7)_;5_%FNY7<\YLVZ!_8*Z+?>F:<O
M0\SJ\YZ7=\7N8_?^3<8@\<OU#6#N+HD!^3-([Z-N%Z+S_>S-2([DK6F#JH<L
M<M6-G<Z5ME,<DYD5*;34?`;(;[>(/5:0""TY"ZF&7!#P%\6R62_;$X'KR#H'
M6G4_WYDAN5FLR,7G)QR9@%EH-H=*FUGK8FE&^ET*/62J@F";;3&QB4#Q>("_
M<<L8!*GUI@W;?%E3IP*A/-V]/-,O:.<Y%E-.^CV4)#>*$]9SC%@,)H1TZ].'
M01@GHO;3;3WFE0-"^I2/L3G2&F2;+Z2DB`."<6TK(B@HK8&10=FFDY*1QD])
M;ST<C3T_#7R)2LW..,ZM9PM"KC&YJ',5&4+#]([Q)KSGF)X,1<<4CZCF\N)P
MTQ3\W9\--H1O-1_!,QDYM-<;J*71WRT$XX</*3.9"^99Y6Q!825@)M[X+2)]
M>#ZE4M;0[-R,]HJ>A^6&D*Y4(D02Y.?!<BIC*ST9*%+,P24UXN56*930XX='
M2TF2J.UDF;@D=A2QT8LOR&KYK2RN`)26$K'#_,+'TM,6QC(_-%W-P^7)1\V3
M\M")S(0=+[/C1VHS71C">?4=1["@=>TU-?40AJ0JC?`N.4B1Z+:8,@J14T-=
M:8\.KI)0('&8+D>#Q7PS]IF.JWPQ,@]'NF-2TZ$'7T>+M&RZOHL<M8=2:3OF
M-SEEE*C-)6$E&/#$)8=[H"9X'`+(X*6TVS<8!#3\`4P\YW2`32,TH&YCGIGP
MWS]#%XSN?4SO?3LUM/DDRE&19!B'3],,2Q*.RVDZ>B"B^).@5\Z>T^19!6%E
M?MCT%;S*D)U9",)OH6/1)952JN*ZL+()).-!*F4KM/'C,+GG['9R9N?,A2`Y
MYLS1Y&;;`8,CK.+X!:"49?BT5=<A$9TAB;4Y87C)M83G9%:>L81*H,F24N('
MV11GZ"^C;P#1&TMMA&)#`JHAW:4<,&L.LXJZ*->FYQ2J[&\F-A,>C):+;/GE
M5SKC8+O_`%$.$LW)$49539*5'Z6<*D]2CAEQ3=N"84('T&21B+$:JZ6L\45G
MJ2D?5BQX55).8GUA:1'IQO9'>.#<[9+6C;[LG2*V&NT!I529?9<8IBS)H[<5
MWD7EUR2LXE-5>6*PG2I%Y1SGG(9/!M9BO1PM)LR"72G^CI&11%`9AH25Q<1,
M641AC#YWL2$Z=XIPA2(6S'6)%(314L^\%HZ20E][.E*`5'L]W&^5?BKAD576
MWBK\(J.0V*.<5CH08AG,:R6E(*/9/0DX1N7_`(5E&7?$O90@H!0"@%`*`4`H
M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0$%?
MU05[#.,_?.,ST5S10W1?E\HKP5D[GZTMT1%0&MN="HKZE`'RCR*ZM5K;BV($
MUK-=_2L55GAF\%5X.B3FU(ZTJ'\S*B975ME,!U@!JYPVGY&A5(JJ%B0LU.CS
MJ+>&7.&5ODD^G9W([#B)]N]?<KS:*0@HMSIQ?CQ&(+[V*8\;+`A`-I*5&\Z4
MXRIJ9@4)*"S/(I@L4Q.YG1C27@7NJDAS(S&_-&I4RIQ42PEQ:6UI=(:?S#"2
M4YKLQPMZ2RTA:J9>:&H-+?:ZBL)/+N=Q::=-R7'RH[%R/5-@(8#L2SKOR*&4
M-V$4T4:PQCUQQPA*,\W-RMXNFW53%DC,J.9Y`%DTLH+-H\$<;>%*\567@LN:
M$B*^J$54O$;*P>F+$3Y%Q=*421T9A$"+&0]1MG`*Y#T)(Y]4!I.6N[^OYQBT
MPLRM3CBEEM1\2/Q!&+;E1R8OF,]ZW7+)>47E!+XR2TK@VQ7K,A\X6L()]8)?
M)-QN%C>V>-AN7&U7P]F9PS<*5C$YHP9W1EXZ@%#<WGPONF#V:VI--ON%P5N.
M4^;,G&B(Y`MJ+C_H2=*R#U,D?!7%5+%46Y@GTJD.AG1@U]D'>A/V>5UGBMRX
M8J</#5C'_J\O[-?\=QRS@Q":R!&#='D`4YD$=8V<E\"CDR=CAH+`V$]NDL3C
M8N1(,H<N5Z6B^]%-"%.'OQ;C`W:7%L=)^3A%,QXG&L?$_)L?Z/7MJ+2-S1T6
MKS%@5DO22>MZ@M+ZGBM.MV<B])Q6/DTBBNR[]O%CAQLI+#=)-Y?--6S7O=).
MKQQ"Z.'[H=U-3X'H<>)XX3@XW7]LR96)!U3E8<;CK1M-D?*\U'U2Y9RP^9U&
MW2FRW4FQI9#Q5"4LWAL]BOF+E"B(:NFV8:5L$6#);CE^A-QCXF$Q.&L?'?`Y
M7I!U3$H?:[I;^FR/UV9E%4P+.J(CFHRZ(VFPE7R6K9J9"5KPXI8.0?#$HB96
M3K,9'OG=9,X\;QZ$7N?#";X:Q\=_@Y)!U3I\1M)T-C39'SCF)34P2[PB8]J-
MNWFXTTK(%:R&4TZ4[PXK8.D<(8FAA8IUF0B7%P6C0O&P^@]PU`(4O'#)Q?D'
M3(.J=.BAGN9J:;(^<\O*I\`!Z14H:C;MINM!/S+*P@Y],DZ\.+&+L&`-%4<M
M@1LRT+A@U8P8XR'T+N"="%-X6L'#ND'5.EQ<RW&SM-D?.R5E<P7P?$8J6HV[
M60&86S)GQ3!A+DB\-K>+OS`.`IY3`"S/0.'#/#&N%"XCP!D(4WA:P<O*0=4Z
M3&C'<+)TV1\\)16,B]GY&RGJ-NTD)DXB$3(QG))D2\.+V+RN7/AE26&-FDW>
M'",B'-H7%^+C`HERX63Q<\L@]Y!U3(\<L1>8FFV/GK):R&5R?\=JNHR[.1&,
M((G9#FPTA_WAQPXO7$JI6Q3PQ,6JW.,@97/[P'>\5N$*;PM8#[D'5.BL!@K<
M?Z;(^?4B+90J+(;"5]1MV4C,,V(F!&#95'?.4..3%\!EE3(9-#-8MEM<9`"Q
M4>!!X7BF`)*7+A9.+_@YD"0=4R&Q8^68ZTVQ^_G\N)Q,>1F.LZC+L5)8"D*D
MDS1Q.1GIE#CGL^P2BP*=2@C^+<;%C18F&J<5`L;L2`!)2Y<+)Q?\'$BR#JF0
M6;'JM&NFR/I#>RZEES,CLY;U&78*9'ZKFE)IDPF(SMRAQU6?A<!6,*:7@I8H
M+8L.73@%/B871"Q(J"C-PLL.^_=)4@ZIF^U(^4HPTV1])#N7$O$S(S67=1EX
M]3F`K734HQFEHSFRAQV6?9?%3,JR=92Q16Q;(!++J'$\>B=BA,%&,N-,)_Q[
M\1*$@ZIFZW8_/Q5ILCZ37(N)8IF1&\OZC+QN28*KB11A@DQ&7LH<>%GR7%/F
MULCDI8I;9L&"CE3O$\^BUBQ`%&,N%EA,_CJQ*D@ZIVVBL$W$NFR/I27%M+,F
M9"1G#J-O&95AJP91%%*I:.KY0X\[/@N9.&UPKFI8I[:L7#1BIKB8O1BP">"C
M&7&F$SQT]^(EB0=4S936.8B#39'\K*:PEFC+]3G%J,O%X#(50RZ1F43$E0RA
MQZ].8!DP:60!%&Q1NV+8))8?B@W17@B()+&7&F$S^#B6Y!U3M@LS1(=TV1]+
M!I62S!E[%G'J-O%H;.5L`T[(NEIAC*&WOTVEQQ!U(/-2L"@V`LG@9\3%X_O2
MH*'=QIA)S,$@ZIFMTJ=1G39'TNW4TP<P[NF749>*>E55PXGQ=,3M]#CZZ9P!
M^%.[]1MT%L!Q0+[$%XW^X`H<RXTNY.)BD'5.U##:PA739'TP%U!+%,N@PYM1
MMXFS;:MCF#8%+(@90V^^F(N*'D-GDI6%2;!7!QPXGGPN^P!0YEQI=R)FD'5.
MTS[?`A+39'TQIQY+$,N(^Y]1MXC&0%;$>V`:63(YPV_>CI<0#:-DI6,IE@\[
M<#Q//;PE@4.[CE)YS/(&J1IKB(3A'3='\R()Q-N875MT:B[Q&;15/C@H5DTH
MC9PZ_KK`%R6(1NZA913[6%$R*<5OP?#Y@HS<<IDYF)_ZHVJY4)/A?3>P)?:Y
MQ."'7W(Y=1-XG/(:EDH&`!4\FWLX>?5UH$).P+G\3_19-L(,/F1XKAP'&A`4
M8RXTPF=N\Q+K_P!4;7=J"F0YIOC^6F>=3RH[@=;CU$WBQ10E(13-%S:>3:^<
M//>ZV"52PBBD&?LMIMC(YH1.XJ#Q;C8P)*,7#TB?P)7?^J-LO9`2(BTWQ_*C
M%.IZ<.XGHX=1-XQ54%2,*QXJIIY-GY0\]+K@*<C@D%4`_9P)EE`P>%2^*E+D
MKG3`*,W#X2)2?^J-N/QOHL3Z;X_D^/CQ%)&<3Z<&HF\:JZ`?,JYXJL$2;)RA
MYXY+@*4C`D%8L=LY$SHH9/#)7%B5R7'C(*(Q</2)]_Z_KB2Y`U2-Z0D%"B[3
M='\DQP=+(PC@D!=U%7CM90C)M5-%ELN38F4.NW);#1DD,HJ%3%G0F]%S!H1-
ML$0N6XX,$*+P](.9$?\`JC0I(0$"-M-\?R%&)W%"NX9&6]1-V$N(.9U3&+K^
M)./LH>=.2Y9#2\`5(IE9UIO1H<;).MBFW"XV("B,7#TQ?N</V0-4B+)R$W8]
MTW1^^XK."-_%?DQ8U%79"\AA'E"X#C$*1SE#KER6LD!.V'R0=G>G='1K\1MD
MF;.,W"%%X>D'+V?^J-(E5";3%TWQ^](D.FVV$ORDJZB;LYPH910/8`N8T4C.
M\/.'):$;A"^9XB5L\T[I@%PL2L,E;_C&(*(Q</2)]P\'_JC2I:0VPS--\?NZ
M'SB@V`%^5U/43=J.-#35$X`$Z5`I%UX>7<EH9LDLS!P@0L]DZ[C%`P*6-)'#
M<8#"%%\=(^3AU2!JD39=2&NTM-\?NB&S2BVRZQ+2AJ*NV7(DIB@(6Q<RB6BN
M\.K.:H.W`Q#0A%/Z>"-W!D6P#L:2N,;\(,(OCCA'3'U]CEQO_5&0F%-:K9TW
ML!Q0N846^`IR\>U$W;[E3DT\$5R<2@!%%X>5<E`9`%$-!$R'3T4NN8E<!+&D
MWC-L`@PB^.D?(79`U1DID)M1`TWQ^N0H*I(1<[,)O45=%<Y-,.DB8R^HA1+>
M'5',V.AGA3I,HG]/@'1H(H&<L:3N-\7`#"+XZ1\]\PKO_5&5F@!I(^F^/U:$
M,U%&`,3(9U%72W0`FFTHF96U#"(KPZ=S'&1U<4ZE%2'3\%T6+DPE.QHA8WQ(
M`,(OCI'SWS"@_P#5&!-(;23=-\?J$'Y**8`+,PVHFY!TAIIA&*FU50QB&\/&
MLQ!DQ:%-HY<AT_X=$2I4-6XT3L9X@"$*+XZ1\@P_]4>$TXM$OIOC\Q!UU$J!
ME,V>HJX#IQ31$8(V:4+1!U'1<\ABRWD,C!D.G^W&2H6*OQH&PO$,`PB9QTCY
M%W_JCM-/2C;3?']X.Z(X@7F;KB;V=/0VZ+8WDH=2#J/7SX;%;VHUB'3_`/7%
M;=%^-6M?B%@A1?'2/D`R!JCSFF[2'TWQ^#!UE$<"TS8:BKC.FZ;@C"&RZCU(
M>HZ'G88=;Q#1\R'3_>X!43)6XT)P?$,PPB9QTQW_`*!%_P"J,::<VB?TWQ^1
M@ZR@H@!S,#J)N==.:<`BF3::H7B#J/%L\!E!<#*HPY'I_P`KD"ID18XR:XMT
M/&#")G'3'?\`H)4@:HS,T#-)7TWQ^E0?BHK``,RE]15U-T"II1'.FD51RB&T
M.DLPAEA:!(I!DAT_YW22QT55N:/<3XB8#"+XZ1\A$?\`JC.3*;::[IOC]$A,
M)06P"<Q%-1-UESFTXF0-CH2@)$EH>3\RHRVH!$R!HCT^#W1@38AZYE0XKQ8<
M,(OCI'R&\_\`5&>F)0:KCTWQ^WX6`4%\!-E\EJ)NO.90321<UFWE`:)[0\EY
MD!EXP&4`.$.GLU=#P-"#W-*?%N"&#"+XZ1\AKO\`U1*,O*S6=>F]@-B&BJBX
MP$>6R&HF[D<BLFD,C-FTH&8JM#R/DEC.+$,KD=(=/)ZZ!<SGC<TJ\7VBAA$S
MCI_?]=`TG_JC5);6VP\=-\?M.'B:@Y@$*6$W43=TN-:34\R8#:Z@;BVT/(F:
M.,Y2N!<R?(=.RC=NB&,R]S2OP'#"`THP<O2.N(9<@:HU>5EQM/C3?'[,B,F<
M<H2#*:7J*N[W"MDD\Z*"V#AN,K0Z@9(HKD(XA'#Q3IS4>EX47(G<=6X/C&8.
M(P<O2(]PQ'_JC6I07FY(&F^/V-%)(9PX-^3DC43=ZKZZ"14.`;@QR-[0\V\D
M3)P)VU0.A7>"ET!&^P+B*G^M6"%%Y>D'$>2!JD79)76_)&FZ/X^C`G9=Z`2.
MBZBKOQ<7+DE((N@6-Q[C#K7R1>CB9D*HF[W=BET%'"Q3[]$N$XW@#B,'+TB/
M<YC5_P"J-P2(OH4GZ;X_C>-B0"UFWI"0]1-Y"6EXP452I9#`.,+&'FGDAX+*
M0(;5#0]W2I]"#!4-,N&H<9XZ"#B,'+TB/<1>_P#5&XW^OHDK:;X_C&/"1)7&
M;S]0-1-Y(6%X\55R)5&)G&/C#S/NAA*R,,?5C)N[F4^A1DB"E7`/<=X\6!Q&
M#EZ1'N(H?^J-S/9?2)=TWQ_%;%))RD.WGJWM15Y.55Y2+JY`JF)YQG8P\R[H
M8*BCC*"L.?NX5.R>9(@I=RIJYVQXL#B,'+TB/?'./?FB1_ZHW0[UY+F+3?'\
M3,TDG'!V^[FYJ)O*2DNJ02F4+DD\XU<(>9%T0$XE"G%,4_=<4K%!R@:=Q4Q<
MU8V`#C)SR@0](&J-U.=<3IHTWQ_$+5)IPPZ"YFUJ*O*Y];4L%`N``G&VYA#K
M%NB@C)PAD_D?NKJ-@1B^!'BHEQ^,A`XPASRB!#+_`-4;L7EPE-NF^/X<;Y-.
MX=!76QJ)O+9Q;4N.!A=#S:)A#S"NC`\2R$.<?NI*-N%#L4XK^Z</B#C)R^$$
M%N[./_5`[]);-*SOIQ84*HQ344QC"&K-/4/U9#2TIYQI,P8R<:2K1#'?0<`$
MK?(SBH<?4.%$QL6XIAON&Q&Z4IP<X/*,T7!EEM1VF[LPER8,WBZYOWYI^C]W
MR$X=*L%2$6C25EJ,!!8UC]JS@[YE(SVQ#+W;PB:I&EJ,(=568WU1:(!JJCQX
MVZ%)-!-^")B[B7BIQ<+#J^!L3T.8H!0%"R)]H$_\>HO])C1JJ_)[,CMS6Z,/
M-T_]A-*/XVP%_6*B>BNN*W+D_MJ_BS7<KN><V;=`_L%=%OO3-.7H>9U><]+N
M^+W*-U_:C9*TSQ"T'?%)5C&'4ZI6;S!X:0D%?<K?()JFVGBX#ASH,VW@QE$T
M>WS8`*EK],18N#8T*,*"9OA@%>I2X),)MXPK3&:6CU(@7QNKVN%GLIWN[$/2
MFH9-9KN!QXD,H2ETMB=R1$DVIV*9&;:H![E[&;E>!N/8`:X5L^$L$)O=Y??_
M`(_7V_LRJTVEX7BTO,LW]ILMDQLC!0J8SMC;,<N`-E;';O;9"A8YY6QVWO?>
MVOE>UMM[WV=F]ZYFCV*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`05_5!7L,XS]\XS
M/17-%#=%^7RBR#0U(PE,&Z\++A3B^C]0>S9>+>@="(SY&SV;NLZ+UIEICL;S
M](1$MHL3GV^=3'8;,F%!"&=DDY7+HQT^(0-(Y)PFD?`6&J/W8XW_`$NV7IW8
MV0<\\`L,Q!,\0PP\<LQ!,\K888886OEEGGEE>V....-KY9997M:UK7O>]K6H
M<RC!9*CDNK-!`'?[*!79!(CJ;"1174A!JSW32Q/!1,J#03LS^)QRD2Z>(&>'
M-HP)T`(GG@:$$Q`RQSN![3:?C'>91./L]YM1UD5@!6,I)UM.)(72BH603Q5+
M73"<92SAH$Z`BJ9XDG*PI;,4-./'"I0YD"8,!!YA!Z$B?:!/_'J+_28T:JOR
M>S([<UNC#S=/_832C^-L!?UBHGHKKBMRY/[:OXLUW*[GG-FW0/[!71;[TS3E
MZ'F=7G/2[OB]S%G=>/N!Q%[Y%H>CB6*U1YESV9FKRU<%_*DUZIL^XS+GN8OW
M_I56KL<J//3]U.Z-V!,^UJ?[1*?\N'7G.Q$3NL,AR.RQ-."2PI'?T>%7,M2<
M(X!&`[EQFGEBR&@MP5*`/J+?.D#PY4H*H&QL"N1CB^0HEA!`\LL`[XZH2;QT
M#<4MJ\K).\ZX$4Z#-L_I+XB<P#J*U!&\#4XP2C'B*O,T@K*4HI#AF-CH"VEJ
M24J+QM//D%-'4CQ`V6-%Q0A`#(EM[;+9E;;IIAX9>IBFNJJJ'$0_VTY)O0VW
M*Y&Q0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`05_5!7L,XS]\XS/17-%#=%^7RB]DB:ZY48
M>Z+-S2"C0>EBMV0,V69(.H)K22==3O1\R34,O>1!G,F-XO&Z,SV<A+#A2R`J
MLOJRKDLQ*YT94!1NF)D!J(*F:?%-ITY*\^V:)-I$01'0Q'@VPF^V76*NMQ72
M0VV\C&15J+>9\D,6Q3G"9Q0'3D"DF;B6#.B8MQ:OB#?*]DXU?]SN,$=R5HWF
M$9.B1`<>45V2B44Z&([D\ZGO%W'5!O#:)Y@>$IY#QZ7&C=)L[R4SDW($T%JZ
MRI1P99*=8\:#Q>UA0R-/Z-3?C5'_`"P]N9W#3T:2O$DHMMSP])!)+9A5?2$E
M<3'(MF%-:$C%"5X<&P*;1V&HEE=P+S3;,JL=;(D#C)(#D%>'7"IK#@=41$E5
M4"96-_S.TRKYY,S=E!/,F4U`-A+*H0")/F.+#)Q3%*R(J?&)':(8=S]SJ8<.
MVN4RMPI;B!TC:XE[\9L9#V!VJSX/9F'EQ6Z,2-T]!$QT4RAE<V8$M9VP%MPS
MQ*VQR_[143VY;AEL,^WM^MRQY;6[6VURNN*W+D_MJ_BS7DKN><V9-!``M]"^
MBZ]CAG&U])NG.]L<<2>]QM>'F=LM;?%,LMENUOLLK]V]Z\YZ7=\7N8M[KJ$)
MA`L199&1Q;=<@T;;P3$M;'[G$K\NT(N'GMMLY/KMG+?;:_)LU1YESV9E^2K@
MOY4FOC-GW&9<]S%^_P#2JM78Y4>>G[J=T;JR87%Z&I_V<:M]@E?X!+D^QP^Q
MM)]KM;=O9OMV\FSSG8A?W7X//!8TJWR,##;5:9-EA,0+6Q_\WF?V.!!"OXOK
MKWY/'RUNB_+Y1*O)5QI^2),M:]W=$5K7OC>^H+3C:V5MFW&]YZCGEMOK98[;
M=FV^QO;;V;7MR5T=GP>QS^GYEPJ_BS<:XN+SXUY-X2[NWF?P>3Q\M<#J.+B\
M^-?()=WVG\'D\?+0<^]1Q<7GQKY!+]3[?8_-R\M`.+B\^-=K^`2Y?_!]OM[-
MG8Y-G+M`<7%Y\:[7\`EX_P#<^WV_);9LY=H#BXO/C7R"7<V<S[?9\O8Y.2@'
M%Q>?&OD$NYLYG\/E\7)0#BXO/C7R"7<]I_#Y?%R4',<7%Y\:^02[FSF?:[/E
M[/)R4`XN+SXUV_X!+Q?[GVNUY;[=O)L#F.+B\OV<:MV?X!+D[');:3[78MMV
M]F^W;?9L`<7%Y\:^02[OM/X/)X^6@'%Q>?&OD$N[MYG\'D\?+0#BXO/C7DWA
M+N[>9_!Y/'RT`XN+SXU\@EW?:?P>3Q\M`.+B\^-=K^`2_4^WV_YME!S[T'%Q
M>?&NU_`)?J?;[?\`-LH!Q<7GQKY!+E_\'V^SR?!LM0<]L/;>1Q<7GQKY!+N;
M.9]OL^7L<G)0#BXW/C7R"7<V<S^'R^+DH!Q<7GQKY!+N;.9_#Y?%R4',<7%Y
M\:[?\`E^I]KM?S[:`<7%Y\:[?\`EV_\`]'VNU_/MH!Q<;GQKY!+D['^Y]KQ[
M>S?;VM@#BXO/C7R"7=]I_!Y/'RT`XN+SXUY-X2[NWF?P>3Q\M`.+B\^-?()=
MW;S/X/)X^6@'%Q>?&OD$N7_P?;[')\&R]`.+B\^-=K^`2Y?_``?;[>S9V.39
MR[0'%QN?&OD$OU/_`!L\NT!Q<7GQKY!+N>T_A\MNYMM<!Q<7GQKY!+N;.9_#
MY?%R4`XN+SXU\@EW/:?P^7Q<E`.+B\^-?()=S9S/M=GR]GDY*`<7%Y\:[?\`
M`)?J?:[7\^V@Y[?@<7%Y\:^02Y.Q_N?:\>WLWV]K8`XN+SXU\@EW?:?P>2_=
MV7L`XN+SXU\@EW?:?P>3Q\M`.+B\^-?()=W;S/X/)X^6@'%Q>?&OD$N[[3^#
MR>/EH!Q<7GQKY!+N^T_@\GCY:`<7%Y\:^02Y>S_N?;\6SL6V=O:`XN-SXU\@
ME^I_XV>7:`XN+SXU\@EW-G,^WV?+V.3DH!Q<;GQKY!+N;.9_#Y?%R4`XN+SX
MU\@EW-G,_A\OBY*`@N^J"`1,=&D9WR-#B6ZYMFVWN>)6UK?YJYGY?W,MAEMM
MLO\`PMGUU^3_`$=@W1=\/E&*FO**WI-VZ0.F*8KU+N-@2&X4MDG6VX66Y-T7
M(JL$/;J&.-.CQGKR+"C8/:.06\XW[9ES*I.B27JVG6"E@GD!7;R^B*A`!4%I
M:5,M)\?!CJ\?U>F&'!FT)A;+'#&V>6_SMCC;+/>VQW^5K6MEEO;;;8[Z^V^]
MM?9;;LM0YGE0"@*%D3[0)_X]1?Z3&C55^3V9';FMT8>;I_[":4?QM@+^L5$]
M%=<5N7)_;5_%FNY7<\YLVZ!_8*Z+?>F:<O0\SJ\YZ7=\7N8L[KQ]P.(O?(M#
MT<2Q6J/,N>S,U>6K@OY4FO5-GW&9<]S%^_\`2JM78Y4>>G[J=T;L"9]K4_VB
M4_Y<.O.=B%O=@OMOI4__`!:9/^GFA6Z+\OE$J\E7&GY(CBO_`*7Q#[X/3AZ>
MHYKH[/@]CG]/S+A5_%FY'7`ZB@%`*`4`H!0"@%`*`4`H"/;5?J*FJ$9`L,"(
MB1CIZ1XU37@MSDOZ<Y7U'-K!SA+[K#>Z$_<HADQE*L&LUBLY(:[E-R4[$!P-
M$Z`[E50/JS=(1VL%UT:23XS:4M[_`!SPZNVN%\(;8D9==,,%CIY%U,23`\7M
M]L.W,^XY1),-4??#GD%IHJ,[W>I.,B@,T%24TA'03W#8*1A4R#1T!#6%`F$8
MI3DFYRP[ZG1QAN@"D^';@X>I@OF]/KY7]*"8R9`P-MA,6V;EJOBJ-G-'R6\&
MH(X3BTMG##UD!(1G`>1`<239++R4,7R<)8BOFD@(]<<?9O\`&]L#KM.NZ+Y2
M>FZ=6TM1F\G,[GS&>FDS+ST9+=4LFFT)/GJ%63+`8!)("+J>>+-22;V;IQS+
M!U<*]*I!SI6882\637(=10:OSCA,=_XFY\TS7J+1YHG!I1.KP8EM&!-+\2:@
M5-(E!D/5357\JOQX:FTM7;0<CM^5&PDQBCED:!$P(HXSD:R.(FG7`HJQQ)4R
MA`!)%"%">.+:P]%3UOZ%NAMT@2$DNH+2JPE?!N'7RWD@HNNC))BQF1TC+.F+
M3%/F"#(TE.1Q+37!>ZOG/XP#5NOA1LBJUV^Y4$SFG])EW6\`\/=\VK:88WU]
M"J"VZ+,P^M2B5*1J]"[58&,MIZ1(2]OT%F.)UPY)9.)%ILJ*X;3,TQNG'H]C
M1@I%>!<\XU)ZEDE1`R1T=QBHS<6`\-L<7&''O'#J=6B;I(V5<*,^.Q$]66,]
MGX^8Z<1^2CH$:-1H.EC/AKLC-N8NA\IJ"7..YY".Q.<,>-!QDV2M.I!+*=@P
M2:Z6`1#8.EKI.$/!YWZZ%W-.&L]OZDW@IH+:C:0D)LC-U;=[*?ZRC'L&TZ&\
M@.@DU1LSYS)/+D&ZM+N:FFN1HH-E)8-+C2&.J!@1*5D)>0DP1J..G??*&\T*
M$%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@(*_J@KV&<9^^<9G
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M5TM=OO\`,X%_YJ>S,9;7(G'B[FPTR>#NCU0R-.9?2D$MBGI4BM$RIGLAU0V5
M"L332WV0?,WRL"3`_=3&88?UU59\'LS#R6;:CJB/'=*=3VFIP:-I,2D'4-!J
MVJ#NF#!0$U(EE@J1\8(EJ`BT^=%")DU\8P(&4(EC)PUG@'?$N4+CF!;X`A"9
MXE=<5N:AP\'Y:LG_`+60`]6N&N^W&7T\:OK6NTK5=4</!7_MJ_\`E_@V0]#.
MJ73(C:)M'B.L:C((2E9*TLZ?4U42U*78_(J*:HD8E:)4Z0/DC3A",DSI,R$*
M7-%3`08Y<<,0$8/`3#+&W`]#3EX.[R,9=U>U*Z<W+!D4E&Y/T)KYLKJ&:A\T
M51)48JJ8+$0H]E$N(='!(KPX@)0,<R6!S,"8X@X#&``\L[9BAXY:I\RY[,S5
M2_#5@[+)_P"Y$!TR3%$1R(95*%)3C@T:-1N^"Y8L7?#9',&#`[85`@0``0E3
M(08883+$,((/'+,3/+'##&^5[6KK*U75'.FFKQ4_IJ\RR>IN2)NK;2IBG$,<
MM36GS'+$D5MEC>9XXM>U[`!VO:]KN3;:]K\E[7Y;7K@=8>CZ,AYW6?49I[<J
MIIA$;D[PTX,$U5ES)1S1)09"K@0Q-H#3P*W.Y$%P>Q6QG,(7`O<>^%AL@Q,0
M]]?#*UM4-)XN,/E$JI?@:AS-.3]2*<K-,.=-L4"=5F,^#+3UIZ.F,^GQK;PN
M3(3C'QT\;&RZ*[`BI,F`.;-CYWQ"+E@11QL\`@\\[=&U#Q5GF8HIJ52FFI85
M9/\`VLVZ^NWTI^$WI[\]$<?M)7$Z0]'T9`ONJVH."7EJ"AX)'U`QRLMPC#;K
M$'Q;,SHG0<!;&>R1CAD;N@.@,GT2S(X96"L9O<SQ7'/@[<%OJU1$XQ$9P2M5
M>%0JI\3LG,0C$+3-,\+M?57IA5R\YLY,(@R^`$O&S4SE;I>"(,R7K@8Q6>/.
ML1/LFYF;D\1+GL>+<8XMMO87@JU7X8PB^4&*%7.*JMFF;4O7;Z4_";T]^>B.
M/VDKF=(>CZ,C=U)[LS%T*3&IQ:PR$&RPE)+3:KC'?)C5,W&@FF3CF'7@\T5.
M*)$>R$6-"I`:*&(?,9K``N.2B7#N1#QMB*+4IS2C5B(O37RIGY1^&G3=GHPF
M68T"+GTF0;%:0OH3G50GR6U4-QW$$\XW"I0V&G*9)7CN/BQ:RM@8$")F<5H0
M3C`/!XDA;9WS#-1FGP82F<*U&M,3[LDIZ[?2GX3>GOST1Q^TE00]'T8Z[?2G
MX3>GOST1Q^TE!#T?1CKM]*?A-Z>_/1''[24$/1]&.NWTI^$WI[\]$<?M)00]
M'T8Z[?2GX3>GOST1Q^TE!#T?1CKM]*?A-Z>_/1''[24$/1]&6(DM?W.68'%@
MZ)'FC3ZY%*Z$2:ZH7$U'(Z8W74UDU04E4BV'ZT4:1$YIR&VBJ@LJYD-OOI%<
M*/;)34,;D[AFQ\!!8J63Z;88<BGG":W,9T*RTN*\TZ>[J:^]`I$/F$S5"10,
M`GGT#5FTIKB0509/3"C?&=:`NJZ2_P`L@`)A&1B1X8%^%7'CO-X'ZM'T_H\F
MT'N836<+/=;8E+36FGV&G,Y+:9,IJ(0A&JE!QVSRK`81[I*$D05F'UYE,XF7
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M>F53]S&)DTE.`EN`[)R2O''0*FB:GPATYS+Z@M)[D/J<AD!Y0%*2>.<<:61<
M!G&1@72$,N`W5A`\E`8<P*'ZM'TVPPY%>L!_;G[%KA77,P9U@%N'W#DK9G")
M;46A&6P0R7UF[C7^EAE'Y`-LYF8KR_EDMKF#00D/!85<LCZEB9-99"W"*GD^
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MB./VDH(>CZ,]%0UE:04DMD=5=5>FU,)X9889FU"<HP)%L<Q+[T/#(<RZ`PL<
ML\OK<,;YVOE?DM:]Z"'H^C.@Z_;0QX:&D[_]Q</_`+8T$/1]&59CJYTHYXXY
M8ZG=/66.5K98Y8S3&]\<L;VVVRQO9RWM>U[7VVO;DO;EM00]'T9QGJ[TGAVM
M?/4]IYPM?DM?.:HVQM>_<M>[EM00]'T9^=M7^DN][6MJBTZWO?DM:TV1K>][
MW[%K6Z9J"'H^C(4]WDU#P`]=(4<I3-G.'7:J%]2#04!TUL2:REX^`0"C&8"P
MIX8FE+9LP&3#,&RH`AG,/$'`8R7"RSMF,'CD-T)S9VT>J#<;$D.W6Z@ZV).5
M8+>$;NO6FK:4(Y400=4R>ZF"K0NY9+AH(BT&X%-!>+2Q19?#`749:7UU@K20
MN/X8\NETDJVU@B>*A^WPJ9\,NV,P[Q-FL/0V-J',L:[].T:/B3$:5E\HNB.1
M*#8F!HB3<BP1;#E$BMQN1XQ:8=3;+FL$Q:,1V[G>XG.UQ!@L.`6CX)P_BH9)
M2+BFBSWQOU.G<NEF'W:_$Z25E)617:1=X#T'/@.)7+A*ZF25X><*625BH9C@
M!D5(<6G^&UQ-2R^!4$$^QBN(EQB2XZRB^$OOG^7UX%S)*!"';9($<(,8$5\1
MA@($+AB($)AE);2MEAF'G:^.>-[<E\<K7M>W9M55^3V9EVYK=%27;;>O;9=!
M1;VOVKI9&]O^!4*>/2PVO^[R'_))#]7H#SLW&];DL@HUK6Y+6LED>3_^"@.+
MMMNY6V9("+>W<NED;V_G`H#QZ6&U_P!WD/\`DDA^KT!Y]+C>_B%&_DLC_84!
MQ=M-W+_20$7+9W4HC?\`.!0'CTLMO_N\A_R20_5Z`\^EQO?Q$C?R61_L*`\;
MMIN9?Z2`B9;.ZE$;_G`H!9LMNU]MF^B6O;MV22%K_P#+T!Y=+C>_B)&_DLC_
M`&%`>-VTW,K[<F^B7OW;I1"]_P"<"@%FTW,;[<6^B6OW;)1"U_Y@*`\NEQO?
MQ$C?R61_L*`@0U&;F3J:D'4E/$I1^W-+:HR9.>J$Z&W=[22^VLZ"),A&$?,L
MX15D1&T[/A**"8K#34C1:Y%S*`0Y$T5'%L6,B#E0=JN%$>_]$JI548M0HM.;
M>JU+]:`M!,TZ>9G>LC3*A0`30UF,,62CI\8.]T/<^.JB.M-713JH$YX:C(H0
M)@$T_(`$0L853`PQB^.0)<+"^><JJ\481`25*:3;EIVBT^KU)=>EQO?Q$C?R
M61_L*R4TZ'*W&X+)^H3(5!1!,^NMU<8;X1+(YY;P/4U+`8>.W("]]Z&'CCAA
MCV,<,<<<;6QM:U=Z;+@<OJ>9\*?XHE9W(!O-^SOU4AXH:-8+!+@'/$.R82WF
M.>>4SVSRQQL!O;99VPPMG>UMN5L,+7O?>VV<Z[\OEFZ/)_RJVI)D)`;K?LPG
MO>R$CVO9HN2]KV3"5KVO9&.[+VOP')>U8-&FW%J4EY1E'662:0RRR8C1OEE<
MF7O>][M]/O>][W#VWO>_+>]^6]Z]!P=WQ>YL(;DDA(@VF1UY#(R4+E:?)6PM
MD*GE!,K8XF4?>XVOD#>]L;;;[+=BW:M7&OS/ELCNO+1]JW9U^ZZMY`MIYC+&
MR&CVQ$U$L;`3&R82M;/#I.D;+>9VX#9ECOL<<M[EMMOL<;[-MK4H\RY[,E7E
MJX+^5)KQ30VFX%#LL"!H"(&('&C[S#$P2B.&>&>#75<L<\,L0+98Y8Y6MECE
MC>U[7M:]KVO:NKL^#V.--UQ6YNO)#<;W0E+_`,A(WVN)?_19+FP7_J*X'<AT
MW8IO('032P'T#1]X)+[RX3#H82WF>]B1X98[_'@-F6]RMOL=MK[+\MN6M4>9
M<]C-7E?+=$,J@VVZ$8;`@2`BAB8R#&=\<PTHCAGCMD-L6OO<L0+96VVO>W)?
ML7O:NM5GP9SH\RY[&YMTN-[^(D;^2R/]A7`[$!NZW(J,#J&TU8`I*8%AG#,[
MY9XAD"N&.66+W@^V.66.(5K998VRRMC>]KWM;+*UNS>MT7Y?*,5VY_#,'812
M$J^H[3'C=,3[XYZ@XRPSQN2+7QRPR6+VRQRMP>S+&]N2^-]MK]NU;K\KY;F?
MI^;E5_%FVITN-[^(D;^2R/\`85Q.IK8[IFW&]GKN6L,T%&SPPTKP!GAADED<
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M*@HHF?74:K,-\(ED<\MX%J.E$,/'?9`7OO0P\,`\,=NS##'''&UL<;6MVH\J
MY[LY?4\SX4_Q1)EN0+=;^,IZL@K(2/8/%@:7Q,0[)A*V&.8CBU08YYVPL!O;
M9YXA!XYY6MMRL'A:][VPQV8KOR^6;H\G_*K:DG1Z7&]_$2-_)9'^PK!H^-=K
M%PP#U<ZIPP\<<`\-1TWX8888VQPPPQDUSXXXXXXVMCCCCC:UL<;6M:UK6M:V
MRJ[OBSW4>2G[:=D?0=^I:D=).[E8BCG$M.-C7GR8L;C&218<7>XC-W>X\(*%
MGGO<=M]EMNRVWDJ'E^K_`*E7+^*)K=7;?00])VI_/!$2,,\-/$U9X9X)I+'+
M#+&-G+?'+'*P-KXY8WM:]KVO:]KVM>U]M#"NN*W-60BD)/$B?^2T[_52_P!Y
M%O\`[+#_`-57H/,;`NY.H*&-H?88@R,DBY]5;57COQ$XGGGO<-6$VX88[[(&
M]][AACCAC;;LQQQMC;9:UK5P=WQ>YZ,E]M/\45)NJ:"A@;FGKU&!1DH$8+23
M/8@0H2<3#$#SQC9PWQS#SP!MEAGC>UKXY8WM>U[;;7VT5^3V95YJ?OH_DCY#
M-0]Y]CC0P@((NB71V((B)`@@FEC3YF()FFD\\\\\XE:.66>>60-\LLLLKWRR
MRRO>][WO>][WO5=WQ>YX'=\7N8R;K<AH@&F-JY@(Z6#G>?8FPOF$GE`\KXY'
M%;?8WRP!M>^.7;MMV7[=JM/F7>1'Y:_M>Z-?634U.M&\@WLGDK7LR'7>U[%0
M+7M>R"?O:]KV#VVO:_8O78X*ZXK<W%XU;K?O'+`O="1[WNRFK>][IA*][WNA
M$+WO>]P-M[WOV;UYSN1-;L,AHH*3I6L"CI87"2X]<<^#3RF&_M:)7;E:V>]!
MMOK6RM;*UK[;6O:U[<M:H\RY[&:_*^6Z(;%1)2L1FQ?%,3[7ZH<86VV)%K7V
M92,UK7MML'V+VO>U[=NU[VOR7KJ[/@]C'T_/3Q)7_J@-%1RNC:-!"R2F%Q+Z
MFF;A?,`@5!SOA>+)FROC?(,+'*^-\L<;WQO?9>^-K[-MK5P/11?E\HODZ(AW
M-V%]?#,6E=@OPIJ5?SI(2VE\0-3RXH&:<H3,>?##;\G+;.++)^`6)*$L++:?
MJ`DNH5MDUY3<)5653)DDL*V"NHA-3I>G*6EC>[2E83A@2ZT,"@%`4+(GV@3_
M`,>HO])C1JJ_)[,CMS6Z*ZJ%%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0&.:UH
M\TD.195W$XM+6G-?<"^J*"VO+JU",9JBRMK2L;&/JJNKJ9YL#G5)44CQ@<ZH
M'S@XQLX;'&,F11!A,\\A9>KZEQ(YAN(8>*JA*(XJC>+22V8+FEHI'+&;#(*J
MYHH&("4,JA=LI:8$?,%0A10BXQO`40$,43`/+''/*UQ);NY*B>I,RH,UVD"0
M.9@X>;*\3*%P[6N(.9,I1L$`$.U[VM?,47/##&U[VMOLK<MJ`U&6'`&I=#8S
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M,&H0]D?IA]\+&/\`3%ZW7Y7RW1GZ?F7"K^+-MVN)U-;'=,?9XKGO5=/WI4U3
M5T^GGR^3'U+4\:MJ2B=#/LW=.7MR5_0N_JM=N?PR?3O5]O\`VI-H2N1T-5?6
M#[.363[J$6_U2M-U=:+<_A'/ZEZ?M_[5%_-R^]F89]['+?I4T[U/J9<_@OT[
M5<:=JC8LKF;-/U\?==U$^^JU8?UDI3KM1Y5SW9R^IYGPI_BB3#<@ONK:L_<]
MTN?]2:I*Q7?E\LW1Y/\`E5M23I5@T?&7UD>R\U4^^0G'TG.BJ[OB]SW4>2G[
M:=D?0L^I8/\`93HON_3'_P`9NU#R_5_U*N7\439ZOO8F:H?>[39Z-7-0PKKB
MMS5>(_ZD3]JE_P#A85Z#S&P5N3/L'&'[K&J[^ME-U<'=\7N>C)?;3_%%1[JQ
M_LSM?'O1I]]&KBHK\GLRT^:C[Z/Y(^0)4/>?9/T*^PBT<>]6T]>B1H57=\7N
M>!W?%[F,.ZY^QA:GN_Q+_P`ZK5:/,N>S(_+7]KW1KW2=]S:0OQ'=G]`GZ['!
M77%;FY%&GW.&!^)+5_H(A7G.Y$MNQ7VITI^ZZ]O1&[:U1YESV9FOROENB&A5
M_?FQ[HD7^D=JUU=GP>QCZ?GIXDL7U05[#.,_?.,ST5S17`]%%^7RCVH!TNRH
MLZZIBU/2A',?Q&PX\?$@KT9N[!F1.Z&>ZT%<?[ZLM+C/<2]-TW.UGK+T8V23
M(,F2(P6IHW-!R6N.9*>[$EXMF;/HHC:\*2;]<>'HN&/BPM!+7(CY7$`D]2X2
M:89:*CQTKN@O.#E,L4S&B&KEL1,`DQ31S#]27D*<)![%<<8V@IK4$(A9@YNC
M`YEB4S&>XSV[T(YD75),SI4-.HZ))Z<,MOF'-%:ZC,4JA,DZB3<ZI>?#_:6J
MI8."!(0[HRM`#4;Z8_5-)C9P-4NPC)87%^EE!)<22FEQJ%CAG5CI%NKPQN5%
M%VI341'4C,J,]0X`SP%5%BT>77$/%HX"+K]6G+"22KY!&T=I,Y-<74ZPE!*7
MTXFSD9)`&C468C[O$..^"3@"X$)V]<-$IXWSG/T9(-*)Q3`3V\6*(^9XB:?,
M<W/J6)XH7Q3+@R.T,RULB@^5C!SC8E[A6XO:]@+VWXNS&]57Y/9F'EQ6Z+C\
M,/S3/\J!^G4+WWVCCAA^:"?E0/T_@_NY:#'OOOV.>&'YIG^5`[G_`+?P>7Q<
MM!R[[X_!QPQCF8GY4#^T^#^Z@.>&'YIG^5`_3H.7??$<,/S3/\J!^G0''##\
MT$_*@?IT)CI[_P!=^YSPP_-,_P`J#W?_`&_A\GCY*#'3W[_SZ2UQPP_-!/RH
M'Z?P_P!_)0ISPP_-,_RH'Z?P_P!]!WWW^1PP_-,_RH'Z=!R[]^]!PP_-,_RH
M')_[_:\7P;:#EWW;X'##\TS_`"H'Z?\`C;Y=@F.GOWW//CAA^:"?E0/TZ%[[
M[1SPP_-,_P`J!^G\']U!CWWJ.&'YIG^5`_3^#^Z@[[[8X8?FF?Y4#]/M]C\_
M)RT)CI[]_/,<,/S3/M__`#H'Z?;[7DY=E"X]]_G\<<,/S03\J!R_^_0=_C+O
MU.>&'YIG^5`_3^'^^@Q[[[]QPP_-,_RH'Z?P_P!]!R[[_P`G'##\T$_*@?I_
M#_?R4!SPP_-,_P`J!^G\/]_)08]]]OJ<<,8YF)^5`_M*`YX8?FF?Y4#].@..
M&'YH)^5`_3H.^^_P1*[J_'TEOUMZ=CC`C1]/^S4E-RJ+A*L5NGW8I)2>I1HZ
M4@H>-)J*$:.X$Q%(T6)Y&;`Y!!C#A8YY8VSM>M4N&F^\"--II;I::P1%8P5J
M)651JIY33=J!!%S?D>F,S"E$;R2T\J5(/AO'SIL\I*"87)$2A0D5,&3!DR,&
M"$"%GGEE:UJVZJ8>.7J8IHJ33<1C^ZG3B;;_``QCF8GY4#^T^#^ZN1T(#=UO
MS$SU$::M^%D%LA>=]FW/#+?;7Q!VW9O+WV;/'LV[>2MT7Y?*,5VY_#,'(3O?
M'4;IBOCC?/*VH2,=F-KVM?+_`"Q?DM?*]K6^&]K5NOROENC/T_,N%7\6;:O#
M&.9B?E0/[2N)U-;C=+<L\M=Z[?,.X=^M6T_6MC?+'+;;JJ:I?KMN%[VV7Y>2
M_+R<MJZ?3SY?)CZEJ>-6U)1.AS++'6WIROAA<3+CDK?6VRQQO?\`S+OW;?;E
M>UN3L]GR5:[<_AD^G>K[?^U)L_<,/S3/\J!^G\/]]<CH:KVKZ^66N+61?+"X
M>5Y0BW;A>^.5[?\`9+TW=O&]\;[;<O)?M]VNM%N?PCG]2]/V_P#:HOUN86>>
M&LLQ?`+(6]],DMVO;'+#'9;JJ:=^7;G?&U_);;?Q5/J9<_@OT[5<:=JC8GX8
M?FF?Y4#]/_&WR[.9OEWW\^DZ@KWO>\MZA[WQOC>^JG5?>^-[VO?&_7(REMM>
M]KWM?9V-MKWMW*[4>5<]V<OJ>;E3_%$EFY#YB82MJRW@.0NV/=+NW>YAX[W8
MY-4>S_3RQV[?%V.W6*[\OEFZ/)_RJVI)SN&'YIG^5`_3^#^ZL&N7?KVSXS^L
M?;?5WJIVVV7ZX^<=MNSLOU3G1R;?%5=WQ9[J/)3]M.R/H3_4L@@N.Y4HML`,
MA+=7V8[[ZP@>-MO#-WDV9Y6O\.S9XZAY?J_ZE7+^*)L-7HH_6FZH;7*YVMUN
M\V6V\*#LV=35R\O)GM\?8V^*ABFZXKX[N:LY'_4B?M4O_P`+"O0>8V`]R<$%
MQT/,2V)?(3&TL:K=F5A`L;7_`.UE-NWDRRM>VS;?LV[7)VMO!W?%[G?)8?MI
MT_VKO^L2HMU6%&ON:&O>V1;/"U](\^[<KB`WM:W4U<7+LQSO>_=Y+45^3V9J
MGS4??1_)'R#*A[S[(^A84>VB31U:Q7/*UM*^GNULN%!MOK=21HVM?9?/;;;;
MEV7Y=E^[R57=\6>!W?'Y,8MUP$%RTQM2V9?(.W5^B7ZZX@65K?9BMR;,<KW_
M`)ME6CS+GLR?MK^WY1KZR=]S:0OQ'=G]`GZ['!77%;FXS&HP_4Y8'V)G?_S)
M:G+PH'\0D.[G;R?W5YSN1-;L-F)FE:5+9@9!6M+CVV7RS#RVWZDCMY-F&65_
MCY.2M4>9<]F9J\KY;HAL5MMA6Q>UMM[2'%^RW);;?JCM;DVWY+;?'R5U=GP>
MQCZ?GIXDKGU00(-EHTC.V1?+"W7-LWEN(%>U[]2N9^39CE>_;OVMG)Y-O`]'
MT[\OQW<RD<^B'<^W7J'6([7HU<@[V>K=6=0CKB4E*$[)&GAZ%S3V+I#@=3Q@
MA'D(CI[<ZRMO!6XXX"*]'Y\1RG#IQ87"RD.*,9N)-4>EIA3P3NL/4DVM:UK6
MM:UK6M:UK6M;9:UK<EK6M;DM:UNQ:ADYH!0%"R)]H$_\>HO])C1JJ_)[,CMS
M6Z*ZJ%%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H##G
M4YHBBK56Y&,['VY)(;*['Z(Z6ZBFV`O(B1B827>?;:DK%U0!<;#D!,WL<:J2
M*4%`P*B@6Q'POF)@->V-3:L,'@TGU^&BSD?;EM`T>2`QI&)OV<G"K1\Z$QX(
M:8Y78T3"$*MH^>8J<*HEDA@HQXR`7&SL-P`:B7P$SPPL+OP]]AE74W@WL$DL
M52D]<7?BV24UD&MONGA%<*ZX#ZO@T7XIHZCI@@Y/)J[>8#U<Z2,H),GZE#"F
MGV4VX@JA'!0(%UA*,&R(@^!H`NI$1Q`K!&@<\^E#2F7%ODS72ZDH4PZIY^&-
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M^RG1?=^F/_C-VH>7ZO\`J5<OXHFSU?>Q,U0^]VFST:N:AA77%;FJ\1_U(G[5
M+_\`"PKT'F-@K<F?8.,/W6-5W];*;JX.[XO<]&2^VG^**CW5C_9G:^/>C3[Z
M-7%17Y/9EI\U'WT?R1\@2H>\^R?H5]A%HX]ZMIZ]$C0JN[XO<\#N^+W,8=US
M]C"U/=_B7_G5:K1YESV9'Y:_M>Z->Z3ON;2%^([L_H$_78X*ZXK<W(HT^YPP
M/Q):O]!$*\YW(EMV*^U.E/W77MZ(W;6J/,N>S,U^5\MT0T*O[\V/=$B_TCM6
MNKL^#V,?3\]/$EB^J"O89QG[YQF>BN:*X'HHOR^44]+KZF##=>T-`;^HAFD(
M^3#4(-MXLK.6UA'=3&0G:`WG"VH_"@I,8&9AZ"RRX6Z^@CDB&W>>9I=/D)!*
MK9EKKL:H1!RBI+P3&..6GK.$881EZD\JLKI*`FG5I=4T]%1TPN(;4E96.EDY
M-3R@-M\*:.GC@H)4H7"Q^N$&'%##PMRY96M0YG4%WLS#9AME"KN;!DT\2!A4
M:)8NOI0QAU)A0L&<-*+;!#-Y"+A`L4&!-&#:9B:+@EA0QQ!,0A,<K@>XCN9M
MN(L4.M]P(BZ3/X*`A`VCJQ!3+'<$@[@G*N90<D8'",X)B@(&04,@<L[$CN>!
M4S<,?+'"X'02)]H$_P#'J+_28T:JOR>S([<UNBNJA10"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`Q>D#11I)E5Y+LB2/
MIXBEYOESB)PSB=:^T4T^N+8R0C)K=3!5,^(%PQP4B@HZ4D%1!LL\PDY.)%<<
MK`EPL<0*AB?2GIN@E?/NJ'(3CF-G*J(XK?4%UI-H@D*AM#,'2*D.DC'"X>(V
M1`<^F)QP8MO[!"F")07/'+,`*^(&0%`:?KX^Z[J)]]5JP_K)2G7:CRKGNSE]
M3S/A3_%$F&Y!?=6U9^Y[I<_ZDU25BN_+Y9NCR?\`*K:DG2K!H^,OK(]EYJI]
M\A./I.=%5W?%[GNH\E/VT[(^A9]2P?[*=%]WZ8_^,W:AY?J_ZE7+^*)L]7WL
M3-4/O=IL]&KFH85UQ6YJO$?]2)^U2_\`PL*]!YC8*W)GV#C#]UC5=_6RFZN#
MN^+W/1DOMI_BBH]U8_V9VOCWHT^^C5Q45^3V9:?-1]]'\D?($J'O/LGZ%?81
M:./>K:>O1(T*KN^+W/`[OB]S&'=<_8PM3W?XE_YU6JT>9<]F1^6O[7NC7ND[
M[FTA?B.[/Z!/UV."NN*W-R*-/N<,#\26K_01"O.=R);=BOM3I3]UU[>B-VUJ
MCS+GLS-?E?+=$-"K^_-CW1(O]([5KJ[/@]C'T_/3Q)8OJ@KV&<9^^<9GHKFB
MN!Z*+\OE&+ZK)K`DS=.()Z=433BX'&<U#O=>(R$GZ==2P$B-)QPM)4G:26YF
M++9;4H88[)37ZXH64XP;2<JQL>8<EO:.CKI6&J7RS9ZD`+#5+O$+-1BD[1EX
MN,&P!+[5E$XC/)<C541G@X3#/P1FA#TJ8MLC"6;LQ6"9PH]G(JI,>+4G#G4<
M,/(SBC%G/9"5+$P2`)-!430;I2QC#/KG^#`YN:(Y+(JS-!,(+`))2GU!%)\N
M3-]G5-W,YP1#J6G34!)AUGX),8----@:@;RZ803*6WNIZCL5.7G2B$R1QO)*
M`FJ`L\<_=):NT>I5;&T?39",GM59AN0"`;`)K:<W%@D[#;<4%K*+TU9A4P?Q
M$"PBSB1)7=#4:\GM=9+,`5BB*)U)T]+#@5EHZTG<J'PE-.5C?#7'UX7G/(SJ
ME%..&D]O'`%Y632Y%\QS8RDD@4(1/6.,2.T`PKJ(BBBGU0*Y'.UQBO0A22[9
MBWO8[8X#L"M5GP>S,/+BMT7&XN+SXUVOX!+]3[?9OY.39:H4<7%Y\:^02[FS
MF?P^7Q<E!S'%QN?&OD$NYLYG\/E\7)0#BXW/C7R"/<]I]KL^7L[;<E`.+C<^
M-?()?J?^-ODV`.+B\^-?()?J?:__`-Y=O)0<QQ<7GQKY!+]3[78^'EVWV7H!
MQ<7GQKY!+N^T_@\GCY:`<7%Y\:^02[NWF?P>3Q\M`.+B\^-?()=WVG\'D\?+
M0#BXO/C7R"7ZGV^Q^;EY:#G/?H.+B\^-=K^`2Y?_``?;[>S9V.39R[0YCBXO
M/C7:_@$O'_N?;[?DMLV<NT.??>_`<7%Y\:^02[FSF?;[/E[')R4',<7%Y\:^
M02[FSF?P^7Q<E`.+B\^-?()=S9S/X?+XN2@'%Q>?&OD$NYLYGVNSY>SR<E`.
M+C<^-?()?J?^-ODV`.+B\OV<:MV?X!+D[');:3[78MMV]F^W;?9L`<7%Y\:^
M02[OM/X/)X^6@'%Q>?&OD$N[[3^#R>/EH.?>HXN+SXU\@EW=O,_@\GCY:`<7
M&Y\:^02Y>7VG\'D\?+0#BXO/C7R"7ZGV^Q\')LOMO0#BXW/C7R"7ZG_C9Y=H
M#BXW/C7R"/ZGV^S^;DH!Q<;GQKY!+N;.9_#Y?%R4`XN-SXU\@EW-G,_A\OBY
M*`<7&Y\:^02[FSF?P^7Q<E`.+C<^-?()?J?^-ODV`.+C<^-=O^`2_4^UVOY]
MM`.+C<^-?()<G8_W/M>/;V;[>UL`<7&Y\:^02Y.7VG\'D\?+0#BXO/C7R"7=
MV\S^#R>/EH!Q<7GQKY!+N[>9_!Y/'RT`XN+SXU\@ER_^#[?8Y/@V7H!Q<;GQ
MKM?P"7ZGV^W_`#;*#GW_`%_D<7&Y\:^02_4_\;/+M`TUY(?[$1)HU'):R^&F
MFJ1355JLQ-$E1R(A`^#D)J-D\8/C)0<V7%!R%!$#&QMD"';(,3#/#'>98WOV
MH\JY[LYUI^)X.U.7_JB43<;EQ#<\G:MCC;<::KDP&'I?*C&D%13%4M@9LX-4
M`N1<8<OQP(,?`(4(6X5\\,[8"AYY8WQSQO?%=^7RS5*?AS7ZGM23R<7%Y\:^
M02[FSF?P^7Q<E8-'QH-8_)J[U4VVWOLU'SCRWV;;_P"<YT<M]EK6VW\5K6[E
MK57=\7N>ZCR4_;3LCZ$WU+*$)GN5*+?$R.#;J^S';>AXEKX[>&;O+^ZEQ<MO
M_P";9XJAY?J_ZE7+^*)L=7H`MM)NJ&]SIF__`&=YLOLO@3V7_P`VKEY.0I:^
MSDV<E]NR]^7;LO885UQ1JSD?]2)^U2__``L*]!YC8"W)T$3/0\Q,L31@*UY8
MU6[,,,2M\;;-64V]BXA83/EV;;[<[]F^S9;9LX.[XO<]&2^VG^**CW54`7'<
MT->^5SAC.UM(T^[<,L2EL<O\VSBOLO?`KAGXOK<L>3Q\M%?D]F5>:C[Z/Y(^
M094/>?9&T+`"WT2:.;V.&<;7TKZ>[VQMB3WN-KQ*T;[VV^*99;+6^MMMROEL
MM;;>^6V]Z[OB]SP.[XLQCW7`$3#3&T[Y&AQ;6GZ)?K!,2UL;_9BORWN$7#RV
M\NWDRM;DMR=G;:/,N>S(_+7]KW1KZR=]S:0OQ'=G]`GZ['!77%;FXQ&I<7J<
ML#[.-6VLEJ\F\)<G^02/8VD[W\?+>_+;N;;7\YW(FMV&"SP2M*E\C`PUKRX]
MK;T3$O:UK]2-V\MN!`"OM\M[VY;\G8V:H\RY[,S7Y7RW1#:K6VBMFUKWQO>0
MXOM;*VS;;;([6Y;;ZU[;;=FVVU[=VU[<E=79\'L8^GYZ>)*Y]4$`B8Z-(SOD
M:'$MUS;-MO<\2MK6_P`U<S\O[F6PRVVV7_A;/KK\G^CLX'H^G?E\HD*;6B#1
M8D3`_)0:<4M$E,"W+#2FZ1%-%=#EP4Q9/2"SU/--QN%NE7-=,)!"FI!>KP`;
MPZ06;*T\%TW(1M&/N\(JOEQF7"4X0XX.^WM%C-&A!0"@*%D3[0)_X]1?Z3&C
M55^3V9';FMT5U4**`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`I<RQV4=,#FSC0:YLV9%S',FC+?21S!@<7*^8@
MPXPI3,0443.]\LQ!,LL\\KWRRO>][WH#LDI`0D*P^*(BI*-B9N'D9Q2DTFGV
M,7"MG8*X]B@(-A;AV$SL'<3?7PMGGO=F^OM`[:@-:N1_J63<[Y0D-^28XI$U
M4@N"1'FZ'TN@I<@1R63`EEVKAY?4PDXN/$9H<`B&=4!\"@(QHR*$7L'@(.-G
MC<3(\<3HOJUI)*(2BVA,)H+T+1#N=T!E].D(+#[7&,5=[D>@1V159&6G'94=
M%R.2B#D>0F^V2.1(/(@%<J%T,L,'OQ+"&!;7QWHQ4W4VW=_X+CZOO8F:H?>[
M39Z-7-0*ZXK<U7B/^I$_:I?_`(6%>@\QL%;DS[!QA^ZQJN_K93=7!W?%[GHR
M7VT_Q14>ZL?[,[7Q[T:??1JXJ*_)[,M/FH^^C^2/D"5#WGV3]"OL(M''O5M/
M7HD:%5W?%[G@=WQ>YC#NN?L86I[O\2_\ZK5:/,N>S(_+7]KW1KW2=]S:0OQ'
M=G]`GZ['!77%;FY%&GW.&!^)+5_H(A7G.Y$MNQ7VITI^ZZ]O1&[:U1YESV9F
MOROENB&A5_?FQ[HD7^D=JUU=GP>QCZ?GIXDL7U05[#.,_?.,ST5S17`]%%^7
MRBWTMO\`#:>[0-=&13;V055YJ\(-ESQZB:CIH:3BF1)Q8"\>3I=1H!;\=FX>
M?L(1)B94$"1%-W/XHJ`*R:[AL,"0B>BIR^*O(^>/A3CTF93=_P`Y3R.]Y%6J
MD+AXJGCNE:1$<5<NST58:"8XCZ>`)C@,9`$>CE:C>)%0+7S%'4%M>24T(($7
M?&^&X,$0<S$AM:_(N=`344"+&E#%O+Y5CF%IU8%H^56\R[RC*DA0O%F2B;;\
MAK`[R3I*D"-5HBSG#$I616VIHJNT7;DK@-5SIZQ<6/5>^2EY9>I5$&:W(7GL
MRW4YMC*;=5G(ECJA1,=BDQ010\A12G2ZE@G&^]'$EKRP[R=W"?0R+1/.+BN#
M%?)!RBM]:0;IAD&FNWWW@5OJ;FN(H*CHJ\YFDIE1@U0'U&/"K[W<*:W4S'@Y
M):8@GV2HF`,,K!AXWS$OAOK!XVWV>]MLJKX>S)#>"4N5@O1R_8ZXQK0TF%86
M):C3.HN(`(&4E3)#(2Z*^4+!@'%C!5.(>2:7<ES=DT4YBL)YU-N!B-?.QPJ.
M!LWX>5K0L.8ASI&/0'-:&DQ.A9*U''M140%(&7501#1I='?*$&P%-8"55)#%
M323DR-V31SF"PC*J9D`&-?.QQ/-@7MOP<[6"',0YTC'I<*6M#28CPN@ZC%74
M7$"?`[H5!$1N2X;?*$"P5M7!4EA'%34UR9F[)QHX&JMY<3\P`ALL\3:2?!O;
M?EQ+6"',0YTAST"QK0TF-Z&FYJ(7-140)4%O!4NB-:63SY0B[#7U?$TM$;IJ
M4XQ#=DXX<L<;JZ6N`"-EG89)/A[-\6$MB$.8ASIGTOFNH7]9^DUK0\U]0;CU
M%1`B0>]E3!$:,K*3Y0BC%<:N)DM8!IJ.XA3>*>>.9Y-Q>QQ``&R$O=(/VV?8
MPF]"',0YTC'I<.76AI,9L0M&?G7J*B!O0F_50%$9<I*SY0B3'="N8!6S`":B
M.`8WB04#@H#;7Q<`"XV>>0:.H96ML+";`2;<)-O1)R'5K/TF,>)F=.[PU%1`
MVH9D)0`2F-)RR^4(BRG6I&2RN<+D4)?'-X$%$R,405HP&$7%SSR"2SN=K;"X
ME[`DVX2;>B6(=^M#28P(M94W/;45$#6B&1S!<HPI(7'RA)[.=YDV3/J!8!`7
M#!O`BI"CD4M1-!8%A<[Y@$C(EOK0LKV"&W"3G2,0\]:&DR.XS8\SOK45$#2B
M>3,BV$?2&O/E"3FB\LCA$RIE<6ZM&#>!)3N83R9HX%8L+GORY<42VW'#*]@A
MS$.5=1CA</C6?I-C2.&',$@ZBH@9T6R@&5&CI_N%\H28U7J$>3LE<F(VUDR;
MP)JN)E+PR/@W*B"6S*XW&M]9;;0)-MI)MJZ2Q7%!^:T-)D71^P)7D745$#*C
M652A4]&SY<CY0DILO@F>3`EHF:;*L:-AE%8$RDC@J((A003$0H)@-C>^&5KT
M$-RDFVKX6XZ',@ZS])L3L2/)/DO45$+%CN6DXFKQD]'.^$-(;C[2U!))KQ$^
MUU0V;#*JY4VBJ!%4`&*""8"$C0!C&]PQ,;W"'C@\+X/#CH<2-K0TF1`S(\D6
M4=140,%B2VEEUN,7:ZGRA(Z"^T@VE)JX64FNI'#8997)CHZPEJ80Y3,3#,D?
M*CVO<,;"]P2;LFXT38DO6AI,AIJ1Z^I7U%1!'K-EE+Q6XS<SM?*$BHKZ2,TU
M*6<5)L'SAL,!7)Y)2ZCJ-ARF8F%RBF2'M?>#X7N"3>"3;5X5LA*.L_2;"3=C
MYVR]J*B"-VQ*Z6*MQJO/!\H2&EOE(`((RH,I-DX>-A`JQ,).<2$=S'*9"!XE
ME8@+>^\,AWR!)NR;X(2MK0TF08BL!QS'J*B",T&5$LRMQNKO-\H2"0>Z02*(
MA\VI-HR>-A!JQ,N2<B`:&'*Y"88`+">)E>V)D*^0)-V3<8.%,9;G,M:S])L#
M)K&6)HU%1#%Z7)J6:6H]4'L^$-`*/)((ET@V<46Z,?-@X*A,L6<"(.,.5OG@
M&$JD<\KVQ,!WR!)NR;C!PIC+<XEW6AI,@(LS#DUZBX@BTI(B686V(8>[Y0F^
M"[4@H&G"F5)!S/FP<5(F`$KI8@HY:^>&&"@4RO>UAL-H)-V3?!-B8=9^DW3Y
M9IWG#45$$4V?:886F9=]/E";W3.DE.)\9447H@;!X^3`Z(D>%'`W^&'&P-M_
MW3':"3=DWP4B9-:&DS3P8;)6<]1<01.9>:6,N-,!^/E";@KA1RX@(0RDDX*)
ML&YTF$(9`PS'!MEACD,':]]N5J!)NR;X*1-&M#29IT/M]*G?47$$2*3K2Q5M
MM$7\^4)MF5Q(!'Q+"J28$HFP<S9,,QEB#F.%;+#$2]L+WVWH$F[)O@FSRFG6
M9I/TY+B&V9XU$1%$;A<R;=8;Z,_GPAMM164JQP1/NH)Q52-@BFBECP0I2XP6
M.6'#AY![=]:]J!)NR;X*3F8]9>E#3TYD%F3EJ'B**'8Z$X)6;K>?;X0VZKK2
M8,H&$D$^FDE$V",:*B*94R1P&"QRPR-`"@VOO\+VL"3>*3:U2DYE[65I1@!V
MH#"FS4/$46/1U)Y16;;7?#X0V\MK:8?4S:,2/IJ>H&P3!LJ:5B)Q.`&"PRP$
M-E1P,;WS#RM8$F[)N+QC`EC67I0@A[-^-IFU#Q%&+^=:>FJS:9[T?"&@N!<3
M%A6/(*6?3$P^;",FRJ@M)BBEE!@L,L!CI(R7PO<0+*U@2;LF^"DXE/67I0@]
M^M^+9@U#Q%&TC.PBDJ;:9+Q?"&A.1=3EY8/M]%.IB4>-A&C9946TM12B0H0>
M6)@\2,EP[W$"SM8$F[)O@F)-UF:4(8D-`B26-1$11W)SI+(IQN,1W/A#1'0M
ME7&JFT-!,)J0=-A&S82NL$#B:GYA!Y8F3A48`.^68>5K`DWBDVM4I$BZR]*$
M124@0Y)^H>(F%*KJQ0<VW'SI?"&CNQ;P="F,C-W)-1CAL,X;Q6E8N.G)MP@\
MK&C80@(6^SQO:@AQ,.%G&'4/_69I0BN3T*%)(U$1$R);<XC>!;L<N5\(:2[U
MH5V*%TILAIJ(:-AG362ZI6N13+!!97-F;7""WV?)0B3:E*4LUBNH>^LO2A&L
MK(,&2!J'B)G3&Z#;;(-V,W"^$-,>:T=>)[!,:I5-03)O`\:'<"B(&220P@LL
MCIG/$(&V65[6H6&U*3:UAP<O'65I1CV6T*!'QJ'B)J32YU%L)#=BY=>Z&G/9
M:4WJ<`3FD03F^8-X'S1IQGC18HD`A`Y9G1QPPP;999VM0)-J4FTL95NMCAU:
MS-*#&E](@!XZB(B;4VKZDVT=%BQ9?"&0?"HJ/`0L$UB!)O#F\%`P:<`ATI@E
M`A@WS.9&`;`VROGCM"'$PXUC`Y<FLK2BSYC3=/3IU#Q$WYR6%%OI*5%"J]T,
MD^U!3=8149M$"C=&-XJ`QI<".E!$P'`&^9O`R#<*V5L\=H0XF'&N6%\;8'"[
MK+TH-B9B6G9PZB(B1IU45%"2",2J+X0RK]-JCG)$U%ND`&X*;Q41#2T04")M
M.!Q!OF:+F@!0K98B8WN$.)AQK&'4*^LO2@@327TXK6H>(DN>3:BC)!:(CKX0
MR[_'4W$E$UU"(!-H0W92S-*R,H$5,@#8&^9DD;`'#ME@)C>X0XF'&L8=;'*C
MK+TH)$UA:;U/4/$1">QE%+2`HA-/A#!D`136D8HXD@A@VLS=E+(THH1XFK$P
M;`;\<@9!,86N&)C>X0XF'&L8=;'!C67I0*S7CIO,ZAXB`GO-1*I&,0B/A#PD
M#)4.HH3C*$+-JYOHE<T901P5<$'@=^(GBX&<;7#RME00XF'&L8:7XX"^LO2A
MC-?6WY:AXBM/?1'%(ZD-WPAVD#HIDBV<>)#I:XWT2XUD@WLKV!X'?W3[V,VM
MP?UU!#B8<:QAI<X`UF:3S,UWTX%]1$1#3WBI#H^40AOA#R?]E0JC".(P0NVK
M&^B7&@4($57$!X'?XD`\S-[<%C?*@AQ,.-8PTOQP.2.LO2@IS7GIO3M0\1'9
M\#4%%)$B`L^$,60,%-)1#+D4R.3:P-W4K&B"`2-K!H&X&_!3RXQG.U@L,LK!
M#B8<:PXZV"5K,TH+LU#:<$;41$2G/1=164@>(23X0QW^$J-Y'.N%=("-H,W=
M2Q-)*&FGU4^#<'?EB!,P9$MB&%EE8(<3#C6''4Y0]96E%S3.<TZM_4/$2S.R
M>HKB2=B1.>Z&:?I53;*>;57`0';81O)1#-(R:0.GE$'(&V94L5'&%MC@'E>P
M0XF'%YRZV.&[K+TH.V8U'3TV-0\1+LY)*BOI*G%"6^$,V^R"FU2YHTY"!INA
M&\E$$TAEB)P=3!S!MF4"+#9BVQQPRO8(<3#C6,"DU74OHVGYS27H[*ZA8L<T
MF+R)(T:OF*6R_P!#SD9-``255!?J=DD`&!E!.5$$GDHXGLA"N6::,!EF,'M"
MOC00UC#C6,/0C19VD_<TGU+*SI_8^N)YN>:&N><B*NQ8B3/#RB]T519)@<BZ
MD]00`(S$4"QIN&BA@LKA#!6$)#`"8#VQRQO6O'5K[(G@24NC#7]4=9,[](<I
MZ'8OQQT30'J58L@OZ-W%+1I:81V2&PYY4)N([(SH>$FV<*<C@)>0)A%>3C6B
MYTL$D$@TD/$(AF%C<OOLLE:<3X6E"C!Q$0L7Z>IC?NC6LG2E*FB'=%80C?4+
M$CWF!L:3-3Y9PQJV7LB*SR1AVDQG"DN<%10BAH0^5$05/[`5,!`L;DS7[B-;
M'/DJJ_)[,J33H;3CQT8QAYD]L3Y3-0]Q];[<TM8>E>6=-^E^%XRU!1,^Y99>
ME6&;NR.VP]417=S=LU8\9#><EU=$*&A#I'H&NFRJ2I\.%AQ0^8"+"[T3.V-Z
M[OBSPU4M-MII2\6FC%[=']9&E.<8B*1/#VH6))+DMJ3E'JDY6*S'LB+SG0R#
M?<AA`7#BFD$#0QLH72EM33TL\**'CB7/'"Y<2^(@N-KVCS+GL1IJFIM-)TX.
M'#L09+DV1%(;5E1JL62&<['(CQZ]CJJAH*Z14E-/*$4X=..&#90L+F,""6/F
MRI0;//&V(9@<(+*]LL\;7ZRG9HX>&I.ENFI)M0VFD^#9MN:6-96E&?$EOQ]"
MNH>(Y2?#5CE!5G(U&0]T-P+J&F)Q5%13Y]33D\V,8*%2BN?))Q@87#'`,X:`
M`RO;,3&U^!W:=.+4+5X)\'9D3.Z2:Q=*NHI1TY,N"=0<32V[6M)CZ5W&W&"]
M45RK"(F`QFYTH4^I$4TT..4*AJ1DN1S&%PQPQ-#!`WOO\\;7U1YESV9FNEJA
MMII88M>O]$53;FV(9-5DE)CV2&:\U-(?47GE0BW5T@J&2!.TG-,M<R;"*C"9
M@`V,9X@W$SM;&PF5L=NV]=&TTX:LS%%-5-=+JIJI4W::75DCV[-ZR=*6I;24
MSD#3]J%B28UMMZBF,L+Z5'CV1'.>1THQ&DS$@%!0+IAH<0L4%-Y8E@QA<<<,
MALK86OOK[*XGHH33Q36&::S+O2"\G+GNT(;97'TMDFZ0/P>79+1<6H76BVTH
MP&?CPV?<&3#AV(6$;TMN-/.*@MLEDE.#L+J)E?`/J!DY@E&D$@3!1X/7'&*7
MGFW^I<B<YT1VA.(145B-\V>^5%%";X,G-5,;04A)24`HEU4(B07%U!7@!D[$
M\6#'$1E=/5$,U>XF)M,,8B96N.>VA8)`T61,W5IOK916?QH5.5DES.LBH+Z>
M8391>+=ER0Y[;3O?I?!#!$LL-V:)6?DBIA1EC,UO765@HGGT,ZVVXUT-%%E]
MY98<E!4;BTH10Y7ZF2.=#7R[D(.TN[C61!2*`$ED4@X8==R0A'RPB:-D4;J.
M[8#BMR$22`,B&LU1OJ/'SQTF\7L4<83EWG^677D@L7%14D<0`$0<N^HRX`;,
M+#,4#A)*:.(G`B98WS#X3'ZW/>7QWUN3+;:JK\GLS+MS6Z*_WN/X-OBM4*<;
MW'\''XK>3\W)0%,([U9+B65]N-]VM9=<+3'"+.E!1UY)4UEM&1[9\`77TLD:
M'.HPXU@A>""40"P@E@\]YC?>9;`.TR6$3`Z"FYJJ5@HF#@J>`0R/%,3HQ\!-
MP6!R()6XMAQ#@*.(&JBEL`[C!IN>![/"Q7+$6X'OCBERP(QDR("7+@!"#&!Q
M\\`@000L+YBBC"B7QP#"##QOF()GE;###&^65[6M>]`>6%PA,,1`[AB!B8VS
MPSPOCEAGAG:U\<L<L=MLL<L=E[96O>U[;+VO>U`>6]Q_!Q^*U`=8*LH@">35
MAE5*!2E`9(`(*8IXH&GGAW`=)IR$"3.9BV+&1EM14"!%(#!$SS4CIXF6)V&'
M,@X9@?J*I)0"B22!SZ>"K*18^=3DL4T6#43Y-+$(AJ9LD2S$L9-%DX533<#X
MX`0@1,10(XF,P\C8%A`/?WN/X-OBMY?ST`WN/<M\5J`XWN/X./Q6[78H#G>X
M_@V^*U`<;W'\''XK4!SO<?P;?%;R?FH!O<?P;?%;R?FH#C>X_@X_%:@.=[C^
M#;XK4!QO<?P<?BM0'.]Q_!M\5O+^>@&]Q_!M\5O+^>@.-[C^#C\5O+^?EH!O
M<?P<?BM0#>X_@X_%:@.=[C^#;XK4`WN/X-OBM0'&]Q_!Q^*U`-[C^#C\5O)^
M;DH!O<?P<?BMY/S<E`<[W'\&WQ6H#C>X_@X_%;M]F@&]Q_!Q^*U`<[W'\&WQ
M6\OYZ`XWN/X./Q6\OY^6@.=[C^#;XK>7\]`-[C^#;XK=KL4!QO<?P<?BMVNQ
M0'.]Q_!M\5J`XWN/X./Q6H!O<?P<?BMY/S<E`<[W'\&WQ6\GYJ`XWN/X./Q6
MH#G>X_@V^*U`<;W'\''XK=OLT`WN/X./Q6H#G>X_@V^*WE_/0&(^OF)WK.NB
M/5G#$:)1=:D*5=/4LQ^RDDPH)Z074G.[&6L(J*2'554P434X$PH'``Q3AXT`
M5+X99"C"XX8WO55\?78J<.EZ54M\%4F_8^=A_P#)G=V`\'UF^?>&/VUJ'I_\
M]&E71?D^D9I58CCC#2_IOC5YD`DQX1Y`D/,9V)P1HHH!)[E:4>MU!7209\@,
M8(G@RBJ0-`8'"1@<H9QPL.7&%!SPSRKN^+/,\6WZF&>ZYVM;3"U-EK6_S_Q+
MV+6YXK5:/,N>S(_+7]KW1KWR=]S:0OQ'=G]`GZ['!77%;FY#&F./4Y8'UMO_
M`$):G:M_$1"O.=R);=B;6LDZ5-EK6_SNO;L6V?\`U1NVM4>9<]F9K\KY;HAI
M5?WYL>Z)%_I':M=79\'L8^GYZ>)+#]4%6M;1I&=[6M:_7.,SM?\`W5S1_P#"
MU<#T47Y?*/!PW6]0VZ#,"5(8GJ,VTP([G518,@-M7UV:EFU(3G5H&6'Q$DHQ
ML7T)EDM,A)0X\_6T<Q1W6:7<\7(FIQ-[9DU@J>")GPM2Y5UA^FG.&GX[VRY8
M$[%#`H!0%"R)]H$_\>HO])C1JJ_)[,CMS6Z+8ZNHB=4_Z6-1<&L9QE&>\Y>A
M62HW:CK/CJ)4BVW"\VBK("0MFS*.&,J@%DP\?`.#"IH0IX,,++(L'F-;#&\-
M)PT[PT^C(_-Q@W/*>MSD@F4XOU`3,WYK<CYEK-_(J^W51Y*Q5)0\F<V6]9('
M&>I(B?#'L?13AW@B@>9/@S6&>_X;(7&PU74JG*481[LNV\-#;Q.`/ARM]^XJ
M+\=,ER:HII%24T=JH#9B:5):)R@Z6HVEXG%#Q4"SD6E=LL%66%A_-J5BX(K9
M4&\S,623<IA<("*KO@HU7K:.<%`INA'4"F-=U)B;,A)%>KL&CUPNF4DE[/G)
MU/YP-[2@QX)=B4X05%OG"Z4"N/1EJ#G+O<(PX5C-.?)T^.VBZVTDP!:"5IKR
MQGTX1^65$=T'R2XVYDFK<I+!(R/'V#`"*'Y1>KW(HJ4O+6J?-^)X>"8V(G:J
MVDJK9FZ/&ZD%;1VW.AB+&J*@!8@EFHUU&X>+1*\S'#B\M<9+MRAIQE9X0+$L
M<-`^V68NLE(5DI9;Y"4)-3FJ"HJ#`<;30'>DOMOM])>JVIQXY51-?S<1%9$2
M2)]7)!VZ)("TDMUTI@)I/''_`#QS6#XE<0IIX>$8OI5=Z_(*D[>F@O-.#RQ/
M.)V*%E\T[YN4'W%AL)'5#HZ$A](<=JA]F7*()5-*%!#0A9,"%3<0Q,1&_33;
M'J^\2PL3Z(G['S1CU"P>!)!.Q>PM'\>MH!OR'**FU3`6GN<UI]RH[S38-W0D
M8LKS@PA$%$.I(B<JB(PI<=HB.A2;)(LI&Q96EY>6:PZ/\G<Z5M*4X1.^DY\2
MY(J,[!")600L4E.7U)PE")U]-B!DM2,-VX[#8)1"1E1QQ2Y'2.W;)9TRG#N<
M+$ZY7:L9K#B/@VLO3VGCD_8D:H9%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!&'NM2<K']+J&(DH;@7LTR
M<(K5#Q5MH"RY5$NFECZC@9/9)B"145'(H6R&"XP.&5S#`QSQS%RPP^NK5/F7
M/895+6E[HUW9`LN*3#>R<084L&CQ]HN0D2*@P[*F0IDV:1CH!<`+'I/^N$&&
M$P#PQ[>65K5U\2U74Y*FJ5AFLU^3<MCL`8M'[%+&012Y@NSFP`.`.'F$,`,$
MB$0Q01@A+8YABAYXY8"!YXXYX9XWQRM:]KVK@=2)'=BOM3I3]UU[>B-VUJCS
M+GLS-?E?+=$-"K^_-CW1(O\`2.U:ZNSX/8Q]/ST\26+ZH*]AG&?OG&9Z*YHK
M@>BB_+Y1(['&A'2-%[O59)0=/\2J$K*\K2A,YB7W)&[$6Y:!?4M2$ZI)<9XG
M(QAN8NPL`G++O4TML!8*G#(39`3$(N9S+$0[Y#+J;SR2Y)07!E^3Y$8R6Y\6
M+!S[D%4(-Q-.MY<3C+($:!YP++D3&W@CG$T)[X29GTM%5,5[.80@PQ2(K11%
M8!!5E)T9IJ"<$Y]]^I&M'FKS4`YC<-E%EZ`)3[6T/3^52(S7V(W&H+.ZG(NH
M&:8KG-TW;HX:J\R:9"T<,=LRH&1CUQD`VF1N;/2`*X$5R(MB@U"QSOCIA*ZV
MV+DQ=JMFYA2,RHOU%D3JT=6%FT=XJR.$P>,K,BK;EA)(4P#(Z+=NI2F''8DK
M(*L0*L),.YGXU7'RINZP#PA!SDU,&EBU;VSYY1C&/H\)"I-.FP$]OE`D<^<+
M''U&_&E0N,EX$DG@9(:.87'@C:B641N-Y7X(#H804-YG:]S7%P]@EZL^#V9A
MY<5NBYE0HH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@(8-V*^U.E/W77MZ(W;
M6J/,N>S,U^5\MT0T*O[\V/=$B_TCM6NKL^#V,?3\]/$EB^J"O89QG[YQF>BN
M:*X'HHOR^43J4,"@%`*`H61/M`G_`(]1?Z3&C55^3V9';FMT=5,\G$H9BYZ2
M>HI1Q<)LY)Z*"I!`<`L;4,LC1<F"7",&=H`&_'-![\83'.P8=L\[!B96L'E%
MC@6V)9S2OJM2-4))Z&4YF*K-'99I#`-%U)4(JP9T)>"5!"HQ<<F"6N'F%FD&
ML!P10-EK9`9ABB;_`#P"K48,B:>*GFH^66D!U[ADWC**,OQ&H"->/G,^V>1<
M#1>J:=5%5T,N24F/2+76"LCHL3,-(=S\!/JCO8S3;<H/M=56ZT'7QHFGJ)5)
M)+4-^'UT>*PAJ^>"LW`*;HK&XB>L.Y19+L0XS*N9MH+9?"H=;^%W\`\M.[&U
M`M@5NM\!0'4TA54"4@MMM#)K\NSDTD85D]0%<&6>*ZEH`>%\].<=]L[5>W0:
M.$M"-K"=&\K*V11B*;P&WY)E)Z604PC,[I+<:"FKY/8S8<^\G%IW?Z.@N-ID
MG<R,@1&XX3+F";;A3588/"]5IGZ>GJ7;?VI]&C*+8_DMV1K)7&)``/CEF(AX
M,-7=B*&BQP\)6<`ZL:R?1)GY%4ADL5PJF6:<Z3QI0%")):82-K)\!-H1*<UQ
MYP=]'&H]AR@\3#/;I!T`6'+2&<:;E5DY/*MU_E8A>Z7&LK#->Y=7.+Q;%@/U
M;2&RK8.]!:HBJ94`5%IX.-"P,*H(1WQQ74L"V=T%CE18K.=C@9#](F7,UHS$
M%P02:&LH8LIR-%<<3`7AYO*!Y>1%A3<A)DR<@+N"XJ-Y!99PA@H%L'+@X$U1
M0BHOA>/I/13C['?J&OB'T4N(?<#:DI!24(!8RDM74$AK"D(C/H;KF!DGDAZ=
M#7DH&E<_9R0/*!+`:,RLA)5@$`JJ#*0*2X6X>5@\+[SM^5>.I6$9ZNV3*[G;
M30:S'DSHVOV=YD[8XGLW)):R2RP6,,IKBRXTM\*;=5$TSE)+/*$<60JNY1Z)
MGU))4$]/4VPZRB&(U$^D:Y]YP=>LZSX\25DT@%V5)RXJ&G6X64Q"Z2EM##&4
MW"RI5(0B_P`JS!UE[)`">`Q9154QKKYV0Q&(3'X^`NMX9=;/"+(81WIA.VDG
MMN?5LVT-JP`_TEAO9U,B>6TJ/4!53A&NF*3(:*;%AV6,UAQ(:^X4L<Z-@@D1
M@C:4@F5)1`'`,XE03YC$H4/!%U,/35S;3J4,O:^(Y9Y`XL/1DO=MIY8%`5+I
MALVQ+O8BTUE&.N$R]55FBO$L<-(*4@%R:\?(L<V^7>GI*L1Z.M9$5[&4<`(]
M5_>G^=C*"(Y!$D]FB.L5*P1L\'I*#2XB&<R/8WPCN37?'H9[C&18I>V2L&U\
M%7,OP.PGF=R)XC&<0+&11'A[>ZDN90"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`1>ZYD:?7U.L'QC!2F]4U6<.FK6*X4T\@SD^(0:;3DY
MO/72"@1A)KY&9I17`D(DQ+OAV9%8[<K9=:(O$UM;XPWCV``O!C2B&WK3E.$5
M3PLL3'DYN@6H4&29J8325(M>%F5'\Z9I02ZS.+/9F21!^H.#X/+YR`P&9*JL
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M`X2DC-W.&-Y"/!HKA45ZS&:<?`L!X$>*/U/5FFHJ3I$A*+XQ,<<5QZXY%N5C
M='9DR;!<XV)'B`HYBD42X]F:SWQ&B(:<^IB4([D!/;#6A2'%.,-3+V9#JZ?\
MC72ZG/*,U201C2FH%3EFZAJ+><;:N*J5$N;I-K)1BW*WC#J7+?VNC4"@JLSE
M6J>B99=K5ZZXCC"HK#<Q]ZP<FPD^;M:%92E$P0D,F?7VE.R'@ENY-2141B=,
M*?(35NPU\=/:[A55T2%A>,,=9NEAQUL>$O:T-1T(FWFWGB[8C/8QA-[Q8*LX
MT6/TQ-D*3$8O`^FJ:VH'%<(/W4&RR[^-IQZ;G4SG0VF');@E)QY-AI%8[9BV
MX5M;"3G??OT+"POBIO;%K%QA:>&9>O3;JMF66=3<A1H\NI4A-UMK<^(9B,;*
M2*GS0SR<9RF69T8NXXW@WZM.U0;<BLX,9VJ2TX&$U$`_@YV4H,55/(0UAW",
MM89Y8Y6Q]R3"A"&#=BOM3I3]UU[>B-VUJCS+GLS-?E?+=$-"K^_-CW1(O]([
M5KJ[/@]C'T_/3Q)8OJ@KV&<9^^<9GHKFBN!Z*+\OE$ZE#!ZYHV5(EACATR7)
ME"P>0I@T:&#+E@`L>7(08<;+`((/&W+EGGECC;MWH#KB[C;QL1,"*KR,9%6L
M#HJ.&75"(PBL&FWMBHB)F`8^61_`AE>V)W,K87$K>]K#W#O>U`>T154M3"!'
M35(@H`&;&KEQB)PN;"'L1,6*';@B`""8"V*&KV+&KX7RL7,7L"+O!/K:`I21
M/M`G_CU%_I,:-57Y/9D=N:W1VKP9[:?[86F:\4DNNMEPDLT]92360X8!TIGE
MAG</(0L*`9"RQ$##%"&+C!#@BX8"A"8"88Y6A2CHL@^*X4*K!.+V@3:@"^8*
M&5CBYY641CXI`,<(EPQE94%$S8,K@9,\``&-@`'D8,"8AV$&$RR3-Q$6/<7H
M<BUSH`[676*W5!`,.LX^A$T0A@$%TXJ2D=5E)RA"%[@C@+"F>4E,12/`"AC*
M`*FIDSF0Q-1.%QPEZE*AZ8]/8)0XGX0ZP+)J@E(Z*<2LF\2S21DU`8^$9HQ>
MZ5F'DGX9$(]!*,H$R&6P-=+*>E(^8^9)*302HLO7N^^/$[HI!$.$R0:?A'+5
M,%0RJ82RQ4DT-7$,ED<\\E--"/F56YPRI<549#?1W'-0&,B"&7:OC"Y"9J9J
MX@DG:6B.-+M=NLL5F(9MK-(JHDFVBJ!:ZD41RBLW5MH*8!/C^9D7`,\UG(O-
M\Q;(7*XB0K'B-[\7'RPH#Q:D/Q>QG&M.UGL1M-QR.$+,!65DI-!*FC``YG`\
M=""WEN#)!JJB&$JK>!`,MBN*X02LKV.J(>!K$)*8*::H"(*!55)Q$PRQXDBM
M]ODQ`6^2P#*)35*-M.;P)8M;#BH!A*2V:T$@LH!`XJ/09JMM'$-YIB&F%"HL
MO7ME&.K1_"3PDYGR<KMHAQMG#.`\`V2[88&*`O*[F5GZO*RLY5$=FF'VI9&%
MV37PM"(P3T*-8TJ.-9.GT`V.L+&:@$M*/E_GT+LLJ'XQCG,H*R66B-X<B24T
MPD9)`9Y&RJ8L"H8JBF@&S(@YD-.'NV6X%B1Q%L4+E4)()E002B<4!"$/0)P3
M#A!RJKP)QLT2[F6EHHXU!9P1RW'!%TFLY.,-5+Y98WP('1W)GFY%`8A@6R57
M%GFNJ?&U;+(Y<67JSV5B%HH7VTSF<KL%M'6O'UBF+(0\TX,-/:X1%`.M4N61
MP`."L3)V;*B?;XQ(._%#2,<,IIH$8H,(%D))TCMTY02^QPS+PBEE.`P&1#2N
M'4$4L(**D!IH"3BC&A,;89'$6Y`F0"S1S5QDP41,23(I7,TDIHQ4):L730T!
M%;1"Z6WTLBCIUU!85;DD\N&6+74G`KGE]</7"#MCCQE56U-05#PNS?F#QPP8
M$O<07*]P.WH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@*;NT&UD[PW]=(*W>(3;%:`:_\`NO'<6T.J`K0R1;]TX'BHBH7`
M.Y?N7"\*'CL$MAMQN!4E`*`4`H"&#=BOM3I3]UU[>B-VUJCS+GLS-?E?+=$-
M"K^_-CW1(O\`2.U:ZNSX/8Q]/ST\26+ZH*]AG&?OG&9Z*YHK@>BB_+Y1.I0P
M8XZ@8E7)29D@M\RJ+#J:+I9(+>SB0H,S6T7/*@2\GJF;@)/59:R^<`5L"A3,
MN625L,ZTCV6.)91)@!F13P`J<=9,&&YHWG$=P,DT]$6.C.0HT*6L]4L\VT%T
M0\TH9U.SW+YYKII)C1\S44ZYI/AN3&A$SQ78^3VJE+3AM("RKXY(]T:RV+XM
M)SYRDM7ZO,JZ/-(4UP%);0.0R[`1HX3EDHUC95UCL@PJ%XV!7H2.N$T;)IT=
MI2:D&WFUVY**(J%8U+-D^JN)JZ<%MS&CXB?(ZH9"4TY7KSQ]>#Q]?1&?<FD3
M0Z>WS@2PI$BY)]1OQE*+!)&9!7X>2&C@%T0$.)1M4#XGE;ABW0I23-\)>]C?
M&@M@5JL^#V9AY<5NBYE0HH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@(8-V*^
MU.E/W77MZ(W;6J/,N>S,U^5\MT0T*O[\V/=$B_TCM6NKL^#V,?3\]/$EB^J"
MO89QG[YQF>BN:*X'HHOR^43J4,"@%`*`H61/M`G_`(]1?Z2VE55^3V9';FMT
M5U4**`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"*7=3X:F66F[I],0[%SCE0T
MRI.<JNYDEKJC+35%-2%6.7*AE5++IW=;1(&2]U0X4*B!E#Q@YA<?$7BUP<1!
M,-4N&F^\"-2FI2XSKZ)D30>D?6<KJK5)Y:2I62@,7W'Q\ZJ*;F@K%/34Y)>[
M?55-0.<1F(^>N7))Y(R9$P)DC9H3$*X9<L,-E@'EMU4P\<O4E-'AJ3=5,)_^
MW_\`)G7]4%>PSC/WSC,]%<T5R.M%^7RB=2A@MK+LM,F#X[<\G2`I636PU2I,
M8]GAF4Q,F3:LJ$4%"22?'C1$C@?7G`J):&G"*)Y/3<3Z@6NH*!`G8<V"%RP1
M?6W%XYIJ8=+CT%2'`C1PM+CL13T7O1HL$.8GN\HVB@DXUY@R6ZBKA.OQ],5<
M;29>++2*12#^:9D[#K=*J18QD+'S[7Z>L'=PCK&B">#"(GM;-915=:215>R0
MZ!6H`:(AC6)&&V2'-(+J<*2H*3T2A5E:;)-O*2WGF19KV+K62*L-E02\`::[
M?RN\"\,JJZ2CMDB95E1.2R^#VC(7,=1.EB0.(04EM"XHN0ID4+#$,*U[7$SO
ME;'"U[7RO;;:JOA[,R\N*W1V/50C/OB,7Z7('K"H4=5",^^(Q?I<@>L*`=5"
M,^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*
M`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<
M@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(
MQ?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5"
M,^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*
M`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<
M@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(
MQ?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5"
M,^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*
M`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<
M@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(
MQ?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5"
M,^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*
M`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`=5",^^(Q?I<@>L*`@ZW?E]L=8T=
M1L627DU%0SAJ79P^9=.<*0='P`QBV9`\AL@BQP43$+$04/#(2^-L+9B88WOO
ML\;73%S=%^7RB?\`H8+,R9`47RI@IG5YLI:<]#Y)M%"<H(*0@E),0<F2\T21
MF4,D.PZD*)G(%JO]M-]X):(K`JK8&6D@KFK(:D4R,%!Q9C\>VQ9]OZ)8P;S@
M27"`Z9'/#XN%'>3Y(*"FT[I<L/5LS'(NH%J.Q]%R+,(BD5)LS)*;Q?281CDP
MP6Z.<-)B2KHBHVT!#14\)[TPC;#&>IWB[HZA]=?R+(V6"\EKR,[@'=<!&&0B
M:6H9$G/#[U2VZ.4R;XXB8VDIX07'SE*DFT903HZJ$YQE-2/AOEY!+@3WU_+[
M@R)<31:CO*7(.QL-YT$<@\PLB3B14U;*9!"9!YB!W+*18R#<,3,$+//"^&]R
MR"#RRM>^&-["%O.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@
MR?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT
M^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R
M?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^
M=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?
M4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=
MXF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4
M=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=X
MF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=
M`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF
M&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`
M.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&
M_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.
MMTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_
M-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`.M
MTT^=XF&_-@R?4=`.MTT^=XF&_-@R?4=`>&>G'3R);>B0-#&=K7VVMG%S'RM:
2_+;;LR0[VV[+WMM\=Z"8L?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g887761g99m46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887761g99m46.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0A^4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````A@```<8````&`&<`.0`Y
M`&T`-``V`````0`````````````````````````!``````````````'&````
MA@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!>$````!````<````"$`
M``%0```K4```!<4`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``A`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U&O(IM`V.!F8!T.AVN]KO=])J(L^M@#<4BL']([](0`6_SAC:?>M!
M)35RNFXV78++M^YHVC:]S!$SPQS54<SHSKK*QE.99-C[&,R'M@RYUY=6VS:W
M9N_ZVM5"^S8^XN])FYTASMHDS]*?ZR2FLWIN*]K'UW7$")>R]\OVRV++&OW6
M*3>ET-<'>KD$@@P;[2#$Z%IL^C[E:8QC&AK&AK1PUH@?@I)*:)Z1CD-_2Y`+
M0&[Q?8'.`+G#U'A^ZSZ?YZC;B84/Q[;;@T18YSKK!H[?6!ZCG_UO8M!57M/V
MNQP9O/I,&TZ-,.>[Z1_.U24PLZ5BW5"M[[7-T.[U7[M"Y[??OW?X1W^NQ2'3
M,87>M-A?NW'](_;/?]&'>G[OZB)A?T.CM^C;I\D=)3E9&)TO%;6R_+MQV[8K
M:<FQDAD3M_2#Z,JWAUXM;[&TW/M>=I>U]KK"--S=K;'.V;FO_-1K**;8]6MM
MD<;@#$_UD[::6/<]C&M>[Z3@`"?ZQ24S22224__0]`.UE%/Z1S;)N<UDB)BY
MVNW<W=7_`%D>_`Q65VY+6N%XK<18'OW?1/YV]3?C9!QF4M<PN&[<XB`9#VB&
ML_KI[&YEE;ZMM8:YA;NW'D@M^CM_-24DNRJ*&;KGANFZ.\#D[1[E*JZJX34\
M.CF.1/[P_-0'#)K>ZV*BYS`QK2XB2W>_VN(_.W)B<C?8]CJ6N<T5@R3#FEW^
M=_._024W$EGMKZAZQ(R=PTVL=L+>9>SV5,N^@W]_\]$MKZBXDLM:P2-K61QP
M[<ZRM_\`724W%2M#!EVN>\UM]&L2TZ_3L^/]7Z"/CMRF[A>YKQ^:X<\<.AK6
MI>E8+WW-<#NK#&L(B""]WTXW;7;DE..6,N:&6$V5M95M:7';]!CYVSM^E[EI
M].,4N!)(#X&XDP(;I[E6_9^8)(],DAC8EWYK6UD_1\MRF_"R3BOI>*BTO;82
MXF(86/@M+/\`@TE-RK)HN+A4\/+3#@#P40N:.2!\5DMP;!96^,=I8\.89@D-
MA_M.U/D85E]K[7BFS>\0TO)VP&,]L^WV[/424ZR2S6X62<5V/-;F/L#P=SB`
M&N8[TXC^1^\A5])MKL:]E5%9K>UP+9!<![N6M_.^BDI__]'U5)?*J22GZ7Z_
M_0F_\8/R.5-O-W_$N_*Q?.B22GZ+Z9_3Z/ZMG_?EOKY5224_522^54DE/U4A
MY']'M_J._(OEE))3]#U?T,_\8_\`ZEJ;,_GW_P!3^"^>4DE/U%@?T2OY_E*L
M+Y5224__V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H
M`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`
M;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E
M`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#_\``$0@`A@'&`P$1``(1`0,1`?_=``0`.?_$`*,``0`"`P`#`0$`
M```````````'"`4&"0,$"@(!`0$!`0$``````````````````0(#$```!@,`
M``0!"`4("`,)```"`P0%!@<``0@1$A,)%!46UI<8.%@9(1>W>)@BU+56EG>X
M.3$R(R0E=H8W03-UD[35QB=7UTA9$0$``@$#!`("`00#`````````1%1(3$"
M06%Q$H$RT5(B\)&AL<%"8O_:``P#`0`"$0,1`#\`^_C`8#`8#`8#`8#`H%[I
M=@S>IO;\ZDLVM92]PF?06M5,BB<ICRXYO=65X2.C8`A60:4+0#0Z`<((BC0F
M$F!%O0P"UB5X[PY\3V_[O+Z/Z'B14AN6NXY#?93<NA(S%I!/$:PTFZ$,RGK"
MFMQN41*<S`C2Q0UQ](0$"E66(1R4PXU)H9PC3HM1_EH\&Z$OUUG7MP,AK]>%
MIH[Q]JV%7):$7B5CO+&Z/EHRE]HMO?+E<7`N2L:\C4/13]V=%29M&/8DH-E$
M(C?3(+`PM1_+RNKW#+;2II^]LV"QVPK,?C)GTG&:=M51'I)\UY)<D<24U-G-
MS)>#BWV.M:1VD4AC"9<(_2Q&(D[S!"H`4,S0F$C7V:K373_8E"H:<YDZ.KUA
MO+H8N@+#Z2M*=([)01HUBJ*'7_'8(K;3$C)7;RV6!94.K>?MRTP*':$AZ6-Q
MZ8LT1PP+%`F(FYC9JEA>ZO,G=NYT;*FJMICTLOIV]N"R&7<TDYSNT'4/VW<;
M]"3&IU<6*,J2(E9*$B'C1*BMEN1*0AT$M2[5F(]D"6>N_P`LET9[CC\Z\_=$
MS.N:PM!@B-83>90!);\4F2&(NI,MI_J"`TC(X\>KE-1SADB[W,0NB]T:THT3
MR%6PHE):L;8L-)`$5MJG.">XHLF?2$0HPVF$S4P2_J#J'E1+.2[+-<'A)->9
MZO5VPLD!\*%7:!$.+2^/H#2"AA>_BT2SR!$0<6+9H*E:6A:R+`MQ^]R6^.?&
MF1W*?7;ARSSX[M14"GZJ.(Z8E5D6U,(;(KJ"G^<K2M5`8FEH1CVA3)W)(8<2
M':E(%&8O4!G5=/6)25,_<N6P:QNP*]=Z8CR@?+?.TNZRCSVU7:A<45Z4(P5]
M\\&F1PHE/7NS6^0KWO>FIP0F[4)&H(RE?QRDI2B"I6>ND,"?[I3DE.=(VHY^
M3BL!-;7#M;MK*DMP*F*KFWO-"(VL'U=+]UL2M:'N*."<TI_9Q-)NR"/14IU2
MDI05YEGKW;`@]QVPE:*W`)^/Y_))-1CS)Z\LF*UY+AS1:T7#%J4KRX#HDWJ]
M01G2O\9?E,X.8&=R1>L[NSFW?[LS&!5I=&"NZ/7+W9(=*F5`WQV%K6A)9]9V
M4Y5E9!LCFT:C+Y8$,5W,U/E1M4F>Z(<$\)O2(H:X0N"UAE;>TK"!N8PIDSD%
M,0)Q6>KVZ2]S1H'4U'`=X-.I,>"N_;4:+'F,HE38XRXR8]ZQI&FB3B40QP9A
M1V(HC[FH0'R!P0H&0M4:O4[0MX1I!)-K)X[I5Y$]Q15U)9-<0953*>`-EK\Y
MV7T-$'Y/9)DO7DH:HOELH:31B2,1E?11.UJU3P\IUZ!4E7KP')O4`:60,(?4
MJ3%0@&%>XM-H=\YXGJN'2S)?(.F?<SBS)NPKJ0M[/'D7&[L\2E3'6U_C5"!<
M$L+<VDL:)A3GM:]>V$EE%JE:W])H8M)[Z'M>2VQ[;[]VM7,OGM1+@<!6KTM"
MXM'9"-&I03&7\Y?K%KY3)79M^%`^"K94(8RTPBO@EBT8330;+*T4,1O7=4TS
MW!IER14S3(9+&I3T`X2'VUX=WNYJ9E;ZYG,3R"-G4'5DS@3)\7!)DH:V^:/%
MD#D?Q?KFD)%H3TQ2(!)Q8R!5_P!TZ2_W17UCL^85LQ<_-+R9';TZ?H!L>':Y
M5D?`[2WFGF1CZG6.J]"CJ&2"9XY+H0Y*$!1A9JU2C=2"P"(.3G"4$K/7NS\4
M]U&%RUH@LC25-*$K!(6[V^3I4>I?"!NT:=/<,3;/K]`P,R9E/,G*2"#<&P+N
MI)-2".^*/TD*--1C*&L]>[4R/=.EB2D&?I65<N+F.AWN>SB!BL-GLE\GI<)W
M6\ZO*N)E,K3B\+IIWF40K]KE-3-@-NZ1O=TI9$E*&IVG$FV6H6>NM7JLWVO;
M5KM7(\F=.:5"D=]V=`U^J45Q.+OMIDD/PX:X3/3FG115A>U:AL5-;6-`@=S$
M.V\EV<6\2CR`.UK=2-]=E';'[3L_HAM]LN6\]S(Z!PWJ2NN@[5FQ;&^H&EY1
M2VFZ=3R$V"K%[E!K`0FHH;-QN:!Q1FICTZU4CT`S0?3`<&+57$I%YJ]R:?6)
M!.9V:3TXJG]R6CS%2G3EBIZW6.12%G@5PW`DJPQ_C+0HBAR58"$HBW-^>D*E
MQ2[0MS<`@E4O5*B=C63QWPM;RSU58'2S=8\NU1J.(5Y#99;%?QQ^3VFED\AF
M$YIZTIG6<C:#HF9"HV".M[@.*EK4*P2]6$P*O91A96RO.94F*ZZH&]OZ<VIU
MKQ_2/3EE7!*HA9M@6/*I+.6)D.;VV%H69CN*508OGT$05D@+8$+:UL:9LVN*
M&GE0GDK9RE8=ZJA$<)TFG/'@KKV^K0O_`)/J-WMR>%+I3*>_WNWEEK.*ASB-
MVU/6%FRV!5A`Z=4JC5Q_ZVZL=&U,M7[;SV-:F8`&*EORH686`,:F(J9IT3]L
M>RY/;W'JYZN.S)0^RB5W[TI6J&2O,O<4\G&BC=OSR(1%DC3I\84L2.+-%F`L
M*?:3RG_[L-0/8C-&F;0G+2=$,>WI9UL.-[7!R5T1>$QF5D<[H9A**;GJAZ>T
MRKJ*C+'G3FW,5YNB%P(3Q21JZB7-`8KZ2%`)E)7&F'^"T)J8X`G:)B-$4Q;K
MKI)74O.3,]3Z0R!?;/N`]O4I.[+$D8&5[#`:,)Z<=:]B:(49:F1"P*U:BMFH
M?KMZ=.(Q*TGDC\0*#=#+47\);YSZGZ&M2=^T,]3>8NS<W=5\A7W9UQ0,#'$6
MYBD4XKR$42HC,W0F-\?3OS<B?]V"N="T`5NT``JR?*2'T@>5A)B/Y>4@=@K+
M)@O8'$T99+GM1!#NI^B;$CDYBC/+W=B:6J$1?EE6%KB<;`UJR=M)1<VC)TC$
MM(]%<8XKQ@&8,@HHL(C:='H0/W$9?&8RC;I;3ZM\B\8ZH+]OIEMARM(;I*;+
MOR'6YNEG:42>',M7GJHXPRAO9ED@*4ISG%0>OU\F:3!,.(/,%-O7^Y:L8I]3
ME>2KGQXBTCLR;\\UK)6%SL5G62RM)G?P+62HR)3&6&./!["R,;U6@`)%$@.C
MJN2(%AZQI2*0MZDO!7=5Z'^[Q:$;YM@-J672$2FDOEM!];]/N)<8LEPAS&D@
M?.%SH8<NB;<C5UM)50'X3#)22F_UCCBU.V_0E2HL:D8REGK>TK%)?=$$HE;K
M6.J(5J;8^T%(J(B$:9YXY/$=E1K-RF#JU`]CDR>LP.C0Z/;`I3L135IH5>5W
M4!%I4-(`Y04L]>[]KO<U?2+6!6Y?.YS8F)Z'YBYP>UTJLLUEED?EW5//[7>$
M-7+82DKEW1#)B*EX*9GY-MZ*.(,+-/3;4^0)`Q7=9/V\[[L+J'C>C>@;0;HX
MU3"UXRKERU#%350F5*E<'QU^3DB1.M1IE*$"!$`"<)(S5IF@$A$8I/,$,>5)
MBIF%T,(8#`8#`8#`8#`8'__0^_C`8#`8#`8#`8#`TBQJV@=NPQ[KNS8JT3>"
MR5.!'(HE(4VE["_(@'%J-(7AM&+29R0[/*`,1!P1E"$$.]AWO6L&S0''F2A7
M=Z=I(ZUE'G&0/U7ZI%\>UGQZAU>*<\3!BJQS7FK1*5U?G''&&F-!HA(33S3#
M1E",,&(1;EYHSS914-?H'*(M6<;89#5T(#6=<N[:4J3KH36X!D#!7T9."I\6
MB$`VD)UII)\J#04Y0=%>4HO01<MIG-15K9;O!WZ>0YHE#S6DA#+:_<70LXU5
M#94!.8D+DD=,`<7MJ?BT9YA(597E/"2:87H6@#&$1'NJ*R@"JQVVWU$4:#+/
M:(BO@+;.-I]AD*2%.CHG>W**EK@""/;"O>49"LY-OQ*,4IB31:V,DH0!V:,K
MYBYS7,1D86T54JJ.F*X6MVR'P",&MA9];N*IVKS2=&-MV0F3P5R7J#F<DO0"
M6T:D[:<)?K&^<6]%WY1YG?B)XF=*'JI03:+@C=K&++A3$DU-G1"X-3NG<I+M
M$C3B=G#Y584"DPX[8C#CT*<9FQ"(*V`MSED&CFFA&"4-DV9JJB#=+F>?S:U6
MR1I6[R/".RK)9`1JP)T2N]39_P`Z9I'0?`.:W>]GK48A$FB$6,8=BY?V3\V4
M7,Y+,)C**UCSS*+"B1$`G;XJ"M^/F$"2C.-3P>2'%*R_EF'$GJ33`M9^AH=&
M&C'Z7F&+>Q<HPO;B6C+OKR>P\^),,8D\NJ^Y:K8K)2LX724UZSWM!-US8"N(
M"6+"@H#7.+EIR-IPC"D&%$F`86,DD!>")F&;@_'=`1&N(C7RNK:Z=0QE\KZ;
MK'E!"VR-J9!:-8M+:T0^T7$+<88J'-6(II3C1+3%)QZ$9)>R!@](OR"Y2$Y\
M]40]2^03]VIRM'&;RPEH(E$L60J/GR"1!8`D%L9CVZC0;6.:IH(3%%)CCAC.
M)(*`4$6BP!#H7.7HCYIH`PA0F'4$"$6M->%+AO<>0^LYN$@*DY+P\.JGT_B'
M5^7:F[X(3@H$:MT:]N)@3=&+E8CA<L@S<^T?'BXH4R5/`FT,&9(7&X>)+&6L
M!T<8JV(=4U;M;2?M/L](DKE,_+RX^$(O^"%KU(47H:4':&2Y>C7_`#90U4NL
M<?*VJF&PEVB$0?J_BZZ.M1;:<PP>42KY]2.)MGH""%*P/LST%U5I0ZT4>X%@
M/&'9A8!!+<RQ/V3^;_BRU^J;@^EQ+S:LB)6::M:5$/\`>:`39<KR0?HSU27.
MST(Q%OAP=Z,<O.+9VQB$+>Q<Y;T=3M7GU/JB380P[IP,+(KC5;A2[+B7ZOD[
M66QE0?Y)+&%/N(Z82@M^V[P^$$@_W81>R-[+V2];ZM&DG)W,DT9H='9M0=33
M=BK^(J8!"V>;06/2]NC<$6"9A*(6V))(A<R28H/YN-^M-_AM(`*(@(2]!*!H
M);G+\;Y-YMVXGNX*9@I#DID\TFIJQ*T!1G?.ZQH456TZDI>THR=$/<KKL@#"
MM4@T$TYG!I'O?P^M%X+G+:&3G^D(X&)`8ZG@#=J",T*CL.V1%VGSQUCK4ET3
MULU-9AB89B=%7*=]7EQ\&M[TR%KU(47H!4':&2Y8]MYLH5GA:*N6VIX4E@S:
MMEK@VQ<#,0-H;ED^-<CIX<WI3/.%%\]Q/:\+P$KR!="W%8!3HT"M2$TMRD,V
M$14Y[8Y'\C)R'N-1YYB<?<$1BE`:S1J0F,ISVR-P4)Z<I*W.1\;;3#2PAT$1
MK<E'_K)R=@(B>)\H\X034)!#J:@L;*K9QF[M`"&EG`E30YQLM/M+8BF.I0#^
M':Q3E.(878)00@<-&F>OH>S#/,6Y>5EY3YEC@H(./\_TZR#K!$XME>#:J[BJ
M`<-:W8Y.I<6F/"3-98FUI5K$:<\:4OP3_$)2#?)ZA!(@"YRD2O:R@%4,JZ.5
MQ%&>&L3E(7Z6+FIC3[2HE,EE+@:[21[,(\P@?*+\[GF*UAFO`2A4:8</S&&#
M$(C"M-'4ZP29TF;!6,(8I6].C@_ND@9(XV-+HKD;ND&@=Y0-4WITY@)4[(!^
M@J=`^5P4$:T68<(`0ZT+:4U\D\TLB"'-K12L";$M>3=YLJ`?`LQ:55!Y_(]J
M1R.7P]>2,"^-/TA-6&F+U"(TD:TXP1AVQCWYL+<O)'>4>=8D6P$Q>IHLP$11
MVF#_`!9,T%K4*:,R"P6Q\9YS(8\F3K`$,C_+VR3N)+BN3!*5+`+C_5,%ZH_$
M7++I.;J+02>!35#64:13"K84;6];2A*0H3O\#@1R(QN-B$2=BE`%S"P"0F>E
M\,F&67Y`@UX?R`>47+]L'.%$Q>'&5\PU5#6^#F2-RE^HH!H).8B)6]'."E[D
MB-N4[.3H'Q[4.ZL:U41HLY6-4=LT0]FF>87++'T?4BB9PBPQP)@+FM:,:J+U
MY(4R<Q&M@\9<"$25RC<4TD-((8(^ZI6U,4K1)0%)E1:<L)H!A`'6A<[/>F%1
M5K8$F@DSF<.:)%*JO=5;Y73\XEG&.4)>EZ03>O=HTH`<`32XKVXP28\XGRF'
M)1")'L10MAV1K!G-=`GPR7UTLJ"`.,$GTR=+%F42=8XWNS!(;`>GDJ1NDY<&
MUR*5)AR]9(R`.0G((0K-.(`JM&:/#HS1;EBC^3>8%,I1S<[GRG!S!N70AT02
M;]7<6"^(W6M5C@O@+JF<@-@51+I$53JI$@4A%H]/HX00B\N_+@N<L,/BWDT2
M!2U%\\5*C:EC#.8LK:FR&M#4UJHS9KDE=["CREM;$Z1$>R31>WIAN240-D*P
MI$X#`B`02$`N<LXLY4YN<DKPB=J2KAZ32"8L-AO`'V,-SX);/8NQI8Q'IJ,U
MV*6&ERIHC"(EM)<`""J"WE!3>?T`Z!@N<O.9R[SR:_'R<5/04+^HF\%LHUT*
M92"%6Y]6+`**5U+P")],)3]"(N+Y-:U`-!&B0!"G*V$H`0:%RW^N:PKBGXLE
MA%4P2)5Q#D*A4J11:$Q]KC+`D4+3?64FIFEH3)$1`C!>&OY(-:"`(0:\`A#K
M1&]8#`8#`8#`8#`8#`__T?OXP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P,)(Y+'(<QN4FES^R1:-LR?XMWD,C=4+&QM270P%[4N3LYGI4"%/HP
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M=3$W/$G8IH`&]-X7$)\A8I/#D)Q8"64YP1)7*8,K$WJWR/#D*(AW;2C1N#*K
M4!3+R4ZCQ*T6I3=A#`8#`8#`8#`8%!^_NGK'Y:C?-3]7:.(+]6]V-0//$R+E
M4-F,X5HH7;;ZO:GQYB#)")3&WE7+VDA'YT1&BW#2DW>BM)AC$'6RQ%VH=</N
M<]%0VM/<CL&',=1&`X]OWF>KZP03:I+;8%[_`!J[GVIVB0*K$8W>SXO("WYH
M!9)@D0R$[44/20`QD#`=K89:^L:)Z#VI?+KVWTQQ\U.5,M3K7JOG-LHI:Z5%
M93SJ:OUG47<]ZSICL)_;;C;VF+IR&*F5:=J<"D_B2:I#L:1=Z8PX*BHE9KL?
MIJ3T%5<*L6KV^!38E]O^B*@D)ST\."I*U-MLVU#:X<E;6DCVP!<'MM32<1P`
M'K4I9`P!$(!VM[+RI$6V&2]EU3&WZ0,NVN;/B>/W1$.<C)!'FIE<&5SO>:!A
MBAMK%J"9(DKT<[-[=.4BE>O-1DL:(!"LHQ=I2E.("*6TPA@,!@,!@,!@,!@,
M!@0%T\44EHVQ9<->_-RFLHK([3;CHTZQUA>#7&`QYVD"5$F?Y/'Y.U,(5^TF
MR1K!)!"3A'L>MZUK?B6-T6\=[EKJQR]VL!XD,^?6>2*&*.67*XI)HNM<HZX,
M\;<G=C8&^<P6$2E`UM<@2^@MT`*Q"J7)-"T<$\HY(D$MH5]@U$B4,Z0\F;$J
MY"^*(HQ(ED27-3DZS$<EMN)QZ'IFAY&W.Y<CE[M2$CTA(-(+"06D+$N$CVH(
MT8*2%6O0=,6VO.8(+94*>YHWMAKI(JZ22N.++#B)*16F;G(N5P]O=5KPRC:G
M584E/&87Z&CS`:`8,)A8ABDRX0P&`P&`P&`P&!S][`ZIL+GF].(8!&4$97PK
MHVV)Q`[%&L@$]GLU;6F+5N\SA(K@;?!)$C5[<U2MJTG-T:U.H0$F;-]/6BQ8
M6(N)4=C_`+EO2SXWPIS`U4H6FE'O,R?VXC2EM66BQN!5/,Q$O4(9L:T/-NIG
M5EM(XN+!TH*6$A2)QG[`-"`96PBBU'^$Z\T]N7;>EVW_`%"YNE,L;M1_6M\U
MX4UEU98J)-)^<J&5\^-TJDJBP%EO+6"/6@E/OM.<`/P"Q&J+1;")(E"9H\(F
M(JUA.G[VZ#K"4\].]*QZG[#K"QKMJRII4Q.2V3KK0EB:?OKNDECU5JR/K28F
MTE5-$&@^2.!CD6X%JVI`Y"'I`!#H]14B-[;O&^RZIELDKN.L#7-G`JWK"L.N
MJJD:=J93X[/%U1G31-:$B:E*>1'.#;$(8J@BPLQ:Z)F_Y1]5,-M+6E*2AB%+
M:80P&`P&`P&`P&`P/__3^L*:([&#VSKY+D\A`C4*Z;5.R6%B;HW'"8@2]OPT
M[?/F25=:P)5+W5<C)7IA.;+"G_6R-EEB3G&)@HPEZ+ZSVL8C91+>5*4JXTQH
M$H.9UC:[.+,X-#@:8B4IG=L7-BA,I1O#4O;4ZI&I`+1B520`P&]"#A+4:ZUY
M*H%DY(Z?7'P!#*A,7.UVO,;23]2MG[;%9*352_2J7Q=MF![RC89B\*HZC5+7
M1,`M<H6E"4;,]8X\9I8F;W7SKG_M[`_^3(O_`$(AP3O+<\(8#`8#`8#`8%=N
MB>:(1TNCJ5%.'R8LA=,7A770</,AZUA1&CL6JW$YUAI[QM]CDB+6LZ)>>(PU
M*`)6E'^J,6P_HPL32O=B^VI1UGLG4D>DDQMTMLZ^L>K[1MPIL>X2E,^<E/K8
MHOA1,7..K]48RM24^$-?KE#VH,4!2^`C/]H=Z@N=$[5]RQ`:ZO\`NOI%N?)>
M]6#?:*K4DX(D1L451]..GHQ(H?"5T:1-\2:W%B<$S#+7(E08!6+2D*P>AZ\O
ME"$7I$-9L/A^@9M6C14,9BZ*CJ_:K>AUYG1RA8S7E=-KW8\&E+%,V-\?$">$
MN#>L/'(HTA/5F`)*/6Z3@+.,&7KRX+G<>N,:]=7I]>TDUM*.&/-O`OY*ACSY
M&DK?'KHW#$,#76`R%+8@X*!+71A2&B.;UIJUD"M6'*R412GTC2A:WN$,!@,!
M@,!@,!@,!@,"">H/B0\Y7HH3.!K;M%4U@."DXF-QZ8#/;T$5=5CFWZC$K5H(
MX^"<V\DU/I.M4)TQ@C-:-,"#S;PL;H'X(W%C:_FZJ)/-3.C8?-"=?"4W8$`L
M**M)A4;92_AE#A!6ANVW/!X/`PU.N-4'A+$7L'IE[T'!*P#WSE3,B<MN[M#O
M7<?.Z*`*$\AE3?Z#DZO<UDACZE*;GQ(2DDS<^V.^JFUT*"!Q:3711M"<G\_A
M@M7M7"8I!N].66B*,:)G2)^*>WD(C"@F*')>2VW/[=1*4YY>5ABEX?G#01C$
M8J6GJ%1QI@S##!F#&(0Z3Y7RPA@,!@,!@,!@,"NUO\T0BZ;.Y^MB3ODQ;9)S
M7,7Z<UXECRUA3,RA]DD:6Q!V%)$SI''=8Y)#H^XGD!+)4)O)LSSAWHP(1!+$
MU:NR;VT:12_)/EG%Q#^1^WWGW!TWJ/4#_P!KT2_?*_RBN4>2N2_-$#/EY9Y6
ML/D`#U]^`_Y!?D%_Z3;3G(534S^OXENT\3AOZ5M.QK=L]GLA/$)&U+9';+3&
MV*?M*%(FB;3H$.D;1$&Y.H:E.U24T"8/GT+>Q;$+V1U//;^J6722K7.*3FX*
M&A=0,BN-Q"E^<I)&*8IXMA>I$5)9@T+(K$84E7";IVJ3$DO!!"X@I2G*T$(2
MQB,&,7+<(GQI7<(?8"]QB8V>UEU9)K!?:Z9"GV/#8XHU6O-?GU8L(2IS8F-6
MYQ.3N@"T_P#Q`]8Z-[>5I,@6I"Q&Z,%K=80P&`P&`P&`P&`P/__4^K^SH\TS
MCI&#7F@:VM9'8S;L$I1!:#@ILML6PJ61.<N+7,HXDK9OK5W@=F,,WE"C41(E
M;R\MX8Z_'B^3]Z,2:&I+T=.<(K1VC]SKK']VB]OV6RK"QO"9*Y_[>P/_`),B
M_P#0B'!.\MSPA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"%.@'H*2MW.)
M)G*4LTCML9E/PUYA>D09(P2B?-KDU(Y6WJ7%ZCJ)%\R$6E#V:9M:2?Z+<("4
M)RL2=.:6$3\CQM;"-W5!W9*B8W:-V8049%X\U+VF#I&I7#XZ<RR>')W.S+17
MA139(':U6`]2UJ"5^C@&MP1ZVX.(GHN'A%-IQ_F#\P_N;=V_MM]NC"])\KDX
M0P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]7Z]96MYLC5VPYB`3;$LD4F
MM@UQ55Q'IC*%M:P6T=3)H7I)Q,ZD>9>U(&DYSE3V*4-XTS4K2JQ(EDG3D"TD
M.<P%UI=*PA2$N"3`^)!=S)0EC;RLCJ9@-CZ=Z7O2)`>K;6QM42MJ?(VF5NBL
MD"8)BU(>G+]7S"#X:\=$<M^GR.SHSSQUXP*WMLMV,I^99R@<Y-:**)54T-[>
MUT.F03:2PXZK(C)G.?RF=R(3RY$(5J6-H&39&T9FME&HU`XU%:.HU<_]O8'_
M`,F1?^A$.5)WEN>$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@15<Z.M7&
M`N*"W&$Y_@JE8U"="B8](I#II4HEY#DU24W<50K7F-@C;FB*6Z>B_APLQA(5
M8E"<)6S@!#_(4I@$FALI.K*JGZNXF*5#<4S^[Z>'`FS%"YM1(M2PF7R`OY2G
M2Y.UM"1$:Y$*7=JTE3I4Z%T5E$;`G++(WM$KH?G\IPJZ3S.--Z"M)F0H^;:J
M*+_E29N*AO98LF01>5O\9;%2UL9GMX=!'J'%K+VXM[4'2O105))PA5RN==`Z
M[GYE#>J*#M^P<0=CEQE)'USRXS$L\NXO;U!)!V(I5.;Y'=.QYX4IA134O<4Y
M`A'%;5J]`+4&1=*FLNH^5DP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/__6
M^P$%.SN*7!+YFGJ5QM5^D$K,D,&GLIOAL:F"ND93](WPIL0J4D!0V7"$+R0^
M_)CLW($TI1N#0B0H#S#D1/PY9;TW7Q3?$?#D?%^C\7Z)7Q7PWG^'^(\@?6]#
MU?\`:>CZGCY?-_*\OAX_IPBMW:/W.NL?W:+V_9;*L+&\)DKG_M[`_P#DR+_T
M(AP3O+<\(8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`A'H&J%-QU\.*H53
M,F<$KRVOZ$$B;2WAC7*&O2C6VYQ;EA#FS#`M)4C`4H7-CP0WG[+6%HC52=.(
MLL,/2,)GL3/=#Y)`Z9K-`XI$X'!DK:12VR)!*Y`B*1(TDSEMFR2'U6<Z.HFE
M.).I"J8%S@L'Z1ICGX%>B,+#813:<?Y@_,/[FW=O[;?;HPO2?*Y.$,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,#_]?ZG+:D:I-WM63>X-424GNS=$%Q:.:1
MHR7.<-8HW:!L+!(8A+6J[8JSP!1+W&<,0R4JY@<U!ZQP3:+)/.]4D,:Z.FLU
MF<:KN)2.=3%STS1:)M"Y]?G/:5<O$C;&\@2A2:4@;$RUS<%'D!X%)TQ)R@\S
M82R@#&((=UE2GJ#H.H)YR1U4WQJ7A/.6<KW2ZMI[HQ26-MKRE75&K6@`PO$E
M9FAI?UR0F5-NEB5$>>J0&K22U)91@]`PL1-PG296NVT-R9*KR>FI<^L],<[/
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MJ[H6JHNLG=C<<+F2$,RYA(D3PVWY7+\N:T+Y(&N/Z7D,R9O(4.0DJAU`/90!
MA$,.M^&]94J,K]80P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!!_2A1*F@KD1.2A
MN;XVOJRR$4P>W%^=8Z&.Q11!)$!Y?DB]EA\Y<-JVTKP'H);<<,!?G-``TPL"
M<XL;PK1[=B$#964S1CC%:Q%8*7-CB>SUO#$D&3;)=X9''%&M>6I)SES42I=!
M%*-IS3@M3AHE0F.1C5A4)#TB82M#-.@JCKV9%5[+)6)MF:B-HY8E82V&2.)Z
MMF<G)U96D296VLZMM-<7EY95"-&AT?\`&JU00%%%#&:5H9*5@!9]?69WYS0K
M@DM9I'M%Q?V\<ZMZ-5HI]8/E.Z_;P$A32>.*PIG^+N!_P9VM)G!,F4!$28$0
M-"`+6B])\I>Z"ZPBW/DMKJ"+JXMFSY?9L=L66L+%53/$')2CC=7.=;LTK=GD
M^8S>$(4I!+G:[,22`HT\XT1X]^302Q;QOLG2[4_MGH7GV_$K*AO3VU[CNE%&
MU"Q7'4=LTCRS8R5A5.)9!+@I94\PN5Y):U"XE*4`X9&BQ&A+#H6]Z#KPOK."
MZVY*42N`\:.5[TW,6/V>2T5916%7,TV#&@<L\9(R'^12I16`Z]<#H\GL3;4^
M#8"H\]:`>IWHU#\8+1/CZYOA/6<+[:3_`"6VJRU^4:+D"N64E[6%A4[*7!I/
M85\EJSG?DBO9`M8E*M$O4LJMYB5MM#BI:5"YN3G#3#,$2,T@L>P[$`.]7UG"
M7>_);>I.V8K:MKLE.*Z;O>K)3)HG+YC'55GL-?HV-Y;8,LBR.1)4JV&65-E)
M3BE%,$0P@/(*+,`(7@/S!\NY4QN>)71P&`P&`P&`P&`P&`P&`P&`P&`P&`P/
M_]#ZC+CC46UWC"Y!+)2N<GYO75&B86AODL1B;NB9YC8*!<S,J:K5LJ*+NZ-C
MEU=HESP^+60Y='R&DE2UG#7-(36^-1LZHR-@12=F6L;@<XITJX)/F4-#FN9W
M).:F4DK$JA(XMQZ=40:0J3@'X>;99FM;`8$98A@%67._J_D7GZ.\B=/*AU^W
MRCY!YXO![C:.>GJ9VUQ:3AJUQ&NF$6:94:ZML<E[TM8$BM8Y(RB59RTL1_G"
M8<<(PL3-PV_M'_*VZQ_<#O;_``[RK)T6/M'E?S*R8#`IM[@7W1;;_P"@OVFP
MS"QNN3A#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$*=(DG&T!<XR5TC0;25A.'$
MW<3CL4E\A7)FV-N2Y4S-L6F[,_1>1'/B9.))\$K3;`J"=LO0RA"T8$L;JX^W
M^WQ!J@ECH(<NC3RB)L(`EC]`[(A%PP)T6F1..[]-CLN%5)3ORXYM:;1:5P2.
M#>I5MAA0""U`D>DP"Q*Q]CT#7=K/[-)9B5)%3E'-H5<?"W2^2LZ%DD#.DEB&
M/S!I;VQR3)&Z8QY/.'321Q)`!0$2@`A[,$E2;3BU7TU65_5W>_,J"#Q9G8S%
MG%W;Q+T[ID*4,ADYS;=?MX:3.,K?M%:=)(Z>HM/,$H6&FF[,/,%XZV,7B.D^
M6H=:??7Y/_=;[A_:SP!FN._PSR^L^?RR&;<S`8&@0S[]O-7]R/5?]*\[YGGT
M=.&W+X=:,PI@,!@,!@,!@,!@,!@,!@,!@,!@,#__T?JCBESP"8]MO;5++KB4
M$DQ:M[B\2@$7MJ&DN+@YU9:+M7B>&V!$Y*R'/9DQM)(H+=TB5I.0J3FC19&P
MJM)RE8HUT=5<K*M':/W.NL?W:+V_9;*L+&\(:[1_RMNL?W`[V_P[RK)T6/M'
ME?S*R8#`IM[@7W1;;_Z"_:;#,+&ZY.$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@50[-E06&E5T;4J(VU,MM/">H)3*)DR2&1Q*(Q&<M+TDD[Z_,L6D<.?%J<QE
M3G(4^B79N\BU:0,1V@AV`98W>'BV8Q2?T=%9A'99-)$Z2-AB;[-F:=3>43IZ
M@,R>8@QNCU!C'&6^#JDVP*%>RC"1:#OU="$+6AB%@G=;7"*;3C_,'YA_<V[M
M_;;[=&%Z3Y0?UI]]?D_]UON']K/`&:X[_#/+ZSY_+(9MS,!@:!#/OV\U?W(]
M5_TKSOF>?1TX;<OAUHS"F`P&`P&`P&`P&`P&`P&`P&`P&`P/_]+[1K0FMWL]
M\0"+PY,\#KA]*A`GT*2H7&5)U8]2]X+FAH;:32A#'*N*:8R)(<K(>FAT->$^
MO1:AHU>AG#+I2<;672)LKF8.$12R==)D3(J4LB&%E1LZ5+G`KRB(1,>I@A=(
MP4N5[UZ835R5401H6S!$F^7TQ$<M^BE_:J?FCK,IS$V3J.K>8IUMR-M%M8:E
M:HFU)J*)3R]=$S8!')E([$E\J?#7=86E<B(VB:3$HDY@`%'HS-QJ*T6-[1_R
MMNL?W`[V_P`.\JQT(^T>5_,K)@,"FWN!?=%MO_H+]IL,PL;KDX1'=K6K!Z3@
M3W9=C.3BU1"/FLR=P5,\8E4T>#%DB?FN+L+<T1.#LLCELA='B0O25(F2MZ%2
MI-./#H(-_I\`J5/>NJ$L*)/$/<6'OF/(GD"0!SQ`N%_<H@<M1?!KTKB6-GED
M5YP:WYI&::D"6;L@\'K)QC*'YBS!AV6I[*#W,\UJ4S0O=/3#WC%+P.WJD*F0
M3ZL]VP(2JE-GK&"UU)?SAJ-.GV<F@NUHP:3[$OV+6OA0B/\`('<7^RP,1G/,
MD.DS)*4DD]W![5,3@0XIVF747[NLKC*\U/O8@)WN-O=)K&A[;Q"_UTZDHPDS
M6O`0=Z_1@U[+:LG<5#/4IB$/,0=$Q1VG<D0P^+*[,XR[&J2+.4G="E)S:R&S
MBT:&B$*;%S@!&9H@*MP(]40?*'>Q;UK=2I6[PA@,!@,!@,!@,!@,!@,!@,#1
MK,E2>$5[,Y8H<FQIVR1QU6(UKP],D<;PNOPIA+,G.?)*(#`VC7NQI!!1BSQ3
MZ-,#H>A:WX;"$>6K$L.P669&V,[C>G9D?&QN(4CJY;2NR"1,*$TU,.MY#+)O
M+D0SU'F6!<U+D:WNQ"LHUO`60'8<++!WXXW[\^2V:HU=C,C8IKIP,4R1HB5=
M2V,-KVL2S9N2CC[1)2F]6X3EJ5C0.Y_RJZ$M026M"B2(UQCHX>@(5\KIQO\`
M<.Z.917FPQ%I]+A[L4,;7MC^>OG3\J_7![>8)0Y6+&D449(="G%0K+3'I4#.
MX/!)(#S"3#M")T(V+I4UE[O6GWU^3_W6^X?VL\`9OCO\,<OK/G\LAFW,P&!H
M$,^_;S5_<CU7_2O.^9Y]'3AMR^'6C,*Q3L^LC"26I?'AJ9DYQOH$GNS@D;B3
M3O((ST2S5AQ(!F^0&]^76][\-;W_`.&!!=KV-+_DUJW1L]YV^6/CC?EL-KR9
MSVV[;=I]^CMJ%$'#2K2[2K6O-H[6R]E[_1O6]?I+684ZE?2O7L5LNIJV,?N%
MG!1:WS[^&>TLIL[3;'_F,P)GX[Y5T)9L8OE8"CT2/+O7@8'?CXY%J.ZR]86+
M=>Y(/]=$^Y(#$--BK9>JPDDL')!O/JIM(@C%*W(#64V:(V<(T6M#-V/0`AUX
M;$(-2L1*R[5+(L^J!I&.2Q]Y5EDB4F)6IY;G%06G`,LH9XR$BDXP)(3#@!V+
M>O+H0M:\?'>L(V#`8&L2N;PR"(2'2<2Z,0UL5*PH$KC*W]JCR%2N&2<H`B(5
MNZM&G.5C3IS!Z+"+8]@+$+P\`[WH-!^T9SW_`/?:FOK/A'_QS"U.&>C=Q5%,
MG4IBB%IUQ*GL\HX\EGC<XC+XZG$I@;-4'%-[8Z*E9A1!6MB&+0-Z"'7COPUA
M$CX#`8#`8#`8#`__T_LHB=-<M*[^?9?%:HIN03]Y=I;:4LFKM#V%PL2+V#&Y
M0QUBB7Q5R=F(;PSMZR10=_&J-2J0``\HC%)>MC6FFC+K2Z&$5H[1^YUUC^[1
M>W[+95A8WA#7:/\`E;=8_N!WM_AWE63HL?:/*_F5DP&!3;W`ONBVW_T%^TV&
M86-UR<(IMWO]VQQ_OEY5_P`55+86%R<(8#`IMV-_^K'[Y-'_`/S/A8ZKDX0P
M&`P&`P&`P&`P&`P&`P&!#5SM,`?DE>,T[>7!C4+;5B!T#5-J,I<H43QG"YR!
MM;#"%K%(F?X)S9VE>0H$M3Z)"0,6RC2%7PYH"HWY)K*'0V#N<\A0"4#'=*UN
MGC(P,;V6]P%@ANFHAKKU/6^QMJ)>TQ!RA"9"O);33#R&P:L21&%.A(3)21*U
MN$4VG'^8/S#^YMW;^VWVZ,+TGR@_K3[Z_)_[K?</[6>`,UQW^&>7UGS^60S;
MF8#`T"&??MYJ_N1ZK_I7G?,\^CIPVY?#K1F%<I^]H-"K#Z2X]CL_A\6G,?U`
M^J'+3',(^TR9GTXI#.?B4J_38])%J+2U,2K-"6;Y/4`$T>M;UH6_&\=R9F(F
MI1E]E3E[\-U"?4]7GT=SI488]N7[2?94Y>_#=0GU/5Y]'<5&#VY?M)]E3E[\
M-U"?4]7GT=Q48/;E^TO0K&H:FK/MOE5;6]7UW7ZQV8^A$3HKA$*C444N2,F!
M-2DE(X'L+8@-6)BE`=&!+,V((1Z\VM>/Z<QRZ-<9F;N7;3,JI%UY?%PU5):*
M@5+IJU+D5N/4^*<'RSV642-E:&F"Q0#^82C98I*8<N.<7-2J+!HX:WTB2RQ:
MV4/8]"`B+FC:)F58)7,NQYVA(:YP1PQ,FQ*K"O2MTKY^M*0H4RX!)R<"TA([
MWFL3DJP)U!@-&!#H>@&"#X^`MZWKT[I[1B4'2"J+QD$I@,I,A'MYH#8$XOSB
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ML1<TNT<II5>54I:\R0D-SOW+VJC3IE85I9D5L2MX(N$<`DXC0#W2$5%'G-4D
MV`\6]IS3AD"'H(]@V,`!!UZPQ[S^L-"^R9-OQ[>XE_$RH^B6/6%]Y_6&<CO-
MMBQ9U(>6SN[O94L3@/++)D5Y,4P:A!4%#),V>PRVO'MC5#"`>]@$:G&(H?@,
M&PBUK>GK![S^L)!B;K=];]*\?M*OJ"\;(BUJW5.Z\FT.L7]4JU@=&%#R=TM:
M+<,L46JB)/:)Q03*M6I06:4M!K8"AEC",!@M9.41%4L<O:](=E,R/__4^I9G
M0V4T=LNC&R49+6Y*)^#*768HYVYIV@VJ9)9<I<]R0YJ#VH%J/9W*6J75<8V:
MA8C?7.-,&SZT9H`HUT=8LK*CW8]OURKYK['@8)*41)6;FV^4ZDAP;GAJ:U:L
MFK%_QJ!BDCFWI(U)G%J,DB`I<F;5BL]`>K**4`*,'H.%B-81SV5.X.I]L#JQ
M"FF444+E'!=YI"$9$B:#51ZHWGN4$E)B4Y:P1QB@PX6@!`'6Q;%OPUKQR=%B
M/Y1Y7U_6+7W]>X;_`&G9/Y]E9/UBU]_7N&_VG9/Y]@/UBU]_7N&_VG9/Y]@4
M\[ZGL&5\EVPG2S.)J5!GS$],A/(F<XX?DLN&C%Y"BU@AB\H`[WOPU^C6M[PL
M;KA?K&KW^OD,_M0R?S[!4X4][OGL%5\XN)"6:1-2=NXN6S-$IY&SG&[+(ZDI
MH\\S19:P0_(204(8]^'@$`=[W^C6\$1.%P_UBU]_7N&_VG9/Y]A#]8M??U[A
MO]IV3^?8#]8M??U[AO\`:=D_GV!3SL">P91]EWX>:1,_T.PZ34G^C(F<WT4Y
M7SF]4\WR+!>F27YM>86_`.O'].\+'5<+]8U>_P!?(9_:AD_GV"IPJQU-?CW%
MTM'1JF+8JB*R6VKV9ZU=99*&Y%8;=&8T?75F31<YEQI#.(9ZZLUPA25*$PU<
M646%2+^2(>P8(C,(<LVLNG[+C.XU^9=5<`\7!(O^7ZRHQ)%)-KX31VO@M.OV
MEU__``]3ZO\`M2_3_E["'].O#!<85R-XIZB,&F&#WIYR0$@X1II145;-@6`V
MG/(TF4[/O4XP)(3#@G:V2(HSU"@ZV+9>Q@'%N,)`KGF?J"NI4CE.O=O(G7PB
M=:GW'+&K5%*(JKTM3&)_66-`NAD>S5"38_4)'HP.P&!UO].O'6ZEQA,A=NW?
M5MZ<[Q6Q.GJ#MF!W!*I_$Y&ACU3D5N[1[YN5#.;!:'E-(M7A.4V@FO,4(2&$
MG(_(86H%H(PC\N#>ZA?/]8U>_P!?(9_:AD_GV"IPIMTG;+^XVQS=5M6]'ME0
M-MBK;94325QI+4\O=-IH7#43RQ(``L-DEC*W$JG)0+0QA(`:9K7ET+!6DW#4
MI;2=I2PE&1^:U<,:TC---V9$HUQPSG*]F@"#0%ANZ64C.**\N]@#KRZUL6][
M\?T>`OLTC[+MI?\`]A^F/_9<=?\`X-R?*W_YAM$4H2THJN/7?FSWA(]*$@DF
MT4K8^.'A"5L1Q)VE1!.Z33C*5@]'8-"T+P\@Q:WK?CK>JE]H9ZN;$FU=]6,E
M5SOK8%VP*5<]V'8/FEK+1L5,8)?$K'JF.->D+I6L3B`S@+F:8+O43JA':%LL
M(PZUY-[P;QLO\TR>-/YAQ+%(6-Z-3@"8>4TNR!Q,(+$+RA,.`C4'"+`(7Z-;
M%K6M[PC.8#`J]US#I+,ZI3I8;`7RQ)6S2^/O["U1F6KX-(6Q8C"N2FOS1*&J
M[>?7)K4H42XTL6R9(0,91PP;)/"(0<+".?;\:I$V44W"=:\EM9QMP*CB^N(W
M*IR^S0)%?'P]@W&@,!3YT9TB9%6%&@T$@EK)<6LE-Z6]:0@WO9I@G=<R1R-F
MB;,MD$@6A;VIO"3\0H]%2J-&:J4DHD2-&B1$J5[BXN*]24G2I4Y1JA4H-`44
M`9@PAV131RDC+,.Z>39-'5OR@RO'%G=:M`JVF5HC1%[N_P!NHLPI2A<"$K@W
MK4QQ8BCTZ@HI0G.`(LP`!A$'1>D^46=:??7Y/_=;[A_:SP!FN._PSR^L^?RR
M&;<S`8&@0S[]O-7]R/5?]*\[YGGT=.&W+X=:,PKFAV-]ZKC[^[;K#_WCG?-<
M=TGZR\V;<S`8$<-'WTN1?_3>B/V>->9Y]&^'5UPS#3FSVS_W_P"+/_4N@?V;
MMF7CO"3]9?C.CF8#`B\W[V_$']Y-S?X9+@S/+:&^/5UYS#3G%W7_`-U.&O[[
MK1_PRW'EX[P3]>3T\Z.1@,")9%]Y[V^OWI+$_P`!G:F9Y[1Y;X?]O'_,.P>8
M:?_5^Z`-)P$,]-LT()D&:'^@6<YAM&T-(SD*5P4NJ5D-8-3'YNF1E,X+#C2V
MK:3;<`1H_`C6A"\2VEC"(#D?+]#S9_>)!/ZVC=C[>%Q[KIAL=`3/(<S.ZY(T
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M+JVOG]^*KQ2IL0]@:_\`Z72K<T0N*>*#T^,82TQBF,A<CP'Z&F"6:(F<K1?8
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MB:`$S\A<YN10X];R5X1%1"OHXUM\64)(<H>YH\0,JFGING:N/2%`PM3;L;TU
MG(AR108$LXOU!%BYJ=5C/L7<=?A.YH^HFK?HK@N<GV+N.OPG<T?435OT5P7.
M6_U]0M&5*X+G>JJ8J>LW5T1:;G)SKZNH?#'!Q;PGEJ0H%RV.,[:I5HM*2@&:
M*,$('G#H7AXZUO")8P&!K\EB[%,&L;+(T/RBV&'$J!IOB5B3Q.3BV(H?K(5"
M51KR;W_HT/PW_P".MX&,@]>PVM68,>@S"FCC(7Z&B6M$:K&C3%I4I"%,0D)5
M*#PI$R9(F`6645Y"P`#K6@ZP;O<F42;)Q'%T:=C5R9.K-;EB9P:U.D;JSO#(
MYHGV/OK4I$6>42ZL+\VIEJ;9A9I/KD!]0LPOS`$%8S_;ZX>=QA<)GR1S79$I
M/)3!?)Y8]#U),9U*UQ"<I.8\RB3.\-.7.SLKT5K9A@MA`']`"P%EA``);G+P
M_ET>WQ^!+C;^&&DOH/@N<R?ET>WQ^!+C;^&&DOH/@N<R@Q_]N[@-1T=6#=OA
MGFU"@0U%<;Z`#?1M$(H!(5NY53;.--)H65`3UT@D,<3N&CFU<<8E(;BERD!0
M5(U1FTD6YK=.?Y='M\?@2XV_AAI+Z#Y4N<R?ET>WQ^!+C;^&&DOH/@N<R?ET
M>WQ^!+C;^&&DOH/@N<R?ET>WQ^!+C;^&&DOH/@N<R?ET>WQ^!+C;^&&DOH/@
MN<RK/9/"/M\M?0-`-)O$/+!"%:OD[(8B8::I5N95;G*H'/'AI/L.#%56K+?6
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M>X4Y(4B56D\MRYC0U14L,;GEO6UY+"WDZ51U'2$J0SI@BT8TXO:9,K6LP`2!
MM:RP'[,4Z\D6)G765B_RZ/;X_`EQM_##27T'RI<YD_+H]OC\"7&W\,-)?0?!
M<YE^P^W9[?@`F!!PMQR`)P-%G!#S'2@0FEZ,+.T69K4(UH8-&E!%X;\=>8.M
M_P"G6L%SF7__UOOXP&`P&`P/P866<682<6`THT`BS2C`A&686,.PC+,`+6PC
M`,.]ZWK>MZWK>!^\!@,!@0O9G0-75"XEM,Z<Y,E7#BSM-SRX[6]E3PIMB#$X
MMK6]25\50.(R5(P,S4K=B/B%"X:<LHG8SA;T24:,!:;.*?U4^'NK2*;5\\*8
MX5IX>VP4DCC@>Q$MI8'73JZHMK3C&LI`2`*GUS@@T4'6C/-K6M;PC&R2[*OB
M\=^=:R5IW=DW,6ROM'PEO>;%6"FSNYIF9#&`M$`;I,\">-N2LLLTG2?S)_-Y
MC?('Q%H41"[:JG+<SN+#-&HO;[N7`;6>1`6PR6&&0%]>8S-R5,+F25AE[<HB
M3_'ER5Q+4H2AHS4IFC=!\N]X*>XR6_6$G=UK!%YU&Y2]((BBGA[;%W(F2*S(
MBXN;TRH7Q"4R;7;<TBEWCRQ*'2;U3/7)\GE\P@:$&`A/052S]N4NS')E;<WI
MI)(XAH^=128UAM;)HA)'>'REG:";*C\34/BN/R=B5(5>D03PD'EZ"/>O.#S"
MF?=+AJ9E9$$D=;-@2%A=FIY?&=V/EK#I"\M$=2'+WYQ93]+Q`>$C.C3F&J1I
MO5T2`&]B\/#`]1KM:F9?\VUC78-=/ASF-C61;0))'E#@>IE3<O41X34E-5_'
MEN#ZV)%>TP``">>42=H.MZ`9K0985IUB!$W.0['@8&YX=CV!H<!2^/A1.KZF
M4A1J65N5;<=$+G9.K'HH:8H0C@&;T'8="WX8&5A<TBEBQ1AG,&?FZ41&4-Q#
MLP/[2?I0WNC>HUO92E,;K0=[#O8=A$$6@C`,.PBUH6MZT&SX#`8'XV67LP)V
MRP;-``PL!NPAV8`LT18C2PC\/,$!@B0;%K6_#>P:\?\`1K`_>`P&`P&`P&`P
M&`P&!X1)DXE!2L1!(E9!)Z8A4(H&U!*=4-,:J(*/V'U"R5)B,D1@=;T$8B@;
MWK>PA\`\V`P&`P(&0=-4HO?-,.Y8N:CAR&QXDF>I-"YW$84XR>HUTC06+'VB
MPI3&6>"/+O&#(:\'&)TKD<:<C:%RHG1J9(H-++39SYA2B].VV@IE-6K4K*2X
M(FBPSWN)J$[2G7L@)"Z)&V6F*AEH"5L;("N4%E*`!,0@T</6RM>;"/>F-K0.
M"19GFC\\J#XW(G2,,L>7Q=BD,Z-?G&9K$R&+DLK;!VJ1.KJ4\J%A7I'$$&$^
MF/1@AA+\1:#'0Z[ZHGA+(..S9I^-D;M,F%ECS^%9#YBO>Z]>G"/3=I!!Y>E8
MI@6X1=W:SREA1B$`R@AT9O7IC`,0ID&2WJMDS\S1F-6#$)(]R%FDTA9$,>?F
MY\VXLT-=F1BE"Y.H:SU:38&5XD21.<'9FAZ-,WK0=^F;Y`U.,='T[*QOX$DE
M<V`$9DQ4+>%5A0F>U6W$R\].D5DQ=(YV9&(DW.L@-2KR3`HTAIY^P#T+0?#Q
MWHM2W(-KU:-"@=`65`!-CI(]P]L<0S&.B0N,M"=\.*+(%>G':=7(]*/Y&T)8
MA*?/_)\GC^C"-`*NOF.6$0Z=&V92[ELII#*H/('F30\ES;6B2:2,PGID.>51
M#JS$O`G`A$88#1.S1G`('XB%H&RU*07*U:O9M2(3O9$":@P]6B02T3E,(\AU
M%USDG-5MR*1;5.)6F16O2D#,)+4^D,TL`A!UO6M[PC(Q.=PZ=EOQL-DC3)2H
MQ(UT1?SFA6!84UR5L3(5B]F5&E^)>EB5*Y$&"#K>]>4T._'].!MF`P&!X1ID
MYIQ"@P@DQ0F]7X8\90!G)_6#H!WH&B#L97J@UX"\N]>;7Z-X'FP&`P/_U_OX
MP&`P&`P&`P&`P&!2?HN#MLLL!4<EO!XJEW#SG:+5,T#'7HI@^*Z@7O<;,E4C
MBSJ<G6(625LJL@DM'KX1T/&8?H0$1WDWK"QMLYK:KGDXN>1U1'NA7]:RDOX'
M!U1.\#NMICOV?&J2=#22?1YD&IB;Y"I'$90F72>-R=8TFQR-I4Z8A>>`#J47
M\I1K6MED(Y#.3D/.KFGF%RO[_21?0-,.'RC,(-93-'#5K$@KM/7$;844P2+5
MID`F32D:3DKBQ#(A($JH&V1.WMP"TX":WMJ]JR89Q>_M$B5L-QQ."5"HB==I
M)2S0^%IGQD3%I%/1)<1=V1["V.+.C;%\@>9H9,$QZ1R).4M"X*\2`PQV$L&N
M$M\\1NL68;:K:;*N6:JEBJ/:=&QQA?2D9E#>_&W#>[A%SY;N2JU=G(H:DDJV
M5M[JEGBMW2G:2)#W!4`O:;XBI*-;BAG)JFK'5)8UPR1NB1N_<A"-T:(I*AR-
M.IF-IS5?T,..E,D=7OORI4#TH<4"/X0@TQV1$&&DA5)Q#$*+%](02KKKF(]I
MB)KWT9=R5I.LN+GR5*]51U&2OU8#3T.@>FQ)+13K;Q*8^@DMC+$+-X6.9(2M
M*TNCV@Y"JVX''C7#?7*!<=Z@:=OD%[J#GA/)')3(I%$(#(&^=N;C]JSD]]=T
M#<TLS0\35K2"M=BBK(B$#:D193YI048:%*(X`UPT"L*]XQ*B3L27T%9:X0ZG
MM5J-76+6][MCR5%5<<XJ3JI,UH;L;W65C<&6%Q>%')BDAWPJU))31MJ4AN2@
M2HQK>SK_`$H@:VNH:R;F!_\`G3&D<&C)$4D(FI0RG.T0`TI=1)8K;58Q*2'`
M<<^%TIV,).S#]#'Z)'F]$NLRD_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8')BR*
MQK-1$6M9*NFWQ#6?VJ>B'VI&9CJ%\,>$G0*J:]$/5H0]T<6(I5.9.WM8-SYG
M0;:-1]P/\"#FESTY::U(R_"#F>ON="7.5?+E^2A0W)T2U,S*G>"W8?(W+H%;
MTQ+IHY.BV,GQIGF;7>D?<!%PYI2-\A4V2Y,_BL).2*0)G`^+KA=^P8[SZ7R7
M2C7<%A.:BG&E_HU:CE$SCLH(52Q6AD+.JB+1)&9V0FRQC3/SEZ"8S;IK:U(7
MO6UB@9P3#A5(NYI'$EB'(3XH`N@]MPZ$UE\@\UE2./PJ(LSS'3R&GI2W'&H%
M46?S&ERCC*]R.^E4J0S<)Z1V5C"G-^4PM@O65GC4H^*4XSL4<6MELW%,F@+7
M:!9#0TP#I^,R]2QJOLSH3CX@,*];<S7&F84<CZPG7Q:]L7))"?\`)P4[,0G3
M(@WR<1CGD:Y2HEUE/928/5]G/ZQO21V0_%FV>MY`LB/O\";%36SG.!:AGJ]8
MN?V]P2>89KFC)2IC!JS"B1C516*UCR\=6JU/%NG;Q2MHF^3M<G<7.GNHAR3Y
M`4U/SLF;7YW0331\[3,#37\:C2DXQT-4P5:AD/IE-J<!;/\`)D77";W*`\G!
MC*=-*+Z"<$.VPTAR'7KHD4BCN_;ZN^+1)&M1J6Q<I'HGF]R=9,<H%Z9*AU;#
M$P2DYZ@*'0UPPU:0GD,GH-0YI+JM!=)R[\D;I&XO9,#O]$S;EJFV[N7RJ+-+
M[;Z-1#7)M16RZO2,A9&RVQ"4H:]:5;6+SAK#1KA?SDMD@K#4J!'64W#/(`(3
M&.+NVX\LCQY+<5!XBC*(/*6:(^-"K`ETM*,`F3!*)5!(V$0B1&#J3W6<PA@,
'!@,!@,#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
